PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Funari, SS; Rapp, G; Perbandt, M; Dierks, K; Vallazza, M; Betzel, C; Erdmann, VA; Svergun, DI				Funari, SS; Rapp, G; Perbandt, M; Dierks, K; Vallazza, M; Betzel, C; Erdmann, VA; Svergun, DI			Structure of free Thermus flavus 5 S rRNA at 1.3 nm resolution from synchrotron x-ray solution scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-ANGLE-SCATTERING; 50S RIBOSOMAL SUBUNITS; PRELIMINARY DIFFRACTION; BACILLUS-STEAROTHERMOPHILUS; BIOLOGICAL MACROMOLECULES; CRYSTAL-STRUCTURE; DOMAIN-E; RNA; PROTEIN; CRYSTALLIZATION	The shape of free Thermus flavus 5 S rRNA in solution at 1.3 nm resolution is restored from synchrotron x-ray scattering data using an ab initio simulated annealing algorithm. The free 5 S rRNA is a bent elongated molecule displaying a compact central region and two projecting arms, similar to those of the tRNA The atomic models of the 5 S rRNA domains A-D-E and B-C in the form of elongated helices can be well accommodated within the shape, yielding a tentative model of the structure of the free 5 S rRNA in solution. Its comparison with the recent protein-RNA map in the ribosome (Svergun, D. I., and Nierhaus, K. H. (2000) J. Biol. Chem. 275, 14432-14439) indicates that the 5 S rRNA becomes essentially more compact upon complex formation with specific ribosomal proteins, A conceivable conformational change involves rotation of the B-C domain toward the A-D-E domain. The model of free 5 S rRNA displays no interactions between domains E and C, but such interactions are possible in the bound molecule.	Deutsch Elekrtonen Synchrotron, Univ Hamburg Hosp, Inst Physiol Chem, D-22603 Hamburg, Germany; Dierks & Partner Syst Technol, D-20257 Hamburg, Germany; Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany; DESY, European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia	Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Hamburg; University Medical Center Hamburg-Eppendorf; Free University of Berlin; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS	Betzel, C (corresponding author), Deutsch Elekrtonen Synchrotron, Univ Hamburg Hosp, Inst Physiol Chem, Bldg 22a,Notkestra 85, D-22603 Hamburg, Germany.	betzel@unisgi1.desy.de	Betzel, Christian/G-8105-2018; Perbandt, Markus/K-7603-2018	Betzel, Christian/0000-0002-3879-5019; Svergun, Dmitri/0000-0003-0830-5696				Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BETZEL C, 1994, FEBS LETT, V351, P159, DOI 10.1016/0014-5793(94)00834-5; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; Correll CC, 1997, CELL, V91, P705, DOI 10.1016/S0092-8674(00)80457-2; ERDMANN VA, 1971, P NATL ACAD SCI USA, V68, P2932, DOI 10.1073/pnas.68.12.2932; Feigin L.A., 1987, STRUCTURE ANAL SMALL; GABRIEL A, 1982, NUCL INSTRUM METHODS, V201, P223, DOI 10.1016/0167-5087(82)90031-X; HANCOCK J, 1982, NUCLEIC ACIDS RES, V10, P1257, DOI 10.1093/nar/10.4.1257; HARTMANN RK, 1988, NUCLEIC ACIDS RES, V16, P3511, DOI 10.1093/nar/16.8.3511; HORNE JR, 1972, MOL GEN GENET, V119, P337, DOI 10.1007/BF00272091; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Konig S, 1998, BIOCHEMISTRY-US, V37, P5329, DOI 10.1021/bi972125v; Kozin MB, 1997, J APPL CRYSTALLOGR, V30, P811, DOI 10.1107/S0021889897001830; LORENZ S, 1991, J MOL BIOL, V219, P399, DOI 10.1016/0022-2836(91)90181-5; Lorenz S, 2000, ACTA CRYSTALLOGR D, V56, P498, DOI 10.1107/S0907444900001736; LORENZ S, 1993, ACTA CRYSTALLOGR D, V49, P418, DOI 10.1107/S0907444993001520; Lu M, 2000, P NATL ACAD SCI USA, V97, P2023, DOI 10.1073/pnas.97.5.2023; MOORE PB, 1980, J APPL CRYSTALLOGR, V13, P168, DOI 10.1107/S002188988001179X; MULLER JJ, 1986, EUR BIOPHYS J BIOPHY, V13, P301, DOI 10.1007/BF00254212; NOLTE A, 1995, FEBS LETT, V374, P292, DOI 10.1016/0014-5793(95)01136-3; NOMURA M, 1970, NATURE, V228, P744, DOI 10.1038/228744a0; OSTERBERG R, 1976, EUR J BIOCHEM, V68, P481, DOI 10.1111/j.1432-1033.1976.tb10835.x; Perbandt M, 1998, FEBS LETT, V429, P211, DOI 10.1016/S0014-5793(98)00436-0; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; SCHULZE T, 1996, THESIS U HAMBURG HAM; Serdyuk I N, 1979, Methods Enzymol, V59, P750; Shannon C. E., 1949, MATH THEORY COMMUNIC; SPECHT T, 1990, NUCLEIC ACIDS RES, V18, P2215, DOI 10.1093/nar/18.suppl.2215; Stoldt M, 1999, EMBO J, V18, P6508, DOI 10.1093/emboj/18.22.6508; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 2000, J BIOL CHEM, V275, P4210, DOI 10.1074/jbc.275.6.4210; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 2000, J BIOL CHEM, V275, P14432, DOI 10.1074/jbc.275.19.14432; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 1996, ACTA CRYSTALLOGR A, V52, P419, DOI 10.1107/S0108767396000177; SVERGUN DI, 1993, J APPL CRYSTALLOGR, V26, P258, DOI 10.1107/S0021889892011828; WESTHOF E, 1989, J MOL BIOL, V207, P417, DOI 10.1016/0022-2836(89)90264-7	42	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31283	31288		10.1074/jbc.M004974200	http://dx.doi.org/10.1074/jbc.M004974200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896668	hybrid			2022-12-27	WOS:000089762700076
J	Meijer, HA; Dictus, WJAG; Keuning, ED; Thomas, AAM				Meijer, HA; Dictus, WJAG; Keuning, ED; Thomas, AAM			Translational control of the Xenopus laevis Connexin-41 5 '-untranslated region by three upstream open reading frames	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA SECONDARY STRUCTURE; MESSENGER-RNA; GAP-JUNCTIONS; 3'-UNTRANSLATED REGION; EUKARYOTIC RIBOSOMES; MOLECULAR-CLONING; GENE; EXPRESSION; TERMINATION; INITIATION	The Xenopus laevis Connexin-41 (Cx41) mRNA contains three upstream open reading frames (uORFs) in the 5'-untranslated region (UTR). We analyzed the translation efficiency of constructs containing the Cx41 5'-UTR linked to the green fluorescent protein reporter after injection of transcripts into one-cell stage Xenopus embryos. The translational efficiency of the wild-type Cx41 5'-UTR was only 2% compared with that of the beta-globin 5'-UTR. Mutation of each of the three uAUGs into AAG codons enhanced translation 82-, 9-, and 4-fold compared with the wild-type Cx41 5'-UTR. Based on these increased translation efficiencies, the percentages of ribosomes that recognized the uAUGs were calculated. Only 0.03% of the ribosomes that entered at the cap structure scanned the entire 5'-UTR and translated the main ORF. The results indicate that all uAUGs are recognized by the majority of the scanning ribosomes and that the three uAUGs strongly modulate translation efficiency in Xenopus laevis embryos. Based on these data, a model of ribosomal flow along the mRNA is postulated. We conclude that the three uORFs may play an important role in the regulation of Cx41 expression.	Univ Utrecht, Dept Dev Biol, NL-3584 CH Utrecht, Netherlands	Utrecht University	Thomas, AAM (corresponding author), Univ Utrecht, Dept Dev Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	A.A.M.Thomas@bio.uu.nl						ABASTADO JP, 1991, NEW BIOL, V3, P511; Beardslee MA, 1998, CIRC RES, V83, P629, DOI 10.1161/01.RES.83.6.629; Belluardo N, 1999, J NEUROSCI RES, V57, P740, DOI 10.1002/(SICI)1097-4547(19990901)57:5<740::AID-JNR16>3.0.CO;2-Z; BERNSTEIN J, 1995, J BIOL CHEM, V270, P10559, DOI 10.1074/jbc.270.18.10559; BROWN CM, 1993, NUCLEIC ACIDS RES, V21, P3119, DOI 10.1093/nar/21.13.3119; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Cao JH, 1996, MOL CELL BIOL, V16, P7109; Cao JH, 1998, RNA, V4, P181; GIMLICH RL, 1988, J CELL BIOL, V107, P1065, DOI 10.1083/jcb.107.3.1065; GIMLICH RL, 1990, J CELL BIOL, V110, P597, DOI 10.1083/jcb.110.3.597; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GREEN CR, 1998, PR MED BIOL, V11, P103; HENNEMANN H, 1992, EUR J CELL BIOL, V58, P81; HINNEBUSCH AG, 1988, P NATL ACAD SCI USA, V85, P7279, DOI 10.1073/pnas.85.19.7279; HOUTZAGER E, 1998, THESIS UTRECHT U UTR, P67; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Kumar NM, 1999, NOVART FDN SYMP, V219, P6; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Neve RL, 1999, MOL BRAIN RES, V65, P52, DOI 10.1016/S0169-328X(98)00337-4; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; O'Brien J, 1998, J NEUROSCI, V18, P7625; Ruan HJ, 1996, J BIOL CHEM, V271, P29576, DOI 10.1074/jbc.271.47.29576; Saez JC, 1998, BRAZ J MED BIOL RES, V31, P593, DOI 10.1590/S0100-879X1998000500001; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEPER GC, 1992, J BIOL CHEM, V267, P7269; Schiavi A, 1999, FEBS LETT, V464, P118, DOI 10.1016/S0014-5793(99)01699-3; Sohl G, 1996, EUR J CELL BIOL, V69, P267; Sosinsky G, 2000, CURR TOP MEMBR, V49, P1; SULLIVAN R, 1993, GENE, V130, P191, DOI 10.1016/0378-1119(93)90419-4; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; van Oers MM, 1999, J GEN VIROL, V80, P2253, DOI 10.1099/0022-1317-80-8-2253; Wang LJ, 1998, PLANT CELL, V10, P1733, DOI 10.1105/tpc.10.10.1733; WU M, 1991, METHOD CELL BIOL, V36, P3; YOSHIZAKI G, 1995, MOL REPROD DEV, V42, P7, DOI 10.1002/mrd.1080420103; Zuker M, 1994, Methods Mol Biol, V25, P267	41	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30787	30793		10.1074/jbc.M005531200	http://dx.doi.org/10.1074/jbc.M005531200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896676	hybrid			2022-12-27	WOS:000089762700009
J	Morrow, G; Inaguma, Y; Kato, K; Tanguay, RM				Morrow, G; Inaguma, Y; Kato, K; Tanguay, RM			The small heat shock protein Hsp22 of Drosophila melanogaster is a mitochondrial protein displaying oligomeric organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; OXIDATIVE STRESS; ALPHA-CRYSTALLIN; PROTECTIVE ACTIVITY; NEUROSPORA-CRASSA; GENE-CLUSTER; RODENT CELLS; EXPRESSION; LOCALIZATION; PHOSPHORYLATION	Drosophila melanogaster has four main small heat shock proteins (Hsps), D. melanogaster Hsp22 (DmHsp22), Hsp23 (DmHsp23), Hsp26 (DmHsp26), and Hsp27 (DmHsp27). These proteins, although they have high sequence homology, show distinct developmental expression patterns. The function(s) of each small heat shock protein is unknown. DmHsp22 is shown to localize in mitochondria both in D. melanogaster 52 cells and after heterologous expression in mammalian cells. Fractionation of mitochondria indicates that DmHsp22 resides in the mitochondrial matrix, where it is found in oligomeric complexes, as shown by sedimentation and gel filtration analysis and by cross-linking experiments. Deletion analysis using a DmHsp22-EGFP construct reveals that residues 1-17 and an unknown number of residues between 17-28 are necessary for import. Site-directed mutagenesis within a putative mitochondrial motif (WRMAEE) at positions 8-13 shows that the first four residues are necessary for mitochondrial localization. Immunoprecipitation results indicate that there is no interaction between DmHsp22 and the other small heat shock proteins. The mitochondrial localization of this small Hsp22 of Drosophila and its high level of expression in aging suggests a role for this small heat shock protein in protection against oxidative stress.	Univ Laval, Dept Med, Lab Genet Cellulaire & Dev, Ste Foy, PQ G1K 7P4, Canada; Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Kasugai, Aichi 4800392, Japan	Laval University	Tanguay, RM (corresponding author), Univ Laval, Dept Med, Lab Genet Cellulaire & Dev, Pavillon Marchand, Ste Foy, PQ G1K 7P4, Canada.	Robert.Tanguay@rsvs.ulaval.ca						Arrigo A P, 1991, Results Probl Cell Differ, V17, P106; ARRIGO AP, 1988, EXP CELL RES, V175, P169, DOI 10.1016/0014-4827(88)90264-9; ARRIGO AP, 1981, MOL GEN GENET, V184, P73, DOI 10.1007/BF00271198; ARRIGO AP, 1987, DEV BIOL, V122, P39, DOI 10.1016/0012-1606(87)90330-7; Arrigo AP, 1998, BIOL CHEM, V379, P19; AYME A, 1985, EMBO J, V4, P2949, DOI 10.1002/j.1460-2075.1985.tb04028.x; Banzet N, 1998, PLANT J, V13, P519, DOI 10.1046/j.1365-313X.1998.00056.x; BEAULIEU JF, 1989, J CELL SCI, V92, P29; BERGER EM, 1983, EXP CELL RES, V147, P437, DOI 10.1016/0014-4827(83)90225-2; CARBAJAL EM, 1993, EXP CELL RES, V207, P300, DOI 10.1006/excr.1993.1197; Debel K, 1997, PLANTA, V201, P326, DOI 10.1007/s004250050074; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DUBAND JL, 1986, CAN J GENET CYTOL, V28, P1088, DOI 10.1139/g86-152; DUBROVSKY EB, 1994, J MOL BIOL, V241, P353, DOI 10.1006/jmbi.1994.1512; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; EHRNSPERGER M, 1997, MOL CHAPERONES LIFE, P533; ENRIQUEZ J, 1996, METHOD ENZYMOL, P183; FAURE R, 1995, J CELL BIOCHEM, V59, P389, DOI 10.1002/jcb.240590310; Felts SJ, 2000, J BIOL CHEM, V275, P3305, DOI 10.1074/jbc.275.5.3305; Gershon D, 1999, EXP GERONTOL, V34, P613, DOI 10.1016/S0531-5565(99)00010-8; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Joanisse DR, 1998, BIOCHEM BIOPH RES CO, V244, P102, DOI 10.1006/bbrc.1998.8214; King V, 1999, DEV BIOL, V207, P107, DOI 10.1006/dbio.1998.9147; KLEMENZ R, 1986, MOL CELL BIOL, V6, P2011, DOI 10.1128/MCB.6.6.2011; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; LaFayette PR, 1996, PLANT MOL BIOL, V30, P159, DOI 10.1007/BF00017810; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Laplante AF, 1998, J HISTOCHEM CYTOCHEM, V46, P1291, DOI 10.1177/002215549804601109; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; LENNE C, 1995, BIOCHEM J, V311, P805, DOI 10.1042/bj3110805; Liu JA, 1999, PLANT CELL PHYSIOL, V40, P1297, DOI 10.1093/oxfordjournals.pcp.a029518; Marin R, 1996, CHROMOSOMA, V105, P142, DOI 10.1007/s004120050169; MARIN R, 1993, DEV GENET, V14, P69, DOI 10.1002/dvg.1020140109; MASON PJ, 1984, MOL GEN GENET, V194, P73, DOI 10.1007/BF00383500; MCEWEN CR, 1967, ANAL BIOCHEM, V20, P114, DOI 10.1016/0003-2697(67)90271-0; MCMULLIN TW, 1987, MOL CELL BIOL, V7, P4414, DOI 10.1128/MCB.7.12.4414; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Michaud S, 1997, J CELL SCI, V110, P1989; Michaud S, 1997, CELL MOL LIFE SCI, V53, P104, DOI 10.1007/PL00000572; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PAULI D, 1990, J CELL BIOL, V111, P817, DOI 10.1083/jcb.111.3.817; PINELLI E, 1990, EUR J BIOCHEM, V194, P685, DOI 10.1111/j.1432-1033.1990.tb15669.x; Plesofsky N, 1999, BIOL CHEM, V380, P1231, DOI 10.1515/BC.1999.156; PLESOFSKYVIG N, 1990, J BIOL CHEM, V265, P15432; Preville X, 1998, J CELL BIOCHEM, V69, P436, DOI 10.1002/(SICI)1097-4644(19980615)69:4<436::AID-JCB5>3.0.CO;2-O; PUGSLEY AP, 1989, PROTEIN TARGETING, P139; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROLLET E, 1992, BIOCHEM BIOPH RES CO, V185, P116, DOI 10.1016/S0006-291X(05)80963-5; SCHNAITMAN C, 1967, J CELL BIOL, V32, P719, DOI 10.1083/jcb.32.3.719; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SIROTKIN K, 1982, DEV BIOL, V89, P196, DOI 10.1016/0012-1606(82)90307-4; SOUTHGATE R, 1983, J MOL BIOL, V165, P35, DOI 10.1016/S0022-2836(83)80241-1; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; WHEELER JC, 1995, P NATL ACAD SCI USA, V92, P10408, DOI 10.1073/pnas.92.22.10408	63	65	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31204	31210		10.1074/jbc.M002960200	http://dx.doi.org/10.1074/jbc.M002960200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896659	hybrid			2022-12-27	WOS:000089762700065
J	Trejo, J; Altschuler, Y; Fu, HW; Mostov, KE; Coughlin, SR				Trejo, J; Altschuler, Y; Fu, HW; Mostov, KE; Coughlin, SR			Protease-activated receptor-1 down-regulation - A mutant HeLa cell line suggests novel requirements for PAR1 phosphorylation and recruitment to clathrin-coated pits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE CASCADE; THROMBIN-RECEPTOR; COUPLED RECEPTOR; STRUCTURAL REQUIREMENTS; VESICLE FORMATION; BETA-ARRESTIN; SUBSTANCE-P; INTERNALIZATION; DYNAMIN; RESENSITIZATION	Protease-activated receptor-1 (PAR1), a G protein-coupled receptor (GPCR) for thrombin, is irreversibly activated by a proteolytic mechanism, then internalized and degraded in lysosomes. The latter is critical for temporal fidelity of thrombin signaling. Toward understanding PAR1 down-regulation, we first investigated the pathway of PAR1 internalization. Activated PAR1 was rapidly recruited to clathrin-coated pits, where it colocalized with transferrin receptor (TfnR). Dominant-negative dynamin and clathrin hub mutants both blocked PAR1 internalization, Blockade of PARI internalization with dynamin K44A also inhibited activation-dependent PAR1 degradation. Thus activated PAR1 internalizes via clathrin-coated pits together with receptors that recycle and is then sorted away from such receptors and delivered to lysosomes. In the course of these studies we identified a mutant HeLa cell line, designated JT1, that was defective in PAR1 internalization. PAR1 signaled robustly in JT1 cells but was not phosphorylated or recruited to clathrin-coated pits after activation. Internalization of TfnR was intact in JT1 cells and internalization of beta(2)-adrenergic receptor, a GPCR that internalizes and recycles, was present but perhaps reduced. Taken together, these studies suggest that PAR1 is internalized in a dynamin- and clathrin-dependent manner like TfnR and beta(2)-adrenergic receptor but requires a distinct gene product for recruitment into this pathway.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Coughlin, SR (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.			Fu, Hua-Wen/0000-0002-6346-2785; mostov, keith/0000-0002-8123-6247; TREJO, JOANN/0000-0003-4405-6228	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44907] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACTON SL, 1990, J CELL BIOL, V111, P1419, DOI 10.1083/jcb.111.4.1419; Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; CHEN J, 1994, J BIOL CHEM, V269, P16041; CHOI KY, 1994, CELL, V78, P499; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Glantz SA., 2012, PRIMER BIOSTATISTICS, V7; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; HEIN L, 1994, J BIOL CHEM, V269, P27719; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; Krueger KM, 1997, J BIOL CHEM, V272, P5; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; LIU LW, 1991, J BIOL CHEM, V266, P16977; Liu SH, 1998, J CELL BIOL, V140, P1023, DOI 10.1083/jcb.140.5.1023; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P77622; MATHEWS II, 1994, BIOCHEMISTRTY, V33, P326; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PRINTEN JA, 1994, GENETICS, V138, P609; SANAN DA, 1991, J HISTOCHEM CYTOCHEM, V39, P1017, DOI 10.1177/39.8.1906908; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shapiro MJ, 1998, J BIOL CHEM, V273, P29009, DOI 10.1074/jbc.273.44.29009; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	47	65	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31255	31265		10.1074/jbc.M003770200	http://dx.doi.org/10.1074/jbc.M003770200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10893235	hybrid			2022-12-27	WOS:000089762700072
J	Ablooglu, AJ; Till, JH; Kim, K; Parang, K; Cole, PA; Hubbard, SR; Kohanski, RA				Ablooglu, AJ; Till, JH; Kim, K; Parang, K; Cole, PA; Hubbard, SR; Kohanski, RA			Probing the catalytic mechanism of the insulin receptor kinase with a tetrafluorotyrosine-containing peptide substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PHOSPHORYL-TRANSFER-REACTIONS; TYROSINE KINASE; TRANSITION-STATE; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS; ACTIVE-SITE; AUTOPHOSPHORYLATION; SUBUNIT; DOMAIN	The interaction of a synthetic tetrafluorotyrosyl peptide substrate with the activated tyrosine kinase domain of the insulin receptor was studied by steady-state kinetics and x-ray crystallography. The pH-rate profiles indicate that the neutral phenol, rather than the chemically more reactive phenoxide ion, is required for enzyme-catalyzed phosphorylation. The pK(alpha) of the tetrafluorotyrosyl hydroxyl is elevated 2 pH units on the enzyme compared with solution, whereas the phenoxide anion species behaves as a weak competitive inhibitor of the tyrosine kinase. A structure of the binary enzyme-substrate complex shows the tetrafluorotyrosyl OH group at hydrogen bonding distances from the side chains of Asp(1132) and Arg(1136), consistent with elevation of the pK(alpha). These findings strongly support a reaction mechanism favoring a dissociative transition state.	CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; New York University; New York University; Johns Hopkins University	Kohanski, RA (corresponding author), CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA.		Parang, Keykavous/F-9236-2010; Parang, Keykavous/ABC-1584-2021	Parang, Keykavous/0000-0001-8600-0893; Hubbard, Stevan/0000-0002-2707-9383	NCI NIH HHS [CA74305] Funding Source: Medline; NIDDK NIH HHS [DK52916, DK50074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074305, R01CA074305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050074, R01DK052916] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; Adams JA, 1996, BIOCHEMISTRY-US, V35, P10949, DOI 10.1021/bi960613h; ADMIRAAL SJ, 1995, CHEM BIOL, V2, P729, DOI 10.1016/1074-5521(95)90101-9; Admiraal SJ, 2000, J AM CHEM SOC, V122, P2145, DOI 10.1021/ja993942g; Bishop SM, 1999, BIOCHEMISTRY-US, V38, P3079, DOI 10.1021/bi982546s; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cann AD, 1997, BIOCHEMISTRY-US, V36, P7681, DOI 10.1021/bi970170x; Cann AD, 1997, ANAL BIOCHEM, V247, P327, DOI 10.1006/abio.1997.2077; Cleland W W, 1979, Methods Enzymol, V63, P103; COLE PA, 1995, J BIOL CHEM, V270, P22105, DOI 10.1074/jbc.270.38.22105; Cole PA, 1999, PHARMACOL THERAPEUT, V82, P219, DOI 10.1016/S0163-7258(98)00046-1; COLE PA, 1994, J BIOL CHEM, V269, P30880; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EPSTEIN J, 1964, J AM CHEM SOC, V86, P3075, DOI 10.1021/ja01069a021; FEENER EP, 1993, J BIOL CHEM, V268, P11256; Florian J, 1997, J AM CHEM SOC, V119, P5473, DOI 10.1021/ja964270m; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Grace MR, 1997, BIOCHEMISTRY-US, V36, P1874, DOI 10.1021/bi962138t; GRANOT J, 1980, BIOCHEMISTRY-US, V19, P3537, DOI 10.1021/bi00556a019; Grant BD, 1996, BIOCHEMISTRY-US, V35, P2022, DOI 10.1021/bi952144+; HERSCHLAG D, 1987, J AM CHEM SOC, V109, P4665, DOI 10.1021/ja00249a033; HERSCHLAG D, 1989, J AM CHEM SOC, V111, P7587, DOI 10.1021/ja00201a048; HERSCHLAG D, 1989, J AM CHEM SOC, V111, P7597; HO MF, 1988, J AM CHEM SOC, V110, P2680, DOI 10.1021/ja00216a068; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; JONES JP, 1991, BIOCHEMISTRY-US, V30, P3624; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KHAN SA, 1970, J CHEM SOC B, P1172, DOI 10.1039/j29700001172; Kim K, 1997, J AM CHEM SOC, V119, P11096, DOI 10.1021/ja972110k; Kim K, 1998, J AM CHEM SOC, V120, P6851, DOI 10.1021/ja9808393; KIRBY AJ, 1968, J CHEM SOC B, P135, DOI 10.1039/j29680000135; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5766, DOI 10.1021/bi00073a007; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5773, DOI 10.1021/bi00073a008; KOHANSKI RA, 1991, BIOCHEMISTRY-US, V30, P2406, DOI 10.1021/bi00223a016; LANE MD, 1985, BIOCHIMIE, V67, P1069, DOI 10.1016/S0300-9084(85)80104-8; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; MARTIN BL, 1990, J BIOL CHEM, V265, P7108; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TRAFNY EAM, 1994, PROTEIN SCI, V3, P176; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; YUAN CJ, 1990, J BIOL CHEM, V265, P16205; Zhou J, 1997, BIOCHEMISTRY-US, V36, P2977, DOI 10.1021/bi9619132	50	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30394	30398		10.1074/jbc.M003524200	http://dx.doi.org/10.1074/jbc.M003524200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10869355	hybrid			2022-12-27	WOS:000089577900065
J	Battistutta, R; Sarno, S; De Moliner, E; Papinutto, E; Zanotti, G; Pinna, LA				Battistutta, R; Sarno, S; De Moliner, E; Papinutto, E; Zanotti, G; Pinna, LA			The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-2; TYROSINE KINASE; ZEA-MAYS; II-ALPHA; SUBUNIT; ENZYME; CLASSIFICATION; TRANSFORMATION; PROLIFERATION; PURIFICATION	The structure of a complex between the catalytic subunit of Zea mays CK2 and the nucleotide binding site-directed inhibitor emodin (3-methyl-1,6,8-trihydroxyanthraquinone) was solved at 2.6-Angstrom resolution. Emodin enters the nucleotide binding site of the enzyme, filling a hydrophobic pocket between the N-terminal and the C-terminal lobes, in the proximity of the site occupied by the base rings of the natural co-substrates. The interactions between the inhibitor and CK2 alpha are mainly hydrophobic. Although the C-terminal domain of the enzyme is essentially identical to the ATP-bound form, the beta-sheet in the N-terminal domain is altered by the presence of emodin. The structural data presented here highlight the flexibility of the kinase domain structure and provide information for the design of selective ATP competitive inhibitors of protein kinase CK2.	Univ Padua, Dept Biol Chem, I-35121 Padua, Italy; Univ Padua, CNR, Biomembrane Res Ctr, I-35121 Padua, Italy; Univ Padua, Dept Organ Chem, I-35131 Padua, Italy; Univ Padua, CNR, Biopolymer Res Ctr, I-35131 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Zanotti, G (corresponding author), Univ Padua, Dept Biol Chem, Viale G Colombo 3, I-35121 Padua, Italy.	zanotti@chor.unipd.it		Zanotti, Giuseppe/0000-0002-0945-6501				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DOBROWOLSKA G, 1992, EUR J BIOCHEM, V204, P299, DOI 10.1111/j.1432-1033.1992.tb16637.x; FREDENHAGEN A, 1995, J ANTIBIOT, V48, P1355, DOI 10.7164/antibiotics.48.1355; Guerra B, 1998, ACTA CRYSTALLOGR D, V54, P143, DOI 10.1107/S0907444997010184; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; JAYASURIYA H, 1992, J NAT PROD, V55, P696, DOI 10.1021/np50083a026; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIVAK KJ, 1990, GENETICS, V124, P303; MEGGIO F, 1990, EUR J BIOCHEM, V187, P89, DOI 10.1111/j.1432-1033.1990.tb15280.x; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; Niefind K, 1999, NAT STRUCT BIOL, V6, P1100, DOI 10.1038/70033; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; STIGARE J, 1994, CELL MOL BIOL RES, V40, P463; SZYSZKA R, 1995, BIOCHEM BIOPH RES CO, V208, P418, DOI 10.1006/bbrc.1995.1354; Yim H, 1999, PLANTA MED, V65, P9, DOI 10.1055/s-1999-13953; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; Zhang LS, 1998, ONCOGENE, V16, P2855, DOI 10.1038/sj.onc.1201813	28	132	136	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29618	29622		10.1074/jbc.M004257200	http://dx.doi.org/10.1074/jbc.M004257200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882732	hybrid			2022-12-27	WOS:000089439800059
J	Nusrat, A; Chen, JA; Foley, CS; Liang, TW; Tom, J; Cromwell, M; Quan, C; Mrsny, RJ				Nusrat, A; Chen, JA; Foley, CS; Liang, TW; Tom, J; Cromwell, M; Quan, C; Mrsny, RJ			The coiled-coil domain of occludin can act to organize structural and functional elements of the epithelial tight junction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-ZETA; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; POSSIBLE INVOLVEMENT; MEMBRANE-PROTEIN; ZO-1; CELLS; PERMEABILITY; INTERACTS; RECEPTOR	Occludin is an integral membrane protein that has been suggested to play a role in the organization and dynamic function of the epithelial tight junction (TJ). A number of other proteins have also been described to localize to the TJ, We have used a novel bait peptide method to investigate potential protein-protein interactions of the putative coiled-coil domain of occludin with some of these other TJ proteins. A 27-amino acid peptide of the human occludin sequence was synthesized, biotinylated at the N terminus, and modified to contain a photoactive moiety at either its hydrophobic or hydrophilic surface. These bait peptides were alpha-helical in solution, characteristic of coiled-coil structures. Photoactivation studies in the presence and absence of control peptides were used to assess the potential interactions in polarized sheets of a human intestinal cell line T84. Although a large number of proteins associated with the TJ or that are known to be involved in regulatory events of epithelial cells failed to be specifically labeled, occludin itself, ZO-1, protein kinase C-zeta c-Yes, the regulatory subunit of phosphatidylinositol 3-kinase, and the gap junction component connexin 26 were specifically labeled. Our data demonstrate the potential of one specific domain of occludin, contained within 27 amino acids, to coordinate the binding of proteins that have been previously suggested to modulate TJ structure and function.	Genentech Inc, Dept Pharmaceut Res & Dev, Drug Delivery Biol Grp, S San Francisco, CA 94080 USA; Emory Univ, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, Atlanta, GA 30322 USA; Genentech Inc, Dept Immunol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Bioorgan Chem, S San Francisco, CA 94080 USA	Roche Holding; Genentech; Emory University; Roche Holding; Genentech; Roche Holding; Genentech	Mrsny, RJ (corresponding author), Genentech Inc, Dept Pharmaceut Res & Dev, Drug Delivery Biol Grp, MS 6,1 DNA Way, S San Francisco, CA 94080 USA.		Nusrat, Asma/B-3887-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK055679] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29-DK55679] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED ARH, 1992, BIOCHEM J, V286, P377, DOI 10.1042/bj2860377; AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; Bamforth SD, 1999, J CELL SCI, V112, P1879; Chanson M, 1996, AM J PHYSIOL-CELL PH, V271, pC533, DOI 10.1152/ajpcell.1996.271.2.C533; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; Chen YH, 1997, J CELL BIOL, V138, P891, DOI 10.1083/jcb.138.4.891; Cordenonsi M, 1999, J CELL BIOL, V147, P1569, DOI 10.1083/jcb.147.7.1569; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; Dodane V, 1996, J MEMBRANE BIOL, V149, P199, DOI 10.1007/s002329900020; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Furuse M, 1996, J CELL SCI, V109, P429; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Gomez J, 1997, J IMMUNOL, V158, P1516; Gomez J, 1996, EUR J IMMUNOL, V26, P1781, DOI 10.1002/eji.1830260818; Goodenough DA, 1999, P NATL ACAD SCI USA, V96, P319, DOI 10.1073/pnas.96.2.319; GORRY PA, 1990, ANAL CHEM, V62, P570, DOI 10.1021/ac00205a007; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; KAOUTZANI P, 1993, AM J PHYSIOL, V264, pC1327, DOI 10.1152/ajpcell.1993.264.5.C1327; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kojima T, 1999, BIOCHEM BIOPH RES CO, V266, P222, DOI 10.1006/bbrc.1999.1778; Lacaz-Vieira F, 1999, J MEMBRANE BIOL, V168, P289, DOI 10.1007/s002329900518; Li DX, 2000, J CELL BIOL, V148, P791, DOI 10.1083/jcb.148.4.791; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Massoumi R, 1998, EUR J CELL BIOL, V76, P185, DOI 10.1016/S0171-9335(98)80033-2; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; Ptasznik A, 1997, J CELL BIOL, V137, P1127, DOI 10.1083/jcb.137.5.1127; Rasenick Mark M., 1993, Methods (Orlando), V5, P252, DOI 10.1006/meth.1993.1031; ROMERO P, 1993, J EXP MED, V177, P1247, DOI 10.1084/jem.177.5.1247; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; SCHONBRUNN A, 1993, ENDOCRINOLOGY, V132, P146, DOI 10.1210/en.132.1.146; SHAPIRO M, 1991, J CLIN INVEST, V87, P1903, DOI 10.1172/JCI115215; SINGER KL, 1994, J BIOL CHEM, V269, P16108; STADDON JM, 1995, J CELL SCI, V108, P609; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; TAKEDA H, 1995, CELL STRUCT FUNCT, V20, P387, DOI 10.1247/csf.20.387; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; VanItallie CM, 1997, J CELL SCI, V110, P1113; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; WONG V, 1997, AM J PHYSIOL, V42, pC1859; Yap AS, 1998, J MEMBRANE BIOL, V163, P159, DOI 10.1007/s002329900380	55	153	162	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29816	29822		10.1074/jbc.M002450200	http://dx.doi.org/10.1074/jbc.M002450200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887180	hybrid			2022-12-27	WOS:000089439800087
J	Roman, LJ; Martasek, P; Miller, RT; Harris, DE; de la Garza, MA; Shea, TM; Kim, JJP; Masters, BSS				Roman, LJ; Martasek, P; Miller, RT; Harris, DE; de la Garza, MA; Shea, TM; Kim, JJP; Masters, BSS			The C termini of constitutive nitric-oxide synthases control electron flow through the flavin and heme domains and affect modulation by calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RELAXING FACTOR; BINDING DOMAIN; REDUCTASE; ISOFORMS; IDENTIFICATION; MACROPHAGES; ACTIVATION; EXPRESSION; ARGININE	The sequences of nitric-oxide synthase flavin domains closely resemble that of NADPH-cytochrome P450 reductase (CPR). However, all nitric-oxide synthase (NOS) isoforms are 20-40 residues longer in the C terminus, forming a "tail" that is absent in CPR. To investigate its function, we removed the 33 and 42 residue C termini from neuronal NOS (nNOS) and endothelial NOS (eNOS), respectively. Both truncated enzymes exhibited cytochrome c reductase activities without calmodulin that were 7-21-fold higher than the nontruncated forms. With calmodulin, the truncated and wild-type enzymes reduced cytochrome c at approximately equal rates. Therefore, calmodulin functioned as a nonessential activator of the wild-type enzymes and a partial noncompetitive inhibitor of the truncated mutants. Truncated nNOS and eNOS plus calmodulin catalyzed NO formation at rates that were 45 and 33%, respectively, those of their intact forms. Without calmodulin, truncated nNOS and eNOS synthesized NO at rates 14 and 20%, respectively, those with calmodulin. By using stopped-flow spectrophotometry, we demonstrated that electron transfer into and between the two flavins is faster in the absence of the C terminus. Although both CPR and intact NOS can exist in a stable, one-electron-reduced semiquinone form, neither of the truncated enzymes do so. We propose negative modulation of FAD-FMN interaction by the C termini of both constitutive NOSs.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	University of Texas System; University of Texas Health San Antonio; Medical College of Wisconsin	Roman, LJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.		Martásek, Pavel/G-6622-2017	Martásek, Pavel/0000-0001-6165-4444	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419, R01GM052682] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52682, GM52419] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; ALEXANDER LM, 1980, MICROSOMES DRUG OXID, P285; ANAGLI J, 1995, EUR J BIOCHEM, V233, P701, DOI 10.1111/j.1432-1033.1995.701_3.x; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; DINERMAN JL, 1993, CIRC RES, V73, P217, DOI 10.1161/01.RES.73.2.217; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; FURCHGOTT R F, 1988, P401; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; IGNARRO L J, 1988, P427; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Martasek P, 1999, METHOD ENZYMOL, V301, P70; MASTERS BSS, 2000, IN PRESS NITRIC OXID; Matsuda H, 1999, BBA-GEN SUBJECTS, V1473, P345, DOI 10.1016/S0304-4165(99)00193-2; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; Narayanasami R, 1997, NITRIC OXIDE-BIOL CH, V1, P39, DOI 10.1006/niox.1996.0103; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1989, J EXP MED, V169, P1011, DOI 10.1084/jem.169.3.1011; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; XIE QW, 1994, J BIOL CHEM, V269, P28500; ZHANG MJ, 1994, J BIOL CHEM, V269, P981; Zoche M, 1996, BIOCHEMISTRY-US, V35, P8742, DOI 10.1021/bi960445t	40	109	110	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29225	29232		10.1074/jbc.M004766200	http://dx.doi.org/10.1074/jbc.M004766200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10871625	hybrid			2022-12-27	WOS:000089439800008
J	Baugh, RJ; Dickinson, CD; Ruf, W; Krishnaswamy, S				Baugh, RJ; Dickinson, CD; Ruf, W; Krishnaswamy, S			Exosite interactions determine the affinity of factor X for the extrinsic Xase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR PATHWAY; FACTOR-FACTOR-VIIA; MACROMOLECULAR SUBSTRATE RECOGNITION; CATALYZED PROTEASE INACTIVATION; COAGULATION-FACTOR-VIIA; ACTIVE-SITE; CRYSTAL-STRUCTURE; PROTHROMBINASE COMPLEX; TRANSIENT KINETICS; BLOOD-COAGULATION	The initiation of coagulation results from the activation of factor X by an enzyme complex (Xase) composed of the trypsin-like serine proteinase, factor VIIa, bound to tissue factor (TF) on phospholipid membranes. We have investigated the basis for the protein substrate specificity of Xase using TF reconstituted into vesicles of phosphatidylcholine, phosphatidylserine, or pure phosphatidylcholine. We show that occupation of the active site of VIIa within Xase by a reversible inhibitor or an alternate peptidyl substrate is sufficient to exclude substrate interactions at the active site but does not alter the affinity of Xase for factor X, This is evident as classical competitive inhibition of peptidyl substrate cleavage but as classical noncompetitive inhibition of factor X activation by active site-directed ligands. This implies that the productive recognition of factor X by Xase arises from a multistep reaction requiring an initial interaction at sites on the enzyme complex distinct from the active site (exosites), followed by active site interactions and bond cleavage. Exosite interactions determine protein substrate affinity, whereas the second binding step influences the maximum catalytic rate for the reaction. We also show that competitive inhibition can be achieved by interfering with exosite binding using factor X derivatives that are expected to have limited or abrogated interactions with the active site of VIIa within Xase. Thus, substrate interactions at exosites, sites removed from the active site of VIIa within the enzyme complex, determine affinity and binding specificity in the productive recognition of factor X by the VIIa-TF complex. This may represent a prevalent strategy through which distinctive protein substrate specificities are achieved by the homologous enzymes of coagulation.	Childrens Hosp Philadelphia, Joseph Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Scripps Research Institute; Scripps Research Institute	Krishnaswamy, S (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Res Inst, 310 Abramson,3516 Civic Ctr Blvd, Philadelphia, PA 19104 USA.	skrishna@mail.med.upenn.edu	Krishnaswamy, Sriram/Z-4380-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047465, R01HL048752, R01HL062523] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48752, HL-62523, HL-47465] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Baugh RJ, 1998, J BIOL CHEM, V273, P4378, DOI 10.1074/jbc.273.8.4378; Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; Betz A, 1997, BIOCHEMISTRY-US, V36, P181, DOI 10.1021/bi962060g; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bevington P. R., 1992, DATA REDUCTION ERROR, P141; Bode W, 1997, THROMB HAEMOSTASIS, V78, P501; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BROZE GJ, 1995, ANNU REV MED, V46, P103, DOI 10.1146/annurev.med.46.1.103; BUTENAS S, 1993, BIOCHEMISTRY-US, V32, P6531, DOI 10.1021/bi00077a006; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; Dickinson CD, 1998, J MOL BIOL, V277, P959, DOI 10.1006/jmbi.1998.1639; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; EVANS SA, 1982, J BIOL CHEM, V257, P3014; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1993, METHOD ENZYMOL, V222, P177; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; Nemerson Y, 1987, Adv Exp Med Biol, V214, P83; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; OLSON ST, 1988, J BIOL CHEM, V263, P1698; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; RUF W, 1992, J BIOL CHEM, V267, P6375; Ruf W, 1999, BIOCHEMISTRY-US, V38, P1957, DOI 10.1021/bi982254r; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; RUF W, 1991, J BIOL CHEM, V266, P15719; RUF W, 1991, J BIOL CHEM, V266, P16256; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; Shobe J, 1999, J BIOL CHEM, V274, P24171, DOI 10.1074/jbc.274.34.24171; Shobe J, 1999, BIOCHEMISTRY-US, V38, P2745, DOI 10.1021/bi981951g; STRAUME M, 1992, METHOD ENZYMOL, V210, P87	51	83	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28826	28833		10.1074/jbc.M005266200	http://dx.doi.org/10.1074/jbc.M005266200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10889208	hybrid			2022-12-27	WOS:000089330700065
J	Lesage, F; Terrenoire, C; Romey, G; Lazdunski, M				Lesage, F; Terrenoire, C; Romey, G; Lazdunski, M			Human TREK2, a 2P domain mechano-sensitive K+ channel with multiple regulations by polyunsaturated fatty acids, lysophospholipids, and G(s), G(i), and G(q) protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; POTASSIUM CHANNELS; FUNCTIONAL EXPRESSION; CLONING; LOCALIZATION; ACTIVATION; NEURONS; CELLS; TASK; PH	Mechano-sensitive and fatty acid-activated K+ belong to the structural class of K+ channel with two pore domains. Here, we report the isolation and the characterization of a novel member of this family. This channel, called TREK2, is closely related to TREK1 (78% of homology), Its gene is located on chromosome 14q31. TREK2 is abundantly expressed in pancreas and kidney and to a lower level in brain, testis, colon, and small intestine. In the central nervous system, TREK2 has a widespread distribution with the highest levels of expression in cerebellum, occipital lobe, putamen, and thalamus. In transfected cells, TREK2 produces rapidly activating and non-inactivating outward rectifier K+ currents. The single-channel conductance is 100 picosiemens at +40 mV in 150 mM K+, The currents can be strongly stimulated by polyunsaturated fatty acid such as arachidonic, docosahexaenoic, and linoleic acids and by lysophosphatidylcholine, The channel is also activated by acidification of the intracellular medium. TREK2 is blocked by application of intracellular cAMP. As with TREK1, TREK2 is activated by the volatile general anesthetics chloroform, halothane, and isoflurane and by the neuroprotective agent riluzole. TREK2 can be positively or negatively regulated by a variety of neurotransmitter receptors, Stimulation of the G(s)-coupled receptor 5HT4sR or the G(q)-coupled receptor mGluR1 inhibits channel activity, whereas activation of the G(1)-coupled receptor mGluR2 increases TREK2 currents. These multiple types of regulations suggest that TREK2 plays an important role as a target of neurotransmitter action.	Inst Pharmacol Mol & Cellulaire, CNRS UPR 411, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lazdunski, M (corresponding author), Inst Pharmacol Mol & Cellulaire, CNRS UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.		Lesage, Florian/P-9780-2019; Lesage, Florian/D-5097-2011	Lesage, Florian/0000-0002-4406-7106; Lesage, Florian/0000-0002-4406-7106				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arrighi I, 1998, FEBS LETT, V425, P310, DOI 10.1016/S0014-5793(98)00260-9; Bang H, 2000, J BIOL CHEM, V275, P17412, DOI 10.1074/jbc.M000445200; CARMAN WF, 1989, LANCET, V2, P588; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Duprat F, 2000, MOL PHARMACOL, V57, P906; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; KIM DH, 1995, J PHYSIOL-LONDON, V484, P643, DOI 10.1113/jphysiol.1995.sp020693; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 1998, GENOMICS, V51, P478, DOI 10.1006/geno.1998.5397; Lesage F, 1999, CURR TOP MEMBR, V46, P199; Lesage F, 2000, FEBS LETT, V471, P137, DOI 10.1016/S0014-5793(00)01388-0; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; LOPES CM, 1994, NATURE, V367, P607; Maingret F, 2000, J BIOL CHEM, V275, P10128, DOI 10.1074/jbc.275.14.10128; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; Millar JA, 2000, P NATL ACAD SCI USA, V97, P3614, DOI 10.1073/pnas.050012597; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; PREMKUMAR LS, 1990, P ROY SOC B-BIOL SCI, V242, P17, DOI 10.1098/rspb.1990.0097; Rajan S, 2000, J BIOL CHEM, V275, P16650, DOI 10.1074/jbc.M000030200; Reyes R, 2000, NEUROSCIENCE, V95, P893; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; Salinas M, 1999, J BIOL CHEM, V274, P11751, DOI 10.1074/jbc.274.17.11751; Talley EM, 2000, NEURON, V25, P399, DOI 10.1016/S0896-6273(00)80903-4; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Wang ZW, 1999, ANN NY ACAD SCI, V868, P286, DOI 10.1111/j.1749-6632.1999.tb11294.x	34	257	273	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28398	28405		10.1074/jbc.M002822200	http://dx.doi.org/10.1074/jbc.M002822200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10880510	hybrid			2022-12-27	WOS:000089330700010
J	Sabatino, DE; Wong, C; Cline, AP; Pyle, L; Garrett, LJ; Gallagher, PG; Bodine, DM				Sabatino, DE; Wong, C; Cline, AP; Pyle, L; Garrett, LJ; Gallagher, PG; Bodine, DM			A minimal ankyrin promoter linked to a human gamma-globin gene demonstrates erythroid specific copy number dependent expression with minimal position or enhancer dependence in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; HIGH-LEVEL EXPRESSION; BETA-GLOBIN; HYPERSENSITIVE SITE; HEREDITARY SPHEROCYTOSIS; DEVELOPMENTAL REGULATION; INDEPENDENT EXPRESSION; MESSENGER-RNA; CELLS; SEQUENCE	In red blood cells ankyrin (ANK-1) provides the primary linkage between the erythrocyte membrane skeleton and the plasma membrane. We have previously demonstrated that a 2-71-bp 5'-flanking region of the ANK-1 gene has promoter activity in erythroid, but not non-erythroid, cell lines. To determine whether the ankyrin promoter could direct erythroid-specific expression in vivo, we analyzed transgenic mice containing the ankyrin promoter fused to the human (A)gamma-globin gene. Sixteen of 17 lines expressed the transgene in erythroid cells indicating nearly position-independent expression. We also observed a significant correlation between the level of Ank/(A)gamma-globin mRNA and transgene copy number. The level of Ank/(A)gamma mRNA averaged 11% of mouse alpha-globin mRNA per gene copy at all developmental stages. The addition of the HS2 enhancer from the beta-globin locus control region to the Ank/(A)gamma-globin transgene resulted in Ank/(A)gamma-globin mRNA expression in embryonic and fetal erythroid cells in six of eight lines but resulted in absent or dramatically reduced levels of Ank/(A)gamma-globin mRNA in adult erythroid cells in eight of eight transgenic lines. These data indicate that the minimal ankyrin promoter contains all sequences necessary and sufficient for erythroid-specific, copy number-dependent, position-independent expression of the human (A)gamma-globin gene.	NHGRI, Hematopoiesis Sect, Genet & Mol Biol Branch, Bethesda, MD 20892 USA; George Washington Univ, Grad Program Genet, Washington, DC 20052 USA; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); George Washington University; Yale University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Bodine, DM (corresponding author), NHGRI, Hematopoiesis Sect, Genet & Mol Biol Branch, Bldg 49,Room 3A14 MSC 4442, Bethesda, MD 20892 USA.		Pyle, Louise C/AAR-3513-2021	Pyle, Louise C/0000-0002-8933-9320				BENZ EJ, 1993, MOL BASIS BLOOD DIS, P257; Birkenmeier CS, 1998, GENOMICS, V50, P79, DOI 10.1006/geno.1998.5305; BIRKENMEIER CS, 1993, J BIOL CHEM, V268, P9533; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CHADA K, 1986, NATURE, V319, P685, DOI 10.1038/319685a0; DAVIS LH, 1992, J BIOL CHEM, V267, P18966; Eber SW, 1996, NAT GENET, V13, P214, DOI 10.1038/ng0696-214; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; Gallagher PG, 1997, J BIOL CHEM, V272, P19220, DOI 10.1074/jbc.272.31.19220; Gallagher PG, 1998, J BIOL CHEM, V273, P1339, DOI 10.1074/jbc.273.3.1339; Gallagher PG, 2000, BLOOD, V96, P1136, DOI 10.1182/blood.V96.3.1136.015k48_1136_1143; Gallagher PG, 1999, J BIOL CHEM, V274, P6062, DOI 10.1074/jbc.274.10.6062; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HOGAN B, 1986, MANIPULATING MOUSE E; KOLLIAS G, 1986, CELL, V46, P89, DOI 10.1016/0092-8674(86)90862-7; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LAMBERT S, 1993, J NEUROSCI, V13, P3725; LAMBERT S, 1993, EUR J BIOCHEM, V211, P1, DOI 10.1111/j.1432-1033.1993.tb19863.x; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MAGRAM J, 1985, NATURE, V315, P338, DOI 10.1038/315338a0; Maniatis T., 1989, MOL CLONING LAB MANU; MORROW JS, 1996, HDB PHYSL, P485; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; NICOLIS S, 1991, NUCLEIC ACIDS RES, V19, P5285, DOI 10.1093/nar/19.19.5285; ORKIN SH, 1992, BLOOD, V80, P575; PAWLIK KM, 1995, DEV BIOL, V169, P728, DOI 10.1006/dbio.1995.1182; PETERS LL, 1993, BLOOD, V81, P2144; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; PORCHER C, 1995, J BIOL CHEM, V270, P17368, DOI 10.1074/jbc.270.29.17368; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; Sabatino DE, 1998, MOL CELL BIOL, V18, P6634, DOI 10.1128/MCB.18.11.6634; SAVVIDES P, 1993, BLOOD, V82, P2953; STAMATOYANNOPOU.G, 1993, MOL BASIS BLOOD DISE, P107; STARCK J, 1994, BLOOD, V84, P1656; STOLLE CA, 1988, GENE, V62, P65, DOI 10.1016/0378-1119(88)90580-X; TOWNES TM, 1985, EMBO J, V4, P1715, DOI 10.1002/j.1460-2075.1985.tb03841.x; Vyas P, 1999, DEVELOPMENT, V126, P2799; Zhou DX, 1997, J CELL BIOL, V136, P621, DOI 10.1083/jcb.136.3.621; ZON LI, 1992, NUCLEIC ACIDS RES, V20, P1812, DOI 10.1093/nar/20.7.1812	40	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28549	28554		10.1074/jbc.M004043200	http://dx.doi.org/10.1074/jbc.M004043200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878017	hybrid			2022-12-27	WOS:000089330700030
J	Shiina, T; Kawasaki, A; Nagao, T; Kurose, H				Shiina, T; Kawasaki, A; Nagao, T; Kurose, H			Interaction with beta-arrestin determines the difference in internalization behavior between beta(1)- and beta(2)-adrenergic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; BETA-2-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; BETA(1)-ADRENERGIC RECEPTOR; DESENSITIZATION; SEQUESTRATION; TRAFFICKING; PHOSPHORYLATION; ENDOCYTOSIS; DOMAINS	The beta(1)-adrenergic receptor (beta(1)AR) shows the resistance to agonist-induced internalization. As beta-arrestin is important for internalization, we examine the interaction of beta-arrestin with beta(1)AR with three different methods: intracellular trafficking of beta-arrestin, binding of in vitro translated beta-arrestin to intracellular domains of beta(1)- and beta(2)ARs, and inhibition of beta AR-stimulated adenylyl cyclase activities by beta-arrestin. The green fluorescent protein-tagged beta-arrestin 2 translocates to and stays at the plasma membrane by beta(2)AR stimulation. Although green fluorescent protein-tagged beta-arrestin 2 also translocates to the plasma membrane, it returns to the cytoplasm 10-30 min after beta(1)AR stimulation. The binding of in vitro translated beta-arrestin 1 and beta-arrestin 2 to the third intracellular loop and the carboxyl tail of beta(1)AR is lower than that of beta(2)AR, The fusion protein of beta-arrestin 1 with glutathione S-transferase inhibits the beta(1)- and beta(2)AR-stimulated adenylyl cyclase activities, although inhibition of the beta(1)AR-stimulated activity requires a higher concentration of the fusion protein than that of the beta(1)AR-stimulated activity. These results suggest that weak interaction of beta(1)AR with beta-arrestins explains the resistance to agonist-induced internalization. This is further supported by the finding that beta-arrestin can induce internalization of beta(1)AR when beta-arrestin 1 does not dissociate from beta(1)AR by fusing to the carboxyl tail of beta(1)AR.	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Kurose, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	kurose@mol.f.u-tokyo.ac.jp						Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Bohm SK, 1997, BIOCHEM J, V322, P1; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Furukawa H, 2000, J BIOCHEM-TOKYO, V127, P151, DOI 10.1093/oxfordjournals.jbchem.a022577; GREEN SA, 1994, J BIOL CHEM, V269, P26215; Groarke DA, 1999, J BIOL CHEM, V274, P23263, DOI 10.1074/jbc.274.33.23263; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; Jockers R, 1996, J BIOL CHEM, V271, P9355, DOI 10.1074/jbc.271.16.9355; Krueger KM, 1997, J BIOL CHEM, V272, P5; KUROSE H, 1993, MOL PHARMACOL, V43, P444; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; NANOFF C, 1989, J CARDIOVASC PHARM, V13, P198, DOI 10.1097/00005344-198902000-00004; PARKER EM, 1995, J BIOL CHEM, V270, P6482, DOI 10.1074/jbc.270.12.6482; Rousseau G, 1996, MOL PHARMACOL, V49, P752; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sato Y, 1996, EUR J PHARMACOL, V315, P363, DOI 10.1016/S0014-2999(96)00648-6; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; ZHOU XM, 1991, J BIOL CHEM, V266, P7462; ZHOU XM, 1995, CELL SIGNAL, V7, P207, DOI 10.1016/0898-6568(94)00091-O	32	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29082	29090		10.1074/jbc.M909757199	http://dx.doi.org/10.1074/jbc.M909757199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10862778	hybrid			2022-12-27	WOS:000089330700096
J	Yamaguchi, K; von Knoblauch, K; Subramanian, AR				Yamaguchi, K; von Knoblauch, K; Subramanian, AR			The plastid ribosomal proteins - Identification of all the proteins in the 30 S subunit of an organelle ribosome (chloroplast)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; NUCLEOTIDE-SEQUENCE; AMINO-ACID; BACTERIAL-RIBOSOMES; GENE-EXPRESSION; BINDING-PROTEIN; MESSENGER-RNAS; IN-VIVO; TRANSLATION; TRANSCRIPTION	Identification of all the protein components of a plastid (chloroplast) ribosomal 30 S subunit has been achieved, using two-dimensional gel electropholesis, high performance liquid chromatography purification, N-terminal sequencing, polymerase chain reaction-based screening of cDNA library, nucleotide sequencing, and mass spectrometry (electrospray ionization, matrixassisted laser desorption/ionization time-of-flight, and reversed-phase HPLC coupled with electrospray ionization mass spectrometry), 25 proteins were identified, of which 21 are orthologues of all Escherichia coli 30 S ribosomal proteins (S1-S21), and 4 are plastid-specific ribosomal proteins (PSRPs) that have no homologues in the mitochondrial, archaebacterial, or cytosolic ribosomal protein sequences in data bases. 12 of the 25 plastid 30 S ribosomal proteins (PRPs) are encoded in the plastid genome, whereas the remaining 13 are encoded by the nuclear genome. Post-translational transit peptide cleavage sites for the maturation of the 13 cytosolically synthesized PRPs, and post-translational N-terminal processing in the maturation of the 12 plastid synthesized PRPs are described. Post-translational modifications in several PRPs were observed: alpha-N-acetylation of S9, N-terminal processings leading to five mature forms of S6 and two mature forms of S10, C-terminal and/or internal modifications in S1, 514, S18, and S19, leading to two distinct forms differing in mass and/or charge (the corresponding modifications are not observed in E, coli). The four PSRPs in spinach plastid 30 S ribosomal subunit (PSRP-1, 26.8 kDa, pi 6.2; PSRP-2, 21.7 kDa, pi 5.0; PSRP-3, 13.8 kDa, pI 4.9; PSRP-4, 5.2 kDa, pI 11.8) comprise 16% (67.6 kDa) of the total protein mass of the 30 S subunit (429.3 kDa), PSRP-1 and PSRP-3 show sequence similarities with hypothetical photosynthetic bacterial proteins, indicating their possible origins in photosynthetic bacteria. We propose the hypothesis that PSRPs form a ''plastid translational regulatory module" on the 30 S ribosomal subunit structure for the possible mediation of nuclear factors on plastid translation.	Univ Arizona, Dept Biochem Biosci W, Tucson, AZ 85721 USA; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	University of Arizona; Max Planck Society	Subramanian, AR (corresponding author), Univ Arizona, Dept Biochem Biosci W, Tucson, AZ 85721 USA.							Agalarov SC, 2000, SCIENCE, V288, P107, DOI 10.1126/science.288.5463.107; Arnold RJ, 1999, ANAL BIOCHEM, V269, P105, DOI 10.1006/abio.1998.3077; BARKAN A, 1993, PLANT CELL, V5, P389, DOI 10.1105/tpc.5.4.389; BARTSCH M, 1985, J BIOL CHEM, V260, P237; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; BUBUNENKO MG, 1994, J BIOL CHEM, V269, P18223; Clemons WM, 1999, NATURE, V400, P833, DOI 10.1038/23631; CUMBERLIDGE AG, 1979, J MOL BIOL, V25, P169; FRANZETTI B, 1992, J BIOL CHEM, V267, P19075; FRANZETTI B, 1992, NUCLEIC ACIDS RES, V20, P4153, DOI 10.1093/nar/20.16.4153; FROMM H, 1985, EMBO J, V4, P291, DOI 10.1002/j.1460-2075.1985.tb03628.x; *GEN COMP GROUP, 1998, WISC PACK VERS 10 0; GIESE K, 1989, BIOCHEMISTRY-US, V28, P3525, DOI 10.1021/bi00434a056; Graack HR, 1998, BIOCHEM J, V329, P433, DOI 10.1042/bj3290433; HARDY SJS, 1969, BIOCHEMISTRY-US, V8, P2897, DOI 10.1021/bi00835a031; HARRIS EH, 1994, MICROBIOL REV, V58, P700, DOI 10.1128/MMBR.58.4.700-754.1994; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HITZ H, 1977, EUR J BIOCHEM, V75, P497, DOI 10.1111/j.1432-1033.1977.tb11551.x; JOHNSON CH, 1990, J BIOL CHEM, V265, P12790; KAMP RM, 1983, H-S Z PHYSIOL CHEM, V364, P1777, DOI 10.1515/bchm2.1983.364.2.1777; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI K, 1975, ANAL BIOCHEM, V64, P121, DOI 10.1016/0003-2697(75)90413-3; LINDAHL M, 1994, EMBO J, V13, P1249, DOI 10.1002/j.1460-2075.1994.tb06376.x; MALONE P, 1988, J CELL BIOL, V106, P609; Mueller F, 1997, J MOL BIOL, V271, P545, DOI 10.1006/jmbi.1997.1211; Nakamura T, 1999, FEBS LETT, V460, P437, DOI 10.1016/S0014-5793(99)01390-3; Planta RJ, 1998, YEAST, V14, P471, DOI 10.1002/(SICI)1097-0061(19980330)14:5<471::AID-YEA241>3.0.CO;2-U; Price CA, 1996, PLANT MOL BIOL, V30, P225, DOI 10.1007/BF00020109; Richter S, 1998, P NATL ACAD SCI USA, V95, P7463, DOI 10.1073/pnas.95.13.7463; Rochaix JD, 1996, PLANT MOL BIOL, V32, P327, DOI 10.1007/BF00039389; SCHMIDT J, 1992, PLANT MOL BIOL, V20, P459, DOI 10.1007/BF00040605; SCHMIDT J, 1993, BIOCHEM MOL BIOL INT, V29, P25; SCHUSTER G, 1991, EMBO J, V10, P1493, DOI 10.1002/j.1460-2075.1991.tb07669.x; Sorensen MA, 1998, J MOL BIOL, V280, P561, DOI 10.1006/jmbi.1998.1909; Stern DB, 1997, TRENDS PLANT SCI, V2, P308, DOI 10.1016/S1360-1385(97)89953-0; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; SUBRAMANIAN AR, 1974, EUR J BIOCHEM, V45, P541, DOI 10.1111/j.1432-1033.1974.tb03579.x; SUBRAMANIAN AR, 1993, TRENDS BIOCHEM SCI, V18, P177, DOI 10.1016/0968-0004(93)90110-9; SUBRAMANIAN AR, 1990, MOL BIOL PLASTIDS, P191; Sugiura M, 1998, ANNU REV GENET, V32, P437, DOI 10.1146/annurev.genet.32.1.437; TAN XL, 1994, J BIOL CHEM, V269, P20905; WALSH MJ, 1988, BIOCHEMISTRY-US, V27, P6867, DOI 10.1021/bi00418a032; WEGLOHNER W, 1991, FEBS LETT, V279, P193, DOI 10.1016/0014-5793(91)80147-U; Weglohner W, 1995, BIOCHEM MOL BIOL INT, V36, P265; Weglohner W, 1997, EUR J BIOCHEM, V249, P383, DOI 10.1111/j.1432-1033.1997.00383.x; WELLNER D, 1990, P NATL ACAD SCI USA, V87, P1947, DOI 10.1073/pnas.87.5.1947; WITTMANN HG, 1982, ANNU REV BIOCHEM, V51, P155, DOI 10.1146/annurev.bi.51.070182.001103; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101; Yamaguchi K, 2000, J BIOL CHEM, V275, P28466, DOI 10.1074/jbc.M005012200; Yohn CB, 1998, P NATL ACAD SCI USA, V95, P2238, DOI 10.1073/pnas.95.5.2238; ZHOU DX, 1989, MOL GEN GENET, V219, P204, DOI 10.1007/BF00261178	52	152	188	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28455	28465		10.1074/jbc.M004350200	http://dx.doi.org/10.1074/jbc.M004350200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10874039	hybrid			2022-12-27	WOS:000089330700018
J	Fontaine, T; Simenel, C; Dubreucq, G; Adam, O; Delepierre, M; Lemoine, J; Vorgias, CE; Diaquin, M; Latge, JP				Fontaine, T; Simenel, C; Dubreucq, G; Adam, O; Delepierre, M; Lemoine, J; Vorgias, CE; Diaquin, M; Latge, JP			Molecular organization of the alkali-insoluble fraction of Aspergillus fumigatus cell wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAS-LIQUID-CHROMATOGRAPHY; PH-REGULATED GENE; SACCHAROMYCES-CEREVISIAE; CANDIDA-ALBICANS; 1,3-BETA-D-GLUCAN SYNTHASE; MASS-SPECTROMETRY; BETA-GLUCAN; GLYCOPROTEIN GLYCANS; METHYL GLYCOSIDES; BGL2 GENE	Physical and biological properties of the fungal cell wall are determined by the composition and arrangement of the structural polysaccharides. Cell wall polymers of fungi are classically divided into two groups depending on their solubility in hot alkali. We have analyaed the alkali-insoluble fraction of the Aspergillus fumigatus cell wall, which is the fraction believed to be responsible for fungal cell wall rigidity. Using enzymatic digestions with recombinant endo-beta-1,3-glucanase and chitinase, fractionation by gel filtration, affinity chromatography with immobilized lectins, and high performance liquid chromatography, Several fractions that contained specific interpolysaccharide covalent linkages were isolated. Unique features of the A. fumigatus cell wall are (i) the absence of beta-1,6-glucan and (ii) the presence of a linear beta-1,3/1,4-glucan, never previously described in fungi. Galactomannan, chitin, and beta-1,3-glucan were also found in the alkali-insoluble fraction. The beta-1,3-glucan is a branched polymer with 4% of beta-1,6 branch points. Chitin, galactomannan, and the Linear beta-1,3/1,4-glucan were covalently linked to the nonreducing end of beta-1,3-glucan side chains. As in Saccharomyces cerevisiae, chitin was linked via a beta-1,4 linkage to beta-1,3-glucan. The data obtained suggested that the branching of beta-1,3-glucan is an early event in the construction of the cell wall, resulting in an increase of potential acceptor sites for chitin, galactomannan, and the linear beta-1,3/1,4-glucan.	Inst Pasteur, Lab Aspergillus, F-75724 Paris 15, France; Inst Pasteur, Lab Resonance Magnet Nucl, F-75724 Paris 15, France; Univ Sci & Tech Lille Flandres Artois, Chim Biol Lab, F-59655 Villeneuve Dascq, France; Univ Athens, Dept Biol, Div Biochem & Mol Biol, GR-15701 Athens, Greece	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Lille - ISITE; Universite de Lille; National & Kapodistrian University of Athens	Fontaine, T (corresponding author), Inst Pasteur, Lab Aspergillus, 25 Rue Dr Roux, F-75724 Paris 15, France.	tfontain@pasteur.fr	Fontaine, thierry/Q-2201-2018; lemoine, jerome/C-4272-2014; Fontaine, Thierry/F-8227-2011; latge, jean paul/F-3581-2011; Latge, Jean Paul/C-9846-2014	Fontaine, thierry/0000-0002-8184-789X; lemoine, jerome/0000-0002-5497-6880; 				ARAKI Y, 1979, EUR J BIOCHEM, V102, P35, DOI 10.1111/j.1432-1033.1979.tb06260.x; ARONSON JM, 1981, BIOL CONIDIAL FUNGI, V2, P459; AufauvreBrown A, 1997, FUNGAL GENET BIOL, V21, P141, DOI 10.1006/fgbi.1997.0959; BARRETOBERGTER E, 1981, CARBOHYD RES, V95, P205, DOI 10.1016/S0008-6215(00)85577-9; BARTNICK.S, 1968, ANNU REV MICROBIOL, V22, P87, DOI 10.1146/annurev.mi.22.100168.000511; BEAUVAIS A, 1993, J GEN MICROBIOL, V139, P3071, DOI 10.1099/00221287-139-12-3071; BJORNDAL H, 1970, ANGEW CHEM INT EDIT, V9, P610, DOI 10.1002/anie.197006101; BOYD J, 1985, CARBOHYD RES, V139, P35; BULIGA GS, 1986, CARBOHYD RES, V157, P139, DOI 10.1016/0008-6215(86)85065-0; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; Delay C, 1997, CARBOHYD RES, V302, P67, DOI 10.1016/S0008-6215(97)00101-8; DESVAUX H, 1994, J MAGN RESON SER A, V108, P219, DOI 10.1006/jmra.1994.1114; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Ferguson M. A. J., 1993, GLYCOBIOLOGY, P349; Fleet G.H., 1991, YEASTS, VVol. 4, P199, DOI [10.1002/jobm.19720120411, DOI 10.1002/JOBM.19720120411]; Fontaine T, 1997, EUR J BIOCHEM, V243, P315, DOI 10.1111/j.1432-1033.1997.0315a.x; FONTAINE T, 1991, ANAL BIOCHEM, V199, P154, DOI 10.1016/0003-2697(91)90083-6; FOURNET B, 1981, ANAL BIOCHEM, V116, P489, DOI 10.1016/0003-2697(81)90393-6; Fujii T, 1999, BBA-GEN SUBJECTS, V1427, P133, DOI 10.1016/S0304-4165(99)00012-4; GOLDMAN RC, 1995, EUR J BIOCHEM, V227, P372, DOI 10.1111/j.1432-1033.1995.tb20399.x; GOLDSTEIN I. J., 1965, METHOD CARBOHYD CHEM, V5, P361; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HARTLAND RP, 1991, P ROY SOC B-BIOL SCI, V246, P155, DOI 10.1098/rspb.1991.0138; HARTLAND RP, 1994, YEAST, V10, P1591, DOI 10.1002/yea.320101208; Hartland RP, 1996, J BIOL CHEM, V271, P26843, DOI 10.1074/jbc.271.43.26843; HEARN VM, 1994, MICROBIOL-UK, V140, P789, DOI 10.1099/00221287-140-4-789; JOHNSON AR, 1971, ANAL BIOCHEM, V44, P628, DOI 10.1016/0003-2697(71)90252-1; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KAPTEYN JC, 1994, EUR J CELL BIOL, V65, P402; Kapteyn JC, 1996, GLYCOBIOLOGY, V6, P337, DOI 10.1093/glycob/6.3.337; KLEBL F, 1989, J BACTERIOL, V171, P6259, DOI 10.1128/jb.171.11.6259-6264.1989; KOLLAR R, 1995, J BIOL CHEM, V270, P1170, DOI 10.1074/jbc.270.3.1170; Kollar R, 1997, J BIOL CHEM, V272, P17762, DOI 10.1074/jbc.272.28.17762; LATGE JP, 1994, INFECT IMMUN, V62, P5424; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MANNERS DJ, 1973, BIOCHEM J, V135, P19, DOI 10.1042/bj1350019; Mazur P, 1996, J BIOL CHEM, V271, P14604, DOI 10.1074/jbc.271.24.14604; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MELLADO E, 1995, MOL GEN GENET, V246, P353, DOI 10.1007/BF00288608; MOL PC, 1987, FEMS MICROBIOL LETT, V41, P95; MONTIJN RC, 1994, J BIOL CHEM, V269, P19338; Mouyna I, 1998, MICROBIOL-SGM, V144, P3171, DOI 10.1099/00221287-144-11-3171; MSRA V, 1997, YEAST, V13, P1145; Muhlschlegel FA, 1997, MOL CELL BIOL, V17, P5960; Nakazawa T, 1998, J BACTERIOL, V180, P2079, DOI 10.1128/JB.180.8.2079-2086.1998; PARENTE JP, 1985, CARBOHYD RES, V141, P41, DOI 10.1016/S0008-6215(00)90753-5; PARRISH FW, 1960, CAN J CHEM, V38, P2094, DOI 10.1139/v60-284; PERLIN AS, 1962, CAN J CHEM, V40, P50, DOI 10.1139/v62-009; Popolo L, 1999, BBA-GEN SUBJECTS, V1426, P385, DOI 10.1016/S0304-4165(98)00138-X; POPOLO L, 1993, J BACTERIOL, V175, P1879, DOI 10.1128/JB.175.7.1879-1885.1993; QODATA H, 1996, SCIENCE, V272, P279; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; SAPORITOIRWIN SM, 1995, MOL CELL BIOL, V15, P601; Sarthy AV, 1997, MICROBIOL-SGM, V143, P367, DOI 10.1099/00221287-143-2-367; SAWARDEKER JS, 1965, ANAL CHEM, V37, P1602, DOI 10.1021/ac60231a048; SHEMATEK EM, 1980, J BIOL CHEM, V255, P888; SIETSMA JH, 1979, J GEN MICROBIOL, V114, P99, DOI 10.1099/00221287-114-1-99; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; TAKADA H, 1981, J BIOCHEM-TOKYO, V89, P1265; VANDERVAART JM, 1995, J BACTERIOL, V177, P3104, DOI 10.1128/jb.177.11.3104-3110.1995; VORGIAS CE, 1993, CHITIN ENZYMOLOGY, P417; Vossen JH, 1997, J BACTERIOL, V179, P2202, DOI 10.1128/jb.179.7.2202-2209.1997; WAGNER G, 1983, J MAGN RESON, V55, P151, DOI 10.1016/0022-2364(83)90284-6; WILLKER W, 1993, MAGN RESON CHEM, V31, P287, DOI 10.1002/mrc.1260310315; YU LP, 1993, J BIOMOL NMR, V3, P429	68	255	275	1	35	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27594	27607						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869365				2022-12-27	WOS:000089197100012
J	Tanimura, A; Tojyo, Y; Turner, RJ				Tanimura, A; Tojyo, Y; Turner, RJ			Evidence that type I, II, and III inositol 1,4,5-trisphosphate receptors can occur as integral plasma membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; OPERATED HTRP3 CHANNELS; IP3 RECEPTOR; CARCINOMA-CELLS; RAT-LIVER; LOCALIZATION; ACTIVATION; IDENTIFICATION; RETICULUM; NEURONS	A number of previous reports have suggested that inositol 1,4,5-trisphosphate receptors (IP(3)Rs) are present in the plasma membranes of cells. We confirm this directly in the present study by demonstrating that a significant proportion of the IP,Rs found in A431 cells, Jurkat cells, and rat parotid acini can be biotinylated by the extracellular application of sulfo-N-hydroxysuccinimide-biotin to intact cells. This labeling cannot be accounted for by the reaction of sulfo-N-hydroxysuccinimide-biotin with intracellular IP(3)Rs since calnexin and the SERCA2 ATPase, both integral membrane proteins of the endoplasmic reticulum, are not labeled under the same experimental conditions. individual IP3R subtypes were detected using subtype-specific antibodies. A431 cells expressed only the type-3 IP3R, and 23% of this protein was in the biotinylated (plasma membrane) fraction. Jurkat cells and rat parotid cells expressed all three IP3R subtypes. Contrary to earlier results suggesting that only the type-3 IP3R might localize to the plasma membrane, we found that significant amounts (5-14%) of all three subtypes could be identified in the biotinylated fractions of Jurkat and rat parotid cells. Our results suggest a role for IP,Rs in plasma membrane as well as intracellular membrane function.	Hlth Sci Univ Hokkaido, Sch Dent, Dept Dent Pharmacol, Ishikari, Hokkaido 0610293, Japan; NIDCR, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA	Health Sciences University of Hokkaido; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Tanimura, A (corresponding author), Hlth Sci Univ Hokkaido, Sch Dent, Dept Dent Pharmacol, Ishikari, Hokkaido 0610293, Japan.	tanimura@hoku-iryo-u.ac.jp			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000415, ZIADE000415] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; DeLisle S, 1996, AM J PHYSIOL-CELL PH, V270, pC1255; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FADOOL DA, 1994, P NATL ACAD SCI USA, V91, P9471, DOI 10.1073/pnas.91.20.9471; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; HURLEY WL, 1985, J IMMUNOL METHODS, V85, P195, DOI 10.1016/0022-1759(85)90287-X; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kiselyov KI, 1997, FEBS LETT, V407, P309, DOI 10.1016/S0014-5793(97)00366-9; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LIEVREMONT JP, 1994, BIOCHEM J, V300, P419, DOI 10.1042/bj3000419; Lischka FW, 1999, BIOPHYS J, V76, P1410, DOI 10.1016/S0006-3495(99)77302-9; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; MOZHAYEVA GN, 1990, FEBS LETT, V277, P233, DOI 10.1016/0014-5793(90)80853-B; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SHARP AH, 1992, J BIOL CHEM, V267, P7444; TANIMURA A, 1990, BIOCHIM BIOPHYS ACTA, V1055, P273, DOI 10.1016/0167-4889(90)90043-D; TJOELKER LW, 1994, BIOCHEMISTRY-US, V33, P3229, DOI 10.1021/bi00177a013; Ueda H, 2000, MOL PHARMACOL, V57, P108; Ueda H, 1996, J NEUROSCI, V16, P2891; VACA L, 1995, AM J PHYSIOL-CELL PH, V269, pC733, DOI 10.1152/ajpcell.1995.269.3.C733; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5	32	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27488	27493						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10874040				2022-12-27	WOS:000089144800108
J	Tulk, BM; Schlesinger, PH; Kapadia, SA; Edwards, JC				Tulk, BM; Schlesinger, PH; Kapadia, SA; Edwards, JC			CLIC-1 functions as a chloride channel when expressed and purified from bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; SUBCELLULAR-DISTRIBUTION; CYSTIC-FIBROSIS; PROTEIN; P64; PURIFICATION; EPITHELIA; KIDNEY	CLIC-1 is a member of a family of proteins related to the bovine intracellular chloride channel p64 which has been proposed to function as a chloride channel. We expressed CLIC-1 as a glutathione S-transferase fusion protein in bacteria. The fusion protein was purified by glutathione affinity, and CLIC-1 was released from its fusion partner by digestion with thrombin. After further purification, CLIC-1 was reconstituted into phospholipid vesicles by detergent dialysis. Chloride permeability of reconstituted vesicles was assessed using a valinomycin dependent chloride efflux assay, demonstrating increased vesicular chloride permeability with CLIC-1 compared with control. CLIC-1-dependent chloride permeability was inhibited by indanyloxyacetic acid-94 with an apparent IC50 of 8.6 mu M. The single channel properties of CLIC-1 were determined using the planar lipid bilayer technique. We found that CLIC-1 forms a voltage-dependent, Cl-selective channel with a rectifying current-voltage relationship and single channel conductances of 161 +/- 7.9 and 67.5 +/- 6.9 picosiemens in symmetric 300 and 150 mM KCI, respectively. The anion selectivity of this activity is Pr approximate to Cl > I. The open probability of CLIC-1 channels in planar bilayers was decreased by indanyloxyacetic acid-94 with an apparent IC50 of 86 mu M at 50 mV. These data convincingly demonstrate that CLIC-1 is capable of forming a novel, chloride-selective channel in the absence of other subunits or proteins.	St Louis VA Med Ctr, Renal Div 657111JC, St Louis, MO 63106 USA; St Louis Univ, Dept Internal Med, St Louis, MO 63106 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63106 USA	Saint Louis University; Washington University (WUSTL)	Edwards, JC (corresponding author), St Louis VA Med Ctr, Renal Div 657111JC, 915 N Grand Blvd, St Louis, MO 63106 USA.		Schlesinger, Paul H/C-6049-2012		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046212] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR44838] Funding Source: Medline; NIDDK NIH HHS [R29 DK46212] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1995, CURR OPIN CELL BIOL, V7, P504, DOI 10.1016/0955-0674(95)80006-9; ARMITAGE P, 1971, STATISTICAL METHODS, P189; Chuang JZ, 1999, J NEUROSCI, V19, P2919; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; Colombini M., 1986, ION CHANNEL RECONSTI, P533; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Edwards JC, 1998, J MEMBRANE BIOL, V163, P119; Edwards JC, 1999, AM J PHYSIOL-RENAL, V276, pF398, DOI 10.1152/ajprenal.1999.276.3.F398; FRENCH RJ, 1986, ION CHANNEL RECONSTI, P363; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARLOW E, 1988, ANTIBODIES LABORATOR, P635; Heiss NS, 1997, GENOMICS, V45, P224, DOI 10.1006/geno.1997.4922; HILLE B, 1992, ION CHANNELS EXCITAB, P183; Hosie AM, 1997, TRENDS NEUROSCI, V20, P578, DOI 10.1016/S0166-2236(97)01127-2; JENTSCH TJ, 1994, CURR OPIN CELL BIOL, V6, P600, DOI 10.1016/0955-0674(94)90082-5; Jentsch TJ, 1997, BIOESSAYS, V19, P117, DOI 10.1002/bies.950190206; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482, P19; LANDRY D, 1993, J BIOL CHEM, V268, P14948; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LANDRY DW, 1987, J GEN PHYSIOL, V90, P779, DOI 10.1085/jgp.90.6.779; LEHNINGER AL, 1976, BIOCHEMISTRY; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; Nishizawa T, 2000, J BIOL CHEM, V275, P11164, DOI 10.1074/jbc.275.15.11164; PRESTON CL, 1992, AM J PHYSIOL, V263, pC879, DOI 10.1152/ajpcell.1992.263.4.C879; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; Redhead C, 1997, MOL BIOL CELL, V8, P691, DOI 10.1091/mbc.8.4.691; Sambrook J., 2002, MOL CLONING LAB MANU; Schlesinger PH, 1997, J BIOL CHEM, V272, P18636, DOI 10.1074/jbc.272.30.18636; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Seibert FS, 1997, J BIOENERG BIOMEMBR, V29, P429, DOI 10.1023/A:1022478822214; TILMANN M, 1991, PFLUG ARCH EUR J PHY, V418, P556, DOI 10.1007/BF00370571; TULK BM, 1998, AM J PHYSIOL, V274, pF1140; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; WELSH MJ, 1989, J CLIN INVEST, V84, P2002, DOI 10.1172/JCI114391	34	82	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26986	26993						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10874038				2022-12-27	WOS:000089144800043
J	Smyth, EM; Austin, SC; Reilly, MP; FitzGeralds, GA				Smyth, EM; Austin, SC; Reilly, MP; FitzGeralds, GA			Internalization and sequestration of the human prostacyclin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; PROTEIN-KINASE-C; ANGIOTENSIN-II RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; BETA-ARRESTIN; PULMONARY-HYPERTENSION; PLATELET ACTIVATION; COUPLED RECEPTORS; PHOSPHORYLATION; DESENSITIZATION	Prostacyclin (PGI(2)), the major product of cyolooxygenase in macrovascular endothelium, mediates its biological effects through its cell surface G protein-coupled receptor, the IF. PKC-mediated phosphorylation of human (h) IP is a critical determinant of agonist-induced desensitization (Smyth, E. M., Hong Li, W., and FitzGerald, G. A. (1998) J. Biol. Chem. 273, 23258-23266). The regulatory events that follow desensitization are unclear. We have examined agonist-induced sequestration of hIP. Human IF, tagged at the N terminus with hemagglutinin (HA) and fused at the C terminus to the green fluorescent protein (GFP), was coupled to increased cAMP (EC50 = 0.39 +/- 0.09 nM) and inositol phosphate (EC50 = 86.6 +/- 18.3 nM) generation when overexpressed in HEK 293 cells. Iloprost-induced Sequestration of HA-hIP-GFP, followed in real time by confocal microscopy, was partially colocalized to clathrin-coated vesicles. Iloprost induced a time- and concentration-dependent loss of cell surface HA, indicating receptor internalization, which was prevented by inhibitors of clathrin-mediated trafficking and partially reduced by cotransfection of cells with a dynamin dominant negative mutant. Sequestration (EC50 = 27.6 +/- 5.7 nM) was evident at those concentrations of iloprost that induce PKC-dependent desensitization. Neither the PKC inhibitor GF109203X nor mutation of Ser-328, the site for PKC phosphorylation, altered receptor sequestration indicating that, unlike desensitization, internalization is PKC-independent. Deletion of the C terminus prevented iloprost-induced internalization, demonstrating the critical nature of this region for sequestration. Internalization was unaltered by cotransfection of cells with G;protein-coupled receptor kinases (GRK)-2, -3, -5, -6, arrestin-2, or an arrestin-2 dominant negative mutant, indicating that GRKs and arrestins do not play a role in hIP trafficking. The hip is sequestered in response to agonist activation via a PKC-independent pathway that is distinct from desensitization. Trafficking is dependent on determinants located in the C terminus, is GRK/arrestin-independent, and proceeds in part via a dynamin-dependent clathrin-coated vesicular endocytotic pathway although other dynamin-independent pathways may also be involved.	Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA	University of Pennsylvania	FitzGeralds, GA (corresponding author), Univ Penn, Ctr Expt Therapeut, 153 Johnson Pavil,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	garret@spirit.gcrc.upenn.edu		Reilly, Muredach/0000-0002-3035-9386	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057847, P01HL062250] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-57847, HL-62250] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Archer SL, 1996, CHEST, V109, P750, DOI 10.1378/chest.109.3.750; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BOIE Y, 1994, J BIOL CHEM, V269, P12173; Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FITZGERALD DJ, 1986, J CLIN INVEST, V77, P496, DOI 10.1172/JCI112329; FITZGERALD GA, 1984, NEW ENGL J MED, V310, P1065, DOI 10.1056/NEJM198404263101701; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Fukushima Y, 1997, J BIOL CHEM, V272, P19464, DOI 10.1074/jbc.272.31.19464; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Geraci MW, 1999, J CLIN INVEST, V103, P1509, DOI 10.1172/JCI5911; Giovanazzi S, 1997, BIOCHEM J, V325, P71, DOI 10.1042/bj3250071; Go WY, 1998, AM J PHYSIOL-GASTR L, V275, pG56, DOI 10.1152/ajpgi.1998.275.1.G56; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GOODMAN RP, 1982, AM J OBSTET GYNECOL, V142, P817, DOI 10.1016/S0002-9378(16)32525-X; Haga K, 1996, J BIOL CHEM, V271, P2776, DOI 10.1074/jbc.271.5.2776; Herschman HR, 1998, TRENDS CARDIOVAS MED, V8, P145, DOI 10.1016/S1050-1738(98)00004-8; ISHII K, 1994, J BIOL CHEM, V269, P1125; Iwai N, 1999, CIRCULATION, V100, P2231, DOI 10.1161/01.CIR.100.22.2231; Kallal L, 2000, TRENDS PHARMACOL SCI, V21, P175, DOI 10.1016/S0165-6147(00)01477-2; KRANE A, 1994, BIOCHEM PHARMACOL, V47, P953, DOI 10.1016/0006-2952(94)90405-7; Krueger KM, 1997, J BIOL CHEM, V272, P5; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; MATSUMURA K, 1995, NEUROSCIENCE, V65, P493, DOI 10.1016/0306-4522(94)00505-Y; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; McLaughlin VV, 1998, NEW ENGL J MED, V338, P273, DOI 10.1056/NEJM199801293380501; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MONCADA S, 1981, CLIN SCI, V61, P369, DOI 10.1042/cs0610369; MOORE RH, 1995, J CELL SCI, V108, P2983; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; NAMBA T, 1994, J BIOL CHEM, V269, P9986; Neuschafer-Rube F, 1999, MOL PHARMACOL, V56, P419, DOI 10.1124/mol.56.2.419; OATES JA, 1988, NEW ENGL J MED, V319, P689, DOI 10.1056/NEJM198809153191106; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Schonbeck U, 1999, AM J PATHOL, V155, P1281, DOI 10.1016/S0002-9440(10)65230-3; Siegle I, 2000, J HISTOCHEM CYTOCHEM, V48, P631, DOI 10.1177/002215540004800507; Smyth EM, 1996, J BIOL CHEM, V271, P33698, DOI 10.1074/jbc.271.52.33698; Smyth EM, 1998, J BIOL CHEM, V273, P23258, DOI 10.1074/jbc.273.36.23258; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; Todaka T, 1999, STROKE, V30, P419, DOI 10.1161/01.STR.30.2.419; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; VANE JR, 1995, AM J CARDIOL, V75, pA3, DOI 10.1016/S0002-9149(99)80377-4; VANE JR, 1969, BRIT J PHARMACOL, V35, P209, DOI 10.1111/j.1476-5381.1969.tb07982.x; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; ZHAO J, 1999, BIOCHEM BIOPH RES CO, V238, P71; Zucker TP, 1998, EUR J PHARMACOL, V345, P213, DOI 10.1016/S0014-2999(98)00022-3	59	68	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32037	32045		10.1074/jbc.M003873200	http://dx.doi.org/10.1074/jbc.M003873200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10889200	hybrid			2022-12-27	WOS:000089858900067
J	Jin, YH; Yoo, KJ; Lee, YH; Lee, SK				Jin, YH; Yoo, KJ; Lee, YH; Lee, SK			Caspase 3-mediated cleavage of p21(WAF1/CIP1) associated with the cyclin A-cyclin-dependent kinase 2 complex is a prerequisite for apoptosis in SK-HEP-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLORECTAL-CARCINOMA CELLS; ACTIVATION; P21(CIP1/WAF1); P27(KIP1); DEATH; CDK2	Apoptosis of SK-HEP-1 human hepatoma cells induced by treatment with ginsenoside Rh2 (G-Rh2) is associated with rapid and selective activation of cyclin A-associated cyclin-dependent kinase 2 (Cdk2). Here, we show that in apoptotic cells, the Cdk inhibitory protein p21(WAF1/CIP1), which is associated with the cyclin A-Cdk2 complex, undergoes selective proteolytic cleavage. In contrast, another Cdk inhibitory protein, p27(KIP1), which is associated with cyclin A-Cdk2 and cyclin E-Cdk2 complexes, remained unaltered during apoptosis, Ectopic overexpression of p21(WAF1/CIP1) suppressed apoptosis as well as cyclin A-Cdk2 activity induced by treatment of SK-HEP-1 cells with G-Rh2. The suppressive effects of p21(WAF1/CIP1) were much higher in the cells transfected with p21D112N, an expression vector that encodes a p21(WAF1/CIP1) mutant resistant to caspase 3 cleavage. Overexpression of cyclin A in SK-HEP-1 cells dramatically up-regulated cyclin A-Cdk2 activity and accordingly enhances apoptosis induced by treatment with G-Rh2. These up-regulating effects were blocked by coexpression of a dominant negative allele of cdk2. Furthermore, olomoucine, a specific inhibitor of Cdks, also blocked G-Rh2-induced apoptosis. These data suggest that the induction of apoptosis in human hepatoma cells treated with G-Rh2 occurs by a mechanism that involves the activation of cyclin A-Cdk2 by caspase 3-mediated cleavage of p21(WAF1/CIP1).	Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; Korea Ginseng & Tobacco Res Inst, Taejon 305345, South Korea	Seoul National University (SNU)	Lee, SK (corresponding author), Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea.		jin, yun/GQZ-6618-2022					CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Lee KY, 1996, CANCER LETT, V110, P193, DOI 10.1016/S0304-3835(96)04502-8; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; OTTA T, 1997, LIFE SCI, V60, pPL39; Park JA, 1997, CANCER LETT, V121, P73, DOI 10.1016/S0304-3835(97)00333-9; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Shi LF, 1996, J IMMUNOL, V157, P2381; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785	17	132	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30256	30263		10.1074/jbc.M001902200	http://dx.doi.org/10.1074/jbc.M001902200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10884382	hybrid			2022-12-27	WOS:000089577900048
J	Kratzmeier, M; Albig, W; Hanecke, K; Doenecke, D				Kratzmeier, M; Albig, W; Hanecke, K; Doenecke, D			Rapid dephosphorylation of H1 histones after apoptosis induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-ACTIVATED DNASE; PROTEIN-KINASE-C; PHOSPHORYLATION SITES; CAPILLARY ELECTROPHORESIS; PHORBOL ESTER; HL60 CELLS; EXPRESSION; PHOSPHATASE; SEPARATION; CHROMATIN	H1 histones are involved in the formation of higher order chromatin structures and in the modulation of gene expression. Changes in chromatin structure are a characteristic initial feature of apoptosis. We therefore have investigated the histone H1 pattern of the human leukemic cell line HL60 undergoing programmed cell death, as induced by topoisomerase I inhibition. Histone H1 proteins were isolated and analyzed by high performance liquid chromatography and capillary zone electrophoresis. DNA fragmentation after apoptosis induction was monitored by agarose gel electrophoresis. The patterns of the three H1 histone subtypes extractable from apoptotic HL60 cells significantly differed from those of control cells in showing a decrease of phosphorylated H1 subtypes and an increase of the respective dephosphorylated forms. This dephosphorylation of H1 histones could be observed already 45 min after apoptosis induction and preceded internucleosomal DNA cleavage by approximately 2 h. We conclude that during apoptotic DNA fragmentation, the H1 histones become rapidly dephosphorylated by a yet unknown protein phosphatase.	Univ Gottingen, Inst Biochem & Mol Cell Biol, D-37073 Gottingen, Germany	University of Gottingen	Doenecke, D (corresponding author), Univ Gottingen, Inst Biochem & Mol Cell Biol, Humboldtallee 23, D-37073 Gottingen, Germany.	ddoenec@gwdg.de						AIBIG W, 1998, FEBS LETT, V435, P245; Ajiro K, 2000, J BIOL CHEM, V275, P439, DOI 10.1074/jbc.275.1.439; ALLAN J, 1986, J MOL BIOL, V187, P591, DOI 10.1016/0022-2836(86)90337-2; Bamford M, 2000, EXP CELL RES, V256, P1, DOI 10.1006/excr.2000.4837; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; DAWSON JF, 1994, ANAL BIOCHEM, V220, P340, DOI 10.1006/abio.1994.1347; DOENECKE D, 1994, J CELL BIOCHEM, V54, P423, DOI 10.1002/jcb.240540409; DRABENT B, 1993, BIOCHIM BIOPHYS ACTA, V1216, P311, DOI 10.1016/0167-4781(93)90162-7; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Finucane DM, 1999, EXP CELL RES, V251, P166, DOI 10.1006/excr.1999.4527; Gamble TN, 1999, ANAL CHEM, V71, P3469, DOI 10.1021/ac990276t; Guo CY, 1999, J BIOL CHEM, V274, P18715, DOI 10.1074/jbc.274.26.18715; HUANG HC, 1985, FEBS LETT, V183, P270, DOI 10.1016/0014-5793(85)80791-2; JERZMANOWSKI A, 1992, J BIOL CHEM, V267, P8514; Kaneko YS, 1999, LIFE SCI, V65, P2251, DOI 10.1016/S0024-3205(99)00490-7; Kantarjian H, 1999, SEMIN HEMATOL, V36, P16; Kratzmeier M, 1999, BIOCHEM J, V337, P319, DOI 10.1042/0264-6021:3370319; LINDNER H, 1992, J CHROMATOGR, V608, P211, DOI 10.1016/0021-9673(92)87126-S; LINDNER H, 1995, ELECTROPHORESIS, V16, P604, DOI 10.1002/elps.1150160197; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Masuda Y, 1997, INT J CANCER, V71, P691, DOI 10.1002/(SICI)1097-0215(19970516)71:4<691::AID-IJC29>3.0.CO;2-D; Meergans T, 1997, DNA CELL BIOL, V16, P1041, DOI 10.1089/dna.1997.16.1041; Mills JC, 1998, J CELL SCI, V111, P625; Mizzen CA, 1999, J BIOL CHEM, V274, P14533, DOI 10.1074/jbc.274.21.14533; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OLINS DE, 1978, AM SCI, V66, P704; Paulson JR, 1996, J CELL SCI, V109, P1437; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schmitt CA, 1999, J PATHOL, V187, P127; SOLA MM, 1991, BIOCHIM BIOPHYS ACTA, V1094, P211, DOI 10.1016/0167-4889(91)90011-L; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Swank RA, 1997, BIOCHEMISTRY-US, V36, P13761, DOI 10.1021/bi9714363; Talasz H, 1998, J BIOL CHEM, V273, P32236, DOI 10.1074/jbc.273.48.32236; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; Wei J, 1998, ELECTROPHORESIS, V19, P2356, DOI 10.1002/elps.1150191316; Widlak P, 2000, J BIOL CHEM, V275, P8226, DOI 10.1074/jbc.275.11.8226; Wolffe A. P., 1999, CHROMATIN STRUCTURE; Wolffe AP, 1997, INT J BIOCHEM CELL B, V29, P1463, DOI 10.1016/S1357-2725(97)00026-5; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zhu WH, 1996, BIOCHEM PHARMACOL, V51, P1229	45	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30478	30486		10.1074/jbc.M003956200	http://dx.doi.org/10.1074/jbc.M003956200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10874037	hybrid			2022-12-27	WOS:000089577900077
J	von der Haar, T; Ball, PD; McCarthy, JEG				von der Haar, T; Ball, PD; McCarthy, JEG			Stabilization of eukaryotic initiation factor 4E binding to the mRNA 5 '-cap by domains of eIF4G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSLATION INITIATION; MESSENGER-RNA 5'-CAP; FACTOR 4G EIF4G; FACTOR EIF-4E; CAP-AFFINITY; PROTEIN; YEAST; ANALOGS; SUBUNITS; P20	The eukaryotic cap-binding complex eIF4F is an essential component of the translational machinery. Recognition of the mRNA cap structure through its subunit eIF4E is a requirement for the recruitment of other translation initiation factors to the mRNA 5'-end and thereby for the attachment of the 40 S ribosomal subunit. In this study, we have investigated the mechanistic basis of the observation that eIF4E binding to the cap is enhanced in the presence of the large eIF4F subunit, eIF4G. We show that eIF4E requires access to both the mRNA 5'-cap and eIF4G to form stable complexes with short RNAs. This stabilization can be achieved using fragments of eIF4G that contain the eIF4E binding site but not the RNA recognition motifs. Full-length eIF4G is shown to induce increased eIF4E binding to cap analogues that do not contain an RNA body. Both results show that interaction of eIF4G with the mRNA is not necessary to enhance cap binding by eIF4E. Moreover, we show that the effect of binding of full-length eIF4G on the cap affinity of eIF4E can be further modulated through binding of Pab1 to eIF4G. These data are consistent with a model in which heterotropic cooperativity underlies eIF4F function.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Posttranscript Control Grp, Manchester M60 1QD, Lancs, England	University of Manchester	von der Haar, T (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Posttranscript Control Grp, POB 88, Manchester M60 1QD, Lancs, England.			von der Haar, Tobias/0000-0002-6031-9254				Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; CARBERRY SE, 1989, BIOCHEMISTRY-US, V28, P8078, DOI 10.1021/bi00446a017; EDERY I, 1987, TRANSLATIONAL REGULA, P335; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Hershey PEC, 1999, J BIOL CHEM, V274, P21297, DOI 10.1074/jbc.274.30.21297; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LANG V, 1994, J BIOL CHEM, V269, P6117; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; MADER S, 1995, MOL CELL BIOL, V15, P4990; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; McCarthy JEG, 1998, MICROBIOL MOL BIOL R, V62, P1492, DOI 10.1128/MMBR.62.4.1492-1553.1998; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Morley SJ, 1997, RNA, V3, P1085; NIEDZWIECKAKORM.A, 1999, RNA; Ptushkina M, 1999, EMBO J, V18, P4068, DOI 10.1093/emboj/18.14.4068; Ptushkina M, 1998, EMBO J, V17, P4798, DOI 10.1093/emboj/17.16.4798; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SHA M, 1995, J BIOL CHEM, V270, P29904; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Vilela C, 2000, EMBO J, V19, P4372, DOI 10.1093/emboj/19.16.4372; Wei CC, 1998, BIOCHEMISTRY-US, V37, P1910, DOI 10.1021/bi9724570; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wieczorek Z, 1999, Z NATURFORSCH C, V54, P278; YOUTANI T, 2000, BIOCHEM MOL BIOL INT, V49, P27	31	116	118	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30551	30555		10.1074/jbc.M004565200	http://dx.doi.org/10.1074/jbc.M004565200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10887196	hybrid			2022-12-27	WOS:000089577900087
J	Lee, JY; Hannun, YA; Obeid, LM				Lee, JY; Hannun, YA; Obeid, LM			Functional dichotomy of protein kinase C (PKC) in tumor necrosis factor-alpha (TNF-alpha) signal transduction in L929 cells - Translocation and inactivation of PKC by TNF-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; DNA-SYNTHESIS; SACCHAROMYCES-CEREVISIAE; GROWTH-INHIBITION; INDUCED APOPTOSIS; ARACHIDONIC-ACID; CYTOTOXIC ACTION; RAT FIBROBLASTS; PHOSPHOLIPASE-D; AKT KINASE	Tumor necrosis factor-alpha (TNF-alpha) is capable of inducing a variety of biologic responses through multiple signaling pathways. Because of the potential role of protein kinase C (PKC) in apoptosis, we examined the effects and mechanisms of TNF-alpha on PKC regulation, specifically on PKC alpha. In L929 murine fibroblasts, TNF-alpha (0.55 nM) caused potent inhibition of PBC alpha activity and induced translocation of PKC alpha from the cytosol to the membrane. Treatment of cells with TNF-alpha also induced dephosphorylation of PKC alpha as detected by a mobility shift on SDS-polyacrylamide gel and inhibition of PKC phosphorylation as probed by anti-phospho-PKC antibodies. Since PKC is activated directly by diacylglycerol and inactivated indirectly by ceramide, we next examined the roles of these lipid mediators in the regulation of PKC alpha, Addition of TNF-alpha led to accumulation of both ceramide and diacylglycerol, Fumonisin B-1, an inhibitor of ceramide synthase, and glutathione, an inhibitor of neutral sphingomyelinase, both reversed the effect of TNF-alpha on PKC alpha activity, suggesting that ceramide production is necessary for the action of TNF-alpha. The diacylglycerol mimic phorbol 12-myristate 13-acetate was sufficient to cause translocation of PKC alpha, but not the mobility shift. Okadaic acid at 2 nM, a potent protein phosphatase inhibitor, blocked the effects of TNF-alpha on PKC alpha activity, but not on PKC alpha translocation, thus demonstrating that dephosphorylation and translocation are independent processes. These results demonstrate that PKC alpha acts as a downstream target for TNF-alpha and that different lipid-mediated pathways in TNF-alpha signaling lead to opposing signals in the regulation of PKC alpha activity.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27710 USA	Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, 602 Strom Thurmond Bldg,114 Doughty St, Charleston, SC 29403 USA.			obeid, lina/0000-0002-0734-0847	NIA NIH HHS [AG-16853-0, 1R29-AG-12467, 5T32 AG00029] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R29AG012467, T32AG000029] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BERRY N, 1990, EUR J BIOCHEM, V189, P205, DOI 10.1111/j.1432-1033.1990.tb15478.x; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; BORNER C, 1989, J BIOL CHEM, V264, P13902; CACACE AM, 1993, ONCOGENE, V8, P2095; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; COPPOCK DL, 1992, CELL GROWTH DIFFER, V3, P485; DICKER P, 1978, NATURE, V276, P723, DOI 10.1038/276723a0; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; Hanna AN, 1999, J BIOL CHEM, V274, P12722, DOI 10.1074/jbc.274.18.12722; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; HAYAKAWA M, 1991, CELL STRUCT FUNCT, V16, P333, DOI 10.1247/csf.16.333; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG CL, 1987, NATURE, V329, P849, DOI 10.1038/329849a0; Ibitayo AI, 1998, AM J PHYSIOL-GASTR L, V275, pG705, DOI 10.1152/ajpgi.1998.275.4.G705; Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KARIYA K, 1987, FEBS LETT, V219, P119, DOI 10.1016/0014-5793(87)81202-4; KARIYA K, 1987, FEBS LETT, V217, P69, DOI 10.1016/0014-5793(87)81245-0; Kelly ML, 1998, BLOOD, V92, P416, DOI 10.1182/blood.V92.2.416.414k01_416_424; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PREISS J, 1986, J BIOL CHEM, V261, P8597; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; Salinas M, 2000, MOL CELL NEUROSCI, V15, P156, DOI 10.1006/mcne.1999.0813; Sawai H, 1997, J BIOL CHEM, V272, P2452; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; WANG E, 1991, J BIOL CHEM, V266, P14486; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; ZHOU W, 1993, J BIOL CHEM, V268, P23041; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	68	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29290	29298		10.1074/jbc.M000170200	http://dx.doi.org/10.1074/jbc.M000170200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887171	hybrid			2022-12-27	WOS:000089439800017
J	Pector, V; Backmann, J; Maes, D; Vandenbranden, M; Ruysschaert, JM				Pector, V; Backmann, J; Maes, D; Vandenbranden, M; Ruysschaert, JM			Biophysical and structural properties of DNA center dot diC(14)-amidine complexes - Influence of the DNA/lipid ratio	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC LIPOSOME COMPLEXES; VIVO GENE-TRANSFER; IN-VIVO; DNA COMPLEXES; CRYOELECTRON MICROSCOPY; MAMMALIAN-CELLS; LIPID VESICLES; FUSION; DELIVERY; THERAPY	Cationic liposomes are used as vectors for gene delivery both in vitro and in vivo. Comprehension of both DNA/liposome interactions on a molecular level and a description of structural modifications involved, are prerequisites to an optimization of the transfection protocol and, thus, successful application in therapy. Formation and stability of a DNA/cationic liposome complex were investigated here at different DNA:lipid molar ratios (rho). Isothermal titration calorimetry (ITC) of cationic liposomes with plasmid DNA was used to characterize the DNA-lipid interaction. Two processes were shown to be involved in the complex formation. A fast exothermic process was attributed to the electrostatic binding of DNA to the liposome surface. A subsequent slower endothermic reaction is likely to be caused by the fusion of the two components and their rearrangement into a new structure. Fluorescence and differential scanning calorimetry confirmed this interpretation. A kinetic model analyzes the ITC profile in terms of DNA/cationic liposome interactions.	Free Univ Brussels, Chim Phys Macromol Interfaces Lab, B-1050 Brussels, Belgium; Free Univ Brussels, Dept Ultrastruct, B-1640 Rhode St Genese, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Pector, V (corresponding author), Free Univ Brussels, Chim Phys Macromol Interfaces Lab, Campus Plaine CP 206-2, B-1050 Brussels, Belgium.			Backmann, Jan/0000-0002-3323-8838				ALI M, 1994, GENE THER, V1, P367; Battersby BJ, 1998, BBA-BIOMEMBRANES, V1372, P379, DOI 10.1016/S0005-2736(98)00062-5; BEHR JP, 1994, BIOCONJUGATE CHEM, V5, P382, DOI 10.1021/bc00029a002; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; DUZGUNES N, 1989, BIOCHEMISTRY-US, V28, P9179, DOI 10.1021/bi00449a033; DUZGUNES N, 1993, METHOD ENZYMOL, V220, P3, DOI 10.1016/0076-6879(93)20069-F; ElOuahabi A, 1996, FEBS LETT, V380, P108, DOI 10.1016/0014-5793(96)00038-5; ElOuahabi A, 1997, FEBS LETT, V414, P187, DOI 10.1016/S0014-5793(97)00973-3; EPAND RM, 1995, BIOSCIENCE REP, V15, P151, DOI 10.1007/BF01207455; Felgner JH, 1997, PHARMACEUT RES, V14, P1269, DOI 10.1023/A:1012131613160; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; Felgner PL, 1996, HUM GENE THER, V7, P1791, DOI 10.1089/hum.1996.7.15-1791; Ferrari ME, 1998, HUM GENE THER, V9, P341, DOI 10.1089/hum.1998.9.3-341; Fortunati E, 1996, BBA-GENE STRUCT EXPR, V1306, P55, DOI 10.1016/0167-4781(95)00217-0; Gao X, 1995, GENE THER, V2, P710; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; GUNZBURG WH, 1995, MOL MED TODAY, V1, P410, DOI 10.1016/S1357-4310(95)90771-8; Hirsch-Lemer D, 1998, BBA-BIOMEMBRANES, V1370, P17, DOI 10.1016/S0005-2736(97)00239-3; Huebner S, 1999, BIOPHYS J, V76, P3158, DOI 10.1016/S0006-3495(99)77467-9; KENNETH WCM, 1997, BIOPHYS J, V73, P2534; KERENZUR M, 1989, BIOCHIM BIOPHYS ACTA, V983, P253, DOI 10.1016/0005-2736(89)90241-1; Lasic DD, 1997, J AM CHEM SOC, V119, P832, DOI 10.1021/ja962713g; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; Liu F, 1997, GENE THER, V4, P517, DOI 10.1038/sj.gt.3300424; NIEVA JL, 1994, EMBO J, V13, P2797, DOI 10.1002/j.1460-2075.1994.tb06573.x; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V394, P483, DOI 10.1016/0005-2736(75)90299-0; Pires P, 1999, BBA-BIOMEMBRANES, V1418, P71, DOI 10.1016/S0005-2736(99)00023-1; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; RUYSSCHAERT JM, 1994, BIOCHEM BIOPH RES CO, V203, P1622, DOI 10.1006/bbrc.1994.2372; SEELIG J, 1993, BIOCHEMISTRY-US, V32, P9714, DOI 10.1021/bi00088a025; Seelig J, 1997, BBA-REV BIOMEMBRANES, V1331, P103, DOI 10.1016/S0304-4157(97)00002-6; Sternberg B, 1998, BBA-BIOMEMBRANES, V1375, P23, DOI 10.1016/S0005-2736(98)00129-1; STERNBERG B, 1994, FEBS LETT, V356, P361, DOI 10.1016/0014-5793(94)01315-2; TAKEHARA T, 1995, HEPATOLOGY, V21, P746, DOI 10.1002/hep.1840210323; THOMAS PG, 1993, BIOCHEM J, V291, P397, DOI 10.1042/bj2910397; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yang JP, 1998, GENE THER, V5, P380, DOI 10.1038/sj.gt.3300596; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073; Zuidam NJ, 1997, BBA-BIOMEMBRANES, V1329, P211, DOI 10.1016/S0005-2736(97)00110-7	39	47	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29533	29538		10.1074/jbc.M909996199	http://dx.doi.org/10.1074/jbc.M909996199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896680	hybrid			2022-12-27	WOS:000089439800048
J	Rauen, M; Burtelow, MA; Dufault, VM; Karnitz, LM				Rauen, M; Burtelow, MA; Dufault, VM; Karnitz, LM			The human checkpoint protein hRad17 interacts with the PCNA-like proteins hRad1, hHus1, and hRad9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION-FACTOR-C; DNA-DAMAGE CHECKPOINT; SCHIZOSACCHAROMYCES-POMBE RAD1(+); SACCHAROMYCES-CEREVISIAE; HUMAN HOMOLOG; CONTROL GENE; STRUCTURAL HOMOLOG; CDC25 PHOSPHATASE; ATPASE ACTIVITY; MOUSE HOMOLOGS	DNA damage activates cell cycle checkpoints that prevent progression through the cell cycle. In yeast, the DNA damage checkpoint response is regulated by a series of genes that have mammalian homologs, including rad1, rad9, hus1, and rad17. On the basis of sequence homology, yeast and human Rad1, Rad9, and Hus1 protein homologs are predicted to structurally resemble the sliding clamp PCNA. Likewise, Rad17 homologs have extensive homology with replication factor C (RFC) subunits (p36, p37, p38, p40, and p140), which form a clamp loader for PCNA. These observations predict that Rad1, Hus1, and Rad9 might interact with Rad17 as a clamp-clamp loader pair during the DNA damage response. In this report, we demonstrate that endogenous human Rad17 (hRad17) interacts with the PCNA-related checkpoint proteins hRad1, hRad9, and hHus1. Mutational analysis of hRad1 and hRad17 demonstrates that this interaction has properties similar to the interaction between RFC and PCNA, a well characterized clamp-clamp loader pair. Moreover, we show that DNA damage affects the association of hRad17 with the clamp-like checkpoint proteins. Collectively, these data provide the first experimental evidence that hRad17 interacts with the PCNA-like proteins hRad1, hHus1, and hRad9 in manner similar to the interaction between RFC and PCNA.	Mayo Clin, Div Dev Oncol Res, Rochester, MN 55902 USA; Mayo Clin, Div Radiat Oncol, Rochester, MN 55902 USA; Mayo Clin, Dept Immunol, Rochester, MN 55902 USA; Mayo Clin, Dept Mol Pharmacol, Rochester, MN 55902 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Karnitz, LM (corresponding author), Mayo Clin & Mayo Fdn, Guggenheim 13, Rochester, MN 55905 USA.	karnitz.larry@mayo.edu						Bao SD, 1998, CELL GROWTH DIFFER, V9, P961; Bao SD, 1999, CANCER RES, V59, P2023; Bessho T, 2000, J BIOL CHEM, V275, P7451, DOI 10.1074/jbc.275.11.7451; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Bluyssen HAR, 1998, GENOMICS, V54, P331, DOI 10.1006/geno.1998.5582; Bluyssen HAR, 1999, GENOMICS, V55, P219, DOI 10.1006/geno.1998.5642; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Cai JS, 1998, P NATL ACAD SCI USA, V95, P11607, DOI 10.1073/pnas.95.20.11607; Caspari T, 1999, BIOCHIMIE, V81, P173, DOI 10.1016/S0300-9084(99)80050-9; CASPARI T, 2000, MOL CELL BIOL, V74, P1264; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Dean FB, 1998, GENOMICS, V54, P424, DOI 10.1006/geno.1998.5587; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Ellison V, 1998, J BIOL CHEM, V273, P5979, DOI 10.1074/jbc.273.10.5979; Freire R, 1998, GENE DEV, V12, P2560, DOI 10.1101/gad.12.16.2560; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; Li L, 1999, ONCOGENE, V18, P1689, DOI 10.1038/sj.onc.1202469; LONG KE, 1994, GENE, V148, P155, DOI 10.1016/0378-1119(94)90250-X; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; Marathi UK, 1998, GENOMICS, V54, P344, DOI 10.1006/geno.1998.5589; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Parker AE, 1998, J BIOL CHEM, V273, P18340, DOI 10.1074/jbc.273.29.18340; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Podust VN, 1997, J BIOL CHEM, V272, P6303, DOI 10.1074/jbc.272.10.6303; Podust VN, 1998, J BIOL CHEM, V273, P12935, DOI 10.1074/jbc.273.21.12935; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; THELEN MP, 1994, J BIOL CHEM, V269, P747; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zeng Y, 1999, MOL CELL BIOL, V19, P7410; Zhang G, 1999, P NATL ACAD SCI USA, V96, P1869, DOI 10.1073/pnas.96.5.1869	47	83	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29767	29771		10.1074/jbc.M005782200	http://dx.doi.org/10.1074/jbc.M005782200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10884395	hybrid			2022-12-27	WOS:000089439800080
J	Runge, S; Nielsen, FC; Nielsen, J; Lykke-Andersen, J; Wewer, UM; Christiansen, J				Runge, S; Nielsen, FC; Nielsen, J; Lykke-Andersen, J; Wewer, UM; Christiansen, J			H19 RNA binds four molecules of insulin-like growth factor II mRNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASH1 MESSENGER-RNA; ROUGH ENDOPLASMIC-RETICULUM; LARGE RIBOSOMAL-RNA; XENOPUS-OOCYTES; GERM PLASM; NUCLEAR-LOCALIZATION; STRUCTURAL ELEMENTS; VEGETAL CORTEX; HNRNP-I; GENE	H19 RNA is a major oncofetal 2.5-kilobase untranslated RNA of unknown function. The maternally expressed H19 gene is located 90 kilobase pairs downstream from the paternally expressed insulin-like growth factor II (IGF-II) gene on human chromosome 11 and mouse chromosome 7; and due to their reciprocal imprinting and identical spatiotemporal expression, it is assumed that the two genes are functionally coupled. Here we show that human H19 RNA contains four attachment sites for the oncofetal IGF-II mRNA-binding protein (IMP) with apparent K-d values in the 0.4-1.3 nM range. The multiple attachment sites are clustered within a 700-nucleotide segment encoded by exons 4 and 5. This 3'-terminal segment targets H19 RNA to lamellipodia and perinuclear regions in dispersed fibroblasts where IMP is also localized. The results suggest that IMP participates in H19 RNA localization and provides a link between the IGF-II and H19 genes at post-transcriptional events during mammalian development.	Univ Copenhagen, Inst Mol Biol, Dept Biol Chem, RNA Regulat Ctr, DK-1307 Copenhagen K, Denmark; Univ Copenhagen, Inst Mol Pathol, DK-1307 Copenhagen, Denmark; Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen O, Denmark	University of Copenhagen; University of Copenhagen; Rigshospitalet	Christiansen, J (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Biol Chem, RNA Regulat Ctr, Solvgade 83 H, DK-1307 Copenhagen K, Denmark.		Christiansen, Jan/L-3312-2014; Nielsen, Finn Cilius/AAA-4926-2020	Christiansen, Jan/0000-0001-8624-4601; Nielsen, Jacob/0000-0001-9842-2276; Lykke-Andersen, Jens/0000-0003-1821-0754; Nielsen, Finn Cilius/0000-0002-9829-1031				Adam GIR, 1996, DEVELOPMENT, V122, P839; Ariel I, 1997, J CLIN PATHOL-MOL PA, V50, P34, DOI 10.1136/mp.50.1.34; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; Bashirullah A, 1998, ANNU REV BIOCHEM, V67, P335, DOI 10.1146/annurev.biochem.67.1.335; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; Chartrand P, 1999, CURR BIOL, V9, P333, DOI 10.1016/S0960-9822(99)80144-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIANSEN J, 1994, NUCLEIC ACIDS RES, V22, P5709, DOI 10.1093/nar/22.25.5709; Cote CA, 1999, MOL CELL, V4, P431, DOI 10.1016/S1097-2765(00)80345-7; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; Eggenschwiler J, 1997, GENE DEV, V11, P3128, DOI 10.1101/gad.11.23.3128; Evdokimova VM, 1998, J BIOL CHEM, V273, P3574, DOI 10.1074/jbc.273.6.3574; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Gautreau D, 1997, DEVELOPMENT, V124, P5013; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; Gonzalez I, 1999, CURR BIOL, V9, P337, DOI 10.1016/S0960-9822(99)80145-6; Havin L, 1998, GENE DEV, V12, P1593, DOI 10.1101/gad.12.11.1593; Hurst LD, 1999, TRENDS GENET, V15, P134, DOI 10.1016/S0168-9525(99)01696-0; Jaenisch R, 1998, CIBA F SYMP, V214, P200; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; King ML, 1999, BIOESSAYS, V21, P546, DOI 10.1002/(SICI)1521-1878(199907)21:7<546::AID-BIES3>3.0.CO;2-Z; KLOC M, 1995, DEVELOPMENT, V121, P287; KLOC M, 1994, SCIENCE, V265, P1101, DOI 10.1126/science.7520603; KLOC M, 1993, SCIENCE, V262, P1712, DOI 10.1126/science.7505061; Kobayashi S, 1998, CURR BIOL, V8, P1117, DOI 10.1016/S0960-9822(98)70466-X; KOBAYASHI S, 1993, SCIENCE, V260, P1521, DOI 10.1126/science.7684857; LEE JE, 1990, DEVELOPMENT, V110, P151; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; Li YM, 1998, J BIOL CHEM, V273, P28247, DOI 10.1074/jbc.273.43.28247; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; Marion RM, 1999, MOL CELL BIOL, V19, P2212; Matzura O, 1996, COMPUT APPL BIOSCI, V12, P247; Nakamura A, 1996, SCIENCE, V274, P2075, DOI 10.1126/science.274.5295.2075; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; POIRIER F, 1991, DEVELOPMENT, V113, P1105; Ripoche MA, 1997, GENE DEV, V11, P1596, DOI 10.1101/gad.11.12.1596; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; Schmidt JV, 1999, P NATL ACAD SCI USA, V96, P9733, DOI 10.1073/pnas.96.17.9733; SVENSSON K, 1995, MECH DEVELOP, V51, P31, DOI 10.1016/0925-4773(94)00345-N; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Wickham L, 1999, MOL CELL BIOL, V19, P2220	46	139	147	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29562	29569		10.1074/jbc.M001156200	http://dx.doi.org/10.1074/jbc.M001156200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10875929	hybrid			2022-12-27	WOS:000089439800052
J	Yamaguchi, H; Yamashita, H; Mori, H; Okazaki, I; Nomizu, M; Beck, K; Kitagawa, Y				Yamaguchi, H; Yamashita, H; Mori, H; Okazaki, I; Nomizu, M; Beck, K; Kitagawa, Y			High and low affinity heparin-binding sites in the G domain of the mouse laminin alpha 4 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG ARM; BASEMENT-MEMBRANES; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; GAMMA-3 CHAIN; EXPRESSION; DYSTROGLYCAN; GLYCOPROTEIN; RECOMBINANT; PROTEINS	G domains of the mouse laminin alpha 1 and alpha 4 chains consisting of its five subdomains LG1-LG5 were overexpressed in Chinese hamster ovary cells and purified by heparin chromatography. alpha 1LG1-LG5 and alpha 4LG1-LG5 eluted at NaCl concentrations of 0.30 and 0.47 M, respectively. In solid phase binding assays with immobilized heparin, half-maximal concentrations of 14 (alpha 1LG1-LG5) and 1.4 nM (alpha 4LG1-LG5) were observed. N-Glycan cleavage of alpha 4LG1-LG5 did not affect affinity to heparin. The affinity of ru4LG1-LG5 was significantly reduced upon denaturation with 8 M urea but could be recovered by removing urea. Chymotrypsin digestion of alpha 4LG1-LG5 yielded high and low heparin affinity fragments containing either the alpha 4LG4-LG5 or alpha 4LG2-LG3 modules, respectively. Trypsin digestion of heparin-bound alpha 4LG1-LG5 yielded a high affinity fragment of about 190 residues corresponding to the alpha 4LG4 module indicating that the high affinity binding site is contained within alpha 4LG4. Competition for heparin binding of synthetic peptides covering the alpha 4LG4 region with complete alpha 4LG1-LG5 suggests that the sequence AHGRL1521 is crucial for high affinity binding. Introduction of mutation of H1518A or R1520A in glutathione S-transferase fusion protein of the alpha 4LG4 module produced in Escherichia coli markedly reduced heparin binding activity of the wild type. When compared with the known structure of alpha 2LG5, this sequence corresponds to the turn connecting strands E and F of the 14-stranded beta-sheet sandwich, which is opposite to the proposed binding sites for calcium ion, alpha-dystroglycan, and heparan sulfate.	Nagoya Univ, Grad Sch Bioagr Sci, Grad Course Regulat Biol Signals, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Biosci Ctr, Nagoya, Aichi 4648601, Japan; Hokkaido Univ, Grad Sch Environm Earth Sci, Sapporo, Hokkaido 0600810, Japan	Nagoya University; Nagoya University; Hokkaido University	Kitagawa, Y (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Grad Course Regulat Biol Signals, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.		Beck, Konrad/AAX-1351-2020	Beck, Konrad/0000-0001-5098-9484; Yamashita, Hironobu/0000-0003-2587-7100				Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; ARATANI Y, 1988, J BIOL CHEM, V263, P16163; AUMAILLEY M, 1989, EUR J BIOCHEM, V184, P241, DOI 10.1111/j.1432-1033.1989.tb15013.x; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; Colognato H, 1997, J BIOL CHEM, V272, P29330, DOI 10.1074/jbc.272.46.29330; Delacoux F, 1998, J BIOL CHEM, V273, P15069, DOI 10.1074/jbc.273.24.15069; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Frieser M, 1997, EUR J BIOCHEM, V246, P727, DOI 10.1111/j.1432-1033.1997.t01-1-00727.x; GEE SH, 1993, J BIOL CHEM, V268, P14972; Hill JS, 1998, J BIOL CHEM, V273, P30979, DOI 10.1074/jbc.273.47.30979; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; Iivanainen A, 1999, J BIOL CHEM, V274, P14107, DOI 10.1074/jbc.274.20.14107; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; Iivanainen A, 1997, J BIOL CHEM, V272, P27862, DOI 10.1074/jbc.272.44.27862; Kapila YL, 1997, J BIOL CHEM, V272, P18932, DOI 10.1074/jbc.272.30.18932; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JG, 1996, MATRIX BIOL, V15, P433, DOI 10.1016/S0945-053X(96)90162-6; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Nielsen PK, 2000, J BIOL CHEM, V275, P14517, DOI 10.1074/jbc.275.19.14517; Niimi T, 1997, FEBS LETT, V400, P71, DOI 10.1016/S0014-5793(96)01355-5; Niimi T, 1997, J BIOCHEM, V121, P854; Niimi T, 1997, MATRIX BIOL, V16, P223, DOI 10.1016/S0945-053X(97)90011-1; Nomizu M, 1998, J BIOL CHEM, V273, P32491, DOI 10.1074/jbc.273.49.32491; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; RYAN MC, 1994, J BIOL CHEM, V269, P22779; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOROKIN L, 1994, EUR J BIOCHEM, V223, P603, DOI 10.1111/j.1432-1033.1994.tb19031.x; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Sung U, 1997, EUR J BIOCHEM, V250, P138, DOI 10.1111/j.1432-1033.1997.00138.x; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Talts JF, 1998, FEBS LETT, V426, P71, DOI 10.1016/S0014-5793(98)00312-3; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; TOKIDA Y, 1990, J BIOL CHEM, V265, P18123; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	46	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29458	29465		10.1074/jbc.M003103200	http://dx.doi.org/10.1074/jbc.M003103200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893232	hybrid, Green Accepted			2022-12-27	WOS:000089439800039
J	Finlay, GA; Thannickal, VJ; Fanburg, BL; Paulson, KE				Finlay, GA; Thannickal, VJ; Fanburg, BL; Paulson, KE			Transforming growth factor-beta 1-induced activation of the ERK pathway/activator protein-1 in human lung fibroblasts requires the autocrine induction of basic fibroblast growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL KINASE SAPK/JNK; BETA SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; GENE-EXPRESSION; AP-1 COMPLEX; II RECEPTOR; PATHWAY; JUN; STRESS; RESPONSES	Transforming growth factor-beta (TGF-beta) is involved in multiple processes including cell growth and differentiation. In particular, TGF-beta has been implicated in the pathogenesis of fibrotic lung diseases. In this study, we examined regulation of the mitogen-activated protein kinase pathway by TGF-beta 1 in primary human lung fibroblasts. TGF-beta 1 treatment resulted in extracellular signal-regulated kinase (ERK) pathway activation in a delayed manner, with maximal activity at 16 h, ERK activation occurred concomitantly with the induction of activator protein-1 (AP-1) binding, a nuclear factor required for activation of multiple genes involved in fibrosis. AP-1 binding was dependent on ERK activation, since the MEK-1 (mitogen-activated protein kinase kinase) inhibitor PD98059 inhibited TGF-beta 1-induced binding. Induction of the receptor tyrosine kinase-linked growth factor, basic fibroblast growth factor (bFGF) protein expression temporally paralleled the activation of ERK/AP-1. Induction of AP-1 by TGF-beta 1-conditioned medium was observed at 2 h, similar to AP-1 induction in response to exogenous bFGF, Dependence of ERK/AP-1 activation on bFGF induction was demonstrated by inhibition of TGF-beta 1-induced ERK/AP-1 activation when conditioned medium from TGF-beta 1-treated cells was incubated with bFGF-neutralizing antibody. Together, these results demonstrate that TGF-beta 1 regulates the autocrine induction of bFGF, resulting in activation of the ERK mitogen-activated protein kinase pathway and induction of AP-1 binding.	Tufts Univ, Jean Mayer Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; New England Med Ctr, Dept Med, Tupper Res Inst, Div Pulm & Crit Care, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts Medical Center	Paulson, KE (corresponding author), Tufts Univ, Jean Mayer Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.				NHLBI NIH HHS [1K08 HLO3552, R01 HL42376] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003552, R01HL042376] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1992, P MATR MET C, P156; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Axmann A, 1998, BIOCHEM BIOPH RES CO, V249, P456, DOI 10.1006/bbrc.1998.9188; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER DA, 1994, J LAB CLIN MED, V124, P755; Chatani Y, 1995, J BIOL CHEM, V270, P30686, DOI 10.1074/jbc.270.51.30686; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; CUTHILL S, 1991, MOL CELL BIOL, V11, P401, DOI 10.1128/MCB.11.1.401; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Dixon M, 1999, HEPATOLOGY, V29, P1418, DOI 10.1002/hep.510290516; FAFEUR V, 1993, MOL BIOL CELL, V4, P135, DOI 10.1091/mbc.4.2.135; Force T, 1998, HYPERTENSION, V31, P152, DOI 10.1161/01.HYP.31.1.152; Frey RS, 1997, CANCER RES, V57, P628; GEISER AG, 1992, J BIOL CHEM, V267, P2588; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; HUWILER A, 1994, FEBS LETT, V354, P255, DOI 10.1016/0014-5793(94)01132-X; Ichiki Y, 1997, J RHEUMATOL, V24, P90; Jones SG, 1999, KIDNEY INT, V56, P83, DOI 10.1046/j.1523-1755.1999.00517.x; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kay EP, 1998, CURR EYE RES, V17, P286, DOI 10.1076/ceyr.17.3.286.5212; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mattey DL, 1997, ANN RHEUM DIS, V56, P426, DOI 10.1136/ard.56.7.426; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; MUSCI I, 1996, J BIOL CHEM, V271, P16567; Nakamura K, 1999, EXP CELL RES, V250, P351, DOI 10.1006/excr.1999.4535; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; Pilcher BK, 1997, J BIOL CHEM, V272, P18147, DOI 10.1074/jbc.272.29.18147; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; ROBERTS AB, 1991, PEPTIDE GROWTH FACTO, P421; ROSENBAUM J, 1995, GASTROENTEROLOGY, V109, P1986, DOI 10.1016/0016-5085(95)90767-X; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shinozaki M, 1997, BIOCHEM BIOPH RES CO, V237, P292, DOI 10.1006/bbrc.1997.7134; Thannickal VJ, 1998, BIOCHEM BIOPH RES CO, V251, P437, DOI 10.1006/bbrc.1998.9443; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; VAN BT, 1995, NATURE, V376, P781; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	52	83	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27650	27656						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862759				2022-12-27	WOS:000089197100018
J	Inohara, N; Koseki, T; Lin, JM; del Peso, L; Lucas, PC; Chen, FF; Ogura, Y; Nunez, G				Inohara, N; Koseki, T; Lin, JM; del Peso, L; Lucas, PC; Chen, FF; Ogura, Y; Nunez, G			An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CYTOCHROME-C; PROCASPASE-9 ACTIVATION; KINASE-ACTIVITY; DEATH DOMAIN; IKK-BETA; COMPLEX; RECEPTOR; PROTEIN; APOPTOSIS	Nod1 is an Apaf-1-like molecule composed of a caspase-recruitment domain (CARD), nucleotide-binding domain, and leucine-rich repeats that associates with the CARD-containing kinase RICK and activates nuclear factor kappa B (NF-kappa B). We show that self-association of Nod1 mediates proximity of RICK and the interaction of RICK with the gamma subunit of the I kappa B kinase (IKK gamma). Similarly, the RICK-related kinase RIP associated via its intermediate region with IKK gamma, A mutant form of IKK gamma deficient in binding to IKK alpha and IKK beta inhibited NF-kappa B activation induced by RICK or RIP. Enforced oligomerization of RICK or RIP as well as of IKK gamma, IKK alpha, or IKK beta was sufficient for induction of NF-kappa B activation. Thus, the proximity of RICK, RIP, and IKK complexes may play an important role for NF-kappa B activation during Nod1 oligomerization or trimerization of the tumor necrosis factor alpha receptor.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		Nuñez, Gabriel/A-7160-2014; del Peso, Luis/K-9391-2014	del Peso, Luis/0000-0003-4014-5688	NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; INCHARA N, 1998, J BIOL CHEM, V273, P12296; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; KOIKE T, 1994, BIOCHEM BIOPH RES CO, V202, P225, DOI 10.1006/bbrc.1994.1916; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; Pazdernik NJ, 1999, MOL CELL BIOL, V19, P6500; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	40	430	456	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27823	27831						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10880512				2022-12-27	WOS:000089197100042
J	Lokeshwar, VB; Selzer, MG				Lokeshwar, VB; Selzer, MG			Differences in hyaluronic acid-mediated functions and signaling in arterial, microvessel, and vein-derived human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; RECEPTOR RHAMM; ANGIOGENIC OLIGOSACCHARIDES; TUMOR ANGIOGENESIS; BINDING PROTEINS; BLADDER-CANCER; URINE MARKER; CD44; IDENTIFICATION; PROLIFERATION	Hyaluronic acid (HA), a nonsulfated glycosaminoglycan, regulates cell adhesion and migration. Small HA fragments (3-25 disaccharide units) induce neovascularization, We investigated the effect of HA and a HA fragment (10-15 disaccharide units, F1) on primary human endothelial cells (ECs). Human pulmonary ECs (HPAEC) and lung microvessel ECs (HMVEC-L) bound HA (K-d similar to 1 and 2.3 nM, respectively) and expressed 17,780 and 16,690 HA binding sites, respectively. Both ECs showed HA-mediated cell adhesion; however, HMVEC-L was 1.5-fold better. Human umbilical vein ECs neither bound HA nor showed HA-mediated adhesion. All three ECs expressed CD44 (similar to 110 kDa). The expression of receptor for HA-mediated motility (RHAMM) (similar to 80 kDa) was the highest in HMVEC-L, followed by HPAEC and human umbilical vein ECs, RHAMM, not CD44, bound HA in all three ECs. Fl was better than HA and stimulated a 2.5- and 1.8-fold mitogenic response in HMVEC-L and HPAEC, respectively. Both HA and F1 induced tyrosine phosphorylation of p125(FAK), paxillin, and p42/44 ERK in HMVEC-L and HPAEC, which was blocked by an anti-RHAMM antibody. These results demonstrate that RHARIM is the functional HA receptor in primary human ECs. Heterogeneity exists among primary human ECs of different vascular origins, with respect to functional HA receptor expression and function.	Univ Miami, Sch Med, Dept Urol M 800, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA	University of Miami; University of Miami	Lokeshwar, VB (corresponding author), Univ Miami, Sch Med, Dept Urol M 800, POB 016960, Miami, FL 33101 USA.							Abmann V., 1996, CLIN CANCER RES, V2, P1607; Assmann V, 1998, J CELL SCI, V111, P1685; BENERSON GS, 1988, ARCH PATHOL LAB MED, V112, P1002; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Deed R, 1997, INT J CANCER, V71, P251, DOI 10.1002/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO;2-J; Delpech B, 1997, J INTERN MED, V242, P41, DOI 10.1046/j.1365-2796.1997.00172.x; English NM, 1998, CANCER RES, V58, P3736; Entwistle J, 1996, J CELL BIOCHEM, V61, P569, DOI 10.1002/(SICI)1097-4644(19960616)61:4<569::AID-JCB10>3.0.CO;2-B; ENTWISTLE J, 1995, GENE, V163, P233, DOI 10.1016/0378-1119(95)00398-P; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; Griffioen AW, 1997, BLOOD, V90, P1150, DOI 10.1182/blood.V90.3.1150.1150_1150_1159; Gross N, 1997, CANCER RES, V57, P1387; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HOARE K, 1993, CONNECT TISSUE RES, V30, P117, DOI 10.3109/03008209309041327; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KEEGAN A, 1982, J CELL SCI, V55, P261; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Knudson W, 1996, AM J PATHOL, V148, P1721; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEVESQUE H, 1994, ATHEROSCLEROSIS, V105, P51, DOI 10.1016/0021-9150(94)90007-8; LOEKSHWAR VB, 2000, J UROLOGY, V163, P348; Lokeshwar VB, 1997, CANCER RES, V57, P773; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; Lokeshwar VB, 1996, CANCER RES, V56, P651; Lokeshwar VB, 1999, CANCER RES, V59, P4464; MARITA H, 1990, BIOCHEM J, V265, P61; MARTIN JF, 1990, ENDOTHELIUM INTRO CU, P95; MasellisSmith A, 1996, BLOOD, V87, P1891; MCCOURT PAG, 1994, J BIOL CHEM, V269, P30081; MONTESANO R, 1996, LAB INVEST, V75, P211; NISHINA H, 1994, BIOCHEM BIOPH RES CO, V203, P1318, DOI 10.1006/bbrc.1994.2326; PAKU S, 1991, LAB INVEST, V65, P334; Pham HT, 1997, CANCER RES, V57, P778; Roden L, 1989, CIBA F SYMP, P76; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; SATTAR A, 1994, J INVEST DERMATOL, V103, P576, DOI 10.1111/1523-1747.ep12396880; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHEN JK, 1995, MICROVASC RES, V50, P360, DOI 10.1006/mvre.1995.1064; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; Slevin M, 1998, LAB INVEST, V78, P987; TEDER P, 1995, CANCER RES, V55, P3908; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; Tsifrina E, 1999, AM J PATHOL, V155, P1625, DOI 10.1016/S0002-9440(10)65478-8; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; UNDERHILL C, 1992, J CELL SCI, V103, P293; Wang C, 1996, AM J PATHOL, V148, P1861; West D. C., 1989, CIBA F SYMP, V143, P201; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; YANNARIELLOBROWN J, 1992, J BIOL CHEM, V267, P20451; Zhang SW, 1998, J BIOL CHEM, V273, P11342, DOI 10.1074/jbc.273.18.11342; ZOLLER M, 1995, J MOL MED, V73, P425	58	170	180	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27641	27649						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10882722				2022-12-27	WOS:000089197100017
J	Pederson, BA; Cheng, C; Wilson, WA; Roach, PJ				Pederson, BA; Cheng, C; Wilson, WA; Roach, PJ			Regulation of glycogen synthase - Identification of residues involved in regulation by the allosteric ligand glucose-6-P and by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSYLATING INITIATOR PROTEINS; SACCHAROMYCES-CEREVISIAE; BRANCHING ENZYME; CDNA CLONING; ACTIVE-SITE; YEAST; BIOSYNTHESIS; SUBUNIT; ACCUMULATION; METABOLISM	The major yeast glycogen synthase, Gsy2p, is inactivated by phosphorylation and activated by the allosteric ligand glucose-6-P. From studies of recombinant proteins, the control can be accommodated by a three-state model, in which unphosphorylated enzyme has intermediate activity (state II). Glucose-6-P increased V-max/K-m by about 2-fold (state III), whereas phosphorylation by the cyclin-dependent protein kinase Pcl10p/Pho85p decreased V-max/K-m by similar to 30-fold (state I). In the presence of glucose-6-P, state III is achieved regardless of phosphorylation state. The enzyme forms complexes in solution with the yeast glycogenin Glg2p, but this interaction appears not to affect control either by glucose-6-P binding or by phosphorylation, Scanning mutagenesis was applied to identify residues potentially involved in ligand binding. Of 22 mutant enzymes analyzed, seven were essentially inactive. Five mutant proteins were altered in their activation by glucose-6-P, and two were completely unaffected by the hexose phosphate, One of these, R586A/R588A/R591A (all three of the indicated Arg residues mutated to Ala), had wild-type activity and was normally inactivated by phosphorylation. A second mutant, R579A/R580A/R582A, had somewhat reduced V-max, but its activity was not greatly reduced by phosphorylation. The Arg residues in these two mutants are restricted to a highly conserved, 13-residue segment of Gsy2p that me propose to be important for glucose-6-P binding and/or the ability of the enzyme to undergo transitions between activity states.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Ctr Diabet Res, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Roach, PJ (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.			Wilson, Wayne/0000-0003-2417-5756	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020542, R01DK042576] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20542, DK42576] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALGRANATI ID, 1962, J BIOL CHEM, V237, P1007; BAI G, 1990, J BIOL CHEM, V265, P7843; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; CARABAZA A, 1990, BIOCHEM J, V268, P401, DOI 10.1042/bj2680401; Cardenas ML, 1998, BBA-MOL CELL RES, V1401, P242, DOI 10.1016/S0167-4889(97)00150-X; CHENG C, 1995, MOL CELL BIOL, V15, P6632; FARKAS I, 1991, J BIOL CHEM, V266, P15602; HARDY TA, 1994, J BIOL CHEM, V269, P27907; HARDY TA, 1993, J BIOL CHEM, V268, P23799; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Huang DQ, 1996, MOL CELL BIOL, V16, P4357; Huang DQ, 1998, MOL CELL BIOL, V18, P3289, DOI 10.1128/MCB.18.6.3289; HUANG KP, 1974, J BIOL CHEM, V249, P3851; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; Lin A, 1999, ARCH BIOCHEM BIOPHYS, V363, P163, DOI 10.1006/abbi.1998.1073; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; MAHRENHOLZ AM, 1988, J BIOL CHEM, V263, P10561; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; NUTTALL FQ, 1994, ARCH BIOCHEM BIOPHYS, V311, P443, DOI 10.1006/abbi.1994.1260; Orho M, 1998, J CLIN INVEST, V102, P507, DOI 10.1172/JCI2890; Orho-Melander M, 1999, DIABETES, V48, P918, DOI 10.2337/diabetes.48.4.918; PITCHER J, 1987, EUR J BIOCHEM, V169, P497, DOI 10.1111/j.1432-1033.1987.tb13637.x; Preiss J, 1987, Basic Life Sci, V41, P133; PREISS J, 1994, PROG NUCLEIC ACID RE, V47, P299, DOI 10.1016/S0079-6603(08)60255-X; ROACH PJ, 1977, MOL CELL BIOCHEM, V15, P179, DOI 10.1007/BF01734108; ROACH PJ, 1981, CURR TOP CELL REGUL, V20, P45; Roach PJ, 1997, PROG NUCLEIC ACID RE, V57, P289, DOI 10.1016/S0079-6603(08)60284-6; ROTHMAN LB, 1967, BIOCHEMISTRY-US, V6, P2098, DOI 10.1021/bi00859a030; ROTHMANDENES LB, 1971, BIOCHEMISTRY-US, V10, P1236; ROWEN DW, 1992, MOL CELL BIOL, V12, P22, DOI 10.1128/MCB.12.1.22; Schulz AR, 1998, ARCH BIOCHEM BIOPHYS, V353, P172, DOI 10.1006/abbi.1998.0643; Shimomura H, 1997, DIABETOLOGIA, V40, P947, DOI 10.1007/s001250050772; SKURAT AV, 1995, DIABETES MELLITUS FU, P213; TAGAYA M, 1985, J BIOL CHEM, V260, P6670; TAKEDA Y, 1975, J BIOL CHEM, V250, P8943; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; THON VJ, 1992, J BIOL CHEM, V267, P15224; Williamson BD, 1996, DEV GENET, V19, P350, DOI 10.1002/(SICI)1520-6408(1996)19:4<350::AID-DVG8>3.0.CO;2-8; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; Wilson WA, 1999, MOL CELL BIOL, V19, P7020; ZHANG WM, 1993, ARCH BIOCHEM BIOPHYS, V304, P219, DOI 10.1006/abbi.1993.1342	43	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27753	27761						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10874034				2022-12-27	WOS:000089197100033
J	Yamashita, H; Tyska, MJ; Warshaw, DM; Lowey, S; Trybus, KM				Yamashita, H; Tyska, MJ; Warshaw, DM; Lowey, S; Trybus, KM			Functional consequences of mutations in the smooth muscle myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESSENTIAL LIGHT-CHAIN; BETA-CARDIAC MYOSIN; SKELETAL-MUSCLE; LASER TRAP; ACTIN-BINDING; MOTOR DOMAIN; ADP RELEASE; IN-VITRO; COMPLEX; GENE	Familial hypertrophic cardiomyopathy (FHC) is frequently associated with mutations in the beta-cardiac myosin heavy chain. Many of the implicated residues are located in highly conserved regions of the myosin II class, suggesting that these mutations may impair the basic functions of the molecular motor. To test this hypothesis, we have prepared recombinant smooth muscle heavy meromyosin with mutations at sites homologous to those associated with FHC by using a baculovirus/ insect cell expression system. Several of the heavy meromyosin mutants, in particular R403Q, showed an increase in actin filament velocity in a motility assay and an enhanced actin-activated ATPase activity. Single molecule mechanics, using a laser trap, gave unitary displacements and forces for the mutants that were similar to wild type, but the attachment times to actin following a unitary displacement were markedly reduced. These results suggest that the increases in activity are due to a change in kinetics and not due to a change in the intrinsic mechanical properties of the motor. In contrast to earlier reports, we find that mutations in residues implicated in FHC affect motor function by enhancing myosin activity rather than by a loss of function.	Univ Vermont, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo 1138655, Japan; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA	University of Vermont; University of Tokyo; Brandeis University	Lowey, S (corresponding author), Univ Vermont, Dept Mol Physiol & Biophys, Given E209, Burlington, VT 05405 USA.				NHLBI NIH HHS [HL54568, HL51126] Funding Source: Medline; NIAMS NIH HHS [AR17350] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054568, R01HL051126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR017350, R01AR017350] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bonne G, 1998, CIRC RES, V83, P580, DOI 10.1161/01.RES.83.6.580; Cuda G, 1997, J MUSCLE RES CELL M, V18, P275, DOI 10.1023/A:1018613907574; CUDA G, 1993, J CLIN INVEST, V91, P2861, DOI 10.1172/JCI116530; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Dupuis DE, 1997, J MUSCLE RES CELL M, V18, P17, DOI 10.1023/A:1018672631256; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; Fujita H, 1997, J CLIN INVEST, V99, P1010, DOI 10.1172/JCI119228; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; Guilford WH, 1997, BIOPHYS J, V72, P1006, DOI 10.1016/S0006-3495(97)78753-8; Gulick AM, 1997, BIOESSAYS, V19, P561, DOI 10.1002/bies.950190707; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lauzon AM, 1998, J MUSCLE RES CELL M, V19, P825, DOI 10.1023/A:1005489501357; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MARGOSSIAN SS, 1985, J BIOL CHEM, V260, P3747; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; NABESHIMA Y, 1987, J BIOL CHEM, V262, P10608; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Palmiter KA, 1999, CIRCULATION, V100, P193; Palmiter KA, 1999, J PHYSIOL-LONDON, V519, P669, DOI 10.1111/j.1469-7793.1999.0669n.x; PATLAK JB, 1993, BIOPHYS J, V65, P29, DOI 10.1016/S0006-3495(93)81041-5; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1995, P NATL ACAD SCI USA, V92, P3864, DOI 10.1073/pnas.92.9.3864; Roopnarine O, 1998, BIOPHYS J, V75, P3023, DOI 10.1016/S0006-3495(98)77743-4; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; Sata M, 1996, J CLIN INVEST, V98, P2866, DOI 10.1172/JCI119115; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TRYBUS KM, 1989, J CELL BIOL, V109, P2879, DOI 10.1083/jcb.109.6.2879; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; Trybus KM, 1998, J BIOL CHEM, V273, P18423, DOI 10.1074/jbc.273.29.18423; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; Tyska MJ, 2000, CIRC RES, V86, P737, DOI 10.1161/01.RES.86.7.737; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; VANBUREN P, 1994, P NATL ACAD SCI USA, V91, P12403, DOI 10.1073/pnas.91.26.12403; VANBUREN P, 1995, CIRC RES, V77, P439, DOI 10.1161/01.RES.77.2.439; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; Wendt T, 1999, J CELL BIOL, V147, P1385, DOI 10.1083/jcb.147.7.1385; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0; Yengo CM, 1999, BIOCHEMISTRY-US, V38, P14515, DOI 10.1021/bi991226l	45	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28045	28052						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10882745				2022-12-27	WOS:000089197100070
J	Hyyrylainen, HL; Vitikainen, M; Thwaite, J; Wu, HY; Sarvas, M; Harwood, CR; Kontinen, VP; Stephenson, K				Hyyrylainen, HL; Vitikainen, M; Thwaite, J; Wu, HY; Sarvas, M; Harwood, CR; Kontinen, VP; Stephenson, K			D-Alanine substitution of teichoic acids as a modulator of protein folding and stability at the cytoplasmic membrane/cell wall interface of Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LIPOTEICHOIC ACID; STAPHYLOCOCCUS-AUREUS; PERIPLASMIC PROTEIN; CELL-ENVELOPE; DLT OPERON; SECRETION; GENE; EXPRESSION; GROWTH	The extracytoplasmic folding of secreted proteins in Gram-positive bacteria is influenced by the microenvironment of the compartment into which they are translocated, namely the negatively charged matrix of the cell wall polymers. In this compartment, the PrsA lipoprotein facilitates correct post-translocational folding or prevents misfolding of secreted proteins. In this study, a secretion mutant of B, subtilis (prsA3) encoding a defective PrsA protein was mutagenized and screened for restored secretion of the AmyQ alpha-amylase, One mini-Tn10 insertion, which partially suppressed the secretion deficiency, was found to interrupt dht, the operon involved in the D-alanylation of teichoic acids. The inactivation of dlt rescued the mutant PrsA3 protein from degradation, and the increased amount of PrsA3 was shown to enhance the secretion of PrsA-dependent proteins. Heterologous or abnormal secreted proteins, which are prone to degradation after translocation, were also stabilized and secreted in increased quantities from a dlt prsA(+) strain, Furthermore, the dlt mutation partially suppressed the lethal effect of PrsA depletion, suggesting that the dlt deficiency also leads to stabilization of an essential cell wall protein(s), Our results suggest that main influence of the increased net negative charge of the wall caused by the absence of D-alanine is to increase the rate of post-translocational folding of exported proteins.	Natl Publ Hlth Inst, Vaccine Dev Lab, FI-00300 Helsinki, Finland; Newcastle Univ, Sch Med, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Finland National Institute for Health & Welfare; Newcastle University - UK	Kontinen, VP (corresponding author), Natl Publ Hlth Inst, Vaccine Dev Lab, FI-00300 Helsinki, Finland.	Vesa.Kontinen@ktl.fi	Kontinen, Vesa P/A-2260-2012; Harwood, Colin/AGF-0120-2022	Harwood, Colin/0000-0002-3624-0001				ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; Archibald A. R., 1993, P381; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BEVERIDGE TJ, 1980, J BACTERIOL, V141, P876, DOI 10.1128/JB.141.2.876-887.1980; Bolhuis A, 1998, J BIOL CHEM, V273, P21217, DOI 10.1074/jbc.273.33.21217; Bolhuis A, 1999, J BIOL CHEM, V274, P24531, DOI 10.1074/jbc.274.35.24531; CHAMBERT R, 1990, BIOCHEM J, V265, P375, DOI 10.1042/bj2650375; Danese PN, 1997, GENE DEV, V11, P1183, DOI 10.1101/gad.11.9.1183; Dartigalongue C, 1998, EMBO J, V17, P3968, DOI 10.1093/emboj/17.14.3968; Driessen AJM, 1998, CURR OPIN MICROBIOL, V1, P216, DOI 10.1016/S1369-5274(98)80014-3; HUGHES AH, 1973, BIOCHEM J, V132, P83, DOI 10.1042/bj1320083; JACOBS M, 1993, MOL MICROBIOL, V8, P957, DOI 10.1111/j.1365-2958.1993.tb01640.x; KONTINEN VP, 1993, MOL MICROBIOL, V8, P727, DOI 10.1111/j.1365-2958.1993.tb01616.x; KONTINEN VP, 1991, MOL MICROBIOL, V5, P1273, DOI 10.1111/j.1365-2958.1991.tb01901.x; KONTINEN VP, 1988, J GEN MICROBIOL, V134, P2333; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAMBERT PA, 1975, BIOCHEM J, V151, P671, DOI 10.1042/bj1510671; Lazar SW, 1996, J BACTERIOL, V178, P1770, DOI 10.1128/jb.178.6.1770-1773.1996; Leloup L, 1997, MICROBIOL-UK, V143, P3295, DOI 10.1099/00221287-143-10-3295; Leskela S, 1999, MOL MICROBIOL, V31, P533, DOI 10.1046/j.1365-2958.1999.01194.x; Leskela S, 1999, MOL MICROBIOL, V31, P1075, DOI 10.1046/j.1365-2958.1999.01247.x; MACARTHUR AE, 1984, J BACTERIOL, V160, P792, DOI 10.1128/JB.160.2.792-793.1984; MEENS J, 1993, MOL MICROBIOL, V9, P847, DOI 10.1111/j.1365-2958.1993.tb01743.x; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; Missiakas D, 1997, TRENDS BIOCHEM SCI, V22, P59, DOI 10.1016/S0968-0004(96)10072-4; Neuhaus FC, 1996, MICROB DRUG RESIST, V2, P77, DOI 10.1089/mdr.1996.2.77; PALVA I, 1982, GENE, V19, P81, DOI 10.1016/0378-1119(82)90191-3; PEREGO M, 1995, J BIOL CHEM, V270, P15598, DOI 10.1074/jbc.270.26.15598; Peschel A, 1999, J BIOL CHEM, V274, P8405, DOI 10.1074/jbc.274.13.8405; PETIT MA, 1990, J BACTERIOL, V172, P6736, DOI 10.1128/jb.172.12.6736-6740.1990; PETITGLATRON MF, 1993, MOL MICROBIOL, V9, P1097, DOI 10.1111/j.1365-2958.1993.tb01239.x; Pogliano J, 1997, GENE DEV, V11, P1169, DOI 10.1101/gad.11.9.1169; Raivio TL, 1999, CURR OPIN MICROBIOL, V2, P159, DOI 10.1016/S1369-5274(99)80028-9; Rouviere PE, 1996, GENE DEV, V10, P3170, DOI 10.1101/gad.10.24.3170; RUDD KE, 1995, TRENDS BIOCHEM SCI, V20, P12, DOI 10.1016/S0968-0004(00)88940-9; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Spatafora GA, 1999, J BACTERIOL, V181, P2363, DOI 10.1128/JB.181.8.2363-2372.1999; Stephenson K, 1998, FEBS LETT, V430, P385, DOI 10.1016/S0014-5793(98)00698-X; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; Swaving J, 1999, J BACTERIOL, V181, P7021, DOI 10.1128/JB.181.22.7021-7027.1999; THOMAS M, 1975, J MOL BIOL, V91, P315, DOI 10.1016/0022-2836(75)90383-6; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; Tjalsma H, 1999, J BIOL CHEM, V274, P28191, DOI 10.1074/jbc.274.40.28191; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; Wecke J, 1996, MICROB DRUG RESIST, V2, P123, DOI 10.1089/mdr.1996.2.123	47	97	99	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26696	26703						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10871614				2022-12-27	WOS:000089144800006
J	Shao, HP; Andres, DA				Shao, HP; Andres, DA			A novel RalGEF-like protein, RGL3, as a candidate effector for Rit and Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; GTP-BINDING PROTEINS; C-FOS PROMOTER; PUTATIVE EFFECTOR; CELLULAR-TRANSFORMATION; SIGNALING PATHWAY; EXCHANGE FACTORS; H-RAS; R-RAS; ACTIVATION	The small GTPase Rit is a close relative of Ras, and constitutively active Rit can induce oncogenic transformation. Although the effector loops of Rit and Ras are highly related, Rit fails to interact with the majority of the known Ras candidate effector proteins, suggesting that novel cellular targets may be responsible for Rit transforming activity. To gain insight into the cellular function of Rit, we searched for Rit-binding proteins by yeast two-hybrid screening. We identified the C-terminal Rit/Ras interaction domain of a protein we have designated RGL3 (Ral GEF-like 3) that shares 35% sequence identity with the known Ral guanine nucleotide exchange factors (RalGEFs). RGL3, through a C-terminal 99-amino acid domain, interacted in a GTP- and effector loop-dependent manner with Rit and Ras. Importantly, RGL3 exhibited guanine nucleotide exchange activity toward the small GTPase Ral that was stimulated in vivo by the expression of either activated Rit or Res. These data suggest that RGL3 functions as an exchange factor for Ral and may serve as a downstream effector for both Rit and Ras.	Univ Kentucky, Coll Med, Dept Biochem, Lexington, KY 40536 USA	University of Kentucky	Andres, DA (corresponding author), Univ Kentucky, Coll Med, Dept Biochem, 800 Rose St, Lexington, KY 40536 USA.				NATIONAL EYE INSTITUTE [R29EY011231] Funding Source: NIH RePORTER; NEI NIH HHS [EY11231] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Andres DA, 1997, ARCH BIOCHEM BIOPHYS, V346, P113, DOI 10.1006/abbi.1997.0296; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Finlin BS, 1999, ARCH BIOCHEM BIOPHYS, V368, P401, DOI 10.1006/abbi.1999.1316; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; James P, 1996, GENETICS, V144, P1425; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JULIENFLORES V, 1995, J BIOL CHEM, V270, P22473; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Lee CHJ, 1996, J NEUROSCI, V16, P6784; Lee T, 1996, DEVELOPMENT, V122, P409; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Murai H, 1997, J BIOL CHEM, V272, P10483; Nancy V, 1999, J BIOL CHEM, V274, P8737, DOI 10.1074/jbc.274.13.8737; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; ORITA S, 1993, J BIOL CHEM, V268, P25542; Park SH, 1995, ONCOGENE, V11, P2349; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sawamoto K, 1999, J CELL BIOL, V146, P361, DOI 10.1083/jcb.146.2.361; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	62	58	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26914	26924						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10869344				2022-12-27	WOS:000089144800035
J	Lu, W; Peterson, R; Dasgupta, A; Scovell, WM				Lu, W; Peterson, R; Dasgupta, A; Scovell, WM			Influence of HMG-1 and adenovirus oncoprotein E1A on early stages of transcriptional preinitiation complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; RNA-POLYMERASE-II; MOBILITY GROUP PROTEIN-1; MAJOR LATE PROMOTER; DNA-BINDING; GENE-TRANSCRIPTION; FACTOR TFIIB; FUNCTIONAL INTERACTION; CRYSTAL-STRUCTURE; CORE DOMAIN	The TATA-binding protein (TBP) in the TFIID complex binds specifically to the TATA-box to initiate the stepwise assembly of the preinitiation complex (PIC) for RNA polymerase II transcription. Transcriptional activators and repressors compete with general transcription factors at each step to influence the course of the assembly. To investigate this process, the TBP.TATA complex was titrated with HMG-1 and the interaction monitored by electrophoretic mobility shift assays. The titration produced a ternary HMG-1.TBP.TATA complex, which exhibits increased mobility relative to the TBP.TATA complex. The addition of increasing levels of TFIIB to this complex results in the formation of the TFIIB.TBP.TATA complex. However, in the reverse titration, with very high mole ratios of HMG-1 present, TFIIB is not dissociated off and a complex is formed that contains all factors. The simultaneous addition of E1A to a mixture of TBP and TATA; or HMG-1, TBP, and TATA; or TFIIB, TBP, and TATA inhibits complex formation. On the other hand, E1A added to the pre-established complexes shows a significantly reduced capability to disrupt the complex. In add-back experiments with all complexes, increased levels of TBP re-established the complexes, indicating that the primary target for E1A in all complexes is TBP.	Bowling Green State Univ, Dept Chem, Bowling Green, OH 43403 USA; Ohio No Univ, Dept Chem, Ada, OH 45810 USA	Bowling Green State University; Ohio Northern University	Scovell, WM (corresponding author), Bowling Green State Univ, Dept Chem, Overman Hall, Bowling Green, OH 43403 USA.			DASGUPTA, ATREYI/0000-0002-4734-9766	PHS HHS [R15] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; BURTOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509; BURTOWSKI S, 1992, SCIENCE, V255, P1130; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; GE H, 1994, J BIOL CHEM, V269, P17136; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; GOODBOURN S, 1990, BIOCHIM BIOPHYS ACTA, V1032, P53, DOI 10.1016/0304-419X(90)90012-P; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; KIM TK, 1995, J BIOL CHEM, V270, P10976, DOI 10.1074/jbc.270.18.10976; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LILJELUND P, 1993, MOL GEN GENET, V241, P694, DOI 10.1007/BF00279913; Marmillot P, 1998, BBA-GENE STRUCT EXPR, V1395, P228, DOI 10.1016/S0167-4781(97)00153-X; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; Phillips AC, 1997, J GEN VIROL, V78, P905, DOI 10.1099/0022-1317-78-4-905; Pugh B F, 1995, Methods Mol Biol, V37, P359; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; ROBERTS SGE, 1995, CURR BIOL, V5, P508, DOI 10.1016/S0960-9822(95)00103-5; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; Sutrias-Grau M, 1999, J BIOL CHEM, V274, P1628, DOI 10.1074/jbc.274.3.1628; TAYLOR DA, 1993, MOL CELL BIOL, V13, P4714, DOI 10.1128/MCB.13.8.4714; WATT F, 1988, NUCLEIC ACIDS RES, V16, P1471, DOI 10.1093/nar/16.4.1471; Wu WH, 1999, P NATL ACAD SCI USA, V96, P2764, DOI 10.1073/pnas.96.6.2764; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	61	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35006	35012		10.1074/jbc.M004735200	http://dx.doi.org/10.1074/jbc.M004735200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10882737	hybrid			2022-12-27	WOS:000165422800026
J	Matsuura, I; Bondarenko, VA; Maeda, T; Kachi, S; Yamazaki, M; Usukura, J; Hayashi, F; Yamazaki, A				Matsuura, I; Bondarenko, VA; Maeda, T; Kachi, S; Yamazaki, M; Usukura, J; Hayashi, F; Yamazaki, A			Phosphorylation by cyclin-dependent protein kinase 5 of the regulatory subunit of retinal cGMP phosphodiesterase I. Identification of the kinase and its role in the turnoff of phosphodiesterase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATESBIANA ROD PHOTORECEPTORS; TRANSDUCIN ALPHA-SUBUNIT; BRAIN-SPECIFIC ACTIVATOR; GTP-BINDING PROTEIN; GAMMA-SUBUNIT; INHIBITORY SUBUNIT; GMP PHOSPHODIESTERASE; BOVINE BRAIN; ADP-RIBOSYLATION; OUTER SEGMENTS	Cyclic GMP phosphodiesterase (PDE) is an essential component in retinal phototransduction. PDE is regulated by P gamma, the regulatory subunit of PDE, and GTP/T alpha, the GTP-bound cu subunit of transducin. In previous studies (Tsuboi, S., Matsumoto, H., Jackson, K. W., Tsujimoto, K., Williamas, T., and Yamazaki, A. (1994) J. Biol. Chem. 269, 15016-15023; Tsuboi, S., Matsumoto, H., and Yamazaki, A. (1994) J. Biol. Chem. 269, 15024-15029), we showed that P gamma is phosphorylated by a previously unknown kinase (Py kinase) in a GTP-dependent manner in photoreceptor outer segment membranes. We also showed that phosphorylated P gamma loses its ability to interact with GTP/T alpha, but gains a 10-15 times higher ability to inhibit GTP/T alpha -activated PDE than that of nonphosphorylated P gamma. Thus, we propose that the P gamma phosphorylation is probably involved in the recovery phase of phototransduction through shut off of GTP/T alpha -activated PDE. Here we demonstrate that all known P gammas preserve a consensus motif for cyclin-dependent protein kinase 5 (Cdk5), a protein kinase believed to be involved in neuronal cell development, and that P gamma kinase is Cdk5 complexed with p35, a neuronal Cdk5 activator. Mutational analysis of P gamma indicates that all known P gammas contain a P-X-T-P-R sequence and that this sequence is required for the P gamma phosphorylation by P gamma kinase. In three different column chromatographies of a cytosolic fraction of frog photoreceptor outer segments, the P gamma kinase activity exactly coelutes with Cdk5 and p35. The P gamma kinase activity (similar to 85%) is also immunoprecipitated by a Cdk5-specific antibody, and the immunoprecipitate phosphorylates P gamma. Finally, recombinant Cdk5/p35, which were expressed using clones from a bovine retina cDNA library, phosphorylates P gamma in frog outer segment membranes in a GTP-dependent manner. These observations suggest that Cdk5 is probably involved in the recovery phase of phototransduction through phosphorylation of P gamma complexed with GTP/T alpha in mature vertebrate retinal photoreceptors.	Wayne State Univ, Sch Med, Kresge Eye Inst, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Ophthalmol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Kobe Univ, Fac Sci, Dept Biol, Kobe, Hyogo 657, Japan; Nagoya Univ, Sch Med, Dept Anat, Nagoya, Aichi 466, Japan	Wayne State University; Wayne State University; Wayne State University; Kobe University; Nagoya University	Yamazaki, A (corresponding author), Wayne State Univ, Sch Med, Kresge Eye Inst, Detroit, MI 48201 USA.	ayamazak@med.wayne.edu	Bondarenko, Vladimir/AFY-8370-2022	Usukura, Jiro/0000-0003-2286-5403	NATIONAL EYE INSTITUTE [R01EY009631, R01EY007546] Funding Source: NIH RePORTER; NEI NIH HHS [EY09631, EY07546] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAEHR W, 1979, J BIOL CHEM, V254, P1669; BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Bondarenko VA, 1997, J BIOL CHEM, V272, P15856, DOI 10.1074/jbc.272.25.15856; Bondarenko VA, 1999, BIOCHEMISTRY-US, V38, P7755, DOI 10.1021/bi990106a; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATTY P, 1992, J BIOL CHEM, V267, P19489; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CLERC A, 1992, J BIOL CHEM, V267, P6620; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COTE RH, 1993, J BIOL CHEM, V268, P17190; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; HAMILTON SE, 1990, J BIOL CHEM, V265, P11259; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4333, DOI 10.1073/pnas.88.10.4333; Hayashi F, 2000, J BIOL CHEM, V275, P32958, DOI 10.1074/jbc.M000703200; Hirooka K, 1996, J NEUROCHEM, V67, P2478; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; Kwon YT, 1999, J COMP NEUROL, V415, P218, DOI 10.1002/(SICI)1096-9861(19991213)415:2<218::AID-CNE6>3.0.CO;2-F; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIN W, 1998, J BIOL CHEM, V273, P34284; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; Nakayama T, 1999, J NEUROBIOL, V41, P326, DOI 10.1002/(SICI)1097-4695(19991115)41:3<326::AID-NEU2>3.0.CO;2-W; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; TSUBOI S, 1994, J BIOL CHEM, V269, P15024; TSUBOI S, 1994, J BIOL CHEM, V269, P15016; TUTEJA N, 1990, GENE, V88, P227, DOI 10.1016/0378-1119(90)90035-P; TUTEJA N, 1988, FEBS LETT, V232, P182, DOI 10.1016/0014-5793(88)80413-7; UDOVICHENKO IP, 1994, J BIOL CHEM, V269, P9850; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; Xu LX, 1998, BIOCHEMISTRY-US, V37, P6205, DOI 10.1021/bi973087i; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; Yamazaki A., 1998, IOVS, V39, pS953; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; Yamazaki A, 1996, J BIOL CHEM, V271, P32495, DOI 10.1074/jbc.271.51.32495	58	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32950	32957		10.1074/jbc.M000702200	http://dx.doi.org/10.1074/jbc.M000702200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10884378	hybrid			2022-12-27	WOS:000090003800079
J	Nagasawa, K; Kitamura, K; Yasui, A; Nimura, Y; Ikeda, K; Hirai, M; Matsukage, A; Nakanishi, M				Nagasawa, K; Kitamura, K; Yasui, A; Nimura, Y; Ikeda, K; Hirai, M; Matsukage, A; Nakanishi, M			Identification and characterization of human DNA polymerase beta 2, a DNA polymerase beta-related enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; OVARIAN-CANCER; LONG ARM; GENE; MUTATIONS; BRCA1; PROTEINS; RNA; CHROMOSOME-10; REQUIREMENT	The BRCA1 COOH terminus (BRCT) motif is present in many nuclear proteins that contribute to cell cycle regulation or DNA repair. Polymerase chain reaction-based screening with degenerate primers targeted to the BRCT motif resulted in the isolation of a human cDNA for a previously unidentified DNA polymerase (designated DNA polymerase beta 2) that is closely related to DNA polymerase beta (Pol beta). The predicted Pol beta 2 protein contains a BRCT motif in its NH2-terminal region; its COOH-terminal region exhibits 33% sequence identity to a corresponding region of human Pol beta. The Pol beta 2 gene is expressed in a tissue-specific manner, with transcripts being most abundant in testis. A fusion con struct comprising Pol beta 2 and green fluorescent protein exhibited a predominantly nuclear localization in transfected HeLa cells. Recombinant human Pol beta 2 from insect cells exhibited substantial DNA polymerase activity, but it did not possess terminal deoxyribonucleotidyl transferase activity. A truncated Pd beta 2 mutant lacking the BRCT motif retained substantial DNA polymerase activity, whereas a mutant Pol beta 2 with two alanine point mutations within the DNA polymerase active site did not. These results indicate that Pol beta 2 is a Pol beta-related DNA polymerase with a BRCT motif that is dispensable for its polymerase activity.	Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Natl Inst Longev Sci, Dept Geriatr Res, Obu, Aichi 4748522, Japan; Natl Chubu Hosp, Dept Surg, Obu, Aichi 4748511, Japan; Nagoya Univ, Sch Med, Dept Surg, Nagoya, Aichi 4648550, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 113, Japan; Aichi Canc Ctr, Res Inst, Cell Biol Lab, Nagoya, Aichi 4648681, Japan	Nagoya City University; Nagoya University; University of Tokyo; Aichi Cancer Center	Nakanishi, M (corresponding author), Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.	mkt-naka@med.nagoya-cu.ac.jp						Albarosa R, 1996, AM J HUM GENET, V58, P1260; Bhattacharyya N, 1999, DNA CELL BIOL, V18, P549, DOI 10.1089/104454999315097; Bienstock RJ, 1996, CANCER RES, V56, P2539; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; DOBASHI Y, 1994, CANCER RES, V54, P2827; Ford S, 1998, CANCER GENET CYTOGEN, V102, P6, DOI 10.1016/S0165-4608(97)00250-1; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; HAMMOND RA, 1990, BIOCHEMISTRY-US, V29, P286, DOI 10.1021/bi00453a039; HIRAI M, 1994, CYTOGENET CELL GENET, V66, P149, DOI 10.1159/000133687; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HORTON JK, 1995, NUCLEIC ACIDS RES, V23, P3810, DOI 10.1093/nar/23.19.3810; Iwanaga A, 1999, MUTAT RES-DNA REPAIR, V435, P121, DOI 10.1016/S0921-8777(99)00036-1; Kim SK, 1998, ONCOGENE, V17, P1749, DOI 10.1038/sj.onc.1202073; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; LARIMER FW, 1989, J BACTERIOL, V171, P230, DOI 10.1128/jb.171.1.230-237.1989; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Matsuzaki J, 1996, MOL CARCINOGEN, V15, P38, DOI 10.1002/(SICI)1098-2744(199601)15:1<38::AID-MC6>3.0.CO;2-O; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mizushina Y, 1998, BIOCHEM J, V330, P1325, DOI 10.1042/bj3301325; Oda N, 1996, J BIOL CHEM, V271, P13816, DOI 10.1074/jbc.271.23.13816; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; WANG LM, 1992, CANCER RES, V52, P4824; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WILSON S, 1988, BIOCHIM BIOPHYS ACTA, V949, P149, DOI 10.1016/0167-4781(88)90078-4; WILSON SH, 1992, DNA REPAIR MECH, V35, P343; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; Yan ZJ, 1995, BIOCHEM MOL BIOL INT, V37, P175; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404	37	59	62	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31233	31238		10.1074/jbc.M004263200	http://dx.doi.org/10.1074/jbc.M004263200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10887191	hybrid			2022-12-27	WOS:000089762700069
J	Deng, H; Callender, R; Dale, GE				Deng, H; Callender, R; Dale, GE			A vibrational structure of 7,8-dihydrobiopterin bound to dihydroneopterin aldolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DIHYDROFOLATE-REDUCTASE; ESCHERICHIA-COLI; RAMAN DIFFERENCE; CRYSTAL-STRUCTURES; TRANSITION-STATE; MECHANISM; COMPLEX; BINDING; SPECTROSCOPY; SUBSTRATE	(D)ihydroneopterin aldolase (DHNA) catalyzes the conversion of 7,8-dihhydroneopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde. An inhibitor of the enzyme, 7,8-dihydrobiopterin, free in solution and bound in its complex with the enzyme has been studied by Raman difference spectroscopy. By using isotopically labeled 7,8-dihydrobiopterin and normal mode analyses based on ab initio quantum mechanic methods, we have positively identified some of the Raman bands in the enzyme-bound inhibitor, particularly the important N5=C6 stretch mode. The spectrum of the enzyme-bound inhibitor shows that the pK(alpha) of N5 is not significantly increased in the complex. This result suggests that N5 of 7,8-dihydroneopterin is not protonated before the bond cleavage of 7,8-dihydroneopterin during the DHNA-catalyzed reaction as has been suggested. Our results also show that the N5=C6 stretch mode of 7,8- dihydrobiopterin shifts 19 cm(-1) upon binding to DHNA. Various possibilities on how the enzyme can bring about such large frequency change of the N5=C6 stretch mode are discussed.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; F Hoffmann La Roche & Co Ltd, Preclin Res, CH-4070 Basel, Switzerland	Yeshiva University; Albert Einstein College of Medicine; Roche Holding	Callender, R (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NIGMS NIH HHS [GM35183] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035183] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENKOVIC SJ, 1988, SCIENCE, V239, P1105, DOI 10.1126/science.3125607; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; CALLENDER R, 1994, ANNU REV BIOPH BIOM, V23, P215, DOI 10.1146/annurev.bb.23.060194.001243; CHEN YQ, 1994, BIOCHEMISTRY-US, V33, P7021, DOI 10.1021/bi00189a001; Deng H, 1998, BIOCHEMISTRY-US, V37, P4968, DOI 10.1021/bi9727904; Deng H, 1998, BIOCHEMISTRY-US, V37, P10972, DOI 10.1021/bi980556n; Deng H, 1998, J AM CHEM SOC, V120, P7730, DOI 10.1021/ja9814974; FIERKE CA, 1987, BIOCHEMISTRY-US, V26, P4085, DOI 10.1021/bi00387a052; Hennig M, 1998, NAT STRUCT BIOL, V5, P357, DOI 10.1038/nsb0598-357; HOWELL EE, 1986, SCIENCE, V231, P1123, DOI 10.1126/science.3511529; KRAUT J, 1987, BIOL MACROMOL ASSEM, V3, P1; Lee H, 1996, BIOCHEMISTRY-US, V35, P7012, DOI 10.1021/bi960028g; MAHARAJ G, 1990, BIOCHEMISTRY-US, V29, P4554, DOI 10.1021/bi00471a008; MCTIGUE MA, 1992, BIOCHEMISTRY-US, V31, P7264, DOI 10.1021/bi00147a009; MORRISON JF, 1988, BIOCHEMISTRY-US, V27, P5499, DOI 10.1021/bi00415a017; STONE SR, 1984, BIOCHEMISTRY-US, V23, P2753, DOI 10.1021/bi00307a034; Wang JH, 1998, BIOCHEMISTRY-US, V37, P11106, DOI 10.1021/bi980471m	17	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30139	30143		10.1074/jbc.M004464200	http://dx.doi.org/10.1074/jbc.M004464200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896664	hybrid			2022-12-27	WOS:000089577900032
J	Kan, HY; Georgopoulos, S; Zannis, V				Kan, HY; Georgopoulos, S; Zannis, V			A hormone response element in the human apolipoprotein CIII (ApoCIII) enhancer is essential for intestinal expression of the ApoA-I and ApoCIII genes and contributes to the hepatic expression of the two linked genes in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-III GENE; A-I; TRANSCRIPTIONAL REGULATION; MESSENGER-RNA; DENSITY LIPOPROTEIN; PROXIMAL PROMOTERS; RECEPTOR; REGION; CELLS; SITES	We have generated transgenic mice carrying wildtype promoters of the human apolipoprotein A-I (apoA-I)-apoCIII gene cluster or promoters mutated in their hormone response elements. The wild-type cluster directed high levels of apoA-I gene expression in liver and intestine, moderate expression in kidney, and low to minimal expression in other tissues. It also directed high levels of chloramphenicol acetyltransferase (CAT) expression (used as a reporter for the apoCIII gene) in liver, low levels in intestine and kidney, and no expression in other tissues. Mutations in the apoCIII promoter and enhancer abolished the intestinal and renal expression of the apoA-I gene, reduced hepatic apoA-I expression by 80%, and abolished CAT expression in all tissues. A similar pattern of expression was obtained by mutations in the apoCIII enhancer alone. Mutations in the proximal apoA-I promoter reduced by 85% hepatic and intestinal apoA-I expression and did not affect CAT expression, The findings suggest that a hormone response element within the apoCIII enhancer is essential for intestinal and renal expression of apoA-I and apoCIII genes and also enhances hepatic expression. The hormone response elements of the proximal apoA-I pro meter or the apoCIII enhancer can promote independently low levels of hepatic and intestinal expression of the apoA-I gene in vivo.	Boston Univ, Sch Med, Dept Med, Whitaker Cardiovasc Inst,Sect Mol Genet, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Zannis, V (corresponding author), Boston Univ, Sch Med, Dept Med, Whitaker Cardiovasc Inst,Sect Mol Genet, Boston, MA 02118 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033952] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33952] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agarwal M, 1998, J VIROL, V72, P3720, DOI 10.1128/JVI.72.5.3720-3728.1998; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; BROWN WV, 1972, BIOCHEM BIOPH RES CO, V46, P375; CASTELLI WP, 1977, CIRCULATION, V55, P767, DOI 10.1161/01.CIR.55.5.767; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; GE RW, 1994, J BIOL CHEM, V269, P13185; GINSBURG GS, 1995, J CLIN INVEST, V96, P528, DOI 10.1172/JCI118065; GLUECK CJ, 1976, J LAB CLIN MED, V88, P941; HEISS G, 1982, NIH831266 PUBL, P7; Herbert P. N., 1982, METABOLIC BASIS INHE, P589; HOGAN B, 1986, MANIPULATING MOUSE E; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; KADDA IA, 1986, J BIOL CHEM, V28, P13268; KARATHANASIS SK, 1983, P NATL ACAD SCI-BIOL, V80, P6147, DOI 10.1073/pnas.80.20.6147; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; KARATHANASIS SK, 1986, BIOCHEMISTRY-US, V25, P3962, DOI 10.1021/bi00361a034; Kardassis D, 1997, ARTERIOSCL THROM VAS, V17, P222, DOI 10.1161/01.ATV.17.1.222; Kardassis D, 1996, HYPERTENSION, V27, P980, DOI 10.1161/01.HYP.27.4.980; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAUER SJ, 1991, CIRCULATION S2, V84, P17; Lavrentiadou SN, 1999, BIOCHEMISTRY-US, V38, P964, DOI 10.1021/bi981068i; Le Beyec J, 1999, J BIOL CHEM, V274, P4954, DOI 10.1074/jbc.274.8.4954; LENICH C, 1988, J LIPID RES, V29, P755; Li JX, 2000, GENE DEV, V14, P464; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; OGAMI K, 1990, J BIOL CHEM, V265, P9808; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; QUARFORDT SH, 1982, J BIOL CHEM, V257, P4642; REUE K, 1988, J BIOL CHEM, V263, P6857; ROGHANI A, 1988, BIOCHEMISTRY-US, V27, P7428, DOI 10.1021/bi00419a038; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; Tzameli I, 1996, J BIOL CHEM, V271, P8402, DOI 10.1074/jbc.271.14.8402; WALSH A, 1993, J LIPID RES, V34, P617; WALSH A, 1989, J BIOL CHEM, V264, P6488; WINDLER E, 1980, J BIOL CHEM, V255, P5475; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028	44	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30423	30431		10.1074/jbc.M005641200	http://dx.doi.org/10.1074/jbc.M005641200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893424	hybrid			2022-12-27	WOS:000089577900069
J	Kurys, G; Tagaya, Y; Bamford, R; Hanover, JA; Waldmann, TA				Kurys, G; Tagaya, Y; Bamford, R; Hanover, JA; Waldmann, TA			The long signal peptide isoform and its alternative processing direct the intracellular trafficking of interleukin-15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED KILLER-CELLS; IL-15 MESSENGER-RNA; GROWTH-FACTOR; BETA-CHAIN; TRANSLATIONAL EFFICIENCY; ENDOPLASMIC-RETICULUM; MICROSOMAL-MEMBRANES; TRANSLOCATION; EXPRESSION; PROTEINS	Two isoforms of interleukin (IL)-15 exist: one with a short and another with a long signal peptide (LSP). Experiments using combinations of the LSP and mature proteins IL-2, IL-15, and green fluorescent protein revealed complex pathways of intracellular trafficking. In one pathway, the LSP was unprocessed, and IL-15 was not glycosylated, remained in the cytoplasm, and was degraded. The second trafficking pathway involved endoplasmic reticulum entry, N-linked glycosylation, and alternative partial LSP processing. The third pathway involved endoplasmic reticulum entry, followed by glycosylation, complete processing, and ultimately secretion. The complex intracellular trafficking patterns of LSP-IL-15 with its impediments to secretion as well as impediments to translation may be required due to the potency of IL-15 as an inflammatory cytokine. In terms of a more positive role, we propose that intracellular infection may relieve the burdens on translation and intracellular trafficking to yield effective IL-15 expression.	NCI, Metab Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Waldmann, TA (corresponding author), NCI, Metab Branch, NIH, Bldg 10,Rm 4N115,10 Ctr Dr,MSC 1374, Bethesda, MD 20892 USA.		Waldmann, Thomas/AAT-5972-2021	Waldmann, Thomas/0000-0003-4500-6660	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ALT FW, 1980, CELL, V20, P293, DOI 10.1016/0092-8674(80)90615-7; Bamford RN, 1998, J IMMUNOL, V160, P4418; Bamford RN, 1996, P NATL ACAD SCI USA, V93, P2897, DOI 10.1073/pnas.93.7.2897; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; Belin D, 1996, EMBO J, V15, P468, DOI 10.1002/j.1460-2075.1996.tb00379.x; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; McInnes IB, 1997, NAT MED, V3, P189, DOI 10.1038/nm0297-189; Meazza R, 1997, EUR J IMMUNOL, V27, P1049, DOI 10.1002/eji.1830270502; Meazza R, 1996, ONCOGENE, V12, P2187; Nishimura H, 1998, J IMMUNOL, V160, P936; Onu A, 1997, J IMMUNOL, V158, P255; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; Perera LP, 1999, J IMMUNOL, V162, P2606; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; Tagaya Y, 1997, P NATL ACAD SCI USA, V94, P14444, DOI 10.1073/pnas.94.26.14444; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; WESSENDORF JHM, 1993, J BIOL CHEM, V268, P22100; YANG H, 1995, MOL ENDOCRINOL, V9, P1380, DOI 10.1210/me.9.10.1380	29	87	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30653	30659		10.1074/jbc.M002373200	http://dx.doi.org/10.1074/jbc.M002373200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10869346	hybrid			2022-12-27	WOS:000089577900101
J	Farias, WRL; Valente, AP; Pereira, MS; Mourao, PAS				Farias, WRL; Valente, AP; Pereira, MS; Mourao, PAS			Structure and anticoagulant activity of sulfated galactans - Isolation of a unique sulfated galactan from the red algae Botryocladia occidentalis and comparison of its anticoagulant action wtth that of sulfated galactans from invertebrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN COFACTOR-II; BRANCHED CHONDROITIN SULFATE; PLICATA CHORDATA-TUNICATA; DERMATAN SULFATE; ANTITHROMBIN ACTIVITY; ASCIDIANS TUNICATES; FUCOIDAN FRACTION; SEA-CUCUMBER; HUMAN-PLASMA; GLYCOSAMINOGLYCANS	We have characterized the structure of a sulfated D-galactan from the red algae Botryocladia occidentalis. The following repeating structure (-4-alpha-D-Galp-1-->3-beta-D-Galp-1-->) was found for this polysaccharide, but with a variable sulfation pattern. Clearly one-third of the total alpha-units are 2,3-di-O-sulfated and another one-third are 2-O-sulfated, The algal sulfated D-galactan has a potent anticoagulant activity (similar potency as unfractionated heparin) due to enhanced inhibition of thrombin and factor Xa by antithrombin and/or heparin cofactor II. We also extended the experiments to several sulfated polysaccharides from marine invertebrates with simple structures, composed of a single repeating structure. A 2-O- or 3-O-sulfated L-galactan las well as a S-O-sulfated L-fucan) has a weak anticoagulant action when compared with the potent action of the algal sulfated D-galactan. Possibly, the addition of two sulfate esters to a single alpha-galactose residue has an "amplifying effect" on the anticoagulant action, which cannot be totally ascribed to the increased charge density of the polymer. These results indicate that the wide diversity of polysaccharides from marine alga and invertebrates is a useful tool to elucidate structure/anticoagulant activity relationships.	Hosp Univ Clementino Fraga Filho, Lab Tecido Conjunt, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Ceara, Dept Engn Pesca, BR-60365000 Fortaleza, Ceara, Brazil; Univ Fed Rio de Janeiro, Dept Bioquim Med, Ctr Nacl Ressonancia Nucl Magnet Macromol, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Ceara; Universidade Federal do Rio de Janeiro	Mourao, PAS (corresponding author), Hosp Univ Clementino Fraga Filho, Lab Tecido Conjunt, Caixa Postal 68041, BR-21941590 Rio De Janeiro, Brazil.		Sá Pereira, Mariana/C-2211-2015; Pereira, Mariana/GSE-3546-2022; Mourao, Paulo/AAA-5386-2020; Valente, Ana Paula/J-3010-2017	Valente, Ana Paula/0000-0001-7219-1123				ABILDGAARD U, 1984, THROMB RES, V35, P257, DOI 10.1016/0049-3848(84)90357-8; ALBAN S, 1995, THROMB RES, V78, P210; ALBANO RM, 1990, CARBOHYD RES, V208, P163, DOI 10.1016/0008-6215(90)80096-L; ALBANO RM, 1986, J BIOL CHEM, V261, P758; Alves AP, 1997, J BIOL CHEM, V272, P6965, DOI 10.1074/jbc.272.11.6965; ANDERSSON LO, 1976, THROMB RES, V9, P575, DOI 10.1016/0049-3848(76)90105-5; Carlucci MJ, 1997, INT J BIOL MACROMOL, V20, P97, DOI 10.1016/S0141-8130(96)01145-2; CHURCH FC, 1989, J BIOL CHEM, V264, P3618; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COLLIEC S, 1991, THROMB RES, V64, P143, DOI 10.1016/0049-3848(91)90114-C; CONTRERAS RR, 1988, CARBOHYD RES, V179, P411; DANISHEFSKY I, 1969, J BIOL CHEM, V244, P1741; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Falshaw R, 1996, CARBOHYD RES, V285, P81, DOI 10.1016/0008-6215(96)00031-6; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; KAKKAR VV, 1989, HEPARIN CHEM BIOL PR, P455; KIRCHER HW, 1960, ANAL CHEM, V32, P1103, DOI 10.1021/ac60165a016; Mathews MB., 1975, CONNECT TISSUE, P93; MAURAY S, 1995, THROMB HAEMOSTASIS, V74, P1280; MOURAO PAS, 1987, EUR J BIOCHEM, V166, P431, DOI 10.1111/j.1432-1033.1987.tb13534.x; Mourao PAS, 1996, J BIOL CHEM, V271, P23973, DOI 10.1074/jbc.271.39.23973; MULLOY B, 1994, J BIOL CHEM, V269, P22113; NISHINO T, 1991, THROMB RES, V64, P723, DOI 10.1016/0049-3848(91)90072-5; Painter T.J., 1983, POLYSACCHARIDES, P196, DOI DOI 10.1016/B978-0-12-065602-8.50009-1; PATANKAR MS, 1993, J BIOL CHEM, V268, P21770; Pavao MSG, 1995, J BIOL CHEM, V270, P31027, DOI 10.1074/jbc.270.52.31027; PAVAO MSG, 1989, J BIOL CHEM, V264, P9972; Pavao MSG, 1998, J BIOL CHEM, V273, P27848, DOI 10.1074/jbc.273.43.27848; PAVAO MSG, 1990, CARBOHYD RES, V208, P153, DOI 10.1016/0008-6215(90)80095-K; Pereira MS, 1999, J BIOL CHEM, V274, P7656, DOI 10.1074/jbc.274.12.7656; SAITO H, 1968, J BIOL CHEM, V243, P1536; SANTOS JA, 1992, EUR J BIOCHEM, V204, P669, DOI 10.1111/j.1432-1033.1992.tb16680.x; SCUDDER P, 1986, EUR J BIOCHEM, V157, P365, DOI 10.1111/j.1432-1033.1986.tb09678.x; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VIEIRA RP, 1988, J BIOL CHEM, V263, P18176; VIEIRA RP, 1991, J BIOL CHEM, V266, P13530; Vilela-Silva ACES, 1999, GLYCOBIOLOGY, V9, P927, DOI 10.1093/glycob/9.9.927; Yamada T, 2000, CARBOHYD POLYM, V41, P115, DOI 10.1016/S0144-8617(99)00083-1	41	214	240	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29299	29307		10.1074/jbc.M002422200	http://dx.doi.org/10.1074/jbc.M002422200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882718	hybrid			2022-12-27	WOS:000089439800018
J	Kiyono, M; Kato, J; Kataoka, T; Kaziro, Y; Satoh, T				Kiyono, M; Kato, J; Kataoka, T; Kaziro, Y; Satoh, T			Stimulation of Ras guanine nucleotide exchange activity of Ras-GRF1/CDC25(Mm) upon tyrosine phosphorylation by the Cdc42-regulated kinase ACK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HEMATOPOIETIC-CELLS; SIGNALING PATHWAY; MAP KINASE; DEPENDENT ACTIVATION; PROTEIN; BINDING; CLONING; CDC25; GRF	Ras-GRF1 is a brain-specific guanine nucleotide exchange factor (GEF) for Ras, whose activity is regulated in response to Ca2+ influx and G protein-coupled receptor signals. In addition, Ras-GRF1 acts as a GEF for Rac when tyrosine-phosphorylated following G protein-coupled receptor stimulation. However, the mechanisms underlying the regulation of Ras-GRF1 functions remain incompletely understood. We show here that activated ACK1, a nonreceptor tyrosine kinase that belongs to the focal adhesion kinase family, causes tyrosine phosphorylation of Ras-GRF1. On the other hand, kinase-deficient ACK1 exerted no effect. GEF activity of Ras-GRF1 toward Ha-Has, as defined by in vitro GDP binding and release assays, was augmented after tyrosine phosphorylation by ACK1. In contrast, GEF activity toward Rad remained latent, implying that ACK1 does not represent a tyrosine kinase that acts downstream of G protein-coupled receptors. Consistent with enhanced Ras-GEF activity, accumulation of the GTP-bound form of Ras within the cell was shown through the use of has-binding domain pull-down assays. Furthermore, Ras-dependent activation of ERK2 by Ras-GRF1 was enhanced following co-expression of activated ACK1. These results implicate ACK1 as an upstream modulator of Ras-GRF1 and suggest a signaling cascade consisting of Cdc42, ACK1, Ras-GRF1, and Has in neuronal cells.	Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, Kobe, Hyogo 6500017, Japan; Tokyo Inst Technol, Fac Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan	Kobe University; Tokyo Institute of Technology	Satoh, T (corresponding author), Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.		Satoh, Takaya/K-2628-2014					Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Fan WT, 1998, CURR BIOL, V8, P935, DOI 10.1016/S0960-9822(07)00376-4; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Hoehn GT, 1996, ONCOGENE, V12, P903; ITO A, 1995, FEBS LETT, V368, P183, DOI 10.1016/0014-5793(95)00643-N; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; Kato J, 2000, BIOCHEM BIOPH RES CO, V268, P141, DOI 10.1006/bbrc.2000.2106; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Kins S, 2000, NAT NEUROSCI, V3, P22, DOI 10.1038/71096; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Mattingly RR, 1999, J BIOL CHEM, V274, P37379, DOI 10.1074/jbc.274.52.37379; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; SATOH T, 1988, BIOCHIM BIOPHYS ACTA, V949, P97, DOI 10.1016/0167-4781(88)90059-0; Satoh T, 1996, FEBS LETT, V386, P230, DOI 10.1016/0014-5793(96)00449-8; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; Tago K, 1998, J BIOCHEM-TOKYO, V123, P659; VAN BT, 1995, NATURE, V376, P781; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Yang WN, 1999, J BIOL CHEM, V274, P8524, DOI 10.1074/jbc.274.13.8524	42	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29788	29793		10.1074/jbc.M001378200	http://dx.doi.org/10.1074/jbc.M001378200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882715	hybrid			2022-12-27	WOS:000089439800083
J	Wankhade, S; Yu, YH; Weinberg, J; Tainsky, MA; Kannan, P				Wankhade, S; Yu, YH; Weinberg, J; Tainsky, MA; Kannan, P			Characterization of the activation domains of AP-2 family transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; DNA-BINDING; MOUSE EMBRYOGENESIS; DROSOPHILA HOMOLOG; MAMMARY-CARCINOMA; DOWN-REGULATION; MESSENGER-RNA; HTLV-I; GROWTH; MELANOMA	Despite sequence variation, all AP-2 isotypes are capable of activating transcription, which indicates a functional conservation. We used this property to gain a unique insight into the structure and function of the activation motifs of AP-2 family transcription factors. We have precisely localized the activation motif of human AP-2 alpha to amino acids 52-108. Our experiments indicate that similar sequence of amino acids in all AP-2 isotypes except Drosophila AP-2 alpha harbor their activation motifs, Within this sequence, fewer than 36 residues are critical for transcription activation. Our comparison studies and site-directed mutagenic analyses show that these critical amino acids are strategically placed within this sequence. These residues are interspersed with nonessential and influential residues that vary in composition and length, indicating a structural flexibility. The Drosophila AP-2 alpha has its partly conserved activation motif in an extended region about twice the length of other AP-2 isotypes. Our results reveal essential elements of the amino acid composition of activators in general and shed new light on the mechanism of transcription activation.	Case Western Reserve Univ, Rammelkamp Ctr Educ & Res, Cleveland, OH 44109 USA; Wayne State Univ, Karmanos Canc Inst, Program Mol Biol & Genet, Detroit, MI 48201 USA	Case Western Reserve University; MetroHealth System; Barbara Ann Karmanos Cancer Institute; Wayne State University	Kannan, P (corresponding author), Case Western Reserve Univ, Rammelkamp Ctr Educ & Res, Metrohlth Campus,2500 Metrohlth Dr, Cleveland, OH 44109 USA.		Weinbaum, Justin S/C-3192-2009	Weinbaum, Justin S/0000-0002-0626-6083; Tainsky, Michael/0000-0002-0261-831X	NATIONAL CANCER INSTITUTE [R01CA053475, R29CA067036, R01CA084278] Funding Source: NIH RePORTER; NCI NIH HHS [CA67036, CA84278, CA53475] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C; Bauer R, 1998, ONCOGENE, V17, P1911, DOI 10.1038/sj.onc.1202114; Berk AJ, 1999, CURR OPIN CELL BIOL, V11, P330, DOI 10.1016/S0955-0674(99)80045-3; Bisgrove DA, 1999, DEV DYNAM, V214, P195, DOI 10.1002/(SICI)1097-0177(199903)214:3<195::AID-AJA3>3.0.CO;2-8; Bjorklund S, 1999, CELL, V96, P759, DOI 10.1016/S0092-8674(00)80586-3; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925-4773(95)00463-7; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRECO D, 1995, J NEUROCHEM, V65, P510; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang X, 1991, ADV APPL MATH, V12, P373; Huang YH, 1999, ARCH BIOCHEM BIOPHYS, V364, P241, DOI 10.1006/abbi.1999.1142; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Kannan F, 1999, MOL CELL BIOL, V19, P899; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P549; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; MILLER JH, 1979, J MOL BIOL, V131, P223, DOI 10.1016/0022-2836(79)90074-3; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Monge I, 1998, MECH DEVELOP, V76, P191, DOI 10.1016/S0925-4773(98)00125-7; MOSER M, 1993, NUCLEIC ACIDS RES, V21, P4844, DOI 10.1093/nar/21.20.4844; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; MOSER M, 1995, DEVELOPMENT, V121, P2779; MUCHARDT C, 1992, NEW BIOL, V4, P541; MUCHARDT C, 1992, EMBO J, V11, P2573, DOI 10.1002/j.1460-2075.1992.tb05322.x; PERKINS ND, 1994, J VIROL, V68, P6820, DOI 10.1128/JVI.68.10.6820-6823.1994; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Shen H, 1997, DEV BIOL, V188, P248, DOI 10.1006/dbio.1997.8617; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Turner BC, 1998, CANCER RES, V58, P5466; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhang LJ, 1998, ONCOGENE, V17, P1261, DOI 10.1038/sj.onc.1202050	57	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29701	29708		10.1074/jbc.M000931200	http://dx.doi.org/10.1074/jbc.M000931200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10899156	hybrid			2022-12-27	WOS:000089439800070
J	Hutt, JA; O'Rourke, JP; DeWille, J				Hutt, JA; O'Rourke, JP; DeWille, J			Signal transducer and activator of transcription 3 activates CCAAT enhancer-binding protein delta gene transcription in G(0) growth-arrested mouse mammary epithelial cells and in involuting mouse mammary gland	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; BREAST-CANCER CELLS; C/EBP-DELTA; CONSTITUTIVE ACTIVATION; STAT3 ACTIVATION; DOWN-REGULATION; EXPRESSION; INTERLEUKIN-6; DIFFERENTIATION; PROLIFERATION	The CCAAT enhancer-binding protein (C/EBP) family of transcription factors is implicated in the regulation of cell proliferation and differentiation in a variety of tissues. C/EBP delta is involved in regulating G(0) growth arrest and apoptosis of mouse mammary epithelial cells. This study shows that activation of signal transducer and activator of transcription 3 (Stat3), but not activation of Stat1 or Stat5, occurs concurrently with G(0) growth arrest of HC11 mouse mammary epithelial cells, but not NIH 3T3 fibroblasts. Promoter analysis demonstrates that the C/EBP delta promoter fragment involved in transcriptional activation during G(0) growth arrest contains a Stat3 binding site and that mutation of this site eliminates the G(0) growth arrest inducibility of the C/EBP delta promoter. Overexpression of Stat3 increases C/EBP delta promoter activity during G(0) growth arrest of HC11 cells, whereas dominant negative Stat3 decreases C/EBP delta promoter activity under the same conditions. Neither Stat3 overexpression nor dominant negative Stat3 expression influences C/EBP delta promoter activity in growing HC11 cells or G(0) growth-arrested NIH3T3 cells, demonstrating that the effect is specific to G(0) growth arrest of mammary epithelial cells. Band shift assays and antibody interference assays demonstrate specific binding of Stat3 to the acute phase response element in the C/EBP delta promoter in G(0) growth-arrested HC11 cell extracts and 24 h involuting mouse mammary gland extracts. These data indicate that Stat3 activates C/EBP delta transcription in G(0) growth-arrested mouse mammary epithelial cells and binds to the C/EBP delta promoter during involution, An autocrine mechanism of Stat3 activation is proposed.	Ohio State Univ, Dept Vet Biosci, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Div Mol Biol & Canc Genet, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	DeWille, J (corresponding author), Ohio State Univ, Dept Vet Biosci, Ctr Comprehens Canc, 1900 Coffey Rd, Columbus, OH 43210 USA.				NCI NIH HHS [P30CA16058, CA 57607] Funding Source: Medline; NCRR NIH HHS [RR00136CA] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA057607, R01CA057607, P30CA016058] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000136] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALAM T, 1992, J BIOL CHEM, V267, P5021; Basolo F, 1996, CANCER RES, V56, P3118; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CASELLA G, 1990, STAT INFERENCE, P328; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; CHEN L, 1991, J BIOL REG HOMEOS AG, V5, P125; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chiu JJ, 1996, CLIN CANCER RES, V2, P215; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DOPPLER W, 1995, J BIOL CHEM, V270, P17962, DOI 10.1074/jbc.270.30.17962; Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Gigliotti AP, 1998, J CELL PHYSIOL, V174, P232, DOI 10.1002/(SICI)1097-4652(199802)174:2<232::AID-JCP10>3.0.CO;2-E; HURST HC, 1994, PROTEIN PROFILE, V1, P123; Ji CH, 1999, ENDOCRINOLOGY, V140, P4564, DOI 10.1210/en.140.10.4564; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Liu JW, 1997, CELL GROWTH DIFFER, V8, P667; Liu JW, 1998, CYTOKINE, V10, P295, DOI 10.1006/cyto.1997.0283; Mayol Xavier, 1998, Frontiers in Bioscience, V3, pD11; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Narimatsu M, 1997, BIOCHEM BIOPH RES CO, V238, P764, DOI 10.1006/bbrc.1997.7387; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; O'Rourke JP, 1999, BIOCHEM BIOPH RES CO, V262, P696, DOI 10.1006/bbrc.1999.1256; Okada H, 1997, J VET MED SCI, V59, P503, DOI 10.1292/jvms.59.503; Oritani K, 1999, BLOOD, V93, P1346, DOI 10.1182/blood.V93.4.1346.404k15_1346_1354; ORourke J, 1997, J BIOL CHEM, V272, P6291, DOI 10.1074/jbc.272.10.6291; Petersen H, 1998, EXP CELL RES, V243, P347, DOI 10.1006/excr.1998.4160; Philp JAC, 1996, FEBS LETT, V396, P77, DOI 10.1016/0014-5793(96)01069-1; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sambrook J., 2002, MOL CLONING LAB MANU; Sartor CI, 1997, CANCER RES, V57, P978; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Skov S, 1998, BLOOD, V91, P3566; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Tone E, 1998, BIOCHEM BIOPH RES CO, V253, P147, DOI 10.1006/bbrc.1998.9767; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Yamada T, 1997, J BIOCHEM-TOKYO, V121, P731; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zushi SI, 1998, INT J CANCER, V78, P326, DOI 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4	52	64	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29123	29131		10.1074/jbc.M004476200	http://dx.doi.org/10.1074/jbc.M004476200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10867011	hybrid			2022-12-27	WOS:000089330700101
J	Wieland, T; Bahtijari, N; Zhou, XB; Kleuss, C; Simon, MI				Wieland, T; Bahtijari, N; Zhou, XB; Kleuss, C; Simon, MI			Polarity exchange at the interface of regulators of G protein signaling with G protein alpha-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; HETEROTRIMERIC G-PROTEINS; PHOSPHOLIPASE-C; RGS PROTEINS; ADENYLYL-CYCLASE; BINDING; TRANSDUCIN; GAIP; SELECTIVITY; INHIBITION	RGS proteins are GTPase-activating proteins (GAPs) for G protein alpha-subunits. This GAP activity is mediated by the interaction of conserved residues on regulator of G protein signaling (RGS) proteins and G alpha-subunits. We mutated the important contact sites Glu-89, Asn-90, and Asn-130 in RGS16 to lysine, aspartate, and alanine, respectively. The interaction of RGS16 and its mutants with G alpha(t) and G alpha(i1) was studied. The GAP activities of RGS16N90D and RGS16N130A were strongly attenuated. RGS16E89K increased GTP hydrolysis of G alpha(i1) by a similar extent, but with an about 100-fold reduced affinity compared with non-mutated RGS16. As Glu-89 in RGS16 is interacting with Lys-210 in G alpha(i1), this lysine was changed to glutamate for compensation. G alpha(i1)K210E was insensitive to RGS16 but interacted with RGS16E89K. In rat uterine smooth muscle cells, wild type RGS16 abolished G(1)-mediated alpha(2)-adrenoreceptor signaling, whereas RGS16E89K was without effect. Both G alpha(i1) and G alpha(i1) K210E mimicked the effect of alpha(2)-adrenoreceptor stimulation. G alpha(i1)K210E was sensitive to RGS16E89K and 10-fold more potent than G alpha(i1). Analogous mutants of G alpha(q) (G alpha(q)K215E) and RGS4 (RGS4E87K) were created and studied in COS-7 cells. The activity of wild type G alpha(q) was counteracted by wild type RGS4 but not by RGS4E87K. The activity of G alpha(q)K215E was inhibited by RGS4E87K, whereas non-mutated RGS4 was ineffective. We conclude that mutation of a conserved lysine residue to glutamate in G alpha(i) and G alpha(q) family members renders these proteins insensitive to wild type RGS proteins. Nevertheless, they are sensitive to glutamate to lysine mutants of RGS proteins. Such mutant pairs will be helpful tools in analyzing G alpha-RGS specificities in living cells.	Univ Hamburg, Inst Expt & Klin Pharmakol & Toxikol, Krankenhaus Eppendorf, D-20246 Hamburg, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany; CALTECH, Div Biol, Pasadena, CA 91125 USA	University of Hamburg; Free University of Berlin; California Institute of Technology	Wieland, T (corresponding author), Univ Hamburg, Inst Expt & Klin Pharmakol & Toxikol, Krankenhaus Eppendorf, Martinistr 52, D-20246 Hamburg, Germany.		Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261				Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Ingi T, 1998, J NEUROSCI, V18, P7178; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LEE E, 1994, METHOD ENZYMOL, V237, P146; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; Natochin M, 1998, J BIOL CHEM, V273, P6731, DOI 10.1074/jbc.273.12.6731; Nekrasova ER, 1997, BIOCHEMISTRY-US, V36, P7638, DOI 10.1021/bi970427r; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Offermanns S, 1996, CANCER SURV, V27, P177; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P238; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Posner BA, 1999, BIOCHEMISTRY-US, V38, P7773, DOI 10.1021/bi9906367; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WIELAND T, 1990, FEBS LETT, V274, P111, DOI 10.1016/0014-5793(90)81342-L; WIELAND T, 1991, EUR J BIOCHEM, V196, P707, DOI 10.1111/j.1432-1033.1991.tb15869.x; Wieland T, 1997, J BIOL CHEM, V272, P8853; WIELAND T, 1999, N-S ARCH PHARMACOL, V360, P99; WU DQ, 1992, J BIOL CHEM, V267, P1811; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	33	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28500	28506		10.1074/jbc.M004187200	http://dx.doi.org/10.1074/jbc.M004187200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878019	Green Accepted, hybrid			2022-12-27	WOS:000089330700023
J	Trainor, CD; Ghirlando, R; Simpson, MA				Trainor, CD; Ghirlando, R; Simpson, MA			GATA zinc finger interactions modulate DNA binding and transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; LOCUS-CONTROL REGION; EPSILON-GLOBIN GENE; REGULATORY GENE; COFACTOR FOG; MICE LACKING; PROTEIN; EXPRESSION; PROMOTER; FAMILY	GATA-1 and other vertebrate GATA factors contain a DNA binding domain composed of two adjacent homologous zinc fingers. Whereas only the C-terminal finger of GATA-1 is capable of independent binding to the GATA recognition sequence, double GATA sites that require both fingers for high affinity interaction are found in several genes. We propose a mechanism whereby adjacent zinc fingers interact to influence the binding and transactivation properties of GATA-1 at a subset of DNA-binding sites. By using two such double GATA sites we demonstrate that the N-terminal finger and adjacent linker region can alter the binding specificity of the C-terminal finger sufficiently to prevent it from recognizing some consensus GATA sequences. Therefore, the two zinc fingers form a composite binding domain having a different DNA binding specificity from that shown by the constituent single C-terminal finger. Furthermore, we compare two of these double sites and show that high affinity binding of GATA-1 to a reporter gene does not necessarily induce transactivation, namely the sequence of the DNA-binding site can alter the ability of GATA-1 to stimulate transcription.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Trainor, CD (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	cecelia@intra.niddk.nih.gov	Ghirlando, Rodolfo/A-8880-2009		NHLBI NIH HHS [HL03601] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036121] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEUG H, 1982, J CELL PHYSIOL, P195; Boyes J, 1998, J MOL BIOL, V279, P529, DOI 10.1006/jmbi.1998.1783; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FU YH, 1990, MOL CELL BIOL, V10, P1056, DOI 10.1128/MCB.10.3.1056; Ghirlando R, 2000, J BIOL CHEM, V275, P28152; GROSVELD F, 1993, BAILLIERE CLIN HAEM, V6, P31, DOI 10.1016/S0950-3536(05)80065-4; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; Holmes M, 1999, J BIOL CHEM, V274, P23491, DOI 10.1074/jbc.274.33.23491; Imagawa S, 1997, BLOOD, V89, P1430, DOI 10.1182/blood.V89.4.1430; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KLUG A, 1995, ANN NY ACAD SCI, V758, P143, DOI 10.1111/j.1749-6632.1995.tb24814.x; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; Kowalski K, 1999, J BIOMOL NMR, V13, P249, DOI 10.1023/A:1008309602929; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Mackay JP, 1998, J BIOL CHEM, V273, P30560, DOI 10.1074/jbc.273.46.30560; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; Menetski JP, 2000, J BIOL CHEM, V275, P7619, DOI 10.1074/jbc.275.11.7619; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; Onodera K, 1997, J BIOCHEM, V121, P251; ORKIN SH, 1992, BLOOD, V80, P575; Osada H., 1997, Leukemia (Basingstoke), V11, P307; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Pedone PV, 1997, EMBO J, V16, P2874, DOI 10.1093/emboj/16.10.2874; PETERS B, 1993, J BIOL CHEM, V268, P3430; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Pomerantz O, 1998, NUCLEIC ACIDS RES, V26, P5684, DOI 10.1093/nar/26.24.5684; RAICH N, 1995, EMBO J, V14, P801, DOI 10.1002/j.1460-2075.1995.tb07058.x; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; STAMATOYANNOPOULOS JA, 1995, EMBO J, V14, P106, DOI 10.1002/j.1460-2075.1995.tb06980.x; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; WHYATT DJ, 1993, EMBO J, V12, P4993, DOI 10.1002/j.1460-2075.1993.tb06193.x; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; Zhu JW, 1997, GENE DEV, V11, P2883, DOI 10.1101/gad.11.21.2883	55	81	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28157	28166						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862757				2022-12-27	WOS:000089197100083
J	Spady, DK; Willard, MN; Meidell, RS				Spady, DK; Willard, MN; Meidell, RS			Role of acyl-coenzyme A : cholesterol acyltransferase-1 in the control of hepatic very low density lipoprotein secretion and low density lipoprotein receptor expression in the mouse and hamster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; B-CONTAINING LIPOPROTEINS; ADENOVIRUS-MEDIATED TRANSFER; ELEMENT-BINDING PROTEIN-1; MESSENGER-RNA LEVELS; APOLIPOPROTEIN-B; HEPG2 CELLS; FATTY-ACIDS; IN-VIVO; ABETALIPOPROTEINEMIA GENE	Cholesteryl esters present in nascent very low density lipoproteins are generated in a reaction catalyzed by acyl CoA:cholesterol acyltransferase (ACAT), To examine the effect of cholesteryl esters on the secretion of apoB-containing lipoproteins, we transiently overexpressed human (h) ACAT-1 in the livers of low density lipoprotein (LDL) receptor(-/-) mice using adenovirus-mediated gene transfer. Overexpression of hACAT-1 increased hepatic total and esterified cholesterol but did not reduce hepatic free cholesterol due to a compensatory increase in the rate of de novo cholesterol synthesis. Overexpression of hACAT-1 markedly increased the plasma concentration and hepatic secretion of apoB-containing lipoproteins but had no effect on the clearance of very low density lipoprotein-apoB from plasma indicating that cholesteryl esters play an important role in regulating the assembly and secretion of apoB-containing lipoproteins. ACAT activity has been implicated in the regulation of the LDL receptor pathway by dietary fatty acids. it has been hypothesized that unsaturated fatty acids, by enhancing ACAT activity, reduce the amount of free cholesterol in a putative regulatory pool that feeds back on LDL receptor expression. We directly tested this hypothesis in hamsters by transiently overexpressing hACAT-1 in the liver. Enhanced cholesterol esterification in the liver resulted in a compensatory increase in de novo cholesterol synthesis but no induction of LDL receptor expression suggesting that fatty acids regulate LDL receptor expression via a mechanism independent of ACAT.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Spady, DK (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	spady@utsw.swmed.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047551, R01HL038049] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38049, HL-47551] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; Burnett JR, 1999, J LIPID RES, V40, P1317; CARR TP, 1995, J LIPID RES, V36, P25; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CHIANG JYL, 1991, METHOD ENZYMOL, V206, P483; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; DASHTI N, 1992, J BIOL CHEM, V267, P7160; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DIXON JL, 1993, J LIPID RES, V34, P167; GERARD RD, 1995, DNA CLONING PRACTICA; GLASS CK, 1983, J BIOL CHEM, V258, P7161; Gordon DA, 1997, CURR OPIN LIPIDOL, V8, P131, DOI 10.1097/00041433-199706000-00002; Graham A, 1996, BBA-LIPID LIPID MET, V1302, P46, DOI 10.1016/0005-2760(96)00030-6; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HOLMQUIST L, 1978, ANAL BIOCHEM, V88, P457, DOI 10.1016/0003-2697(78)90444-X; HORTON JD, 1993, J CLIN INVEST, V92, P743, DOI 10.1172/JCI116645; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Jamil H, 1998, J LIPID RES, V39, P1448; Joyce C, 1999, CURR OPIN LIPIDOL, V10, P89, DOI 10.1097/00041433-199904000-00002; Lee O, 1998, J LIPID RES, V39, P1722; Li XH, 1996, J LIPID RES, V37, P210; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Musanti R, 1996, J LIPID RES, V37, P1; Ooyen C, 1997, ATHEROSCLEROSIS, V130, P143, DOI 10.1016/S0021-9150(96)06060-1; PAPE ME, 1995, J LIPID RES, V36, P823; PULLINGER CR, 1989, J LIPID RES, V30, P1065; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Rudel LL, 1998, PROG LIPID RES, V37, P353, DOI 10.1016/S0163-7827(98)00015-0; RUMSEY SC, 1995, J BIOL CHEM, V270, P10008, DOI 10.1074/jbc.270.17.10008; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SATO R, 1990, BIOCHIM BIOPHYS ACTA, V1042, P36, DOI 10.1016/0005-2760(90)90053-Z; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; SPADY DK, 1993, ANNU REV NUTR, V13, P355, DOI [10.1146/annurev.nutr.13.1.355, 10.1146/annurev.nu.13.070193.002035]; SPADY DK, 1995, J CLIN INVEST, V96, P700, DOI 10.1172/JCI118113; Spady DK, 1998, J BIOL CHEM, V273, P126, DOI 10.1074/jbc.273.1.126; SPECTOR AA, 1980, J LIPID RES, V21, P169; TABAS I, 1986, J BIOL CHEM, V261, P3147; TANAKA M, 1993, J BIOL CHEM, V268, P12713; Tietge UJF, 1999, J LIPID RES, V40, P2134; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; Wang SL, 1997, J BIOL CHEM, V272, P19351, DOI 10.1074/jbc.272.31.19351; WETTERAU JR, 1992, SCIENCE, V258, P999; Wilcox LJ, 1999, ARTERIOSCL THROM VAS, V19, P939, DOI 10.1161/01.ATV.19.4.939; WU XJ, 1994, J BIOL CHEM, V269, P12375; YAO ZM, 1988, J BIOL CHEM, V263, P2998; Zhang ZJ, 1999, ARTERIOSCL THROM VAS, V19, P743, DOI 10.1161/01.ATV.19.3.743	52	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27005	27012						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10869364				2022-12-27	WOS:000089144800046
J	Kuang, AA; Diehl, GE; Zhang, JK; Winoto, A				Kuang, AA; Diehl, GE; Zhang, JK; Winoto, A			FADD is required for DR4-and DR5-mediated apoptosis - Lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOTOXIC LIGAND TRAIL; NF-KAPPA-B; CELL-DEATH INDUCTION; SIGNALING COMPLEX; DEPENDENT APOPTOSIS; MEDIATED APOPTOSIS; MOLECULAR-CLONING; APO-2 LIGAND; RECEPTOR; FAMILY	TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is a member of the tumor necrosis factor family that can kill a wide variety of tumor cells but not normal cells. TRAIL-induced apoptosis in humans is mediated by its receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2). What constitutes the signaling molecules downstream of these receptors, however, remains highly controversial. Using the FADD dominant negative molecule, several groups have reached different conclusions with respect to the role of FADD in TRAIL-induced apoptosis. More recently, using FADD-deficient (-/-) mouse embryonic fibroblasts, Yeh ct at (Yeh, W. C., Pompa, J. L., McCurrach, M. E., Shu, H.-B., Elia, A. J,, Shahinian, A, Ng, M., Wakeham, A, Khoo, W., Mitchell, K., El-Deiry, W. S., Lowe, S. W., Goeddel, D. V., and Mak, T,W. (1998) Science 279, 1954-1958) concluded that DR4 utilizes a FADD-independent apoptotic pathway. The latter experiment, however, involved transient overexpression, which often leads to nonspecific aggregation of death domain-containing receptors. To address this issue in a more physiological setting, we stably transfected mouse DR4/5, human DR4, or human DR5 into FADD(-/-) mouse embryonic fibroblast cells. We showed that FADD(-/-) MEF cells stably transfected with TRAIL receptors are resistant to TRAIL-mediated cell death. In contrast, TRAIL receptors stably transfected into heterozygous FADD(+/-) cells or FADD(-/-) cells reconstituted with a FADD retroviral construct are sensitive to the TRAIL cytotoxic effect. We conclude that FADD is required for DR4- and DR5-mediated apoptosis.	Univ Calif Berkeley, Dept Mol & Cell Biol, Canc Res Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Div Immunol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Winoto, A (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Canc Res Lab, 229 Stanley Hall, Berkeley, CA 94720 USA.			Zhang, Jianke/0000-0002-5822-2226; Diehl, Gretchen/0000-0002-1841-2842	NCI NIH HHS [CA75162] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075162] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Mongkolsapaya J, 1998, J IMMUNOL, V160, P3; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Scaffidi C, 1999, CURR OPIN IMMUNOL, V11, P277, DOI 10.1016/S0952-7915(99)80045-4; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, CANCER RES, V59, P2770; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	35	196	211	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25065	25068		10.1074/jbc.C000284200	http://dx.doi.org/10.1074/jbc.C000284200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10862756	hybrid			2022-12-27	WOS:000088849400004
J	Nyyssola, A; Kerovuo, J; Kaukinen, P; von Weymarn, N; Reinikainen, T				Nyyssola, A; Kerovuo, J; Kaukinen, P; von Weymarn, N; Reinikainen, T			Extreme halophiles synthesize betaine from glycine by methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDEHYDE DEHYDROGENASE GENE; COMPATIBLE SOLUTES; ESCHERICHIA-COLI; ECTOTHIORHODOSPIRA-HALOCHLORIS; N-METHYLTRANSFERASE; BACILLUS-SUBTILIS; STRESS TOLERANCE; CHOLINE OXIDASE; WATER-STRESS; RAT-LIVER	Glycine betaine is a compatible solute, which is able to restore and maintain osmotic balance of living cells. It is synthesized and accumulated in response to abiotic stress. Betaine acts also as a methyl group donor and has a number of important applications including its use as a feed additive. The known biosynthetic pathways of betaine are universal and very well characterized. A number of enzymes catalyzing the two-step oxidation of choline to betaine have been isolated. In this work we have studied a novel betaine biosynthetic pathway in two phylogenically distant extreme halophiles, Actinopolyspora halophila and Ectothiorhodospira halochloris. We have identified a three-step series of methylation reactions from glycine to betaine, which is catalyzed by two methyltransferases, glycine sarcosine methyltransferase and sarcosine dimethylglycine methyltransferase, with partially overlapping substrate specificity. The methyltransferases from the two organisms show high sequence homology. E. halochloris methyltransferase genes were successfully expressed in Escherichia coli, and betaine accumulation and improved salt tolerance were demonstrated.	Danisco Cultor Innovat, FIN-02460 Kantvik, Finland		Reinikainen, T (corresponding author), Danisco Cultor Innovat, Sokeritehtaantie 20, FIN-02460 Kantvik, Finland.			Nyyssola, Antti/0000-0002-8195-3967				Atkinson D, 1977, CELLULAR ENERGY META, P72; Ausubel FM., 2006, ENZYMATIC MANIPULATI; Boch J, 1996, J BACTERIOL, V178, P5121, DOI 10.1128/jb.178.17.5121-5129.1996; Bohnert HJ, 1996, TRENDS BIOTECHNOL, V14, P89, DOI 10.1016/0167-7799(96)80929-2; BORK P, 1992, PROTEIN SCI, V1, P1677, DOI 10.1002/pro.5560011216; Fu ZJ, 1996, BIOCHEMISTRY-US, V35, P11985, DOI 10.1021/bi961068n; GALINSKI EA, 1994, FEMS MICROBIOL REV, V15, P95, DOI 10.1111/j.1574-6976.1994.tb00128.x; GORHAM J, 1995, AMINO ACIDS THEIR DE, P170; Guo Y, 1997, SCI CHINA SER C, V40, P496, DOI 10.1007/BF03183588; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HANSON AD, 1985, P NATL ACAD SCI USA, V82, P3678, DOI 10.1073/pnas.82.11.3678; Hayashi H, 1997, PLANT J, V12, P133, DOI 10.1046/j.1365-313X.1997.12010133.x; HOLMBERG N, 1996, THESIS LUND U; IMHOFF JF, 1977, ARCH MICROBIOL, V114, P115, DOI 10.1007/BF00410772; ISHITANI M, 1993, PLANT CELL PHYSIOL, V34, P493; ISHITANI M, 1995, PLANT MOL BIOL, V27, P307, DOI 10.1007/BF00020185; JONES RGW, 1981, BETAINES PHYSL BIOCH, P171; Kerovuo J, 1998, APPL ENVIRON MICROB, V64, P2079; KISHITANI S, 1994, PLANT CELL ENVIRON, V17, P89, DOI 10.1111/j.1365-3040.1994.tb00269.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai MC, 1999, APPL ENVIRON MICROB, V65, P828; LAI MC, 1991, J BACTERIOL, V173, P5352, DOI 10.1128/jb.173.17.5352-5358.1991; LAMARK T, 1991, MOL MICROBIOL, V5, P1049, DOI 10.1111/j.1365-2958.1991.tb01877.x; Lilius G, 1996, BIO-TECHNOL, V14, P177, DOI 10.1038/nbt0296-177; MILLER JH, 1977, EXPT MOL GENETICS, P431; MORI N, 1992, J FERMENT BIOENG, V73, P352, DOI 10.1016/0922-338X(92)90277-2; Nakamura T, 1997, PLANT J, V11, P1115, DOI 10.1046/j.1365-313X.1997.11051115.x; NOMURA M, 1995, PLANT PHYSIOL, V107, P703, DOI 10.1104/pp.107.3.703; OGAWA H, 1993, COMP BIOCHEM PHYS B, V106, P601, DOI 10.1016/0305-0491(93)90137-T; OHTAFUKUYAMA M, 1980, J BIOCHEM-TOKYO, V88, P197; Pocard JA, 1997, MICROBIOL-SGM, V143, P1369, DOI 10.1099/00221287-143-4-1369; RAHA A, 1994, J BIOL CHEM, V269, P5750; RAJAKYLA E, 1983, J CHROMATOGR, V282, P595, DOI 10.1016/S0021-9673(00)91636-4; REED RH, 1986, FEMS MICROBIOL LETT, V39, P51; RHODES D, 1993, ANNU REV PLANT PHYS, V44, P385; ROBERTS MF, 1992, J BACTERIOL, V174, P6688, DOI 10.1128/JB.174.20.6688-6693.1992; Sambrook J., 1989, MOL CLONING, pA1; SEHGAL SN, 1960, CAN J MICROBIOL, V6, P165, DOI 10.1139/m60-018; SEVERIN J, 1992, J GEN MICROBIOL, V138, P1629, DOI 10.1099/00221287-138-8-1629; Sutherland IW, 1971, METHOD MICROBIOL, V5, P345, DOI [DOI 10.1016/S0580-9517(08)70642-1, 10.1016/S0580-9517(08)70642-1]; TAKUSAGAWA F, 1998, COMPREHENSIVE BIOL C, V1, P1; TANI Y, 1979, AGR BIOL CHEM TOKYO, V43, P815, DOI 10.1080/00021369.1979.10863527; TRUPER HG, 1990, FEMS MICROBIOL LETT, V75, P247; TSCHICHHOLZ I, 1990, FEMS MICROBIOL ECOL, V73, P181, DOI 10.1016/0378-1097(90)90728-9; Velasco-Garcia R, 1999, J BACTERIOL, V181, P1292; WERETILNYK EA, 1989, ARCH BIOCHEM BIOPHYS, V271, P56, DOI 10.1016/0003-9861(89)90255-5; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	47	127	141	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22196	22201		10.1074/jbc.M910111199	http://dx.doi.org/10.1074/jbc.M910111199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10896953	hybrid			2022-12-27	WOS:000088363800062
J	Nemoto, Y; Kearns, BG; Wenk, MR; Chen, H; Mori, K; Alb, JG; De Camilli, P; Bankaitis, VA				Nemoto, Y; Kearns, BG; Wenk, MR; Chen, H; Mori, K; Alb, JG; De Camilli, P; Bankaitis, VA			Functional characterization of a mammalian Sac1 and mutants exhibiting substrate-specific defects in phosphoinositide phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; PHOSPHOLIPID TRANSFER PROTEIN; RETINAL-DEGENERATION-B; YEAST GOLGI-COMPLEX; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; GENE ENCODES; SIGNAL-TRANSDUCTION; IN-VIVO; TRANSPORT	The Saccharomyces cerevisiae SAC1 gene was identified via independent analyses of mutations that modulate yeast actin function and alleviate the essential requirement for phosphatidylinositol transfer protein (Sec14p) activity in Golgis secretory function. The SAC1 gene product (Sac1p) is an integral membrane protein of the endoplasmic reticulum and the Golgi complex, Sac1p shares primary sequence homology with a subfamily of cytosolic/peripheral membrane phosphoinositide phosphatases, the synaptojanins, and these Sad domains define novel phosphoinositide phosphatase modules. We now report the characterization of a rat counterpart of Sac1p, Rat Sad is a ubiquitously expressed 65-kDa integral membrane protein of the endoplasmic reticulum that is found at particularly high levels in cerebellar Purkinje cells. Like Sac1p, rat Sad exhibits intrinsic phosphoinositide phosphatase activity directed toward phosphatidylinositol 3-phosphate, phosphatidylinositol 4-phosphate, and phosphatidylinositol 3,5-bisphosphate substrates, and we identify mutant rat sad alleles that evoke substrate-specific defects in this enzymatic activity. Finally, rat Sad expression in Delta sac1 yeast strains complements a wide phenotypes associated with Sac1p insufficiency. Biochemical and in vivo data indicate that rat Sad phosphatidylinositol-4-phosphate phosphatase activity, but not its phosphatidylinositol-3-phosphate or pho sphatidylinositol-3,5 bisphosphate phosphatase activities, is essential for the heterologous complementation of Sac1p defects in vivo. Thus, yeast Sac1p and rat Sad are integral membrane lipid phosphatases that play evolutionary conserved roles in eukaryotic cell physiology.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Inst Phys & Chem Res, Brain Sci Inst, Wako, Saitama 3510198, Japan; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	Howard Hughes Medical Institute; Yale University; Yale University; RIKEN; University of Alabama System; University of Alabama Birmingham	De Camilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA.		Wenk, Markus Rene/D-1441-2014	Mori, Kensaku/0000-0001-7853-9370	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS037723, R01NS036251, R56NS037723] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44530] Funding Source: Medline; NINDS NIH HHS [NS37723, NS36251] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATKINSON KD, 1984, J BACTERIOL, V160, P80, DOI 10.1128/JB.160.1.80-86.1984; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; Cockcroft S, 1999, CHEM PHYS LIPIDS, V98, P23, DOI 10.1016/S0009-3084(99)00015-8; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Erdman S, 1998, J CELL BIOL, V140, P461, DOI 10.1083/jcb.140.3.461; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fang M, 1996, EMBO J, V15, P6447, DOI 10.1002/j.1460-2075.1996.tb01036.x; Fleischer S, 1974, Methods Enzymol, V31, P6; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; Hamilton BA, 1997, NEURON, V18, P711, DOI 10.1016/S0896-6273(00)80312-8; Harlow E., 1988, ANTIBODIES LAB MANUA; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Hughes WE, 1999, YEAST, V15, P1111, DOI 10.1002/(SICI)1097-0061(199908)15:11<1111::AID-YEA440>3.0.CO;2-H; Hughes WE, 2000, J BIOL CHEM, V275, P801, DOI 10.1074/jbc.275.2.801; Huijbregts RPH, 2000, TRAFFIC, V1, P195, DOI 10.1034/j.1600-0854.2000.010301.x; HWANG PM, 1990, SCIENCE, V249, P802, DOI 10.1126/science.1975122; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jin MJ, 1996, J BIOL CHEM, V271, P30105, DOI 10.1074/jbc.271.47.30105; Kearns BG, 1998, TRENDS CELL BIOL, V8, P276, DOI 10.1016/S0962-8924(98)01281-1; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Kirk CJ., 1990, PEPTIDE HORMONE ACTI, P151; Kochendorfer KU, 1999, EMBO J, V18, P1506, DOI 10.1093/emboj/18.6.1506; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MAYINGER P, 1995, J CELL BIOL, V131, P1377, DOI 10.1083/jcb.131.6.1377; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Milligan SC, 1997, J CELL BIOL, V139, P351, DOI 10.1083/jcb.139.2.351; Nemoto Y, 1997, J BIOL CHEM, V272, P30817, DOI 10.1074/jbc.272.49.30817; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NOVICK P, 1989, GENETICS, V121, P659; Phillips SE, 1999, MOL CELL, V4, P187, DOI 10.1016/S1097-2765(00)80366-4; Rivas MP, 1999, MOL BIOL CELL, V10, P2235, DOI 10.1091/mbc.10.7.2235; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN F, 1983, METHODS YEAST GENITC; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; Srinivasan S, 1997, EUR J CELL BIOL, V74, P350; Stock SD, 1999, J BIOL CHEM, V274, P12979, DOI 10.1074/jbc.274.19.12979; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; TAKEI K, 1992, J NEUROSCI, V12, P489; TANAKA S, 1994, J BIOCHEM-TOKYO, V115, P981, DOI 10.1093/oxfordjournals.jbchem.a124448; VIHTELIC TS, 1993, J CELL BIOL, V122, P1013, DOI 10.1083/jcb.122.5.1013; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; WEIMAR WR, 1982, BRAIN RES, V251, P357, DOI 10.1016/0006-8993(82)90754-5; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007	67	96	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34293	34305		10.1074/jbc.M003923200	http://dx.doi.org/10.1074/jbc.M003923200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10887188	hybrid			2022-12-27	WOS:000165095300042
J	Grimme, S; Honing, S; von Figura, K; Schmidt, B				Grimme, S; Honing, S; von Figura, K; Schmidt, B			Endocytosis of insulin-like growth factor II by a mini-receptor based on repeat 11 of the mannose 6-phosphate/insulin-like growth factor II receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; 6-PHOSPHATE RECEPTOR; IGF-II; CYTOPLASMIC DOMAIN; LYSOSOMAL-ENZYMES; MANNOSE-6-PHOSPHATE RECEPTORS; MICROSATELLITE INSTABILITY; PERINATAL LETHALITY; OVERLAP EXTENSION; HUMAN-FIBROBLASTS	The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF-II receptor) plays an important role in controlling the extracellular level of the insulin-like growth factor II (IGF-II) by mediating its binding at the cell surface and delivery to lysosomes. Loss of the receptor is associated with an accumulation of IGF-II, which can cause perinatal lethality if it is systemic, or local proliferation and tumorgenesis if it is spatially restricted. The extracytoplasmic domain of the receptor consists of 15 homologous repeats, of which repeat 11 carries the IGF-II-binding site of the multifunctional receptor. To investigate whether repeat 11 is sufficient to mediate binding and internalization of IGF-II, a construct consisting of repeat 11 fused to the transmembrane and cytoplasmic domain of the M6P/IGF-II receptor was transfected into mouse embryonic fibroblasts. The construct was expressed as a stable membrane protein which binds IGF-II with a 10-fold lower affinity as observed for the M6P/IGF-II receptor and is found at the cell surface and in endosomes. It mediates the internalization of IGF-II and its delivery to lysosomes, suggesting that it can function as a IGF-II mini-receptor controlling the extracellular IGF-II level.	Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany	University of Gottingen	Schmidt, B (corresponding author), Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.	bschmidt@uni-bc2.gwdg.de						AULETTA M, 1992, J NEUROSCI RES, V31, P14, DOI 10.1002/jnr.490310103; BALLARD FJ, 1988, BIOCHEM J, V249, P721, DOI 10.1042/bj2490721; Boker C, 1997, J CELL SCI, V110, P1023; BRAULKE T, 1988, BIOCHEM BIOPH RES CO, V150, P1287, DOI 10.1016/0006-291X(88)90769-3; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CHEN JW, 1985, ARCH BIOCHEM BIOPHYS, V239, P574, DOI 10.1016/0003-9861(85)90727-1; CREEK KE, 1983, BIOCHEM J, V214, P353, DOI 10.1042/bj2140353; DAHMS NM, 1993, ENDOCRINOLOGY, V133, P440, DOI 10.1210/en.133.2.440; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; Devi GR, 1998, MOL ENDOCRINOL, V12, P1661, DOI 10.1210/me.12.11.1661; DINTZIS SM, 1990, EMBO J, V9, P77, DOI 10.1002/j.1460-2075.1990.tb08082.x; Garmroudi F, 1996, MOL ENDOCRINOL, V10, P642, DOI 10.1210/me.10.6.642; GARTUNG C, 1985, EMBO J, V4, P1725, DOI 10.1002/j.1460-2075.1985.tb03842.x; Hankins GR, 1996, ONCOGENE, V12, P2003; HEMER F, 1993, J BIOL CHEM, V268, P17108; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOSSENLOPP P, 1986, FEBS LETT, V208, P439, DOI 10.1016/0014-5793(86)81065-1; Iacopetta BJ, 1999, J PATHOL, V187, P428, DOI 10.1002/(SICI)1096-9896(199903)187:4<428::AID-PATH264>3.0.CO;2-A; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; KIESS W, 1988, J BIOL CHEM, V263, P9339; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LUDWIG T, 1995, TRENDS CELL BIOL, V5, P202, DOI 10.1016/S0962-8924(00)89000-5; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; NIELSEN FC, 1991, J NEUROCHEM, V56, P12, DOI 10.1111/j.1471-4159.1991.tb02556.x; OKA Y, 1985, J BIOL CHEM, V260, P9435; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; Ouyang H, 1997, CANCER RES, V57, P1851; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; POHLMANN R, 1996, BIOMEMBR, V4, P223; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; ROSORIUS O, 1993, BIOCHEM J, V292, P833, DOI 10.1042/bj2920833; SAHAGIAN GG, 1983, J BIOL CHEM, V258, P7121; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; SCHULZEGARG C, 1993, J CELL BIOL, V122, P541, DOI 10.1083/jcb.122.3.541; SOSA MA, 1993, J BIOL CHEM, V268, P12537; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; TONG PY, 1988, J BIOL CHEM, V263, P2585; VONFIGURA K, 1984, EMBO J, V3, P1281, DOI 10.1002/j.1460-2075.1984.tb01963.x; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Wang SN, 1997, CANCER RES, V57, P2543; WENDLAND M, 1989, BIOCHEM J, V260, P201, DOI 10.1042/bj2600201; YU KT, 1986, J BIOL CHEM, V261, P1341	52	17	27	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33697	33703		10.1074/jbc.M003789200	http://dx.doi.org/10.1074/jbc.M003789200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10884392	hybrid			2022-12-27	WOS:000090104600072
J	Miller, T; Williams, K; Johnstone, RW; Shilatifard, A				Miller, T; Williams, K; Johnstone, RW; Shilatifard, A			Identification, cloning, expression, and biochemical characterization of the testis-specific RNA polymerase II elongation factor ELL3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ELONGATION; MYELOID-LEUKEMIA; TIGHT JUNCTIONS; PURIFICATION; PROTEIN; DROSOPHILA; GENE; LOCALIZATION; OCCLUDIN; COMPLEX	The human ELL gene, which is a frequent target for translocation in acute myeloid leukemia, was initially isolated from rat liver nuclei and found to be an RNA polymerase II elongation factor. Based on homology to ELL, we later cloned ELL2 and demonstrated that it can also increase the catalytic rate of transcription elongation by RNA polymerase II. To better understand the role of ELL proteins in the regulation of transcription by RNA polymerase II, we have initiated a search for proteins related to ELLs. In this report, we describe the molecular cloning, expression, and characterization of ELL3, a novel RNA polymerase II elongation factor approximately 50% similar to both ELL and ELL2. Our transcriptional studies have demonstrated that ELLS can also increase the catalytic rate of transcription elongation by RNA polymerase II, The C-terminal domain of ELL, which we recently demonstrated to be required and sufficient for the immortalization of myeloid progenitor cells, shares strong similarities to the C-terminal domain of ELL3. ELL3 was localized by immunofluorescence to the nucleus of cells, and Northern analysis indicated that ELL3 is a testis-specific RNA polymerase II elongation factor.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem, St Louis, MO 63104 USA; Peter MacCallum Canc Inst, Canc Immunol Div, E Melbourne, Vic 3000, Australia	Saint Louis University; Peter Maccallum Cancer Center	Shilatifard, A (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem, 1402 S Grand Blvd, St Louis, MO 63104 USA.		Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237				Aso T, 2000, J BIOL CHEM, V275, P6546, DOI 10.1074/jbc.275.9.6546; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; Conaway JW, 1999, ANNU REV BIOCHEM, V68, P301, DOI 10.1146/annurev.biochem.68.1.301; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Maki K, 1999, BLOOD, V93, P3216, DOI 10.1182/blood.V93.10.3216.410k45_3216_3224; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; Reines D, 1999, CURR OPIN CELL BIOL, V11, P342, DOI 10.1016/S0955-0674(99)80047-7; SCHMIDT EE, 1995, DEVELOPMENT, V121, P2373; Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639; Shilatifard A, 1998, J BIOL CHEM, V273, P11212, DOI 10.1074/jbc.273.18.11212; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; Shilatifard A, 1998, BIOL CHEM, V379, P27; Shilatifard A, 1997, J BIOL CHEM, V272, P22355, DOI 10.1074/jbc.272.35.22355; Shinobu N, 1999, J BIOL CHEM, V274, P17003, DOI 10.1074/jbc.274.24.17003; Thirman MJ, 1997, P NATL ACAD SCI USA, V94, P1408, DOI 10.1073/pnas.94.4.1408; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; Tollefson AE, 1998, NATURE, V392, P726, DOI 10.1038/33712; Umehara T, 1995, GENE, V167, P297, DOI 10.1016/0378-1119(95)00634-6; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Weaver ZA, 1997, GENOMICS, V46, P516, DOI 10.1006/geno.1997.5073; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; [No title captured]	33	60	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32052	32056		10.1074/jbc.M005175200	http://dx.doi.org/10.1074/jbc.M005175200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10882741	hybrid			2022-12-27	WOS:000089858900069
J	Nardini, M; Lang, DA; Liebeton, K; Jaeger, KE; Dijkstra, BM				Nardini, M; Lang, DA; Liebeton, K; Jaeger, KE; Dijkstra, BM			Crystal structure of Pseudomonas aeruginosa lipase in the open conformation - The prototype for family I.1 of bacterial lipases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA/BETA-HYDROLASE FOLD; BIOTECHNOLOGICAL APPLICATIONS; TRIACYLGLYCEROL LIPASE; BIOCHEMICAL-PROPERTIES; EXTRACELLULAR LIPASE; PROTEIN STRUCTURES; ENZYMES; REVEALS; ERRORS	The x-ray structure of the lipase from Pseudomonas aeruginosa PAO1 has been determined at 2.54 Angstrom resolution. It is the first structure of a member of homology family I.1 of bacterial lipases. The structure shows a variant of the alpha/beta hydrolase fold, with Ser(82), Asp(229), and His(251) as the catalytic triad residues. Compared with the "canonical" alpha/beta hydrolase fold, the first two P-strands and one alpha-helix (alpha E) are not present. The absence of helix alpha E allows the formation of a stabilizing intramolecular disulfide bridge. The loop containing His251 is stabilized by an octahedrally coordinated calcium ion. On top of the active site a lid subdomain is in an open conformation, making the catalytic cleft accessible from the solvent region. A triacylglycerol analogue is covalently bound to Ser(82) in the active site, demonstrating the position of the oxyanion hole and of the three pockets that accommodate the sn-1, sn-2, and sn-3 fatty acid chains. The inhibited enzyme can be thought to mimic the structure of the tetrahedral intermediate that occurs during the acylation step of the reaction. Analysis of the binding mode of the inhibitor suggests that the size of the acyl pocket and the size and interactions of the sn-2 binding pocket are the predominant determinants of the regio- and enantio-preference of the enzyme.	Univ Groningen, Dept Chem, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Chem, BIOSON Res Inst, NL-9747 AG Groningen, Netherlands; Ruhr Univ Bochum, Lehrstuhl Biol Mikroorganismen, D-44780 Bochum, Germany	University of Groningen; University of Groningen; Ruhr University Bochum	Dijkstra, BM (corresponding author), Univ Groningen, Dept Chem, Biophys Chem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	bauke@chem.rug.nl	jaeger, karl/ABB-1955-2020; Nardini, Marco/B-7842-2017	Nardini, Marco/0000-0002-3718-2165				Arpigny JL, 1999, BIOCHEM J, V343, P177, DOI 10.1042/0264-6021:3430177; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Borgstrom B, 1984, LIPASES; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cygler M, 1997, METHOD ENZYMOL, V284, P3; GILBERT EJ, 1993, ENZYME MICROB TECH, V15, P634, DOI 10.1016/0141-0229(93)90062-7; Heikinheimo P, 1999, STRUCTURE, V7, pR141, DOI 10.1016/S0969-2126(99)80079-3; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JAEGER KE, 1994, IMMUN INFEKT, V22, P177; JAEGER KE, 1994, FEMS MICROBIOL REV, V15, P29, DOI 10.1016/0168-6445(94)90025-6; Jaeger KE, 1999, ANNU REV MICROBIOL, V53, P315, DOI 10.1146/annurev.micro.53.1.315; Jaeger KE, 1998, TRENDS BIOTECHNOL, V16, P396, DOI 10.1016/S0167-7799(98)01195-0; JAEGER KE, 1992, BIOCHIM BIOPHYS ACTA, V1120, P315, DOI 10.1016/0167-4838(92)90254-B; Jaeger KE, 1997, J MOL CATAL B-ENZYM, V3, P3, DOI 10.1016/S1381-1177(96)00039-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kazlauskas RJ, 1998, CURR OPIN CHEM BIOL, V2, P121, DOI 10.1016/S1367-5931(98)80043-4; Kim KK, 1997, STRUCTURE, V5, P173, DOI 10.1016/S0969-2126(97)00177-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lang D, 1996, J MOL BIOL, V259, P704, DOI 10.1006/jmbi.1996.0352; Lang DA, 1998, EUR J BIOCHEM, V254, P333, DOI 10.1046/j.1432-1327.1998.2540333.x; Lang DA, 1998, CHEM PHYS LIPIDS, V93, P115, DOI 10.1016/S0009-3084(98)00035-8; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MANNESSE MLM, 1995, BBA-LIPID LIPID MET, V1259, P56, DOI 10.1016/0005-2760(95)00145-3; Nardini M, 1999, CURR OPIN STRUC BIOL, V9, P732, DOI 10.1016/S0959-440X(99)00037-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOBLE MEM, 1993, FEBS LETT, V331, P123, DOI 10.1016/0014-5793(93)80310-Q; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; Schrag JD, 1997, METHOD ENZYMOL, V284, P85; Schrag JD, 1997, STRUCTURE, V5, P187, DOI 10.1016/S0969-2126(97)00178-0; STUER W, 1986, J BACTERIOL, V168, P1070, DOI 10.1128/jb.168.3.1070-1074.1986; SVENDSEN A, 1995, BBA-LIPID LIPID MET, V1259, P9, DOI 10.1016/0005-2760(95)00117-U; THEIL F, 1995, CHEM REV, V95, P2203, DOI 10.1021/cr00038a017; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	37	207	218	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31219	31225		10.1074/jbc.M003903200	http://dx.doi.org/10.1074/jbc.M003903200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10893416	hybrid, Green Published			2022-12-27	WOS:000089762700067
J	Ono, T; Kitaura, H; Ugai, H; Murata, T; Yokoyama, KK; Iguchi-Ariga, SMM; Ariga, H				Ono, T; Kitaura, H; Ugai, H; Murata, T; Yokoyama, KK; Iguchi-Ariga, SMM; Ariga, H			TOK-1, a novel p21(Cip1)-binding protein that cooperatively enhances p21-dependent inhibitory activity toward CDK2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CELL NUCLEAR ANTIGEN; DNA-REPLICATION; MAMMALIAN-CELLS; TRANSCRIPTIONAL ACTIVATION; BINDING DOMAINS; E7 ONCOPROTEIN; P21; PCNA; IDENTIFICATION	A p21(Cip1/Waf1/Sdi1) is known to act as a negative cell-cycle regulator by inhibiting kinase activity of a variety of cyclin-dependent kinases. In addition to binding of the cyclin-dependent kinase to the N-terminal region of p21, p21 is also bound at its C-terminal region by proliferating cell nuclear antigen (PCNA), SET/TAF1, and calmodulin, indicating the versatile function of p21. In this study, we cloned cDNA encoding a novel protein named TOK-1 as a p21 C-terminal-binding protein by a two-hybrid system. Two splicing isoforms of TOK-1, TOK-1 alpha and TOK-1 beta, comprising 322 and 314 amino acids, respectively, were co-localized with p21 in nuclei and showed a similar expression profile to that of p21 in human tissues. TOK-1 alpha, but not TOK-1 beta, directly bound to the C-terminal proximal region of p21, and both were expressed at the G(1)/S boundary of the cell cycle. TOK-1 alpha also preferentially bound to an active form of cyclin-dependent kinase 2 (CDK2) via p21, and these made a ternary complex in human cells. Furthermore, the results of three different types of experiments showed that TOK-1 alpha enhanced the inhibitory activity of pal toward histone Ill kinase activity of CDK2. TOK-1 alpha is thus thought to be a new type of CDK2 modulator.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Hokkaido Univ, Coll Med Technol, Kita Ku, Sapporo, Hokkaido 0600812, Japan; RIKEN, Tsukuba Inst, Tsukuba, Ibaraki 3050074, Japan; CREST, Japan Sci & Technol Corp, Kawaguchi, Saitama, Japan	Hokkaido University; Hokkaido University; RIKEN; Japan Science & Technology Agency (JST)	Ariga, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.	hiro@pharm.hokudai.ac.jp	Ariga, Sanae/H-9647-2013; Ugai, Hideyo/K-4920-2017; Ariga, Hiroyoshi/B-5895-2013	Ugai, Hideyo/0000-0002-9121-8480; Ariga, Hiroyoshi/0000-0001-7384-2143; Ono, Takashi/0000-0002-1820-8040				CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOUBIN F, 1995, ONCOGENE, V10, P2281; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; KATO J, 1999, FRONT BIOSCI, V4, P787; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NEGISHI Y, 1994, ONCOGENE, V9, P1133; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Taules M, 1999, J BIOL CHEM, V274, P24445, DOI 10.1074/jbc.274.35.24445; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3	35	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31145	31154		10.1074/jbc.M003031200	http://dx.doi.org/10.1074/jbc.M003031200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10878006	hybrid			2022-12-27	WOS:000089762700057
J	Wu, GY; Toyokawa, T; Hahn, H; Dorn, GW				Wu, GY; Toyokawa, T; Hahn, H; Dorn, GW			epsilon Protein kinase C in pathological myocardial hypertrophy - Analysis by combined transgenic expression of translocation modifiers and G alpha(q)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; GROWTH; MICE; OVEREXPRESSION; CARDIOMYOPATHY; HEART; RAT	The epsilon isoform of protein kinase C (PKC) has a critical cardiotrophic function in normal postnatal developing heart as demonstrated by cardiac-specific transgenic expression of epsilon PKC-selective translocation inhibitor (epsilon V1) and activator (psi epsilon RACK) peptides (Mochly-Rosen, D., Wu, G., Hahn, H., Osinska, H., Liron, T., Lorenz, J. N., Robbins, J., and Dorn, G. W., II (2000) Circ. Res. 86, 1173-1179), To define the role of epsilon PKC signaling in pathological myocardial hypertrophy, epsilon V1 or psi epsilon RACK were coexpressed in mouse hearts with G alpha(q), a PKC-linked hypertrophy signal transducer. Compared with G alpha(q) overexpression alone, co-expression of psi epsilon RACK with G alpha(q) increased epsilon PKC particulate partitioning by 30 +/- 2%, whereas co-expression of epsilon V1 with G alpha(q) reduced particulate-associated epsilon PKC by 22 +/- 1%. Facilitation of epsilon PKC translocation by psi epsilon RACK in G alpha(q) mice improved cardiac contractile function measured as left ventricular fractional shortening (30 +/- 3% G alpha(q) versus 43 +/- 2% psi epsilon RACK/ G alpha(q), p < 0.05). Conversely, inhibition of epsilon PKC by epsilon V1 modified the G alpha(q) nonfailing hypertrophy phenotype to that of a lethal dilated cardiomyopathy. These opposing effects of epsilon PKC translocation activation and inhibition in G alpha(q) -hypertrophy indicate that epsilon PKC signaling is a compensatory event in myocardial hypertrophy, rather than a pathological event, and support the possible therapeutic efficacy of selective epsilon PKC translocation enhancement in cardiac insufficiency.	Univ Cincinnati, Med Ctr, Div Cardiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Dorn, GW (corresponding author), Univ Cincinnati, Med Ctr, Div Cardiol, 231 Bethesda Ave, Cincinnati, OH 45267 USA.	dorngw@ucmail.uc.edu			NHLBI NIH HHS [HL52318, HL58010] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058010, P50HL052318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Bowman JC, 1997, J CLIN INVEST, V100, P2189, DOI 10.1172/JCI119755; Chen CH, 1999, P NATL ACAD SCI USA, V96, P12784, DOI 10.1073/pnas.96.22.12784; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Dorn GW, 2000, MOL PHARMACOL, V57, P278; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; Fazio S, 1996, NEW ENGL J MED, V334, P809, DOI 10.1056/NEJM199603283341301; GU X, 1994, CIRC RES, V75, P926, DOI 10.1161/01.RES.75.5.926; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Qiu YM, 1998, J CLIN INVEST, V101, P2182, DOI 10.1172/JCI1258; Sakata Y, 1998, CIRCULATION, V97, P1488; SCHUNKERT H, 1995, CIRC RES, V76, P489, DOI 10.1161/01.RES.76.3.489; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320	17	66	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29927	29930		10.1074/jbc.C000380200	http://dx.doi.org/10.1074/jbc.C000380200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10899155	hybrid			2022-12-27	WOS:000089577900002
J	Chatterjee, TK; Fisher, RA				Chatterjee, TK; Fisher, RA			Novel alternative splicing and nuclear localization of human RGS12 gene products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; GTPASE-ACTIVATING PROTEINS; TRANSITION-STATE; PHOSPHOLIPASE-C; HEAVY-CHAIN; DNA-DAMAGE; PML-RAR; RNA; ALPHA; TRANSCRIPTION	RGS proteins are GTPase-activating proteins for certain Ga subunits, accelerating the shutoff mechanism of G protein signaling, and also may interact with receptors and effecters to modulate G protein signaling. Here, we report identification of 12 distinct transcripts of human RGS12 that arise by unusually complex splicing of the RGS12 gene, which spans 76 kilobase pairs of genomic DNA and contains 16 exons, These transcripts arise by both cis- and trans-splicing mechanisms, are expressed in a tissue-specific manner, and encode proteins ranging in size from 356 to 1447 amino acids. Both 5'- and 3'-splicing of two primary RGS12 transcripts occur to generate RGS12 mRNAs encoding proteins with four distinct N-terminal domains, three distinct C-terminal domains, and a common internal region where the semiconserved RGS domain is located. Confocal microscopy and subcellular fractionation of COS-7 cells expressing RGS12 proteins with three different N termini (brain (B), peripheral (P), and trans-spliced (TS)) and a shared short (S) C-terminal domain demonstrated exclusive nuclear localization of these proteins and an influence of the N-terminal region on the pattern of intranuclear distribution. Both native RGS12TS-S in HEK-293T cells and ectopically expressed RGS12TS-S localized to discrete nuclear foci (dots), a characteristic of various tumor suppressor proteins. Subnuclear localization of RGS12TS-S into nuclear dots was cell cycle-dependent. Native RGS12TS-S associated with the metaphase chromosome during mitosis, and ectopically expressed RGS12TS-S induced formation of abnormally shaped and multiple nuclei in COS-7 cells, Expression of RGS12 proteins with long and intermediate C-terminal domains was not observed in COS-7 cells, suggesting that 3'-splicing of RGS12 transcripts may influence the expression or stability of the encoded proteins. These results document extraordinary structural complexity in the RGS12 family and the role of alternative splicing and cell cycle-dependent mechanisms in expression and subnuclear targeting of RGS12 proteins.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Fisher, RA (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA.		Chatterjee, Rima/J-8066-2017	Fisher, Rory/0000-0003-3108-4836	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041071, R01HL041071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41071] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BONEN L, 1993, FASEB J, V7, P40, DOI 10.1096/fasebj.7.1.8422973; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Chatterjee TK, 1997, J BIOL CHEM, V272, P12122, DOI 10.1074/jbc.272.18.12122; Chatterjee TK, 1997, J BIOL CHEM, V272, P15481, DOI 10.1074/jbc.272.24.15481; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Coleman DE, 1999, J BIOL CHEM, V274, P16669, DOI 10.1074/jbc.274.24.16669; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EASTON DF, 1993, AM J HUM GENET, V52, P678; Fujieda S, 1996, J IMMUNOL, V157, P3450; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Park JG, 1999, EMBO J, V18, P4004, DOI 10.1093/emboj/18.14.4004; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SHIMIZU A, 1993, FASEB J, V7, P149, DOI 10.1096/fasebj.7.1.7916698; Snow BE, 1997, BIOCHEM BIOPH RES CO, V233, P770, DOI 10.1006/bbrc.1997.6537; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; SULLIVAN PM, 1991, J BIOL CHEM, V266, P143; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	38	61	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29660	29671		10.1074/jbc.M000330200	http://dx.doi.org/10.1074/jbc.M000330200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10869340	hybrid			2022-12-27	WOS:000089439800066
J	Chung, L; Shimokawa, K; Dinakarpandian, D; Grams, F; Fields, GB; Nagase, H				Chung, L; Shimokawa, K; Dinakarpandian, D; Grams, F; Fields, GB; Nagase, H			Identification of the (RWTNNFREY191)-R-183 region as a critical segment of matrix metalloproteinase 1 for the expression of collagenolytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; ALANINE SCANNING MUTAGENESIS; HUMAN FIBROBLAST COLLAGENASE; HUMAN NEUTROPHIL COLLAGENASE; HEMOPEXIN-LIKE DOMAIN; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; GELATINASE-A; I COLLAGEN; CATALYTIC DOMAIN	Matrix metalloproteinase 1 (MMP-1) cleaves types I, II, and III collagen triple helices into 3/4 and 1/4 fragments. To understand the structural elements responsible for this activity, various lengths of MMP-1 segments have been introduced into MMP-3 (stromelysin 1) starting from the C-terminal end. MMP-3/MMP-1 chimeras and variants were overexpressed in Escherichia coli, folded from inclusion bodies, and isolated as zymogens, After activation, recombinant chimeras were tested for their ability to digest triple helical type I collagen at 25 degrees C. The results indicate that the nine residues (RWTNNFREY191)-R-183 located between the fifth beta-strand and the second alpha-helix in the catalytic domain of MMP-1 are critical for the expression of collagenolytic activity. Mutation of Tyr(191) of MMP-1 to Thr, the corresponding residue in MMP-3, reduced collagenolytic activity about 5-fold. Replacement of the nine residues with those of the MMP-3 sequence further decreased the activity 2-fold. Those variants exhibited significant changes in substrate specificity and activity against gelatin and synthetic substrates, further supporting the notion that this region plays a critical role in the expression of collagenolytic activity. However, introduction of this sequence into MMP-3 or a chimera consisting of the catalytic domain of MMP-3 with the hinge region and the C-terminal hemopexin domain of MMP-1 did not express any collagenolytic activity. It is therefore concluded that RWTNNFREY, together with the C-terminal hemopexin domain, is essential for collagenolytic activity but that additional structural elements in the catalytic domain are also required. These elements probably act in a concerted manner to cleave the collagen triple helix.	Imperial Coll Sch Med, Kennedy Inst Rheumatol, London W6 8LH, England; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; F Hoffmann La Roche & Co Ltd, Div Pharmaceut, CH-4070 Basel, Switzerland; Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA	Imperial College London; University of Oxford; University of Kansas; University of Kansas Medical Center; Roche Holding; State University System of Florida; Florida Atlantic University	Nagase, H (corresponding author), Imperial Coll Sch Med, Kennedy Inst Rheumatol, 1 Aspenlea Rd, London W6 8LH, England.				NATIONAL CANCER INSTITUTE [R01CA077402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039189] Funding Source: NIH RePORTER; NCI NIH HHS [CA77402] Funding Source: Medline; NIAMS NIH HHS [AR39189] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; Dhanaraj V, 1996, STRUCTURE, V4, P375, DOI 10.1016/S0969-2126(96)00043-3; Fields GB, 1995, CONNECT TISSUE RES, V31, P235, DOI 10.3109/03008209509010815; FRASER RDB, 1979, J MOL BIOL, V129, P463, DOI 10.1016/0022-2836(79)90507-2; Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347; GLIMCHER MJ, 1964, BIOCHIM BIOPHYS ACTA, V93, P585, DOI 10.1016/0304-4165(64)90342-3; Gohlke U, 1996, FEBS LETT, V378, P126, DOI 10.1016/0014-5793(95)01435-7; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; Kafienah W, 1998, BIOCHEM J, V330, P897, DOI 10.1042/bj3300897; Knauper V, 1997, FEBS LETT, V405, P60, DOI 10.1016/S0014-5793(97)00158-0; KNAUPER V, 1993, BIOCHEM J, V291, P847; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LIBSON AM, 1995, NAT STRUCT BIOL, V2, P938, DOI 10.1038/nsb1195-938; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MURPHY G, 1994, J BIOL CHEM, V269, P6632; MURPHY G, 1992, J BIOL CHEM, V267, P9612; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nagase H, 1996, BIOPOLYMERS, V40, P399, DOI 10.1002/(SICI)1097-0282(1996)40:4<399::AID-BIP5>3.0.CO;2-R; Nagase H, 1997, BIOL CHEM, V378, P151; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA Y, 1986, J BIOL CHEM, V261, P14245; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; Sang QXA, 1996, J PROTEIN CHEM, V15, P137, DOI 10.1007/BF01887395; SAUS J, 1988, J BIOL CHEM, V263, P6742; Shipley JM, 1996, J BIOL CHEM, V271, P4335; SPURLINO JC, 1994, PROTEINS, V19, P98, DOI 10.1002/prot.340190203; STARKEY PM, 1977, BIOCHIM BIOPHYS ACTA, V483, P386, DOI 10.1016/0005-2744(77)90066-3; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; TRENTHAM DE, 1977, J EXP MED, V146, P857, DOI 10.1084/jem.146.3.857; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOESSNER JF, 2000, MATRIX METALLOPROTEI; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481	44	115	118	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29610	29617		10.1074/jbc.M004039200	http://dx.doi.org/10.1074/jbc.M004039200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10871619	hybrid			2022-12-27	WOS:000089439800058
J	Ledoux, D; Papy-Garcia, D; Escartin, Q; Sagot, MA; Cao, YH; Barritault, D; Courtois, J; Hornebeck, W; Caruelle, JP				Ledoux, D; Papy-Garcia, D; Escartin, Q; Sagot, MA; Cao, YH; Barritault, D; Courtois, J; Hornebeck, W; Caruelle, JP			Human plasmin enzymatic activity is inhibited by chemically modified dextrans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICOAGULANT ACTIVITY; DERIVATIZED DEXTRANS; HEPARIN; KINETICS; SULFATE; BINDING; ACID; REGENERATION; BENZYLAMIDE; ACTIVATION	Some synthetic dextran derivatives that mimic the action of heparin/heparan sulfate were shown to promote in vivo tissue repair when added alone to wounds. These biofunctional mimetics were therefore designated as "regenerating agents" in regard to their in vivo properties. In vitro, these biopolymers were able to protect various heparin-binding growth factors against proteolytic degradation as well as to inhibit the enzymatic activity of neutrophil elastase. In the present work, different dextran derivatives were tested for their capacity to inhibit the enzymatic activity of human plasmin. We show that dextran containing carboxymethyl, sulfate as well as benzylamide groups (RG1192 compound), was the most efficient inhibitor of plasmin amidolytic activity. The inhibition of plasmin by RG1192 can be classified as tight binding hyperbolic noncompetitive. One molecule of RG1192 bound 20 molecules of plasmin with a K-i of 2.8 x 10(-8) M. Analysis with an optical biosensor confirmed the high affinity of RG1192 for plasmin and revealed that this polymer equally binds plasminogen with a similar affinity (K-d = 3 x 10(-8) M), Competitive experiments carried out with 6-aminohexanoic acid and kringle proteolytic fragments identified the lysine-binding site domains of plasmin as the RG1192 binding sites. In addition, RG1192 blocked the generation of plasmin from Glu-plasminogen and inhibited the plasmin-mediated proteolysis of fibronectin and laminin, Data from the present in vitro investigation thus indicated that specific dextran derivatives can contribute to the regulation of plasmin activity by impeding the plasmin generation, as a result of their binding to plasminogen and also by directly affecting the catalytic activity of the enzyme.	Univ Paris 12, Lab CRRET, CNRS, UPRESA 7053, F-94010 Creteil, France; CEA Saclay, Lab Pharmacol & Immunol, F-91191 Gif Sur Yvette, France; Karolinska Inst, Dept Cell & Mol Biol, Lab Angiogenesis Res, S-17177 Stockholm, Sweden; IUT Amiens, Lab Biotechnol Microbienne, F-80025 Amiens 1, France; Univ Reims, Fac Med, IFR Biomol 53, Lab Biochim,CNRS,UPRESA 6021, F-51095 Reims, France	Centre National de la Recherche Scientifique (CNRS); Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CEA; UDICE-French Research Universities; Universite Paris Saclay; Karolinska Institutet; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne	Barritault, D (corresponding author), Univ Paris 12, Lab CRRET, CNRS, UPRESA 7053, Av Gen de Gaulle, F-94010 Creteil, France.			LEDOUX, DOMINIQUE/0000-0002-5886-2266				AKASHI H, 1994, BIOL PHARM BULL, V17, P446; Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; ANDRADEGORDON P, 1986, BIOCHEMISTRY-US, V25, P4033, DOI 10.1021/bi00362a007; BAICI A, 1993, BIOCHEM PHARMACOL, V46, P1545, DOI 10.1016/0006-2952(93)90321-M; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; Blanquaert F, 1995, BONE, V17, P499, DOI 10.1016/8756-3282(95)00402-5; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; Christensen U, 1996, FEBS LETT, V387, P58, DOI 10.1016/0014-5793(96)00429-2; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; Desgranges P, 1999, FASEB J, V13, P761, DOI 10.1096/fasebj.13.6.761; DEWIT P, 1988, RECL TRAV CHIM PAY B, V107, P668; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; FREDJREYGROBELLET D, 1994, OPHTHALMIC RES, V26, P325, DOI 10.1159/000267497; HIGAZI AA, 1990, BIOCHEM J, V269, P299, DOI 10.1042/bj2690299; HIGAZI AA, 1992, BIOCHEM J, V282, P863, DOI 10.1042/bj2820863; HIGAZI AAR, 1989, BIOCHEM J, V260, P609, DOI 10.1042/bj2600609; Krentsel L, 1997, CARBOHYD POLYM, V33, P63, DOI 10.1016/S0144-8617(96)00173-7; LEGRAS S, 1992, INT J BIOL MACROMOL, V14, P97, DOI 10.1016/0141-8130(92)90005-S; LERCH PG, 1980, EUR J BIOCHEM, V107, P7, DOI 10.1111/j.1432-1033.1980.tb04617.x; MaigaRevel O, 1997, CARBOHYD POLYM, V32, P89, DOI 10.1016/S0144-8617(96)00171-3; MAUZAC M, 1984, BIOMATERIALS, V5, P301, DOI 10.1016/0142-9612(84)90078-4; Meddahi A, 1996, J BIOMED MATER RES, V31, P293, DOI 10.1002/(SICI)1097-4636(199607)31:3<293::AID-JBM1>3.0.CO;2-H; Meddahi A, 1996, INT J BIOL MACROMOL, V18, P141, DOI 10.1016/0141-8130(95)01074-2; MEDDAHI A, 1994, PATHOL RES PRACT, V190, P923; MOSER TL, 1993, J BIOL CHEM, V268, P18917; NADKARNI VD, 1994, ANAL BIOCHEM, V222, P59, DOI 10.1006/abio.1994.1454; Okada Y, 2000, CHEM PHARM BULL, V48, P184; Sanders TC, 1999, J MED CHEM, V42, P2969, DOI 10.1021/jm990110k; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; SZEDLACSEK SE, 1988, BIOCHEM J, V254, P311, DOI 10.1042/bj2540311; TARDIEU M, 1992, J CELL PHYSIOL, V150, P194, DOI 10.1002/jcp.1041500126; THEWES T, 1990, J BIOL CHEM, V265, P3906; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WU HL, 1990, J BIOL CHEM, V265, P19658	36	55	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29383	29390		10.1074/jbc.M000837200	http://dx.doi.org/10.1074/jbc.M000837200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10889187	hybrid			2022-12-27	WOS:000089439800029
J	Liu, MQ; Spremulli, L				Liu, MQ; Spremulli, L			Interaction of mammalian mitochondrial ribosomes with the inner membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATIONAL ACTIVATOR PROTEINS; SACCHAROMYCES-CEREVISIAE; DEHYDROGENASE SUBUNIT; YEAST; DNA; IDENTIFICATION; EXPRESSION; MUTATIONS; EXPORT; MATRIX	All of the products of mitochondrial protein biosynthesis in animals are hydrophobic proteins that are localized in the inner membrane. Hence, it is possible that the synthesis of these proteins could occur on ribosomes associated with the inner membrane. To examine this possibility, inner membrane and matrix fractions of bovine mitochondria were examined for the presence of ribosomes using probes for the rRNAs. Between 40 and 50% of the ribosomes were found to fractionate with the inner membrane. About half of the ribosomes associated with the inner membrane could be released by high salt treatment, indicating that they interact with the membrane largely through electrostatic forces. No release of the ribosome was observed upon treatment with puromycin, suggesting that the association observed is not due to insertion of a nascent polypeptide chain into the membrane. A fraction of the ribosomes remained with residual portions of the membranes that cannot be solubilized in the presence of Triton X-100. These ribosomes may be associated with large oligomeric complexes in the membrane.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Spremulli, L (corresponding author), Univ N Carolina, Dept Chem, Campus Box 3290, Chapel Hill, NC 27599 USA.				NIGMS NIH HHS [GM32734] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELMAN M, 2000, J CELL BIOL, V56, P206; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; ATTARDI G, 1985, INT REV CYTOL, V93, P93, DOI 10.1016/S0074-7696(08)61373-X; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; CAHILL A, 1995, ANAL BIOCHEM, V232, P47, DOI 10.1006/abio.1995.9962; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; CHOMYN A, 1985, NATURE, V314, P596; Crowley KS, 1998, J BIOL CHEM, V273, P17278, DOI 10.1074/jbc.273.27.17278; DAUM G, 1982, J BIOL CHEM, V257, P3028; EBERLY SL, 1985, J BIOL CHEM, V260, P8721; FOX TD, 1996, TRANSLATIONAL CONTRO, P733; Goldschmidt-Reisin S, 1998, J BIOL CHEM, V273, P34828, DOI 10.1074/jbc.273.52.34828; Graack HR, 1999, BIOCHEMISTRY-US, V38, P16569, DOI 10.1021/bi991543s; Greenawalt J W, 1974, Methods Enzymol, V31, P310; GURTUBAY JIG, 1980, J BIOENERG BIOMEMBR, V12, P47, DOI 10.1007/BF00745012; He SC, 1999, MOL CELL BIOL, V19, P6598; HERRMANN JM, 1995, J BIOL CHEM, V270, P27079, DOI 10.1074/jbc.270.45.27079; Jacobs HT, 2000, HUM MOL GENET, V9, P463, DOI 10.1093/hmg/9.4.463; Johnson CH, 1999, YEAST, V15, P799, DOI 10.1002/(SICI)1097-0061(19990630)15:9&lt;799::AID-YEA419&gt;3.0.CO;2-N; Koc EC, 1999, BIOCHEM BIOPH RES CO, V266, P141, DOI 10.1006/bbrc.1999.1785; LINNANE A, 1973, YEAST MOLD PLANT PRO, P344; Manthey GM, 1998, EUR J BIOCHEM, V255, P156, DOI 10.1046/j.1432-1327.1998.2550156.x; MATTHEWS DE, 1982, J BIOL CHEM, V257, P8788; MCCONKEY EH, 1979, MOL GEN GENET, V169, P1, DOI 10.1007/BF00267538; MCMULLIN TW, 1993, J BIOL CHEM, V268, P11737; MICHAELIS U, 1991, MOL GEN GENET, V230, P177, DOI 10.1007/BF00290666; Obbink D J, 1977, Mol Gen Genet, V151, P127; PEL HJ, 1994, MOL BIOL REP, V19, P183, DOI 10.1007/BF00986960; Poluektova LY, 1999, IMMUNOPHARMACOLOGY, V41, P77, DOI 10.1016/S0162-3109(98)00057-5; RUSSELL DW, 1980, ARCH BIOCHEM BIOPHYS, V201, P518, DOI 10.1016/0003-9861(80)90540-8; Sambrook J., 2002, MOL CLONING LAB MANU; Scheffler IE, 1999, MITOCHONDRIA; Smith J.A., 2000, CURRENT PROTOCOLS MO; SPITHILL TW, 1978, MOL GEN GENET, V164, P155, DOI 10.1007/BF00267380; SPREMULLI L, 1987, BIOCHEM BIOPH RES CO, V147, P1077, DOI 10.1016/S0006-291X(87)80180-8; TREMBATH MK, 1973, MOL GEN GENET, V121, P35, DOI 10.1007/BF00353691; Warburg O., 1942, BIOCHEM Z, V310, P384; WITTMANNLIEBOLD B, 1980, RIBOSOMES STRUCTURE, P51; Wollman FA, 1999, BBA-BIOENERGETICS, V1411, P21, DOI 10.1016/S0005-2728(99)00043-2; Wolstenholme D. R., 1992, Mitochondrial genomes., P173	41	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29400	29406		10.1074/jbc.M002173200	http://dx.doi.org/10.1074/jbc.M002173200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887179	hybrid, Green Published			2022-12-27	WOS:000089439800031
J	Sun, F; Hug, MJ; Lewarchik, CM; Yun, CHC; Bradbury, NA; Frizzell, RA				Sun, F; Hug, MJ; Lewarchik, CM; Yun, CHC; Bradbury, NA; Frizzell, RA			E3KARP mediates the association of ezrin and protein kinase A with the cystic fibrosis transmembrane conductance regulator in airway cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER NA+/H+ EXCHANGER; PLASMA-MEMBRANE; BETA(2)-ADRENERGIC RECEPTOR; PDZ DOMAINS; CFTR; CYTOSKELETON; BINDING; NHE3; RECOGNITION; INHIBITION	Although it is generally recognized that cystic fibrosis transmembrane conductance regulator (CFTR) contains a PSD-95/Disc-large/ZO-1 (PDZ)-binding motif at its COOH terminus, the identity of the PDZ domain protein(s) that interact with CFTR is uncertain, and the functional impact of this interaction is not fully understood. By using human airway epithelial cells, we show that CFTR associates with Na+/H+ exchanger (NHE) type 3 kinase A regulatory protein (E3KARP), an EBP50/ NHE regulatory factor (NHERF)-related PDZ domain protein. The PDZ binding motif located at the COOH terminus of CFTR interacts preferentially with the second PDZ domain of E3KARP, with nanomolar affinity. In contrast to EBP50/NHERF, E3KARP is predominantly localized (>95%) in the membrane fractions of Calu-3 and T84 cells, where CFTR is located. Moreover, confocal immunofluorescence microscopy of polarized Calu-3 monolayers shows that E3KARP and CFTR are co-localized at the apical membrane domain. We also found that ezrin associates with E3KARP in vivo. Go-expression of CFTR with E3KARP and ezrin in Xenopus oocytes potentiated cAMP-stimulated CFTR Cl- currents. These results support the concept that E3KARP functions as a scaffold protein that links CFTR to ezrin, Since ezrin has been shown previously to function as a protein kinase A anchoring protein, we suggest that one function served by the interaction of E3KARP with both ezrin and CFTR is to localize protein kinase A in the vicinity of the R-domain of CFTR. Since ezrin is also an actin-binding protein, the formation of a CFTR E3KARP ezrin complex may be important also in stabilizing CFTR at the apical membrane domain of airway cells.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21205 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University	Frizzell, RA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S362 BST,3500 Terrace St, Pittsburgh, PA 15261 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK056490, P01DK044484] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44484, DK56490] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRANT SR, 1995, AM J PHYSIOL-CELL PH, V269, pC198, DOI 10.1152/ajpcell.1995.269.1.C198; Cantiello HF, 1996, EXP PHYSIOL, V81, P505, DOI 10.1113/expphysiol.1996.sp003953; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; DEJONGE HR, 1975, BIOCHIM BIOPHYS ACTA, V381, P128, DOI 10.1016/0304-4165(75)90195-6; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; Gadsby David C., 1999, Physiological Reviews, V79, pS77; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; Huang P, 2000, AM J PHYSIOL-CELL PH, V278, pC417, DOI 10.1152/ajpcell.2000.278.2.C417; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Loffing J, 1998, AM J PHYSIOL-CELL PH, V275, pC913, DOI 10.1152/ajpcell.1998.275.4.C913; Mickle JE, 1998, HUM MOL GENET, V7, P729, DOI 10.1093/hmg/7.4.729; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Peters KW, 1999, AM J PHYSIOL-CELL PH, V277, pC174, DOI 10.1152/ajpcell.1999.277.1.C174; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; PRAT AG, 1995, AM J PHYSIOL-CELL PH, V268, pC1552, DOI 10.1152/ajpcell.1995.268.6.C1552; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Sheppard David N., 1999, Physiological Reviews, V79, pS23; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204; Weixel KM, 2000, J BIOL CHEM, V275, P3655, DOI 10.1074/jbc.275.5.3655; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zerhusen B, 1999, J BIOL CHEM, V274, P7627, DOI 10.1074/jbc.274.12.7627	43	175	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29539	29546		10.1074/jbc.M004961200	http://dx.doi.org/10.1074/jbc.M004961200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893422	hybrid			2022-12-27	WOS:000089439800049
J	Chen, JW; Dodia, C; Feinstein, SI; Jain, MK; Fisher, AB				Chen, JW; Dodia, C; Feinstein, SI; Jain, MK; Fisher, AB			1-Cys peroxiredoxin, a bifunctional enzyme with glutathione peroxidase and phospholipase A2 activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; CRYSTAL-STRUCTURE; A(2); PROTEIN; LUNG; DEGRADATION; EXPRESSION	This report provides definitive evidence that the protein 1-Cys peroxiredoxin is a bifunctional ("moonlighting") enzyme with two distinct active sites. We have previously shown that human, rat, and bovine lungs contain an acidic Ca2+-independent phospholipase A(2) (aiPLA(2)). The cDNA encoding aiPLA(2) was found to be identical to that of a non-selenium glutathione peroxidase (NSGPx). Protein expressed using a previously reported E, coli construct which has a His-tag and 50 additional amino acids at the NH2 terminus, did not exhibit aiPLA(2) activity. A new construct which contains the His-tag plus two extra amino acids at the COOH terminus when expressed in Escherichia coli generated a protein that hydrolyzed the sn-2 acyl chain of phospholipids at pH 4, and exhibited NSGPx activity with H2O2 at pH 8. The expressed 1-Cys peroxiredoxin has identical functional properties to the native lung enzyme: aiPLA(2) activity is inhibited by the serine protease inhibitor, diethyl p-nitrophenyl phosphate, by the tetrahedral mimic 1-hexadecyl-3-trifluoroethylglycero-sn-2-phosphomethanol (MJ33), and by 1-Cys peroxiredoxin monoclonal antibody (mAb) 8H11 but these agents have no effect on NSGPx activity; NSGPx activity is inhibited by mercaptosuccinate and by 1-Cys peroxiredoxin mAb 8B3 antibody which have no effect on aiPLA(2) activity. Mutation of Ser(32) to Ala abolishes aiPLA(2) activity, yet the NSGPx activity remains unaffected; a Cys(47) to Ser mutant is devoid of peroxidase activity but aiPLA(2) activity remains intact. These results suggest that Ser32 in the GDSWG consensus sequence provides the catalytic nucleophile for the hydrolase activity of aiPLA(2) while Cys47 in the PVCTTE consensus sequence is at the active site for peroxidase activity. The bifunctional catalytic properties of 1-Cys peroxiredoxin are compatible with a simultaneous role for the protein in the regulation of phospholipid turnover as well as in protection against oxidative injury.	Univ Penn, Med Ctr, Inst Environm Med, Philadelphia, PA 19104 USA; Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA	University of Pennsylvania; University of Delaware	Fisher, AB (corresponding author), Univ Penn, Sch Med, Inst Environm Med, 1 John Morgan Bldg,3620 Hmailton Walk, Philadelphia, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL19737] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akiba S, 1998, COMP BIOCHEM PHYS B, V120, P393, DOI 10.1016/S0305-0491(98)10046-9; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; CHANDER A, 1986, J BIOL CHEM, V261, P6126; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; DEREWENDA ZS, 1993, TRENDS BIOCHEM SCI, V18, P20, DOI 10.1016/0968-0004(93)90082-X; FISHER AB, 1992, BIOCHEM J, V288, P407, DOI 10.1042/bj2880407; FISHER AB, 1994, AM J PHYSIOL, V267, pL335, DOI 10.1152/ajplung.1994.267.3.L335; Fisher AB, 1996, J LIPID RES, V37, P1057; Fisher AB, 1999, J BIOL CHEM, V274, P21326, DOI 10.1074/jbc.274.30.21326; FORMAN HJ, 1983, LAB INVEST, V49, P148; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P10256, DOI 10.1021/bi00106a025; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kim TS, 1998, AM J PHYSIOL-LUNG C, V274, pL750, DOI 10.1152/ajplung.1998.274.5.L750; Kim TS, 1997, J BIOL CHEM, V272, P2542; LEWIS SD, 1976, BIOCHEMISTRY-US, V15, P5009, DOI 10.1021/bi00668a010; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; PATHAK D, 1991, PROTEINS, V9, P267, DOI 10.1002/prot.340090405; Peshenko IV, 1996, FEBS LETT, V381, P12, DOI 10.1016/0014-5793(96)00071-3; Rice SQJ, 1998, BIOCHEM J, V330, P1309; Sato T, 1997, J BIOL CHEM, V272, P2192; SHICHI H, 1990, EXP EYE RES, V50, P513, DOI 10.1016/0014-4835(90)90040-2; Singh AK, 1998, J BIOL CHEM, V273, P26171, DOI 10.1074/jbc.273.40.26171; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; Wang AJ, 1997, J BIOL CHEM, V272, P12723, DOI 10.1074/jbc.272.19.12723	26	256	283	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28421	28427		10.1074/jbc.M005073200	http://dx.doi.org/10.1074/jbc.M005073200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893423	hybrid			2022-12-27	WOS:000089330700013
J	Das, SK; Tan, J; Raja, S; Halder, J; Paria, BC; Dey, SK				Das, SK; Tan, J; Raja, S; Halder, J; Paria, BC; Dey, SK			Estrogen targets genes involved in protein processing, calcium homeostasis, and Wnt signaling in the mouse uterus independent of estrogen receptor-alpha and -beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM; EXPRESSION PATTERNS; ADENYLATE-CYCLASE; MOLECULAR-CLONING; DOWN-REGULATION; BINDING-SITES; RAT UTERUS; CELL; PROGESTERONE; STIMULATION	Estrogen actions in target organs are normally mediated via activation of nuclear estrogen receptors (ERs). By using mRNA differential display technique, we show, herein, that estradiol-17 beta (E-2) and its catechol metabolite 4-hydroxy-E-2 (4OHE(2)) can modulate uterine gene expression in ER alpha(-/-) mice. Whereas administration of E-2 or 4OHE(2) rapidly up-regulated (4-8-fold) the expression of immunoglobulin heavy chain binding protein (Bip), calpactin I (CalP), calmodulin (CalM), and Sih similar protein (Sik-SP) genes in ovariectomized wildtype or ER alpha(-/-) mice, the expression of secreted frizzled related protein-2 (SFRP-2) gene was down-regulated (4-fold). Bip, CalP, and CalM are calcium-binding proteins and implicated in calcium homeostasis, whereas SFRP-2 is a negative regulator of Wnt signaling. Bip and Sik-SP also possess chaperone-like functions, Administration of ICI-182,780 or cycloheximide failed to influence these estrogenic responses, demonstrating that these effects occur independent of ER alpha, ER beta, or protein synthesis. In situ hybridization showed differential cell-specific expression of these genes in wild-type and ER alpha(-/-) uteri, Although progesterone can antagonize or synergize estrogen actions, it had minimal effects on these estrogenic responses. Collectively, the results demonstrate that estrogens have a unique ability to influence specific genes in the uterus not involving classical nuclear ERs.	Univ Kansas, Med Ctr, Dept Obstet & Gynaecol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Ralph L Smith Res Ctr, Dept Pediat, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Das, SK (corresponding author), Univ Kansas, Med Ctr, Dept Obstet & Gynaecol, 3901 Rainbow Blvd,MRRC 37-3004, Kansas City, KS 66160 USA.				NICHD NIH HHS [HD-29968, HD-12304] Funding Source: Medline; NIEHS NIH HHS [ES-07814] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012304, U01HD029968, R37HD012304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007814] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aarli A, 1998, SCAND J IMMUNOL, V48, P522; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; AURICCHIO F, 1984, J STEROID BIOCHEM, V20, P31, DOI 10.1016/0022-4731(84)90185-7; Batra S, 1998, LIFE SCI, V62, P2093, DOI 10.1016/S0024-3205(98)00184-2; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bevan C, 1999, EXP CELL RES, V253, P349, DOI 10.1006/excr.1999.4719; BOUHOUTE A, 1995, BIOCHEM BIOPH RES CO, V208, P748, DOI 10.1006/bbrc.1995.1401; Brewer J. W., 1997, MOL CHAPERONE PROTEI, P415; Bui TD, 1997, BRIT J CANCER, V75, P1131, DOI 10.1038/bjc.1997.195; Cardone A, 1998, GEN COMP ENDOCR, V110, P227, DOI 10.1006/gcen.1998.7063; CHEUNG WY, 1975, BIOCHEM BIOPH RES CO, V66, P1055, DOI 10.1016/0006-291X(75)90747-0; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; Dale TC, 1998, BIOCHEM J, V329, P209; Das SK, 1997, DEV BIOL, V190, P178, DOI 10.1006/dbio.1997.8694; Das SK, 1998, ENDOCRINOLOGY, V139, P2905, DOI 10.1210/en.139.6.2905; Das SK, 1997, P NATL ACAD SCI USA, V94, P12786, DOI 10.1073/pnas.94.24.12786; Das SK, 1999, J MOL ENDOCRINOL, V22, P91, DOI 10.1677/jme.0.0220091; DAS SK, 1995, MOL ENDOCRINOL, V9, P691, DOI 10.1210/me.9.6.691; Dey SK, 1996, REPROD ENDOCRINOLOGY, V1, P421; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; FERNANDEZ AI, 1992, GEN PHARMACOL, V23, P291, DOI 10.1016/0306-3623(92)90026-G; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GORSKI J, 1964, ARCH BIOCHEM BIOPHYS, V105, P517, DOI 10.1016/0003-9861(64)90045-1; HARRIS J, 1978, ENDOCRINOLOGY, V103, P204; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; JacquierSarlin MR, 1996, BIOCHEM BIOPH RES CO, V226, P166, DOI 10.1006/bbrc.1996.1327; JENSEN TS, 1995, APMIS, V103, P433, DOI 10.1111/j.1699-0463.1995.tb01129.x; KAKIUCHI S, 1970, BIOCHEM BIOPH RES CO, V41, P1104, DOI 10.1016/0006-291X(70)90199-3; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Kelly MJ, 1999, TRENDS ENDOCRIN MET, V10, P369, DOI 10.1016/S1043-2760(99)00190-3; KIRKLAND JL, 1977, ENDOCRINOLOGY, V101, P403, DOI 10.1210/endo-101-2-403; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Ladher RK, 2000, DEV BIOL, V218, P183, DOI 10.1006/dbio.1999.9586; Lammers CH, 1999, SYNAPSE, V34, P222, DOI 10.1002/(SICI)1098-2396(19991201)34:3<222::AID-SYN6>3.0.CO;2-J; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; Leimeister C, 1998, MECH DEVELOP, V75, P29, DOI 10.1016/S0925-4773(98)00072-0; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; LIEBERHERR M, 1993, J BONE MINER RES, V8, P1365; Lim HJ, 1999, MOL ENDOCRINOL, V13, P1005, DOI 10.1210/me.13.6.1005; LOOSEMITCHELL DS, 1988, MOL ENDOCRINOL, V2, P946, DOI 10.1210/mend-2-10-946; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Ma L, 1998, DEV BIOL, V197, P141, DOI 10.1006/dbio.1998.8907; MATSUI K, 1983, J ENDOCRINOL, V97, P11, DOI 10.1677/joe.0.0970011; McDonnell D P, 1997, Osteoporos Int, V7 Suppl 1, pS29; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Miller C, 1998, MECH DEVELOP, V76, P91, DOI 10.1016/S0925-4773(98)00112-9; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Nickenig G, 1998, CIRCULATION, V97, P2197, DOI 10.1161/01.CIR.97.22.2197; PERSICO E, 1990, BIOCHEM BIOPH RES CO, V171, P287, DOI 10.1016/0006-291X(90)91390-E; Picotto G, 1996, MOL CELL ENDOCRINOL, V119, P129, DOI 10.1016/0303-7207(96)03799-9; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; SCHULMAN H, 1978, NATURE, V271, P478, DOI 10.1038/271478a0; Simmons DG, 2000, BIOL REPROD, V62, P1168, DOI 10.1095/biolreprod62.5.1168; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; Yang RZ, 1998, CONTRACEPTION, V58, P315; Yang YF, 2000, MOL BIOL CELL, V11, P567, DOI 10.1091/mbc.11.2.567; YOSHIDA T, 1985, TOHOKU J EXP MED, V145, P381, DOI 10.1620/tjem.145.381	69	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28834	28842		10.1074/jbc.M003827200	http://dx.doi.org/10.1074/jbc.M003827200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893236	hybrid			2022-12-27	WOS:000089330700066
J	Dennler, S; Prunier, C; Ferrand, N; Gauthier, JM; Atfi, A				Dennler, S; Prunier, C; Ferrand, N; Gauthier, JM; Atfi, A			c-Jun inhibits transforming growth factor beta-mediated transcription by repressing Smad3 transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; SKI ONCOPROTEIN; DIRECT BINDING; PROMOTER; ACTIVATION; PROTEINS; AP-1; PATHWAY; EXPRESSION; ELEMENTS	Transforming growth factor beta (TGF-beta) is a pleiotropic cytokine that exerts its effects through a heteromeric complex of transmembrane serine/threonine kinase receptors, At least two intracellular pathways are activated by TGF-beta as follows: the SAPK/JNK, involving the MEKK1, MKK4, and JNK cascade, and the Smad pathway. Here, we report that the SAPK/JNK pathway inhibits the Smad3 pathway. Expression of dominant negative or constitutively active mutants of kinases of the SAPK/JNK pathway, respectively, activates or represses a TGF-beta-induced reporter containing Smad3-binding sites. This effect is not dependent on blocking of Smad3 nuclear translocation but involves a functional interaction between Smad3 and c-Jun, a transcription factor activated by the SAPK/JNK pathway. Overexpression of constitutively active MEKK1 or MKK4 mutants stabilizes the physical interaction between Smad3 and c-Jun, whereas dominant negative mutants inhibit this interaction. Moreover, overexpression of wild-type c-Jun inhibits Smad3-dependent transcription. However, c-Jun does not inhibit Smad3 binding to DNA in vitro. The repression obtained with a c-Jun mutant unable to activate transcription through AP-1 sites indicates that the inhibitory mechanism does not rely on the induction of a Smad3 repressor by c-Jun, suggesting that c-Jun could act as a Smad3 co-repressor. The inhibition of the Smad3 pathway by the SAPK/JNK pathway, both triggered by TGF-beta, could participate in a negative feedback loop to control TGF-beta responses.	Lab GlaxoWellcome, F-91951 Les Ulis, France; Hop St Antoine, INSERM U482, F-75571 Paris 12, France	GlaxoSmithKline; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Gauthier, JM (corresponding author), Lab GlaxoWellcome, 25 Ave Quebec, F-91951 Les Ulis, France.		Frottier, Celine Prunier/G-8259-2017	Frottier, Celine Prunier/0000-0002-7784-0273				Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; Chen Y, 1996, J BIOL CHEM, V271, P31602, DOI 10.1074/jbc.271.49.31602; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Datto M, 2000, CYTOKINE GROWTH F R, V11, P37, DOI 10.1016/S1359-6101(99)00027-1; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	36	78	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28858	28865		10.1074/jbc.M910358199	http://dx.doi.org/10.1074/jbc.M910358199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10871633	hybrid			2022-12-27	WOS:000089330700069
J	Jensen, SA; Vrhovski, B; Weiss, AS				Jensen, SA; Vrhovski, B; Weiss, AS			Domain 26 of tropoelastin plays a dominant role in association by coacervation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HUMAN ELASTIN; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; ESCHERICHIA-COLI; FIBER FORMATION; EXPRESSION; PEPTIDES; POLYMERS; CHAINS	The temperature-dependent association of tropoelastin molecules through coacervation is an essential step in their assembly leading to elastogenesis. The relative contributions of C-terminal hydrophobic domains in coacervation were assessed. Truncated tropoelastins were constructed with N termini positioned variably downstream of domain 25. The purified proteins were assessed for their ability to coacervate. Disruption to domain 26 had a substantial effect and abolished coacervation. Circular dichroism spectroscopy of an isolated peptide comprising domain 26 showed that it undergoes a structural transition to a state of increased order with increasing temperature. Protease mapping demonstrated that domain 26 is flanked by surface sites and is likely to be in an exposed position on the surface of the tropoelastin molecule. These results suggest that the hydrophobic domain 26 is positioned to play a dominant role in the intermolecular interactions that occur during coacervation.	Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia	University of Sydney	Weiss, AS (corresponding author), Univ Sydney, Dept Biochem, G08, Sydney, NSW 2006, Australia.		Weiss, Anthony S/F-8103-2010; Jensen, Sacha A./AAB-4034-2019; Weiss, Anthony S/GYV-0157-2022	Weiss, Anthony S/0000-0002-8106-4836; Jensen, Sacha A./0000-0002-0560-9531; 				Alonso MC, 1998, EMBO J, V17, P945, DOI 10.1093/emboj/17.4.945; Bisaccia F, 1998, BIOCHEMISTRY-US, V37, P11128, DOI 10.1021/bi9802566; BOYD CD, 1991, MATRIX, V11, P235, DOI 10.1016/S0934-8832(11)80230-1; BRESSAN GM, 1986, J ULTRA MOL STRUCT R, V94, P209, DOI 10.1016/0889-1605(86)90068-6; Broch H, 1998, J BIOMOL STRUCT DYN, V15, P1073, DOI 10.1080/07391102.1998.10509002; BROWNAUGSBURGER P, 1995, J BIOL CHEM, V270, P17778, DOI 10.1074/jbc.270.30.17778; COX BA, 1974, J BIOL CHEM, V249, P997; COX BA, 1973, BIOCHIM BIOPHYS ACTA, V317, P209, DOI 10.1016/0005-2795(73)90215-8; Debelle L, 1998, EUR J BIOCHEM, V258, P533, DOI 10.1046/j.1432-1327.1998.2580533.x; Debelle L, 1999, INT J BIOCHEM CELL B, V31, P261, DOI 10.1016/S1357-2725(98)00098-3; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P5586, DOI 10.1021/bi9526995; GOWDA DC, 1995, INT J PEPT PROT RES, V46, P453; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; KONDO M, 1987, J BIOCHEM-TOKYO, V101, P89, DOI 10.1093/oxfordjournals.jbchem.a121911; MARTIN SL, 1995, GENE, V154, P159, DOI 10.1016/0378-1119(94)00848-M; NARAYANAN AS, 1978, BIOCHEM J, V173, P857, DOI 10.1042/bj1730857; RAPAKA RS, 1978, INT J PEPT PROT RES, V11, P97; Reiersen H, 1998, J MOL BIOL, V283, P255, DOI 10.1006/jmbi.1998.2067; ROMERO N, 1986, ARCH BIOCHEM BIOPHYS, V244, P161, DOI 10.1016/0003-9861(86)90105-0; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STARCHER BC, 1973, BIOCHIM BIOPHYS ACTA, V310, P481, DOI 10.1016/0005-2795(73)90132-3; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMBURRO AM, 1992, J BIOMOL STRUCT DYN, V10, P441, DOI 10.1080/07391102.1992.10508661; Urry D W, 1977, Adv Exp Med Biol, V79, P685; URRY DW, 1978, PERSPECT BIOL MED, V21, P265; URRY DW, 1983, ULTRASTRUCT PATHOL, V4, P227, DOI 10.3109/01913128309140793; URRY DW, 1969, NATURE, V222, P795, DOI 10.1038/222795a0; URRY DW, 1982, METHOD ENZYMOL, V82, P673; Urry DW, 1995, CIBA F SYMP, V192, P4; Urry DW, 1997, J PHYS CHEM B, V101, P11007, DOI 10.1021/jp972167t; Vrhovski B, 1997, EUR J BIOCHEM, V250, P92, DOI 10.1111/j.1432-1033.1997.00092.x; Wu WJ, 1999, J BIOL CHEM, V274, P21719, DOI 10.1074/jbc.274.31.21719; Wu WJ, 1999, EUR J BIOCHEM, V266, P308, DOI 10.1046/j.1432-1327.1999.00891.x; YANG JT, 1986, METHOD ENZYMOL, V130, P208	35	52	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28449	28454		10.1074/jbc.M004265200	http://dx.doi.org/10.1074/jbc.M004265200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10862774	hybrid			2022-12-27	WOS:000089330700017
J	Li, BM; Comai, L				Li, BM; Comai, L			Functional interaction between Ku and the Werner syndrome protein in DNA end processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; HELICASE ACTIVITY; SYNDROME GENE; EXONUCLEASE; REPAIR; SYSTEM; CELLS	Werner syndrome (WS) is an autosomal recessive disease characterized by premature aging. The gene responsible for the syndrome was recently cloned and shown to encode a protein, with strong homology to DNA/RNA helicases. In addition, the Werner syndrome protein (WRN) possesses an exonuclease activity. Eased on the homology to helicases it has been proposed that WRN functions in some aspects of DNA replication, recombination, or repair. However, there is currently no evidence of a role of WRN in any of these processes; therefore, its biological function remains unknown. Using a biochemical approach, we have identified two polypeptides that bind to the WRN protein. Peptide sequence analysis indicates that the two proteins are identical to Ku70 and Ku80, a heterodimer involved in double strand DNA break repair by non-homologous DNA end joining. Protein-protein interaction studies reveal that WRN binds directly to Ku80 and that this interaction is mediated by the amino terminus of WRN. In addition, we show that the binding of Ku alters the specificity of the WRN exonuclease. These results suggest a potential involvement of WRN in the repair of double strand DNA breaks.	Univ So Calif, Dept Mol Microbiol & Immunol, Keck Sch Med, Los Angeles, CA 90033 USA	University of Southern California	Comai, L (corresponding author), Univ So Calif, Dept Mol Microbiol & Immunol, Keck Sch Med, 2011 Zonal Ave,HMR-509, Los Angeles, CA 90033 USA.		Comai, Lucio/H-9524-2019; Comai, Lucio/L-5905-2019	Comai, Lucio/0000-0003-3109-1841				Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; Cooper MP, 2000, GENE DEV, V14, P907; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dyer CAE, 1998, AGE AGEING, V27, P73, DOI 10.1093/ageing/27.1.73; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; Fry M, 1998, NAT GENET, V19, P308, DOI 10.1038/1188; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Lieber MR, 1998, AM J PATHOL, V153, P1323, DOI 10.1016/S0002-9440(10)65716-1; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Tham WH, 2000, NATURE, V403, P34, DOI 10.1038/47385; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	28	151	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28349	28352		10.1074/jbc.C000289200	http://dx.doi.org/10.1074/jbc.C000289200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10880505	hybrid			2022-12-27	WOS:000089330700003
J	McDonough, J; Francis, N; Miller, T; Deneris, ES				McDonough, J; Francis, N; Miller, T; Deneris, ES			Regulation of transcription in the neuronal nicotinic receptor subunit gene cluster by a neuron-selective enhancer and ETS domain factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; RAT-BRAIN; MESSENGER-RNAS; ALPHA-3 GENE; MICE LACKING; POU DOMAIN; EXPRESSION; ELEMENT; BETA-4; PROMOTER	Expression of neurotransmitter receptors encoded by the nicotinic acetylcholine receptor (nAchR) subunit gene cluster depends on coexpression of the beta 4, alpha 3, and alpha 5 subunits in certain kinds of neurons. One way in which coexpression might be achieved is through the regulation of promoters in the cluster by neuron-selective enhancers. The beta 43' enhancer is located between the beta 4 and alpha 3 promoters and it directs cell type-specific expression in cell lines. It is not known, however, whether beta 43' is active in neurons, Therefore, we assayed beta 43' in dissociated rat sympathetic ganglia cultures, which contain nAchR-positive neurons as well as nAchR-negative non-neuronal cells. Reporters controlled by the alpha 3 promoter and beta 43' were expressed in a neuron-selective manner; greater than 90% and up to 100% of luciferase expression was detected in neurons. Neuron selectivity was maintained when beta 43' was placed next to ubiquitously active viral promoters. In contrast, replacing beta 43' with the SV40 enhancer eliminated neuron selectivity. The enhancer is composed of at least two separate but functionally interdependent elements, each of which interacts with a different type of ETS domain factor. These findings support a model in which beta 43' controls neuronal expression of one or more genes in the cluster through interactions with a combination of ETS factors.	Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA	Case Western Reserve University	Deneris, ES (corresponding author), Case Western Reserve Univ, Sch Med, Dept Neurosci, 2109 Adelbert Rd, Cleveland, OH 44106 USA.				NINDS NIH HHS [NS29123] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029123] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDWIN AS, 1988, CURRENT PROTOCOLS MO, V2; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; BOULTER J, 1990, J BIOL CHEM, V265, P4472; Boyd RT, 1996, NEUROSCI LETT, V208, P73, DOI 10.1016/0304-3940(96)12561-1; CamposCaro A, 1997, J NEUROCHEM, V68, P488; Chang LF, 1996, J BIOL CHEM, V271, P6467, DOI 10.1074/jbc.271.11.6467; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; Francis NJ, 1997, DEV BIOL, V182, P76, DOI 10.1006/dbio.1996.8464; Fromm L, 1998, GENE DEV, V12, P3074, DOI 10.1101/gad.12.19.3074; Fyodorov D, 1996, MOL CELL BIOL, V16, P5004; Fyodorov D, 1998, J NEUROBIOL, V34, P151, DOI 10.1002/(SICI)1097-4695(19980205)34:2<151::AID-NEU5>3.0.CO;2-1; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Hawrot E, 1979, Methods Enzymol, V58, P574; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; Hendricks T, 1999, J NEUROSCI, V19, P10348; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HU MJ, 1995, J BIOL CHEM, V270, P4497, DOI 10.1074/jbc.270.19.11619; Jones S, 1999, TRENDS NEUROSCI, V22, P555, DOI 10.1016/S0166-2236(99)01471-X; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; MANDELZYS A, 1994, J NEUROSCI, V14, P2357; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MATTER JM, 1995, J NEUROSCI, V15, P5919; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; McDonough J, 1997, J NEUROSCI, V17, P2273; Myers SJ, 1998, J NEUROSCI, V18, P6723; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Pastorcic M, 1999, J BIOL CHEM, V274, P24297, DOI 10.1074/jbc.274.34.24297; PETERSOHN D, 1995, J BIOL CHEM, V270, P24361, DOI 10.1074/jbc.270.41.24361; Sapru MK, 1998, P NATL ACAD SCI USA, V95, P1289, DOI 10.1073/pnas.95.3.1289; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Weber JRM, 1997, J NEUROSCI, V17, P7583; WinzerSerhan UH, 1997, J COMP NEUROL, V386, P540, DOI 10.1002/(SICI)1096-9861(19971006)386:4<540::AID-CNE2>3.0.CO;2-2; Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Xu W, 1999, P NATL ACAD SCI USA, V96, P5746, DOI 10.1073/pnas.96.10.5746; Xu W, 1999, J NEUROSCI, V19, P9298; YANG XD, 1994, J BIOL CHEM, V269, P10252; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514; Yang XD, 1997, J NEUROBIOL, V32, P311, DOI 10.1002/(SICI)1097-4695(199703)32:3<311::AID-NEU5>3.0.CO;2-A	46	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28962	28970		10.1074/jbc.M004181200	http://dx.doi.org/10.1074/jbc.M004181200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878018	hybrid			2022-12-27	WOS:000089330700082
J	Tamrakar, S; Ludlow, JW				Tamrakar, S; Ludlow, JW			The carboxyl-terminal region of the retinoblastoma protein binds non-competitively to protein phosphatase type 1 alpha and inhibits catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; SV40 LARGE-T; RABBIT SKELETAL-MUSCLE; E2F TRANSCRIPTION FACTOR; GENE-PRODUCT; CELL-CYCLE; SUSCEPTIBILITY GENE; GROWTH SUPPRESSION; OKADAIC ACID; PRB	pRB, a negative-growth regulatory protein, is a demonstrated substrate for type 1 serine/threonine protein phosphatases (PP1), In a recent report from this laboratory, we demonstrated that select forms of phosphorylated as well as hypophosphorylated pRB can be found complexed with the alpha-isotype of PP1 (PP1 alpha). This complex can also be observed when PP1 is rendered catalytically dead by toxin inhibition. These data suggested to us that pRB may bind to PP1 at one or more sites other than the catalytically active one on the enzyme and that such binding may play a role other than bringing the substrate into contact with the enzyme to facilitate catalysis. To address this possibility we utilized a series of PRE deletion mutants and coprecipitation studies to map the pRB domain involved in binding to PP1. Together with competition assays using in vivo expression of SV40 T-antigen, we show here that the carboxyl-terminal region of PRE is both necessary and sufficient for physical interaction with PP1. Subsequent biochemical analyses demonstrated inhibition of PP1 catalytic activity toward the standard substrate phosphorylase a when this enzyme is bound to pRB containing this region. K-m and V-max calculations revealed that pRB binds to PP1 in a non-competitive manner. These data support the notion that pRB, in addition to being a substrate for PP1, also functions as a PP1 inhibitor. The significance of this finding with respect to the functional importance of this interaction is discussed.	Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Ludlow, JW (corresponding author), Univ Rochester, Ctr Canc, Box 704,601 Elmwood Ave, Rochester, NY 14642 USA.							ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHRISHOLM AA, 1988, BIOCHIM BIOPHYS ACTA, V971, P163; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; GAVIN AC, 1991, EXP CELL RES, V192, P75, DOI 10.1016/0014-4827(91)90159-R; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KATO J, 1993, GENE DEV, V7, P331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu CWY, 1999, J BIOL CHEM, V274, P29470, DOI 10.1074/jbc.274.41.29470; Ludlow JW, 1998, METH MOL B, V93, P137; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Nelson DA, 1997, ONCOGENE, V14, P2407, DOI 10.1038/sj.onc.1201081; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Siegert JL, 1999, MOL CELL BIOL, V19, P846; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; Tamrakar S, 1999, ONCOGENE, V18, P7803, DOI 10.1038/sj.onc.1203211; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Tognarini M, 1998, EUR J CELL BIOL, V76, P212, DOI 10.1016/S0171-9335(98)80036-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUNG HYL, 1984, EUR J BIOCHEM, V145, P57, DOI 10.1111/j.1432-1033.1984.tb08521.x; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	52	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27784	27789						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10889204				2022-12-27	WOS:000089197100037
J	Yun, M; Park, CG; Kim, JY; Rock, CO; Jackowski, S; Park, HW				Yun, M; Park, CG; Kim, JY; Rock, CO; Jackowski, S; Park, HW			Structural basis for the feedback regulation of Escherichia coli pantothenate kinase by coenzyme A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFUR-AROMATIC INTERACTIONS; CRYSTAL-STRUCTURE; ADENYLATE KINASE; PROTEINS; PHOSPHORIBULOKINASE; REVEALS; COMPLEX; DOMAIN; BIOSYNTHESIS; RESOLUTION	Pantothenate kinase (PanK) is a key regulatory enzyme in the coenzyme A (CoA) biosynthetic pathway and catalyzes the phosphorylation of pantothenic acid to form phosphopantothenate, CoA is a feedback inhibitor of PanK activity by competitive binding to the ATP site. The structures of the Escherichia coli enzyme, in complex with a nonhydrolyzable analogue of ATP, 5'-adenylimido-diphosphate (AMPPNP), or with CoA, were determined at 2.6 and 2.5 Angstrom respectively. Both structures show that two dimers occupy an asymmetric unit; each subunit has a alpha/beta mononucleotide-binding fold with an extensive antiparallel coiled coil formed by two long helices along the dimerization interface. The two ligands, AMPPNP and CoA, associate with PanK in very different ways, but their phosphate binding sites overlap, explaining the kinetic competition between CoA and ATP, Residues Asp(127), His(177) and Arg(243) are proposed to be involved in catalysis, based on modeling of the pentacoordinate transition state. The more potent inhibition by CoA, compared with the CoA thioesters, is explained by a tight interaction of the CoA thiol group with the side chains of aromatic residues, which is predicted to discriminate against the CoA thioesters. The PanK structure provides the framework for a more detailed understanding of the mechanism of catalysis and feedback regulation of PanK.	St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Park, HW (corresponding author), St Jude Childrens Res Hosp, Dept Biol Struct, 332 N Lauderdale St, Memphis, TN 38105 USA.	hee-won.park@stjude.org	Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R37GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NIGMS NIH HHS [GM 45737, GM 34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABIKO Y, 1967, J BIOCHEM, V61, P290, DOI 10.1093/oxfordjournals.jbchem.a128547; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, X PLOR VERSION 3 1; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Calder RB, 1999, J BIOL CHEM, V274, P2014, DOI 10.1074/jbc.274.4.2014; CHARLIER HA, 1994, BIOCHEMISTRY-US, V33, P9343, DOI 10.1021/bi00197a039; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Engel C, 1996, CURR OPIN STRUC BIOL, V6, P790, DOI 10.1016/S0959-440X(96)80009-1; FISHER MN, 1985, J BIOL CHEM, V260, P5745; FISHER MN, 1985, FEBS LETT, V190, P293, DOI 10.1016/0014-5793(85)81303-X; HALVORSEN O, 1982, EUR J BIOCHEM, V124, P211, DOI 10.1111/j.1432-1033.1982.tb05927.x; Harrison DHT, 1998, BIOCHEMISTRY-US, V37, P5074, DOI 10.1021/bi972805y; Hasemann CA, 1996, STRUCTURE, V4, P1017, DOI 10.1016/S0969-2126(96)00109-8; HELLINGA HW, 1987, NATURE, V327, P437, DOI 10.1038/327437a0; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Izard T, 1999, EMBO J, V18, P2021, DOI 10.1093/emboj/18.8.2021; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; Jackowski S., 1996, ESCHERICHIA COLI SAL, P687; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARASAWA T, 1972, J BIOCHEM-TOKYO, V71, P1065, DOI 10.1093/oxfordjournals.jbchem.a129854; KRAGELUND BB, 1993, J MOL BIOL, V230, P1260, DOI 10.1006/jmbi.1993.1240; MCREE DE, 1998, XTALVIEW 3 2 1; MORGAN RS, 1978, INT J PEPT PROT RES, V11, P209; MORGAN RS, 1980, INT J PEPT PROT RES, V15, P177; MULLERDIECKMANN HJ, 1995, J MOL BIOL, V246, P522; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pal D, 1998, J BIOMOL STRUCT DYN, V15, P1059, DOI 10.1080/07391102.1998.10509001; REID KSC, 1985, FEBS LETT, V190, P209, DOI 10.1016/0014-5793(85)81285-0; Reuter K, 1999, EMBO J, V18, P6823, DOI 10.1093/emboj/18.23.6823; ROBISHAW JD, 1984, AM J PHYSIOL, V246, pH532, DOI 10.1152/ajpheart.1984.246.4.H532; Rock CO, 2000, J BIOL CHEM, V275, P1377, DOI 10.1074/jbc.275.2.1377; Runquist JA, 1998, BIOCHEMISTRY-US, V37, P1221, DOI 10.1021/bi972052f; Schlauderer GJ, 1996, PROTEIN SCI, V5, P434; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SONG WJ, 1994, J BIOL CHEM, V269, P27051; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; SUMMERS L, 1984, PEPTIDE PROTEIN REV, V3, P147; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P501, DOI 10.1107/S0907444998012657; VALLARI DS, 1987, J BACTERIOL, V169, P5795, DOI 10.1128/jb.169.12.5795-5800.1987; VALLARI DS, 1987, J BIOL CHEM, V262, P2468; WOLOSIUK RA, 1993, FASEB J, V7, P622, DOI 10.1096/fasebj.7.8.8500687	43	86	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28093	28099						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862768				2022-12-27	WOS:000089197100075
J	Bae, KA; Longobardi, L; Karasawa, K; Malone, B; Inoue, T; Aoki, J; Arai, H; Inoue, K; Lee, TC				Bae, KA; Longobardi, L; Karasawa, K; Malone, B; Inoue, T; Aoki, J; Arai, H; Inoue, K; Lee, TC			Platelet-activating factor (PAF)-dependent transacetylase and its relationship with PAF acetylhydrolases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA-INDEPENDENT TRANSACETYLASE; BETA-SUBUNIT; HL-60 CELLS; PURIFICATION; BRAIN; ACYLTRANSFERASE; BIOSYNTHESIS; EXPRESSION; CLONING; ANALOGS	Platelet-activating factor (PAF)-dependent transacetylase (TA) is an enzyme that transfers an acetyl group from PAF to acceptor lipids such as lysophospholipids and sphingosine, This enzyme is distributed in membrane and cytosol of the cells. We previously revealed that TA purified from rat kidney membrane showed an amino acid sequence similarity to that of bovine PAF-acetylhydrolase (AH) (II), In the present study, we purified TA from the rat kidney cytosol and analyzed its amino acid sequence, The amino acid sequence of the cytosolic TA is similar to that of bovine PAF-AH (II) and membrane TA, To clarify the relationship between TA and PAF-AH (II), we isolated cDNA of rat PAF-AH (II), The predicted amino acid sequence of rat PAF-AH (II) from isolated cDNA included all the sequences found in TAs purified from the membrane and cytosolic TAs, In addition, monoclonal antibody to recombinant PAF-AH (II) cross-reacted with both cytosolic and membrane TAs, Consistent with sequence identity, recombinant PAF-AH (II) showed TA activity, whereas recombinant PAF-AH Ib, which is a different subtype of intracellular PAF-AHs, did not possess TA activity. Analysis of a series of site-directed mutant PAF-AH (II) proteins showed that TA activity was decreased, whereas PAF-AH activity was not affected in C120S and G2A mutant proteins. Thus, Cys(120) and Gly(2) are implicated in the catalysis of TA reaction in this enzyme. Furthermore, the transfer of acetate from PAF to endogenous acceptor lipids was significantly increased in a time-dependent manner in CHO-KI cells transfected with PAF-AH (II) gene. These results demonstrate that PAF-AH (II) can function, as a TA in intact cells, and PAF-AH (II) and TA are the same enzyme.	Oak Ridge Associated Univ, Basic & Appl Res Unit, Oak Ridge, TN 37831 USA; Univ Tokyo, Fac Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 113, Japan	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tokyo	Lee, TC (corresponding author), Oak Ridge Associated Univ, Basic & Appl Res Unit, Oak Ridge, TN 37831 USA.	leetc@orau.gov		Aoki, Junken/0000-0001-9435-1896	NHLBI NIH HHS [HL-52492] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052492] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi H, 1997, BIOCHEM BIOPH RES CO, V233, P10, DOI 10.1006/bbrc.1997.6383; Balestrieri ML, 1997, J BIOL CHEM, V272, P17431, DOI 10.1074/jbc.272.28.17431; BLANK ML, 1981, J BIOL CHEM, V256, P175; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOURIN JA, 1997, CELL SIGNAL, V9, P15; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; Karasawa K, 1999, J BIOL CHEM, V274, P8655, DOI 10.1074/jbc.274.13.8655; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee TC, 1996, J BIOL CHEM, V271, P209, DOI 10.1074/jbc.271.1.209; Lee TC, 1996, ADV EXP MED BIOL, V416, P113; LEE TC, 1992, J BIOL CHEM, V267, P19992; Lio YC, 1998, BBA-LIPID LIPID MET, V1392, P320, DOI 10.1016/S0005-2760(98)00049-6; LIU M, 1993, BIOCHIM BIOPHYS ACTA, V1168, P144, DOI 10.1016/0005-2760(93)90118-S; Manya H, 1998, J BIOL CHEM, V273, P18567, DOI 10.1074/jbc.273.29.18567; Matsuzawa A, 1997, J BIOL CHEM, V272, P32315, DOI 10.1074/jbc.272.51.32315; Stafforini DM, 1997, J BIOL CHEM, V272, P17895, DOI 10.1074/jbc.272.29.17895; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0	24	29	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26704	26709						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10867005				2022-12-27	WOS:000089144800007
J	Sweeney, C; Lai, C; Riese, DJ; Diamonti, AJ; Cantley, LC; Carraway, KL				Sweeney, C; Lai, C; Riese, DJ; Diamonti, AJ; Cantley, LC; Carraway, KL			Ligand discrimination in signaling through an ErbB4 receptor homodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE; EGF-RECEPTOR; FACTOR-ALPHA; DIMERIZATION; NEUREGULIN-2; TRANSDUCTION; ONCOGENESIS; ACTIVATION; COMPLEXES	The epidermal growth factor (EGF)-like family of growth factors elicits cellular responses by stimulating the dimerization, autophosphorylation, and tyrosine kinase activities of the ErbB family of receptor tyrosine kinases, Although several different EGF-like ligands are capable of binding to a single ErbB family member, it is generally thought that the biological and biochemical responses of a single receptor dimer to different ligands are indistinguishable. To test whether an ErbB receptor dimer is capable of discriminating among ligands we have examined the effect of four EGF-like growth factors on signaling through the ErbB4 receptor homodimer in CEM/HER4 cells, a transfected human T cell line ectopically expressing ErbB4 in an ErbB-null background. Despite stimulating similar levels of gross receptor tyrosine phosphorylation, the EGF-like growth factors betacellulin, neuregulin-1 beta, neuregulin-2 beta, and neuregulin-3 exhibited different biological potencies in a cellular growth assay. Moreover, the different ligands induced different patterns of recruitment of intracellular signaling proteins to the activated receptor and induced differential usage of intracellular kinase signaling cascades. Finally, two-dimensional phosphopeptide mapping of ligand-stimulated ErbB4 revealed that the different growth factors induce different patterns of receptor tyrosine phosphorylation, These results indicate that ErbB4 activation by growth factors is not generic and suggest that individual ErbB receptors can discriminate between different EGF-like ligands within the context of a single receptor dimer. More generally, our observations significantly modify our understanding of signaling through receptor tyrosine kinases and point to a number of possible models for ligand-mediated signal diversification.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA; Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA; Scripps Res Inst, Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA; Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Scripps Research Institute; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Sweeney, C (corresponding author), Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Rm 1018,330 Brookline Ave, Boston, MA 02215 USA.	ccrovell@caregroup.harvard.edu	Cantley, Lewis C/D-1800-2014; Riese, David/AAF-3581-2020	Cantley, Lewis C/0000-0002-1298-7653; Riese, David/0000-0002-8823-5802	NATIONAL CANCER INSTITUTE [R01CA071702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NCI NIH HHS [CA71702] Funding Source: Medline; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; Crovello CS, 1998, J BIOL CHEM, V273, P26954, DOI 10.1074/jbc.273.41.26954; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Huang GC, 1998, BIOCHEM J, V331, P113, DOI 10.1042/bj3310113; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Lenferink AEG, 1997, BIOCHEM J, V327, P859; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	29	90	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19803	19807		10.1074/jbc.C901015199	http://dx.doi.org/10.1074/jbc.C901015199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867024	hybrid			2022-12-27	WOS:000087941300051
J	Liu, BR; Lee, HY; Weinzimer, SA; Powell, DR; Clifford, JL; Kurie, JM; Cohen, P				Liu, BR; Lee, HY; Weinzimer, SA; Powell, DR; Clifford, JL; Kurie, JM; Cohen, P			Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; BREAST-CANCER CELLS; EPITHELIAL-CELLS; PROSTATE-CANCER; FACTOR-I; FACTOR BINDING-PROTEIN-3; NUCLEAR TRANSPORT; SURFACE BINDING; THYROID-HORMONE; ACID	Insulin-like growth factor-binding protein (IGFBP)-3 regulates apoptosis in an IGF-independent fashion and has been shown to localize to nuclei. We cloned the nuclear receptor retinoid X receptor-alpha>(*) over bar * (RXR-alpha) as an IGFBP-3 protein partner in a yeast two-hybrid screen. Multiple methodologies showed that IGFBP-3 and RXR-alpha bind each other within the nucleus. IGFBP-3-induced apoptosis was abolished in RXR-alpha -knockout cells. IGFBP-3 and RXR ligands mere additive in inducing apoptosis in prostate cancer cells. IGFBP-3 enhanced RXR response element and inhibited RARE signaling. Thus, RXR-alpha -IGFBP-3 interaction leads to modulation of the transcriptional activity of RXR-alpha and is essential for mediating the effects of IGFBP-3 on apoptosis.	Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90095 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	University of California System; University of California Los Angeles; University of Texas System; UTMD Anderson Cancer Center; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Baylor College of Medicine	Cohen, P (corresponding author), Univ Calif Los Angeles, Mattel Childrens Hosp, Dept Pediat, Div Endocrinol, 10833 Le Conte Ave,MDCC 22-315, Los Angeles, CA 90095 USA.	hassy@mednet.ucla.edu		Lee, Ho-Young/0000-0001-7556-9312	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047591] Funding Source: NIH RePORTER; NIAID NIH HHS [1RO1 AI40203] Funding Source: Medline; NIDDK NIH HHS [2R01 DK47591] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Campbell PG, 1999, J BIOL CHEM, V274, P30215, DOI 10.1074/jbc.274.42.30215; Campbell PG, 1998, AM J PHYSIOL-ENDOC M, V275, pE321, DOI 10.1152/ajpendo.1998.275.2.E321; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; Clifford JL, 1999, CANCER RES, V59, P14; Collett-Solberg PF, 1998, J CLIN ENDOCR METAB, V83, P2843, DOI 10.1210/jc.83.8.2843; Collingwood TN, 1997, J BIOL CHEM, V272, P13060, DOI 10.1074/jbc.272.20.13060; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; deVos S, 1997, PROSTATE, V32, P115; Feldser D, 1999, CANCER RES, V59, P3915; Ferry RJ, 1999, HORM RES, V51, P53; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hembree JR, 1996, CANCER RES, V56, P1794; Janosi JBM, 1999, J BIOL CHEM, V274, P23328, DOI 10.1074/jbc.274.33.23328; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Leal SM, 1999, J BIOL CHEM, V274, P6711, DOI 10.1074/jbc.274.10.6711; Lee HY, 1998, J CLIN INVEST, V101, P1012, DOI 10.1172/JCI1329; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; Li WL, 1997, ENDOCRINOLOGY, V138, P1763, DOI 10.1210/en.138.4.1763; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH YM, 1993, J BIOL CHEM, V268, P14964; Perez-Juste G, 1999, ONCOGENE, V18, P5393, DOI 10.1038/sj.onc.1202906; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Solomin L, 1998, NATURE, V395, P398, DOI 10.1038/26515; Solomon C, 1999, J CLIN INVEST, V103, P1729, DOI 10.1172/JCI6871; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Wendling O, 1999, P NATL ACAD SCI USA, V96, P547, DOI 10.1073/pnas.96.2.547; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040	44	257	266	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33607	33613		10.1074/jbc.M002547200	http://dx.doi.org/10.1074/jbc.M002547200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10874028	hybrid			2022-12-27	WOS:000090104600061
J	Pryde, JG; Walker, A; Rossi, AG; Hannah, S; Haslett, C				Pryde, JG; Walker, A; Rossi, AG; Hannah, S; Haslett, C			Temperature-dependent arrest of neutrophil apoptosis - Failure of Bax insertion into mitochondria at 15 degrees C prevents the release of cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; PERMEABILITY TRANSITION PORE; DRUG-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; IN-VITRO; VITRONECTIN RECEPTOR; AGING NEUTROPHILS; PROTEASE ACTIVITY; NUCLEAR-CHANGES; BCL-2	Apoptosis is essential for the resolution of neutrophilic inflammation. To define the mechanisms triggering the execution phase of apoptosis we developed and utilized a model in which culture of human neutrophils at 15 degreesC for 20 h arrested apoptosis and subsequent warming to 37 degreesC triggered a synchronous burst of apoptosis. Treatment of 15 degreesC cultured neutrophils with the pan-caspase inhibitor zVAD-fmk just before warming to 37 degreesC inhibited the morphological changes associated with apoptosis, but did not prevent the insertion of the proapoptotic protein Bax into mitochondria nor the inhibition of secretion and the externalization of phosphatidylserine, indices of neutrophil apoptosis. In both intact neutrophils and a cell-free extract, cytochrome c released from mitochondria induced proteolytic cleavage of procaspase-3. At 15 degreesC the binding of Bax to mitochondria was uncoupled from Bax insertion into the mitochondrial membrane required for the release of cytochrome c. Apoptosis was also inhibited by low pH during warming to 37 degreesC, suggesting that changes to the conformation of Bax, necessary for membrane insertion, were being inhibited. Bax insertion was only sensitive to zVAD-fmk when added at the start of the 15 degreesC culture period, suggesting that a cytoplasmic substrate of the effector caspases may mediate in the mechanism of Bax insertion into mitochondria.	Univ Edinburgh, Sch Med, Dept Med RIE, Rayne Lab,Resp Med Unit, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Pryde, JG (corresponding author), Univ Edinburgh, Sch Med, Dept Med RIE, Rayne Lab,Resp Med Unit, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	j.pryde@ed.ac.uk						Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Benson RSP, 1999, J CELL SCI, V112, P1755; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Furlong IJ, 1997, J CELL SCI, V110, P653; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREGORY CD, 1994, INT J CANCER, V57, P419, DOI 10.1002/ijc.2910570321; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; HANNAH S, 1995, FEBS LETT, V372, P233, DOI 10.1016/0014-5793(95)00986-J; HASLETT C, 1985, AM J PATHOL, V119, P101; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KUMAMOTO J, 1971, J THEOR BIOL, V31, P47, DOI 10.1016/0022-5193(71)90120-2; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Liu GY, 1996, J BIOL CHEM, V271, P19717, DOI 10.1074/jbc.271.33.19717; MANARA FS, 1985, BIOCHEM BIOPH RES CO, V132, P696, DOI 10.1016/0006-291X(85)91188-X; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; MEAGHER LC, 1992, J LEUKOCYTE BIOL, V52, P269, DOI 10.1002/jlb.52.3.269; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; Murphy KM, 1999, ONCOGENE, V18, P5991, DOI 10.1038/sj.onc.1203001; Musgrove E A, 1990, Methods Cell Biol, V33, P59; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NICHOLSON DW, 1984, CAN J BIOCHEM CELL B, V62, P1205, DOI 10.1139/o84-155; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PRYDE JG, 1994, J CELL SCI, V107, P3425; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sanghavi DM, 1998, FEBS LETT, V422, P179, DOI 10.1016/S0014-5793(98)00004-0; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimura M, 1997, FEBS LETT, V417, P379, DOI 10.1016/S0014-5793(97)01327-6; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; TARTAKOFF AM, 1986, EMBO J, V5, P1477, DOI 10.1002/j.1460-2075.1986.tb04385.x; Trevani AS, 1999, J IMMUNOL, V162, P4849; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Vander Heiden MG, 1999, MOL CELL, V3, P159; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Weinmann P, 1999, BLOOD, V93, P3106; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zhuang JG, 1998, J BIOL CHEM, V273, P15628, DOI 10.1074/jbc.273.25.15628; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	81	62	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33574	33584		10.1074/jbc.M001008200	http://dx.doi.org/10.1074/jbc.M001008200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10896657	hybrid			2022-12-27	WOS:000090104600057
J	Fridman, M; Maruta, H; Gonez, J; Walker, F; Treutlein, H; Zeng, J; Burgess, A				Fridman, M; Maruta, H; Gonez, J; Walker, F; Treutlein, H; Zeng, J; Burgess, A			Point mutants of c-RAF-1 RBD with elevated binding to v-Ha-Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; ACTIVATING PROTEIN GAP; MOLECULAR-DYNAMICS; ESCHERICHIA-COLI; MEMBRANE ASSOCIATION; RAS/RAF INTERACTION; DOWNSTREAM TARGETS; GTPASE ACTIVITY; P21 PROTEINS	A mutational analysis of the Ras-binding domain (RBD) of c-Raf-1 identified three amino acid positions (Asn(64), Ala(85), and Val(88)) where amino acid substitution with basic residues increases the binding of RBD to recombinant v-Ha-Ras. The greatest increase in binding (6-9-fold) was observed with the A85K-RBD mutant. The elevated binding for the A85K-RBD and V88R-RBD mutants was also detected with Ras expressed in cultured mammalian cells, namely NIH-3T3 and BAF cells. None of the wild type residues in RBD positions Asn64, Ala85, and Val(88) have been previously implicated in the interaction with Ras (Block, C., Janknecht, R., Herrmann, C., Nassar, N., and Wittinghofer, A. (1996) Nat. Struct. Biol. 3, 244-251; Nassar, N,, Horn, G., Herrmann, C., Scherer, A. McCormick, F., and Wittinghofer, A. (1995) Nature 375, 554-560). The discovery of elevated binding among the mutants in these positions implies that additional RBD residues can be used to generate the Ras.RBD complex. These findings are of particular significance in the design of Ras antagonists based on the RBD prototype. The A85K-RBD mutant can be used to develop an assay for measuring the level of activated Ras in cultured cells; Sepharose-linked A85K-RBD.GST fusion protein served as an activation-specific probe to precipitate Ras.GTP but not Ras.GDP from epidermal growth factor-stimulated cells. A85K-RBD precipitates up to 5-fold more Ras.GTP from mammalian cells than wild type RBD.	Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic 3050, Australia; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Burgess, A (corresponding author), Cooperat Res Ctr Cellular Growth Factors, POB 2008, Melbourne, Vic 3050, Australia.	tony.burgess@ludwig.edu.au	Treutlein, Herbert Rudolf/AAC-7648-2021	Treutlein, Herbert Rudolf/0000-0001-5553-5553; Zeng, Jun/0000-0002-2736-1928				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Barnard D, 1995, ONCOGENE, V10, P1283; BASU T, 1994, ONCOGENE, V9, P3483; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Dalley BK, 1996, ONCOGENE, V13, P1209; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Downward J, 1996, CANCER SURV, V27, P87; EMERSON SD, 1995, BIOCHEMISTRY-US, V34, P6911, DOI 10.1021/bi00021a001; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; FRIDMAN M, 1994, J BIOL CHEM, V269, P30105; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Geyer M, 1996, BIOCHEMISTRY-US, V35, P10308, DOI 10.1021/bi952858k; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; Gorman C, 1996, J BIOL CHEM, V271, P6713, DOI 10.1074/jbc.271.12.6713; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; Herrmann C, 1998, J BIOL CHEM, V273, P16134, DOI 10.1074/jbc.273.26.16134; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Higuchi R., 1989, PCR TECHNOLOGY, P61; Horn IR, 1999, FEBS LETT, V463, P115, DOI 10.1016/S0014-5793(99)01617-8; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; Hwang MCC, 1996, J BIOL CHEM, V271, P8196, DOI 10.1074/jbc.271.14.8196; Ito Y, 1997, BIOCHEMISTRY-US, V36, P9109, DOI 10.1021/bi970296u; Jaitner BK, 1997, J BIOL CHEM, V272, P29927, DOI 10.1074/jbc.272.47.29927; JOHNSON BH, 1994, BIO-TECHNOL, V12, P1357, DOI 10.1038/nbt1294-1357; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; LACAL JC, 1986, CELL, V44, P609, DOI 10.1016/0092-8674(86)90270-9; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mangues R, 1992, Semin Cancer Biol, V3, P229; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOODIE SA, 1995, ONCOGENE, V11, P447; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORI S, 1995, J BIOL CHEM, V270, P28834, DOI 10.1074/jbc.270.48.28834; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; Ohnishi M, 1998, J BIOL CHEM, V273, P10210, DOI 10.1074/jbc.273.17.10210; OSTEROP APRM, 1993, EUR J BIOCHEM, V212, P477, DOI 10.1111/j.1432-1033.1993.tb17684.x; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PORFIRI E, 1995, METHOD ENZYMOL, V255, P13; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHEFFLER JE, 1994, J BIOL CHEM, V269, P22340; SCHEFFZEK K, 1998, G PROTEINS CYTOSKELE; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STEIN RB, 1984, J VIROL, V50, P343, DOI 10.1128/JVI.50.2.343-351.1984; Sydor JR, 1998, BIOCHEMISTRY-US, V37, P14292, DOI 10.1021/bi980764f; Terada T, 1999, J MOL BIOL, V286, P219, DOI 10.1006/jmbi.1998.2472; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; Weber CK, 2000, ONCOGENE, V19, P169, DOI 10.1038/sj.onc.1203261; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; Wittinghofer A, 1997, FEBS LETT, V410, P63, DOI 10.1016/S0014-5793(97)00321-9; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; YAN MH, 1994, J BIOL CHEM, V269, P19067; Zeng J, 1998, PROTEINS, V31, P186, DOI 10.1002/(SICI)1097-0134(19980501)31:2<186::AID-PROT8>3.0.CO;2-K; Zeng J, 1999, PROTEIN SCI, V8, P50; Zeng J, 1999, PROTEINS, V35, P89; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	76	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30363	30371		10.1074/jbc.M003193200	http://dx.doi.org/10.1074/jbc.M003193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10887184	hybrid			2022-12-27	WOS:000089577900061
J	Liang, L; Lim, KL; Seow, KT; Ng, CH; Pallen, CJ				Liang, L; Lim, KL; Seow, KT; Ng, CH; Pallen, CJ			Calmodulin binds to and inhibits the activity of the membrane distal catalytic domain of receptor protein-tyrosine phosphatase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-FAMILY KINASES; 2 POINT MUTATIONS; PTP-ALPHA; CYTOPLASMIC DOMAIN; STRUCTURAL BASIS; KINETIC-ANALYSIS; DOWN-REGULATION; CD45; LAR; PURIFICATION	cDNA expression library screening revealed binding between the membrane distal catalytic domain (D2) of protein-tyrosine phosphatase alpha (PTP alpha) and calmodulin. Characterization using surface plasmon resonance showed that calmodulin bound to PTP alpha-D2 in a Ca2+-dependent manner but did not bind to the membrane proximal catalytic domain (D1) of PTP alpha, to the two tandem catalytic domains (D1D2) of PTP alpha, nor to the closely related D2 domain of PTP epsilon. Calmodulin bound to PTP alpha-D2 with high affinity, exhibiting a K-D similar to 3 nM. The calmodulin-binding site was localized to amino acids 520-538 in the N-terminal region of D2. Site-directed mutagenesis showed that Lys-521 and Asn-534 were required for optimum calmodulin binding and that restoration of these amino acids to the counterpart PTP epsilon sequence could confer calmodulin binding. The overlap of the binding site with the predicted lip of the catalytic cleft of PTP alpha-D2, in conjunction with the observation that calmodulin acts as a competitive inhibitor of D2-catalyzed dephosphorylation (K-i similar to 340 nM), suggests that binding of calmodulin physically blocks or distorts the catalytic cleft of PTP alpha-D2 to prevent interaction with substrate. When expressed in cells, full-length PTP alpha and PTP alpha lacking only D1, but not full-length PTP epsilon, bound to calmodulin beads in the presence of Ca2+. Also, PTP alpha was found in association with calmodulin immunoprecipitated from cell lysates. Thus calmodulin does associate with PTP alpha in vivo but not with PTP alpha-D1D2 in vitro, highlighting a potential conformational difference between these forms of the tandem catalytic domains. The above findings suggest that calmodulin is a possible specific modulator of PTP alpha-D2 and, via D2, of PTP alpha.	Inst Mol & Cell Biol, Cell Regulat Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Pallen, CJ (corresponding author), Inst Mol & Cell Biol, Cell Regulat Lab, 30 Med Dr, Singapore 117609, Singapore.		Lim, Kah-Leong/AAY-3308-2020; Lim, Kah/L-5426-2019	Lim, Kah-Leong/0000-0002-5440-2588; Pallen, Catherine/0000-0002-3576-5295; Ng, Chee Hoe/0000-0001-8545-0497				Bhandari V, 1998, J BIOL CHEM, V273, P8691, DOI 10.1074/jbc.273.15.8691; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Blanchetot C, 2000, J BIOL CHEM, V275, P12446, DOI 10.1074/jbc.275.17.12446; Buist P, 1999, BIOCHEMISTRY-US, V38, P914, DOI 10.1021/bi981936b; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; COX JA, 1985, J BIOL CHEM, V260, P2527; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; GEBBINK MFBG, 1993, BIOCHEMISTRY-US, V32, P13516, DOI 10.1021/bi00212a017; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; Kashio N, 1998, J BIOL CHEM, V273, P33856, DOI 10.1074/jbc.273.50.33856; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Lim KL, 1997, EUR J BIOCHEM, V245, P693, DOI 10.1111/j.1432-1033.1997.00693.x; Lim KL, 1998, J BIOL CHEM, V273, P28986, DOI 10.1074/jbc.273.44.28986; Lim KL, 1999, BBA-PROTEIN STRUCT M, V1434, P275, DOI 10.1016/S0167-4838(99)00189-2; MAULET Y, 1983, BIOCHEMISTRY-US, V22, P5680, DOI 10.1021/bi00293a035; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; POT DA, 1991, J BIOL CHEM, V266, P19688; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SU J, 1994, J BIOL CHEM, V269, P18731; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6016; Tsai W, 1999, EMBO J, V18, P109, DOI 10.1093/emboj/18.1.109; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	39	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30075	30081		10.1074/jbc.M004843200	http://dx.doi.org/10.1074/jbc.M004843200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893241	hybrid			2022-12-27	WOS:000089577900023
J	Pandit, J; Danley, DE; Schulte, GK; Mazzalupo, S; Pauly, TA; Hayward, CM; Hamanaka, ES; Thompson, JF; Harwood, HJ				Pandit, J; Danley, DE; Schulte, GK; Mazzalupo, S; Pauly, TA; Hayward, CM; Hamanaka, ES; Thompson, JF; Harwood, HJ			Crystal structure of human squalene synthase - A key enzyme in cholesterol biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESQUALENE DIPHOSPHATE; SYNTHETASE INHIBITORS; PROTEIN; MECHANISM; ANALOGS; PYROPHOSPHATE; INTERMEDIATE; INSIGHTS	Squalene synthase catalyzes the biosynthesis of squalene, a key cholesterol precursor, through a reductive dimerization of two farnesyl diphosphate (FPP) molecules. The reaction is unique when compared with those of other FPP-utilizing enzymes and proceeds in two distinct steps, both of which involve the formation of carbocationic reaction intermediates. Because FPP is located at the final branch point in the isoprenoid biosynthesis pathway, its conversion to squalene through the action of squalene synthase represents the first committed step in the formation of cholesterol, making it an attractive target for therapeutic intervention. We have determined, for the first time, the crystal structures of recombinant human squalene synthase complexed with several different inhibitors. The structure shows that SQS is folded as a single domain, with a large channel in the middle of one face. The active sites of the two half-reactions catalyzed by the enzyme are located in the central channel, which is Lined on both sides by conserved aspartate and arginine residues, which are known from mutagenesis experiments to be involved in FPP binding. One end of this channel is exposed to solvent, whereas the other end leads to a completely enclosed pocket surrounded by conserved hydrophobic residues. These observations, along with mutagenesis data identifying residues that affect substrate binding and activity, suggest that two molecules of FPP bind at one end of the channel, where the active center of the first half-reaction is located, and then the stable reaction intermediate moves into the deep pocket, where it is sequestered from solvent and the second half-reaction occurs. Five alpha helices surrounding the active center are structurally homologous to the active core in the three other isoprenoid biosynthetic enzymes whose crystal structures are known, even though there is no detectable sequence homology.	Pfizer Inc, Cent Res, Dept Exploratory Med Sci, Groton, CT 06340 USA; Pfizer Inc, Cent Res, Dept Cardiovasc & Metab Dis, Groton, CT 06340 USA	Pfizer; Pfizer	Pandit, J (corresponding author), Pfizer Inc, Cent Res, Dept Exploratory Med Sci, MS 4039,Eastern Point Rd, Groton, CT 06340 USA.			Pandit, Jayvardhan/0000-0001-6128-7779; Thompson, John/0000-0001-8568-3311				ASHBY MN, 1992, J BIOL CHEM, V267, P4128; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERGSTROM JD, 1995, ANNU REV MICROBIOL, V49, P607, DOI 10.1146/annurev.mi.49.100195.003135; Biller SA, 1996, CURR PHARM DESIGN, V2, P1; BRUNGER AT, 1996, XPLOR ONLINE SYSTEM; COREY EJ, 1976, J AM CHEM SOC, V98, P1291, DOI 10.1021/ja00421a056; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DEMONTELLANO PRO, 1977, BIOCHEMISTRY-US, V16, P2680; Gu PD, 1998, J BIOL CHEM, V273, P12515, DOI 10.1074/jbc.273.20.12515; Harwood HJ, 1997, BIOCHEM PHARMACOL, V53, P839, DOI 10.1016/S0006-2952(96)00892-1; Jarstfer MB, 1996, J AM CHEM SOC, V118, P13089, DOI 10.1021/ja963308s; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lesburg CA, 1997, SCIENCE, V277, P1820, DOI 10.1126/science.277.5333.1820; LINDSEY S, 1995, J BIOL CHEM, V270, P9083, DOI 10.1074/jbc.270.16.9083; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOOKHTIAR KA, 1994, J BIOL CHEM, V269, P11201; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ourisson G, 1994, CHEM BIOL, V1, P11, DOI 10.1016/1074-5521(94)90036-1; Petras SF, 1999, J LIPID RES, V40, P24; POPJAK G, 1979, MOL CELL BIOCHEM, V27, P97; Poulter C, 1981, BIOSYNTHESIS ISOPREN, P413; POULTER CD, 1990, ACCOUNTS CHEM RES, V23, P70, DOI 10.1021/ar00171a003; POULTER CD, 1989, J AM CHEM SOC, V111, P3734, DOI 10.1021/ja00192a036; ROBINSON GW, 1993, MOL CELL BIOL, V13, P2706, DOI 10.1128/MCB.13.5.2706; Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788; Starks CM, 1997, SCIENCE, V277, P1815, DOI 10.1126/science.277.5333.1815; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; Thompson JF, 1998, ARCH BIOCHEM BIOPHYS, V350, P283, DOI 10.1006/abbi.1997.0502; TONG L, 1993, J APPL CRYSTALLOGR, V26, P15, DOI 10.1107/S0021889892007295; WASHBURN W N, 1977, Tetrahedron Letters, V18, P1555, DOI 10.1016/S0040-4039(01)93101-6; Wendt KU, 1998, STRUCTURE, V6, P127, DOI 10.1016/S0969-2126(98)00015-X; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; [No title captured]	37	193	214	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30610	30617		10.1074/jbc.M004132200	http://dx.doi.org/10.1074/jbc.M004132200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896663	hybrid			2022-12-27	WOS:000089577900095
J	Terao, M; Kurosaki, M; Saltini, G; Demontis, S; Marini, M; Salmona, M; Garattini, E				Terao, M; Kurosaki, M; Saltini, G; Demontis, S; Marini, M; Salmona, M; Garattini, E			Cloning of the cDNAs coding for two novel molybdo-flavoproteins showing high similarity with aldehyde oxidase and xanthine oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; AMINO-ACID-SEQUENCE; MOLECULAR-CLONING; DROSOPHILA-MELANOGASTER; DEHYDROGENASE OXIDASE; RABBIT LIVER; IN-VIVO; GENE; EXPRESSION; PURIFICATION	The cDNAs coding for two novel mouse molybdo-flavoproteins, AOH1 and AOH2 (aldehyde oxidase homolog 1 and 2), were isolated. The AOH1 and AOH2 cDNAs code for polypeptides of 1336 amino acids. The two proteins have similar primary structure and show striking amino acid identity with aldehyde oxidase and xanthine oxidoreductase, two other molybdo-flavoenzymes. AOH1 and AOH2 contain consensus sequences for a molybdopterin-binding site and two distinct 2Fe-2S redox centers. In its native conformation, AOH1 has a molecular weight consistent with a homotetrameric structure. Transfection of the AOH1 and AOH2 cDNAs results in the production of proteins with phenanthridine but not hypoxanthine oxidizing activity. Furthermore, the AOH1 protein has benzaldehyde oxidizing activity with electrophoretic characteristics identical to those of a previously identified aldehyde oxidase isoenzyme (Holmes, R. S. (1979) Biochem. Genet. 17, 517-528). The AOH1 transcript is expressed in the hepatocytes of the adult and fetal liver and in spermatogonia. In liver, the AOH1 protein is synthesized in a gender-specific fashion. The expression of AOH2 is limited to keratinized epithelia and the basal layer of the epidermis and hair folliculi. The selective cell and tissue distribution of AOH1 and AOH2 mRNAs is consistent with the localization of the respective protein products.	Mario Negri Inst Pharmacol Res, Ctr Catullo & Daniela Borgomainerio, Mol Biol Lab, I-20157 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Garattini, E (corresponding author), Mario Negri Inst Pharmacol Res, Ctr Catullo & Daniela Borgomainerio, Mol Biol Lab, Via Eritrea 62, I-20157 Milan, Italy.	egarattini@irfmn.mnegri.it	salmona, mario/AAA-7116-2020; salmona, mario/ABI-4066-2020; Garattini, Enrico/AAI-1998-2019; terao, mineko/AAU-8089-2020; Terao, Mineko/AAA-6415-2020; KUROSAKI, Mami/ABG-2224-2020	salmona, mario/0000-0002-9098-9873; Terao, Mineko/0000-0002-9976-9869; KUROSAKI, Mami/0000-0001-8231-713X; Garattini, Enrico/0000-0001-8983-886X	Telethon [D.088] Funding Source: Medline	Telethon(Fondazione Telethon)		AKAIKE T, 1990, J CLIN INVEST, V85, P739, DOI 10.1172/JCI114499; AMAYA Y, 1990, J BIOL CHEM, V265, P14170; Angerer L.M., 1992, IN SITU HYBRIDIZATIO, P15; BERGER R, 1995, SOMAT CELL MOLEC GEN, V21, P121, DOI 10.1007/BF02255787; Berglund L, 1996, J DAIRY SCI, V79, P198, DOI 10.3168/jds.S0022-0302(96)76351-8; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CARPANI G, 1990, ARCH BIOCHEM BIOPHYS, V279, P237, DOI 10.1016/0003-9861(90)90487-J; CATES LA, 1980, J MED CHEM, V23, P300, DOI 10.1021/jm00177a018; CAZZANIGA G, 1994, GENOMICS, V23, P390, DOI 10.1006/geno.1994.1515; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; Demontis S, 1999, BBA-GENE STRUCT EXPR, V1489, P207, DOI 10.1016/S0167-4781(99)00174-8; FABRE G, 1986, BIOCHEM PHARMACOL, V35, P1325, DOI 10.1016/0006-2952(86)90277-7; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; GARRETT RM, 1995, BIOCHIM BIOPHYS ACTA, V126, P147; Glatigny A, 1998, J MOL BIOL, V278, P431, DOI 10.1006/jmbi.1998.1707; GLATIGNY A, 1995, J BIOL CHEM, V270, P3534, DOI 10.1074/jbc.270.8.3534; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; HOLMES RS, 1978, COMP BIOCHEM PHYS B, V61, P339, DOI 10.1016/0305-0491(78)90134-7; HOLMES RS, 1979, BIOCHEM GENET, V17, P517, DOI 10.1007/BF00498887; Hosler BA, 1998, NEUROGENETICS, V2, P34, DOI 10.1007/s100480050049; HOUDE M, 1989, GENE, V85, P391, DOI 10.1016/0378-1119(89)90432-0; Huang DY, 1999, ARCH BIOCHEM BIOPHYS, V364, P264, DOI 10.1006/abbi.1999.1129; HUANG DY, 1994, BIOCHEM BIOPH RES CO, V205, P1278, DOI 10.1006/bbrc.1994.2803; KEITH TP, 1987, GENETICS, V116, P67; KRENITSKY TA, 1972, ARCH BIOCHEM BIOPHYS, V150, P585, DOI 10.1016/0003-9861(72)90078-1; Kurosaki M, 1996, BIOCHEM J, V319, P801, DOI 10.1042/bj3190801; Kurosaki M, 1999, BIOCHEM J, V341, P71, DOI 10.1042/0264-6021:3410071; KUROSAKI M, 1995, BIOCHEM J, V306, P225, DOI 10.1042/bj3060225; Li Calzi Marco, 1995, Journal of Biological Chemistry, V270, P31037; MCGEER EJ, 1978, MOL NEUROBIOLOGY MAM; NISHINO T, 1989, J BIOL CHEM, V264, P5468; Ori N, 1997, J BIOL CHEM, V272, P1019, DOI 10.1074/jbc.272.2.1019; Page S, 1998, BBA-GEN SUBJECTS, V1381, P191, DOI 10.1016/S0304-4165(98)00028-2; PARKS DA, 1983, AM J PHYSIOL, V245, P285; PERSICO MG, 1986, NUCLEIC ACIDS RES, V14, P2511, DOI 10.1093/nar/14.6.2511; Rebelo J, 2000, J MOL BIOL, V297, P135, DOI 10.1006/jmbi.2000.3552; Reiss J, 2000, HUM GENET, V106, P157, DOI 10.1007/s004390051023; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; Saksela M, 1996, BIOCHEM J, V315, P235, DOI 10.1042/bj3150235; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; SATO A, 1995, J BIOL CHEM, V270, P2818, DOI 10.1074/jbc.270.6.2818; Sekimoto H, 1998, PLANT CELL PHYSIOL, V39, P433, DOI 10.1093/oxfordjournals.pcp.a029387; Sekimoto H, 1997, J BIOL CHEM, V272, P15280, DOI 10.1074/jbc.272.24.15280; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TAYLOR SM, 1984, BIOCHEM J, V220, P67, DOI 10.1042/bj2200067; Terao M, 1997, BIOCHEM SOC T, V25, P791, DOI 10.1042/bst0250791; Terao M, 1998, BIOCHEM J, V332, P383, DOI 10.1042/bj3320383; TERAO M, 1992, BIOCHEM J, V283, P863, DOI 10.1042/bj2830863; THOENES U, 1994, EUR J BIOCHEM, V220, P901, DOI 10.1111/j.1432-1033.1994.tb18693.x; Wright RM, 1997, BIOCHEM SOC T, V25, P799, DOI 10.1042/bst0250799; Wright RM, 1999, J BIOL CHEM, V274, P3878, DOI 10.1074/jbc.274.6.3878; WRIGHT RM, 1993, P NATL ACAD SCI USA, V90, P10690, DOI 10.1073/pnas.90.22.10690; Yasukochi Y, 1998, GENET RES, V71, P11, DOI 10.1017/S0016672397003078; YOSHIHARA S, 1985, ARCH BIOCHEM BIOPHYS, V242, P213, DOI 10.1016/0003-9861(85)90495-3	57	61	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30690	30700		10.1074/jbc.M005355200	http://dx.doi.org/10.1074/jbc.M005355200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893244	hybrid			2022-12-27	WOS:000089577900106
J	Delacoux, F; Fichard, A; Cogne, S; Garrone, R; Ruggiero, F				Delacoux, F; Fichard, A; Cogne, S; Garrone, R; Ruggiero, F			Unraveling the amino acid sequence crucial for heparin binding to collagen V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EHLERS-DANLOS-SYNDROME; FIBROBLAST GROWTH-FACTOR; ALPHA-1(V) CHAIN; COL5A1 GENE; SITE; DOMAIN; XI; IDENTIFICATION; MUTAGENESIS; MUTATIONS	We have previously shown that a recombinant 18-kDa fragment of the collagen alpha 1(V) chain (Ile(824)-Pro(950)), referred to as HepV, binds to heparin and heparan sulfate (Delacoux, F., Fichard, A, Geourjon, C., Garrone, R., and Ruggiero, F, (1998) J, Biol, Chem. 273, 15069-15076), No consensus sequence was found in the alpha 1(V) primary sequence, but a cluster of 7 basic amino acids tin the Arg(900)-Arg(924) region) was postulated to contain the heparin-binding site, The contribution of individual basic amino acids within this sequence was examined by site-directed mutagenesis, Further evidence for the precise localization of the heparin-binding site was provided by experiments based on the fact that heparin can protect the alpha 1(V) chain heparin-binding site from trypsin digestion. The results parallel the alanine scanning mutagenesis data, i.e. heparin binding to the alpha 1(V) chain involved Arg(912), Arg(918), and Arg(921) and two additional neighboring basic residues, Lys(905) and Arg(909), Our data suggest that this extended sequence functions as a heparin-binding site in both collagens V and XI, indicating that these collagens use a novel sequence motif to interact with heparin.	Univ Lyon 1, Inst Biol & Chim Prot, CNRS, UPR 412, F-69367 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Ruggiero, F (corresponding author), Univ Lyon 1, Inst Biol & Chim Prot, CNRS, UPR 412, 7 Passage Vercors, F-69367 Lyon 07, France.	f.ruggiero@ibcp.fr		RUGGIERO, Florence/0000-0003-2915-5359				ANDRIKOPOULOS K, 1995, NAT GENET, V9, P31, DOI 10.1038/ng0195-31; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Delacoux F, 1998, J BIOL CHEM, V273, P15069, DOI 10.1074/jbc.273.24.15069; DePaepe A, 1997, AM J HUM GENET, V60, P547; FICHARD A, 1995, MATRIX BIOL, V14, P515, DOI 10.1016/S0945-053X(05)80001-0; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; Giry-Lozinguez C, 1998, MATRIX BIOL, V17, P145, DOI 10.1016/S0945-053X(98)90027-0; Imamura Y, 2000, J BIOL CHEM, V275, P8749, DOI 10.1074/jbc.275.12.8749; KAMMANN M, 1989, NUCLEIC ACIDS RES, V17, P5404, DOI 10.1093/nar/17.13.5404; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; KOLIAKOS GG, 1989, J BIOL CHEM, V264, P2313; Kridel SJ, 1996, J BIOL CHEM, V271, P20935, DOI 10.1074/jbc.271.34.20935; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MAYNE R, 1993, J BIOL CHEM, V268, P9381; Michalickova K, 1998, HUM MOL GENET, V7, P249, DOI 10.1093/hmg/7.2.249; Mizuno K, 1996, J BIOCHEM-TOKYO, V120, P934; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; Ruggiero F, 1996, J CELL SCI, V109, P1865; RUGGIERO F, 1994, EXP CELL RES, V210, P215, DOI 10.1006/excr.1994.1032; SANANTONIO JD, 1994, J CELL BIOL, V125, P1179, DOI 10.1083/jcb.125.5.1179; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; SMITH GN, 1987, COLLAGEN REL RES, V7, P315; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; Tillet E, 1997, J BIOL CHEM, V272, P10769; Toriello HV, 1996, NAT GENET, V13, P361, DOI 10.1038/ng0796-361; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; WONG P, 1995, J BIOL CHEM, V270, P25805, DOI 10.1074/jbc.270.43.25805; YAOI Y, 1990, BIOCHIM BIOPHYS ACTA, V1035, P139, DOI 10.1016/0304-4165(90)90108-9; Zhao MM, 1998, J BIOL CHEM, V273, P31153, DOI 10.1074/jbc.273.47.31153	31	27	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29377	29382		10.1074/jbc.M004724200	http://dx.doi.org/10.1074/jbc.M004724200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10862775	hybrid			2022-12-27	WOS:000089439800028
J	Masuda, A; Matsuguchi, T; Yamaki, K; Hayakawa, T; Kubo, M; LaRochelle, WJ; Yoshikai, Y				Masuda, A; Matsuguchi, T; Yamaki, K; Hayakawa, T; Kubo, M; LaRochelle, WJ; Yoshikai, Y			Interleukin-15 induces rapid tyrosine phosphorylation of STAT6 and the expression of interleukin-4 in mouse mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN T-CELLS; BETA-CHAIN; IL-4 PRODUCTION; GROWTH-FACTOR; GM-CSF; RECEPTOR; CYTOKINE; LYMPHOKINE; DIFFERENTIATION; ACTIVATION	Interleukin (IL)-4 plays an important role in the differentiation of naive T helper (Th) cells into Th2. Mast cells can produce a significant amount of IL-4 and have been proposed to play a major role in the induction of Th2 responses. Recently, it has been reported that mast cells have a distinct IL-15 receptor system different from that of T or natural killer cells. In the present study, we demonstrated that IL-15 induced IL-4 production from a mouse mast cell line, MC/9, and bone marrow-derived mast cells. IL-4 mRNA expression was increased by IL-15, suggesting that IL-15 promotes IL-4 expression at the transcriptional Level. In these mast cells, signal transducer and activator of transcription (STAT) 6 were rapidly tyrosine-phosphorylated in response to IL-15. In MC/9 cells, the expression of a C-terminally truncated dominant negative form of STAT6 significantly suppressed the IL-4 mRNA up-regulation by IL-15, suggesting that STAT6 activation is essential for the IL-15-mediated IL-4 production. Additionally, tyrosine phosphorylation of Tyk2 was rapidly increased by IL-15 treatment in this cell line. Altogether, our results suggest that IL-15 plays an important role in stimulating early IL-4 production in mast cells that may be responsible for the initiation of Th2 response.	Nagoya Univ, Sch Med, Dis Mechanism & Control Res Inst, Lab Host Def & Germfree Life,Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dis Mechanism & Control Res Inst, Dept Internal Med 2,Showa Ku, Nagoya, Aichi 4668550, Japan; Sci Univ Tokyo, Res Inst Biol Sci, Div Immunobiol, Tokyo 2780022, Japan; NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	Nagoya University; Nagoya University; Tokyo University of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Matsuguchi, T (corresponding author), Nagoya Univ, Sch Med, Dis Mechanism & Control Res Inst, Lab Host Def & Germfree Life,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Masuda, Akio/H-6323-2012					BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; Coffman RL, 1997, J EXP MED, V185, P373, DOI 10.1084/jem.185.3.373; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Doherty TM, 1996, J IMMUNOL, V156, P735; GALLI SJ, 1991, CURR OPIN IMMUNOL, V3, P865, DOI 10.1016/S0952-7915(05)80005-6; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; Georas SN, 1998, BLOOD, V92, P4529, DOI 10.1182/blood.V92.12.4529.424k39_4529_4538; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; Hirose K, 1998, INFECT IMMUN, V66, P5677, DOI 10.1128/IAI.66.12.5677-5683.1998; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; Huang H, 1997, J IMMUNOL, V159, P3731; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; Kubo M, 1997, EMBO J, V16, P4007, DOI 10.1093/emboj/16.13.4007; Lederer JA, 1996, J EXP MED, V184, P397, DOI 10.1084/jem.184.2.397; MARTINEZ OM, 1990, J IMMUNOL, V144, P2211; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Nishimura H, 1996, J IMMUNOL, V156, P663; PAUL WE, 1991, BLOOD, V77, P1859; PELEMAN R, 1989, J EXP MED, V170, P1751, DOI 10.1084/jem.170.5.1751; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Ruckert R, 1998, EUR J IMMUNOL, V28, P3312; Sakai T, 1998, GASTROENTEROLOGY, V114, P1237, DOI 10.1016/S0016-5085(98)70430-5; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Sherman MA, 1999, J IMMUNOL, V163, P1733; Sherman MA, 1999, EUR J IMMUNOL, V29, P1235, DOI 10.1002/(SICI)1521-4141(199904)29:04<1235::AID-IMMU1235>3.3.CO;2-S; Sherman MA, 1999, J IMMUNOL, V162, P2703; SWAIN SL, 1990, J IMMUNOL, V144, P1788; Szabo SJ, 1997, CURR OPIN IMMUNOL, V9, P776, DOI 10.1016/S0952-7915(97)80177-X; Tagaya Y, 1996, EMBO J, V15, P4928, DOI 10.1002/j.1460-2075.1996.tb00873.x; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; Yoshikawa H, 1999, J IMMUNOL, V162, P6162; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	43	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29331	29337		10.1074/jbc.M910290199	http://dx.doi.org/10.1074/jbc.M910290199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882748	hybrid			2022-12-27	WOS:000089439800022
J	Tzivion, G; Luo, ZJ; Avruch, J				Tzivion, G; Luo, ZJ; Avruch, J			Calyculin A-induced vimentin phosphorylation sequesters 14-3-3 and displaces other 14-3-3 partners in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT REORGANIZATION; KINASE-ACTIVITY; DNA-DAMAGE; 14-3-3-PROTEINS; BINDING; RAF; CHECKPOINT; CELLS; ASSOCIATION; INHIBITION	14-3-3 proteins bind their targets through a specific serine/threonine-phosphorylated motif present on the target protein. This binding is a crucial step in the phosphorylation-dependent regulation of various key proteins involved in signal transduction and cell cycle control, We report that treatment of COS-7 cells with the phosphatase inhibitor calyculin A induces association of 14-3-3 with a 55-kDa protein, identified as the intermediate filament protein vimentin, Association of vimentin with 14-3-3 depends on vimentin phosphorylation and requires the phosphopeptide-binding domain of 14-3-3, The region necessary for binding to 14-3-3 is confined to the vimentin amino-terminal head domain (amino acids 1-96). Monomeric forms of 14-3-3 do not bind vimentin in vivo or in vitro, indicating that a stable complex requires the binding of a 14-3-3 dimer to two sites on a single vimentin polypeptide. The calyculin A-induced association of vimentin with 14-3-3 in vivo results in the displacement of most other 14-3-3 partners, including the protooncogene Raf, which nevertheless remain capable of binding 14-3-3 in vitro, Concomitant with 14-3-3 displacement, calyculin A treatment blocks Raf activation by EGF; however, this inhibition is completely overcome by 14-3-3 overexpression in vivo or by the addition of prokaryotic recombinant 14-3-3 in vitro, Thus, phosphovimentin, by sequestering 14-3-3 and limiting its availability to other target proteins can affect intracellular signaling processes that require 14-3-3.	Massachusetts Gen Hosp, Dept Mol Biol, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; Boston Univ, Med Ctr, Diabet & Metab Unit, Boston, MA 02118 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Boston University	Tzivion, G (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Coll Med, Div Mol Cardiol,Cardiovasc Res Inst, 1901 S 1st St,Bldg 162, Temple, TX 76504 USA.		Tzivion, Guri/D-8954-2011; Luo, Zhijun/AAE-9302-2019	Luo, Zhijun/0000-0001-8105-5289				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; CHOU YH, 1991, J BIOL CHEM, V266, P7325; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; ERIKSSON JE, 1992, P NATL ACAD SCI USA, V89, P11093, DOI 10.1073/pnas.89.22.11093; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Honda R, 1997, BIOCHEM BIOPH RES CO, V230, P262, DOI 10.1006/bbrc.1996.5933; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; KLYMKOWSKY MW, 1995, CURR OPIN CELL BIOL, V7, P46, DOI 10.1016/0955-0674(95)80044-1; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rommel C, 1996, ONCOGENE, V12, P609; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	32	123	131	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29772	29778		10.1074/jbc.M001207200	http://dx.doi.org/10.1074/jbc.M001207200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887173	hybrid, Green Published			2022-12-27	WOS:000089439800081
J	Hunt, MC; Yang, YZ; Eggertsen, G; Carneheim, CM; Gafvels, M; Einarsson, C; Alexson, SEH				Hunt, MC; Yang, YZ; Eggertsen, G; Carneheim, CM; Gafvels, M; Einarsson, C; Alexson, SEH			The peroxisome proliferator-activated receptor alpha (PPAR alpha) regulates bile acid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL 12-ALPHA-HYDROXYLASE; FATTY-ACIDS; CHOLESTEROL-METABOLISM; RESPONSIVE ELEMENT; ADAPTIVE RESPONSE; GENE-EXPRESSION; IDENTIFICATION; MOUSE; MICE; EICOSANOIDS	Fibrates are a group of hypolipidemic agents that efficiently lower serum triglyceride levels by affecting the expression of many genes involved in lipid metabolism. These effects are exerted via the peroxisome proliferator-activated receptor alpha (PPAR alpha). In addition, fibrates also lower serum cholesterol levels, suggesting a possible link between the PPAR alpha and cholesterol metabolism. Bile acid formation represents an important pathway for elimination of cholesterol, and the sterol 12 alpha-hydroxylase is a branch-point enzyme in the bile acid biosynthetic pathway, which determines the ratio of cholic acid to chenodeoxycholic acid. Treatment of mice for 1 week with the peroxisome proliferator WY-14,643 or fasting for 24 h both induced the sterol 12 alpha-hydroxylase mRNA in liver. Using the PPAR alpha knockout mouse model, we show that the induction by both treatments was dependent on the PPAR alpha. A reporter plasmid containing a putative peroxisome proliferator-response element (PPRE) identified in the rat sterol 12 alpha-hydroxylase promoter region was activated by treatment with WY-14,643 in HepG2 cells, being dependent on co-transfection with a PPAR alpha expression plasmid, The rat 12 alpha-hydroxylase PPRE bound in vitro translated PPAR alpha and retinoid X receptor alpha, albeit weakly, in electrophoretic mobility shift assay, Treatment of wild-type mice with WY-14,643 for 1 week resulted in an increased relative amount of cholic acid, an effect that was abolished in the PPAR alpha null mice, verifying the functionality of the PPRE in vivo.	Huddinge Univ Hosp, Karolinska Inst, Div Clin Chem, Dept Med Lab Sci & Technol, S-14186 Huddinge, Sweden; Pharmacia & Upjohn AB, Plasma Prod R&D, S-11287 Stockholm, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Med, Div Gastroenterol & Hepatol, S-14186 Huddinge, Sweden	Karolinska Institutet; Pfizer; Pharmacia Corporation; Karolinska Institutet	Alexson, SEH (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Div Clin Chem, Dept Med Lab Sci & Technol, S-14186 Huddinge, Sweden.	stefan.alexson@chemlab.hs.sll.se						Andersson U, 1999, BBA-MOL CELL BIOL L, V1438, P167, DOI 10.1016/S1388-1981(99)00036-0; ANGELIN B, 1976, BIOCHEM J, V156, P445, DOI 10.1042/bj1560445; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; del Castillo-Olivares A, 2000, J BIOL CHEM, V275, P17793, DOI 10.1074/jbc.M000996200; Eggertsen G, 1996, J BIOL CHEM, V271, P32269, DOI 10.1074/jbc.271.50.32269; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Gafvels M, 1999, GENOMICS, V56, P184, DOI 10.1006/geno.1998.5606; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; GRUNDY SM, 1972, J LIPID RES, V13, P531; Hunt MC, 2000, J LIPID RES, V41, P814; ISHIDA H, 1992, J BIOL CHEM, V267, P21319; Ishida H, 1999, J BIOCHEM-TOKYO, V126, P19, DOI 10.1093/oxfordjournals.jbchem.a022422; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; KESANIEMI YA, 1984, JAMA-J AM MED ASSOC, V251, P2241, DOI 10.1001/jama.251.17.2241; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; Osada S, 1997, GENES CELLS, V2, P315, DOI 10.1046/j.1365-2443.1997.1220319.x; Princen HMG, 1997, CURR PHARM DESIGN, V3, P59; Repa JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2; Schoonjans K, 1996, J LIPID RES, V37, P907; STAHLBERG D, 1995, HEPATOLOGY, V21, P1025, DOI 10.1016/0270-9139(95)90250-3; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Wang DQH, 1999, J LIPID RES, V40, P2066; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	31	128	132	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28947	28953		10.1074/jbc.M002782200	http://dx.doi.org/10.1074/jbc.M002782200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10867000	hybrid			2022-12-27	WOS:000089330700080
J	Priel-Halachmi, S; Ben-Dor, I; Shpungin, S; Tennenbaum, T; Molavani, H; Bachrach, M; Salzberg, S; Nir, U				Priel-Halachmi, S; Ben-Dor, I; Shpungin, S; Tennenbaum, T; Molavani, H; Bachrach, M; Salzberg, S; Nir, U			FER kinase activation of Stat3 is determined by the N-terminal sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; C-FES; CONSTITUTIVE ACTIVATION; TRANSCRIPT FERT; SRC-FAMILY; CELLS; GENE; NUCLEAR	p94(fer) and p51(ferT) are two tyrosine kinases that share identical SH2 and kinase domains but differ in their N-terminal regions. To further explore the cellular functions of these two highly related tyrosine kinases, their subcellular distribution profiles and in vivo phosphorylation activity were followed using double immunofluorescence assay. When combined with immunoprecipitation analysis, this assay showed that p94(fer) can lead to the tyrosine phosphorylation and activation of Stat3 but not of Stat1 or Stat2. Native p94fer exerted this activity when residing in the cytoplasm, However, modified forms of p94(fer), which are constitutively nuclear, could also lead to the phosphorylation of Stat3. Endogenous Stat3 and p94(fer) co-immunoprecipitated with each other, thus proving the interaction of these two proteins in vivo. Unlike p94(fer), p51(ferT) did not induce the phosphorylation of Stat3 but led to the phosphorylation of other nuclear proteins. Replacing the unique 43-amino acid-long N-terminal tail of p51(ferT) with a parallel segment from the N-terminal tail of p94fer did not change the subcellular localization of p51(ferT) but enabled it to activate Stat3. Thus the different N-terminal sequences of p94(fer) and p51(ferT) can affect their ability to induce phosphorylation of Stat3 and most probably direct their different cellular functions.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Nir, U (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.		Salzberg, Steven/Q-6514-2019	Salzberg, Steven/0000-0002-8859-7432				Allard P, 2000, MOL CELL ENDOCRINOL, V159, P63, DOI 10.1016/S0303-7207(99)00205-1; Ben-Dor I, 1999, CELL GROWTH DIFFER, V10, P113; Bern O, 1997, FEBS LETT, V403, P45, DOI 10.1016/S0014-5793(97)00028-8; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Craig AWB, 1999, J BIOL CHEM, V274, P19934, DOI 10.1074/jbc.274.28.19934; DAMELL JE, 1997, SCIENCE, V277, P1630; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Halachmy S, 1997, ONCOGENE, V14, P2871, DOI 10.1038/sj.onc.1201145; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HAO QL, 1991, MOL CELL BIOL, V11, P1180, DOI 10.1128/MCB.11.2.1180; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; HAZAN B, 1993, CELL GROWTH DIFFER, V4, P443; Ihle JN, 1997, STEM CELLS, V15, P105, DOI 10.1002/stem.5530150814; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Karras JG, 1997, J EXP MED, V185, P1035, DOI 10.1084/jem.185.6.1035; KATCOFF DJ, 1993, NUCLEIC ACIDS RES, V21, P5101, DOI 10.1093/nar/21.22.5101; KESHET E, 1990, MOL CELL BIOL, V10, P5021, DOI 10.1128/MCB.10.9.5021; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; KIM L, 1995, MOL CELL BIOL, V15, P4553; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LETWIN K, 1988, ONCOGENE, V3, P621; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Park WY, 1998, CANCER LETT, V129, P29, DOI 10.1016/S0304-3835(98)00077-9; Paulson R, 1997, ONCOGENE, V14, P641, DOI 10.1038/sj.onc.1200875; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; PENHALLOW RC, 1995, J BIOL CHEM, V270, P23362, DOI 10.1074/jbc.270.40.23362; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Sartor CI, 1997, CANCER RES, V57, P978; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WeberNordt RM, 1996, BLOOD, V88, P809; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILKS AF, 1988, ONCOGENE, V3, P289; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YATES KE, 1995, ONCOGENE, V10, P1239; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x	48	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28902	28910		10.1074/jbc.M003402200	http://dx.doi.org/10.1074/jbc.M003402200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878010	hybrid			2022-12-27	WOS:000089330700075
J	van Rossum, DB; Patterson, RL; Ma, HT; Gill, DL				van Rossum, DB; Patterson, RL; Ma, HT; Gill, DL			Ca2+ entry mediated by store depletion, S-nitrosylation and TRP3 channels - Comparison of coupling and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; THAPSIGARGIN-RESISTANT CELLS; OPERATED HTRP3 CHANNELS; INTRACELLULAR CA2+; ADENYLATE-CYCLASE; POOL DEPLETION; RECEPTOR; RELEASE; GROWTH; ACTIVATION	The mechanism for coupling between Ca2+ stores and store-operated channels (SOCs) is an important but unresolved question. SOC-mediated Ca2+ entry is complex and may reflect more than one type of channel and coupling mechanism. To assess such possible divergence the function and coupling of SOCs was compared with two other distinct yet related Ca2+ entry mechanisms. SOC coupling in DDT1MF-2 smooth muscle cells was prevented by the permeant inositol 1,4,5-trisphosphate (InsP(3)) receptor blockers, 2-aminoethoxydiphenyl borate (2-APB) and xestospongin C. In contrast, Ca2+ entry induced by S-nitrosylation and potentiated by store depletion (Ma, H-T., Favre, C. J., Patterson, R. L., Stone, M. R., and Gill, D. L. (1999) J. Biol Chem. 274, 35318-35324) was unaffected by 2-APB, suggesting that this entry mechanism is independent of InsP(3) receptors. The cycloalkyl lactamimide, MDL-12,330A (MDL), prevented SOC activation (IC50 10 mu M) and similarly completely blocked S-nitrosylation-mediated Ca2+ entry. Ca2+ entry mediated by the TRP3 channel stably expressed in HEK293 cells was activated by phospholipase C-coupled receptors but independent of Ca2+ store depletion (Ma, B-T., Patterson, R. L., van Rossum, D. B., Birnbaumer, L., Mikoshiba, K., and Gill, D. L. (2000) Science 287, 1647-1651). Receptor-induced TRP3 activation was 2-APB-sensitive and fully blocked by MDL. Direct stimulation of TRP3 channels by the permeant diacylglycerol derivative, 1-oleoyl-2-acetyl-sn-glycerol, was not blocked by 2-APB, but was again prevented by MDL. The results indicate that although the activation and coupling processes for each of the three entry mechanisms are distinct, sensitivity to MDL is a feature shared by all three mechanisms, suggesting there may be a common structural feature in the channels themselves or an associated regulatory component.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Gill, DL (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.			van Rossum, Damian/0000-0003-1011-2586	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055426] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55426] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Berridge MJ, 2000, SCIENCE, V287, P1604, DOI 10.1126/science.287.5458.1604; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CORREIADESA P, 1994, EUR J PHARMACOL, V271, P349, DOI 10.1016/0014-2999(94)90793-5; Favre CJ, 1998, J BIOL CHEM, V273, P30855, DOI 10.1074/jbc.273.47.30855; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; Gill DL, 1996, BIOSCIENCE REP, V16, P139, DOI 10.1007/BF01206203; Graber MN, 1997, J BIOL CHEM, V272, P29546, DOI 10.1074/jbc.272.47.29546; GRUPP G, 1980, BRIT J PHARMACOL, V70, P429, DOI 10.1111/j.1476-5381.1980.tb08721.x; GUELLAEN G, 1977, BIOCHIM BIOPHYS ACTA, V484, P465, DOI 10.1016/0005-2744(77)90102-4; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; LEE HR, 1985, J PHARMACOL EXP THER, V233, P611; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; LOUAZO CM, 1996, J BIOL CHEM, V271, P14807; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 1999, J BIOL CHEM, V274, P35318, DOI 10.1074/jbc.274.50.35318; Maruyama T, 1997, BIOMED RES-TOKYO, V18, P297; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RAMPE D, 1987, J PHARMACOL EXP THER, V243, P402; RAMPE D, 1989, J CARDIOVASC PHARM, V13, P547, DOI 10.1097/00005344-198913040-00006; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; UFRETVINCENTY CA, 1995, J BIOL CHEM, V270, P26790, DOI 10.1074/jbc.270.45.26790; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; Waldron RT, 1997, J BIOL CHEM, V272, P6440, DOI 10.1074/jbc.272.10.6440; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	44	114	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28562	28568		10.1074/jbc.M003147200	http://dx.doi.org/10.1074/jbc.M003147200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878007	hybrid			2022-12-27	WOS:000089330700032
J	Zharkov, DO; Rosenquist, TA; Gerchman, SE; Grollman, AP				Zharkov, DO; Rosenquist, TA; Gerchman, SE; Grollman, AP			Substrate specificity and reaction mechanism of murine 8-oxoguanine-DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; 7,8-DIHYDRO-8-OXOGUANINE DNA GLYCOSYLASE; OXIDATIVELY DAMAGED DNA; ESCHERICHIA-COLI MUTY; DEOXYRIBOPHOSPHODIESTERASE DRPASE ACTIVITY; NUCLEIC-ACID ADDUCTS; SACCHAROMYCES-CEREVISIAE; FPG PROTEIN; CATALYTIC MECHANISM; HUMAN HOMOLOG	Genomic DNA is prone to oxidation by reactive oxygen species. A major product of DNA oxidation is the miscoding base 8-oxoguanine (8-oxoG). The mutagenic effects of 8-oxoG in mammalian cells are prevented by a DNA repair system consisting of 8-oxoguanine-DNA glycosylase (Ogg1), adenine-DNA glycosylase, and 8-oxo-dGTPase. We have cloned, overexpressed, and characterized mOgg1, the product of the murine ogg1 gene. mOgg1 is a DNA glycosylase/AP lyase belonging to the endonuclease III family of DNA repair enzymes. The AP lyase activity of mOgg1 is significantly lower than its glycosylase activity. mOgg1 releases 8-oxoG from DNA when paired with C, T, or G, but efficient DNA strand nicking is observed only with 8-oxoG:C. Binding of mOgg1 to oligonucleotides containing 8-oxoG:C is strong (K-D = 51.5 nM), unlike other mispairs. The average residence time for mOgg1 bound to substrate containing 8-oxoG:C is 18.3 min; the time course for accumulation of the NaBH4-sensitive intermediate suggests a two-step reaction mechanism. Various analogs of 8-oxoG were tested as substrates for mOgg1. An electron-withdrawing or hydrogen bond acceptor moiety at CS is required for efficient binding of mOgg1. A substituent at C6 and a keto group at C8 are required for cleavage. The proposed mechanism of 8-oxoG excision involves protonation of O-8 Or the deoxyribose oxygen moiety.	SUNY Stony Brook, Biol Chem Lab, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Russian Acad Sci, Novosibirsk Bioorgan Chem Inst, Siberian Div, Novosibirsk 630090, Russia; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences; United States Department of Energy (DOE); Brookhaven National Laboratory	Zharkov, DO (corresponding author), SUNY Stony Brook, Biol Chem Lab, Stony Brook, NY 11794 USA.		Zharkov, Dmitry/K-2158-2012	Zharkov, Dmitry/0000-0001-5013-0194	NATIONAL CANCER INSTITUTE [R01CA017395, R37CA017395] Funding Source: NIH RePORTER; NCI NIH HHS [CA17395] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aburatani H, 1997, CANCER RES, V57, P2151; AIDA M, 1987, MUTAT RES, V192, P83, DOI 10.1016/0165-7992(87)90101-1; Alamo MJP, 1998, NUCLEIC ACIDS RES, V26, P5199, DOI 10.1093/nar/26.22.5199; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bhagwat M, 1996, BIOCHEMISTRY-US, V35, P659, DOI 10.1021/bi9522662; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; BODEPUDI V, 1992, CHEM RES TOXICOL, V5, P608, DOI 10.1021/tx00029a004; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Bruner SD, 1998, CURR BIOL, V8, P393, DOI 10.1016/S0960-9822(98)70158-7; Bulychev NV, 1996, BIOCHEMISTRY-US, V35, P13147, DOI 10.1021/bi960694h; CHEN H, 1996, MAGN RESON CHEM, V0034; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHO BP, 1993, MAGN RESON CHEM, V31, P1048, DOI 10.1002/mrc.1260311204; CHO BP, 1991, NUCLEIC ACIDS RES, V19, P1041, DOI 10.1093/nar/19.5.1041; CHO BP, 1990, CHEM RES TOXICOL, V3, P445, DOI 10.1021/tx00017a010; CULP SJ, 1989, CHEM RES TOXICOL, V2, P416, DOI 10.1021/tx00012a010; CYSEWSKI P, 1997, THEOCHEM-J MOL STRUC, V397, P167; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; DEMPLE B, 1995, CURR BIOL, V5, P719, DOI 10.1016/S0960-9822(95)00143-6; Deng L, 1997, J AM CHEM SOC, V119, P7865, DOI 10.1021/ja970828u; Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001; DIZDAROGLU M, 1985, BIOCHEMISTRY-US, V24, P4476, DOI 10.1021/bi00337a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; Fersht A., 1985, ENZYME STRUCTURE MEC; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; GERCHMAN SE, 1994, PROTEIN EXPRES PURIF, V5, P242, DOI 10.1006/prep.1994.1037; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; Girard PM, 1998, CARCINOGENESIS, V19, P1299, DOI 10.1093/carcin/19.7.1299; Gogos A, 1996, BIOCHEMISTRY-US, V35, P16665, DOI 10.1021/bi960843w; Grollman AP, 1999, NATO ADV SCI I A-LIF, V302, P135; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Hazra IK, 1998, NUCLEIC ACIDS RES, V26, P5116, DOI 10.1093/nar/26.22.5116; HORENSTEIN BA, 1993, BIOCHEMISTRY-US, V32, P7089, DOI 10.1021/bi00079a004; Jiang DY, 1997, J BIOL CHEM, V272, P32230, DOI 10.1074/jbc.272.51.32230; Johnson F, 1998, CHEM RES TOXICOL, V11, P193, DOI 10.1021/tx9701539; KAMIYA H, 1995, NUCLEIC ACIDS RES, V23, P2893, DOI 10.1093/nar/23.15.2893; Karahalil B, 1998, NUCLEIC ACIDS RES, V26, P1228, DOI 10.1093/nar/26.5.1228; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; Kennedy LJ, 1997, CHEM RES TOXICOL, V10, P386, DOI 10.1021/tx960102w; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0; Kuo FC, 1997, J EXP MED, V186, P1547, DOI 10.1084/jem.186.9.1547; LIN TS, 1985, J MED CHEM, V28, P1194, DOI 10.1021/jm00147a012; LIPSCOMB LA, 1995, P NATL ACAD SCI USA, V92, P719, DOI 10.1073/pnas.92.3.719; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MCAULEYHECHT KE, 1994, BIOCHEMISTRY-US, V33, P10266, DOI 10.1021/bi00200a006; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; ODA Y, 1992, NUCLEOS NUCLEOT, V11, P261, DOI 10.1080/07328319208021701; ODA Y, 1991, NUCLEIC ACIDS RES, V19, P1407, DOI 10.1093/nar/19.7.1407; Ohtsubo T, 1998, MOL GEN GENET, V259, P577, DOI 10.1007/s004380050851; PLUM GE, 1995, BIOCHEMISTRY-US, V34, P16418; Purmal AA, 1996, MUTAT RES-DNA REPAIR, V364, P193, DOI 10.1016/S0921-8777(96)00032-8; Rabow LE, 1997, BIOCHEMISTRY-US, V36, P5084, DOI 10.1021/bi963005a; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Rieger RA, 1999, NUCLEOS NUCLEOT, V18, P73, DOI 10.1080/07328319908045595; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Sandigursky M, 1997, J BIOL CHEM, V272, P17480, DOI 10.1074/jbc.272.28.17480; Sandigursky M, 1997, NUCLEIC ACIDS RES, V25, P4557, DOI 10.1093/nar/25.22.4557; SCHARER OD, 1995, J AM CHEM SOC, V117, P6623, DOI 10.1021/ja00129a039; Scharer OD, 1998, J BIOL CHEM, V273, P8592, DOI 10.1074/jbc.273.15.8592; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Shinmura K, 1997, MUTAT RES-DNA REPAIR, V385, P75, DOI 10.1016/S0921-8777(97)00041-4; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; SODUM RS, 1993, CHEM RES TOXICOL, V6, P269, DOI 10.1021/tx00033a004; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TCHOU J, 1994, J BIOL CHEM, V269, P15318; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Varaprasad CV, 1996, TETRAHEDRON LETT, V37, P9, DOI 10.1016/0040-4039(95)02069-1; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Williams SD, 1998, NUCLEIC ACIDS RES, V26, P5123, DOI 10.1093/nar/26.22.5123; Zharkov DO, 1998, BIOCHEMISTRY-US, V37, P12384, DOI 10.1021/bi981066y; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	85	168	175	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28607	28617		10.1074/jbc.M002441200	http://dx.doi.org/10.1074/jbc.M002441200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10884383	hybrid			2022-12-27	WOS:000089330700038
J	Baulard, AR; Betts, JC; Engohang-Ndong, J; Quan, S; McAdam, RA; Brennan, PJ; Locht, C; Besra, GS				Baulard, AR; Betts, JC; Engohang-Ndong, J; Quan, S; McAdam, RA; Brennan, PJ; Locht, C; Besra, GS			Activation of the pro-drug ethionamide is regulated in mycobaeteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOLIC ACID SYNTHESIS; MYCOBACTERIUM-TUBERCULOSIS; ISONIAZID RESISTANCE; CATALASE PEROXIDASE; GENE; BIOACTIVATION; OXIDATION; TARGET	The anti-tuberculosis drug ethionamide (ETH), which is a structural analog of isoniazid (INH), is known to strongly inhibit mycolic acid synthesis in Mycobacterium tuberculosis. Although several targets have been identified for INH, only speculative information is available concerning ETH, Mutations within the promoter and the coding region of enoyl-acyl carrier protein reductase (InhA) were found to confer resistance to both drugs, thus leading to the impression that INR and ETH may: share a common mode of action. However, a notable distinction between the two drugs Lies in the lack of cross-resistance in clinical isolates. This may be attributed in part to the fact that the pro-drug INH must be activated via KatG, and no activation step for ETH has yet been described. Here we report the identification of an activator for ETH, The ETH activator (Rv3854c), which we have termed EthA, was found to be homologous to various monooxygenases and induced ETR sensitivity when overexpressed in mycobacteria, Interestingly, the neighboring open reading frame (Rv3855), which was found homologous to transcriptional repressors of the tetR family, led to ETH resistance when overexpressed. In addition, chromosomal inactivation of this gene by transposition led to ETH hypersensitivity. These data strongly suggest that Rv3855, which me have termed EthR, regulates the production of EthA, which subsequently activates the pro-drug ETH, This study opens up new avenues of research relating to ETR activation in mycobacteria, possibly leading to an improved efficacy of ETH and to the generation of new anti-mycobacterial agents.	Newcastle Univ, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Glaxo Wellcome Res & Dev Ltd, Stevenage SG1 2NY, Herts, England; Inst Pasteur, Inst Biol, INSERM, U447, F-59019 Lille, France	Newcastle University - UK; Colorado State University; GlaxoSmithKline; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Besra, GS (corresponding author), Newcastle Univ, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	g.s.besra@newcastle.ac.uk	Locht, Camille/L-3516-2018; Baulard, Alain R/E-6830-2017	Baulard, Alain R/0000-0002-0150-5241; Betts, Joanna/0000-0003-1729-1839; Besra, Gurdyal/0000-0002-5605-0395	NIAID NIH HHS [AI-18357, AI-38087, AI-33706] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI018357, R01AI033706, U19AI038087, R01AI018357, R37AI018357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Bardarov S, 1997, P NATL ACAD SCI USA, V94, P10961, DOI 10.1073/pnas.94.20.10961; Barry CE, 1998, DRUG RESIST UPDATE, V1, P128, DOI 10.1016/S1368-7646(98)80028-9; BAULARD A, 1992, NUCLEIC ACIDS RES, V20, P4105, DOI 10.1093/nar/20.15.4105; BECK CF, 1988, MICROBIOL REV, V52, P318, DOI 10.1128/MMBR.52.3.318-326.1988; CHIELI E, 1985, BIOCHEM PHARMACOL, V34, P395, DOI 10.1016/0006-2952(85)90056-5; De Cock KM, 1999, INT J TUBERC LUNG D, V3, P457; DELENCASTRE H, 1983, J GEN MICROBIOL, V129, P3203; ESPINAL M, 1999, 260 WHO; Fattorini L, 1999, MICROB DRUG RESIST, V5, P265, DOI 10.1089/mdr.1999.5.265; GUYER MS, 1978, J MOL BIOL, V126, P347, DOI 10.1016/0022-2836(78)90045-1; Heym B., 1999, Tubercle and Lung Disease, V79, P267, DOI 10.1054/tuld.1998.0208; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; Lei BF, 2000, J BIOL CHEM, V275, P2520, DOI 10.1074/jbc.275.4.2520; LIU J, 1999, MYCOBACTERIA MOL BIO; Loewen PC, 2000, ASM NEWS, V66, P76; QUEMARD A, 1992, ANTIMICROB AGENTS CH, V36, P1316, DOI 10.1128/AAC.36.6.1316; RIST NOEL, 1960, ADVANCES TUBERC RES, V10, P69; Rollier R, 1972, Maroc Med, V52, P148; RUSE MJ, 1991, BIOCHEM SOC T, V19, pS233, DOI 10.1042/bst019233s; RUSE MJ, 1991, TOXICOL LETT, V58, P37, DOI 10.1016/0378-4274(91)90188-C; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sauton B, 1912, CR HEBD ACAD SCI, V155, P860; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P399, DOI 10.1128/AAC.27.3.399; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; TAKAYAMA K, 1974, ANN NY ACAD SCI, V235, P426, DOI 10.1111/j.1749-6632.1974.tb43281.x; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; WANG L, 1972, ANTIMICROB AGENTS CH, V2, P438, DOI 10.1128/AAC.2.6.438; Wards BJ, 1996, FEMS MICROBIOL LETT, V145, P101, DOI 10.1016/0378-1097(96)00394-1; WATERS MFR, 1989, BIOL MYCOBACTERIA, V3, P405; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833; Winder F. G., 1982, The biology of the mycobacteria. Volume 1, P353; WINDER F G, 1970, Journal of General Microbiology, V63, P41; WINDER FG, 1971, J GEN MICROBIOL, V66, P379, DOI 10.1099/00221287-66-3-379; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	38	244	266	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28326	28331						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869356				2022-12-27	WOS:000089197100105
J	Brown, AJ; Watts, GF; Burnett, JR; Dean, RT; Jessup, W				Brown, AJ; Watts, GF; Burnett, JR; Dean, RT; Jessup, W			Sterol 27-hydroxylase acts on 7-ketocholesterol in human atherosclerotic lesions and macrophages in culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CEREBROTENDINOUS XANTHOMATOSIS; CHOLESTEROL TRANSPORT; SIDE-CHAIN; BILE-ACIDS; FOAM CELLS; MECHANISM; 27-HYDROXYCHOLESTEROL; ELIMINATION; OXYSTEROLS	27-Hydroxycholesterol (27OH) is the major oxysterol in human atherosclerotic lesions, followed by 7-ketocholesterol (7K), Whereas 7K probably originates nonenzymically, 27OH arises by the action of sterol 27-hydroxylase, a cytochrome P450 enzyme expressed at particularly high levels in the macrophage and proposed to represent an important pathway by which macrophages eliminate excess cholesterol, We hypothesized and here show that 27-hydroxylated 7-ketocholesterol (27OH-7K) is present in human lesions, probably generated by the action of sterol 27-hydroxylase on 7K. Moreover, [SH]27OH-7K was produced by human monocyte-derived macrophages (HMDMs) supplied with [H-3]7K but not in HMDMs from a patient with cerebrotendinous xanthomatosis (CTX) shown to have a splice-junction mutation of sterol 27-hydroxylase. Whereas [H-3]27OH-7K was predominantly secreted into the medium, [H-3]-27OH formed from [H-3] cholesterol was mostly cell-associated. The majority of supplied [H-3]7K was metabolized beyond 27OH-7K to aqueous-soluble products (apparently bile acids derived from the sterol 27-hydroxylase pathway). Metabolism to aqueous-soluble products was ablated by a sterol 27-hydroxylase inhibitor and absent in CTX cells. Sterol 27-hydroxylase therefore appears to represent an important pathway by which macrophages eliminate not only cholesterol but also oxysterols such as 7K, The fact that 7K (and cholesterol) still accumulates in lesions and foam cells indicates that this pathway may be perturbed in atherosclerosis and affords a new opportunity for the development of therapeutic strategies to regress atherosclerotic lesions.	Heart Res Inst, Cell Biol Grp, Sydney, NSW 2050, Australia; Univ Western Australia, Dept Med, Perth, WA, Australia; Royal Perth Hosp, W Australian Heart Res Inst, Perth, WA 6000, Australia; Royal Perth Hosp, Dept Core Clin Pathol & Biochem, Perth, WA 6000, Australia	University of Sydney; Heart Research Institute; University of Western Australia; Royal Perth Hospital; University of Sydney; Heart Research Institute; University of Western Australia; Royal Perth Hospital; University of Western Australia	Brown, AJ (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Watts, Gerald/0000-0003-2276-1524; Dean, Roger Thornton/0000-0002-8859-8902				AXELSON M, 1995, J BIOL CHEM, V270, P15102, DOI 10.1074/jbc.270.25.15102; Babiker A, 1997, J BIOL CHEM, V272, P26253, DOI 10.1074/jbc.272.42.26253; Babiker A, 1998, BBA-LIPID LIPID MET, V1392, P333, DOI 10.1016/S0005-2760(98)00047-2; BJORKHEM I, 1992, J LIPID RES, V33, P455; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; BOYUM A, 1984, METHOD ENZYMOL, V108, P88; Brown AJ, 2000, J LIPID RES, V41, P226; Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8; Brown AJ, 1997, J LIPID RES, V38, P1730; CHIANG JL, 1998, FRONT BIOSCI, V15, P176; Crisby M, 1997, BBA-LIPID LIPID MET, V1344, P278, DOI 10.1016/S0005-2760(96)00152-X; Duane WC, 1999, J LIPID RES, V40, P1194; Fielding CJ, 1997, J LIPID RES, V38, P1503; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUJIYAMA J, 1991, CLIN CHIM ACTA, V200, P1, DOI 10.1016/0009-8981(91)90328-A; GARNER B, 1994, BIOCHEM J, V301, P421, DOI 10.1042/bj3010421; Gelissen IC, 1999, J LIPID RES, V40, P1636; Gelissen IC, 1996, J BIOL CHEM, V271, P17852, DOI 10.1074/jbc.271.30.17852; Graham A, 1996, ATHEROSCLEROSIS, V120, P135, DOI 10.1016/0021-9150(95)05695-5; ISHII I, 1995, ARTERIOSCL THROM VAS, V15, P1189, DOI 10.1161/01.ATV.15.8.1189; JAVITT NB, 1994, FASEB J, V8, P1308, DOI 10.1096/fasebj.8.15.8001744; KRITHARIDES L, 1995, ARTERIOSCL THROM VAS, V15, P276, DOI 10.1161/01.ATV.15.2.276; LEITERSDORF E, 1993, J CLIN INVEST, V91, P2488, DOI 10.1172/JCI116484; Lund E, 1996, ARTERIOSCL THROM VAS, V16, P208, DOI 10.1161/01.ATV.16.2.208; Lyons MA, 1999, INT J BIOCHEM CELL B, V31, P369, DOI 10.1016/S1357-2725(98)00123-X; Pikuleva IA, 1998, J BIOL CHEM, V273, P18153, DOI 10.1074/jbc.273.29.18153; Rees D, 1999, J BIOL CHEM, V274, P27925, DOI 10.1074/jbc.274.39.27925; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SCALIA S, 1994, ANAL LETT, V27, P1789, DOI 10.1080/00032719408007436; TANIGUCHI S, 1973, EUR J BIOCHEM, P602; van Reyk DM, 1999, J LEUKOCYTE BIOL, V66, P557, DOI 10.1002/jlb.66.4.557; Verrips A, 1997, HUM GENET, V100, P284, DOI 10.1007/s004390050506; YANCEY PG, 1994, J LIPID RES, V35, P2114	33	71	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27627	27633						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869358				2022-12-27	WOS:000089197100015
J	Dong, AC; Randolph, TW; Carpenter, JF				Dong, AC; Randolph, TW; Carpenter, JF			Entrapping intermediates of thermal aggregation in alpha-helical proteins with low concentration of guanidine hydrochloride	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; SECONDARY STRUCTURE; DENATURED STATE; BETA-SHEET; STABILITY; PEPTIDES; SPECTRA; CHYMOTRYPSINOGEN; CONFORMATION; TEMPERATURE	Aggregation of proteins is a problem with serious medical implications and economic importance. To develop strategies for preventing aggregation, the mechanism(s) and pathways by which proteins aggregate must be characterized. In this study, the thermally induced aggregation processes of three alpha-helix proteins (myoglobin, cytochrome c, and lysozyme) in the presence and absence of 1.0 M guanidine hydrochloride (GdnHCl) were investigated by means of infrared spectroscopy. In the absence of GdnHCl, intensities of the alpha-helix bands (similar to 1656 cm(-1)) decrease as a function of temperature at above 50 degrees C. With myoglobin and cytochrome c, the loss of helix bands was accompanied by the appearance of two new bands at 1694 and 1623 cm(-1), indicative of the formation of intermolecular beta-sheet aggregates. For lysozyme, bands indicative of intermolecular beta-sheet aggregates did not appear in any significant intensity. In the presence of 1.0 M GdnHCl, two major intermediate states rich in 3(10)-helix (represented by the band at 1663 cm(-1)) and beta-turn structure (represented by the band at cm 1667 cm(-1)), respectively, were observed. These findings demonstrated that IR spectroscopic studies of protein aggregation using a combination of thermal and chemical denaturing factors could provide a means to populate and characterize aggregation intermediates.	Univ No Colorado, Dept Chem & Biochem, Greeley, CO 80639 USA; Univ Colorado, Dept Chem Engn, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA	University of Northern Colorado; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Dong, AC (corresponding author), Univ No Colorado, Dept Chem & Biochem, Greeley, CO 80639 USA.	adong@unco.edu	randolph, theodore/A-3301-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM055889] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R15GM5588901] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD Z, 1994, BBA-PROTEIN STRUCT M, V1207, P223, DOI 10.1016/0167-4838(94)00045-X; Allison SD, 1996, BIOPHYS J, V71, P2022, DOI 10.1016/S0006-3495(96)79400-6; ARCHARYA KR, 1989, J MOL BIOL, V208, P99; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BOSCH R, 1983, ACTA CRYSTALLOGR C, V39, P776, DOI 10.1107/S0108270183006289; BOWLER BE, 1994, BIOCHEMISTRY-US, V33, P2402, DOI 10.1021/bi00175a008; Carpenter JF, 1999, METHOD ENZYMOL, V309, P236; CASAL HL, 1988, BIOCHIM BIOPHYS ACTA, V957, P11, DOI 10.1016/0167-4838(88)90152-5; CLARK AH, 1980, INT J PEPT PROT RES, V16, P339; CLARK AH, 1981, INT J PEPT PROT RES, V17, P353; Damaschun G, 2000, PROTEINS, V39, P204, DOI 10.1002/(SICI)1097-0134(20000515)39:3<204::AID-PROT20>3.0.CO;2-8; Dhodapkar MV, 1997, HEMATOL ONCOL CLIN N, V11, P89, DOI 10.1016/S0889-8588(05)70417-2; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; DONG AC, 1994, METHOD ENZYMOL, V232, P139; DONG AC, 1995, J PHARM SCI-US, V84, P415, DOI 10.1002/jps.2600840407; Dong AC, 1997, ARCH BIOCHEM BIOPHYS, V347, P213, DOI 10.1006/abbi.1997.0349; DONG AC, 1995, ARCH BIOCHEM BIOPHYS, V320, P59, DOI 10.1006/abbi.1995.1342; Dornberger U, 1996, BBA-PROTEIN STRUCT M, V1294, P168, DOI 10.1016/0167-4838(96)00018-0; EPAND RM, 1974, BIOPOLYMERS, V13, P359, DOI 10.1002/bip.1974.360130211; FABIAN H, 1995, BIOCHEMISTRY-US, V34, P13651, DOI 10.1021/bi00041a046; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Goedert M, 1998, MOL PSYCHIATR, V3, P462, DOI 10.1038/sj.mp.4000458; Gupta R, 1996, BIOCHEMISTRY-US, V35, P11925, DOI 10.1021/bi961079g; ISMAIL AA, 1992, BIOCHIM BIOPHYS ACTA, V1121, P183, DOI 10.1016/0167-4838(92)90353-F; KENNEDY DF, 1991, BIOCHEMISTRY-US, V30, P6541, DOI 10.1021/bi00240a026; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; Kim YS, 2000, J BIOL CHEM, V275, P1570, DOI 10.1074/jbc.275.3.1570; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; MANNING MC, 1989, PHARM RES-DORDR, V6, P903, DOI 10.1023/A:1015929109894; MANNING MC, 1999, IN PRESS PEPTIDE PRO; Martinez A, 1996, J BIOL CHEM, V271, P19737, DOI 10.1074/jbc.271.33.19737; MILLHAUSER GL, 1995, BIOCHEMISTRY-US, V34, P3873, DOI 10.1021/bi00012a001; Nozaki Y, 1972, Methods Enzymol, V26, P43; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; PRESTRELSKI SJ, 1993, BIOPHYS J, V65, P661, DOI 10.1016/S0006-3495(93)81120-2; PRESTRELSKI SJ, 1991, BIOCHEMISTRY-US, V30, P133, DOI 10.1021/bi00215a020; SHAMALA N, 1977, BIOCHEM BIOPH RES CO, V79, P292, DOI 10.1016/0006-291X(77)90094-8; SHIBATA A, 1992, BIOCHEMISTRY-US, V31, P5728, DOI 10.1021/bi00140a006; Shortle D, 1996, FASEB J, V10, P27, DOI 10.1096/fasebj.10.1.8566543; Smith MA, 1998, INT REV NEUROBIOL, V42, P1, DOI 10.1016/S0074-7742(08)60607-8; SOMAN KV, 1991, BIOPOLYMERS, V31, P1351, DOI 10.1002/bip.360311202; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; SUSI H, 1986, METHOD ENZYMOL, V130, P290; TIFFANY ML, 1969, BIOPOLYMERS, V8, P347, DOI 10.1002/bip.1969.360080306; TIRADORIVES J, 1991, BIOCHEMISTRY-US, V30, P3864, DOI 10.1021/bi00230a009; Wetzel R, 1997, ADV PROTEIN CHEM, V50, P183, DOI 10.1016/S0065-3233(08)60322-8; WILDER CL, 1992, BIOCHEMISTRY-US, V31, P27, DOI 10.1021/bi00116a006	48	87	87	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27689	27693						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871628				2022-12-27	WOS:000089197100023
J	Fukuda, M; Mikoshiba, K				Fukuda, M; Mikoshiba, K			Distinct self-oligomerization activities of synaptotagmin family - Unique calcium-dependent oligomerization properties of synaptotagmin VII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C2B DOMAIN; INOSITOL-1,3,4,5-TETRAKISPHOSPHATE BINDING; PHOSPHOLIPID-BINDING; SYNAPTIC-VESICLE; PROTEINS; ISOFORMS; CELLS	Synaptotagmins constitute a large protein family, characterized by one transmembrane region and two C2 domains, and can be classified into several subclasses based on phylogenetic relationships and biochemical activities (Fukuda, M., Kanno, E., and Mikoshiba, K. (1999) J, Biol. Chem. 274, 31421-31427). Synaptotagmin I (Syt I), a possible Ca2+ sensor for neurotransmitter release, showed both Ca2+-dependent (via the C2 domain) and -independent (via the NH2-terminal domain) self-oligomerization, which are thought to be important for synaptic vesicle exocytosis. However, little is known about the relationship between these two interactions and the Ca2+-dependent oligomerization properties of other synaptotagmin isoforms, In this study, we first examined the Ca2+-dependent self-oligomerization properties of synaptotagmin family by co-expression of T7- and FLAG-tagged Syts (full-length or cytoplasmic domain) in COS-7 cells. We found that Syt VII is a unique class of synaptotagmins that only showed robust Ca2+-dependent self-oligomerization at the cytoplasmic domain with EC50 values of about 150 mu M Ca2+. In addition, Syt VII preferentially interacted with the previously described subclass of Syts (V, VI, and X) in a Ca2+-dependent manner. Co-expression of full-length and cytoplasmic portion of Syts VII (or II) indicate that Syt VII cytoplasmic domain oligomerizes in a Ca2+-dependent manner without being tethered at the NH2-terminal domain, whereas Ca2+-dependent self-oligomerization at the cytoplasmic domain of other isoforms (e,g. Syt II) occurs only when the two molecules are tethered at the NH2-terminal domain.	RIKEN, Inst Phys & Chem Res, Inst Basic Sci, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, Exploratory Res Adv Technol, Calciosignal Net Project, Bunkyo Ku, Tokyo 1130021, Japan	RIKEN; University of Tokyo; Japan Science & Technology Agency (JST)	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Inst Basic Sci, Dev Neurobiol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015; Mikoshiba, Katsuhiko/N-7943-2015	Fukuda, MItsunori/0000-0002-8620-5853; 				Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; Butz S, 1999, J BIOL CHEM, V274, P18290, DOI 10.1074/jbc.274.26.18290; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Chapman ER, 1996, BIOCHEM BIOPH RES CO, V225, P326, DOI 10.1006/bbrc.1996.1174; Damer CK, 1996, J NEUROCHEM, V67, P1661; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 1997, BIOCHEM J, V323, P421, DOI 10.1042/bj3230421; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; Ibata K, 1998, J BIOL CHEM, V273, P12267, DOI 10.1074/jbc.273.20.12267; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Linial M, 1997, J NEUROCHEM, V69, P1781; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Mehrotra B, 1997, J BIOL CHEM, V272, P4237, DOI 10.1074/jbc.272.7.4237; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mizuta M, 1997, DIABETES, V46, P2002, DOI 10.2337/diabetes.46.12.2002; Mizutani A, 1997, BIOCHEM BIOPH RES CO, V240, P128, DOI 10.1006/bbrc.1997.7578; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; PERIN MS, 1991, J BIOL CHEM, V266, P623; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; ULLRICH B, 1995, NEUROPHARMACOLOGY, V34, P1371, DOI 10.1016/0028-3908(95)00132-P; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	33	69	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28180	28185						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871604				2022-12-27	WOS:000089197100086
J	Kalinec, F; Zhang, M; Urrutia, R; Kalinec, G				Kalinec, F; Zhang, M; Urrutia, R; Kalinec, G			Rho GTPases mediate the regulation of cochlear outer hair cell motility by acetylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROKINETIC SHAPE CHANGES; GUINEA-PIG; SUBSURFACE CISTERNAE; PLASMA-MEMBRANE; FAMILY GTPASES; LATERAL WALL; PROTEIN; ACTIN; CYTOSKELETON; MECHANISM	Outer hair cells are the mechanical effecters of the cochlear amplifier, an active process that improves the sensitivity and frequency discrimination of the mammalian ear. In vivo the gain of the cochlear amplifier is regulated by the efferent neurotransmitter acetylcholine through the modulation of outer hair cell mobility. Little is known, however, regarding the molecular mechanisms activated by acetylcholine. In this study, intracellular signaling pathways involving the small GTPases RhoA, Rac1, and Cdc42 have been identified as regulators of outer hair cell motility, Changes in cell length (slow motility) and in the amplitude of electrically induced movement (fast motility) were measured in isolated outer hair cells patch clamped in whole-cell mode, internally perfused through the patch pipette with different inhibitors and activators of these small GTPases while being externally stimulated with acetylcholine. me found that acetylcholine induces outer hair cell shortening and a simultaneous increase in the amplitude of fast motility through Rad and Cdc42 activation. In contrast, a RhoA- and Rac1-mediated signaling pathway induces outer hair cell elongation and decreases fast motility amplitude. These two opposing processes preside the basis for a regulatory mechanism of outer hair cell mobility.	House Ear Res Inst, Dept Cell & Mol Biol, Los Angeles, CA 90057 USA; Mayo Clin, GI Res Inst, Rochester, MN 55905 USA; Mayo Clin, Dept Mol Neurosci, Rochester, MN 55905 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Dept Tumor Biol, Rochester, MN 55905 USA	House Research Institute; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Kalinec, F (corresponding author), House Ear Res Inst, Dept Cell & Mol Biol, 2100 W 3rd St, Los Angeles, CA 90057 USA.	fkalinec@hei.org						ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; DALLOS P, 1991, NATURE, V350, P155, DOI 10.1038/350155a0; DALLOS P, 1992, J NEUROSCI, V12, P4575; DRENCKHAHN D, 1991, J CELL BIOL, V112, P641, DOI 10.1083/jcb.112.4.641; DULON D, 1992, AM J OTOL, V13, P108; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FLOCK A, 1986, ARCH OTO-RHINO-LARYN, V243, P83, DOI 10.1007/BF00453755; FORGE A, 1993, HEARING RES, V64, P175, DOI 10.1016/0378-5955(93)90003-J; Frolenkov GI, 1997, BIOPHYS J, V73, P1665, DOI 10.1016/S0006-3495(97)78198-0; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; GRIECO F, 1992, BIOTECHNIQUES, V13, P856; Guinan J.J., 1996, COCHLEA EDITED, P435; GULLEY RL, 1977, ANAT RECORD, V189, P109, DOI 10.1002/ar.1091890108; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOLLEY MC, 1988, PROC R SOC SER B-BIO, V232, P413, DOI 10.1098/rspb.1988.0004; HOLLEY MC, 1992, J CELL SCI, V102, P569; HOLLEY MC, 1996, SPR HDB AUD, V8, P386; HUANG GJ, 1994, P NATL ACAD SCI USA, V91, P12268, DOI 10.1073/pnas.91.25.12268; IWASA KH, 1991, NEUROSCI LETT, V133, P171, DOI 10.1016/0304-3940(91)90562-8; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KACHAR B, 1986, NATURE, V322, P365, DOI 10.1038/322365a0; KALINEC F, 1992, P NATL ACAD SCI USA, V89, P8671, DOI 10.1073/pnas.89.18.8671; Kalinec F, 1997, HEARING RES, V110, P141, DOI 10.1016/S0378-5955(97)00076-2; Kalinec F, 1993, BIOPHYSICS HAIR CELL, P175; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lim DJ, 1998, KIDNEY INT, pS104; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; McCallum SJ, 1998, J BIOL CHEM, V273, P22537, DOI 10.1074/jbc.273.35.22537; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; POLLICE PA, 1993, HEARING RES, V70, P187, DOI 10.1016/0378-5955(93)90157-V; RAPHAEL Y, 1986, J SUBMICR CYTOL PATH, V18, P731; RAPHAEL Y, 1994, HEARING RES, V76, P173, DOI 10.1016/0378-5955(94)90098-1; SAITO K, 1983, CELL TISSUE RES, V229, P467; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Udagawa T, 1996, J BIOL CHEM, V271, P12542, DOI 10.1074/jbc.271.21.12542; VAN AL, 1997, GENE DEV, V11, P2295; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Weil D, 1996, P NATL ACAD SCI USA, V93, P3232, DOI 10.1073/pnas.93.8.3232; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Wiederhold M. L., 1986, NEUROBIOLOGY HEARING, P349; ZAJIC G, 1987, HEARING RES, V26, P249, DOI 10.1016/0378-5955(87)90061-X; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77	49	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28000	28005						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862776				2022-12-27	WOS:000089197100064
J	Kustedjo, K; Bracey, MH; Cravatt, BF				Kustedjo, K; Bracey, MH; Cravatt, BF			Torsin A and its torsion dystonia-associated mutant forms are lumenal glycoproteins that exhibit distinct subcellular localizations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; ENDOPLASMIC-RETICULUM; ASHKENAZI JEWS; PROTEIN; DYT1; HSP104; CHAPERONES; MUTATION; MEMBRANE; CLPAP	Early-onset torsion dystonia is an autosomal dominant hyperkinetic movement disorder that has recently been linked to a 3-base pair deletion in the DYT1 gene. The DYT1 gene encodes a 332-amino acid protein, torsin Ih, that bears low but significant homology to the Hsp100/Clp family of ATPase chaperones. The deletion in DYT1 associated with torsion dystonia results in the loss of one of a pair of glutamic acid residues residing near the C terminus of torsin A (Delta E-torsin A). At present, Little is known about the expression, subcellular distribution, and/or function of either the torsin A or Delta E-torsin A protein. When transfected into mammalian cells, both torsin A and Delta E-torsin A were found to behave as lumenally oriented glycoproteins. Immunofluorescence studies revealed that torsin A localized to a diffuse network of intracellular membranes displaying significant co-immunoreactivity for the endoplasmic reticulum resident protein BiP, whereas Delta E-torsin A resided in large spheroid intracellular structures exclusive of BiP immunoreactivity. These results initially suggested that Delta E-torsin A might exist as insoluble aggregates. However, both torsin A and Delta E-torsin A were readily solubilized by nonionic detergents, were similarly accessible to proteases, and displayed equivalent migration patterns on sucrose gradients. Collectively, these data support that both the wild type and torsion dystonia-associated forms of torsin A are properly folded, lumenal proteins of similar oligomeric states. The potential relationship between the altered subcellular distribution of Delta E-torsin A and the disease-inducing phenotype of the protein is discussed.	Scripps Res Inst, Skaggs Inst Chem Res, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Cravatt, BF (corresponding author), Scripps Res Inst, Skaggs Inst Chem Res, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.							BRESSMAN SB, 1994, ANN NEUROL, V36, P771, DOI 10.1002/ana.410360514; COLEMAN RA, 1980, BIOCHIM BIOPHYS ACTA, V595, P184, DOI 10.1016/0005-2736(80)90082-6; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; DEPIERRE JW, 1975, BIOCHIM BIOPHYS ACTA, V415, P411, DOI 10.1016/0304-4157(75)90006-4; Eidelberg D, 1998, ANN NEUROL, V44, P303, DOI 10.1002/ana.410440304; Fahn S, 1998, Adv Neurol, V78, P1; Fahn S, 1988, Adv Neurol, V50, P1; Feng HP, 1998, CURR BIOL, V8, pR464, DOI 10.1016/S0960-9822(98)70294-5; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; GREENE P, 1995, MOVEMENT DISORD, V10, P143, DOI 10.1002/mds.870100204; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; Hedreen J C, 1988, Adv Neurol, V50, P123; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Lebre AS, 1999, BRAIN, V122, P41, DOI 10.1093/brain/122.1.41; Maurizi MR, 1998, BIOCHEMISTRY-US, V37, P7778, DOI 10.1021/bi973093e; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; Ozelius L J, 1998, Adv Neurol, V78, P93; Ozelius LJ, 1997, NAT GENET, V17, P40, DOI 10.1038/ng0997-40; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; RISCH NJ, 1990, AM J HUM GENET, V46, P533; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Valente EM, 1998, BRAIN, V121, P2335, DOI 10.1093/brain/121.12.2335; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x	26	141	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27933	27939						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871631				2022-12-27	WOS:000089197100056
J	Taylor, MK; Uhler, MD				Taylor, MK; Uhler, MD			The amino-terminal cyclic nucleotide binding site of the type II cGMP-dependent protein kinase is essential for full cyclic nucleotide-dependent activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT; CAMP BINDING; CATALYTIC SUBUNIT; GMP; AMP; EXPRESSION; ALPHA; MUTATIONS; DISTINCT; DOMAINS	For the type I cGMP-dependent protein kinases (cGKI alpha and cGKI beta), a high affinity interaction exists between the C2 amino group of cGMP and the hydroxyl side chain of a threonine conserved in most cGMP binding sites. To examine the effect of this interaction on ligand binding and kinase activation in the type II isozyme of cGMP-dependent protein kinase (cGKII), alanine was substituted for the conserved threonine or serine. cGKII was found to require the C2 amino group of cGMP and its cognate serine or threonine hydroxyl for efficient cGMP activation. Of the two binding sites, disruption of cGMP-specific binding in the NH2-terminal binding site had the greatest effect on cGMP-dependent kinase activation, like cGKI. However, ligand dissociation studies showed that the location of the rapid and slow dissociation sites of cGKII was reversed relative to cGKI, Another set of mutations that prevented cyclic nucleotide binding demonstrated the necessity of the NH2-terminal, rapid dissociation binding site for cyclic nucleotide-dependent activation of cGKII. These findings suggest distinct mechanisms of activation for cGKII and cGKI isoforms, Because cGKII mediates the effects of heat-stable enterotoxins via the cystic fibrosis transmembrane regulator Cl- channel, these findings define a structural target for drug design.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48104 USA; Univ Michigan, Grad Program Neurosci, Ann Arbor, MI 48104 USA; Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Uhler, MD (corresponding author), Univ Michigan, Dept Biol Chem, Neurosci Labs Bldg,1103 E Huron St, Ann Arbor, MI 48104 USA.	muhler@umich.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050791] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50791] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BUBIS J, 1988, J BIOL CHEM, V263, P9668; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; Collins SP, 1997, J BIOL CHEM, V272, P18169, DOI 10.1074/jbc.272.29.18169; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; CORBIN JD, 1986, J BIOL CHEM, V261, P1208; DMACKENZIE CW, 1981, INT J BIOCHEM, V13, P273; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; DOSKELAND SO, 1987, J BIOL CHEM, V262, P3534; DOSKELAND SO, 1984, J BIOL CHEM, V259, P2291; Francis S H, 1994, Adv Pharmacol, V26, P115, DOI 10.1016/S1054-3589(08)60053-8; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; FRANCIS SH, 1991, METHOD ENZYMOL, V200, P332; FRENCH PJ, 1995, J BIOL CHEM, V270, P26626, DOI 10.1074/jbc.270.44.26626; Gamm DM, 1996, J BIOL CHEM, V271, P15736, DOI 10.1074/jbc.271.26.15736; GAMM DM, 1995, J BIOL CHEM, V270, P7227, DOI 10.1074/jbc.270.13.7227; Gibson RM, 1997, J BIOL CHEM, V272, P16343, DOI 10.1074/jbc.272.26.16343; Gibson RM, 1997, J BIOL CHEM, V272, P31998, DOI 10.1074/jbc.272.51.31998; Hedlund P, 2000, P NATL ACAD SCI USA, V97, P2349, DOI 10.1073/pnas.030419997; Herberg FW, 1996, BIOCHEMISTRY-US, V35, P2934, DOI 10.1021/bi951647c; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; HOUGE G, 1990, J BIOL CHEM, V265, P19507; Huang LJS, 1998, J BIOL CHEM, V273, P26739, DOI 10.1074/jbc.273.41.26739; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; KALDERON D, 1989, J BIOL CHEM, V264, P10738; LANDGRAF W, 1990, BIOCHEMISTRY-US, V29, P9921, DOI 10.1021/bi00494a024; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MACKENZIE CW, 1982, J BIOL CHEM, V257, P5589; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; OGREID D, 1981, FEBS LETT, V129, P282, DOI 10.1016/0014-5793(81)80184-6; OGREID D, 1981, FEBS LETT, V129, P287, DOI 10.1016/0014-5793(81)80185-8; OGREID D, 1988, J BIOL CHEM, V263, P17397; Osborne KA, 1997, SCIENCE, V277, P834, DOI 10.1126/science.277.5327.834; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; RANNELS SR, 1981, J BIOL CHEM, V256, P7871; RANNELS SR, 1983, METHOD ENZYMOL, V99, P168; RANNELS SR, 1980, J BIOL CHEM, V255, P7085; Reed RB, 1997, ADV SEC MESS PHOSPH, V31, P205; Reed RB, 1996, J BIOL CHEM, V271, P17570, DOI 10.1074/jbc.271.29.17570; SARASWAT LD, 1988, J BIOL CHEM, V263, P18241; SHABB JB, 1992, J BIOL CHEM, V267, P5723; STEINBERG RA, 1987, J BIOL CHEM, V262, P2664; STEINBERG RA, 1991, J BIOL CHEM, V266, P3547; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SYMCOX MM, 1994, J BIOL CHEM, V269, P23025; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; Vaandrager AB, 1997, J BIOL CHEM, V272, P11816, DOI 10.1074/jbc.272.18.11816; Wagner C, 1998, J CLIN INVEST, V102, P1576, DOI 10.1172/JCI4044; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEN W, 1995, J BIOL CHEM, V270, P2041, DOI 10.1074/jbc.270.5.2041; WOLFE L, 1987, J BIOL CHEM, V262, P16906; WOODFORD TA, 1989, J BIOL CHEM, V264, P13321; Zhao JK, 1997, J BIOL CHEM, V272, P31929, DOI 10.1074/jbc.272.50.31929	58	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28053	28062						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10864932				2022-12-27	WOS:000089197100071
J	Lemaire, M; Collart, MA				Lemaire, M; Collart, MA			The TATA-binding protein-associated factor yTaf(II)19p functionally interacts with components of the global transcriptional regulator Ccr4-not complex and physically interacts with the NOT5 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; TAF(II)-CONTAINING COMPLEX; NUCLEOSOME ACETYLATION; DIFFERENTIALLY AFFECTS; HISTONE ACETYLASE; YEAST; GENE; ELEMENT; TAFS	The Saccharomyces cerevisiae HIS3 gene is a model system to characterize transcription initiation from different types of core promoters. The NOT genes were identified by mutations that preferentially increased transcription of the HIS3 promoter lacking a canonical TATA sequence. They encode proteins associated in a complex that also contains the Caf1 and Ccr4 proteins. It has been suggested that the Ccr4-Not complex represses transcription by inhibiting factors more specifically required for promoters lacking a TATA sequence. A potential target is the yTaf(11)19 subunit of TFIID, which, when depleted, leads to a preferential decrease of HIS3 TATA-less transcription. We isolated conditional taf19 alleles that display synthetic growth phenotypes when combined with not4 or specific not5 alleles. Inactivation of yTaf(11)19p by shifting these mutants to the restrictive temperature led to a more rapid and striking decrease in transcription from promoters that do not contain a canonical TATA sequence. We demonstrated by the two-hybrid assay and directly in vitro that yTaf(11)19p and Not5p could interact. Finally, we found by the two-hybrid assay that yTaf(11)19p also interacted with many components of the Ccr4 Not complex, Taken together, our results provide evidence that interactions between Not5p and yTaf(11)19p may be involved in transcriptional regulation by the Ccr4-Not complex.	Ctr Med Univ Geneva, Dept Biochim Med, CH-1211 Geneva 4, Switzerland	University of Geneva	Collart, MA (corresponding author), Ctr Med Univ Geneva, Dept Biochim Med, 1 Rue Michel St, CH-1211 Geneva 4, Switzerland.							Albert TK, 2000, NUCLEIC ACIDS RES, V28, P809, DOI 10.1093/nar/28.3.809; Benson JD, 1998, EMBO J, V17, P6714, DOI 10.1093/emboj/17.22.6714; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COLLART MA, 1993, EMBO J, V12, P177, DOI 10.1002/j.1460-2075.1993.tb05643.x; Collart MA, 1996, MOL CELL BIOL, V16, P6668; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; Klebanow ER, 1997, J BIOL CHEM, V272, P9436; Lee TI, 1998, MOL CELL BIOL, V18, P4455, DOI 10.1128/MCB.18.8.4455; Liu HY, 1998, EMBO J, V17, P1096, DOI 10.1093/emboj/17.4.1096; MAHADEVAN S, 1990, MOL CELL BIOL, V10, P4447, DOI 10.1128/MCB.10.9.4447; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Oberholzer U, 1998, GENE, V207, P61, DOI 10.1016/S0378-1119(97)00605-7; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; PELLMAN D, 1990, NATURE, V348, P82, DOI 10.1038/348082a0; POON D, 1994, J BIOL CHEM, V269, P23135; REMACLE JE, 1992, MOL CELL BIOL, V12, P5516, DOI 10.1128/MCB.12.12.5516; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	34	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26925	26934						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10864925				2022-12-27	WOS:000089144800036
J	de Chaves, EIP; Vance, DE; Campenot, RB; Kiss, RS; Vance, JE				de Chaves, EIP; Vance, DE; Campenot, RB; Kiss, RS; Vance, JE			Uptake of lipoproteins for axonal growth of sympathetic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; RECEPTOR-RELATED PROTEIN; RAT SCIATIC-NERVE; SCAVENGER RECEPTOR; PERIPHERAL-NERVE; CHOLESTEROL TRANSPORT; CEREBROSPINAL-FLUID; CELLULAR CHOLESTEROL; MEDIATED ENDOCYTOSIS	Lipoproteins originating from axon and myelin breakdown in injured peripheral nerves are believed to supply cholesterol to regenerating axons. We have used compartmented cultures of rat sympathetic neurons to investigate the utilization of lipids from lipoproteins for axon elongation. Lipids and proteins from human low density lipoproteins (LDL) and high density lipoproteins (HDL) were taken up by distal axons and transported to cell bodies, whereas cell bodies/proximal axons internalized these components from only LDL, not HDL. Consistent with these observations, the impairment of axonal growth, induced by inhibition of cholesterol synthesis, was reversed when LDL or HDL were added to distal axons or when LDL, but not HDL, were added to cell bodies. LDL receptors (LDLRs) and LR7/8B (apoER2) were present in cell bodies/proximal axons and distal axons, with LDLRs being more abundant in the former. Inhibition of cholesterol biosynthesis increased LDLR expression in cell bodies/proximal axons but not distal axons. LR11 (SorLA) was restricted to cell bodies/proximal axons and was undetectable in distal axons, Neither the LDL receptor-related protein nor the HDL receptor, SR-B1, was detected in sympathetic neurons. These studies demonstrate for the first time that lipids are taken up from lipoproteins by sympathetic neurons for use in axonal regeneration.	Univ Alberta, Fac Med, Dept Med, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta	Vance, JE (corresponding author), Univ Alberta, Fac Med, Dept Med, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada.							Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; BLUE ML, 1982, J BIOL CHEM, V257, P1151; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BOYLES JK, 1990, J BIOL CHEM, V265, P17805; Brown MD, 1997, BRAIN RES, V747, P313, DOI 10.1016/S0006-8993(96)01321-2; BROWN MS, 1979, P NATL ACAD SCI USA, V76, P3330, DOI 10.1073/pnas.76.7.3330; BU GJ, 1994, J BIOL CHEM, V269, P18521; Campenot R B, 1979, Methods Enzymol, V58, P302; CAMPENOT RB, 1991, J NEUROSCI, V11, P1126; CAMPENOT RB, 1992, CELL CELL INTERACTIO, P275; Charest MC, 1999, EUR J BIOCHEM, V263, P402, DOI 10.1046/j.1432-1327.1999.00527.x; CHIBA H, 1991, NEUROSCI LETT, V133, P207, DOI 10.1016/0304-3940(91)90571-A; CIDARREGUI A, 1995, J NEUROSCI, V15, P4259; DAWSON PA, 1986, J BIOL CHEM, V261, P5681; de Chaves EIP, 1997, J BIOL CHEM, V272, P30766, DOI 10.1074/jbc.272.49.30766; deChaves EIP, 1997, J BIOL CHEM, V272, P3028, DOI 10.1074/jbc.272.5.3028; DELAMATRE JG, 1993, J CELL PHYSIOL, V157, P164, DOI 10.1002/jcp.1041570121; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; Garcia A, 1996, BIOCHEMISTRY-US, V35, P13064, DOI 10.1021/bi952223l; GOODRUM JF, 1993, J NEUROCHEM, V60, P1564, DOI 10.1111/j.1471-4159.1993.tb03322.x; GOODRUM JF, 1991, J NEUROCHEM, V56, P2082, DOI 10.1111/j.1471-4159.1991.tb03469.x; GOODRUM JF, 1990, J NEUROCHEM, V54, P1709, DOI 10.1111/j.1471-4159.1990.tb01225.x; GREEN SR, 1991, J LIPID RES, V32, P667; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Hammad SM, 1997, J BIOL CHEM, V272, P18644, DOI 10.1074/jbc.272.30.18644; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HARA H, 1991, J BIOL CHEM, V266, P3080; Hermans-Borgmeyer I, 1998, MECH DEVELOP, V70, P65, DOI 10.1016/S0925-4773(97)00177-9; Hermo L, 1999, MOL REPROD DEV, V53, P282, DOI 10.1002/(SICI)1098-2795(199907)53:3&lt;282::AID-MRD4&gt;3.0.CO;2-A; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; IGNATIUS MJ, 1987, SCIENCE, V236, P959, DOI 10.1126/science.3576212; ISHIGURO M, 1995, MOL BRAIN RES, V33, P37, DOI 10.1016/0169-328X(95)00104-Z; Jareb M, 1997, J NEUROSCI, V17, P8955; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JUREVICS H, 1995, J NEUROCHEM, V64, P895; Jurevics H, 1998, NEUROCHEM RES, V23, P401, DOI 10.1023/A:1022469803426; JUREVICS HA, 1994, J LIPID RES, V35, P112; Jurevics HA, 1997, J LIPID RES, V38, P723; Kanaki T, 1998, DNA CELL BIOL, V17, P647, DOI 10.1089/dna.1998.17.647; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Kiss RS, 1999, BIOCHEMISTRY-US, V38, P4327, DOI 10.1021/bi982597p; Klinger A, 1997, BBA-LIPID LIPID MET, V1345, P65, DOI 10.1016/S0005-2760(96)00164-6; Kounnas M Z, 1994, In Vivo, V8, P343; Kozyraki R, 1999, NAT MED, V5, P656, DOI 10.1038/9504; Krieger M, 1998, P NATL ACAD SCI USA, V95, P4077, DOI 10.1073/pnas.95.8.4077; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; LAMONFAVA S, 1992, J LIPID RES, V33, P831; LEBLANC AC, 1990, J NEUROSCI RES, V25, P162, DOI 10.1002/jnr.490250203; LEBLANC AC, 1989, J CELL BIOL, V109, P1245, DOI 10.1083/jcb.109.3.1245; Lemieux MJ, 1995, NEUROCHEM RES, V20, P1239; LI CX, 1991, J BIOL CHEM, V266, P9263; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; Moestrup SK, 1998, J BIOL CHEM, V273, P5235, DOI 10.1074/jbc.273.9.5235; Morwald S, 1997, ARTERIOSCL THROM VAS, V17, P996, DOI 10.1161/01.ATV.17.5.996; Motoi Y, 1999, BRAIN RES, V833, P209, DOI 10.1016/S0006-8993(99)01542-5; Narita M, 1997, J NEUROCHEM, V68, P587; Ness GC, 1997, AM J MED GENET, V68, P294, DOI 10.1002/(SICI)1096-8628(19970131)68:3<294::AID-AJMG9>3.0.CO;2-M; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; PITTMAN RC, 1984, J LIPID RES, V25, P1577; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; RAJAVASHISTH TB, 1987, J BIOL CHEM, V262, P7058; RAMANUJAM KS, 1991, BIOCHEM BIOPH RES CO, V179, P543, DOI 10.1016/0006-291X(91)91405-2; Rebeck GW, 1998, EXP NEUROL, V149, P175, DOI 10.1006/exnr.1997.6710; REYNOLDS GD, 1985, AM J PATHOL, V121, P200; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; ROTHE T, 1991, J NEUROCHEM, V57, P2016, DOI 10.1111/j.1471-4159.1991.tb06417.x; Schneider WJ, 1997, CURR OPIN LIPIDOL, V8, P315, DOI 10.1097/00041433-199710000-00011; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; Steinberg D, 1996, SCIENCE, V271, P460, DOI 10.1126/science.271.5248.460; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Turley SD, 1996, J LIPID RES, V37, P1953; VANCE JE, 1994, J NEUROCHEM, V62, P329; WOLF BB, 1992, AM J PATHOL, V141, P37; Xu SZ, 1997, J LIPID RES, V38, P1289; Yamamoto M, 1998, Brain Tumor Pathol, V15, P23, DOI 10.1007/BF02482097; Yamauchi K, 1999, CLIN CHEM, V45, P1431; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761	87	92	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19883	19890		10.1074/jbc.275.26.19883	http://dx.doi.org/10.1074/jbc.275.26.19883			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867025				2022-12-27	WOS:000087941300062
J	Inoue, K; Mizuno, T; Wada, K; Hagiwara, M				Inoue, K; Mizuno, T; Wada, K; Hagiwara, M			Novel RING finger proteins, Air1p and Air2p, interact with Hmt1p and inhibit the arginine methylation of Npl3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEINS; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; NUCLEOLAR ACCUMULATION; N-METHYLTRANSFERASE; NUCLEAR-PROTEIN; HNRNP PROTEINS; IN-VITRO; RGG BOX; YEAST	Heterogeneous nuclear ribonucleoproteins (hnRNPs) are involved in the mRNA processing and export and are post-translationally modified by methylation at arginine residues in their arginine-glycine-rich (RGG) domains. We screened the factors that can interact with the RGG domain of Np13p only in the presence of Hmt1p with the two-hybrid system in Saccharomyces cerevisiae, An isolated clone, YIL079, encodes a novel RING finger protein that was not directly bound to Np13p but associated with the N terminus of Hmt1p. Thus, we designated the gene product Air1p (arginine methyltransferase-interacting RING finger protein). Air1p inhibited the Hmt1p-mediated methylation of Np13p in vitro. Overexpression of Air1p repressed the Hmt1p-dependent growth of cells. Since homology searches indicate that the YDL175 gene product has significant identity (45%) with Air1p, we designated the gene AIR2. Air2p also has a RING finger domain and was bound to Hmt1p. Although single disruption of either gene gave no effect on the cell growth, cells lacking Air1p and Air2p grew at an extremely slow rate with accumulated poly(A)(+) RNA in the nucleus. Thus, Air1p and Air2p may affect mRNA transport by regulating the arginine methylation state of heterogeneous nuclear ribonucleoproteins.	Tokyo Med & Dent Univ, Med Res Inst, Dept Funct Genom, Bunkyo Ku, Tokyo 1138510, Japan; Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, SEEDS Lab, Tsukuba, Ibaraki 3058585, Japan	Tokyo Medical & Dental University (TMDU); Astellas Pharmaceuticals	Hagiwara, M (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Funct Genom, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.		Wada, Kazuhiro/A-6548-2012	Wada, Kazuhiro/0000-0001-8137-9144				Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Adams A, 1997, METHODS YEAST GENETI; Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; AMERO SA, 1992, P NATL ACAD SCI USA, V89, P8409, DOI 10.1073/pnas.89.18.8409; ANDERSON JT, 1993, MOL CELL BIOL, V13, P2730, DOI 10.1128/MCB.13.5.2730; BARTA I, 1995, EMBO J, V14, P3800, DOI 10.1002/j.1460-2075.1995.tb00049.x; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bohm S, 1997, NUCLEIC ACIDS RES, V25, P2464, DOI 10.1093/nar/25.12.2464; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; BOSSIE MA, 1992, MOL BIOL CELL, V3, P875, DOI 10.1091/mbc.3.8.875; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; GIRARD JP, 1994, J BIOL CHEM, V269, P18499; Henry MF, 1996, MOL CELL BIOL, V16, P3668; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; Kessler MM, 1997, GENE DEV, V11, P2545, DOI 10.1101/gad.11.19.2545; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KITADA K, 1995, GENE, V165, P203, DOI 10.1016/0378-1119(95)00552-H; KONKEL LMC, 1995, P NATL ACAD SCI USA, V92, P5558, DOI 10.1073/pnas.92.12.5558; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; LIN JJ, 1994, NUCLEIC ACIDS RES, V22, P4906, DOI 10.1093/nar/22.23.4906; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LIU Q, 1995, MOL CELL BIOL, V15, P2800; McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128; Mears WE, 1996, J VIROL, V70, P7445, DOI 10.1128/JVI.70.11.7445-7453.1996; MICHAEL WM, 1995, CELL, V83, P415; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; PAIK WK, 1967, BIOCHEM BIOPH RES CO, V29, P14, DOI 10.1016/0006-291X(67)90533-5; Pan C, 1997, J BIOL CHEM, V272, P8165, DOI 10.1074/jbc.272.13.8165; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Shiratori A, 1999, YEAST, V15, P219, DOI 10.1002/(SICI)1097-0061(199902)15:3<219::AID-YEA349>3.3.CO;2-V; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; STANLEY JP, 1998, CELL, V92, P315; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; TANI T, 1995, MOL BIOL CELL, V6, P1515, DOI 10.1091/mbc.6.11.1515; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Williams BA, 1996, CURR GENET, V30, P305, DOI 10.1007/s002940050137; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173	47	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32793	32799		10.1074/jbc.M004560200	http://dx.doi.org/10.1074/jbc.M004560200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10896665	hybrid			2022-12-27	WOS:000090003800058
J	Haertel-Wiesmann, M; Liang, YX; Fantl, WJ; Williams, LT				Haertel-Wiesmann, M; Liang, YX; Fantl, WJ; Williams, LT			Regulation of cyclooxygenase-2 and periostin by Wnt-3 in mouse mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; BETA-CATENIN; GROWTH-FACTOR; SIGNALING PATHWAY; COLON-CANCER; CYCLIN D1; EXPRESSION; ACTIVATION; PROTEIN; IDENTIFICATION	Wnt family members are critical in developmental processes and have been shown to promote carcinogenesis when ectopically expressed in the mouse mammary gland. The gene expression pattern mediated by Wnt is pivotal for these diverse responses. The Wnt pathway has been conserved among different species. Genetic studies have shown that Wnt effects are mediated, at least in part, by beta-catenin, which regulates transcription of "downstream genes." Wnt stimulation inactivates glycogen-synthase kinase-3 beta (GSK-8) with subsequent stabilization of beta-catenin, which after heterodimerizing with lymphocyte enhancer factor-YT-cell factor cofactors stimulates transcription. To establish whether Wnt-stimulated transcription is mediated solely by beta-catenin, a comparison was made of gene expression profiles in response to Wnt-3, overexpression of beta-catenin, and inhibition of GSK-3. Infection of cells with Wnt-3 and inhibition of GSK-3 regulate a set of genes that include cyclooxygenase-2 and periostin. Interestingly, overexpression of beta-catenin or reducing beta-catenin levels with antisense oligonucleotide transfection did not have any effect on cyclooxygenase-2 or periostin expression, thereby defining a Wnt pathway, which cannot be mimicked by beta-catenin overexpression.	Chiron Corp, Emeryville, CA 94608 USA	Novartis	Fantl, WJ (corresponding author), Chiron Corp, 4560 Horton St 4-6, Emeryville, CA 94608 USA.							Brannon M, 1996, DEV BIOL, V180, P344, DOI 10.1006/dbio.1996.0306; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Carnac G, 1996, DEVELOPMENT, V122, P3055; Cohen Y, 1998, MED ONCOL, V15, P32, DOI 10.1007/BF02787342; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Genini M, 1996, INT J CANCER, V66, P571; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; Howe LR, 1999, CANCER RES, V59, P1572; Hwang D, 1998, J NATL CANCER I, V90, P455, DOI 10.1093/jnci/90.6.455; Issack PS, 1998, CELL GROWTH DIFFER, V9, P837; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Murphy JE, 1998, P NATL ACAD SCI USA, V95, P1517, DOI 10.1073/pnas.95.4.1517; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SUGIURA T, 1995, PROTEIN EXPRES PURIF, V6, P305, DOI 10.1006/prep.1995.1040; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; van der Heyden MAG, 1998, J CELL SCI, V111, P1741	37	92	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32046	32051		10.1074/jbc.M000074200	http://dx.doi.org/10.1074/jbc.M000074200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10884377	hybrid			2022-12-27	WOS:000089858900068
J	Hoggatt, AM; Kriegel, AM; Smith, AF; Herring, BP				Hoggatt, AM; Kriegel, AM; Smith, AF; Herring, BP			Hepatocyte nuclear factor-3 homologue 1 (HFH-1) represses transcription of smooth muscle-specific genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; ALPHA-ACTIN GENE; HEAVY-CHAIN GENE; TRANSGENIC MICE; CELL-DIFFERENTIATION; ESCHERICHIA-COLI; TINMAN HOMOLOG; FORK HEAD; IN-VIVO; EXPRESSION	Results show that smooth muscle-specific promoters represent novel downstream targets of the winged helix factor hepatocyte nuclear factor-3 homologue 1 (HFH-1). HFH-1 strongly represses telokin promoter activity when overexpressed in A10 vascular smooth muscle cells. HFH-1 was also found to repress transcription of several other smooth muscle-specific promoters, including the SM22 alpha: promoter. HFH-1 inhibits telokin promoter activity, by binding to a forkhead consensus site located within an AT-rich region of the telokin promoter. The DNA-binding domain alone was sufficient to mediate inhibition, suggesting that binding of HFH-1 blocks the binding of other positive-acting factors. HFH-1 does not disrupt serum response factor binding to an adjacent CArG box within the telokin promoter, implying that HFH-1 must compete with other unidentified trans-activators to mediate repression. The localization of HFH-1 mRNA to the epithelial cell layer of mouse bladder and stomach implicates HFH-1 in repressing telokin expression in epithelial cells. This suggests that cell-specific expression of telokin is likely mediated by both positive-acting factors in smooth muscle cells and negative-acting factors in nonmuscle cell types. We propose a model in which the smooth muscle specificity of the telokin promoter is regulated by interactions between positive- and negative-acting members of the hepatocyte nuclear factor-3/forkhead family of transcription factors.	Indiana Univ, Sch Med, Dept Physiol & Biophys, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Herring, BP (corresponding author), Indiana Univ, Sch Med, Dept Physiol & Biophys, 635 Barnhill Dr, Indianapolis, IN 46202 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058571] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-58571] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Browning CL, 1998, DEV BIOL, V194, P18, DOI 10.1006/dbio.1997.8808; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Chen CY, 1996, MOL CELL BIOL, V16, P6372; CLEVIDENCE DE, 1994, DEV BIOL, V166, P195, DOI 10.1006/dbio.1994.1307; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; Frank S, 1998, DNA CELL BIOL, V17, P679, DOI 10.1089/dna.1998.17.679; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; HALAYKO AJ, 1994, CAN J PHYSIOL PHARM, V72, P1448, DOI 10.1139/y94-209; Hautmann MB, 1998, J BIOL CHEM, V273, P8398, DOI 10.1074/jbc.273.14.8398; Hautmann MB, 1999, ARTERIOSCL THROM VAS, V19, P2049, DOI 10.1161/01.ATV.19.9.2049; Herring BP, 1997, AM J PHYSIOL-CELL PH, V272, pC1394, DOI 10.1152/ajpcell.1997.272.4.C1394; HERRING BP, 1996, AM J PHYSIOL, V270, pC1665; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Hong HK, 1999, HUM MOL GENET, V8, P625, DOI 10.1093/hmg/8.4.625; Johnson AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1420, DOI 10.1152/ajpcell.1999.276.6.C1420; KAISER P, 1993, BIOTECHNIQUES, V14, P552; KATAYAMA E, 1995, J BIOL CHEM, V270, P3919, DOI 10.1074/jbc.270.8.3919; Katoh Y, 1998, J BIOL CHEM, V273, P1511, DOI 10.1074/jbc.273.3.1511; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kelm RJ, 1996, J BIOL CHEM, V271, P24278, DOI 10.1074/jbc.271.39.24278; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Kimura K, 1998, NUCLEIC ACIDS RES, V26, P2420, DOI 10.1093/nar/26.10.2420; Kopachik W, 1998, DEV DYNAM, V211, P131, DOI 10.1002/(SICI)1097-0177(199802)211:2<131::AID-AJA2>3.0.CO;2-I; Landerholm TE, 1999, DEVELOPMENT, V126, P2053; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; Mack CP, 1999, CIRC RES, V84, P852; Madsen CS, 1998, CIRC RES, V82, P908; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; MAJESKY MW, 1992, CIRC RES, V71, P759, DOI 10.1161/01.RES.71.4.759; Miano JM, 2000, J BIOL CHEM, V275, P9814, DOI 10.1074/jbc.275.13.9814; MIN BH, 1990, J BIOL CHEM, V265, P16667; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Owens GK, 1998, ACTA PHYSIOL SCAND, V164, P623, DOI 10.1111/j.1365-201X.1998.tb10706.x; OWENS GK, 1995, PHYSIOL REV, V75, P487; PATAPOUTIAN A, 1993, DEVELOPMENT, V118, P61; Peterson RS, 1997, MECH DEVELOP, V69, P53, DOI 10.1016/S0925-4773(97)00153-6; Qian J, 1996, DEV DYNAM, V207, P135; RUIZ I, 1993, MECH DEVELOP, V44, P91; SAWAYA PL, 1994, J BIOL CHEM, V269, P22211; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; Smith AF, 1998, AM J PHYSIOL-CELL PH, V274, pC1188, DOI 10.1152/ajpcell.1998.274.5.C1188; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; STEWART AG, 1993, TRENDS PHARMACOL SCI, V14, P275, DOI 10.1016/0165-6147(93)90130-C; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; Swartz EA, 1998, AM J PHYSIOL-CELL PH, V275, pC608, DOI 10.1152/ajpcell.1998.275.2.C608; Tichelaar JW, 1999, DEV BIOL, V213, P405, DOI 10.1006/dbio.1999.9380; Winnier GE, 1999, DEV BIOL, V213, P418, DOI 10.1006/dbio.1999.9382; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x; Zilberman A, 1998, CIRC RES, V82, P566, DOI 10.1161/01.RES.82.5.566	58	37	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31162	31170		10.1074/jbc.M005595200	http://dx.doi.org/10.1074/jbc.M005595200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896677	hybrid			2022-12-27	WOS:000089762700059
J	Gotoh, T; Cai, DP; Tian, XJ; Feig, LA; Lerner, A				Gotoh, T; Cai, DP; Tian, XJ; Feig, LA; Lerner, A			p130(Cas) regulates the activity of AND-34, a novel Ra1, Rap1, and R-Ras guanine nucleotide exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAY; PUTATIVE EFFECTOR; PROTEIN-KINASE; DIRECT BINDING; BREAST-CANCER; FACTOR C3G; V-SRC; ACTIVATION; IDENTIFICATION; GTPASE	We previously identified a novel murine protein, AND-34, with a carboxyl-terminal domain homologous to Ras family guanine nucleotide exchange factors (GEFs), which bound to the focal adhesion docking protein p130(Cas). Work by others has implicated both the human homologue of AND-34, BCAR3, and human p130(Cas) BCAR1, in the resistance of breast cancer cells to the anti-estrogen tamoxifen. Here we report that AND-34 displays GEF activity on Ra1A, Rap1A, and R-Ras but not Ha-Ras GTPases in cells. In contrast to several other Ra1-GEFs, the Ra1 GEF activity of AND-34 is not augmented by constitutively active Ha-Ras(Val-12), consistent with the absence of a detectable Ras-binding domain. Efficient binding to AND-34 required both the Src-binding domain and a flanking carboxyl-terminal region of p130(Cas). The p130(Cas)-binding site mapped to a carboxyl-terminal sequence within the AND-34 GEF domain. Overexpression of p130(Cas), but not an AND-34-binding mutant of p130(Cas), inhibited the Ra1 GEF activity of co-transfected AND-34. This work identifies a new potential function for p130(Cas) and a new regulatory pathway involved in the control of Ra1, Rap, and R-Ras GTPases that may participate in the progression of breast cancer cells to tamoxifen resistance.	Boston Univ, Med Ctr, Dept Med, Evans Biomed Res Ctr,Sect Hematol & Oncol, Boston, MA 02118 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA	Boston University; Tufts University; Boston University	Lerner, A (corresponding author), Boston Univ, Med Ctr, Dept Med, Evans Biomed Res Ctr,Sect Hematol & Oncol, Rm 427,650 Albany St, Boston, MA 02118 USA.							Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Brinkman A, 2000, JNCI-J NATL CANCER I, V92, P112, DOI 10.1093/jnci/92.2.112; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Cai DP, 1999, J IMMUNOL, V163, P2104; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Dodelet VC, 1999, J BIOL CHEM, V274, P31941, DOI 10.1074/jbc.274.45.31941; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Kirsch KH, 1998, J BIOL CHEM, V273, P25673, DOI 10.1074/jbc.273.40.25673; Lu YM, 1999, J BIOL CHEM, V274, P10047, DOI 10.1074/jbc.274.15.10047; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NICHOLSON S, 1989, LANCET, V1, P182; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Park SH, 1995, ONCOGENE, V11, P2349; Rebhun JF, 2000, J BIOL CHEM, V275, P13406, DOI 10.1074/jbc.C000085200; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sakakibara A, 2000, J BIOL CHEM, V275, P6404, DOI 10.1074/jbc.275.9.6404; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Suzuki J, 1997, ONCOGENE, V15, P1689, DOI 10.1038/sj.onc.1201333; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; van der Flier S, 2000, JNCI-J NATL CANCER I, V92, P120, DOI 10.1093/jnci/92.2.120; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	32	79	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30118	30123		10.1074/jbc.M003074200	http://dx.doi.org/10.1074/jbc.M003074200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896938	hybrid			2022-12-27	WOS:000089577900029
J	Gribble, FM; Loussouarn, G; Tucker, SJ; Zhao, C; Nichols, CG; Ashcroft, FM				Gribble, FM; Loussouarn, G; Tucker, SJ; Zhao, C; Nichols, CG; Ashcroft, FM			Novel method for measurement of submembrane ATP concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE K+ CHANNELS; ISLET BETA-CELLS; SULFONYLUREA RECEPTOR; RELEASE; RECONSTITUTION; STOICHIOMETRY; NA,K-ATPASE; ADP	There has been considerable debate as to whether adenosine triphosphate (ATP) is compartmentalized within cells and, in particular, whether the ATP concentration directly beneath the plasma membrane, experienced by membrane proteins, is the same as that of the bulk cytoplasm. This issue has been difficult to address because there is no indicator of cytosolic ATP, such as those available for Ca2+, capable of resolving the submembrane ATP concentration ([ATP](sm)) in real time within a single cell. We show here that mutant ATP-sensitive K+ channels can be used to measure [ATP](sm) by comparing the increase in current amplitude on patch excision with the ATP dose-response curve. In Xenopus oocytes, [ATP](sm) was 4.6 +/- 0.3 mM (n = 29) under resting conditions, slightly higher than that measured for the bulk cytoplasm (2.3 mM). In mammalian (COSm6) cells, [ATP](sm) was slightly lower and averaged 1.4 +/- 0.1 mM (n = 66). Metabolic poisoning (10 min of 3 mM azide) produced a significant fall in [ATP](sm) in both types of cells: to 1.2 +/- 0.1 mM (n = 24) in oocytes and 0.8 +/- 0.11 mM for COSm6 cells. We conclude that [ATP](sm) lies in the low millimolar range and that there is no gradient between bulk cytosolic and submembrane [ATP].	Univ Oxford, Univ Lab Physiol, Oxford OX1 3PT, England; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	University of Oxford; Washington University (WUSTL)	Ashcroft, FM (corresponding author), Univ Oxford, Univ Lab Physiol, Parks Rd, Oxford OX1 3PT, England.	frances.ashcroft@physiol.ox.ac.uk	Nichols, Colin/D-6336-2012; Loussouarn, Gildas/D-3590-2015; Tucker, Stephen J./ABE-7468-2020; Loussouarn, Gildas/ABH-6043-2020; Tucker, Stephen J./ABE-6741-2020	Loussouarn, Gildas/0000-0001-8007-5931; Tucker, Stephen J./0000-0001-8996-2000; Loussouarn, Gildas/0000-0001-8007-5931; Tucker, Stephen J./0000-0001-8996-2000; Gribble, Fiona/0000-0002-4232-2898	NHLBI NIH HHS [HL45742] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045742] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; AW TY, 1985, AM J PHYSIOL, V249, pC385, DOI 10.1152/ajpcell.1985.249.5.C385; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; GHOSH A, 1991, J BIOL CHEM, V266, P22887; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; HUME RI, 1983, NATURE, V305, P632, DOI 10.1038/305632a0; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; JONES DP, 1986, AM J PHYSIOL, V250, pC663, DOI 10.1152/ajpcell.1986.250.5.C663; KAKEI M, 1986, FEBS LETT, V208, P63, DOI 10.1016/0014-5793(86)81533-2; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; Koster JC, 1999, J GEN PHYSIOL, V114, P203, DOI 10.1085/jgp.114.2.203; MILLER DS, 1986, J BIOL CHEM, V261, P13911; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; NIKI I, 1989, FEBS LETT, V257, P361, DOI 10.1016/0014-5793(89)81572-8; Prakriya M, 1996, J NEUROSCI, V16, P4344; PROVERBIO F, 1977, J GEN PHYSIOL, V69, P605, DOI 10.1085/jgp.69.5.605; Ripoll C, 1996, DIABETES, V45, P1431, DOI 10.2337/diabetes.45.10.1431; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Sippel CJ, 1997, J BIOL CHEM, V272, P18290, DOI 10.1074/jbc.272.29.18290; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Wang RH, 1997, J BIOL CHEM, V272, P26405, DOI 10.1074/jbc.272.42.26405	28	227	232	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30046	30049		10.1074/jbc.M001010200	http://dx.doi.org/10.1074/jbc.M001010200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10866996	hybrid			2022-12-27	WOS:000089577900018
J	Logan, C; Mayhew, SG				Logan, C; Mayhew, SG			Cloning, overexpression, and characterization of peroxiredoxin and NADH peroxiredoxin reductase from Thermus aquaticus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL-HYDROPEROXIDE REDUCTASE; PROTEIN SECONDARY STRUCTURE; FLAVOPROTEIN DISULFIDE OXIDOREDUCTASES; THIOL-SPECIFIC ANTIOXIDANT; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; AMPHIBACILLUS-XYLANUS; THIOREDOXIN REDUCTASE; PEROXIDASE-ACTIVITY; EXPRESSION VECTORS	The genes for peroxiredoxin (Prx) and NADH:peroxiredoxin oxidoreductase (PrxR) have been cloned from the thermophilic bacterium Thermus aquaticus, prx is located upstream from prxR, the two genes being separated by 13 bases. The amino acid sequences show that Prx is related to two-cysteine peroxiredoxins from a range of organisms and that PrxR resembles NADH-dependent flavoenzymes that catalyze the reduction of peroxiredoxins in mesophilic bacteria. The sequence of PrxR also resembles those of thioredoxin reductases (TrxR) from thermophiles but with an N-terminal extension of about 200 residues. PrxR has motifs for two redox-active disulfides, one in the FAD-binding site, as occurs in TrxR, and the other in the N-terminal extension. The molecular masses of the monomers of Prx and PrxR are 21.0 and 54.9 kDa, respectively; both enzymes exist as multimers. The recombinant flavoenzyme requires 3 mol equivalents of dithionite for full reduction, as is consistent with 1 FAD and 2 disulfides per monomer, PrxR and Prx together catalyze the anaerobic reduction of hydrogen peroxide. The activity of Prx is much less than has been observed with homologous proteins. Prx appears to be inactivated by cumene hydroperoxide. PrxR itself has low peroxidase activity.	Univ Coll Dublin, Dept Biochem, Dublin 4, Ireland	University College Dublin	Mayhew, SG (corresponding author), Univ Coll Dublin, Dept Biochem, Dublin 4, Ireland.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chakravarty S, 2000, FEBS LETT, V470, P65, DOI 10.1016/S0014-5793(00)01267-9; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; COCCO D, 1988, EUR J BIOCHEM, V174, P267, DOI 10.1111/j.1432-1033.1988.tb14093.x; COHEN G, 1994, J BACTERIOL, V176, P973, DOI 10.1128/JB.176.4.973-984.1994; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; Jeong W, 2000, J BIOL CHEM, V275, P2924, DOI 10.1074/jbc.275.4.2924; Kitano K, 1999, J BIOCHEM, V126, P313, DOI 10.1093/oxfordjournals.jbchem.a022451; KLEINER D, 1988, J GEN MICROBIOL, V134, P1779; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGAN C, 1999, FLAVINS FLAVOPROTEIN, P401; MAYHEW SG, 1974, EUR J BIOCHEM, V44, P579, DOI 10.1111/j.1432-1033.1974.tb03515.x; Mayhew SG, 1999, METH MOL B, V131, P49; NEMOTO Y, 1990, GENE, V91, P261, DOI 10.1016/0378-1119(90)90097-B; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Niimura Y, 1996, J BIOL CHEM, V271, P30459, DOI 10.1074/jbc.271.48.30459; NIIMURA Y, 1995, J BIOL CHEM, V270, P25645, DOI 10.1074/jbc.270.43.25645; OHNISHI K, 1994, J BIOL CHEM, V269, P31418; Poole LB, 1996, BIOCHEMISTRY-US, V35, P56, DOI 10.1021/bi951887s; Poole LB, 1996, BIOCHEMISTRY-US, V35, P65, DOI 10.1021/bi951888k; POOLE LB, 2000, IN PRESS EUR J BIOCH; PRONGAY AJ, 1992, J BIOL CHEM, V267, P25181; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOEPFER R, 1993, GENE, V124, P83, DOI 10.1016/0378-1119(93)90764-T; Schroder E, 1998, PROTEIN SCI, V7, P2465, DOI 10.1002/pro.5560071125; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SHAU HG, 1994, IMMUNOGENETICS, V40, P129; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; Toomey D, 1998, EUR J BIOCHEM, V251, P935, DOI 10.1046/j.1432-1327.1998.2510935.x; TOOMEY D, 1997, FLAVINS FLAVOPROTEIN, P785; WHITBY LG, 1953, BIOCHEM J, V54, P437, DOI 10.1042/bj0540437; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Wilkinson SR, 2000, J BIOL CHEM, V275, P8220, DOI 10.1074/jbc.275.11.8220; WILSON K, 1994, CURRENT PROTOCOLS MO	47	16	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30019	30028		10.1074/jbc.M004161200	http://dx.doi.org/10.1074/jbc.M004161200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10862622	hybrid			2022-12-27	WOS:000089577900015
J	Mattagajasingh, SN; Huang, SC; Hartenstein, JS; Benz, EJ				Mattagajasingh, SN; Huang, SC; Hartenstein, JS; Benz, EJ			Characterization of the interaction between protein 4.1R and ZO-2 - A possible link between the tight junction and the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; MEMBRANE SKELETAL PROTEIN-4.1; EPITHELIAL-CELLS; ERYTHROCYTE PROTEIN-4.1; STRUCTURAL PROTEIN-4.1; POSSIBLE INVOLVEMENT; NONEPITHELIAL CELLS; FUNCTIONAL DOMAINS; MULTIPLE ISOFORMS; SEPTATE JUNCTIONS	Multiple isoforms of the red cell protein 4.1R are expressed in nonerythroid cells, including novel 135-kDa isoforms. Using a yeast two-hybrid system, immunocolocalization, immunoprecipitation, and in vitro binding studies, we found that two 4.1R isoforms of 135 and 150 kDa specifically interact with the protein ZO-2 (zonula occludens-2). 4.1R is colocalized with ZO-2 and occludin at Madin-Darby canine kidney (MDCK) cell tight junctions. Both isoforms of 4.1R coprecipitated with proteins that organize tight junctions such as ZO-2, ZO-1, and occludin. Western blot analysis also revealed the presence of actin and cu-spectrin in these immunoprecipitates. Association of 4.1R isoforms with these tight junction and cytoskeletal proteins was found to be specific for the tight junction and was not seen in nonconfluent MDCK cells. The amino acid residues that sustain the interaction between 4.1R and ZO-2 reside within the amino acids encoded by exons 19-21 of 4.1R and residues 1054-1118 of ZO-2. Exogenously expressed 4.1R containing the spectrin/actin- and ZO-2-binding domains was recruited to tight junctions in confluent MDCK cells. Taken together, our results suggest that 4.1R might play an important role in organization and function of the tight junction by establishing a link between the tight junction and the actin cytoskeleton.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Huang, SC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 1033 Ross Res Bldg, Baltimore, MD 21205 USA.	schuang@welch.jhu.edu			NHLBI NIH HHS [HL44985] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044985] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; ANDERSON RA, 1988, J CELL BIOCHEM, V37, P269, DOI 10.1002/jcb.240370303; AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; Baklouti F, 1997, GENOMICS, V39, P289, DOI 10.1006/geno.1996.4512; Balda MS, 1996, FEBS LETT, V399, P326, DOI 10.1016/S0014-5793(96)01352-X; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; Beatch M, 1996, J BIOL CHEM, V271, P25723, DOI 10.1074/jbc.271.42.25723; BENTZEL CJ, 1976, NATURE, V264, P666, DOI 10.1038/264666a0; BENZ EJ, 1994, MOL BASIS BLOOD DIS, P257; Chasis JA, 1996, BLOOD, V87, P5324, DOI 10.1182/blood.V87.12.5324.bloodjournal87125324; Citi S, 1998, BBA-MOL CELL RES, V1448, P1, DOI 10.1016/S0167-4889(98)00125-6; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; COHEN CM, 1982, NATURE, V299, P648, DOI 10.1038/299648a0; COLLINS JR, 1992, BIOCHEM BIOPH RES CO, V252, P617; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; CORREAS I, 1988, BIOCHEM J, V255, P217; CORREAS I, 1986, J BIOL CHEM, V261, P3310; DeCarcer G, 1995, BIOCHEM J, V312, P871, DOI 10.1042/bj3120871; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; DISCHER D, 1993, J BIOL CHEM, V268, P7186; DUCLOS F, 1994, HUM MOL GENET, V3, P909, DOI 10.1093/hmg/3.6.909; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FEHON RG, 1994, DEVELOPMENT, V120, P545; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gascard P, 1998, BLOOD, V92, P4404, DOI 10.1182/blood.V92.11.4404.423k50_4404_4414; Gascard P, 1999, MOL BIOL CELL, V10, P1783, DOI 10.1091/mbc.10.6.1783; Gonzalez-Mariscal L, 1999, MOL BIOL CELL, V10, p407A; GRANGER BL, 1984, CELL, V37, P595, DOI 10.1016/0092-8674(84)90390-8; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hecht G, 1996, AM J PHYSIOL-CELL PH, V271, pC1678, DOI 10.1152/ajpcell.1996.271.5.C1678; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; HORNE WC, 1993, BLOOD, V82, P2558; HOWARTH AG, 1992, AM J PHYSIOL, V262, pC461, DOI 10.1152/ajpcell.1992.262.2.C461; HOWARTH AG, 1995, CELL MOTIL CYTOSKEL, V31, P323, DOI 10.1002/cm.970310408; HUANG SC, 1992, T ASSOC AM PHYSICIAN, V105, P165; Huang SC, 1999, BLOOD, V94, p194A; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; Krauss SW, 1997, P NATL ACAD SCI USA, V94, P7297, DOI 10.1073/pnas.94.14.7297; LaJeunesse DR, 1998, J CELL BIOL, V141, P1589, DOI 10.1083/jcb.141.7.1589; Leclerc E, 1998, EUR J BIOCHEM, V258, P567, DOI 10.1046/j.1432-1327.1998.2580567.x; LETO TL, 1986, J CELL PHYSIOL, V127, P423, DOI 10.1002/jcp.1041270311; LETO TL, 1984, J BIOL CHEM, V259, P4603; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; MONTERMINI L, 1995, AM J HUM GENET, V57, P1520; MONTERMINI L, 1995, AM J HUM GENET, V57, P1061; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; PANDOLFO M, 1994, BIOCHEM MED METAB B, V52, P115, DOI 10.1006/bmmb.1994.1041; Saitou M, 1997, EUR J CELL BIOL, V73, P222; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANG UH, 1979, EXP CELL RES, V122, P384, DOI 10.1016/0014-4827(79)90315-X; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; STEVENSON BR, 1994, J CELL SCI, V107, P367; SUBRAHMANYAM G, 1991, P NATL ACAD SCI USA, V88, P5222, DOI 10.1073/pnas.88.12.5222; TANAKA T, 1991, J BIOL CHEM, V266, P1134; Tang CJC, 1998, BLOOD, V92, P1442, DOI 10.1182/blood.V92.4.1442.416k14_1442_1447; TANG TK, 1990, J CELL BIOL, V110, P617, DOI 10.1083/jcb.110.3.617; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; Tsukamoto T, 1997, J BIOL CHEM, V272, P16133, DOI 10.1074/jbc.272.26.16133; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Walensky LD, 1998, J CELL BIOL, V141, P143, DOI 10.1083/jcb.141.1.143; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469	77	119	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30573	30585		10.1074/jbc.M004578200	http://dx.doi.org/10.1074/jbc.M004578200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10874042	hybrid			2022-12-27	WOS:000089577900091
J	Pol, A; Lu, A; Pons, M; Peiro, S; Enrich, C				Pol, A; Lu, A; Pons, M; Peiro, S; Enrich, C			Epidermal growth factor-mediated caveolin recruitment to early endosomes and MAPK activation - Role of cholesterol and actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; CELL-SURFACE; ENDOCYTIC COMPARTMENT; INTRACELLULAR PATHWAY; RECYCLING ENDOSOMES; SIGNAL-TRANSDUCTION; KINASE CASCADE; ANNEXIN-II; PROTEIN; RECEPTOR	The endocytic compartment of eukaryotic cells is a complex intracellular structure involved in sorting, processing, and degradation of a great variety of internalized molecules. Recently, the uptake through caveolae has emerged as an alternative internalization pathway, which seems to be directly related with some signal transduction pathways. However, the mechanisms, molecules, and structures regulating the transport of caveolin from the cell surface into the endocytic compartment are largely unknown. In this study, normal quiescent fibroblasts (normal rat kidney (NRK)) were used to demonstrate that epidermal growth factor causes partial redistribution of caveolin from the cell surface into a cellubrevin early endocytic compartment. Treatment of NRK cells with cytochalasin D or latrunculin A inhibits this pathway and the concomitant activation of Mek and mitotic-activated protein (MAP) kinase; however, if cells were pre-treated with filipin, cytochalasin D does not inhibit the phosphorylation of MAP kinase induced by epidermal growth factor. From these results we conclude that in NRK cells the intact actin cytoskeleton is necessary for the EGF-mediated transport of caveolin from the cell surface into the early endocytic compartment and the activation of MAP kinase pathway.	Univ Barcelona, Fac Med, Inst Invest Biomed August Pi Sunyer, Dept Cellular Biol, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Enrich, C (corresponding author), Univ Barcelona, Fac Med, Inst Invest Biomed August Pi Sunyer, Dept Cellular Biol, Casanova 143, E-08036 Barcelona, Spain.	enrich@medicina.ub.es	LU, ALBERT/AAB-6134-2019; Pons, Monica/AAB-5309-2019; Pol, Albert/M-1865-2014	LU, ALBERT/0000-0002-7507-3330; Pol, Albert/0000-0002-1750-1085; Enrich, Carlos/0000-0003-0382-2993				ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Annaert WG, 1997, J CELL BIOL, V139, P1397, DOI 10.1083/jcb.139.6.1397; APODACA G, 1994, J BIOL CHEM, V269, P19005; Bottger G, 1996, J BIOL CHEM, V271, P29191, DOI 10.1074/jbc.271.46.29191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUNS RR, 1968, J CELL BIOL, V37, P277, DOI 10.1083/jcb.37.2.277; Calvo M, 2000, J BIOL CHEM, V275, P7910, DOI 10.1074/jbc.275.11.7910; CARPENTIER JL, 1989, J CELL PHYSIOL, V138, P519, DOI 10.1002/jcp.1041380311; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gekle M, 1997, AM J PHYSIOL-RENAL, V272, pF668, DOI 10.1152/ajprenal.1997.272.5.F668; Gilbert A, 1999, J CELL SCI, V112, P1101; Gingras D, 1998, BIOCHEM BIOPH RES CO, V247, P888, DOI 10.1006/bbrc.1998.8885; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; Kiss AL, 1997, EUR J CELL BIOL, V73, P19; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Majo G, 1998, LIFE SCI, V62, P607, DOI 10.1016/S0024-3205(97)01156-9; MALABA L, 1995, J BIOL CHEM, V270, P15686, DOI 10.1074/jbc.270.26.15686; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; PALADE GR, 1953, J APPL PHYS, V24, P364; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Pol A, 1998, FEBS LETT, V441, P34, DOI 10.1016/S0014-5793(98)01517-8; Pol A, 1999, HEPATOLOGY, V29, P1848, DOI 10.1002/hep.510290602; POL A, 2000, IN PRESS CELL SIGNAL; Pons M, 2000, EXP CELL RES, V257, P33, DOI 10.1006/excr.2000.4861; Predescu SA, 1997, AM J PHYSIOL-HEART C, V272, pH937, DOI 10.1152/ajpheart.1997.272.2.H937; Prekeris R, 1999, MOL BIOL CELL, V10, P3891, DOI 10.1091/mbc.10.11.3891; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SANDVIG K, 1990, J BIOL CHEM, V265, P6382; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Teter K, 1998, J BIOL CHEM, V273, P19625, DOI 10.1074/jbc.273.31.19625; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; Van Deurs Bo, 1993, Trends in Cell Biology, V3, P249; VANDEURS B, 1989, INT REV CYTOL, V117, P131; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4	70	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30566	30572		10.1074/jbc.M001131200	http://dx.doi.org/10.1074/jbc.M001131200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10889188	hybrid			2022-12-27	WOS:000089577900090
J	Wastl, J; Duin, EC; Iuzzolino, L; Dorner, W; Link, T; Hoffmann, S; Sticht, H; Dau, H; Lingelbach, K; Maier, UG				Wastl, J; Duin, EC; Iuzzolino, L; Dorner, W; Link, T; Hoffmann, S; Sticht, H; Dau, H; Lingelbach, K; Maier, UG			Eukaryotically encoded and chloroplast-located rubredoxin is associated with photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; MEMBRANES; SPECTROSCOPY; FERREDOXIN; TRANSPORT; SPINACH; COMPLEX; ORIGIN	We analyzed a eukaryotically encoded rubredoxin from the cryptomonad Guillardia theta and identified additional domains at the N- and C-termini in comparison to known prokaryotic paralogous molecules. The cryptophytic N-terminal extension was shown to be a transit peptide for intracellular targeting of the protein to the plastid, whereas a C-terminal domain represents a membrane anchor. Rubredoxin was identified in all tested phototrophic eukaryotes. Presumably facilitated by its C-terminal extension, nucleomorph-encoded rubredoxin (nmRub) is associated with the thylakoid membrane. Association with photosystem II (PSII) was demonstrated by co-localization of nmRub and PSII membrane particles and PSII core complexes and confirmed by comparative electron paramagnetic resonance measurements. The midpoint potential of nmRub was determined as +125 mV, which is the highest redox potential of all known rubredoxins. Therefore, nmRub provides a striking example of the ability of the protein environment to tune the redox potentials of metal sites, allowing for evolutionary adaption in specific electron transport systems, as for example that coupled to the PSII pathway.	Univ Marburg, Fachbereich Biol, D-35032 Marburg, Germany; Max Planck Inst Terr Mikrobiol, D-35043 Marburg, Germany; Goethe Univ Frankfurt, Inst Biophys, D-60590 Frankfurt, Germany; Univ Bayreuth, Lehrstuhl Biopolymere, D-95440 Bayreuth, Germany; Free Univ Berlin, Fachbereich Phys, Inst Expt Phys, D-14195 Berlin, Germany	Philipps University Marburg; Max Planck Society; Goethe University Frankfurt; University of Bayreuth; Free University of Berlin	Maier, UG (corresponding author), Univ Marburg, Fachbereich Biol, Karl-von-Frisch-Str, D-35032 Marburg, Germany.	maier@mailer.uni-marburg.de	Hoffmann, Silke/H-5059-2013; Wastl, Juergen/C-6876-2016	Hoffmann, Silke/0000-0003-1414-8957; Wastl, Juergen/0000-0001-7757-8001; Sticht, Heinrich/0000-0001-5644-045X; Dau, Holger/0000-0001-6482-7494				BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Catucci L, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P973; CHEN JC, 1992, BIOCHIM BIOPHYS ACTA, V1131, P122, DOI 10.1016/0167-4781(92)90111-C; Dorner W, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1343; Eidsness MK, 1999, BIOCHEMISTRY-US, V38, P14803, DOI 10.1021/bi991661f; Fraunholz MJ, 1998, MOL GEN GENET, V260, P207, DOI 10.1007/s004380050887; GHANOTAKIS DF, 1987, BIOCHIM BIOPHYS ACTA, V891, P15, DOI 10.1016/0005-2728(87)90078-8; GIBBS SP, 1981, ANN NY ACAD SCI, V361, P193; Gilson PR, 1997, CURR OPIN GENET DEV, V7, P800, DOI 10.1016/S0959-437X(97)80043-3; HAGEN WR, 1989, EUR J BIOCHEM, V182, P523, DOI 10.1111/j.1432-1033.1989.tb14859.x; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; Iuzzolino L, 1998, BIOCHEMISTRY-US, V37, P17112, DOI 10.1021/bi9817360; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; Kyritsis P, 1998, J BIOL CHEM, V273, P15404, DOI 10.1074/jbc.273.25.15404; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Meurer J, 1998, EMBO J, V17, P5286, DOI 10.1093/emboj/17.18.5286; MEYER J, 1995, BIOCHEM BIOPH RES CO, V212, P827, DOI 10.1006/bbrc.1995.2043; MILLER AF, 1991, BIOCHIM BIOPHYS ACTA, V1056, P1, DOI 10.1016/S0005-2728(05)80067-2; Morais F, 1998, J BIOL CHEM, V273, P29315, DOI 10.1074/jbc.273.45.29315; SCHINDLER C, 1987, Z NATURFORSCH C, V42, P103; STAEHELIN LA, 1984, J CELL BIOCHEM, V24, P261, DOI 10.1002/jcb.240240307; Wastl J, 2000, FEBS LETT, V471, P191, DOI 10.1016/S0014-5793(00)01399-5; Wastl J, 2000, J BIOL CHEM, V275, P23194, DOI 10.1074/jbc.M003125200; Xiao ZG, 2000, J BIOL INORG CHEM, V5, P75, DOI 10.1007/PL00010656; Yoon KS, 1999, J BIOL CHEM, V274, P29772, DOI 10.1074/jbc.274.42.29772; Zauner S, 2000, P NATL ACAD SCI USA, V97, P200, DOI 10.1073/pnas.97.1.200	26	18	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30058	30063		10.1074/jbc.M004629200	http://dx.doi.org/10.1074/jbc.M004629200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10878021	hybrid			2022-12-27	WOS:000089577900020
J	Mitton, KP; Swain, PK; Chen, SM; Xu, SQ; Zack, DJ; Swaroop, A				Mitton, KP; Swain, PK; Chen, SM; Xu, SQ; Zack, DJ; Swaroop, A			The leucine zipper of NRL interacts with the CRX homeodomain - A possible mechanism of transcriptional synergy in rhodopsin regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEBER CONGENITAL AMAUROSIS; CONE-ROD DYSTROPHY; RAT OPSIN GENE; HOMEOBOX GENE; DNA-BINDING; PHOTORECEPTOR DIFFERENTIATION; BETA ENHANCEOSOME; CRYSTAL-STRUCTURE; UPSTREAM REGION; C-JUN	Photoreceptor-specific expression of rhodopsin is mediated by multiple cis-acting elements in the proximal promoter region. NRL (neural retina leucine zipper) and CRX (cone rod homeobox) proteins bind to the adjacent NRE and Ret-4 sites, respectively, within this region. Although NRL and CRX are each individually able to induce rhodopsin promoter activity, when expressed together they exhibit transcriptional synergy in rhodopsin promoter activation. Using the yeast two-hybrid method and glutathione S-transferase pull-down assays, we demonstrate that the leucine zipper of NRL can physically interact with CRX Deletion analysis revealed that the CRX homeodomain (CRX-HD) plays an important role in the interaction with the NRL leucine zipper. Although binding with the CRX-HD alone was weak, a strong interaction was detected when flanking regions including the glutamine-rich and the basic regions that follow the HD were included. A reciprocal deletion analysis showed that the leucine zipper of NRL is required for interaction with CRX-HD, Two disease-causing mutations in CRX-HD (R41W and R90W) that exhibit reduced DNA binding and transcriptional synergy also decrease its interaction with NRL, These studies suggest novel possibilities for protein-protein interaction between two conserved DNA-binding motifs and imply that cross-talk among distinct regulatory pathways contributes to the establishment and maintenance of photoreceptor function.	Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA; Univ Michigan, WK Kellogg Eye Ctr, Dept Human Genet, Ann Arbor, MI 48105 USA; Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Washington University (WUSTL); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Swaroop, A (corresponding author), Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, 1000 Wall St, Ann Arbor, MI 48105 USA.	swaroop@umich.edu	mitton, kenneth/Y-1974-2019	mitton, kenneth/0000-0002-4751-7440; Swaroop, Anand/0000-0002-1975-1141; Zack, Don/0000-0002-7966-1973	NATIONAL EYE INSTITUTE [R01EY011115, R01EY012543, R01EY009769] Funding Source: NIH RePORTER; NEI NIH HHS [EY11115, EY09769, EY07003, R01 EY012543] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahmad I, 1995, DEV BRAIN RES, V90, P184, DOI 10.1016/0165-3806(96)83500-0; ARTANDI S, 1993, METHODS MOL GENET, V1, P267; Bessant DAR, 1999, NAT GENET, V21, P355, DOI 10.1038/7678; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Carr A, 1999, EMBO J, V18, P1598, DOI 10.1093/emboj/18.6.1598; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chen SM, 1996, J BIOL CHEM, V271, P28549, DOI 10.1074/jbc.271.45.28549; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; DesJardin LE, 1996, INVEST OPHTH VIS SCI, V37, P154; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; Freund C, 1996, HUM MOL GENET, V5, P1471, DOI 10.1093/hmg/5.Supplement_1.1471; Freund CL, 1998, NAT GENET, V18, P311, DOI 10.1038/ng0498-311; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kimura A, 2000, J BIOL CHEM, V275, P1152, DOI 10.1074/jbc.275.2.1152; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; LEFTSIN J, 1998, NATURE, V392, P885; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Liu Q, 1996, ONCOGENE, V12, P207; Livesey FJ, 2000, CURR BIOL, V10, P301, DOI 10.1016/S0960-9822(00)00379-1; Martinez JA, 1998, BIOCHEM BIOPH RES CO, V250, P175, DOI 10.1006/bbrc.1998.9261; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Moore DD, 1995, GLOB MOB SURV; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; Morrow EM, 1998, TRENDS CELL BIOL, V8, P353, DOI 10.1016/S0962-8924(98)01341-5; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; Nie ZQ, 1996, J BIOL CHEM, V271, P2667, DOI 10.1074/jbc.271.5.2667; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; SCHNARR M, 1991, BIOCHIMIE, V73, P423, DOI 10.1016/0300-9084(91)90109-E; Swain PK, 1997, NEURON, V19, P1329, DOI 10.1016/S0896-6273(00)80423-7; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Swaroop A, 1999, HUM MOL GENET, V8, P299, DOI 10.1093/hmg/8.2.299; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; TIMMERS AM, 1993, EXP EYE RES, V56, P257, DOI 10.1006/exer.1993.1034; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TREISMAN JE, 1988, MOL CELL BIOL, V8, P1570, DOI 10.1128/MCB.8.4.1570; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Yamaguchi Y, 1998, NUCLEIC ACIDS RES, V26, P3854, DOI 10.1093/nar/26.16.3854; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4	60	167	171	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29794	29799		10.1074/jbc.M003658200	http://dx.doi.org/10.1074/jbc.M003658200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887186	hybrid			2022-12-27	WOS:000089439800084
J	Boule, JB; Rougeon, F; Papanicolaou, C				Boule, JB; Rougeon, F; Papanicolaou, C			Comparison of the two murine deoxynucleotidyltransferase terminal isoforms - A 20-amino acid insertion in the highly conserved carboxyl-terminal region modifies the thermosensitivity but not the catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAIN; NUCLEOTIDYLTRANSFERASE SUPERFAMILY; ESCHERICHIA-COLI; N-REGIONS; TRANSFERASE; TDT; EXPRESSION; IDENTIFICATION; TEMPERATURE	Terminal deoxynucleotidyltransferase (TdT) catalyzes the addition of nucleotides to 3'-hydroxyl ends of DNA strands in a template-independent manner and has been shown to add N-regions to gene segment junctions during V(D)J recombination, TdT is highly conserved in all vertebrate species, with a second isoform, characterized by a 20-amino acid insertion near the COOH-terminal end, described only in the mouse. The two murine isoforms differ in their subcellular localization, and the long isoform (TdTL) has previously been found to be unable to add N-regions, Using purified protein produced in a high level expression system in Escherichia coli, we were able to carry out detailed catalytic comparisons of these two TdT isoforms. We discovered that TdTL exhibits terminal transferase activity with kinetic parameters similar to those of the conserved TdT isoform (TdTS), We observed, however, that TdTL is inactivated at physiologic temperature but stable at lower temperatures. This thermal sensitivity of TdTL polymerase activity is not correlated with a significant change in the circular dichroism spectrum of the protein. Thus, the 20-amino acid insertion in TdTL does not affect the catalytic activity but modifies the thermosensitivity.	Inst Pasteur, Unite Genet & Biochim Dev, F-75015 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Papanicolaou, C (corresponding author), Inst Pasteur, Unite Genet & Biochim Dev, 25 Rue Dr Roux, F-75015 Paris, France.	papanico@pasteur.fr	Boulé, Jean-Baptiste/M-8200-2017	Boulé, Jean-Baptiste/0000-0002-0994-5831				Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1609, DOI 10.1093/nar/27.7.1609; BENTOLILA LA, 1995, EMBO J, V14, P4221, DOI 10.1002/j.1460-2075.1995.tb00096.x; Berson JF, 2000, J BIOL CHEM, V275, P12281, DOI 10.1074/jbc.275.16.12281; BOLLUM JF, 1974, ENZYMES, V10, P145; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Boule LB, 1998, MOL BIOTECHNOL, V10, P199, DOI 10.1007/BF02740839; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DOYEN N, 1993, NUCLEIC ACIDS RES, V21, P1187, DOI 10.1093/nar/21.5.1187; EVANS RK, 1989, BIOCHEMISTRY-US, V28, P707, DOI 10.1021/bi00428a044; EVANS RK, 1989, BIOCHEMISTRY-US, V28, P713, DOI 10.1021/bi00428a045; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hansen JD, 1997, IMMUNOGENETICS, V46, P367, DOI 10.1007/s002510050290; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; JAWORSKI CJ, 1989, NATURE, V337, P752, DOI 10.1038/337752a0; KOIWAI O, 1986, NUCLEIC ACIDS RES, V14, P5777, DOI 10.1093/nar/14.14.5777; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LEE A, 1994, J IMMUNOL, V152, P4500; Mahajan KN, 1999, P NATL ACAD SCI USA, V96, P13926, DOI 10.1073/pnas.96.24.13926; PETERSON RC, 1985, J BIOL CHEM, V260, P495; PETERSON RC, 1984, P NATL ACAD SCI-BIOL, V81, P4363, DOI 10.1073/pnas.81.14.4363; YANG BL, 1994, J BIOL CHEM, V269, P11859; YANG BL, 1995, NUCLEIC ACIDS RES, V23, P2041, DOI 10.1093/nar/23.11.2041	26	13	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28984	28988		10.1074/jbc.M005544200	http://dx.doi.org/10.1074/jbc.M005544200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878023	hybrid			2022-12-27	WOS:000089330700084
J	Kubota, H; Yokota, S; Yanagi, H; Yura, T				Kubota, H; Yokota, S; Yanagi, H; Yura, T			Transcriptional regulation of the mouse cytosolic chaperonin subunit gene Ccta/t-complex polypeptide 1 by selenocysteine tRNA gene transcription activating factor family zinc finger proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; EUKARYOTIC CYTOSOL; ENDOPLASMIC-RETICULUM; STAF; EXPRESSION; TCP-1; IDENTIFICATION; REQUIRES; ACTIN; MOTIF	The chaperonin containing t-complex polypeptide 1 (CCT) is a molecular chaperone assisting in the folding of proteins in eukaryotic cytosol, and the Ccta (encoding the alpha subunit of CCT)lt-complex polypeptide 1 gene encodes the cw subunit of CCT. We show here that transcription of the mouse Ccta gene is regulated by selenocysteine tRNA gene transcription activating factor (Staf) family zinc-finger transcription factors ZNF143 and ZNF76. Reporter gene assay using HeLa cells indicated that the Ccta gene promoter contains two 18-base pair-long cis-acting elements with similar sequences at -70 and -20 base pairs (designated CCT or subunit gene transcription activating element 1 (CAE1) and CAE2, respectively). By yeast one-hybrid screening of CAE1-binding factors, we isolated human ZNF143, which is known to activate transcription of selenocysteine tRNA and small nuclear RNA genes. DNA binding domains of ZNF143 and ZNF76 produced in E. coli recognized CAE1 and CAE2 elements in electrophoretic mobility shift assay. HeLa cell nuclear extract contained a protein that specifically binds to CAE1 and CAE2 and recognized by anti-ZNF143 antibody. Transcription from a minimal Ccta promoter containing CAE2 element in HeLa cells was enhanced by overexpression of full-length ZNF143 and ZNF76 but inhibited by that of their DNA binding domains alone. These results demonstrate that the Staf family proteins control transcription of at least one of the chaperone-encoding genes besides that of tRNA and small nuclear RNA genes. These RNA and chaperone genes are suggested to be coregulated to facilitate synthesis of mature proteins during active cell growth.	HSP Res Inst, Shimogyo Ku, Kyoto 6008813, Japan		Kubota, H (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Sakyo Ku, Kawahara Cho, Kyoto 6068397, Japan.		Yokota, Shin-ichi/K-8139-2019	Yokota, Shin-ichi/0000-0002-0831-3429				Adachi K, 1998, J BIOL CHEM, V273, P8598, DOI 10.1074/jbc.273.15.8598; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Kubota H, 1999, FEBS LETT, V461, P125, DOI 10.1016/S0014-5793(99)01437-4; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; Kubota H, 1999, EUR J BIOCHEM, V262, P492, DOI 10.1046/j.1432-1327.1999.00405.x; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; KUBOTA H, 1995, GENE, V154, P231, DOI 10.1016/0378-1119(94)00880-2; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; Llorca O, 1999, NATURE, V402, P693, DOI 10.1038/45294; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998; MYSLINSKI E, 1992, NUCLEIC ACIDS RES, V20, P203, DOI 10.1093/nar/20.2.203; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; RAGOUSSIS J, 1992, GENOMICS, V14, P673, DOI 10.1016/S0888-7543(05)80167-3; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; Schuster C, 1998, MOL CELL BIOL, V18, P2650, DOI 10.1128/MCB.18.5.2650; SCHUSTER C, 1995, EMBO J, V14, P3777, DOI 10.1002/j.1460-2075.1995.tb00047.x; Stoldt V, 1996, YEAST, V12, P523, DOI 10.1002/(SICI)1097-0061(199605)12:6<523::AID-YEA962>3.3.CO;2-3; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; Willison Keith R., 1996, P107, DOI 10.1016/B978-012237455-5/50006-3; WILLISON KR, 1990, GENET RES, V56, P193, DOI 10.1017/S0016672300035291; Won KA, 1998, MOL CELL BIOL, V18, P7584, DOI 10.1128/MCB.18.12.7584; Yokota S, 2000, EUR J BIOCHEM, V267, P1658, DOI 10.1046/j.1432-1327.2000.01157.x; Yokota S, 1999, J BIOL CHEM, V274, P37070, DOI 10.1074/jbc.274.52.37070; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	32	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28641	28648		10.1074/jbc.M005009200	http://dx.doi.org/10.1074/jbc.M005009200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893243	hybrid			2022-12-27	WOS:000089330700042
J	Kamohara, M; Takasaki, J; Matsumoto, M; Saito, T; Ohishi, T; Ishii, H; Furuichi, K				Kamohara, M; Takasaki, J; Matsumoto, M; Saito, T; Ohishi, T; Ishii, H; Furuichi, K			Molecular cloning and characterization of another leukotriene B-4 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE D4 RECEPTOR; IN-VITRO; CDNA CLONING; IDENTIFICATION; INFLAMMATION; ACTIVATION; EXPRESSION; POTENT; EOSINOPHILS; DISEASE	Leukotriene B-4 is a potent lipid mediator known to be implicated mainly in inflammatory actions. Previous pharmacological studies indicated the existence of only one class of G protein-coupled receptor for leukotriene B-4, for which a candidate gene, namely BLT, had been identified. Here we report the isolation of another gene encoding a functional G protein-coupled receptor for leukotriene B-4, named JULF2. JULF2 is a novel G protein-coupled receptor of 358 amino acids that shares 36.6% amino acid identity with human BLT, According to genomic information, the JULF2 gene is located on the chromosome 14, about 4 kilobases upstream of the BLT gene. During screening of endogenous ligands for JULF2, we found that leukotriene B-4 induced inhibition of forskolin-stimulated cAMP accumulation in Chinese hamster ovary cells, stably expressing JULF2, Additionally, Chinese hamster ovary cells expressing exogenous JULF2 showed chemotactic responses with leukotriene B-4 in a pertussis toxin-sensitive manner. A large amount of JULF2 mRNA was detected in the human spleen and the peripheral blood leukocytes. Furthermore, JULF2 mRNA was expressed in mononuclear lymphocytes, in which BLT mRNA was barely detected. The discovery of this second leukotriene B-4 receptor will eventually lead to a better understanding of the classification of leukotriene B-4 receptors and reconsideration of the pathophysiological role of leukotriene B-4.	Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Labs, Tsukuba, Ibaraki 3058585, Japan	Astellas Pharmaceuticals	Kamohara, M (corresponding author), Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Labs, 21 Miyukigaoka, Tsukuba, Ibaraki 3058585, Japan.	kamohara@yamanouchi.co.jp	Matsumoto, Mitsuyuki/G-3207-2012	Matsumoto, Mitsuyuki/0000-0002-1172-2354; Saito, Tetsu/0000-0002-9045-6743				Ali H, 1997, MED CLIN N AM, V81, P1, DOI 10.1016/S0025-7125(05)70503-4; Boie Y, 1999, EUR J PHARMACOL, V380, P203, DOI 10.1016/S0014-2999(99)00514-2; DEGIULIO R, 1993, ANN NY ACAD SCI, V685, P614, DOI 10.1111/j.1749-6632.1993.tb35925.x; EVANS JF, 1987, BIOCHIM BIOPHYS ACTA, V917, P406, DOI 10.1016/0005-2760(87)90119-6; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Gao JL, 1996, BIOCHEM BIOPH RES CO, V223, P679, DOI 10.1006/bbrc.1996.0955; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Gladue RP, 1996, J EXP MED, V183, P1893, DOI 10.1084/jem.183.4.1893; GOLDMAN DW, 1984, J ALLERGY CLIN IMMUN, V74, P373, DOI 10.1016/0091-6749(84)90133-7; GOLDMAN DW, 1984, J EXP MED, V159, P1027, DOI 10.1084/jem.159.4.1027; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; Huang WW, 1998, J EXP MED, V188, P1063, DOI 10.1084/jem.188.6.1063; Lynch KR, 1999, NATURE, V399, P789; Masuda K, 1999, BIOCHEM J, V342, P79, DOI 10.1042/0264-6021:3420079; Matsumoto M, 2000, GENE, V248, P183, DOI 10.1016/S0378-1119(00)00123-2; Matsumoto M, 1996, J NEUROCHEM, V66, P915; Matsumoto M, 1996, J BIOL CHEM, V271, P27217, DOI 10.1074/jbc.271.44.27217; MATSUMOTO M, 1995, MOL BRAIN RES, V29, P157, DOI 10.1016/0169-328X(94)00245-A; Medhurst AD, 2000, J NEUROSCI METH, V98, P9, DOI 10.1016/S0165-0270(00)00178-3; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nohgawa M, 1997, J LEUKOCYTE BIOL, V62, P203, DOI 10.1002/jlb.62.2.203; PAYAN DG, 1984, P NATL ACAD SCI-BIOL, V81, P3501, DOI 10.1073/pnas.81.11.3501; POST TW, 1995, J IMMUNOL, V155, P5299; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; SHARON P, 1984, GASTROENTEROLOGY, V86, P453; Showell HJ, 1996, BRIT J PHARMACOL, V117, P1127, DOI 10.1111/j.1476-5381.1996.tb16706.x; SHOWELL HJ, 1995, J PHARMACOL EXP THER, V273, P176; Toda A, 1999, BIOCHEM BIOPH RES CO, V262, P806, DOI 10.1006/bbrc.1999.1284; Turner CR, 1996, J CLIN INVEST, V97, P381, DOI 10.1172/JCI118426; YE RD, 1992, BIOCHEM BIOPH RES CO, V184, P582, DOI 10.1016/0006-291X(92)90629-Y; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	36	106	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27000	27004						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10889186				2022-12-27	WOS:000089144800045
J	Taggart, C; Cervantes-Laurean, D; Kim, G; McElvaney, NG; Wehr, N; Moss, J; Levine, RL				Taggart, C; Cervantes-Laurean, D; Kim, G; McElvaney, NG; Wehr, N; Moss, J; Levine, RL			Oxidation of either methionine 351 or methionine 358 in alpha(1)-antitrypsin causes loss of anti-neutrophil elastase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-PROTEINASE INHIBITOR; CYSTIC-FIBROSIS; SERINE PROTEINASES; ESCHERICHIA-COLI; REACTIVE-CENTER; ALPHA-1-ANTITRYPSIN; EMPHYSEMA; RESIDUES; DEFICIENCY; INACTIVATION	Hydrogen peroxide is a component of cigarette smoke known to be essential for inactivation of alpha(1)-antitrypsin, the primary inhibitor of neutrophil elastase, To establish the molecular basis of the inactivation of alpha(1)-antitrypsin, we determined the sites oxidized by hydrogen peroxide, Two of the nine methionines were particularly susceptible to oxidation, One was methionine 358, whose oxidation was known to cause loss of antielastase activity. The other, methionine 351, was as susceptible to oxidation as methionine 358, Its oxidation also resulted in loss of anti-elastase activity, an effect not previously recognized, The equal susceptibility of methionine 358 and methionine 351 to oxidation was confirmed by mass spectrometry. To verify this finding, we produced recombinant alpha(1)-antitrypsins in which one or both of the susceptible methionines were mutated to valine, M351V and M358V were not as rapidly inactivated as wild-type alpha 1-antitrypsin, but only the double mutant M351V/M358V was markedly resistant to oxidative inactivation. We suggest that inactivation of alpha(1)-antitrypsin by oxidation of either methionine 351 or 358 provides a mechanism for regulation of its activity at sites of inflammation.	NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; Royal Coll Surgeons Ireland, Div Pulm, Dublin 9, Ireland; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Royal College of Surgeons - Ireland; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Levine, RL (corresponding author), NHLBI, Biochem Lab, NIH, Bldg 3,Rm 106,MSC 0320, Bethesda, MD 20892 USA.	rlevine@nih.gov	Taggart, Clifford C/G-4492-2014; McElvaney, Noel/A-6809-2010; Levine, Rodney L/D-9885-2011	mcelvaney, Noel/0000-0002-0152-4370; Taggart, Clifford/0000-0002-9930-2978	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000225, Z01HL000225] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALPER CA, 1980, CLIN IMMUNOL IMMUNOP, V16, P84, DOI 10.1016/0090-1229(80)90169-5; APFFEL A, 1995, J CHROMATOGR A, V712, P177, DOI 10.1016/0021-9673(95)00175-M; APFFEL A, 1994, PROTEIN SCI, V3, P99; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANTLY ML, 1991, CHEST, V100, P703, DOI 10.1378/chest.100.3.703; BRAUN J, 1994, EUR RESPIR J, V7, P127, DOI 10.1183/09031936.94.07010127; BROT N, 1983, ARCH BIOCHEM BIOPHYS, V223, P271, DOI 10.1016/0003-9861(83)90592-1; Cabiscol E, 1996, P NATL ACAD SCI USA, V93, P4170, DOI 10.1073/pnas.93.9.4170; CARP H, 1982, P NATL ACAD SCI-BIOL, V79, P2041, DOI 10.1073/pnas.79.6.2041; CARP H, 1983, AM REV RESPIR DIS, V127, P301; COURTNEY M, 1985, NATURE, V313, P149, DOI 10.1038/313149a0; Elliott PR, 1996, NAT STRUCT BIOL, V3, P910, DOI 10.1038/nsb1196-910; EVANS MD, 1991, CHEM-BIOL INTERACT, V79, P151, DOI 10.1016/0009-2797(91)90079-M; FLISS H, 1983, P NATL ACAD SCI-BIOL, V80, P7160, DOI 10.1073/pnas.80.23.7160; GADEK JE, 1979, SCIENCE, V206, P1315, DOI 10.1126/science.316188; GADEK JE, 1981, J CLIN INVEST, V68, P889, DOI 10.1172/JCI110344; GADEK JE, 1983, METABOLIC BASIS INHE, P1450; GONIAS SL, 1988, J BIOL CHEM, V263, P393; Gros E., 1967, METHOD ENZYMOL, V11, P238; HALL PK, 1992, BIOCHIM BIOPHYS ACTA, V1121, P325, DOI 10.1016/0167-4838(92)90164-9; JANOFF A, 1977, AM REV RESPIR DIS, V116, P65; JOHNSON D, 1978, J BIOL CHEM, V253, P7142; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; KWON KS, 1995, BBA-PROTEIN STRUCT M, V1247, P179, DOI 10.1016/0167-4838(94)00224-5; KWON KS, 1994, J BIOL CHEM, V269, P9627; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; Lee KN, 1996, NAT STRUCT BIOL, V3, P497, DOI 10.1038/nsb0696-497; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; LEVINE RL, 1982, BIOCHEMISTRY-US, V21, P2600, DOI 10.1021/bi00540a004; Luisetti M, 1996, CHEST, V110, pS278, DOI 10.1378/chest.110.6_Supplement.278S; MAIER KL, 1989, FEBS LETT, V250, P221, DOI 10.1016/0014-5793(89)80725-2; MATHESON NR, 1981, BIOCHEMISTRY-US, V20, P331, DOI 10.1021/bi00505a016; MCELVANEY NG, 1992, J CLIN INVEST, V90, P1296, DOI 10.1172/JCI115994; MCELVANEY NG, 1991, LANCET, V337, P392, DOI 10.1016/0140-6736(91)91167-S; McElvaney NG, 1997, LUNG SCI FDN, P2205; MCELVANEY NG, 1996, AM J RESP CRIT CARE, V153, P737; MCGUIRE WW, 1982, J CLIN INVEST, V69, P543, DOI 10.1172/JCI110480; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; MORENO JJ, 1992, CHEM RES TOXICOL, V5, P425, DOI 10.1021/tx00027a017; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; OGDEN BE, 1984, AM REV RESPIR DIS, V130, P817; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; REDDY VY, 1994, J BIOL CHEM, V269, P4683; ROSENBERG S, 1984, NATURE, V312, P77, DOI 10.1038/312077a0; ROUM JH, 1993, J APPL PHYSIOL, V75, P2419, DOI 10.1152/jappl.1993.75.6.2419; Ryu SE, 1996, STRUCTURE, V4, P1181, DOI 10.1016/S0969-2126(96)00126-8; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SHECHTER Y, 1975, BIOCHEMISTRY-US, V14, P4497, DOI 10.1021/bi00691a025; STONE PJ, 1983, CLIN CHEST MED, V4, P405; TRAVIS J, 1986, BIOL CHEM H-S, V367, P853, DOI 10.1515/bchm3.1986.367.2.853; TRAVIS J, 1985, J BIOL CHEM, V260, P4384; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704	53	253	265	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27258	27265						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10867014				2022-12-27	WOS:000089144800079
J	Premont, RT; Claing, A; Vitale, N; Perry, SJ; Lefkowitz, RJ				Premont, RT; Claing, A; Vitale, N; Perry, SJ; Lefkowitz, RJ			The GIT family of ADP-ribosylation factor GTPase-activating proteins - Functional diversity of GIT2 through alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR KINASES; PHOSPHOLIPASE-D; ARF PROTEINS; IDENTIFICATION; LOCALIZATION; PURIFICATION; BINDS; MOTIF; SRC; PAK	We recently characterized a novel protein, GIT1, that interacts with G protein-coupled receptor kinases and possesses ADP-ribosylation factor (ARF) GTPase-activating protein activity. A second ubiquitously expressed member of the GIT protein family, GIT2, has been identified in data base searches. GIT2 undergoes extensive alternative splicing and exists in at least 10 and potentially as many as 33 distinct forms. The longest form of GIT2 is colinear with GIT1 and shares the same domain structure, whereas one major splice variant prominent in immune tissues completely lacks the carboxyl-terminal domain. The other 32 potential variants arise from the independent alternative splicing of five internal regions in the center of the molecule but share both the amino-terminal ARF GTPase-activating protein domain and carboxyl-terminal domain. Both the long and short carboxyl-terminal variants of GIT2 are active as GTPase-activating proteins for ARF1, and both also interact with G: protein-coupled receptor kinase 2 and with pal-activated kinase-interacting exchange factors complexed with pal-activated kinase but not with paxillin. Cellular overexpression of the longest variant of GIT2 leads to inhibition of beta(2)-adrenergic receptor sequestration, whereas the shortest splice variant appears inactive. Although GIT2 shares many properties with GIT1, it also exhibits both structural and functional diversity due to tissue-specific alternative splicing.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Ctr Neurochim, INSERM U 338, F-67084 Strasbourg, France	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Institut National de la Sante et de la Recherche Medicale (Inserm)	Premont, RT (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3083, Durham, NC 27710 USA.	richard.premont@duke.edu	Lefkowitz, Robert/AAW-2649-2021; Vitale, Nicolas/G-5967-2014	Vitale, Nicolas/0000-0002-4752-4907; Premont, Richard/0000-0002-8053-5026	NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreev J, 1999, MOL CELL BIOL, V19, P2338; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; King FJ, 1999, MOL CELL BIOL, V19, P2330; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; Mandiyan V, 1999, EMBO J, V18, P6890, DOI 10.1093/emboj/18.24.6890; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; Oh WK, 1997, BIOCHEM BIOPH RES CO, V235, P794, DOI 10.1006/bbrc.1997.6875; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Vitale N, 2000, J BIOL CHEM, V275, P13901, DOI 10.1074/jbc.275.18.13901	26	114	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22373	22380		10.1074/jbc.275.29.22373	http://dx.doi.org/10.1074/jbc.275.29.22373			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10896954	hybrid			2022-12-27	WOS:000088363800084
J	MacLachlan, TK; Dash, BC; Dicker, DT; El Deiry, WS				MacLachlan, TK; Dash, BC; Dicker, DT; El Deiry, WS			Repression of BRCA1 through a feedback loop involving p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	91st Annual Meeting of the American-Association-for-Cancer-Research	APR 01-05, 2000	SAN FRANCISCO, CA	Amer Assoc Canc Res			DNA-DAMAGE RESPONSE; WILD-TYPE P53; CELL-CYCLE; CANCER-CELLS; TRANSCRIPTIONAL REPRESSION; EXPRESSION; GENE; PHOSPHORYLATION; ASSOCIATION; RADIATION	The BRCA1 and p53 tumor suppressors have been shown to interact and cooperate to activate transcription of p53-responsive genes. In this study, we show that BRCA1 is initially up-regulated, followed by a reduction to below basal levels in response to treatment with the DNA-damaging agents adriamycin and mitomycin C, and that the reduction of BRCA1 expression is dependent on the presence of wild-type p53. Elimination of p53 by expression of human papilloma virus E6 resulted in an inability to down-regulate BRCA1 in response to adriamycin. Ectopic expression of p53 resulted in a rapid decrease in BRCA1 protein and RNA levels and BRCA1 promoter-driven luciferase activity even in null p21 cells deficient in p53-dependent G(1) arrest. ATM(-/-) lymphoblastoid cells were deficient in their ability to reduce BRCA1 protein in response to DNA damage, whereas the wild-type counterparts reduced BRCA1 protein levels after exposure to adriamycin. These results, in conjunction with others, suggest a loop wherein BRCA1 initially participates in accumulation of p53 protein, whereas later p53 acts to reduce BRCA1 expression.	Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Canc, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania	El Deiry, WS (corresponding author), Univ Penn, Sch Med, Dept Med, CRB 437A,415 Curie Blvd, Philadelphia, PA 19104 USA.	weldeir@hhmi.upenn.edu	El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266				Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Blagosklonny MV, 1998, INT J CANCER, V75, P933, DOI 10.1002/(SICI)1097-0215(19980316)75:6<933::AID-IJC17>3.0.CO;2-3; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan SJ, 1998, INT J CANCER, V77, P600, DOI 10.1002/(SICI)1097-0215(19980812)77:4<600::AID-IJC21>3.0.CO;2-8; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Irminger-Finger I, 1999, BIOL CHEM, V380, P117, DOI 10.1515/BC.1999.019; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MIYASHITA T, 1994, CANCER RES, V54, P3131; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu GS, 1996, CLIN CANCER RES, V2, P623; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	43	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31869	31875		10.1074/jbc.M003338200	http://dx.doi.org/10.1074/jbc.M003338200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	363VT	10884389	hybrid			2022-12-27	WOS:000089858900046
J	Dubuisson, J; Duvet, S; Meunier, JC; De Beeck, AO; Cacan, R; Wychowski, C; Cocquerel, L				Dubuisson, J; Duvet, S; Meunier, JC; De Beeck, AO; Cacan, R; Wychowski, C; Cocquerel, L			Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCOSYLATION; PRIMARY STRUCTURAL REQUIREMENTS; RECOMBINANT VACCINIA VIRUS; DISULFIDE BOND FORMATION; ENDOPLASMIC-RETICULUM; CORE-GLYCOSYLATION; PLASMINOGEN-ACTIVATOR; IMPORTANT DETERMINANT; GLYCOPROTEIN E1; INSECT CELLS	The addition of N-linked oligosaccharides to Asn-X-(Ser/Thr) sites is catalyzed by the oligosaccharyltransferase, an enzyme closely associated with the translocon and generally thought to have access only to nascent chains as they emerge from the ribosome. However, the presence of the sequon does not automatically ensure core glycosylation because many proteins contain sequons that remain either nonglycosylated or glycosylated to a variable extent. In this study, hepatitis C virus (HCV) envelope protein E1 was used as a model to study the efficiency of N-glycosylation. HCV envelope proteins, E1 and E2, were released from a polyprotein precursor after cleavage by host signal peptidase(s). When expressed alone, E1 was not efficiently glycosylated. However, E1 glycosylation was improved when expressed as a polyprotein including full-length or truncated forms of E2. These data indicate that glycosylation of E1 is dependent on the presence of polypeptide sequences located downstream of E1 on HCV polyprotein.	Inst Pasteur, Inst Biol Lille, CNRS, Unite Mixte Rech 8526, F-59021 Lille, France; Univ Sci & Tech Lille Flandres Artois, CNRS, UMR8576, F-59655 Villeneuve Dascq, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Dubuisson, J (corresponding author), Inst Biol Lille, CNRS, UMR8526, Equipe Hepatitis C, 1 Rue Calmette,BP447, F-59021 Lille, France.		Cocquerel, Laurence/P-1951-2016; Dubuisson, Jean/E-6813-2016	Cocquerel, Laurence/0000-0002-2136-5178; Dubuisson, Jean/0000-0003-1626-7693				ALLEN S, 1995, J BIOL CHEM, V270, P4797, DOI 10.1074/jbc.270.9.4797; BAUSE E, 1982, BIOCHEM J, V203, P761, DOI 10.1042/bj2030761; BAUSE E, 1979, FEBS LETT, V108, P341, DOI 10.1016/0014-5793(79)80559-1; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BULLEID NJ, 1992, BIOCHEM J, V286, P275, DOI 10.1042/bj2860275; Capellari S, 1999, J BIOL CHEM, V274, P34846, DOI 10.1074/jbc.274.49.34846; Choukhi A, 1998, J VIROL, V72, P3851, DOI 10.1128/JVI.72.5.3851-3858.1998; Cocquerel L, 2000, J VIROL, V74, P3623, DOI 10.1128/JVI.74.8.3623-3633.2000; Cocquerel L, 1999, J VIROL, V73, P2641, DOI 10.1128/JVI.73.4.2641-2649.1999; Dubuisson J, 2000, CURR TOP MICROBIOL, V242, P135; Dubuisson J, 1996, J VIROL, V70, P778, DOI 10.1128/JVI.70.2.778-786.1996; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FournillierJacob A, 1996, J GEN VIROL, V77, P1055, DOI 10.1099/0022-1317-77-5-1055; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Holst B, 1996, EMBO J, V15, P3538, DOI 10.1002/j.1460-2075.1996.tb00723.x; IMPERIALI B, 1991, BIOCHEMISTRY-US, V30, P4374, DOI 10.1021/bi00232a002; IMPERIALI B, 1992, J AM CHEM SOC, V114, P7042; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KIENY MP, 1984, NATURE, V312, P163, DOI 10.1038/312163a0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LANFORD RE, 1993, VIROLOGY, V197, P225, DOI 10.1006/viro.1993.1583; LEHLE L, 1984, BIOCHIM BIOPHYS ACTA, V799, P246, DOI 10.1016/0304-4165(84)90267-8; LIVI GP, 1991, J BIOL CHEM, V266, P15348; Marshall R D, 1974, Biochem Soc Symp, P17; MATSUURA Y, 1992, J VIROL, V66, P1425, DOI 10.1128/JVI.66.3.1425-1431.1992; Mellquist JL, 1998, BIOCHEMISTRY-US, V37, P6833, DOI 10.1021/bi972217k; Meunier JC, 1999, J GEN VIROL, V80, P887, DOI 10.1099/0022-1317-80-4-887; Michalak JP, 1997, J GEN VIROL, V78, P2299, DOI 10.1099/0022-1317-78-9-2299; Nilsson I, 2000, J BIOL CHEM, V275, P17338, DOI 10.1074/jbc.M002317200; NILSSON I, 1993, J BIOL CHEM, V268, P5798; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RICE CM, 1996, FIELDS VIROLOGY, P931; Schroder K, 1999, EMBO J, V18, P4804, DOI 10.1093/emboj/18.17.4804; SHAKINESHLEMAN SH, 1992, J BIOL CHEM, V267, P10690; SHAKINESHLEMAN SH, 1993, BIOCHEMISTRY-US, V32, P9465, DOI 10.1021/bi00087a026; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; [No title captured]	45	47	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30605	30609		10.1074/jbc.M004326200	http://dx.doi.org/10.1074/jbc.M004326200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10882734	hybrid			2022-12-27	WOS:000089577900094
J	Becker, MN; Diamond, G; Verghese, MW; Randell, SH				Becker, MN; Diamond, G; Verghese, MW; Randell, SH			CD14-dependent lipopolysaccharide-induced ss-defensin-2 expression in human tracheobronchial epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; HUMAN AIRWAY EPITHELIA; FACTOR-KAPPA-B; BETA-DEFENSIN; GENE-EXPRESSION; ANTIMICROBIAL PEPTIDE; HUMAN BETA-DEFENSIN-2; CELL ACTIVATION; FAMILY; HBD-1	The induction of host antimicrobial molecules following binding of pathogen components to pattern recognition receptors such as CD14 and the Toll-like receptors (TLRs) is a key feature of innate immunity. The human airway epithelium is an important environmental interface, but LPS recognition pathways have not been determined. We hypothesized that LPS would trigger beta-defensin (hBD2) mRNA in human tracheobronchial epithelial (hTBE) cells through a CD14-dependent mechanism, ultimately activating NF-kappa B. An average 3-fold increase in hBD2 mRNA occurs 24 h after LPS challenge of hTBE cells. For the first time, we demonstrate the presence of CD14 mRNA and cell surface protein in hTBE cells and show that CD14 neutralization abolishes LPS induction of hBD2 mRNA. Furthermore, we demonstrate TLR mRNA in hTBE cells and NF-kappa B activation following LPS. Thus, LPS induction of hBD2 in hTBE cells requires CD14, which may complex with a TLR to ultimately activate NF-kappa B.	Univ N Carolina, Sch Med, Dept Med, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Anat Cell Biol & Injury Sci, Newark, NJ 07103 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center	Randell, SH (corresponding author), Univ N Carolina, Cyst Fibrosis Ctr, 4006 Thurston Bowles,CB 7248, Chapel Hill, NC 27599 USA.				NHLBI NIH HHS [HL53400] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Bernacki SH, 1999, AM J RESP CELL MOL, V20, P595, DOI 10.1165/ajrcmb.20.4.3442; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Diamond G, 2000, IMMUNOL REV, V173, P27, DOI 10.1034/j.1600-065X.2000.917304.x; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; DIAMOND G, 1993, P NATL ACAD SCI USA, V90, P4596, DOI 10.1073/pnas.90.10.4596; Diamond G, 2000, INFECT IMMUN, V68, P113, DOI 10.1128/IAI.68.1.113-119.2000; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEARNS C, 1995, J EXP MED, V181, P857, DOI 10.1084/jem.181.3.857; Fraser IP, 1998, SEMIN IMMUNOL, V10, P363, DOI 10.1006/smim.1998.0141; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Heine H, 1999, J IMMUNOL, V162, P6971; Kastenbauer S, 1999, INFECT IMMUN, V67, P1553; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Krisanaprakornkit S, 1998, INFECT IMMUN, V66, P4222; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Liu L, 1998, GENE, V222, P237, DOI 10.1016/S0378-1119(98)00480-6; MARCHANT A, 1992, EUR J IMMUNOL, V22, P1663, DOI 10.1002/eji.1830220650; Mathews M, 1999, INFECT IMMUN, V67, P2740, DOI 10.1128/IAI.67.6.2740-2745.1999; McNamara NA, 1999, EXP EYE RES, V69, P483, DOI 10.1006/exer.1999.0722; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; MEDZHITOV R, 1997, NATURE, V388, P397; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; O'Neil DA, 1999, J IMMUNOL, V163, P6718; Pickles RJ, 1998, J VIROL, V72, P6014, DOI 10.1128/JVI.72.7.6014-6023.1998; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pugin J, 1998, INFECT IMMUN, V66, P1174, DOI 10.1128/IAI.66.3.1174-1180.1998; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Schottelius AJG, 1999, J BIOL CHEM, V274, P31868, DOI 10.1074/jbc.274.45.31868; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Wu LP, 1998, NATURE, V392, P93, DOI 10.1038/32195; Yang RB, 1999, J IMMUNOL, V163, P639; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Young RS, 1998, J PHARM PHARMACOL, V50, P11, DOI 10.1111/j.2042-7158.1998.tb03299.x; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4; ZIEGLERHEITBROCK HWL, 1994, J BIOL CHEM, V269, P17001	48	259	278	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29731	29736		10.1074/jbc.M000184200	http://dx.doi.org/10.1074/jbc.M000184200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882713	Green Published, hybrid			2022-12-27	WOS:000089439800074
J	Huang, XF; Van, LT				Huang, XF; Van, LT			Molecular characterization of a first human 3(alpha ->beta)-hydroxysteroid epimerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOSE 4'-EPIMERASE; RETINOL DEHYDROGENASE; DEFICIENCY GALACTOSEMIA; CLONING; CDNA; IDENTIFICATION; OXIDATION; GENE; RAT; 17-BETA-HYDROXYSTEROID-DEHYDROGENASE	In this report, we describe the isolation and characterization of a cDNA encoding an enzyme that exhibits catalytic characteristics of a 3(alpha-->beta)-hydroxysteroid epimerase (3(alpha-->beta)-HSE). The enzyme overexpressed in human 293 embryonic kidney cells transforms androsterone into epi-androsterone in two steps: the oxidation of androsterone to 5 alpha-androstane-3,17-dione, followed by the reduction of the latter to epi-androsterone. The reverse reaction, 3(beta-->alpha)-hydroxysteroid epimeration, is approximately 10-fold weaker. These results are confirmed by V-max/K-m determination, which shows that the enzyme catalyzes the oxidation of androsterone to 5 alpha-androstane-3,17-dione and the reduction of 5 alpha-androstane-3,17-dione to epi-androsterone more efficiently than the reverse reactions. The selective catalysis of the reaction following the 3(alpha-->beta) direction is also observed in intact transfected cells in culture, which better reflect physiological conditions. In vitro assays reveal that the recombinant enzyme prefers NAD(+) and NADH as cofactors and could recognize both C-19 and C-21 3 alpha-hydroxysteroids as substrates, DNA sequence analysis predicts a protein of 317 amino acids. Tissue distribution analysis using RT-PCR reveals that the mRNA of the enzyme is expressed in various tissues, including liver, brain, prostate, adrenal, and uterus, with the most abundant expression in the liver. Because active hydroxysteroids generally exert their effect in a stereospecific manner, 3(alpha-->beta)-HSE could thus potentially play an important role in regulating the biological activities of various steroids.	Univ Laval, Med Ctr, Oncol & Mol Endocrinol Res Ctr, Quebec City, PQ G1V 4G2, Canada	Laval University	Van, LT (corresponding author), Univ Laval, Med Ctr, Oncol & Mol Endocrinol Res Ctr, 2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.							Alano A, 1998, J INHERIT METAB DIS, V21, P341, DOI 10.1023/A:1005342306080; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; Calogero AE, 1998, J ENDOCRINOL, V158, P121, DOI 10.1677/joe.0.1580121; Carnell A J, 1999, Adv Biochem Eng Biotechnol, V63, P57; Chai XY, 1996, GENE, V169, P219, DOI 10.1016/0378-1119(95)00833-0; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; DAHM K, 1968, BIOCHIM BIOPHYS ACTA, V159, P377, DOI 10.1016/0005-2744(68)90086-7; DAUDE N, 1995, BIOCHEM MOL MED, V56, P1, DOI 10.1006/bmme.1995.1048; Dufort I, 1999, ENDOCRINOLOGY, V140, P568, DOI 10.1210/en.140.2.568; ECKSTEIN B, 1970, ENDOCRINOLOGY, V89, P347; ERTESVAG H, 1995, MOL MICROBIOL, V16, P719, DOI 10.1111/j.1365-2958.1995.tb02433.x; GENAZZANI AR, 1995, EUR J ENDOCRINOL, V133, P375, DOI 10.1530/eje.0.1330375; Gough WH, 1998, J BIOL CHEM, V273, P19778, DOI 10.1074/jbc.273.31.19778; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Jurukovski V, 1999, MOL GENET METAB, V67, P62, DOI 10.1006/mgme.1999.2840; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; KINGSTON RE, 1991, CURRENT PROTOCOLS MO; LuuThe V, 1995, J STEROID BIOCHEM, V55, P581, DOI 10.1016/0960-0760(95)00209-X; Maceratesi P, 1998, MOL GENET METAB, V63, P26, DOI 10.1006/mgme.1997.2645; Mahendroo MS, 1996, MOL ENDOCRINOL, V10, P380, DOI 10.1210/me.10.4.380; MAYER RT, 1979, STEROIDS, V34, P555, DOI 10.1016/S0039-128X(79)80016-1; MEIERDIETER U, 1990, J BIOL CHEM, V265, P13490; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; MONDER C, 1980, J BIOL CHEM, V255, P7192; Rheault P, 1999, BBA-GENE STRUCT EXPR, V1447, P17, DOI 10.1016/S0167-4781(99)00106-2; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Siu-Caldera ML, 1999, BONE, V24, P457, DOI 10.1016/S8756-3282(99)00019-8; SIUCALDERA ML, 1998, J BONE MINER RES S, V23, pS426; Smith SS, 1998, NATURE, V392, P926, DOI 10.1038/31948; Wohlers TM, 1999, AM J HUM GENET, V64, P462, DOI 10.1086/302263	31	61	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29452	29457		10.1074/jbc.M000562200	http://dx.doi.org/10.1074/jbc.M000562200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896656	hybrid			2022-12-27	WOS:000089439800038
J	Arrizubieta, MJ; Polaina, J				Arrizubieta, MJ; Polaina, J			Increased thermal resistance and modification of the catalytic properties of a beta-glucosidase by random mutagenesis and in vitro recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-SEQUENCE SIMILARITIES; SITE-DIRECTED MUTAGENESIS; BINDING PROTEIN HU; BACILLUS-POLYMYXA; GLYCOSYL HYDROLASES; CRYSTAL-STRUCTURE; T4 LYSOZYME; ESCHERICHIA-COLI; SULFOLOBUS-SOLFATARICUS; SWISS-MODEL	The bglB gene from Paenibacillus polymyxa was subjected to random mutagenesis mediated by error prone polymerase chain reaction amplification and DNA shuffling. After this treatment, mutant variants of the encoded p-glucosidase with enhanced thermal resistance were selected. We identified five amino acid substitutions at four different positions of the sequence that increased the resistance of the enzyme to heat denaturation, Four of the mutations, H62R, M319V, M319I, and M361I, did not change the kinetic parameters of the enzyme. However, mutant N223Y, which caused only a marginal increase in thermoresistance, showed an 8-fold decrease in K-m. Copies of the bglB gene carrying each one of the individual mutations were recombined in vitro by DNA shuffling. As a result, we obtained an enzyme that simultaneously exhibited a 20-fold increase in heat resistance and an 8-fold increase in the catalytic efficiency. The structural basis of the properties conferred by the mutations was analyzed using homology-based structural models. The four mutations causing a more pronounced effect on thermoresistance were located in loops, on the periphery of the (alpha/beta)(8) barrel that conforms the structure of the protein. Mutation N223Y, which modifies the catalytic properties of the enzyme, was on one of the barrel beta-strands that shape the active center.	CSIC, Inst Agroquim & Tecnol Alimentos, E-46100 Burjassot, Valencia, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA)	Polaina, J (corresponding author), CSIC, Inst Agroquim & Tecnol Alimentos, Apdo 73, E-46100 Burjassot, Valencia, Spain.		Polaina, Julio/H-4498-2012	Polaina, Julio/0000-0001-9912-0640				Aguilar CF, 1997, J MOL BIOL, V271, P789, DOI 10.1006/jmbi.1997.1215; Akanuma S, 1998, PROTEIN SCI, V7, P698, DOI 10.1002/pro.5560070319; AKASAKO A, 1995, BIOCHEMISTRY-US, V34, P8115, DOI 10.1021/bi00025a018; Auerbach G, 1998, STRUCTURE, V6, P769, DOI 10.1016/S0969-2126(98)00078-1; BARRETT T, 1995, STRUCTURE, V3, P951, DOI 10.1016/S0969-2126(01)00229-5; Burmeister WP, 1997, STRUCTURE, V5, P663, DOI 10.1016/S0969-2126(97)00221-9; CHEN KQ, 1993, P NATL ACAD SCI USA, V90, P5618, DOI 10.1073/pnas.90.12.5618; Cherry JR, 1999, NAT BIOTECHNOL, V17, P379, DOI 10.1038/7939; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; ESTELL DA, 1985, J BIOL CHEM, V260, P6518; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; Giordano A, 1999, BIOCHEMISTRY-US, V38, P3043, DOI 10.1021/bi982326e; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; Gonzalez-Blasco G, 2000, J BIOL CHEM, V275, P13708, DOI 10.1074/jbc.275.18.13708; GONZALEZCANDELAS L, 1989, APPL ENVIRON MICROB, V55, P3173; GONZALEZCANDELAS L, 1990, GENE, V95, P31, DOI 10.1016/0378-1119(90)90410-S; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gunata Z, 1996, ENZYME MICROB TECH, V18, P286, DOI 10.1016/0141-0229(95)00124-7; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HURLEY JH, 1992, J MOL BIOL, V224, P1143, DOI 10.1016/0022-2836(92)90475-Y; IMANAKA T, 1986, NATURE, V324, P695, DOI 10.1038/324695a0; Kawamura S, 1997, J BIOCHEM-TOKYO, V121, P448; Kawamura S, 1998, J BIOL CHEM, V273, P19982, DOI 10.1074/jbc.273.32.19982; Kuchner O, 1997, TRENDS BIOTECHNOL, V15, P523, DOI 10.1016/S0167-7799(97)01138-4; LIAO XB, 1990, GENE, V88, P107, DOI 10.1016/0378-1119(90)90066-Z; LOPEZCAMACHO C, 1993, MUTAT RES, V301, P73, DOI 10.1016/0165-7992(93)90027-S; LopezCamacho C, 1996, BIOCHEM J, V314, P833, DOI 10.1042/bj3140833; MATSUMURA M, 1986, NATURE, V323, P356, DOI 10.1038/323356a0; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V46, P249, DOI 10.1016/S0065-3233(08)60337-X; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; Oue S, 1999, J BIOL CHEM, V274, P2344, DOI 10.1074/jbc.274.4.2344; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Peterson RW, 1999, J MOL BIOL, V286, P1609, DOI 10.1006/jmbi.1999.2574; Sanz-Aparicio J, 1998, PROTEINS, V33, P567, DOI 10.1002/(SICI)1097-0134(19981201)33:4<567::AID-PROT9>3.0.CO;2-U; Sanz-Aparicio J, 1998, J MOL BIOL, V275, P491, DOI 10.1006/jmbi.1997.1467; SANZAPARICIO J, 1994, J MOL BIOL, V240, P267, DOI 10.1006/jmbi.1994.1441; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Vetriani C, 1998, P NATL ACAD SCI USA, V95, P12300, DOI 10.1073/pnas.95.21.12300; Vieille C, 1996, Biotechnol Annu Rev, V2, P1, DOI 10.1016/S1387-2656(08)70006-1; Vogt G, 1997, J MOL BIOL, V269, P631, DOI 10.1006/jmbi.1997.1042; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WIESMANN C, 1995, STRUCTURE, V3, P961, DOI 10.1016/S0969-2126(01)00230-1; Xu JA, 1998, PROTEIN SCI, V7, P158, DOI 10.1002/pro.5560070117; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yano T, 1998, P NATL ACAD SCI USA, V95, P5511, DOI 10.1073/pnas.95.10.5511; Yip KSP, 1998, EUR J BIOCHEM, V255, P336, DOI 10.1046/j.1432-1327.1998.2550336.x; ZHANG XJ, 1992, PROTEIN SCI, V1, P761, DOI 10.1002/pro.5560010608; Zhang XJ, 1995, PROTEIN ENG, V8, P1017, DOI 10.1093/protein/8.10.1017	55	51	62	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28843	28848		10.1074/jbc.M003036200	http://dx.doi.org/10.1074/jbc.M003036200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10871610	hybrid			2022-12-27	WOS:000089330700067
J	Bertram, JG; Bloom, LB; Hingorani, MM; Beechem, JM; O'Donnell, M; Goodman, MF				Bertram, JG; Bloom, LB; Hingorani, MM; Beechem, JM; O'Donnell, M; Goodman, MF			Molecular mechanism and energetics of clamp assembly in Escherichia coli - The role of ATP hydrolysis when gamma complex loads beta on DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; CHROMOSOMAL REPLICATION MACHINE; ACCESSORY PROTEINS; SLIDING CLAMPS; SUBUNIT; PURIFICATION; PARTICLE; DELTA	Escherichia coli DNA polymerase III holoenzyme is a multisubunit composite containing the beta sliding clamp and clamp loading gamma complex. The gamma complex requires ATP to load beta onto DNA. A two-color fluorescence spectroscopic approach was utilized to study this system, wherein both assembly (red fluorescence; X-rhodamine labeled DNA anisotropy assay) and ATP hydrolysis (green fluorescence; phosphate binding protein assay) were simultaneously measured with millisecond timing resolution. The two temporally correlated stopped-flow signals revealed that a preassembled beta.gamma complex composite rapidly binds primer/template DNA in an ATP hydrolysis independent step. Once bound, two molecules of ATP are rapidly hydrolyzed (similar to 34 s(-1)). Following hydrolysis, gamma complex dissociates from the DNA (similar to 22 s(-1)). Once dissociated, the next cycle of loading is severely compromised, resulting in steady-state ATP hydrolysis rates with a maximum of only similar to 3 s(-1). Two single-site beta dimer interface mutants were examined which had impaired steady-state rates of ATP hydrolysis. The pre-steady-state correlated kinetics of these mutants revealed a pattern essentially identical to wild type. The anisotropy data showed that these mutants decrease the steady-state rates of ATP hydrolysis by causing a buildup of "stuck" binary-ternary complexes on the primer/template DNA.	Univ So Calif, Hedco Mol Biol Lab, Dept Biol Sci & Chem, Los Angeles, CA 90089 USA; Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA; Vanderbilt Univ, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	University of Southern California; State University System of Florida; University of Florida; Rockefeller University; Howard Hughes Medical Institute; Vanderbilt University	Goodman, MF (corresponding author), Univ So Calif, Dept Sci Biol, Los Angeles, CA 90089 USA.		Bloom, Linda B/F-3684-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R01GM021422, R01GM038839, R37GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38839, GM21422, GM55596] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; Ason B, 2000, J BIOL CHEM, V275, P3006, DOI 10.1074/jbc.275.4.3006; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; Berdis AJ, 1997, BIOCHEMISTRY-US, V36, P2733, DOI 10.1021/bi962139l; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; BULT CJ, 1996, SCIENCE, V273, P1017; DONG ZM, 1993, J BIOL CHEM, V268, P11758; DOWNEY KM, 1990, BIOESSAYS, V12, P231, DOI 10.1002/bies.950120507; FAY PJ, 1981, J BIOL CHEM, V256, P976; Hingorani MM, 1999, EMBO J, V18, P5131, DOI 10.1093/emboj/18.18.5131; JOHANSON KO, 1980, J BIOL CHEM, V255, P984; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; XIAO H, 1993, J BIOL CHEM, V268, P11773; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	29	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28413	28420		10.1074/jbc.M910441199	http://dx.doi.org/10.1074/jbc.M910441199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10874049	hybrid			2022-12-27	WOS:000089330700012
J	Good, PJ; Chen, QD; Warner, SJ; Herring, DC				Good, PJ; Chen, QD; Warner, SJ; Herring, DC			A family of human RNA-binding proteins related to the Drosophila Bruno translational regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSKAR MESSENGER-RNA; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; AU-RICH ELEMENT; ELAV-LIKE GENES; MYOTONIC-DYSTROPHY; HNRNP A1; TRINUCLEOTIDE REPEAT; CAENORHABDITIS-ELEGANS; CONSERVED FAMILY; REPRESSOR BRUNO	The post-transcriptional regulation of gene expression by RNA-binding proteins is an. important element in controlling both normal cell functions and animal development. The diverse roles are demonstrated by the Elav family of RNA-binding proteins, where various members have been shown to regulate several processes involving mRNA We have identified another family of RNA-binding proteins distantly related to the Elav family but closely related to Bruno, a translational regulator in Drosophila melanogaster, In humans, six Bruno-like genes have been identified, whereas other species such as Drosophila, Xenopus laevis, and Caenorhabditis elegans have at least two members of this family, and related genes have also been detected in plants and ascidians. The human BRUNOL2 and BRUNOL3 are 92% identical in the RNA-binding domains, although the BRUNOL2 gene is expressed ubiquitously whereas BRUNOL3 is expressed predominantly in the heart, muscle, and nervous system. Both of these proteins bind the same target RNA the Bruno response element. The RNA-binding domain that recognizes the Bruno response element is composed of two consecutive RNA recognition motifs at the amino terminus of vertebrate Bruno protein. The possible involvement of the Bruno family of proteins in the CUG repeat expansion disease myotonic dystrophy is discussed.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Good, PJ (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Hwy, Shreveport, LA 71130 USA.	pgood@lsuhsc.edu						Abe R, 1996, NUCLEIC ACIDS RES, V24, P4895, DOI 10.1093/nar/24.24.4895; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Akamatsu W, 1999, P NATL ACAD SCI USA, V96, P9885, DOI 10.1073/pnas.96.17.9885; Amack JD, 1999, HUM MOL GENET, V8, P1975, DOI 10.1093/hmg/8.11.1975; Anderson P, 1995, Curr Top Microbiol Immunol, V198, P131; Antic D, 1999, GENE DEV, V13, P449, DOI 10.1101/gad.13.4.449; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Antic D, 1998, J CELL SCI, V111, P183; Atasoy U, 1998, J CELL SCI, V111, P3145; Audic Y, 1998, MOL CELL BIOL, V18, P6879, DOI 10.1128/MCB.18.12.6879; Bhagwati S, 1999, BBA-MOL BASIS DIS, V1453, P221, DOI 10.1016/S0925-4439(98)00104-5; BIAMONTI G, 1994, FEBS LETT, V340, P1, DOI 10.1016/0014-5793(94)80162-2; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; Caskey CT, 1996, COLD SPRING HARB SYM, V61, P607; Choi DK, 1999, GENE, V237, P135, DOI 10.1016/S0378-1119(99)00312-1; Choi DK, 1998, GENE, V223, P21, DOI 10.1016/S0378-1119(98)00364-3; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Draper DE, 1999, J MOL BIOL, V293, P255, DOI 10.1006/jmbi.1999.2991; Ebersole TA, 1996, NAT GENET, V12, P260, DOI 10.1038/ng0396-260; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Good PJ, 1997, SEMIN CELL DEV BIOL, V8, P577, DOI 10.1006/scdb.1997.0183; GOOD PJ, 1993, NUCLEIC ACIDS RES, V21, P999, DOI 10.1093/nar/21.4.999; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Hamshere MG, 1997, P NATL ACAD SCI USA, V94, P7394, DOI 10.1073/pnas.94.14.7394; Harlow E., 1988, ANTIBODIES LAB MANUA; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; Jeongsil KH, 1999, MOL CELL BIOL, V19, P2505; Kasashima K, 1999, GENES CELLS, V4, P667, DOI 10.1046/j.1365-2443.1999.00292.x; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIMHA J, 1995, CELL, V81, P403, DOI 10.1016/0092-8674(95)90393-3; KNECHT AK, 1995, DEVELOPMENT, V121, P1927; Koushika SP, 1996, CURR BIOL, V6, P1634, DOI 10.1016/S0960-9822(02)70787-2; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; Lie YS, 1999, DEVELOPMENT, V126, P4989; Lie YS, 1999, DEVELOPMENT, V126, P1129; Lu XH, 1999, HUM MOL GENET, V8, P53, DOI 10.1093/hmg/8.1.53; Lundquist EA, 1996, DEVELOPMENT, V122, P1601; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; Margolis RL, 1997, HUM GENET, V100, P114, DOI 10.1007/s004390050476; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; Milne CA, 1999, CURR BIOL, V9, P1243, DOI 10.1016/S0960-9822(99)80504-1; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Norvell A, 1999, GENE DEV, V13, P864, DOI 10.1101/gad.13.7.864; Paillard L, 1998, EMBO J, V17, P278, DOI 10.1093/emboj/17.1.278; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Perez I, 1997, BIOCHEMISTRY-US, V36, P11881, DOI 10.1021/bi9711745; Perron M, 1999, INT J DEV BIOL, V43, P295; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; PinolRoma S, 1997, SEMIN CELL DEV BIOL, V8, P57, DOI 10.1006/scdb.1996.0122; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; Reddy PS, 1997, CURR OPIN CELL BIOL, V9, P364, DOI 10.1016/S0955-0674(97)80009-9; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; Roberts R, 1997, P NATL ACAD SCI USA, V94, P13221, DOI 10.1073/pnas.94.24.13221; Rose MD., 1990, METHODS YEAST GENETI; Sakashita E, 1996, J BIOCHEM, V120, P1028; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Samuels M, 1998, NUCLEIC ACIDS RES, V26, P2625, DOI 10.1093/nar/26.11.2625; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Serin G, 1997, J BIOL CHEM, V272, P13109, DOI 10.1074/jbc.272.20.13109; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Sonoda J, 1999, GENE DEV, V13, P2704, DOI 10.1101/gad.13.20.2704; STEBBINSBOAZ B, 1994, MOL CELL BIOL, V14, P5870, DOI 10.1128/MCB.14.9.5870; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; Suzuki H, 2000, MECH DEVELOP, V93, P205, DOI 10.1016/S0925-4773(00)00270-7; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; Wakamatsu Y, 1997, DEVELOPMENT, V124, P3449; Wang JW, 1997, J BIOL CHEM, V272, P22227, DOI 10.1074/jbc.272.35.22227; Webster PJ, 1997, GENE DEV, V11, P2510, DOI 10.1101/gad.11.19.2510; White JA, 1997, GENOMICS, V45, P468, DOI 10.1006/geno.1997.4979; YAO KM, 1993, J NEUROBIOL, V24, P723, DOI 10.1002/neu.480240604; Zhang BL, 1999, METHOD ENZYMOL, V306, P93	83	109	126	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28583	28592		10.1074/jbc.M003083200	http://dx.doi.org/10.1074/jbc.M003083200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893231	hybrid			2022-12-27	WOS:000089330700035
J	Segev, DL; Ha, TU; Tran, TT; Kenneally, M; Harkin, P; Jung, M; MacLaughlin, DT; Donahoe, PK; Maheswaran, S				Segev, DL; Ha, TU; Tran, TT; Kenneally, M; Harkin, P; Jung, M; MacLaughlin, DT; Donahoe, PK; Maheswaran, S			Mullerian inhibiting substance inhibits breast cancer cell growth through an NF kappa B-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; HUMAN OVARIAN-CANCER; FETAL-RAT LUNG; FACTOR-BETA; TRANSCRIPTIONAL ACTIVATION; SEXUAL DEVELOPMENT; B/REL EXPRESSION; RESPONSE GENE; TUMOR-GROWTH; II RECEPTOR	Mullerian inhibiting substance (MIS), a member of the transforming growth factor-beta superfamily, induces regression of the Mullerian duct in male embryos. In this report, we demonstrate MMS type II receptor expression in normal breast tissue and in human breast cancer cell lines, breast fibroadenoma, and ductal adenocarcinomas. MIS inhibited the growth of both estrogen receptor (ER)-positive T47D and ER-negative MDA-MB-231 breast cancer cell lines, suggesting a broader range of target tissues for MIS action. Inhibition of growth was manifested by an increase in the fraction of cells in the G(1) phase of the cell cycle and induction of apoptosis, Treatment of breast cancer cells with MIS activated the NF kappa B pathway and selectively up-regulated the immediate early gene IEX-1S, which, when overexpressed, inhibited breast cancer cell growth. Dominant negative I kappa B alpha expression ablated both MIS-mediated induction of IEX-1S and inhibition of growth, indicating that activation of the NF kappa B signaling pathway was required for these processes. These results identify the NF kappa B-mediated signaling pathway and a target gene for MIS action and suggest a putative role for the MIS ligand and its downstream interactors in the treatment of ER-positive as well as negative breast cancers.	Massachusetts Gen Hosp, Pediat Surg Res Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Queens Univ, Dept Oncol, Belfast BT9 7AB, Antrim, North Ireland; Georgetown Univ, Med Ctr, Dept Radiat Med, Washington, DC 20057 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Queens University Belfast; Georgetown University	Maheswaran, S (corresponding author), Massachusetts Gen Hosp, Pediat Surg Res Lab, WRN1024,55 Fruit St, Boston, MA 02114 USA.				NCI NIH HHS [CA17393] Funding Source: Medline; NICHD NIH HHS [HD32112] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032112] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA017393] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnold SF, 1999, CYTOKINE, V11, P1031, DOI 10.1006/cyto.1999.0508; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; ARTEAGA CL, 1988, CANCER RES, V48, P3898; BAARENDS WM, 1994, DEVELOPMENT, V120, P189; Baichwal V. R., 1997, CURR BIOL, V7, P94; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BEHRINGER RR, 1994, CELL, V79, P415, DOI 10.1016/0092-8674(94)90251-8; BOVERI JF, 1993, INT J ONCOL, V2, P135; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Catlin EA, 1997, ENDOCRINOLOGY, V138, P790, DOI 10.1210/en.138.2.790; CATLIN EA, 1988, AM J OBSTET GYNECOL, V159, P1299, DOI 10.1016/0002-9378(88)90467-X; CATLIN EA, 1990, AM REV RESPIR DIS, V141, P466, DOI 10.1164/ajrccm/141.2.466; Chen TP, 1998, CANCER RES, V58, P4805; CHIN TW, 1991, CANCER RES, V51, P2101; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Clarkson RWE, 2000, J BIOL CHEM, V275, P12737, DOI 10.1074/jbc.275.17.12737; Clement JH, 1999, INT J CANCER, V80, P250, DOI 10.1002/(SICI)1097-0215(19990118)80:2<250::AID-IJC14>3.0.CO;2-D; Davis JN, 1999, NUTR CANCER, V35, P167, DOI 10.1207/S15327914NC352_11; Di Loreto C, 1999, EUR J ENDOCRINOL, V141, P190, DOI 10.1530/eje.0.1410190; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; Dixon EP, 1997, BRAIN RES, V776, P222, DOI 10.1016/S0006-8993(97)01040-8; DONAHOE PK, 1981, ANN SURG, V194, P472, DOI 10.1097/00000658-198110000-00010; DONAHOE PK, 1992, MOL REPROD DEV, V32, P168, DOI 10.1002/mrd.1080320213; FULLER AF, 1985, GYNECOL ONCOL, V22, P135, DOI 10.1016/0090-8258(85)90019-8; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HOSOBUCHI M, 1989, IN VITRO CELL DEV B, V25, P705; HUDSON PL, 1990, J CLIN ENDOCR METAB, V70, P16, DOI 10.1210/jcem-70-1-16; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kondratyev AD, 1996, CANCER RES, V56, P1498; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; KURIAN MS, 1995, CLIN CANCER RES, V1, P343; Lee MM, 1996, J CLIN ENDOCR METAB, V81, P571, DOI 10.1210/jc.81.2.571; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Liu QY, 1996, CANCER RES, V56, P1155; Loser P, 1998, J VIROL, V72, P180; Masiakos PT, 1999, CLIN CANCER RES, V5, P3488; Mishina Y, 1996, GENE DEV, V10, P2577, DOI 10.1101/gad.10.20.2577; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; PARRY RL, 1992, CANCER RES, V52, P1182; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Phippard DJ, 1996, DEVELOPMENT, V122, P2729; RAGIN RC, 1992, PROTEIN EXPRES PURIF, V3, P236, DOI 10.1016/1046-5928(92)90020-W; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; TAKAHASHI M, 1986, BIOL REPROD, V35, P447, DOI 10.1095/biolreprod35.2.447; Teixeira J, 1996, ENDOCRINOLOGY, V137, P160, DOI 10.1210/en.137.1.160; Teixeira J, 1999, ENDOCRINOLOGY, V140, P4732, DOI 10.1210/en.140.10.4732; Teixeira J, 1996, J ANDROL, V17, P336; UENO S, 1988, ENDOCRINOLOGY, V123, P1652, DOI 10.1210/endo-123-3-1652; VALVERIUS EM, 1989, CANCER RES, V49, P6269; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wolff B, 1999, ONCOGENE, V18, P2663, DOI 10.1038/sj.onc.1202617; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217; ZUGMAIER G, 1990, ANN NY ACAD SCI, V593, P272, DOI 10.1111/j.1749-6632.1990.tb16118.x	65	116	127	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28371	28379		10.1074/jbc.M004554200	http://dx.doi.org/10.1074/jbc.M004554200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10874041	hybrid			2022-12-27	WOS:000089330700007
J	Cozier, GE; Lockyer, PJ; Reynolds, JS; Kupzig, S; Bottomley, JR; Millard, TH; Banting, G; Cullen, PJ				Cozier, GE; Lockyer, PJ; Reynolds, JS; Kupzig, S; Bottomley, JR; Millard, TH; Banting, G; Cullen, PJ			GAP1(IP4BP) contains a novel group I pleckstrin homology domain that directs constitutive plasma membrane association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; 1,3,4,5-TETRAKISPHOSPHATE RECEPTORS GAP1(IP4BP); INOSITOL 1,3,4,5-TETRAKISPHOSPHATE; HUMAN PLATELETS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE BINDING; STIMULATED TRANSLOCATION; FUNCTIONAL-ANALYSIS; CA2+ MOBILIZATION; PHOSPHOLIPASE-C	The group I family of pleckstrin homology (PH) domains are characterized by their inherent ability to specifically bind phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) and its corresponding inositol headgroup inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P-4). In vivo this interaction results in the regulated plasma membrane recruitment of cytosolic group I PH domain-containing proteins following agonist-stimulated PtdIns(3,4,5)P-3 production. Among group I PH domain-containing proteins, the Pas GTPase-activating protein GAP1(IP4BP) is unique in being constitutively associated with the plasma membrane. Here we show that, although the GAP1(IP4BP) PH domain interacts with PtdIns(3,4,5)P-3, it also binds, with a comparable affinity, phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) (K-d values of 0.5 +/- 0.2 and 0.8 +/- 0.5 mu M, respectively). Intriguingly, whereas this binding site overlaps with that for Ins(1,3,4,5)P-4, consistent with the constitutive plasma membrane association of GAP1(IP4BP) resulting from its PH domain-binding PtdIns(4,5)P-2, we show that in vivo depletion of PtdIns(4,5)P-2, but not PtdIns(3,4,5)P-3, results in dissociation of GAP1(IP4BP) from this membrane. Thus, the Ins(1,3,4,5)P-4-binding PH domain from GAP1(IP4BP) defines a novel class of group I PH domains that constitutively targets the protein to the plasma membrane and may allow GAP1(IP4BP) to be regulated in vivo by Ins(1,3,4,5)P-4 rather than PtdIns(3,4,5)P-3.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Cullen, PJ (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.	pete.cullen@bristol.ac.uk	Cozier, Gyles/A-5891-2009	Cullen, Peter/0000-0002-9070-8349; Banting, George/0000-0001-8249-1621; Cozier, Gyles/0000-0003-2851-0902				BATTY IR, 1985, BIOCHEM J, V232, P211, DOI 10.1042/bj2320211; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Bottomley JR, 1998, BIOCHEM BIOPH RES CO, V250, P143, DOI 10.1006/bbrc.1998.9179; Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; CULLEN PJ, 1994, BIOCHEM J, V298, P739, DOI 10.1042/bj2980739; CULLEN PJ, 1990, BIOCHEM J, V271, P549, DOI 10.1042/bj2710549; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Cullen PJ, 1998, BBA-MOL CELL BIOL L, V1436, P35, DOI 10.1016/S0005-2760(98)00149-0; Fukuda M, 1996, J BIOL CHEM, V271, P18838, DOI 10.1074/jbc.271.31.18838; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Irvine R, 1998, CURR BIOL, V8, pR557, DOI 10.1016/S0960-9822(07)00360-0; Katan M, 1999, FEBS LETT, V452, P36, DOI 10.1016/S0014-5793(99)00531-1; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lockyer PJ, 1997, CURR BIOL, V7, P1007, DOI 10.1016/S0960-9822(06)00423-4; Lockyer PJ, 1999, BIOCHEM BIOPH RES CO, V255, P421, DOI 10.1006/bbrc.1999.0217; Lockyer PJ, 1999, CURR BIOL, V9, P265, DOI 10.1016/S0960-9822(99)80116-X; Loomis-Husselbee JW, 1998, BIOCHEM J, V331, P947, DOI 10.1042/bj3310947; LoomisHusselbee JW, 1996, BIOCHEM J, V314, P811, DOI 10.1042/bj3140811; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; ORourke F, 1996, BIOCHEM J, V315, P1027, DOI 10.1042/bj3151027; Powe AC, 1999, MECH DEVELOP, V81, P89, DOI 10.1016/S0925-4773(98)00230-5; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Venkateswarlu K, 1999, J CELL SCI, V112, P1957; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Willars GB, 1998, J BIOL CHEM, V273, P5037, DOI 10.1074/jbc.273.9.5037; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	45	65	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28261	28268						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869341				2022-12-27	WOS:000089197100097
J	Wei, G; Bai, XM; Gabb, MMG; Bame, KJ; Koshy, TI; Spear, PG; Esko, JD				Wei, G; Bai, XM; Gabb, MMG; Bame, KJ; Koshy, TI; Spear, PG; Esko, JD			Location of the glucuronosyltransferase domain in the heparan sulfate copolymerase EXT1 by analysis of Chinese hamster ovary cell mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY MULTIPLE EXOSTOSES; HERPES-SIMPLEX VIRUS; D-GLUCOSAMINYLTRANSFERASE REACTIONS; TUMOR-SUPPRESSOR GENE; N-ACETYLGLUCOSAMINYLTRANSFERASE; CAPSULAR POLYSACCHARIDE; POLYMER-MODIFICATION; LINKAGE REGION; TOUT-VELU; BIOSYNTHESIS	Heparan sulfate formation occurs by the copolymerization of glucuronic acid (GlcA) and N-acetylglucosamine (GlcNAc) residues. Recent studies have shown that these reactions are catalyzed by a copolymerase encoded by EXT1 and EXT2, members of the exostosin family of putative tumor suppressors linked to hereditary multiple exostoses. Previously, we identified a collection of Chinese hamster ovary cell mutants (pgsD) that failed to make heparan sulfate (Lidholt, K,, Weinke, J. L., Riser, C. S., Lugemwa, F. N., Bame, K. J., Cheifetz, S., Massague, J,, Lindahl, U., and Esko, J. D. (1992) Proc. Natl. Acad, Sci. U.S.A. 89, 2267-2271). Here, we show that pgsD mutants contain mutations that either alter GlcA transferase activity selectively or that affect both GlcNAc and GlcA transferase activities. Expression of EXT1 corrects the deficiencies in the mutants, whereas EXT2 and the related EXT-like cDNAs do not. Analysis of the EXT1 mutant alleles revealed clustered missense mutations in a domain that included a (D/E)X(D/E) motif thought to bind the nucleotide sugar from studies of other transferases. These findings provide insight into the location of the GlcA transferase subdomain of the enzyme and indicate that loss of the GlcA transferase domain may be sufficient to cause hereditary multiple exostoses.	Univ Calif San Diego, Glycobiol Res & Training Program, Dept Cellular & Mol Biol, La Jolla, CA 92093 USA; Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA; Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	University of California System; University of California San Diego; University of Missouri System; University of Missouri Kansas City; Northwestern University	Esko, JD (corresponding author), Univ Calif San Diego, Glycobiol Res & Training Program, Dept Cellular & Mol Biol, CMM E Rm 1054,9500 Gilman Dr, La Jolla, CA 92093 USA.	jesko@ucsd.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036293, R37AI036293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033063, R37GM033063] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36293] Funding Source: Medline; NIGMS NIH HHS [GM33063] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BANFIELD BW, 1995, VIROLOGY, V208, P531, DOI 10.1006/viro.1995.1184; BANFIELD BW, 1995, J VIROL, V69, P3290, DOI 10.1128/JVI.69.6.3290-3298.1995; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Blanton SH, 1996, AM J MED GENET, V62, P150; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; ESKO JD, 1989, METHOD CELL BIOL, V32, P387; ESKO JD, 1986, J BIOL CHEM, V261, P5725; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; Ferguson CM, 1998, ANN NY ACAD SCI, V857, P33, DOI 10.1111/j.1749-6632.1998.tb10105.x; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; Fritz TA, 1997, GLYCOBIOLOGY, V7, P587, DOI 10.1093/glycob/7.5.587-c; Fukuda M, 1996, GLYCOBIOLOGY, V6, P683, DOI 10.1093/glycob/6.7.683; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; HAM RG, 1965, P NATL ACAD SCI USA, V53, P288, DOI 10.1073/pnas.53.2.288; HECHT JT, 1995, AM J HUM GENET, V56, P1125; Hecht JT, 1997, AM J HUM GENET, V60, P80; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; KUSCHE M, 1991, BIOCHEM J, V275, P151, DOI 10.1042/bj2750151; LANDER A, 1999, CELL SURFACE PROTEOG; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; LegeaiMallet L, 1997, CLIN GENET, V52, P12; LegeaiMallet L, 1997, HUM GENET, V99, P298, DOI 10.1007/s004390050361; LEMERRER M, 1994, HUM MOL GENET, V3, P717, DOI 10.1093/hmg/3.5.717; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIDHOLT K, 1994, CARBOHYD RES, V255, P87, DOI 10.1016/S0008-6215(00)90972-8; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIN X, 2000, IN PRESS DEVELOPMENT; LIND T, 1993, J BIOL CHEM, V268, P20705; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Manez S, 1999, J NAT PROD, V62, P601, DOI 10.1021/np980132u; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Michaelis L, 1913, BIOCHEM Z, V49, P333; MONTGOMERY RI, 1992, P NATL ACAD SCI USA, V89, P11327, DOI 10.1073/pnas.89.23.11327; RASKIND WH, 1995, AM J HUM GENET, V56, P1132; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; Saito T, 1998, BIOCHEM BIOPH RES CO, V243, P61, DOI 10.1006/bbrc.1997.8062; SHIEH MT, 1994, J VIROL, V68, P1224, DOI 10.1128/JVI.68.2.1224-1228.1994; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; SOLOMON L, 1964, AM J HUM GENET, V16, P351; Stickens D, 1996, NAT GENET, V14, P25, DOI 10.1038/ng0996-25; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; Watanabe R, 1998, EMBO J, V17, P877, DOI 10.1093/emboj/17.4.877; Wei G, 1999, J BIOL CHEM, V274, P7857, DOI 10.1074/jbc.274.12.7857; Wells DE, 1997, HUM GENET, V99, P612, DOI 10.1007/s004390050415; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10; WU YQ, 1994, HUM MOL GENET, V3, P167, DOI 10.1093/hmg/3.1.167; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; Wuyts W, 1997, EUR J HUM GENET, V5, P382, DOI 10.1159/000484796; Wuyts W, 1996, HUM MOL GENET, V5, P1547, DOI 10.1093/hmg/5.10.1547; Wuyts W, 1998, AM J HUM GENET, V62, P346, DOI 10.1086/301726; WUYTS W, 1995, AM J HUM GENET, V57, P382	63	67	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27733	27740						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10864928				2022-12-27	WOS:000089197100030
J	Kotani, K; Ogawa, W; Hashiramoto, M; Onishi, T; Ohno, S; Kasuga, M				Kotani, K; Ogawa, W; Hashiramoto, M; Onishi, T; Ohno, S; Kasuga, M			Inhibition of insulin-induced glucose uptake by atypical protein kinase C isotype-specific interacting protein in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; CAENORHABDITIS-ELEGANS; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PHOSPHATIDYLINOSITOL 3-KINASE; STIMULATED TRANSLOCATION; DROSOPHILA NEUROBLASTS; MAMMALIAN HOMOLOG; GROWTH-HORMONE; IN-VITRO; ZETA	Atypical protein kinase C (PKC) isotype-specific interacting protein (ASIP) specifically interacts with the atypical protein kinase C isozymes PKC lambda and PKC zeta. ASIP and atypical PKC, as well as their Caenorhabditis elegans counterparts (PAR-3 and PKC-3, respectively), are thought to coordinately participate in intracellular signaling that contributes to the maintenance of cellular polarity and to the formation of junctional complexes. The potential role of ASIP in other cellular functions of atypical PKC was investigated by examining the effect of overexpression of ASIP on insulin-induced glucose uptake, previously shown to be mediated through PKC lambda, in 3T3-L1 adipocytes. When overexpressed in these cells, which contain PKC lambda but not PKC zeta, ASIP was co-immunoprecipitated with endogenous PKC lambda but not with PKC epsilon or with Akt, The subcellular localization of PKC lambda was also altered in cells overexpressing ASIP. Overexpression of ASIP inhibited insulin stimulation of both glucose uptake and translocation of the glucose transporter GLUT4 to the plasma membrane, but it did not inhibit glucose uptake induced by either growth hormone or hyperosmolarity both of which promote glucose uptake in a PKC lambda-independent manner. Moreover, glucose uptake stimulated by a constitutively active mutant of PKC lambda, but not that induced by an active form of Akt, was inhibited by ASIP. Insulin-induced activation of PKC lambda, but not that of phosphoinositide 3-kinase or Akt, was also inhibited by overexpression of ASIP. These data suggest that overexpression of ASIP inhibits insulin-induced glucose uptake by specifically interfering with signals transmitted through PKC lambda.	Kobe Univ, Sch Med, Dept Internal Med, Chuo Ku, Kobe, Hyogo 6500017, Japan; Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, Yokohama, Kanagawa 232, Japan	Kobe University; Yokohama City University	Ogawa, W (corresponding author), Kobe Univ, Sch Med, Dept Internal Med, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.		Ohnishi, Tetsuo/AAC-2767-2022; OGAWA, Wataru/AAQ-9586-2020; Ohnishi, Tetsuo/AAC-5694-2019; Ohnishi, Tetsuo/D-3791-2018; Ohno, Shigeo/B-1768-2010	Ohnishi, Tetsuo/0000-0002-6696-9725; Ohnishi, Tetsuo/0000-0002-6696-9725; Ohno, Shigeo/0000-0002-1294-5269				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Imamura T, 1999, MOL CELL BIOL, V19, P6765; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Kuroda S, 1999, J CELL BIOL, V144, P403, DOI 10.1083/jcb.144.3.403; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; TANNER JW, 1992, BIOCHEM J, V282, P99, DOI 10.1042/bj2820099; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TOYODA N, 1986, J BIOL CHEM, V261, P2117; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395	39	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26390	26395		10.1074/jbc.M002537200	http://dx.doi.org/10.1074/jbc.M002537200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10869347	hybrid			2022-12-27	WOS:000088999700070
J	Xiao, GT; Sun, SC				Xiao, GT; Sun, SC			Negative regulation of the nuclear factor kappa B-inducing kinase by a cis-acting domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; IKK-ALPHA; ACTIVATION; PROTEIN; COMPLEX; BETA; PHOSPHORYLATION; REQUIRES; SIGNALS; TARGET	Nuclear factor kappa B (NF-kappa B)-inducing kinase (NIK) participates in the activation of NF-kappa B, a family of eukaryotic transcription factors that mediate cell growth and transformation. NIK activates the I kappa B kinase both in vivo and in vitro, although how the activity of NIK is regulated has remained unclear. Here we show that the N-terminal region of NIK contains a negative-regulatory domain (NRD), which is composed of a basic motif and a proline-rich repeat motif. Deletion of these motifs leads to a marked enhancement of NIK function. We further demonstrate that the N-terminal NRD interacts with the C-terminal region of NIK, thereby inhibiting the binding of NIK to its substrate I kappa B kinase. Consistently, when expressed alone, the NRD potently inhibits NIK-mediated NF-kappa B signaling. These results provide a new insight into the mechanism of NIK regulation.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, POB 850, Hershey, PA 17033 USA.				NIAID NIH HHS [1 RO1 AI45045] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Foo SY, 1999, TRENDS GENET, V15, P229; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Hardy K, 1997, IMMUNOL CELL BIOL, V75, P528, DOI 10.1038/icb.1997.84; Harhaj EW, 1998, J BIOL CHEM, V273, P25185, DOI 10.1074/jbc.273.39.25185; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Kaga S, 1998, J IMMUNOL, V160, P4182; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; LEE KAW, 1992, J CELL SCI, V103, P9; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547	32	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21081	21085		10.1074/jbc.M002552200	http://dx.doi.org/10.1074/jbc.M002552200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10887201	hybrid			2022-12-27	WOS:000088230600018
J	Krijgsveld, J; Zaat, SAJ; Meeldijk, J; van Veelen, PA; Fang, G; Poolman, B; Brandt, E; Ehlert, JE; Kuijpers, AJ; Engbers, GHM; Feijen, J; Dankert, J				Krijgsveld, J; Zaat, SAJ; Meeldijk, J; van Veelen, PA; Fang, G; Poolman, B; Brandt, E; Ehlert, JE; Kuijpers, AJ; Engbers, GHM; Feijen, J; Dankert, J			Thrombocidins, microbicidal proteins from human flood platelets, are C-terminal deletion products of CXC chemokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PEPTIDE-2; ANTIMICROBIAL PEPTIDE; INFECTIVE ENDOCARDITIS; BETA-DEFENSINS; HOST-DEFENSE; VIRIDANS STREPTOCOCCI; HUMAN BETA-DEFENSIN-1; INNATE IMMUNITY; SMALL-INTESTINE; PANETH CELLS	Antibacterial proteins are components of the innate immune system found in many organisms and produced by a variety of cell types. Human blood platelets contain a number of antibacterial proteins in their cu-granules that are released upon thrombin activation. The present study was designed to purify these proteins obtained from human platelets and to characterize them chemically and biologically. Two antibacterial proteins were purified from platelet granules in a two-step protocol using cation exchange chromatography and continuous acid urea polyacrylamide gel electrophoresis and were designated thrombocidin (TC)-1 and TC-2, Characterization of these proteins using mass spectrometry and N-terminal sequencing revealed that TC-1 and TC-2 are variants of the CXC chemokines neutrophil-activating peptide-2 and connective tissue-activating peptide-III, respectively. TC-1 and TC-2 differ from these chemokines by a C-terminal truncation of 2 amino acids. Both TCs, but not neutrophil-activating peptide-2 and connective tissue-activating peptide-III, were bactericidal for Bacillus subtilis, Escherichia coli, Staphylococcus aureus, and Lactococcus lactis and fungicidal for Cryptococcus neoformans. Killing of B. subtilis by either TC appeared to be very rapid. Because TCs were unable to dissipate the membrane potential of L. lactis, the mechanism of TC-mediated killing most probably does not involve pore formation.	Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, NL-1105 AZ Amsterdam, Netherlands; Leiden State Univ, Ctr Med, Dept Immunohaematol, NL-2333 AA Leiden, Netherlands; Leiden State Univ, Ctr Med, Blood Bank, NL-2333 AA Leiden, Netherlands; Univ Groningen, Dept Microbiol, NL-9751 AA Haren, Netherlands; Forschungszentrum Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany; Univ Twente, Inst Biomed Technol, Dept Chem Technol, NL-8500 AE Enschede, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; University of Groningen; Forschungszentrum Borstel; University of Twente	Zaat, SAJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, Rm L1-163,Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.		Poolman, Bert/D-1882-2012; Krijgsveld, Jeroen/F-5974-2011	van Veelen, Peter/0000-0002-7898-9408; Kuijpers, Alma/0000-0002-6191-1815	NHLBI NIH HHS [HL-18574, HL-50590] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050590, P01HL018574] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Boman HG, 1998, SCAND J IMMUNOL, V48, P15; BRANDT E, 1992, J IMMUNOL, V149, P1356; BRANDT E, 1993, MOL IMMUNOL, V30, P979, DOI 10.1016/0161-5890(93)90123-S; BRANDT E, 1991, CYTOKINE, V3, P311, DOI 10.1016/1043-4666(91)90499-4; CASTOR CW, 1989, BIOCHEM BIOPH RES CO, V163, P1071, DOI 10.1016/0006-291X(89)92330-9; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; COHEN AB, 1992, AM J PHYSIOL, V263, pL249, DOI 10.1152/ajplung.1992.263.2.L249; DANKERT J, 1995, INFECT IMMUN, V63, P663, DOI 10.1128/IAI.63.2.663-671.1995; Dankert J., 1988, THESIS U GRONINGEN G; Dhawan VK, 1998, INFECT IMMUN, V66, P3476, DOI 10.1128/IAI.66.7.3476-3479.1998; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; DIAMOND G, 1993, P NATL ACAD SCI USA, V90, P4596, DOI 10.1073/pnas.90.10.4596; DONALDSON DM, 1977, BACTERIOL REV, V41, P501, DOI 10.1128/MMBR.41.2.501-513.1977; FIJNHEER R, 1990, TRANSFUSION, V30, P634, DOI 10.1046/j.1537-2995.1990.30790385523.x; FONTANA R, 1990, ANTIMICROB AGENTS CH, V34, P314, DOI 10.1128/AAC.34.2.314; FORD I, 1993, BRIT J HAEMATOL, V84, P95, DOI 10.1111/j.1365-2141.1993.tb03030.x; FUKAMI MH, 1992, METHOD ENZYMOL, V215, P36; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; Ganz T, 1997, SEMIN HEMATOL, V34, P343; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GOODE J, 1994, CIBA F S, V186, P1; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HARTER L, 1994, J IMMUNOL, V153, P5698; HARWIG SSL, 1993, ANAL BIOCHEM, V208, P382, DOI 10.1006/abio.1993.1065; HERZBERG MC, 1983, INFECT IMMUN, V39, P1457, DOI 10.1128/IAI.39.3.1457-1469.1983; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; JOHNSON FB, 1968, J BACTERIOL, V96, P589, DOI 10.1128/JB.96.3.589-595.1968; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KAPLAN KL, 1979, BLOOD, V53, P604; Koo SP, 1999, INFECT IMMUN, V67, P2475, DOI 10.1128/IAI.67.5.2475-2481.1999; KRIJGSVELD J, 1998, C MICR HAEM VASC BIO; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; LOLKEMA JS, 1996, TRANSPORT PROCESSES, P229; LUDWIG A, 1997, BLOOD, V90, P3488; MALKOWSKI MG, 1995, J BIOL CHEM, V270, P7077, DOI 10.1074/jbc.270.13.7077; Marciset O, 1997, J BIOL CHEM, V272, P14277, DOI 10.1074/jbc.272.22.14277; MEYLAN PR, 1986, ANTIMICROB AGENTS CH, V29, P418, DOI 10.1128/AAC.29.3.418; Moore AJ, 1996, J ANTIMICROB CHEMOTH, V37, P1077, DOI 10.1093/jac/37.6.1077; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; O'Neil DA, 1999, J IMMUNOL, V163, P6718; OUELLETTE AJ, 1990, J BIOL CHEM, V265, P9831; Petersen F, 1996, J IMMUNOL, V156, P1954; POOLMAN B, 1991, J BACTERIOL, V173, P6030, DOI 10.1128/jb.173.19.6030-6037.1991; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Schroder JM, 1999, BIOCHEM PHARMACOL, V57, P121, DOI 10.1016/S0006-2952(98)00226-3; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686; SULLAM PM, 1993, J INFECT DIS, V168, P910, DOI 10.1093/infdis/168.4.910; Tarver AP, 1998, INFECT IMMUN, V66, P1045, DOI 10.1128/IAI.66.3.1045-1056.1998; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; WALTZ A, 1990, J EXP MED, V171, P449; WEKSLER BB, 1971, J EXP MED, V134, P1114, DOI 10.1084/jem.134.5.1114; WESTERHOFF HV, 1989, P NATL ACAD SCI USA, V86, P6597, DOI 10.1073/pnas.86.17.6597; Wieprecht T, 1997, BIOCHEMISTRY-US, V36, P12869, DOI 10.1021/bi971398n; Yeaman MR, 1997, INFECT IMMUN, V65, P1023, DOI 10.1128/IAI.65.3.1023-1031.1997; YEAMAN MR, 1993, ANTIMICROB AGENTS CH, V37, P546, DOI 10.1128/AAC.37.3.546; Yeaman MR, 1996, INFECT IMMUN, V64, P1379, DOI 10.1128/IAI.64.4.1379-1384.1996; Yeaman MR, 1998, J CLIN INVEST, V101, P178, DOI 10.1172/JCI562; YEAMAN MR, 1992, INFECT IMMUN, V60, P1202, DOI 10.1128/IAI.60.3.1202-1209.1992; Yeaman MR, 1997, CLIN INFECT DIS, V25, P951, DOI 10.1086/516120; Zaat SAJ, 1997, ADV EXP MED BIOL, V418, P709; ZAAT SAJ, 1994, PATHOGENIC STREPTOCO, P473	70	238	250	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20374	20381		10.1074/jbc.275.27.20374	http://dx.doi.org/10.1074/jbc.275.27.20374			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10877842	hybrid, Green Published			2022-12-27	WOS:000088084500023
J	Fosang, AJ; Last, K; Stanton, H; Weeks, DB; Campbell, IK; Hardingham, TE; Hembry, RM				Fosang, AJ; Last, K; Stanton, H; Weeks, DB; Campbell, IK; Hardingham, TE; Hembry, RM			Generation and novel distribution of matrix metalloproteinase-derived aggrecan fragments in porcine cartilage explants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; HYALURONAN-BINDING REGION; ANTIGEN-INDUCED ARTHRITIS; HUMAN SYNOVIAL-FLUID; INTERGLOBULAR DOMAIN; BOVINE CARTILAGE; KERATAN SULFATE; ADAMTS FAMILY; CLEAVAGE-SITE; LINK-PROTEIN	We have studied aggrecan catabolism mediated by matrix metalloproteinases (MMPs) in a porcine cartilage culture system. Using antibodies specific for DIPEN341 and (342)FFGVG neoepitopes, we have detected MMP-derived fragments in conditioned medium and cultured cartilage, by radioimmunoassay, Western blotting, and immunolocalization. Radioimmunoassay revealed that the amount (pmol of epitope/mg of total glycosaminoglycan) of (342)FFGVG epitope released from cartilage remained constant over a 5-day culture period and was not increased by IL-1 alpha or retinoate. However, the proportion (pmol of epitope/mg of released glycosaminoglycan) of (342)FFGVG epitope released was decreased upon stimulation, consistent with the involvement of a non-MMP proteinase, such as aggrecanase. The data suggest that in vitro MMPs may be involved in the base-line catabolism of aggrecan, Immunolocalization experiments showed that DIPEN341 and ITEGE(373) epitopes were increased by treatment with IL-1 alpha and retinoate. Confocal microscopy revealed that ITEGE(373) epitope was largely intracellular but with matrix staining in the superficial zone, whereas DIPEN341 epitope was cell-associated and widely distributed in the matrix. Surprisingly, the majority of (342)FFGVG epitope, determined by radioimmunoassay and Western blotting, was retained in the tissue despite the absence of a G1 domain anchor. Interleukin-1 alpha stimulation caused a marked increase in tissue DIPEN341 and (342)FFGVG epitope, and the (342)FFGVG fragments retained in the tissue were larger than those released into the medium. Active porcine aggrecanase was unable to cleave (342)FFGVG fragments at the down arrow Glu(373) down arrow Ala(374) bond but cleaved intact aggrecan at this site, suggesting that (342)FFGVG fragments are not substrates for aggrecanase, The apparent retention of large (342)FFGVG fragments within cartilage, and their resistance to N-terminal cleavage by aggrecanase suggests that (342)FF6V6 fragments may have a role in cartilage homeostasis.	Univ Melbourne, Dept Paediat, Orthopaed Mol Biol Res Unit, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Murdock Childrens Res Inst, Parkville, Vic 3052, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia; Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Walter & Eliza Hall Institute; University of Manchester; University of East Anglia	Fosang, AJ (corresponding author), Univ Melbourne, Dept Paediat, Orthopaed Mol Biol Res Unit, Parkville, Vic 3052, Australia.	fosang@cryptic.rch.unimelb.edu.au		Last, Karena/0000-0002-4396-8404; Hardingham, Timothy/0000-0001-8271-6763; Fosang, Amanda/0000-0002-5523-5427; STANTON, HEATHER/0000-0002-3427-5614				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; BARRY FP, 1995, J BIOL CHEM, V270, P20516, DOI 10.1074/jbc.270.35.20516; BARRY FP, 1992, BIOCHEM J, V286, P761, DOI 10.1042/bj2860761; BOLIS S, 1989, BIOCHIM BIOPHYS ACTA, V993, P157, DOI 10.1016/0304-4165(89)90158-X; BONASSAR LJ, 1995, ARTHRITIS RHEUM, V38, P173, DOI 10.1002/art.1780380205; CARNEY SL, 1986, ANAL BIOCHEM, V156, P38, DOI 10.1016/0003-2697(86)90150-8; COMPER WD, 1987, J BIOL CHEM, V262, P13464; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; Dudhia J, 1996, BIOCHEM J, V313, P933, DOI 10.1042/bj3130933; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FLANNERY CR, 1993, T ORTHOP RES SOC, V18, P190; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FOSANG AJ, 1995, BIOCHEM J, V310, P337, DOI 10.1042/bj3100337; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; Fosang AJ, 1996, J CLIN INVEST, V98, P2292, DOI 10.1172/JCI119040; Fosang AJ, 1998, FEBS LETT, V430, P186, DOI 10.1016/S0014-5793(98)00667-X; FOSANG AJ, 1998, T ORTHOP RES SOC, V23, P83; FOSANG AJ, 1999, PROG INFLAM RES, P117; FRANZEN A, 1981, BIOCHEM J, V195, P535, DOI 10.1042/bj1950535; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HASCALL VC, 1999, BIOL SYNOVIAL JOINT; Hughes CE, 1998, J BIOL CHEM, V273, P30576, DOI 10.1074/jbc.273.46.30576; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; Ilic MZ, 1995, ACTA ORTHOP SCAND, V66, P33, DOI 10.3109/17453679509157644; ILIC MZ, 1995, ARCH BIOCHEM BIOPHYS, V322, P22, DOI 10.1006/abbi.1995.1431; Ilic MZ, 1998, J BIOL CHEM, V273, P17451, DOI 10.1074/jbc.273.28.17451; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; Little CB, 1999, BIOCHEM J, V344, P61, DOI 10.1042/0264-6021:3440061; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOHMANDER S, 1977, ARCH BIOCHEM BIOPHYS, V180, P93, DOI 10.1016/0003-9861(77)90012-1; Mercuri FA, 1999, J BIOL CHEM, V274, P32387, DOI 10.1074/jbc.274.45.32387; Mercuri FA, 2000, J BIOL CHEM, V275, P33038, DOI 10.1074/jbc.275.42.33038; MOK SS, 1994, J BIOL CHEM, V269, P33021; Mort JS, 1998, BIOCHEM J, V335, P491, DOI 10.1042/bj3350491; Mudgett JS, 1998, ARTHRITIS RHEUM-US, V41, P110, DOI 10.1002/1529-0131(199801)41:1<110::AID-ART14>3.0.CO;2-G; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; PLAAS AHK, 1983, BIOCHEM J, V214, P855, DOI 10.1042/bj2140855; SAH RLY, 1990, BIOCHEM J, V267, P803, DOI 10.1042/bj2670803; SANDY JD, 1978, BIOCHIM BIOPHYS ACTA, V543, P536, DOI 10.1016/0304-4165(78)90308-2; Sandy JD, 1995, ACTA ORTHOP SCAND, V66, P26, DOI 10.3109/17453679509157643; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P21; Singer II, 1997, OSTEOARTHR CARTILAGE, V5, P407, DOI 10.1016/S1063-4584(97)80045-3; Sztrolovics R, 1997, BIOCHEM J, V326, P235, DOI 10.1042/bj3260235; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; van Meurs J, 1999, ARTHRITIS RHEUM-US, V42, P2074, DOI 10.1002/1529-0131(199910)42:10<2074::AID-ANR7>3.0.CO;2-5; van Meurs JBJ, 1998, ARTHRITIS RHEUM, V41, P647, DOI 10.1002/1529-0131(199804)41:4<647::AID-ART11>3.0.CO;2-T; van Meurs JBJ, 1999, ANN RHEUM DIS, V58, P350, DOI 10.1136/ard.58.6.350; van Meurs JBJ, 1999, ARTHRITIS RHEUM, V42, P1128, DOI 10.1002/1529-0131(199906)42:6<1128::AID-ANR9>3.0.CO;2-2; WITT M, 1995, T ORTHOP RES SOC, V20, P122	55	60	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33027	33037		10.1074/jbc.M910207199	http://dx.doi.org/10.1074/jbc.M910207199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10882746	hybrid			2022-12-27	WOS:000090003800089
J	Hayashi, F; Matsuura, I; Kachi, S; Maeda, T; Yamamoto, M; Fujii, Y; Liu, H; Yamazaki, M; Usukura, J; Yamazaki, A				Hayashi, F; Matsuura, I; Kachi, S; Maeda, T; Yamamoto, M; Fujii, Y; Liu, H; Yamazaki, M; Usukura, J; Yamazaki, A			Phosphorylation by cyclin-dependent protein kinase 5 of the regulatory subunit of retinal cGMP phosphodiesterase II. Its role in the turnoff of phosphodiesterase in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; GTP-BINDING PROTEIN; GMP PHOSPHODIESTERASE; INHIBITORY SUBUNIT; GAMMA-SUBUNIT; ADP-RIBOSYLATION; IN-VIVO; PHOTORECEPTORS; ACTIVATION; TRANSDUCIN	Retinal cGMP phosphodiesterase (PDE) is regulated by P gamma, the regulatory subunit of PDE, and GTP/T alpha, the GTP-bound cu subunit of transducin. In the accompanying paper (Matsuura, I., Bondarenko, V. A., Maeda, T., Kachi, S., Yamazahi, M., Usukura, J., Hayashi, F., and Yamazaki, A. (2000) J. Biol. Chem. 275, 32950-32957), we have shown that all known P gammas contain a specific phosphorylation motif for cyclin-dependent protein kinase 5 (Cdk5) and that the unknown kinase is Cdk5 complexed with its activator. Here, using frog rod photoreceptor outer segments (ROS) isolated by a new method, we show that Cdk5 is involved in light-dependent P gamma phosphorylation in vivo. Under dark conditions only negligible amounts of P gamma were phosphorylated. However, under illumination that bleached less than 0.3% of the rhodopsin, similar to4% of the total P gamma was phosphorylated in less than 10 s. P gamma dephosphorylation occurred in less than 1 s after the light was turned off. Analysis of the phosphorylated amino acid, inhibition of P gamma phosphorylation by Cdk inhibitors in vivo and in vitro, and two-dimensional peptide map analysis of P gamma phosphorylated in vivo and in vitro indicate that Cdk5 phosphorylates a P gamma threonine in the same manner in vivo and in vitro. These observations, together with immunological data showing the presence of Cdk5 in ROS, suggest that Cdk5 is involved in light-dependent P gamma phosphorylation in ROS and that the phosphorylation is significant and reversible. In an homogenate of frog ROS, PDE activated by light/guanosine 5'-O-(3-thiotriphosphate) (GTP gammaS) was inhibited by P gamma alone, but not by P gamma complexed with GDP/T alpha or GTP gammaS/T alpha. Under these conditions, Py phosphorylated by Cdk5 inhibited the light/GTP gammaS-activated PDE even in the presence of GTP gammaS/T alpha. These observations suggest that phosphorylated P gamma interacts with and inhibits light/GTP gammaS-activated PDE, but does not interact with GTP gammaS/T alpha in the homogenate. Together, our results strongly suggest that after activation of PDE by light/GTP, P gamma is phosphorylated by Cdk5 and the phosphorylated P gamma inhibits GTP/T alpha -activated PDE, even in the presence of GTP/T alpha in ROS.	Kobe Univ, Fac Sci, Dept Biol, Kobe, Hyogo 657, Japan; Wayne State Univ, Sch Med, Kresge Eye Inst, Dept Ophthalmol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Kresge Eye Inst, Dept Pharmacol, Detroit, MI 48201 USA; Nagoya Univ, Sch Med, Dept Anat, Nagoya, Aichi 466, Japan	Kobe University; Wayne State University; Wayne State University; Nagoya University	Hayashi, F (corresponding author), Kobe Univ, Fac Sci, Dept Biol, Kobe, Hyogo 657, Japan.	fhayashi@kobe-u.ac.jp		Usukura, Jiro/0000-0003-2286-5403	NATIONAL EYE INSTITUTE [R01EY009631, R01EY007546] Funding Source: NIH RePORTER; NEI NIH HHS [EY07546, EY09631] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; BAEHR W, 1979, J BIOL CHEM, V254, P1669; Bondarenko VA, 1997, J BIOL CHEM, V272, P15856, DOI 10.1074/jbc.272.25.15856; Bondarenko VA, 1999, BIOCHEMISTRY-US, V38, P7755, DOI 10.1021/bi990106a; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLACK JW, 1983, NATURE, V305, P50, DOI 10.1038/305050a0; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; ERICKSON MA, 1992, SCIENCE, V257, P1255, DOI 10.1126/science.1519062; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GEER PD, 1905, PROTEIN PHOSPHORYLAT, P31; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4333, DOI 10.1073/pnas.88.10.4333; HAYASHI F, 1994, FEBS LETT, V338, P203, DOI 10.1016/0014-5793(94)80365-X; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hirooka K, 1996, J NEUROCHEM, V67, P2478; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; Matsuura I, 2000, J BIOL CHEM, V275, P32950, DOI 10.1074/jbc.M000702200; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MIKI N, 1975, J BIOL CHEM, V250, P6320; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; Nishizawa Y, 1999, EXP EYE RES, V69, P195, DOI 10.1006/exer.1999.0693; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Sagoo MS, 1997, NATURE, V389, P392, DOI 10.1038/38750; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P2106; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; TSUBOI S, 1994, J BIOL CHEM, V269, P15024; TSUBOI S, 1994, J BIOL CHEM, V269, P15016; UDOVICHENKO IP, 1994, J BIOL CHEM, V269, P9850; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; Wu M, 1998, J EXP MED, V187, P1671, DOI 10.1084/jem.187.10.1671; Xu LX, 1998, BIOCHEMISTRY-US, V37, P6205, DOI 10.1021/bi973087i; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1993, J BIOL CHEM, V268, P8899; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445	42	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32958	32965		10.1074/jbc.M000703200	http://dx.doi.org/10.1074/jbc.M000703200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10884379	hybrid			2022-12-27	WOS:000090003800080
J	Miyagi, T; Chuang, LF; Doi, RH; Carlos, MP; Torres, JV; Chuang, RY				Miyagi, T; Chuang, LF; Doi, RH; Carlos, MP; Torres, JV; Chuang, RY			Morphine induces gene expression of CCR5 in human CEM x174 lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; ENVELOPE GLYCOPROTEIN; CHEMOKINE RECEPTORS; OPIOID RECEPTORS; CELL-LINE; T-CELL; ACTIVATION; INFECTION; SULFATE; TYPE-1	All HIV-1 strains studied to date use CCR5, CXCR4, or both receptors to enter cells, Simian immunodeficiency virus (SIV) infection of non-human primates has served as a useful model for understanding AIDS pathogenesis in humans. Research on several genetically divergent SIV isolates has revealed that SIV uses CCR5, and not CXCR4, for entry. CEMx174, a human lymphoid cell line, has been routinely used to cultivate and maintain various SIV strains, However, questions have arisen about how CEMx174, which reportedly was unable to express detectable amounts of CCR5 transcripts, efficiently supports the growth of SIV. In searching for an answer, we resorted to a sensitive competitive reverse transcriptase-polymerase chain reaction procedure in an attempt to detect as well as quantify the amount of CCR5 expression. Here we present our findings, which indicate that CEMx174 indeed expresses CCR5 and that the amount of CCR5 is increased in cells pretreated with morphine. These results correlate well with our previous observations that morphine treatment causes CEMx174 cells to be more susceptible to SIV infection, Similar morphine effect was not observed on CEMx174 cells infected with simian retroviruses, which do not depend on CCR5 for entry. These findings suggest a plausible mechanism whereby opiate drug users render themselves more susceptible to HIV infection, thereby explaining the vast prevalence of HIV infection among endemic drug use populations.	Univ Calif Davis, Dept Med Pharmacol & Toxicol, Sch Med, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Dept Med Microbiol & Immunol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Chuang, RY (corresponding author), Univ Calif Davis, Dept Med Pharmacol & Toxicol, Sch Med, Davis, CA 95616 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005901, R01DA010433] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 10433, DA 05901] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Anderson DE, 1999, VIRAL IMMUNOL, V12, P47, DOI 10.1089/vim.1999.12.47; CHAO CC, 1993, INT J IMMUNOPHARMACO, V15, P447, DOI 10.1016/0192-0561(93)90057-6; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; Choi Y, 1999, IN VIVO, V13, P389; Chuang L F, 1993, In Vivo, V7, P159; CHUANG LF, 1993, BIOCHEM BIOPH RES CO, V195, P1165, DOI 10.1006/bbrc.1993.2167; Chuang LF, 1997, ADDICT BIOL, V2, P421, DOI 10.1080/13556219772471; CHUANG LF, 1995, BIOCHEM BIOPH RES CO, V209, P1003, DOI 10.1006/bbrc.1995.1597; CHUANG LF, 1994, BIOCHEM BIOPH RES CO, V202, P1291, DOI 10.1006/bbrc.1994.2071; Chuang LF, 1997, J BIOL CHEM, V272, P26815, DOI 10.1074/jbc.272.43.26815; CHUANG TK, 1995, BIOCHEM BIOPH RES CO, V216, P922, DOI 10.1006/bbrc.1995.2709; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Davey RA, 1997, J VIROL, V71, P8096, DOI 10.1128/JVI.71.11.8096-8102.1997; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Franchin G, 2000, J IMMUNOL, V164, P2592, DOI 10.4049/jimmunol.164.5.2592; Fraziano M, 1999, AIDS RES HUM RETROV, V15, P869, DOI 10.1089/088922299310575; Grimm MC, 1998, J EXP MED, V188, P317, DOI 10.1084/jem.188.2.317; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; Kirchhoff F, 1997, J VIROL, V71, P6509, DOI 10.1128/JVI.71.9.6509-6516.1997; Law PY, 1999, J PHARMACOL EXP THER, V289, P607; Lee B, 1999, J LEUKOCYTE BIOL, V65, P552; LIU Y, 1992, J PHARMACOL EXP THER, V263, P533; MAZZONE A, 1994, INT J IMMUNOPHARMACO, V16, P959, DOI 10.1016/0192-0561(94)90049-3; Miyagi T, 2000, IMMUNOPHARMACOLOGY, V47, P53, DOI 10.1016/S0162-3109(99)00188-5; Morgan EL, 1996, J NEUROIMMUNOL, V65, P21, DOI 10.1016/0165-5728(95)00171-9; PARK IW, 1991, J VIROL, V65, P2987, DOI 10.1128/JVI.65.6.2987-2992.1991; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; Rosenblum LL, 2000, J VIROL, V74, P3449, DOI 10.1128/JVI.74.8.3449-3454.2000; Roy S, 1998, BIOCHEM BIOPH RES CO, V245, P392, DOI 10.1006/bbrc.1998.8415; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; TORRES JV, 1991, J MED PRIMATOL, V20, P218; Trkola A, 1998, J VIROL, V72, P396, DOI 10.1128/JVI.72.1.396-404.1998; VEYRIES ML, 1995, J PHARMACOL EXP THER, V272, P498; Vodicka MA, 1997, VIROLOGY, V233, P193, DOI 10.1006/viro.1997.8606	36	60	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31305	31310		10.1074/jbc.M001269200	http://dx.doi.org/10.1074/jbc.M001269200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10887175	hybrid			2022-12-27	WOS:000089762700079
J	Ackmann, M; Wiech, H; Mandelkow, E				Ackmann, M; Wiech, H; Mandelkow, E			Nonsaturable binding indicates clustering of Tau on the microtubule surface in a paired helical filament-like conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TAU; ALZHEIMERS-DISEASE; BETA-TUBULIN; NEURODEGENERATIVE DISEASES; NERVOUS-SYSTEM; ALPHA-TUBULIN; LIVING CELLS; C-TERMINUS; PHOSPHORYLATION; DOMAIN	Tau protein modulates microtubule dynamics and forms insoluble aggregates in Alzheimer's disease. Because there is a discrepancy between reported affinities of Tau to microtubules, we determined the interaction over a wide concentration range using a sensitive enzyme -linked immunosorbent assay. We found that the interaction is biphasic and not monophasic as assumed earlier. The first binding phase is typical for identical and noninteracting binding sites, with dissociation constants around 0.1 mu M and stoichiometries around 0.2 Tau/tubulin dimer. Surprisingly, the second phase is nonsaturable and shows a nearly linear increase in bound Tau versus free Tau for free Tau concentrations higher than 2 mu M. The slope is proportional to the microtubule concentration. From this we define an overloading parameter with values around 50 mu M. The influence of Tau isoform, phosphorylation, and dimerization on both phases was investigated. Remarkably the overloading of Tau on microtubules leads to a thioflavin S fluorescence increase reminiscent of that seen with Tau aggregated into Alzheimer paired helical filaments. Because polyanions stimulate Tau aggregation and because the C-terminal domain of tubulin is polyanionic, we suggest that an early conformational change in Tau leading to paired helical filament aggregation occurs right on the microtubule surface.	DESY, Max Planck Unit Struct Mol Biol, D-22607 Hamburg, Germany	Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society	Mandelkow, E (corresponding author), DESY, Max Planck Unit Struct Mol Biol, Notkestr 85, D-22607 Hamburg, Germany.							Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; AMOS LA, 1977, J CELL BIOL, V72, P642, DOI 10.1083/jcb.72.3.642; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X; BOUCHER D, 1994, BIOCHEMISTRY-US, V33, P12471, DOI 10.1021/bi00207a014; BRAMBLETT GT, 1992, LAB INVEST, V66, P212; BRANDT R, 1994, J BIOL CHEM, V269, P11776; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Chau MF, 1998, BIOCHEMISTRY-US, V37, P17692, DOI 10.1021/bi9812118; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; COFFEY RL, 1995, J BIOL CHEM, V270, P1035, DOI 10.1074/jbc.270.3.1035; COFFEY RL, 1994, BIOCHEMISTRY-US, V33, P13199, DOI 10.1021/bi00249a006; CROSS D, 1991, BIOCHEMISTRY-US, V30, P4362, DOI 10.1021/bi00231a036; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; DeTure M, 2000, BRAIN RES, V853, P5, DOI 10.1016/S0006-8993(99)02124-1; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; Friedhoff P, 1998, P NATL ACAD SCI USA, V95, P15712, DOI 10.1073/pnas.95.26.15712; Friedhoff P, 1998, BIOCHEMISTRY-US, V37, P10223, DOI 10.1021/bi980537d; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HILLER G, 1978, CELL, V14, P795, DOI 10.1016/0092-8674(78)90335-5; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; Kampers T, 1996, FEBS LETT, V399, P344, DOI 10.1016/S0014-5793(96)01386-5; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; King ME, 1999, BIOCHEMISTRY-US, V38, P14851, DOI 10.1021/bi9911839; LITMAN P, 1993, NEURON, V10, P627, DOI 10.1016/0896-6273(93)90165-N; MACCIONI RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P568, DOI 10.1016/0003-9861(89)90403-7; MACCIONI RB, 1988, EMBO J, V7, P1957, DOI 10.1002/j.1460-2075.1988.tb03033.x; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; MANDELKOW EM, 1985, J MOL BIOL, V185, P911; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; PANDA D, 1995, BIOCHEMISTRY-US, V34, P11117, DOI 10.1021/bi00035a017; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; Perez M, 1996, J NEUROCHEM, V67, P1183; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; SCHOENFELD TA, 1994, INT REV CYTOL, V151, P67, DOI 10.1016/S0074-7696(08)62631-5; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Thormahlen' M, 1998, J MOL BIOL, V275, P795, DOI 10.1006/jmbi.1997.1503; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; VOTER WA, 1982, J ULTRA MOL STRUCT R, V80, P374, DOI 10.1016/S0022-5320(82)80051-8; WALLIS KT, 1993, J BIOL CHEM, V268, P15158; Westermann S, 1999, J CELL SCI, V112, P2185; Wilhelmsen KC, 1999, P NATL ACAD SCI USA, V96, P7120, DOI 10.1073/pnas.96.13.7120; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x; ZINGSHEIM HP, 1979, EUR J CELL BIOL, V19, P175	61	111	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30335	30343		10.1074/jbc.M002590200	http://dx.doi.org/10.1074/jbc.M002590200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10869348	hybrid			2022-12-27	WOS:000089577900058
J	Murthy, KS; Makhlouf, GM				Murthy, KS; Makhlouf, GM			Heterologous desensitization mediated by G protein-specific binding to caveolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE CELLS; PLASMA-MEMBRANE; TYROSINE KINASE; SOMATOSTATIN RECEPTOR; SIGNAL-TRANSDUCTION; SCAFFOLDING DOMAIN; COUPLED RECEPTOR; CARDIAC MYOCYTES; ALPHA-SUBUNITS	We examined the notion that sequestration of G protein subunits by binding to caveolin impedes G protein reassociation and leads to transient, G protein-specific desensitization of response in dispersed smooth muscle cells. Cholecystokinin octapeptide (CCK-8) and substance P (SP) were used to activate G(q/11) cyclopentyl adenosine (CPA) was used to activate G(i3), and acetylcholine (ACh) was used to activate both G(q/11) and G(i3) via m3 and m2 receptors, respectively. CCK-8 and SP increased only G alpha(q/11), and CPA increased only G alpha(i3) in caveolin immunoprecipitates; caveolin and other G proteins were not increased. ACh increased both G alpha(q/11) and G alpha(i3) in a time- and concentration-dependent fashion: only G alpha(q/11) was increased in the presence of an m2 antagonist, and only G alpha(i3) was increased in the presence of an m3 antagonist. To determine whether transient G protein binding to caveolin affected subsequent responses mediated by the same G protein, PLC-beta activity was measured in cells stimulated sequentially with two different agonists that activate either the same or a different G;protein. After treatment of the cells with ACh and an m2 antagonist, the phospholipase C-beta (PLC-beta) response to CCK-8 and SP, but not CPG was decreased; conversely, after treatment of the cells with ACh and an m3 antagonist, the PLC-beta response to CPA, but not CCK-8 or SP, was decreased. Similarly, after treatment with CCK-8 or SP, the PLC-beta response mediated by G(q/11) only was decreased, whereas after treatment with CPA, the PLC-beta response mediated by G(i3) only was decreased. A caveolin-binding G alpha(q/11) fragment blocked the binding of activated G alpha(q/11) but not G alpha(i3) to caveolin-3 and prevented desensitization of the PLC-beta response mediated only by other G(q/11)-coupled receptors. A caveolin-binding G alpha(i3) fragment had the reverse effect. Thus, transient binding of receptor-activated G protein subunits to caveolin impedes reassociation of the heterotrimeric species and leads to desensitization of response mediated by other receptors coupled to the same G protein.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Murthy, KS (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, POB 980711, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015564, R37DK015564] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK15564] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Filtz TM, 1999, BIOCHEM J, V338, P257, DOI 10.1042/0264-6021:3380257; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; KOSAZA T, 1996, J BIOL CHEM, V271, P12562; KURZCHALIA TV, 1994, FEBS LETT, V346, P88, DOI 10.1016/0014-5793(94)00466-8; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURTHY KS, 1991, AM J PHYSIOL, V261, pG945, DOI 10.1152/ajpgi.1991.261.6.G945; MURTHY KS, 1995, MOL PHARMACOL, V47, P1172; Murthy KS, 1999, J BIOL CHEM, V274, P17587, DOI 10.1074/jbc.274.25.17587; Murthy KS, 1997, J BIOL CHEM, V272, P21317, DOI 10.1074/jbc.272.34.21317; MURTHY KS, 1995, AM J PHYSIOL-CELL PH, V269, pC969, DOI 10.1152/ajpcell.1995.269.4.C969; MURTHY KS, 1995, AM J PHYSIOL-GASTR L, V269, pG93, DOI 10.1152/ajpgi.1995.269.1.G93; Murthy KS, 2000, AM J PHYSIOL-CELL PH, V279, pC925, DOI 10.1152/ajpcell.2000.279.4.C925; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; MURTHY KS, 1996, MOL PHARMACOL, V50, P770; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OKAMOTO T, 1992, FEBS LETT, V305, P125, DOI 10.1016/0014-5793(92)80878-K; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; PRMONT RT, 1995, FASEB J, V9, P175; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schwencke C, 1999, J CELL BIOCHEM, V75, P64, DOI 10.1002/(SICI)1097-4644(19991001)75:1<64::AID-JCB7>3.0.CO;2-L; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SOHN UD, 1995, J PHARMACOL EXP THER, V273, P482; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, CELL MOL BIOL, V43, P293; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554	54	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30211	30219		10.1074/jbc.M002194200	http://dx.doi.org/10.1074/jbc.M002194200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10862762	hybrid			2022-12-27	WOS:000089577900042
J	Stevens, K; Cirillo, L; Zaret, KS				Stevens, K; Cirillo, L; Zaret, KS			Creating temperature-sensitive winged helix transcription factors - Amino acids that stabilize the DNA binding domain of HNF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; TURN-HELIX; FORK HEAD; SITE; PROTEINS; MOTIF; SPECTROSCOPY; NUCLEOSOME; REPRESSOR; COMPLEX	Winged helix transcription factors contain two polypeptide loops, or "wings," that make minor groove contacts with DNA from either side of a three-helix bundle that binds the DNA major groove. While wing 1 is stabilized by a beta-sheet, parameters that stabilize wing 2 are unknown. Herein we identify two bulky aromatic residues in wing 2 that stabilize the loop structure and, thereby, the entire protein's DNA binding and transcriptional stimulatory activity by interacting with other residues in the three-helix bundle. Mutations of these wing 2 residues create proteins that are temperature-sensitive for transcriptional activity. Aromatic and/or hydrophobic residues are highly conserved among the 150 known winged helix proteins, suggesting conserved function. We suggest that the winged helix structure evolved by the acquisition of aromatic and/or hydrophobic residues in distal polypeptide sequences that helped stabilize the association of a protein loop (wing 2) with the three helix bundle, thereby enhancing DNA binding.	Fox Chase Canc Ctr, Program Cell & Dev Biol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Zaret, KS (corresponding author), Fox Chase Canc Ctr, Program Cell & Dev Biol, Rm W410,7701 Burholme Ave, Philadelphia, PA 19111 USA.				NIGMS NIH HHS [GM47903] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047903] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; CERF C, 1994, BIOCHEMISTRY-US, V33, P11079, DOI 10.1021/bi00203a004; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DAMBERGER FF, 1994, PROTEIN SCI, V3, P1806, DOI 10.1002/pro.5560031020; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; FOGH RH, 1994, EMBO J, V13, P3936, DOI 10.1002/j.1460-2075.1994.tb06709.x; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; QIU XY, 1995, STRUCTURE, V3, P87, DOI 10.1016/S0969-2126(01)00137-X; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; VUISTER GW, 1994, BIOCHEMISTRY-US, V33, P10, DOI 10.1021/bi00167a002; WILSON DB, 1992, NUCLEIC ACIDS RES, V20, P699; Zaret KS, 1995, PROTEIN EXPRES PURIF, V6, P821, DOI 10.1006/prep.1995.0014; ZARET KS, 1988, P NATL ACAD SCI USA, V85, P9076, DOI 10.1073/pnas.85.23.9076	26	10	10	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30471	30477		10.1074/jbc.M004891200	http://dx.doi.org/10.1074/jbc.M004891200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896667	hybrid			2022-12-27	WOS:000089577900076
J	Berger, AL; Welsh, MJ				Berger, AL; Welsh, MJ			Differences between cystic fibrosis transmembrane conductance regulator and HisP in the interaction with the adenine ring of ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAINS; CFTR CHLORIDE CHANNEL; PROTEIN-KINASE-A; ABC TRANSPORTER; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; HISTIDINE PERMEASE; SYNTHETIC PEPTIDE; CRYSTAL-STRUCTURE; SUBUNIT	The cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel is a member of the ATP-binding cassette transporter family. The most conserved features of this family are the nucleotide-binding domains. As in other members of this family, these domains bind and hydrolyze ATP; in CFTR this opens and closes the channel pore. The recent crystal structures of related bacterial transporters show that an aromatic residue interacts with the adenine ring of ATP to stabilize nucleotide binding. CFTR contains six aromatic residues that are candidates to coordinate the nucleotide base, We mutated each to cysteine and examined the functional consequences. None of the mutations disrupted channel function or the ability to discriminate between ATP, GTP, and CTP. We also applied [2-(triethylammonium)ethyl] methanethiosulfonate to covalently modify the introduced cysteines, The mutant channels CFTR-F429C, F430C, F433C, and F1232C showed no difference from wild-type CFTR, indicating that either the residues were not accessible to modification, or cysteine modification did not affect function. Although modification inactivated CFTR-Y1219C more rapidly than wild-type CFTR, and inactivation of CFTR-F446C was nucleotide-dependent; failure of these mutations to alter gating suggested that Tyr(1219) and Phe(446) were not important for nucleotide binding. The results suggest that ATP binding may not involve the coordination of the adenine ring by an aromatic residue analogous to that in some bacterial transporters. Taken together with earlier work, this study points to a model in which most of the binding energy for ATP is contributed by the phosphate groups.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Biophys, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa	Welsh, MJ (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Internal Med, 500 EMRB, Iowa City, IA 52242 USA.			Welsh, Michael/0000-0002-1646-6206				ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GF, 1989, J BIOL CHEM, V264, P3998; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARMSTRONG S, 1998, PEDIAT PULMONOL, V17, P91; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; Briozzo P, 1998, STRUCTURE, V6, P1517, DOI 10.1016/S0969-2126(98)00150-6; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; Cotten JF, 1998, J BIOL CHEM, V273, P31873, DOI 10.1074/jbc.273.48.31873; Croop JM, 1998, METHOD ENZYMOL, V292, P101; DAWSON DC, 1999, PHYSIOL REV, V79, P47; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; Foskett JK, 1998, ANNU REV PHYSIOL, V60, P689, DOI 10.1146/annurev.physiol.60.1.689; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Ikuma M, 2000, P NATL ACAD SCI USA, V97, P8675, DOI 10.1073/pnas.140220597; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; MORBACH S, 1993, J BIOL CHEM, V268, P18617; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Ramjeesingh M, 1999, BIOCHEMISTRY-US, V38, P1463, DOI 10.1021/bi982243y; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; SCHULTZ BD, 1995, J GEN PHYSIOL, V105, P329, DOI 10.1085/jgp.105.3.329; Sheppard DN, 1999, PHYSIOL REV, V79, P23; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; TRAVIS SM, 1993, J BIOL CHEM, V268, P15336; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Weinreich F, 1999, J GEN PHYSIOL, V114, P55, DOI 10.1085/jgp.114.1.55; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; Zhong XT, 1998, J BACTERIOL, V180, P1347, DOI 10.1128/JB.180.6.1347-1353.1998	43	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29407	29412		10.1074/jbc.M004790200	http://dx.doi.org/10.1074/jbc.M004790200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893239	hybrid			2022-12-27	WOS:000089439800032
J	Schweizer, A; Stahl, PD; Rohrer, J				Schweizer, A; Stahl, PD; Rohrer, J			A di-aromatic motif in the cytosolic tail of the mannose receptor mediates endosomal sorting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; TRANS-GOLGI NETWORK; 6-PHOSPHATE RECEPTOR; CYTOPLASMIC TAIL; ALVEOLAR MACROPHAGES; LYSOSOMAL MEMBRANE; DENDRITIC CELLS; CANDIDA-ALBICANS; PROTEIN; PHAGOCYTOSIS	The mannose receptor (MR), the prototype of a new family of multilectin receptor proteins important in innate immunity, undergoes rapid internalization and recycling from the endosomal system back to the cell surface. Sorting of the MR in endosomes prevents the receptor from entering lysosomes where it would be degraded. Here, we focused on a diaromatic sequence (Tyr(18)-Phe(19)) in the MR cytoplasmic tail as an endosomal sorting signal. The subcellular distribution of chimeric constructs between the MR and the cation-dependent mannose 6-phosphate receptor was assessed by Percoll density gradients and cell surface assays. Unlike the wild type constructs, mutant receptors with alanine substitutions of Tyr(18)-Phe(19) were highly missorted to lysosomes, indicating that the di-aromatic motif of the MR cytoplasmic tail mediates sorting in endosomes. Within this sequence Tyr(18) is the key residue with Phe(19) contributing to this function. Moreover, Tyr(18) was also found to be essential for internalization, consistent with the presence of overlapping signals for internalization and endosomal sorting in the cytosolic tail of the MR. A di-aromatic amino acid sequence in the cytosolic tail has now been shown to function in two receptors known to be internalized from the plasma membrane, the MR and the cation-dependent mannose 6-phosphate receptor. This feature therefore appears to be a general determinant for endosomal sorting.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Friedrich Miescher Institute for Biomedical Research; Washington University (WUSTL)	Rohrer, J (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.		Stahl, Philip/D-6315-2012	Rohrer, Jack/0000-0002-2058-490X	NIAID NIH HHS [2R01AI20015-16] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020015] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Behrendt N, 2000, J BIOL CHEM, V275, P1993, DOI 10.1074/jbc.275.3.1993; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; Brodsky FM, 1997, TRENDS CELL BIOL, V7, P175, DOI 10.1016/S0962-8924(97)01038-6; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Engering AJ, 1997, EUR J IMMUNOL, V27, P2417, DOI 10.1002/eji.1830270941; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GARNER RE, 1994, J LEUKOCYTE BIOL, V55, P161, DOI 10.1002/jlb.55.2.161; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRUSKAL BA, 1992, J EXP MED, V176, P1673, DOI 10.1084/jem.176.6.1673; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LARGENT BL, 1984, J BIOL CHEM, V259, P1764; LENNARTZ MR, 1989, J BIOL CHEM, V264, P2385; LUDWIG T, 1995, TRENDS CELL BIOL, V5, P202, DOI 10.1016/S0962-8924(00)89000-5; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MATOVCIK LM, 1990, EUR J CELL BIOL, V53, P203; MESSNER DJ, 1993, ARCH BIOCHEM BIOPHYS, V306, P391, DOI 10.1006/abbi.1993.1528; Orsel JG, 2000, P NATL ACAD SCI USA, V97, P9047, DOI 10.1073/pnas.160251397; PARISE ER, 1984, J LAB CLIN MED, V104, P908; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; PISKURICH JF, 1995, J IMMUNOL, V154, P1735; Pontow SE, 1996, J BIOL CHEM, V271, P30736, DOI 10.1074/jbc.271.48.30736; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Sambrook J, 1998, MOL CLONING LAB MANU, V2nd; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schweizer A, 1997, P NATL ACAD SCI USA, V94, P14471, DOI 10.1073/pnas.94.26.14471; Shibata Y, 1997, J IMMUNOL, V159, P2462; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; SUNG SSJ, 1983, J CELL BIOL, V96, P160, DOI 10.1083/jcb.96.1.160; SWIGGARD WJ, 1995, CELL IMMUNOL, V165, P302, DOI 10.1006/cimm.1995.1218; Tan MCAA, 1997, EUR J IMMUNOL, V27, P2426, DOI 10.1002/eji.1830270942; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TIETZE C, 1982, J CELL BIOL, V92, P417, DOI 10.1083/jcb.92.2.417; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wu K, 1996, J BIOL CHEM, V271, P21323, DOI 10.1074/jbc.271.35.21323; Yamamoto Y, 1997, INFECT IMMUN, V65, P1077, DOI 10.1128/IAI.65.3.1077-1082.1997	50	49	51	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29694	29700		10.1074/jbc.M000571200	http://dx.doi.org/10.1074/jbc.M000571200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896932	hybrid			2022-12-27	WOS:000089439800069
J	Srinivasan, C; Liba, A; Imlay, JA; Valentine, JS; Gralla, EB				Srinivasan, C; Liba, A; Imlay, JA; Valentine, JS; Gralla, EB			Yeast lacking superoxide dismutase(s) show elevated levels of "free iron" as measured by whole cell electron paramagnetic resonance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; IN-VIVO; STATIONARY-PHASE; DNA-DAMAGE; MITOCHONDRIAL; ACONITASE; INACTIVATION; DEHYDRATASE	A current hypothesis explaining the toxicity of superoxide anion in vivo is that it oxidizes exposed [4Fe-4S] clusters in certain vulnerable enzymes causing release of iron and enzyme inactivation. The resulting increased levels of "free iron" catalyze deleterious oxidative reactions in the cell. In this study, we used low temperature Fe(III) electron paramagnetic resonance (EPR) spectroscopy to monitor iron status in whole cells of the unicellular eukaryote, Saccharomyces cerevisiae. The experimental protocol involved treatment of the cells with desferrioxamine, a cell-permeant, Fe(III)-specific chelator, to promote oxidation of all of the "free iron" to the Fe(III) state wherein it is EPR-detectable. Using this method, a small amount of EPR-detectable iron was detected in the wild-type strain, whereas significantly elevated levels were found in strains lacking CuZn-superoxide dismutase (CuZn-SOD) (sod1 Delta), Mn-SOD (sod2 Delta), or both SODs, throughout their growth but particularly in stationary phase, The accumulation was suppressed by expression of wild-type human CuZn-SOD (in the sod1 Delta mutant), by pmr1, a genetic suppressor of the sod Delta mutant phenotype (in the sod1 Delta sod2 Delta double knockout strain), and by anaerobic growth. In wild-type cells, an increase in the EPR-detectable iron pool could be induced by treatment with paraquat, a redox-cycling drug that generates superoxide. Cells that were not pretreated with desferrioxamine had Fe(III) EPR signals that were equally as strong as those from treated cells, indicating that "free iron" accumulated in the ferric form in our strains in vivo. Our results indicate a relationship between superoxide stress and iron handling and support the above hypothesis for superoxide-related oxidative damage.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of California System; University of California Los Angeles; University of Illinois System; University of Illinois Urbana-Champaign	Gralla, EB (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.	egralla@chem.ucla.edu	Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X	NIDDK NIH HHS [DK46828] Funding Source: Medline; NIGMS NIH HHS [GM59030] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059030] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Bencini A, 1999, INORGANIC ELECTRONIC STRUCTURE AND SPECTROSCOPY, VOL I, P93; Benov L, 1998, J BIOL CHEM, V273, P10313, DOI 10.1074/jbc.273.17.10313; BEYER W, 1991, PROG NUCLEIC ACID RE, V40, P221; Chen OS, 2000, J BIOL CHEM, V275, P7626, DOI 10.1074/jbc.275.11.7626; Corson LB, 1999, J BIOL CHEM, V274, P27590, DOI 10.1074/jbc.274.39.27590; Csere P, 1998, FEBS LETT, V441, P266, DOI 10.1016/S0014-5793(98)01560-9; De Freitas JM, 2000, J BIOL CHEM, V275, P11645, DOI 10.1074/jbc.275.16.11645; Fleming RE, 1999, P NATL ACAD SCI USA, V96, P3143, DOI 10.1073/pnas.96.6.3143; FLINT DH, 1993, J BIOL CHEM, V268, P25547; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; Gardner PR, 1997, BIOSCIENCE REP, V17, P33, DOI 10.1023/A:1027383100936; GARDNER PR, 1993, ARCH BIOCHEM BIOPHYS, V301, P98, DOI 10.1006/abbi.1993.1120; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; Gort AS, 1998, J BACTERIOL, V180, P1402, DOI 10.1128/JB.180.6.1402-1410.1998; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GRALLA EB, 1997, COLD SPRING HARBOR M, V34, P495; Guthrie C, 1991, METHODS ENZYMOL, V194; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; Kaiser C., 1994, METHODS YEAST GENETI; Keyer K, 1997, J BIOL CHEM, V272, P27652, DOI 10.1074/jbc.272.44.27652; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Kozlov AV, 1996, BIOMETALS, V9, P98, DOI 10.1007/BF00188097; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; Lin SJ, 1996, MOL CELL BIOL, V16, P6303; LIOCHEV SI, 1993, ARCH BIOCHEM BIOPHYS, V301, P379, DOI 10.1006/abbi.1993.1159; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; Liochev SI, 1996, FREE RADICAL RES, V25, P369, DOI 10.3109/10715769609149059; LIU XF, 1992, J BIOL CHEM, V267, P18298; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Longo VD, 1999, ARCH BIOCHEM BIOPHYS, V365, P131, DOI 10.1006/abbi.1999.1158; Maringanti S, 1999, J BACTERIOL, V181, P3792, DOI 10.1128/JB.181.12.3792-3802.1999; MCCORD JM, 1971, P NATL ACAD SCI USA, V68, P1024, DOI 10.1073/pnas.68.5.1024; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; Murakami K, 1997, BIOCHEM MOL BIOL INT, V41, P481; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; SAWYER DT, 1981, ACCOUNTS CHEM RES, V14, P393, DOI 10.1021/ar00072a005; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Valentine JS, 1998, CURR OPIN CHEM BIOL, V2, P253, DOI 10.1016/S1367-5931(98)80067-7; Vasquez-Vivar J, 2000, J BIOL CHEM, V275, P14064, DOI 10.1074/jbc.275.19.14064	53	107	109	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29187	29192		10.1074/jbc.M004239200	http://dx.doi.org/10.1074/jbc.M004239200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882731	hybrid			2022-12-27	WOS:000089439800003
J	Strano, S; Munarriz, E; Rossi, M; Cristofanelli, B; Shaul, Y; Castagnoli, L; Levine, AJ; Sacchi, A; Cesareni, G; Oren, M; Blandino, G				Strano, S; Munarriz, E; Rossi, M; Cristofanelli, B; Shaul, Y; Castagnoli, L; Levine, AJ; Sacchi, A; Cesareni, G; Oren, M; Blandino, G			Physical and functional interaction between p53 mutants and different isoforms of p73	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-BINDING DOMAIN; KINASE C-ABL; LUNG-CANCER; SV40-TRANSFORMED CELLS; P53-RELATED PROTEIN; APOPTOTIC RESPONSE; INDUCE APOPTOSIS; DNA-DAMAGE; T-ANTIGEN; GENE	p53 is the most frequently inactivated tumor suppressor gene in human cancer, whereas its homologue, p73, is rarely mutated. Similarly to p53, p73 can promote growth arrest or apoptosis when overexpressed in certain p53-null tumor cells. It has previously been shown that some human tumor-derived p53 mutants can exert gain of function activity. The molecular mechanism underlying this activity remains to be elucidated. We show here that human tumor-derived p53 mutants (p53His175 and p53Gly281) associate in vitro and in vivo with p73 alpha, beta, gamma, and delta. This association occurs under physiological conditions, as verified in T47D and SKBR3 breast cancer cell lines. The core domain of mutant p53 is sufficient for the association with p73, whereas both the specific DNA binding and the oligomerization domains of p73 are required for the association with mutant p53. Furthermore, p53His175 and p53Gly281 mutants markedly reduce the transcriptional activity of the various isoforms of p73. Thus, human tumor-derived p53 mutants can associate with p73 not only physically but also functionally. These findings define a network involving mutant p53 and the various spliced isoforms of p73 that may confer upon tumor cells a selective survival advantage.	Regina Elena Canc Ctr, Mol Oncogenesis Lab, I-00158 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Biol, I-00100 Rome, Italy; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Rockefeller Univ, New York, NY 10021 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	University of Rome Tor Vergata; Weizmann Institute of Science; Rockefeller University; Weizmann Institute of Science	Blandino, G (corresponding author), Regina Elena Canc Ctr, Mol Oncogenesis Lab, Via Messi Doro 156, I-00158 Rome, Italy.	blandino@ifo.it	Strano, Sabrina/K-9654-2016; strano, sabrina/B-6743-2013; Cesareni, Gianni/AAW-1382-2020; Blandino, Giovanni/B-1137-2013; Rossi, Mario/E-7666-2012	strano, sabrina/0000-0002-6341-4230; Blandino, Giovanni/0000-0002-6970-2241; Rossi, Mario/0000-0001-6349-8895; Munarriz, Eliana/0000-0002-3556-117X; Castagnoli, Luisa/0000-0001-5283-8671; Oren, Moshe/0000-0003-4311-7172	Telethon [369/BI] Funding Source: Medline	Telethon(Fondazione Telethon)		Agami R, 1999, NATURE, V399, P809; Almog Nava, 1998, Biochimica et Biophysica Acta, V1378, pR43; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gong JG, 1999, NATURE, V399, P806; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kroiss MM, 1998, MELANOMA RES, V8, P504, DOI 10.1097/00008390-199812000-00005; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Matoskova B, 1996, ONCOGENE, V12, P2679; Matoskova B, 1996, ONCOGENE, V12, P2563; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nimura Y, 1998, INT J CANCER, V78, P437, DOI 10.1002/(SICI)1097-0215(19981109)78:4<437::AID-IJC8>3.0.CO;2-V; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Nomoto S, 1998, CANCER RES, V58, P1380; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Prabhu NS, 1998, INT J ONCOL, V13, P5; Prives C, 1999, J PATHOL, V187, P112; Scharnhorst V, 2000, J BIOL CHEM, V275, P10202, DOI 10.1074/jbc.275.14.10202; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Takahashi H, 1998, CANCER RES, V58, P2076; Tsao H, 1999, CANCER RES, V59, P172; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	55	205	212	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29503	29512		10.1074/jbc.M003360200	http://dx.doi.org/10.1074/jbc.M003360200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10884390	hybrid			2022-12-27	WOS:000089439800044
J	Han, DC; Shen, TL; Guan, JL				Han, DC; Shen, TL; Guan, JL			Role of Grb7 targeting to focal contacts and its phosphorylation by focal adhesion kinase in regulation of cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE KINASE; SH2 DOMAIN PROTEINS; SRC FAMILY KINASES; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ESOPHAGEAL-CARCINOMA; PLECKSTRIN HOMOLOGY; COMPLEX-FORMATION	We have previously described Grb7 association with focal adhesion kinase (FAR) and its possible roles in cell migration. In this paper, we investigated the mechanisms by which Grb7 and its association with FAK regulate cell migration. We found that deletion of the Grb7 SH2 domain eliminated partial Grb7 localization to focal contacts and its ability to stimulate cell. migration. Replacement of the SH2 domain with the focal adhesion targeting sequence from FAK resulted in the focal contacts localization of the chimeric molecule and restored its activity to stimulate cell migration. We also found that Grb7 could be phosphorylated by FAK, which was dependent on the FAK kinase activity but not the presence of the Src family kinases, Cell adhesion also enhanced Grb7 phosphorylation in FAK+/+ cells but not FAK-/- cells, suggesting that Grb7 is a physiological substrate of FAK, Furthermore, both Grb7 and the chimeric molecule did not increase migration of FAK-/- cells, although the chimeric molecule was targeted to the focal contacts. Last, we showed that other Grb7 family members could not stimulate cell migration under similar experimental conditions. Together, these results demonstrate a role for Grb7 targeting to focal contacts and its phosphorylation by FAK in the regulation of cell migration.	Cornell Univ, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA	Cornell University	Guan, JL (corresponding author), Cornell Univ, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA.		Shen, Tang-Long/C-7460-2011	Shen, Tang-Long/0000-0001-6264-3608	NIGMS NIH HHS [GM48050] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cary LA, 1996, J CELL SCI, V109, P1787; CHAN PY, 1994, J BIOL CHEM, V269, P20567; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Janes PW, 1997, J BIOL CHEM, V272, P8490, DOI 10.1074/jbc.272.13.8490; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Manser J, 1997, DEV BIOL, V184, P150, DOI 10.1006/dbio.1997.8516; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Tanaka S, 1997, CANCER RES, V57, P28; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; TURNER CE, 1994, J CELL SCI, V107, P1583; Vuori K, 1996, MOL CELL BIOL, V16, P2606; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	48	86	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28911	28917		10.1074/jbc.M001997200	http://dx.doi.org/10.1074/jbc.M001997200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893408	hybrid			2022-12-27	WOS:000089330700076
J	Hasler, U; Greasley, PJ; von Heijne, G; Geering, K				Hasler, U; Greasley, PJ; von Heijne, G; Geering, K			Determinants of topogenesis and glycosylation of type II membrane proteins - Analysis of Na,K-ATPase beta(1) and beta(3) subunits by glycosylation mapping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; ALPHA-SUBUNIT; FUNCTIONAL EXPRESSION; TRANSMEMBRANE ORIENTATION; INTRACELLULAR-TRANSPORT; STRUCTURE PREDICTION; CHARGED RESIDUES; PRIMARY SEQUENCE; INVARIANT CHAIN; SIGNAL SEQUENCE	The structural and molecular determinants that govern the correct membrane insertion and folding of membrane proteins are still ill-defined. By following the addition of sugar chains to engineered glycosylation sites (glycosylation mapping) in Na,R-ATPase beta isoforms expressed in vitro and in Xenopus oocytes, in combination with biochemical techniques, we have defined the C-terminal end of the transmembrane domain of these type II proteins. N-terminal truncation and the removal of a single charged residue at the N-terminal start of the putative transmembrane domain influence the proper positioning of the transmembrane domain in the membrane as reflected by a repositioning of the transmembrane domain, the exposure of a putative cryptic signal peptidase cleavage site, and the production of protein species unable to insert into the membrane. Glycosylation mapping in vivo revealed that the degree of glycosylation at acceptor sites located close to the membrane increases with the time proteins spend in the endoplasmic reticulum. Furthermore, core sugars added to such acceptor sites cannot be processed to fully glycosylated species even when the protein is transported to the cell surface. Thus, the glycosylation mapping strategy applied in intact cells is a useful tool for the study of determinants for the correct membrane insertion of type II and probably other membrane proteins, as well as for the processing of sugar chains in glycoproteins.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Stockholm Univ, Dept Biochem, S-10691 Stockholm, Sweden	University of Lausanne; Stockholm University	Geering, K (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, 27 Rue Bugnon, CH-1005 Lausanne, Switzerland.	kaethi.geering@ipharm.unil.ch	von Heijne, Gunnar/F-5576-2011; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; 				ACKERMANN U, 1992, J BIOL CHEM, V267, P12911; Beggah A, 1996, J BIOL CHEM, V271, P20895, DOI 10.1074/jbc.271.34.20895; Beggah AT, 1999, J BIOL CHEM, V274, P8217, DOI 10.1074/jbc.274.12.8217; Beggah AT, 1997, J BIOL CHEM, V272, P10318; BEGGAH AT, 1993, BIOCHEMISTRY-US, V32, P14117, DOI 10.1021/bi00214a007; Beguin P, 1998, J BIOL CHEM, V273, P24921, DOI 10.1074/jbc.273.38.24921; BELTZER JP, 1991, J BIOL CHEM, V266, P973; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; Drickamer K, 1998, TRENDS BIOCHEM SCI, V23, P321, DOI 10.1016/S0968-0004(98)01246-8; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; GALLAGHER P, 1988, J CELL BIOL, V107, P2059, DOI 10.1083/jcb.107.6.2059; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; GEERING K, 1997, MOL B INT U, P173; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; GOOD PJ, 1988, J VIROL, V62, P944, DOI 10.1128/JVI.62.3.944-953.1988; GOOD PJ, 1990, P NATL ACAD SCI USA, V87, P9088, DOI 10.1073/pnas.87.23.9088; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hasler U, 1998, J BIOL CHEM, V273, P30826, DOI 10.1074/jbc.273.46.30826; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; Melle-Milovanovic D, 1998, J BIOL CHEM, V273, P11075, DOI 10.1074/jbc.273.18.11075; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; Nilsson I, 1998, J MOL BIOL, V284, P1165, DOI 10.1006/jmbi.1998.2217; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Or E, 1999, J BIOL CHEM, V274, P2802, DOI 10.1074/jbc.274.5.2802; ROST B, 1996, ISMB, V4, P192; SARVAZYAN NA, 1995, J BIOL CHEM, V270, P26528, DOI 10.1074/jbc.270.44.26528; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; Schroder K, 1999, EMBO J, V18, P4804, DOI 10.1093/emboj/18.17.4804; Shainskaya A, 1996, J BIOL CHEM, V271, P10309, DOI 10.1074/jbc.271.17.10309; Shainskaya A, 2000, J BIOL CHEM, V275, P2019, DOI 10.1074/jbc.275.3.2019; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; VERREY F, 1989, AM J PHYSIOL, V256, pF1034, DOI 10.1152/ajprenal.1989.256.6.F1034; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wang XY, 1996, MOL PHARMACOL, V50, P687; WOLFE PB, 1983, J BIOL CHEM, V258, P2073	54	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29011	29022		10.1074/jbc.M002867200	http://dx.doi.org/10.1074/jbc.M002867200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10887183	hybrid			2022-12-27	WOS:000089330700088
J	Pearce, MC; Rubin, H; Bottomley, SP				Pearce, MC; Rubin, H; Bottomley, SP			Conformational change and intermediates in the unfolding of alpha(1)-antichymotrypsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINEAR EXTRAPOLATION METHOD; TUMOR-SUPPRESSING SERPIN; GUANIDINIUM CHLORIDE; HUMAN ALPHA(1)-ANTITRYPSIN; MECHANISM; DISEASE; COMPLEX; ALPHA-1-ANTITRYPSIN; ASSOCIATION; RECOMBINANT	Serpins are the prototypical members of the conformational disease family, a group of proteins that undergoes a change in shape that subsequently leads to tissue deposition. One specific example is alpha(1)-antichymotrypsin (ACT), which undergoes misfolding and aggregation that has been implicated in emphysema and Alzheimer's disease. In this study we have used guanidine hydrochloride (GdnHCl)-induced denaturation to investigate the conformational changes involved in the folding and unfolding of ACT. When the reaction was followed by circular dichroism spectroscopy, one stable intermediate was observed in 1.5 M GdnHCl. The same experiment monitored by fluorescence revealed a second intermediate formed in 2.5 M GdnHCl. Both these intermediates bound the hydrophobic dye ANS. These data suggest a four-state model for ACT folding N <----> I-1 <----> I-2 <----> U. I-1 and I-2 both have a similar loss of secondary structure (20%) compared with the native state. In I-2 however, there is a significant loss of tertiary interactions as revealed by changes in fluorescence emission maximum and intensity. Kinetic analysis of the unfolding reaction indicated that the native state is unstable with a fast rate of unfolding in water of 0.4 s(-1). The implications of these data for both ACT function and associated diseases are discussed.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Monash University; University of Pennsylvania	Bottomley, SP (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.							BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BOLEN DW, 1988, BIOCHEMISTRY-US, V27, P8069, DOI 10.1021/bi00421a015; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Carrell RW, 1998, CURR OPIN STRUC BIOL, V8, P799, DOI 10.1016/S0959-440X(98)80101-2; Carrell RW, 1996, BIOL CHEM H-S, V377, P1; Chang WSW, 1998, J BIOL CHEM, V273, P3695, DOI 10.1074/jbc.273.6.3695; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; HERVE M, 1990, EUR J BIOCHEM, V191, P653, DOI 10.1111/j.1432-1033.1990.tb19171.x; Im H, 1999, J BIOL CHEM, V274, P11072, DOI 10.1074/jbc.274.16.11072; Jackson SE, 1998, FOLD DES, V3, pR81, DOI 10.1016/S1359-0278(98)00033-9; James EL, 1998, ARCH BIOCHEM BIOPHYS, V356, P296, DOI 10.1006/abbi.1998.0751; James EL, 1999, J BIOL CHEM, V274, P9482, DOI 10.1074/jbc.274.14.9482; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LEBONNIEC BF, 1995, BIOCHEMISTRY-US, V34, P12241, DOI 10.1021/bi00038a019; Liu T, 1999, J BIOL CHEM, V274, P29628, DOI 10.1074/jbc.274.42.29628; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Pace C N, 1986, Methods Enzymol, V131, P266; Plotnick MI, 1997, BIOCHEMISTRY-US, V36, P14601, DOI 10.1021/bi971530j; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; RUBIN H, 1990, J BIOL CHEM, V265, P1199; Sager R, 1997, ADV EXP MED BIOL, V425, P77; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHINDLER T, 1995, NAT STRUCT BIOL, V2, P663, DOI 10.1038/nsb0895-663; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Tang KS, 1999, J MOL BIOL, V285, P1869, DOI 10.1006/jmbi.1998.2420; Uversky VN, 1996, J MOL BIOL, V255, P215, DOI 10.1006/jmbi.1996.0018; VILLANUEVA GB, 1983, J BIOL CHEM, V258, P1010; Wang ZL, 1996, BIOCHEMISTRY-US, V35, P16443, DOI 10.1021/bi961214p; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WILEZYNSKA M, 1997, NAT STRUCT BIOL, V4, P354; YU MH, 1995, NAT STRUCT BIOL, V2, P363, DOI 10.1038/nsb0595-363	37	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28513	28518		10.1074/jbc.M004310200	http://dx.doi.org/10.1074/jbc.M004310200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878020	hybrid			2022-12-27	WOS:000089330700025
J	Herzig, S; Fuzesi, L; Knepel, W				Herzig, S; Fuzesi, L; Knepel, W			Heterodimeric Pbx-Prep1 homeodomain protein binding to the glucagon gene restricting transcription in a cell type-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN PROTOONCOGENE PBX1; COOPERATIVE INTERACTIONS; PANCREAS DEVELOPMENT; PROGLUCAGON GENE; HOMEOBOX GENES; HOX PROTEINS; ISLET CELLS; SOMATOSTATIN PROMOTER; FUNCTIONAL COMPLEX; REGULATORY ELEMENT	Homeodomain proteins specify developmental pathways and cell-specific gene transcription whereby proteins of the PBC subclass can direct target gene specificity of Hox proteins. Proteins encoded by nonclustered homeobox genes have been shown to be essential for cell lineage differentiation and gene expression in pancreatic islets. Using specific antiserum in an electrophoretic mobility shift assay and in vitro transcribed/ translated proteins, the nuclear proteins binding domain B of the G3 enhancer-like element of the glucagon gene were identified in the present study as heterodimers consisting of the ubiquitously expressed homeodomain protein Prep1 and the also widely expressed PBC homeoprotein Pbx (isoform 1a, 1b, or 2), These heterodimeric complexes were found to bind also to the glucagon cAMP response element and to a newly identified element termed G5 (from -169 to -140). Whereas the expression of Prep1 or Pbx forms alone had no effect, coexpression of Pbx1a/1b-Prep1 inhibited the glucagon promoter when activated by cotransfected Pax6 or another transcription factor in non-glucagon-producing cells. In contrast, in glucagon-producing pancreatic islet cells, Pbx-Prep1 had no effect on GAL4-Pax6-induced mutant glucagon promoter activity or on Pax6-dependent wild-type glucagon promoter activity. Furthermore, 5'-deletion of G5 enhanced glucagon promoter activity in a non-glucagon producing cell line but not in glucagon-producing islet cells. This study thus identifies a novel target and Hox-independent function of Pbx-Prep1 heterodimers that, through repression of glucagon gene transcription in non-glucagon-producing cells, may help to establish islet cell-specific expression of the glucagon gene.	Univ Gottingen, Dept Mol Pharmacol, D-37070 Gottingen, Germany; Univ Gottingen, Dept Gastroenteropathol, D-37070 Gottingen, Germany	University of Gottingen; University of Gottingen	Knepel, W (corresponding author), Univ Gottingen, Dept Mol Pharmacol, Robert Koch Str 40,Postfach 3742, D-37070 Gottingen, Germany.			Herzig, Stephan/0000-0003-3950-3652				Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Andersen FG, 1999, FEBS LETT, V445, P306, DOI 10.1016/S0014-5793(99)00145-3; Andersen FG, 1999, FEBS LETT, V445, P315, DOI 10.1016/S0014-5793(99)00144-1; Asahara H, 1999, MOL CELL BIOL, V19, P8219; Beimesche S, 1999, MOL ENDOCRINOL, V13, P718, DOI 10.1210/me.13.5.718; Berthelsen J, 1996, J BIOL CHEM, V271, P3822; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Casares F, 1998, NATURE, V392, P723, DOI 10.1038/33706; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; CORDIERBUSSAT M, 1995, MOL CELL BIOL, V15, P3904; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DeCesare D, 1996, ONCOGENE, V13, P2551; Diedrich T, 1997, BIOL CHEM, V378, P89, DOI 10.1515/bchm.1997.378.2.89; DIEDRICH T, 1996, THESIS U GOTTINGEN G; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; Ferretti E, 2000, DEVELOPMENT, V127, P155; Ferretti E, 1999, MECH DEVELOP, V83, P53, DOI 10.1016/S0925-4773(99)00031-3; Furstenau U, 1997, MOL CELL BIOL, V17, P1805; GAJIC D, 1993, ENDOCRINOLOGY, V132, P1055, DOI 10.1210/en.132.3.1055; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; Habener JF, 1998, P ASSOC AM PHYSICIAN, V110, P12; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; Harrison KA, 1999, NAT GENET, V23, P71, DOI 10.1038/12674; Hussain MA, 1997, MOL CELL BIOL, V17, P7186, DOI 10.1128/MCB.17.12.7186; JAMES R, 1994, J BIOL CHEM, V269, P15229; Jin TR, 1996, MOL CELL BIOL, V16, P19; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Jun S, 1996, DEVELOPMENT, V122, P2639; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1993, EXP CLIN ENDOCRINOL, V101, P39, DOI 10.1055/s-0029-1211206; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KNEPEL W, 2000, MOL BASIS ENDOCRINE; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Laser B, 1996, J BIOL CHEM, V271, P28984, DOI 10.1074/jbc.271.46.28984; LEE YC, 1992, J BIOL CHEM, V267, P10705; LEFEBVRE PJ, 1996, HDB EXPT PHARM, V30, P115; Li H, 1999, NAT GENET, V23, P67; Lu Q, 1996, P NATL ACAD SCI USA, V93, P470, DOI 10.1073/pnas.93.1.470; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MILLER CP, 1993, MOL CELL BIOL, V13, P7080, DOI 10.1128/MCB.13.11.7080; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OETJEN E, 1994, J BIOL CHEM, V269, P27036; Offield MF, 1996, DEVELOPMENT, V122, P983; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; PEERS B, 1995, MOL CELL BIOL, V15, P7091; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; Phelan ML, 1997, J BIOL CHEM, V272, P8635, DOI 10.1074/jbc.272.13.8635; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; Ryoo HD, 1999, DEVELOPMENT, V126, P5137; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SANDER M, 1997, MOL MED, V75, P327; Schnabel CA, 2000, ONCOGENE, V19, P608, DOI 10.1038/sj.onc.1203371; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; Scott MP, 2000, CELL, V100, P27, DOI 10.1016/S0092-8674(00)81681-5; Shanmugam K, 1999, MOL CELL BIOL, V19, P7577; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; St-Onge L, 1999, CURR OPIN GENET DEV, V9, P295, DOI 10.1016/S0959-437X(99)80044-6; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; SUH E, 1994, MOL CELL BIOL, V14, P7430; Sussel L, 1998, DEVELOPMENT, V125, P2213; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; UNGER RH, 1981, NEW ENGL J MED, V304, P1518, DOI 10.1056/NEJM198106183042504; VANDIJK MA, 1995, MECH DEVELOP, V52, P99, DOI 10.1016/0925-4773(95)00394-G; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WANG M, 1995, J BIOL CHEM, V270, P12646, DOI 10.1074/jbc.270.21.12584; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Wrege Antje, 1995, Gene Expression, V4, P205	102	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27989	27999						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869353				2022-12-27	WOS:000089197100063
J	Lombard, M; Touati, D; Fontecave, M; Niviere, V				Lombard, M; Touati, D; Fontecave, M; Niviere, V			Superoxide reductase as a unique defense system against superoxide stress in the microaerophile Treponema pallidum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-DESULFURICANS ATCC-27774; COMPLETE GENOME SEQUENCE; VULGARIS HILDENBOROUGH; ESCHERICHIA-COLI; DISMUTASE; DESULFOFERRODOXIN; OXYGEN; IRON; PROTEIN; RBO	Aerobic life requires the presence of antioxidant enzymes, such as superoxide dismutase, catalase, and per oxidase to eliminate deleterious oxygen derivatives, Treponema pallidum, a microaerophilic bacterium responsible for venereal syphilis, is an interesting organism because it lacks all of the above-mentioned enzymes, as deduced from its recently sequenced genome. In this paper, we describe a gene in T. pallidum with sequence homologies to a new class of antioxidant systems, named superoxide reductases, recently isolated from sulfate-reducing bacteria (Lombard, M., Fontecave, M., Touati, D., and Niviere, V. (2000) J. Biol. Chem. 275, 115-121). We report that (i) expression of the T. pallidum gene fully restored to a superoxide dismutase-deficient Escherichia coli mutant the ability to grow under aerobic conditions; (ii) the corresponding protein displays a strong superoxide reductase activity; and (iii) the T. pallidum protein contains only one mononuclear nonheme ferrous center, able to reduce superoxide selectively and efficiently, whereas previously characterized superoxide reductase from Desulfoarculus baarsii contains an additional rubredoxin-like ferric center. These results suggest that T, pallidum antioxidant defenses rely on a new class of superoxide reductase and raise the question of the importance of superoxide reductases in mechanisms for detoxifying superoxide radicals.	Univ Grenoble 1, CNRS, CEA, DBMS,Lab Chim & Biochim,Ctr Redox Biol, F-38054 Grenoble 9, France; Univ Paris 06, CNRS, Inst Jacques Monod, F-75251 Paris 05, France; Univ Paris 07, CNRS, Inst Jacques Monod, F-75251 Paris 05, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Niviere, V (corresponding author), Univ Grenoble 1, CNRS, CEA, DBMS,Lab Chim & Biochim,Ctr Redox Biol, 17 Ave Martyrs, F-38054 Grenoble 9, France.	vniviere@cea.fr	Lombard, Murielle/E-4974-2019	Lombard, Murielle/0000-0002-4775-3494; Niviere, Vincent/0000-0002-5132-457X				ARCHIBALD FS, 1981, J BACTERIOL, V146, P928, DOI 10.1128/JB.146.3.928-936.1981; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUMLIK MJ, 1989, J BACTERIOL, V171, P4996, DOI 10.1128/jb.171.9.4996-5004.1989; CHEN LA, 1994, EUR J BIOCHEM, V226, P613, DOI 10.1111/j.1432-1033.1994.tb20087.x; Choudhury SB, 1999, BIOCHEMISTRY-US, V38, P3744, DOI 10.1021/bi982537j; Coelho AV, 1997, J BIOL INORG CHEM, V2, P680, DOI 10.1007/s007750050184; COX DL, 1990, APPL ENVIRON MICROB, V56, P3063, DOI 10.1128/AEM.56.10.3063-3072.1990; Dos Santos WG, 2000, J BACTERIOL, V182, P796, DOI 10.1128/JB.182.3.796-804.2000; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; HALLIWELL B, 1989, FREE RADICAL BIO MED, P71; HATCHIKIAN EC, 1977, BIOCHIMIE, V59, P153, DOI 10.1016/S0300-9084(77)80286-1; Jenney FE, 1999, SCIENCE, V286, P306, DOI 10.1126/science.286.5438.306; KEYER K, 1995, J BACTERIOL, V177, P6782, DOI 10.1128/jb.177.23.6782-6790.1995; KLUG D, 1972, J BIOL CHEM, V247, P4839; Lombard M, 2000, J BIOL CHEM, V275, P115, DOI 10.1074/jbc.275.1.115; MOURA I, 1990, J BIOL CHEM, V265, P21596; Pianzzola MJ, 1996, J BACTERIOL, V178, P6736, DOI 10.1128/jb.178.23.6736-6742.1996; SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; TAVARES P, 1994, J BIOL CHEM, V269, P10504; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; VERHAGEN MFJM, 1993, FEBS LETT, V336, P13, DOI 10.1016/0014-5793(93)81599-U; Voordouw JK, 1998, APPL ENVIRON MICROB, V64, P2882; [No title captured]	24	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27021	27026						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10867007				2022-12-27	WOS:000089144800048
J	Wrenger, S; Faust, J; Mrestani-Klaus, C; Fengler, A; Stockel-Maschek, A; Lorey, S; Kahne, T; Brandt, W; Neubert, K; Ansorge, S; Reinhold, D				Wrenger, S; Faust, J; Mrestani-Klaus, C; Fengler, A; Stockel-Maschek, A; Lorey, S; Kahne, T; Brandt, W; Neubert, K; Ansorge, S; Reinhold, D			Down-regulation of T cell activation following inhibition of dipeptidyl peptidase IV/CD26 by the N-terminal part of the thromboxane A2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 TAT PROTEIN; IV DP-IV; CORRELATION SPECTROSCOPY; COHERENCE TRANSFER; HUMAN-LYMPHOCYTES; ROTATING FRAME; FORCE-FIELD; CD26; GROWTH; SUPPRESSION	Using synthetic inhibitors, it has been shown that the ectopeptidase dipeptidyl peptidase IV (DP IV) (CD26) plays an important role in the activation and proliferation of T lymphocytes, The human immunodeficiency virus-1 Tat protein, as well as the N-terminal nonapeptide Tat(1-9) and other peptides containing the N-terminal sequence XXP, also inhibit DP TV and therefore T cell activation. Studying the effect of amino acid exchanges in the N-terminal three positions of the Tat(1-9) sequence, we found that tryptophan in position 2 strongly improves DP IV inhibition. NMR spectroscopy and molecular modeling show that the effect of Trp(2)-Tat(1-9) could not be explained by significant alterations in the backbone structure and suggest that tryptophan enters favorable interactions with DP IV. Data base searches revealed the thromboxane A2 receptor (TXA2-R) as a membrane protein extracellularly exposing N-terminal MWP. TXA2-R is expressed within the immune system on antigen-presenting cells, namely monocytes, The N-terminal nonapeptide of TXA2-R, TXA2-R(1-9), inhibits DP IV and DNA synthesis and IL-2 production of tetanus toroid-stimulated peripheral blood mononuclear cells. Moreover, TXA2-R(1-9) induces the production of the immunosuppressive cytokine transforming growth factor-pi. These data suggest that the N-terminal part of TXA2-R is an endogenous inhibitory ligand of DP TV and may modulate T cell activation via DP IV/CD26 inhibition.	Otto Von Guericke Univ, Dept Internal Med, Inst Expt Internal Med, D-39120 Magdeburg, Germany; Univ Halle Wittenberg, Dept Biochem & Biotechnol, Inst Biochem, D-06120 Halle, Germany	Otto von Guericke University; Martin Luther University Halle Wittenberg	Wrenger, S (corresponding author), Otto Von Guericke Univ, Dept Internal Med, Inst Expt Internal Med, Leipziger Str 44, D-39120 Magdeburg, Germany.	sabine.wrenger@medizin.uni-magdeburg.de	Kaehne, Thilo/E-4858-2012	Wrenger, Sabine/0000-0002-9733-6162				ALLAN CJ, 1994, J PHARMACOL EXP THER, V270, P446; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRANDT W, 2000, IN PRESS ADV EXP MED, V477; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; DANIELPOUR D, 1993, J IMMUNOL METHODS, V158, P17, DOI 10.1016/0022-1759(93)90254-5; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; Fengler A, 1998, J MOL MODEL, V4, P200, DOI 10.1007/s0089480040200; FLEISCHER B, 1994, IMMUNOL TODAY, V15, P180, DOI 10.1016/0167-5699(94)90316-6; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; GUTHEIL WG, 1994, P NATL ACAD SCI USA, V91, P6594, DOI 10.1073/pnas.91.14.6594; HEINS J, 1988, BIOCHIM BIOPHYS ACTA, V954, P161, DOI 10.1016/0167-4838(88)90067-2; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; HOFFMANN T, 1995, J CHROMATOGR A, V716, P355, DOI 10.1016/0021-9673(95)00411-F; Kahne T, 1999, INT J MOL MED, V4, P3; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; Korom S, 1997, TRANSPLANTATION, V63, P1495, DOI 10.1097/00007890-199705270-00021; KUBOTA T, 1992, CLIN EXP IMMUNOL, V89, P192; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Miggin SM, 1998, BBA-GEN SUBJECTS, V1425, P543, DOI 10.1016/S0304-4165(98)00109-3; Mrestani-Klaus C, 1998, J PEPT SCI, V4, P400, DOI 10.1002/(SICI)1099-1387(199809)4:6<400::AID-PSC162>3.0.CO;2-G; MULLER L, 1979, MOL PHYS, V38, P963, DOI 10.1080/00268977900102161; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Reinhold D, 1997, IMMUNOL LETT, V58, P29, DOI 10.1016/S0165-2478(97)02716-8; Reinhold D, 1997, IMMUNOLOGY, V91, P354, DOI 10.1046/j.1365-2567.1997.d01-2258.x; Reinhold D, 1997, J IMMUNOL METHODS, V209, P203, DOI 10.1016/S0022-1759(97)00160-9; REINHOLD D, 1993, IMMUNOBIOLOGY, V188, P403, DOI 10.1016/S0171-2985(11)80223-8; Reinhold D, 1996, IMMUNOBIOLOGY, V195, P119, DOI 10.1016/S0171-2985(96)80010-6; Rubartelli A, 1998, IMMUNOL TODAY, V19, P543, DOI 10.1016/S0167-5699(98)01351-6; SIMMONS TR, 1993, J LEUKOCYTE BIOL, V53, P173, DOI 10.1002/jlb.53.2.173; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STEINBRECHER A, 2000, IN PRESS ADV EXP MED, V477; SUBRAMANYAM M, 1993, J IMMUNOL, V150, P2544; Tanaka S, 1997, INT J IMMUNOPHARMACO, V19, P15, DOI 10.1016/S0192-0561(97)00004-0; Tanaka S, 1998, IMMUNOPHARMACOLOGY, V40, P21, DOI 10.1016/S0162-3109(98)00014-9; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Wrenger S, 1996, FEBS LETT, V383, P145, DOI 10.1016/0014-5793(96)00221-9; Wrenger S, 2000, FEBS LETT, V466, P155, DOI 10.1016/S0014-5793(99)01779-2; Wrenger S, 1997, J BIOL CHEM, V272, P30283, DOI 10.1074/jbc.272.48.30283; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	52	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22180	22186		10.1074/jbc.M002338200	http://dx.doi.org/10.1074/jbc.M002338200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10896952				2022-12-27	WOS:000088363800060
J	Yang, H; Young, DW; Gusovsky, F; Chow, JC				Yang, H; Young, DW; Gusovsky, F; Chow, JC			Cellular events mediated by lipopolysaccharide-stimulated toll-like receptor 4 - MD-2 is required for activation of mitogen-activated protein kinases and Elk-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; SIGNAL-TRANSDUCTION; INTERLEUKIN-8 PRODUCTION; GENE; ENDOTOXIN; CELLS; TLR4; TRANSCRIPTION; EXPRESSION; MECHANISMS	Lipopolysaccharide (LPS) stimulates multiple signaling events, including nuclear factor-kappa B (NF-kappa B) activity and the mitogen-activated protein (MAP) kinases, ERK, JNK, and p38 in LPS-responsive cells, resulting in transcriptional activation and cytokine generation. LPS-induced signaling via toll-like receptor 4 (TLR4) results in the activation of the transcription factor NF-kappa B. Since LPS activates other signaling cascades in responsive cells, the objective of this study was to determine whether such events are mediated by TLR4 in response to LPS, me generated human embryonic kidney cells (HEK293) that stably express TLR4 (HEK-TLR4) and examined their responsiveness to LPS by measuring NF-kappa B activity and production of interleukin-8 (IL-8). A trans-reporting system was used to measure the activity of Elk-1, an ETS-domain transcription factor targeted by MAP kinase pathways. LPS stimulated NF-kappa B reporter activity and IL-8 production but not Elk-1 activity in HEK-TLR4 cells. When MD-2, a protein associated with the extracellular domain of TLR4, was expressed in these cells, there was a marked increase in Elk-1 activity as well as ERK, JNK, and p38 MAP kinase phosphorylation in response to LPS. TLR4-mediated NF-kappa B reporter activity and IL-8 production was enhanced by the expression of MD-2. This study demonstrates that expression of both TLR4 and MD-2 is required for LPS to activate or augment the MAP kinase pathways, Elk-1 stimulation, and IL-8 generation.	Eisai Res Inst, Div Infect Dis, Andover, MA 01810 USA	Eisai Co Ltd	Chow, JC (corresponding author), Eisai Res Inst, 100 Res Dr, Wilmington, MA 01887 USA.							Akashi S, 2000, BIOCHEM BIOPH RES CO, V268, P172, DOI 10.1006/bbrc.2000.2089; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; DIBB CR, 1992, INFECT IMMUN, V60, P3052, DOI 10.1128/IAI.60.8.3052-3058.1992; Feoktistov I, 1999, MOL PHARMACOL, V55, P726; GEPPERT TD, 1994, MOL MED, V1, P93; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Hoshino K, 1999, J IMMUNOL, V162, P3749; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Murayama T, 1997, J VIROL, V71, P5692, DOI 10.1128/JVI.71.7.5692-5695.1997; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Scherle PA, 1998, J IMMUNOL, V161, P5681; Schletter J, 1995, ARCH MICROBIOL, V164, P383, DOI 10.1007/BF02529735; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	29	230	256	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20861	20866		10.1074/jbc.M002896200	http://dx.doi.org/10.1074/jbc.M002896200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10877845	hybrid			2022-12-27	WOS:000088084500090
J	Katagiri, T; Takahashi, T; Sasaki, T; Nakamura, S; Hattori, S				Katagiri, T; Takahashi, T; Sasaki, T; Nakamura, S; Hattori, S			Protein-tyrosine kinase Pyk2 is involved in interleukin-2 production by Jurkat T cells via its tyrosine 402	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SIGNALING PATHWAY; CO-STIMULATION; ACTIVATION; LYMPHOCYTES; PHOSPHORYLATION; IDENTIFICATION; JNK; INTEGRIN; FAK	We established Jurkat transfectants that overexpress Pyk2 or its mutants, K457A (lysine 457 was mutated to alanine), Pyk2-Y402F (tyrosine 402 to phenylalanine), and Pyk2-Y881F to investigate the role of Pyk2 in T cell activation. Pyk2 as well as kinase-inactive Pyk2-K457A, was phosphorylated at tyrosine residues 402, 580, and 881 upon T cell antigen receptor cross-linking, indicating that these residues are phosphorylated by other tyrosine kinase(s), However, no tyrosine phosphorylation of Pyk2-Y402F was detected while more than 60% of the tyrosine phosphorylation was observed in Pyk2-Y881F. Pyk2-Y402F inhibited the activation of endogenous Pyk2. The degree of activation of both c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase but not extracellular signal-regulated protein kinase after concurrent ligation of T cell antigen receptor and CD28 was reduced by more than 50% in the clones expressing Pyk2-Y402F. Consistent with this inhibition, IL-2 production was significantly diminished in the Pyk2-Y402F-expressing clones. Furthermore, we found that Pyk2, when overexpressed, associates with Zap70 and Vav. Taken together, these findings suggest that Pyk2 is involved in the activation of T cells through its tyrosine 402.	Natl Inst Neurosci, Div Biochem & Cellular Biol, Tokyo 1878502, Japan; Olympus Opt Co Ltd, Life Sci Technol Res Ctr, Tokyo 1928512, Japan; Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Biochem, Sapporo, Hokkaido 0608556, Japan	National Center for Neurology & Psychiatry - Japan; Olympus Corporation; Sapporo Medical University	Katagiri, T (corresponding author), Natl Inst Neurosci, Div Biochem & Cell Biol, 4-1-1 Ogawahigashi, Tokyo 1878502, Japan.	katagiri@ncnp.go.jp						Andreev J, 1999, MOL CELL BIOL, V19, P2338; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Berg NN, 1997, J IMMUNOL, V159, P1753; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dustin ML, 1999, SCIENCE, V283, P649, DOI 10.1126/science.283.5402.649; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FISHER MJ, 1995, NATURE, V376, P473, DOI 10.1038/376473a0; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Girault JA, 1999, TRENDS NEUROSCI, V22, P257, DOI 10.1016/S0166-2236(98)01358-7; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Katagiri K, 1996, J BIOL CHEM, V271, P11557, DOI 10.1074/jbc.271.19.11557; Lev S, 1999, MOL CELL BIOL, V19, P2278; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; Ma EA, 1997, EUR J IMMUNOL, V27, P329, DOI 10.1002/eji.1830270147; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Powell JD, 1998, IMMUNOL REV, V165, P287, DOI 10.1111/j.1600-065X.1998.tb01246.x; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rodriguez-Fernandez JL, 1999, MOL BIOL CELL, V10, P1891, DOI 10.1091/mbc.10.6.1891; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Sunder-Plassmann R, 1998, J BIOL CHEM, V273, P24249, DOI 10.1074/jbc.273.37.24249; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tsuchida M, 1999, J BIOL CHEM, V274, P6735, DOI 10.1074/jbc.274.10.6735; van Seventer GA, 1998, EUR J IMMUNOL, V28, P3867, DOI 10.1002/(SICI)1521-4141(199811)28:11<3867::AID-IMMU3867>3.3.CO;2-B; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; Xiong WC, 1998, J CELL SCI, V111, P1981; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	42	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19645	19652		10.1074/jbc.M909828199	http://dx.doi.org/10.1074/jbc.M909828199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867021	hybrid			2022-12-27	WOS:000087941300029
J	Jeoung, MK; Phang, T; Song, YS; Ji, I; Tae, TH				Jeoung, MK; Phang, T; Song, YS; Ji, I; Tae, TH			Hormone interactions to Leu-rich repeats in the gonadotropin receptors - III. Photoaffinity labeling of human chorionic gonadotropin with receptor Leu-rich repeat 4 peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; HIGH-AFFINITY; EXTRACELLULAR DOMAIN; BINDING-SITE; LH RECEPTOR; PROTEIN; HCG; SUBUNIT; IDENTIFICATION; MUTAGENESIS	Human chorionic gonadotropin (hCG) binds to the extracellular N-terminal domain, exodomain, of its receptor, and the resulting hCG-exodomain complex is thought to modulate the membrane associated domain, endodomain, of the receptor to generate hormone signal. The bulk of the exodomain is speculated to assume a crescent structure consisting of eight to nine Leu-rich repeats (LRRs), which may provide the hormone contact sites. Unfortunately, little experimental evidence is available for the precise hormone contact points in the exodomain and the endodomain. The two preceding articles (Song, Y., Ji, I., Beauchamp, J., Isaacs, N., and Ji, T. (2001) J. Biol. Chem. 276, 3426-3435; Song, Y., Ji, I., Beauchamp, J., Isaacs, N., and Ji, T. (2001) J. Biol. Chem. 276, 3436-3442) show that putative LRR2 and LRR4 are crucial for hormone binding. In particular; the N-terminal region of LRR4 assumes the hydrophobic core of the LRR4 loop, whereas the C-terminal region is crucial for signal generation. However, it is unclear whether LRR4 interacts hCG and the endodomain and how it might be involved in signal generation. In this article, our affinity labeling results present the first evidence that the N-terminal region of LRR4 interacts with hCG, preferentially the hCG alpha subunit and that the hCG/LRR4 complex interacts with exoloop 2 of the endodomain. This interaction offers a mechanism to generate hormone signal.	Univ Kentucky, Dept Chem, Lexington, KY 40506 USA; Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul 110744, South Korea	University of Kentucky; Seoul National University (SNU)	Tae, TH (corresponding author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.		Song, Yong Sang/E-7824-2012	SONG, YONGSANG/0000-0001-7115-4021	NICHD NIH HHS [HD-18702] Funding Source: Medline; NIDDK NIH HHS [DK-51469] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051469] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; Cosowsky L, 1997, J BIOL CHEM, V272, P3309, DOI 10.1074/jbc.272.6.3309; Couture L, 1996, J MOL ENDOCRINOL, V16, P15, DOI 10.1677/jme.0.0160015; JI I, 1980, P NATL ACAD SCI-BIOL, V77, P7167, DOI 10.1073/pnas.77.12.7167; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; JI TH, 1979, BIOCHIM BIOPHYS ACTA, V559, P39, DOI 10.1016/0304-4157(79)90007-8; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; JI TH, 1983, METHOD ENZYMOL, V91, P580; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LEVITZKI A, 1984, RECEPTORS QUANTITATI; LIU C, 1993, J BIOL CHEM, V268, P21613; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MORBECK DE, 1993, MOL CELL ENDOCRINOL, V97, P173, DOI 10.1016/0303-7207(93)90225-9; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; Phang T, 1998, J BIOL CHEM, V273, P13841, DOI 10.1074/jbc.273.22.13841; Puett D, 1996, MOL CELL ENDOCRINOL, V125, P55, DOI 10.1016/S0303-7207(96)03954-8; Remy JJ, 1996, MOL CELL ENDOCRINOL, V125, P79, DOI 10.1016/S0303-7207(96)03955-X; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; Ryu K, 1998, J BIOL CHEM, V273, P28953, DOI 10.1074/jbc.273.44.28953; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; Song YS, 2001, J BIOL CHEM, V276, P3426, DOI 10.1074/jbc.M003772200; Song YS, 2001, J BIOL CHEM, V276, P3436, DOI 10.1074/jbc.M003773200; Thomas D, 1996, MOL ENDOCRINOL, V10, P760, DOI 10.1210/me.10.6.760; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; XIE YB, 1990, J BIOL CHEM, V265, P21411	34	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3443	3450		10.1074/jbc.M003774200	http://dx.doi.org/10.1074/jbc.M003774200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	10880517	hybrid			2022-12-27	WOS:000166784900060
J	Begley, GS; Furie, BC; Czerwiec, E; Taylor, KL; Furie, GL; Bronstein, L; Stenflo, J; Furie, B				Begley, GS; Furie, BC; Czerwiec, E; Taylor, KL; Furie, GL; Bronstein, L; Stenflo, J; Furie, B			A conserved motif within the vitamin K-dependent carboxylase gene is widely distributed across animal phyla	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC-ACID; GLUTAMYL CARBOXYLASE; RECOGNITION SITE; CONANTOKIN-G; CONUS TEXTILE; FACTOR-IX; SNAIL; IDENTIFICATION; PROTHROMBIN; PROPEPTIDE	The vitamin K-dependent gamma -glutamyl carboxylase catalyzes the posttranslational conversion of glutamic acid to gamma -carboxyglutamic acid, an amino acid critical to the function of the vitamin K-dependent blood coagulation proteins. Given the functional similarity of mammalian vitamin K-dependent carboxylases and the vitamin K-dependent carboxylase from Conus textile, a marine invertebrate, we hypothesized that structurally conserved regions would identify sequences critical to this common functionality. Furthermore, we examined the diversity of animal species that maintain vitamin K-dependent carboxylation to generate gamma -carboxyglutamic acid. We have cloned carboxylase homologs in full-length or partial form from the beluga whale (Delphinapterus leucas), toadfish (Opsanus tau), chicken (Gallus gallus), hagfish (Myxine glutinosa), horseshoe crab (Limulus polyphemus), and cone snail (Conus textile) to compare these structures to the known bovine, human, rat, and mouse cDNA sequences, Comparison of the predicted amino acid sequences identified a nearly perfectly conserved 38-amino acid residue region in all of these putative carboxylases. In addition, this amino acid motif is also present in the Drosophila genome and identified a Drosophila homolog of the gamma -carboxylase, Assay of hagfish liver demonstrated vitamin K-dependent carboxylase activity in this hemichordate. These results demonstrate the broad distribution of the vitamin K-dependent carboxylase gene, including a highly conserved motif that is likely critical for enzyme function. The vitamin K-dependent biosynthesis of gamma -carboxyglutamic acid appears to be a highly conserved function in the animal kingdom.	Marine Biol Lab, Woods Hole, MA 02543 USA; Harvard Univ, Sch Med, Ctr Hemostasis & Thrombosis Res, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Univ Lund, Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden	Marine Biological Laboratory - Woods Hole; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Lund University; Skane University Hospital	Furie, B (corresponding author), Marine Biol Lab, Woods Hole, MA 02543 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038216, R37HL038216, P01HL042443] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38216, HL42443] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bandyopadhyay PK, 1998, J BIOL CHEM, V273, P5447, DOI 10.1074/jbc.273.10.5447; Brenner B, 1998, BLOOD, V92, P4554, DOI 10.1182/blood.V92.12.4554.424k42_4554_4559; BUCHER D, 1976, FEBS LETT, V68, P293, DOI 10.1016/0014-5793(76)80456-5; Bush KA, 1999, BIOCHEMISTRY-US, V38, P14660, DOI 10.1021/bi991640l; ESMON CT, 1976, J BIOL CHEM, V251, P6238; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; Furie B, 1999, BLOOD, V93, P1798, DOI 10.1182/blood.V93.6.1798.406k22_1798_1808; HAUSCHKA PV, 1975, P NATL ACAD SCI USA, V72, P3925, DOI 10.1073/pnas.72.10.3925; HAUSCHKA PV, 1988, CURRENT ADV VITAMIN, P237; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; Li T, 2000, J BIOL CHEM, V275, P18291, DOI 10.1074/jbc.M001790200; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P3374, DOI 10.1073/pnas.73.10.3374; Prorok M, 1996, BIOCHEMISTRY-US, V35, P16528, DOI 10.1021/bi9621122; REHEMTULLA A, 1993, P NATL ACAD SCI USA, V90, P4611, DOI 10.1073/pnas.90.10.4611; Rigby AC, 1997, BIOCHEMISTRY-US, V36, P15677, DOI 10.1021/bi9718550; Rigby AC, 1999, P NATL ACAD SCI USA, V96, P5758, DOI 10.1073/pnas.96.10.5758; Romero EE, 1998, BIOCHEM BIOPH RES CO, V248, P783, DOI 10.1006/bbrc.1998.8987; ROTH DA, 1995, J BIOL CHEM, V270, P5305, DOI 10.1074/jbc.270.10.5305; SHAH DV, 1979, P SOC EXP BIOL MED, V161, P498, DOI 10.3181/00379727-161-40582; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; Stanley TB, 1997, FEBS LETT, V407, P85, DOI 10.1016/S0014-5793(97)00299-8; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; Sugiura I, 1996, J BIOL CHEM, V271, P17837, DOI 10.1074/jbc.271.30.17837; TAI JY, 1977, J BIOL CHEM, V252, P2178; ULRICH MMW, 1988, J BIOL CHEM, V263, P9697; VANBUSKIRK JJ, 1978, BIOCHEM BIOPH RES CO, V80, P1329; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935	30	31	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36245	36249		10.1074/jbc.M003944200	http://dx.doi.org/10.1074/jbc.M003944200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10893417	hybrid, Green Published			2022-12-27	WOS:000165382000085
J	Horibata, Y; Okino, N; Ichinose, S; Omori, A; Ito, M				Horibata, Y; Okino, N; Ichinose, S; Omori, A; Ito, M			Purification, characterization, and cDNA cloning of a novel acidic endoglycoceramidase from the jellyfish, Cyanea nozakii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERAMIDE-GLYCANASE; SEQUENCE; GLYCOSPHINGOLIPIDS; ELECTROPHORESIS; SPHINGOMYELIN; SUBSTRATE; PROTEINS; CLEAVES; LINKAGE; STRAIN	Endoglycoceramidase (EC 3.2.1.123) is an enzyme capable of cleaving the glycosidic linkage between oligosaccharides and ceramides in various glycosphingolipids, We report here the purification, characterization, and cDNA cloning of a novel endoglycoceramidase from the jellyfish, Cyanea nozakii. The purified enzyme showed a single protein band estimated to be 51 kDa on SDS-polyacrylamide gel electrophoresis. The enzyme showed a pH optimum of 3.0 and was activated by Triton X-100 and Lubrol PX but not by sodium taurodeoxycholate. This enzyme preferentially hydrolyzed gangliosides, especially GT1b and GQ1b, whereas neutral glycosphingolipids were somewhat resistant to hydrolysis by the enzyme. A full-length cDNA encoding the enzyme was cloned by 5'- and 3'-rapid amplification of cDNA ends using a partial amino acid sequence of the purified enzyme. The open reading frame of 1509 nucleotides encoded a polypeptide of 503 amino acids including a signal sequence of 25 residues and six potential N-glycosylation sites. Interestingly, the Asn-Glu-Pro sequence, which is the putative active site of Rhodococcus endoglycoceramidase, was conserved in the deduced amino acid sequences. This is the first report of the cloning of an endoglycoceramidase from a eukaryote.	Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, Fukuoka 8128581, Japan; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan	Kyushu University	Ito, M (corresponding author), Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.		Ito, Makoto/Q-6164-2019; Okino, Nozomu/AAY-2635-2021	ito, Makoto/0000-0003-3159-7818				ASHIDA H, 1992, EUR J BIOCHEM, V205, P729, DOI 10.1111/j.1432-1033.1992.tb16836.x; BASU SS, 1994, ANAL BIOCHEM, V222, P270, DOI 10.1006/abio.1994.1484; DAINESE HP, 1997, EUR J BIOCHEM, V264, P336; Fukano Y, 1997, APPL ENVIRON MICROB, V63, P1861, DOI 10.1128/AEM.63.5.1861-1865.1997; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; ISHIZUKA I, 1972, BIOCHIM BIOPHYS ACTA, V260, P279, DOI 10.1016/0005-2760(72)90039-2; ITO M, 1986, J BIOL CHEM, V261, P14278; ITO M, 1989, J BIOL CHEM, V264, P9510; ITO M, 1995, J BIOL CHEM, V270, P24370, DOI 10.1074/jbc.270.41.24370; Izu H, 1997, J BIOL CHEM, V272, P19846, DOI 10.1074/jbc.272.32.19846; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; LI YT, 1987, BIOCHEM BIOPH RES CO, V149, P167, DOI 10.1016/0006-291X(87)91619-6; Miura Y, 1999, GLYCOBIOLOGY, V9, P957, DOI 10.1093/glycob/9.9.957; MOORE GL, 1969, ANAL BIOCHEM, V32, P122, DOI 10.1016/0003-2697(69)90111-0; Nakagawa T, 1999, J BIOCHEM, V126, P604, DOI 10.1093/oxfordjournals.jbchem.a022492; OHSAWA K, 1983, ANAL BIOCHEM, V135, P409, DOI 10.1016/0003-2697(83)90703-0; PAUL LM, 1981, J CELL SCI, V49, P311; Sakaguchi K, 1999, BIOCHEM BIOPH RES CO, V260, P89, DOI 10.1006/bbrc.1999.0855; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Tani M, 1998, ANAL BIOCHEM, V263, P183, DOI 10.1006/abio.1998.2781; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; ZHOU B, 1989, J BIOL CHEM, V264, P12272	27	19	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31297	31304		10.1074/jbc.M003575200	http://dx.doi.org/10.1074/jbc.M003575200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10882727	hybrid			2022-12-27	WOS:000089762700078
J	Andersen, JF; Montfort, WR				Andersen, JF; Montfort, WR			The crystal structure of nitrophorin 2 - A trifunctional antihemostatic protein from the saliva of Rhodnius prolixus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE-BINDING; BLOODSUCKING INSECT; HEME PROTEIN; TRANSPORT PROTEIN; MAXIMUM-LIKELIHOOD; HISTAMINE-BINDING; CIMEX LECTULARIUS; LIGAND-BINDING; CDNA CLONING; PURIFICATION	Nitrophorin 2 (NP2) (also known as prolixin-S) is a salivary protein that transports nitric oxide, binds histamine, and acts as an anticoagulant during blood feeding by the insect Rhodnius prolixus. The 2.0-Angstrom crystal structure of NP2 reveals an eight-stranded antiparallel beta-barrel containing a ferric heme coordinated through His(57), Similar to the structures of NP1 and NP4. All four Rhodnius nitrophorins transport NO and sequester histamine through heme binding, but only NP2 acts as an anticoagulant, Here, we demonstrate that recombinant NP2, but not recombinant NP1 or NP4, is a potent anticoagulant; recombinant NP3 also displays minor activity. Comparison of the nitrophorin structures suggests that a surface region near the C terminus and the loops between beta strands B-C and E-F is responsible for the anticoagulant activity. NP2 also displays larger NO association rates and smaller dissociation rates than NP1 and NP4, which may result from a more open and more hydrophobic distal pocket, allowing more rapid solvent reorganization on ligand binding. The NP2 protein core differs from NP1 and NP4 in that buried Glu(53), which allows for larger NO release rates when deprotonated, hydrogen bonds to invariant Tyr(81). Surprisingly, this tyrosine lies on the protein surface in NP1 and NP4.	Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA	University of Arizona	Montfort, WR (corresponding author), Univ Arizona, Dept Biochem, BSW 518, Tucson, AZ 85721 USA.	montfort@u.arizona.edu			NCI NIH HHS [T32 CA09213] Funding Source: Medline; NHLBI NIH HHS [HL54826] Funding Source: Medline; NIGMS NIH HHS [GM58727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009213] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Andersen JF, 2000, BIOCHEMISTRY-US, V39, P10118, DOI 10.1021/bi000766b; Andersen JF, 1997, BIOCHEMISTRY-US, V36, P4423, DOI 10.1021/bi9628883; Andersen JF, 1998, STRUCTURE, V6, P1315, DOI 10.1016/S0969-2126(98)00131-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CHAMPAGNE DE, 1995, J BIOL CHEM, V270, P8691, DOI 10.1074/jbc.270.15.8691; CHAMPAGNE DE, 1994, PARASITOL TODAY, V10, P430, DOI 10.1016/0169-4758(94)90173-2; Ding XD, 1999, J AM CHEM SOC, V121, P128, DOI 10.1021/ja982979i; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; HOSHINO M, 1993, J AM CHEM SOC, V115, P9568, DOI 10.1021/ja00074a023; Isawa H, 2000, J BIOL CHEM, V275, P6636, DOI 10.1074/jbc.275.9.6636; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Kaneko Y, 1999, BBA-PROTEIN STRUCT M, V1431, P492, DOI 10.1016/S0167-4838(99)00082-5; KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, BIOCHEMISTRY-US, V33, P5518, DOI 10.1021/bi00184a021; LAW JH, 1992, ANNU REV BIOCHEM, V61, P87, DOI 10.1146/annurev.bi.61.070192.000511; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MONTFORT WR, 2000, IN PRESS BIOCH BIOPH; Paesen GC, 1999, MOL CELL, V3, P661, DOI 10.1016/S1097-2765(00)80359-7; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; RIBEIRO JMC, 1994, J EXP MED, V180, P2251, DOI 10.1084/jem.180.6.2251; RIBEIRO JMC, 1995, BIOCHEM J, V308, P243, DOI 10.1042/bj3080243; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; Sharma VS, 1999, METHODS, V19, P494, DOI 10.1006/meth.1999.0892; SHAW AW, 1977, J CHEM SOC FARAD T 1, V73, P1239, DOI 10.1039/f19777301239; Shelnutt JA, 1998, CHEM SOC REV, V27, P31; Sun JX, 1996, THROMB HAEMOSTASIS, V75, P573; Sun JX, 1998, INSECT BIOCHEM MOLEC, V28, P191, DOI 10.1016/S0965-1748(97)00115-X; VALENZUELA JG, 1995, J EXP BIOL, V198, P1519; Valenzuela JG, 1998, J EXP BIOL, V201, P2659; Weichsel A, 1998, NAT STRUCT BIOL, V5, P304, DOI 10.1038/nsb0498-304; Weichsel A, 2000, NAT STRUCT BIOL, V7, P551, DOI 10.1038/76769; Yuda M, 1997, EUR J BIOCHEM, V249, P337, DOI 10.1111/j.1432-1033.1997.00337.x; Zhang Y, 1998, BIOCHEMISTRY-US, V37, P10681, DOI 10.1021/bi973050y	41	92	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30496	30503		10.1074/jbc.M002857200	http://dx.doi.org/10.1074/jbc.M002857200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10884386	hybrid			2022-12-27	WOS:000089577900079
J	Funakoshi, T; Yasuda, S; Fukasawa, M; Nishijima, M; Hanada, K				Funakoshi, T; Yasuda, S; Fukasawa, M; Nishijima, M; Hanada, K			Reconstitution of ATP- and cytosol-dependent transport of de Novo synthesized ceramide to the site of sphingomyelin synthesis in semi-intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL-TRANSFER PROTEIN; HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; RAT-LIVER; SERINE PALMITOYLTRANSFERASE; GLUCOSYLCERAMIDE SYNTHESIS; INTRACELLULAR-TRANSPORT; GLYCOPROTEIN TRANSPORT; PLASMA-MEMBRANE	Transport of ceramide synthesized at the endoplasmic reticulum to the Golgi compartment, where sphingomyelin (SM) synthase exists, was reconstituted within semi-intact Chinese hamster ovary cells. When [H-3]ceramide that had been produced from [H-3]sphingosine at 15 degrees C in perforated cells was chased at 37 degrees C, [H-3]ceramide-to-[H-3]SM conversion occurred in a cytosol-dependent manner. In various aspects (i.e. kinetics, ATP dependence, and temperature dependence), [H-3]ceramide-to-[H-3]SM conversion in perforated cells was consistent with that in intact cells. The cytosol from LY-A strain, a Chinese hamster ovary cell mutant defective in endoplasmic reticulum-to-Golgi transport of ceramide, did not support [H-3]ceramide-to-[H-3] SM conversion in perforated wild-type cells, whereas the wild-type cytosol rescued the conversion in perforated LY-A cells. Brefeldin A-treated cells, in which the endoplasmic reticulum and the Golgis apparatus were merged, no longer required cytosol for conversion of [H-3]ceramide to [H-3]SM. These results indicated that the assay of [H-3]ceramide-to-[H-3]SM conversion in semi-intact cells is a faithful in vitro assay for the activity of cytosol-dependent transport of ceramide and that LY-A cells are defective in a cytosolic factor involved in ceramide transport. In addition, conversion of [H-3]ceramide to [H-3]glucosylceramide in semi-intact cells was little dependent on cytosol, suggesting that ceramide reached the site of glucosylceramide synthesis by a cytosol-independent (or less dependent) pathway.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan; Japan Sci & Technol Corp, CREST, Natl Inst Infect Dis, Shinjuku Ku, Tokyo 1628640, Japan	National Institute of Infectious Diseases (NIID); Japan Science & Technology Agency (JST); National Institute of Infectious Diseases (NIID)	Hanada, K (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.			YASUDA, Satoshi/0000-0002-1011-0815; Hanada, Kentaro/0000-0003-1383-2781				Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DEVRIES KJ, 1995, BIOCHEM J, V310, P643, DOI 10.1042/bj3100643; Fukasawa M, 1999, J CELL BIOL, V144, P673, DOI 10.1083/jcb.144.4.673; Fukasawa M, 1997, EXP CELL RES, V230, P154, DOI 10.1006/excr.1996.3403; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HANADA K, 1991, BIOCHIM BIOPHYS ACTA, V1086, P151, DOI 10.1016/0005-2760(91)90002-Y; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; HOEKSTRA D, 1992, BIOCHIM BIOPHYS ACTA, V1113, P277, DOI 10.1016/0304-4157(92)90002-R; Hong WJ, 1998, J CELL SCI, V111, P2831; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kok JW, 1998, BIOCHEM J, V333, P779, DOI 10.1042/bj3330779; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; Merrill Jr A. H., 1996, BIOCH LIPIDS LIPOPRO, P309; Michel C, 1997, FEBS LETT, V416, P153, DOI 10.1016/S0014-5793(97)01187-3; MOREAU P, 1993, BIOCHIM BIOPHYS ACTA, V1146, P9, DOI 10.1016/0005-2736(93)90332-T; MORELL P, 1970, J BIOL CHEM, V245, P342; ROSENWALD AG, 1993, ADV LIPID RES, V26, P101; SLOMIANY A, 1992, ARCH BIOCHEM BIOPHYS, V298, P167, DOI 10.1016/0003-9861(92)90108-9; TANAKA S, 1994, J BIOCHEM-TOKYO, V115, P981, DOI 10.1093/oxfordjournals.jbchem.a124448; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; URBANI L, 1990, J BIOL CHEM, V265, P1919; van Meer G, 1993, CURR OPIN CELL BIOL, V5, P661, DOI 10.1016/0955-0674(93)90137-F; van Tiel CM, 2000, BIOCHEM J, V346, P537, DOI 10.1042/0264-6021:3460537; VANHELVOOT A, 1997, J CELL SCI, V11, P75; WANG E, 1991, J BIOL CHEM, V266, P14486; WATTENBERG BW, 1990, J CELL BIOL, V111, P421, DOI 10.1083/jcb.111.2.421	35	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29938	29945		10.1074/jbc.M004470200	http://dx.doi.org/10.1074/jbc.M004470200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10882735	hybrid			2022-12-27	WOS:000089577900005
J	Van Uden, E; Sagara, Y; Van Uden, J; Orlando, R; Mallory, M; Rockenstein, E; Masliah, E				Van Uden, E; Sagara, Y; Van Uden, J; Orlando, R; Mallory, M; Rockenstein, E; Masliah, E			A protective role of the low density lipoprotein receptor-related protein against amyloid beta-protein toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; SPORADIC ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E RECEPTOR; KINASE-II; CELL-SURFACE; CALMODULIN ANTAGONIST; SCAVENGER RECEPTOR; ENDOCYTIC PATHWAY; PRECURSOR PROTEIN; TRANSGENIC MICE	In order to delineate the neuroprotective role of the low density lipoprotein receptor-related protein (LRP) against amyloid beta-protein toxicity, studies were performed in C6 cells challenged with amyloid beta-protein in the presence or absence of activated alpha(2)-macroglobulin. Toxicity was assessed via two cell viability assays. We found that this endocytic receptor conferred protection against amyloid beta-protein toxicity in the presence of activated alpha(2)-macroglobulin and its down-regulation via inhibition by receptor-associated protein or transfection of cells with presenilin 1, increased susceptibility to amyloid beta-protein toxicity. Increased surface LRP immunoreactivity in response to amyloid beta-protein challenge was associated with increased translocation of LRP from the endoplasmic reticulum to the surface. rather than from increased mRNA or protein expression. Furthermore, this translocation of LRP to the surface was mediated by a calcium/calmodulin protein kinase II-dependent signaling pathway. These studies provide evidence for a protective role of LRP against amyloid beta-protein toxicity and may explain the aggressive nature of presenilin-1 mutation in familial Alzheimer's disease.	Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Masliah, E (corresponding author), Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA.				NIA NIH HHS [AG5131, AG10869] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R29AG010869] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AOYAGI T, 1992, EXPERIENTIA, V48, P656, DOI 10.1007/BF02118312; APODACA G, 1994, J BIOL CHEM, V269, P19005; Arredondo L, 1998, GENETICS, V150, P265; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Colombo MI, 1997, J BIOL CHEM, V272, P7707, DOI 10.1074/jbc.272.12.7707; CZEKAY RP, 1995, J CELL SCI, V108, P1433; Du YS, 1997, J NEUROCHEM, V69, P299; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; Feng TP, 1995, PROG BRAIN RES, V105, P55; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; Haas C, 1997, BIOCHEM J, V325, P169, DOI 10.1042/bj3250169; Huang F, 1999, AM J PATHOL, V155, P1741, DOI 10.1016/S0002-9440(10)65489-2; Hughes SR, 1998, P NATL ACAD SCI USA, V95, P3275, DOI 10.1073/pnas.95.6.3275; HUNZIKER W, 1994, J BIOL CHEM, V269, P29003; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; LaDu MJ, 1997, J NEUROSCI RES, V49, P9, DOI 10.1002/(SICI)1097-4547(19970701)49:1<9::AID-JNR2>3.0.CO;2-H; Li WP, 1997, J MOL NEUROSCI, V8, P75, DOI 10.1007/BF02736774; LICASTRO F, 1995, J NEUROIMMUNOL, V57, P71, DOI 10.1016/0165-5728(94)00163-I; LIN JW, 1990, P NATL ACAD SCI USA, V87, P8257, DOI 10.1073/pnas.87.21.8257; LOPES MBS, 1994, FEBS LETT, V338, P301, DOI 10.1016/0014-5793(94)80288-2; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; Masliah E, 1998, J NEUROPATH EXP NEUR, V57, P1041, DOI 10.1097/00005072-199811000-00007; McKee AC, 1998, AMYLOID, V5, P1, DOI 10.3109/13506129809007283; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; Miguel-Hidalgo JJ, 1998, ACTA NEUROPATHOL, V95, P455, DOI 10.1007/s004010050825; Narita M, 1997, J NEUROCHEM, V69, P1904; Nayak AS, 1996, P NATL ACAD SCI USA, V93, P15451, DOI 10.1073/pnas.93.26.15451; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; ORLANDO RA, 1993, P NATL ACAD SCI USA, V90, P4082, DOI 10.1073/pnas.90.9.4082; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; Pillot T, 1999, J NEUROCHEM, V72, P230, DOI 10.1046/j.1471-4159.1999.0720230.x; Qiu ZH, 1999, J NEUROCHEM, V73, P1393, DOI 10.1046/j.1471-4159.1999.0731393.x; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; REBECK GW, 1993, NEURON, V11, P575; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Taddei K, 1997, NEUROSCI LETT, V223, P29, DOI 10.1016/S0304-3940(97)13394-8; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Van Uden E, 1999, MOL CELL NEUROSCI, V14, P129, DOI 10.1006/mcne.1999.0772; Wang WS, 1997, BRAIN RES, V778, P6, DOI 10.1016/S0006-8993(97)00877-9; Wernyj RP, 1999, MOL BRAIN RES, V64, P69, DOI 10.1016/S0169-328X(98)00307-6; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	47	36	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30525	30530		10.1074/jbc.M001151200	http://dx.doi.org/10.1074/jbc.M001151200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10899157	hybrid			2022-12-27	WOS:000089577900083
J	Yue, CP; Kus, CY; Liu, MY; Simon, MI; Sanborn, BM				Yue, CP; Kus, CY; Liu, MY; Simon, MI; Sanborn, BM			Molecular mechanism of the inhibition of phospholipase C beta(3) by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-BETA-3 PHOSPHORYLATION; CELLULAR-RESPONSES; ACTIVATION; CLONING; EXPRESSION; GAMMA; CELLS; DESENSITIZATION; PURIFICATION; STIMULATION	Activation of protein kinase C (PKC) can result from stimulation of the receptor-G protein-phospholipase C (PLC beta) pathway. In turn, phosphorylation of PLC beta by PKC may play a role in the regulation of receptor-mediated phosphatidylinositide (PI) turnover and intracellular Ca2+ release. Activation of endogenous PRC by phorbol 12-myristate 13 acetate inhibited both G alpha(q)-coupled (oxytocin and M1 muscarinic) and G alpha(i)-coupled (formyl-Met-Leu-Phe) receptor-stimulated PI turnover by 50-100% in PHM1, HeLa, COSM6, and RBL-2H3 cells expressing PLC beta(3). Activation of conventional PKCs with thymeleatoxin similarly inhibited oxytocin or formyl-Met-Leu-Phe receptor-stimulated PI turnover. The PKC inhibitory effect was also observed when PLC beta(3) was stimulated directly by G alpha(q) or G beta gamma in overexpression assays. PKC phosphorylated PLC beta(3) at the same predominant site in vivo and in vitro. Peptide sequencing of in vitro phosphorylated recombinant PLC beta(3) and site-directed mutagenesis identified Ser(1105) as the predominant phosphorylation site. Ser(1105) is also phosphorylated by protein kinase A (PKA; Yue, C., Dodge, K. L., Weber, G., and Sanborn, B. M. (1998) J. Biol. Chem. 273, 18023-18027). Similar to PKA, the inhibition by PKC of G alpha(q)-stimulated PLC beta(3) activity was completely abolished by mutation of Ser(1105) to Ala. In contrast, mutation of Ser(1105) or Ser(26), another putative phosphorylation target, to Ala had no effect on inhibition of G beta gamma-stimulated PLC beta(3) activity by PKC or PKA. These data indicate that PKC and PKA act similarly in that they inhibit G alpha(q)-stimulated PLC beta(3) as a result of phosphorylation of Ser(1105). Moreover, PKC and PKA both inhibit G beta gamma-stimulated activity by mechanisms that do not involve Ser(1105).	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA; Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Canc Biol & Nutr,Dept Med Biochem & Genet, Houston, TX 77030 USA; CALTECH, Dept Biol, Pasadena, CA 91125 USA	University of Texas System; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; California Institute of Technology	Sanborn, BM (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708, Houston, TX 77225 USA.				NICHD NIH HHS [HD09618] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009618, R37HD009618] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; ALVAREZ RA, 1995, GENOMICS, V29, P53, DOI 10.1006/geno.1995.1214; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BAHK YY, 1994, J BIOL CHEM, V269, P8240; BELL RM, 1991, J BIOL CHEM, V266, P4661; Cunningham ML, 1999, MOL PHARMACOL, V56, P265, DOI 10.1124/mol.56.2.265; Dodge KL, 1998, ENDOCRINOLOGY, V139, P2265, DOI 10.1210/en.139.5.2265; Dodge KL, 1999, MOL ENDOCRINOL, V13, P1977, DOI 10.1210/me.13.12.1977; Filtz TM, 1999, BIOCHEM J, V338, P257, DOI 10.1042/0264-6021:3380257; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; JHON DY, 1993, J BIOL CHEM, V268, P6654; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; KIM MJ, 1993, BIOCHEM BIOPH RES CO, V194, P706, DOI 10.1006/bbrc.1993.1879; KU CY, 1995, ENDOCRINOLOGY, V136, P1509, DOI 10.1210/en.136.4.1509; LEE CW, 1993, J BIOL CHEM, V268, P21318; Litosch I, 1996, RECEPT SIGNAL TRANS, V6, P87; Litosch I, 1997, BIOCHEM J, V326, P701, DOI 10.1042/bj3260701; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; Monga M, 1996, BIOL REPROD, V55, P427, DOI 10.1095/biolreprod55.2.427; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; PARK D, 1992, J BIOL CHEM, V267, P16048; Phillippe M, 1997, AM J PHYSIOL-ENDOC M, V273, pE665, DOI 10.1152/ajpendo.1997.273.4.E665; QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RICHARDON RM, 1995, J BIOL CHEM, V270, P27829, DOI 10.1074/jbc.270.46.27829; Richardson RM, 1998, J BIOL CHEM, V273, P10690, DOI 10.1074/jbc.273.17.10690; RYU SH, 1990, J BIOL CHEM, V265, P17941; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Stalberg P, 1999, FEBS LETT, V450, P210, DOI 10.1016/S0014-5793(99)00457-3; Strassheim D, 1998, MOL PHARMACOL, V53, P1047; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; Wang S, 1998, FEBS LETT, V441, P261, DOI 10.1016/S0014-5793(98)01518-X; WEBER G, 1994, HUM MOL GENET, V3, P1775, DOI 10.1093/hmg/3.10.1775; Woodruff ML, 1999, AM J PHYSIOL-LUNG C, V276, pL669, DOI 10.1152/ajplung.1999.276.4.L669; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; Xie W, 1999, P NATL ACAD SCI USA, V96, P10385, DOI 10.1073/pnas.96.18.10385; Yang H, 1998, ANTICANCER RES, V18, P1399; Yue CP, 1998, J BIOL CHEM, V273, P18023, DOI 10.1074/jbc.273.29.18023	40	79	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30220	30225		10.1074/jbc.M004276200	http://dx.doi.org/10.1074/jbc.M004276200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893237	Green Accepted, hybrid			2022-12-27	WOS:000089577900043
J	Mordier, S; Deval, C; Bechet, D; Tassa, A; Ferrara, M				Mordier, S; Deval, C; Bechet, D; Tassa, A; Ferrara, M			Leucine limitation induces autophagy and activation of lysosome-dependent proteolysis in C2C12 myotubes through a mammalian target of rapamycin-independent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CONJUGATION SYSTEM; ISOLATED RAT HEPATOCYTES; AMINO-ACID-UPTAKE; P70 S6 KINASE; SKELETAL-MUSCLE; MESSENGER-RNAS; L6 MYOBLASTS; DEGRADATION; PROTEASOME; LIVER	Loss of muscle mass usually characterizes different pathologies (sepsis, cancer, trauma) and also occurs during normal aging. One reason for muscle wasting relates to a decrease in food intake. This study addressed the role of leucine as a regulator of protein breakdown in mouse C2C12 myotubes and aimed to determine which cellular responses regulate the process. Determination of the rate of protein breakdown indicated that leucine is one key regulator of this process in myotubes because starvation for this amino acid is responsible for 30-40% of the total increase generated by total amino acid starvation. Leucine restriction rapidly accelerates the rate of protein breakdown (+11 to 15% (p < 0.001) after 1 h of starvation) in a dose-dependent manner. By using various inhibitors, evidence is provided that acceleration of protein catabolism results mainly from an induction of autophagy, activation of lysosome-dependent proteolysis, without modification of mRNA levels encoding the lysosomal cathepsins B, L, or D. Those results suggest that autophagy is an essential cellular response for increasing protein breakdown in muscle following food deprivation, Induction of autophagy precedes a decrease in global protein synthesis (-20% to -30% (p < 0.001)) that occurs after 3 h of leucine starvation. Inhibition of the mammalian target of rapamycin (mTOR) activity does not abolish the effect of leucine starvation and the level of phosphorylated ribosomal S6 protein is not affected by leucine withdrawal. These latter data provide clear evidence that the mTOR signaling pathway is not involved in the mediation of leucine effects on both protein synthesis and degradation in C2C12 myotubes.	Inst Natl Rech Agron Theix, Unite Nutr Cellulaire & Mol, F-63122 St Genes Champanelle, France	INRAE	Mordier, S (corresponding author), Inst Natl Rech Agron Theix, Unite Nutr Cellulaire & Mol, F-63122 St Genes Champanelle, France.	mordier@clermont.inra.fr		Bechet, Daniel/0000-0002-3812-8099				ADIBI SA, 1973, AM J PHYSIOL, V225, P408, DOI 10.1152/ajplegacy.1973.225.2.408; Attaix D, 1998, ADV MOL CEL, V27, P235, DOI 10.1016/S1569-2558(08)60463-4; BARACOS VE, 1995, AM J PHYSIOL-ENDOC M, V268, pE996, DOI 10.1152/ajpendo.1995.268.5.E996; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BERGSTROM J, 1990, CLIN SCI, V79, P331, DOI 10.1042/cs0790331; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BUSE MG, 1975, J CLIN INVEST, V56, P1250, DOI 10.1172/JCI108201; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DICE JF, 1992, ANN NY ACAD SCI, V674, P58, DOI 10.1111/j.1749-6632.1992.tb27477.x; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; GARCIAMARTINEZ C, 1995, MOL CELL BIOCHEM, V148, P17, DOI 10.1007/BF00929498; Grimble RF, 1996, CLIN SCI, V91, P121, DOI 10.1042/cs0910121; Grizard Jean, 1995, Nutrition Research Reviews, V8, P67, DOI 10.1079/NRR19950007; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HASSELGREN PO, 1988, ARCH SURG-CHICAGO, V123, P992; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOLEN I, 1993, EUR J BIOCHEM, V215, P113, DOI 10.1111/j.1432-1033.1993.tb18013.x; HONG SOC, 1984, J NUTR, V114, P1204; Hulsewe KWE, 1997, P NUTR SOC, V56, P801, DOI 10.1079/PNS19970081; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Jousse C, 1999, Curr Opin Clin Nutr Metab Care, V2, P297, DOI 10.1097/00075197-199907000-00008; Kimball SR, 1998, J BIOL CHEM, V273, P30945, DOI 10.1074/jbc.273.47.30945; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; Kirschke H., 1987, CHEM LYSOSOMAL PROTE, P193; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mansoor O, 1996, P NATL ACAD SCI USA, V93, P2714, DOI 10.1073/pnas.93.7.2714; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Rehfeldt C, 1997, ANAL BIOCHEM, V251, P294, DOI 10.1006/abio.1997.2285; Rooyackers OE, 1997, ANNU REV NUTR, V17, P457, DOI 10.1146/annurev.nutr.17.1.457; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUGDEN PH, 1991, BIOCHEM J, V273, P21, DOI 10.1042/bj2730021; Tanaka K, 1998, BIOCHEM BIOPH RES CO, V247, P537, DOI 10.1006/bbrc.1998.8617; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; TEMPARIS S, 1994, CANCER RES, V54, P5568; Tiao G, 1997, J CLIN INVEST, V99, P163, DOI 10.1172/JCI119143; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Voisin L, 1996, J CLIN INVEST, V97, P1610, DOI 10.1172/JCI118586; WARNER BW, 1989, JPEN-PARENTER ENTER, V13, P344, DOI 10.1177/0148607189013004344; WING SS, 1991, BIOCHEM J, V275, P165, DOI 10.1042/bj2750165; WING SS, 1993, AM J PHYSIOL, V264, pE668, DOI 10.1152/ajpendo.1993.264.4.E668	48	159	177	3	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29900	29906		10.1074/jbc.M003633200	http://dx.doi.org/10.1074/jbc.M003633200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893413	hybrid, Green Published			2022-12-27	WOS:000089439800098
J	Diverse-Pierluissi, M; McIntire, WE; Myung, CS; Lindorfer, MA; Garrison, JC; Goy, MF; Dunlap, K				Diverse-Pierluissi, M; McIntire, WE; Myung, CS; Lindorfer, MA; Garrison, JC; Goy, MF; Dunlap, K			Selective coupling of G protein beta gamma complexes to inhibition of Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODULATE CALCIUM CHANNELS; ATRIAL POTASSIUM CHANNEL; PHOSPHOLIPASE-C; ALPHA-SUBUNIT; N-TYPE; MOLECULAR-CLONING; SENSORY NEURONS; BOVINE BRAIN; KINASE-C; ACTIVATION	Several mechanisms couple heterotrimeric guanine nucleotide-binding proteins (G proteins) to cellular effecters. Although alpha subunits of G proteins (G alpha) were the first recognized mediators of receptor-effector coupling, G beta gamma regulation of effecters is now well known. Five G beta and 12 G gamma subunit genes have been identified, suggesting through their diversity that specific subunits couple selectively to effecters. The molecular determinants of G beta gamma-effector coupling, however, are not well understood, and most studies of G protein-effector coupling do not support selectivity of G beta gamma action. To explore this issue further, we have introduced recombinant G beta gamma complexes into avian sensory neurons and measured the inhibition of Ca2+ currents mediated by an endogenous phospholipase C beta- (PLC beta) and protein kinase C-dependent pathway. Activities of G beta gamma in the native cells were compared with enzyme assays performed in vitro. We report a surprising selective activation of the PLC beta pathway by G beta gamma complexes containing beta(1) subunits, whereas beta(2)-containing complexes produced no activation. In contrast, when assayed in vitro, PLC beta and type II adenylyl cyclase did not discriminate among these same G beta gamma complexes, suggesting the possibility that additional cellular determinants confer specificity in vivo.	Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA; CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	Tufts University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Virginia; University of North Carolina; University of North Carolina Chapel Hill	Dunlap, K (corresponding author), Tufts Univ, Sch Med, Dept Neurosci, 136 Harrison Ave, Boston, MA 02111 USA.			Myung, Chang-Seon/0000-0002-6292-2911	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037443, R01NS016483] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19952] Funding Source: Medline; NINDS NIH HHS [NS16483, NS37443] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOYER JL, 1994, J BIOL CHEM, V269, P2814; BROOKER G, 1976, SCIENCE, V194, P270, DOI 10.1126/science.184530; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COX DH, 1992, J NEUROSCI, V12, P906; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DIVERSEPIERLUISSI M, 1993, NEURON, V10, P753, DOI 10.1016/0896-6273(93)90175-Q; Dunlap KL, 1998, SEMIN NEUROSCI, V9, P198, DOI 10.1006/smns.1997.0119; Exner T, 1999, P NATL ACAD SCI USA, V96, P1327, DOI 10.1073/pnas.96.4.1327; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; GRABER SG, 1994, METHOD ENZYMOL, V237, P212; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HARISH OE, 1992, INT J DEV NEUROSCI, V10, P421, DOI 10.1016/0736-5748(92)90032-U; HSU WH, 1990, J BIOL CHEM, V265, P11220; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Jarvis SE, 2000, J BIOL CHEM, V275, P6388, DOI 10.1074/jbc.275.9.6388; Lindorfer MA, 1998, J BIOL CHEM, V273, P34429, DOI 10.1074/jbc.273.51.34429; Lu Q, 2000, BIOPHYS J, V78, p265A; McIntire WE, 1998, BIOCHEMISTRY-US, V37, P14651, DOI 10.1021/bi981642q; Myung CS, 1999, ANAL BIOCHEM, V270, P303, DOI 10.1006/abio.1999.4086; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Ruiz-Velasco V, 2000, J NEUROSCI, V20, P2183; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; UEDA N, 1994, J BIOL CHEM, V269, P4388; WALDO GL, 1991, MOL PHARMACOL, V40, P480; Waldo GL, 1996, BIOCHEM J, V316, P559, DOI 10.1042/bj3160559; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WILCOX MD, 1995, J BIOL CHEM, V270, P4189, DOI 10.1074/jbc.270.9.4189; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yan K, 1997, J BIOL CHEM, V272, P2056; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	37	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28380	28385		10.1074/jbc.M003571200	http://dx.doi.org/10.1074/jbc.M003571200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10880514	hybrid			2022-12-27	WOS:000089330700008
J	Moreno, B; Urbina, JA; Oldfield, E; Bailey, BN; Rodrigues, CO; Docampo, R				Moreno, B; Urbina, JA; Oldfield, E; Bailey, BN; Rodrigues, CO; Docampo, R			P-31 NMR spectroscopy of Trypanosoma brucei, Trypanosoma cruzi, and Leishmania major - Evidence for high levels of condensed inorganic phosphates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; VACUOLAR H+-PYROPHOSPHATASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; GLUCOSE-METABOLISM; CO2 FIXATION; ACIDOCALCISOMES; POLYPHOSPHATE; GLYCOLYSIS; INVIVO; PLANT	High resolution P-31 nuclear magnetic resonance spectra at 303.6 MHz (corresponding to a H-1 resonance frequency of 750 MHz) have been obtained of perchloric acid extracts of Trypanosoma brucei, Trypanosoma cruzi, and Leishmania major, the causative agents of African sleeping sickness, Chagas' disease, and leishmaniasis, Essentially complete assignments have been made based on chemical shifts and by direct addition of authentic reference compounds. The results indicate the presence of high levels of short chain condensed polyphosphates: di-, tri-, tetra-, and pentapolyphosphate. P-31 NMR spectra of purified T. brucei, T. cruzi, and L. major acidocalcisomes, calcium and phosphorus storage organelles, indicate that polyphosphates are abundant in these organelles and have an average chain length of 3.11-3.39 phosphates, In the context of the recent discovery of several pyrophosphate-utilizing enzymes in trypanosomatids, the presence of these inorganic polyphosphates implies a critical role for these molecules in these parasites and a potential new route to chemotherapy.	Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Dept Biophys, Urbana, IL 61801 USA; Inst Venezolano Invest Cient, Caracas 1020A, Venezuela; Univ Illinois, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Venezuelan Institute Science Research; University of Illinois System; University of Illinois Urbana-Champaign	Oldfield, E (corresponding author), Univ Illinois, Dept Chem, 600 S Mathews Ave, Urbana, IL 61801 USA.	eo@chad.scs.uiuc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023259, R21AI023259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23259] Funding Source: Medline; NIGMS NIH HHS [GM-50694] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONE GJ, 1956, NATURE, V178, P308, DOI 10.1038/178308a0; BOWES AE, 1993, J BIOL CHEM, V268, P13885; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; BRUN R, 1979, ACTA TROP, V36, P289; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CRUTCHFI.MM, 1965, J AM CHEM SOC, V87, P2815, DOI 10.1021/ja01091a007; CRUTCHFIELD MM, 1962, INORG CHEM, V1, P813, DOI 10.1021/ic50004a020; DELOSSANTOS C, 1985, EUR J BIOCHEM, V149, P421, DOI 10.1111/j.1432-1033.1985.tb08942.x; DESLAURIERS R, 1982, BIOCHIM BIOPHYS ACTA, V720, P329, DOI 10.1016/0167-4889(82)90109-4; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Eisenthal R, 1998, J BIOL CHEM, V273, P5500, DOI 10.1074/jbc.273.10.5500; FAN TWM, 1991, BIOCHIM BIOPHYS ACTA, V1092, P39, DOI 10.1016/0167-4889(91)90176-X; FRYDMAN B, 1990, EUR J BIOCHEM, V192, P363, DOI 10.1111/j.1432-1033.1990.tb19235.x; GLONEK T, 1972, INORG CHEM, V11, P567, DOI 10.1021/ic50109a029; HAMMOND DJ, 1980, MOL BIOCHEM PARASIT, V2, P63, DOI 10.1016/0166-6851(80)90032-8; HAROLD FM, 1966, BACTERIOL REV, V30, P772, DOI 10.1128/MMBR.30.4.772-794.1966; HART DT, 1984, MOL BIOCHEM PARASIT, V12, P25, DOI 10.1016/0166-6851(84)90041-0; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; KORNBERG SR, 1956, J BIOL CHEM, V218, P23; Kulaev I S, 1999, Prog Mol Subcell Biol, V23, P27; KULAEV IS, 1983, ADV MICROB PHYSIOL, V24, P83, DOI 10.1016/S0065-2911(08)60385-9; Kumble KD, 1996, J BIOL CHEM, V271, P27146, DOI 10.1074/jbc.271.43.27146; Lu HG, 1997, J BIOL CHEM, V272, P9464, DOI 10.1074/jbc.272.14.9464; Luo SH, 1999, FEBS LETT, V460, P217, DOI 10.1016/S0014-5793(99)01353-8; MACKENZIE NE, 1982, EUR J BIOCHEM, V121, P657, DOI 10.1111/j.1432-1033.1982.tb05836.x; MACKENZIE NE, 1983, BIOSCIENCE REP, V3, P141, DOI 10.1007/BF01121945; MACKENZIE NE, 1984, MOL BIOCHEM PARASIT, V13, P13, DOI 10.1016/0166-6851(84)90097-5; Marchesini N, 2000, BIOCHEM J, V347, P243, DOI 10.1042/0264-6021:3470243; MARTIN JB, 1993, EUR J BIOCHEM, V214, P711, DOI 10.1111/j.1432-1033.1993.tb17972.x; MERTENS E, 1993, PARASITOL TODAY, V9, P122, DOI 10.1016/0169-4758(93)90169-G; Myler PJ, 1999, P NATL ACAD SCI USA, V96, P2902, DOI 10.1073/pnas.96.6.2902; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Pereira CA, 2000, J BIOL CHEM, V275, P1495, DOI 10.1074/jbc.275.2.1495; Platzer EG, 1999, J PARASITOL, V85, P603, DOI 10.2307/3285730; RAINEY PM, 1991, MOL BIOCHEM PARASIT, V45, P307, DOI 10.1016/0166-6851(91)90099-R; REEVES RE, 1974, J BIOL CHEM, V249, P7737; REEVES RE, 1968, J BIOL CHEM, V243, P3202; REEVES RE, 1975, BIOCHEM BIOPH RES CO, V66, P1389, DOI 10.1016/0006-291X(75)90513-6; REEVES RE, 1970, BIOCHIM BIOPHYS ACTA, V220, P346, DOI 10.1016/0005-2744(70)90021-5; ROBERTS MF, 1987, PHOSPHORUS NMR BIOL, P85; Rodrigues CO, 1999, BIOCHEM J, V340, P759, DOI 10.1042/0264-6021:3400759; Rodrigues CO, 1999, MOL CELL BIOL, V19, P7712; Rodrigues CO, 2000, BIOCHEM J, V349, P737, DOI 10.1042/bj3490737; SAMAD A, 1988, MOL BIOCHEM PARASIT, V29, P159, DOI 10.1016/0166-6851(88)90071-0; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Scott DA, 1997, J BIOL CHEM, V272, P28020, DOI 10.1074/jbc.272.44.28020; Scott DA, 2000, J BIOL CHEM, V275, P24215, DOI 10.1074/jbc.M002454200; THOMPSON SN, 1992, MAGNET RESON MED, V28, P311, DOI 10.1002/mrm.1910280213; Urbina JA, 1999, J BIOL CHEM, V274, P33609, DOI 10.1074/jbc.274.47.33609; URBINA JA, 1990, ARCH BIOCHEM BIOPHYS, V282, P91, DOI 10.1016/0003-9861(90)90091-C; Van Wazer J. R., 1987, PHOSPHORUS NMR BIOL, P1; Vanderheyden N, 2000, BIOCHEM J, V346, P53, DOI 10.1042/0264-6021:3460053; VERCESI AE, 1994, BIOCHEM J, V304, P227, DOI 10.1042/bj3040227; VIEIRA L, 1995, J BIOL CHEM, V270, P5299, DOI 10.1074/jbc.270.10.5299; WAKI H, 1982, POLYHEDRON, V1, P69, DOI 10.1016/S0277-5387(00)81071-2; ZHEN RG, 1994, PLANT PHYSIOL, V104, P153, DOI 10.1104/pp.104.1.153	56	77	78	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28356	28362		10.1074/jbc.M003893200	http://dx.doi.org/10.1074/jbc.M003893200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10871617	hybrid			2022-12-27	WOS:000089330700005
J	Tobacman, LS; Butters, CA				Tobacman, LS; Butters, CA			A new model of cooperative myosin-thin filament binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; TROPONIN-TROPOMYOSIN COMPLEX; F-ACTIN; SUBFRAGMENT-1; CONTRACTION; DYNAMICS	Cooperative myosin binding to the thin filament is critical to regulation of cardiac and skeletal muscle contraction. This report delineates and fits to experimental data a new model of this process, in which specific tropomyosin-actin interactions are important, the tropomyosin-tropomyosin polymer is continuous rather than disjointed, and tropomyosin affects myosin-actin binding by shifting among three positions as in recent structural studies. A myosin- and tropomyosin-induced conformational change in actin is proposed, rationalizing the similar to 10,000-fold strengthening effect of myosin on tropomyosin-actin binding. Also, myosin S1 binding to regulated filaments containing mutant tropomyosins with internal deletions exhibited exaggerated cooperativity, implying an allosteric effect of tropomyosin on actin and allowing the effect's measurement. Comparisons among the mutants suggest the change in actin is promoted much more strongly by the middle of tropomyosin than by its ends. Regardless of calcium binding to troponin, this change in actin facilitates the shift in tropomyosin position to the actin inner domain, which is required for tight myosin-actin association. It also increases myosin-actin affinity 7-fold compared with the absence of troponin-tropomyosin, Finally, initiation of a shift in tropomyosin position is 100-fold more difficult than is its extension from one actin to the next, producing the myosin binding cooperativity that underlies cooperative activation of muscle contraction.	Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Tobacman, LS (corresponding author), Univ Iowa, Dept Internal Med, 200 Hawkins Dr SE 610,GH, Iowa City, IA 52242 USA.	larry-tobacman@uiowa.edu			NHLBI NIH HHS [HL-38834] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038834, R29HL038834] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; Cassell M, 1996, J BIOL CHEM, V271, P12867, DOI 10.1074/jbc.271.22.12867; Chen Y, 2000, BIOPHYS J, V78, p236A; EATON BL, 1976, SCIENCE, V192, P1337, DOI 10.1126/science.131972; Feng L, 1997, J BIOL CHEM, V272, P16829, DOI 10.1074/jbc.272.27.16829; GEEVES MA, 1986, PROC R SOC SER B-BIO, V229, P85, DOI 10.1098/rspb.1986.0076; GEEVES MA, 1994, BIOPHYS J, V67, P273, DOI 10.1016/S0006-3495(94)80478-3; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GREENE LE, 1980, P NATL ACAD SCI-BIOL, V77, P2616, DOI 10.1073/pnas.77.5.2616; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; HILL TL, 1985, COOPERATIVITY THEORY, P321; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HOLMES KC, 1995, BIOPHYS J, V68, pS2; HUXLEY HE, 1973, COLD SPRING HARB SYM, V37, P361, DOI 10.1101/SQB.1973.037.01.046; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Landis C, 1999, J BIOL CHEM, V274, P31279, DOI 10.1074/jbc.274.44.31279; Landis CA, 1997, J BIOL CHEM, V272, P14051, DOI 10.1074/jbc.272.22.14051; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; NAGASHIMA H, 1982, J MOL BIOL, V155, P409, DOI 10.1016/0022-2836(82)90479-X; Orlova A, 1997, J MOL BIOL, V265, P469, DOI 10.1006/jmbi.1996.0761; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; Prochniewicz E, 1999, BIOCHEMISTRY-US, V38, P14860, DOI 10.1021/bi991343g; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Rosol M, 2000, BIOPHYS J, V78, P908, DOI 10.1016/S0006-3495(00)76648-3; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILLIAMS DL, 1983, BIOCHEMISTRY-US, V22, P2770, DOI 10.1021/bi00280a027; Xu C, 1999, BIOPHYS J, V77, P985, DOI 10.1016/S0006-3495(99)76949-3	36	105	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27587	27593						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10864931				2022-12-27	WOS:000089197100011
J	Rigourd, M; Lanchy, JM; Le Grice, SFJ; Ehresmann, B; Ehresmann, C; Marquet, R				Rigourd, M; Lanchy, JM; Le Grice, SFJ; Ehresmann, B; Ehresmann, C; Marquet, R			Inhibition of the initiation of HIV-1 reverse transcription by 3 '-azido-3 '-deoxythymidine - Comparison with elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; STATE KINETIC CHARACTERIZATION; BINDING-SITE COMPLEMENTARY; STRAND DNA-SYNTHESIS; AZT RESISTANCE; TRANSFER-RNAS; TEMPLATE-PRIMER; TYPE-1; MECHANISM; POLYMERIZATION	Initiation of human immunodeficiency virus-1 reverse transcription requires formation of a complex containing the viral RNA, primer tRNA(3)(Lys), and reverse transcriptase, Initiation, corresponding to addition of the first six nucleotides to tRNA(3)(Lys), is distinguished from elongation by its high specificity and low efficiency (processivity), Here, we compared the inhibition of initiation and elongation of reverse transcription by 3'-azido-3'-deoxythymidine 5'-triphosphate (AZTTP), the active form of 3'-azido-3'-deoxythymidine. We report the first detailed study of nucleotide binding, discrimination, and pyrophosphorolysis by the authentic initiation complex, We showed that the initiation and elongation complexes bound AZTTP and dTTP with the same affinity, while the polymerization rates were reduced by 148-160-fold during initiation. The pyrophosphorolysis rate of dTTP was reduced by the same extent, indicating that the polymerization equilibrium is the same in the two phases. The efficient unblocking of the 3'-azido-3'-deoxythymidine 5'-monophosphate (AZTMP)-terminated primer by pyrophosphorolysis significantly relieved inhibition of DNA synthesis during elongation in the presence of physiological pyrophosphate concentrations. Remarkably, although pyrophosphorolysis of dTMP and AZTMP were equally efficient during elongation, reverse transcriptase was almost totally unable to unblock the AZTMP-terminated primer during initiation. As a result, inhibition of reverse transcription by AZTTP was more efficient during initiation than elongation of reverse transcription, despite a reduced selectivity of incorporation.	Inst Biol Mol & Cellulaire, CNRS, UPR 9002, F-67084 Strasbourg, France; NCI, Frederick Canc Res & Dev Ctr, Resistance Mechanisms Lab, NIH, Frederick, MD 21702 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Marquet, R (corresponding author), Inst Biol Mol & Cellulaire, CNRS, UPR 9002, 15 Rue Rene Descartes, F-67084 Strasbourg, France.			Marquet, Roland/0000-0002-4209-3976				Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Arts EJ, 1998, PROG NUCLEIC ACID RE, V58, P339; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; BARSHOP BA, 1991, ANAL BIOCHEM, V197, P266, DOI 10.1016/0003-2697(91)90387-9; Canard B, 1998, J BIOL CHEM, V273, P14596, DOI 10.1074/jbc.273.23.14596; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; CARROLL SS, 1994, BIOCHEMISTRY-US, V33, P2113, DOI 10.1021/bi00174a018; ERIKSSON BFH, 1989, ANTIMICROB AGENTS CH, V33, P663, DOI 10.1128/AAC.33.5.663; Font E, 1999, ANTIMICROB AGENTS CH, V43, P2964, DOI 10.1128/AAC.43.12.2964; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GANGLOFF J, 1984, J BIOCHEM BIOPH METH, V9, P201, DOI 10.1016/0165-022X(84)90025-3; Gotte M, 1999, ARCH BIOCHEM BIOPHYS, V365, P199, DOI 10.1006/abbi.1999.1209; Gu ZX, 1995, J BIOL CHEM, V270, P31046, DOI 10.1074/jbc.270.52.31046; Isel C, 1998, NUCLEIC ACIDS RES, V26, P1198, DOI 10.1093/nar/26.5.1198; ISEL C, 1993, J BIOL CHEM, V268, P25269; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; JAJU M, 1995, J BIOL CHEM, V270, P9740, DOI 10.1074/jbc.270.17.9740; Kang SM, 1997, J VIROL, V71, P207, DOI 10.1128/JVI.71.1.207-217.1997; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14064, DOI 10.1021/bi9713862; KOSHIDA R, 1989, ANTIMICROB AGENTS CH, V33, P778, DOI 10.1128/AAC.33.5.778; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; Lanchy JM, 1998, J BIOL CHEM, V273, P24425, DOI 10.1074/jbc.273.38.24425; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; Mak J, 1997, J VIROL, V71, P8087, DOI 10.1128/JVI.71.11.8087-8095.1997; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; OBRIEN WE, 1976, ANAL BIOCHEM, V76, P423, DOI 10.1016/0003-2697(76)90337-7; REARDON JE, 1993, J BIOL CHEM, V268, P8743; SKALKA A, 1993, REVERSE TRANSCRIPTAS; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; Tachedjian G, 1996, J VIROL, V70, P7171, DOI 10.1128/JVI.70.10.7171-7181.1996; Thrall SH, 1998, BIOCHEMISTRY-US, V37, P13349; Vaccaro JA, 1999, BIOCHEMISTRY-US, V38, P15978, DOI 10.1021/bi990945x; Vaccaro JA, 1998, BIOCHEMISTRY-US, V37, P14189, DOI 10.1021/bi9810353; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996; Zhang ZJ, 1998, AIDS RES HUM RETROV, V14, P979, DOI 10.1089/aid.1998.14.979; Zhang ZJ, 1998, RNA, V4, P394	45	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26944	26951						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10864929				2022-12-27	WOS:000089144800038
J	Banky, P; Newlon, MG; Roy, M; Garrod, S; Taylor, SS; Jennings, PA				Banky, P; Newlon, MG; Roy, M; Garrod, S; Taylor, SS; Jennings, PA			Isoform-specific differences between the type I alpha and II alpha cyclic AMP-dependent protein kinase anchoring domains revealed by solution NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL-SHIFT INDEX; REGULATORY SUBUNIT; A-KINASE; SECONDARY STRUCTURE; SCAFFOLD PROTEINS; ESCHERICHIA-COLI; LARGER PROTEINS; SPECTROSCOPY; C-13; H-1	Cyclic AMP dependent protein kinase (PKA) is controlled, in part, by the subcellular localization of the enzyme (1). Discovery of dual Specificity anchoring proteins (D-AKAPs) indicates that not only is the type II, but also the type I, enzyme localized (2). It appears that the type I enzyme is localized in a novel, dynamic fashion as opposed to the apparent static localization of the type II enzyme. Recently, the structure of the dimerization/docking (D/D) domain from the type II enzyme was solved (3), This work revealed an X-type four-helix bundle motif with a hydrophobic patch that modulates AKAP interactions. To understand the dynamic versus static localization of PKA, multidimensional NMR techniques were used to investigate the structural features of the type I D/D domain. Our results indicate a conserved helix-turn-helix motif in the type I and type II D/D domains. However, important differences between the two-domains are evident in the extreme NH2 terminus: this region is extended in the type II domain, whereas it is helical in the type I protein. The NH2-terminal residues in RII alpha contain determinants for anchoring, and the orientation and packing of this helical element in the RI alpha structure may have profound consequences in:the recognition surface presented to the AKAPs.	Univ Calif San Diego, Dept Biochem & Chem, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, Sch Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Jennings, PA (corresponding author), Univ Calif San Diego, Dept Biochem & Chem, Sch Med, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK5444(P4)] Funding Source: Medline; NIGMS NIH HHS [GM34921] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; Angelo R, 1998, J BIOL CHEM, V273, P14633, DOI 10.1074/jbc.273.23.14633; Banky P, 1998, J BIOL CHEM, V273, P35048, DOI 10.1074/jbc.273.52.35048; BANKY P, 2000, THESIS U CALIFORNIA; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; BRUNGER AT, 1991, ACCOUNTS CHEM RES, V24, P54; BUBIS J, 1987, J BIOL CHEM, V262, P14961; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; GARCIA GM, 1986, CELL, V45, P453, DOI 10.1016/0092-8674(86)90331-4; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; HARPER JF, 1985, VITAM HORM, V42, P197; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Leon DA, 1997, J BIOL CHEM, V272, P28431, DOI 10.1074/jbc.272.45.28431; Lester LB, 1997, RECENT PROG HORM RES, V52, P409; Maniatis T., 1986, MOL CLONING LAB MANU; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P608; MCCOY MA, 1992, J MAGN RESON, V98, P674, DOI 10.1016/0022-2364(92)90023-Z; MCCOY MA, 1992, J AM CHEM SOC, V114, P2108, DOI 10.1021/ja00032a026; Miki E, 1998, J BIOL CHEM, V273, P34384, DOI 10.1074/jbc.273.51.34384; Miki K, 1999, J BIOL CHEM, V274, P29057, DOI 10.1074/jbc.274.41.29057; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Newlon MG, 1997, J BIOL CHEM, V272, P23637, DOI 10.1074/jbc.272.38.23637; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; ODonoghue SI, 1996, J BIOMOL NMR, V8, P193, DOI 10.1007/BF00211165; PATT SL, 1992, J MAGN RESON, V96, P94, DOI 10.1016/0022-2364(92)90289-J; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Reinitz CA, 1997, ARCH BIOCHEM BIOPHYS, V348, P391, DOI 10.1006/abbi.1997.0401; Robinson ML, 1996, ARCH BIOCHEM BIOPHYS, V330, P181, DOI 10.1006/abbi.1996.0240; RUBIN CS, 1972, J BIOL CHEM, V247, P6135; RUBIN CS, 1994, BIOCHIM BIOPHYS ACTA, V1224, P407; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; Schillace RV, 1999, CURR BIOL, V9, P321, DOI 10.1016/S0960-9822(99)80141-9; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; VUISTER GW, 1993, J AM CHEM SOC, V115, P772; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yang WL, 1998, BIOCHEMISTRY-US, V37, P14175, DOI 10.1021/bi981402a	61	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35146	35152		10.1074/jbc.M003961200	http://dx.doi.org/10.1074/jbc.M003961200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10899163	hybrid			2022-12-27	WOS:000165422800044
J	Achenbach, TV; Muller, R; Slater, EP				Achenbach, TV; Muller, R; Slater, EP			Bcl-2 independence of flavopiridol-induced apoptosis - Mitochondrial, depolarization in the absence of cytochrome c release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; CELL-CYCLE ARREST; CARCINOMA-CELLS; CANCER-CELLS; CASPASE ACTIVATION; LEUKEMIA-CELLS; DEATH; INDUCTION; MYC; EXPRESSION	The new chemotherapeutic agent, flavopiridol, presently in clinical trials, has been extensively studied yet little is known about its mechanism of action. In this study we show that the induction of apoptosis by flavopiridol is largely independent of Bcl-2. This is indicated by the observation that neither overexpression nor the antisense oligonucleotide-mediated down-regulation of Bcl-2 had any effect on flavopiridol-induced cell killing. Our results suggest that flavopiridol can induce apoptosis through different pathways of caspase activation with caspase 8 playing a pivotal role. In human lung carcinoma cells, which contain high levels of endogenous Bcl-2 and lack procaspase 8, flavopiridol treatment leads to mitochondrial depolarization in the absence of cytochrome c release, followed by the activation of caspase 3 and cell death. These results clearly differ from observations made with other anti-tumor drugs and might explain, at least in part, the unusual anti-tumor properties of flavopirido.	Univ Marburg, Inst Mol Biol & Tumor Res, D-35033 Marburg, Germany	Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, Inst Mol Biol & Tumor Res, Emil Mannkopff Str 2, D-35033 Marburg, Germany.	mueller@imt.uni.marburg.de	Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ADAMS JM, 1992, CANCER SURV, V15, P119; Arguello F, 1998, BLOOD, V91, P2482; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bible KC, 1996, CANCER RES, V56, P4856; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brusselbach S, 1998, INT J CANCER, V77, P146; Byrd JC, 1998, BLOOD, V92, P3804, DOI 10.1182/blood.V92.10.3804; Carlson BA, 1996, CANCER RES, V56, P2973; Chaloupka R, 1999, FEBS LETT, V462, P295, DOI 10.1016/S0014-5793(99)01538-0; Cory S, 1999, CANCER RES, V59, p1685S; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; CZECH J, 1995, INT J ONCOL, V6, P31; Deigner HP, 1999, CURR MED CHEM, V6, P399; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dobbelstein M, 1996, J VIROL, V70, P6479, DOI 10.1128/JVI.70.9.6479-6485.1996; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; Hooijberg JH, 1999, BRIT J CANCER, V81, P269, DOI 10.1038/sj.bjc.6690687; Houghton Janet A., 1999, Current Opinion in Oncology, V11, P475, DOI 10.1097/00001622-199911000-00008; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KAUR G, 1992, J NATL CANCER I, V84, P1736, DOI 10.1093/jnci/84.22.1736; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Konig A, 1997, BLOOD, V90, P4307; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Motwani M, 1999, CLIN CANCER RES, V5, P1876; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Parker BW, 1998, BLOOD, V91, P458, DOI 10.1182/blood.V91.2.458.458_458_465; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Reed J C, 1996, Behring Inst Mitt, P72; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Sauter ER, 1999, CANCER RES, V59, P4876; Schrump DS, 1998, CLIN CANCER RES, V4, P2885; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; Shapiro GI, 1999, CLIN CANCER RES, V5, P2925; Shimizu S, 1996, ONCOGENE, V12, P2251; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wagenknecht B, 1998, CELL DEATH DIFFER, V5, P894, DOI 10.1038/sj.cdd.4400435; Wright J, 1998, Oncology (Williston Park), V12, P1023; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593; Ziegler A, 1997, JNCI-J NATL CANCER I, V89, P1027, DOI 10.1093/jnci/89.14.1027	58	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32089	32097		10.1074/jbc.M005267200	http://dx.doi.org/10.1074/jbc.M005267200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10896673	hybrid			2022-12-27	WOS:000089858900074
J	Hebbes, TR; Allen, SCH				Hebbes, TR; Allen, SCH			Multiple histone acetyltransferases are associated with a chicken erythrocyte chromatin fraction enriched in active genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIC-STRENGTH; ACETYLATION; TRANSCRIPTION; SUBUNIT; DOMAIN; ALTERS; CELLS; YEAST	We have examined salt-soluble chromatin released by micrococcal nuclease from a 15-day-old chicken embryo erythrocyte nuclei for histone acetyltransferase (HAT) activities. This chromatin is enriched in transcriptionally active sequences from within the active beta-globin locus and contains elevated levels of acetylated core histones. HAT activities present in this fraction target histones H4, H3, and H2A when the chromatin itself is used as the substrate. In gel HAT activity assay demonstrates that the salt-soluble chromatin fraction contains four acetyltransferase molecules distinguished by their different molecular masses (47, 33, 32, and 28 kDa). Further separation of the chromatin by centrifugation through sucrose gradients shows that the acetyltransferases segregate into chromatin-bound and chromatin-free populations. The 32- and 28-kDa HATs are associated with chromatin, whereas the 47- and 33-kDa HAT molecules are not. The chromatin-bound HAT activities predominantly target H4 to give the diacetyl and tri-acetyl species; some acetylation of H2A can also be seen. Our results suggest that the chromatin-associated acetyltransferases have a role in gene regulation.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Warwick	Hebbes, TR (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.							ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; BOHM J, 1980, EUR J BIOCHEM, V112, P353, DOI 10.1111/j.1432-1033.1980.tb07212.x; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DORBIC T, 1987, EMBO J, V6, P2393, DOI 10.1002/j.1460-2075.1987.tb02517.x; Elefant F, 2000, J BIOL CHEM, V275, P13827, DOI 10.1074/jbc.275.18.13827; Grant PA, 1999, SEMIN CELL DEV BIOL, V10, P169, DOI 10.1006/scdb.1999.0298; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Herrera JE, 1999, MOL CELL BIOL, V19, P3466; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; O'Neill LP, 1999, EMBO J, V18, P2897, DOI 10.1093/emboj/18.10.2897; RIDSDALE JA, 1987, BIOCHEMISTRY-US, V26, P290, DOI 10.1021/bi00375a040; RIDSDALE JA, 1987, NUCLEIC ACIDS RES, V15, P1081, DOI 10.1093/nar/15.3.1081; RIDSDALE JA, 1990, J BIOL CHEM, V265, P5150; Schubeler D, 2000, GENE DEV, V14, P940; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; SUN YL, 1986, EMBO J, V5, P293, DOI 10.1002/j.1460-2075.1986.tb04212.x; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659	28	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31347	31352		10.1074/jbc.M004830200	http://dx.doi.org/10.1074/jbc.M004830200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896666	hybrid			2022-12-27	WOS:000089762700085
J	Sangan, P; Brill, SR; Sangan, S; Forbush, B; Binder, HJ				Sangan, P; Brill, SR; Sangan, S; Forbush, B; Binder, HJ			Basolateral K-Cl cotransporter regulates colonic potassium absorption in potassium depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT DISTAL COLON; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; VOLUME REGULATION; ALPHA-SUBUNIT; TRANSPORT; MEMBRANE; CELLS; H+,K+-ATPASE; ALDOSTERONE	Active potassium absorption in the rat distal colon is electroneutral, Na+-independent, partially chloride-dependent, and energized by an apical membrane H,K-ATPase, Both dietary sodium and dietary potassium depletion substantially increase active potassium absorption. We have recently reported that sodium depletion up regulates H,K-ATPase alpha-subunit mRNA and protein expression, whereas potassium depletion upregulates H,K-ATPase beta-subunit mRNA and protein expression. Because overall potassium absorption is non-conductive, H-CL cotransport (KCC) at the basolateral membrane may also be involved in potassium absorption. Although KCC1 has not been cloned from the colon, we established, in Northern blot analysis with mRNA from the rat distal colon using rabbit kidney KCC1 cDNA as a probe, the presence of an expected size mRNA in the rat colon, This KCC1 mRNA is substantially increased by potassium depletion but only minimally by sodium depletion. KCC1-specific antibody identified a 155-kDa protein in rat colonic basolateral membrane. Potassium depletion but not sodium depletion resulted in an increase in KCC1 protein expression in basolateral membrane. The increase of colonic KCC1 mRNA abundance and KCC1 protein expression in potassium depletion of the rat colonic basolateral membrane suggests that K-CI cotransporter: 1) is involved in transepithelial potassium absorption and 2) regulates the increase in potassium absorption induced by dietary potassium depletion, We conclude that active potassium absorption in the rat distal colon involves the coordinated regulation of both apical membrane II,K-ATPase and basolateral membrane KCC1 protein.	Yale Univ, Sch Med, Sect Digest Dis, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University; Yale University	Binder, HJ (corresponding author), Yale Univ, Sch Med, Sect Digest Dis, Dept Internal Med, 333 Cedar St,89 LMP, New Haven, CT 06520 USA.				NIDDK NIH HHS [DK 18877, DK47661] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047661] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIANCHINI L, 1988, J EXP BIOL, V137, P303; BINDER HJ, 1994, PHYSL GASTROINTESTIN, V2, P2133; BRUGNARA C, 1989, AM J PHYSIOL, V256, pC994, DOI 10.1152/ajpcell.1989.256.5.C994; Codina J, 1996, J BIOL CHEM, V271, P29759, DOI 10.1074/jbc.271.47.29759; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; DELGASILLO JR, 1991, AM J PHYSIOL, V261, pG1005; FOSTER ES, 1984, AM J PHYSIOL, V246, pG611, DOI 10.1152/ajpgi.1984.246.5.G611; FOSTER ES, 1986, AM J PHYSIOL, V251, pG619, DOI 10.1152/ajpgi.1986.251.5.G619; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Hiki K, 1999, J BIOL CHEM, V274, P10661, DOI 10.1074/jbc.274.15.10661; JAISSER F, 1993, AM J PHYSIOL, V265, pC1080, DOI 10.1152/ajpcell.1993.265.4.C1080; KAJI DM, 1993, AM J PHYSIOL, V264, pC376, DOI 10.1152/ajpcell.1993.264.2.C376; KRAMHOFT B, 1986, AM J PHYSIOL, V251, pC369, DOI 10.1152/ajpcell.1986.251.3.C369; LARSON M, 1984, J MEMBRANE BIOL, V81, P219, DOI 10.1007/BF01868715; Lauf P K, 1981, Prog Clin Biol Res, V56, P13; LEE J, 1995, J CLIN INVEST, V96, P2001; Liapis H, 1998, AM J PHYSIOL-CELL PH, V275, pC1432, DOI 10.1152/ajpcell.1998.275.6.C1432; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; PERRY PB, 1993, AM J PHYSIOL, V265, pC763, DOI 10.1152/ajpcell.1993.265.3.C763; Race JE, 1999, AM J PHYSIOL-CELL PH, V277, pC1210, DOI 10.1152/ajpcell.1999.277.6.C1210; Rajendran VM, 2000, J BIOL CHEM, V275, P13035, DOI 10.1074/jbc.275.17.13035; Rajendran VM, 1998, AM J PHYSIOL-GASTR L, V274, pG424, DOI 10.1152/ajpgi.1998.274.2.G424; RAJENDRAN VM, 1991, J CLIN INVEST, V88, P1379, DOI 10.1172/JCI115444; RAJENDRAN VM, 1989, J BIOL CHEM, V264, P18638; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; Sangan P, 2000, AM J PHYSIOL-CELL PH, V278, pC182, DOI 10.1152/ajpcell.2000.278.1.C182; Sangan P, 1999, AM J PHYSIOL-CELL PH, V276, pC350, DOI 10.1152/ajpcell.1999.276.2.C350; Sangan PC, 1997, AM J PHYSIOL-CELL PH, V272, pC685, DOI 10.1152/ajpcell.1997.272.2.C685; SASAKI S, 1988, J CLIN INVEST, V81, P194, DOI 10.1172/JCI113294; SWEIRY JH, 1989, J CLIN INVEST, V83, P844, DOI 10.1172/JCI113967; TURNAMIAN SG, 1989, J CLIN INVEST, V84, P1924, DOI 10.1172/JCI114380	33	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30813	30816		10.1074/jbc.M003931200	http://dx.doi.org/10.1074/jbc.M003931200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10878016	hybrid			2022-12-27	WOS:000089762700013
J	Jedlitschky, G; Burchell, B; Keppler, D				Jedlitschky, G; Burchell, B; Keppler, D			The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELL-LINES; NITRIC-OXIDE; SUBSTRATE-SPECIFICITY; CONJUGATE TRANSPORT; HUMAN ERYTHROCYTES; DRUG-RESISTANCE; SMOOTH-MUSCLE; GENE; EGRESSION; FAMILY	Cellular export of cyclic nucleotides has been observed in various tissues and may represent an elimination pathway for these signaling molecules, in addition to degradation by phosphodiesterases. In the present study we provide evidence that this export is mediated by the multidrug resistance protein isoform MRP5 (gene symbol ABCC5). The transport function of MRP5 was studied in V79 hamster lung fibroblasts transfected with a human MRP5 cDNA. An MRP5-specific antibody detected an overexpression of the glycoprotein of 185 +/- 15 kDa in membranes from MRP5-transfected cells and a low basal expression of hamster Mrp5 in control membranes. ATP-dependent transport of 3',5'-cyclic GMP at a substrate concentration of 1 mu M was 4-fold higher in membrane vesicles from MRP5-transfected cells than in control membranes. This transport was saturable with a K-m value of 2.1 mu M. MRP5-mediated transport was also detected for 3',5'-cyclic AMP at a lower affinity, with a K-m value of 379 mu M. A potent inhibition of MRP5-mediated transport was observed by several compounds, known as phosphodiesterase modulators, including trequinsin, with a K-i of 240 nM, and sildenafil, with a K-i value of 267 nM. Thus, cyclic nucleotides are physiological substrates for MRP5; moreover, MRP5 may represent a novel pharmacological target for the enhancement of tissue levels of cGMP.	Deutsch Krebsforschungszentrum, Div Tumor Biochem, D-69120 Heidelberg, Germany; Univ Dundee, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland	Helmholtz Association; German Cancer Research Center (DKFZ); University of Dundee	Jedlitschky, G (corresponding author), Deutsch Krebsforschungszentrum, Div Tumor Biochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	g.jedlitschky@dkfz-heidelberg.de	Keppler, Dietrich/A-5528-2013	Keppler, Dietrich/0000-0003-2964-2333				Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; ASHMAN DF, 1963, BIOCHEM BIOPH RES CO, V11, P330, DOI 10.1016/0006-291X(63)90566-7; Bellamy TC, 2000, P NATL ACAD SCI USA, V97, P2928, DOI 10.1073/pnas.97.6.2928; BILLIAR TR, 1992, AM J PHYSIOL, V262, pC1077, DOI 10.1152/ajpcell.1992.262.4.C1077; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; BRUNTON LL, 1988, METHOD ENZYMOL, V159, P83; BUEHLER M, 1996, J BIOL CHEM, V271, P15091; BUTCHER RW, 1962, J BIOL CHEM, V237, P1244; CARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683; Chen WY, 1997, P NATL ACAD SCI USA, V94, P5798, DOI 10.1073/pnas.94.11.5798; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cui YH, 1999, MOL PHARMACOL, V55, P929; FEHR TF, 1990, J BIOL CHEM, V265, P10974; FRIEDLANDER G, 1995, KIDNEY INT, V47, P1500, DOI 10.1038/ki.1995.212; HAMET P, 1989, J BIOL CHEM, V264, P12364; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; JANSSENS PMW, 1987, MICROBIOL REV, V51, P396, DOI 10.1128/MMBR.51.4.396-418.1987; Jedlitschky G, 1999, BIOCHEM J, V340, P837, DOI 10.1042/0264-6021:3400837; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; Keppler D, 1998, METHOD ENZYMOL, V292, P607; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Kool M, 1997, CANCER RES, V57, P3537; Kruh GD, 1999, J NATL CANCER I, V91, P888; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; McAleer MA, 1999, J BIOL CHEM, V274, P23541, DOI 10.1074/jbc.274.33.23541; MILLUL V, 1996, AM J PHYSIOL, V39, pC1051; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; PATEL MJ, 1995, J PHARMACOL EXP THER, V273, P16; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; PODEVIN RA, 1980, BIOCHIM BIOPHYS ACTA, V629, P135, DOI 10.1016/0304-4165(80)90272-X; Sager G, 1996, SCAND J CLIN LAB INV, V56, P289, DOI 10.3109/00365519609090579; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Schultz C, 1998, BIOCHEMISTRY-US, V37, P1161, DOI 10.1021/bi9713409; Sundkvist E, 2000, BBA-BIOMEMBRANES, V1463, P121, DOI 10.1016/S0005-2736(99)00184-4; Suzuki T, 2000, GENE, V242, P167, DOI 10.1016/S0378-1119(99)00529-6; Suzuki T, 1997, BIOCHEM BIOPH RES CO, V238, P790, DOI 10.1006/bbrc.1997.7346; Taniguchi K, 1996, CANCER RES, V56, P4124; Warrington JS, 2000, DRUG METAB DISPOS, V28, P392; Wijnholds J., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P315; Wijnholds J, 2000, P NATL ACAD SCI USA, V97, P7476, DOI 10.1073/pnas.120159197; WOODS M, 1991, BIOCHEM PHARMACOL, V41, P385, DOI 10.1016/0006-2952(91)90535-D	44	360	371	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30069	30074		10.1074/jbc.M005463200	http://dx.doi.org/10.1074/jbc.M005463200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893247	hybrid			2022-12-27	WOS:000089577900022
J	Rangasamy, D; Wilson, VG				Rangasamy, D; Wilson, VG			Bovine papillomavirus E1 protein is sumoylated by the host cell Ubc9 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; GTPASE-ACTIVATING PROTEIN; DNA-POLYMERASE-ALPHA; LARGE T-ANTIGEN; REPLICATION PROTEIN; SUMO-1 MODIFICATION; COVALENT MODIFICATION; TYPE-1 E1; IN-VITRO; PML	Papillomavirus E1 protein is the replication initiator that recognizes and binds to the viral origin and initiates DNA strand separation through its ATP-dependent helicase activity. The E1 protein also functions in viral DNA replication by recruiting several cellular proteins to the origin, including host DNA polymerase alpha and replication protein A To identify other cellular proteins that interact with bovine papillomavirus E1, an HeLa cDNA library was screened using a yeast two hybrid assay. The host cell sumoylating enzyme, Ubc9, was found to interact specifically with E1 both in vitro and in vivo. Mapping studies localized critical E1 sequences for interaction to amino acids 315-459 and strongly implicated leucine 420 as critical for E1.Ubc9 complex formation. In addition to binding E1, Ubc9 catalyzed the covalent linkage of the ubiquitin-like protein, SUMO-1, to E1, An E1 mutant unable to bind Ubc9 showed normal intracellular stability, but was impaired for intranuclear distribution. Failure to accumulate in appropriate nuclear subdomains may account for the previously demonstrated replication defect of a human papillomavirus 16 E1 protein that was also unable to bind Ubc9 and suggests that sumoylation is a functionally important modification with regulatory implications for papillomavirus replication.	Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Microbiol & Immunol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Wilson, VG (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Microbiol & Immunol, College Stn, TX 77843 USA.	v-wilson@tamu.edu	, Van G Wilson/B-1868-2009					BONNEANDREA C, 1995, J VIROL, V69, P2341, DOI 10.1128/JVI.69.4.2341-2350.1995; BONNEANDREA C, 1995, J VIROL, V69, P3201, DOI 10.1128/JVI.69.5.3201-3205.1995; Chakrabarti SR, 1999, P NATL ACAD SCI USA, V96, P7467, DOI 10.1073/pnas.96.13.7467; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gonzalez A, 2000, J VIROL, V74, P245, DOI 10.1128/JVI.74.1.245-253.2000; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Han YF, 1999, J VIROL, V73, P4899, DOI 10.1128/JVI.73.6.4899-4907.1999; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; Hodges M, 1998, CURR BIOL, V8, pR749, DOI 10.1016/S0960-9822(07)00477-0; Hofmann H, 2000, J VIROL, V74, P2510, DOI 10.1128/JVI.74.6.2510-2524.2000; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Johnson PR, 1997, TRENDS CELL BIOL, V7, P408, DOI 10.1016/S0962-8924(97)01132-X; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kretz-Remy C, 1999, BIOCHEM CELL BIOL, V77, P299, DOI 10.1139/bcb-77-4-299; LAW MF, 1981, P NATL ACAD SCI-BIOL, V78, P2727, DOI 10.1073/pnas.78.5.2727; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; LENTZ MR, 1993, J VIROL, V67, P1414, DOI 10.1128/JVI.67.3.1414-1423.1993; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Liu JS, 1998, J BIOL CHEM, V273, P30704, DOI 10.1074/jbc.273.46.30704; Ma TL, 1999, P NATL ACAD SCI USA, V96, P382, DOI 10.1073/pnas.96.2.382; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Mansky KC, 1997, J VIROL, V71, P7600, DOI 10.1128/JVI.71.10.7600-7608.1997; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; McShan GD, 2000, J GEN VIROL, V81, P1995, DOI 10.1099/0022-1317-81-8-1995; MELENDY T, 1995, J VIROL, V69, P7857, DOI 10.1128/JVI.69.12.7857-7867.1995; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 1999, J VIROL, V73, P5137; PARK P, 1994, P NATL ACAD SCI USA, V91, P8700, DOI 10.1073/pnas.91.18.8700; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Sanders CM, 2000, J BIOL CHEM, V275, P3522, DOI 10.1074/jbc.275.5.3522; SANTUCCI S, 1990, J VIROL, V64, P6027, DOI 10.1128/JVI.64.12.6027-6039.1990; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Swindle CS, 1998, J VIROL, V72, P1994, DOI 10.1128/JVI.72.3.1994-2001.1998; Swindle CS, 1999, J VIROL, V73, P1001, DOI 10.1128/JVI.73.2.1001-1009.1999; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; WILSON VG, 1991, J VIROL, V65, P5314, DOI 10.1128/JVI.65.10.5314-5322.1991; XIAO XL, 1994, J GEN VIROL, V75, P2463, DOI 10.1099/0022-1317-75-9-2463; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; Yasugi T, 1997, J VIROL, V71, P5942, DOI 10.1128/JVI.71.8.5942-5951.1997	54	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30487	30495		10.1074/jbc.M003898200	http://dx.doi.org/10.1074/jbc.M003898200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10871618	hybrid			2022-12-27	WOS:000089577900078
J	Poppers, DM; Schwenger, P; Vilcek, J				Poppers, DM; Schwenger, P; Vilcek, J			Persistent tumor necrosis factor signaling in normal human fibroblasts prevents the complete resynthesis of I kappa B-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAF-INTERACTING PROTEIN; FACTOR-RECEPTOR; KINASE ACTIVATION; SODIUM-SALICYLATE; TNF; PHOSPHORYLATION; EXPRESSION; CELLS; INTERNALIZATION; INHIBITION	Transcription factor NF-kappa B is normally sequestered in the cytoplasm, complexed with I kappa B inhibitory proteins. Tumor necrosis factor (TNF) and interleukin-1 induce I kappa B-alpha phosphorylation, leading to I kappa B-alpha degradation and translocation of NF-kappa B to the nucleus where it activates genes important in inflammatory and immune responses. TNF and interleukin-1 actions are typically terminated by desensitization, and I kappa B-alpha reappearance normally occurs within 30-60 min. We found that in normal human FS-4 fibroblasts maintained in the presence of TNF, I kappa B-alpha protein failed to return to base-line levels for up to 15 h. Removal of TNF at any time during the 15-h period resulted in complete I kappa B-alpha resynthesis, suggesting that I kappa B-alpha reappearance was prevented by continued TNF signaling. Long term exposure of FS-4 fibroblasts to TNF led to a persistent presence of I kappa B-alpha mRNA, sustained I kappa B kinase activation, continuous proteasome-mediated degradation of I kappa B-alpha, and sustained nuclear localization of NF-kappa B. Continuous exposure of FS-4 cells to TNF did not bad to a sustained activation of p38 or ERK mitogen-activated protein kinases, suggesting that not all TNF-induced signaling pathways are persistently activated. These findings challenge the notion that all cytokine-mediated signals are rapidly terminated by desensitization and illustrate the need to elucidate the process of deactivation of TNF-induced signaling.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	New York University; New York University	Schwenger, P (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.				NATIONAL CANCER INSTITUTE [R35CA049731, R01CA075071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007308] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA49731, R01-CA75071] Funding Source: Medline; NIGMS NIH HHS [5T32-GM07308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderka Dan, 1996, Cytokine and Growth Factor Reviews, V7, P231, DOI 10.1016/S1359-6101(96)00026-3; Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; Decoster E, 1998, J BIOL CHEM, V273, P3271, DOI 10.1074/jbc.273.6.3271; DeLuca C, 1999, J BIOL CHEM, V274, P13010, DOI 10.1074/jbc.274.19.13010; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; Feldmann M, 1998, Int Rev Immunol, V17, P217, DOI 10.3109/08830189809084493; Gerecitano J, 1999, J INTERF CYTOK RES, V19, P393, DOI 10.1089/107999099314108; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HIGUCHI M, 1994, J IMMUNOL, V152, P3550; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; IMAMURA K, 1987, J IMMUNOL, V139, P2989; Jaattela M, 1996, J IMMUNOL, V156, P1166; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kollias G, 1999, IMMUNOL REV, V169, P175, DOI 10.1111/j.1600-065X.1999.tb01315.x; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Madge LA, 1999, J BIOL CHEM, V274, P13643, DOI 10.1074/jbc.274.19.13643; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; McKinsey TA, 1997, J BIOL CHEM, V272, P22377, DOI 10.1074/jbc.272.36.22377; PALOMBELLA VJ, 1988, J CELL PHYSIOL, V135, P23, DOI 10.1002/jcp.1041350104; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pinckard JK, 1997, J IMMUNOL, V158, P3869; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothwarf D.M., 1999, SCI STKE, V1999, pRE1; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schwenger P, 1999, J CELL PHYSIOL, V179, P109, DOI 10.1002/(SICI)1097-4652(199904)179:1<109::AID-JCP13>3.0.CO;2-W; Schwenger P, 1996, J BIOL CHEM, V271, P8089, DOI 10.1074/jbc.271.14.8089; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; VANOSTADE X, 1993, NATURE, V361, P266; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Zandi E, 1999, MOL CELL BIOL, V19, P4547; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	45	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29587	29593		10.1074/jbc.M002806200	http://dx.doi.org/10.1074/jbc.M002806200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10869349	hybrid			2022-12-27	WOS:000089439800055
J	Baumeister, H; Meyerhof, W				Baumeister, H; Meyerhof, W			The POU domain transcription factor Tst-1 activates somatostatin receptor 1 gene expression in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; DIFFERENTIAL EXPRESSION; INSULIN-SECRETION; SUBTYPES SSTR1; GLIAL-CELLS; RAT; PROMOTER; IDENTIFICATION; FAMILY; ACID	The peptide hormone somatostatin inhibits the release of insulin. The gene encoding somatostatin receptor 1 is expressed in pancreatic p-cells and insulinoma RIN 1046-38 cells. In the present study the mechanisms underlying the regulation of the somatostatin receptor 1 gene in pancreatic p-cells were investigated. Transient transfections of RIN 1046-38 cells with promoter/reporter gene constructs and footprint analysis revealed two regions, fp1 and fp2, that were necessary for the observed promoter activity. Mutagenesis of the fp2 region delineated the cis-acting element to the motif 5'-TTAATCATT-3'. The POU domain transcription factor Tst-1 was identified as trans-activator mediating the 5'-TTAATCATT-3' motif-dependent transcription in RIN 1046-38 cells and heterologous CV1 cells. Tst-1, known as a transcriptional regulator in keratinocytes, glial cells, and neurons, has been detected by immunohistochemistry in pancreatic islets. Altogether, we demonstrate Tst-1 as transcriptional regulator in pancreatic neuroendocrine cells.	Deutsch Inst Ernahruungsforsch, Abt Mol Genet, D-14558 Potsdam, Germany; Univ Potsdam, D-14558 Potsdam, Germany	Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); University of Potsdam	Meyerhof, W (corresponding author), Deutsch Inst Ernahruungsforsch, Abt Mol Genet, Arthur Scheunert Allee 114-116, D-14558 Potsdam, Germany.	meyerhof@www.dife.de						Andersen B, 1997, GENE DEV, V11, P1873, DOI 10.1101/gad.11.14.1873; ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; Baumeister H, 2000, MOL ENDOCRINOL, V14, P255, DOI 10.1210/me.14.2.255; BRUNO JF, 1993, ENDOCRINOLOGY, V133, P2561, DOI 10.1210/en.133.6.2561; Chen LC, 1997, J BIOL CHEM, V272, P18666, DOI 10.1074/jbc.272.30.18666; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Fagan SP, 1998, SURGERY, V124, P254, DOI 10.1016/S0039-6060(98)70128-X; FULLER PJ, 1995, J CELL BIOCHEM, V58, P260, DOI 10.1002/jcb.240580214; Genuth SM., 1993, PHYSIOLOGY, P851; GHERZI R, 1995, EXP CELL RES, V218, P460, DOI 10.1006/excr.1995.1179; GROMADA J, 1998, PFLUEGERS ARCH, V5, P583; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HARTMANN D, 1995, DEV NEUROSCI-BASEL, V17, P246, DOI 10.1159/000111293; HAUSER F, 1994, FEBS LETT, V345, P225, DOI 10.1016/0014-5793(94)00444-7; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HSU WH, 1991, J BIOL CHEM, V266, P837; Hussain MA, 1997, MOL CELL BIOL, V17, P7186, DOI 10.1128/MCB.17.12.7186; Jaegle M, 1998, MICROSC RES TECHNIQ, V41, P372; KONG H, 1994, NEUROSCIENCE, V59, P175, DOI 10.1016/0306-4522(94)90108-2; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P16050, DOI 10.1074/jbc.273.26.16050; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Kumar U, 1999, DIABETES, V48, P77, DOI 10.2337/diabetes.48.1.77; LEGER H, 1995, MOL CELL BIOL, V15, P3738; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; Liapakis G, 1996, J PHARMACOL EXP THER, V276, P1089; Liapakis G, 1996, J BIOL CHEM, V271, P20331, DOI 10.1074/jbc.271.34.20331; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; McEvilly RJ, 2000, PROG NUCLEIC ACID RE, V63, P223, DOI 10.1016/S0079-6603(08)60724-2; Meyerhof W, 1998, Rev Physiol Biochem Pharmacol, V133, P55; Mitra SW, 1999, ENDOCRINOLOGY, V140, P3790, DOI 10.1210/en.140.8.3790; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; Poitout V, 1996, DIABETES METAB, V22, P7; Portois L, 1999, J BIOL CHEM, V274, P8181, DOI 10.1074/jbc.274.12.8181; RAULF F, 1994, DIGESTION, V55, P46, DOI 10.1159/000201201; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAYNOR K, 1993, MOL PHARMACOL, V43, P838; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; Renner K, 1996, NUCLEIC ACIDS RES, V24, P4552, DOI 10.1093/nar/24.22.4552; RENNER K, 1994, P NATL ACAD SCI USA, V91, P6433, DOI 10.1073/pnas.91.14.6433; Rohrer SP, 1998, SCIENCE, V282, P737, DOI 10.1126/science.282.5389.737; Roosterman D, 1998, FEBS LETT, V425, P137, DOI 10.1016/S0014-5793(98)00221-X; Roosterman D, 1997, J NEUROENDOCRINOL, V9, P741, DOI 10.1046/j.1365-2826.1997.00632.x; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROSSOWSKI WJ, 1994, PEPTIDES, V15, P1421, DOI 10.1016/0196-9781(94)90118-X; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Schafer J, 1999, NEUROPEPTIDES, V33, P457, DOI 10.1054/npep.1999.0762; Schonemann MD, 1998, ADV EXP MED BIOL, V449, P39; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; Wierman ME, 1997, MOL CELL BIOL, V17, P1652, DOI 10.1128/MCB.17.3.1652; WILSON CM, 1979, ANAL BIOCHEM, V96, P263, DOI 10.1016/0003-2697(79)90581-5; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	56	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28882	28887		10.1074/jbc.M002175200	http://dx.doi.org/10.1074/jbc.M002175200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10866997	hybrid			2022-12-27	WOS:000089330700072
J	Bdeir, K; Kuo, A; Mazar, A; Sachais, BS; Xiao, WZ; Gawlak, S; Harris, S; Higazi, A; Cines, DB				Bdeir, K; Kuo, A; Mazar, A; Sachais, BS; Xiao, WZ; Gawlak, S; Harris, S; Higazi, A; Cines, DB			A region in domain II of the urokinase receptor required for urokinase binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN UROKINASE; PLASMINOGEN-ACTIVATOR; LIGAND-BINDING; RECOGNITION; AFFINITY; PATHWAY; COMPLEX; SITES; CELLS	The urokinase receptor is composed of three homologous domains based on disulfide spacing. The contribution of each domain to the binding and activation of single chain urokinase (scuPA) remains poorly understood. In the present paper we examined the role of domain II (DII) in these processes. Repositioning DII to the amino or carboxyl terminus of the molecule abolished binding of scuPA as did deleting the domain entirely. By using alanine-scanning mutagenesis, we identified a g-amino acid continuous sequence in DII (Arg(137)-Arg(145)) required for both activities. Competition-inhibition and surface plasmon resonance studies demonstrated that mutation of Lys(139) and His(143) to alanine in soluble receptor (suPAR) reduced the affinity for scuPA similar to 5-fold due to an increase in the "off rate." Mutation of Arg(137), Arg(142), and Arg(145), each to alanine, leads to an similar to 100-fold decrease in affinity attributable to a 10-fold decrease in the apparent "on rate" and a 6-fold increase in off rate. These differences were confirmed on cells expressing variant urokinase receptor. suPAR-K139A/H143A displayed a 50% reduction in scuPA-mediated plasminogen activation activity, whereas the 3-arginine variant was unable to stimulate scuPA activity at all. Mutation of the three arginines did not affect binding of a decamer peptide antagonist of scuPA known to interact with DI and DIII. However, this mutation abolished both the binding of soluble DI to DII-III in the presence of scuPA and the synergistic activation of scuPA mediated by DI and wild type DII-DIII. These data show that DII is required for high affinity binding of scuPA and its activation. DII does not serve merely as a spacer function but appears to be required for interdomain cooperativity.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Angstrom Pharmaceut, San Diego, CA 92121 USA; Hadassah Med Org, Dept Clin Biochem, IL-91120 Jerusalem, Israel	University of Pennsylvania; University of Pennsylvania; Hebrew University of Jerusalem; Hadassah University Medical Center	Cines, DB (corresponding author), Univ Penn, Dept Pathol & Lab Med, 513A Stellat Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.	dcines@mail.med.upenn.edu	Sachais, Bruce/D-1236-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007775, R01HL060169, R01HL058107] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58107, T32 HL007775, HL60169] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aceto J, 1999, BIOCHEMISTRY-US, V38, P992, DOI 10.1021/bi9810914; Behrendt N, 1996, J BIOL CHEM, V271, P22885, DOI 10.1074/jbc.271.37.22885; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; Dumler I, 1999, CURR BIOL, V9, P1468, DOI 10.1016/S0960-9822(00)80116-5; Gardsvoll H, 1999, J BIOL CHEM, V274, P37995, DOI 10.1074/jbc.274.53.37995; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; Higazi AAR, 1997, J BIOL CHEM, V272, P5348, DOI 10.1074/jbc.272.8.5348; Higazi AAR, 1996, BIOCHEMISTRY-US, V35, P6884, DOI 10.1021/bi9514774; HOYERHANSEN G, 1992, J BIOL CHEM, V267, P18224; JOHNSSON B, 1995, J MOL RECOGNIT, V8, P125, DOI 10.1002/jmr.300080122; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; LANDT O, 1990, GENE AMST, P125; LEERINK CB, 1992, THROMB HAEMOSTASIS, V68, P185; Longstaff C, 1999, BLOOD, V93, P3839, DOI 10.1182/blood.V93.11.3839.411k08_3839_3846; May AE, 1998, J EXP MED, V188, P1029, DOI 10.1084/jem.188.6.1029; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Newman PM, 1999, BRIT J HAEMATOL, V107, P303, DOI 10.1046/j.1365-2141.1999.01717.x; Oda M, 1998, EUR J BIOCHEM, V256, P411, DOI 10.1046/j.1432-1327.1998.2560411.x; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; Ploug M, 1998, BIOCHEMISTRY-US, V37, P16494, DOI 10.1021/bi981203r; PLOUG M, 1991, J BIOL CHEM, V266, P1926; Ploug M, 1998, BIOCHEMISTRY-US, V37, P3612, DOI 10.1021/bi972787k; POLLANEN JJ, 1993, BLOOD, V82, P2719; Preissner KT, 1999, BASIC RES CARDIOL, V94, P315, DOI 10.1007/s003950050157; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Riittinen L, 1996, FEBS LETT, V381, P1, DOI 10.1016/0014-5793(96)00033-6; Schwartz BS, 1999, J BIOL CHEM, V274, P15278, DOI 10.1074/jbc.274.21.15278; Sitrin RG, 1999, J IMMUNOL, V163, P6193; Wang JY, 1997, EUR J BIOCHEM, V247, P256, DOI 10.1111/j.1432-1033.1997.00256.x; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767	33	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28532	28538		10.1074/jbc.M001595200	http://dx.doi.org/10.1074/jbc.M001595200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10864923	hybrid			2022-12-27	WOS:000089330700028
J	Ceponis, PJM; Botelho, F; Richards, CD; McKay, DM				Ceponis, PJM; Botelho, F; Richards, CD; McKay, DM			Interleukins 4 and 13 increase intestinal epithelial permeability by a phosphatidylinositol 3-kinase pathway - Lack of evidence for STAT 6 involvement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA; SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASE; INDUCED APOPTOSIS; BARRIER FUNCTION; CROHNS-DISEASE; ION-TRANSPORT; CELLS; EXPRESSION; IL-4	Interleukins 4 and 13 can affect their target cells by activation of signal transducer and activator of transcription 6 (STAT 6) or phosphatidylinositol 3-kinase (PI3K). We examined the signal transduction events involved in IL-4 and IL-13 regulation of epithelial paracellular permeability using T84 cells, a model human colonic epithelium. T84 cells treated with IL-4 or IL-13 displayed virtually identical dose- and time-dependent STAT 6 activation as assessed by electrophoretic mobility shift assay (EMSA) and decreases in transepithelial resistance (TER), STAT 6 DNA binding activity was maximal in nuclear extracts 30 min after exposure to IL-4 or IL-13, and TER was maximally reduced by 24 h posttreatment. Pretreatment of epithelia with transcription factor decoys (phosphorothioated DNA oligonucleotides containing the STAT 6 binding site) dramatically reduced STAT 6 activation as detected by EMSA, but did not attenuate the TER reduction by IL-4 or IL-13. In contrast, although the PI3K inhibitors wortmannin and LY294002 did not affect IL-4 or IL-13 STAT 6 activation, they significantly inhibited the ability of either cytokine to lower TER. Thus, we provide evidence for PI3K as the major proximal signaling event in IL-4 and IL-13 regulation of TER and speculate that pharmacological targeting of enterocytic PI3K activity may represent a means to manipulate epithelial permeability.	McMaster Univ, Intestinal Dis Res Programme, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Infect & Immun Programme, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	McKay, DM (corresponding author), McMaster Univ, Intestinal Dis Res Programme, HSC-3N5,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.		McKay, Derek/HCH-3240-2022	Richards, Carl/0000-0002-0081-2231				Ahmad F, 1999, J IMMUNOL, V162, P4864; ANDERSON JM, 1995, AM J PHYSIOL, V269, P467; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BERNARD A, 1996, J ALLERGY CLIN IMMUN, V97, P1173; BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Botelho FM, 1998, J BIOL CHEM, V273, P5211, DOI 10.1074/jbc.273.9.5211; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; COLGAN SP, 1994, J IMMUNOL, V153, P2122; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Desreumaux P, 1997, GASTROENTEROLOGY, V113, P118, DOI 10.1016/S0016-5085(97)70116-1; Donnelly GAE, 1999, J INFECT DIS, V180, P1590, DOI 10.1086/315075; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Guo FH, 1997, J CLIN INVEST, V100, P829, DOI 10.1172/JCI119598; Hershberg RM, 2000, IMMUNOL TODAY, V21, P123, DOI 10.1016/S0167-5699(99)01575-3; Ikizawa K, 1996, CELL IMMUNOL, V170, P134, DOI 10.1006/cimm.1996.0143; Jobin C, 1998, J IMMUNOL, V160, P410; Khaled AR, 1998, CLIN IMMUNOL IMMUNOP, V86, P170, DOI 10.1006/clin.1997.4486; Liang QW, 1998, INVEST OPHTH VIS SCI, V39, P1329; Lu J, 1998, J PHARMACOL EXP THER, V287, P128; MADARA JL, 1989, J CLIN INVEST, V83, P724, DOI 10.1172/JCI113938; McKay DM, 1999, GUT, V44, P283, DOI 10.1136/gut.44.2.283; Mizoguchi A, 1999, GASTROENTEROLOGY, V116, P320, DOI 10.1016/S0016-5085(99)70128-9; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Ohmori Y, 1996, J IMMUNOL, V157, P2058; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Pan ZXK, 2000, J IMMUNOL, V164, P404, DOI 10.4049/jimmunol.164.1.404; Park YG, 1999, J BIOL CHEM, V274, P1573, DOI 10.1074/jbc.274.3.1573; Patel BKR, 1998, P NATL ACAD SCI USA, V95, P172, DOI 10.1073/pnas.95.1.172; Pfeffer LM, 2000, AM J PHYSIOL-CELL PH, V278, pC331, DOI 10.1152/ajpcell.2000.278.2.C331; Philpott DJ, 1998, INFECT IMMUN, V66, P1680, DOI 10.1128/IAI.66.4.1680-1687.1998; Reinecker HC, 1996, GASTROENTEROLOGY, V111, P1706, DOI 10.1016/S0016-5085(96)70036-7; Schmitz H, 1999, GASTROENTEROLOGY, V116, P301, DOI 10.1016/S0016-5085(99)70126-5; Sherman MA, 1999, J IMMUNOL, V162, P2703; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Siemasko K, 1998, J IMMUNOL, V160, P1581; Soderholm JD, 1999, GASTROENTEROLOGY, V117, P65, DOI 10.1016/S0016-5085(99)70551-2; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Turner JR, 1999, AM J PHYSIOL-CELL PH, V277, pC554, DOI 10.1152/ajpcell.1999.277.3.C554; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walter MJ, 1997, J BIOL CHEM, V272, P28582, DOI 10.1074/jbc.272.45.28582; Wang LH, 2000, BLOOD, V95, P1249, DOI 10.1182/blood.V95.4.1249.004k39_1249_1257; Wright K, 1999, J BIOL CHEM, V274, P17193, DOI 10.1074/jbc.274.24.17193; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yu CR, 1998, J IMMUNOL, V161, P218; Zund G, 1996, J BIOL CHEM, V271, P7460	46	103	110	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29132	29137		10.1074/jbc.M003516200	http://dx.doi.org/10.1074/jbc.M003516200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10871612	hybrid			2022-12-27	WOS:000089330700102
J	Lame, MW; Jones, AD; Wilson, DW; Dunston, SK; Segall, HJ				Lame, MW; Jones, AD; Wilson, DW; Dunston, SK; Segall, HJ			Protein targets of monocrotaline pyrrole in pulmonary artery endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRROLIZIDINE ALKALOID MONOCROTALINE; IMMOBILIZED PH GRADIENTS; CHAPERONE-LIKE ACTIVITY; RED-BLOOD-CELLS; DISULFIDE-ISOMERASE; GLUTATHIONE CONJUGATE; REACTIVE METABOLITES; C-14 MONOCROTALINE; SAMPLE APPLICATION; ESCHERICHIA-COLI	A single administration of monocrotaline to rats results in pathologic alterations in the lung and heart similar to human pulmonary hypertension. In order to produce these lesions, monocrotaline is oxidized to monocrotaline pyrrole in the liver followed by hematogenous transport to the lung where it injures pulmonary endothelium. In this study, we determined specific endothelial targets for C-14-monocrotaline pyrrole using two-dimensional gel electrophoresis and autoradiographic detection of protein metabolite adducts, Selective labeling of specific proteins was observed. Labeled proteins were digested with trypsin, and the resulting peptides were analyzed using matrix-assisted laser desorption ionization mass spectrometry, The results were searched against sequence data bases to identify the adducted proteins, Five abundant adducted proteins were identified as galectin-1, protein-disulfide isomerase, probable protein-disulfide isomerase (ER60), beta- or gamma-cytoplasmic actin, and cytoskeletal tropomyosin (TM30-NM). With the exception of actin, the proteins identified in this study have never been identified as potential targets for pyrroles, and the majority of these proteins have either received no or minimal attention as targets for other electrophilic compounds. The known functions of these proteins are discussed in terms of their potential for explaining the pulmonary toxicity of monocrotaline.	Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA; Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA; Penn State Univ, Davey Lab 152, Dept Chem, University Pk, PA 16802 USA; Penn State Univ, Davey Lab 152, Intercoll Mass Spectrometry Ctr, University Pk, PA 16802 USA	University of California System; University of California Davis; University of California System; University of California Davis; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Segall, HJ (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, 1 Shields Ave, Davis, CA 95616 USA.	HJSegall@ucdavis.edu	Jones, Arthur D/C-2670-2013	Jones, A. Daniel/0000-0002-7408-6690	NCRR NIH HHS [RR11318] Funding Source: Medline; NHLBI NIH HHS [HL48411] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011318] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048411] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUM LG, 1995, GLYCOCONJUGATE J, V12, P63, DOI 10.1007/BF00731870; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; BOELSTERLI UA, 1993, DRUG METAB REV, V25, P395, DOI 10.3109/03602539308993981; BONIFACE JJ, 1990, SCIENCE, V247, P61, DOI 10.1126/science.2104678; BURGESS DR, 1987, J CELL BIOL, V104, P29, DOI 10.1083/jcb.104.1.29; CAI H, 1994, J BIOL CHEM, V269, P24550; CERRA RF, 1984, J CELL BIOL, V98, P1580, DOI 10.1083/jcb.98.4.1580; CHESNEY CF, 1973, AM J PATHOL, V70, P489; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P15810, DOI 10.1021/bi971504l; CLAUSER KR, 1996, P 44 ASMS C MASS SPE, P365; Cohen SD, 1997, DRUG METAB REV, V29, P59, DOI 10.3109/03602539709037573; COLES B, 1985, DRUG METAB REV, V15, P1307, DOI 10.3109/03602538409029962; Cotran R.S., 1994, ROBBINS PATHOLOGIC B, V5th ed., P51; Coulombe RA, 1999, TOXICOL APPL PHARM, V154, P198, DOI 10.1006/taap.1998.8552; CULVENOR CC, 1970, AUST J CHEM, V23, P1853, DOI 10.1071/CH9701853; FATTOUM A, 1983, BIOCHEMISTRY-US, V22, P1187, DOI 10.1021/bi00274a031; Ferraro A, 1999, J CELL BIOCHEM, V72, P528, DOI 10.1002/(SICI)1097-4644(19990315)72:4<528::AID-JCB8>3.0.CO;2-V; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; Garcia Joe G. N., 1996, Seminars in Thrombosis and Hemostasis, V22, P309, DOI 10.1055/s-2007-999025; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; HOORN CM, 1993, TOXICOL APPL PHARM, V120, P281, DOI 10.1006/taap.1993.1113; HOORN CM, 1992, AM J PHYSIOL, V262, pL740, DOI 10.1152/ajplung.1992.262.6.L740; HUXTABLE RJ, 1979, GEN PHARMACOL, V10, P159, DOI 10.1016/0306-3623(79)90082-X; Jones PL, 1996, CIRC RES, V79, P1131, DOI 10.1161/01.RES.79.6.1131; KAJIKAWA T, 1986, LIFE SCI, V39, P1177, DOI 10.1016/0024-3205(86)90349-8; Kay JM, 1969, CROTALARIA SPECTABIL, P1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAME MW, 1995, DRUG METAB DISPOS, V23, P422; Lame MW, 1996, J LABELLED COMPD RAD, V38, P1053, DOI 10.1002/(SICI)1099-1344(199612)38:12<1053::AID-JLCR927>3.0.CO;2-Q; LAME MW, 1990, TOXICOL LETT, V51, P321, DOI 10.1016/0378-4274(90)90075-W; LAME MW, 1991, DRUG METAB DISPOS, V19, P516; Lame MW, 1997, CHEM RES TOXICOL, V10, P694, DOI 10.1021/tx960173v; Langenbach KJ, 1999, J BIOL CHEM, V274, P7032, DOI 10.1074/jbc.274.11.7032; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LIU H, 1989, CELL, V57, P233, DOI 10.1016/0092-8674(89)90961-6; LOPES AA, 1993, ANGIOLOGY, V44, P701, DOI 10.1177/000331979304400905; LUM H, 1994, AM J PHYSIOL, V267, pL223, DOI 10.1152/ajplung.1994.267.3.L223; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; LYLES MM, 1994, J BIOL CHEM, V269, P30946; MARTIN JL, 1991, BIOCHEM BIOPH RES CO, V178, P679, DOI 10.1016/0006-291X(91)90161-Y; MATTOCKS AR, 1990, CHEM-BIOL INTERACT, V76, P19; MATTOCKS AR, 1983, TOXICOL LETT, V16, P1, DOI 10.1016/0378-4274(83)90002-4; MATTOCKS AR, 1989, TOXICON, V27, P561, DOI 10.1016/0041-0101(89)90117-7; MATTOCKS AR, 1990, CHEM-BIOL INTERACT, V75, P225; MATTOCKS AR, 1968, NATURE, V217, P723, DOI 10.1038/217723a0; MEYRICK BO, 1982, AM J PATHOL, V106, P84; Moiseeva EP, 1999, J VASC RES, V36, P47, DOI 10.1159/000025625; Nagayama Sekio, 1994, Journal of Toxicological Sciences, V19, P155; NOMURA M, 1987, EUR J BIOCHEM, V163, P467, DOI 10.1111/j.1432-1033.1987.tb10892.x; PAN LC, 1993, TOXICOLOGY, V79, P21, DOI 10.1016/0300-483X(93)90203-5; PAN LC, 1993, TOXICOL APPL PHARM, V118, P87, DOI 10.1006/taap.1993.1013; PAN LC, 1991, TOXICOL APPL PHARM, V110, P336, DOI 10.1016/S0041-008X(05)80016-X; Pappin Darryl J. C., 1997, V64, P165; PEARSON RG, 1967, J AM CHEM SOC, V89, P1827, DOI 10.1021/ja00984a014; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; POHL LR, 1989, DRUG METAB REV, V20, P203, DOI 10.3109/03602538909103537; Pohl LR, 1990, BIOL REACT INTERMED, VIV, P111; Qiu YC, 1998, J BIOL CHEM, V273, P17940, DOI 10.1074/jbc.273.28.17940; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; RABILLOUD T, 1994, ELECTROPHORESIS, V15, P1552, DOI 10.1002/elps.11501501223; Rabinovich GA, 1999, CELL DEATH DIFFER, V6, P711, DOI 10.1038/sj.cdd.4400535; REED RL, 1992, XENOBIOTICA, V22, P1321, DOI 10.3109/00498259209053160; Reid MJ, 1998, J BIOCHEM MOL TOXIC, V12, P157; ROBERTSON KA, 1977, CANCER RES, V37, P3141; Sanchez JC, 1997, ELECTROPHORESIS, V18, P324, DOI 10.1002/elps.1150180305; SANFORD GL, 1990, FASEB J, V4, P2912, DOI 10.1096/fasebj.4.11.2379767; SEAWRIGHT AA, 1991, VET HUM TOXICOL, V33, P286; SEGALL HJ, 1991, HDB NATURAL TOXINS, V6, P3; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; Taylor DW, 1997, TOXICOL APPL PHARM, V143, P196, DOI 10.1006/taap.1996.8083; Thomas HC, 1998, TOXICOL APPL PHARM, V151, P236, DOI 10.1006/taap.1998.8458; Thomas HC, 1998, AM J RESP CELL MOL, V19, P129, DOI 10.1165/ajrcmb.19.1.2895; Thomas HC, 1996, TOXICOL APPL PHARM, V141, P319; VANDRIEL R, 1991, J CELL BIOCHEM, V47, P311, DOI 10.1002/jcb.240470405; Voelkel NF, 1995, EUR RESPIR J, V8, P2129, DOI 10.1183/09031936.95.08122129; VUORI K, 1992, J BIOL CHEM, V267, P7211; WAGENVOORT CA, 1993, CHEST, V103, P844, DOI 10.1378/chest.103.3.844; WAGNER JG, 1993, AM J PHYSIOL, V264, pL517, DOI 10.1152/ajplung.1993.264.5.L517; Walker KW, 1997, J BIOL CHEM, V272, P8845; WHITNEY PL, 1986, BIOCHEM J, V238, P683, DOI 10.1042/bj2380683; WILSON DW, 1989, MICROVASC RES, V38, P57; WILSON DW, 1992, CRIT REV TOXICOL, V22, P307, DOI 10.3109/10408449209146311; Wilson DW, 1998, TOXICOL APPL PHARM, V152, P138, DOI 10.1006/taap.1998.8488; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637; Yamaoka K, 1996, J BIOCHEM-TOKYO, V119, P878; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651; ZEECE MG, 1979, BIOCHIM BIOPHYS ACTA, V581, P365, DOI 10.1016/0005-2795(79)90258-7	90	64	71	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29091	29099		10.1074/jbc.M001372200	http://dx.doi.org/10.1074/jbc.M001372200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10875930	hybrid			2022-12-27	WOS:000089330700097
J	Matsuo, M; Tanabe, K; Kioka, N; Amachi, T; Ueda, K				Matsuo, M; Tanabe, K; Kioka, N; Amachi, T; Ueda, K			Different binding properties and affinities for ATP and ADP among sulfonylurea receptor subtypes, SUR1, SUR2A, and SUR2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE K+ CHANNELS; TRANSMEMBRANE CONDUCTANCE REGULATOR; PANCREATIC BETA-CELLS; HAMSTER OVARY CELLS; P-GLYCOPROTEIN; SUBUNIT STOICHIOMETRY; POTASSIUM CHANNELS; INSULIN-SECRETION; SKELETAL-MUSCLE; ACTIVATION	ATP-sensitive potassium (K-ATP) channels, composed of sulfonylurea receptor (SURx) and Kir6.x, play important roles by linking cellular metabolic state to membrane potential in various tissues. Pancreatic, cardiac, and vascular smooth muscle K-ATP channels, which consist of different subtypes of SURx, differ in their responses to cellular metabolic state, To explore the possibility that different interactions of SURx with nucleotides cause differential regulation of K-ATP, channels, we analyzed the properties of nucleotide-binding folds (NBFs) of SUR1, SUR2A, and SUR2B. SURx in crude membrane fractions was incubated with 8-azido[alpha-P-32]ATP Or 8-azido-[gamma-P-32]ATP under various conditions and was photoaffinity-labeled. Then, SURx was digested mildly with trypsin, and partial tryptic fragments were immunoprecipitated with antibodies against NBF1 and NBF2. Some nucleotide-binding properties were different among SUR subtypes as follows. 1) Mg2+ dependence of nucleotide binding of NBF2 of SUR1 was high, whereas those of SUR2A and SUR2B were low. 2) The affinities of NBF1 of SUR1 for ATP and ADP, especially for ATP, were significantly higher than those of SUR2A and SUR2B. 3) The affinities of NBF2 of SUR2B for ATP and ADP were significantly higher than those of SUR2A This is the first biochemical study to analyze and compare the nucleotide-binding properties of NBFs of three SUR subtypes, and our results suggest that their different properties may explain, in part, the differential regulation of KATP channel subtypes. The high nucleotide-binding affinities of SUR1 may explain the high ability of SUR1 to stimulate pancreatic K-ATP channels. It is also suggested that the C-terminal 42 amino acids affect the physiological roles of SUR2A and SUR2B by changing the nucleotide-binding properties of their NBFs.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Biochem Lab, Kyoto 6068502, Japan	Kyoto University	Ueda, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Biochem Lab, Kyoto 6068502, Japan.	uedak@kais.kyoto-u.ac.jp		Kioka, Noriyuki/0000-0002-2708-537X; Ueda, Kazumitsu/0000-0003-2980-6078				Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; ASHCROFT FM, 1989, J PHYSIOL-LONDON, V416, P349, DOI 10.1113/jphysiol.1989.sp017765; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Babenko AP, 1999, J BIOL CHEM, V274, P11587, DOI 10.1074/jbc.274.17.11587; Babenko AP, 2000, J BIOL CHEM, V275, P717, DOI 10.1074/jbc.275.2.717; Bear CE, 1997, J BIOENERG BIOMEMBR, V29, P465, DOI 10.1023/A:1022435007193; Beguin P, 1999, EMBO J, V18, P4722, DOI 10.1093/emboj/18.17.4722; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; D'Hahan N, 1999, MOL PHARMACOL, V56, P308, DOI 10.1124/mol.56.2.308; D'hahan N, 1999, P NATL ACAD SCI USA, V96, P12162, DOI 10.1073/pnas.96.21.12162; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gribble FM, 2000, MOL PHARMACOL, V57, P1256; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Gribble FM, 1998, P NATL ACAD SCI USA, V95, P7185, DOI 10.1073/pnas.95.12.7185; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1997, JPN J PHYSIOL, V47, P11, DOI 10.2170/jjphysiol.47.11; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Matsuo M, 1999, FEBS LETT, V458, P292, DOI 10.1016/S0014-5793(99)01170-9; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Proks P, 1999, J BIOL CHEM, V274, P25393, DOI 10.1074/jbc.274.36.25393; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Schwanstecher M, 1998, EMBO J, V17, P5529, DOI 10.1093/emboj/17.19.5529; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; Shindo T, 1998, BRIT J PHARMACOL, V124, P985, DOI 10.1038/sj.bjp.0701927; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; Tanabe K, 2000, BIOCHEM BIOPH RES CO, V272, P316, DOI 10.1006/bbrc.2000.2780; Tanabe K, 1999, J BIOL CHEM, V274, P3931, DOI 10.1074/jbc.274.7.3931; Tanizawa Y, 2000, DIABETES, V49, P114, DOI 10.2337/diabetes.49.1.114; Trapp S, 1997, P NATL ACAD SCI USA, V94, P8872, DOI 10.1073/pnas.94.16.8872; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1999, BBA-BIOMEMBRANES, V1461, P305, DOI 10.1016/S0005-2736(99)00157-1; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; Uhde I, 1999, J BIOL CHEM, V274, P28079, DOI 10.1074/jbc.274.40.28079; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; Yamada M, 1997, J PHYSIOL-LONDON, V499, P715, DOI 10.1113/jphysiol.1997.sp021963; Yokoshiki H, 1998, AM J PHYSIOL-CELL PH, V274, pC25, DOI 10.1152/ajpcell.1998.274.1.C25; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	58	114	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28757	28763		10.1074/jbc.M004818200	http://dx.doi.org/10.1074/jbc.M004818200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893240	hybrid			2022-12-27	WOS:000089330700057
J	Patel, AJ; Maingret, F; Magnone, V; Fosset, M; Lazdunski, M; Honore, E				Patel, AJ; Maingret, F; Magnone, V; Fosset, M; Lazdunski, M; Honore, E			TWIK-2, an inactivating 2P domain K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; CLONING; PORE; SUBUNIT; ACID; PH	We cloned human and rat TWIK-2 and expressed this novel 2P domain K+ channel in transiently transfected COS cells. TWIK-2 is highly expressed in the gastrointestinal tract, the vasculature, and the immune system. Rat TWIK-2 currents are about 15 times larger than human TWIK-2 currents, but both exhibit outward rectification in a physiological K+ gradient and mild inward rectification in symmetrical K+ conditions. TWIK-2 currents are inactivating at depolarized potentials, and the kinetic of inactivation is highly temperature-sensitive. TWIK-2 shows an extremely low conductance, which prevents the visualization of discrete single channel events. The inactivation and rectification are intrinsic properties of TWIK-2 channels. In a physiological K+ gradient, TWIK-2 is half inhibited by 0.1 mM Ba2+, quinine, and quinidine, Finally, cysteine 53 in the M1P1 external loop is required for functional expression of TWIK-2 but is not critical for subunit self-assembly. TWIK-2 is the first reported 2P domain K+ channel that inactivates. The base-line, transient, and delayed activities of TWIK-2 suggest that this novel 2P domain K+ channel may play an important functional role in cell electrogenesis.	Inst Pharmacol Mol & Cellulaire, CNRS UPR 411, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lazdunski, M (corresponding author), Inst Pharmacol Mol & Cellulaire, CNRS UPR 411, 660 Route des Lucioles, F-06560 Valbonne, France.	ipmc@ipmc.cnrs.fr		HONORE, Eric/0000-0002-8007-0919				Bang H, 2000, J BIOL CHEM, V275, P17412, DOI 10.1074/jbc.M000445200; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Buckler KJ, 2000, J PHYSIOL-LONDON, V525, P135, DOI 10.1111/j.1469-7793.2000.00135.x; Buckler KJ, 1997, J PHYSIOL-LONDON, V498, P649, DOI 10.1113/jphysiol.1997.sp021890; Chavez RA, 1999, J BIOL CHEM, V274, P7887, DOI 10.1074/jbc.274.12.7887; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Immke D, 1999, J GEN PHYSIOL, V113, P819, DOI 10.1085/jgp.113.6.819; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 1996, EMBO J, V15, P6400, DOI 10.1002/j.1460-2075.1996.tb01031.x; Lesage F, 1999, CURR TOP MEMBR, V46, P199; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Maingret F, 2000, EMBO J, V19, P2483, DOI 10.1093/emboj/19.11.2483; Maingret F, 2000, J BIOL CHEM, V275, P10128, DOI 10.1074/jbc.275.14.10128; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; Millar JA, 2000, P NATL ACAD SCI USA, V97, P3614, DOI 10.1073/pnas.050012597; Nobile M, 1997, EXP BRAIN RES, V114, P138, DOI 10.1007/PL00005613; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Pountney DJ, 1999, FEBS LETT, V450, P191, DOI 10.1016/S0014-5793(99)00495-0; Rajan S, 2000, J BIOL CHEM, V275, P16650, DOI 10.1074/jbc.M000030200; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Salinas M, 1999, J BIOL CHEM, V274, P11751, DOI 10.1074/jbc.274.17.11751; Talley EM, 2000, NEURON, V25, P399, DOI 10.1016/S0896-6273(00)80903-4; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975	31	98	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28722	28730		10.1074/jbc.M003755200	http://dx.doi.org/10.1074/jbc.M003755200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10887187	hybrid			2022-12-27	WOS:000089330700053
J	Puig-Kroger, A; Lopez-Rodriguez, C; Relloso, M; Sanchez-Elsner, T; Nueda, A; Munoz, E; Bernabeu, C; Corbi, AL				Puig-Kroger, A; Lopez-Rodriguez, C; Relloso, M; Sanchez-Elsner, T; Nueda, A; Munoz, E; Bernabeu, C; Corbi, AL			Polyomavirus enhancer-binding protein 2/core binding factor/acute myeloid leukemia factors contribute to the cell type-specific activity of the CD11a integrin gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; NUCLEAR FACTOR-I; TRANSCRIPTION FACTOR; MURINE MYELOPEROXIDASE; ADHESION MOLECULES; EXPRESSION; IDENTIFICATION; CLONING; LFA-1; LEUKEMOGENESIS	The CD11a/CD18 leukocyte integrin (LFA-1; also known as alpha L/beta 2) mediates leukocyte transendothelial migration during immune and inflammatory responses and participates in lymphoma metastasis. CD11a/CD18 leukocyte-restricted expression is controlled by the CD11a gene promoter, which confers tissue-specific expression to reporter genes in vitro and in vivo. DNase I protection analysis of the CD11a proximal gene promoter revealed DNA-protein interactions centered at position -110 (CD11a-110). Disruption of CD11a-110 reduced CD11a promoter activity in a cell type-specific manner, as it reduced its activity by 70% in Jurkat lymphoid cells, whereas the effect was considerably lower in K562 and HepG2 cells. Electrophoretic mobility shift assays showed evidence of cell type-specific differences in CD11a-110 binding and indicated its specific recognition by members of the polyomavirus enhancer-binding protein 2/core binding factor (CBF)/acute myeloid leukemia (AML) family of transcription factors. AML1B/CBF beta transactivated the CD11a promoter, with AML1B/CBF beta-mediated transactivation being completely dependent on the integrity of the CD11a-110 element. Therefore, CBF/AML factors play a role in the cell type-restricted transcription of the CD11a integrin gene through recognition of CD11a-110, The involvement of CBF/AML factors in CD11a expression raises the possibility that CD11a/CD18 expression might be deregulated in acute myeloid and B-lineage acute lymphoblastic leukemias, thus contributing to their altered adhesion and metastatic potential.	CSIC, Ctr Invest Biol, Madrid 28006, Spain; Univ Cordoba, Fac Med, Dept Inmunol, Cordoba 14071, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Universidad de Cordoba	Corbi, AL (corresponding author), CSIC, Ctr Invest Biol, Madrid 28006, Spain.	acorbi@cib.csic.es	Lopez-Rodriguez, C/G-4482-2014; Corbi, Angel/B-7194-2011; Relloso, Miguel/K-2238-2014; Munoz, Eduardo/I-5225-2012; Bernabeu, Carmelo/L-3226-2014; Corbí, Angel L./ABC-8146-2020; Puig, Amaya/B-6164-2015; Bernabeu, Carmelo/P-4662-2019	Lopez-Rodriguez, C/0000-0002-2311-2406; Corbi, Angel/0000-0003-1980-5733; Relloso, Miguel/0000-0002-9181-2244; Munoz, Eduardo/0000-0001-8478-5842; Bernabeu, Carmelo/0000-0002-1563-6162; Corbí, Angel L./0000-0003-1980-5733; Puig, Amaya/0000-0003-2943-9757; Bernabeu, Carmelo/0000-0002-1563-6162; Nueda, Arsenio/0000-0001-8373-500X; Sanchez-Elsner, Tilman/0000-0003-1915-2410				AGURA ED, 1992, BLOOD, V79, P602; ARNAOUT MA, 1990, IMMUNOL REV, V114, P145, DOI 10.1111/j.1600-065X.1990.tb00564.x; Bae SC, 1999, HISTOL HISTOPATHOL, V14, P1213, DOI 10.14670/HH-14.1213; Behre G, 1999, METHODS, V17, P231, DOI 10.1006/meth.1998.0733; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CORBI AL, 1996, LEUKOCYTE INTEGRINS; CORNWELL RD, 1993, P NATL ACAD SCI USA, V90, P4221, DOI 10.1073/pnas.90.9.4221; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; DEFOUGEROLLES AR, 1993, J EXP MED, V177, P1187, DOI 10.1084/jem.177.4.1187; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Geijtenbeek TBH, 1999, BLOOD, V94, P754, DOI 10.1182/blood.V94.2.754.414k11_754_764; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Kawada H, 1996, LEUKEMIA RES, V20, P327, DOI 10.1016/0145-2126(95)00113-1; LopezRodriguez C, 1996, J IMMUNOL, V156, P3780; LopezRodriguez C, 1995, EUR J IMMUNOL, V25, P3496, DOI 10.1002/eji.1830251243; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Ning YM, 1999, J BIOL CHEM, V274, P30624, DOI 10.1074/jbc.274.43.30624; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUEDA A, 1993, J BIOL CHEM, V268, P19305; PANTALEO G, 1991, J EXP MED, V173, P511, DOI 10.1084/jem.173.2.511; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; RITCHIE KA, 1995, BLOOD, V86, P147, DOI 10.1182/blood.V86.1.147.bloodjournal861147; ROOS E, 1991, CANCER METAST REV, V10, P33, DOI 10.1007/BF00046842; ROSMARIN AG, 1992, BLOOD, V79, P2598; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHELLEY CS, 1993, P NATL ACAD SCI USA, V90, P5364, DOI 10.1073/pnas.90.11.5364; Speck NA, 1999, CANCER RES, V59, p1789S; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; VEDDER NB, 1988, J CLIN INVEST, V81, P939, DOI 10.1172/JCI113407; Westendorf JJ, 1999, J CELL BIOCHEM, P51	42	26	26	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28507	28512		10.1074/jbc.M004323200	http://dx.doi.org/10.1074/jbc.M004323200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10882733	hybrid, Green Published			2022-12-27	WOS:000089330700024
J	Quimby, BB; Lamitina, T; L'Hernault, SW; Corbett, AH				Quimby, BB; Lamitina, T; L'Hernault, SW; Corbett, AH			The mechanism of Ran import into the nucleus by nuclear transport factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; CAENORHABDITIS-ELEGANS; PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; SACCHAROMYCES-CEREVISIAE; GENE ENCODES; FACTOR P10; C-ELEGANS; IN-VIVO; NTF2	The small GTPase Ran is essential for virtually all nucleocytoplasmic transport events. It is hypothesized that Ran drives vectorial transport of macromolecules into and out of the nucleus via the establishment of a Ran gradient between the cytoplasm and nucleoplasm. Although Ran shuttles between the nucleus and cytoplasm, it is concentrated in the nucleus at steady state. We show that nuclear transport factor 2 (NTF2) is required to concentrate Ran in the nucleus in the budding yeast, Saccharomyces cerevisiae. To analyze the mechanism of Ran import into the nucleus by NTF2, we use mutants in a variety of nuclear transport factors along with biochemical analyses of NTF2 complexes. We find that Ran remains concentrated in the nucleus when importin-mediated protein import is disrupted and demonstrate that NTF2 does not form a stable complex with the transport receptor, importin-beta. Consistent with a critical role for NTF2 in establishing and maintaining the Ran gradient, we show that NTP2 is required for early embryogenesis in Caenorhabditis elegans. Our data distinguish between two possible mechanisms for Ran import by NTF2 and demonstrate that Ran import is independent from importin-beta-mediated protein import.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Dept Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Corbett, AH (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd NE, Atlanta, GA 30322 USA.	acorbe2@emory.edu	Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040697, T32GM008367] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM08367, 5F32GMF19681, GMRO1GM40697] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; Ashcroft NR, 1999, DEV BIOL, V206, P15, DOI 10.1006/dbio.1998.9135; Bayliss R, 1999, J MOL BIOL, V293, P579, DOI 10.1006/jmbi.1999.3166; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; Boxem M, 1999, DEVELOPMENT, V126, P2227; BRENNER S, 1974, GENETICS, V77, P71; Chaillan-Huntington C, 2000, J BIOL CHEM, V275, P5874, DOI 10.1074/jbc.275.8.5874; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Clarkson WD, 1996, J MOL BIOL, V263, P517, DOI 10.1006/jmbi.1996.0594; Cole CN, 1998, CURR BIOL, V8, pR368, DOI 10.1016/S0960-9822(98)70239-8; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; Corbett AH, 1996, J BIOL CHEM, V271, P18477, DOI 10.1074/jbc.271.31.18477; Feldherr C, 1998, J CELL SCI, V111, P1889; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Guo S, 1996, NATURE, V382, P455, DOI 10.1038/382455a0; Hieda M, 1999, J CELL BIOL, V144, P645, DOI 10.1083/jcb.144.4.645; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Iborra FJ, 2000, J CELL SCI, V113, P291; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; KAHANA JA, 1995, P NATL ACAD SCI USA, V92, P9707, DOI 10.1073/pnas.92.21.9707; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P4318, DOI 10.1073/pnas.92.10.4318; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Okkema PG, 1997, DEVELOPMENT, V124, P3965; Paschal BM, 1997, J BIOL CHEM, V272, P21534, DOI 10.1074/jbc.272.34.21534; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Percipalle P, 1997, J MOL BIOL, V266, P722, DOI 10.1006/jmbi.1996.0801; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; ROSE MD, 1990, METHODS YEAST GENETI, P145; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Sambrook J., 1989, MOL CLONING, pA1; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Singson A, 1998, CELL, V93, P71, DOI 10.1016/S0092-8674(00)81147-2; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; Steggerda SM, 2000, MOL BIOL CELL, V11, P703, DOI 10.1091/mbc.11.2.703; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wong DH, 1997, MOL CELL BIOL, V17, P3755, DOI 10.1128/MCB.17.7.3755; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416	56	32	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28575	28582		10.1074/jbc.M005055200	http://dx.doi.org/10.1074/jbc.M005055200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10889207	hybrid			2022-12-27	WOS:000089330700034
J	Bambai, B; Kulmacz, RJ				Bambai, B; Kulmacz, RJ			Prostaglandin H synthase - Effects of peroxidase cosubstrates on cyclooxygenase velocity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER OXIDATION-STATES; ENDOPEROXIDE SYNTHASE; ARACHIDONIC-ACID; VESICULAR GLAND; CIS,CIS-EICOSA-11,14-DIENOIC ACID; PROTOPORPHYRIN-IX; REACTION-KINETICS; BIOSYNTHESIS; PURIFICATION; OXYGENATION	Many cosubstrates for the peroxidase activity of prostaglandin H synthase-1 (PGHS-1) have been reported to produce a large (2-7-fold) increase in the cyclooxygenase velocity in addition to a substantial increase in the number of cyclooxygenase catalytic turnovers. The large stimulation of cyclooxygenase velocity has become an important criterion for evaluation of putative PGHS reaction mechanisms. This criterion has been a major weakness of branched-chain tyrosyl radical mechanisms, which correctly predict many other cyclooxygenase characteristics. Our computer simulations based on a branched-chain mechanism indicated that the uncorrected oxygen electrode signals commonly used to monitor activity can seriously overestimate the effects of cosubstrate on cyclooxygenase velocity, The simulation results prompted re-examination of the effect of several cosubstrates (phenol, acetaminophen, N,N,N',N'-tetramethylphenylenediamine, and Trolox) on PGHS-1 cyclooxygenase velocity, Cyclooxygenase kinetics were examined at reduced temperature or elevated pH, where the oxygen electrode signal can be corrected to provide reliable oxygen consumption trajectories. The cosubstrates produced only a slight (10-60%) stimulation of the cyclooxygenase velocity. Peroxidase cosubstrates thus have a much smaller stimulatory effect on cyclooxygenase velocity than previously reported. This corrects a longstanding misperception of cosubstrate effects, provides more realistic kinetic constraints on PGHS mechanisms, and removes what was a major deficiency of branched-chain tyrosyl radical mechanisms.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Kulmacz, RJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, MSB 5 284,6431 Fannin St, Houston, TX 77030 USA.			Bambai, Bijan/0000-0002-9947-1691	NIGMS NIH HHS [GM 52170] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052170] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bakovic M, 1996, PROSTAG LEUKOTR ESS, V54, P341, DOI 10.1016/S0952-3278(96)90048-4; BAKOVIC M, 1994, BIOCHEMISTRY-US, V33, P6475, DOI 10.1021/bi00187a013; Chen W, 1999, J BIOL CHEM, V274, P20301, DOI 10.1074/jbc.274.29.20301; COOK HW, 1979, ANAL BIOCHEM, V96, P341, DOI 10.1016/0003-2697(79)90591-8; DEWHIRST FE, 1980, PROSTAGLANDINS, V20, P209, DOI 10.1016/S0090-6980(80)80040-2; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; EGAN RW, 1976, J BIOL CHEM, V251, P7329; HANEL AM, 1982, BIOCHEM PHARMACOL, V31, P3307, DOI 10.1016/0006-2952(82)90565-2; HARVISON PJ, 1988, CHEM-BIOL INTERACT, V64, P251, DOI 10.1016/0009-2797(88)90101-9; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HSUANYU YC, 1992, J BIOL CHEM, V267, P17649; Koshkin V, 1998, J BIOL CHEM, V273, P6046, DOI 10.1074/jbc.273.11.6046; Koshkin V, 1999, BBA-PROTEIN STRUCT M, V1430, P341, DOI 10.1016/S0167-4838(99)00016-3; KULMACZ RJ, 1985, PROSTAGLANDINS, V29, P175, DOI 10.1016/0090-6980(85)90200-X; KULMACZ RJ, 1994, BIOCHEMISTRY-US, V33, P5428, DOI 10.1021/bi00184a011; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527; Kulmacz RJ, 1998, FEBS LETT, V430, P154, DOI 10.1016/S0014-5793(98)00657-7; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LANDS WEM, 1983, PROSTAGLANDINS RELAT, P203; Lu GQ, 1999, J BIOL CHEM, V274, P16162, DOI 10.1074/jbc.274.23.16162; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; NUGTEREN DH, 1966, RECL TRAV CHIM PAY-B, V85, P405; O'BRIEN P J, 1981, Progress in Lipid Research, V20, P295, DOI 10.1016/0163-7827(81)90059-X; OGINO N, 1979, BIOCHEM BIOPH RES CO, V87, P184, DOI 10.1016/0006-291X(79)91664-4; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; SAMUELSSON B., 1967, PROGR BIOCHEM PHARMACOL, V3, P59; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; Tsai AL, 1997, BIOCHEMISTRY-US, V36, P13085, DOI 10.1021/bi970397s; Tsai AL, 1998, J BIOL CHEM, V273, P3888, DOI 10.1074/jbc.273.7.3888; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WEI CH, 1995, BIOCHEMISTRY-US, V34, P8499, DOI 10.1021/bi00026a034; Wu G, 1999, J BIOL CHEM, V274, P9231, DOI 10.1074/jbc.274.14.9231	43	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27608	27614						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862771				2022-12-27	WOS:000089197100013
J	Jang, GF; McNee, JK; Alekseev, AM; Haeseleer, F; Palczewski, K				Jang, GF; McNee, JK; Alekseev, AM; Haeseleer, F; Palczewski, K			Stereoisomeric specificity of the retinoid cycle in the vertebrate retina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; SHORT-CHAIN DEHYDROGENASE/REDUCTASE; RETINALDEHYDE-BINDING PROTEIN; LIVER ALCOHOL-DEHYDROGENASE; PIGMENT EPITHELIUM; VISUAL CYCLE; CDNA CLONING; CONGENITAL AMAUROSIS; RIM PROTEIN; PHOTORECEPTORS	Understanding of the stereospecificity of enzymatic reactions that regenerate the universal chromophore required to sustain vision in vertebrates, 11-cis-retinal, is needed for an accurate molecular model of retinoid transformations. Ln rod outer segments (ROS), the redox reaction involves all-trans-retinal and pro-S-NADPH that results in the production of pro-R-all-trans-retinol. A recently identified all-trans-retinol dehydrogenase (photoreceptor retinol dehydrogenase) displays identical stereospecificity to that of the ROS enzyme(s), This result is unusual, because photoreceptor retinol dehydrogenase is a member of a short chain alcohol dehydrogenase family, which is often pro-S-specific toward their hydrophobic alcohol substrates. The second redox reaction occurring in retinal pigment epithelium, oxidation of 11-cis-retinol, which is largely catalyzed by abundantly expressed 11-cis-retinol dehydrogenase, is pro-S-specific to both 11-cis-retinol and NADH, However, there is notable presence of pro-R-specific activities. Therefore, multiple retinol dehydrogenases are involved in regeneration of 11-cis-retinal. Finally, the cellular retinaldehyde-binding protein-induced isomerization of all-trans-retinol to 11-cis-retinol proceeds with inversion of configuration at the C-15 carbon of retinol, Together, these results provide important additions to our understanding of retinoid transformations in the eye and a prelude for in vivo studies that ultimately may result in efficient pharmacological intervention to restore and prevent deterioration of vision in several inherited eye diseases.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu			NEI NIH HHS [EY08061, R01 EY008061] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY008061, R01EY008061] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; CIDECIYAN AV, 2000, IN PRESS VISUAL NEUR; Crabb JW, 1998, METH MOL B, V89, P91; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DONNINGER C, 1964, BIOCHEM J, V91, pP11; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Driessen CAGG, 1998, FEBS LETT, V428, P135, DOI 10.1016/S0014-5793(98)00473-6; DRIESSEN CAGG, 1995, INVEST OPHTH VIS SCI, V36, P1988; EKLUND H, 1982, J BIOL CHEM, V257, P4349; FUTTERMAN S, 1970, J NEUROCHEM, V17, P149, DOI 10.1111/j.1471-4159.1970.tb02195.x; Gamble MV, 1999, J LIPID RES, V40, P2279; Gamble MV, 2000, BBA-PROTEIN STRUCT M, V1476, P3, DOI 10.1016/S0167-4838(99)00232-0; Garwin GG, 2000, METHOD ENZYMOL, V316, P313; Gonzalez-Fernandez F, 1999, MOL VIS, V5, pU1; Gough WH, 1998, J BIOL CHEM, V273, P19778, DOI 10.1074/jbc.273.31.19778; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; JONES JB, 1982, CAN J CHEM, V60, P19, DOI 10.1139/v82-005; JONES JB, 1976, TECHNIQUES CHEM 1, V10, P260; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAW WC, 1989, J AM CHEM SOC, V111, P793, DOI 10.1021/ja00184a090; LAW WC, 1988, BIOCHEMISTRY-US, V27, P4147, DOI 10.1021/bi00411a037; LEVY HR, 1983, BIOCHEMISTRY-US, V22, P2792, DOI 10.1021/bi00281a004; LEVY HR, 1957, J BIOL CHEM, V228, P85; Ma HC, 1999, P NATL ACAD SCI USA, V96, P11161, DOI 10.1073/pnas.96.20.11161; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; Mata NL, 1998, BBA-LIPID LIPID MET, V1394, P16, DOI 10.1016/S0005-2760(98)00078-2; MATSCHINSKY FM, 1968, J NEUROCHEM, V15, P643, DOI 10.1111/j.1471-4159.1968.tb08963.x; MERCER EI, 1997, CONCISE ENCY BIOCH M; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; Nakajima K, 1999, J BIOL CHEM, V274, P16563, DOI 10.1074/jbc.274.23.16563; NAKAJIMA N, 1989, J BIOCHEM-TOKYO, V106, P515, DOI 10.1093/oxfordjournals.jbchem.a122884; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; Romert A, 1998, P NATL ACAD SCI USA, V95, P4404, DOI 10.1073/pnas.95.8.4404; Saari JC, 2000, METHOD ENZYMOL, V316, P359; Simon A, 2000, METHOD ENZYMOL, V316, P344; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Simon A, 1999, J CELL SCI, V112, P549; Stecher H, 2000, METHOD ENZYMOL, V316, P330; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; Su J, 1998, J BIOL CHEM, V273, P17910, DOI 10.1074/jbc.273.28.17910; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; SUZUKI Y, 1993, BIOCHIM BIOPHYS ACTA, V1163, P201, DOI 10.1016/0167-4838(93)90182-Q; van der Werf MJ, 1999, J BIOL CHEM, V274, P26296, DOI 10.1074/jbc.274.37.26296; Wang J, 1999, BIOCHEM J, V338, P23, DOI 10.1042/0264-6021:3380023; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Winston A, 1998, BIOCHEMISTRY-US, V37, P2044, DOI 10.1021/bi971908d; WONG SS, 1983, INT J BIOCHEM, V15, P147, DOI 10.1016/0020-711X(83)90057-5; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707; ZIMMERMAN WF, 1976, EXP EYE RES, V23, P159, DOI 10.1016/0014-4835(76)90199-8	68	49	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28128	28138						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871622				2022-12-27	WOS:000089197100079
J	Lintschinger, B; Balzer-Geldsetzer, M; Baskaran, T; Graier, WF; Romanin, C; Zhu, MX; Groschner, K				Lintschinger, B; Balzer-Geldsetzer, M; Baskaran, T; Graier, WF; Romanin, C; Zhu, MX; Groschner, K			Coassembly of Trp1 and Trp3 proteins generates diacylglycerol- and Ca2+-sensitive cation channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; ENDOTHELIAL-CELLS; DROSOPHILA TRP; FUNCTIONAL EXPRESSION; STORE DEPLETION; HTRP3 CHANNELS; CA2+ ENTRY; RECEPTOR; PHOTOTRANSDUCTION; ACTIVATION	To analyze the functional consequences of coassembly of transient receptor potential 1 (Trp1) and Trp3 channel proteins, we characterized membrane conductances and divalent cation entry derived by separate overexpression and by coexpression of both Trp isoforms, Trp1 expression generated a 1-oleoyl-2-acetyl-sn-glycerol (OAG)-activated conductance that was detectable only in Ca2+-free extracellular solution. Trp3 expression gave rise to an OAG-activated conductance that was suppressed but clearly detectable at physiological Ca2+ concentrations. Coexpression of both species resulted in a constitutively active, OAG-sensitive conductance, which exhibited distinctive cation selectivity and high sensitivity to inhibition by intracellular Ca2+. Trp1-expressing cells displayed only modest carbachol-induced Ca2+ entry and lacked OAG-induced Sr2+ entry, whereas Trp3-expressing cells responded to both agents with a substantial divalent cation entry, Coexpression of Trp1 plus Trp3 suppressed carbachol-induced Ca2+ entry compared with Trp3 expression and abolished OAG-induced Sr2+ entry signals, We concluded that coassembly of Trp1 and Trp3 resulted in the formation of oligomeric Trp channels that are subject to regulation by phospholipase C and Ca2+. The distinguished Ca2+ sensitivity of these Trp1/Trp3 hetero-oligomers appeared to limit Trp-mediated Ca2+ signals and may be of importance for negative feedback control of Trp function in mammalian cells.	Graz Univ, Dept Pharmakol & Toxicol, A-8010 Graz, Austria; Graz Univ, Dept Med Biochem & Med Mol Biol, A-8010 Graz, Austria; Univ Linz, Dept Biophys, A-4040 Linz, Austria; Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA	University of Graz; University of Graz; Johannes Kepler University Linz; University System of Ohio; Ohio State University	Groschner, K (corresponding author), Graz Univ, Dept Pharmakol & Toxicol, Univ Pl 2, A-8010 Graz, Austria.		Groschner, Klaus/A-2550-2010; Graier, Wolfgang F./B-7052-2008; Romanin, Christoph/D-5399-2009	Groschner, Klaus/0000-0002-8659-377X; Graier, Wolfgang F./0000-0003-1871-3298; Romanin, Christoph/0000-0003-3756-4136				Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Chang AS, 1997, FEBS LETT, V415, P335, DOI 10.1016/S0014-5793(97)01155-1; Garcia RL, 1997, BIOCHEM BIOPH RES CO, V239, P279, DOI 10.1006/bbrc.1997.7458; GRAIER WF, 1995, J PHYSIOL-LONDON, V482, P259, DOI 10.1113/jphysiol.1995.sp020515; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; HARDIE RC, 1994, J GEN PHYSIOL, V103, P409, DOI 10.1085/jgp.103.3.409; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Paltauf-Doburzynska J, 1998, J PHYSIOL-LONDON, V513, P369, DOI 10.1111/j.1469-7793.1998.369bb.x; Paltauf-Doburzynska J, 2000, J PHYSIOL-LONDON, V524, P701, DOI 10.1111/j.1469-7793.2000.00701.x; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; Putney JW, 1999, BIOESSAYS, V21, P38; Sinkins WG, 1998, BIOCHEM J, V331, P331, DOI 10.1042/bj3310331; Teubl M, 1999, J BIOL CHEM, V274, P29529, DOI 10.1074/jbc.274.41.29529; Warnat J, 1999, J PHYSIOL-LONDON, V518, P631, DOI 10.1111/j.1469-7793.1999.0631p.x; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	25	237	248	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27799	27805						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10882720				2022-12-27	WOS:000089197100039
J	Antes, TJ; Chen, J; Cooper, AD; Levy-Wilson, B				Antes, TJ; Chen, J; Cooper, AD; Levy-Wilson, B			The nuclear matrix protein CDP represses hepatic transcription of the human cholesterol-7 alpha hydroxylase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B GENE; CCAAT DISPLACEMENT PROTEIN; CHROMOSOMAL LOOP ANCHORAGE; BILE-ACID BIOSYNTHESIS; RECEPTOR LXR-ALPHA; 7-ALPHA-HYDROXYLASE GENE; ATTACHMENT REGIONS; REGULATORY REGION; ENHANCER ELEMENTS; TRANSGENIC MICE	To date, the molecular mechanisms that govern hepatic-specific transcription of the human cholesterol 7 alpha-hydroxylase (CYP7A1) gene are poorly understood. We recently reported that the region extending from -1888 to +46, which includes the promoter, is not capable of conferring expression to human CYP7A1 promoter lacZ transgenes in the livers of mice, but that expression is observed with transgenes containing the entire structural gene. To locate liver-specific elements in other segments of the human gene, DNase I hypersensitivity studies were performed with transcriptionally active, liver derived HepG2 cells and with transcriptionally inactive HeLa cells. Three DNase I hypersensitivity sites were detected within the first intron of the human CYP7A1 gene, but only in HepGa cells. Transient transfection experiments with HepG2 cells revealed a transcriptional repressor within intron 1. Five binding sites for the CAAT displacement protein (CDP) were detected within intron 1. Since CDP is a nuclear matrix protein, two methods were employed to localize nuclear matrix attachment sites within intron 1 of the human CYP7A1 gene. A matrix attachment site was found throughout the entirety of intron 1. Gel retardation experiments and cell transfection studies provided evidence for the repression mechanism. Repression is achieved by displacement by CDP of two hepatic activators, namely HNF-1 alpha and C/EBP alpha, that bind to three different sites within intron 1. Additionally, CDP represses transactivation mediated by these two activators.	Palo Alto Med Fdn, Res Inst, Palo Alto, CA 94301 USA; Stanford Univ, Dept Med, Div Gastroenterol, Stanford, CA 94303 USA	Palo Alto Medical Foundation Research Institute; Stanford University	Levy-Wilson, B (corresponding author), Palo Alto Med Fdn, Res Inst, 795 El Camino Real,Ames Bldg, Palo Alto, CA 94301 USA.			Antes, Travis/0000-0002-2294-8797	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054775] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54775] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ai WD, 1999, J VIROL, V73, P4220, DOI 10.1128/JVI.73.5.4220-4229.1999; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; Banan M, 1997, J BIOL CHEM, V272, P18440, DOI 10.1074/jbc.272.29.18440; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BROOKS AR, 1994, MOL CELL BIOL, V14, P2243, DOI 10.1128/MCB.14.4.2243; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; Chattopadhyay S, 1998, J BIOL CHEM, V273, P29838, DOI 10.1074/jbc.273.45.29838; Chen J, 1999, BIOCHEM BIOPH RES CO, V260, P829, DOI 10.1006/bbrc.1999.0980; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; Cooper AD, 1997, J BIOL CHEM, V272, P3444, DOI 10.1074/jbc.272.6.3444; COOPER AD, 1992, SEMIN LIVER DIS, V12, P386, DOI 10.1055/s-2008-1040408; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; Goodart SA, 1999, BIOCHEM BIOPH RES CO, V266, P454, DOI 10.1006/bbrc.1999.1799; Hoover T, 1996, NUCLEIC ACIDS RES, V24, P1895, DOI 10.1093/nar/24.10.1895; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; KAI MH, 1995, J LIPID RES, V36, P367; KAS E, 1987, J MOL BIOL, V198, P677, DOI 10.1016/0022-2836(87)90209-9; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; Lee SY, 1996, J BIOL CHEM, V271, P707, DOI 10.1074/jbc.271.2.707; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; LEVYWILSON B, 1995, PROG NUCLEIC ACID RE, V50, P161, DOI 10.1016/S0079-6603(08)60814-4; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; Liu JQ, 1999, MOL CELL BIOL, V19, P4918; Liu JQ, 1997, MOL CELL BIOL, V17, P5275, DOI 10.1128/MCB.17.9.5275; Massimi M, 1998, HEPATOLOGY, V28, P1064, DOI 10.1002/hep.510280422; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; PAULWEBER B, 1991, J BIOL CHEM, V266, P21956; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RONIG H, 1994, EUR J BIOCHEM, V221, P411; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Stunkel W, 2000, J VIROL, V74, P2489, DOI 10.1128/JVI.74.6.2489-2501.2000; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Wang DM, 1996, J LIPID RES, V37, P2117; WANG DP, 1994, GENOMICS, V20, P320, DOI 10.1006/geno.1994.1177; Wang ZY, 1999, MOL CELL BIOL, V19, P284	47	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26649	26660		10.1074/jbc.M002852200	http://dx.doi.org/10.1074/jbc.M002852200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10869351	hybrid			2022-12-27	WOS:000088999700104
J	Mackie, GA				Mackie, GA			Stabilization of circular rpsT mRNA demonstrates the 5 '-end dependence of RNase E action in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; CLEAVAGE SITES; IN-VITRO; DEGRADATION; SEQUENCE; RIBOZYMES; INTRON	RNase E is the major intracellular endonuclease in Escherichia coli. Its ability to cleave susceptible substrates in vitro depends on both the cleavage site itself and the availability of an unstructured 5' terminus. To test whether RNase E activity is 5'-end-dependent in vivo in the presence of all the components of the RNA degradative machinery, a known substrate, the rpsT mRNA, has been embedded in a permuted group I intron to permit its efficient, precise circularization in E. coli. Circular rpsT mRNAs are 4-6-fold more stable in vivo than their linear counterparts. Even partial inactivation of RNase E activity further enhances this stability 6-fold. However, the stabilization of circular rpsT mRNAs depends strongly on their efficient translation. These results show unambiguously the importance of an accessible 5'-end in controlling mRNA stability in vivo and support a two-step ("looping") model for RNase E action in which the first step is end recognition and the second is actual cleavage.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Mackie, GA (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, DH Copp Bldg,2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	gamackie@interchange.ubc.ca						Belasco J, 1993, CONTROL MESSENGER RN, P3; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; EMORY SA, 1992, GENE DEV, V6, P135, DOI 10.1101/gad.6.1.135; FORD E, 1994, P NATL ACAD SCI USA, V91, P3117, DOI 10.1073/pnas.91.8.3117; Goodrich AF, 1999, RNA, V5, P972, DOI 10.1017/S1355838299990398; HANSEN MJ, 1994, MOL MICROBIOL, V12, P707, DOI 10.1111/j.1365-2958.1994.tb01058.x; Jiang XQ, 2000, J BACTERIOL, V182, P2468, DOI 10.1128/JB.182.9.2468-2475.2000; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; MACKIE GA, 1989, J BACTERIOL, V171, P4112, DOI 10.1128/JB.171.8.4112-4120.1989; MACKIE GA, 1993, J MOL BIOL, V234, P998, DOI 10.1006/jmbi.1993.1654; Mackie GA, 1997, J BIOL CHEM, V272, P609; Mackie GA, 1998, NATURE, V395, P720, DOI 10.1038/27246; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; MELEFORS O, 1993, CONTROL MESSENGER RN, P53; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; PARSONS GD, 1988, J BACTERIOL, V170, P2485, DOI 10.1128/jb.170.6.2485-2492.1988; Perriman R, 1998, RNA, V4, P1047, DOI 10.1017/S135583829898061X; PUTTARAJU M, 1992, NUCLEIC ACIDS RES, V20, P5357, DOI 10.1093/nar/20.20.5357; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; SALVO JLG, 1990, J MOL BIOL, V211, P537, DOI 10.1016/0022-2836(90)90264-M; Tanner MA, 1997, RNA, V3, P1037; Tock MR, 2000, J BIOL CHEM, V275, P8726, DOI 10.1074/jbc.275.12.8726	24	63	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25069	25072		10.1074/jbc.C000363200	http://dx.doi.org/10.1074/jbc.C000363200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10871599	hybrid			2022-12-27	WOS:000088849400005
J	Rohwer, JM; Meadow, ND; Roseman, S; Westerhoff, HV; Postman, PW				Rohwer, JM; Meadow, ND; Roseman, S; Westerhoff, HV; Postman, PW			Understanding glucose transport by the bacterial phosphoenolpyruvate : glycose phosphotransferase system on the basis of kinetic measurements in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOCARRIER PROTEIN-IIIGLC; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; SUGAR-TRANSPORT; ENZYME-I; INDUCER EXCLUSION; FLUORESCENCE ANISOTROPY; CONTROL COEFFICIENTS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING	The kinetic parameters in vitro of the components of the phosphoenolpyruvate:glycose phosphotransferase system (PTS) in enteric bacteria were collected. To address the issue of whether the behavior in vivo of the PTS can be understood in terms of these enzyme kinetics, a detailed kinetic model was constructed. Each overall phosphotransfer reaction was separated into two elementary reactions, the first entailing association of the phosphoryl donor and acceptor into a complex and the second entailing dissociation of the complex into dephosphorylated donor and phosphorylated acceptor. Literature data on the K-m values and association constants of PTS proteins for their substrates, as well as equilibrium and rate constants for the overall phosphotransfer reactions, were related to the rate constants of the elementary steps in a set of equations; the rate constants could be calculated by solving these equations simultaneously. No kinetic parameters were fitted. As calculated by the model, the kinetic parameter values in vitro could describe experimental results in vivo when varying each of the PTS protein concentrations individually while keeping the other protein concentrations constant. Using the same kinetic constants, but adjusting the protein concentrations in the model to those present in cell-free extracts, the model could reproduce experiments in vitro analyzing the dependence of the flux on the total PTS protein concentration. For modeling conditions in vivo it was crucial that the PTS protein concentrations be implemented at their high in vivo values. The model suggests a new interpretation of results hitherto not understood; in vivo, the major fraction of the PTS proteins may exist as complexes with other PTS proteins or boundary metabolites, whereas in vitro, the fraction of complexed proteins is much smaller.	Univ Stellenbosch, Dept Biochem, ZA-7602 Matieland, South Africa; Univ Amsterdam, BioCentrum, EC Slater Inst, NL-1018 TV Amsterdam, Netherlands; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Vrije Univ Amsterdam, BioCentrum, Inst Mol Biol Sci, NL-1081 HV Amsterdam, Netherlands	Stellenbosch University; University of Amsterdam; Johns Hopkins University; Vrije Universiteit Amsterdam	Rohwer, JM (corresponding author), Univ Stellenbosch, Dept Biochem, Private Bag X1, ZA-7602 Matieland, South Africa.	jr@maties.sun.ac.za	Westerhoff, Hans V/I-5762-2012; Rohwer, Johann/A-2027-2008	Westerhoff, Hans V/0000-0002-0443-6114; Rohwer, Johann/0000-0001-6288-8904				ANDERSON JW, 1991, BIOCHEMISTRY-US, V30, P9601, DOI 10.1021/bi00104a006; BENESKI DA, 1982, J BIOL CHEM, V257, P4492; BOUMA CL, 1987, P NATL ACAD SCI USA, V84, P930, DOI 10.1073/pnas.84.4.930; Briggs GE, 1925, BIOCHEM J, V19, P338, DOI 10.1042/bj0190338; CHAUVIN F, 1994, J BIOL CHEM, V269, P20263; CHAUVIN F, 1994, J BIOL CHEM, V269, P20270; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME; FEESE M, 1994, P NATL ACAD SCI USA, V91, P3544, DOI 10.1073/pnas.91.9.3544; GARNER MM, 1994, AM J PHYSIOL, V266, pC877, DOI 10.1152/ajpcell.1994.266.4.C877; GRENIER FC, 1986, J CELL BIOCHEM, V31, P97, DOI 10.1002/jcb.240310203; HAN MK, 1990, J BIOL CHEM, V265, P1996; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; HELLINGWERF KJ, 1995, FEMS MICROBIOL REV, V16, P309; Hoch JA, 1995, 2 COMPONENT SIGNAL T; Hogema BM, 1998, MOL MICROBIOL, V30, P487, DOI 10.1046/j.1365-2958.1998.01053.x; HOVING H, 1982, BIOCHEMISTRY-US, V21, P3128, DOI 10.1021/bi00256a015; JABLONSKI EG, 1983, J BIOL CHEM, V258, P9690; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; KHOLODENKO BN, 1995, BIOPHYS CHEM, V56, P215, DOI 10.1016/0301-4622(95)00039-Z; KHOLODENKO BN, 1995, BBA-BIOENERGETICS, V1229, P256, DOI 10.1016/0005-2728(95)00014-A; KHOLODENKO BN, 1995, TRENDS BIOCHEM SCI, V20, P52, DOI 10.1016/S0968-0004(00)88955-0; KODAKI T, 1981, J BIOCHEM-TOKYO, V90, P1437, DOI 10.1093/oxfordjournals.jbchem.a133610; KUKURUZINSKA MA, 1984, J BIOL CHEM, V259, P1679; LENGELER JW, 1994, BBA-BIOENERGETICS, V1188, P1, DOI 10.1016/0005-2728(94)90017-5; LICALSI C, 1991, J BIOL CHEM, V266, P19519; LOLKEMA JS, 1995, BBA-PROTEIN STRUCT M, V1252, P284, DOI 10.1016/0167-4838(95)00112-8; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MATTOO RL, 1983, CAN J BIOCHEM CELL B, V61, P29, DOI 10.1139/o83-005; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; Meadow ND, 1996, J BIOL CHEM, V271, P33440, DOI 10.1074/jbc.271.52.33440; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MENDES P, 1996, BIOTHERMOKINETICS LI, P258; MINTON AP, 1983, MOL CELL BIOCHEM, V55, P119, DOI 10.1007/BF00673707; MISSET O, 1983, BIOCHEMISTRY-US, V22, P6163, DOI 10.1021/bi00295a019; MISSET O, 1980, BIOCHEMISTRY-US, V19, P883, DOI 10.1021/bi00546a009; MORIKAWA M, 1980, J BIOCHEM-TOKYO, V87, P441, DOI 10.1093/oxfordjournals.jbchem.a132764; NINFA AJ, 1996, CELLULAR MOL BIOL, V1, P1246; Plumbridge J, 1999, MOL MICROBIOL, V33, P260, DOI 10.1046/j.1365-2958.1999.01462.x; POSTMA PW, 1977, J BACTERIOL, V129, P630, DOI 10.1128/JB.129.2.630-639.1977; POSTMA PW, 1996, CELLULAR MOL BIOL, V1, P1149; REIZER J, 1992, J BIOL CHEM, V267, P9158; ROBILLARD GT, 1988, BIOCHIM BIOPHYS ACTA, V947, P493, DOI 10.1016/0304-4157(88)90005-6; ROHWER J, 1997, THESIS U AMSTERDAM; Rohwer JM, 1998, MOL MICROBIOL, V29, P641, DOI 10.1046/j.1365-2958.1998.00963.x; Rohwer JM, 1998, P NATL ACAD SCI USA, V95, P10547, DOI 10.1073/pnas.95.18.10547; ROHWER JM, 1998, BIOTHERMOKINETICS PO, P340; RUIJTER GJG, 1992, J BACTERIOL, V174, P2843, DOI 10.1128/JB.174.9.2843-2850.1992; RUIJTER GJG, 1991, J BACTERIOL, V173, P6184; SAFFEN DW, 1987, J BIOL CHEM, V262, P16241; SAIER MH, 1980, J BIOL CHEM, V255, P8579; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SAURO HM, 1993, COMPUT APPL BIOSCI, V9, P441; SCHOLTE BJ, 1981, J BACTERIOL, V148, P257, DOI 10.1128/JB.148.1.257-264.1981; SCHUSTER S, 1992, BIOSYSTEMS, V27, P1, DOI 10.1016/0303-2647(92)90042-W; STOCK JB, 1982, J BIOL CHEM, V257, P4543; VANDAM K, 1993, EUR J BIOCHEM, V212, P791; VANDERVLAG J, 1995, MOL GEN GENET, V248, P236, DOI 10.1007/BF02190806; VANDERVLAG J, 1995, EUR J BIOCHEM, V230, P170; VOGLER AP, 1988, MOL MICROBIOL, V2, P719, DOI 10.1111/j.1365-2958.1988.tb00082.x; WAEBER U, 1993, FEBS LETT, V324, P109, DOI 10.1016/0014-5793(93)81542-8; WAYGOOD EB, 1987, J BACTERIOL, V169, P2810, DOI 10.1128/jb.169.6.2810-2818.1987; WAYGOOD EB, 1980, CAN J BIOCHEM CELL B, V58, P40, DOI 10.1139/o80-006; WEIGEL N, 1982, J BIOL CHEM, V257, P4461; WEIGEL N, 1982, J BIOL CHEM, V257, P4477; WINKLER HH, 1966, J BIOL CHEM, V241, P2200; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331; ZWAIG N, 1970, J BACTERIOL, V102, P753, DOI 10.1128/JB.102.3.753-759.1970	69	98	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34909	34921		10.1074/jbc.M002461200	http://dx.doi.org/10.1074/jbc.M002461200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10889194	Green Published, hybrid			2022-12-27	WOS:000165422800014
J	Guerini, D; Zecca-Mazza, A; Carafoli, E				Guerini, D; Zecca-Mazza, A; Carafoli, E			Single amino acid mutations in transmembrane domain 5 confer to the plasma membrane Ca2+ pump properties typical of the Ca2+ pump of endo(sarco)plasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SARCOPLASMIC-RETICULUM; FUNCTIONAL DOMAINS; CA-2+ PUMP; ENDOPLASMIC-RETICULUM; CALCIUM-PUMP; CA2+-ATPASE; EXPRESSION; MECHANISM; ATPASE	Conserved residues in some of the transmembrane domains are proposed to mediate ion translocation by P-type pumps. The plasma membrane Ca2+ pump (PMCA) lacks 2 of these residues in transmembrane domains (TM) 5 and 8, In particular, a glutamic acid (Glu-771) residue in TM5, which is proposed to be involved in the binding and transport of Ca2+ by the sarcoplasmic reticulum Ca2+ pump (SERCA), is replaced by an alanine (Ala-854) in the PMCA pump. Ala-854 has been mutated to Glu, Asp, or Gin; Glu-975 in TM8, which is an Ala in the SERCA pump, has been mutated to Gin, Asp, or Ala, The mutants have been expressed in three cell systems, with or without the help of viruses. When expressed in large amounts in Sf9 cells, the mutated pumps were isolated and analyzed in the purified state. Two of the three TM8 mutants were correctly delivered to the plasma membrane and were active. AU the TM5 mutants were retained in the endoplasmic reticulum; two of them (A854Q and A854E) retained activity. Their properties (La3+ sensitivity and decay of the phosphorylated intermediate, higher cooperativity of Ca2+ binding with a Hill's coefficient approaching 2) differed from those of the expressed wild type PMCA pump, and resembled those of the SERCA pump.	Univ Padua, Dept Biochem, I-35121 Padua, Italy; Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland	University of Padua; Swiss Federal Institutes of Technology Domain; ETH Zurich	Carafoli, E (corresponding author), Univ Padua, Dept Biochem, I-35121 Padua, Italy.	carafoli@civ.bio.unipd.it	Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094	Telethon [963] Funding Source: Medline	Telethon(Fondazione Telethon)		ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; ADAMO HP, 1992, J BIOL CHEM, V267, P14244; ADEBAYO AO, 1995, J BIOL CHEM, V270, P27812, DOI 10.1074/jbc.270.46.27812; ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; CARAFOLI E, 1994, J NEUROBIOL, V25, P312, DOI 10.1002/neu.480250311; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FOLETTI D, 1995, FASEB J, V9, P670, DOI 10.1096/fasebj.9.8.7768360; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GARRAHAN PJ, 1978, BIOCHIM BIOPHYS ACTA, V513, P59, DOI 10.1016/0005-2736(78)90111-6; Guerini D, 1998, ACTA PHYSIOL SCAND, V163, P265; Guerini D, 1996, BIOCHEMISTRY-US, V35, P3290, DOI 10.1021/bi952572f; Guerini D, 1999, CALCIUM AS A CELLULAR REGULATOR, P249; HAO LN, 1994, J BIOL CHEM, V269, P14268; HEIM R, 1992, J BIOL CHEM, V267, P24476; Herscher CJ, 1997, ANN NY ACAD SCI, V834, P407, DOI 10.1111/j.1749-6632.1997.tb52284.x; Herscher CJ, 1996, BIOCHEMISTRY-US, V35, P14917, DOI 10.1021/bi961879r; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1992, ANN NY ACAD SCI, V671, P32, DOI 10.1111/j.1749-6632.1992.tb43782.x; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES P, 1987, BIOCHEM BIOPH RES CO, V149, P7, DOI 10.1016/0006-291X(87)91597-X; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; NIGGLI V, 1982, J BIOL CHEM, V257, P2350; NIGGLI V, 1981, J BIOL CHEM, V256, P395; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; SCHATZMANN HJ, 1966, EXPERIENTIA, V22, P364, DOI 10.1007/BF01901136; SCOFANO HM, 1981, J BIOL CHEM, V256, P4282; Seiz Preiano Brigitta, 1996, Biochemistry, V35, P7946, DOI 10.1021/bi9527404; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; SUISSA M, 1983, ANAL BIOCHEM, V133, P511, DOI 10.1016/0003-2697(83)90117-3; SUMMERS MD, 1988, TEXAS AGR EXP STN B, V1555; VERMA AK, 1988, J BIOL CHEM, V263, P14152; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; ZVARITCH E, 1995, J BIOL CHEM, V270, P2679, DOI 10.1074/jbc.270.6.2679	41	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31361	31368		10.1074/jbc.M003474200	http://dx.doi.org/10.1074/jbc.M003474200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10899160	hybrid			2022-12-27	WOS:000089762700087
J	Jones, PC; Hermolin, J; Jiang, WP; Fillingame, RH				Jones, PC; Hermolin, J; Jiang, WP; Fillingame, RH			Insights into the rotary catalytic mechanism of F0F1 ATP synthase from the cross-linking of subunits b and c in the Escherichia coli enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING H+ TRANSPORT; POLAR LOOP REGION; EPSILON-SUBUNIT; PROPIONIGENIUM-MODESTUM; PROTON TRANSLOCATION; GAMMA-SUBUNIT; ALPHA-SUBUNIT; ENERGY TRANSDUCTION; MOLECULAR MACHINE; F-0 COMPLEX	The transmembrane sector of the F0F1 rotary ATP synthase is proposed to organize with an oligomeric ring of c subunits, which function as a rotor, interacting with two b subunits at the periphery of the ring, the b subunits functioning as a stator, In this study, cysteines were introduced into the C-terminal region of subunit c and the N-terminal region of subunit b, Cys of N2C subunit b was cross-linked with Cys at positions 74, 75, and 78 of subunit c, In each case, a maximum of 50% of the b subunit could be cross-linked to subunit c, which suggests that either only one of the two b subunits lie adjacent to the c-ring or that both b subunits interact with a single subunit c, The results support a topological arrangement of these subunits, in which the respective Nand C-terminal ends of subunits b and c extend to the periplasmic surface of the membrane and cAsp-61 lies at the center of the membrane, The cross-linking of Cys between bN2C and cV78C was shown to inhibit ATP-driven proton pumping, as would be predicted from a rotary model for ATP synthase function, but unexpectedly, cross-linking did not lead to inhibition of ATPase activity. ATP hydrolysis and proton pumping are therefore uncoupled in the cross-linked enzyme. The c subunit lying adjacent to subunit b was shown to be mobile and to exchange with c subunits that initially occupied non-neighboring positions. The movement or exchange of subunits at the position adjacent to subunit b was blocked by dicyclohexylcarbodiimide. These experiments provide a biochemical verification that the oligomeric c-ring can move with respect to the b-stator and provide further support for a rotary catalytic mechanism in the ATP synthase.	Univ Wisconsin, Dept Biomol Chem, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fillingame, RH (corresponding author), Univ Wisconsin, Dept Biomol Chem, Sch Med, 1300 Univ Ave, Madison, WI 53706 USA.	rhfillin@facstaff.wise.edu			NIGMS NIH HHS [GM23105] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023105, R01GM023105] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Birkenhager R, 1999, EUR J BIOCHEM, V264, P385, DOI 10.1046/j.1432-1327.1999.00652.x; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1982, J BIOL CHEM, V257, P7354; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; Fillingame RH, 1997, J EXP BIOL, V200, P217; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1989, J BIOL CHEM, V264, P6797; FRAGA D, 1994, J BIOL CHEM, V269, P7532; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; HATCH LP, 1995, J BIOL CHEM, V270, P29407, DOI 10.1074/jbc.270.49.29407; HERMOLIN J, 1995, J BIOL CHEM, V270, P2815, DOI 10.1074/jbc.270.6.2815; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jones PC, 2000, J BIOL CHEM, V275, P11355, DOI 10.1074/jbc.275.15.11355; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Kaim G, 1998, EMBO J, V17, P688, DOI 10.1093/emboj/17.3.688; Kaim G, 1997, BIOCHEMISTRY-US, V36, P9185, DOI 10.1021/bi970831q; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; KLUGE C, 1993, BIOCHEMISTRY-US, V32, P10378, DOI 10.1021/bi00090a013; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4128, DOI 10.1021/bi00313a018; McLachlin DT, 2000, BIOCHEMISTRY-US, V39, P3486, DOI 10.1021/bi992586b; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schulenberg B, 1999, J BIOL CHEM, V274, P34233, DOI 10.1074/jbc.274.48.34233; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsunoda SP, 2000, FEBS LETT, V470, P244, DOI 10.1016/S0014-5793(00)01336-3; UNLIN U, 1997, STRUCTURE, V5, P1219; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; VIK SB, 1994, J BIOL CHEM, V269, P30364; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Walker JE, 1998, ANGEW CHEM INT EDIT, V37, P2309, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2308::AID-ANIE2308>3.0.CO;2-W; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; WIENER MC, 1992, BIOPHYS J, V61, P434, DOI 10.1016/S0006-3495(92)81849-0; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; ZHANG Y, 1994, J BIOL CHEM, V269, P5473; ZHANG Y, 1995, J BIOL CHEM, V270, P87, DOI 10.1074/jbc.270.1.87; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; ZHANG Y, 1994, J BIOL CHEM, V269, P10221	71	44	47	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31340	31346		10.1074/jbc.M003687200	http://dx.doi.org/10.1074/jbc.M003687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10882728	hybrid			2022-12-27	WOS:000089762700084
J	Piper, MD; Hong, SP; Ball, GE; Dawes, IW				Piper, MD; Hong, SP; Ball, GE; Dawes, IW			Regulation of the balance of one-carbon metabolism in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-13 NMR ANALYSIS; MOLECULAR CHARACTERIZATION; GLYCINE; GENE; SERINE; PROTEIN; COMPARTMENTATION; TRANSCRIPTION; BIOSYNTHESIS; ACTIVATION	One-carbon metabolism in yeast is an essential process that relies on at least one of three one-carbon donor molecules: serine, glycine, or formate, By a combination of genetics and biochemistry we have shown how cells regulate the balance of one-carbon mow between the donors by regulating cytoplasmic serine hydroxymethyltransferase activity in a side reaction occurring in the presence of excess glycine, This control governs the level of 5,10-methylene tetrahydrofolate (5,10-CH2-H(4)folate) in the cytoplasm, which has a direct role in signaling transcriptional control of the expression of key genes, particularly those encoding the unique components of the glycine decarboxylase complex (GCV1, GCV2, and GCV3), Based on these and other observations, we propose a model for how cells balance the need to supplement their one-carbon pools when charged folates are limiting or when glycine is in excess. We also propose that under normal conditions, cytoplasmic 5,10-CH2-H(4)folate is mainly directed to generating methyl groups via methionine, whereas one-carbon units generated from glycine in mitochondria are more directed to purine biosynthesis, When glycine is in excess, 5,10-CH2-H(4)folate is decreased, and the regulation loop shifts the balance of generation of one-carbon units into the mitochondrion.	Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia; Univ New S Wales, NMR Facil, Sydney, NSW 2052, Australia	University of New South Wales Sydney; University of New South Wales Sydney	Dawes, IW (corresponding author), Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia.		Piper, Matthew/C-1714-2008; Ball, Graham/L-6638-2015	Piper, Matthew/0000-0003-3245-7219; Ball, Graham/0000-0002-0716-2286				APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; BARLOWE C K, 1989, Biofactors, V2, P57; BARLOWE C K, 1988, Biofactors, V1, P171; BARLOWE CK, 1990, MOL CELL BIOL, V10, P5679, DOI 10.1128/MCB.10.11.5679; Buc PS, 1999, YEAST, V15, P1347, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1347::AID-YEA461>3.0.CO;2-A; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; Hong SP, 1999, J BIOL CHEM, V274, P10523, DOI 10.1074/jbc.274.15.10523; HONG SP, 1999, THESIS U NEW S WALES; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; Kastanos EK, 1997, BIOCHEMISTRY-US, V36, P14956, DOI 10.1021/bi971610n; MCKENZIE KQ, 1977, GENETICS, V86, P85; McNeil JB, 1997, GENE, V186, P13, DOI 10.1016/S0378-1119(96)00670-1; McNeil JB, 1996, GENETICS, V142, P371; Nagarajan L, 1997, J BIOL CHEM, V272, P4444, DOI 10.1074/jbc.272.7.4444; OGUR M, 1977, J BACTERIOL, V129, P926, DOI 10.1128/JB.129.2.926-933.1977; PASTERNACK LB, 1994, BIOCHEMISTRY-US, V33, P7166, DOI 10.1021/bi00189a020; Pasternack LB, 1996, ARCH BIOCHEM BIOPHYS, V326, P158, DOI 10.1006/abbi.1996.0060; PASTERNACK LB, 1992, BIOCHEMISTRY-US, V31, P8713, DOI 10.1021/bi00152a005; PASTERNACK LB, 1994, BIOCHEMISTRY-US, V33, P74, DOI 10.1021/bi00167a010; RUET A, 1984, EMBO J, V3, P343, DOI 10.1002/j.1460-2075.1984.tb01809.x; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; Sinclair DA, 1996, MOL MICROBIOL, V19, P611, DOI 10.1046/j.1365-2958.1996.419947.x; SINCLAIR DA, 1994, MOL CELL BIOL, V14, P214, DOI 10.1128/MCB.14.1.214; SINCLAIR DA, 1995, GENETICS, V140, P1213; SINCLAIR DA, 1995, THESIS U NEW S WALES; STOVER P, 1990, J BIOL CHEM, V265, P14227; Tizon B, 1999, YEAST, V15, P145, DOI 10.1002/(SICI)1097-0061(19990130)15:2<145::AID-YEA346>3.0.CO;2-J; West MG, 1996, BIOCHEMISTRY-US, V35, P3122, DOI 10.1021/bi952713d; ZAROW C, 1983, PREP BIOCHEM, V12, P381	30	64	64	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30987	30995		10.1074/jbc.M004248200	http://dx.doi.org/10.1074/jbc.M004248200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10871621	hybrid			2022-12-27	WOS:000089762700037
J	Thuveson, M; Fries, E				Thuveson, M; Fries, E			The low pH in trans-Golgi triggers autocatalytic cleavage of pre-alpha-inhibitor heavy chain precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY CROSS-LINKS; AMINO-ACID-SEQUENCE; TRYPSIN-INHIBITOR; SECRETORY PROTEINS; RAT HEPATOCYTES; ACIDIFICATION; BIKUNIN; CELLS; BIOSYNTHESIS; PROPEPTIDE	Pre-alpha-inhibitor is a plasma protein whose physiological function is still unknown, but in vitro studies suggest that it might be involved in inflammatory reactions. Pre-alpha-inhibitor consists of a 25- and a 75-kDa polypeptide: bikunin and heavy chain 3 (H3), respectively. H3 is synthesized with a 30-kDa C-terminal extension, which is released in the Golgi complex through cleavage between an Asp and a Pro residue. We now provide evidence that this cleavage is triggered by the low pH in the late Golgi and occurs through an intramolecular process. First, incubation in vitro of the H3 precursor (proH3) at pH 6.0 or lower results in rapid cleavage of the protein. Second, the rate of the cleavage reaction does not depend on the concentration of proH3 and is not affected by the presence of various protease inhibitors. Third, raising the pH in organelles of cells producing proH3 abolishes cleavage during secretion. The amino acid residues near the cleavage site of proH3 differ from those of previously described self-cleaving proteins, indicating that the mechanisms of scission are different.	Agr Univ Sweden, Biomed Ctr, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	Swedish University of Agricultural Sciences	Thuveson, M (corresponding author), Agr Univ Sweden, Biomed Ctr, Dept Vet Med Chem, S-75123 Uppsala, Sweden.							Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Blom AM, 1997, BIOCHEM J, V328, P185; BOURGUIGNON J, 1993, EUR J BIOCHEM, V212, P771, DOI 10.1111/j.1432-1033.1993.tb17717.x; CHAN P, 1995, BIOCHEM J, V306, P505, DOI 10.1042/bj3060505; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; GEBHARD W, 1989, EUR J BIOCHEM, V181, P571, DOI 10.1111/j.1432-1033.1989.tb14762.x; HALBAN PA, 1994, BIOCHEM J, V299, P1; Hui N, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P46; Landon, 1977, Methods Enzymol, V47, P145; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Martin-Vandelet N, 1999, EUR J BIOCHEM, V259, P476, DOI 10.1046/j.1432-1327.1999.00067.x; MELLMAN I, 1992, J EXP BIOL, V172, P39; MORELLE W, 1994, EUR J BIOCHEM, V221, P881, DOI 10.1111/j.1432-1033.1994.tb18803.x; ODA K, 1986, BIOCHEM J, V240, P739, DOI 10.1042/bj2400739; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; PISZKIEW.D, 1970, BIOCHEM BIOPH RES CO, V40, P1173, DOI 10.1016/0006-291X(70)90918-6; Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SJOBERG EM, 1992, ARCH BIOCHEM BIOPHYS, V295, P217, DOI 10.1016/0003-9861(92)90509-U; THOGERSEN IB, 1995, J BIOL CHEM, V270, P18700; Thuveson M, 1999, J BIOL CHEM, V274, P6741, DOI 10.1074/jbc.274.10.6741; VETR H, 1990, BIOL CHEM H-S, V371, P1185, DOI 10.1515/bchm3.1990.371.2.1185; WISNIEWSKI HG, 1994, BIOCHEMISTRY-US, V33, P7423, DOI 10.1021/bi00189a049; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657	28	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30996	31000		10.1074/jbc.M002399200	http://dx.doi.org/10.1074/jbc.M002399200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10893227	hybrid			2022-12-27	WOS:000089762700038
J	Giallourakis, C; Kashiwada, M; Pan, PY; Danial, N; Jiang, H; Cambier, J; Coggeshall, KM; Rothman, P				Giallourakis, C; Kashiwada, M; Pan, PY; Danial, N; Jiang, H; Cambier, J; Coggeshall, KM; Rothman, P			Positive regulation of interleukin-4-mediated proliferation by the SH2-containing inositol-5 '-phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHATASE SHIP; PROTEIN-KINASE-B; FC-GAMMA-RIIB; PHOSPHOTYROSINE-BINDING DOMAIN; INSULIN-RECEPTOR SUBSTRATE-1; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; IL-4 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; CYTOKINE STIMULATION	The SH2-containing inositol 5'-phosphatase (SHIP) is tyrosine-phosphorylated in response to cytokines such as interleukin (LL)-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor. SHIP has been shown to modulate negatively these cytokine signalings; however, a potential role in IL-4 signaling remains uncharacterized, It has been recently shown that IL-4 induces tyrosine phosphorylation of SKIP, implicating the phosphatase in IL-4 processes. Tyrosine kinases, Jak1 and Jak3, involved in IL-4 signaling can associate with SHIP, yet only Jak1 can tyrosine-phosphorylate SHIP when co-expressed. In functional studies, cells overexpressing wild type SHIP are found to be hyperproliferative in response to IL-4 in comparison to parental cells. In contrast, cells expressing catalytically inactive form, SHIP(D672A), show reduced proliferation in response to IL-4. These changes in IL-4-induced proliferation correlate with alterations in phosphatidylinositol 3,4,5-triphosphate levels. However, no differential activation of STAT6, Akt, IRS-2, or p70(S6k), in response to IL-4, was observed in these cells. These data suggest that the catalytic activity of SHIP acts in a novel manner to influence IL-4 signaling. In addition, these data support recent findings that suggest there are uncharacterized signaling pathways downstream of phosphatidylinositol 3,4,5-triphosphate.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Natl Jewish Med & Res Ctr, Dept Immunol, Denver, CO 80206 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA	Columbia University; Columbia University; National Jewish Health; University System of Ohio; Ohio State University	Rothman, P (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St,P&S 8-425, New York, NY 10032 USA.			Cambier, John/0000-0002-7803-242X	NCI NIH HHS [CA64628] Funding Source: Medline; NIAID NIH HHS [AI33450, AI41447] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033450, R01AI041447, R01AI033450] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Cerezo A, 1998, MOL BIOL CELL, V9, P3107, DOI 10.1091/mbc.9.11.3107; Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; DAmbrosio D, 1996, IMMUNOL LETT, V54, P77, DOI 10.1016/S0165-2478(96)02653-3; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dhe-Paganon S, 1999, P NATL ACAD SCI USA, V96, P8378, DOI 10.1073/pnas.96.15.8378; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Helgason CD, 2000, J EXP MED, V191, P781, DOI 10.1084/jem.191.5.781; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Howell BW, 1999, MOL CELL BIOL, V19, P5179; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Ingham RJ, 1999, J IMMUNOL, V163, P5891; Jacob A, 1999, J BIOL CHEM, V274, P13704, DOI 10.1074/jbc.274.19.13704; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1998, MOL CELL BIOL, V18, P1996, DOI 10.1128/MCB.18.4.1996; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P8983; Liu QR, 1998, J EXP MED, V188, P1333, DOI 10.1084/jem.188.7.1333; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Nakamura K, 2000, J IMMUNOL, V164, P631, DOI 10.4049/jimmunol.164.2.631; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PAUL WE, 1991, BLOOD, V77, P1859; Pearse RN, 1999, IMMUNITY, V10, P753, DOI 10.1016/S1074-7613(00)80074-6; Reichel M, 1997, J IMMUNOL, V158, P5860; Rohrschneider LR, 2000, GENE DEV, V14, P505; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Stenmark H, 1999, J CELL SCI, V112, P4175; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Tridandapani S, 1998, MOL IMMUNOL, V35, P1135, DOI 10.1016/S0161-5890(98)00097-2; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Wang HY, 1997, J IMMUNOL, V158, P1037; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; Ware MD, 1996, BLOOD, V88, P2833, DOI 10.1182/blood.V88.8.2833.bloodjournal8882833; Welham MJ, 1997, J BIOL CHEM, V272, P1377, DOI 10.1074/jbc.272.2.1377; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Zamorano J, 1998, J IMMUNOL, V161, P859	60	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29275	29282		10.1074/jbc.M002853200	http://dx.doi.org/10.1074/jbc.M002853200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10875931	hybrid			2022-12-27	WOS:000089439800015
J	Phelps, CB; Sengchanthalangsy, LL; Huxford, T; Ghosh, G				Phelps, CB; Sengchanthalangsy, LL; Huxford, T; Ghosh, G			Mechanism of I kappa B alpha binding to NF-kappa B dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; NUCLEAR-LOCALIZATION; PHOSPHORYLATION; HOMODIMER; DNA; DEGRADATION; ACTIVATION; SEQUENCES; PROTEINS; COMPLEX	X-ray crystal structures of the NF-kappa B I kappa B alpha complex revealed an extensive and complex protein-protein interface involving independent structural elements present in both I kappa B alpha and NF-kappa B. In this study, we employ a gel electrophoretic mobility shift assay to assess and quantitate the relative contributions of the observed interactions toward overall complex binding affinity. I kappa B alpha preferentially binds to the p50/p65 heterodimer and p65 homodimer, with binding to p50 homodimer being significantly weaker. Our results indicate that the nuclear localization sequence and the region C-terminal to it of the NF-kappa B p65 subunit is a major contributor to NF-kappa B I kappa B alpha complex formation. Additionally, there are no contacts between the corresponding nuclear localization signal tetrapeptide of p50 and I kappa B alpha. A second set of interactions involving the acidic C-terminal/PEST-like region of I kappa B alpha and the NF-kappa B p65 subunit N-terminal domain also contributes binding energy toward formation of the complex. This interaction is highly dynamic and nonspecific in nature, as shown by oxidative cysteine cross-linking. Phosphorylation of the C-terminal/ PEST-like region by casein kinase II further enhances binding.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, MC 0359,9500 Gilman Dr, La Jolla, CA 92093 USA.			Huxford, Tom/0000-0002-1939-7373	NCI NIH HHS [CA-78749] Funding Source: Medline; NIGMS NIH HHS [2-T32-GM07240-2] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Chen FE, 1999, PROTEIN ENG, V12, P423, DOI 10.1093/protein/12.5.423; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Siebel CW, 1999, P NATL ACAD SCI USA, V96, P5440, DOI 10.1073/pnas.96.10.5440; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723	22	88	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29840	29846		10.1074/jbc.M004899200	http://dx.doi.org/10.1074/jbc.M004899200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882738	hybrid			2022-12-27	WOS:000089439800090
J	Yang, T; Goldstein, JL; Brown, MS				Yang, T; Goldstein, JL; Brown, MS			Overexpression of membrane domain of SCAP prevents sterols from inhibiting SCAP center dot SREBP exit from endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE-ACTIVATING PROTEIN; CELL-MEMBRANES; IDENTIFICATION; DEGRADATION; REDUCTASE; PATHWAY	SCAP (SREBP cleavage-activating protein) forms a complex with sterol regulatory element-binding proteins (SREBPs) and escorts them from the endoplasmic reticulum (ER) to the Golgi complex where proteases release transcriptionally active segments of SREBPs, which enter the nucleus to activate lipid synthesis. The NH2-terminal segment of SCAP contains eight transmembrane helices, five of which (TM2-6) comprise the sterol-sensing domain. This domain responds to sterols by causing the SCAP SREBP complex to be retained in the ER, preventing proteolytic release and reducing transcription of lipogenic genes. Here, we use transfection techniques to overexpress a segment of SCAP containing transmembrane helices 1-6 in hamster and human cells. This segment does not interfere with SCAP SREBP movement to the Golgi in the absence of sterols, but it prevents sterols from suppressing this movement. This block is abolished when SCAP(TM1-6) contains a point mutation (Y298C) that is known to abolish the activity of the sterol-sensing domain. We interpret these findings to indicate that sterols cause the SCAP SREBP complex to bind to an ER retention protein through an interaction that involves the sterol-sensing domain. The SCAP(TM1-6) segment competes with the SCAP SREBP complex for binding to this putative retention protein, thereby liberating the SCAP SREBP complex so that it can move to the Golgi despite the presence of sterols, These studies provide a potential mechanistic explanation for the ability of sterols to block SCAP SREBP movement from the ER and thereby to control lipid synthesis in animal cells.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Goldstein, JL (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd,Rm L5-238, Dallas, TX 75390 USA.							Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Duncan EA, 1998, J BIOL CHEM, V273, P17801, DOI 10.1074/jbc.273.28.17801; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213	19	72	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29881	29886		10.1074/jbc.M005439200	http://dx.doi.org/10.1074/jbc.M005439200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896675	hybrid			2022-12-27	WOS:000089439800095
J	Goretzki, L; Lombardo, CR; Stallcup, WB				Goretzki, L; Lombardo, CR; Stallcup, WB			Binding of the NG2 proteoglycan to kringle domains modulates the functional properties of angiostatin and plasmin(ogen)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CHONDROITIN SULFATE PROTEOGLYCAN; MEMBRANE-SPANNING PROTEOGLYCAN; FIBROBLAST-GROWTH-FACTOR; PDGF ALPHA-RECEPTOR; HUMAN-PLASMINOGEN; ENDOTHELIAL-CELLS; VI COLLAGEN; EXTRACELLULAR-MATRIX; BOUND PLASMIN	Interactions of the developmentally regulated chondroitin sulfate proteoglycan NG2 with human plasminogen and kringle domain-containing plasminogen fragments have been analyzed by solid-phase immunoassays and by surface plasmon resonance. In immunoassays, the core protein of NG2 binds specifically and saturably to plasminogen, which consists of five kringle domains and a serine protease domain, and to angiostatin, which contains plasminogen kringle domains 1-3. Apparent dissociation constants for these interactions range from 12 to 75 nM. Additional evidence for NG2 interaction with kringle domains comes from its binding to plasminogen kringle domain 4 and to miniplasminogen (kringle domain 5 plus the protease domain) with apparent dissociation constants in the 18-71 nM range. Inhibition of plasminogen and angiostatin binding to NG2 by g-aminohexanoic acid suggests that lysine binding sites are involved in kringle interaction with NG2, The interaction of NG2 with plasminogen and angiostatin has very interesting functional consequences. 1) Soluble NG2 significantly enhances the activation of plasminogen by urokinase type plasminogen activator. 2) The antagonistic effect of angiostatin on endothelial cell proliferation is inhibited by soluble NG2, Both of these effects of NG2 should make the proteoglycan a positive regulator of the cell migration and proliferation required for angiogenesis.	La Jolla Canc Res Ctr, Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Stallcup, WB (corresponding author), La Jolla Canc Res Ctr, Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	stallcup@burnham.org			NATIONAL CANCER INSTITUTE [T32CA009579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044400] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021990] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09579] Funding Source: Medline; NIAMS NIH HHS [R01 AR44400] Funding Source: Medline; NINDS NIH HHS [R01 NS21990] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barritt DS, 2000, J CELL BIOCHEM, V79, P213, DOI 10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; Burg MA, 1996, J BIOL CHEM, V271, P26110, DOI 10.1074/jbc.271.42.26110; Burg MA, 1997, EXP CELL RES, V235, P254, DOI 10.1006/excr.1997.3674; Burg MA, 1998, J CELL PHYSIOL, V177, P299, DOI 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3.3.CO;2-0; Burg MA, 1999, CANCER RES, V59, P2869; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; ELLIS V, 1991, J BIOL CHEM, V266, P12752; Fang XX, 1999, MOL BIOL CELL, V10, P3373, DOI 10.1091/mbc.10.10.3373; Felez J, 1998, FIBRINOLYSIS PROTEOL, V12, P183, DOI 10.1016/S0268-9499(98)80012-X; Folkman J, 1996, SCI AM, V275, P150, DOI 10.1038/scientificamerican0996-150; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; Goretzki L, 1999, J BIOL CHEM, V274, P16831, DOI 10.1074/jbc.274.24.16831; Grako KA, 1999, J CELL SCI, V112, P905; GRAKO KA, 1995, EXP CELL RES, V221, P231, DOI 10.1006/excr.1995.1371; HIGHSMITH RF, 1981, J BIOL CHEM, V256, P6788; Hirschi K K, 1997, EXS, V79, P419; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Ji WDR, 1998, FASEB J, V12, P1731, DOI 10.1096/fasebj.12.15.1731; KOBAYASHI H, 1994, CANCER RES, V54, P844; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LERCH PG, 1980, EUR J BIOCHEM, V107, P7, DOI 10.1111/j.1432-1033.1980.tb04617.x; Lin XH, 1996, J CELL BIOCHEM, V63, P463, DOI 10.1002/(SICI)1097-4644(19961215)63:4<463::AID-JCB8>3.0.CO;2-R; Lin XH, 1996, MOL BIOL CELL, V7, P1977, DOI 10.1091/mbc.7.12.1977; Lindahl P, 1998, CURR OPIN NEPHROL HY, V7, P21, DOI 10.1097/00041552-199801000-00004; Lucas R, 1998, BLOOD, V92, P4730; MacDonald NJ, 1999, BIOCHEM BIOPH RES CO, V264, P469, DOI 10.1006/bbrc.1999.1486; Markus G, 1996, FIBRINOLYSIS, V10, P75, DOI 10.1016/S0268-9499(96)80082-8; MARTI D, 1994, EUR J BIOCHEM, V219, P455, DOI 10.1111/j.1432-1033.1994.tb19959.x; MEISSAUER A, 1992, EXP CELL RES, V199, P179, DOI 10.1016/0014-4827(92)90423-6; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Miles L. A., 1993, Biologia and Clinica Hematologica, V15, P107; MILLER B, 1995, J COMP NEUROL, V355, P615, DOI 10.1002/cne.903550410; MOSER TL, 1993, J BIOL CHEM, V268, P18917; NEHLS V, 1992, CELL TISSUE RES, V270, P469, DOI 10.1007/BF00645048; NEWCOMB PM, 1993, J CELL PHYSIOL, V155, P385, DOI 10.1002/jcp.1041550220; NISHIYAMA A, 1993, MOL BIOL CELL, V4, P1097, DOI 10.1091/mbc.4.11.1097; NISHIYAMA A, 1995, MOL BIOL CELL, V6, P1819, DOI 10.1091/mbc.6.12.1819; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; REJANTE MR, 1991, BIOCHEMISTRY-US, V30, P11081, DOI 10.1021/bi00110a010; Rifkin DB, 1997, FIBRINOLYSIS PROTEOL, V11, P3, DOI 10.1016/S0268-9499(97)80003-3; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P163; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALONEN EM, 1985, J BIOL CHEM, V260, P2302; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHLINGEMANN RO, 1990, AM J PATHOL, V136, P1393; Schlingemann RO, 1996, J PATHOL, V179, P436; SCHRAPPE M, 1991, CANCER RES, V51, P4986; SILVERSTEIN RL, 1985, J BIOL CHEM, V260, P346; SIMS DE, 1986, TISSUE CELL, V18, P153, DOI 10.1016/0040-8166(86)90026-1; SOTTRUPJENSEN L, 1978, ATLAS PROTEIN SEQ S3, V5, P91; STACK MS, 1992, BIOCHEM J, V284, P103, DOI 10.1042/bj2840103; STACK S, 1990, BIOCHEMISTRY-US, V29, P4966, DOI 10.1021/bi00472a029; STALLCUP WB, 1990, J CELL BIOL, V111, P3177, DOI 10.1083/jcb.111.6.3177; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; THEWES T, 1990, J BIOL CHEM, V265, P3906; THOMPSON RW, 1989, ANN NY ACAD SCI, V556, P255; Tillet E, 1997, J BIOL CHEM, V272, P10769; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; Walter JJ, 1999, ARTERIOSCL THROM VAS, V19, P2041, DOI 10.1161/01.ATV.19.9.2041; WESSELING P, 1995, J NEUROPATH EXP NEUR, V54, P304, DOI 10.1097/00005072-199505000-00003; WILHELM O, 1990, BLOOD, V75, P1673; WIMAN B, 1975, EUR J BIOCHEM, V50, P489, DOI 10.1111/j.1432-1033.1975.tb09887.x	74	54	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28625	28633		10.1074/jbc.M002290200	http://dx.doi.org/10.1074/jbc.M002290200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10889192	hybrid			2022-12-27	WOS:000089330700040
J	Berardini, M; Mazurek, A; Fishel, R				Berardini, M; Mazurek, A; Fishel, R			The effect of O-6-methylguanine DNA adducts on the adenosine nucleotide switch functions of hMSH2-hMSH6 and hMSH2-hMSH3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISMATCH REPAIR SYSTEM; DRUG-RESISTANCE; HMUTS-ALPHA; MAMMALIAN-CELLS; BASE PAIRS; MUTS-ALPHA; DAMAGE; RECOGNITION; CISPLATIN; CANCER	The human homologs of prokaryotic mismatch repair have been shown to mediate the toxicity of certain DNA damaging agents; cells deficient in the mismatch repair pathway exhibit resistance to the killing effects of several of these agents. Although previous studies have suggested that the human MutS homologs, hMSH2-hMSH6, bind to DNA containing a variety of DNA adducts, as well as mispaired nucleotides, a number of studies have suggested that DNA binding does not correlate with repair activity. In contrast, the ability to process adenosine nucleotides by MutS homologs appears to be fundamentally linked to repair activity. In this study oligonucleotides containing a single well defined O-6-methylguanine adduct were used to examine the extent of lesion-provoked DNA binding, single-step ADP --> ATP exchange, and steady-state ATPase activity by hMSH2-hMSH3 and hMSH2-hMSH6 heterodimers. Interestingly, O-6-methylguanine lesions when paired with either a C or T were found to stimulate ADP --> ATP exchange, as well as the ATPase activity of purified hMSH2-hMSH6, whereas there was no significant stimulation of hMSH2-hMSH3. These results suggest that O-6-methylguanine uniquely activates the molecular switch functions of hMSH2-hMSH6.	Thomas Jefferson Univ, Kimmel Canc Ctr, Genet & Mol Biol Program, Philadelphia, PA 19107 USA	Jefferson University	Fishel, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Genet & Mol Biol Program, 233 S 10th St, Philadelphia, PA 19107 USA.				NATIONAL CANCER INSTITUTE [R01CA067007] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA067007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Alani E, 1996, MOL CELL BIOL, V16, P5604; Blackwell LJ, 1998, J BIOL CHEM, V273, P32049, DOI 10.1074/jbc.273.48.32049; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Fink D, 1996, CANCER RES, V56, P4881; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; Gong JG, 1999, NATURE, V399, P806; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; HAWN MT, 1995, CANCER RES, V55, P3721; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Humbert O, 1999, CARCINOGENESIS, V20, P205, DOI 10.1093/carcin/20.2.205; JIRICNY J, 1988, NUCLEIC ACIDS RES, V16, P7843, DOI 10.1093/nar/16.16.7843; Jiricny J, 1996, CANCER SURV, V28, P47; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Lage H, 1999, J CANCER RES CLIN, V125, P156, DOI 10.1007/s004320050258; Meikrantz W, 1998, CARCINOGENESIS, V19, P369, DOI 10.1093/carcin/19.2.369; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moreland NJ, 1999, CANCER RES, V59, P2102; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; SINGER B, 1989, P NATL ACAD SCI USA, V86, P8271, DOI 10.1073/pnas.86.21.8271; Umar A, 1997, CANCER RES, V57, P3949; Vaisman A, 1998, CANCER RES, V58, P3579; Wilson T, 1999, J BIOL CHEM, V274, P21659, DOI 10.1074/jbc.274.31.21659; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; Zhang H, 1999, CANCER RES, V59, P3021	41	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27851	27857						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10878012				2022-12-27	WOS:000089197100046
J	Hazra, TK; Izumi, T; Venkataraman, R; Kow, YW; Dizdaroglu, M; Mitra, S				Hazra, TK; Izumi, T; Venkataraman, R; Kow, YW; Dizdaroglu, M; Mitra, S			Characterization of a novel 8-oxoguanine-DNA glycosylase activity in Escherichia coli and identification of the enzyme as endonuclease VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE; BASE EXCISION-REPAIR; SACCHAROMYCES-CEREVISIAE; FPG PROTEIN; DAMAGE; CLONING; SUBSTRATE; HOMOLOG; GUANINE; TRANSVERSIONS	8-Oxoguanine (G*), induced by reactive oxygen species, is mutagenic because it mispairs with A. The major G*-DNA glycosylase (OGG), namely, OGG1 in eukaryotes, or MutM in Escherichia coli, excises G* when paired in DNA with C, G, and T, but not A, presumably because removal of G* from a G*.A pair would be mutagenic. However, repair of G* will prevent mutation when it is incorporated in the nascent strand opposite A. This could be carried out by a second OGG, OGG2, identified in yeast and human cells. We have characterized a new OGG activity in E, coli and then identified it to be endonuclease VIII (Nei), discovered as a damaged py. rimidine-specific DNA glycosylase, Nei shares sequence homology and reaction mechanism with MutM and is similar to human OGG2 in being able to excise G* when paired with A (or G), Kinetic analysis of wild type Nei showed that it has significant activity for excising G* relative to dihydrouracil, The presence of OGG2 type enzyme in both E. coli and eukaryotes, which is at least as efficient in excising G* from a G*.A (or G) pair as from a G*.C pair, supports the possibility of G* repair in the nascent DNA strand.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Emory Univ, Dept Radiat Oncol, Atlanta, GA 30335 USA; NIST, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Emory University; National Institute of Standards & Technology (NIST) - USA	Mitra, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6 136 Med Res Bldg,Rt 1079, Galveston, TX 77555 USA.				NATIONAL CANCER INSTITUTE [R01CA081063, R01CA053791] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008457] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA53791, R01 CA81063] Funding Source: Medline; NIEHS NIH HHS [R01 ES08457] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Augeri L, 1997, BIOCHEMISTRY-US, V36, P721, DOI 10.1021/bi9625511; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; Bauche C, 1999, J BACTERIOL, V181, P262, DOI 10.1128/JB.181.1.262-269.1999; Blaisdell JO, 1999, J BACTERIOL, V181, P6396, DOI 10.1128/JB.181.20.6396-6402.1999; Bruner SD, 1998, CURR BIOL, V8, P393, DOI 10.1016/S0960-9822(98)70158-7; CULP SJ, 1989, CHEM RES TOXICOL, V2, P416, DOI 10.1021/tx00012a010; DEOLIVEIRA R, 1994, NUCLEIC ACIDS RES, V22, P3760, DOI 10.1093/nar/22.18.3760; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOETSCH PW, 1995, BIOCHEMISTRY-US, V34, P737, DOI 10.1021/bi00003a005; Eide L, 1996, P NATL ACAD SCI USA, V93, P10735, DOI 10.1073/pnas.93.20.10735; Grisham MB, 1986, PHYSL OXYGEN RADICAL, P01; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; HALLIWELL B, 1992, FREE RADICAL RES COM, V16, P75, DOI 10.3109/10715769209049161; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; Hazra IK, 1998, NUCLEIC ACIDS RES, V26, P5116, DOI 10.1093/nar/26.22.5116; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Izumi T, 1999, J MOL BIOL, V287, P47, DOI 10.1006/jmbi.1999.2573; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; Jiang DY, 1997, J BIOL CHEM, V272, P32230, DOI 10.1074/jbc.272.51.32230; Karakaya A, 1997, NUCLEIC ACIDS RES, V25, P474, DOI 10.1093/nar/25.3.474; KASAI H, 1991, OXIDATIVE STRESS OXI, P99; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Krokan HE, 1997, BIOCHEM J, V325, P1; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; Mitra S, 1997, MOL CELLS, V7, P305; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Purmal AA, 1998, J BIOL CHEM, V273, P10026, DOI 10.1074/jbc.273.16.10026; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Saito Y, 1997, J BACTERIOL, V179, P3783, DOI 10.1128/jb.179.11.3783-3785.1997; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; WARD JF, 1994, INT J RADIAT BIOL, V66, P427, DOI 10.1080/09553009414551401; Zhang QM, 1998, NUCLEIC ACIDS RES, V26, P4669, DOI 10.1093/nar/26.20.4669; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	39	85	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27762	27767						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862773				2022-12-27	WOS:000089197100034
J	Nakamura, N; Suzuki, Y; Ikeda, Y; Notoya, M; Hirose, S				Nakamura, N; Suzuki, Y; Ikeda, Y; Notoya, M; Hirose, S			Complex structure and regulation of expression of the rat gene for inward rectifier potassium channel Kir7.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRTL-5 THYROID-CELLS; K+ CHANNEL; GENOMIC ORGANIZATION; MESSENGER-RNAS; TRANSCRIPTION; PROMOTER; SUBUNIT; CLONING; NA+,K+-ATPASE; THYROTROPIN	Genomic organization of the rat inward rectifier K+ channel Kir7.1 was determined in an attempt to clarify how multiple species of its mRNA are generated in a tissue-specific manner and how its expression is regulated. The rat Kir7.1 gene spans >40 kilobases (kb) and consists of eight exons; the first four exons encode the 5'-untranslated region that is unusually Long (similar to 3 kb), The coding region is located in exons 5 and 6. In the testis, exon 4 is processed as four exons (4a-4d), whereas it is recognized as a single exon in the small intestine. The three major species of rat Kir7.1 mRNA (1.4, 2.2, and 3.2 kb) were found to arise from alternative usage of the two promoters and polyadenylation signals and by alternative splicing of the 5'-noncoding exons, The splicing pattern of the 5'-noncoding exons is quite complex and highly tissue-specific, suggesting that complex mechanisms may operate to regulate the Kir7.1 expression. Deletion and mutational analysis of the promoter activity indicated that the rat Kir7.1 gene is regulated by cAMP through a CCAAT element. The cAMP induction was also demonstrated using the rat follicular cell line FRTL-5 endogenously expressing Kir7.1.	Tokyo Inst Technol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Hirose, S (corresponding author), Tokyo Inst Technol, Dept Biol Sci, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.	shirose@bio.titech.ac.jp	Nakamura, Nobuhiro/C-4265-2015	Nakamura, Nobuhiro/0000-0002-0249-2665; SUZUKI, YOSHIRO/0000-0003-0010-1867				Bevilacqua MA, 1997, J BIOL CHEM, V272, P20736, DOI 10.1074/jbc.272.33.20736; Bock JH, 1997, GENE, V188, P9, DOI 10.1016/S0378-1119(96)00759-7; BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Derst C, 1998, GENOMICS, V54, P560, DOI 10.1006/geno.1998.5598; Doring F, 1998, J NEUROSCI, V18, P8625; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; Erginel-Unaltuna N, 1998, GENE, V211, P71, DOI 10.1016/S0378-1119(98)00086-9; Faniello MC, 1999, J BIOL CHEM, V274, P7623, DOI 10.1074/jbc.274.12.7623; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Karschin C, 1996, J NEUROSCI, V16, P3559; KATZ B, 1949, ARCH SCI PHYSIOL, V3, P285; Kawahara K, 1997, JPN J PHYSIOL, V47, P1, DOI 10.2170/jjphysiol.47.1; Krapivinsky G, 1998, NEURON, V20, P995, DOI 10.1016/S0896-6273(00)80480-8; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; Kurachi Y., 1999, POTASSIUM ION CHANNE, V1st; MARUYAMA K, 1994, GENE, V138, P171; Nakamura N, 1999, BIOCHEM J, V342, P329, DOI 10.1042/0264-6021:3420329; OOKATA K, 2000, IN PRESS J AM SOC NE; Partiseti M, 1998, FEBS LETT, V434, P171, DOI 10.1016/S0014-5793(98)00972-7; PITTMAN N, 1995, J BIOL CHEM, V270, P28848, DOI 10.1074/jbc.270.48.28848; PRESSLEY TA, 1995, AM J PHYSIOL-CELL PH, V268, pC1252, DOI 10.1152/ajpcell.1995.268.5.C1252; Redell JB, 1998, J BIOL CHEM, V273, P22807, DOI 10.1074/jbc.273.35.22807; Reimann F, 1999, CURR OPIN CELL BIOL, V11, P503, DOI 10.1016/S0955-0674(99)80073-8; SAJI M, 1992, ENDOCRINOLOGY, V130, P520, DOI 10.1210/en.130.1.520; Salkoff L, 1999, CURR TOP MEMBR, V46, P9; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; Schoots O, 1997, GENOMICS, V39, P279, DOI 10.1006/geno.1996.4495; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; Suzuki Y, 1999, J BIOL CHEM, V274, P11376, DOI 10.1074/jbc.274.16.11376; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; Wischmeyer E, 2000, FEBS LETT, V466, P115, DOI 10.1016/S0014-5793(99)01769-X	34	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28276	28284						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871613				2022-12-27	WOS:000089197100099
J	Lesley, J; Hascall, VC; Tammi, M; Hyman, R				Lesley, J; Hascall, VC; Tammi, M; Hyman, R			Hyaluronan binding by cell surface CD44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; CYTOPLASMIC DOMAIN; LINK PROTEIN; ACID BINDING; T-CELLS; ACTIVATION; RECEPTOR; GLYCOSYLATION	CD44 is the primary cell surface receptor for the extracellular matrix glycosaminoglycan hyaluronan, Here we determined the relative avidities of unlabeled hyaluronan preparations for cell surface CD44 by their ability to block the binding of fluorescein-conjugated hyaluronan to a variety of cells. We show that hyaluronan binding at the cell surface is a complex interplay of multivalent binding events affected by the size of the multivalent hyaluronan ligand, the quantity and density of cell surface CD44, and the activation state of CD44 as determined by cell-specific factors and/or treatment with CD44-specific monoclonal antibody (mAb), Using low M-r hyaluronan oligomers of defined sizes, we observed monovalent binding between 6 and 18 sugars. At similar to 20 to similar to 38 sugars, there was an increase in avidity (similar to 3x), suggesting that divalent binding was occurring. In the presence of the inducing mAb IRAWS14, monovalent binding avidity was similar to that of noninduced CD44, but beginning at similar to 20 residues, there was a dramatic and progressive increase in avidity with increasing oligomer size (similar to 22 < 26 < 30 < 34 < 38 sugars). Kinetic studies of binding and dissociation of fluorescein in-conjugated hyaluronan indicated that inducing mAb treatment had little effect on the binding kinetics, but dissociation from the cell surface was greatly delayed by inducing mAb.	Salk Inst, Canc Biol Lab, San Diego, CA 92186 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA; Univ Kuopio, Dept Anat, FIN-70211 Kuopio, Finland	Salk Institute; Cleveland Clinic Foundation; University of Eastern Finland	Lesley, J (corresponding author), Salk Inst, Canc Biol Lab, POB 85800, San Diego, CA 92186 USA.	lesley@salk.edu			NCI NIH HHS [CA-14195] Funding Source: Medline; NIAID NIH HHS [AI-31613] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031613] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMARA J, 1999, P NATL ACAD SCI USA, V94, P10618; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Calabro A, 2000, GLYCOBIOLOGY, V10, P273, DOI 10.1093/glycob/10.3.273; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; DeGrendele HC, 1997, J IMMUNOL, V159, P2549; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; English NM, 1998, CANCER RES, V58, P3736; GROVER J, 1994, BIOCHEM J, V300, P317, DOI 10.1042/bj3000317; HE Q, 1992, J CELL BIOL, V119, P1711, DOI 10.1083/jcb.119.6.1711; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; Kim JH, 2000, EXP CELL RES, V256, P445, DOI 10.1006/excr.2000.4852; KNUDSON W, 1993, P NATL ACAD SCI USA, V90, P4003, DOI 10.1073/pnas.90.9.4003; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LESLEY J, 1993, EUR J IMMUNOL, V23, P1902, DOI 10.1002/eji.1830230826; LESLEY J, 1994, J EXP MED, V180, P383, DOI 10.1084/jem.180.1.383; Lesley J, 1997, GLYCOCONJUGATE J, V14, P611, DOI 10.1023/A:1018540610858; LESLEY J, 1992, EUR J IMMUNOL, V22, P2719, DOI 10.1002/eji.1830221036; Lesley J, 2000, EUR J IMMUNOL, V30, P245, DOI 10.1002/1521-4141(200001)30:1<245::AID-IMMU245>3.3.CO;2-O; LESLEY J, 1995, J EXP MED, V182, P431, DOI 10.1084/jem.182.2.431; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LESLEY J, 1998, FRONT BIOSCI, V3, P616; LIAO HX, 1995, J IMMUNOL, V155, P3938; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; Oertli B, 1998, J IMMUNOL, V161, P3431; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PERSCHL A, 1995, EUR J IMMUNOL, V25, P495, DOI 10.1002/eji.1830250228; Skelton TP, 1998, J CELL BIOL, V140, P431, DOI 10.1083/jcb.140.2.431; Tammi R, 1998, J BIOL CHEM, V273, P28878, DOI 10.1074/jbc.273.44.28878; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; VARELAS JB, 1995, ARCH BIOCHEM BIOPHYS, V321, P21, DOI 10.1006/abbi.1995.1363; Zheng Z, 1997, J CLIN INVEST, V100, P1217, DOI 10.1172/JCI119635; ZHENG Z, 1995, J CELL BIOL, V130, P485, DOI 10.1083/jcb.130.2.485; Zhou J, 1999, IN VITRO CELL DEV-AN, V35, P228	36	364	374	3	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26967	26975						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10871609				2022-12-27	WOS:000089144800041
J	Haniu, M; Denis, P; Young, Y; Mendiaz, EA; Fuller, J; Hui, JO; Bennett, BD; Kahn, S; Ross, S; Burgess, T; Katta, V; Rogers, G; Vassar, R; Citron, M				Haniu, M; Denis, P; Young, Y; Mendiaz, EA; Fuller, J; Hui, JO; Bennett, BD; Kahn, S; Ross, S; Burgess, T; Katta, V; Rogers, G; Vassar, R; Citron, M			Characterization of Alzheimer's beta-secretase protein BACE - A pepsin family member with unusual properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; DISEASE; PURIFICATION; PEPTIDE	The cerebral deposition of amyloid beta-peptide is an early and critical feature of Alzheimer's disease. Amyloid beta-peptide is released from the amyloid precursor protein by the sequential action of two proteases, beta-secretase and gamma-secretase, and these proteases are prime targets for therapeutic intervention. We have recently cloned a novel aspartic protease, BACE, with all the known properties of beta-secretase. Here we demonstrate that BACE is an N-glycosylated integral membrane protein that undergoes constitutive N-terminal processing in the Golgi apparatus. We have used a secreted Fc fusion-form of BACE (BACE-IgG) that contains the entire ectodomain for a detailed analysis of posttranslational modifications, This molecule starts at Glu(46) and contains four N-glycosylation sites (Asn(153) Asn(172), Asn(223), and Asn(354)). The six Cys residues in the ectodomain form three intramolecular disulfide linkages (Cys(216)-Cys(420), Cys(278)-Cys(443), and Cys(330)-Cys(380)). Despite the conservation of the active site residues and the 30-37% amino acid homology with known aspartic proteases, the disulfide motif is fundamentally different from that of other aspartic proteases, This difference may affect the substrate specificity of the enzyme. Taken together, both the presence of a transmembrane domain and the unusual disulfide bond structure lead us to conclude that BACE is an atypical pepsin family member.	Amgen Inc, Thousand Oaks, CA 91320 USA	Amgen	Haniu, M (corresponding author), Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.							Alzheimer A., 1907, Z GESAMTE NEUROL PSY, V18, P177; Anumula KR, 1998, GLYCOBIOLOGY, V8, P685, DOI 10.1093/glycob/8.7.685; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kervinen J, 1999, EMBO J, V18, P3947, DOI 10.1093/emboj/18.14.3947; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1	14	201	219	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21099	21106		10.1074/jbc.M002095200	http://dx.doi.org/10.1074/jbc.M002095200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10887202	hybrid			2022-12-27	WOS:000088230600021
J	Tiku, ML; Shah, R; Allison, GT				Tiku, ML; Shah, R; Allison, GT			Evidence linking chondrocyte lipid peroxidation to cartilage matrix protein degradation - Possible role in cartilage aging and the pathogenesis of osteoarthritis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID COMPOSITION; ARTICULAR CHONDROCYTES; HYALURONIC-ACID; DEPENDENT CHEMILUMINESCENCE; HYDROGEN-PEROXIDE; RADICAL FORMATION; OXIDATIVE DAMAGE; OXYGEN RADICALS; II COLLAGEN; ARTHRITIS	Reactive oxygen species (ROS) are implicated in both cartilage aging and the pathogenesis of osteoarthritis. We developed an in vitro model to study the role of chondrocyte-derived ROS in cartilage matrix protein degradation. Matrix proteins in cultured primary articular chondrocytes were labeled with [H-3]proline, and the washed cell matrix was returned to a serum-free balanced salt solution. Exposure to hydrogen peroxide resulted in oxidative damage to the cell matrix as established by monitoring the release of labeled material into the medium. Calcium ionophore treatment of chondrocytes, in a dose-dependent manner, significantly enhanced the release of labeled matrix, suggesting a chondrocyte-dependent mechanism of matrix degradation. Antioxidant enzymes such as catalase or superoxide dismutase did not influence matrix release by the calcium ionophore-activated chondrocytes. However, vitamin E, at physiological concentrations, significantly diminished the release of labeled matrix by activated chondrocytes. The fact that vitamin E is a chain-breaking antioxidant indicates that the mechanism of matrix degradation and release is mediated by the lipid peroxidation process. Lipid peroxidation was measured in chondrocytes loaded with cis-parinaric acid. Both resting and activated cells showed constitutive and enhanced levels of lipid peroxidation activity, which were significantly reduced in the presence of vitamin E. In an immunoblot analysis, malondialdehyde and hydroxynonenal adducts were observed in chondrocyte-matrix extracts, and the amount of adducts increased with calcium ionophore treatment, Furthermore, vitamin E diminished aldehyde-protein adduct formation in activated extracts, which suggests that vitamin E has an antioxidant role in preventing protein oxidation, This study provides in vitro evidence linking chondrocyte lipid peroxidation to cartilage matrix protein (collagen) oxidation and degradation and suggests that vitamin E has a preventive role. These observations indicate that chondrocyte lipid peroxidation may have a role in the pathogenesis of cartilage aging and osteoarthritis.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Tiku, ML (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, 1 Robert Wood Johnson Pl,MEB-484,POB 19, New Brunswick, NJ 08903 USA.		Allison, Greg/D-3836-2013	Allison, Greg/0000-0002-4294-0442				ADKISSON HD, 1991, FASEB J, V5, P344, DOI 10.1096/fasebj.5.3.2001795; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Aruoma OI, 1996, FREE RADICAL BIO MED, V20, P675, DOI 10.1016/0891-5849(95)02110-8; BATES EJ, 1984, BIOCHEM INT, V8, P629; BIENKOWSKI RS, 1978, J BIOL CHEM, V253, P4356; BONNER WM, 1975, ARTHRITIS RHEUM, V18, P461, DOI 10.1002/art.1780180505; Clancy RM, 1998, ARTHRITIS RHEUM-US, V41, P1141, DOI 10.1002/1529-0131(199807)41:7<1141::AID-ART2>3.0.CO;2-S; DANIEL JC, 1984, J CELL BIOL, V99, P1960, DOI 10.1083/jcb.99.6.1960; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; Girotti AW, 1998, J LIPID RES, V39, P1529; GREENWALD RA, 1979, ARTHRITIS RHEUM, V22, P251, DOI 10.1002/art.1780220307; GREENWALD RA, 1991, SEMIN ARTHRITIS RHEU, V20, P219, DOI 10.1016/0049-0172(91)90018-U; GREENWALD RA, 1980, ARTHRITIS RHEUM-US, V23, P455, DOI 10.1002/art.1780230408; GUTTERIDGE JMC, 1995, CLIN CHEM, V41, P1819; HAMERMAN D, 1989, NEW ENGL J MED, V320, P1322; HEDLEY D, 1992, CYTOMETRY, V13, P686, DOI 10.1002/cyto.990130704; Hiran TS, 1997, FREE RADICAL BIO MED, V23, P736, DOI 10.1016/S0891-5849(97)00054-3; Hollander AP, 1995, J CLIN INVEST, V96, P2859, DOI 10.1172/JCI118357; HORTON WA, 1992, P NATL ACAD SCI USA, V89, P4583, DOI 10.1073/pnas.89.10.4583; Iswasaki Y, 1988, ORTHOPAEDIC T, V12, P438; KEMPSON GE, 1973, BIOCHIM BIOPHYS ACTA, V297, P465; KLEBANOFF SJ, 1992, INFLAMMATION BASIC P, P541; Koyano Y, 1997, BIOTECHNIQUES, V22, P706; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPIELLO L, 1990, P SOC EXP BIOL MED, V195, P282, DOI 10.3181/00379727-195-43149; LIPPIELLO L, 1991, METABOLISM, V40, P571, DOI 10.1016/0026-0495(91)90046-Y; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LUKOSCHEK M, 1988, J ORTHOP RES, V6, P475, DOI 10.1002/jor.1100060403; MCLINDON TE, 1996, ARTHRITIS RHEUM, V39, P648; Monboisse JC, 1984, J TISSUE RES, V5, P385; MUKHOPADHYAY CK, 1994, J BIOL CHEM, V269, P30200; NORTH JA, 1994, AM J PHYSIOL, V267, pC177, DOI 10.1152/ajpcell.1994.267.1.C177; Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853; Poli G, 1997, FREE RADICAL BIO MED, V22, P287, DOI 10.1016/S0891-5849(96)00327-9; RATHAKRISHNAN C, 1992, J BONE MINER RES, V7, P1139; RATHAKRISHNAN C, 1993, FREE RADICAL BIO MED, V15, P143, DOI 10.1016/0891-5849(93)90053-W; ROBERTS CR, 1989, BIOCHEM J, V259, P805, DOI 10.1042/bj2590805; SAURA R, 1993, J RHEUMATOL, V20, P336; SILBERBERG M, 1950, AMA ARCH PATHOL, V50, P828; SILBERBERG M, 1965, GERONTOLOGY, V11, P179, DOI 10.1159/000211491; STANESCU R, 1981, ARTHRITIS RHEUM, V24, P965, DOI 10.1002/art.1780240718; STANESCU V, 1984, J BONE JOINT SURG AM, V66A, P817, DOI 10.2106/00004623-198466060-00002; STOCKWELL RA, 1983, J ANAT, V136, P425; TIKU K, 1992, CELL IMMUNOL, V140, P1, DOI 10.1016/0008-8749(92)90172-L; Tiku ML, 1999, FREE RADICAL RES, V30, P395, DOI 10.1080/10715769900300431; Tiku ML, 1998, FREE RADICAL RES, V29, P177, DOI 10.1080/10715769800300211; UCHIYAMA H, 1990, J BIOL CHEM, V265, P7753; VANACKER SABE, 1993, FREE RADICAL BIO MED, V15, P311, DOI 10.1016/0891-5849(93)90078-9; Watkins BA, 1996, P SOC EXP BIOL MED, V212, P153, DOI 10.3181/00379727-212-44003; XU H, 1994, LIPIDS, V29, P619, DOI 10.1007/BF02536096	52	199	214	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20069	20076		10.1074/jbc.M907604199	http://dx.doi.org/10.1074/jbc.M907604199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867027	hybrid			2022-12-27	WOS:000087941300086
J	Apel, ED; Lewis, RM; Grady, RM; Sanes, JR				Apel, ED; Lewis, RM; Grady, RM; Sanes, JR			Syne-1, a dystrophin- and klarsicht-related protein associated with synaptic nuclei at the neuromuscular junction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE MUSK; DREIFUSS MUSCULAR-DYSTROPHY; ACETYLCHOLINE-RECEPTOR; SKELETAL-MUSCLE; MOLECULAR-CLONING; DROSOPHILA EYE; AGRIN; EXPRESSION; FIBERS; GENE	We describe a novel protein, Syne-1, that is associated with nuclear envelopes in skeletal, cardiac, and smooth muscle cells. Syne-1 contains multiple spectrin repeats similar to those found in dystrophin and utrophin, as well as a domain homologous to the carboxyl-terminal of Klarsicht, a protein associated with nuclei and required for a subset of nuclear migrations in Drosophila. In adult skeletal muscle fibers, levels of Syne-1 are highest in the nuclei that lie beneath the postsynaptic membrane at: the neuromuscular junction. These nuclei are transcriptionally specialized, expressing genes for synaptic components at higher levels than extrasynaptic nuclei in the same cytoplasm. Syne-1 is the first protein found to be selectively associated with synaptic nuclei. Syne-1 becomes concentrated in synaptic nuclei postnatally. It remains synaptically enriched following denervation or degeneration/regeneration, and is also present at high levels in the central nuclei of dystrophic myotubes. The location and structure of Syne-1 suggest that it may participate in the migration of myonuclei in myotubes and/or their anchoring at the postsynaptic apparatus. Finally, we identify a homologous gene, syne-2, that is expressed in an overlapping but distinct pattern.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Sanes, JR (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	sanesj@pcg.wustl.edu						Apel ED, 1997, NEURON, V18, P623, DOI 10.1016/S0896-6273(00)80303-7; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Brosamle C, 1996, J EXP BIOL, V199, P2359; BRUNER JM, 1986, DEV BIOL, V115, P35, DOI 10.1016/0012-1606(86)90225-3; BURDEN SJ, 1993, TRENDS GENET, V9, P12, DOI 10.1016/0168-9525(93)90066-Q; Burgess RW, 1999, NEURON, V23, P33, DOI 10.1016/S0896-6273(00)80751-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; COUTEAUX R, 1981, J NEUROCYTOL, V10, P947, DOI 10.1007/BF01258523; COUTEAUX R, 1973, STRUCTURE FUNCTION M, V2, P483; Davis DB, 2000, HUM MOL GENET, V9, P217, DOI 10.1093/hmg/9.2.217; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; ENGLANDER LL, 1987, J CELL BIOL, V104, P87, DOI 10.1083/jcb.104.1.87; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; FISCHERVIZE JA, 1994, DEVELOPMENT, V120, P2609; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Gillespie SKH, 1996, NEURON, V16, P953, DOI 10.1016/S0896-6273(00)80118-X; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Glass DJ, 1997, P NATL ACAD SCI USA, V94, P8848, DOI 10.1073/pnas.94.16.8848; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; Grady RM, 1999, NAT CELL BIOL, V1, P215, DOI 10.1038/12034; JASMIN BJ, 1990, NATURE, V344, P673, DOI 10.1038/344673a0; Leung CL, 1999, J CELL BIOL, V147, P1275, DOI 10.1083/jcb.147.6.1275; Lumeng C, 1999, NAT NEUROSCI, V2, P611, DOI 10.1038/10165; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; Missias AC, 1996, DEV BIOL, V179, P223, DOI 10.1006/dbio.1996.0253; Morris NR, 2000, J CELL BIOL, V148, P1097, DOI 10.1083/jcb.148.6.1097; MOSCOSO LM, 1995, MOL CELL NEUROSCI, V6, P80, DOI 10.1006/mcne.1995.1008; Mosley-Bishop KL, 1999, CURR BIOL, V9, P1211, DOI 10.1016/S0960-9822(99)80501-6; MOSS BL, 1987, J NEUROBIOL, V18, P101, DOI 10.1002/neu.480180108; Nagano A, 1996, NAT GENET, V12, P254, DOI 10.1038/ng0396-254; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Okuda T, 1999, BIOCHEM BIOPH RES CO, V264, P568, DOI 10.1006/bbrc.1999.1538; Ozawa E, 1998, MUSCLE NERVE, V21, P421, DOI 10.1002/(SICI)1097-4598(199804)21:4<421::AID-MUS1>3.3.CO;2-W; Pascual J, 1997, BIOESSAYS, V19, P811, DOI 10.1002/bies.950190911; PHILLIPS WD, 1991, J CELL BIOL, V115, P1713, DOI 10.1083/jcb.115.6.1713; PIETTE J, 1993, DEV BIOL, V157, P205, DOI 10.1006/dbio.1993.1124; SadouletPuccio HM, 1996, BRAIN PATHOL, V6, P25, DOI 10.1111/j.1750-3639.1996.tb00780.x; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Selkoe DJ, 2000, CURR OPIN NEUROBIOL, V10, P50, DOI 10.1016/S0959-4388(99)00054-9; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Sun YP, 1999, J BIOL CHEM, V274, P33522, DOI 10.1074/jbc.274.47.33522; Swirnoff AH, 1998, MOL CELL BIOL, V18, P512, DOI 10.1128/MCB.18.1.512; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; Welte MA, 1998, CELL, V92, P547, DOI 10.1016/S0092-8674(00)80947-2; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; ZACK S, 1973, MOTOR ENDPLATE; Zhou H, 1999, J CELL BIOL, V146, P1133, DOI 10.1083/jcb.146.5.1133	54	213	224	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31986	31995		10.1074/jbc.M004775200	http://dx.doi.org/10.1074/jbc.M004775200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10878022	hybrid			2022-12-27	WOS:000089858900061
J	Zhu, WG; Williams, RS; Kodadek, T				Zhu, WG; Williams, RS; Kodadek, T			A CDC6 protein-binding peptide selected using a bacterial two-hybrid-like system is a cell cycle inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC SELECTION; DNA-REPLICATION; IN-VIVO; REPRESSOR FUSIONS; EUKARYOTIC CELLS; SMALL MOLECULES; APTAMERS; LIBRARY; ASSAYS; SCREEN	Peptides or small molecules able to modulate protein-protein interactions hold promise as tools with which to probe and manipulate biological pathways. An important issue in this nascent field is to evaluate different methods with which to search libraries for molecules that modulate the function of specific target proteins. One strategy is to screen libraries for molecules that bind specifically to a protein known to be critical in the pathway of interest, with the expectation that the molecules isolated will recognize regions of the target protein important for its function and thereby exhibit biological activity. Here, a peptide library was screened using a two-hybrid-like system for molecules able to bind human CDC6 protein (CDC6p), required for the initiation of DNA replication in eukaryotic cells. From a collection of over a million peptides, a single species that exhibited good affinity and specificity for binding CDC6p was obtained. When expressed in human cells, the peptide inhibited cell cycle progression and exhibited other properties expected of a CDC6p inhibitor. This approach, which does not require detailed knowledge of the mechanism of action of a protein target, may be generally useful for isolating peptides capable of manipulating biological pathways.	Univ Texas, SW Med Ctr, Dept Internal Med, Ryburn Ctr Mol Cardiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Ctr Biomed Invent, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Williams, RS (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Ryburn Ctr Mol Cardiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Kodadek, Thomas/0000-0003-1930-4795	NHLBI NIH HHS [HL06296] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUNKER CA, 1995, NUCLEIC ACIDS RES, V23, P269, DOI 10.1093/nar/23.2.269; Cairns MT, 1997, GENE, V185, P5, DOI 10.1016/S0378-1119(96)00601-4; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; Dong DL, 1999, CHEM BIOL, V6, P133, DOI 10.1016/S1074-5521(99)89005-X; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FREIFELDER D, 1982, PHYSICAL BIOCH APPLI, P654; Geyer CR, 1999, P NATL ACAD SCI USA, V96, P8567, DOI 10.1073/pnas.96.15.8567; Gius DR, 1999, CANCER RES, V59, P2577; HU JC, 1995, STRUCTURE, V3, P431, DOI 10.1016/S0969-2126(01)00176-9; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Hu JC, 2000, METHODS, V20, P80, DOI 10.1006/meth.1999.0908; Hyde-DeRuyscher R, 2000, CHEM BIOL, V7, P17, DOI 10.1016/S1074-5521(00)00062-4; Jappelli R, 1996, J MOL BIOL, V259, P575, DOI 10.1006/jmbi.1996.0340; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; Lee D, 1999, J AM CHEM SOC, V121, P10648, DOI 10.1021/ja992658m; Lindsley CW, 2000, J AM CHEM SOC, V122, P422, DOI 10.1021/ja993674m; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; NEEDELS MC, 1993, P NATL ACAD SCI USA, V90, P10700, DOI 10.1073/pnas.90.22.10700; Norman TC, 1999, SCIENCE, V285, P591, DOI 10.1126/science.285.5427.591; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Scott CP, 1999, P NATL ACAD SCI USA, V96, P13638, DOI 10.1073/pnas.96.24.13638; Singh D, 1998, BIOCHEMISTRY-US, V37, P5798, DOI 10.1021/bi972762l; Stockwell BR, 1999, CHEM BIOL, V6, P71, DOI 10.1016/S1074-5521(99)80004-0; Tan DS, 1999, J AM CHEM SOC, V121, P9073, DOI 10.1021/ja992144n; Tan DS, 1998, J AM CHEM SOC, V120, P8565, DOI 10.1021/ja981746o; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; VAN DG, 1991, SCIENCE, V252, P839; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; YANG MJ, 1995, NUCLEIC ACIDS RES, V23, P1152, DOI 10.1093/nar/23.7.1152; Zhang LS, 1998, P NATL ACAD SCI USA, V95, P9184, DOI 10.1073/pnas.95.16.9184; Zhang ZW, 2000, NAT BIOTECHNOL, V18, P71, DOI 10.1038/71951; Zhang ZW, 1999, CURR BIOL, V9, P417, DOI 10.1016/S0960-9822(99)80188-2	39	14	15	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32098	32105		10.1074/jbc.M001560200	http://dx.doi.org/10.1074/jbc.M001560200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10896933	hybrid			2022-12-27	WOS:000089858900075
J	Baker, RO; Murata, LB; Dodson, MS; Hall, JD				Baker, RO; Murata, LB; Dodson, MS; Hall, JD			Purification and characterization of OF-1, a host factor implicated in herpes simplex replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN-BINDING-PROTEIN; SINGLE-STRANDED-DNA; CORE SEQUENCE; VIRAL ORIGIN; I ORIGIN; VIRUS-1; ORIS; INITIATION; COMPLEX	A human cellular factor (OF-1) has been previously implicated in replication of herpes simplex virus, type 1. This protein binds to three conserved regions (Boxes I, II, and III) in the viral replication origin and appears to be required for viral DNA synthesis (Dabrowski, C. C., Carmillo, P. J., and Schaffer, P. A. (1994) Mol. Cell. Biol. 14, 2545-2555). In the present study, we have partially purified and characterized OF-1 from human cells. This protein appears to consist of a tetramer composed of two heterodimers with subunits of 73 and 90 kDa. The smaller subunit contains the DNA binding activity. We have investigated the binding specificity of OF-1 using a mobility shift analysis. These studies reveal that binding is specific for both duplex and single-stranded Box I sequences and that the strongest preference is for the bottom strand of Box I. We present evidence suggesting that the binding of OF-1 to Box I DNA is enhanced in the presence of the herpes simplex-encoded UL9 protein, which also binds to Box I in oriS and is required for viral replication. Implications of these findings for the initiation step in viral replication are discussed.	Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA	University of Arizona; University of Arizona	Hall, JD (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA.	jdhall@u.arizona.edu						Aslani A, 2000, J BIOL CHEM, V275, P5880, DOI 10.1074/jbc.275.8.5880; AVRAHAMI D, 1995, P NATL ACAD SCI USA, V92, P10511, DOI 10.1073/pnas.92.23.10511; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; DABROWSKI CE, 1994, MOL CELL BIOL, V14, P2545, DOI 10.1128/MCB.14.4.2545; DABROWSKI CE, 1991, J VIROL, V65, P3140, DOI 10.1128/JVI.65.6.3140-3150.1991; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; DODSON MS, 1993, J BIOL CHEM, V268, P1213; ELIAS P, 1990, J BIOL CHEM, V265, P17167; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; Francon P, 1999, FEBS LETT, V452, P87, DOI 10.1016/S0014-5793(99)00585-2; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; Ikeda M, 1996, EUR J BIOCHEM, V238, P38, DOI 10.1111/j.1432-1033.1996.0038q.x; Lee SSK, 1997, P NATL ACAD SCI USA, V94, P2838, DOI 10.1073/pnas.94.7.2838; Lehman IR, 1999, J BIOL CHEM, V274, P28059, DOI 10.1074/jbc.274.40.28059; Makhov AM, 1996, EMBO J, V15, P1742, DOI 10.1002/j.1460-2075.1996.tb00520.x; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Murata LB, 1999, J BIOL CHEM, V274, P37079, DOI 10.1074/jbc.274.52.37079; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; TAKAI T, 1994, NUCLEIC ACIDS RES, V22, P5576, DOI 10.1093/nar/22.25.5576; Toone WM, 1997, ANNU REV MICROBIOL, V51, P125, DOI 10.1146/annurev.micro.51.1.125; TRAUT W, 1988, MOL CELL BIOL, V8, P903, DOI 10.1128/MCB.8.2.903; VOET D, 1995, BIOCHEMISTRY-US, P218; WEIR HM, 1989, NUCLEIC ACIDS RES, V17, P1409, DOI 10.1093/nar/17.4.1409	27	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30050	30057		10.1074/jbc.M002154200	http://dx.doi.org/10.1074/jbc.M002154200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10878004	hybrid			2022-12-27	WOS:000089577900019
J	Gruber, G; Svergun, DI; Godovac-Zimmermann, J; Harvey, WR; Wieczorek, H; Koch, MHJ				Gruber, G; Svergun, DI; Godovac-Zimmermann, J; Harvey, WR; Wieczorek, H; Koch, MHJ			Evidence for major structural changes in the Manduca sexta midgut V(1) ATPase due to redox modulation - A small angle X-ray scattering study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO HORNWORM MIDGUT; VACUOLAR H+-ATPASE; TRANSPORTING PLASMA-MEMBRANES; DISULFIDE BOND FORMATION; VESICLE V-ATPASE; ELECTRON-MICROSCOPY; SYNCHROTRON RADIATION; MASS-SPECTROMETRY; PROTON PUMP; SUBUNIT-A	The shape and overall dimensions of the oxidized and reduced form of the V(1) ATPase from Manduca sexta were investigated by synchrotron radiation x-ray solution scattering. The radius of gyration of the oxidized and reduced complex differ noticeably, with dimensions of 6.20 +/- 0.06 and 5.84 +/- 0.06 nm, respectively, whereas the maximum dimensions remain constant at 22.0 +/- 0.1 nm. Comparison of the low resolution shapes of both forms, determined ab initio, indicates that the main structural alteration occurs in the head piece, where the major subunits A and B are located, and at the bottom of the stalk. In conjunction with the solution scattering data, decreased susceptibility to tryptic digestion and tryptophan fluorescence of the reduced V(1) molecule pro vide the first strong evidence for major structural changes in the V(1) ATPase because of redox modulation.	Univ Osnabruck, Fachbereich Biol Chem, D-49069 Osnabruck, Germany; Univ Florida, Whitney Lab, St Augustine, FL 32086 USA; DESY, European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia; UCL, Ctr Mol Med, London WC1E 6JJ, England	University Osnabruck; State University System of Florida; University of Florida; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; University of London; University College London	Gruber, G (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, D-49069 Osnabruck, Germany.	grueber@biologie.uni-osnabrueck.de	Zimmermann, Jasminka Godovac/E-6863-2010	Svergun, Dmitri/0000-0003-0830-5696	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022444] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 22444] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; Bakhtiari N, 1999, J BIOL CHEM, V274, P16363, DOI 10.1074/jbc.274.23.16363; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Boekema EJ, 1998, PHOTOSYNTH RES, V57, P267, DOI 10.1023/A:1006044931980; Bottcher B, 2000, J MOL BIOL, V296, P449, DOI 10.1006/jmbi.1999.3435; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; BOWMAN BJ, 1997, MYCOTA, V3, P57; Dietz KJ, 1998, BBA-BIOMEMBRANES, V1373, P87, DOI 10.1016/S0005-2736(98)00094-7; DSCHIDA WJA, 1995, J BIOL CHEM, V270, P1557, DOI 10.1074/jbc.270.4.1557; DUNKER AK, 1976, BIOCHEM J, V153, P191, DOI 10.1042/bj1530191; FENG Y, 1992, J BIOL CHEM, V267, P19769; FENG Y, 1994, J BIOL CHEM, V269, P13224; Forgac M, 1999, J BIOL CHEM, V274, P1301, DOI 10.1074/jbc.274.3.1301; Forgac M, 2000, J EXP BIOL, V203, P71; GABRIEL A, 1982, NUCL INSTRUM METHODS, V201, P223, DOI 10.1016/0167-5087(82)90031-X; GRAF R, 1994, J BIOL CHEM, V269, P3767; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; GRAF R, 1992, FEBS LETT, V300, P119, DOI 10.1016/0014-5793(92)80177-I; Gruber G, 2000, BIOCHEMISTRY-US, V39, P8609, DOI 10.1021/bi000103u; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Kane PM, 2000, FEBS LETT, V469, P137, DOI 10.1016/S0014-5793(00)01265-5; KANE PM, 1995, J BIOL CHEM, V270, P17025; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Kozin MB, 1997, J APPL CRYSTALLOGR, V30, P811, DOI 10.1107/S0021889897001830; Kuprin S, 1995, BIOCHEM BIOPH RES CO, V217, P1151, DOI 10.1006/bbrc.1995.2889; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; MASHIMO S, 1991, J CHEM PHYS, V95, P6257, DOI 10.1063/1.461546; Merzendorfer H, 1997, J EXP BIOL, V200, P225; Merzendorfer H, 2000, BBA-BIOMEMBRANES, V1467, P369, DOI 10.1016/S0005-2736(00)00233-9; MOORE PB, 1980, J APPL CRYSTALLOGR, V13, P168, DOI 10.1107/S002188988001179X; NOVAK FJS, 1992, BIOCHIM BIOPHYS ACTA, V1132, P67, DOI 10.1016/0167-4781(92)90053-3; Oluwatosin YE, 1997, J BIOL CHEM, V272, P28149, DOI 10.1074/jbc.272.44.28149; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; Radermacher M, 1999, FEBS LETT, V453, P383, DOI 10.1016/S0014-5793(99)00739-5; Roos M, 1998, J BIOL CHEM, V273, P924, DOI 10.1074/jbc.273.2.924; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; Shannon C. E., 1949, MATH THEORY COMMUNIC; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Svergun DI, 2000, J BIOL CHEM, V275, P4210, DOI 10.1074/jbc.275.6.4210; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; SVERGUN DI, 1993, J APPL CRYSTALLOGR, V26, P258, DOI 10.1107/S0021889892011828; Svergun DI, 1998, BIOCHEMISTRY-US, V37, P17659, DOI 10.1021/bi982367a; SVOBODA M, 1995, J MASS SPECTROM, V30, P1562, DOI 10.1002/jms.1190301107; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Vasilyeva E, 1998, J BIOL CHEM, V273, P23823, DOI 10.1074/jbc.273.37.23823; WIECZOREK H, 1989, J BIOL CHEM, V264, P11143; Wieczorek H, 1999, J BIOENERG BIOMEMBR, V31, P67, DOI 10.1023/A:1005448614450; Wieczorek H, 2000, J EXP BIOL, V203, P127; WIECZOREK H, 1990, METHOD ENZYMOL, V192, P608; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; ZHANG JM, 1995, J BIOL CHEM, V270, P15494, DOI 10.1074/jbc.270.26.15494	60	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30082	30087		10.1074/jbc.M002976200	http://dx.doi.org/10.1074/jbc.M002976200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893230	hybrid			2022-12-27	WOS:000089577900024
J	Paulson, AF; Mooney, E; Fang, X; Ji, H; McCrea, PD				Paulson, AF; Mooney, E; Fang, X; Ji, H; McCrea, PD			Xarvcf, Xenopus member of the p120 catenin subfamily associating with cadherin juxtamembrane region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROXIMAL REGION; ARMADILLO FAMILY MEMBER; SEGMENT POLARITY GENE; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; DESMOSOMAL PLAQUE; CELL-ADHESION; BETA-CATENIN; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS	The catenin ARVCF is a member of the p120(ctn) subfamily of Armadillo proteins. A number of catenins directly bind cadherin cytoplasmic tails, contributing to the modulation of cell-cell adhesion and motility processes. Some catenins, such as beta-catenin (and likely p120(ctn)), have additional roles within signaling pathways regulating gene transcription. We have isolated the Xenopus homolog of human ARVCF. Utilizing the cadherin membrane proximal region known to bind p120(ctn) and delta-catenin, coimmunoprecipitation experiments demonstrate that Xarvcf, likewise, binds cadherin in this region and that corresponding point mutations within conserved residues abrogate the Xarvcf cadherin association. Western blot analysis of Xarvcf protein across a series of developmental stages reveals changes in protein mobility, likely due to changes in phosphorylation. Xarvcf is a maternally provided transcript and expressed in the embryo throughout all stages of development. Interestingly, Xarvcf mRNA is differentially spliced to produce several isoforms, one of which is developmentally regulated. In common with the putative post-translational modifications of the Xarvcf protein, the presence of alternative splice isoforms suggests that Xarvcf possesses the capacity to effect developmental functions in a regulatable manner.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol 117, Program Genes & Dev, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	McCrea, PD (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol 117, Program Genes & Dev, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA-16672] Funding Source: Medline; NIGMS NIH HHS [GM-5-T32-HD07325, R01-GM-52112] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052112] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGHIB DF, 1995, EXP CELL RES, V218, P359, DOI 10.1006/excr.1995.1167; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bonne S, 1999, J CELL SCI, V112, P2265; BUSS JE, 1988, MOL CELL BIOL, V8, P3960, DOI 10.1128/MCB.8.9.3960; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; DOWNING JR, 1991, ONCOGENE, V6, P607; Esser S, 1998, J CELL SCI, V111, P1853; EVANS JP, 1991, XENOPUS LAEVIS PRACT, P133; Faber J., 1994, NORMAL TABLE XENOPUS, P2; Finnemann S, 1997, J BIOL CHEM, V272, P11856, DOI 10.1074/jbc.272.18.11856; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Geis K, 1998, DEV GENES EVOL, V207, P471, DOI 10.1007/s004270050138; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Hatzfeld M, 1996, J CELL SCI, V109, P2767; HEID HW, 1994, DIFFERENTIATION, V58, P113; Hudson C, 1997, CELL, V91, P397, DOI 10.1016/S0092-8674(00)80423-7; Ide N, 1999, BIOCHEM BIOPH RES CO, V256, P456, DOI 10.1006/bbrc.1999.0364; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; Katz BZ, 1998, EXP CELL RES, V243, P415, DOI 10.1006/excr.1998.4194; Keirsebilck A, 1998, GENOMICS, V50, P129, DOI 10.1006/geno.1998.5325; KINTNER CR, 1987, DEVELOPMENT, V99, P311; Lampugnani MG, 1997, J CELL SCI, V110, P2065; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; MACRAE AD, 1994, GENOMICS, V24, P176, DOI 10.1006/geno.1994.1596; Mariner DJ, 2000, J CELL SCI, V113, P1481; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Medina M, 2000, GENOMICS, V63, P157, DOI 10.1006/geno.1999.6090; Mertens C, 1996, J CELL BIOL, V135, P1009, DOI 10.1083/jcb.135.4.1009; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; Paulson AF, 1999, DEV BIOL, V207, P350, DOI 10.1006/dbio.1998.9158; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; REYNOLDS AB, 1997, CYTOSKELETAL MEMBRAN, P1; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; Schmidt A, 1999, DIFFERENTIATION, V64, P291, DOI 10.1046/j.1432-0436.1999.6450291.x; Schmidt A, 1997, CELL TISSUE RES, V290, P481, DOI 10.1007/s004410050956; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; Sirotkin H, 1997, GENOMICS, V41, P75, DOI 10.1006/geno.1997.4627; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; Yap AS, 1998, CANCER INVEST, V16, P252, DOI 10.3109/07357909809039774; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; Zhou JH, 1997, NEUROREPORT, V8, P1489, DOI 10.1097/00001756-199704140-00033	62	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30124	30131		10.1074/jbc.M003048200	http://dx.doi.org/10.1074/jbc.M003048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10899158	hybrid			2022-12-27	WOS:000089577900030
J	Sinnett-Smith, J; Santiskulvong, C; Duque, J; Rozengurt, E				Sinnett-Smith, J; Santiskulvong, C; Duque, J; Rozengurt, E			[D-Arg(1),D-Trp(5,7,9),Leu(11)]substance P inhibits bombesin-induced mitogenic signal transduction mediated by both G(q) and G(12) in Swiss 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; LUNG-CANCER CELLS; ACTIVATED PROTEIN-KINASE; STIMULATES TYROSINE PHOSPHORYLATION; ESTERS RAPIDLY STIMULATE; STRESS FIBER FORMATION; PHORBOL ESTERS; GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; MOLECULAR-CLONING	Substance P (SP) analogues including [D-Arg(1),D-Trp(5,7,9),Leu(11)]SP are broad spectrum neuropeptide antagonists and potential anticancer agents, but their mechanism of action is not fully understood. Here, we examined the mechanism of action of [D-Arg(1),D-Trp(5,7,9),Leu(11)]SP as an inhibitor of G protein-coupled receptor (GPCR)-mediated signal transduction and cellular DNA synthesis in Swiss 3T3 cells. Addition of [D-Arg(1),D-Trp(5,7.9),Leu(11)]SP, at 10 mu M, caused a striking rightward shift in the dose-response curves of DNA synthesis induced by bombesin, bradykinin, or vasopressin and markedly inhibited the activation of p42(mapk) (ERK-2) and p44(mapk) (ERK-1) induced by these GPCR agonists. In addition, this SP analogue also prevented the protein kinase C-dependent activation of protein kinase D induced by these agonists. [D-Arg(1),D-Trp(5,) (7,9),Leu(11)]SP, at a concentration (10 mu M) that inhibited these G(q)-mediated events, also prevented GPCR agonist-induced responses mediated through the G proteins of the G(12) subfamily. These include bombesin-induced assembly of focal adhesions, formation of parallel arrays of actin stress fibers, increase in the tyrosine phosphorylation of focal adhesion kinase (FAK), p130(Cas), and paxillin, and formation of a complex between FAK and Src. We conclude that [D-Arg(1),D-Trp(5,7,9),Leu11]SP acts as a mitogenic antagonist of neuropeptide GPCRs blocking signal transduction via both G(q) and G(12).	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, 900 Vet Ave,Warren Hall Rm 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu						Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Aprikian AG, 1997, INT J CANCER, V72, P498, DOI 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.3.CO;2-P; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BEPLER G, 1988, PEPTIDES, V9, P1367, DOI 10.1016/0196-9781(88)90204-5; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BUNN PA, 1994, CANCER RES, V54, P3602; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Charlesworth A, 1996, ONCOGENE, V12, P1337; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; EVERARD MJ, 1993, EUR J CANCER, V29A, P1450, DOI 10.1016/0959-8049(93)90019-C; Flinn HM, 1996, J CELL SCI, V109, P1133; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; ITO S, 1994, BIOCHEM BIOPH RES CO, V200, P756, DOI 10.1006/bbrc.1994.1515; Jarpe MB, 1998, J BIOL CHEM, V273, P3097, DOI 10.1074/jbc.273.5.3097; Jian XY, 1999, J BIOL CHEM, V274, P11573, DOI 10.1074/jbc.274.17.11573; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Kaufmann R, 1997, NEUROPEPTIDES, V31, P573, DOI 10.1016/S0143-4179(97)90003-2; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; Lacerda HM, 1997, J BIOL CHEM, V272, P9587; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LANGDON S, 1992, CANCER RES, V52, P4554; MacKinnon AC, 1999, BRIT J CANCER, V80, P1026, DOI 10.1038/sj.bjc.6690458; Mann DJ, 1997, ONCOGENE, V14, P1759, DOI 10.1038/sj.onc.1201134; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Nyeki O, 1998, J PEPT SCI, V4, P486, DOI 10.1002/(SICI)1099-1387(199812)4:8<486::AID-PSC168>3.3.CO;2-E; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; Paolucci L, 1999, CANCER RES, V59, P572; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; QIN YF, 1994, CANCER RES, V54, P1035; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rodriguez-Fernandez JL, 1998, J BIOL CHEM, V273, P19321, DOI 10.1074/jbc.273.30.19321; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Rozengurt E, 1998, AM J PHYSIOL-GASTR L, V275, pG177, DOI 10.1152/ajpgi.1998.275.2.G177; Rozengurt Enrique, 1999, Current Opinion in Oncology, V11, P116; SAKAMOTO K, 1994, J BIOL CHEM, V269, P3881; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Seckl MJ, 1996, J BIOL CHEM, V271, P29453, DOI 10.1074/jbc.271.46.29453; Seckl MJ, 1997, CANCER RES, V57, P51; SECKL MJ, 1995, J CELL PHYSIOL, V163, P87, DOI 10.1002/jcp.1041630110; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SETHI T, 1991, CANCER RES, V51, P3621; Seufferlein T, 1996, CANCER RES, V56, P5758; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; Singh D, 2000, P NATL ACAD SCI USA, V97, P388, DOI 10.1073/pnas.97.1.388; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Slice LM, 1999, J BIOL CHEM, V274, P27562, DOI 10.1074/jbc.274.39.27562; Smith JP, 1996, AM J PHYSIOL-REG I, V270, pR1078, DOI 10.1152/ajpregu.1996.270.5.R1078; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Withers DJ, 1997, J BIOL CHEM, V272, P2509; WOLL PJ, 1990, CANCER RES, V50, P3968; WOLL PJ, 1988, P NATL ACAD SCI USA, V85, P1859, DOI 10.1073/pnas.85.6.1859; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZACHARY I, 1987, J BIOL CHEM, V262, P3947; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	72	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30644	30652		10.1074/jbc.M003702200	http://dx.doi.org/10.1074/jbc.M003702200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10880515	hybrid			2022-12-27	WOS:000089577900100
J	Dhanvantari, S; Loh, YP				Dhanvantari, S; Loh, YP			Lipid raft association of carboxypeptidase E is necessary for its function as a regulated secretory pathway sorting receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; INFLUENZA-VIRUS HEMAGGLUTININ; DISULFIDE-BONDED LOOP; TRANS-GOLGI NETWORK; CHROMOGRANIN-B; TRANSMEMBRANE DOMAIN; MEMBRANE DOMAINS; CELL-SURFACE; CHOLESTEROL; IDENTIFICATION	Membrane carboxypeptidase E (CPE) is a sorting receptor for targeting prohormones, such as pro-opiomelanocortin, to the regulated secretory pathway in endocrine cells. Its membrane association is necessary for it to bind a prohormone sorting signal at the trans-Golgi network (TGN) to facilitate targeting. In this study, we examined the lipid interaction of CPE in bovine pituitary secretory granule membranes, which are derived from the TGN. We show that CPE is associated with detergent-resistant lipid domains, or rafts, within secretory granule membranes. Lipid analysis revealed that these rafts are enriched in glycosphingolipids and cholesterol. Pulse-chase and subcellular fractionation experiments in AtT-20 cells show that the association of CPE with membrane rafts occurred only after it reached the Golgi. Cholesterol depletion resulted in dissociation of CPE from secretory granule membranes and decreased the binding of prohormones to membranes, lit vivo cholesterol depletion using lovastatin resulted in the lack of sorting of CPE and its cargo to the regulated secretory pathway. We propose that the sorting receptor function of CPE necessitates its interaction with glycosphingolipid-cholesterol rafts at the TGN, thereby anchoring it in position to bind to its prohormone cargo.	NICHD, Cellular Neurobiol Sect, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Loh, YP (corresponding author), NICHD, Cellular Neurobiol Sect, Dev Neurobiol Lab, NIH, Bldg 49,Rm 5A38,MSC 4480,9000 Rockville Pike, Bethesda, MD 20892 USA.	ypl@codon.nih.gov	Dhanvantari, Savita/B-5362-2015		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000056] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000056] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARIGA T, 1988, BIOCHEMISTRY-US, V27, P52, DOI 10.1021/bi00401a010; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; BUCKLAND RM, 1978, BIOCHIM BIOPHYS ACTA, V513, P321, DOI 10.1016/0005-2736(78)90202-X; Chanat E, 1998, METH MOL B, V88, P285; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; COOL DR, 1994, BIOCHIMIE, V76, P265, DOI 10.1016/0300-9084(94)90156-2; Cool DR, 1998, MOL CELL ENDOCRINOL, V139, P7, DOI 10.1016/S0303-7207(98)00081-1; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; Fernandez CJ, 1997, MOL BIOL CELL, V8, P2171, DOI 10.1091/mbc.8.11.2171; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; Lipardi C, 2000, MOL BIOL CELL, V11, P531, DOI 10.1091/mbc.11.2.531; LOH YP, 1984, J BIOL CHEM, V259, P8238; MACALA LJ, 1983, J LIPID RES, V24, P1243; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Normant E, 1998, ENDOCRINOLOGY, V139, P2137, DOI 10.1210/en.139.4.2137; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; QUINN D, 1991, J CELL BIOL, V113, P987, DOI 10.1083/jcb.113.5.987; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; VILHARDT H, 1972, ACTA ENDOCRINOL-COP, V71, P638, DOI 10.1530/acta.0.0710638; Watanabe R, 1996, J BIOL CHEM, V271, P26868, DOI 10.1074/jbc.271.43.26868; WESTHEAD EW, 1982, NEUROSCIENCE, V7, P1611, DOI 10.1016/0306-4522(82)90018-5; WESTHEAD EW, 1987, ANN NY ACAD SCI, V493, P92, DOI 10.1111/j.1749-6632.1987.tb27186.x; Yoo SH, 1996, J BIOL CHEM, V271, P17041, DOI 10.1074/jbc.271.29.17041; Zhang CF, 1999, MOL ENDOCRINOL, V13, P527, DOI 10.1210/me.13.4.527	47	100	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29887	29893		10.1074/jbc.M005364200	http://dx.doi.org/10.1074/jbc.M005364200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896946	hybrid			2022-12-27	WOS:000089439800096
J	Henneberry, AL; Wistow, G; McMaster, CR				Henneberry, AL; Wistow, G; McMaster, CR			Cloning, genomic organization, and characterization of a human cholinephosphotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDP-CHOLINE PATHWAY; PLATELET-ACTIVATING-FACTOR; SACCHAROMYCES-CEREVISIAE; TRANSFER PROTEIN; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; PHOSPHOLIPID BIOSYNTHESIS; SN-1,2-DIACYLGLYCEROL CHOLINEPHOSPHOTRANSFERASE; PHOSPHATIDYLETHANOLAMINE BIOSYNTHESIS; FINAL STEP; ETHANOLAMINEPHOSPHOTRANSFERASE	A cholinephosphotransferase activity catalyzes the final step in the de novo synthesis of phosphatidylcholine Dia the transfer of a phosphocholine moiety from CDP choline to diacylglycerol. Ethanolaminephosphotransferase activity catalyzes a similar reaction substituting CDP ethanolamine as the phosphobase donor. We report the identification and cloning of a human cDNA (human cholinephosphotransferase (hCPT1)) that codes for a cholinephosphotransferase-specific enzyme. This was demonstrated using in vitro enzyme assays and in vivo measurement of the reconstitution of the phosphatidylcholine and phosphatidylethanolamine biosynthetic pathways in yeast cells devoid of their own endogenous cholinephosphotransferase and ethanolaminephosphotransferase activities. This contrasted with our previously cloned human choline/ethanolaminephosphotransferase cDNA that was demonstrated to code for a dual specificity choline/ethanolaminephosphotransferase. The hCPT1 and human choline/ethanolaminephosphotransferase (hCEPT1) predicted amino acid sequences possessed 60% overall identity and had only one variation in the amino acid residues within the CDP-alcohol phosphotransferase catalytic motif, In vitro assessment of hCPT1 and hCEPT1 derived cholinephosphotransferase activities also revealed differences in diradylglycerol specificities including their capacity to synthesize platelet-activating factor and platelet-activating factor precursor. Expression of the hCPT1 mRNA varied greater than 100-fold between tissues and was most abundant in testis followed by colon, small intestine, heart, prostate, and spleen. This was in marked contrast to the hCEPT1 mRNA, which has been found in similar abundance in all tissues tested to date. Both the hCPT1 and hCEPT1 enzymes were able to reconstitute the synthesis of PC in yeast to levels provided by the endogenous yeast cholinephosphotransferase; however, only hCEPT1-derived activity was able to complement the yeast CPT1 gene in its interaction with SEC14 and affect cell growth.	Dalhousie Univ, IWK Grace Hlth Ctr, Dept Pediat, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, IWK Grace Hlth Ctr, Dept Biochem & Mol Biol, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; NEI, Sect Mol Struct & Funct, NIH, Bethesda, MD 20892 USA	Dalhousie University; Dalhousie University; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	McMaster, CR (corresponding author), Dalhousie Univ, IWK Grace Hlth Ctr, Dept Pediat, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada.			McMaster, Christopher/0000-0003-0822-5776	NATIONAL EYE INSTITUTE [ZIAEY000320, Z01EY000320] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMES BN, 1960, J BIOL CHEM, V235, P769; BRU R, 1993, ARCH BIOCHEM BIOPHYS, V307, P295, DOI 10.1006/abbi.1993.1592; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CORNELL RB, 1992, METHOD ENZYMOL, V209, P267; CUI Z, 1994, J BIOL CHEM, V269, P24531; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; DEWEY RE, 1994, PLANT CELL, V6, P1495, DOI 10.1105/tpc.6.10.1495; FORD DA, 1992, J BIOL CHEM, V267, P11222; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Henneberry AL, 1999, BIOCHEM J, V339, P291, DOI 10.1042/0264-6021:3390291; HJELMSTAD RH, 1994, J BIOL CHEM, V269, P20995; HJELMSTAD RH, 1992, METHOD ENZYMOL, V209, P273; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; JUSTIN AM, 1985, BIOCHIM BIOPHYS ACTA, V836, P1, DOI 10.1016/0005-2760(85)90212-7; Kaiser C., 1994, METHODS YEAST GENETI; Kearns BG, 1998, TRENDS CELL BIOL, V8, P276, DOI 10.1016/S0962-8924(98)01281-1; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; Kuge O, 1998, P NATL ACAD SCI USA, V95, P4199, DOI 10.1073/pnas.95.8.4199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mancini A, 1999, BBA-MOL CELL BIOL L, V1437, P80, DOI 10.1016/S1388-1981(98)00011-0; MCGEE TP, 1994, J BACTERIOL, V176, P6861, DOI 10.1128/JB.176.22.6861-6868.1994; MCMASTER CR, 1992, J BIOL CHEM, V267, P14586; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; McMaster CR, 1996, BIOCHEM J, V313, P729, DOI 10.1042/bj3130729; McMaster CR, 1997, BBA-LIPID LIPID MET, V1348, P100, DOI 10.1016/S0005-2760(97)00097-0; McMaster CR, 1997, BBA-LIPID LIPID MET, V1348, P117, DOI 10.1016/S0005-2760(97)00098-2; MUNBERG D, 1995, GENE, V156, P119; O KM, 1989, BIOCHEM CELL BIOL, V67, P680; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; POLOKOFF MA, 1981, J BIOL CHEM, V256, P7687; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; RIDGWAY ND, 1989, J BIOL CHEM, V264, P1203; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; SLEIGHT R, 1980, J BIOL CHEM, V255, P644; Snyder F, 1997, BBA-LIPID LIPID MET, V1348, P111, DOI 10.1016/S0005-2760(97)00109-4; Stein LD, 1999, TRENDS GENET, V15, P425, DOI 10.1016/S0168-9525(99)01805-3; STERN I, 1953, J CLIN PATHOL, V6, P158, DOI 10.1136/jcp.6.2.158; Stone SJ, 1998, J BIOL CHEM, V273, P7293, DOI 10.1074/jbc.273.13.7293; Tessitore L, 2000, INT J CANCER, V86, P362, DOI 10.1002/(SICI)1097-0215(20000501)86:3&lt;362::AID-IJC10&gt;3.0.CO;2-A; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; VANCE DE, 1996, BIOCH LIPIDS LIPOPRO, P153; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; WEISS SB, 1958, J BIOL CHEM, V231, P53; Williams JG, 1998, J BIOL CHEM, V273, P13482, DOI 10.1074/jbc.273.22.13482; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; WOODARD DS, 1987, J BIOL CHEM, V262, P2520; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; YANG TT, 1995, BIOTECHNIQUES, V18, P498	54	79	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29808	29815		10.1074/jbc.M005786200	http://dx.doi.org/10.1074/jbc.M005786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893425	hybrid			2022-12-27	WOS:000089439800086
J	Pages, S; Heijne, WHM; Kester, HCM; Visser, J; Benen, JAE				Pages, S; Heijne, WHM; Kester, HCM; Visser, J; Benen, JAE			Subsite mapping of Aspergillus niger endopolygalacturonase II by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-SEQUENCE SIMILARITIES; CRYSTAL-STRUCTURE; GENE; ENZYMES; POLYGALACTURONASE; IDENTIFICATION; CLASSIFICATION; FAMILY	To assess the subsites involved in substrate binding in Aspergillus niger endopolygalacturonase II, residues located in the potential substrate binding cleft stretching along the enzyme from the N to the C terminus were subjected to site-directed mutagenesis. Mutant enzymes were characterized with respect to their kinetic parameters using polygalacturonate as a substrate and with respect to their mode of action using oligogalacturonates of defined length (n = 3-6). In addition, the effect of the mutations on the hydrolysis of pectins with various degrees of esterification was studied. Based on the results obtained with enzymes N186E and D282K it was established that the substrate binds with the nonreducing end toward the N terminus of the enzyme. Asn(186) is located at subsite -4, and Asp(282) is located at subsite +2. The mutations D183N and M150Q, both located at subsite -2, affected catalysis, probably mediated via the sugar residue bound at subsite -1. Tyr(291), located at subsite +1 and strictly conserved among endopolygalacturonases appeared indispensable for effective catalysis. The mutations E252A and Q288E, both located at subsite +2, showed only slight effects on catalysis and mode of action. Tyr(326) is probably located at the imaginary subsite +3. The mutation Y326L affected the stability of the enzyme. For mutant E252A, an increased affinity for partially methylesterified substrates was recorded. Enzyme N186E displayed the opposite behavior; the specificity for completely demethylesterified regions of substrate, already high for the native enzyme, was increased. The origin of the effects of the mutations is discussed.	Univ Wageningen & Res Ctr, Sect Mol Genet Ind Microorganisms, NL-6703 HA Wageningen, Netherlands	Wageningen University & Research	Benen, JAE (corresponding author), Univ Wageningen & Res Ctr, Sect Mol Genet Ind Microorganisms, Dreyenlaan 2, NL-6703 HA Wageningen, Netherlands.	jac.benen@algemeen.mgim.wau.nl						ALLEN JD, 1976, BIOCHEM J, V159, P105, DOI 10.1042/bj1590105; Armand S, 2000, J BIOL CHEM, V275, P691, DOI 10.1074/jbc.275.1.691; Benen JAE, 1999, EUR J BIOCHEM, V259, P577, DOI 10.1046/j.1432-1327.1999.00080.x; BUSSINK HJD, 1991, CURR GENET, V20, P301, DOI 10.1007/BF00318519; BUSSINK HJD, 1990, FEBS LETT, V273, P127, DOI 10.1016/0014-5793(90)81066-W; BUSSINK HJD, 1992, EUR J BIOCHEM, V208, P83, DOI 10.1111/j.1432-1033.1992.tb17161.x; DEGRAAFF L, 1992, CURR GENET, V22, P21, DOI 10.1007/BF00351737; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Kester HCM, 2000, BIOCHEM J, V346, P469, DOI 10.1042/0264-6021:3460469; Korner R, 1999, ANAL CHEM, V71, P1421, DOI 10.1021/ac981240o; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Parenicova L, 2000, BIOCHEM J, V345, P637, DOI 10.1042/0264-6021:3450637; Parenicova L, 1998, EUR J BIOCHEM, V251, P72, DOI 10.1046/j.1432-1327.1998.2510072.x; Petersen TN, 1997, STRUCTURE, V5, P533, DOI 10.1016/S0969-2126(97)00209-8; Pickersgill R, 1998, J BIOL CHEM, V273, P24660, DOI 10.1074/jbc.273.38.24660; SOMEREN MAK, 1991, CURR GENET, V20, P293, DOI 10.1007/BF00318518; THOMA JA, 1970, BIOCHEMISTRY-US, V9, P1768, DOI 10.1021/bi00810a016; THOMA JA, 1971, J BIOL CHEM, V246, P5621; van Santen Y, 1999, J BIOL CHEM, V274, P30474, DOI 10.1074/jbc.274.43.30474	20	41	41	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29348	29353		10.1074/jbc.M910112199	http://dx.doi.org/10.1074/jbc.M910112199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893426	hybrid			2022-12-27	WOS:000089439800024
J	Braybrooke, JP; Spink, KG; Thacker, J; Hickson, ID				Braybrooke, JP; Spink, KG; Thacker, J; Hickson, ID			The RAD51 family member, RAD51L3, is a DNA-stimulated ATPase that forms a complex with XRCC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; ESCHERICHIA-COLI RECA; SACCHAROMYCES-CEREVISIAE; REPAIR GENE; HOMOLOGOUS RECOMBINATION; IONIZING-RADIATION; PROKARYOTIC RECA; MAMMALIAN-CELLS; PROTEIN; MOUSE	The Rad51 protein in eukaryotic cells is a structural and functional homolog of Escherichia coli RecA with a role in DNA repair and genetic recombination, Several proteins showing sequence similarity to Rad51 have previously been identified in both yeast and human cells. In Saccharomyces cerevisiae, two of these proteins, Rad55p and Rad57p, form a heterodimer that can stimulate Rad51-mediated DNA strand exchange, Here, we report the purification of one of the representatives of the RAD51 family in human cells. We demonstrate that the purified RAD51L3 protein possesses single-stranded DNA binding activity and DNA-stimulated ATPase activity, consistent with the presence of "Walker box" motifs in the deduced RAD51L3 sequence. We have identified a protein complex in human cells containing RAD51L3 and a second RAD51 family member, XRCC2. By using purified proteins, we demonstrate that the interaction between RAD51L3 and XRCC2 is direct. Given the requirements for XRCC2 in genetic recombination and protection against DNA-damaging agents, we suggest that the complex of RAD51L3 and XRCC2 is likely to be important for these functions in human cells.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England; MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Oxon, England	Cancer Research UK; University of Oxford	Hickson, ID (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England.		Hickson, Ian/AAJ-7548-2020	Braybrooke, Jeremy/0000-0003-1943-7360; Hickson, Ian/0000-0002-0583-566X				ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; Albala JS, 1997, GENOMICS, V46, P476, DOI 10.1006/geno.1997.5062; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P1653, DOI 10.1093/nar/26.7.1653; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; DONOVAN JW, 1994, GENE DEV, V8, P2552, DOI 10.1101/gad.8.21.2552; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; Kawabata M, 1998, BBA-GENE STRUCT EXPR, V1398, P353, DOI 10.1016/S0167-4781(98)00061-X; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; MURIS DFR, 1993, NUCLEIC ACIDS RES, V21, P4586, DOI 10.1093/nar/21.19.4586; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pittman DL, 1998, GENOMICS, V49, P103, DOI 10.1006/geno.1998.5226; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUGAWARA N, 1995, NATURE, V373, P84, DOI 10.1038/373084a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Tambini CE, 1997, GENOMICS, V41, P84, DOI 10.1006/geno.1997.4636; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; Thacker J, 1999, BIOCHIMIE, V81, P77, DOI 10.1016/S0300-9084(99)80041-8; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; TUCKER JD, 1991, MUTAT RES, V254, P143, DOI 10.1016/0921-8777(91)90005-A; Van Dyck E, 1998, J MOL BIOL, V284, P1027, DOI 10.1006/jmbi.1998.2203; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; Zaitseva EM, 1999, J BIOL CHEM, V274, P2907, DOI 10.1074/jbc.274.5.2907	45	82	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29100	29106		10.1074/jbc.M002075200	http://dx.doi.org/10.1074/jbc.M002075200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10871607	hybrid			2022-12-27	WOS:000089330700098
J	Dua, R; Edwards, S; Levy, DL; Campbell, JL				Dua, R; Edwards, S; Levy, DL; Campbell, JL			Subunit interactions within the Saccharomyces cerevisiae DNA polymerase epsilon (pol epsilon) complex - Demonstration of a dimeric pol epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE CHECKPOINT; CHROMOSOMAL REPLICATION; PURIFICATION; YEAST; DELTA; HOLOENZYME; CLONING; DPB11; IDENTIFICATION; PROTEINS	Saccharomyces cerevisiae DNA polymerase epsilon (pol epsilon) is essential for chromosomal replication. A major form of pol epsilon purified from yeast consists of at least four subunits: Pol2p, Dpb2p, Dpb3p, and Dpb4p. We have investigated the protein/protein interactions between these polypeptides by using expression of individual subunits in baculovirus-infected Sf9 insect cells and by using the yeast two-hybrid assay. The essential subunits, Pol2p and Dpb2p, interact directly in the absence of the other two subunits, and the C-terminal half of POL2, the only essential portion of Pol2p, is sufficient for interaction with Dpb2p. Dpb3p and Dpb4p, non-essential subunits, also interact directly with each other in the absence of the other two subunits. We propose that Pol2p Dpb2p and Dpb3p.Dpb4p complexes interact with each other and document several interactions between individual members of the two respective complexes. We present biochemical evidence to support the proposal that pol epsilon may be dimeric in vivo. Gel filtration of the Pol2p.Dpb2p complexes reveals a novel heterotetrameric form, consisting of two heterodimers of Pol2p.Dpb2p. Dpb2p, but not Pol2p, exists as a homodimer, and thus the Pol2p dimerization may be mediated by Dpb2p. The pol2-E and pol2-F mutations that cause replication defects in vivo weaken the interaction between Pol2p and Dpb2p and also reduce dimerization of Pol2p. This suggests, but does not prove, that dimerization may also occur in vivo and be essential for DNA replication.	CALTECH, Braun Labs 14775, Pasadena, CA 91125 USA	California Institute of Technology	Campbell, JL (corresponding author), CALTECH, Braun Labs 14775, Pasadena, CA 91125 USA.		Levy, Daniel/AAA-7205-2019	Levy, Daniel/0000-0002-7853-3275	PHS HHS [25508] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARAKI H, 1991, NUCLEIC ACIDS RES, V19, P4867, DOI 10.1093/nar/19.18.4867; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; Berdis AJ, 1996, P NATL ACAD SCI USA, V93, P12822, DOI 10.1073/pnas.93.23.12822; BUDD ME, 1989, J BIOL CHEM, V264, P6557; Budd ME, 1997, MUTAT RES-DNA REPAIR, V384, P157, DOI 10.1016/S0921-8777(97)00024-4; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; Dua R, 1998, J BIOL CHEM, V273, P30046, DOI 10.1074/jbc.273.45.30046; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; DUrso G, 1997, P NATL ACAD SCI USA, V94, P12491, DOI 10.1073/pnas.94.23.12491; Ehrenhofer-Murray AE, 1999, GENETICS, V153, P1171; Frei C, 2000, GENE DEV, V14, P81; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Jessberger R, 1996, MUTAT RES-FUND MOL M, V350, P217, DOI 10.1016/0027-5107(95)00106-9; Kamimura Y, 1998, MOL CELL BIOL, V18, P6102, DOI 10.1128/MCB.18.10.6102; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KESTI T, 1993, J BIOL CHEM, V268, P10238; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Li Y, 1997, J BIOL CHEM, V272, P32337, DOI 10.1074/jbc.272.51.32337; Li Y, 2000, J BIOL CHEM, V275, P23247, DOI 10.1074/jbc.M002548200; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Makiniemi M, 1999, TRENDS BIOCHEM SCI, V24, P14, DOI 10.1016/S0968-0004(98)01327-9; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NIRANJANAKUMARI S, 1993, J BIOL CHEM, V268, P15557; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Smith JS, 1999, MOL CELL BIOL, V19, P3184; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; Wang H, 1999, P NATL ACAD SCI USA, V96, P3824, DOI 10.1073/pnas.96.7.3824; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WINTERSBERGER U, 1970, EUR J BIOCHEM, V13, P11, DOI 10.1111/j.1432-1033.1970.tb00893.x; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	39	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28816	28825		10.1074/jbc.M002376200	http://dx.doi.org/10.1074/jbc.M002376200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878005	hybrid			2022-12-27	WOS:000089330700064
J	Gomez, M; Scales, SJ; Kreis, TE; Perez, F				Gomez, M; Scales, SJ; Kreis, TE; Perez, F			Membrane recruitment of coatomer and binding to dilysine signals are separate events	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; VESICULAR STOMATITIS-VIRUS; PUTATIVE CARGO RECEPTORS; EARLY SECRETORY PATHWAY; COP-COATED VESICLES; TO-GOLGI TRANSPORT; ENDOPLASMIC-RETICULUM; EPSILON-COP; INTRACELLULAR-TRANSPORT; TRANSMEMBRANE PROTEIN	It has previously been shown that transport of newly synthesized proteins and the structure of the Golgi complex are affected in the Chinese hamster ovary cell line IdlF, which bears a temperature-sensitive mutation in the Coat protein I (COPI) subunit E-COP (Guo, &,, Vasile, E., and Krieger, M. (1994) J. Cell Biol. 125, 1213-1224; Hobble, L., Fisher, A. S., Lee, S., Flint, k, and Krieger, M, (1994) J. Biol. Chen. 269, 20958-20970). Here, we pinpoint the site of the secretory block to an intermediate compartment between the endoplasmic reticulum (ER) and the Golgi complex and show that the distributions of ER-Golgi recycling proteins, such as KDEL receptor and p23, as well as resident Golgi proteins, such as mannosidase II, are accordingly affected. At the nonpermissive temperature, neither the stability of the COPI complex nor its recruitment to donor Golgi membranes is affected. However, the binding of coatomer to the dilysine-based ER-retrieval motif is impaired in the absence of epsilon-COP, suggesting that dilysine signal binding is not the major means of COPI recruitment. Because expression of the exogenous chimera of E-COP and green fluorescent protein in IdlF cells at nonpermissive temperature rapidly restores the wild type properties, E-COP is likely to play an important role in the cargo selection events mediated by COPI.	Univ Geneva, Dept Cell Biol, CH-1211 Geneva 4, Switzerland	University of Geneva	Perez, F (corresponding author), Inst Curie, CNRS, UMR 144, 26 Rue Ulm, F-75248 Paris 05, France.		Scales, Suzie J./H-4507-2019; Perez, Franck/A-1558-2014	Scales, Suzie J./0000-0003-2544-0283; Perez, Franck/0000-0002-9129-9401				ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BERGMANN JE, 1983, J CELL BIOL, V97, P1777, DOI 10.1083/jcb.97.6.1777; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; Duden R, 1998, EMBO J, V17, P985, DOI 10.1093/emboj/17.4.985; Faulstich D, 1996, J CELL BIOL, V135, P53, DOI 10.1083/jcb.135.1.53; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; GODLBERG J, 2000, CELL, V100, P671; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; Guo Q, 1996, J BIOL CHEM, V271, P11191, DOI 10.1074/jbc.271.19.11191; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; Harter C, 1996, P NATL ACAD SCI USA, V93, P1902, DOI 10.1073/pnas.93.5.1902; HOBBIE L, 1994, J BIOL CHEM, V269, P20958; Hudson RT, 1997, MOL BIOL CELL, V8, P1901, DOI 10.1091/mbc.8.10.1901; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavoie C, 1999, J CELL BIOL, V146, P285, DOI 10.1083/jcb.146.2.285; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Lowe M, 1998, BBA-MOL CELL RES, V1404, P53, DOI 10.1016/S0167-4889(98)00046-9; Lowe M, 1996, J BIOL CHEM, V271, P30725, DOI 10.1074/jbc.271.48.30725; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; MIESENBOCK G, 1995, J CELL BIOL, V129, P309, DOI 10.1083/jcb.129.2.309; Nickel W, 1997, P NATL ACAD SCI USA, V94, P11393, DOI 10.1073/pnas.94.21.11393; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Pavel J, 1998, P NATL ACAD SCI USA, V95, P2140, DOI 10.1073/pnas.95.5.2140; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Rojo M, 2000, J CELL SCI, V113, P1043; Rojo M, 1997, J CELL BIOL, V139, P1119, DOI 10.1083/jcb.139.5.1119; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Scales SJ, 2000, INT REV CYTOL, V195, P67; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Scheel J, 1997, J CELL BIOL, V137, P319, DOI 10.1083/jcb.137.2.319; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Shima DT, 1999, CURR BIOL, V9, P821, DOI 10.1016/S0960-9822(99)80365-0; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STROUS GJ, 1991, BIOL CELL, V71, P25, DOI 10.1016/0248-4900(91)90048-R; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; Zhao LY, 1999, J BIOL CHEM, V274, P14198, DOI 10.1074/jbc.274.20.14198; Zhu YX, 1999, MOL BIOL CELL, V10, P537, DOI 10.1091/mbc.10.3.537	63	20	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29162	29169		10.1074/jbc.M003630200	http://dx.doi.org/10.1074/jbc.M003630200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10864930	hybrid			2022-12-27	WOS:000089330700106
J	Shearwin, KE; Egan, JB				Shearwin, KE; Egan, JB			Establishment of lysogeny in bacteriophage 186 - DNA binding and transcriptional, activation by the CII protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RNA-POLYMERASE; ANALYTICAL ULTRACENTRIFUGATION; INTERDOMAIN LINKER; OPERATOR COMPLEX; GENE-EXPRESSION; CLONING VECTORS; COLIPHAGE 186; ARAC PROTEIN; REPRESSOR	The CII protein of bacteriophage 186 is a transcriptional activator of the helix-turn helix family required for establishment of the lysogenic state. DNA binding by 186 CII is unusual in that the invertedly repeated half sites are separated by 20 base pairs, or two turns of the DNA helix, rather than the one turn usually associated with this class of proteins. Here, we investigate quantitatively the DNA binding properties of CII and its interaction with RNA polymerase at the establishment promoter, p(E). The stoichiometry of CII binding was determined by sedimentation equilibrium experiments using a fluorescein-labeled oligonucleotide and purified CII, These experiments indicate that the CII species bound to DNA is a dimer, with additional weak binding of a tetrameric species at high concentrations. Examination of the thermodynamic linkages between CII self-association and DNA binding shows that CII binds to the DNA as a preformed dimer (binding free energy, 9.9 kcal/mol at 4 degrees C) rather than by association of monomers on the DNA, CII binding induces in the DNA a bend of 41 (+/- 5) degrees. The spacing between the binding half sites was shown to be important for CII binding, insertion or removal of just 1 base pair significantly reducing the affinity for CII, Removal of 5 or 10 base pairs between binding half sites eliminated binding, as did insertion of an additional 10 base pairs. CII binding at p(E) was improved marginally by the presence of RNA polymerase (Delta Delta G = -0.5 (+/- 0.3) kcal/mol). In contrast, the binding of RNA polymerase at p(E) was undetectable in the absence of CII but was improved markedly by the presence of CII, Thus, CII appears to recruit RNA polymerase to the promoter. The nature of the base pair changes in mutant phage, selected by their inability to establish lysogeny, are consistent with this mechanism of CII action.	Univ Adelaide, Dept Biochem, Adelaide, SA 5001, Australia	University of Adelaide	Shearwin, KE (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5001, Australia.		Shearwin, Keith/AAS-1247-2021	Shearwin, Keith/0000-0002-7736-2742				ACKERS GK, 1982, P NATL ACAD SCI-BIOL, V79, P1129, DOI 10.1073/pnas.79.4.1129; ARGAET VP, 1994, J BIOL CHEM, V269, P5171; Artsimovitch I, 1996, J BIOL CHEM, V271, P32343, DOI 10.1074/jbc.271.50.32343; Bailey MF, 1996, J MOL BIOL, V263, P671, DOI 10.1006/jmbi.1996.0607; BRENOWITZ M, 1989, CURRENT PROTOCOLS MO, V2; BROWN BM, 1993, BIOCHEMISTRY-US, V32, P1354, DOI 10.1021/bi00056a022; Burz DS, 1998, EMBO J, V17, P5998, DOI 10.1093/emboj/17.20.5998; CARRA JH, 1993, EMBO J, V12, P35, DOI 10.1002/j.1460-2075.1993.tb05629.x; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Cho S, 1998, BIOCHEMISTRY-US, V37, P11301, DOI 10.1021/bi972916x; COHEN G, 1968, BIOPOLYMERS, V6, P1077, DOI 10.1002/bip.1968.360060805; COX EC, 1982, GENETICS, V100, P7; DalmaWeiszhausz DD, 1996, BIOCHEMISTRY-US, V35, P3735, DOI 10.1021/bi952408s; DEBOER HA, 1984, GENE, V30, P251, DOI 10.1016/0378-1119(84)90129-X; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; DODD IB, 1993, MOL MICROBIOL, V10, P1139, DOI 10.1111/j.1365-2958.1993.tb00983.x; DODD IB, 1990, J MOL BIOL, V214, P27, DOI 10.1016/0022-2836(90)90144-B; DODD IB, 1999, ENCY VIROLOGY, P1087; EUSTANCE RJ, 1994, J MOL BIOL, V242, P330; HAGMAR P, 1995, BBA-GEN SUBJECTS, V1244, P259, DOI 10.1016/0304-4165(95)00015-4; HO YS, 1992, J BIOL CHEM, V267, P14388; HO YS, 1983, NATURE, V304, P703, DOI 10.1038/304703a0; HO YS, 1982, J BIOL CHEM, V257, P9128; HOCHSCHILD A, 1994, CURR BIOL, V4, P440, DOI 10.1016/S0960-9822(00)00097-X; JACOB F, 1956, ANN I PASTEUR PARIS, V91, P486; Jorgensen CI, 1998, MOL MICROBIOL, V27, P41, DOI 10.1046/j.1365-2958.1998.00655.x; KALIONIS B, 1986, J MOL BIOL, V191, P199, DOI 10.1016/0022-2836(86)90257-3; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; Koudelka GB, 1998, NUCLEIC ACIDS RES, V26, P669, DOI 10.1093/nar/26.2.669; LAMONT I, 1993, J BACTERIOL, V175, P5286, DOI 10.1128/JB.175.16.5286-5288.1993; LAUE TM, 1993, BIOCHEMISTRY-US, V32, P2469, DOI 10.1021/bi00061a003; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Neufing PJ, 1996, MOL MICROBIOL, V21, P751, DOI 10.1046/j.1365-2958.1996.351394.x; NUEZ B, 1992, P NATL ACAD SCI USA, V89, P11401, DOI 10.1073/pnas.89.23.11401; POWELL BS, 1994, NUCLEIC ACIDS RES, V22, P5765, DOI 10.1093/nar/22.25.5765; Rippe K, 1998, J MOL BIOL, V278, P915, DOI 10.1006/jmbi.1998.1746; Rusinova E, 1997, BIOCHEMISTRY-US, V36, P12994, DOI 10.1021/bi971368k; SANDALTZOPOULOS R, 1994, NUCLEIC ACIDS RES, V22, P1511, DOI 10.1093/nar/22.8.1511; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Steinmetzer K, 1998, J MOL BIOL, V283, P595, DOI 10.1006/jmbi.1998.2122; Streaker ED, 1998, BIOCHEMISTRY-US, V37, P3210, DOI 10.1021/bi9715019; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SzalewskaPalasz A, 1996, FEMS MICROBIOL LETT, V144, P21, DOI 10.1016/0378-1097(96)00332-1; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; Wu XL, 1998, J BIOL CHEM, V273, P20820, DOI 10.1074/jbc.273.33.20820; Wulff DL, 1983, LAMBDA, VII, P53; Xu J, 1998, J BIOL CHEM, V273, P24165, DOI 10.1074/jbc.273.37.24165; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZWIEB C, 1994, METHODS MOL BIOL, V30	51	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29113	29122		10.1074/jbc.M004574200	http://dx.doi.org/10.1074/jbc.M004574200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10871623	hybrid			2022-12-27	WOS:000089330700100
J	Wang, XY; Kumar, R; Navarre, J; Casanova, JE; Goldenring, JR				Wang, XY; Kumar, R; Navarre, J; Casanova, JE; Goldenring, JR			Regulation of vesicle trafficking in Madin-Darby canine kidney cells by Rab11a and Rab25	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED TRANSCYTOSIS; APICAL RECYCLING ENDOSOMES; POLARIZED EPITHELIAL-CELLS; GASTRIC PARIETAL-CELLS; GTP-BINDING PROTEIN; MDCK CELLS; SUBAPICAL COMPARTMENT; ENDOCYTIC PATHWAYS; PLASMA-MEMBRANE; CACO-2 CELLS	Polarized epithelial cells maintain the polarized distribution of basolateral and apical membrane proteins through a process of receptor-mediated endocytosis, sorting, and then recycling to the appropriate membrane domain. We have previously shown that the small GTP-binding proteins, Rab11a and Rab25, are associated with the apical recycling system of Madin-Darby canine kidney cells. Here we have utilized inducible expression of wild-type, dominant negative, and constitutively active mutants to directly compare the functions of Rab25 and Rab11a in postendocytic vesicular transport. We found that a Rab11a mutant deficient in GTP binding, Rab11aS25N, potently inhibited both transcytosis and apical recycling yet failed to inhibit transferrin recycling. Similarly, expression of either wild type Rab25 or the active mutant Rab25S21V inhibited both apical recycling and transcytosis of IgA by greater than 50% but had no effect on basolateral recycling of transferrin, Interestingly, the GTPase-deficient mutant Rab11aS20V inhibited basolateral to apical transcytosis of IgG but had no effect on either apical or basolateral recycling, These results indicate that neither Rab11a nor Rab25 function in the basolateral recycling of transferrin in polarized Madin-Darby canine kidney cells cells, consistent with recent morphological observations by others. Thus, transferrin receptors must be recycled to the plasma membrane prior to sorting of apically directed cargoes into Rab11a/Rab25-positive apical recycling endosomes.	Med Coll Georgia, Inst Mol Med & Genet, Dept Med, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Dept Surg, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Dept Anat & Cellular Biol, Augusta, GA 30912 USA; Vet Affairs Med Ctr, Augusta, GA 30912 USA; Massachusetts Gen Hosp E, Pediat Gastroenterol Unit, Charlestown, MA USA; Program Biol & Biomed Sci, Charlestown, MA USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Goldenring, JR (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Dept Med, CB-2803,1120 15th St, Augusta, GA 30912 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032991, R29AI032991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048370, R01DK043405, R29DK043405] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32991] Funding Source: Medline; NIDDK NIH HHS [DK43405, DK48370] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; Brown PS, 2000, TRAFFIC, V1, P124, DOI 10.1034/j.1600-0854.2000.010205.x; Calhoun BC, 1997, BIOCHEM J, V325, P559, DOI 10.1042/bj3250559; Casanova JE, 1999, MOL BIOL CELL, V10, P47, DOI 10.1091/mbc.10.1.47; Duman JG, 1999, AM J PHYSIOL-CELL PH, V277, pC361, DOI 10.1152/ajpcell.1999.277.3.C361; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Gibson A, 1998, J CELL BIOL, V143, P81, DOI 10.1083/jcb.143.1.81; Goldenring JR, 1996, AM J PHYSIOL-GASTR L, V270, pG515, DOI 10.1152/ajpgi.1996.270.3.G515; GOLDENRING JR, 1993, J BIOL CHEM, V268, P18419; GOLDENRING JR, 1994, AM J PHYSIOL, V267, pG187, DOI 10.1152/ajpgi.1994.267.2.G187; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P522; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; HUGHSON EJ, 1990, J CELL BIOL, V110, P337, DOI 10.1083/jcb.110.2.337; Hunziker W, 1998, J BIOL CHEM, V273, P15734, DOI 10.1074/jbc.273.25.15734; KNIGHT A, 1995, MOL BIOL CELL, V6, P597, DOI 10.1091/mbc.6.5.597; Kumar R, 1999, MOL BIOL CELL, V10, p163A; Lazar T, 1997, TRENDS BIOCHEM SCI, V22, P468, DOI 10.1016/S0968-0004(97)01150-X; LUTCKE A, 1994, J CELL SCI, V107, P3437; Mammoto A, 1999, J BIOL CHEM, V274, P25517, DOI 10.1074/jbc.274.36.25517; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MERESSE S, 1995, J CELL SCI, V108, P3349; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; Olkkonen VM, 1997, INT REV CYTOL, V176, P1, DOI 10.1016/S0074-7696(08)61608-3; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; van Ijzendoorn SCD, 1999, TRENDS CELL BIOL, V9, P144, DOI 10.1016/S0962-8924(99)01512-3; van Ijzendoorn SCD, 1999, MOL BIOL CELL, V10, P3449, DOI 10.1091/mbc.10.10.3449; Zacchi P, 1998, J CELL BIOL, V140, P1039, DOI 10.1083/jcb.140.5.1039	38	191	193	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29138	29146		10.1074/jbc.M004410200	http://dx.doi.org/10.1074/jbc.M004410200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10869360	hybrid			2022-12-27	WOS:000089330700103
J	Guan, KL; Figueroa, C; Brtva, TR; Zhu, TQ; Taylor, J; Barber, TD; Vojtek, AB				Guan, KL; Figueroa, C; Brtva, TR; Zhu, TQ; Taylor, J; Barber, TD; Vojtek, AB			Negative regulation of the serine/threonine kinase B-Raf by Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; PROTEIN-KINASE; GROWTH-FACTOR; ACTIVATION; DIFFERENTIATION; PHOSPHORYLATION; EXPRESSION; COMPLEXITY; MECHANISM; PATHWAY	B-Raf contains multiple Akt consensus sites located within its amino-terminal regulatory domain. One site, Ser(364), is conserved with c-Raf but two additional sites, Ser(428) and Thr(439), are unique to B-Raf, We have investigated the role of both the conserved and unique phosphorylation sites in the regulation of B-Raf activity in vitro and in vivo. We show that phosphorylation of B-Raf by Abt occurs at multiple residues within its aminoterminal regulatory domain, at both the conserved and unique phosphorylation sites. The alteration of the serine residues within the Akt consensus sites to alanines results in a progressive increase in enzymatic activity in vitro and in vivo. Furthermore, expression of Akt inhibits epidermal growth factor-induced B-Raf activity and inhibition of Akt with LY294002 up-regulates B-Raf activity, suggesting that Akt negatively regulates B-Raf in vivo. Our results demonstrate that B-Raf activity can be negatively regulated by Akt through phosphorylation in the amino-terminal regulatory domain of B-Raf. This cross-talk between the B-Raf and Akt serine/threonine kinases is likely to play an important role in modulating the signaling specificity of the Ras/Raf pathway and in promoting biological outcome.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Vojtek, AB (corresponding author), Univ Michigan, Dept Biol Chem, 3323 MSRB III Box 0606, Ann Arbor, MI 48109 USA.			Figueroa-Romero, Claudia/0000-0001-7546-4190	NIGMS NIH HHS [GM51586] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051586] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	21	206	220	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27354	27359						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10869359				2022-12-27	WOS:000089144800092
J	Zhou, XL; Espey, MG; Chen, JX; Hofseth, LJ; Miranda, KM; Hussain, SP; Wink, DA; Harris, CC				Zhou, XL; Espey, MG; Chen, JX; Hofseth, LJ; Miranda, KM; Hussain, SP; Wink, DA; Harris, CC			Inhibitory effects of nitric oxide and nitrosative stress on dopamine-beta-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NG-MONOMETHYL ARGININE; ANOCOCCYGEUS MUSCLE; STRIATAL SLICES; H-3 DOPAMINE; RELEASE; RAT; RELAXATION; KINETICS; INSIGHTS; ASSAY	Dopamine-beta-hydroxylase (D beta H) is a copper-containing enzyme that uses molecular oxygen and ascorbate to catalyze the addition of a hydroxyl group on the beta-carbon of dopamine to form norepinephrine. While norepinephrine causes vasoconstriction following reflex sympathetic stimulation, nitric oxide (NO) formation results in vasodilatation via a guanylyl cyclase-dependent mechanism. In this report, we investigated the relationship between NO and D beta H enzymatic activity. In the initial in vitro experiments, the activity of purified D beta H was inhibited by the NO donor, diethylamine/NO (DEA/NO), with an IC50 of 1 mM. The inclusion of either azide or GSH partially restored D beta H activity, suggesting the involvement of the reactive nitrogen oxide species, N2O3. Treatment of human neuroblastoma cells (SK-N-MC) with diethylamine/NO decreased cellular D beta H activity without affecting their growth rate and was augmented by the depletion of intracellular GSH. Coculture of the SK-N-MC cells with interferon-gamma and lipopolysaccharide-activated macrophages, which release NO, also reduced the D beta H activity in the neuroblastoma cells. Our results are consistent with the hypothesis that nitrosative stress, mediated by N2O3, can result in the inhibition of norepinephrine biosynthesis and may contribute to the regulation of neurotransmission and vasodilatation.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; NCI, Radiat Biol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, Bldg 37,Rm 2C05,37 Convent Dr, Bethesda, MD 20892 USA.		Miranda, Katrina M/B-7823-2009	Wink, David/0000-0002-5652-7480; Azad, Mahan/0000-0002-8633-3513	NATIONAL CANCER INSTITUTE [Z01BC010033, ZIABC010033] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AXELROD J, 1972, PHARMACOL REV, V24, P233; BREWSTER MA, 1979, ANN CLIN LAB SCI, V9, P343; CEDERQVIST B, 1991, NEUROSCI LETT, V127, P67, DOI 10.1016/0304-3940(91)90896-2; Espey MG, 2000, J BIOL CHEM, V275, P11341, DOI 10.1074/jbc.275.15.11341; FITZPATRICK PF, 1987, ARCH BIOCHEM BIOPHYS, V257, P231, DOI 10.1016/0003-9861(87)90563-7; FORD PC, 1993, FEBS LETT, V326, P1, DOI 10.1016/0014-5793(93)81748-O; GIBSON A, 1990, BRIT J PHARMACOL, V99, P602, DOI 10.1111/j.1476-5381.1990.tb12976.x; Griscavage J M, 1995, Adv Pharmacol, V34, P215; HANBAUER I, 1992, NEUROREPORT, V3, P409, DOI 10.1097/00001756-199205000-00008; KATO T, 1978, BIOCHEM PHARMACOL, V27, P829, DOI 10.1016/0006-2952(78)90538-5; KATO T, 1974, BIOCHEM MED METAB B, V10, P320, DOI 10.1016/0006-2944(74)90035-0; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; KOBAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P1089, DOI 10.1093/nar/17.3.1089; LI CG, 1989, CLIN EXP PHARMACOL P, V16, P933, DOI 10.1111/j.1440-1681.1989.tb02404.x; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; LONART G, 1993, J NEUROSCI RES, V35, P192, DOI 10.1002/jnr.490350210; LORRAIN DS, 1993, NEUROREPORT, V5, P87, DOI 10.1097/00001756-199310000-00024; Miles AM, 1996, METHOD ENZYMOL, V268, P105; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; NAGATSU T, 1991, NEUROSCI RES, V12, P315, DOI 10.1016/0168-0102(91)90001-F; PALACIOS M, 1989, BIOCHEM BIOPH RES CO, V165, P802, DOI 10.1016/S0006-291X(89)80037-3; ROBERTSON D, 1991, HYPERTENSION, V18, P1, DOI 10.1161/01.HYP.18.1.1; RUSH RA, 1980, CRC CR REV CL LAB SC, V12, P241, DOI 10.3109/10408368009108731; SAMS CF, 1984, BIOCHIM BIOPHYS ACTA, V787, P61, DOI 10.1016/0167-4838(84)90108-0; SEILICOVICH A, 1995, P NATL ACAD SCI USA, V92, P11299, DOI 10.1073/pnas.92.24.11299; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; SOKOLOFF RL, 1985, J NEUROCHEM, V44, P411, DOI 10.1111/j.1471-4159.1985.tb05431.x; TERRY LC, 1985, NEUROENDOCRINOLOGY, V41, P467, DOI 10.1159/000124221; THOENEN H, 1971, P NATL ACAD SCI USA, V68, P1598, DOI 10.1073/pnas.68.7.1598; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TODA N, 1990, JPN J PHARMACOL, V52, P170, DOI 10.1254/jjp.52.170; Williams DLH, 1997, NITRIC OXIDE-BIOL CH, V1, P522, DOI 10.1006/niox.1997.0159; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; Wink DA, 1996, METHOD ENZYMOL, V268, P120; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007	36	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21241	21246		10.1074/jbc.M904498199	http://dx.doi.org/10.1074/jbc.M904498199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10887204	hybrid			2022-12-27	WOS:000088230600039
J	Chrysina, ED; Brew, K; Acharya, KR				Chrysina, ED; Brew, K; Acharya, KR			Crystal structures of apo- and holo-bovine alpha-lactalbumin at 2.2-A resolution reveal an effect of calcium on inter-lobe interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATE; AMINO-ACID-SEQUENCE; GUINEA-PIG; BINDING SITE; CA2+ BINDING; PROTEIN; LYSOZYME; ENVIRONMENTS; FLUORESCENCE; ASSOCIATION	High affinity binding of Ca2+ to a-lactalbumin (LA) stabilizes the native structure and is required for the efficient generation of native protein with correct disulfide bonds from the reduced denatured state. A progressive increase in affinity of LA conformers for Ca2+ as they develop increasingly native structures can account for the tendency of the apo form to assume a molten globule state and the large acceleration of folding by Ca2+. To investigate the effect of calcium on structure of bovine LA, x-ray structures have been determined for crystals of the apo and hole forms at 2.2-Angstrom resolution. In both crystal forms, which were grown at high ionic strength, the protein is in a similar global native conformation consisting of alpha -helical and beta -subdomains separated by a cleft. Even though alternative cations and Ca2+ liganding solvent molecules are absent, removal of Ca2+ has only minor effects on the structure of the metal-binding site and a structural change was observed in the cleft on the opposite face of the molecule adjoining Tyr(103) of the helical lobe and Gln(54) of the beta -lobe. Changes include increased separation of the lobes, loss of a buried solvent molecule near the Ca2+-binding site, and the replacement of inter- and intra-lobe II-bonds of Tyr(103) by interactions with new immobilized water molecules. The more open cleft structure in the apo protein appears to be an effect of calcium binding transmitted via a change in orientation of helix H3 relative to the beta -lobe to the inter-lobe interface. Calcium is well known to promote the folding of Lk The results from the comparison of apo and hole structures of LA provide high resolution structural evidence that the acceleration of folding by Ca2+ is mediated by an effect on interactions between the two subdomains.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Bath; University of Miami	Acharya, KR (corresponding author), Univ Bath, Dept Biol & Biochem, Claverton Down, Bath BA2 7AY, Avon, England.	K.R.Acharya@bath.ac.uk	Brew, Keith/A-6746-2009; Brew, Keith/W-1643-2019; Chrysina, Evangelia/E-6464-2016	Brew, Keith/0000-0003-1306-1032; Chrysina, Evangelia/0000-0001-8147-9030; Acharya, K. Ravi/0000-0002-3009-4058	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058773] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58773] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; ACHARYA KR, 1991, J MOL BIOL, V221, P571; ALEXANDRESCU AT, 1992, EUR J BIOCHEM, V210, P699, DOI 10.1111/j.1432-1033.1992.tb17471.x; ALEXANDRESCU AT, 1993, BIOCHEMISTRY-US, V32, P1707, DOI 10.1021/bi00058a003; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arai M, 1996, FOLD DES, V1, P275, DOI 10.1016/S1359-0278(96)00041-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BERLINER LJ, 1983, BIOCHEMISTRY-US, V22, P5061, DOI 10.1021/bi00291a002; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; BREW K, 1967, J BIOL CHEM, V242, P3747; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brunger AT, 1992, XPLOR VERSION 3 1 MA; Calderone V, 1996, FEBS LETT, V394, P91, DOI 10.1016/0014-5793(96)00933-7; Chandra N, 1998, BIOCHEMISTRY-US, V37, P4767, DOI 10.1021/bi973000t; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3677, DOI 10.1021/bi00065a022; Forge V, 1999, J MOL BIOL, V288, P673, DOI 10.1006/jmbi.1999.2687; GERKEN TA, 1984, BIOCHEMISTRY-US, V23, P4688, DOI 10.1021/bi00315a026; GROBLER JA, 1994, ARCH BIOCHEM BIOPHYS, V313, P360, DOI 10.1006/abbi.1994.1399; GROBLER JA, 1992, ADV DAIRY CHEM, V1, P191; Guss JM, 1997, ACTA CRYSTALLOGR D, V53, P355, DOI 10.1107/S0907444996015831; GUSSAKOVSKY EE, 1995, PROTEIN SCI, V4, P2319, DOI 10.1002/pro.5560041109; HARATA K, 1992, J BIOL CHEM, V267, P1419; HILL RL, 1975, ADV ENZYMOL RAMB, V43, P411; HIRAOKA Y, 1985, INT J PEPT PROT RES, V26, P252; IKEGUCHI M, 1986, J BIOCHEM-TOKYO, V99, P1191, DOI 10.1093/oxfordjournals.jbchem.a135582; INAKA K, 1991, J BIOL CHEM, V266, P20666; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRONMAN MJ, 1981, J BIOL CHEM, V256, P8582; KRONMAN MJ, 1989, CRIT REV BIOCHEM MOL, V24, P565, DOI 10.3109/10409238909080054; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1989, J MOL BIOL, V206, P547, DOI 10.1016/0022-2836(89)90500-7; LALA AK, 1992, J BIOL CHEM, V267, P19914; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PENG ZY, 1994, BIOCHEMISTRY-US, V33, P2136, DOI 10.1021/bi00174a021; PEPYS MB, 1993, NATURE, V362, P553, DOI 10.1038/362553a0; PERMYAKOV EA, 1981, BIOCHEM BIOPH RES CO, V100, P191, DOI 10.1016/S0006-291X(81)80081-2; Pike ACW, 1996, STRUCTURE, V4, P691, DOI 10.1016/S0969-2126(96)00075-5; RAO KR, 1989, BIOCHEM BIOPH RES CO, V163, P1390, DOI 10.1016/0006-291X(89)91133-9; REN JS, 1993, J BIOL CHEM, V268, P19292; SCHAER JJ, 1985, FEBS LETT, V190, P77, DOI 10.1016/0014-5793(85)80431-2; SMITH SG, 1987, BIOCHEM J, V242, P353, DOI 10.1042/bj2420353; SONG HW, 1994, J MOL BIOL, V244, P522, DOI 10.1006/jmbi.1994.1750; Steinrauf LK, 1998, ACTA CRYSTALLOGR D, V54, P767, DOI 10.1107/S0907444997016922; STUART DI, 1986, NATURE, V324, P84, DOI 10.1038/324084a0; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; Svensson M, 1999, J BIOL CHEM, V274, P6388, DOI 10.1074/jbc.274.10.6388; THUNNISSEN AMWH, 1995, PROTEINS, V22, P245, DOI 10.1002/prot.340220305; TSUGE H, 1992, J BIOCHEM-TOKYO, V111, P141, DOI 10.1093/oxfordjournals.jbchem.a123727; VANDERHEEREN G, 1994, J BIOL CHEM, V269, P7090; Veillon C, 1978, Methods Enzymol, V54, P446; WANG M, 1989, J BIOL CHEM, V264, P21116; WU LC, 1995, NAT STRUCT BIOL, V2, P281, DOI 10.1038/nsb0495-281	59	208	216	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37021	37029		10.1074/jbc.M004752200	http://dx.doi.org/10.1074/jbc.M004752200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10896943	hybrid			2022-12-27	WOS:000165577700080
J	Hacker, C; Glinski, M; Hornbogen, T; Doller, A; Zocher, R				Hacker, C; Glinski, M; Hornbogen, T; Doller, A; Zocher, R			Mutational analysis of the N-methyltransferase domain of the multifunctional enzyme enniatin synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; S-ADENOSYLMETHIONINE; CRYSTAL-STRUCTURE; DEPENDENT METHYLTRANSFERASES; MOLECULAR CHARACTERIZATION; PEPTIDE SYNTHETASES; SEQUENCE MOTIFS; DNA; SUGGESTS; BINDING	N-Methylcyclopeptides Like cyclosporins and enniatins are synthesized by multifunctional enzymes representing hybrid systems of peptide synthetases and S-adenosyl-L-methionine (AdoMet)-dependent N-methyltransferases. The latter constitute a new family of N-methyltransferases sharing high homology within procaryotes and eucaryotes. Here we describe the mutational analysis of the N-methyltransferase domain of enniatin synthetase from Fusarium scirpi to gain insight into the assembly of the AdoMet-binding site. The role of four conserved motifs (I, (2085)VLEIGTGSGMIL; II/Y, (2105)SYVGLDPS; IV, (2152)DLVVFNSVVQYFTPPEYL; and V, (2194)ATNGHFLAARA) in cofactor binding as measured by photolabeling was studied. Deletion of the first 21 N-terminal amino acid residues of the N-methyltransferase domain did not affect AdoMet binding. Further shortening close to motif I resulted in loss of binding activity. Truncation of 38 amino acids from the C terminus and also internal deletions containing motif V led to complete loss of AdoMet-binding activity. Point mutations converting the conserved Tyr(223) (corresponding to position 2106 in enniatin synthetase) in motif II/Y (close to motif I) into Val, Ala, and Ser, respectively, strongly diminished AdoMet binding, whereas conversion of this residue to Phe restored AdoMet-binding activity to similar to 70%, indicating that Tyr(223) is important for AdoMet binding and that the aromatic Tyr(223) may be crucial for AdoMet binding in N-methylpeptide synthetases.	Tech Univ Berlin, Fachgebiet Biochem & Mol Biol, Max Volmer Inst BIophys Chem & Biochem, D-10587 Berlin, Germany	Technical University of Berlin	Zocher, R (corresponding author), Tech Univ Berlin, Fachgebiet Biochem & Mol Biol, Max Volmer Inst BIophys Chem & Biochem, Franklinstr 29, D-10587 Berlin, Germany.	razzo@chem.tu-berlin.de		Hacker, Christine/0000-0002-6545-0104				BILLICH A, 1987, BIOL CHEM H-S, V368, P521, DOI 10.1515/bchm3.1987.368.1.521; BILLICH A, 1987, BIOCHEMISTRY-US, V26, P8417, DOI 10.1021/bi00399a058; BILLICH A, 1990, BIOCH PEPTIDE ANTIBI, P57; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Burmester J, 1995, BIOCHEM MOL BIOL INT, V37, P201; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; deCrecyLagard V, 1997, ANTIMICROB AGENTS CH, V41, P1904, DOI 10.1128/AAC.41.9.1904; Djordjevic S, 1997, STRUCTURE, V5, P545, DOI 10.1016/S0969-2126(97)00210-4; Fischer D, 1999, PROTEINS, P209; FRIEDMAN S, 1991, NUCLEIC ACIDS RES, V19, P5403, DOI 10.1093/nar/19.19.5403; Fu ZJ, 1996, BIOCHEMISTRY-US, V35, P11985, DOI 10.1021/bi961068n; GLINSKI M, 1999, THESIS TU BERLIN; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; HAESE A, 1994, J MOL BIOL, V243, P116, DOI 10.1006/jmbi.1994.1634; HAESE A, 1993, MOL MICROBIOL, V7, P905, DOI 10.1111/j.1365-2958.1993.tb01181.x; HIGUCHI R, 1991, PCR PROTOCOLS GUIDE, P177; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KELLER U, 1987, J BIOL CHEM, V262, P5852; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWEN A, 1990, J BIOL CHEM, V265, P11355; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; Nishizawa T, 1999, J BIOCHEM-TOKYO, V126, P520, DOI 10.1093/oxfordjournals.jbchem.a022481; OGAWA H, 1987, EUR J BIOCHEM, V168, P141, DOI 10.1111/j.1432-1033.1987.tb13398.x; PEETERS H, 1983, J ANTIBIOT, V36, P1762, DOI 10.7164/antibiotics.36.1762; PIEPER R, 1995, EUR J BIOCHEM, V230, P119, DOI 10.1111/j.1432-1033.1995.tb20541.x; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schauwecker F, 2000, CHEM BIOL, V7, P287, DOI 10.1016/S1074-5521(00)00103-4; Schluckebier G, 1997, J MOL BIOL, V265, P56, DOI 10.1006/jmbi.1996.0711; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; TAKATA Y, 1992, BIOCHEMISTRY-US, V31, P4369, DOI 10.1021/bi00132a030; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; WEBER G, 1994, CURR GENET, V26, P120, DOI 10.1007/BF00313798; ZOCHER R, 1983, BIOCHEM BIOPH RES CO, V110, P292, DOI 10.1016/0006-291X(83)91294-9; Zocher R, 1997, ADV MICROB PHYSIOL, V38, P85; ZOCHER R, 1986, BIOCHEMISTRY-US, V25, P550, DOI 10.1021/bi00351a005	42	29	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30826	30832		10.1074/jbc.M002614200	http://dx.doi.org/10.1074/jbc.M002614200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10887181	hybrid			2022-12-27	WOS:000089762700015
J	Horie, K; Insel, PA				Horie, K; Insel, PA			Retrovirally mediated transfer of a G protein-coupled receptor kinase (GRK) dominant-negative mutant enhances endogenous calcitonin receptor signaling in Chinese hamster ovary cells - GRK inhibition enhances expression of receptors and receptor mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(1B)-ADRENERGIC RECEPTOR; DOWN-REGULATION; DESENSITIZATION; PHOSPHORYLATION; IDENTIFICATION; ISOFORMS	G protein-coupled receptor kinases (GRKs) initiate pathways leading to agonist-dependent phosphorylation and desensitization of G protein-coupled receptors. However, the role of GRKs in modulation of signaling properties of native receptors has not been clearly defined. Here we addressed this question by generating Chinese hamster ovary (CHO) cells stably expressing a dominant-negative mutant of GRK2 (DN-GRK2), K220R, using retrovirally mediated gene transfer, and we assessed function of the endogenously expressed calcitonin (CT) receptors. We found that CT-mediated responses were prominently enhanced in CHO cells expressing DN-GRK2 compared with mock-infected control CHO cells with similar to 3-fold increases in CT-promoted cAMP production in whole cells and adenylyl cyclase activity in membrane fractions. CT-promoted phosphoinositide hydrolysis was also enhanced in DN-GRK2 cells. The number of CT receptors was increased similar to 3-fold in DN-GRK2 cells, as assessed by I-125-salmon CT-specific binding, and this was associated with increased CT receptor mRNA levels. These results indicate that DN-GRK2 has multiple consequences for CT receptor signaling, but a primary effect is an increase in CT receptor mRNA and receptor number and, in turn, enhanced CT receptor signaling. As such, our findings provide a mechanistic basis for previous observations regarding agonist-promoted down-regulation of CT receptors and for resistance and escape from response to CT in vitro and in vivo. Moreover, the data suggest that blunting of receptor desensitization by DN-GRK2 blocks a GRK-mediated tonic inhibition of CT receptor expression and response. We speculate that GRKs play a similar role for other G protein-coupled receptors as well.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.							Aragay AM, 1998, P NATL ACAD SCI USA, V95, P2985, DOI 10.1073/pnas.95.6.2985; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Chen ST, 1996, P NATL ACAD SCI USA, V93, P10057, DOI 10.1073/pnas.93.19.10057; Diviani D, 1996, J BIOL CHEM, V271, P5049; FORCE T, 1992, AM J PHYSIOL, V262, pF1110, DOI 10.1152/ajprenal.1992.262.6.F1110; George SE, 1997, J NEUROCHEM, V69, P1278; GOTTESMAN M, 1983, METHOD ENZYMOL, V99, P197; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; HORIE K, 1995, MOL PHARMACOL, V48, P392; HORIE K, 1993, INVEST OPHTH VIS SCI, V34, P2769; HOUSSAMI S, 1994, ENDOCRINOLOGY, V135, P183, DOI 10.1210/en.135.1.183; Hughes RJ, 1996, AM J PHYSIOL-CELL PH, V270, pC885, DOI 10.1152/ajpcell.1996.270.3.C885; Iacovelli L, 1999, MOL PHARMACOL, V56, P316, DOI 10.1124/mol.56.2.316; Inoue D, 1999, ENDOCRINOLOGY, V140, P1060, DOI 10.1210/en.140.3.1060; KLIJN K, 1991, MOL PHARMACOL, V39, P407; KONG GH, 1994, J BIOL CHEM, V269, P13084; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Mundell SJ, 1997, MOL PHARMACOL, V51, P991, DOI 10.1124/mol.51.6.991; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; SEXTON PM, 1993, MOL ENDOCRINOL, V7, P815, DOI 10.1210/me.7.6.815; Shetzline MA, 1998, J BIOL CHEM, V273, P6756, DOI 10.1074/jbc.273.12.6756; Tucker C, 1997, J BIOL CHEM, V272, P9481; WADA S, 1995, ENDOCRINOLOGY, V136, P2611, DOI 10.1210/en.136.6.2611; Wada S, 1996, ENDOCRINOLOGY, V137, P1042, DOI 10.1210/en.137.3.1042; Xing MZ, 1999, J BIOL CHEM, V274, P10035, DOI 10.1074/jbc.274.15.10035	27	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29433	29440		10.1074/jbc.M003413200	http://dx.doi.org/10.1074/jbc.M003413200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10889199	hybrid			2022-12-27	WOS:000089439800036
J	Nguyen, VT; Ndoye, A; Grando, SA				Nguyen, VT; Ndoye, A; Grando, SA			Pemphigus vulgaris antibody identifies pemphaxin - A novel keratinocyte annexin-like molecule binding acetylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	60th Annual Meeting of the Society-for-Investigative-Dermatology	MAY 05-09, 1999	CHICAGO, IL	Soc Investigat Dermatol			DERMO-EPIDERMAL SEPARATION; BLISTER-CAUSING ANTIBODIES; CELL-SURFACE; HUMAN SKIN; SUBCELLULAR-LOCALIZATION; CHOLINERGIC RECEPTORS; MUSCARINIC RECEPTOR; NEONATAL MICE; TENASCIN-C; CADHERIN	Because pemphigus vulgaris (PV) IgGs adsorbed on the rDsg3-Ig-His baculoprotein induced blisters in neonatal mice, it was proposed that anti-desmoglein 3 (Dsg 3) autoantibody causes PV. However, we found that rDsg3-Ig-His absorbs autoantibodies to different antigens, including a non-Dsg 3 keratinocyte protein of 130 kDa. This prompted our search for novel targets of PV autoimmunity. The PV IgG eluted from a 75-kDa keratinocyte protein band both stained epidermis in a pemphigus-like pattern and induced acantholysis in keratinocyte monolayers. Screening of a keratinocyte lambda gt11 cDNA library with this antibody identified clones carrying cDNA inserts encoding a novel molecule exhibiting similar to 40% similarity with annexin-2, named pemphaxin (PX). Recombinant PX (rPX-His) was produced in Escherichia coli M15 cells, and, because annexins can act as cholinergic receptors, its conformation was tested in a cholinergic radioligand binding assay, rPX-His specifically bound [H-3]acetylcholine, suggesting that PX is one of the keratinocyte cholinergic receptors known to be targeted by disease-causing PV antibodies. Preabsorption of PV sera with rPX-His eliminated acantholytic activity, and eluted antibody immunoprecipitated native PX This antibody alone did not cause skin blisters in vivo, but its addition to the preabsorbed PV IgG fraction restored acantholytic activity, indicating that acantholysis in PV results from synergistic action of antibodies to different keratinocyte self-antigens, including both acetylcholine receptors and desmosomal cadherins.	Univ Calif Davis, Med Ctr, Dept Dermatol, Sacramento, CA 95817 USA	University of California System; University of California Davis	Grando, SA (corresponding author), Univ Calif Davis, Med Ctr, Dept Dermatol, 4860 Y St,Suite 3400, Sacramento, CA 95817 USA.	sagrando@ucdavis.edu		Nguyen, Vu/0000-0002-1142-6352				AHMED AR, 1982, J AM ACAD DERMATOL, V7, P221; AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; Amagai M, 2000, J CLIN INVEST, V105, P625, DOI 10.1172/JCI8748; AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; AMAGAI M, 1994, J CLIN INVEST, V94, P59, DOI 10.1172/JCI117349; Amagai M, 1998, J CLIN INVEST, V102, P775, DOI 10.1172/JCI3647; Amagai M, 1999, J DERMATOL SCI, V20, P92, DOI 10.1016/S0923-1811(99)00016-X; ANHALT GJ, 1982, NEW ENGL J MED, V306, P1189, DOI 10.1056/NEJM198205203062001; Barwise JL, 1996, J CELL SCI, V109, P247; BASTIAN BC, 1993, J INVEST DERMATOL, V101, P359, DOI 10.1111/1523-1747.ep12365541; BEUTNER EH, 1985, INT J DERMATOL, V24, P405, DOI 10.1111/j.1365-4362.1985.tb05507.x; Chung CY, 1996, MOL BIOL CELL, V7, P883, DOI 10.1091/mbc.7.6.883; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; Cohen Lisa M., 1997, P209; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CULARD JF, 1992, J INVEST DERMATOL, V98, P436, DOI 10.1111/1523-1747.ep12499850; CURTIS CAM, 1989, J BIOL CHEM, V264, P489; DEMANGE P, 1994, TRENDS BIOCHEM SCI, V19, P272, DOI 10.1016/0968-0004(94)90002-7; Ding X, 1999, J INVEST DERMATOL, V112, P739, DOI 10.1046/j.1523-1747.1999.00585.x; Donnelly SR, 1997, CELL MOL LIFE SCI, V53, P533, DOI 10.1007/s000180050068; FALCONE DJ, 1995, FASEB J, V9, pA412; Fan JL, 1999, J IMMUNOL, V163, P6228; FAVA RA, 1993, J INVEST DERMATOL, V101, P732, DOI 10.1111/1523-1747.ep12371684; Feliciani C, 2000, J INVEST DERMATOL, V114, P71, DOI 10.1046/j.1523-1747.2000.00835.x; Fujimoto K, 1997, J CELL SCI, V110, P311; Grando S. A., 1993, J EUR ACAD DERMATOL, V2, P72; GRANDO SA, 1989, AUTOIMMUNITY, V3, P247, DOI 10.3109/08916938908997095; GRANDO SA, 1993, SKIN PHARMACOL, V6, P135; GRANDO SA, 1990, J CLIN LAB IMMUNOL, V32, P137; GRANDO SA, 1989, ARCH DERMATOL, V125, P925, DOI 10.1001/archderm.125.7.925; Grando SA, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P41, DOI 10.1038/jidsymp.1997.10; GRANDO SA, 1997, CURR OPIN DERMATOL, V4, P262; Hajjar KA, 1997, ANN NY ACAD SCI, V811, P337, DOI 10.1111/j.1749-6632.1997.tb52013.x; HASHIMOTO K, 1989, J INVEST DERMATOL, V92, P310, DOI 10.1111/1523-1747.ep12277087; Hu ZL, 2000, NAT GENET, V24, P61, DOI 10.1038/71701; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IWATSUKI K, 1995, BRIT J DERMATOL, V133, P209, DOI 10.1111/j.1365-2133.1995.tb02617.x; JONES PG, 1992, J BIOL CHEM, V267, P13993; JOST M, 1992, EUR J BIOCHEM, V207, P923, DOI 10.1111/j.1432-1033.1992.tb17125.x; JOST M, 1994, BIOCHEM J, V298, P553, DOI 10.1042/bj2980553; KARPATI S, 1993, J CELL BIOL, V122, P409, DOI 10.1083/jcb.122.2.409; KAWANA S, 1989, J INVEST DERMATOL, V92, P588, DOI 10.1111/1523-1747.ep12709624; Keith D, 1999, HUM MOL GENET, V8, P143, DOI 10.1093/hmg/8.1.143; Kitajima Y, 1999, J INVEST DERM SYMP P, V4, P137, DOI 10.1038/sj.jidsp.5640197; KITAJIMA Y, 1987, J INVEST DERMATOL, V89, P167, DOI 10.1111/1523-1747.ep12470554; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lin MS, 1997, CLIN EXP IMMUNOL, V107, P9; Ma ASP, 1996, ARCH DERMATOL RES, V288, P596, DOI 10.1007/s004030050109; Mahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252; MATUSLEIBOVITCH N, 1992, BIOCHEM J, V285, P753, DOI 10.1042/bj2850753; Memar OM, 1996, J INVEST DERMATOL, V106, P261, DOI 10.1111/1523-1747.ep12340663; MEMAR OM, 1995, CHARACTERIZATION PEM; Morgan RO, 1997, CELL MOL LIFE SCI, V53, P508, DOI 10.1007/s000180050064; Moss SE, 1997, TRENDS CELL BIOL, V7, P87, DOI 10.1016/S0962-8924(96)10049-0; NAKAO H, 1994, EUR J BIOCHEM, V223, P901, DOI 10.1111/j.1432-1033.1994.tb19067.x; Nguyen VT, 1998, ARCH DERMATOL, V134, P971, DOI 10.1001/archderm.134.8.971; NGUYEN VT, 2000, IN PRESS AM J PATHOL; NGUYEN VT, 1993, J INVEST DERMATOL, V100, P349; Ohata Y, 1995, CLIN EXP DERMATOL, V20, P454, DOI 10.1111/j.1365-2230.1995.tb01376.x; PATEL HP, 1984, J INVEST DERMATOL, V83, P409, DOI 10.1111/1523-1747.ep12273480; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; Reutelingsperger CPM, 1997, CELL MOL LIFE SCI, V53, P527, DOI 10.1007/s000180050067; Rickman L, 1999, HUM MOL GENET, V8, P971, DOI 10.1093/hmg/8.6.971; Robinson JC, 1997, ORAL SURG ORAL MED O, V84, P349, DOI 10.1016/S1079-2104(97)90030-5; ROSENBERG FR, 1976, ARCH DERMATOL, V112, P962, DOI 10.1001/archderm.112.7.962; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; SCHENK S, 1995, BRIT J DERMATOL, V133, P13; Shtrom SS, 1996, J BIOL CHEM, V271, P25506, DOI 10.1074/jbc.271.41.25506; Siever DA, 1997, INT J BIOCHEM CELL B, V29, P1219, DOI 10.1016/S1357-2725(97)00057-5; SMITH PD, 1994, TRENDS GENET, V10, P241, DOI 10.1016/0168-9525(94)90171-6; STANLEY JR, 1995, CIBA F SYMP, V189, P107; STANLEY JR, 1984, J CLIN INVEST, V74, P313, DOI 10.1172/JCI111426; STANLEY JR, 1982, J CLIN INVEST, V70, P281, DOI 10.1172/JCI110615; STERZ R, 1986, BRAIN RES, V385, P99, DOI 10.1016/0006-8993(86)91551-9; SWANSON DL, 1983, J INVEST DERMATOL, V81, P258, DOI 10.1111/1523-1747.ep12518278; TAYLOR IK, 1975, EUR J PHARMACOL, V31, P319, DOI 10.1016/0014-2999(75)90055-2; Toto P, 2000, J IMMUNOL, V164, P522, DOI 10.4049/jimmunol.164.1.522; TRESSLER RJ, 1993, J CELL BIOCHEM, V53, P265, DOI 10.1002/jcb.240530311; Udey MC, 1999, JAMA-J AM MED ASSOC, V282, P572, DOI 10.1001/jama.282.6.572; ULUS IH, 1988, BIOCHEM PHARMACOL, V37, P2747, DOI 10.1016/0006-2952(88)90037-8; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; vonderMark K, 1997, CELL MOL LIFE SCI, V53, P539, DOI 10.1007/s000180050069; Whittock NV, 1999, J INVEST DERMATOL, V113, P940, DOI 10.1046/j.1523-1747.1999.00783.x; Witcher LL, 1996, J BIOL CHEM, V271, P10904, DOI 10.1074/jbc.271.18.10904; ZIMMERMAN UJP, 1995, BIOCHEM MOL BIOL INT, V35, P307	87	99	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29466	29476		10.1074/jbc.M003174200	http://dx.doi.org/10.1074/jbc.M003174200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	356JH	10899159	hybrid			2022-12-27	WOS:000089439800040
J	Yieh, L; Kassavetis, G; Geiduschek, EP; Sandmeyer, SB				Yieh, L; Kassavetis, G; Geiduschek, EP; Sandmeyer, SB			The Brf and TATA-binding protein subunits of the RNA polymerase III transcription factor IIIB mediate position-specific integration of the gypsy-like element, Ty3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROVIRUS-LIKE ELEMENT; FACTOR-TFIIIB; IN-VITRO; U6 GENE; YEAST; PROMOTER; BOX; INITIATION; TRANSPOSITION; COMPONENTS	Ty3 integrates into the transcription initiation sites of genes transcribed by RNA polymerase III. It is known that transcription factors (TF) IIIB and IIIC are important for recruiting Ty3 to its sites of integration upstream of tRNA genes, but that RNA polymerase III is not required. In order to investigate the respective roles of TFIIIB and TFIIIC, we have developed an in vitro integration assay in which Ty3 is targeted to the U6 small nuclear RNA gene, SNR6. Because TFIIIB can bind to the TATA box upstream of the U6 gene through contacts mediated by TATA-binding protein (TBP), TFIIIC is dispensable for in vitro transcription. Thus, this system offers an opportunity to test the role of TFIIIB independent of a requirement of TFIIIC. We demonstrate that the recombinant Brf and TBP subunits of TFIIIB, which interact over the SNR6 TATA box, direct integration at the SNR6 transcription initiation site in the absence of detectable TFIIIC or TFIIIB subunit B". These findings suggest that the minimal requirements for pol III transcription and Ty3 integration are very similar.	Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Diego; University of California System; University of California San Diego	Sandmeyer, SB (corresponding author), Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.				NIGMS NIH HHS [GM18386, GM33281] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018386, R37GM018386, R01GM033281] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1983, CELL, V34, P655, DOI 10.1016/0092-8674(83)90398-7; Andrau JC, 1999, J MOL BIOL, V288, P511, DOI 10.1006/jmbi.1999.2724; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; Bartholomew B, 1995, METHOD ENZYMOL, V262, P476; Boeke JD, 1998, CELL, V93, P1087, DOI 10.1016/S0092-8674(00)81450-6; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BURNOL AF, 1993, J MOL BIOL, V233, P644, DOI 10.1006/jmbi.1993.1542; BURNOL AF, 1993, NATURE, V362, P475, DOI 10.1038/362475a0; CHALKER DL, 1993, P NATL ACAD SCI USA, V90, P4927, DOI 10.1073/pnas.90.11.4927; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; CHALKER DL, 1990, GENETICS, V126, P837; Colbert T, 1998, MOL CELL BIOL, V18, P1682, DOI 10.1128/MCB.18.3.1682; Connolly CM, 1997, FEBS LETT, V405, P305, DOI 10.1016/S0014-5793(97)00200-7; Devine SE, 1996, GENE DEV, V10, P620, DOI 10.1101/gad.10.5.620; ESCHENLAUER JB, 1993, MOL CELL BIOL, V13, P3015, DOI 10.1128/MCB.13.5.3015; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Ferri ML, 2000, MOL CELL BIOL, V20, P488, DOI 10.1128/MCB.20.2.488-495.2000; Flores A, 1999, P NATL ACAD SCI USA, V96, P7815, DOI 10.1073/pnas.96.14.7815; Grove A, 1999, J MOL BIOL, V285, P1429, DOI 10.1006/jmbi.1998.2347; Grove A, 1998, J MOL BIOL, V282, P731, DOI 10.1006/jmbi.1998.2058; Hani J, 1998, NUCLEIC ACIDS RES, V26, P689, DOI 10.1093/nar/26.3.689; HANSEN LJ, 1992, J VIROL, V66, P1414, DOI 10.1128/JVI.66.3.1414-1424.1992; JOAZEIRO CAP, 1994, MOL CELL BIOL, V14, P2798, DOI 10.1128/MCB.14.4.2798; KAISER MW, 1995, J BIOL CHEM, V270, P11398, DOI 10.1074/jbc.270.19.11398; KAMPS MP, 1988, ONCOGENE, V2, P305; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; Kassavetis GA, 1998, MOL CELL BIOL, V18, P5587, DOI 10.1128/MCB.18.9.5587; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; Kassavetis GA, 1999, EMBO J, V18, P5042, DOI 10.1093/emboj/18.18.5042; Kassavetis GA, 1998, P NATL ACAD SCI USA, V95, P9196, DOI 10.1073/pnas.95.16.9196; Kassavetis GA, 1997, MOL CELL BIOL, V17, P5299, DOI 10.1128/MCB.17.9.5299; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; Kim JM, 1998, GENOME RES, V8, P464, DOI 10.1101/gr.8.5.464; KINSEY PT, 1995, GENETICS, V139, P81; KIRCHNER J, 1995, SCIENCE, V267, P1488, DOI 10.1126/science.7878467; Librizzi MD, 1998, J BIOL CHEM, V273, P4563, DOI 10.1074/jbc.273.8.4563; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MENEES TM, 1994, MOL CELL BIOL, V14, P8229, DOI 10.1128/MCB.14.12.8229; Mielke C, 1996, BIOCHEMISTRY-US, V35, P2239, DOI 10.1021/bi952393y; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; NICHOLS M, 1989, J BIOL CHEM, V264, P17084; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; Sandmeyer S, 1998, GENOME RES, V8, P416, DOI 10.1101/gr.8.5.416; Shah SMA, 1999, J BIOL CHEM, V274, P28736, DOI 10.1074/jbc.274.40.28736; Shen YH, 1998, MOL CELL BIOL, V18, P1692, DOI 10.1128/MCB.18.3.1692; WERNER M, 1993, J BIOL CHEM, V268, P20721; White R. J., 1998, RNA POLYMERASE 3 TRA; WHITEHALL SK, 1995, GENE DEV, V9, P2974, DOI 10.1101/gad.9.23.2974; Zou S, 1997, P NATL ACAD SCI USA, V94, P7412, DOI 10.1073/pnas.94.14.7412	53	63	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29800	29807		10.1074/jbc.M003149200	http://dx.doi.org/10.1074/jbc.M003149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882723	Green Published, hybrid			2022-12-27	WOS:000089439800085
J	Bruck, I; O'Donnell, M				Bruck, I; O'Donnell, M			The DNA replication machine of a gram-positive organism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI; ACCESSORY PROTEINS; BACILLUS-SUBTILIS; SLIDING CLAMPS; GAMMA-SUBUNIT; LAGGING-STRAND; PURIFICATION; COMPLEX; LOADER	This report outlines the protein requirements and subunit organization of the DNA replication apparatus of Streptococcus pyogenes, a Gram-positive organism. Five proteins coordinate their actions to achieve rapid and processive DNA synthesis. These proteins are: the PolC DNA polymerase, tau, delta, delta', and beta. S. pyogenes dnaX encodes only the full-length tau, unlike the Escherichia coli system in which dnaX encodes two proteins, tau and gamma. The S. pyogenes tau binds PolC, but the interaction is not as firm as the corresponding interaction in E. coli, underlying the inability to purify a PolC holoenzyme from Gram-positive cells. The tau also binds the delta and delta' subunits to form a tau delta delta' "clamp loader." PolC can assemble with tau delta delta' to form a PolC.tau delta delta' complex. After PolC.tau delta delta' clamps beta to a primed site, it extends DNA 700 nucleotides/second in a highly processive fashion. Gram-positive cells contain a second DNA polymerase, encoded by dnaE, that has homology to the E. coli alpha subunit off. coli DNA polymerase III. We show here that the S. pyogenes DnaE polymerase also functions with the beta clamp.	Rockefeller Univ, Lab DNA Replicat, Howard Hughes Med Inst, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	O'Donnell, M (corresponding author), Rockefeller Univ, Lab DNA Replicat, Howard Hughes Med Inst, 1230 York Ave, New York, NY 10021 USA.	odonnell@rockvax.rockefeller.edu		O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [GM 38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ason B, 2000, J BIOL CHEM, V275, P3006, DOI 10.1074/jbc.275.4.3006; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BARNES MH, 1979, NUCLEIC ACIDS RES, V6, P1203, DOI 10.1093/nar/6.3.1203; BARNES MH, 1994, MOL MICROBIOL, V13, P843, DOI 10.1111/j.1365-2958.1994.tb00476.x; BLINKOVA A, 1993, J BACTERIOL, V175, P6018, DOI 10.1128/JB.175.18.6018-6027.1993; Blinkova A, 1997, J BACTERIOL, V179, P4438, DOI 10.1128/jb.179.13.4438-4442.1997; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BONNER CA, 1992, J BIOL CHEM, V267, P11431; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; CAPARON MG, 1991, METHOD ENZYMOL, V204, P556; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; COZZARELLI NR, 1973, BIOCHEM BIOPH RES CO, V51, P151, DOI 10.1016/0006-291X(73)90521-4; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Flett F, 1999, MOL MICROBIOL, V31, P949, DOI 10.1046/j.1365-2958.1999.01237.x; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; GASS KB, 1973, P NATL ACAD SCI USA, V70, P103, DOI 10.1073/pnas.70.1.103; GASS KB, 1973, J BIOL CHEM, V248, P7688; Hingorani MM, 1999, EMBO J, V18, P5131, DOI 10.1093/emboj/18.18.5131; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; Kelman Z, 2000, J BIOL CHEM, V275, P7327, DOI 10.1074/jbc.275.10.7327; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION, P165; Larsen B, 2000, P NATL ACAD SCI USA, V97, P1683, DOI 10.1073/pnas.97.4.1683; LEE SH, 1991, J BIOL CHEM, V266, P594; LOW RL, 1974, P NATL ACAD SCI USA, V71, P2973, DOI 10.1073/pnas.71.8.2973; LOW RL, 1976, J BIOL CHEM, V251, P1311; MACKENZIE JM, 1973, P NATL ACAD SCI USA, V70, P512, DOI 10.1073/pnas.70.2.512; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ODONNELL ME, 1985, J BIOL CHEM, V260, P2875; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; ROWEN L, 1978, J BIOL CHEM, V253, P758; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TINKER RL, 1994, CELL, V77, P225, DOI 10.1016/0092-8674(94)90315-8; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Turner J, 1995, METHOD ENZYMOL, V262, P442; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; WHEELER J, 1980, J GEN MICROBIOL, V120, P27; WU CA, 1992, J BIOL CHEM, V267, P4064; XIAO H, 1993, J BIOL CHEM, V268, P11773; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Yao N, 2000, J BIOL CHEM, V275, P1421, DOI 10.1074/jbc.275.2.1421; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	69	76	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28971	28983		10.1074/jbc.M003565200	http://dx.doi.org/10.1074/jbc.M003565200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878011	hybrid			2022-12-27	WOS:000089330700083
J	Patzlaff, JS; Brooker, RJ; Barry, BA				Patzlaff, JS; Brooker, RJ; Barry, BA			A reaction-induced Fourier transform-infrared spectroscopic study of the lactose permease - A transmembrane potential perturbs carboxylic acid residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TRANSPORT PROTEIN; HALOBACTERIUM-HALOBIUM; ESCHERICHIA-COLI; PURPLE MEMBRANE; AMINO-ACID; BACTERIORHODOPSIN; RECONSTITUTION; VESICLES; SPECTRA; LIPOSOMES	In chemiosmotic coupling, a transmembrane ion gradient is used as the source of energy to drive reactions. This process occurs in all cells, but the microscopic mechanism is not understood. Here, Escherichia coli lactose permease was used in a novel spectroscopic method to investigate the mechanism of chemiosmotic coupling in secondary active transporters. To provide a light-triggered electrochemical gradient, bacteriorhodopsin was co-reconstituted with the permease, and reaction-induced Fourier transform-infrared spectra were obtained from the co-reconstituted samples. The bacteriorhodopsin contributions were subtracted from these data to give spectra reflecting permease conformational changes that are induced by an electrochemical gradient. Positive bands in the 1765-1730 cm(-1) region are attributable to carboxylic acid residues in the permease and are consistent with changes of pK(a), protonation state, or environment. This is the first direct information concerning gradient-induced structural changes in the permease at the single amino acid level. Ultimately, these structural changes facilitate galactoside binding and may be involved in the storage of free energy.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Gortner Lab 140, St Paul, MN 55108 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, Biol Proc Technol Inst, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Barry, BA (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, Gortner Lab 140, 1479 Gortner Ave, St Paul, MN 55108 USA.	barry@biosci.cbs.umn.edu			NIGMS NIH HHS [GM 53259] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL LA, 1980, BRIT J SOCIOL EDUC, V1, P183, DOI 10.1080/0142569800010204; BRAIMAN MS, 1987, P NATL ACAD SCI USA, V84, P5221, DOI 10.1073/pnas.84.15.5221; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BRAIMAN MS, 1991, P NATL ACAD SCI USA, V88, P2388, DOI 10.1073/pnas.88.6.2388; BRAIMAN MS, 1988, ANNU REV BIOPHYS BIO, V17, P541; DIOUMAEV AK, 1995, J AM CHEM SOC, V117, P10572, DOI 10.1021/ja00147a020; EYTAN GD, 1982, BIOCHIM BIOPHYS ACTA, V694, P185, DOI 10.1016/0304-4157(82)90024-7; FLETT MS, 1962, SPECTROCHIM ACTA, V18, P1537, DOI 10.1016/S0371-1951(62)80282-3; GERBER GE, 1977, P NATL ACAD SCI USA, V74, P5426, DOI 10.1073/pnas.74.12.5426; HENDERSON R, 1977, ANNU REV BIOPHYS BIO, V6, P87, DOI 10.1146/annurev.bb.06.060177.000511; Hutchison RS, 1999, J BIOL CHEM, V274, P31987, DOI 10.1074/jbc.274.45.31987; Johnson JL, 1999, J BIOL CHEM, V274, P4074, DOI 10.1074/jbc.274.7.4074; Kaback HR, 1999, ACCOUNTS CHEM RES, V32, P805, DOI 10.1021/ar970256i; Kaback HR, 1997, Q REV BIOPHYS, V30, P333, DOI 10.1017/S0033583597003387; KABACK HR, 1986, ANNU REV BIOPHYS BIO, V15, P279; KACZOROWSKI GJ, 1979, BIOCHEMISTRY-US, V18, P3697, DOI 10.1021/bi00584a010; Kamikubo H, 1997, BIOCHEMISTRY-US, V36, P12282, DOI 10.1021/bi9712302; KASAHARA M, 1976, P NATL ACAD SCI USA, V73, P396, DOI 10.1073/pnas.73.2.396; KORENSTEIN R, 1977, NATURE, V270, P184, DOI 10.1038/270184a0; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LeCoutre J, 1997, P NATL ACAD SCI USA, V94, P10167, DOI 10.1073/pnas.94.19.10167; LOZIER RH, 1976, BIOCHIM BIOPHYS ACTA, V440, P545, DOI 10.1016/0005-2728(76)90041-4; MAYER LD, 1985, BIOCHIM BIOPHYS ACTA, V817, P193, DOI 10.1016/0005-2736(85)90084-7; OESTERHELT D, 1982, METHOD ENZYMOL, V88, P10; OHNO K, 1977, BIOCHIM BIOPHYS ACTA, V462, P575, DOI 10.1016/0005-2728(77)90102-5; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Patzlaff JS, 1998, BIOCHEMISTRY-US, V37, P15363, DOI 10.1021/bi981142x; PEROZO E, 1993, BIOCHEMISTRY-US, V32, P10471, DOI 10.1021/bi00090a025; PICK U, 1981, ARCH BIOCHEM BIOPHYS, V212, P186, DOI 10.1016/0003-9861(81)90358-1; RACKER E, 1974, J BIOL CHEM, V249, P662; RAMIREZ FJ, 1995, SPECTROCHIM ACTA A, V51, P293, DOI 10.1016/0584-8539(94)00188-H; ROTHSCHILD KJ, 1992, J BIOENERG BIOMEMBR, V24, P147, DOI 10.1007/BF00762674; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P1295, DOI 10.1021/bi00172a002; SASAKI J, 1994, BIOCHEMISTRY-US, V33, P3178, DOI 10.1021/bi00177a006; Steenhuis JJ, 1996, J AM CHEM SOC, V118, P11927, DOI 10.1021/ja961691v; STOECKENIUS W, 1982, ANNU REV BIOCHEM, V51, P587, DOI 10.1146/annurev.bi.51.070182.003103; WEST IC, 1973, BIOCHEM J, V132, P587, DOI 10.1042/bj1320587; WINKLER HH, 1966, J BIOL CHEM, V241, P2200	38	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28695	28700		10.1074/jbc.M005129200	http://dx.doi.org/10.1074/jbc.M005129200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10874047	hybrid			2022-12-27	WOS:000089330700049
J	Shenai, BR; Sijwali, PS; Singh, A; Rosenthal, PJ				Shenai, BR; Sijwali, PS; Singh, A; Rosenthal, PJ			Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LYTIC PROTEASE; HUMAN CATHEPSIN-K; ESCHERICHIA-COLI; MALARIA PARASITES; PLASMEPSIN-II; ACTIVE-SITE; PRO-REGION; INTRAMOLECULAR CHAPERONE; PROTEINASE-INHIBITORS; HUMAN-ERYTHROCYTES	Trophozoites of the malaria parasite Plasmodium falciparum hydrolyze erythrocyte hemoglobin in an acidic food vacuole to provide amino acids for parasite protein synthesis, Cysteine protease inhibitors block hemoglobin degradation, indicating that a cysteine protease plays a key role in this process. A principal trophozoite cysteine protease was purified by affinity chromatography, Sequence analysis indicated that the protease is encoded by a previously unidentified gene, falcipain-2. Falcipain-2 was predominantly expressed in trophozoites, was concentrated in food vacuoles, and was responsible for at least 93% of trophozoite soluble cysteine protease activity. A construct encoding mature falcipain-2 and a small portion of the prodomain was expressed in Escherichia coli and refolded to active enzyme. Specificity for the hydrolysis of peptide substrates by native and recombinant falcipain-2 was very similar, and optimal at acid pH in a reducing environment, Under physiological conditions (pH 5.5, 1 mM glutathione), falcipain-2 hydrolyzed both native hemoglobin and denatured globin, Our results suggest that falcipain-2 can initiate cleavage of native hemoglobin in the P. falciparum food vacuole, that, following initial cleavages, the protease plays a key role in rapidly hydrolyzing globin fragments, and that a drug discovery effort targeted at this protease is appropriate.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Rosenthal, PJ (corresponding author), Univ Calif San Francisco, Box 0811, San Francisco, CA 94143 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035800, R56AI035800, R29AI035800] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01081] Funding Source: Medline; NIAID NIH HHS [AI35800] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ascoli F, 1981, Methods Enzymol, V76, P72; ATAMNA H, 1994, MOL BIOCHEM PARASIT, V67, P79, DOI 10.1016/0166-6851(94)90098-1; Atamna H, 1997, EUR J BIOCHEM, V250, P670, DOI 10.1111/j.1432-1033.1997.00670.x; Ayi K, 1998, FEBS LETT, V424, P257, DOI 10.1016/S0014-5793(98)00185-9; BAILLY E, 1992, J PROTOZOOL, V39, P593, DOI 10.1111/j.1550-7408.1992.tb04856.x; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMME D, 1994, J BIOL CHEM, V269, P30238; CHAKRABARTI D, 1994, MOL BIOCHEM PARASIT, V66, P97, DOI 10.1016/0166-6851(94)90039-6; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; deDominguez NDG, 1996, BLOOD, V87, P4448, DOI 10.1182/blood.V87.10.4448.bloodjournal87104448; DLUZEWSKI AR, 1986, EXP PARASITOL, V62, P416, DOI 10.1016/0014-4894(86)90050-0; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Francis SE, 1996, MOL BIOCHEM PARASIT, V83, P189, DOI 10.1016/S0166-6851(96)02772-7; GABAY T, 1993, EXP PARASITOL, V77, P261, DOI 10.1006/expr.1993.1084; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; Haque TS, 1999, J MED CHEM, V42, P1428, DOI 10.1021/jm980641t; HILL J, 1994, FEBS LETT, V352, P155, DOI 10.1016/0014-5793(94)00940-6; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; Jerala R, 1998, J BIOL CHEM, V273, P11498, DOI 10.1074/jbc.273.19.11498; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P7134, DOI 10.1073/pnas.92.15.7134; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; LaLonde JM, 1999, BIOCHEMISTRY-US, V38, P862, DOI 10.1021/bi9822271; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; Marie-Claire C, 1999, J MOL BIOL, V285, P1911, DOI 10.1006/jmbi.1998.2449; MASON RW, 1987, BIOCHEM J, V248, P449, DOI 10.1042/bj2480449; McQueney MS, 1997, J BIOL CHEM, V272, P13955, DOI 10.1074/jbc.272.21.13955; Mills BJ, 1996, BIOCHEM PHARMACOL, V52, P401, DOI 10.1016/0006-2952(96)00241-9; Moon RP, 1998, ADV EXP MED BIOL, V436, P397; Mukhopadhyay A, 1997, Adv Biochem Eng Biotechnol, V56, P61; Olliaro P, 1996, JAMA-J AM MED ASSOC, V275, P230, DOI 10.1001/jama.275.3.230; Olliaro PL, 1999, PHARMACOL THERAPEUT, V81, P91, DOI 10.1016/S0163-7258(98)00036-9; Olson JE, 1999, BIOORGAN MED CHEM, V7, P633, DOI 10.1016/S0968-0896(99)00004-8; Pasquier C, 1999, PROTEIN ENG, V12, P381, DOI 10.1093/protein/12.5.381; Peters RJ, 1998, BIOCHEMISTRY-US, V37, P12058, DOI 10.1021/bi980883v; Podobnik M, 1997, J MOL BIOL, V271, P774, DOI 10.1006/jmbi.1997.1218; RAMOS C, 1994, J BIOL CHEM, V269, P7006; RICH DH, 1986, BIOCHEM J, V235, P731, DOI 10.1042/bj2350731; ROSENTHAL PJ, 1993, BIOCHIM BIOPHYS ACTA, V1173, P91, DOI 10.1016/0167-4781(93)90250-H; ROSENTHAL PJ, 1989, MOL BIOCHEM PARASIT, V35, P177, DOI 10.1016/0166-6851(89)90120-5; ROSENTHAL PJ, 1994, J MOL BIOL, V241, P312, DOI 10.1006/jmbi.1994.1506; Rosenthal PJ, 1996, ANTIMICROB AGENTS CH, V40, P1600, DOI 10.1128/AAC.40.7.1600; ROSENTHAL PJ, 1991, J CLIN INVEST, V88, P1467, DOI 10.1172/JCI115456; ROSENTHAL PJ, 1992, MOL BIOCHEM PARASIT, V51, P143, DOI 10.1016/0166-6851(92)90209-3; Rosenthal PJ, 1996, MOL BIOCHEM PARASIT, V83, P131, DOI 10.1016/S0166-6851(96)02763-6; ROSENTHAL PJ, 1988, J CLIN INVEST, V82, P1560, DOI 10.1172/JCI113766; ROSENTHAL PJ, 1987, J EXP MED, V166, P816, DOI 10.1084/jem.166.3.816; ROSENTHAL PJ, 1993, J CLIN INVEST, V91, P1052, DOI 10.1172/JCI116262; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; SALAS F, 1995, INFECT IMMUN, V63, P2120, DOI 10.1128/IAI.63.6.2120-2125.1995; SAUL A, 1990, MOL BIOCHEM PARASIT, V42, P55, DOI 10.1016/0166-6851(90)90112-Y; SAUL A, 1988, MOL BIOCHEM PARASIT, V27, P35, DOI 10.1016/0166-6851(88)90022-9; Semenov A, 1998, ANTIMICROB AGENTS CH, V42, P2254, DOI 10.1128/AAC.42.9.2254; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; Silva AM, 1996, P NATL ACAD SCI USA, V93, P10034, DOI 10.1073/pnas.93.19.10034; SMITH SM, 1989, J BIOL CHEM, V264, P20487; TAYLOR MAJ, 1992, PROTEIN ENG, V5, P455, DOI 10.1093/protein/5.5.455; Thompson SK, 1997, P NATL ACAD SCI USA, V94, P14249, DOI 10.1073/pnas.94.26.14249; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VITALE A, 1992, BIOESSAYS, V14, P151, DOI 10.1002/bies.950140303; White NJ, 1998, BRIT MED BULL, V54, P703, DOI 10.1093/oxfordjournals.bmb.a011721; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x	78	301	309	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29000	29010		10.1074/jbc.M004459200	http://dx.doi.org/10.1074/jbc.M004459200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10887194	hybrid			2022-12-27	WOS:000089330700087
J	Alam, J; Wicks, C; Stewart, D; Gong, PF; Touchard, C; Otterbein, S; Choi, AMK; Burow, ME; Tou, JS				Alam, J; Wicks, C; Stewart, D; Gong, PF; Touchard, C; Otterbein, S; Choi, AMK; Burow, ME; Tou, JS			Mechanism of heme oxygenase-1 gene activation by cadmium in MCF-7 mammary epithelial cells - Role of p38 kinase and Nrf2 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; HEAVY-METALS; C-FOS; MEDIATED INDUCTION; OXIDATIVE STRESS; SODIUM ARSENITE; HEPATOMA-CELLS; BASAL LEVEL; EXPRESSION; IDENTIFICATION	The mouse heme oxygenase-1 (HO-1) gene, ho-1, contains two inducible enhancers, E1 and E2. Of several cell Lines tested, induction of an E1/luciferase fusion construct, pE1-luc, by CdCL2 is most pronounced in MCF-7 cells. In these cells, El, but not E2, is necessary and sufficient for ho-1 gene activation. Exposure of MCF-7 cells to 10 mu M CdCl2 stimulates phosphorylation of ERK, JNK, and p38 mitogen-activated protein kinases, implicating one or more of these signaling pathways in ho-1 gene induction. SB203580, an inhibitor of p38, diminishes cadmium-stimulated pE1-luc expression and HO-1 mRNA levels by up to 70-80%. PD098059, an ERK pathway inhibitor, does not affect HO-1 mRNA induction at the highest concentration (40 mu M) tested. Similarly, coexpression of a dominant-negative mutant of p38 alpha, but not of ERK1, ERK2, JNK1, or JNK2, reduces basal and cadmium-induced pE1-luc activity. E1 contains binding sites for the activator protein-1 (Fos/Jun), Cap'n'Collar/basic leucine zipper (CNC-bZIP), and CCAAT/enhancer-binding protein (C/EBP) families of transcription factors. A dominant-negative mutant of Nrf2 (a CNC-bZIP member), but not of c-Jun or C/EBP beta, inhibits pE1-luc activation by cadmium. Induction of the endogenous ho-1 gene is also inhibited by the Nrf2 mutant. Flutations of E1 that inhibit cadmium inducibility also suppress the trans-activation and DNA binding activities of Nrf2, and SB203580, but not PD098059, attenuates Nrf2-mediated trans-activation of pE1-luc. Taken together, these results indicate that cadmium induces ho-1 gene expression via sequential activation of the p38 kinase pathway and Nrf2.	Alton Ochsner Med Fdn & Ochsner Clin, Dept Mol Genet, New Orleans, LA 70121 USA; Tulane Univ, Sch Med, Tulane Xavier Ctr Bioenvironm Res, New Orleans, LA 70112 USA; Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA	Ochsner Health System; Tulane University; Xavier University of Louisiana; Yale University	Alam, J (corresponding author), Alton Ochsner Med Fdn & Ochsner Clin, Dept Mol Genet, 1516 Jefferson Highway, New Orleans, LA 70121 USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X	NHLBI NIH HHS [HL60234] Funding Source: Medline; NIDDK NIH HHS [DK-43135] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043135] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; ALAM J, 1994, J BIOL CHEM, V269, P1001; ALAM J, 1994, J BIOL CHEM, V269, P25049; ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; ALAM J, 1992, J BIOL CHEM, V267, P21894; ALAM J, 1989, J BIOL CHEM, V264, P6371; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Beyersmann D, 1997, TOXICOL APPL PHARM, V144, P247, DOI 10.1006/taap.1997.8125; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Hung JJ, 1998, J BIOL CHEM, V273, P31924, DOI 10.1074/jbc.273.48.31924; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; ITOH K, 1998, GENE DEV, V13, P67; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; KOIZUMI T, 1995, J BIOL CHEM, V270, P21779, DOI 10.1074/jbc.270.37.21779; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; Masuya Y, 1998, J BIOCHEM-TOKYO, V124, P628; Matsuoka M, 1998, BIOCHEM BIOPH RES CO, V251, P527, DOI 10.1006/bbrc.1998.9487; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Numazawa S, 1997, EXP CELL RES, V237, P434, DOI 10.1006/excr.1997.3825; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; TAKEDA K, 1994, J BIOL CHEM, V269, P22858; VANDELFT S, 1993, BIOCHEM BIOPH RES CO, V197, P542, DOI 10.1006/bbrc.1993.2513; Wang Z, 1998, J BIOL CHEM, V273, P73, DOI 10.1074/jbc.273.1.73; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165	39	358	365	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27694	27702						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10874044				2022-12-27	WOS:000089197100024
J	McMahon, B; Stenson, C; McPhillips, F; Fanning, A; Brady, HR; Godson, C				McMahon, B; Stenson, C; McPhillips, F; Fanning, A; Brady, HR; Godson, C			Lipoxin A(4) antagonizes the mitogenic effects of leukotriene D-4 in human renal mesangial cells - Differential activation of MAP kinases through distinct receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; THP-1 CELLS; RAT-KIDNEY; INHIBITION; PROLIFERATION; CASCADES; PATHWAY	The lipoxygenase-derived eicosanoids leukotrienes and lipoxins are well defined regulators of hemeodynamics and leukocyte recruitment in inflammatory conditions. Here, we describe a novel bioaction of lipoxin A(4) (LXA(4)), namely inhibition of leukotriene D-4 (LTD4)-induced human renal mesangial cell proliferation, and investigate the signal transduction mechanisms involved. LXA(4) blocked LTD4-stimulated phosphatidylinositol 3-kinase (PI 3-kinase) activity in parallel to inhibition of LTD4-induced mesangial cell proliferation. Screening of a human mesangial cell cDNA library revealed expression of the recently described cys-leukotriene(1)/LTD4 receptor. LTD4-induced mesangial cell proliferation required both extracellular-related signal regulated kinase (erk) and PI 3-kinase activation and may involve platelet-derived growth factor receptor transactivation, LTD4-stimulated the MAP kinases erk and p38 via a pertussis toxin (PTX)-sensitive pathway dependent on PI 3-kinase and protein kinase C activation. On screening a cDNA library, mesangial cells were found to express the previously described LXA(4) receptor. In contrast to LTD4, LXA(4) showed differential activation of erk and p38. LXA(4) activation of erk was insensitive to PTX and PI 3-kinase inhibition, whereas LXA(4) activation of p38 was sensitive to PTX and could be blocked by the LTD4 receptor antagonist SKF 104353. These data suggest that LXA(4) stimulation of the MAP kinase superfamily involves two distinct receptors: one shared with LTD4 and coupled to a PTX-sensitive G protein (G(i)) and a second coupled via an alternative G protein, such as G(q) or G(12), to erk activation. These data expand on the spectrum of LXA(4) bioactions within an inflammatory milieu.	Mater Misericordiae Hosp, Dept Med & Therapeut, Ctr Mol Inflammat & Vasc Res, Dublin 7, Ireland; Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 7, Ireland	Mater Misericordiae University Hospital; University College Dublin; University College Dublin	Godson, C (corresponding author), Mater Misericordiae Hosp, Dept Med & Therapeut, Ctr Mol Inflammat & Vasc Res, Dublin 7, Ireland.		Fanning, Aine/Q-1084-2018	Fanning, Aine/0000-0001-8050-1769; Godson, Catherine/0000-0003-0655-1041				ABBOUD HE, 1995, ANNU REV PHYSIOL, V57, P297; ADOEMIT A, 1999, MOL CELL BIOL, V8, P5289; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BADR KF, 1989, P NATL ACAD SCI USA, V86, P3438, DOI 10.1073/pnas.86.9.3438; BADR KF, 1989, AM J PHYSIOL, V257, pF280, DOI 10.1152/ajprenal.1989.257.2.F280; BADR KF, 1987, AM J PHYSIOL, V253, pF239, DOI 10.1152/ajprenal.1987.253.2.F239; BADR KF, 1988, J CLIN INVEST, V81, P1702, DOI 10.1172/JCI113509; Bokemeyer D, 1996, KIDNEY INT, V49, P1187, DOI 10.1038/ki.1996.172; BRADY HR, 1990, AM J PHYSIOL, V259, pF809, DOI 10.1152/ajprenal.1990.259.5.F809; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; CHAN CC, 1994, J PHARMACOL EXP THER, V269, P891; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; Claria J, 1996, MOL MED, V2, P583, DOI 10.1007/BF03401642; Clarkson MR, 1998, NEPHROL DIAL TRANSPL, V13, P3043, DOI 10.1093/ndt/13.12.3043; CROOKE ST, 1989, TRENDS PHARMACOL SCI, V10, P103, DOI 10.1016/0165-6147(89)90206-X; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dixon RJ, 1999, KIDNEY INT, V56, P2064, DOI 10.1046/j.1523-1755.1999.00797.x; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; EUL J, 1989, EMBO J, V8, P83, DOI 10.1002/j.1460-2075.1989.tb03351.x; EXTON JH, 1994, ANNU REV PHYSIOL, V56, P349; FERBY IM, 1994, J BIOL CHEM, V269, P30485; Fiore S, 1995, BIOCHEMISTRY-US, V34, P16678, DOI 10.1021/bi00051a016; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; GARRICK R, 1989, BIOCHEM BIOPH RES CO, V162, P626, DOI 10.1016/0006-291X(89)92356-5; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; Godson C, 1997, ENDOCRINOLOGY, V138, P397, DOI 10.1210/endo.138.1.4824; Gronert K, 1998, J EXP MED, V187, P1285, DOI 10.1084/jem.187.8.1285; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; Hoshino M, 1998, J BIOL CHEM, V273, P4878, DOI 10.1074/jbc.273.9.4878; KATOH T, 1993, J CLIN INVEST, V91, P1507, DOI 10.1172/JCI116356; KELEFIOTIS D, 1995, PROSTAGLANDINS, V49, P269, DOI 10.1016/0090-6980(95)00049-G; Kovalenko M, 1997, BIOCHEMISTRY-US, V36, P6260, DOI 10.1021/bi962553l; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Lynch KR, 1999, NATURE, V399, P789; Maddox JF, 1997, J BIOL CHEM, V272, P6972, DOI 10.1074/jbc.272.11.6972; Mayadas TN, 1996, KIDNEY INT, V49, P1342, DOI 10.1038/ki.1996.190; Meng XJ, 1997, J CLIN INVEST, V99, P2915, DOI 10.1172/JCI119486; Mondorf UF, 1999, KIDNEY INT, V55, P1359, DOI 10.1046/j.1523-1755.1999.00367.x; Morgenstern B, 1998, BIOINFORMATICS, V14, P290, DOI 10.1093/bioinformatics/14.3.290; Munger KA, 1999, P NATL ACAD SCI USA, V96, P13375, DOI 10.1073/pnas.96.23.13375; Ochsner M, 1996, EXPERIENTIA, V52, P856, DOI 10.1007/BF01938870; OMEARA YM, 1997, KIDNEY INT S, V58, pS56; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; Papayianni A, 1996, J IMMUNOL, V156, P2264; PAPAYIANNI A, 1995, KIDNEY INT, V47, P1295, DOI 10.1038/ki.1995.184; Ruan XZ, 1999, KIDNEY INT, V56, P440, DOI 10.1046/j.1523-1755.1999.00587.x; Schocklmann HO, 1999, KIDNEY INT, V56, P1199, DOI 10.1046/j.1523-1755.1999.00710.x; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; Serhan CN, 1997, PROSTAG OTH LIPID M, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; SIMONSON MS, 1988, AM J PHYSIOL, V255, pC771, DOI 10.1152/ajpcell.1988.255.6.C771; Sodin-Semrl S, 2000, J IMMUNOL, V164, P2660, DOI 10.4049/jimmunol.164.5.2660; SPURNEY RF, 1991, KIDNEY INT, V39, P95, DOI 10.1038/ki.1991.12; SRAER D, 1996, KIDNEY INT, V40, P267; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; Tombes RM, 1998, BIOCHEM J, V330, P1451; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; YOKAMIZO T, 1997, NATURE, V387, P620	64	110	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27566	27575						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869343				2022-12-27	WOS:000089197100009
J	van Beest, M; Dooijes, D; van de Wetering, M; Kjaerulff, S; Bonvin, A; Nielsen, O; Clevers, H				van Beest, M; Dooijes, D; van de Wetering, M; Kjaerulff, S; Bonvin, A; Nielsen, O; Clevers, H			Sequence-specific high mobility group box factors recognize 10-12-base pair minor groove motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROPERTIES; TCR-ALPHA ENHANCER; HMG-BOX; TRANSCRIPTION FACTOR; SCHIZOSACCHAROMYCES-POMBE; NUCLEOPROTEIN STRUCTURES; ACTIVATION DOMAIN; PROTEIN NHP6A; FISSION YEAST; BETA-CATENIN	Sequence-specific high mobility group (HMG) box factors bind and bend DNA via interactions in the minor groove. Three-dimensional NMR analyses have provided the structural basis for this interaction. The cognate HMG domain DNA motif is generally believed to span 6-8 bases. However, alignment of promoter elements controlled by the yeast genes ste11 and Rox1 has indicated strict conservation of a larger DNA motif, By site selection, we identify a highly specific 12-base pair motif for Ste11, AGAACAAAGAAA. Similarly, we show that Tcf1, MatMc, and Sox4 bind unique, highly specific DNA motifs of 12, 12, and 10 base pairs, respectively. Footprinting with a deletion mutant of Ste11 reveals a novel interaction between the 3' base pairs of the extended DNA motif and amino acids C-terminal to the HMG domain. The sequence-specific interaction of Ste11 with these 3' base pairs contributes significantly to binding and bending of the DNA motif.	Univ Utrecht, Med Ctr, Dept Immunol, NL-3584 CX Utrecht, Netherlands; Univ Copenhagen, Dept Genet, DK-1353 Copenhagen, Denmark; Univ Utrecht, Bijvoet Inst Biomol Chem, Sect NMR Spect, NL-3584 CH Utrecht, Netherlands	Utrecht University; University of Copenhagen; Utrecht University	Clevers, H (corresponding author), Univ Utrecht, Med Ctr, Dept Immunol, Heidelberglaan 100 Rm F03-821, NL-3584 CX Utrecht, Netherlands.	h.clevers@lab.azu.nl	Nielsen, Olaf/G-4980-2012; Bonvin, Alexandre M.J.J./A-5420-2009	Nielsen, Olaf/0000-0001-7440-5201; Bonvin, Alexandre M.J.J./0000-0001-7369-1322				Allain FHT, 1999, EMBO J, V18, P2563, DOI 10.1093/emboj/18.9.2563; BALASUBRAMANIAN B, 1993, MOL CELL BIOL, V13, P6071, DOI 10.1128/MCB.13.10.6071; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; CHURCHILL MEA, 1995, EMBO J, V14, P1264, DOI 10.1002/j.1460-2075.1995.tb07110.x; CONNER F, 1994, NUCLEIC ACIDS RES, V22, P3339, DOI 10.1093/nar/22.16.3339; Deckert J, 1999, NUCLEIC ACIDS RES, V27, P3518, DOI 10.1093/nar/27.17.3518; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; DOOIJES D, 1993, J BIOL CHEM, V268, P24813; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JONES DNM, 1994, STRUCTURE, V2, P609, DOI 10.1016/S0969-2126(00)00063-0; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; KJAERULFF S, 1994, MOL CELL BIOL, V14, P3895, DOI 10.1128/MCB.14.6.3895; Kjaerulff S, 1997, EMBO J, V16, P4021, DOI 10.1093/emboj/16.13.4021; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; Laurent MN, 1997, DEVELOPMENT, V124, P4905; LnenicekAllen M, 1996, NUCLEIC ACIDS RES, V24, P1047, DOI 10.1093/nar/24.6.1047; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; READ CM, 1994, EMBO J, V13, P5639, DOI 10.1002/j.1460-2075.1994.tb06902.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; TEO SH, 1995, EUR J BIOCHEM, V230, P943, DOI 10.1111/j.1432-1033.1995.tb20640.x; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VANHOUTE L, 1993, J BIOL CHEM, V268, P18083; vanHoute LPA, 1995, J BIOL CHEM, V270, P30516, DOI 10.1074/jbc.270.51.30516; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WEMER MH, 1995, CELL, V81, P705; Yamaguchi TP, 1999, GENE DEV, V13, P3185, DOI 10.1101/gad.13.24.3185; Yen YM, 1998, J BIOL CHEM, V273, P4424, DOI 10.1074/jbc.273.8.4424; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	53	99	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27266	27273						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10867006				2022-12-27	WOS:000089144800080
J	Nandigama, RK; Edmondson, DE				Nandigama, RK; Edmondson, DE			Influence of FAD structure on its binding and activity with the C406A mutant of recombinant human liver monoamine oxidase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY-BOUND FLAVIN; GAMMA-LACTONE OXIDASE; ESCHERICHIA-COLI; KINETIC MECHANISM; ANALOGS; FLAVINYLATION; OXIDATION; PEPTIDE; STATE	The FAD binding site of human liver monoamine oxidase A (MAO A) has been investigated by mutagenesis of the amino acid site of covalent FAD attachment (Cys-406) to an alanyl residue. Expression of the C406A mutant in Saccharomyces ces cerevisiae results in the formation of an active enzyme, as found previously with the rat liver enzyme. The activity of this mutant enzyme is labile to solubilization, thus requiring all experiments to be done with membrane preparations. C406A MAO A was expressed in a rib 5(-) strain of S. cerevisiae in the presence of 16 different riboflavin analogues. Inactive apoC406A MAO A is formed by induction of the enzyme in the absence of riboflavin. FAD but not FMN or riboflavin restores catalytic activity with an apparent K-d of 62 +/- 5 nM. The results from both in vivo and in vitro reconstitution experiments show increased activity levels (up to similar to 7-fold higher) with those analogues exhibiting higher oxidation-reduction potentials than normal flavin and decreased activity levels with analogues exhibiting lower potentials. Analogues with substituents on the pyrimidine ring bind to C406A MAO A more weakly than normal FAD, suggesting specific interactions with the N(3) and N(1) positions. Analogues with substituents in the 7 and 8 positions bind to C406A MAO A with affinities comparable with that of normal FAD. These results are discussed in regard to functional significance of 8 alpha-covalent binding of flavins to proteins.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Chem, Atlanta, GA 30322 USA	Emory University; Emory University	Edmondson, DE (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029433] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29433] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER MJ, 1987, BIOCHEM J, V242, P89, DOI 10.1042/bj2420089; BLAUT M, 1989, J BIOL CHEM, V264, P13599; DRAPER RD, 1968, ARCH BIOCHEM BIOPHYS, V125, P802, DOI 10.1016/0003-9861(68)90517-1; ECKSTEIN JW, 1993, BIOCHEMISTRY-US, V32, P404, DOI 10.1021/bi00053a004; Edmondson D.E., 1999, FLAVINS FLAVOPROTEIN, P71; Efimov I, 1998, BIOCHEMISTRY-US, V37, P9716, DOI 10.1021/bi972817j; Fraaije MW, 1999, J BIOL CHEM, V274, P35514, DOI 10.1074/jbc.274.50.35514; GOMEZ N, 1986, BIOCHEM PHARMACOL, V35, P4467, DOI 10.1016/0006-2952(86)90765-3; Hiro I, 1996, J BIOCHEM-TOKYO, V120, P759; KEARNEY EB, 1971, EUR J BIOCHEM, V24, P321, DOI 10.1111/j.1432-1033.1971.tb19689.x; KENNEY WC, 1976, BIOCHEM BIOPH RES CO, V71, P1194, DOI 10.1016/0006-291X(76)90780-4; KIUCHI K, 1982, BIOCHEMISTRY-US, V21, P5076, DOI 10.1021/bi00263a035; KRAJL M, 1965, BIOCHEM PHARMACOL, V14, P1684, DOI 10.1016/0006-2952(65)90025-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDWIG ML, 1990, BIOCHEMISTRY-US, V29, P10364, DOI 10.1021/bi00497a011; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; Miller JR, 1999, BIOCHEMISTRY-US, V38, P13670, DOI 10.1021/bi990920y; Miller JR, 1999, J BIOL CHEM, V274, P23515, DOI 10.1074/jbc.274.33.23515; MOORE EG, 1979, J BIOL CHEM, V254, P8173; Murthy YVSN, 1998, J BIOL CHEM, V273, P8975, DOI 10.1074/jbc.273.15.8975; NAGY J, 1981, ARCH BIOCHEM BIOPHYS, V208, P388, DOI 10.1016/0003-9861(81)90523-3; NISHIKIMI M, 1994, BIOCHEM MOL BIOL INT, V33, P313; OCARROLL AM, 1989, BIOCHEM PHARMACOL, V38, P901, DOI 10.1016/0006-2952(89)90278-5; RAMSAY RR, 1991, BIOCHEMISTRY-US, V30, P4624, DOI 10.1021/bi00232a038; SCRUTTON NS, 1994, J BIOL CHEM, V269, P13942; SPENCER R, 1976, BIOCHEMISTRY-US, V15, P1043, DOI 10.1021/bi00650a015; SPENCER R, 1993, BIOCHEMISTRY-US, V16, P3594; WEYLER W, 1990, BIOCHEM BIOPH RES CO, V173, P1205, DOI 10.1016/S0006-291X(05)80914-3; WU HF, 1993, MOL PHARMACOL, V43, P888	29	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20527	20532		10.1074/jbc.M002132200	http://dx.doi.org/10.1074/jbc.M002132200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10877844	hybrid			2022-12-27	WOS:000088084500044
J	Miles, CA; Sionkowska, A; Hulin, SL; Sims, TJ; Avery, NC; Bailey, AJ				Miles, CA; Sionkowska, A; Hulin, SL; Sims, TJ; Avery, NC; Bailey, AJ			Identification of an intermediate state in the helix-coil degradation of collagen by ultraviolet light	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT TAIL TENDON; THERMAL-STABILITY; CROSS-LINKING; TRIPLE HELIX; DENATURATION; MECHANISM; PROTEINS	Differential scanning calorimetry has revealed the presence of a new denaturation endotherm at 32 degreesC following UV irradiation of collagen, compared with 39 degreesC for the native triple helix. Kinetic analyses showed that the new peak was a previously unknown intermediate state in the collagen helix-coil transition induced by UV light, and at least 80% of the total collagen was transformed to random chains via this state. Its rate of formation was increased by hydrogen peroxide and inhibited by free radical scavengers. SDS-polyacrylamide gels showed evidence of competing reactions of crosslinking and random primary chain scission. The crosslinking was evident from initial gelling of the collagen solution, but there was no evidence for a dityrosine cross-link. Primary chain scission was confirmed by end group analysis using fluorescamine. Electron microscopy showed that the segment long spacing crystallites formed from the intermediate state were identical to the native molecules. Clearly, collagen can undergo quite extensive damage by cleavage of peptide bonds without disorganizing the triple helical structure. This leads to the formation of a damaged intermediate state prior to degradation of the molecules to short random chains.	Univ Bristol, Collagen Res Grp, Sch Vet Sci, Bristol BS40 5DU, Avon, England; Nicholas Copernicus Univ, Dept Chem, PL-87100 Torun, Poland	University of Bristol; Nicolaus Copernicus University	Miles, CA (corresponding author), Univ Bristol, Collagen Res Grp, Sch Vet Sci, Bristol BS40 5DU, Avon, England.		Curtis, Sarah/AAM-5290-2020; Sionkowska, Alina/I-5599-2014	Curtis, Sarah/0000-0003-0889-964X				Atkins PW, 1978, PHYSICAL CHEM, P868; BAILEY AJ, 1967, RADIAT RES, V31, P206, DOI 10.2307/3572321; BERGMAN I, 1963, ANAL CHEM, V35, P1961, DOI 10.1021/ac60205a053; BURJANADZE TV, 1992, BIOPOLYMERS, V32, P951, DOI 10.1002/bip.360320806; DANIELSEN CC, 1990, BIOCHEM J, V272, P697, DOI 10.1042/bj2720697; FUJIMORI E, 1988, FEBS LETT, V235, P98, DOI 10.1016/0014-5793(88)81241-9; GRANT RA, 1964, J CLIN PATHOL, V17, P685, DOI 10.1136/jcp.17.6.685; HARRINGTON WF, 1969, ADV PROTEIN CHEM, V16, P1; HAYASHI T, 1979, BIOCHEMISTRY-US, V18, P4182, DOI 10.1021/bi00586a022; Kaminska A, 1996, POLYM DEGRAD STABIL, V51, P19, DOI 10.1016/0141-3910(95)00159-X; KATO Y, 1995, PHOTOCHEM PHOTOBIOL, V61, P367, DOI 10.1111/j.1751-1097.1995.tb08624.x; KATO Y, 1994, PHOTOCHEM PHOTOBIOL, V59, P343, DOI 10.1111/j.1751-1097.1994.tb05045.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILES CA, 1995, J MOL BIOL, V245, P437, DOI 10.1006/jmbi.1994.0035; Miles CA, 1999, BIOPHYS J, V76, P3243, DOI 10.1016/S0006-3495(99)77476-X; NOMURA K, 1990, BIOCHEMISTRY-US, V29, P4525, DOI 10.1021/bi00471a004; PRIVALOV PL, 1979, J MOL BIOL, V127, P203, DOI 10.1016/0022-2836(79)90240-7; ROSE C, 1988, BIOCHEM J, V249, P127, DOI 10.1042/bj2490127; Rossi A, 1997, J MOL BIOL, V269, P488, DOI 10.1006/jmbi.1997.1046; SIMS TJ, 1992, J CHROMATOGR-BIOMED, V582, P49, DOI 10.1016/0378-4347(92)80301-6; Sionkowska A, 1999, INT J BIOL MACROMOL, V24, P337, DOI 10.1016/S0141-8130(99)00047-1; SMOLENSKI KA, 1983, BIOCHEM J, V213, P525, DOI 10.1042/bj2130525; Tiktopulo EI, 1998, BIOCHEMISTRY-US, V37, P8147, DOI 10.1021/bi980360n; [No title captured]	24	90	96	3	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33014	33020		10.1074/jbc.M002346200	http://dx.doi.org/10.1074/jbc.M002346200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10893225	hybrid			2022-12-27	WOS:000090003800087
J	Boutaud, A; Borza, DB; Bondar, O; Gunwar, S; Netzer, KO; Singh, N; Ninomiya, Y; Sado, Y; Noelken, ME; Hudson, BG				Boutaud, A; Borza, DB; Bondar, O; Gunwar, S; Netzer, KO; Singh, N; Ninomiya, Y; Sado, Y; Noelken, ME; Hudson, BG			Type IV collagen of the glomerular basement membrane - Evidence that the chain specificity of network assembly is encoded by the noncollagenous NC1 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHMID METAPHYSEAL CHONDRODYSPLASIA; RECESSIVE ALPORT-SYNDROME; GOODPASTURE ANTIGEN; GLOBULAR DOMAIN; MONOCLONAL-ANTIBODIES; ALPHA-3(IV) CHAIN; X COLLAGEN; IDENTIFICATION; ORGANIZATION; MUTATIONS	The ultrafiltration function of the glomerular basement membrane (GBM) of the kidney is impaired in genetic and acquired diseases that affect type IV collagen. The GEM is composed of five (alpha 1 to alpha 5) of the six chains of type IV collagen, organized into an alpha 1.alpha 2(IV) and an alpha 3.alpha 4.alpha 5(IV) network. In Alport syndrome, mutations in any of the genes encoding the alpha 3(IV), alpha 4(IV), and alpha 5(IV) chains cause the absence of the alpha 3.alpha 4.alpha 5 network, which leads to progressive renal failure. In the present study, the molecular mechanism underlying the network defect was explored by further characterization of the chain organization and elucidation of the discriminatory interactions that govern network assembly. The existence of the two networks was further established by analysis of the hexameric complex of the noncollagenous (NC1) domains, and the alpha 5 chain was shown to be linked to the alpha 3 and alpha 4 chains by interaction through their respective NC1 domains. The potential recognition function of the NC1 domains in network assembly was investigated by comparing the composition of native NC1 hexamers with hexamers that were dissociated and reconstituted in vitro and with hexamers assembled in vitro from purified alpha 1-alpha 5(IV) NC1 monomers. The results showed that NC1 monomers associate to form nativelike hexamers characterized by two distinct populations, an alpha 1.alpha 2 and alpha 3.alpha 4.alpha 5 heterohexamer. These findings indicate that the NC1 monomers contain recognition sequences for selection of chains and protomers that are sufficient to encode the assembly of the alpha 1.alpha 2 and alpha 3.alpha 4.alpha 5 networks of GEM. Moreover, hexamer formation from the alpha 3, alpha 4, and alpha 5 NC1 monomers required co-assembly of all three monomers, suggesting that mutations in the NC1 domain in Alport syndrome may disrupt the assembly of the alpha 3.alpha 4.alpha 5 network by interfering with the assembly of the alpha 3.alpha 4.alpha 5 NC1 hexamer.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Okayama Univ, Sch Med, Dept Mol Biol & Biochem, Okayama 700, Japan; Shigei Med Res Inst, Div Immunol, Okayama 7010202, Japan	University of Kansas; University of Kansas Medical Center; Okayama University	Hudson, BG (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.		Borza, Dorin-Bogdan/AAF-2156-2020	Borza, Dorin-Bogdan/0000-0003-4568-279X; Hudson, Billy/0000-0002-5420-4100	NIDDK NIH HHS [DK18381, DK53763] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018381, R01DK018381, P01DK053763] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Borza DB, 2000, J BIOL CHEM, V275, P6030, DOI 10.1074/jbc.275.8.6030; BOUTAUD A, 1996, FASEB J, V10, P1259; Boye E, 1998, AM J HUM GENET, V63, P1329, DOI 10.1086/302106; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; Dublet B, 1999, J BIOL CHEM, V274, P18909, DOI 10.1074/jbc.274.27.18909; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; GUNWAR S, 1991, J BIOL CHEM, V266, P14088; Gunwar S, 1998, J BIOL CHEM, V273, P8767, DOI 10.1074/jbc.273.15.8767; Harvey SJ, 1998, KIDNEY INT, V54, P1857, DOI 10.1046/j.1523-1755.1998.00188.x; HEIDET L, 2000, IN PRESS J AM SOC NE, V11; HUDSON BG, 1989, LAB INVEST, V61, P256; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Jais JP, 2000, J AM SOC NEPHROL, V11, P649, DOI 10.1681/ASN.V114649; JOHANSSON C, 1991, CONNECT TISSUE RES, V25, P229, DOI 10.3109/03008209109029159; JOHANSSON C, 1992, J BIOL CHEM, V267, P24533; Kahsai TZ, 1997, J BIOL CHEM, V272, P17023, DOI 10.1074/jbc.272.27.17023; Kalluri R, 1997, J CLIN INVEST, V99, P2470, DOI 10.1172/JCI119431; KLEPPEL MM, 1992, J BIOL CHEM, V267, P4137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; MOCHIZUKI T, 1994, NAT GENET, V8, P77, DOI 10.1038/ng0994-77; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; NINOMIYA Y, 1995, J CELL BIOL, V130, P1219, DOI 10.1083/jcb.130.5.1219; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; RIES A, 1995, J BIOL CHEM, V270, P23790, DOI 10.1074/jbc.270.40.23790; Sado Y, 1998, KIDNEY INT, V53, P664, DOI 10.1046/j.1523-1755.1998.00795.x; SAUS J, 1988, J BIOL CHEM, V263, P13374; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SUSI H, 1986, METHOD ENZYMOL, V130, P290; TIMONEDA J, 1990, CONNECT TISSUE RES, V24, P169, DOI 10.3109/03008209009152147; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; WEBER S, 1984, EUR J BIOCHEM, V139, P401, DOI 10.1111/j.1432-1033.1984.tb08019.x; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564; WIESLANDER J, 1987, CLIN EXP IMMUNOL, V69, P332; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040; Zhang Y, 1999, J BIOL CHEM, V274, P22409, DOI 10.1074/jbc.274.32.22409	42	157	167	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30716	30724		10.1074/jbc.M004569200	http://dx.doi.org/10.1074/jbc.M004569200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896941	hybrid			2022-12-27	WOS:000089577900109
J	Jackson, M; Crick, DC; Brennan, PJ				Jackson, M; Crick, DC; Brennan, PJ			Phosphatidylinositol is an essential phospholipid of mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBERCULOSIS; LIPOARABINOMANNAN; SYNTHASE; SMEGMATIS; GENE; BIOSYNTHESIS; BACTERIA; MUTANTS; ANCHOR	Phosphatidylinositol (PI) and metabolically derived products such as the phosphatidylinositol mannosides and linear and mature branched lipomannan and lipoarabinomannan are prominent phospholipids/lipoglycans of Mycobacterium sp. believed to play important roles in the structure and physiology of the bacterium as well as during host infection. To determine if PI is an essential phospholipid of mycobacteria, we identified the pgsA gene of Mycobacterium tuberculosis encoding the phosphatidylinositol synthase enzyme and constructed a pgsA conditional mutant of Mycobacterium smegmatis. The ability of this mutant to synthesize phosphatidylinositol synthase and subsequently PI was dependent on the presence of a functional copy of the pgsA gene carried on a thermosensitive plasmid. The mutant grew like the control strain under permissive conditions (30 degrees C), but ceased growing when placed at 42 degrees C, a temperature at which the rescue plasmid is lost. Loss of cell viability at 42 degrees C was observed when PI and phosphatidylinositol dimannoside contents dropped to similar to 30 and 50% of the wild-type levels, respectively. This work provides the first evidence of the essentiality of PI to the survival of mycobacteria. PI synthase is thus an essential enzyme of Mycobacterium that shows promise as a drug target for anti-tuberculosis therapy.	Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA	Colorado State University	Brennan, PJ (corresponding author), Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA.	pbrennan@cvmbs.colostate.edu	Crick, Dean/H-8251-2017; Jackson, Mary/D-5345-2017	Crick, Dean/0000-0001-9281-7058; Jackson, Mary/0000-0002-9212-0258	NIAID NIH HHS [AI18357, AI46393] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018357, R01AI018357, R22AI018357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Antonsson B, 1997, BBA-LIPID LIPID MET, V1348, P179, DOI 10.1016/S0005-2760(97)00105-7; BELISLE JT, 1994, J BACTERIOL, V176, P2151, DOI 10.1128/JB.176.8.2151-2157.1994; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; Blanchard JS, 1996, ANNU REV BIOCHEM, V65, P215, DOI 10.1146/annurev.bi.65.070196.001243; BRENNAN P, 1968, BIOCHEM BIOPH RES CO, V30, P69, DOI 10.1016/0006-291X(68)90714-6; BRENNAN P, 1967, J BIOL CHEM, V242, P3046; BRENNAN PJ, 1971, LIPIDS, V6, P401, DOI 10.1007/BF02531377; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; Chopra I, 1998, TUBERCLE LUNG DIS, V78, P89, DOI 10.1016/S0962-8479(98)80001-4; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; CURCIC R, 1994, MOL MICROBIOL, V13, P1057, DOI 10.1111/j.1365-2958.1994.tb00496.x; DITTMER JC, 1964, J LIPID RES, V5, P126; ELSBACH P, 1988, BIOCHIM BIOPHYS ACTA, V947, P29, DOI 10.1016/0304-4157(88)90018-4; Goren M. B., 1984, MYCOBACTERIA SOURC A, P379; GUILHOT C, 1992, FEMS MICROBIOL LETT, V98, P181; HUNTER SW, 1986, J BACTERIOL, V168, P917, DOI 10.1128/jb.168.2.917-922.1986; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; Jackson M, 1997, INFECT IMMUN, V65, P2883, DOI 10.1128/IAI.65.7.2883-2889.1997; KATAOKA T, 1967, BIOCHIM BIOPHYS ACTA, V144, P681, DOI 10.1016/0005-2760(67)90058-6; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; LABIDI A, 1984, CURR MICROBIOL, V11, P235, DOI 10.1007/BF01567167; MATHUR AK, 1976, CAN J MICROBIOL, V22, P354, DOI 10.1139/m76-054; Matsumoto K, 1997, BBA-LIPID LIPID MET, V1348, P214, DOI 10.1016/S0005-2760(97)00110-0; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Nikawa J, 1997, BBA-LIPID LIPID MET, V1348, P173, DOI 10.1016/S0005-2760(97)00103-3; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NIKAWA JI, 1982, EUR J BIOCHEM, V125, P445, DOI 10.1111/j.1432-1033.1982.tb06703.x; Parish T, 1997, J BACTERIOL, V179, P7827, DOI 10.1128/jb.179.24.7827-7833.1997; Pelicic V, 1996, MOL MICROBIOL, V20, P919, DOI 10.1111/j.1365-2958.1996.tb02533.x; Pelicic V, 1997, P NATL ACAD SCI USA, V94, P10955, DOI 10.1073/pnas.94.20.10955; Salman M, 1999, BBA-MOL CELL BIOL L, V1436, P437, DOI 10.1016/S0005-2760(98)00151-9; Schlame M, 1997, BBA-LIPID LIPID MET, V1348, P201, DOI 10.1016/S0005-2760(97)00117-3; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; TABAUD H, 1971, BIOCHIMIE, V53, P55, DOI 10.1016/S0300-9084(71)80083-4; Tropp BE, 1997, BBA-LIPID LIPID MET, V1348, P192, DOI 10.1016/S0005-2760(97)00100-8; YANO I, 1969, J BACTERIOL, V98, P124, DOI 10.1128/JB.98.1.124-130.1969	40	178	187	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30092	30099		10.1074/jbc.M004658200	http://dx.doi.org/10.1074/jbc.M004658200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10889206	hybrid			2022-12-27	WOS:000089577900026
J	Lynch, TW; Sligar, SG				Lynch, TW; Sligar, SG			Macromolecular hydration changes associated with BamHI binding and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTION-ENDONUCLEASE BAMHI; MOLECULAR RECOGNITION; PROTEIN SOLVATION; OSMOTIC-PRESSURE; WATER RELEASE; DNA-BINDING; ECORI; SPECIFICITY; STABILITY; CLEAVAGE	In this report, the effects of osmotic pressure on BamHI cognate binding and catalysis were investigated and compared with a previous study on EcoRI (Robinson, C. R. and Sligar, S. G. (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 2186-2191). Our observation of the dependence of binding and catalytic parameters on osmotic pressure has allowed for the comparison of hydration changes associated with site-specific DNA recognition for both endonucleases. Over a large range of osmotic pressures (pi), the dependence of BamHI on osmotic stress during cognate binding and catalysis was very different from that of the related endonuclease EcoRI. The binding of EcoRI to cognate DNA was dominated by a dehydration of the endonuclease-DNA complex, whereas binding by BamHI to its cognate sequence was accompanied by a solvent release corresponding to some 125 fewer waters. Catalytic analysis at elevated osmotic pressures indicated that both endonucleases had undergone a net hydration of the complex with BamHI displaying a much greater dependence on osmotic stress than EcoRI. Although the enzymes shared core structural motifs, comparisons of high resolution x-ray structures revealed many different secondary structural features of the complexed endonucleases. The large difference in hydration changes by both BamHI and EcoRI could be attributed to these dissimilar secondary structural features, as well as the functional differences of the two endonucleases during site-specific DNA recognition.	Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Sligar, SG (corresponding author), Univ Illinois, Beckman Inst Adv Sci & Technol, 405 N Mathews Ave, Urbana, IL 61801 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031756, R01GM031756, R01GM033775] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33775, GM31756] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K; BROWN BM, 1993, BIOCHEMISTRY-US, V32, P1354, DOI 10.1021/bi00056a022; COLOMBO MF, 1992, SCIENCE, V256, P655, DOI 10.1126/science.1585178; Dorner LF, 1999, J MOL BIOL, V285, P1515, DOI 10.1006/jmbi.1998.2408; GARNER MM, 1995, EMBO J, V14, P1257, DOI 10.1002/j.1460-2075.1995.tb07109.x; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; HENSLEY P, 1990, J BIOL CHEM, V265, P15300; JenJacobson L, 1997, BIOPOLYMERS, V44, P153; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KORNBLATT JA, 1990, BIOCHEMISTRY-US, V29, P9370, DOI 10.1021/bi00492a010; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; NEWMAN M, 1994, STRUCTURE, V2, P439, DOI 10.1016/S0969-2126(00)00045-9; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; Parsegian VA, 2000, P NATL ACAD SCI USA, V97, P3987, DOI 10.1073/pnas.97.8.3987; Parsegian VA, 1995, METHOD ENZYMOL, V259, P43; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; RAND RP, 1993, BIOCHEMISTRY-US, V32, P5925, DOI 10.1021/bi00074a001; RAND RP, 1992, SCIENCE, V256, P618, DOI 10.1126/science.256.5057.618; Robinson CR, 1995, METHOD ENZYMOL, V259, P395; ROBINSON CR, 1995, P NATL ACAD SCI USA, V92, P3444, DOI 10.1073/pnas.92.8.3444; ROBINSON CR, 1994, BIOCHEMISTRY-US, V33, P3787, DOI 10.1021/bi00179a001; Robinson CR, 1998, P NATL ACAD SCI USA, V95, P2186, DOI 10.1073/pnas.95.5.2186; ROBINSON CR, 1993, J MOL BIOL, V234, P302, DOI 10.1006/jmbi.1993.1586; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O; Sen S, 1999, BIOPHYS J, V77, P1782, DOI 10.1016/S0006-3495(99)77024-4; Sidorova NY, 1999, J BIOMOL STRUCT DYN, V17, P19, DOI 10.1080/07391102.1999.10508337; Sidorova NY, 1996, P NATL ACAD SCI USA, V93, P12272, DOI 10.1073/pnas.93.22.12272; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; Timasheff SN, 1998, ADV PROTEIN CHEM, V51, P355; Viadiu H, 1998, NAT STRUCT BIOL, V5, P910, DOI 10.1038/2352; WEBER G, 1983, Q REV BIOPHYS, V16, P89, DOI 10.1017/S0033583500004935; WILSON GA, 1975, J MOL BIOL, V97, P123, DOI 10.1016/S0022-2836(75)80028-3; ZIMMERBERG J, 1986, NATURE, V323, P36, DOI 10.1038/323036a0; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	35	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30561	30565		10.1074/jbc.M000266200	http://dx.doi.org/10.1074/jbc.M000266200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10878000	hybrid			2022-12-27	WOS:000089577900089
J	Perez-Martinez, X; Vazquez-Acevedo, M; Tolkunova, E; Funes, S; Claros, MG; Davidson, E; King, MP; Gonzalez-Halphen, D				Perez-Martinez, X; Vazquez-Acevedo, M; Tolkunova, E; Funes, S; Claros, MG; Davidson, E; King, MP; Gonzalez-Halphen, D			Unusual location of a mitochondrial gene - Subunit III of cytochrome c oxidase is encoded in the nucleus of chlamydomonad algae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; COMPLETE SEQUENCE; APOCYTOCHROME-B; CDNA SEQUENCE; GENOME ORGANIZATION; HEART-MITOCHONDRIA; MEMBRANE-PROTEINS; RIBOSOMAL-RNAS; ALPHA-SUBUNIT; BC(1) COMPLEX	The algae of the family Chlamydomonadaceae lack the gene cox3 that encodes subunit III of cytochrome c oxidase in their mitochondrial genomes. This observation has raised the question of whether this subunit is present in cytochrome c oxidase or whether the corresponding gene is located in the nucleus. Cytochrome c oxidase was isolated from the colorless chlamydomonad Polytomella spp., and the existence of subunit III was established by immunoblotting analysis with an antibody directed against Saccharomyces cerevisiae subunit III. Based partly upon the N-terminal sequence of this subunit, oligodeoxynucleotides were designed and used for polymerase chain reaction amplification, and the resulting product was used to screen a cDNA library of Chlamydomonas reinhardtii. The complete sequences of the cox3 cDNAs from Polytomella spp. and C. reinhardtii are reported. Evidence is provided that the genes for cox3 are encoded by nuclear DNA, and the predicted polypeptides exhibit diminished physical constraints for import as compared with mitochondrial-DNA encoded homologs. This indicates that transfer of this gene to the nucleus occurred before Polytomella diverged from the photosynthetic Chlamydomonas lineage and that this transfer may have occurred in all chlamydomonad algae.	Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Mol Genet, Mexico City 04510, DF, Mexico; Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Univ Malaga, Fac Ciencias, Dept Biol Mol & Bioquim, E-29071 Malaga, Spain	Universidad Nacional Autonoma de Mexico; Jefferson University; Universidad de Malaga	Gonzalez-Halphen, D (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Mol Genet, Apartado Postal 70-243, Mexico City 04510, DF, Mexico.	dhalphen@ifisiol.unam.mx	Funes, Soledad/A-1278-2010; Claros, Manuel Gonzalo/K-2274-2014; Gonzalez-Halphen, Diego/C-2664-2013; Tolkunova, Elena/U-7174-2017	Funes, Soledad/0000-0003-1815-1977; Claros, Manuel Gonzalo/0000-0002-0112-3550; Gonzalez-Halphen, Diego/0000-0003-0654-655X; Tolkunova, Elena/0000-0003-1254-2619	FIC NIH HHS [TW01176-01] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001176] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Adams KL, 1999, P NATL ACAD SCI USA, V96, P13863, DOI 10.1073/pnas.96.24.13863; AMATI BB, 1988, J MOL EVOL, V28, P151, DOI 10.1007/BF02143507; Antaramian A, 1996, BBA-BIOENERGETICS, V1273, P198, DOI 10.1016/0005-2728(95)00158-1; Antaramian A, 1998, ARCH BIOCHEM BIOPHYS, V354, P206, DOI 10.1006/abbi.1998.0680; Asamizu E, 1999, DNA Res, V6, P369, DOI 10.1093/dnares/6.6.369; Atteia A, 1997, BBA-BIOENERGETICS, V1320, P275, DOI 10.1016/S0005-2728(97)00031-5; Atteia A, 1996, EUR J BIOCHEM, V237, P792, DOI 10.1111/j.1432-1033.1996.0792p.x; ATTEIA A, 1994, THESIS U PARIS 7 PAR; BENNOUN P, 1995, P NATL ACAD SCI USA, V92, P10202, DOI 10.1073/pnas.92.22.10202; Blanchard JL, 1996, MOL BIOL EVOL, V13, P537, DOI 10.1093/oxfordjournals.molbev.a025614; BRENNICKE A, 1993, FEBS LETT, V325, P140, DOI 10.1016/0014-5793(93)81430-8; BURGER G, 1995, J MOL BIOL, V245, P522, DOI 10.1006/jmbi.1994.0043; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CAPALDI RA, 1988, J BIOENERG BIOMEMBR, V20, P291, DOI 10.1007/BF00769634; CAPALDI RA, 1972, FEBS LETT, V26, P261, DOI 10.1016/0014-5793(72)80587-8; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CLAROS MG, 1995, EUR J BIOCHEM, V228, P762, DOI 10.1111/j.1432-1033.1995.0762m.x; Claros MG, 1997, CURR OPIN STRUC BIOL, V7, P394, DOI 10.1016/S0959-440X(97)80057-7; COLLEAUX L, 1990, MOL GEN GENET, V223, P288, DOI 10.1007/BF00265065; CONNER TW, 1989, GENE, V84, P345, DOI 10.1016/0378-1119(89)90509-X; CRIMI M, 1991, TRENDS BIOCHEM SCI, V16, P119, DOI 10.1016/0968-0004(91)90046-X; Denovan-Wright  EM, 1998, PLANT MOL BIOL, V36, P285, DOI 10.1023/A:1005995718091; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEAGIN JE, 1992, NUCLEIC ACIDS RES, V20, P879, DOI 10.1093/nar/20.4.879; FOX TD, 1987, ANNU REV GENET, V21, P67, DOI 10.1146/annurev.ge.21.120187.000435; FRANZEN LG, 1992, PLANT MOL BIOL, V19, P771, DOI 10.1007/BF00027073; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GONZALEZHALPHEN D, 1991, J BIOL CHEM, V266, P3870; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; Gray MW, 1998, NUCLEIC ACIDS RES, V26, P865, DOI 10.1093/nar/26.4.865; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; GROHMANN L, 1992, NUCLEIC ACIDS RES, V20, P5641, DOI 10.1093/nar/20.21.5641; Grossman LI, 1997, BBA-GENE STRUCT EXPR, V1352, P174, DOI 10.1016/S0167-4781(97)00025-0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUTIERREZCIRLOS EB, 1994, J BIOL CHEM, V269, P9147; HORIE S, 1963, J BIOL CHEM, V238, P1855; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Kadowaki KI, 1996, EMBO J, V15, P6652, DOI 10.1002/j.1460-2075.1996.tb01055.x; Kroymann J, 1998, J MOL EVOL, V47, P431, DOI 10.1007/PL00006400; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Martin W, 1998, NATURE, V393, P162, DOI 10.1038/30234; Mattox K. R., 1984, SYSTEMATICS GREEN AL, V27, P29; MELKONIAN M, 1995, B SOC ZOOL FR, V120, P191; MELKONIAN N, 1990, HDB PROTOCTISTA, P608; MICHAELIS G, 1990, MOL GEN GENET, V223, P211, DOI 10.1007/BF00265056; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; Nedelcu AM, 1996, J PHYCOL, V32, P103, DOI 10.1111/j.0022-3646.1996.00103.x; Nurani G, 1996, PLANT MOL BIOL, V31, P1105, DOI 10.1007/BF00040828; NURANI G, 1997, THESIS U STOCKHOLM S; POPOT JL, 1994, METH PHYS S, P41; Race HL, 1999, TRENDS GENET, V15, P364, DOI 10.1016/S0168-9525(99)01766-7; ROUND FE, 1980, BIOSYSTEMS, V12, P61, DOI 10.1016/0303-2647(80)90038-6; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; Silflow Carolyn D., 1998, Advances in Photosynthesis, V7, P25; SUN CW, 1993, PLANT CELL, V5, P97, DOI 10.1105/tpc.5.1.97; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TURMEL M, 1993, NUCLEIC ACIDS RES, V21, P5242, DOI 10.1093/nar/21.22.5242; VANDENBOOGAART P, 1982, NATURE, V298, P187, DOI 10.1038/298187a0; VONHEIJNE G, 1986, FEBS LETT, V198, P1, DOI 10.1016/0014-5793(86)81172-3; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; WOLFF G, 1994, J MOL BIOL, V237, P75, DOI 10.1006/jmbi.1994.1210; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60	63	53	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30144	30152		10.1074/jbc.M003940200	http://dx.doi.org/10.1074/jbc.M003940200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10899162	hybrid			2022-12-27	WOS:000089577900033
J	Budiman, T; Bamberg, E; Koepsell, H; Nagel, G				Budiman, T; Bamberg, E; Koepsell, H; Nagel, G			Mechanism of electrogenic cation transport by the cloned organic cation transporter 2 from rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; PUMP CURRENTS; SUBSTRATE-SPECIFICITY; VOLTAGE-DEPENDENCE; ATP CONCENTRATION; MEMBRANE PATCHES; KINETICS; CLONING; KIDNEY; ROCT1	The organic cation transporter 2 (OCT2) is expressed in plasma membranes of kidney and brain. Its transport mechanism and substrates are debated. We studied substrate-induced changes of electrical current with the patch clamp technique after expression of rat OCT2 in oocytes. Activation of current, corresponding to efflux, was observed for small organic cations, e.g. choline. In contrast, the bigger cations quinine and tetrabutylammonium elicited no change in current. However, transport of choline could be inhibited by applying quinine or tetrabutylammonium to the cytoplasmic side. Inhibition of organic cation efflux by quinine was competitive with substrates. Quinine at the inside also inhibited substrate influx from the outside. Current-voltage analysis showed that both maximal turnover and apparent affinity to substrates are voltage-dependent. Substrate-induced currents with organic cations on both membrane sides reversed as predicted from the Nernst potential. Our results clearly identify the electrochemical potential as driving force for transport at neutral pH and exclude an electroneutral H+/organic cation(+) exchange. We suggest the existence of an electroneutral organic cation(+) exchange and propose a model for a carrier-type transport mechanism.	Max Planck Inst Biophys, D-60596 Frankfurt, Germany; Univ Wurzburg, Inst Anat, D-97070 Wurzburg, Germany	Max Planck Society; University of Wurzburg	Nagel, G (corresponding author), Max Planck Inst Biophys, Kennedyallee 70, D-60596 Frankfurt, Germany.	nagel@mpibp-frankfurt.mpg.de		Nagel, Georg/0000-0001-8174-8712				Busch AE, 1996, J BIOL CHEM, V271, P32599, DOI 10.1074/jbc.271.51.32599; DAVID C, 1995, PFLUG ARCH EUR J PHY, V430, P477, DOI 10.1007/BF00373884; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Endou H, 1998, TOXICOL LETT, V103, P29, DOI 10.1016/S0378-4274(98)00275-6; FENDLER K, 1987, FEBS LETT, V224, P83, DOI 10.1016/0014-5793(87)80427-1; Fendler K, 1999, BIOCHEMISTRY-US, V38, P1850, DOI 10.1021/bi982238u; Friedrich T, 1997, BIOPHYS J, V73, P186, DOI 10.1016/S0006-3495(97)78059-7; Friedrich T, 1996, BIOPHYS J, V71, P2486, DOI 10.1016/S0006-3495(96)79442-0; Gorboulev V, 1999, MOL PHARMACOL, V56, P1254, DOI 10.1124/mol.56.6.1254; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; Grundemann D, 1997, J BIOL CHEM, V272, P10408; Grundemann D, 1999, MOL PHARMACOL, V56, P1, DOI 10.1124/mol.56.1.1; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HANSEN UP, 1981, J MEMBRANE BIOL, V63, P165, DOI 10.1007/BF01870979; Hilgemann DW, 1998, METHOD ENZYMOL, V293, P267; HILGEMANN DW, 1989, PFLUG ARCH EUR J PHY, V415, P247, DOI 10.1007/BF00370601; Hille B., 1992, IONIC CHANNELS EXCIT; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Koepsell H, 1998, ANNU REV PHYSIOL, V60, P243, DOI 10.1146/annurev.physiol.60.1.243; Koepsell H, 1999, J MEMBRANE BIOL, V167, P103, DOI 10.1007/s002329900475; Lauger P., 1991, ELECTROGENIC ION PUM; Nagel G, 1995, FEBS LETT, V377, P263, DOI 10.1016/0014-5793(95)01356-3; Nagel G, 1997, J BIOL CHEM, V272, P31953, DOI 10.1074/jbc.272.51.31953; NAKAO M, 1986, NATURE, V323, P628, DOI 10.1038/323628a0; Okuda M, 1999, BBA-BIOMEMBRANES, V1417, P224, DOI 10.1016/S0005-2736(99)00005-X; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; Sweet DH, 1999, AM J PHYSIOL-RENAL, V277, pF890, DOI 10.1152/ajprenal.1999.277.6.F890; Ullrich K, 1999, MEMBRANE TRANSPORTER, P159; Ullrich KJ, 1997, J MEMBRANE BIOL, V158, P95, DOI 10.1007/s002329900247; Urakami Y, 1998, J PHARMACOL EXP THER, V287, P800; Weinreich F, 1999, J GEN PHYSIOL, V114, P55, DOI 10.1085/jgp.114.1.55; Weinreich F, 1997, PFLUG ARCH EUR J PHY, V434, P484, DOI 10.1007/s004240050424	32	71	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29413	29420		10.1074/jbc.M004645200	http://dx.doi.org/10.1074/jbc.M004645200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10889205	hybrid			2022-12-27	WOS:000089439800033
J	Pardali, K; Kurisaki, A; Moren, A; ten Dijke, P; Kardassis, D; Moustakas, A				Pardali, K; Kurisaki, A; Moren, A; ten Dijke, P; Kardassis, D; Moustakas, A			Role of smad proteins and transcription factor Sp1 in p21(Wafl/Cip1) regulation by transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; HUMAN P21(WAF1/CIP1) GENE; TGF-BETA; DNA-BINDING; FUNCTIONAL INTERACTIONS; FAMILY MEMBERS; CDK INHIBITOR; PROMOTER; ACTIVATION; EXPRESSION	Transforming growth factor-beta (TGF-beta) inhibits cell cycle progression, in part through up-regulation of gene expression of the p21(WAF1/Cip1) (p21) cell cycle inhibitor. Previously we have reported that the intracellular effecters of TGF-beta, Smad3 and Smad4, functionally cooperate with Sp1 to activate the human p21 promoter in hepatoma HepG2 cells. In this study we show that Smad3 and Smad4 when overexpressed in HaCaT keratinocytes lead to activation of the p21 promoter. Activation requires the binding sites for the ubiquitous transcription factor Sp1 on the proximal promoter. Induction of the endogenous HaCaT p21 gene by TGF-beta 1 is further enhanced after overexpression of Smad3 and Smad4, whereas dominant negative mutants of Smad3 and Smad4 and the inhibitory Smad7 all inhibit p21 induction by TGF-beta 1 in a dose-dependent manner. We show that Sp1 expressed in the Sp1-deficient Drosophila SL-2 cells binds to the proximal promoter sequences, whereas Smad proteins do not. In support of this finding, we show that DNA-binding domain mutants of Smad3 and Smad4 are capable of transactivating the p21 promoter as efficiently as wild type Smads. Co-expression of Smad3 with Smad4 and Sp1 in SL-2 cells or coincubation of phosphorylated Smad3, Smad4, and Sp1 in vitro results in enhanced binding of Sp1 to the p21 proximal promoter sequences. We demonstrate that Sp1 physically and directly interacts with Smad2, Smad3, and weakly with Smad4 via their amino-terminal (Mad-Homology 1) domain. Finally, by using GAL4 fusion proteins we show that the glutamine-rich sequences in the transactivation domain of Sp1 contribute to the cooperativity with Smad proteins. In conclusion, Smad proteins play important roles in regulation of the p21 gene by TGF-beta, and the functional cooperation of Smad proteins with Sp1 involves the physical interaction of these two types of transcription factors.	Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece; FORTH, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Greece	Ludwig Institute for Cancer Research; Netherlands Cancer Institute; University of Crete; Foundation for Research & Technology - Hellas (FORTH)	Moustakas, A (corresponding author), Ludwig Inst Canc Res, Box 595, SE-75124 Uppsala, Sweden.		Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Pardali, Katerina/0000-0002-4360-730X				Alexandrow MG, 1997, J CELL BIOCHEM, V66, P427, DOI 10.1002/(SICI)1097-4644(19970915)66:4<427::AID-JCB1>3.3.CO;2-Y; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Hu PPC, 1998, ENDOCR REV, V19, P349, DOI 10.1210/er.19.3.349; Hunt KK, 1998, CANCER RES, V58, P5656; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Iavarone A, 1997, NATURE, V387, P417; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kivinen L, 1999, CELL GROWTH DIFFER, V10, P621; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MOSES HL, 1992, MOL REPROD DEV, V32, P179, DOI 10.1002/mrd.1080320215; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Piek E, 1999, J CELL SCI, V112, P4557; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	62	327	346	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29244	29256		10.1074/jbc.M909467199	http://dx.doi.org/10.1074/jbc.M909467199			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10878024	hybrid			2022-12-27	WOS:000089439800011
J	Stopa, M; Anhuf, D; Terstegen, L; Gatsios, P; Gressner, AM; Dooley, S				Stopa, M; Anhuf, D; Terstegen, L; Gatsios, P; Gressner, AM; Dooley, S			Participation of Smad2, Smad3, and Smad4 in transforming growth factor beta (TGF-beta)-induced activation of Smad7 - The TGF-beta response element of the promotor requires functional Smad binding element and E-box sequences for transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR-1 PROMOTER; TUMOR-SUPPRESSOR; GENE; PROTEINS; ACTIVIN; IDENTIFICATION; ANTAGONIST; FAMILY; DNA	Smad7 has recently been identified as a player that antagonizes transforming growth factor beta (TGF-beta) signals by acting downstream of TGF-beta receptors, TGF-beta rapidly induces expression of Smad7 mRNA in a variety of cell types, suggesting participation in a negative feedback loop to control TGF-beta beta responses. We have previously described the genomic locus of rat Smad7 including the promoter region. Here we report polymerase chain reaction cloning of the corresponding promoter regions of human and murine Smad7 genes and functional characterization of the rat Smad7 promoter. Using transient transfection experiments of HepG2 cells, we identified the TGF-beta response element within a strongly conserved region, containing a perfect Smad binding element (SBE; GTCTAGAC). Performing electrophoretic mobility shift assay and cotransfection experiments, we were able to delineate DNA-binding complexes and identified Smad3, Smad4, and Smad2. Mutation of the SBE completely abolished TGF-beta inducibility of Smad7 in HepG2 cells, indicating that this sequence is necessary for TGF-beta-induced transcription. Furthermore, a 3-base pair adjacent E-box is additionally essential for TGF-beta-dependent promoter activation and an overlapping AP1 site is also involved. We conclude that regulation of Smad7 transcription by TGF-beta is mediated via a specific constellation of recognition motifs localized around the SBE, which is conserved in human, rat, and murine genes.	Rhein Westfal TH Klinikum, Inst Klin Chem & Pathobiochem, D-52074 Aachen, Germany; Rhein Westfal TH Klinikum, Inst Biochem, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital	Dooley, S (corresponding author), Rhein Westfal TH Klinikum, Inst Klin Chem & Pathobiochem, Pauwelsstr 30, D-52074 Aachen, Germany.		Dooley, Steven/T-6491-2018; Stopa, Marcin/R-2772-2018	Dooley, Steven/0000-0002-4840-6240; Stopa, Marcin/0000-0001-9540-9500				Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Alevizopoulos A, 1997, BIOESSAYS, V19, P581, DOI 10.1002/bies.950190709; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Cross SH, 1999, NUCLEIC ACIDS RES, V27, P2099, DOI 10.1093/nar/27.10.2099; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishisaki A, 1998, J BIOL CHEM, V273, P24293, DOI 10.1074/jbc.273.38.24293; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Roijer E, 1998, CYTOGENET CELL GENET, V81, P189, DOI 10.1159/000015026; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Stopa M, 2000, MAMM GENOME, V11, P169, DOI 10.1007/s003350010032; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; TOKUNAGA K, 1987, CANCER RES, V47, P5616; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wong C, 1999, MOL CELL BIOL, V19, P1821; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	29	110	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29308	29317		10.1074/jbc.M003282200	http://dx.doi.org/10.1074/jbc.M003282200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887185	hybrid			2022-12-27	WOS:000089439800019
J	Sakash, JB; Kantrowitz, ER				Sakash, JB; Kantrowitz, ER			The contribution of individual interchain interactions to the stabilization of the T and R states of Escherichia coli aspartate transcarbamoylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONCERTED ALLOSTERIC TRANSITION; HETEROTROPIC INTERACTIONS; QUATERNARY STRUCTURE; CATALYTIC SUBUNIT; REGULATORY CHAIN; CARBAMOYLTRANSFERASE; BINDING; SITE; PURIFICATION; CRYSTAL	Stabilization of the T and R allosteric states of Escherichia coli aspartate transcarbamoylase is governed by specific intra- and interchain interactions. The six interchain interactions between Glu-239 in one catalytic chain of one catalytic trimer with both Lys-164 and Tyr-165 of a different catalytic chain in the other catalytic trimer have been shown to be involved in the stabilization of the T state. In this study a series of hybrid versions of aspartate transcarbamoylase was studied to determine the minimum number of these Glu-239 interactions necessary to maintain homotropic cooperativity and the T allosteric state. Hybrids with zero, one, and two Glu-239 stabilizing interactions do not exhibit cooperativity, whereas the hybrids with three or more Glu-239 stabilizing interactions exhibit cooperativity, The hybrid enzymes with one or more of the Glu-239 stabilizing interactions also exhibit heterotropic interactions. Two hybrids with three Glu-239 stabilizing interactions, in different geometric relationships, had identical properties. From this and previous studies, it is concluded that the 239 stabilizing interactions play a critical role in the manifestation of homotropic cooperativity in aspartate transcarbamoylase by the stabilization. of the T state of the enzyme. As substrate binding energy is utilized, more and more of the T state stabilizing interactions are relaxed, and finally the enzyme shifts to the R state. In the case of the Glu-239 stabilizing interactions more than three of the interactions must be broken before the enzyme shifts to the R state. The interactions between the catalytic and regulatory chains and between the two catalytic trimers of aspartate transcarbamoylase provide a global set of interlocking interactions that stabilize the T and R states of the enzyme. The substrate-induced local conformational changes observed in the structure of the isolated catalytic subunit drive the quaternary T to R transition of aspartate transcarbamoylase and functionally induced homotropic cooperativity.	Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA	Boston College	Kantrowitz, ER (corresponding author), Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026237] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26237] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANGEUX JP, 1968, BIOCHEMISTRY-US, V7, P531, DOI 10.1021/bi00842a007; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P680; DEMBOWSKI NJ, 1993, PROTEIN ENG, V6, P123, DOI 10.1093/protein/6.1.123; Endrizzi JA, 2000, P NATL ACAD SCI USA, V97, P5077, DOI 10.1073/pnas.090087197; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GERHART JC, 1963, COLD SPRING HARB SYM, V28, P491, DOI 10.1101/SQB.1963.028.01.065; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1962, J BIOL CHEM, V237, P891; GOUAUX JE, 1990, BIOCHEMISTRY-US, V29, P389, DOI 10.1021/bi00454a013; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; LADJIMI MM, 1985, J MOL BIOL, V186, P715, DOI 10.1016/0022-2836(85)90391-2; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHUE RS, 1984, J BIOL CHEM, V259, P3906; MANIATIS T, 1982, MOL CLONING LABORATO, P368; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; Sakash JB, 2000, J BIOL CHEM, V275, P752, DOI 10.1074/jbc.275.2.752; Sakash JB, 1998, BIOCHEMISTRY-US, V37, P281, DOI 10.1021/bi972102g; SILVER RS, 1983, J MOL BIOL, V168, P729, DOI 10.1016/S0022-2836(83)80072-2; STEBBINS JW, 1989, BIOCHEMISTRY-US, V28, P2592, DOI 10.1021/bi00432a037; TAUC P, 1990, J MOL BIOL, V214, P327, DOI 10.1016/0022-2836(90)90164-H; TAUC P, 1994, PROTEIN SCI, V3, P1998, DOI 10.1002/pro.5560031112; TAUC P, 1982, J MOL BIOL, V155, P155, DOI 10.1016/0022-2836(82)90442-9; WILD JR, 1989, P NATL ACAD SCI USA, V86, P46, DOI 10.1073/pnas.86.1.46	30	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28701	28707		10.1074/jbc.M005079200	http://dx.doi.org/10.1074/jbc.M005079200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10875936	hybrid			2022-12-27	WOS:000089330700050
J	Benzing, T; Yaffe, MB; Arnould, T; Sellin, L; Schermer, B; Schilling, B; Schreiber, R; Kunzelmann, K; Leparc, GG; Kim, E; Walz, G				Benzing, T; Yaffe, MB; Arnould, T; Sellin, L; Schermer, B; Schilling, B; Schreiber, R; Kunzelmann, K; Leparc, GG; Kim, E; Walz, G			14-3-3 Interacts with regulator of G protein signaling proteins and modulates their activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; KINASE-ACTIVITY; RGS PROTEINS; 14-3-3-PROTEINS; BINDING; PHOSPHORYLATION; INHIBITION; MECHANISM; SURVIVAL; FAMILY	Regulator of G protein signaling (RGS) proteins function as GTPase-activating proteins (GAPs) that stimulate the inactivation of heterotrimeric G proteins. We have recently shown that RGS proteins may be regulated on a post-translational level (Benzing, T., Brandes, R., Sellin, L., Schermer, B,, Lecker, S., Walt, G., and Kim, E. (1999) Naf. Med. 5, 913-918). However, mechanisms controlling the GAP activity of RGS proteins are poorly understood. Here we show that 14-3-3 proteins associate with RGS7 and RGS3, Binding of 14-3-3 is mediated by a conserved phosphoserine located in the G alpha-interacting portion of the RGS domain; interaction with 14-3-3 inhibits the GAP activity of RGS7, depends upon phosphorylation of a conserved residue within the RGS domain, and results in inhibition of GAP function. Collectively, these data indicate that phosphorylation-dependent binding of 14-3-3 may act as molecular switch that controls the GAP activity keeping a substantial fraction of RGS proteins in a dormant state.	Univ Hosp Freiburg, Dept Med, D-79106 Freiburg, Germany; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; Univ Freiburg, Dept Physiol, D-79106 Freiburg, Germany	University of Freiburg; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Freiburg	Walz, G (corresponding author), Univ Hosp Freiburg, Dept Med, Hugstetterstr 55, D-79106 Freiburg, Germany.		Schreiber, Robert/Q-7550-2019; Benzing, Thomas/X-5476-2019; Schermer, Bernhard/E-9972-2014	Schermer, Bernhard/0000-0002-5194-9000; Kunzelmann, Karl/0000-0002-4583-7037	NHLBI NIH HHS [HL03601] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; AITKEN A, 1995, BIOCHEM SOC T, V23, P605, DOI 10.1042/bst0230605; Benzing T, 1999, NAT MED, V5, P913, DOI 10.1038/11354; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; Dohlman HG, 1998, SEMIN CELL DEV BIOL, V9, P135, DOI 10.1006/scdb.1998.0218; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Song L, 1999, J BIOL CHEM, V274, P29689, DOI 10.1074/jbc.274.42.29689; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	26	94	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28167	28172						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862767				2022-12-27	WOS:000089197100084
J	Palmer, HR; Bedford, JJ; Leader, JP; Smith, RAJ				Palmer, HR; Bedford, JJ; Leader, JP; Smith, RAJ			P-31 and H-1 NMR studies of the effect of the counteracting osmolyte trimethylamine-N-oxide on interactions of urea with ribonuclease A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-1-NMR SPECTROSCOPY; PROTEIN; EVOLUTION; TISSUES; PROGRAM; FISHES	P-31 NMB spectroscopy has been used to show that the activity of RNase A, which is lowered in the presence of urea, can be recovered with trimethylamine-N-oxide (TMAO). A 1:1 ratio of TMAO:urea was sufficient to recover the enzyme activity. H-1 nuclear Overhauser effect spectroscopy NMR studies with RNase A have shown that even at relatively low effective concentrations of TMAO, some modification of the three-dimensional structure of the biomolecule is apparent.	Univ Otago, Dept Chem, Dunedin 9001, New Zealand; Univ Otago, Sch Med, Dept Physiol, Dunedin 9001, New Zealand	University of Otago; University of Otago	Smith, RAJ (corresponding author), Univ Otago, Dept Chem, POB 56, Dunedin 9001, New Zealand.							Bedford JJ, 1998, COMP BIOCHEM PHYS B, V119, P521, DOI 10.1016/S0305-0491(98)00013-3; Bedford JJ, 1998, J COMP PHYSIOL B, V168, P123, DOI 10.1007/s003600050128; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Burg MB, 1998, AM J PHYSIOL-RENAL, V274, pF762, DOI 10.1152/ajprenal.1998.274.4.F762; Burg MB, 1997, AM J PHYSIOL-RENAL, V273, pF1048, DOI 10.1152/ajprenal.1997.273.6.F1048; BURG MB, 1996, KIDNEY INT S57, V57, P100; DELCARDAYRE SB, 1994, BIOCHEMISTRY-US, V33, P6031, DOI 10.1021/bi00186a001; Holland LZ, 1997, BIOCHEMISTRY-US, V36, P3207, DOI 10.1021/bi962664k; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LIN TY, 1994, BIOCHEMISTRY-US, V33, P12695, DOI 10.1021/bi00208a021; OGG RJ, 1994, J MAGN RESON SER B, V104, P1, DOI 10.1006/jmrb.1994.1048; PERRIN DD, 1965, DISSOCIATION CONSTAN, P32; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; RICO M, 1989, EUR J BIOCHEM, V183, P623, DOI 10.1111/j.1432-1033.1989.tb21092.x; SANTORO J, 1993, J MOL BIOL, V229, P722, DOI 10.1006/jmbi.1993.1075; THOMPSON JE, 1994, BIOCHEMISTRY-US, V33, P7408, DOI 10.1021/bi00189a047; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; Wimmer R, 1997, J BIOMOL NMR, V9, P101, DOI 10.1023/A:1018631903764; Wimmer R, 1997, J BIOTECHNOL, V55, P85, DOI 10.1016/S0168-1656(97)00061-8; YANCEY PH, 1979, BIOCHEM J, V183, P317, DOI 10.1042/bj1830317; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; [No title captured]	22	34	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27708	27711						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862769				2022-12-27	WOS:000089197100026
J	Bennett, RJ; Noirot-Gros, MF; Wang, JC				Bennett, RJ; Noirot-Gros, MF; Wang, JC			Interaction between yeast Sgs1 helicase and DNA topoisomerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WERNERS-SYNDROME GENES; ESCHERICHIA-COLI; SYNDROME PROTEIN; BLOOMS-SYNDROME; SACCHAROMYCES-CEREVISIAE; RECQ; RECOMBINATION; EXONUCLEASE; PRODUCT; MITOSIS	The Saccharomyces cerevisiae Sgs1 protein is a member of the RecQ family of DNA helicases that includes the human Bloom's syndrome and Werner's syndrome proteins. In this work, we report studies on the interaction between Sgs1 and DNA topoisomerase III in vitro and in vivo, Affinity chromatography experiments with various fragments of Sgs1, a 1447-amino acid polypeptide, suggested that its N-terminal one-fifth was sufficient for interaction with DNA topoisomerase III. Gel electrophoretic mobility shift assays also indicated that a fragment Sgs1(1-283), containing residues 1-283, inhibited the binding of DNA topoisomerase III to single-stranded DNA. A shorter protein fragment containing residues 1-107 also showed partial inhibition in these assays. Studies of a sgs1 top1 double mutant lacking both Sgs1 and DNA topoisomerase I showed that the slow growth phenotype of this double mutant is suppressed by expressing full-length Sgs1, but not Sgs1 without the N-terminal 107 amino acid residues. In sgs1 top3 cells devoid of DNA topoisomerase III, however, expression of full-length Sgs1 or Sgs1 lacking the N-terminal 107 amino acid residues has the same effect of reducing the growth rate of the double mutant. These in vitro and in vivo data indicate that Sgs1 and DNA topoisomerase III physically interact and that this interaction is physiologically significant.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Wang, JC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.	jcwang@fas.harvard.edu	noirot-gros, marie-francoise/C-5051-2011; Noirot-Gros, Marie-Françoise/AAY-1001-2021	Bennett, Richard/0000-0001-7563-484X	NIGMS NIH HHS [GM 24544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024544, R37GM024544] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; Davey S, 1998, MOL CELL BIOL, V18, P2721, DOI 10.1128/MCB.18.5.2721; Declais AC, 2000, J BIOL CHEM, V275, P19498, DOI 10.1074/jbc.M910091199; Duguet M, 1997, J CELL SCI, V110, P1345; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Gangloff S, 1999, EMBO J, V18, P1701, DOI 10.1093/emboj/18.6.1701; Goodwin A, 1999, NUCLEIC ACIDS RES, V27, P4050, DOI 10.1093/nar/27.20.4050; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Heo SJ, 1999, GENES CELLS, V4, P619, DOI 10.1046/j.1365-2443.1999.00288.x; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; KIM RA, 1992, J BIOL CHEM, V267, P17178; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; KUSANO K, 1994, P NATL ACAD SCI USA, V91, P1173, DOI 10.1073/pnas.91.3.1173; KUYKENDALL JR, 1992, MUTAT RES, V283, P131, DOI 10.1016/0165-7992(92)90145-8; Li W, 1998, P NATL ACAD SCI USA, V95, P1010, DOI 10.1073/pnas.95.3.1010; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LU J, 1996, SCIENCE, V383, P678; Maftahi M, 1999, NUCLEIC ACIDS RES, V27, P4715, DOI 10.1093/nar/27.24.4715; Mullen JR, 2000, GENETICS, V154, P1101; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Ng SW, 1999, NUCLEIC ACIDS RES, V27, P993, DOI 10.1093/nar/27.4.993; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shimamoto A, 2000, NUCLEIC ACIDS RES, V28, P1647, DOI 10.1093/nar/28.7.1647; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	39	110	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26898	26905						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10862619				2022-12-27	WOS:000089144800033
J	Jain, RK; Joyce, PBM; Gorr, SU				Jain, RK; Joyce, PBM; Gorr, SU			Aggregation chaperones enhance aggregation and storage of secretory proteins in endocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDUCED AGGREGATION; SECRETOGRANIN-II; CHROMOGRANIN-B; IN-VITRO; PITUITARY; GRANULES; PH; MECHANISMS; PATHWAY; 7B2	calcium-induced aggregation has been proposed to play a role in the sorting and storage of secretory proteins in secretary granules of endocrine cells. The regulation of this process is not known. Hexahistidine epitope tags were used to create aggregation chaperones that enhance the calcium-induced aggregation of secretary granule proteins in vitro. Indeed, 100% recovery of the aggregating target protein was achieved without any modification of the target protein. The aggregation chaperone is not trapped in the aggregates. Go-expression of His(6)-tagged secreted alkaline phosphatase and the regulated secretory protein chromogranin A resulted in an increased chromogranin storage in secretary granules, and stimulated secretion of chromogranin A increased 50%. However, secretion of secreted alkaline phosphatase was not affected by the hexahistidine epitope tag. Thus, calcium-induced aggregation is not a passive process; rather, aggregation and sorting of secretory proteins can be regulated by aggregation chaperones in the secretary pathway of endocrine cells.	Univ Louisville, Hlth Sci Ctr, Dept Mol Cellular & Craniofacial Biol, Louisville, KY 40292 USA; Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40292 USA; Concordia Univ, Dept Chem & Biochem, Montreal, PQ H3G 1M8, Canada; Concordia Univ, Ctr Struct & Funct Genomics, Montreal, PQ H3G 1M8, Canada	University of Louisville; University of Louisville; Concordia University - Canada; Concordia University - Canada	Gorr, SU (corresponding author), Univ Louisville, Hlth Sci Ctr, Dept Mol Cellular & Craniofacial Biol, Louisville, KY 40292 USA.		Joyce, Paul/K-3989-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053367] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 53367] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; Arvan Peter, 1992, Trends in Cell Biology, V2, P327; Canaff L, 1996, P NATL ACAD SCI USA, V93, P9483, DOI 10.1073/pnas.93.18.9483; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; Cowley DJ, 2000, J BIOL CHEM, V275, P7743, DOI 10.1074/jbc.275.11.7743; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GORR SU, 1987, BONE MINER, V2, P251; Gorr SU, 1999, BIOCHEM BIOPH RES CO, V257, P545, DOI 10.1006/bbrc.1999.0504; Gorr SU, 1999, AM J PHYSIOL-CELL PH, V277, pC121, DOI 10.1152/ajpcell.1999.277.1.C121; Gorr SU, 1996, J BIOL CHEM, V271, P3575; HASHIMOTO S, 1987, J CELL BIOL, V105, P1579, DOI 10.1083/jcb.105.4.1579; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; Kleene R, 1999, DIGESTION, V60, P305, DOI 10.1159/000007676; Klumperman J, 1996, J NEUROSCI, V16, P7930; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; LINARD CG, 1995, MOL CELL BIOCHEM, V151, P39, DOI 10.1007/BF01076894; Natori S, 1996, P NATL ACAD SCI USA, V93, P4431, DOI 10.1073/pnas.93.9.4431; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Shennan KIJ, 1996, BIOCHEM SOC T, V24, P535, DOI 10.1042/bst0240535; Thiele C, 1997, CURR BIOL, V7, P496; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6	23	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27032	27036						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10862758				2022-12-27	WOS:000089144800050
J	Kuraoka, I; Kobertz, WR; Ariza, RR; Biggerstaff, M; Essigmann, JM; Wood, RD				Kuraoka, I; Kobertz, WR; Ariza, RR; Biggerstaff, M; Essigmann, JM; Wood, RD			Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; ENDONUCLEASE; OLIGONUCLEOTIDES; PROMOTES; PROTEIN; MUTANTS	Interstrand DNA cross-link damage is a severe challenge to genomic integrity. Nucleotide excision repair plays some role in the repair of DNA cross-links caused by psoralens and other agents. However, in mammalian cells there is evidence that the ERCC1-XPF nuclease has a specialized additional function during interstrand DNA cross-link repair, beyond its role in nucleotide excision repair. We placed a psoralen monoadduct or interstrand cross-link in a duplex, 4-6 bases from a junction with unpaired DNA. ERCC1-XPF endonucleolytically cleaved within the duplex on either side of the adduct, on the strand having an unpaired 3' tail. Crosslinks that were cleaved only on the 5' side were purified and reincubated with ERCC1-XPF, A second cleavage was then observed on the 3' side. Relevant partially unwound structures near a cross-link may be expected to arise frequently, for example at stalled DNA replication forks. The results show that the single enzyme ERCC1-XPF can release one arm of a cross-link and suggest a novel mechanism for interstrand cross-link repair.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Wood, RD (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.	wood@icrf.icnet.uk	; Wood, Richard/M-6319-2018	Kuraoka, Isao/0000-0001-6391-3411; Wood, Richard/0000-0002-9495-6892; Rodriguez Ariza, Rafael/0000-0002-0338-7306	NCI NIH HHS [R01 CA086061, CA80024] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA080024, R01CA086061, R01CA080024] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; Bessho T, 1997, MOL CELL BIOL, V17, P6822, DOI 10.1128/MCB.17.12.6822; Brookman KW, 1996, MOL CELL BIOL, V16, P6553; Busch DB, 1997, MUTAT RES-DNA REPAIR, V383, P91, DOI 10.1016/S0921-8777(96)00048-1; CARR AM, 1994, MOL CELL BIOL, V14, P2029, DOI 10.1128/MCB.14.3.2029; CHENG S, 1988, J BIOL CHEM, V263, P15110; COLE RS, 1973, P NATL ACAD SCI USA, V70, P1064, DOI 10.1073/pnas.70.4.1064; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; de Laat WL, 1998, J BIOL CHEM, V273, P7835, DOI 10.1074/jbc.273.14.7835; HOY CA, 1985, CANCER RES, V45, P1737; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; KAYE J, 1980, CANCER RES, V40, P696; Kobertz WR, 1997, J AM CHEM SOC, V119, P5960, DOI 10.1021/ja9703178; Melton DW, 1998, J CELL SCI, V111, P395; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Sargent RG, 1997, P NATL ACAD SCI USA, V94, P13122, DOI 10.1073/pnas.94.24.13122; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; SLADEK FM, 1989, J BIOL CHEM, V264, P6755; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; VANHOUTEN B, 1986, P NATL ACAD SCI USA, V83, P8077	21	248	250	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26632	26636		10.1074/jbc.C000337200	http://dx.doi.org/10.1074/jbc.C000337200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10882712	hybrid			2022-12-27	WOS:000088999700102
J	Crisp, RJ; Knauer, DJ; Knauer, MF				Crisp, RJ; Knauer, DJ; Knauer, MF			Roles of the heparin and low density lipid receptor-related protein-binding sites of protease nexin 1 (PN1) in urokinase-PN1 complex catabolism - The PN1 heparin-binding site mediates complex retention and degradation but not cell surface binding or internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; PLASMINOGEN-ACTIVATOR; ANTITHROMBIN-III; THROMBIN; LIPOPROTEIN; IDENTIFICATION; PURIFICATION; MECHANISM; COFACTOR; PEPTIDE	We have previously described thrombin (Th)-protease nexin 1 (PN1) inhibitory complex binding to cell surface heparins and subsequent low density lipid receptor-related protein (LRP)-mediated internalization. Our present studies examine the catabolism of urinary plasminogen activator (uPA)-PN1 inhibitory complexes, which, unlike Th PN1 complexes, bind almost exclusively through the uPA receptor. In addition, the binding site in PN1 required for the LRP-mediated internalization of Th PN1 complexes is not required for the LRP-mediated internalization of uPA.PN1 complexes. Thus, the protease moiety of the complex partially determines the mechanistic route of entry. Because cell surface heparins are only minimally involved in the binding and internalization of uPA.PN1 complexes, we then predicted that complexes between uPA and the heparin binding-deficient PN1 variant, PN1(K7E), should be catabolized at the same rate as complexes formed with native PN1. Surprisingly, the uPA.PN1(K7E) complexes were degraded at only a fraction of the rate of native complexes. Internalization studies revealed that both uPA.PN1(K7E) and native uPA.PN1 complexes were initially internalized at the same rate, but uPA.PN1(K7E) complexes were rapidly retro-endocytosed in an intact form. By examining the pH dependence of complex binding in the range of 4.0-7.0, it was determined that the uPA.PN1 inhibitory complexes must specifically bind to endosomal heparins at pH 5.5 to be retained and sorted to lysosomes. These studies are the first to document a role for heparins in the catabolism of SERPIN-protease complexes at a point further in the pathway than cell surface binding, and this role may extend to other heparin-binding LRP-internalized ligands.	Univ Calif Irvine, Sch Biol Sci, Dept Dev & Cell Biol, Irvine, CA 92627 USA	University of California System; University of California Irvine	Knauer, MF (corresponding author), Univ Calif Irvine, Sch Biol Sci, Dept Dev & Cell Biol, Irvine, CA 92627 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034001] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM34001-12] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; Bochaton-Piallat ML, 1998, CIRC RES, V82, P1086, DOI 10.1161/01.RES.82.10.1086; COHEN AB, 1977, P NATL ACAD SCI USA, V74, P4311, DOI 10.1073/pnas.74.10.4311; CONESE M, 1994, J BIOL CHEM, V269, P17886; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; CUNNINGHAM DD, 1992, ADV EXP MED BIOL, V313, P297; Cunningham DD, 1997, ADV EXP MED BIOL, V425, P67; DONOVAN FM, 1994, J BIOL CHEM, V269, P17199; Donovan FM, 1998, J BIOL CHEM, V273, P12746, DOI 10.1074/jbc.273.21.12746; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; GRONKE RS, 1987, J BIOL CHEM, V262, P3030; GUENTHER J, 1985, EMBO J, V4, P1963, DOI 10.1002/j.1460-2075.1985.tb03878.x; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JOSLIN G, 1991, J BIOL CHEM, V266, P21897; KNAUER DJ, 1984, J BIOL CHEM, V259, P5623; KNAUER DJ, 1983, J CELL PHYSIOL, V117, P385, DOI 10.1002/jcp.1041170314; Knauer MF, 1999, J BIOL CHEM, V274, P275, DOI 10.1074/jbc.274.1.275; Knauer MF, 1997, J BIOL CHEM, V272, P12261, DOI 10.1074/jbc.272.19.12261; Knauer MF, 1997, J BIOL CHEM, V272, P29039, DOI 10.1074/jbc.272.46.29039; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; Maekawa H, 1996, J BIOL CHEM, V271, P18604, DOI 10.1074/jbc.271.31.18604; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; PERLMUTTER DH, 1988, J CLIN INVEST, V81, P1774, DOI 10.1172/JCI113519; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; Ploug M, 1998, J BIOL CHEM, V273, P13933, DOI 10.1074/jbc.273.22.13933; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SMITH JW, 1990, BIOCHEMISTRY-US, V29, P8950, DOI 10.1021/bi00490a010; SMITH JW, 1987, J BIOL CHEM, V262, P11964; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; VerdiereSahuque M, 1996, EXP CELL RES, V222, P70, DOI 10.1006/excr.1996.0009	37	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19628	19637		10.1074/jbc.M909172199	http://dx.doi.org/10.1074/jbc.M909172199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867020	hybrid			2022-12-27	WOS:000087941300027
J	Fribourg, S; Kellenberger, E; Rogniaux, H; Poterszman, A; Van Dorsselaer, A; Thierry, JC; Egly, JM; Moras, D; Kieffer, B				Fribourg, S; Kellenberger, E; Rogniaux, H; Poterszman, A; Van Dorsselaer, A; Thierry, JC; Egly, JM; Moras, D; Kieffer, B			Structural characterization of the cysteine-rich domain of TFIIH p44 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; DNA-REPAIR; 26S PROTEASOME; BINDING DOMAIN; ZINC-FINGER; CSB PROTEIN	In an effort to understand the structure function relationship of TFIIH, a transcription/repair factor, we focused our attention on the p44 subunit, which plays a central role in both mechanisms. The amino-terminal portion of p44 has been shown to be involved in the regulation of the XPD helicase activity; here we show that its carboxyl-terminal domain is essential for TFIIH transcription activity and that it binds three zinc atoms through two independent modules. The first contains a C4 zinc finger motif, whereas the second is characterized by a CX(2)CX(2-4)FCADCD motif, corresponding to interleaved zinc binding sites. The solution structure of this second module reveals an unexpected homology with the regulatory domain of protein kinase C and provides a framework to study its role at the molecular level.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France; Ecole Super Biotechnol Strasbourg, CNRS UPR 9004, Communaunte Urbaine Strasbourg, F-67400 Illkirch Graffenstaden, France; Ecole Super Biotechnol Strasbourg, CNRS UPR 9004, Lab Resonance Magnet, F-67400 Illkirch Graffenstaden, France; ULP, CNRS UMR 7509, Lab Spectrometrie Masse Bio Organ, F-67008 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Moras, D (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,Boite Postale 163, F-67404 Illkirch, France.		Fribourg, Sebastien/M-7418-2014; Kieffer, Bruno/AAE-8999-2019	Fribourg, Sebastien/0000-0003-4112-7510; Kieffer, Bruno/0000-0002-2033-4679; POTERSZMAN, Arnaud/0000-0002-6702-5777				Adachi N, 1999, YEAST, V15, P255; Alexandrov NN, 1996, PROTEINS, V25, P354, DOI 10.1002/(SICI)1097-0134(199607)25:3<354::AID-PROT7>3.3.CO;2-W; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1998, PROTEIN SCI, V7, P1250, DOI 10.1002/pro.5560070521; BARDWELL L, 1994, P NATL ACAD SCI USA, V91, P3926, DOI 10.1073/pnas.91.9.3926; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Billeter M, 1995, J BIOMOL NMR, V5, P1; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; BRUNGER AT, 1992, XPLOR SOFTWARE MANUA; Coin F, 1998, COLD SPRING HARB SYM, V63, P105, DOI 10.1101/sqb.1998.63.105; Coin F, 1998, NAT GENET, V20, P184, DOI 10.1038/2491; DAIKUN GP, 1986, NATURE, V324, P698; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Holstege FCP, 1997, METHODS, V12, P203, DOI 10.1006/meth.1997.0472; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; LAFITTE D, 1995, BIOCHEMISTRY-US, V34, P13825, DOI 10.1021/bi00042a014; MA LB, 1994, MOL CELL BIOL, V14, P4126, DOI 10.1128/MCB.14.6.4126; MATSUI P, 1995, NUCLEIC ACIDS RES, V23, P767, DOI 10.1093/nar/23.5.767; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Rogniaux H, 1999, J AM SOC MASS SPECTR, V10, P635, DOI 10.1016/S1044-0305(99)00030-6; Schmeichel KL, 1997, MOL BIOL CELL, V8, P219, DOI 10.1091/mbc.8.2.219; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SHANG ZG, 1989, BIOCHEMISTRY-US, V28, P9790, DOI 10.1021/bi00451a037; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Takayama K, 1996, AM J HUM GENET, V58, P263; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Weeda G, 1997, NUCLEIC ACIDS RES, V25, P2274, DOI 10.1093/nar/25.12.2274; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; Zhao XF, 1999, J BIOL CHEM, V274, P1388, DOI 10.1074/jbc.274.3.1388	48	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31963	31971		10.1074/jbc.M004960200	http://dx.doi.org/10.1074/jbc.M004960200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10882739	hybrid			2022-12-27	WOS:000089858900058
J	Chen, WG; Silver, DL; Smith, JD; Tall, AR				Chen, WG; Silver, DL; Smith, JD; Tall, AR			Scavenger receptor-BI inhibits ATP-binding cassette transporter 1-mediated cholesterol efflux in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; SELECTIVE LIPID UPTAKE; SR-BI; TANGIER-DISEASE; CELLULAR CHOLESTEROL; HDL RECEPTOR; CELLS; PROMOTES; SURFACE; GENE	Scavenger receptor BI (SR-BI) facilitates the efflux of cellular cholesterol to plasma high density lipoprotein (HDL). Recently, the ATP-binding cassette transporter 1 (ABC1) was identified as a key mediator of cholesterol efflux to apolipoproteins and HDL. The goal of the present study was to determine a possible interaction between the SR-BI and ABC1 cholesterol efflux pathways in macrophages. Free cholesterol efflux to HDL was increased (similar to 2,2-fold) in SR-BI transfected RAW macrophages in association with increased SR-BI protein levels. Treatment of macrophages with 8-bromo-cAMP (cAMP) resulted in a 4.1-fold increase in ABC1 mRNA level and also increased cholesterol efflux to HDL (2.2-fold) and apoA-I (5.5-fold). However, in SR-BI transfected RAW cells, cAMP treatment produced a much smaller increment in cholesterol efflux to HDL (1.1-fold) or apoA-I (3.3-fold) compared with control cells. In macrophages loaded with cholesterol by acetyl-LDL treatment, SR-BI overexpression did not increase cholesterol efflux to HDL but did inhibit cAMP-mediated cholesterol efflux to apoA-I or HDL. SR-BI neutralizing antibody led to a dose- and time dependent increase of cAMP-mediated cholesterol efflux in both SR-BI transfected and control cells, indicating that SR-BI inhibits ABC1-mediated cholesterol efflux even at low SR-BI expression level. Transfection of a murine ABC1 cDNA into 293 cells led to a 2.3-fold increase of cholesterol efflux to apoA-I, whereas co-transfection of SR-BI with ABC1 blocked this increase in cholesterol efflux, SR-BI and ABC1 appear to have distinct and competing roles in mediating cholesterol flux between HDL and macrophages. In nonpolarized cells, SR-BI promotes the reuptake of cholesterol actively effluxed by ABC1, creating a futile cycle.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA; Rockefeller Univ, Biochem Genet & Metab Lab, New York, NY 10021 USA	Columbia University; Rockefeller University	Tall, AR (corresponding author), Columbia Univ, Dept Med, Div Mol Med, 603 W 168th St, New York, NY 10032 USA.	art1@columbia.edu	Tall, Alan/AAT-8528-2021	Silver, David/0000-0002-7289-9890	NHLBI NIH HHS [HL 22682, HL 56984] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056984, R37HL022682, R01HL022682] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Buton X, 1999, J BIOL CHEM, V274, P32112, DOI 10.1074/jbc.274.45.32112; Costet P, 2000, J BIOL CHEM, V275, P28240; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; HARA H, 1991, J BIOL CHEM, V266, P3080; Huszar D, 2000, ARTERIOSCL THROM VAS, V20, P1068, DOI 10.1161/01.ATV.20.4.1068; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; KARLIN JB, 1987, J BIOL CHEM, V262, P12557; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Marcil M, 1999, ARTERIOSCL THROM VAS, V19, P159, DOI 10.1161/01.ATV.19.1.159; Oram JF, 1996, J LIPID RES, V37, P2473; Panousis CG, 2000, J LIPID RES, V41, P75; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; ROESSNER A, 1987, PATHOL RES PRACT, V182, P694; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sehayek E, 1998, P NATL ACAD SCI USA, V95, P10194, DOI 10.1073/pnas.95.17.10194; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; Tall AR, 1998, EUR HEART J, V19, pA31; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Xu SZ, 1997, J LIPID RES, V38, P1289	46	90	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30794	30800		10.1074/jbc.M004552200	http://dx.doi.org/10.1074/jbc.M004552200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896940	hybrid			2022-12-27	WOS:000089762700010
J	Harbeck, B; Huttelmaier, S; Schluter, K; Jockusch, BM; Illenberger, S				Harbeck, B; Huttelmaier, S; Schluter, K; Jockusch, BM; Illenberger, S			Phosphorylation of the vasodilator-stimulated phosphoprotein regulates its interaction with actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTACT HUMAN PLATELETS; MICROFILAMENT PROTEIN VASP; FOCAL-ADHESION; SMOOTH-MUSCLE; IN-VITRO; LISTERIA-MONOCYTOGENES; MONOCLONAL-ANTIBODY; ENA/VASP FAMILY; CELL-ADHESION; BINDING SITE	The vasodilator-stimulated phosphoprotein (VASP) is a major substrate for cyclic nucleotide-dependent kinases in platelets and other cardiovascular cells. It promotes actin nucleation and binds to actin filaments in vitro and associates with stress fibers in cells. The VASP-actin interaction is salt-sensitive, arguing for electrostatic interactions. Hence, phosphorylation may significantly alter the actin binding properties of VASP. This hypothesis was investigated by analyzing complex formation of recombinant murine VASP with actin after phosphorylation with cAMP-dependent kinase in different assays. cAMP-dependent kinase phosphorylation had a negative effect on both actin nucleation and VASP interaction with actin filaments, with the actin nucleating capacity being more affected than actin filament binding and bundling. Replacing VASP residues known to be phosphorylated in vivo by acidic residues to mimic phosphorylation had similar although less dramatic effects on VASP-actin interactions. In contrast, phosphorylation had no significant effect on VASP oligomerization or its interaction with its known ligands profilin, vinculin, and zyxin. When overexpressing VASP mutants in eukaryotic cells, they all showed targeting to focal contacts and stress fibers, Our results imply that VASP phosphorylation may act as an immediate negative regulator of actin dynamics.	Tech Univ Carolo Wilhelmina Braunschweig, Inst Zool, Dept Cell Biol, Bioctr, D-38092 Braunschweig, Germany	Braunschweig University of Technology	Illenberger, S (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Zool, Dept Cell Biol, Bioctr, Spielmannstr 7, D-38092 Braunschweig, Germany.	S.Illenberger@tu-bs.de	Hüttelmaier, Stefan/AAQ-1203-2021					ABEL K, 1995, FEBS LETT, V370, P184, DOI 10.1016/0014-5793(95)00817-S; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; BUTT E, 1994, J BIOL CHEM, V269, P14509; Carl UD, 1999, CURR BIOL, V9, P715, DOI 10.1016/S0960-9822(99)80315-7; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; Geese M, 2000, J CELL SCI, V113, P1415; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GIEHL K, 1994, EUR J BIOCHEM, V226, P681, DOI 10.1111/j.1432-1033.1994.tb20096.x; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; Hauser W, 1999, P NATL ACAD SCI USA, V96, P8120, DOI 10.1073/pnas.96.14.8120; HORSTRUP K, 1994, EUR J BIOCHEM, V225, P21, DOI 10.1111/j.1432-1033.1994.00021.x; Huttelmaier S, 1999, FEBS LETT, V451, P68, DOI 10.1016/S0014-5793(99)00546-3; Jonckheere V, 1999, FEBS LETT, V447, P257, DOI 10.1016/S0014-5793(99)00293-8; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Lambrechts A, 1997, EMBO J, V16, P484, DOI 10.1093/emboj/16.3.484; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Mahoney NM, 1997, NAT STRUCT BIOL, V4, P953, DOI 10.1038/nsb1197-953; Mayboroda O, 1997, CELL MOTIL CYTOSKEL, V37, P166, DOI 10.1002/(SICI)1097-0169(1997)37:2<166::AID-CM9>3.0.CO;2-6; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; NORTH AJ, 1994, J CELL SCI, V107, P437; Reinhard M, 1996, FEBS LETT, V399, P103, DOI 10.1016/S0014-5793(96)01295-1; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Rudiger M, 1997, BIOTECHNIQUES, V23, P96, DOI 10.2144/97231bm20; Schluter K, 1998, J CELL SCI, V111, P3261; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAKEUCHI K, 1991, J BIOCHEM, V109, P311; Tang JX, 1997, EUR J BIOCHEM, V247, P432, DOI 10.1111/j.1432-1033.1997.00432.x; VanTroys M, 1996, EMBO J, V15, P201, DOI 10.1002/j.1460-2075.1996.tb00350.x; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Wiedemann P, 1996, J BIOL CHEM, V271, P29915, DOI 10.1074/jbc.271.47.29915; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967	42	203	210	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30817	30825		10.1074/jbc.M005066200	http://dx.doi.org/10.1074/jbc.M005066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10882740	hybrid			2022-12-27	WOS:000089762700014
J	Huang, MC; Zollner, O; Moll, T; Maly, P; Thall, AD; Lowe, JB; Vestweber, D				Huang, MC; Zollner, O; Moll, T; Maly, P; Thall, AD; Lowe, JB; Vestweber, D			P-selectin glycoprotein ligand-1 and E-selectin ligand-1 are differentially modified by fucosyltransferases Fuc-TIV and Fuc-TVII in mouse neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELAM-1-DEPENDENT CELL-ADHESION; HAMSTER OVARY CELLS; ROLLING IN-VIVO; FUCOSYL-TRANSFERASE; MOLECULAR-CLONING; EXPRESSION CLONING; MYELOID CELLS; LEWIS-X; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; TYROSINE SULFATION	P-selectin glycoprotein ligand-1 (PSGL-1) and E-selectin ligand-l (ESL-1) are the two major selectin ligands on mouse neutrophils, Transfection experiments demonstrate that each ligand requires alpha 1,3-fucosylation for selectin-binding. However, the relative contributions made by the two known myeloid alpha 1,3-fucosyltransferases Fuc-TVII or Fuc-TIV to this alpha 1,3-fucosylation are not yet clear. To address this issue, we have used mice deficient in Fuc-TIV and/or Fuc-TVII to examine how these enzymes generate selectin-binding glycoforms of PSGL-1 and ESL-1 in mouse neutrophils, Selectin binding was analyzed by affinity isolation experiments using recombinant, antibody-like forms of the respective endothelial selectins, We observe essentially normal binding of E- or P-selectin to PSGL-1 expressed by Fuc-TIV-deficient neutrophils but find that PSGL-1 expressed by Fuc-TVII-deficient neutrophils is not bound by E- or P-selectin, By contrast, E-selectin binds with normal efficiency to ESL-1 on Fuc-TVII-deficient neutrophils but exhibits an 80% reduction in its ability to bind ESL-I isolated from Fuc-TIV-deficient neutrophils, The same specificity with which Fuc-TVII and Fuc-TIV generate selectin-binding forms of PSGL-1 and ESL-I was found in transfection experiments with CHO-Pro(-)5 cells. In contrast, each fucosyltransferase alone could generate selectin-binding glycoforms of each of the two ligands in CHO-DUKX-B1 cells. Our data imply that in mouse neutrophils and their precursors, Fuc-TVII exclusively directs expression of PSGL-1 glycoforms bound with high affinity by P-selectin, By contrast, Fuc-TIV preferentially directs expression of ESL-1 glycoforms that exhibit high affinity for E-selectin, This substrate specificity can be mimicked in CHO-Pro(-)5 cells.	Univ Munster, Inst Cell Biol, ZMBE, D-48149 Munster, Germany; Max Planck Inst Physiol & Clin Res, D-48149 Munster, Germany; Univ Michigan, Howard Hughes Med Inst, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Munster; Max Planck Society; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Vestweber, D (corresponding author), Univ Munster, Inst Cell Biol, ZMBE, Von Esmarch Str 56, D-48149 Munster, Germany.		Malý, Petr/H-5962-2014	Malý, Petr/0000-0001-8118-0581; HUANG, MIN-CHUAN/0000-0002-0704-3447; Vestweber, Dietmar/0000-0002-3517-732X				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Borges E, 1997, J EXP MED, V185, P573, DOI 10.1084/jem.185.3.573; Borges E, 1997, BLOOD, V90, P1934, DOI 10.1182/blood.V90.5.1934; Borges E, 1997, J BIOL CHEM, V272, P28786, DOI 10.1074/jbc.272.45.28786; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; Kudo T, 1998, J BIOL CHEM, V273, P26729, DOI 10.1074/jbc.273.41.26729; Kumar R, 1996, BLOOD, V88, P3872, DOI 10.1182/blood.V88.10.3872.bloodjournal88103872; KUMAR R, 1991, J BIOL CHEM, V266, P21777; Kunkel EJ, 1996, CIRC RES, V79, P1196, DOI 10.1161/01.RES.79.6.1196; LABOW MA, 1994, IMMUNITY, V1, P709, DOI 10.1016/1074-7613(94)90041-8; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; LOWE JB, 1997, ADV VASC BIOL, V3, P143; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Niemela R, 1998, J BIOL CHEM, V273, P4021, DOI 10.1074/jbc.273.7.4021; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SASAKI S, 1994, EXP NEPHROL, V2, P269; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; Steegmaier M, 1997, J CELL SCI, V110, P687; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; TEREILE H, 1990, NATURE, V348, P649; VESTWEBER D, 1997, SELECTINS, V3, P225; Wagers AJ, 1997, J IMMUNOL, V159, P1917; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yang J, 1996, BLOOD, V87, P4176, DOI 10.1182/blood.V87.10.4176.bloodjournal87104176; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769; Zollner O, 1996, J BIOL CHEM, V271, P33002, DOI 10.1074/jbc.271.51.33002	43	50	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31353	31360		10.1074/jbc.M005449200	http://dx.doi.org/10.1074/jbc.M005449200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10882744	hybrid			2022-12-27	WOS:000089762700086
J	Samson, ML				Samson, ML			Drosophila arginase is produced from a nonvital gene that contains the elav locus within its third intron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; MELANOGASTER; PROTEIN; REGION; GENOME; NO; HYBRIDIZATION; MUTATIONS; APOPTOSIS; SEQUENCE	A Drosophila gene encoding a 351-amino acid-long predicted arginase (40% identity with vertebrate arginases) is reported. Interestingly, the third intron of the arginase gene includes the elav locus, whose coding sequence is on the complementary DNA strand to that of the arginase. Terrestrial vertebrates produce two arginases from duplicated genes. One form, essentially present in the liver, is a key enzyme of the urea cycle and eliminates excess ammonia through the excretion of urea. The function of the extrahepatic arginase, more ubiquitous, is not well understood. In macrophages, arginase competes with nitric-oxide synthase, which converts arginine into nitric oxide. Most organisms, including insects, produce only one type of arginase, whose function is not centered on ammonia detoxification. A Drosophila cDNA encoding a predicted arginase was isolated. It produces a 1.3-kilobase transcript present with highest levels toward the end of embryogenesis and thereafter. During embryogenesis, the arginase transcripts localize to the fat body. The first mutant allele of the Drosophila arginase gene was identified. It is predicted to produce a 199-amino acid-long C-terminally truncated protein, likely to be inactive. Preliminary characterization of the mutation shows that this recessive allele causes a developmental delay but does not affect viability.	Univ Paris 11, UPRES A 8080, Lab Embryol Mol & Expt, F-91405 Orsay, France; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	UDICE-French Research Universities; Universite Paris Saclay; University of Nebraska System; University of Nebraska Medical Center	Samson, ML (corresponding author), Univ Paris 11, UPRES A 8080, Lab Embryol Mol & Expt, Batiment 445, F-91405 Orsay, France.	Marie-Laure.Samson@emex.u-psud.fr						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Ash DE, 1998, MOL GENET METAB, V64, P243, DOI 10.1006/mgme.1998.2677; Ashburner M, 1999, GENETICS, V153, P179; Blumenthal T, 1998, BIOESSAYS, V20, P480, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;480::AID-BIES6&gt;3.0.CO;2-Q; Boucher JL, 1999, CELL MOL LIFE SCI, V55, P1015, DOI 10.1007/s000180050352; Braissant O, 1999, MOL BRAIN RES, V70, P231, DOI 10.1016/S0169-328X(99)00151-5; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CAMPOS AR, 1987, EMBO J, V6, P425, DOI 10.1002/j.1460-2075.1987.tb04772.x; CAMPOS AR, 1985, J NEUROGENET, V2, P197, DOI 10.3109/01677068509100150; CAWTHON RM, 1990, GENOMICS, V7, P555, DOI 10.1016/0888-7543(90)90199-5; Cox RA., 1968, METHODS ENZYMOL, V12, P120, DOI 10.1016/0076-6879(67)12123-X; Durner J, 1999, P NATL ACAD SCI USA, V96, P14206, DOI 10.1073/pnas.96.25.14206; Enikolopov G, 1999, CELL DEATH DIFFER, V6, P956, DOI 10.1038/sj.cdd.4400577; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; Gotoh T, 1999, J CELL BIOL, V144, P427, DOI 10.1083/jcb.144.3.427; GREEN SM, 1990, J BIOL CHEM, V265, P1601; HENIKOFF S, 1986, CELL, V44, P33, DOI 10.1016/0092-8674(86)90482-4; Ignarro L., 1995, NITRIC OXIDE BIOCH M; ITOH N, 1985, DROS INF SERVICE, V61, P89; JENKINSON CP, 1996, EMBO J, V114, P107; Kanyo ZF, 1996, NATURE, V383, P554, DOI 10.1038/383554a0; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; LEVINSON B, 1990, GENOMICS, V7, P1, DOI 10.1016/0888-7543(90)90512-S; Maglott DR, 2000, NUCLEIC ACIDS RES, V28, P126, DOI 10.1093/nar/28.1.126; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; OUZOUNIS CA, 1994, J MOL EVOL, V39, P101; PATTERTON D, 1994, J BIOL CHEM, V269, P25328; PEROZICH J, 1998, BIOCHIM BIOPHYS ACTA, V15, P23; Pohar N, 1999, GENOMICS, V57, P293, DOI 10.1006/geno.1999.5776; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; Riechmann V, 1998, DEVELOPMENT, V125, P713; Rizki TM, 1978, GENETICS BIOL DROSOP; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; Rouzaut A, 1999, BBA-MOL CELL RES, V1451, P319, DOI 10.1016/S0167-4889(99)00106-8; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; SAMSON ML, 1995, GENETICS, V141, P1101; Samson ML, 1998, GENETICS, V150, P723; SETTLE SH, 1995, P NATL ACAD SCI USA, V92, P9470, DOI 10.1073/pnas.92.21.9470; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thatcher JW, 1998, P NATL ACAD SCI USA, V95, P253, DOI 10.1073/pnas.95.1.253; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAO KM, 1991, MOL CELL BIOL, V11, P2994, DOI 10.1128/MCB.11.6.2994; YAO KM, 1993, J NEUROBIOL, V24, P723, DOI 10.1002/neu.480240604; Zinke I, 1999, DEVELOPMENT, V126, P5275; 1999, TRENDS GENET, V15, P51	48	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31107	31114		10.1074/jbc.M001346200	http://dx.doi.org/10.1074/jbc.M001346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10878001	hybrid			2022-12-27	WOS:000089762700052
J	Nakabayashi, K; Kudo, M; Kobilka, B; Hsueh, AWJ				Nakabayashi, K; Kudo, M; Kobilka, B; Hsueh, AWJ			Activation of the luteinizing hormone receptor following substitution of Ser-277 with selective hydrophobic residues in the ectodomain hinge region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LEUCINE-RICH REPEATS; HUMAN LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; FOLLICLE-STIMULATING-HORMONE; 3RD INTRACELLULAR LOOP; CHORIONIC-GONADOTROPIN; THYROTROPIN RECEPTOR; CONSTITUTIVE ACTIVATION; MOLECULAR-CLONING; LH RECEPTOR	Glycoprotein hormone receptors are G protein-coupled receptors with ligand-binding ectodomains consisting of leucine-rich repeats. The ectodomain is connected by a conserved cysteine-rich hinge region to the seven transmembrane (TM) region. Gain-of-function mutants of luteinizing hormone (LH) and thyroid-stimulating hormone receptors found in patients allowed identification of residues important for receptor activation. Based on constitutively active mutations at Ser-281 in the hinge region of the thyroid-stimulating hormone receptor, we mutated the conserved serine in the LH (S277I) and follicle-stimulating hormone receptors (S273I) and observed increased basal cAMP production and ligand affinity by mutant receptors, For the LH receptor, conversion of Ser-277 to all natural amino acids led to varying degrees of receptor activation. Hydropathy index analysis indicated that substitution of neutral serine with selective nonpolar hydrophobic residues (Leu>Val>Met>Ile) confers constitutive receptor activation whereas serine deletion or substitution with charged Arg, Lys, or Asp led to defective receptor expression. Furthermore, mutation of the angular proline near Ser-273 to flexible Gly also led to receptor activation. The findings suggest the ectodomain of glycoprotein hormone receptors constrain the TM region. Point mutations in the hinge region of these proteins, or ligand binding to these receptors, could cause conformational changes in the TM region that result in G(S) activation.	Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Hsueh, AWJ (corresponding author), Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA.			Kobilka, Brian/0000-0001-5958-3990	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023273, R37HD023273] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-23273] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Cetani F, 1996, FEBS LETT, V378, P27, DOI 10.1016/0014-5793(95)01384-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVOREN JB, 1985, BIOL REPROD, V33, P37, DOI 10.1095/biolreprod33.1.37; DUFAU ML, 1989, J STEROID BIOCHEM, V33, P715, DOI 10.1016/0022-4731(89)90482-2; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; Duprez L, 1997, FEBS LETT, V409, P469, DOI 10.1016/S0014-5793(97)00532-2; FRASER CM, 1994, PROG NUCLEIC ACID RE, V49, P113; GARNIER J, 1990, BIOCHIMIE, V72, P513, DOI 10.1016/0300-9084(90)90115-W; Gilchrist RL, 1996, J BIOL CHEM, V271, P19283, DOI 10.1074/jbc.271.32.19283; Grewal N, 1997, BIOPHYS J, V73, P1190, DOI 10.1016/S0006-3495(97)78151-7; Gruters A, 1998, J CLIN ENDOCR METAB, V83, P1431, DOI 10.1210/jc.83.5.1431; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Hauser F, 1997, J BIOL CHEM, V272, P1002, DOI 10.1074/jbc.272.2.1002; HELLBERG S, 1987, J MED CHEM, V30, P1126, DOI 10.1021/jm00390a003; Hermey G, 1999, BIOCHEM BIOPH RES CO, V254, P273, DOI 10.1006/bbrc.1998.9882; Hirsch B, 1996, MOL ENDOCRINOL, V10, P1127, DOI 10.1210/me.10.9.1127; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830; JI I, 1993, J BIOL CHEM, V268, P20851; JI I, 1991, J BIOL CHEM, V266, P13076; JI IH, 1993, J BIOL CHEM, V268, P22971; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; Kopp P, 1997, J CLIN INVEST, V100, P1634, DOI 10.1172/JCI119687; Kosugi S, 1998, MOL PHARMACOL, V53, P894; Kosugi S, 1996, J BIOL CHEM, V271, P31813, DOI 10.1074/jbc.271.50.31813; Kudo M, 2000, MOL ENDOCRINOL, V14, P272, DOI 10.1210/me.14.2.272; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; Mancilla EE, 1998, MOL GENET METAB, V64, P198, DOI 10.1006/mgme.1998.2716; McDonald T, 1998, BIOCHEM BIOPH RES CO, V247, P266, DOI 10.1006/bbrc.1998.8774; MIYACHI Y, 1972, J CLIN ENDOCR METAB, V34, P23, DOI 10.1210/jcem-34-1-23; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; NOTHACKER HP, 1993, BIOCHEM BIOPH RES CO, V197, P1062, DOI 10.1006/bbrc.1993.2586; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Parma J, 1997, J CLIN ENDOCR METAB, V82, P2695, DOI 10.1210/jc.82.8.2695; Perez DM, 1996, MOL PHARMACOL, V49, P112; PODESTA EJ, 1983, P NATL ACAD SCI-BIOL, V80, P3986, DOI 10.1073/pnas.80.13.3986; Rapoport B, 1998, ENDOCR REV, V19, P673, DOI 10.1210/er.19.6.673; REN Q, 1993, J BIOL CHEM, V268, P16483; Ryu K, 1998, J BIOL CHEM, V273, P28953, DOI 10.1074/jbc.273.44.28953; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Schulz A, 1999, MOL ENDOCRINOL, V13, P181, DOI 10.1210/me.13.2.181; SHENKER A, 1995, BAILLIERE CLIN ENDOC, V9, P427, DOI 10.1016/S0950-351X(95)80519-2; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SU JGJ, 1992, BIOCHEM BIOPH RES CO, V186, P293, DOI 10.1016/S0006-291X(05)80806-X; Vassart G, 1997, HORM RES, V48, P47, DOI 10.1159/000191313	56	81	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30264	30271		10.1074/jbc.M005568200	http://dx.doi.org/10.1074/jbc.M005568200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10889210	hybrid			2022-12-27	WOS:000089577900049
J	Mulder, LCF; Muesing, MA				Mulder, LCF; Muesing, MA			Degradation of HIV-1 integrase by the N-end rule pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ESCHERICHIA-COLI; MU-TRANSPOSASE; RETROVIRAL DNA; CLPX PROTEIN; IN-VIVO; RECOGNITION; EXPRESSION; COMPLEX; CELLS	Human immunodeficiency virus type-1 (HIV-1) integrase catalyzes the irreversible insertion of the viral genome into host chromosomal DNA. We have developed a mammalian expression system for the synthesis of authentic HIV-1 integrase in the absence of other viral proteins. Integrase, which bears a N-terminal phenylalanine, was found to be a short-lived protein in human embryo kidney 293T cells. The degradation of integrase could be suppressed by proteasome inhibitors. N-terminal phenylalanine is recognized as a degradation signal by a ubiquitin-proteasome proteolytic system known as the N-end rule pathway. The replacement of N-terminal phenylalanine with methionine, valine, or glycine, which are stabilizing residues in the N-end rule, resulted in metabolically stabilized integrase proteins (half-life of N-terminal Met-integrase was at least 3 h). Conversely, the substitution of N-terminal phenylalanine with other destabilizing residues retained the metabolic instability of integrase. These findings indicate that the HIV-1 integrase is a physiological substrate of the N-end rule. We discuss a possible functional similarity to the better understood turnover of the bacteriophage Mu transposase and functions of integrase instability to the maintenance and integrity of the host cell genome.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA	Rockefeller University	Muesing, MA (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.	mmuesing@adarc.org			NIAID NIH HHS [P30 AI42848] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI042848] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Baker RT, 1996, CURR OPIN BIOTECH, V7, P541, DOI 10.1016/S0958-1669(96)80059-0; BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Brown P. O., 1997, P161; Caumont AB, 1996, CURR GENET, V29, P503; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Chou KC, 1996, ANAL BIOCHEM, V233, P1, DOI 10.1006/abio.1996.0001; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; Ferris RL, 1999, J IMMUNOL, V162, P1324; Fouchier RAM, 1999, ADV VIRUS RES, V52, P275, DOI 10.1016/S0065-3527(08)60302-4; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Jones JM, 1998, J BIOL CHEM, V273, P459, DOI 10.1074/jbc.273.1.459; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 1997, GENE DEV, V11, P1561, DOI 10.1101/gad.11.12.1561; *LOS AL NAT LAB TH, 1995, HIV MOL IMM DAT; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; Muller B, 1999, EUR J BIOCHEM, V259, P79, DOI 10.1046/j.1432-1327.1999.00026.x; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; Parissi V, 2000, GENE, V247, P129, DOI 10.1016/S0378-1119(00)00108-6; Parissi V, 2000, J MOL BIOL, V295, P755, DOI 10.1006/jmbi.1999.3416; Petit C, 1999, J VIROL, V73, P5079, DOI 10.1128/JVI.73.6.5079-5088.1999; Pfrepper KI, 1998, J VIROL, V72, P7648, DOI 10.1128/JVI.72.9.7648-7652.1998; Schwartz O, 1998, J VIROL, V72, P3845, DOI 10.1128/JVI.72.5.3845-3850.1998; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Tobery T, 1999, J IMMUNOL, V162, P639; Tobery TW, 1997, J EXP MED, V185, P909, DOI 10.1084/jem.185.5.909; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; VARSHAVSKY A, 2000, IN PRESS METHODS ENZ; WISKERCHEN M, 1995, J VIROL, V69, P597, DOI 10.1128/JVI.69.1.597-601.1995; WISKERCHEN M, 1995, J VIROL, V69, P376, DOI 10.1128/JVI.69.1.376-386.1995; Yewdell J, 1999, IMMUNOL REV, V172, P97, DOI 10.1111/j.1600-065X.1999.tb01359.x; York IA, 1999, IMMUNOL REV, V172, P49, DOI 10.1111/j.1600-065X.1999.tb01355.x	41	81	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29749	29753		10.1074/jbc.M004670200	http://dx.doi.org/10.1074/jbc.M004670200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893419	hybrid			2022-12-27	WOS:000089439800077
J	Ota, K; Sakaguchi, M; Hamasaki, N; Mihara, K				Ota, K; Sakaguchi, M; Hamasaki, N; Mihara, K			Membrane integration of the second transmembrane segment of band 3 requires a closely apposed preceding signal-anchor sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; PROTEIN TRANSLOCATION; CLEAVAGE SITES; IDENTIFICATION; TOPOGENESIS; ORIENTATION; PREDICTION; TRANSPORT; MECHANISM; PEPTIDES	We have investigated the topogenic rules of multispanning membrane proteins using erythrocyte band 3. Here, the fine structural requirements for the correct disposition of its second transmembrane segment (TM2) were assessed. We made fusion proteins where TM1 and the loop sequence preceding TM2 were changed and fused to prolactin, They were expressed in a cell-free system supplemented with rough microsomal membrane, and their topologies on the membrane were assessed by protease sensitivity and N-glycosylation, TM1 was demonstrated to be a signal-anchor sequence that mediates translocation of the downstream portion, and thus TM2 should be responsible to halt the translocation to acquire TM topology. When the loop between TM1 and TM2 was elongated, however, TM2 was readily translocated through the membrane and not integrated. For the membrane integration of TM2, TM2 must be in close proximity to TM1. The TM1 can be replaced with another signal-anchor sequence with a long hydrophobic segment but not with a signal sequence with shorter hydrophobic stretch. The length of the hydrophobic segment affected final topology of TM2. We concluded that the two TM segments work synergistically within the translocon to acquire the correct topology and that the length of the preceding signal sequence is critical for stable transmembrane assembly of TM2. We propose that direct interaction among the TRI segments is one of the critical factors for the transmembrane topogenesis of multispanning membrane proteins.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med, Dept Clin Chem & Lab Med, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Sakaguchi, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; DENZER AJ, 1995, EMBO J, V14, P5311; Hamasaki N, 1998, BIOCHEM CELL BIOL, V76, P729, DOI 10.1139/bcb-76-5-729; Hamasaki N, 1996, CELL MOL BIOL, V42, P1025; Hamasaki N, 1997, J BIOCHEM-TOKYO, V122, P577; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; Kuma H, 1998, J BIOCHEM-TOKYO, V124, P509, DOI 10.1093/oxfordjournals.jbchem.a022142; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; Kuroiwa T, 1996, J BIOL CHEM, V271, P6423, DOI 10.1074/jbc.271.11.6423; KUROIWA T, 1990, J BIOCHEM, V108, P829, DOI 10.1093/oxfordjournals.jbchem.a123288; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LODISH HF, 1988, TRENDS BIOCHEM SCI, V13, P332, DOI 10.1016/0968-0004(88)90101-6; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; OGATA S, 1989, J BIOL CHEM, V264, P3596; Ota K, 1998, J BIOL CHEM, V273, P28286, DOI 10.1074/jbc.273.43.28286; Ota K, 1998, MOL CELL, V2, P495, DOI 10.1016/S1097-2765(00)80149-5; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SAKAGUCHI M, 1992, J BIOCHEM, V112, P243, DOI 10.1093/oxfordjournals.jbchem.a123884; SAKAGUCHI M, 1997, MOL B INT U, P135; Sakaki K, 1999, FEBS LETT, V454, P345, DOI 10.1016/S0014-5793(99)00842-X; TAM LY, 1994, J BIOL CHEM, V269, P32542; Tector M, 1999, EMBO J, V18, P6290, DOI 10.1093/emboj/18.22.6290; Travaglini-Allocatelli C, 1999, J MOL BIOL, V289, P1459, DOI 10.1006/jmbi.1999.2852; Uozumi N, 1998, P NATL ACAD SCI USA, V95, P9773, DOI 10.1073/pnas.95.17.9773; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; WOOD PG, 1992, PROGR CELL RES, V2, P325	35	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29743	29748		10.1074/jbc.M002468200	http://dx.doi.org/10.1074/jbc.M002468200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893228	hybrid			2022-12-27	WOS:000089439800076
J	Carter, MS; Sarnow, P				Carter, MS; Sarnow, P			Distinct mRNAs that encode La autoantigen are differentially expressed and contain internal ribosome entry sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; CAP-INDEPENDENT TRANSLATION; TERMINATION FACTOR LA; TRANS-ACTING FACTORS; 5' NONCODING REGION; SS-B AUTOANTIGEN; LUPUS ANTIGEN-LA; NF-KAPPA-B; LA/SS-B; TRANSCRIPTION TERMINATION	Analysis by reverse transcription-polymerase chain reaction has suggested the existence of at least two La autoantigen-encoding mRNAs that contain different 5' noncoding regions (NCRs) linked to the same La coding region (Troster, H,, Metzger, T, E,, Semsei, I., Schwemmle, M,, Winterpacht, A., Zabel, B,, and Bachmann, M. (1994) J, Exp. Med. 180, 2059-2067). Laencoding transcripts La1 and La1' contain 115- and 483-nucleotide 5' NCRs, respectively. To determine whether the various La transcripts are functional mRNAs, the expression and polysomal association of natural La1 and La1' RNAs were examined. Although La1 transcripts were ubiquitously expressed in human tissues, La1' transcripts were predominantly expressed in peripheral blood leukocytes, especially in B, T, and natural killer cells. Both La1 and La1' transcripts associated with polysomes in natural killer cells, suggesting that these transcripts were functional mRNAs, Upon activation of B cells with the mitogens phorbol 12-myristate 13-acetate and ionomycin, the amount of La1' mRNA, but not La1, declined. In contrast, after chemical activation of T cells, the amount of La 1 mRNA, but not La1', declined. The mechanism by which the La1 and La1' 5' NCRs initiate translation initiation was tested in cultured human HeLa cells and in two different in vitro translation systems. It was found that both 5' NCRs can mediate translation initiation by internal initiation. These findings indicate that the constitutive expression of La1 mRNA and the tissue-specific expression of La1' mRNA can both allow La protein synthesis under conditions when cap-dependent translation is compromised, such as inflammation, apoptosis, or certain viral infections.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University	Sarnow, P (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Fairchild Sci Bldg, Stanford, CA 94305 USA.	psarnow@leland.stanford.edu		Sarnow, Peter/0000-0002-2043-2770	NIGMS NIH HHS [R01 GM55979] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055979] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; ALSPAUGH MA, 1975, J CLIN INVEST, V55, P1067, DOI 10.1172/JCI108007; Ausubel FM, 1988, MOL REPROD DEV; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bai CY, 2000, NUCLEIC ACIDS RES, V28, P1078, DOI 10.1093/nar/28.5.1078; CALZONE FJ, 1982, NUCLEIC ACIDS RES, V10, P2145, DOI 10.1093/nar/10.6.2145; CHAMBERS JC, 1983, J BIOL CHEM, V258, P1438; CIANETTI L, 1990, NUCLEIC ACIDS RES, V18, P4361, DOI 10.1093/nar/18.15.4361; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; Grolz D, 1998, BBA-GENE STRUCT EXPR, V1396, P278, DOI 10.1016/S0167-4781(97)00201-7; Grolz D, 1997, J BIOL CHEM, V272, P12076, DOI 10.1074/jbc.272.18.12076; HAMBIDGE SJ, 1991, J VIROL, V65, P6312, DOI 10.1128/JVI.65.11.6312-6315.1991; Heise T, 1999, J VIROL, V73, P5767, DOI 10.1128/JVI.73.7.5767-5776.1999; Hilker M, 1996, CELL TISSUE RES, V284, P383, DOI 10.1007/s004410050599; Iizuka N, 1995, CURR TOP MICROBIOL, V203, P155; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; Jackson RJ, 1995, RNA, V1, P985; JANEWAY CA, 1997, IMMUNOBIOLOGY IMMUNE, P1; Jitrapakdee S, 1998, J BIOL CHEM, V273, P34422, DOI 10.1074/jbc.273.51.34422; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; KLEIN E, 1968, CANCER RES, V28, P1300; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kremerskothen J, 1998, DNA CELL BIOL, V17, P751, DOI 10.1089/dna.1998.17.751; Krichevsky AM, 1999, J BIOL CHEM, V274, P14295, DOI 10.1074/jbc.274.20.14295; MACDONALD MJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P128, DOI 10.1006/abbi.1995.1274; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; Maraia RJ, 1996, P NATL ACAD SCI USA, V93, P3383, DOI 10.1073/pnas.93.8.3383; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; MATTIOLI M, 1974, ARTHRITIS RHEUM-US, V17, P421, DOI 10.1002/art.1780170413; McBratney S, 1996, MOL CELL BIOL, V16, P3523; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Pannone BK, 1998, EMBO J, V17, P7442, DOI 10.1093/emboj/17.24.7442; Pardigon N, 1996, J VIROL, V70, P1173, DOI 10.1128/JVI.70.2.1173-1181.1996; PARK YW, 1995, J BIOL CHEM, V270, P28433; Peek R, 1996, EUR J BIOCHEM, V236, P649, DOI 10.1111/j.1432-1033.1996.0649d.x; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; Rhoads RE, 1995, CURR TOP MICROBIOL, V203, P131; RINKE J, 1985, NUCLEIC ACIDS RES, V13, P2617, DOI 10.1093/nar/13.7.2617; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; Robertson MJ, 1996, EXP HEMATOL, V24, P406; SCHIBLER U, 1982, ADV EXP MED BIOL, V158, P381; Shiroki K, 1999, J VIROL, V73, P2193, DOI 10.1128/JVI.73.3.2193-2200.1999; Simons FHM, 1996, EXP CELL RES, V224, P224, DOI 10.1006/excr.1996.0132; Sobel SG, 1999, MOL BIOL CELL, V10, P3849, DOI 10.1091/mbc.10.11.3849; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; TROSTER H, 1994, J EXP MED, V180, P2059, DOI 10.1084/jem.180.6.2059; Van Horn DJ, 1997, RNA, V3, P1434; Wallace JC, 1998, INT J BIOCHEM CELL B, V30, P1, DOI 10.1016/S1357-2725(97)00147-7; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WEISS A, 1984, J IMMUNOL, V133, P123; Xue DH, 2000, EMBO J, V19, P1650, DOI 10.1093/emboj/19.7.1650; YOO CJ, 1994, MOL CELL BIOL, V14, P5412, DOI 10.1128/MCB.14.8.5412; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557	62	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28301	28307						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871624				2022-12-27	WOS:000089197100102
J	Tikhomirov, O; Carpenter, G				Tikhomirov, O; Carpenter, G			Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HUMAN-BREAST; ONCOGENIC ACTIVATION; SIGNAL-TRANSDUCTION; CARCINOMA-CELLS; KINASE-ACTIVITY; POINT MUTATION; NEU ONCOGENE; HERBIMYCIN-A; CATHEPSIN-B	Exposure of carcinoma cell lines to the antibiotic geldanamycin induces the degradation of ErbB-2, a coreceptor tyrosine kinase that is frequently overexpressed in certain tumors. Using ErbB-2 mutants expressed as chimeric receptors or green fluorescent protein fusion proteins, we report that the kinase domain of ErbB-2 is essential for geldanamycin-induced degradation. The kinase domain of the related epidermal growth factor receptor was not sensitive to this drug. The data further indicate mechanistic aspects of ErbB-2 degradation by geldanamycin. The data show that exposure to the drug induces at least one cleavage within the cytoplasmic domain of ErbB-2 producing a 135-kDa fragment and a 23-kDa fragment. The latter represents the carboxyl-terminal domain of ErbB-2, whereas the former represents the ectodomain and part of the cytoplasmic domain. Degradation of the carboxyl-terminal fragment is prevented by proteasome inhibitors, whereas degradation of the membrane-anchored 135-kDa ErbB-2 fragment is blocked by inhibitors of the endocytosis-dependent degradation pathway. Confocal microscopy studies confirm a geldanamycin-induced localization of ErbB-2 on intracellular vesicles.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.	Graham.Carpenter@mcmail.vanderbilt.edu			NATIONAL CANCER INSTITUTE [R01CA024071] Funding Source: NIH RePORTER; NCI NIH HHS [CA24071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Authier F, 1999, J BIOL CHEM, V274, P33723, DOI 10.1074/jbc.274.47.33723; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Chavany C, 1996, J BIOL CHEM, V271, P4974; Codony-Servat J, 1999, CANCER RES, V59, P1196; DEBOER C, 1970, J ANTIBIOT, V23, P442, DOI 10.7164/antibiotics.23.442; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; Esparis-Ogando A, 1999, BIOCHEM J, V344, P339, DOI 10.1042/0264-6021:3440339; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Hong RL, 1999, CLIN CANCER RES, V5, P1884; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Kirschbaum MH, 2000, J CELL BIOCHEM, P52; Li YQ, 1999, J BIOL CHEM, V274, P25651, DOI 10.1074/jbc.274.36.25651; MILLER P, 1994, CANCER RES, V54, P2724; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Mort JS, 1997, INT J BIOCHEM CELL B, V29, P715, DOI 10.1016/S1357-2725(96)00152-5; MURAKAMI Y, 1988, CANCER RES, V48, P1587; OMURA S, 1979, J ANTIBIOT, V32, P255, DOI 10.7164/antibiotics.32.255; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SORKIN A, 1993, ONCOGENE, V8, P3021; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; Tagliabue E, 2000, J BIOL CHEM, V275, P5388, DOI 10.1074/jbc.275.8.5388; UEHARA Y, 1989, CANCER RES, V49, P780; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WHITESELL L, 1992, CANCER RES, V52, P1721; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	37	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26625	26631		10.1074/jbc.M003114200	http://dx.doi.org/10.1074/jbc.M003114200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10862618	hybrid			2022-12-27	WOS:000088999700101
J	Ito, Y; Habuchi, O				Ito, Y; Habuchi, O			Purification and characterization of N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase from the squid cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; HAMSTER OVARY CELLS; SEROSAL MAST-CELLS; MOUSE BONE-MARROW; SECRETORY GRANULES; HUMAN-MONOCYTES; CULTURE-MEDIUM; GLYCOSAMINOGLYCAN; 6-SULFOTRANSFERASE; BIOSYNTHESIS	N-Acetylgalactosamine 4-sulfate 6-O-sulfotransferase (GalNAc4S-6ST), which transfers sulfate from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to position 6 of N-acetylgalactosamine 4-sulfate in chondroitin sulfate and dermatan sulfate, was purified 19,600-fold to apparent homogeneity from the squid cartilage. SDS-polyacrylamide gel electrophoresis of the purified enzyme showed a broad protein band with a molecular mass of 63 kDa. The protein band coeluted with GalNAc4S-6ST activity from Toyopearl HW-55 around the position of 66 kDa, indicating that the active form of GalNAc4S-6ST may be a monomer. The purified enzyme transferred sulfate from PAPS to chondroitin sulfate A, chondroitin sulfate C, and dermatan sulfate, The transfer of sulfate to chondroitin sulfate A and dermatan sulfate occurred mainly at position 6 of the internal N-acetylgalactosamine 4-sulfate residues. Chondroitin sulfate E, keratan sulfate, heparan sulfate, and completely desulfated N-resulfated heparin were not efficient accepters of the sulfotransferase. When a trisaccharide or a pentasaccharide having sulfate groups at position 4 of N-acetylgalactosamine was used as acceptor, efficient sulfation of position 6 at the nonreducing terminal N-acetylgalactosamine 4-sulfate residue was observed.	Aichi Univ Educ, Dept Life Sci, Aichi 4488542, Japan	Aichi University Education	Habuchi, O (corresponding author), Aichi Univ Educ, Dept Life Sci, Aichi 4488542, Japan.							ANNO K, 1971, BIOCHIM BIOPHYS ACTA, V237, P173, DOI 10.1016/0304-4165(71)90046-8; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; EDWARDS IJ, 1995, ARTERIOSCL THROM VAS, V15, P400, DOI 10.1161/01.ATV.15.3.400; ELIAKIM R, 1986, P NATL ACAD SCI USA, V83, P461, DOI 10.1073/pnas.83.2.461; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; GUNDLACH MW, 1985, BIOCHEM J, V226, P705, DOI 10.1042/bj2260705; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HABUCHI O, 1971, J BIOL CHEM, V246, P7357; Habuchi O, 1996, GLYCOBIOLOGY, V6, P51, DOI 10.1093/glycob/6.1.51; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; HABUCHI O, 1977, J BIOL CHEM, V252, P4570; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; Habuchi O, 1997, GLYCOBIOLOGY, V7, P405, DOI 10.1093/glycob/7.3.405; INOUE H, 1986, J BIOL CHEM, V261, P4470; INOUE H, 1986, J BIOL CHEM, V261, P4460; KATZ HR, 1986, J BIOL CHEM, V261, P3393; KAWAI Y, 1966, J BIOCHEM-TOKYO, V60, P317, DOI 10.1093/oxfordjournals.jbchem.a128438; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; KOBAYASHI S, 1985, BIOCHIM BIOPHYS ACTA, V841, P71, DOI 10.1016/0304-4165(85)90275-2; KOLSET SO, 1983, BIOCHEM J, V210, P661, DOI 10.1042/bj2100661; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; MCGEE MP, 1995, J BIOL CHEM, V270, P26109, DOI 10.1074/jbc.270.44.26109; NAKANISHI Y, 1981, J BIOL CHEM, V256, P5443; OHHASHI Y, 1984, BIOCHEM J, V217, P199, DOI 10.1042/bj2170199; OTSU K, 1985, BIOCHEM J, V227, P37, DOI 10.1042/bj2270037; Petersen F, 1999, J BIOL CHEM, V274, P12376, DOI 10.1074/jbc.274.18.12376; Plaas AHK, 1998, J BIOL CHEM, V273, P12642, DOI 10.1074/jbc.273.20.12642; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; RAZIN E, 1982, J BIOL CHEM, V257, P7229; SHAKLEE PN, 1985, J BIOL CHEM, V260, P6064; STEVENS RL, 1983, J BIOL CHEM, V258, P5977; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; STROMINGER JL, 1959, J BIOL CHEM, V234, P3263; SUZUKI S, 1968, J BIOL CHEM, V243, P1543; UHLINHANSEN L, 1989, J BIOL CHEM, V264, P14916; UHLINHANSEN L, 1988, J BIOL CHEM, V263, P2526; Yamauchi S, 1999, J BIOL CHEM, V274, P2456, DOI 10.1074/jbc.274.4.2456; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975; YAOITA E, 1990, J BIOL CHEM, V265, P522	44	43	46	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34728	34736		10.1074/jbc.M909633199	http://dx.doi.org/10.1074/jbc.M909633199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10871629	hybrid			2022-12-27	WOS:000165095300097
J	Gouveia, AMM; Reguenga, C; Oliveira, MEM; Sa-Miranda, C; Azevedo, JE				Gouveia, AMM; Reguenga, C; Oliveira, MEM; Sa-Miranda, C; Azevedo, JE			Characterization of peroxisomal Pex5p from rat liver - Pex5p in the Pex5p-Pex14p membrane complex is a transmembrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETING SIGNAL; PTS1 RECEPTOR; SACCHAROMYCES-CEREVISIAE; PICHIA-PASTORIS; IMPORT; PEX14P; IDENTIFICATION; BIOGENESIS; DOCKING; MATRIX	Pex5p is the receptor for the vast majority of peroxisomal matrix proteins. Here, we show that about 15% of rat liver Pex5p is found in the peroxisomal fraction representing 0.06% of total peroxisomal protein. This population of Pex5p displays all the characteristics of an intrinsic membrane protein. Protease protection assays indicate that this pool of Pex5p has domains exposed on both sides of the peroxisomal membrane. The strong interaction of Pex5p with the membrane of the organelle is not affected by mild protease treatment of intact organelles, conditions that result in the partial degradation of Pex13p. Cytosolic Pex5p is a monomeric protein. In contrast, virtually all peroxisomal Pex5p was found to be part of a stable 250-kDa protein assembly. This complex was isolated and shown to comprise just two subunits, Pex5p and Pex14p.	UP, IBMC, P-4150180 Oporto, Portugal; UP, Inst Ciencias Biomed Abel Salazar, P-4150180 Oporto, Portugal; Inst Genet Med Jacinto Magalhaes, P-4050466 Oporto, Portugal	Universidade do Porto; Universidade do Porto	Azevedo, JE (corresponding author), UP, IBMC, Rua do Campo Alegre 823, P-4150180 Oporto, Portugal.	jazevedo@ibmc.up.pt	Gouveia, Alexandra/P-3525-2016; sá Miranda, Maria Clara/K-3920-2013; Azevedo, Jorge E/A-4113-2008	Gouveia, Alexandra/0000-0001-8784-4246; sá Miranda, Maria Clara/0000-0003-0123-5525; Azevedo, Jorge E/0000-0001-7714-5302; Oliveira, Marcia/0000-0003-2437-2004; Reguenga, Carlos/0000-0003-1219-9961				Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Baes M, 1997, NAT GENET, V17, P49, DOI 10.1038/ng0997-49; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; Chang CC, 1997, NAT GENET, V15, P385, DOI 10.1038/ng0497-385; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Elgersma Y, 1998, J CELL BIOL, V140, P807, DOI 10.1083/jcb.140.4.807; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FURUTA S, 1986, P NATL ACAD SCI USA, V83, P313, DOI 10.1073/pnas.83.2.313; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Gouveia AMM, 1999, ANAL BIOCHEM, V274, P270, DOI 10.1006/abio.1999.4281; Harlow E, 1998, ANTIBODIES LAB MANUA; HARTL FU, 1985, ARCH BIOCHEM BIOPHYS, V237, P124, DOI 10.1016/0003-9861(85)90261-9; Hettema EH, 1999, BBA-MOL CELL RES, V1451, P17, DOI 10.1016/S0167-4889(99)00087-7; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MERRIL CR, 1990, METHOD ENZYMOL, V182, P477; Motley AM, 1997, NAT GENET, V15, P377, DOI 10.1038/ng0497-377; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Rehling P, 2000, J BIOL CHEM, V275, P3593, DOI 10.1074/jbc.275.5.3593; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; Urquhart AJ, 2000, J BIOL CHEM, V275, P4127, DOI 10.1074/jbc.275.6.4127; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; Will GK, 1999, MOL CELL BIOL, V19, P2265	40	95	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32444	32451		10.1074/jbc.M004366200	http://dx.doi.org/10.1074/jbc.M004366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10889202	hybrid			2022-12-27	WOS:000090003800011
J	Tynan, SH; Purohit, A; Doxsey, SJ; Vallee, RB				Tynan, SH; Purohit, A; Doxsey, SJ; Vallee, RB			Light intermediate chain 1 defines a functional subfraction of cytoplasmic dynein which binds to pericentrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE ORGANIZATION; GAMMA-TUBULIN; COMPLEX; CENTROSOME; DYNACTIN; MITOSIS; PROTEINS; MICROTUBULES; KINETOCHORES; ALIGNMENT	The light intermediate chains (LICs) of cytoplasmic dynein consist of multiple isoforms, which undergo post-translational modification to produce a large number of species separable by two-dimensional electrophoresis and which we have proposed to represent at least two gene products. Recently, we demonstrated the first known function for the LICs: binding to the centrosomal protein, pericentrin, which represents a novel, non-dynactin-based cargo-binding mechanism. Here we report the cloning of rat LIC1, which is approximately 75% homologous to rat LICE and also contains a P-loop consensus sequence, We compared LIC1 and LICE for the ability to interact with pericentrin, and found that only LIC1 will bind. A functional P-loop sequence is not required for this interaction. We have mapped the interaction to the central region of both LIC1 and pericentrin. Using recombinant LICs, we found that they form homooligomers, but not heterooligomers, and exhibit mutually exclusive binding to the heavy chain. Additionally, overexpressed pericentrin is seen to interact with endogenous LIC1 exclusively. Together these results demonstrate the existence of two subclasses of cytoplasmic dynein: LIC1-containing dynein, and LIC2-containing dynein, only the former of which is involved in pericentrin association with dynein.	Univ Massachusetts, Med Ctr, Dept Cell Biol, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Vallee, RB (corresponding author), Univ Massachusetts, Med Ctr, Dept Cell Biol, 377 Plantat St, Worcester, MA 01605 USA.				NIGMS NIH HHS [GM47434, GM51994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051994, R56GM051994, R01GM047434, R37GM047434] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bowman AB, 1999, J CELL BIOL, V146, P165; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; Gonczy P, 1999, J CELL BIOL, V147, P135, DOI 10.1083/jcb.147.1.135; Harrison A, 1998, J CELL BIOL, V140, P1137, DOI 10.1083/jcb.140.5.1137; HUGHES SM, 1995, J CELL SCI, V108, P17; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Khodjakov A, 1999, J CELL BIOL, V146, P585, DOI 10.1083/jcb.146.3.585; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; Maeda S, 1998, CELL STRUCT FUNCT, V23, P169, DOI 10.1247/csf.23.169; MORRIS NR, 1976, EXP CELL RES, V98, P204, DOI 10.1016/0014-4827(76)90480-8; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; Purohit A, 1999, J CELL BIOL, V147, P481, DOI 10.1083/jcb.147.3.481; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tynan SH, 2000, J BIOL CHEM, V275, P32769, DOI 10.1074/jbc.M001537200; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100; Young A, 2000, MOL BIOL CELL, V11, P2047, DOI 10.1091/mbc.11.6.2047	28	112	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32763	32768		10.1074/jbc.M001536200	http://dx.doi.org/10.1074/jbc.M001536200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10893222	hybrid			2022-12-27	WOS:000090003800054
J	Cha, SS; Sung, BJ; Kim, YA; Song, YL; Kim, HJ; Kim, S; Lee, MS; Oh, BH				Cha, SS; Sung, BJ; Kim, YA; Song, YL; Kim, HJ; Kim, S; Lee, MS; Oh, BH			Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING LIGAND; TNF RECEPTOR SUPERFAMILY; NECROSIS-FACTOR-RECEPTOR; DEATH DOMAIN; ANTITUMOR-ACTIVITY; FAMILY; MEMBER; APO2L/TRAIL; ACTIVATION; RESOLUTION	TRAIL is a cytokine that induces apoptosis in a wide variety of tumor cells but rarely in normal cells. It contains an extraordinarily elongated loop because of an unique insertion of 12-16 amino acids compared with the other members of tumor necrosis factor family. Biological implication of the frame insertion has not been clarified. We have determined the crystal structure of TRAIL in a complex with the extracellular domain of death receptor DR5 at 2.2 Angstrom resolution. The structure reveals extensive contacts between the elongated loop and DR5 in an interaction mode that would not be allowed without the frame insertion. These interactions are missing in the structures of the complex determined by others recently. This observation, along with structure-inspired deletion analysis, identifies the critical role of the frame insertion as a molecular strategy conferring specificity upon the recognition of cognate receptors. The structure also suggests that a built-in flexibility of the tumor necrosis factor receptor family members is likely to play a general and important role in the binding and recognition of tumor necrosis factor family members.	Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, Kyungbuk, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul 135710, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Sungkyunkwan University (SKKU); Samsung Medical Center	Oh, BH (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea.	bhoh@postech.ac.kr	Lee, Myung Shik/C-9606-2011; Oh, Byung-Ha/C-2061-2011	Cha, Sun-Shin/0000-0002-0913-8706				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BAZAN JF, 1993, CURR BIOL, V3, P603, DOI 10.1016/0960-9822(93)90009-D; BRUNGER AT, 1992, XPLOR VERSION 3 843; Cha SS, 1999, IMMUNITY, V11, P253, DOI 10.1016/S1074-7613(00)80100-4; COSMAN D, 1994, STEM CELLS, V12, P440, DOI 10.1002/stem.5530120501; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; DU ZJ, 1995, BIOTECHNIQUES, V18, P376; ECK MJ, 1992, J BIOL CHEM, V267, P2119; Hymowitz SG, 2000, BIOCHEMISTRY-US, V39, P633, DOI 10.1021/bi992242l; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; JONES TA, 1993, O VERSION 5 9; Lotz M, 1996, J LEUKOCYTE BIOL, V60, P1; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; Mongkolsapaya J, 1998, J IMMUNOL, V160, P3; Naismith JH, 1996, STRUCTURE, V4, P1251, DOI 10.1016/S0969-2126(96)00134-7; Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968-0004(97)01164-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; VANOSTADE X, 1994, PROTEIN ENG, V7, P5, DOI 10.1093/protein/7.1.5; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wong BR, 1999, J LEUKOCYTE BIOL, V65, P715, DOI 10.1002/jlb.65.6.715	37	104	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31171	31177		10.1074/jbc.M004414200	http://dx.doi.org/10.1074/jbc.M004414200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10893238	hybrid			2022-12-27	WOS:000089762700060
J	Lund, PE; Shariatmadar, R; Uustare, A; Detheux, M; Parmentier, M; Kukkonen, JP; Akerman, KEO				Lund, PE; Shariatmadar, R; Uustare, A; Detheux, M; Parmentier, M; Kukkonen, JP; Akerman, KEO			The orexin OX1 receptor activates a novel Ca2+ influx pathway necessary for coupling to phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; ADRENAL CHROMAFFIN CELLS; RAT MAST-CELLS; INOSITOL PHOSPHATES; INTRACELLULAR CA2+; G-PROTEIN; HYPOCRETIN OREXIN; HUMAN-NEUTROPHILS; STORE DEPLETION; HEK293 CELLS	Ca2+ elevations in Chinese hamster ovary cells stably expressing OX, receptors were measured using fluorescent Ca2+ indicators fura-2 and fluo-3. Stimulation with orexin-A led to pronounced Ca2+ elevations with an EC50 around 1 nM. When the extracellular [Ca2+] was reduced to a submicromolar concentration, the EC50 was increased 100-fold. Similarly, the inositol 1,4,5-trisphosphate production in the presence of 1 mM external Ca2+ was about 2 orders of magnitude more sensitive to orexin-A stimulation than in low extracellular Ca2+. The shift in the potency was not caused by depletion of intracellular Ca2+ but by a requirement of extracellular Ca2+ for production of inositol 1,4,5-trisphosphate. Fura-a experiments with the "Mn2+-quench technique" indicated a direct activation of a cation influx pathway by OX, receptor independent of Ca2+ release or pool depletion. Furthermore, depolarization of the cells to +60 mV, which almost nullifies the driving force for Ca2+ entry, abolished the Ca2+ response to low concentrations of orexin-A. The results thus suggest that OX, receptor activation leads to two responses, (i) a Ca2+ influx and (ii) a direct stimulation of phospholipase C, and that these two responses converge at the level of phospholipase C where the former markedly enhances the potency of the latter.	Univ Uppsala, Dept Cell Physiol, Dept Physiol, Biomed Ctr BMC, S-75123 Uppsala, Sweden; Euroscreen SA, B-1116 Brussels, Belgium; Free Univ Brussels, Inst Interdisciplinary Res, B-1050 Brussels, Belgium	Uppsala University; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Akerman, KEO (corresponding author), Univ Uppsala, Dept Cell Physiol, Dept Physiol, Biomed Ctr BMC, POB 572, S-75123 Uppsala, Sweden.			Kukkonen, Jyrki/0000-0002-6989-1564; Parmentier, Marc/0000-0001-8081-4685				Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BIRD GS, 1993, J BIOL CHEM, V268, P21486; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Camello C, 1999, J PHYSIOL-LONDON, V516, P399, DOI 10.1111/j.1469-7793.1999.0399v.x; CHEEK TR, 1994, BIOCHEM J, V304, P469, DOI 10.1042/bj3040469; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; DELRIO E, 1994, J NEUROCHEM, V63, P535; FASOLATO C, 1993, PFLUG ARCH EUR J PHY, V423, P225, DOI 10.1007/BF00374399; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; FELDER CC, 1992, P NATL ACAD SCI USA, V89, P509, DOI 10.1073/pnas.89.2.509; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Kukkonen JP, 1996, J PHARMACOL EXP THER, V279, P593; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; LLOPIS J, 1992, BIOCHEM J, V284, P243, DOI 10.1042/bj2840243; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MOZHAYEVA GN, 1991, J MEMBRANE BIOL, V124, P113, DOI 10.1007/BF01870456; Obukhov AG, 1996, EMBO J, V15, P5833, DOI 10.1002/j.1460-2075.1996.tb00970.x; PALMER S, 1986, BIOCHEM J, V238, P491, DOI 10.1042/bj2380491; PARK D, 1992, J BIOL CHEM, V267, P16048; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; Peyron C, 1998, J NEUROSCI, V18, P9996; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; Shuttleworth TJ, 1998, J BIOL CHEM, V273, P32636, DOI 10.1074/jbc.273.49.32636; Taylor CW, 1998, TRENDS PHARMACOL SCI, V19, P370, DOI 10.1016/S0165-6147(98)01243-7; Trivedi P, 1998, FEBS LETT, V438, P71, DOI 10.1016/S0014-5793(98)01266-6; Tsunoda Y, 1998, J RECEPT SIGNAL TR R, V18, P281, DOI 10.3109/10799899809047748; van den Pol AN, 1998, J NEUROSCI, V18, P7962; van den Pol AN, 1999, J NEUROSCI, V19, P3171; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177; WONG K, 1993, CELL CALCIUM, V14, P493, DOI 10.1016/0143-4160(93)90008-T; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Zerbes M, 1998, CELL CALCIUM, V23, P379, DOI 10.1016/S0143-4160(98)90094-X; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	56	134	140	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30806	30812		10.1074/jbc.M002603200	http://dx.doi.org/10.1074/jbc.M002603200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10880509	hybrid			2022-12-27	WOS:000089762700012
J	Bisgrove, DA; Monckton, EA; Packer, M; Godbout, R				Bisgrove, DA; Monckton, EA; Packer, M; Godbout, R			Regulation of brain fatty acid-binding protein expression by differential phosphorylation of nuclear factor I in malignant glioma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ASTROCYTOMA-CELLS; TUMOR-SUPPRESSOR GENE; DNA-REPLICATION; COMPLEMENTARY-DNA; JC-VIRUS; TRANSCRIPTION; PROMOTER; FAMILY; GROWTH; LOCALIZATION	Brain fatty acid-binding protein (B-FABP) is expressed in the radial glial cells of the developing central nervous system as well as in a subset of human malignant glioma cell lines. Most of the malignant glioma lines that express B-FABP also express GFAP, an intermediate filament protein found in mature astrocytes. We are studying the regulation of the B-FABP gene to determine the basis for its differential expression in malignant glioma lines. By DNase I footprinting, we have identified five DNA-binding sites located within 400 base pairs (bp) of the B-FABP transcription start site, including two nuclear factor I (NFL)-binding sites at -35 to -58 bp (footprint 1, fp1) and -237 to -260 bp (fp3), respectively. Competition experiments, supershift experiments with anti-NFI antibody, and methylation interference experiments all indicate that the factor binding to fp1 and fp3 is NFI. By site-directed mutagenesis of both NFI-binding sites, we show that the most proximal NFI site is essential for B-FABP promoter activity in transiently transfected malignant glioma cells. Different band shift patterns are observed with nuclear extracts from B-FABP(+) and B-FABP(-) malignant glioma lines, with the latter generating complexes that migrate more slowly than those obtained with B-FABP(+) extracts. All bands are converted to a faster migrating form with potato acid phosphatase treatment, indicating that NFI is differentially phosphorylated in B-FABP(+) and B-FABP(-) lines. Our results suggest that B-FABP expression in malignant glioma lines is determined by the extent of NFI phosphorylation which, in turn, is controlled by a phosphatase activity specific to B-FABP(+) lines.	Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Edmonton, AB T6G 1Z2, Canada	University of Alberta; University of Alberta	Godbout, R (corresponding author), Cross Canc Inst, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.		Godbout, Roseline/I-4639-2016	Godbout, Roseline/0000-0002-4779-9265				AMEMIYA K, 1992, J BIOL CHEM, V267, P14204; APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; BELIKOV S, 1995, NUCLEIC ACIDS RES, V23, P310, DOI 10.1093/nar/23.2.310; Chaudhry AZ, 1998, J BIOL CHEM, V273, P18538, DOI 10.1074/jbc.273.29.18538; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; Cooke DW, 1999, J BIOL CHEM, V274, P12917, DOI 10.1074/jbc.274.18.12917; das Neves L, 1999, P NATL ACAD SCI USA, V96, P11946, DOI 10.1073/pnas.96.21.11946; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; ENG LF, 1978, J HISTOCHEM CYTOCHEM, V26, P513, DOI 10.1177/26.7.357640; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; FENG L, 1995, DEVELOPMENT, V121, P1719; GARABEDIAN MJ, 1993, GENE TRANSCRIPTION P, P243; Godbout R, 1998, ONCOGENE, V16, P1955, DOI 10.1038/sj.onc.1201740; Gray IC, 1998, BRIT J CANCER, V78, P1296, DOI 10.1038/bjc.1998.674; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P964, DOI 10.1128/MCB.5.5.964; Hatten ME, 1999, ANNU REV NEUROSCI, V22, P511, DOI 10.1146/annurev.neuro.22.1.511; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; INOUE T, 1990, J BIOL CHEM, V265, P19065; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; Josephson R, 1998, DEVELOPMENT, V125, P3087; KAWAMURA H, 1993, BIOCHEM BIOPH RES CO, V192, P1424, DOI 10.1006/bbrc.1993.1575; Krebs CJ, 1996, J NEUROCHEM, V66, P1354; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; KUMAR KU, 1993, J VIROL, V67, P572, DOI 10.1128/JVI.67.1.572-576.1993; KURTZ A, 1994, DEVELOPMENT, V120, P2637; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu YC, 1997, J BIOL CHEM, V272, P10739; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; Murphy KG, 1998, J NEUROSURG, V89, P997, DOI 10.3171/jns.1998.89.6.0997; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Ortiz L, 1999, J BIOL CHEM, V274, P15213, DOI 10.1074/jbc.274.21.15213; QIAN F, 1995, GENOMICS, V28, P66, DOI 10.1006/geno.1995.1107; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; Roulet E, 2000, J MOL BIOL, V297, P833, DOI 10.1006/jmbi.2000.3614; ROY RJ, 1991, BIOTECHNIQUES, V11, P770; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; Russell D, 1989, PATHOLOGY TUMOURS NE; RUTKA JT, 1993, CANCER RES, V53, P3624; RUTKA JT, 1994, CANCER RES, V54, P3267; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHMECHEL DE, 1979, ANAT EMBRYOL, V156, P115, DOI 10.1007/BF00300010; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sumner C, 1996, J NEUROVIROL, V2, P87, DOI 10.3109/13550289609146542; Toda M, 1999, NEUROCHEM RES, V24, P339, DOI 10.1023/A:1022538810581; VANDERMEULEN JDM, 1978, NEUROPATH APPL NEURO, V4, P177; VELASCO ME, 1980, CANCER, V45, P484, DOI 10.1002/1097-0142(19800201)45:3<484::AID-CNCR2820450312>3.0.CO;2-9; VERITY AN, 1988, J NEUROSCI RES, V21, P238, DOI 10.1002/jnr.490210216; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093	54	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30668	30676		10.1074/jbc.M003828200	http://dx.doi.org/10.1074/jbc.M003828200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896661	hybrid			2022-12-27	WOS:000089577900103
J	Jacobson, KA; Xie, RY; Young, L; Chang, L; Liang, BT				Jacobson, KA; Xie, RY; Young, L; Chang, L; Liang, BT			A novel pharmacological approach to treating cardiac ischemia - Binary conjugates of A(1) and A(3) adenosine receptor agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY; RAT-BRAIN; CARDIOPROTECTION; ANTAGONISTS; ACTIVATION; INHIBITION; MYOCYTES; INJURY	Adenosine released during cardiac ischemia exerts a potent, protective effect in the heart via activation of A(1) or A(3) receptors. However, the interaction between the two cardioprotective adenosine receptors and the question of which receptor is the more important anti-ischemic receptor remain largely unexplored. The objective of this study was to test the hypothesis that activation of both receptors exerted a cardioprotective effect that was significantly greater than activation of either receptor individually. This was accomplished by using a novel design in which new binary conjugates of adenosine A(1) and A(3) receptor agonists were synthesized and tested in a novel cardiac myocyte model of adenosine-elicited cardioprotection. Binary drugs having mixed selectivity for both A(1) and A(3) receptors were created through the covalent linking of functionalized congeners of adenosine agonists, each being selective for either the A(1) or A(3) receptor subtype. MRS 1740 and MRS 1741, thiourea-linked, regioisomers of a binary conjugate, were highly potent and selective in radioligand binding assays for A(1) and A(3) receptors (K-i values of 0.7-3.5 nM) versus A(2A) receptors. The myocyte models utilized cultured chick embryo cells, either ventricular cells expressing native adenosine A(1) and A(3) receptors, or engineered atrial cells, in which either human A(3) receptors alone or both human A(1) and A(3) receptors were expressed. The binary agonist MRS 1741 coactivated A(1) and A(3) receptors simultaneously, with full cardioprotection (EC50 similar to 0.1 nM) dependent on expression of both receptors, Thus, co-activation of both adenosine A(1) and A(3) receptors by the binary A(1)/A(3) agonists represents a novel general cardioprotective approach for the treatment of myocardial ischemia.	NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; Univ Penn, Med Ctr, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Pennsylvania; University of Pennsylvania	Jacobson, KA (corresponding author), NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-19, Bethesda, MD 20892 USA.		Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	Intramural NIH HHS [Z01 DK031117-20, Z01 DK031115-24, Z99 DK999999] Funding Source: Medline; NHLBI NIH HHS [R01-HL48225, R01 HL048225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031116, Z01DK031115, Z01DK031117] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auchampach JA, 1997, CIRC RES, V80, P800; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DENNIS D, 1992, AM J PHYSIOL, V262, pH661, DOI 10.1152/ajpheart.1992.262.3.H661; Dougherty C, 1998, FASEB J, V12, P1785, DOI 10.1096/fasebj.12.15.1785; DOWNEY JM, 1992, TRENDS CARDIOVAS MED, V2, P170, DOI 10.1016/1050-1738(92)90045-T; ELY SW, 1992, CIRCULATION, V85, P893, DOI 10.1161/01.CIR.85.3.893; GROSS GJ, 1995, BASIC RES CARDIOL, V90, P85, DOI 10.1007/BF00789438; JACOBSON KA, 1987, J MED CHEM, V30, P1529, DOI 10.1021/jm00391a046; JACOBSON KA, 1985, J MED CHEM, V28, P1341, DOI 10.1021/jm00147a039; Jacobson KA, 1998, TRENDS PHARMACOL SCI, V19, P184, DOI 10.1016/S0165-6147(98)01203-6; JACOBSON KA, 1986, MOL PHARMACOL, V29, P126; JARVIS MF, 1989, J PHARMACOL EXP THER, V251, P888; LI GC, 1990, CIRCULATION, V82, P609, DOI 10.1161/01.CIR.82.2.609; Liang BT, 1996, NUCLEIC ACIDS RES, V24, P1382, DOI 10.1093/nar/24.7.1382; LIANG BT, 1990, CIRC RES, V67, P406, DOI 10.1161/01.RES.67.2.406; Liang BT, 1996, AM J PHYSIOL-HEART C, V271, pH1769, DOI 10.1152/ajpheart.1996.271.5.H1769; Liang BT, 1998, P NATL ACAD SCI USA, V95, P6995, DOI 10.1073/pnas.95.12.6995; Liang BT, 1998, BIOCHEM J, V336, P337, DOI 10.1042/bj3360337; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; OLAH ME, 1994, MOL PHARMACOL, V45, P978; Parsons M, 2000, FASEB J, V14, P1423, DOI 10.1096/fj.14.10.1423; SCHWABE U, 1980, N-S ARCH PHARMACOL, V313, P179, DOI 10.1007/BF00505731; SIDDIQI SM, 1995, BIOORGAN MED CHEM, V3, P1331, DOI 10.1016/0968-0896(95)00116-X; Stambaugh K, 1997, AM J PHYSIOL-HEART C, V273, pH501; STILES GL, 1988, MOL PHARMACOL, V34, P724; Strickler J, 1996, J CLIN INVEST, V98, P1773, DOI 10.1172/JCI118976; Tracey WR, 1997, CARDIOVASC RES, V33, P410, DOI 10.1016/S0008-6363(96)00240-4	27	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30272	30279		10.1074/jbc.M001520200	http://dx.doi.org/10.1074/jbc.M001520200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10887176	Green Accepted, hybrid			2022-12-27	WOS:000089577900050
J	Liu, JH; Itagaki, Y; Ben-Shabat, S; Nakanishi, K; Sparrow, JR				Liu, JH; Itagaki, Y; Ben-Shabat, S; Nakanishi, K; Sparrow, JR			The biosynthesis of A2E, a fluorophore of aging retina, involves the formation of the precursor, A2-PE, in the photoreceptor outer segment membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT EPITHELIUM; MACULAR DEGENERATION; FUNDUS FLAVIMACULATUS; STARGARDTS-DISEASE; LIPOFUSCIN; ABCR; AUTOFLUORESCENCE; PROTEIN	The autofluorescent lipofuscin that accumulates in retinal pigment epithelial cells with age may contribute to an age-related decline in cell function. The major lipofuscin fluorophore, A2E, is a pyridinium bisretinoid. We previously proposed that the biogenesis of A2E involves the following: (i) formation of the Schiff base, N-retinylidene phosphatidylethanolamine from all-trans-retinal and phosphatidylethanolamine in the photoreceptor outer segment membrane; (ii) further reaction of N-retinylidene phosphatidylethanolamine with retinal to yield phosphatidylethanolamine-bisretinoid, A2-PE; (iii) hydrolysis of A2-PE to generate A2E. To provide evidence for this biogenic scheme, all-trans-retinal was reacted with dipalmitoyl-L-alpha-phosphatidylethanolamine to yield DP-A2-PE (A2-PE), as confirmed by UV, with mass spectrometry revealing the molecular ion at m/z 1222.9 (C77H124O8PN) accompanied by product ion at m/z 672.8, representing the phosphoryl-A2E fragment of A2-PE. In reaction mixtures of retinal and outer segments and in samples of Royal College of Surgeons rat retina containing outer segment membranous debris, A2-PE was detected as a series of high performance liquid chromatography peaks, each with UV similar to reference A2-PE. By mass spectrometry, A2-PE consisted of multiple peaks, representing fatty acids with different chain lengths, and the phosphoryl-A2E moiety, m/z 673. Incubation of the retinal/outer segment reaction mixture with phospholipase D generated A2E, as detected by high performance liquid chromatography, thus confirming A2-PE as the A2E precursor.	Columbia Univ, Dept Chem, New York, NY 10027 USA; Columbia Univ Coll Phys & Surg, Dept Ophthalmol, New York, NY 10028 USA	Columbia University; Columbia University	Nakanishi, K (corresponding author), Columbia Univ, Dept Chem, New York, NY 10027 USA.				NATIONAL EYE INSTITUTE [R01EY012951] Funding Source: NIH RePORTER; NEI NIH HHS [EY12951] Funding Source: Medline; PHS HHS [34509] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; ANDERSON RE, 1970, BIOCHEMISTRY-US, V9, P3624, DOI 10.1021/bi00820a019; BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211; BRESSLER SB, 1999, RETINA VITREOUS MACU, P79; BUNTMILAM AH, 1983, INVEST OPHTH VIS SCI, V24, P458; DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327; DOWLING JE, 1962, J CELL BIOL, V14, P73, DOI 10.1083/jcb.14.1.73; Eldred GE, 1995, GERONTOLOGY, V41, P15; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; ELDRED GE, 1998, RETINAL PIGMENT EPIT, P651; Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209; KATZ ML, 1978, INVEST OPHTH VIS SCI, V17, P1049; KATZ ML, 1986, EXP EYE RES, V43, P561, DOI 10.1016/S0014-4835(86)80023-9; Katz ML, 1996, MECH AGEING DEV, V92, P159, DOI 10.1016/S0047-6374(96)01817-9; KATZ ML, 1987, MECH AGEING DEV, V39, P81, DOI 10.1016/0047-6374(87)90088-1; Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.3.CO;2-E; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; POINCELOT RP, 1969, NATURE, V221, P256, DOI 10.1038/221256a0; Ren RXF, 1997, J AM CHEM SOC, V119, P3619, DOI 10.1021/ja9700414; Ryeom SW, 1996, J CELL SCI, V109, P387; SAIKAI N, 1996, J AM CHEM SOC, V118, P1559; Salvador GA, 1998, LIPIDS, V33, P853, DOI 10.1007/s11745-998-0281-z; SHICHI H, 1983, BIOCH VISION, P122; Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988; Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; SZAMIER RB, 1977, INVEST OPHTH VIS SCI, V16, P947; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9	30	197	201	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29354	29360		10.1074/jbc.M910191199	http://dx.doi.org/10.1074/jbc.M910191199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887199	hybrid			2022-12-27	WOS:000089439800025
J	Milstone, AM; Harrison, LM; Bungiro, RD; Kuzmic, P; Cappello, M				Milstone, AM; Harrison, LM; Bungiro, RD; Kuzmic, P; Cappello, M			A broad spectrum Kunitz type serine protease inhibitor secreted by the hookworm Ancylostoma ceylanicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINUM ANTICOAGULANT PEPTIDE; ASCARIS-LUMBRICOIDES; ANISAKIS SIMPLEX; SPLICED LEADER; CLEAVAGE SITES; FACTOR XA; INFECTION; EXPRESSION; NEMATODES; CLONING	Although blood-feeding hookworms infect over a billion people worldwide, little is known about the molecular mechanisms through which these parasitic nematodes cause gastrointestinal hemorrhage and iron deficiency anemia. A cDNA corresponding to a secreted Kunitz type serine protease inhibitor has been cloned from adult Ancylostoma ceylanicum hookworm RNA. The translated sequence of the A. ceylanicum Kunitz type inhibitor 1 (AceKI-1) cDNA predicts a 16-amino acid secretory signal sequence, followed by a 68-amino acid mature protein with a molecular mass of 7889 daltons. Recombinant protein (rAceKI-1) was purified from induced lysates of Escherichia coli transformed with the rAceKI-1/pET 28a plasmid, and in vitro studies demonstrate that rAceKI-1 is a tight binding inhibitor of the serine proteases chymotrypsin, pancreatic elastase, neutrophil elastase, and trypsin, AceKI-1 inhibitory activity is present in soluble protein extracts and excretory/secretory products of adult hookworms but not the infective third stage larvae. The native AceKI-1 inhibitor has been purified to homogeneity from soluble extracts of adult A. ceylanicum using size exclusion and reverse-phase high pressure liquid chromatography. As a potent inhibitor of mammalian intestinal proteases, AceKI-1 may play a role in parasite survival and the pathogenesis of hookworm anemia.	Yale Univ, Sch Med, Dept Pediat, Yale Child Hlth Res Ctr,Infect Dis Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Yale Child Hlth Res Ctr,Infect Dis Sect, New Haven, CT 06520 USA; BioKin Ltd, Madison, WI 53708 USA	Yale University; Yale University	Cappello, M (corresponding author), Yale Univ, Sch Med, Dept Pediat, Yale Child Hlth Res Ctr,Infect Dis Sect, POB 208081, New Haven, CT 06520 USA.	michael.cappello@yale.edu	Bungiro, Rick/AAJ-1736-2021; Bungiro, Richard/AAH-9406-2021; Bungiro, Rick/AAJ-1758-2021	Kuzmic, Petr/0000-0001-5250-8381; Milstone, Aaron/0000-0001-8498-8682; Cappello, Michael/0000-0003-2255-8833	NIAID NIH HHS [K11 AI01299, T32 AI07404] Funding Source: Medline; NICHD NIH HHS [P30 HD2775] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI001299, T32AI007404] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albonico M, 1999, ADV PARASIT, V42, P277, DOI 10.1016/S0065-308X(08)60151-7; ALBONICO M, 1995, T ROY SOC TROP MED H, V89, P538, DOI 10.1016/0035-9203(95)90101-9; Albonico M, 1999, INT J EPIDEMIOL, V28, P591, DOI 10.1093/ije/28.3.591; BABIN DR, 1984, ARCH BIOCHEM BIOPHYS, V232, P143, DOI 10.1016/0003-9861(84)90530-7; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BERNARD VD, 1993, ARCH BIOCHEM BIOPHYS, V303, P367, DOI 10.1006/abbi.1993.1297; Blaxter M, 1996, INT J PARASITOL, V26, P1025, DOI 10.1016/S0020-7519(96)00060-4; Cappello M, 1998, P NATL ACAD SCI USA, V95, P14290, DOI 10.1073/pnas.95.24.14290; CAPPELLO M, 1995, P NATL ACAD SCI USA, V92, P6152, DOI 10.1073/pnas.92.13.6152; Cappello M, 1996, MOL BIOCHEM PARASIT, V80, P113, DOI 10.1016/0166-6851(96)02658-8; CAPPELLO M, 1993, J INFECT DIS, V167, P1474, DOI 10.1093/infdis/167.6.1474; CARROLL SM, 1986, TROP GEOGR MED, V38, P38; CARROLL SM, 1984, J HELMINTHOL, V58, P313, DOI 10.1017/S0022149X00025189; CARROLL SM, 1984, J INFECT DIS, V150, P284, DOI 10.1093/infdis/150.2.284; Chadderdon RC, 1999, J INFECT DIS, V179, P1235, DOI 10.1086/314724; CHOWDHURY AB, 1972, AM J TROP MED HYG, V21, P300, DOI 10.4269/ajtmh.1972.21.300; CREIGHTON TE, 1975, NATURE, V255, P743, DOI 10.1038/255743a0; DeClercq D, 1997, AM J TROP MED HYG, V57, P25, DOI 10.4269/ajtmh.1997.57.25; Delaria KA, 1997, J BIOL CHEM, V272, P12209, DOI 10.1074/jbc.272.18.12209; ENJYOJI K, 1992, J BIOCHEM-TOKYO, V111, P681, DOI 10.1093/oxfordjournals.jbchem.a123818; GARSIDE P, 1989, PARASITOLOGY, V98, P283, DOI 10.1017/S003118200006220X; GILLES HM, 1985, REV INFECT DIS, V7, P111; HARROP SA, 1995, TROP MED PARASITOL, V46, P119; HAWDON JM, 1993, PARASITOLOGY, V106, P163, DOI 10.1017/S0031182000074953; HAWDON JM, 1992, J PARASITOL, V78, P1036, DOI 10.2307/3283226; HOTEZ P, 1990, INFECT IMMUN, V58, P3883, DOI 10.1128/IAI.58.12.3883-3892.1990; HOTEZ P, 1994, J INFECT DIS, V170, P918, DOI 10.1093/infdis/170.4.918; HOTEZ PJ, 1985, J BIOL CHEM, V260, P7343; HOTEZ PJ, 1995, SCI AM, V272, P68, DOI 10.1038/scientificamerican0695-68; Hotez PJ, 1997, PEDIATR INFECT DIS J, V16, P935, DOI 10.1097/00006454-199710000-00006; HOTEZ PJ, 1995, INFECT AGENT DIS, V4, P71; HOTEZ PJ, 1995, MOL APPROACHES PARAS; JESPERS LS, 1995, BIO-TECHNOL, V13, P378, DOI 10.1038/nbt0495-378; KALKOFEN UP, 1970, Z PARASITENK, V33, P339, DOI 10.1007/BF00331470; KEYMER A, 1989, NATURE, V337, P114, DOI 10.1038/337114a0; Kraunsoe JAE, 1996, BIOCHEMISTRY-US, V35, P9090, DOI 10.1021/bi953013b; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Kuzmic P, 2000, ANAL BIOCHEM, V281, P62, DOI 10.1006/abio.2000.4501; Lawson CL, 1974, SOLVING LEAST SQUARE; LAYRISSE M, 1964, AM J HYG, V79, P279, DOI 10.1093/oxfordjournals.aje.a120383; Lu CC, 1998, EXP PARASITOL, V89, P257, DOI 10.1006/expr.1998.4284; Lu WY, 1997, J MOL BIOL, V266, P441, DOI 10.1006/jmbi.1996.0781; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MOYLE M, 1994, J BIOL CHEM, V269, P10008; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PRESS WH, 1992, NUMERICAL RECIPES, P696; Pritchard L, 1999, J MOL BIOL, V285, P1589, DOI 10.1006/jmbi.1998.2437; QUINNELL RJ, 1993, PARASITOLOGY, V106, P379, DOI 10.1017/S0031182000067123; Reynoldson JA, 1997, ACTA TROP, V68, P301, DOI 10.1016/S0001-706X(97)00106-X; Rhoads ML, 2000, EXP PARASITOL, V94, P1, DOI 10.1006/expr.1999.4466; RicoHesse R, 1997, VIROLOGY, V230, P244, DOI 10.1006/viro.1997.8504; ROCHE MARCEL, 1966, AMER J TROP MED HYG, V15, P1031; SASAKI T, 1984, J BIOCHEM-TOKYO, V95, P1009, DOI 10.1093/oxfordjournals.jbchem.a134688; SCHAD GA, 1979, EXP PARASITOL, V47, P246, DOI 10.1016/0014-4894(79)90077-8; SCHAEFER BC, 1995, ANAL BIOCHEM, V227, P255, DOI 10.1006/abio.1995.1279; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Smillie WG, 1926, AM J DIS CHILD, V31, P151, DOI 10.1001/archpedi.1926.04130020003001; Stanssens P, 1996, P NATL ACAD SCI USA, V93, P2149, DOI 10.1073/pnas.93.5.2149; STEPHENSON LS, 1990, T ROY SOC TROP MED H, V84, P277, DOI 10.1016/0035-9203(90)90286-N; Stoltzfus RJ, 1997, AM J CLIN NUTR, V65, P153, DOI 10.1093/ajcn/65.1.153; Stone KL, 1998, ELECTROPHORESIS, V19, P1046, DOI 10.1002/elps.1150190620; STONE KL, 1992, TECHNIQUES PROTEIN C, V3; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Williams J W, 1979, Methods Enzymol, V63, P437; WILLIAMS KR, 1996, PROTEIN PROTOCOLS HD; ZIMMERMAN HM, 1946, AM J PATHOL, V22, P1081	66	65	71	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29391	29399		10.1074/jbc.M002715200	http://dx.doi.org/10.1074/jbc.M002715200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893410	hybrid			2022-12-27	WOS:000089439800030
J	Xie, YM; Tisi, MA; Yeo, TT; Longo, FM				Xie, YM; Tisi, MA; Yeo, TT; Longo, FM			Nerve growth factor (NGF) loop 4 dimeric mimetics activate ERK and AKT and promote NGF-like neurotrophic effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 CELLS; NEURITE OUTGROWTH; RECEPTOR-BINDING; PROTEIN-KINASE; NEURONAL DIFFERENTIATION; SIGNAL-TRANSDUCTION; CARBOXYL-TERMINUS; CRYSTAL-STRUCTURE; CROSS-LINKING; TRKA RECEPTOR	Previous work indicating that nerve growth factor (NGF) protein loops 2 and 4 interact with TrkA receptors raise the possibility that small molecule mimetics corresponding to TrkA-interacting domains that have NGF agonist activity can be developed. We applied our previously developed strategy of dimeric peptidomimetics to address the hypothesis that loop 4 small molecule dimeric mimetics would activate TrkA-related signal transduction and mimic NGF neurotrophic effects in a structure-specific manner. A loop 4 cyclized peptide dimer demonstrated NGF-like neurotrophic activity, whereas peptides with scrambled sequence, added or substituted residues, or cyclized in monomeric form were inactive. Activity was blocked by the TrkA inhibitors K252a and AG879 but not by NGF p75 receptor blocking antibody. Dimeric, but not monomeric, peptides partially blocked NGF activity. This profile was consistent with that of a NGF partial agonist. ERK and AKT phosphorylation was stimulated only by biologically active peptides and was blocked by K252a. The ERK inhibitor U0126 blocked the neurite- but not the survival-promoting activity of both NGF and active peptide. These studies support the proof of concept that small molecule NGF loop 4 mimetics can activate NGF signaling pathways and can mimic death-preventing and neurite-promoting effects of NGF. This finding will guide the rational design of NGF single-domain mimetics and contribute to elucidating NGF signal transduction mechanisms.	Vet Affairs Med Ctr, Dept Neurol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Longo, FM (corresponding author), Vet Affairs Med Ctr, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA.				NINDS NIH HHS [NS37309] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R55NS037309] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashcroft M, 1999, ONCOGENE, V18, P4586, DOI 10.1038/sj.onc.1202814; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BERG MM, 1992, J BIOL CHEM, V267, P13; BOURNE HR, 1998, BASIC CLIN PHARM, P9; BRADSHAW RA, 1994, PROTEIN SCI, V3, P1901, DOI 10.1002/pro.5560031102; Bredesen DE, 1998, CELL DEATH DIFFER, V5, P365, DOI 10.1038/sj.cdd.4400378; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; CLARY DO, 1994, MOL BIOL CELL, V5, P549, DOI 10.1091/mbc.5.5.549; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Cunningham BC, 1997, CURR OPIN STRUC BIOL, V7, P457, DOI 10.1016/S0959-440X(97)80107-8; DRINKWATER CC, 1993, J BIOL CHEM, V268, P23202; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Frade JM, 1998, BIOESSAYS, V20, P137, DOI 10.1002/(SICI)1521-1878(199802)20:2<137::AID-BIES6>3.0.CO;2-Q; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; HOLLAND DR, 1994, J MOL BIOL, V239, P385, DOI 10.1006/jmbi.1994.1380; HRUBY VJ, 1990, BIOCHEM J, V268, P249, DOI 10.1042/bj2680249; HUBER LJ, 1995, J NEUROSCI RES, V40, P557, DOI 10.1002/jnr.490400415; Hughes RA, 1999, DRUG DEVELOP RES, V46, P268, DOI 10.1002/(SICI)1098-2299(199903/04)46:3/4<268::AID-DDR12>3.0.CO;2-G; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; Johnson DL, 1998, BIOCHEMISTRY-US, V37, P3699, DOI 10.1021/bi971956y; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kenakin T, 1999, TRENDS PHARMACOL SCI, V20, P400, DOI 10.1016/S0165-6147(99)01361-9; KieberEmmons T, 1997, CURR OPIN BIOTECH, V8, P435, DOI 10.1016/S0958-1669(97)80065-1; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; KOIZUMI S, 1988, J NEUROSCI, V8, P715; Kruttgen A, 1997, J BIOL CHEM, V272, P29222, DOI 10.1074/jbc.272.46.29222; Kullander K, 1997, J BIOL CHEM, V272, P9300; LESAUTEUR L, 1995, J BIOL CHEM, V270, P6564, DOI 10.1074/jbc.270.12.6564; Lipworth BJ, 1997, BRIT J CLIN PHARMACO, V43, P9, DOI 10.1111/j.1365-2125.1997.tb00025.x; LONGO FM, 1990, CELL REGUL, V1, P189, DOI 10.1091/mbc.1.2.189; Longo FM, 1997, J NEUROSCI RES, V48, P1, DOI 10.1002/(SICI)1097-4547(19970401)48:1<1::AID-JNR1>3.0.CO;2-K; Maliartchouk S, 2000, J BIOL CHEM, V275, P9946, DOI 10.1074/jbc.275.14.9946; Maliartchouk S, 1997, J NEUROSCI, V17, P6031; MCCARTHY KD, 1976, BRAIN RES, V114, P391, DOI 10.1016/0006-8993(76)90962-8; MCDONALD NQ, 1995, J BIOL CHEM, V270, P19669, DOI 10.1074/jbc.270.34.19669; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; McInnes C, 1997, BIOPOLYMERS, V43, P339, DOI 10.1002/(SICI)1097-0282(1997)43:5<339::AID-BIP2>3.0.CO;2-W; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; O'Leary PD, 1998, J NEUROCHEM, V70, P1712; OHMICHI M, 1993, BIOCHEMISTRY-US, V32, P4650, DOI 10.1021/bi00068a024; PELTON JT, 1985, P NATL ACAD SCI USA, V82, P236, DOI 10.1073/pnas.82.1.236; Perron JC, 1999, MOL CELL NEUROSCI, V13, P362, DOI 10.1006/mcne.1999.0753; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; Pliska V, 1999, J RECEPT SIGNAL TR R, V19, P597, DOI 10.3109/10799899909036675; Poduslo JF, 1996, MOL BRAIN RES, V36, P280, DOI 10.1016/0169-328X(95)00250-V; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Ross GM, 1998, EUR J NEUROSCI, V10, P890, DOI 10.1046/j.1460-9568.1998.00094.x; Saltzman WM, 1999, PHARMACEUT RES, V16, P232, DOI 10.1023/A:1018824324275; Shamovsky IL, 1999, PROTEIN SCI, V8, P2223; Shu XQ, 1999, P NATL ACAD SCI USA, V96, P7693, DOI 10.1073/pnas.96.14.7693; SNOW DM, 1992, J NEUROBIOL, V23, P322, DOI 10.1002/neu.480230311; Taglialatela G, 1996, J NEUROCHEM, V66, P1826; VOLONTE C, 1993, J BIOL CHEM, V268, P21410; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; WOO SB, 1995, J BIOL CHEM, V270, P6278, DOI 10.1074/jbc.270.11.6278; Woo SB, 1998, PROTEIN SCI, V7, P1006; Wrighton NC, 1997, NAT BIOTECHNOL, V15, P1261, DOI 10.1038/nbt1197-1261; Xie Y. M., 1997, Society for Neuroscience Abstracts, V23, P1701; Yuen EC, 1996, BRAIN DEV-JPN, V18, P362, DOI 10.1016/0387-7604(96)00051-4; ZHOU J, 1995, J NEUROCHEM, V65, P1146	62	74	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29868	29874		10.1074/jbc.M005071200	http://dx.doi.org/10.1074/jbc.M005071200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896671	hybrid			2022-12-27	WOS:000089439800093
J	Yi, P; Melnyk, S; Pogribna, M; Pogribny, IP; Hines, RJ; James, SJ				Yi, P; Melnyk, S; Pogribna, M; Pogribny, IP; Hines, RJ; James, SJ			Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-HOMOCYSTEINE; SMOOTH-MUSCLE CELLS; ISOLATED RAT-LIVER; METHYL-DEFICIENT; METHYLENETETRAHYDROFOLATE REDUCTASE; METHIONINE METABOLISM; POSTMENOPAUSAL WOMEN; FOLATE-DEFICIENCY; BIOGENIC-AMINES; TISSUE-LEVELS	S-Adenosylmethionine and S-adenosylhomocysteine (SAH), as the substrate and product of essential cellular methyltransferase reactions, are important metabolic indicators of cellular methylation status. Chronic elevation of SAH, secondary to the homocysteine-mediated reversal of the SAH hydrolase reaction, reduces methylation of DNA, RNA, proteins, and phospholipids. High affinity binding of SAH to the active site of cellular methyltransferases results in product inhibition of the enzyme. Using a sensitive new high pressure liquid chromatography method with coulometric electrochemical detection, plasma SAH levels in healthy young women were found to increase linearly with mild elevation in homocysteine levels (r = 0.73; p < 0.001); however, S-adenosylmethionine levels were not affected, Plasma SAH levels were positively correlated with intracellular lymphocyte SAH levels (r = 0.81; p < 0.001) and also with lymphocyte DNA hypomethylation (r = 0.74, p < 0.001). These results suggest that chronic elevation in plasma homocysteine levels, such as those associated with nutritional deficiencies or genetic polymorphisms in the folate pathway, may have an indirect and negative effect on cellular methylation reactions through a concomitant increase in intracellular SAH levels.	US FDA, Div Biochem Toxicol, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA; Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Sch Hlth Related Profess, Little Rock, AR 72202 USA	US Food & Drug Administration (FDA); University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	James, SJ (corresponding author), US FDA, Div Biochem Toxicol, Natl Ctr Toxicol Res, 3900 NCTR Rd, Jefferson, AR 72079 USA.	jjames@nctr.fda.gov						AARBAKKE J, 1986, CANCER RES, V46, P5469; AUSEBEL FM, 1992, CURRENT PROTOCOL MOL; BAILEY LB, 2000, J NUTR S, V130, P919; BAILEY LB, 2000, J NUTR S, V130, P779; Baylin SB, 1998, ADV CANCER RES, V72, P141; BORCHARDT RT, 1978, BIOCHEMISTRY-US, V17, P4145, DOI 10.1021/bi00613a007; BURKE GT, 1971, BIOCHEMISTRY-US, V10, P3079; Cantoni G.L., 1985, Progress in Clinical and Biological Research, V198, P47; Capdevila A, 1997, ARCH BIOCHEM BIOPHYS, V345, P47, DOI 10.1006/abbi.1997.0249; Carmody BJ, 1999, J VASC SURG, V30, P1121, DOI 10.1016/S0741-5214(99)70053-4; Chamberlin ME, 1996, J CLIN INVEST, V98, P1021, DOI 10.1172/JCI118862; Chawla RK, 1996, J CELL BIOCHEM, V61, P72; Chiang PK, 1998, PHARMACOL THERAPEUT, V77, P115, DOI 10.1016/S0163-7258(97)00089-2; CHIANG PK, 1981, SCIENCE, V211, P1164, DOI 10.1126/science.7466386; CHIANG PK, 1980, BIOCHEM BIOPH RES CO, V94, P174, DOI 10.1016/S0006-291X(80)80203-8; CHIANG PK, 1979, BIOCHEM PHARMACOL, V28, P1897, DOI 10.1016/0006-2952(79)90642-7; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; COX R, 1977, BIOCHIM BIOPHYS ACTA, V474, P493, DOI 10.1016/0005-2787(77)90070-3; Cravo ML, 1996, AM J CLIN NUTR, V63, P220, DOI 10.1093/ajcn/63.2.220; Dalton ML, 1997, FASEB J, V11, P703, DOI 10.1096/fasebj.11.8.9240971; DECABO SF, 1995, CYTOGENET CELL GENET, V71, P187, DOI 10.1159/000134104; DEGUCHI T, 1971, J BIOL CHEM, V246, P3175; DIZIK M, 1991, CARCINOGENESIS, V12, P1307, DOI 10.1093/carcin/12.7.1307; DUERRE JA, 1981, BIOCHIM BIOPHYS ACTA, V678, P275, DOI 10.1016/0304-4165(81)90217-8; Eskes TKAB, 1998, NUTR REV, V56, P236, DOI 10.1111/j.1753-4887.1998.tb01755.x; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; FINKELSTEIN JD, 1974, ARCH BIOCHEM BIOPHYS, V165, P774, DOI 10.1016/0003-9861(74)90306-3; Finkelstein JD, 1998, EUR J PEDIATR, V157, pS40, DOI 10.1007/PL00014300; Fowler B, 1997, J INHERIT METAB DIS, V20, P270, DOI 10.1023/A:1005369109055; GARCIACASTRO I, 1983, J BIOL CHEM, V258, P4345; GERMAN DC, 1983, J BIOL CHEM, V258, P997; GLICK JM, 1975, NUCLEIC ACIDS RES, V2, P1639, DOI 10.1093/nar/2.10.1639; Green R, 1999, SEMIN HEMATOL, V36, P47; GREENBERG ML, 1989, J BIOL CHEM, V264, P795; HOFFMAN DR, 1981, LIPIDS, V16, P561, DOI 10.1007/BF02534900; HOFFMAN DR, 1979, CAN J BIOCHEM CELL B, V57, P56, DOI 10.1139/o79-007; HOFFMAN DR, 1980, J BIOL CHEM, V255, P822; Hu YB, 1999, BIOCHEMISTRY-US, V38, P8323, DOI 10.1021/bi990332k; Jacob RA, 1998, J NUTR, V128, P1204, DOI 10.1093/jn/128.7.1204; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; James SJ, 1999, AM J CLIN NUTR, V70, P495; JENCKS DA, 1987, J BIOL CHEM, V262, P2485; Kapusta L, 1999, J PEDIATR-US, V135, P773, DOI 10.1016/S0022-3476(99)70102-2; Koch HG, 1998, EUR J PEDIATR, V157, pS102, DOI 10.1007/PL00014294; KREDICH NM, 1977, CELL, V12, P931, DOI 10.1016/0092-8674(77)90157-X; KREDICH NM, 1979, P NATL ACAD SCI USA, V76, P2450, DOI 10.1073/pnas.76.5.2450; KUTZBACH C, 1967, BIOCHIM BIOPHYS ACTA, V139, P217, DOI 10.1016/0005-2744(67)90140-4; LEONARD EJ, 1978, BIOCHEM BIOPH RES CO, V84, P102, DOI 10.1016/0006-291X(78)90269-3; Loehrer FMT, 1998, NEPHROL DIAL TRANSPL, V13, P656, DOI 10.1093/ndt/13.3.656; Loehrer FMT, 1996, ARTERIOSCL THROM VAS, V16, P727, DOI 10.1161/01.ATV.16.6.727; MAREE KA, 1990, INT J VITAM NUTR RES, V60, P136; Melnyk S, 2000, CLIN CHEM, V46, P265; MILLER JW, 1994, BIOCHEM J, V298, P415, DOI 10.1042/bj2980415; Mills JL, 1996, J NUTR, V126, pS756, DOI 10.1093/jn/126.suppl_3.756S; MOLLOY AM, 1992, BIOCHEM PHARMACOL, V44, P1349, DOI 10.1016/0006-2952(92)90536-R; Pastore A, 1998, CLIN CHEM, V44, P825; Pietrzik K, 1998, EUR J PEDIATR, V157, pS135, DOI 10.1007/PL00014298; Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187; Pogribny IP, 1997, CANCER LETT, V115, P31, DOI 10.1016/S0304-3835(97)04708-3; Post WS, 1999, CARDIOVASC RES, V43, P985, DOI 10.1016/S0008-6363(99)00153-4; PUGH CSG, 1982, BIOCHEMISTRY-US, V21, P1535, DOI 10.1021/bi00536a011; Radomski N, 1999, MOL BIOL CELL, V10, P4283, DOI 10.1091/mbc.10.12.4283; Rampersaud G, 1999, FASEB J, V13, pA700; Robinson K, 1996, CIRCULATION, V94, P2743, DOI 10.1161/01.CIR.94.11.2743; SCHATZ RA, 1981, J NEUROCHEM, V36, P1739, DOI 10.1111/j.1471-4159.1981.tb00426.x; SCOTT JM, 1994, ACTA NEUROL SCAND, V89, P27, DOI 10.1111/j.1600-0404.1994.tb05406.x; SHIVAPURKAR N, 1983, CARCINOGENESIS, V4, P1051, DOI 10.1093/carcin/4.8.1051; Smith SS, 1999, MOL CARCINOGEN, V26, P1, DOI 10.1002/(SICI)1098-2744(199909)26:1<1::AID-MC1>3.0.CO;2-P; Wagner C, 1995, FOLATE HLTH DIS, P23; WEIR DG, 1988, J NEUROCHEM, V51, P1949, DOI 10.1111/j.1471-4159.1988.tb01184.x	70	497	524	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29318	29323		10.1074/jbc.M002725200	http://dx.doi.org/10.1074/jbc.M002725200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10884384	hybrid			2022-12-27	WOS:000089439800020
J	Hartmann, S; Hofsteenge, J				Hartmann, S; Hofsteenge, J			Properdin, the positive regulator of complement, is highly C-mannosylated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST-ATOM-BOMBARDMENT; RNASE U-S; I REPEATS; ALTERNATIVE-PATHWAY; MOLECULAR-CLONING; ADAMTS FAMILY; 3RD COMPONENT; CELL-ADHESION; BINDING-SITE; F-SPONDIN	Properdin is the positive regulator of the alternative pathway of complement activation. The 53-kDa protein. is essentially composed of six thrombospondin type 1 repeats, all of which contain the WXXW motif, the recognition sequence for C-mannosylation. C-Mannosylation is a post-translational modification of tryptophan residues in which, in contrast to the well known N- and O-glycosylation, the carbohydrate is attached via a C-C bond to C-2 of the indole moiety of tryptophan, C-Mannosylation was first found in human RNase 2 and interleukin-12, The terminal complement proteins C6-C9 also carry this modification as part of their thrombospondin type 1 repeats. We studied the C-mannosylation pattern of human properdin by mass spectrometry and Edman degradation. Properdin contains 20 tryptophans of which 17 are part of a WXXW motif. Fourteen tryptophans were found to be modified 100%. This is the first example of a protein in which the majority of tryptophan residues occurs in the C-mannosylated form. These results show that C-mannosylated proteins occur at several steps along the complement activation cascade. Therefore, this system would be ideal to investigate the function of C-mannosylation.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hofsteenge, J (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.							Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Adams RH, 1996, MECH DEVELOP, V57, P33, DOI 10.1016/0925-4773(96)00525-4; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BECCHI M, 1989, BIOMED ENVIRON MASS, V18, P122, DOI 10.1002/bms.1200180207; Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; Crombie R, 1998, J EXP MED, V187, P25, DOI 10.1084/jem.187.1.25; DAOUDAKI ME, 1988, J IMMUNOL, V140, P1577; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DEBEER T, 1995, BIOCHEMISTRY-US, V34, P11785, DOI 10.1021/bi00037a016; DISCIPIO RG, 1981, BIOCHEM J, V199, P485, DOI 10.1042/bj1990485; Doucey MA, 1999, GLYCOBIOLOGY, V9, P435, DOI 10.1093/glycob/9.5.435; Doucey MA, 1998, MOL BIOL CELL, V9, P291, DOI 10.1091/mbc.9.2.291; FARRIES TC, 1988, BIOCHEM J, V252, P47, DOI 10.1042/bj2520047; FARRIES TC, 1988, BIOCHEM J, V253, P667, DOI 10.1042/bj2530667; FARRIES TC, 1989, J IMMUNOL, V142, P842; FEARON DT, 1975, J EXP MED, V142, P856, DOI 10.1084/jem.142.4.856; Gobron S, 1996, J CELL SCI, V109, P1053; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; Gutsche B, 1999, BIOCHEM J, V343, P11, DOI 10.1042/0264-6021:3430011; Higashijima S, 1997, DEV BIOL, V192, P211, DOI 10.1006/dbio.1997.8760; HIGGINS JMG, 1995, J IMMUNOL, V155, P5777; Hofsteenge J, 1999, J BIOL CHEM, V274, P32786, DOI 10.1074/jbc.274.46.32786; HOFSTEENGE J, 1994, BIOCHEMISTRY-US, V33, P13524, DOI 10.1021/bi00250a003; HOLT GD, 1990, J BIOL CHEM, V265, P2852; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; Krieg J, 1998, MOL BIOL CELL, V9, P301, DOI 10.1091/mbc.9.2.301; Krieg J, 1997, J BIOL CHEM, V272, P26687, DOI 10.1074/jbc.272.42.26687; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; LAMBRIS JD, 1984, BIOCHEM J, V217, P323, DOI 10.1042/bj2170323; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LI QM, 1992, BIOL MASS SPECTROM, V21, P213, DOI 10.1002/bms.1200210406; LI WX, 1993, J BIOL CHEM, V268, P16179; Linton SM, 1999, CLIN EXP IMMUNOL, V118, P189; Loffler A, 1996, BIOCHEMISTRY-US, V35, P12005, DOI 10.1021/bi9610515; Manabe S, 1999, J AM CHEM SOC, V121, P9754, DOI 10.1021/ja990926a; Nardi JB, 1999, INSECT BIOCHEM MOLEC, V29, P883, DOI 10.1016/S0965-1748(99)00064-8; NISHIKAWA T, 1998, SYN LETT, V1, P123; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; NOLAN KF, 1991, EUR J IMMUNOL, V21, P771, DOI 10.1002/eji.1830210333; NOLAN KF, 1992, BIOCHEM J, V287, P291, DOI 10.1042/bj2870291; PANGBURN MK, 1989, J IMMUNOL, V142, P202; PISANO A, 1993, GLYCOBIOLOGY, V3, P429, DOI 10.1093/glycob/3.5.429; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Prodinger WM, 1999, FUNDAMENTAL IMMUNOLO, P967; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; SCHWARTZ WE, 1980, ANAL BIOCHEM, V106, P43, DOI 10.1016/0003-2697(80)90116-5; Shiratsuchi T, 1997, CYTOGENET CELL GENET, V79, P103, DOI 10.1159/000134693; Sipes JM, 1999, J BIOL CHEM, V274, P22755, DOI 10.1074/jbc.274.32.22755; STANKOWSKI S, 1991, BIOCHIM BIOPHYS ACTA, V1068, P61, DOI 10.1016/0005-2736(91)90060-L; Tang BL, 1999, FEBS LETT, V445, P223, DOI 10.1016/S0014-5793(99)00119-2; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Umemiya T, 1997, DEV BIOL, V186, P165, DOI 10.1006/dbio.1997.8591; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; [No title captured]	57	75	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28569	28574		10.1074/jbc.M001732200	http://dx.doi.org/10.1074/jbc.M001732200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878002	hybrid			2022-12-27	WOS:000089330700033
J	Kersten, S; Mandard, S; Tan, NS; Escher, P; Metzger, D; Chambon, P; Gonzalez, FJ; Desvergne, B; Wahli, W				Kersten, S; Mandard, S; Tan, NS; Escher, P; Metzger, D; Chambon, P; Gonzalez, FJ; Desvergne, B; Wahli, W			Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA PPAR-ALPHA; TIE2 RECEPTOR; GAMMA; EXPRESSION; MICE; TISSUE; ANGIOPOIETIN-1; METABOLISM; RODENTS; LIGAND	Fasting is associated with significant changes in nutrient metabolism, many of which are governed by transcription factors that regulate the expression of rate-limiting enzymes. One factor that plays an important role in the metabolic response to fasting is the peroxisome proliferator-activated receptor alpha (PPAR alpha). To gain more insight into the role of PPAR alpha during fasting, and into the regulation of metabolism during fasting in general, a search for unknown PPAR alpha target genes was performed. Using subtractive hybridization (SABRE) comparing liver mRNA from wild-type and PPAR alpha null mice, we isolated a novel PPAR alpha target gene, encoding the secreted protein FIAF (for fasting induced adipose factor), that belongs to the family of fibrinogen/angiopoietin-like proteins. FIAF is predominantly expressed in adipose tissue and is strongly up-regulated by fasting in white adipose tissue and liver. Moreover, FIAF mRNA is decreased in white adipose tissue of PPAR gamma +/- mice. FIAF protein can be detected in various tissues and in blood plasma, suggesting that FIAF has an endocrine function. Its plasma abundance is increased by fasting and decreased by chronic high fat feeding. The data suggest that FIAF represents a novel endocrine signal involved in the regulation of metabolism, especially under fasting conditions.	Univ Lausanne, Inst Biol Anim, CH-1015 Lausanne, Switzerland; Univ Louis Pasteur Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	University of Lausanne; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wahli, W (corresponding author), Univ Lausanne, Inst Biol Anim, CH-1015 Lausanne, Switzerland.	walter.wahli@iba.unil.ch	Mandard, Stéphane/J-4800-2019; Wahli, Walter/B-1398-2009; Wahli, Walter/I-3194-2019; Kersten, Sander/A-1116-2011; Tan, Nguan Soon/A-2220-2011; Desvergne, Beatrice/C-8892-2016	Mandard, Stéphane/0000-0002-7298-821X; Wahli, Walter/0000-0002-5966-9089; Kersten, Sander/0000-0003-4488-7734; Tan, Nguan Soon/0000-0003-0136-7341; Desvergne, Beatrice/0000-0001-5483-288X; Metzger, Daniel/0000-0002-5555-046X	NATIONAL CANCER INSTITUTE [Z01BC005708, ZIABC005708] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; CORCOS D, 1987, ONCOGENE RES, V1, P193; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; HAINES DS, 1992, BIOTECHNIQUES, V12, P736; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kim I, 2000, BIOCHEM J, V346, P603, DOI 10.1042/0264-6021:3460603; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lavery DJ, 1997, P NATL ACAD SCI USA, V94, P6831, DOI 10.1073/pnas.94.13.6831; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Peters JM, 1998, CARCINOGENESIS, V19, P1989, DOI 10.1093/carcin/19.11.1989; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Ricote M, 1999, J LEUKOCYTE BIOL, V66, P733, DOI 10.1002/jlb.66.5.733; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TRAYHURN P, 1995, FEBS LETT, V368, P488, DOI 10.1016/0014-5793(95)00719-P; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Wu ZD, 1999, CURR OPIN CELL BIOL, V11, P689, DOI 10.1016/S0955-0674(99)00037-X	25	434	461	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28488	28493		10.1074/jbc.M004029200	http://dx.doi.org/10.1074/jbc.M004029200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10862772	hybrid			2022-12-27	WOS:000089330700021
J	Regier, DS; Greene, DG; Sergeant, S; Jesaitis, AJ; McPhail, LC				Regier, DS; Greene, DG; Sergeant, S; Jesaitis, AJ; McPhail, LC			Phosphorylation of p22phox is mediated by phospholipase D-dependent and -independent mechanisms - Correlation of NADPH oxidase activity and p22phox phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CHRONIC GRANULOMATOUS-DISEASE; CHOLINE-CONTAINING PHOSPHOGLYCERIDES; PERMEABILIZED HUMAN NEUTROPHILS; PHOSPHATIDIC-ACID PRODUCTION; STIMULATED HUMAN-NEUTROPHILS; DIFFERENTIATED HL60 CELLS; RESPIRATORY BURST; CYTOCHROME-B	Human neutrophils participate in the host innate immune response, partly mediated by the multicomponent superoxide-generating enzyme NADPH oxidase. A correlation between phosphorylation of cytosolic NADPH oxidase components and enzyme activation has been identified but is not well understood. We previously showed that p22(phox), the small subunit of the membrane-bound oxidase component flavocytochrome b(558), is an in vitro substrate for both a phosphatidic acid-activated kinase and conventional protein kinase C isoforms (Regier, D. S., Waite, K. A, Wallin, R., and McPhail, L. C. (1999) J. Biol. Chem. 274, 36601-36608). Here we show that several neutrophil agonists (phorbol myristate acetate, opsonized zymosan, and N-formyl-methionyl-leucyl-phenylalanine) induce p22(phox) phosphorylation in intact neutrophils. To determine if phospholipase D (PLD) is needed for p22(phox) phosphorylation, cells were pretreated with ethanol, which reduces phosphatidic acid production by PLD in stimulated cells. Phorbol myristate acetate-induced phosphorylation of p22(phox) and NADPH oxidase activity were not reduced by ethanol, In contrast, ethanol reduced both activities when cells were stimulated by N-formyl-methionyl-leucyl-phenylalanine or opsonized zymosan. Varying the time of stimulation with opsonized zymosan showed that the phosphorylation of p22(phox) coincides with NADPH oxidase activation. GF109203X, an inhibitor of protein kinase C and the phosphatidic acid-activated protein kinase, decreased both p22(phox) phosphorylation and NADPH oxidase activity in parallel in opsonized zymosan-stimulated cells. Stimulus-induced phosphorylation of p22(phox) was on Thr residue(s), in agreement with in vitro results. Overall, these data show that NADPH oxidase activity and p22(phox) phosphorylation are correlated and suggest two mechanisms (PLD-dependent and -independent) by which p22(phox) phosphorylation occurs.	Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Div Infect Dis, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Div Infect Dis, Winston Salem, NC 27157 USA; Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Montana State University System; Montana State University Bozeman	McPhail, LC (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Div Infect Dis, Med Ctr Blvd, Winston Salem, NC 27157 USA.	lmcphail@wfubmc.edu	McPhail, Linda C/D-9505-2013	McPhail, Linda C/0000-0002-8670-306X; Jesaitis, Algirdas/0000-0001-9001-5617	NCI NIH HHS [CA-09422] Funding Source: Medline; NIAID NIH HHS [R01-AI22564, R01 AI022564, R01-AI26711] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026711, R01AI022564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; AGWU DE, 1991, J IMMUNOL, V146, P3895; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AGWU DE, 1989, J BIOL CHEM, V264, P1405; Ahmed S, 1998, J BIOL CHEM, V273, P15693, DOI 10.1074/jbc.273.25.15693; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bauldry SA, 1997, BIOCHEM J, V322, P353, DOI 10.1042/bj3220353; BAULDRY SA, 1992, J BIOL CHEM, V267, P25141; BAULDRY SA, 1992, J BIOL CHEM, V267, P323; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURNHAM DN, 1989, ARCH BIOCHEM BIOPHYS, V269, P345, DOI 10.1016/0003-9861(89)90116-1; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; CHABOT MC, 1992, BIOCHEM J, V286, P693, DOI 10.1042/bj2860693; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; DANA R, 1994, BIOCHEM J, V297, P217, DOI 10.1042/bj2970217; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; DAWSON RMC, 1967, BIOCHEM J, V102, P205, DOI 10.1042/bj1020205; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DELLABIANCA V, 1991, BIOCHEM BIOPH RES CO, V177, P948, DOI 10.1016/0006-291X(91)90630-P; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ElBenna J, 1997, J BIOL CHEM, V272, P17204, DOI 10.1074/jbc.272.27.17204; Escriou V, 1996, BIOCHEM BIOPH RES CO, V219, P930, DOI 10.1006/bbrc.1996.0335; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fuchs A, 1997, EUR J BIOCHEM, V249, P531, DOI 10.1111/j.1432-1033.1997.00531.x; GARCIA RC, 1986, BIOCHEM J, V239, P647, DOI 10.1042/bj2390647; GARCIA RC, 1988, BIOCHEM J, V252, P901, DOI 10.1042/bj2520901; GODFREY RW, 1987, J CELL BIOL, V104, P925, DOI 10.1083/jcb.104.4.925; Hantgan RR, 1998, BLOOD, V92, P2064, DOI 10.1182/blood.V92.6.2064.418k07_2064_2074; HEYWORTH PG, 1989, J BIOL CHEM, V264, P14935; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; Hsu MF, 1997, BRIT J PHARMACOL, V120, P917, DOI 10.1038/sj.bjp.0700974; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; Karlsson A, 2000, J LEUKOCYTE BIOL, V67, P396, DOI 10.1002/jlb.67.3.396; Kent JD, 1996, J IMMUNOL, V157, P4641; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; Korchak HM, 1998, J BIOL CHEM, V273, P27292, DOI 10.1074/jbc.273.42.27292; Koshkin V, 1995, BBA-BIOENERGETICS, V1232, P225, DOI 10.1016/0005-2728(95)00123-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; Li Q, 1999, J BIOL CHEM, V274, P3764, DOI 10.1074/jbc.274.6.3764; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; McPhail LC, 1999, BBA-MOL CELL BIOL L, V1439, P277, DOI 10.1016/S1388-1981(99)00100-6; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; MCPHAIL LC, 1983, J CLIN INVEST, V72, P192, DOI 10.1172/JCI110957; MCPHAIL LC, 1995, P NATL ACAD SCI USA, V92, P7931, DOI 10.1073/pnas.92.17.7931; MCPHAIL LC, 1993, NATURAL IMMUNE SYSTE, P63; MESHULAM T, 1988, BIOCHEM BIOPH RES CO, V150, P532, DOI 10.1016/0006-291X(88)90426-3; MESHULAM T, 1995, J LEUKOCYTE BIOL, V57, P842, DOI 10.1002/jlb.57.6.842; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; Nixon JB, 1999, J IMMUNOL, V163, P4574; OKAMURA N, 1988, BLOOD, V72, P811; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PAI JK, 1988, J BIOL CHEM, V263, P12472; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; QUINN MT, 1995, METHOD ENZYMOL, V255, P476; QUINN MT, 1992, J BIOL CHEM, V267, P7303; Regier DS, 1999, J BIOL CHEM, V274, P36601, DOI 10.1074/jbc.274.51.36601; ROOS D, 1981, J IMMUNOL, V126, P433; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Sergeant S, 1997, J IMMUNOL, V159, P2877; SOZZANI S, 1994, BLOOD, V84, P3895, DOI 10.1182/blood.V84.11.3895.bloodjournal84113895; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; TAYLOR WR, 1993, PROTEIN SCI, V2, P1675, DOI 10.1002/pro.5560021013; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; Waite KA, 1997, J BIOL CHEM, V272, P15569, DOI 10.1074/jbc.272.24.15569; Wayne DW., 1999, BIOSTATISTICS FDN AN, V7 ed	80	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28406	28412		10.1074/jbc.M004703200	http://dx.doi.org/10.1074/jbc.M004703200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893420	hybrid			2022-12-27	WOS:000089330700011
J	Rhodes, A; Deakin, A; Spaull, J; Coomber, B; Aitken, A; Life, P; Rees, S				Rhodes, A; Deakin, A; Spaull, J; Coomber, B; Aitken, A; Life, P; Rees, S			The generation and characterization of antagonist RNA aptamers to human oncostatin M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; IN-VITRO SELECTION; HUMAN SYNOVIAL FIBROBLASTS; LEUKEMIA-INHIBITORY FACTOR; ACUTE-PHASE PROTEINS; EXPONENTIAL ENRICHMENT; VASCULAR-PERMEABILITY; SYSTEMATIC EVOLUTION; RHEUMATOID-ARTHRITIS; NEUTROPHIL ELASTASE	Oncostatin M (OSM) is a multifunctional member of the interleukin-6 cytokine family. OSM has been implicated as a powerful proinflammatory mediator and may represent a potentially important, novel therapeutic opportunity for treatment of established rheumatoid arthritis. To further investigate the role of OSM in inflammatory disorders, we have isolated a series of RNA aptamers that bind specifically to human OSM, The highest affinity aptamer, designated ADR58, has been characterized in a series of in vitro and cell based assays. ADR58 has an affinity of 7 nm for human OSM, and it can antagonize OSM binding to the gp130 receptor and specifically antagonize OSM mediated signaling. The aptamer has been truncated in length to 33 bases, all pyrimidine positions are substituted with 2' fluorine, and 14 of 18 purine positions have been substituted with 2' O-methyl to increase stability toward nucleases, This truncated, modified form of ADR58 retains complete affinity and functional activity for OSM, This aptamer may be used as a tool to further investigate the role of OSM in inflammatory disorders and may also have role as a therapeutic agent.	Glaxo Wellcome Res & Dev Ltd, Mol Discovery Dept, Stevenage SG1 2NY, Herts, England; Glaxo Wellcome Res & Dev Ltd, In Vitro Pharmacol Dept, Stevenage SG1 2NY, Herts, England; Glaxo Wellcome Res & Dev Ltd, Dept Comparat Pathol, Stevenage SG1 2NY, Herts, England; Glaxo Wellcome Res & Dev Ltd, Chem & Analyt Technol Dept, Stevenage SG1 2NY, Herts, England; Glaxo Wellcome Res & Dev Ltd, Dept Mol Pharmacol, Stevenage SG1 2NY, Herts, England	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Rhodes, A (corresponding author), Glaxo Wellcome Res & Dev Ltd, Mol Discovery Dept, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.	adr7003@glaxowellcome.co.uk	Rhodes, Andrew/G-4265-2011	Rhodes, Andrew/0000-0002-8737-574X				ADAMS SM, 1991, FOCUS, V13, P56; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BROWN TJ, 1991, J IMMUNOL, V147, P2175; CAWSTON TE, 1995, BIOCHEM BIOPH RES CO, V215, P377, DOI 10.1006/bbrc.1995.2476; Charlton J, 1997, BIOCHEMISTRY-US, V36, P3018, DOI 10.1021/bi962669h; Charlton J, 1997, CHEM BIOL, V4, P809, DOI 10.1016/S1074-5521(97)90114-9; Davis KA, 1996, NUCLEIC ACIDS RES, V24, P702, DOI 10.1093/nar/24.4.702; Drolet DW, 1996, NAT BIOTECHNOL, V14, P1021, DOI 10.1038/nbt0896-1021; Drolet DW, 1999, COMB CHEM HIGH T SCR, V2, P271; FIRESTEIN G S, 1992, Current Opinion in Rheumatology, V4, P348, DOI 10.1097/00002281-199206000-00012; Fitzwater T, 1996, METHOD ENZYMOL, V267, P275; Floege J, 1999, AM J PATHOL, V154, P169, DOI 10.1016/S0002-9440(10)65263-7; FRITZBERG AR, 1986, J NUCL MED, V27, P111; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Green LS, 1996, BIOCHEMISTRY-US, V35, P14413, DOI 10.1021/bi961544+; GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2; GREEN R, 1991, Methods (Orlando), V2, P75, DOI 10.1016/S1046-2023(05)80127-6; HAMILTON JA, 1991, BIOCHEM BIOPH RES CO, V180, P652, DOI 10.1016/S0006-291X(05)81115-5; Hnatowich D J, 1996, Q J Nucl Med, V40, P202; Hnatowich DJ, 1998, J NUCL MED, V39, P56; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; Hui W, 1997, ANN RHEUM DIS, V56, P184, DOI 10.1136/ard.56.3.184; JELLINEK D, 1993, P NATL ACAD SCI USA, V90, P11227, DOI 10.1073/pnas.90.23.11227; Kerr C, 1999, J INTERF CYTOK RES, V19, P1195, DOI 10.1089/107999099313145; Kitchen D, 1998, BIOCHEMISTRY-US, V37, P10581, DOI 10.1021/bi9727444; Kubo Atsushi, 1998, Kaku Igaku, V35, P909; Langdon C, 1997, ARTHRITIS RHEUM-US, V40, P2139, DOI 10.1002/art.1780401207; Mannironi C, 1997, BIOCHEMISTRY-US, V36, P9726, DOI 10.1021/bi9700633; McDonnell J, 1998, BRIT J PHARMACOL, V125, P717, DOI 10.1038/sj.bjp.0702139; Modur V, 1997, J CLIN INVEST, V100, P158, DOI 10.1172/JCI119508; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; NIEUWLANDT D, 1995, BIOCHEMISTRY-US, V34, P5651, DOI 10.1021/bi00016a041; OConnell D, 1996, P NATL ACAD SCI USA, V93, P5883, DOI 10.1073/pnas.93.12.5883; Okamoto H, 1997, ARTHRITIS RHEUM, V40, P1096, DOI 10.1002/art.1780400614; Pallela VR, 1999, J NUCL MED, V40, P352; Richards CD, 1997, J IMMUNOL, V159, P2431; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TAILLEFER R, 1995, EUR J NUCL MED, V22, P453, DOI 10.1007/BF00839060; Tucker CE, 1999, J CHROMATOGR B, V732, P203, DOI 10.1016/S0378-4347(99)00285-6; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Uphoff KW, 1996, CURR OPIN STRUC BIOL, V6, P281, DOI 10.1016/S0959-440X(96)80045-5; Willis MC, 1998, BIOCONJUGATE CHEM, V9, P573, DOI 10.1021/bc980002x; Yao LB, 1996, J EXP MED, V184, P81, DOI 10.1084/jem.184.1.81; ZYBACK CP, 1999, ARTHRITIS RHEUM, V42, pS123	46	61	71	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28555	28561		10.1074/jbc.M002981200	http://dx.doi.org/10.1074/jbc.M002981200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10882721	hybrid			2022-12-27	WOS:000089330700031
J	Szaszi, K; Kurashima, K; Kapus, A; Paulsen, A; Kaibuchi, K; Grinstein, S; Orlowski, J				Szaszi, K; Kurashima, K; Kapus, A; Paulsen, A; Kaibuchi, K; Grinstein, S; Orlowski, J			RhoA and Rho kinase regulate the epithelial Na+/H+ exchanger NHE3 - Role of myosin light chain phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; RENAL BRUSH-BORDER; PROTEIN-KINASE; FOCAL ADHESIONS; H+ EXCHANGE; MEDIATED INHIBITION; MAMMALIAN-CELLS; ERM PROTEINS; CYTOSKELETON; ISOFORM	The activity of the Na+/H+ exchanger NHE3 isoform, which is found primarily in epithelial cells, is sensitive to the state of actin polymerization. Actin assembly, in turn, is controlled by members of the small GTPase Rho family, namely Rad, Cdc42, and RhoA We therefore investigated the possible role of these GTPases in modulating NHE3 activity. Cells stably expressing NHE3 were transiently transfected with inhibitory forms of Rad, Cdc42, or RhoA and transport activity was assessed using microfluorimetry. NHE3 activity was not adversely affected by either dominant-negative Rad or Cdc42. By contrast, the inhibitory form of RhoA greatly depressed NHE3 activity, without noticeably altering its subcellular distribution. NHE3 activity was equally reduced by inhibiting p160 Rho-associated kinase I (ROK), a downstream effector of RhoA, with the selective antagonist Y-27632 and a dominant-negative form of ROK. Furthermore, inhibition of ROK reduced the phosphorylation of myosin light chain. A comparable net dephosphorylation was achieved by the myosin light chain kinase inhibitor ML9, which similarly inhibited NHE3. These data suggest that optimal NHE3 activity requires a functional RhoA-ROK signaling pathway which acts, at least partly, by controlling the phosphorylation of myosin light chain and, ultimately, the organization of the actin cytoskeleton.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; Toronto Hosp, Dept Surg, Toronto, ON M5G 1L7, Canada; Univ Toronto, Toronto, ON M5G 1L7, Canada; Nara Inst Sci & Technol, Div Signal Transduct, Nara 6300101, Japan	McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Nara Institute of Science & Technology	Orlowski, J (corresponding author), McGill Univ, Dept Physiol, 3655 Promenade Sir William Osler,McIntyre Med Sci, Montreal, PQ H3G 1Y6, Canada.		Szaszi, Katalin/J-7522-2012	Orlowski, John/0000-0001-7371-175X; Szaszi, Katalin/0000-0002-2490-8422				Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; BOIVIN D, 1995, AM J PHYSIOL-RENAL, V269, pF180, DOI 10.1152/ajprenal.1995.269.2.F180; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chow CW, 1999, J BIOL CHEM, V274, P37551, DOI 10.1074/jbc.274.53.37551; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; Gan BS, 1998, AM J PHYSIOL-CELL PH, V275, pC1158, DOI 10.1152/ajpcell.1998.275.4.C1158; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; KAPUS A, 1994, J BIOL CHEM, V269, P23544; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kotani H, 1997, ONCOGENE, V14, P1705, DOI 10.1038/sj.onc.1200998; Kreisberg JI, 1997, AM J PHYSIOL-RENAL, V273, pF283, DOI 10.1152/ajprenal.1997.273.2.F283; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; Leung T, 1996, MOL CELL BIOL, V16, P5313; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; Ramakers GJA, 1998, EXP CELL RES, V245, P252, DOI 10.1006/excr.1998.4224; RESHKIN SJ, 1992, AM J PHYSIOL, V262, pF572, DOI 10.1152/ajprenal.1992.262.4.F572; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; SOLEIMANI M, 1994, J BIOL CHEM, V269, P15613; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vexler ZS, 1996, J BIOL CHEM, V271, P22281, DOI 10.1074/jbc.271.37.22281; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	45	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28599	28606		10.1074/jbc.M001193200	http://dx.doi.org/10.1074/jbc.M001193200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893221	hybrid			2022-12-27	WOS:000089330700037
J	Jefford, G; Dubreuil, RR				Jefford, G; Dubreuil, RR			Receptor clustering drives polarized assembly of ankyrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; MEMBRANE SKELETON; STRUCTURAL REQUIREMENTS; DROSOPHILA-MELANOGASTER; ALPHA-SPECTRIN; BETA-SPECTRIN; BINDING-SITES; L1 FAMILY; NEUROFASCIN; PROTEIN	Expression of the L1 family cell adhesion molecule neuroglian in Drosophila S2 cells leads to cell aggregation and polarized ankyrin accumulation at sites of cell-cell contact. Thus neuroglian adhesion generates a spatial cue for polarized assembly of ankyrin and the spectrin cytoskeleton. Here we characterized a chimera of the extracellular and transmembrane domains of rat CD2 fused to the cytoplasmic domain of neuroglian, The chimera was used to test the hypothesis that clustering of neuroglian at sites of adhesion generates the signal that activates ankyrin binding. Abundant expression of the chimera at the plasma membrane was not a sufficient cue to drive ankyrin assembly, since ankyrin remained diffusely distributed throughout the cytoplasm of CD2-neuroglian-expressing cells. However, ankyrin became highly enriched at sites of antibody-induced capping of CD2-neuroglian. Spectrin codistributed with ankyrin at capped sites. A green fluorescent protein-tagged ankyrin was used to monitor ankyrin distribution in Living cells. Enhanced green fluorescent protein-ankyrin behaved identically to antibody-stained endogenous ankyrin, proving that the polarized accumulation of ankyrin was not an artifact of fixing and staining cells. We propose a model in which clustering of neuroglian induces a conformational change in the cytoplasmic domain that drives polarized assembly of the spectrin cytoskeleton.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Chicago	Dubreuil, RR (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St, Chicago, IL 60637 USA.				NIGMS NIH HHS [GM49301] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049301] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT V, 1992, J BIOL CHEM, V267, P8703; Bennett V, 1997, SOC GEN PHY, V52, P107; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BYERS TJ, 1989, J CELL BIOL, V109, P1633, DOI 10.1083/jcb.109.4.1633; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DUBREUIL R, 1987, J CELL BIOL, V105, P2095, DOI 10.1083/jcb.105.5.2095; DUBREUIL RR, 1994, P NATL ACAD SCI USA, V91, P10285, DOI 10.1073/pnas.91.22.10285; Dubreuil RR, 2000, J CELL BIOL, V149, P647, DOI 10.1083/jcb.149.3.647; Dubreuil RR, 1997, SOC GEN PHY, V52, P91; Dubreuil RR, 1997, MOL BIOL CELL, V8, P1933, DOI 10.1091/mbc.8.10.1933; Dubreuil RR, 1996, J CELL BIOL, V133, P647, DOI 10.1083/jcb.133.3.647; DUNINBORKOWSKI OM, 1995, DEV BIOL, V168, P689, DOI 10.1006/dbio.1995.1115; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; Hortsch M, 1998, J CELL BIOL, V142, P251, DOI 10.1083/jcb.142.1.251; HORTSCH M, 1995, J BIOL CHEM, V270, P18809, DOI 10.1074/jbc.270.32.18809; Hortsch M, 1998, CELL ADHES COMMUN, V5, P61, DOI 10.3109/15419069809005599; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kaplan MR, 1997, NATURE, V386, P724, DOI 10.1038/386724a0; LEE JK, 1993, J CELL BIOL, V123, P1797, DOI 10.1083/jcb.123.6.1797; Li J, 1996, J MOL BIOL, V263, P209, DOI 10.1006/jmbi.1996.0570; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MCCLOSKEY MA, 1986, J CELL BIOL, V102, P2185, DOI 10.1083/jcb.102.6.2185; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; PODACK ER, 1991, ANNU REV CELL BIOL, V7, P479, DOI 10.1146/annurev.cellbio.7.1.479; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Scotland P, 1998, J CELL BIOL, V143, P1305, DOI 10.1083/jcb.143.5.1305; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Tuvia S, 1997, P NATL ACAD SCI USA, V94, P12957, DOI 10.1073/pnas.94.24.12957; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Zhang X, 1998, J BIOL CHEM, V273, P30785, DOI 10.1074/jbc.273.46.30785; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	36	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27726	27732						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871626				2022-12-27	WOS:000089197100029
J	Uddin, S; Lekmine, F; Sharma, N; Majchrzak, B; Mayer, I; Young, PR; Bokoch, GM; Fish, EN; Platanias, LC				Uddin, S; Lekmine, F; Sharma, N; Majchrzak, B; Mayer, I; Young, PR; Bokoch, GM; Fish, EN; Platanias, LC			The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of stat proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VAV PROTOONCOGENE PRODUCT; MEDIATES TYROSINE PHOSPHORYLATION; CELL ANTIGEN RECEPTOR; P38 MAP KINASE; GENE-EXPRESSION; T-LYMPHOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; SIGNALING PATHWAYS; I INTERFERONS	The p38 mitogen-activated protein (MAP) kinase is activated during engagement of the type I interferon (TFN) receptor and mediates signals essential for IFN alpha-dependent transcriptional activation via interferon-stimulated response elements without affecting formation of the ISGF3 complex. In the present study, we provide evidence that the small GTPase Rad is activated in a type I IFN-dependent manner and that its function is required for downstream engagement of the p38 MAP kinase pathway. We also demonstrate that p38 is required for IFN alpha-dependent gene transcription via GAS elements and regulates activation of the promoter of the PML gene that mediates growth inhibitory responses. In studies to determine whether the regulatory effects of p38 are mediated by serine phosphorylation of Stat1 or Stat3, we found that the p38 kinase inhibitors SB203580 or SB202190 or overexpression of a dominant negative p38 mutant do not inhibit phosphorylation of Stat1 or Stat3 on Ser-727 in several IFN alpha-sensitive cell lines. Altogether these data demonstrate that the Rac1/p38 MAP kinase signaling cascade plays a critical role in type I IFN signaling, functioning in cooperation with the Stat-pathway, to regulate transcriptional regulation of IFN alpha-sensitive genes and generation of growth inhibitory responses.	Univ Illinois, MBRB, Hematol Oncol Sect, Chicago, IL 60607 USA; W Side Vet Adm Hosp, Chicago, IL 60607 USA; Univ Toronto, Univ Hlth Network, Toronto Res Inst, Div Cell & Mol Biol, Toronto, ON M5S 3E2, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 3E2, Canada; Dupont Pharmaceut, Dept Cardiovasc Dis, Wilmington, DE 19880 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; DuPont; Scripps Research Institute; Scripps Research Institute	Platanias, LC (corresponding author), Univ Illinois, MBRB, Hematol Oncol Sect, MC-734,Rm 3150,900 S Ashland Ave, Chicago, IL 60607 USA.			Uddin, Shahab/0000-0003-1886-6710	NCI NIH HHS [CA77816, CA73381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA073381, R01CA077816] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 2000, BIOCHEM BIOPH RES CO, V267, P692, DOI 10.1006/bbrc.1999.1978; Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Ghislain JJ, 1996, J BIOL CHEM, V271, P12408, DOI 10.1074/jbc.271.21.12408; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Gollob JA, 1999, J IMMUNOL, V162, P4472; Gotoh A, 1996, BLOOD, V88, P138; Gringhuis SI, 1998, MOL CELL BIOL, V18, P1725, DOI 10.1128/MCB.18.3.1725; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Kuroki M, 1999, BIOCHEM J, V341, P691, DOI 10.1042/0264-6021:3410691; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Micouin A, 1998, EUR CYTOKINE NETW, V9, P356; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Salojin KV, 1999, J IMMUNOL, V163, P844; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Stadler M, 1995, ONCOGENE, V11, P2565; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; Uddin S, 1997, FEBS LETT, V403, P31, DOI 10.1016/S0014-5793(97)00023-9; WEN Z, 1995, CELL, V28, P241; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	57	168	171	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27634	27640						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10878008				2022-12-27	WOS:000089197100016
J	Chikazu, D; Hakeda, Y; Ogata, N; Nemoto, K; Itabashi, A; Takato, T; Kumegawa, M; Nakamura, K; Kawaguchi, H				Chikazu, D; Hakeda, Y; Ogata, N; Nemoto, K; Itabashi, A; Takato, T; Kumegawa, M; Nakamura, K; Kawaguchi, H			Fibroblast growth factor (FGF)-2 directly stimulates mature osteoclast function through activation of FGF receptor 1 and p42/p44 MAP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLASTIC MC3T3-E1 CELLS; MESSENGER-RNA LEVELS; BONE-RESORPTION; PROTEIN-KINASE; CATHEPSIN-K; MATRIX METALLOPROTEINASE-9; MOLECULAR-CLONING; TYROSINE KINASE; IN-VITRO; C-SRC	We previously reported that fibroblast growth factor-2 (FGF-S) acts not only on osteoblasts 60 stimulate osteoclastic bone resorption indirectly but also on mature osteoclasts directly. In this study, we investigated the mechanism of this direct action of FGF-S on mature osteoclasts using mouse and rabbit osteoclast culture systems. FGF-S stimulated pit formation resorbed by isolated rabbit osteoclasts moderately from low concentrations (greater than or equal to 10(-12) M)) whereas at high concentrations (greater than or equal to 10(-9) d it showed stimulation on pit formation resorbed by unfractionated bone cells very potently. FGF-S (greater than or equal to 10(-12) M) also increased cathepsin K and MMP-9 mRNA levels in mouse and rabbit osteoclasts. Among FGF receptors (FGFR1 to 4) only FGFR1 was detected on isolated mouse osteoclasts, whereas all FGFRs were identified on mouse osteoblasts. FGF-P (greater than or equal to 10(-12) M) upregulated the phosphorylation of cellular proteins, including p42/p44 mitogen-activated protein (MAP) kinase, and increased the kinase activity of immunoprecipitated FGFR1 in mouse osteoclasts. The stimulation of FGF-2 on mouse and rabbit osteoclast functions was abrogated by PD-98059, a specific inhibitor of p42/p44 MAP kinase. These results strongly suggest that FGF-2 acts directly on mature osteoclasts through activation of FGFR1 and p42/p44 MAP kinase, causing the stimulation of bone resorption at physiological or pathological concentrations.	Univ Tokyo, Grad Sch Med, Dept Orthopaed Surg, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Oral & Maxillofacial Surg, Tokyo 1138655, Japan; Saitama Med Sch, Clin Lab, Iruma, Saitama 3500495, Japan; Meikai Univ, Sch Dent, Dept Oral Anat, Sakado, Saitama 3500248, Japan	University of Tokyo; University of Tokyo; Saitama Medical University; Meikai University	Kawaguchi, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Orthopaed Surg, Hongo 7-3-1, Tokyo 1138655, Japan.	kawaguchi-ort@h.u-tokyo.ac.jp						AKATSU T, 1992, J BONE MINER RES, V7, P1297; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ASPENBERG P, 1989, ACTA ORTHOP SCAND, V60, P473, DOI 10.3109/17453678909149323; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; Baron R, 1996, REV RHUM, V63, P633; CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490; Chikazu D, 1999, J BONE MINER RES, V14, pS360; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1539, DOI 10.1210/endo-124-3-1539; Hurley MM, 1998, BONE, V22, P309, DOI 10.1016/S8756-3282(97)00292-5; HURLEY MM, 1993, J BIOL CHEM, V268, P5588; HURLEY MM, 1994, J BIOL CHEM, V269, P9392; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790; Inui T, 1997, J BIOL CHEM, V272, P8109, DOI 10.1074/jbc.272.13.8109; JIMI E, 1995, ENDOCRINOLOGY, V136, P808, DOI 10.1210/en.136.2.808; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kameda T, 1996, BIOCHEM BIOPH RES CO, V220, P515, DOI 10.1006/bbrc.1996.0436; Kato T, 1998, J ORTHOP RES, V16, P654, DOI 10.1002/jor.1100160605; KAWAGUCHI H, 1994, ENDOCRINOLOGY, V135, P774, DOI 10.1210/en.135.2.774; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140; Kawaguchi H, 2000, J BONE MINER RES, V15, P466, DOI 10.1359/jbmr.2000.15.3.466; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kozawa O, 1999, J CELL BIOCHEM, V74, P479, DOI 10.1002/(SICI)1097-4644(19990901)74:3<479::AID-JCB15>3.3.CO;2-0; LANDGREN E, 1995, ONCOGENE, V10, P2027; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Manabe N, 1999, RHEUMATOLOGY, V38, P714, DOI 10.1093/rheumatology/38.8.714; Nakagawa N, 1999, BIOCHEM BIOPH RES CO, V265, P158, DOI 10.1006/bbrc.1999.1601; Nakamura K, 1997, J ORTHOPAED RES, V15, P307, DOI 10.1002/jor.1100150222; NAKAMURA T, 1995, ENDOCRINOLOGY, V136, P1276, DOI 10.1210/en.136.3.1276; Nakamura T, 1998, J BONE MINER RES, V13, P942, DOI 10.1359/jbmr.1998.13.6.942; Nakamura YS, 1998, STEM CELLS, V16, P229, DOI 10.1002/stem.160229; OKADA Y, 1995, LAB INVEST, V72, P311; Okazaki H, 1999, CALCIFIED TISSUE INT, V64, P542, DOI 10.1007/s002239900646; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RODAN SB, 1989, J BIOL CHEM, V264, P19934; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; Sato T, 1998, J BONE MINER RES, V13, P59, DOI 10.1359/jbmr.1998.13.1.59; Sato T, 1997, J CELL SCI, V110, P589; Schwartz M A, 1992, Prog Med Chem, V29, P271, DOI 10.1016/S0079-6468(08)70011-0; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SIMMONS HA, 1991, J BONE MINER RES, V6, P1301; Suzuki A, 1996, J CELL BIOCHEM, V63, P491, DOI 10.1002/(SICI)1097-4644(19961215)63:4<491::AID-JCB10>3.0.CO;2-H; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; TEZUKA K, 1994, J BIOL CHEM, V269, P15006; TEZUKA K, 1992, BONE MINER, V17, P347; Votta BJ, 1997, J BONE MINER RES, V12, P1396, DOI 10.1359/jbmr.1997.12.9.1396; Webster MK, 1996, MOL CELL BIOL, V16, P4081; ZHAN X, 1994, J BIOL CHEM, V269, P20221	55	87	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31444	31450		10.1074/jbc.M910132199	http://dx.doi.org/10.1074/jbc.M910132199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896947	hybrid			2022-12-27	WOS:000089762700098
J	Nelson, SW; Choe, JY; Honzatko, RB; Fromm, HJ				Nelson, SW; Choe, JY; Honzatko, RB; Fromm, HJ			Mutations in the hinge of a dynamic loop broadly influence functional properties of fructose-1,6-bisphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG-KIDNEY FRUCTOSE-1,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATE; CRYSTAL-STRUCTURE; LIVER FRUCTOSE-1,6-BISPHOSPHATASE; AMP INHIBITION; MECHANISM; BISPHOSPHATASE; 6-PHOSPHATE; RESOLUTION; TRANSITION	Loop 52-72 of porcine fructose-1,6-bisphosphatase may play a central role in the mechanism of catalysis and allosteric inhibition by AMP. The loop pivots between different conformational states about a hinge located at residues 50 and 51. The insertion of proline separately at positions 50 and 51 reduces k(cat) by up to 3-fold, with no effect on the K-m for fructose 1,6-bisphosphate. The K-a for Mg2+ in the Lys(50) --> Pro mutant increases similar to 15-fold, whereas that for the Ala(51) --> Pro mutant is unchanged. Although these mutants retain wildtype binding affinity for AMP and the fluorescent AMP analog 2'(3')-O-(trinitrophenyl) adenosine 5'-monophosphate, the K-i for AMP increases 8000- and 280-fold in the position 50 and 51 mutants, respectively. In fact, the mutation Lys(50) --> Pro changes the mechanism of AMP inhibition with respect to Mg2+ from competitive to noncompetitive and abolishes K+ activation. The K-i for fructose 2,6-bisphosphate increases similar to 20- and 30-fold in the Lys(50) --> Pro and Ala(51) --> Pro mutants, respectively. Fluorescence from a tryptophan introduced by the mutation of Tyr(57) suggests an altered conformational state for Loop 52-72 due to the proline at position 50. Evidently, the Pro(50) mutant binds AMP with high affinity at the allosteric site, but the mechanism of allosteric regulation of catalysis has been disabled.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Fromm, HJ (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, XPLOR VERSION 3 1; Carcamo JG, 2000, EUR J BIOCHEM, V267, P2242, DOI 10.1046/j.1432-1327.2000.01227.x; Choe JY, 2000, BIOCHEMISTRY-US, V39, P8565, DOI 10.1021/bi000574g; Choe JY, 1998, BIOCHEMISTRY-US, V37, P11441, DOI 10.1021/bi981112u; HORECKER BL, 1975, ADV ENZYMOL RAMB, V42, P193; Iversen LF, 1997, PROTEIN SCI, V6, P971, DOI 10.1002/pro.5560060503; KE HM, 1991, P NATL ACAD SCI USA, V88, P2989, DOI 10.1073/pnas.88.8.2989; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurbanov FT, 1998, J BIOL CHEM, V273, P17511, DOI 10.1074/jbc.273.28.17511; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P52; LEATHERBARROW RJ, 1987, ENZFITTER, P13; LUI F, 1990, J BIOL CHEM, V265, P7401; LUI F, 1988, J BIOL CHEM, V263, P9122; MARCUS F, 1982, P NATL ACAD SCI-BIOL, V79, P7161, DOI 10.1073/pnas.79.23.7161; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NELSON SW, 2000, IN PRESS BIOCHEMISTR; NIMMO HG, 1975, EUR J BIOCHEM, V58, P567, DOI 10.1111/j.1432-1033.1975.tb02407.x; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1981, J BIOL CHEM, V256, P1489; Schaftingen EV, 1981, P NATL ACAD SCI USA, V78, P2861; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; Shyur LF, 1996, J BIOL CHEM, V271, P33301, DOI 10.1074/jbc.271.52.33301; Shyur LF, 1997, J BIOL CHEM, V272, P26295, DOI 10.1074/jbc.272.42.26295; SHYUR LF, 1995, J BIOL CHEM, V270, P123; STONE SR, 1980, BIOCHEMISTRY-US, V19, P620, DOI 10.1021/bi00545a003; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; Van Schaftingen E., 1987, ADV ENZYMOL RELAT AR, V59, P45; XUE YF, 1994, P NATL ACAD SCI USA, V91, P12482, DOI 10.1073/pnas.91.26.12482; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	33	24	24	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29986	29992		10.1074/jbc.M000473200	http://dx.doi.org/10.1074/jbc.M000473200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896931	hybrid, Green Published			2022-12-27	WOS:000089577900011
J	Fujino, H; Pierce, KL; Srinivasan, D; Protzman, CE; Krauss, AH; Woodward, DF; Regan, JW				Fujino, H; Pierce, KL; Srinivasan, D; Protzman, CE; Krauss, AH; Woodward, DF; Regan, JW			Delayed reversal of shape change in cells expressing FPB prostanoid receptors - Possible role of receptor resensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; KINASE-C; ISOFORMS; CLONING; DESENSITIZATION; PHOSPHORYLATION; INVOLVEMENT; TAIL	Prostaglandin F-2 alpha (PGF(2 alpha)) receptors are G-protein-coupled receptors consisting of two alternative mRNA splice variants, named FPA and FPB. As compared with the FPA isoform, the FPB isoform lacks the last 46 amino acids of the carboxyl terminus and, therefore, represents a truncated version of the FPA. We recently found (Pierce, K. L,, Fujino, H., Srinivasan, D., and Began, J. W. (1999) J, Biol; Chem. 274, 35944-35949) that stimulation of both isoforms with PGF(2 alpha) leads to activation of a Rho signaling pathway, resulting in tyrosine phosphorylation of p125 focal adhesion kinase, formation of actin stress fibers, and cell rounding, Although the activation of Rho and subsequent cell rounding occur at a similar rate for both isoforms, we now report that following the removal of PGF(2 alpha) the reversal of cell rounding is much slower for cells expressing the FPB isoform as compared with the FPA isoform, Thus, in HEK-293 cells that stably express the FPA isoform, the reversal of cell rounding appears to be complete after 1 h, whereas for FPB-expressing cells there is essentially no reversal even after 2 h, Similarly, the disappearance of stress fibers and dephosphorylation of p125 focal adhesion kinase following removal of agonist are much slower in FPB-expressing cells than in FPA-expressing cells. The mechanism of this differential reversal appears to involve a difference in receptor resensitization following the removal of agonist, Based upon whole cell radioligand binding, agonist-induced stimulation of inositol phosphate formation, and mobilization. of intracellular Ca2+, the FPB isoform resensitizes more slowly than the FPA isoform, These findings suggest that the carboxyl terminus of the FPA is critical for resensitization and that the slower resensitization of the FPA isoform leads to prolonged signaling. This differential signaling distinguishes the FPA and FPB receptor isoforms and could be important toward understanding the physiological actions of PGF(2 alpha).	Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Allergan Inc, Dept Biol Sci, Irvine, CA 92713 USA	University of Arizona; Duke University; Howard Hughes Medical Institute; AbbVie; Allergan	Regan, JW (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.				NEI NIH HHS [EY11291] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011291] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bastepe M, 1999, BRIT J PHARMACOL, V126, P365, DOI 10.1038/sj.bjp.0702291; Chan BS, 1998, J BIOL CHEM, V273, P6689, DOI 10.1074/jbc.273.12.6689; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Fujino H, 2000, MOL PHARMACOL, V57, P353; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Habib A, 1997, J BIOL CHEM, V272, P7191, DOI 10.1074/jbc.272.11.7191; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Pierce KL, 1997, J BIOL CHEM, V272, P883, DOI 10.1074/jbc.272.2.883; Pierce KL, 1999, J BIOL CHEM, V274, P35944, DOI 10.1074/jbc.274.50.35944; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; REGAN JW, 1994, BRIT J PHARMACOL, V112, P377, DOI 10.1111/j.1476-5381.1994.tb13082.x; Smyth EM, 1998, J BIOL CHEM, V273, P23258, DOI 10.1074/jbc.273.36.23258	16	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29907	29914		10.1074/jbc.M003467200	http://dx.doi.org/10.1074/jbc.M003467200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893233	Green Submitted, hybrid			2022-12-27	WOS:000089439800099
J	Sueishi, M; Takagi, M; Yoneda, Y				Sueishi, M; Takagi, M; Yoneda, Y			The forkhead-associated domain of Ki-67 antigen interacts with the novel kinesin-like protein Hklp2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FHA DOMAIN; CELL-PROLIFERATION; NUCLEAR; LOCALIZATION; CHROMOSOMES	The Ki-67 antigen (pKi-67) is widely used as a cell proliferation marker protein. Its actual role in the cell cycle progression, however, is presently unclear. Using a two-hybrid screening in yeast, a novel protein, termed Hklp2 (human kinesin-like protein 2), was identified and shown to interact with the forkhead-associated (FHA) domain of pKi-67, Hklp2 has 1388 amino acids and shows a striking similarity (a 53% identity in amino acids) to Xklp2, a plus-end directed kinesin-like motor found in Xenopus, The interaction domain of Hklp2 was mapped to the portion that comprised residues 1017-1237 and that was phosphorylated in vitro by incubating with mitotic but not interphasic HeLa cell extracts. That the interaction was striking in the mitotic extract was also verified. In addition, immunofluorescence using specific antibodies revealed an association between pKi-67 and Hklp2 at the periphery of mitotic chromosomes, largely in close proximity to the centromeres, These findings suggest that pKi-67 is involved in the progression of mitosis via its interaction with Hklp2.	Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Yoneda, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.							ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Boleti H, 1996, CELL, V84, P49, DOI 10.1016/S0092-8674(00)80992-7; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FULLER MT, 1995, CELL, V81, P5, DOI 10.1016/0092-8674(95)90364-X; GERDES J, 1984, J IMMUNOL, V133, P1710; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Takagi M, 1999, J CELL SCI, V112, P2463; VERHEIJEN R, 1989, J CELL SCI, V92, P531; Yoda K, 1996, MOL CELL BIOL, V16, P5169	13	55	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28888	28892		10.1074/jbc.M003879200	http://dx.doi.org/10.1074/jbc.M003879200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878014	hybrid			2022-12-27	WOS:000089330700073
J	Blasing, OE; Westhoff, P; Svensson, P				Blasing, OE; Westhoff, P; Svensson, P			Evolution of C4 phosphoenolpyruvate carboxylase in Flaveria, a conserved serine residue in the carboxyl-terminal part of the enzyme is a major determinant for C4-specific characteristics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; TRINERVIA C-4; PRINGLEI C-3; PLANTS; PHOTOSYNTHESIS; LEAVES; GENES	C4 phosphoenolpyruvate carboxylases have evolved from ancestral C3 isoforms during the evolution of angiosperms and gained distinct kinetic and regulatory properties compared with the C3 isozymes, To identify amino acid residues and/or domains responsible for these C4-specific properties the C4 phosphoenolpyruvate carboxylase of Flaveria trinervia (C4) was compared with its orthologue in the closely related C3 plant Flaveria pringlei, Reciprocal enzyme chimera were constructed and the kinetic constants, K-0.5 and k(cat), as well as the Hill coefficient, h, were determined for the substrate phosphoenolpyruvate both in the presence and absence of the activator glucose B-phosphate. By this approach two regions were identified which determined most of the kinetic differences of the C4 and C3 ppcA phosphoenolpyruvate carboxylases with respect to the substrate PEP. In addition, the experiments suggest that the two regions do not act additively but interact with each other. The region between amino acids 296 and 437 is essential for activation by glucose 6-phosphate, The carboxyl-terminal segment between amino acids 645 and 966 contains a C4 conserved serine or a C3 invariant alanine at position 774 in the respective enzyme isoform. Site-directed mutagenesis shows that this position is a key determinant for the kinetic properties of the two isozymes.	Swedish Univ Agr Sci, Dept Plant Biol, S-75007 Uppsala, Sweden; Univ Dusseldorf, Inst Entwicklungs & Mol Biol Pflanzen, D-40225 Dusseldorf, Germany	Swedish University of Agricultural Sciences; Heinrich Heine University Dusseldorf	Svensson, P (corresponding author), Swedish Univ Agr Sci, Dept Plant Biol, POB 7080, S-75007 Uppsala, Sweden.							BAUWE H, 1986, PLANT PHYSIOL, V82, P695, DOI 10.1104/pp.82.3.695; Chollet R, 1996, ANNU REV PLANT PHYS, V47, P273, DOI 10.1146/annurev.arplant.47.1.273; CRETIN C, 1991, PLANT MOL BIOL, V17, P83, DOI 10.1007/BF00036808; Edwards G., 1987, BIOCH PLANTS, P275, DOI DOI 10.1016/B978-0-12-675410-0.50011-7; EHLERINGER JR, 1991, TRENDS ECOL EVOL, V6, P95, DOI 10.1016/0169-5347(91)90183-X; GAO Y, 1995, FEBS LETT, V375, P95, DOI 10.1016/0014-5793(95)01189-L; Gao Y, 1996, FEBS LETT, V392, P285, DOI 10.1016/0014-5793(96)00832-0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HATCH MD, 1987, BIOCHIM BIOPHYS ACTA, V895, P81, DOI 10.1016/S0304-4173(87)80009-5; HERMANS J, 1992, MOL GEN GENET, V234, P275, DOI 10.1007/BF00283848; HERMANS J, 1990, MOL GEN GENET, V224, P459, DOI 10.1007/BF00262441; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; INOUE M, 1989, J MOL BIOL, V208, P509, DOI 10.1016/0022-2836(89)90515-9; JIAO J, 1990, ARCH BIOCHEM BIOPHYS, V283, P300, DOI 10.1016/0003-9861(90)90646-G; Kai Y, 1999, P NATL ACAD SCI USA, V96, P823, DOI 10.1073/pnas.96.3.823; LEPINIEC L, 1994, PLANT SCI, V99, P111, DOI 10.1016/0168-9452(94)90168-6; MONSON RK, 1984, BIOSCIENCE, V34, P563, DOI 10.2307/1309599; MOORE PD, 1982, NATURE, V295, P647, DOI 10.1038/295647a0; POETSCH W, 1991, FEBS LETT, V292, P133, DOI 10.1016/0014-5793(91)80850-3; RAJAGOPALAN AV, 1994, PHOTOSYNTH RES, V39, P115, DOI 10.1007/BF00029380; Romeis T, 1999, PLANT CELL, V11, P273, DOI 10.1105/tpc.11.2.273; SABE H, 1984, GENE, V31, P279, DOI 10.1016/0378-1119(84)90222-1; Sambrook J., 2002, MOL CLONING LAB MANU; Svensson P, 1997, EUR J BIOCHEM, V246, P452, DOI 10.1111/j.1432-1033.1997.t01-1-00452.x; TERADA K, 1991, EUR J BIOCHEM, V202, P797, DOI 10.1111/j.1432-1033.1991.tb16435.x; TING IP, 1973, PLANT PHYSIOL, V51, P439, DOI 10.1104/pp.51.3.439	26	98	102	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27917	27923						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871630				2022-12-27	WOS:000089197100054
J	Filipe, SR; Pinho, MG; Tomasz, A				Filipe, SR; Pinho, MG; Tomasz, A			Characterization of the murMN operon involved in the synthesis of branched peptidoglycan peptides in Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEINS; STAPHYLOCOCCUS-AUREUS; METHICILLIN RESISTANCE; CROSS-BRIDGES; GENES; FEMAB; TRANSFORMATION; MUROPEPTIDES; SEPARATION; ENCODES	The murMN operon, recently identified in the genome of Streptococcus pneumoniae, encodes for enzymes involved in the synthesis of branched structured muropeptides in the pneumococcal peptidoglycan; inactivation of murMN causes production of a peptidoglycan composed exclusively of linear muropeptides and a virtually complete loss of resistance in penicillin-resistant strains (Filipe, S. R., and Tomasz, A. (2000) Proc. Natl. Acad Sci. U.S.A. 97, 4891-4896), The experiments described in this paper follow up these observations. Primer extension analysis was used to identify the putative promoter region of the murMN operon in penicillin-susceptible and -resistant strains. Selective inactivation of the murN gene in the penicillin-resistant strain Pen6 caused production of an unusual peptidoglycan that contained only single amino acid residues in the muropeptide branches, indicating that the product of murN was involved with the addition of the second amino acid and the product of murM was involved with the addition of the first amino acid (alanine or serine) to the peptidoglycan cross-bridge. Allelic replacement of the mosaic murM gene of strain Pen6 with murM of the penicillin-susceptible laboratory strain caused enrichment of the peptidoglycan in linear muropeptides, The findings suggest that the genetic determinant primarily controlling the synthesis of branched muropeptides in the pneumococcal peptidoglycan is murM.	Rockefeller Univ, Microbiol Lab, New York, NY 10021 USA; Univ Nova Lisboa, Inst Tecnol Quim & Biol, Mol Genet Unit, P-2780 Oeiras, Portugal	Rockefeller University; Universidade Nova de Lisboa	Tomasz, A (corresponding author), Rockefeller Univ, Microbiol Lab, 1230 York Ave, New York, NY 10021 USA.		Pinho, Mariana/B-9192-2008; Filipe, Sergio Raposo/B-9167-2008	Pinho, Mariana/0000-0002-7132-8842; Filipe, Sergio Raposo/0000-0002-4485-832X; Tomasz, Alexander/0000-0003-1520-1983	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037275] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI37275] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATHERTON ND, 1989, TECHNIQUES PROTEIN C, P273; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; CHEN JD, 1988, GENE, V64, P155, DOI 10.1016/0378-1119(88)90489-1; DOWSON CG, 1989, P NATL ACAD SCI USA, V86, P8842, DOI 10.1073/pnas.86.22.8842; Filipe SR, 2000, P NATL ACAD SCI USA, V97, P4891, DOI 10.1073/pnas.080067697; GARCIABUSTOS J, 1990, P NATL ACAD SCI USA, V87, P5414; GARCIABUSTOS JF, 1988, J BACTERIOL, V170, P2143, DOI 10.1128/jb.170.5.2143-2147.1988; GARCIABUSTOS JF, 1987, J BIOL CHEM, V262, P15400; GARCIABUSTOS JF, 1987, J BACTERIOL, V169, P447, DOI 10.1128/jb.169.2.447-453.1987; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; Grebe T, 1996, ANTIMICROB AGENTS CH, V40, P829, DOI 10.1128/AAC.40.4.829; HENZE U, 1993, J BACTERIOL, V175, P1612, DOI 10.1128/JB.175.6.1612-1620.1993; LAIBLE G, 1991, MOL MICROBIOL, V5, P1993, DOI 10.1111/j.1365-2958.1991.tb00821.x; MAIDHOF H, 1991, J BACTERIOL, V173, P3507, DOI 10.1128/jb.173.11.3507-3513.1991; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MARTIN C, 1992, EMBO J, V11, P3831, DOI 10.1002/j.1460-2075.1992.tb05475.x; Rohrer S, 1999, P NATL ACAD SCI USA, V96, P9351, DOI 10.1073/pnas.96.16.9351; Sambrook J., 2002, MOL CLONING LAB MANU; Severin A, 1996, J BACTERIOL, V178, P1788, DOI 10.1128/jb.178.7.1788-1792.1996; Severin A, 1996, J BACTERIOL, V178, P168, DOI 10.1128/jb.178.1.168-174.1996; Stranden AM, 1997, J BACTERIOL, V179, P9, DOI 10.1128/jb.179.1.9-16.1997; Sugai M, 1997, J BACTERIOL, V179, P4311, DOI 10.1128/jb.179.13.4311-4318.1997; Thumm G, 1997, MOL MICROBIOL, V23, P1251, DOI 10.1046/j.1365-2958.1997.2911657.x; TIRABY JG, 1973, P NATL ACAD SCI USA, V70, P3541, DOI 10.1073/pnas.70.12.3541; Tschierske M, 1999, FEMS MICROBIOL LETT, V171, P97, DOI 10.1016/S0378-1097(98)00586-2; Vollmer W, 2000, J BIOL CHEM, V275, P20496, DOI 10.1074/jbc.M910189199; Weber B, 2000, FEMS MICROBIOL LETT, V188, P81, DOI 10.1016/S0378-1097(00)00214-7; ZIGHELBOIM S, 1980, ANTIMICROB AGENTS CH, V17, P434, DOI 10.1128/AAC.17.3.434	29	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27768	27774						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869361				2022-12-27	WOS:000089197100035
J	Liu, J; Tian, J; Haas, M; Shapiro, JI; Askari, A; Xie, ZJ				Liu, J; Tian, J; Haas, M; Shapiro, JI; Askari, A; Xie, ZJ			Ouabain interaction with cardiac Na+/K+-ATPase initiates signal cascades independent of changes in intracellular Na+ and Ca2+ concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE GENES; ALPHA-SUBUNIT; SODIUM-IONS; HEART-CELLS; MYOCYTES; HYPERTROPHY; EXPRESSION; CALCIUM; NA+,K+-ATPASE; MITOCHONDRIA	We hare shown previously that partial inhibition of the cardiac myocyte Na+/K+-ATPase activates signal pathways that regulate myocyte growth and growth-related genes and that increases in intracellular Ca2+ concentration ([Ca2+](i)) and reactive oxygen species (ROS) are two essential second messengers within these pathways, The aim of this work was to explore the relation between [Ca2+](i) and ROS. When myocytes were in a Ca2+-free medium, ouabain caused no change in [Ca2+](i), but it increased ROS as it did when the cells were in a Ca2+-containing medium. Ouabain-induced increase in ROS also occurred under conditions where there was little or no change in [Na+](i). Exposure of myocytes in Ca2+-free medium to monensin did not increase ROS, Increase in protein tyrosine phosphorylation, an early event induced by ouabain, was also independent of changes in [Ca2+](i) and [Na+](i). Ouabain-induced generation of ROS in myocytes was antagonized by genistein, a dominant negative Ras, and myxothiazol/diphenyleneiodonium, indicating a mitochondrial origin for the Ras-dependent ROS generation. These findings, along with our previous data, indicate that increases in [Ca2+](i) and ROS in cardiac myocytes are induced by two parallel pathways initiated at the plasma membrane: One being the ouabain-altered transient interactions of a fraction of the Na+/K+-ATPase with neighboring proteins (Src, growth factor receptors, adaptor proteins, and Ras) leading to ROS generation, and the other, inhibition of the transport function of another fraction of the Na+/K+-ATPase leading to rise in [Ca2+](i). Evidently, the gene regulatory effects of ouabain in cardiac myocytes require the downstream collaborations of ROS and [Ca2+](i).	Med Coll Ohio, Dept Pharmacol, Toledo, OH 43614 USA; Med Coll Ohio, Dept Med, Toledo, OH 43614 USA		Xie, ZJ (corresponding author), Med Coll Ohio, Dept Pharmacol, 3035 Arlington Ave, Toledo, OH 43614 USA.				NHLBI NIH HHS [HL-36573, HL-63238] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063238, P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERA T, 1976, J PHARMACOL EXP THER, V199, P287; AKERA T, 1976, LIFE SCI, V18, P135, DOI 10.1016/0024-3205(76)90017-5; AKERA T, 1991, LIFE SCI, V48, P97, DOI 10.1016/0024-3205(91)90402-W; Alto LE, 2000, MOL CELL BIOCHEM, V207, P87, DOI 10.1023/A:1007046316277; BHOJANI IH, 1990, J MOL CELL CARDIOL, V22, P507, DOI 10.1016/0022-2828(90)90953-Y; Eble DM, 1998, AM J PHYSIOL-CELL PH, V274, pC1226, DOI 10.1152/ajpcell.1998.274.5.C1226; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; Eigel BN, 1999, AM J PHYSIOL-HEART C, V277, pH1817, DOI 10.1152/ajpheart.1999.277.5.H1817; EISNER DA, 1992, HEART CARDIOVASCULAR, V1, P863; FURMAN I, 1995, J BIOL CHEM, V270, P19120, DOI 10.1074/jbc.270.32.19120; Haas M, 2000, J BIOL CHEM, V275, P27832; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Huang LY, 1997, J MOL CELL CARDIOL, V29, P429, DOI 10.1006/jmcc.1996.0320; Huang LY, 1997, J MOL CELL CARDIOL, V29, P3157, DOI 10.1006/jmcc.1997.0546; Jansen MA, 1998, AM J PHYSIOL-HEART C, V274, pH846, DOI 10.1152/ajpheart.1998.274.3.H846; KIM D, 1984, J PHARMACOL EXP THER, V231, P326; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu JA, 2000, BIOPHYS J, V78, p79A; MURPHY E, 1985, J MOL CELL CARDIOL, V17, P221, DOI 10.1016/S0022-2828(85)80005-5; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; Perry G, 1997, NEW ENGL J MED, V336, P525; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RuizLarrea MB, 1997, FREE RADICAL RES, V26, P63, DOI 10.3109/10715769709097785; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323; XIE ZJ, 1989, ANAL BIOCHEM, V183, P215, DOI 10.1016/0003-2697(89)90470-3; YAMAMOTO K, 1993, J CLIN INVEST, V92, P1889, DOI 10.1172/JCI116781	33	294	305	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27838	27844						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10874029				2022-12-27	WOS:000089197100044
J	Hoch, U; Falck, JR; de Montellano, PRO				Hoch, U; Falck, JR; de Montellano, PRO			Molecular basis for the omega-regiospecificity of the CYP4A2 and CYP4A3 fatty acid hydroxylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAURIC ACID; CYTOCHROME-P450 4A1; CRYSTAL-STRUCTURE; ARACHIDONIC-ACID; FUSION PROTEIN; SUBSTRATE; SITE; P450BM-3; ENZYMES; (OMEGA-1)-HYDROXYLATION	The CYP4A fatty acid omega-hydroxylases are involved in important physiological processes such as the regulation of vascular pressure. A previous study of chimeras of the rat CYP4A2 and CYP4A3 enzymes established that the regiochemistry of fatty acid hydroxylation is deter mined by the first 119 amino acid residues (Hoch, U,, Zhang, Z. P,, Kroetz, D, L,, and Ortiz de Montellano, P. R. (2000) Arch. Biochem. Biophys. 373, 63-71), The role of the individual amino acid differences in this region has therefore been examined by site-specific mutagenesis to determine which residues actually control the omega- versus (omega-1)-regiospecificity. The results indicate that regio-specificity is controlled by the presence or absence of a three-residue insert (Ser-114, Gly-115, Ile-116) in CYP4A3 and by the residue at position 119 (CYP4A3 numbering). Furthermore, analysis of the absolute stereochemistry of the 11-hydroxylauric acid product indicates that this stereochemistry is not very sensitive to changes in the residues that line the substrate access channel, These results define a model of the specificity determinants of an important class of cytochrome P450 enzymes.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu		Falck, John/0000-0002-9219-7845	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025515, R01GM031278, R01GM025515] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25515, GM31278] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTERMAN MA, 1995, BIOCHEM BIOPH RES CO, V214, P1089, DOI 10.1006/bbrc.1995.2397; ALTERMAN MA, 1995, ARCH BIOCHEM BIOPHYS, V320, P289, DOI 10.1016/0003-9861(95)90012-8; AMET Y, 1994, BIOCHEM BIOPH RES CO, V203, P1168, DOI 10.1006/bbrc.1994.2305; Bambal RB, 1996, BIOCHEM BIOPH RES CO, V219, P445, DOI 10.1006/bbrc.1996.0253; Bambal RB, 1996, ARCH BIOCHEM BIOPHYS, V334, P59, DOI 10.1006/abbi.1996.0429; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; Capdevila JH, 2000, J LIPID RES, V41, P163; Capdevila JH, 1996, J BIOL CHEM, V271, P22663, DOI 10.1074/jbc.271.37.22663; CASTLE PJ, 1995, DRUG METAB DISPOS, V23, P1037; Chang YT, 1999, PROTEINS, V34, P403, DOI 10.1002/(SICI)1097-0134(19990215)34:3<403::AID-PROT12>3.0.CO;2-D; Cosme J, 2000, J BIOL CHEM, V275, P2545, DOI 10.1074/jbc.275.4.2545; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; DEMONTELLANO PRO, 1984, J BIOL CHEM, V259, P4136; Dierks EA, 1998, J BIOL CHEM, V273, P23055, DOI 10.1074/jbc.273.36.23055; Dierks EA, 1998, BIOCHEMISTRY-US, V37, P1839, DOI 10.1021/bi972458s; FUKUDA T, 1994, J BIOCHEM-TOKYO, V115, P338, DOI 10.1093/oxfordjournals.jbchem.a124339; GOTOH O, 1992, J BIOL CHEM, V267, P83; Guengerich FP, 1997, CHEM-BIOL INTERACT, V106, P161, DOI 10.1016/S0009-2797(97)00068-9; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; Harlow GR, 1998, P NATL ACAD SCI USA, V95, P6636, DOI 10.1073/pnas.95.12.6636; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; Helvig C, 1998, BIOCHEMISTRY-US, V37, P12546, DOI 10.1021/bi981048g; Hoch U, 2000, ARCH BIOCHEM BIOPHYS, V373, P63, DOI 10.1006/abbi.1999.1504; IMAOKA S, 1989, BIOCHEM INT, V18, P731; JOHNSON EF, 1992, TRENDS PHARMACOL SCI, V13, P122, DOI 10.1016/0165-6147(92)90042-5; Modi S, 1996, NAT STRUCT BIOL, V3, P414, DOI 10.1038/nsb0596-414; Oliver CF, 1997, BIOCHEMISTRY-US, V36, P1567, DOI 10.1021/bi962826c; OMURA T, 1964, J BIOL CHEM, V239, P2370; Orrenius S, 1972, Biochem Soc Symp, V34, P55; POULOS TL, 1985, J BIOL CHEM, V260, P6122; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; Truan G, 1999, ARCH BIOCHEM BIOPHYS, V366, P192, DOI 10.1006/abbi.1999.1156; Von Wachenfeldt C, 1995, CYTOCHROME P450 STRU, P183	33	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26952	26958						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10869363				2022-12-27	WOS:000089144800039
J	Li, DP; Periyasamy, S; Jones, TJ; Sanchez, ER				Li, DP; Periyasamy, S; Jones, TJ; Sanchez, ER			Heat and chemical shock potentiation of glucocorticoid receptor transactivation requires heat shock factor (HSF) activity - Modulation of HSF by vanadate and wortmannin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MEDIATED GENE-EXPRESSION; NF-KAPPA-B; TUMOR VIRUS TRANSCRIPTION; MESSENGER-RNA EXPRESSION; HAMSTER OVARY CELLS; DNA-BINDING; CROSS-TALK; FUNCTIONAL ANTAGONISM; INDUCED APOPTOSIS	Heat shock and other forms of stress increase glucocorticoid receptor (GR) activity in cells, suggesting cross-talk between the heat shock and GR signal pathways. An unresolved question concerning this cross-talk is whether heat shock factor (HSF1) activity is required for this response, We addressed this issue by modulating HSF1 activity with compounds acting by distinct mechanisms: sodium vanadate (SV), an inhibitor of protein phosphatases; and wortmannin, an inhibitor of DNA-dependent protein kinase, Using HSF1- and OR-responsive CAT reporters, we demonstrate that SV inhibits both HSF1 activity and the stress potentiation of GR, while having no effect on the hormone-free GR or HSF1, Paradoxically, SV increased hormone-induced GR activity in the absence of stress. In contrast, wortmannin increased HSF1 activity in stressed cells and had no effect on HSF1 in the absence of stress. Using the pMMTV-CAT reporter containing the negative regulatory element 1 site for DNA-dependent protein kinase, wortmannin was found to increase the GR response. However, in cells expressing a minimal promoter lacking negative regulatory element 1 sites, wortmannin had no effect on the GR in the absence of stress but increased the stress potentiation of GR, Our results show that the mechanism by which CR activity is increased in stressed cells requires intrinsic HSF1 activity.	Med Coll Ohio, Dept Pharmacol, Toledo, OH 43614 USA		Sanchez, ER (corresponding author), Med Coll Ohio, Dept Pharmacol, 3035 Arlington Ave, Toledo, OH 43614 USA.	esanchez@mco.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043867, R29DK043867] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK043867, DK43867] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DREANO M, 1986, GENE, V49, P1, DOI 10.1016/0378-1119(86)90380-X; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; EDWARDS DP, 1992, BIOCHEMISTRY-US, V31, P2482, DOI 10.1021/bi00124a007; END DW, 1987, RES COMMUN CHEM PATH, V56, P75; ERDOS G, 1995, J CELL PHYSIOL, V164, P404, DOI 10.1002/jcp.1041640221; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIFFIN W, 1994, J BIOL CHEM, V269, P1449; Giffin W, 1999, MOL CELL BIOL, V19, P4065; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GRAZIANI Y, 1979, BIOCHEM PHARMACOL, V28, P397, DOI 10.1016/0006-2952(79)90105-9; GSCHWENDT M, 1983, BIOCHEM BIOPH RES CO, V117, P444, DOI 10.1016/0006-291X(83)91220-2; He LS, 1999, RADIAT RES, V151, P283, DOI 10.2307/3579940; Hu JL, 1996, CELL STRESS CHAPERON, V1, P197, DOI 10.1379/1466-1268(1996)001<0197:EOGRMG>2.3.CO;2; Huang JR, 1997, J BIOL CHEM, V272, P26009, DOI 10.1074/jbc.272.41.26009; Izzard RA, 1999, CANCER RES, V59, P2581; Kang KI, 1999, P NATL ACAD SCI USA, V96, P1439, DOI 10.1073/pnas.96.4.1439; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; KURIKI Y, 1976, BIOCHEMISTRY-US, V15, P4951, DOI 10.1021/bi00668a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDEL CC, 1994, MOL ENDOCRINOL, V8, P1407, DOI 10.1210/me.8.10.1407; Li DP, 1999, CELL STRESS CHAPERON, V4, P223; LIU W, 1995, MOL CELL BIOL, V15, P1005; MATIC G, 1995, CELL BIOL INT, V19, P203, DOI 10.1006/cbir.1995.1063; Matic G, 1995, JUGOSLAV MED BIOHEM, V14, P89; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; MIVECHI NF, 1995, CANCER RES, V55, P5512; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; Nueda A, 1999, J BIOL CHEM, V274, P14988, DOI 10.1074/jbc.274.21.14988; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Rossi A, 1998, J BIOL CHEM, V273, P16446, DOI 10.1074/jbc.273.26.16446; SANCHEZ ER, 1992, J BIOL CHEM, V267, P17; SANCHEZ ER, 1994, MOL ENDOCRINOL, V8, P408, DOI 10.1210/me.8.4.408; Sarkaria JN, 1998, CANCER RES, V58, P4375; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHEN P, 1993, J STEROID BIOCHEM, V47, P55, DOI 10.1016/0960-0760(93)90057-4; SHI YH, 1995, MOL CELL BIOL, V15, P4309; Sivo J, 1996, J IMMUNOL, V156, P3450; Smets LA, 1998, LEUKEMIA, V12, P406, DOI 10.1038/sj.leu.2400941; SRINIVASAN G, 1994, MOL ENDOCRINOL, V8, P189, DOI 10.1210/me.8.2.189; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P17342; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Wong HR, 1997, J CLIN INVEST, V99, P2423, DOI 10.1172/JCI119425; Wong HR, 1999, CELL STRESS CHAPERON, V4, P1; Yang SH, 1996, MOL CELL BIOL, V16, P3799, DOI 10.1128/mcb.16.7.3799; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZOU J, 1995, MOL CELL BIOL, V15, P4319; Zou JY, 1998, CELL STRESS CHAPERON, V3, P130, DOI 10.1379/1466-1268(1998)003<0130:CBGOAT>2.3.CO;2	64	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26058	26065		10.1074/jbc.M004502200	http://dx.doi.org/10.1074/jbc.M004502200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10862623	hybrid			2022-12-27	WOS:000088999700025
J	Bazzoni, G; Martinez-Estrada, OM; Orsenigo, F; Cordenonsi, M; Citi, S; Dejana, E				Bazzoni, G; Martinez-Estrada, OM; Orsenigo, F; Cordenonsi, M; Citi, S; Dejana, E			Interaction of junctional adhesion molecule with the tight junction components ZO-1, cingulin, and occludin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; PERIPHERAL COMPONENT; MEMBRANE-PROTEINS; ATP DEPLETION; DOMAIN; CADHERIN; IDENTIFICATION; INVOLVEMENT; UVOMORULIN; DISTINCT	Junctional adhesion molecule (JAM) is an integral membrane protein that has been reported to colocalize with the tight junction molecules occludin, ZO-1, and cingulin. However, evidence for the association of JAM with these molecules is missing. Transfection of Chinese hamster ovary cells with JAM (either alone or in combination with occludin) resulted in enhanced junctional localization of both endogenous ZO-1 and cotransfected occludin. Additionally, JAM was coprecipitated with ZO-1 in the detergent-insoluble fraction of Caco-2 epithelial cells. A putative PDZ-binding motif at the cytoplasmic carboxyl terminus of JAM was required for mediating the interaction of JAM with ZO-1, as assessed by in vitro binding and coprecipitation experiments. JAM was also coprecipitated with cingulin, another cytoplasmic component of tight junctions, and this association required the amino-terminal globular head of cingulin. Taken together, these data indicate that JAM is a component of the multiprotein complex of tight junctions, which may facilitate junction assembly.	Mario Negri Inst Pharmacol Res, Lab Vasc Biol, I-20157 Milan, Italy; Univ Padua, Dipartimento Biol, I-35121 Padua, Italy; Univ Studi Insubria, Fac Med & Chirurg, Dipartimento Sci Clin & Biol, I-21100 Varese, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Padua; University of Insubria	Bazzoni, G (corresponding author), Mario Negri Inst Pharmacol Res, Lab Vasc Biol, Via Eritrea 62, I-20157 Milan, Italy.	bazzoni@irfmn.mnegri.it	Citi, Sandra/E-4514-2014; Martinez-Estrada, Ofelia M/V-4733-2017; Cordenonsi, Michelangelo/K-7692-2016	Martinez-Estrada, Ofelia M/0000-0002-1814-1974; Cordenonsi, Michelangelo/0000-0002-8253-5724; Orsenigo, Fabrizio/0000-0001-9135-8478; DEJANA, ELISABETTA/0000-0002-0007-0426; Citi, Sandra/0000-0002-6537-4818				Balda MS, 1996, FEBS LETT, V399, P326, DOI 10.1016/S0014-5793(96)01352-X; Balda MS, 1998, J CELL SCI, V111, P541; Bazzoni G, 1999, TRENDS CARDIOVAS MED, V9, P147, DOI 10.1016/S1050-1738(99)00022-5; BEHRENS J, 1985, J CELL BIOL, V101, P1307, DOI 10.1083/jcb.101.4.1307; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; CANFIELD PE, 1991, AM J PHYSIOL, V261, pF1038, DOI 10.1152/ajprenal.1991.261.6.F1038; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Cereijido M, 1998, ANNU REV PHYSIOL, V60, P161, DOI 10.1146/annurev.physiol.60.1.161; CITI S, 1989, J CELL SCI, V93, P107; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; CITI S, 1999, ADV MOL CEL, V28, P203; Cordenonsi M, 1999, J CELL BIOL, V147, P1569, DOI 10.1083/jcb.147.7.1569; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; DOYLE JP, 1995, J CELL BIOL, V131, P465, DOI 10.1083/jcb.131.2.465; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Grignani F, 1998, CANCER RES, V58, P14; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Introna M, 1998, BRIT J HAEMATOL, V103, P449, DOI 10.1046/j.1365-2141.1998.01020.x; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Matter K, 1998, J CELL SCI, V111, P511; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Ohsugi M, 1997, DEV BIOL, V185, P261, DOI 10.1006/dbio.1997.8560; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; SEDAR AW, 1964, J CELL BIOL, V22, P173, DOI 10.1083/jcb.22.1.173; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STEVENSON BR, 1989, AM J PHYSIOL, V257, pC621, DOI 10.1152/ajpcell.1989.257.4.C621; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; STEVENSON BR, 1984, J CELL BIOL, V98, P1209, DOI 10.1083/jcb.98.4.1209; Tsukamoto T, 1997, J BIOL CHEM, V272, P16133, DOI 10.1074/jbc.272.26.16133; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; VanItallie CM, 1997, J CELL SCI, V110, P1113; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	54	341	351	0	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20520	20526		10.1074/jbc.M905251199	http://dx.doi.org/10.1074/jbc.M905251199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10877843	hybrid, Green Published			2022-12-27	WOS:000088084500043
J	Saupe, KW; Spindler, M; Hopkins, JCA; Shen, WQ; Ingwall, JS				Saupe, KW; Spindler, M; Hopkins, JCA; Shen, WQ; Ingwall, JS			Kinetic, thermodynamic, and developmental consequences of deleting creatine kinase isoenzymes from the heart - Reaction kinetics of the creatine kinase isoenzymes in the intact heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLES; MITOCHONDRIAL; ENERGY; MICE; RESPIRATION; DEFICIENT; SHUTTLE	Creatine kinase (CK) exists as a family of isoenzymes in excitable tissue. We studied isolated perfused hearts from mice lacking genes for either the main muscle isoform of CK (M-CK) or both M-CK and the main mitochondrial isoform (Mt-CK) to determine 1) the biological significance of CK isoenzyme shifts, 2) the necessity of maintaining a high CK reaction rate, and 3) the role of CK isoenzymes in establishing the thermodynamics of ATP hydrolysis, P-31 NMR was used to measure [ATP], [PCr], [P-i], [ADP], pH, as well as the unidirectional reaction rate of PCr --> [gamma-P]ATP. Developmental changes in the main fetal isoform of CK (BB-CK) were unaffected by loss of other CK isoenzymes, In hearts lacking both M- and Mt-CK, the rate of ATP synthesis from PCr was only 9% of the rate of ATP synthesis from oxidative phosphorylation demonstrating a lack of any high energy phosphate shuttle. We also found that the intrinsic activities of the BB-CK and the MM-CK isoenzymes were equivalent. Finally, combined loss of M- and Mt-CK (but not loss of only M-CK) prevented the amount of free energy released from ATP hydrolysis from increasing when pyruvate was provided as a substrate for oxidative phosphorylation.	Boston Univ, Sch Med, Cardiac Muscle Res Lab, Boston, MA 02118 USA; Univ Wurzburg, Med Klin, D-97080 Wurzburg, Germany; Brigham & Womens Hosp, Dept Med, Div Cardiovasc, NMR Lab Physiol Chem, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA	Boston University; University of Wurzburg; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Eli Lilly	Ingwall, JS (corresponding author), NMR Lab, 221 Longwood Ave,BLI 247, Boston, MA 02115 USA.	jingwall@rics.bwh.harvard.edu						Aliev MK, 1997, BIOPHYS J, V73, P428, DOI 10.1016/S0006-3495(97)78082-2; Balschi JA, 1997, J MOL CELL CARDIOL, V29, P3123, DOI 10.1006/jmcc.1997.0539; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; FORSEN S, 1963, J CHEM PHYS, V39, P2892, DOI 10.1063/1.1734121; FRIEDRICH J, 1993, MAGNET RESON MED, V30, P45, DOI 10.1002/mrm.1910300108; GIBBS C, 1985, J MOL CELL CARDIOL, V17, P727, DOI 10.1016/S0022-2828(85)80034-1; INGWALL JS, 1980, HEART CREATINE KINAS, P9; KAMMERME.H, 1973, ANAL BIOCHEM, V56, P341, DOI 10.1016/0003-2697(73)90199-1; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEYER RA, 1984, AM J PHYSIOL, V246, pC365, DOI 10.1152/ajpcell.1984.246.5.C365; Nascimben L, 1996, CIRCULATION, V94, P1894, DOI 10.1161/01.CIR.94.8.1894; POLIMENI PI, 1988, J MOL CELL CARDIOL, V20, P15, DOI 10.1016/S0022-2828(88)80175-5; Ponticos M, 1998, EMBO J, V17, P1688, DOI 10.1093/emboj/17.6.1688; Qin WN, 1998, MOL CELL BIOCHEM, V184, P153, DOI 10.1023/A:1006807515892; ROSALKI SB, 1967, J LAB CLIN MED, V69, P696; Saupe KW, 1998, CIRC RES, V82, P898; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; Tian R, 1996, AM J PHYSIOL-HEART C, V270, pH1207, DOI 10.1152/ajpheart.1996.270.4.H1207; Van Dorsten FA, 1998, AM J PHYSIOL-HEART C, V275, pH1191, DOI 10.1152/ajpheart.1998.275.4.H1191; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; vanDorsten FA, 1996, BBA-BIOENERGETICS, V1274, P59, DOI 10.1016/0005-2728(96)00010-2; VEKSLER VI, 1995, J BIOL CHEM, V270, P19921, DOI 10.1074/jbc.270.34.19921; Wallimann T, 1985, Cell Muscle Motil, V6, P239	24	76	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19742	19746		10.1074/jbc.M001932200	http://dx.doi.org/10.1074/jbc.M001932200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867023	hybrid			2022-12-27	WOS:000087941300043
J	Giovannucci, DR; Groblewski, GE; Sneyd, J; Yule, DI				Giovannucci, DR; Groblewski, GE; Sneyd, J; Yule, DI			Targeted phosphorylation of inositol 1,4,5-trisphosphate receptors selectively inhibits localized Ca2+ release and shapes oscillatory Ca2+ signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; EXOCRINE PANCREAS; GENE-EXPRESSION; FLUID SECRETION; DOWN-REGULATION; GLAND CELLS; CALCIUM; CAMP	Current study provides biochemical and functional evidence that the targeting of protein kinase A (PBA) to sites of localized Ca2+ release confers rapid, specific phosphoregulation of Ca2+ signaling in pancreatic acinar cells, Regulatory control of Ca2+ release by PKA-dependent phosphorylation of inositol 1,4,5-trisphosphate (InsP(3)) receptors was investigated by monitoring Ca2+ dynamics in pancreatic acinar cells evoked by the flash photolysis of caged InsP(3) prior to and following PRA activation, Ca2+ dynamics were imaged with high temporal resolution by digital imaging and electrophysiological methods. The whole cell patch clamp technique was used to introduce caged compounds and to record the activity of a Ca2+-activated Cl- current, Photolysis of low concentrations of caged InsP(3) evoked Cl- currents that were inhibited by treatment with dibutryl-cAMP or forskolin. In contrast, PKA activators had no significant inhibitory effect on the activation of Cl- current evoked by uncaging Ca2+ or by the photolytic release of higher concentrations of InsP(3). Treatment with Rp-adenosine-3',5'-cyclic monophoshorothioate, a selective inhibitor of PKA, or with Ht31, a peptide known to disrupt the targeting of PKA, largely abolished forskolin-induced inhibition of Ca2+ release. Further evidence for the targeting of PKA to the sites of Ca2+ mobilization was revealed using immunocytochemical methods demonstrating that the R-II beta subunit of PKA. was localized to the apical regions of acinar cells and co-immunoprecipitated with the type III but not the type I or type II InsP(3) receptors, Finally, we demonstrate that the pattern of signaling evoked by acetylcholine can be converted to one that is more "CCK-like" by raising cAMP levels. Our data provide a simple mechanism by which distinct oscillatory Ca2+ patterns can he shaped.	Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA; Massey Univ, Inst Informat & Mat Sci, Auckland, New Zealand	University of Rochester; University of Wisconsin System; University of Wisconsin Madison; Massey University	Giovannucci, DR (corresponding author), Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA.	david_giovannucci@urmc.rochester.edu	Sneyd, James/C-8995-2009; Giovannucci, David R/A-5657-2018	Sneyd, James/0000-0001-7305-2862; 	NIDDK NIH HHS [DK 54568] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK054568, R01DK054568] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER PF, 1981, PHILOS T R SOC B, V296, P83, DOI 10.1098/rstb.1981.0174; Begenisich T, 1998, J MEMBRANE BIOL, V163, P77, DOI 10.1007/s002329900372; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bugrim AE, 1999, CELL CALCIUM, V25, P219, DOI 10.1054/ceca.1999.0027; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; Camello PJ, 1996, PFLUG ARCH EUR J PHY, V432, P775, DOI 10.1007/s004240050198; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Cancela JM, 1998, PFLUG ARCH EUR J PHY, V435, P746, DOI 10.1007/s004240050578; CARR DW, 1992, J BIOL CHEM, V267, P16816; CHEN Y, 1993, FEBS LETT, V336, P191, DOI 10.1016/0014-5793(93)80800-A; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hirono C, 1998, J MEMBRANE BIOL, V164, P197, DOI 10.1007/s002329900405; Ito K, 1997, EMBO J, V16, P242, DOI 10.1093/emboj/16.2.242; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KASE H, 1991, PFLUG ARCH EUR J PHY, V419, P668, DOI 10.1007/BF00370314; LeBeau AP, 1999, J GEN PHYSIOL, V113, P851, DOI 10.1085/jgp.113.6.851; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; Luo X, 1999, J BIOL CHEM, V274, P17684, DOI 10.1074/jbc.274.25.17684; LYNCH M, 1992, CELL CALCIUM, V13, P227, DOI 10.1016/0143-4160(92)90011-G; Mak DOD, 2000, J GEN PHYSIOL, V115, P241, DOI 10.1085/jgp.115.3.241; Muallem S, 1999, CELL CALCIUM, V26, P173, DOI 10.1054/ceca.1999.0077; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PENNER R, 1988, J EXP BIOL, V139, P329; PETERSEN OH, 1991, CELL CALCIUM, V12, P135, DOI 10.1016/0143-4160(91)90015-7; Petersen OH, 1999, TRENDS NEUROSCI, V22, P488, DOI 10.1016/S0166-2236(99)01456-3; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; RUBIN RP, 1994, J PHARMACOL EXP THER, V268, P600; SCHNEFEL S, 1990, BIOCHEM J, V269, P483, DOI 10.1042/bj2690483; Sjodin L, 1997, PFLUG ARCH EUR J PHY, V433, P397, DOI 10.1007/s004240050294; SNYDER SH, 1989, CELL CALCIUM, V10, P337, DOI 10.1016/0143-4160(89)90059-6; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; Tertyshnikova S, 1998, P NATL ACAD SCI USA, V95, P1613, DOI 10.1073/pnas.95.4.1613; THORN P, 1992, J GEN PHYSIOL, V100, P11, DOI 10.1085/jgp.100.1.11; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Tibbs VC, 1998, J BIOL CHEM, V273, P25783, DOI 10.1074/jbc.273.40.25783; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; WAKUI M, 1991, J MEMBRANE BIOL, V124, P179, DOI 10.1007/BF01870462; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; Wojcikiewicz RJH, 1999, GASTROENTEROLOGY, V116, P1194, DOI 10.1016/S0016-5085(99)70023-5; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wojcikiewicz RJH, 1998, J BIOL CHEM, V273, P5670, DOI 10.1074/jbc.273.10.5670; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yule DI, 1999, AM J PHYSIOL-GASTR L, V276, pG271, DOI 10.1152/ajpgi.1999.276.1.G271; Yule DI, 1997, J BIOL CHEM, V272, P9093; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8; Zeng WZ, 1996, J BIOL CHEM, V271, P18520, DOI 10.1074/jbc.271.31.18520	59	73	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33704	33711		10.1074/jbc.M004278200	http://dx.doi.org/10.1074/jbc.M004278200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10887192	hybrid			2022-12-27	WOS:000090104600073
J	Pinzar, E; Miyano, M; Kanaoka, Y; Urade, Y; Hayaishi, O				Pinzar, E; Miyano, M; Kanaoka, Y; Urade, Y; Hayaishi, O			Structural basis of hematopoietic prostaglandin D synthase activity elucidated by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; D SYNTHETASE; 3-DIMENSIONAL STRUCTURE; CATALYTIC PROPERTIES; D-ISOMERASE; RESIDUE; CELLS; D-2; PURIFICATION; ACTIVATION	Hematopoietic prostaglandin (PG) D synthase (PGDS) is the first identified vertebrate ortholog in the Sigma class of the glutathione S-transferase (GST) family and catalyzes both isomerization of PGH, to PGD, and conjugation of glutathione to 1-chloro-2,4-dinitrobenzene. We introduced site directed mutations of Tyr(8), Arg(14), Trp(104), Lys(112), Tyr(152), Cys(156), Lys(198), and Leu(199), which are presumed to participate in catalysis or PGH(2) substrate binding based on the crystallographic structure. Mutants were analyzed in terms of structure, GST and PGDS activities, and activation of the glutathione thiol group. Of all the mutants, only Y8F, W104I, K112E, and L199F showed minor but substantial differences in their far-UV circular dichrcoism spectra from the wild-type enzyme, Y8F, R14K/E, and W104I were completely inactive. C156L/Y selectively lost only PGDS activity. K112E reduced GST activity slightly and PGDS activity markedly, whereas K198E caused a selective decrease in PODS activity and K-m for glutathione and PGH(2) in the PODS reaction. No significant changes were observed in the catalytic activities of Y152F and L199F, although their K-m for glutathione was increased. Using 5,5'-dithiobis(2-nitrobenzoic acid) as an SE-selective agent, we found that only Y8F and R14E/K did not accelerate the reactivity of the glutathione thiol group under the low reactivity condition of pH 5.0. These results indicate that Lys(112), Cys(156) and Lys(198) are involved in the binding of PGH,; Trp(104) is critical for structural integrity of the catalytic center for GST and PODS activities; and Tyr(8) and Arg(14), essential for activation of the thiol group of glutathione.	Osaka Biosci Inst, Japan Sci Technol Corp, Dept Mol Behav Biol, Suita, Osaka 5650874, Japan; Osaka Biosci Inst, Japan Sci Technol Corp, Core Res Evolut Sci & Technol, Suita, Osaka 5650874, Japan; Japan Tobacco Inc, Cent Pharmaceut Res Inst, Takatsuki, Osaka 5691125, Japan	Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Japan Tobacco Inc.	Hayaishi, O (corresponding author), Osaka Biosci Inst, Japan Sci Technol Corp, Dept Mol Behav Biol, 6-2-4 Furuedai, Suita, Osaka 5650874, Japan.		Miyano, Masashi/R-2785-2016	Miyano, Masashi/0000-0003-2253-6175				ALVING K, 1991, ACTA PHYSIOL SCAND, V143, P93, DOI 10.1111/j.1748-1716.1991.tb09204.x; BJORNESTEDT R, 1995, J MOL BIOL, V247, P765; BOARD PG, 1995, BIOCHEM J, V311, P247, DOI 10.1042/bj3110247; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTHAZELHOF E, 1979, BIOCHIM BIOPHYS ACTA, V572, P43, DOI 10.1016/0005-2760(79)90198-X; DARIUS H, 1994, EUR J PHARMACOL, V258, P207, DOI 10.1016/0014-2999(94)90482-0; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Dumitrascu D, 1996, Rom J Intern Med, V34, P159; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GARCIASAEZ I, 1994, J MOL BIOL, V237, P298, DOI 10.1006/jmbi.1994.1232; HABIG WH, 1974, J BIOL CHEM, V249, P7130; ITO S, 1989, PROSTAG LEUKOTR ESS, V37, P219, DOI 10.1016/0952-3278(89)90033-1; JACOBY WB, 1990, J BIOL CHEM, V265, P20715; JI XH, 1995, BIOCHEMISTRY-US, V34, P5317, DOI 10.1021/bi00016a003; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; KANAOKA Y, 1999, CELL, V96; KONG KH, 1992, BIOCHEM BIOPH RES CO, V182, P1122, DOI 10.1016/0006-291X(92)91848-K; LIU SX, 1992, J BIOL CHEM, V267, P4296; Mahmud I, 1997, J BIOL CHEM, V272, P28263, DOI 10.1074/jbc.272.45.28263; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; Minami T, 1996, J PHARMACOL EXP THER, V278, P1146; Prade L, 1997, STRUCTURE, V5, P1287, DOI 10.1016/S0969-2126(97)00281-5; Pregel MJ, 1997, J BIOL CHEM, V272, P23552, DOI 10.1074/jbc.272.38.23552; Ram A, 1997, BRAIN RES, V751, P81, DOI 10.1016/S0006-8993(96)01401-1; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; SASAKI H, 1994, ANTI-CANCER DRUG, V5, P131, DOI 10.1097/00001813-199404000-00002; STENBERG G, 1991, BIOCHEM J, V274, P549, DOI 10.1042/bj2740549; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TERAO A, 1995, J NEUROCHEM, V65, P2742; Thomson AM, 1998, BIOCHEM J, V333, P317, DOI 10.1042/bj3330317; UENO R, 1982, P NATL ACAD SCI-BIOL, V79, P6093, DOI 10.1073/pnas.79.19.6093; UJIHARA M, 1988, ARCH BIOCHEM BIOPHYS, V264, P428, DOI 10.1016/0003-9861(88)90308-6; URADE Y, 1989, J IMMUNOL, V143, P2982; URADE Y, 1987, J BIOL CHEM, V262, P3820; URADE Y, 1985, J BIOL CHEM, V260, P2410; URADE Y, 1990, J BIOL CHEM, V265, P371; URADE Y, 1999, BIOCHIM BIOPHYS ACTA, V1436, P605; WANG RW, 1993, J BIOL CHEM, V268, P23981; WANG SW, 1992, PROG NAT SCI, V2, P267	40	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31239	31244		10.1074/jbc.M000750200	http://dx.doi.org/10.1074/jbc.M000750200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10871602	hybrid			2022-12-27	WOS:000089762700070
J	Norman, RA; Poh, CL; Pearl, LH; O'Hara, BP; Drew, RE				Norman, RA; Poh, CL; Pearl, LH; O'Hara, BP; Drew, RE			Steric hindrance regulation of the Pseudomonas aeruginosa amidase operon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING ATTENUATION PROTEIN; NIFL-NIFA COMPLEX; TRANSCRIPTION ANTITERMINATION; ALIPHATIC AMIDASE; NUCLEOTIDE-SEQUENCE; NITROGEN-FIXATION; CRYSTAL-STRUCTURE; GENE AMIR; RNA; EXPRESSION	Expression of the amidase operon of Pseudomonas aeruginosa is controlled by AmiC, the ligand sensor and negative regulator, and AmiR the transcription antitermination factor activator. We have titrated out AmiC repression activity in vivo by increased AmiR production in trans and shown AmiC regulation of the antitermination activity of AmiR by a steric hindrance mechanism. In the presence of the co-repressor butyramide we have isolated a stable AmiC.AmiR complex, Addition of the inducing ligand acetamide to the complex trips the molecular switch, causing complex dissociation and release of AmiR. The AmiC.AmiR butyramide complex exhibits acetamide-dependent, sequence-specific RNA binding activity and a K(d) of 1.0 nM has been calculated for the Ami.R RNA interaction. The results show that amidase operon expression is controlled by a novel type of signal transduction system in which activity of a site-specific RNA binding activator is regulated via a sequestration mechanism.	UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Natl Univ Singapore, Dept Microbiol, Singapore 119260, Singapore	University of London; University College London; National University of Singapore	Norman, RA (corresponding author), Imperial Canc Res Fund, Struct Biol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	R.Norman@icrf.icnet.uk	LAA, POH CHIT LAA CL POH CHIT/B-9498-2010	Pearl, Laurence/0000-0002-6910-1809; Poh, Chit-Laa/0000-0001-8475-6291				Antson AA, 1999, NATURE, V401, P235, DOI 10.1038/45730; AUSTIN S, 1994, J BACTERIOL, V176, P3460, DOI 10.1128/JB.176.12.3460-3465.1994; Baumann C, 1996, J BIOL CHEM, V271, P12269, DOI 10.1074/jbc.271.21.12269; BRAMMAR WJ, 1987, FEBS LETT, V215, P291, DOI 10.1016/0014-5793(87)80164-3; BRAMMAR WJ, 1964, J GEN MICROBIOL, V37, P307, DOI 10.1099/00221287-37-3-307; CHEN L, 1995, P NATL ACAD SCI USA, V92, P5077, DOI 10.1073/pnas.92.11.5077; CHEN L, 1994, BIOCHEMISTRY-US, V33, P2708, DOI 10.1021/bi00175a046; COUSENS DJ, 1987, J GEN MICROBIOL, V133, P2041; Dixon R, 1998, ARCH MICROBIOL, V169, P371, DOI 10.1007/s002030050585; DRAPER DE, 1996, ESCHERICHIA COLI SAL, P902; DREW R, 1989, J GEN MICROBIOL, V135, P817; DREW R, 1984, J GEN MICROBIOL, V130, P3101; Govantes F, 1998, EMBO J, V17, P2368, DOI 10.1093/emboj/17.8.2368; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JAEGER JA, 1990, METHODS ENZYMOL, V183, P281; KELLY M, 1962, J GEN MICROBIOL, V27, P305, DOI 10.1099/00221287-27-2-305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HS, 1993, J BACTERIOL, V175, P7683, DOI 10.1128/JB.175.23.7683-7688.1993; Lei S, 1999, J BACTERIOL, V181, P6535, DOI 10.1128/JB.181.20.6535-6539.1999; LOWE N, 1989, FEBS LETT, V246, P39, DOI 10.1016/0014-5793(89)80249-2; Money T, 1999, J BACTERIOL, V181, P4461, DOI 10.1128/JB.181.15.4461-4468.1999; MORRET E, 1993, J BACTERIOL, V175, P6067; NARBERHAUS F, 1995, J BACTERIOL, V177, P5078, DOI 10.1128/jb.177.17.5078-5087.1995; O'Hara BP, 1999, EMBO J, V18, P5175, DOI 10.1093/emboj/18.19.5175; PEARL L, 1994, EMBO J, V13, P5810, DOI 10.1002/j.1460-2075.1994.tb06924.x; Torgov MY, 1998, J BACTERIOL, V180, P4339, DOI 10.1128/JB.180.17.4339-4343.1998; WILSON S, 1991, J BACTERIOL, V173, P4914, DOI 10.1128/jb.173.16.4914-4921.1991; WILSON SA, 1995, J BIOL CHEM, V270, P18818, DOI 10.1074/jbc.270.32.18818; WILSON SA, 1995, J BACTERIOL, V177, P3052, DOI 10.1128/jb.177.11.3052-3057.1995; WILSON SA, 1993, EMBO J, V12, P3637, DOI 10.1002/j.1460-2075.1993.tb06037.x; Wilson SA, 1996, EMBO J, V15, P5907, DOI 10.1002/j.1460-2075.1996.tb00977.x; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	32	15	15	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30660	30667		10.1074/jbc.M000813200	http://dx.doi.org/10.1074/jbc.M000813200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893220	hybrid			2022-12-27	WOS:000089577900102
J	Kawano, Y; Okamoto, I; Murakami, D; Itoh, H; Yoshida, M; Ueda, S; Saya, H				Kawano, Y; Okamoto, I; Murakami, D; Itoh, H; Yoshida, M; Ueda, S; Saya, H			Ras oncoprotein induces CD44 cleavage through phosphoinositide 3-OH kinase and the rho family of small G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-CELL MIGRATION; ACTIN STRESS FIBERS; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; H-RAS; METASTATIC PHENOTYPE; ACTIVATED RAS; MAP KINASE; B-RAF	CD44 is a cell surface adhesion molecule for several extracellular matrix components. We previously showed that CD44 expressed in cancer cells is proteolytically cleaved at the ectodomain through membrane-anchored metalloproteases and that CD44 cleavage plays a critical role in cancer cell migration. Therefore, cellular signals that promote the migration and metastatic activity of cancer cells may regulate the CD44 ectodomain cleavage. Here, we demonstrate that the expression of the dominant active mutant of Ha-has (Ha-Ras(Val-12)) induces redistribution of CD44 to the newly generated membrane ruffling area and CD44 ectodomain cleavage. The migration assay revealed that the CD44 cleavage contributes to the Ha-Ras(Val-12)-induced migration of NIH3T3 cells on hyaluronate substrate. Treatment with LY294002, an inhibitor for phosphoinositide 3-OH kinase (PI3K), significantly inhibits Ha-Ras(Val-12)-induced CD44 cleavage, whereas that with PD98059, an inhibitor for MER, does not. The active mutant p110 subunit of PI3K has also been shown to enhance the CD44 cleavage, suggesting that PI3K mediates the has-induced CD44 cleavage. Moreover, the expression of dominant negative mutants of Cdc42 and Rad inhibits the HaRas(Val-12)-induced CD44 cleavage. These results suggest that Ras > PI3K > Cdc42/Rac1 pathway plays an important role in CD44 cleavage and may provide a novel molecular basis to explain how the activated has facilitates cancer cell migration.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Urol, Kumamoto 8600811, Japan; Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Kumamoto University; Kumamoto University; Tokyo Institute of Technology	Itoh, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013					ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BONDY GP, 1985, CANCER RES, V45, P6005; BOS JL, 1989, CANCER RES, V49, P4682; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Edamatsu H, 1998, FEBS LETT, V440, P231, DOI 10.1016/S0014-5793(98)01457-4; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FOX PL, 1994, ONCOGENE, V9, P3519; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Heino J, 1996, INT J CANCER, V65, P717, DOI 10.1002/(SICI)1097-0215(19960315)65:6<717::AID-IJC1>3.3.CO;2-P; HOFMANN M, 1993, CANCER RES, V53, P1516; JAMAL HH, 1994, ONCOGENE, V9, P417; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LIOTTA LA, 1988, J NATL CANCER I, V80, P468, DOI 10.1093/jnci/80.7.468; Manna SK, 1998, J BIOL CHEM, V273, P33333, DOI 10.1074/jbc.273.50.33333; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Okamoto I, 1999, J BIOL CHEM, V274, P25525, DOI 10.1074/jbc.274.36.25525; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODEIGUEZVICIAN.P, 1997, CELL, V89, P457; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Svee K, 1996, J CLIN INVEST, V98, P1713, DOI 10.1172/JCI118970; Takahashi K, 1999, INT J CANCER, V80, P387, DOI 10.1002/(SICI)1097-0215(19990129)80:3<387::AID-IJC9>3.3.CO;2-K; Tang Y, 1999, MOL CELL BIOL, V19, P1881; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VAN AL, 1997, GENE DEV, V11, P2295; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wells A, 2000, ADV CANCER RES, V78, P31; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	59	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29628	29635		10.1074/jbc.M002440200	http://dx.doi.org/10.1074/jbc.M002440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896935	hybrid			2022-12-27	WOS:000089439800061
J	Lee, H; Mok, KH; Muhandiram, R; Park, KH; Suk, JE; Kim, DH; Chang, J; Sung, YC; Choi, KY; Han, KH				Lee, H; Mok, KH; Muhandiram, R; Park, KH; Suk, JE; Kim, DH; Chang, J; Sung, YC; Choi, KY; Han, KH			Local structural elements in the mostly unstructured transcriptional activation domain of human p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETERONUCLEAR NMR-SPECTROSCOPY; HYDROPHOBIC AMINO-ACIDS; TRANSACTIVATION DOMAIN; ALPHA-HELIX; PROTEIN; BINDING; SENSITIVITY; VP16; RESONANCE; SEQUENCE	DNA transcription is initiated by a small regulatory region of transactivators known as the transactivation domain. In contrast to the rapid progress made on the functional aspect of this promiscuous domain, its structural feature is still poorly characterized. Here, our multidimensional NMR study reveals that an unbound full-length p53 transactivation domain, although similar to the recently discovered group of loosely folded proteins in that it does not have tertiary structure, is nevertheless populated by an amphipathic helix and two nascent turns. The helix is formed by residues Thr(18)-Leu(26) (Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu), whereas the two turns are formed by residues Me(t4)0-Met(44) and Asp(48)- Trp(53), respectively. It is remarkable that these local secondary structures are selectively formed by functionally critical and positionally conserved hydrophobic residues present in several acidic transactivation domains. This observation suggests that such local structures are general features of acidic transactivation domains and may represent "specificity determinants" (Ptashne, M., and Gann, A. A. F. (1997), Nature 386, 569-577) that are important for transcriptional activity.	Korea Res Inst Biosci & Biotechnol, Prot Engn Lab, Taejon 305600, South Korea; Univ Toronto, Dept Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Chem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Prot Engn Network Ctr Excellence, Toronto, ON M5S 1A8, Canada; Pohang Univ Sci & Technol, Sch Environm Engn, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Ctr Biofunct Mol, Pohang 790784, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Toronto; University of Toronto; University of Toronto; University of Toronto; Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Han, KH (corresponding author), Korea Res Inst Biosci & Biotechnol, Prot Engn Lab, POB 115, Taejon 305600, South Korea.		Mok, K. Hun/C-2607-2009	CHANG, JUN/0000-0002-8423-5987; Mok, K Hun/0000-0003-3663-2002; Lee, Hyun/0000-0003-2570-8120; Kim, Do-Hyung/0000-0002-2924-4370				Blommers MJJ, 1997, J AM CHEM SOC, V119, P3425, DOI 10.1021/ja9633171; Botuyan MVE, 1997, FOLD DES, V2, P331, DOI 10.1016/S1359-0278(97)00047-3; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; Cho HS, 1996, PROTEIN SCI, V5, P262; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; Daughdrill GW, 1997, NAT STRUCT BIOL, V4, P285, DOI 10.1038/nsb0497-285; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINK AL, 1995, ANNU REV BIOPH BIOM, V24, P495, DOI 10.1146/annurev.bb.24.060195.002431; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HAN KH, 1986, J MOL BIOL, V189, P541, DOI 10.1016/0022-2836(86)90323-2; HARDWICK JM, 1992, J VIROL, V66, P5500, DOI 10.1128/JVI.66.9.5500-5508.1992; Hi R, 1999, J BIOL CHEM, V274, P35152, DOI 10.1074/jbc.274.49.35152; Hua QX, 1998, BIOCHEMISTRY-US, V37, P5858, DOI 10.1021/bi9800808; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUNOZ V, 1994, NAT STRUCT BIOL, V1, P399, DOI 10.1038/nsb0694-399; Nagadoi A, 1999, J MOL BIOL, V287, P593, DOI 10.1006/jmbi.1999.2620; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; Plaxco KW, 1997, NATURE, V386, P657, DOI 10.1038/386657a0; Privalov PL, 1996, J MOL BIOL, V258, P707, DOI 10.1006/jmbi.1996.0280; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; RAHDAKRISNAN I, 1997, CELL, V91, P741; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; Smith LJ, 1996, J MOL BIOL, V255, P494, DOI 10.1006/jmbi.1996.0041; Tell G, 1998, BIOCHEM J, V329, P395, DOI 10.1042/bj3290395; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wissmann R, 1999, J BIOL CHEM, V274, P35521, DOI 10.1074/jbc.274.50.35521; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YOO SH, 1995, J BIOL CHEM, V270, P12578, DOI 10.1074/jbc.270.21.12578; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	60	274	279	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29426	29432		10.1074/jbc.M003107200	http://dx.doi.org/10.1074/jbc.M003107200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10884388	hybrid			2022-12-27	WOS:000089439800035
J	Anneren, C; Reedquist, KA; Bos, JL; Welsh, M				Anneren, C; Reedquist, KA; Bos, JL; Welsh, M			GTK, a Src-related tyrosine kinase, induces nerve growth factor-independent neurite outgrowth in PC12 cells through activation of the Rap1 pathway - Relationship to Shb tyrosine phosphorylation and elevated levels of focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN PROTEIN SHB; NEURONAL DIFFERENTIATION; PHEOCHROMOCYTOMA CELLS; MAP KINASE; SIGNAL-TRANSDUCTION; EXCHANGE FACTOR; RAS EFFECTOR; ONCOGENE; BINDING; GENE	The rat pheochromocytoma cell line PC12 is extensively used as a model for studies of neuronal cell differentiation. These cells develop a sympathetic neuronlike phenotype when cultured in the presence of nerve growth factor. The present study was performed in or der to assess the role of mouse GTK (previously named BSK/IYK), a cytoplasmic tyrosine kinase belonging to the Src family, for neurite outgrowth in PC12 cells. We report that PC12 cells stably overexpressing GTK exhibit a larger fraction of cells with neurites as compared with control cells, and this response is not accompanied by an increased ERK activity. Treatment of the cells with the MEK inhibitor PD98059 did not reduce the GTK-dependent increased in neurite outgrowth. GTK expression induces a nerve growth factor-independent Rap1 activation, probably through altered CrkII signaling. We observe increased CrkII complex formation with p130(Cas), focal adhesion kinase (FAK), and Shb in PC12-GTK cells. The expression of GTK also correlates with a markedly increased content of FAK, phosphorylation of the adaptor protein Shb, and an association between these two proteins. Transient transfection of GTK-over-expressing cells with RalGDS-RBD or Rap1GAP, inhibitors of the Rap1 pathway, reduces the GTK-dependent neurite outgrowth. These data suggest that GTK participates in a signaling pathway, perhaps involving Shb, FAK and Rap1, that induces neurite outgrowth in PC12 cells.	Uppsala Univ, Biomedicum, Dept Med Cell Biol, S-75123 Uppsala, Sweden; Univ Utrecht, Physiol Chem Lab, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands	Uppsala University; Utrecht University; Utrecht University	Welsh, M (corresponding author), Uppsala Univ, Biomedicum, Dept Med Cell Biol, Box 571, S-75123 Uppsala, Sweden.	Michael.Welsh@medcellbiol.uu.se	Welsh, Michael/AAF-8564-2020	Welsh, Michael/0000-0002-5467-9755; Anneren, Cecilia/0000-0003-3600-6650				ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Anneren C, 2000, GROWTH FACTORS, V17, P233, DOI 10.3109/08977190009028969; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CANCE WG, 1994, CELL GROWTH DIFFER, V5, P1347; CLARY DO, 1994, MOL BIOL CELL, V5, P549, DOI 10.1091/mbc.5.5.549; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Giasson BI, 1999, J NEUROCHEM, V72, P1081, DOI 10.1046/j.1471-4159.1999.0721081.x; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grewal SS, 2000, J BIOL CHEM, V275, P3722, DOI 10.1074/jbc.275.5.3722; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HUNDLE B, 1995, J BIOL CHEM, V270, P30134; KARLSSON T, 1995, ONCOGENE, V10, P1475; Karlsson T, 1998, CELL GROWTH DIFFER, V9, P757; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Klesse LJ, 1999, MICROSC RES TECHNIQ, V45, P210, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<210::AID-JEMT4>3.3.CO;2-6; LEE J, 1994, GENE, V138, P247, DOI 10.1016/0378-1119(94)90817-6; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA M, 1993, J BIOL CHEM, V268, P4441; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Oberg-Welsh C, 1998, GROWTH FACTORS, V16, P111; OBERGWELSH C, 1995, GENE, V152, P239, DOI 10.1016/0378-1119(94)00718-8; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PIZON V, 1988, ONCOGENE, V3, P201; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Serebriiskii I, 1997, ONCOGENE, V15, P1043, DOI 10.1038/sj.onc.1201268; SUNITHA I, 1994, BBA-MOL CELL RES, V1221, P348, DOI 10.1016/0167-4889(94)90260-7; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; THUVESON M, 1995, BIOCHEM BIOPH RES CO, V209, P582, DOI 10.1006/bbrc.1995.1540; TISCHLER AS, 1975, NATURE, V258, P341, DOI 10.1038/258341a0; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	51	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29153	29161		10.1074/jbc.M003926200	http://dx.doi.org/10.1074/jbc.M003926200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878015	hybrid			2022-12-27	WOS:000089330700105
J	Traut, TW; Temple, BRS				Traut, TW; Temple, BRS			The chemistry of the reaction determines the invariant amino acids during the evolution and divergence of orotidine 5 '-monophosphate decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URIDINE 5'-PHOSPHATE SYNTHASE; 3-HEXULOSE-6-PHOSPHATE SYNTHASE; OROTIDINE-5'-PHOSPHATE DECARBOXYLASE; CONFORMATION STATES; PROTEIN; GENE; AGGREGATION; DEPENDENCE; KINGDOMS; ENZYMES	Orotidine 5'-phosphate (OMP) decarboxylase has the largest rate enhancement for any known enzyme. For an average protein. of 270 amino acids from more than 80 species, only 8 amino acids are invariant, and 7 of these correspond to ligand-binding residues in the crystal structures of the enzyme from four species. It appears that the chemistry required for catalysis determines the invariant residues for this enzyme structure. A motif of three invariant amino acids at the catalytic site (DXKXXD) is also found in the enzyme hexulose-phosphate synthase. Although the core of OMP decarboxylase is conserved, it has undergone a variety of changes in subunit size or fusion to other protein domains, such as orotate phosphoribosyltransferase, during evolution in different kingdoms. The phylogeny of OMP decarboxylase shows a unique subgroup distinct from the three kingdoms of life. The enzyme subunit size almost doubles from Archaea (average mass of 24.5 kDa) to certain fungi (average mass of 41.7 kDa), These observed changes in subunit size are produced by insertions at 12 sites, largely in loops and on the exterior of the core protein. The consensus for all sequences has a minimal size of <20 kDa.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Traut, TW (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [P30CA016086] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appleby TC, 2000, P NATL ACAD SCI USA, V97, P2005, DOI 10.1073/pnas.259441296; CHRISTOPHER J, 1998, PROGRAM MANUAL; Cui WD, 1999, BIOCHEM BIOPH RES CO, V259, P133, DOI 10.1006/bbrc.1999.0737; Doolittle RF, 1996, SCIENCE, V271, P470, DOI 10.1126/science.271.5248.470; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FERENCI T, 1974, BIOCHEM J, V144, P477, DOI 10.1042/bj1440477; Gao GH, 1999, J MOL BIOL, V285, P149, DOI 10.1006/jmbi.1998.2293; Harris P, 2000, BIOCHEMISTRY-US, V39, P4217, DOI 10.1021/bi992952r; KATO N, 1990, METHOD ENZYMOL, V188, P397; KIMSEY HH, 1992, J BIOL CHEM, V267, P819; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Miller BG, 1999, J BIOL CHEM, V274, P23841, DOI 10.1074/jbc.274.34.23841; Miller BG, 2000, P NATL ACAD SCI USA, V97, P2011, DOI 10.1073/pnas.030409797; MULLER RH, 1990, METHOD ENZYMOL, V188, P401; RADFORD A, 1993, J MOL EVOL, V36, P389; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; Rivera MC, 1998, P NATL ACAD SCI USA, V95, P6239, DOI 10.1073/pnas.95.11.6239; SCAPIN G, 1994, BIOCHEMISTRY-US, V33, P1287, DOI 10.1021/bi00172a001; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRAUT TW, 1980, BIOCHEMISTRY-US, V19, P6068, DOI 10.1021/bi00567a019; Traut TW, 1996, PROG NUCLEIC ACID RE, V53, P1, DOI 10.1016/S0079-6603(08)60142-7; TRAUT TW, 1980, BIOCHEMISTRY-US, V19, P6062, DOI 10.1021/bi00567a018; TRAUT TW, 1989, ARCH BIOCHEM BIOPHYS, V268, P108, DOI 10.1016/0003-9861(89)90570-5; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; Wu N, 2000, P NATL ACAD SCI USA, V97, P2017, DOI 10.1073/pnas.050417797; Yablonski MJ, 1996, J BIOL CHEM, V271, P10704, DOI 10.1074/jbc.271.18.10704; Yanase H, 1996, FEMS MICROBIOL LETT, V135, P201, DOI 10.1016/0378-1097(95)00450-5	29	31	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28675	28681		10.1074/jbc.M003468200	http://dx.doi.org/10.1074/jbc.M003468200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893234	hybrid, Green Published			2022-12-27	WOS:000089330700046
J	Paik, JH; Ju, JH; Lee, JY; Boudreau, MD; Hwang, DH				Paik, JH; Ju, JH; Lee, JY; Boudreau, MD; Hwang, DH			Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase - Mediation through different signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NECROSIS-FACTOR-ALPHA; COLON-CANCER CELLS; SODIUM-SALICYLATE; MESSENGER-RNA; COMPLEMENTARY-DNA; EPITHELIAL-CELLS	The efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) is considered to be a result of their inhibitory effect on cyclooxygenase (COX) activity. Here, we report that flufenamic acid shows two opposing effects on COX-2 expression; it induces COX-2 expression in the colon cancer cell line (HT-29) and macrophage cell line (RAW 264.7); conversely, it inhibits tumor necrosis factor alpha (TNF alpha)- or lipopolysaccharide (LPS)-induced COX-2 expression. This inhibition correlates with the suppression of TNF alpha- or LPS-induced NF kappa B activation by flufenamic acid. The inhibitor of extracellular signal-regulated protein kinase, p38, or NF kappa B does not affect the NSAID-induced COX-2 expression. These results suggest that the NSAID-induced COX-2 expression is not mediated through activation of NF kappa B and mitogen-activated protein kinases, An activator of peroxisome proliferator activated receptor gamma, 15-deoxy-Delta(12,14)-prostaglandin J(2), also induces COX-2 expression and inhibits TNF alpha-induced NF kappa B activation and COX-2 expression, Flufenamic acid and 15-deoxy-Delta(12,14)-prostaglandin J(2) also inhibit LPS-induced expression of inducible form of nitric-oxide synthase and interleukin-1 alpha in RAW 264.7 cells. Together, these results indicate that the NSAIDs inhibit mitogen-induced COX-2 expression while they induce COX-2 expression. Furthermore, the results suggest that the anti-inflammatory effects of flufenamic acid and some other NSAIDs are due to their inhibitory action on the mitogen-induced expression of COX-2 and downstream markers of inflammation in addition to their inhibitory effect on COX enzyme activity.	Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Hwang, DH (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.		Boudreau, Mary/E-4721-2015		NCI NIH HHS [CA-75613] Funding Source: Medline; NIDDK NIH HHS [DK-41868] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041868] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berger J, 1999, J BIOL CHEM, V274, P6718, DOI 10.1074/jbc.274.10.6718; CHANMUGAM P, 1995, J BIOL CHEM, V270, P5418, DOI 10.1074/jbc.270.10.5418; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; Ferreira V, 1999, J IMMUNOL, V162, P6442; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Hwang D, 1998, J NATL CANCER I, V90, P455, DOI 10.1093/jnci/90.6.455; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; JONES DA, 1993, J BIOL CHEM, V268, P9049; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1992, J BIOL CHEM, V267, P25934; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LU XJ, 1995, P NATL ACAD SCI USA, V92, P7961, DOI 10.1073/pnas.92.17.7961; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MCEVOY GK, 1997, AHFS 97 DRUG INFORMA; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; OBANION MK, 1991, J BIOL CHEM, V266, P23261; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Thieringer R, 2000, J IMMUNOL, V164, P1046, DOI 10.4049/jimmunol.164.2.1046; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Xu XM, 1999, P NATL ACAD SCI USA, V96, P5292, DOI 10.1073/pnas.96.9.5292; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	43	99	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28173	28179						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10866999				2022-12-27	WOS:000089197100085
J	Giannini, AL; Vivanco, MDM; Kypta, RM				Giannini, AL; Vivanco, MDM; Kypta, RM			alpha-Catenin inhibits beta-catenin signaling by preventing formation of a beta-catenin T-cell factor DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-CADHERIN; TRANSCRIPTIONAL ACTIVATION; JUNCTIONAL COMPLEX; ADHESION COMPLEX; COLON-CARCINOMA; CYCLIN D1; IN-VITRO; PROTEIN; ACTIN; EXPRESSION	alpha-Catenin and beta-catenin link cadherins to the cytoskeleton at adherens junctions. beta-Catenin also associates with members of the T-cell factor (Tcf) family of transcription factors, and mutations in beta-catenin lead to activation of Tcf-dependent transcription and increased cell growth. Although the loss of alpha-catenin expression can also promote cell growth, the role of endogenous alpha-catenin in beta-catenin signaling is unclear. Here we show that loss of alpha-catenin expression in a colon cancer cell line correlates with increased Tcf-dependent transcription. The presence of alpha-catenin in colon cancer cell nuclei suggests that it inhibits transcription directly, and, in agreement with this, ectopic expression of alpha-catenin in the nucleus represses Tcf-dependent transcription. Furthermore, recombinant alpha-catenin disrupts the interaction between the beta-catenin Tcf complex and DNA. We conclude that alpha-catenin inhibits beta-catenin signaling in the nucleus by interfering with the formation of a beta-cateni.Tcf.DNA complex.	UCL, LMCB, MRC, London WC1E 6BT, England; Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England	University of London; University College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Kypta, RM (corresponding author), UCL, LMCB, MRC, Gower St, London WC1E 6BT, England.	r.kypta@ucl.ac.uk	Vivanco, Maria/G-2393-2011; Kypta, Robert/F-7699-2011	Vivanco, Maria/0000-0002-9540-247X; Kypta, Robert/0000-0002-2389-310X				ABERLE H, 1994, J CELL SCI, V107, P3655; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; CLAVERIE JM, 1993, GENOMICS, V15, P13, DOI 10.1006/geno.1993.1004; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; FISCHERFANTUZZI L, 1988, MOL CELL BIOL, V8, P5495, DOI 10.1128/MCB.8.12.5495; Gallet A, 1999, EMBO J, V18, P2208, DOI 10.1093/emboj/18.8.2208; Giannini AL, 2000, EXP CELL RES, V255, P207, DOI 10.1006/excr.1999.4785; Gofuku J, 1999, AM J CLIN PATHOL, V111, P29; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Huber O, 1997, J CELL SCI, V110, P1759; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Koslov ER, 1997, J BIOL CHEM, V272, P27301, DOI 10.1074/jbc.272.43.27301; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nieset JE, 1997, J CELL SCI, V110, P1013; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; Obama H, 1997, J BIOL CHEM, V272, P11017; Ozawa M, 1998, J BIOL CHEM, V273, P29524, DOI 10.1074/jbc.273.45.29524; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sehgal RNM, 1997, J CELL BIOL, V139, P1033, DOI 10.1083/jcb.139.4.1033; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Torres M, 1997, P NATL ACAD SCI USA, V94, P901, DOI 10.1073/pnas.94.3.901; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VIVANCO MD, 1995, EMBO J, V14, P2217, DOI 10.1002/j.1460-2075.1995.tb07216.x; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119	44	72	74	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21883	21888		10.1074/jbc.M001929200	http://dx.doi.org/10.1074/jbc.M001929200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10896949	hybrid			2022-12-27	WOS:000088363800020
J	Fuh, G; Pisabarro, MT; Li, Y; Quan, C; Lasky, LA; Sidhu, SS				Fuh, G; Pisabarro, MT; Li, Y; Quan, C; Lasky, LA; Sidhu, SS			Analysis of PDZ domain-ligand interactions using carboxyl-terminal phage display	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE RECOGNITION; PROTEIN; RECEPTOR; MEMBRANE; LIBRARIES; COMPLEXES; PTB	PDZ domains mediate protein-protein interactions at specialized subcellular sites, such as epithelial cell tight junctions and neuronal post-synaptic densities. Because most PDZ domains bind extreme carboxyl-terminal sequences, the phage display method has not been amenable to the study of PDZ domain binding specificities. For the first time, we demonstrate the functional display of a peptide library fused to the carboxyl terminus of the M13 major coat protein. We used this library to analyze carboxyl-terminal peptide recognition by two PDZ domains. For each PDZ domain, the library provided specific ligands with sub-micromolar binding affinities. Synthetic peptides and homology modeling were used to dissect and rationalize the binding interactions. Our results establish carboxyl-terminal phage display as a powerful new method for mapping PDZ domain binding specificity.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioorgan Chem, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Sidhu, SS (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, San Francisco, CA 94080 USA.	sidhu@gene.com	Pisabarro, M. Teresa/D-4270-2012					Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Cowburn D, 1997, CURR OPIN STRUC BIOL, V7, P835, DOI 10.1016/S0959-440X(97)80155-8; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Gee SH, 1998, J BIOL CHEM, V273, P21980, DOI 10.1074/jbc.273.34.21980; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kortemme T, 1998, SCIENCE, V281, P253, DOI 10.1126/science.281.5374.253; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lowman HB, 1998, BIOCHEMISTRY-US, V37, P8870, DOI 10.1021/bi980426e; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Marvin DA, 1998, CURR OPIN STRUC BIOL, V8, P150, DOI 10.1016/S0959-440X(98)80032-8; *MOL SIM INC, 1999, INS 2; Oschkinat H, 1999, NAT STRUCT BIOL, V6, P408, DOI 10.1038/8203; Palzkill T, 1998, GENE, V221, P79, DOI 10.1016/S0378-1119(98)00425-9; Pearce KH, 1997, J BIOL CHEM, V272, P20595, DOI 10.1074/jbc.272.33.20595; SIDHU SS, 2000, IN PRESS METHODS ENZ; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; Tsunoda S, 1998, CURR OPIN GENET DEV, V8, P419, DOI 10.1016/S0959-437X(98)80112-3; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Wilson DR, 1998, CAN J MICROBIOL, V44, P313, DOI 10.1139/cjm-44-4-313; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	30	110	125	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21486	21491		10.1074/jbc.275.28.21486	http://dx.doi.org/10.1074/jbc.275.28.21486			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10887205	hybrid			2022-12-27	WOS:000088230600071
J	Holloway, AF; Occhiodoro, F; Mittler, G; Meisterernst, M; Shannon, MF				Holloway, AF; Occhiodoro, F; Mittler, G; Meisterernst, M; Shannon, MF			Functional interaction between the HIV transactivator Tat and the transcriptional coactivator PC4 in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RNA-POLYMERASE-II; LONG TERMINAL REPEAT; ACTIVATION-RESPONSIVE REGION; TYPE-1 TAT; TRANS-ACTIVATION; HIGH-AFFINITY; PROTEIN; DOMAIN; BINDING	The human immunodeficiency virus (HIV) transactivator Tat is a potent activator of transcription from the HIV long terminal repeat and is essential for efficient viral gene expression and replication. Tat has been shown to interact with components of the basal transcription machinery and transcriptional activators. Here we identify the cellular coactivator PC4 as a Tat-interacting protein using the yeast two-hybrid system and confirmed this interaction both in vitro and in vivo by coimmunoprecipitation. We found that this interaction has a functional outcome in that PC4 overexpression enhanced activation of the HIV long terminal repeat in transient transfection studies in a Tat-dependent manner. The domains of PC4 and Tat required for the interaction were mapped. In vitro binding studies showed that the basic transactivation-responsive binding domain of Tat is required for the interaction with PC4. The minimum region of PC4 required for Tat binding was amino acids 22-91, whereas mutation of the lysine-rich domain between amino acids 22 and 43 prevented interaction with Tat. Tat-PC4 interactions may be controlled by phosphorylation, because phosphorylation of PC4 by casein kinase II inhibited interactions with Tat both in vivo and in vitro. We propose that PC4 may be involved in linking Tat to the basal transcription machinery.	Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 2601, Australia; CSIRO, Div Human Nutr, Cooperat Res Ctr Tissue Growth & Repair, Adelaide, SA 5000, Australia; GSF Munich, Dept Prot Biochem, Inst Mol Immunol, D-81377 Munich, Germany	Australian National University; John Curtin School of Medical Research; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Shannon, MF (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 2601, Australia.	frances.shannon@anu.edu.au		Holloway, Adele/0000-0003-2213-1717				ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Blau J, 1996, MOL CELL BIOL, V16, P2044; Brandsen J, 1997, NAT STRUCT BIOL, V4, P900, DOI 10.1038/nsb1197-900; CHANG YN, 1992, NUCLEIC ACIDS RES, V20, P5465, DOI 10.1093/nar/20.20.5465; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Cujec TP, 1997, MOL CELL BIOL, V17, P1817, DOI 10.1128/MCB.17.4.1817; Currie RA, 1998, J BIOL CHEM, V273, P18220, DOI 10.1074/jbc.273.29.18220; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; FAVIER D, 1994, ONCOGENE, V9, P305; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; Himes SR, 1996, J VIROL, V70, P4001, DOI 10.1128/JVI.70.6.4001-4008.1996; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; Kannan F, 1999, MOL CELL BIOL, V19, P899; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LIU JS, 1992, J VIROL, V66, P3883, DOI 10.1128/JVI.66.6.3883-3887.1992; Macian F, 1999, MOL CELL BIOL, V19, P3645, DOI 10.1128/mcb.19.5.3645; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; Mavankal G, 1996, P NATL ACAD SCI USA, V93, P2089, DOI 10.1073/pnas.93.5.2089; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; Ott M, 1998, J IMMUNOL, V160, P2872; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROSEN CA, 1986, NATURE, V319, P555, DOI 10.1038/319555a0; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; Ulich C, 1999, J VIROL, V73, P2499, DOI 10.1128/JVI.73.3.2499-2508.1999; VESCHAMBRE P, 1995, J MOL BIOL, V250, P169, DOI 10.1006/jmbi.1995.0368; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Werten S, 1998, EMBO J, V17, P5103, DOI 10.1093/emboj/17.17.5103; Werten S, 1998, J MOL BIOL, V276, P367, DOI 10.1006/jmbi.1997.1534; Yankulov K, 1998, CURR BIOL, V8, pR447, DOI 10.1016/S0960-9822(98)70289-1; YU L, 1995, J VIROL, V69, P3007, DOI 10.1128/JVI.69.5.3007-3016.1995; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681	56	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21668	21677		10.1074/jbc.M909058199	http://dx.doi.org/10.1074/jbc.M909058199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10887206	hybrid			2022-12-27	WOS:000088230600094
J	Lin, RT; Mamane, Y; Hiscott, J				Lin, RT; Mamane, Y; Hiscott, J			Multiple regulatory domains control IRF-7 activity in response to virus infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-ALPHA GENES; JAK-STAT PATHWAY; TRANSCRIPTION FACTOR; POSITIVE FEEDBACK; IFN; INDUCTION; EXPRESSION; ACTIVATION; ELEMENTS; BINDS	Recent studies implicate the interferon regulatory factors (IRF), IRF-3 and IRF-7, as key activators of Type 1 interferon genes, as well as the RANTES (regulated on activation normal T cell expressed) chemokine gene. Both IRF-3 and IRF-7 are regulated in part by virus-induced C-terminal phosphorylation, leading to nuclear translocation, stimulation of DNA binding, and transcriptional activities, Structure-function studies with IRF-7 suggested a complex organization of the C-terminal region, with a constitutive activation domain located between amino acids 150-246, an accessory inducibility region at the very end of IRF-7 between amino acids 467 and 503, and an inhibitory region (amino acids 341-467) adjacent to the C-terminal end that interferes with transactivation, Furthermore, an element that increases basal and virus-inducible activity is located between amino acids 278 and 305, A transcriptionally active form of IRF-7 was also generated by substitution of Ser-477 and Ser-479 residues with the phosphomimetic Asp, IRF-7, particularly IRF-7(S477D/S479D), was a strong transactivator of type I interferon and RANTES chemokine gene expression. Unlike wild type IRF-3, IRF-7 overexpression was able to stimulate inteferon gene expression in the absence of virus infection. Using tagged versions of IRF-7 and IRF-8, the formation of homo- and heterodimers was detected by eo-immunoprecipitation. These results demonstrate that IRF-5 and IRF-7 transcription factors possess distinct structural characteristics that impart complementary rather than redundant functional roles in cytokine gene activation.	Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Lin, RT (corresponding author), Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	mdli@musica.mcgill.ca	Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Genin P, 2000, J IMMUNOL, V164, P5352, DOI 10.4049/jimmunol.164.10.5352; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hiscott J, 1999, J INTERF CYTOK RES, V19, P1, DOI 10.1089/107999099314360; HISCOTT J, 1995, SEMIN VIROL, V6, P161, DOI 10.1006/smvy.1995.0021; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; LEVY DE, 1995, SEMIN VIROL, V6, P181, DOI 10.1006/smvy.1995.0023; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nonkwelo C, 1997, J VIROL, V71, P6887, DOI 10.1128/JVI.71.9.6887-6897.1997; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; PITHA PM, 1995, SEMIN VIROL, V6, P151, DOI 10.1006/smvy.1995.0020; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; VILCEK J, 1996, VIROLOGY, P375; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; YEOW W, 1998, J BIOL CHEM, V275, P6313; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748	38	194	202	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34320	34327		10.1074/jbc.M002814200	http://dx.doi.org/10.1074/jbc.M002814200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10893229	hybrid			2022-12-27	WOS:000165095300045
J	Xie, MH; Aggarwal, S; Ho, WH; Foster, J; Zhang, ZM; Stinson, J; Wood, WI; Goddard, AD; Gurney, AL				Xie, MH; Aggarwal, S; Ho, WH; Foster, J; Zhang, ZM; Stinson, J; Wood, WI; Goddard, AD; Gurney, AL			Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY; PHOSPHORYLATION; SPECIFICITY; COMPLEXES; PATHWAY; STAT3; MICE	We report the identification of a novel human cytokine, distantly related to interleukin (IL)-10, which we term IL-22, IL-22 is produced by activated T cells. IL-22 is a ligand for CRF2-4, a member of the class II cytokine receptor family. No high affinity ligand has yet been reported for this receptor, although it has been reported to serve as a second component in IL-10 signaling, A new member of the interferon receptor family, which we term IL-22R, functions as a second component together with CRF2-4 to enable IL-22 signaling. IL-22 does not bind the IL-10R, Cell lines were identified that respond to IL-22 by activation of STATs 1, 3, and 5, but were unresponsive to IL-10, In contrast to IL-10, IL-22 does not inhibit the production of proinflammatory cytokines by monocytes in response to LPS nor does it impact IL-10 function on monocytes, but it has modest inhibitory effects on IL-4 production from Th2 T cells.	Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA	Roche Holding; Genentech	Gurney, AL (corresponding author), Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA.							ADAMS RL, 1999, Patent No. 9907848; Chatterjee-Kishore M, 2000, TRENDS CELL BIOL, V10, P106, DOI 10.1016/S0962-8924(99)01709-2; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; Dumoutier L, 2000, J IMMUNOL, V164, P1814, DOI 10.4049/jimmunol.164.4.1814; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; Gibbs VC, 1997, GENE, V186, P97, DOI 10.1016/S0378-1119(96)00690-7; Grotzinger J, 1997, PROTEINS, V27, P96; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; He YW, 1998, CRIT REV IMMUNOL, V18, P503, DOI 10.1615/CritRevImmunol.v18.i6.20; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LOK S, 1999, Patent No. 5965704; LUTFALLA G, 1993, GENOMICS, V16, P366, DOI 10.1006/geno.1993.1199; Pennica Diane, 1996, Cytokine and Growth Factor Reviews, V7, P81, DOI 10.1016/1359-6101(96)00007-X; Rennick DM, 1997, J LEUKOCYTE BIOL, V61, P389, DOI 10.1002/jlb.61.4.389; Spencer SD, 1998, J EXP MED, V187, P571, DOI 10.1084/jem.187.4.571; Wehinger J, 1996, FEBS LETT, V394, P365, DOI 10.1016/0014-5793(96)00990-8; Xie MH, 1999, CYTOKINE, V11, P729, DOI 10.1006/cyto.1999.0485	19	428	535	3	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31335	31339		10.1074/jbc.M005304200	http://dx.doi.org/10.1074/jbc.M005304200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10875937	hybrid			2022-12-27	WOS:000089762700083
J	Jeon, H; Shipley, GG				Jeon, H; Shipley, GG			Localization of the N-terminal domain of the low density lipoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; CYSTEINE-RICH REPEAT; LIGAND-BINDING DOMAIN; LDL RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA; 3-DIMENSIONAL STRUCTURE; NUCLEOTIDE-SEQUENCE; FACTOR PRECURSOR; CALCIUM-BINDING; PROTEINS	The low density lipoprotein (LDL) receptor is a transmembrane glycoprotein performing "receptor-mediated endocytosis" of cholesterol-rich lipoproteins. At the N terminus, the LDL receptor has modular cysteine-rich repeats in both the ligand binding domain and the epidermal growth factor (EGF) precursor homology domain. Each repeat contains six disulfide-bonded cysteine residues, and this structural motif has also been found in many other proteins. The bovine LDL receptor has been purified and reconstituted into egg yolk phosphatidylcholine vesicle bilayers, Using gel electrophoresis and cryoelectron microscopy (cryoEM), the ability of the reconstituted LDL receptor to bind its ligand LDL has been demonstrated. After reduction of the disulfide-bonds in the N-terminal domain of the receptor, the reduced LDL receptor was visualized using cryoEM; reduced LDL receptors showed images with a diffuse density region at the distal end of the extracellular domain. Gold labeling of the reduced cysteine residues was achieved with monomaleimido-Nanogold, and the bound Nanogold was visualized in cryoEM images of the reduced, gold-labeled receptor. Multiple gold particles were observed in the diffuse density region at the distal end of the receptor. Thus, the location of the ligand binding domain of the LDL receptor has been determined, and a model is suggested for the arrangement of the seven cysteine-rich repeats of the ligand binding domain and two EGF-like cysteine-rich repeats of the EGF precursor homology domain.	Boston Univ, Sch Med, Ctr Adv Biomed Res, Dept Biophys, Boston, MA 02118 USA; Boston Univ, Sch Med, Ctr Adv Biomed Res, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Shipley, GG (corresponding author), Boston Univ, Sch Med, Ctr Adv Biomed Res, Dept Biophys, 715 Albany St, Boston, MA 02118 USA.	shipley@med-biophd.bu.edu		Shipley, G./0000-0001-9603-5555	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057405, P01HL026335] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 57405, HL 26335] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bieri S, 1998, BIOCHEMISTRY-US, V37, P10994, DOI 10.1021/bi980452c; BISHOP RW, 1992, J LIPID RES, V33, P549; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DAHLBACK B, 1986, P NATL ACAD SCI USA, V83, P4199, DOI 10.1073/pnas.83.12.4199; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; Dirlam KA, 1996, PROTEIN EXPRES PURIF, V8, P489, DOI 10.1016/S1046-5928(96)90129-1; DOOLITTLE RF, 1985, TRENDS BIOCHEM SCI, V10, P233, DOI 10.1016/0968-0004(85)90140-9; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOFFER MJV, 1993, BIOCHEM BIOPH RES CO, V191, P880, DOI 10.1006/bbrc.1993.1299; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; JACKMAN RW, 1986, P NATL ACAD SCI USA, V83, P8834, DOI 10.1073/pnas.83.23.8834; Jeon H, 2000, J BIOL CHEM, V275, P30458, DOI 10.1074/jbc.M002583200; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE LY, 1989, NUCLEIC ACIDS RES, V17, P1259, DOI 10.1093/nar/17.3.1259; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; MONTELIONE GT, 1992, BIOCHEMISTRY-US, V31, P236, DOI 10.1021/bi00116a033; North CL, 1999, BIOCHEMISTRY-US, V38, P3926, DOI 10.1021/bi9821622; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SCHNEIDER WJ, 1985, METHOD ENZYMOL, V109, P405; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; Simmons T, 1997, J BIOL CHEM, V272, P25531, DOI 10.1074/jbc.272.41.25531; Spin JM, 1997, THESIS BOSTON U; SUDHOF TC, 1985, SCIENCE, V228, P893, DOI 10.1126/science.3873704; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	41	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30465	30470		10.1074/jbc.M002582200	http://dx.doi.org/10.1074/jbc.M002582200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10889195	hybrid			2022-12-27	WOS:000089577900075
J	Ryu, J; Pyo, H; Jou, I; Joe, EH				Ryu, J; Pyo, H; Jou, I; Joe, EH			Thrombin induces NO release from cultured rat microglia via protein kinase C, mitogen-activated protein kinase, and NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ENDOTHELIAL-CELLS; TYROSINE KINASE; GLIOMA-CELLS; RECEPTOR; BRAIN; LIPOPOLYSACCHARIDE; ASTROCYTES; PATHWAY; INDUCTION	Microglia, brain resident macrophages, become activated in brains injured due to trauma, ischemia, or neurodegenerative diseases. In this study, we found that thrombin treatment of microglia induced NO release/ inducible nitric-oxide synthase expression, a prominent marker of activation. The effect of thrombin on NO release increased dose-dependently within the range of 5-20 units/ml. In immunoblot analyses, inducible nitric-oxide synthase expression was detected within 9 h after thrombin treatment. This effect of thrombin was significantly reduced by protein kinase C inhibitors, such as Go6976, bisindolylmaleimide, and Ro31-8220. Within 15 min, thrombin activated three subtypes of mitogen-activated protein kinases: extracellular signal-regulated kinase, p38, and c-Jun N-terminal kinase/stress-activated protein kinase. Inhibition of the extracellular signal-regulated kinase pathway and p38 reduced the NO release of thrombin-treated microglia. Thrombin also activated nuclear factor kappa B (NF-kappa KB) within 5 min, and N-acetyl cysteine, an inhibitor of NF-kappa B, reduced NO release. However, thrombin receptor agonist peptide (an agonist of protease activated receptor-1 (PAR-1)), could not mimic the effect of thrombin, and cathepsin G, a PAR 1 inhibitor, did not reduce the effect of thrombin. These results suggest that thrombin can activate microglia via protein kinase C, mitogen-activated protein kinases, and NF-kappa B but that this occurs independently of PAR-1.	Ajou Univ, Sch Med, Dept Pharmacol, Suwon 442721, South Korea	Ajou University	Joe, EH (corresponding author), San-5 Woncheon-dong, Suwon 442721, Kyunggido, South Korea.							BHAT NR, 1995, J CELL PHYSIOL, V165, P417, DOI 10.1002/jcp.1041650223; Bonaiuto C, 1997, J NEUROIMMUNOL, V77, P51, DOI 10.1016/S0165-5728(97)00054-4; Brass LF, 1997, THROMB HAEMOSTASIS, V78, P234; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; Chinni C, 1999, J BIOL CHEM, V274, P9169, DOI 10.1074/jbc.274.14.9169; Debeir T, 1997, EUR J PHARMACOL, V323, P111, DOI 10.1016/S0014-2999(97)00018-6; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; DING AH, 1988, J IMMUNOL, V141, P2407; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; FENTON JW, 1991, HAEMOSTASIS, V21, P27; Fiebich BL, 1998, J NEUROIMMUNOL, V92, P170, DOI 10.1016/S0165-5728(98)00201-X; GIULIAN D, 1986, J NEUROSCI, V6, P2163; GLENN KC, 1980, J BIOL CHEM, V255, P6609; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; Hellendall RP, 1997, J NEUROIMMUNOL, V74, P19, DOI 10.1016/S0165-5728(96)00202-0; Holland JA, 1998, ENDOTHELIUM-NEW YORK, V6, P113, DOI 10.3109/10623329809072198; JONES A, 1990, IMMUNOLOGY, V71, P236; Kaufmann R, 1996, J NEUROSCI RES, V46, P641, DOI 10.1002/(SICI)1097-4547(19961215)46:6<641::AID-JNR1>3.0.CO;2-F; Krymskaya VP, 1999, AM J PHYSIOL-LUNG C, V277, pL65; Kurkowska-Jastrzebska I, 1999, EXP NEUROL, V156, P50, DOI 10.1006/exnr.1998.6993; LEE SC, 1993, J IMMUNOL, V150, P2659; LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300; McMillian MK, 1997, J NEUROPATH EXP NEUR, V56, P301, DOI 10.1097/00005072-199703000-00009; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MINGHETTI L, 1995, J NEUROCHEM, V65, P2690; Nakai M, 1999, J NEUROCHEM, V72, P1179, DOI 10.1046/j.1471-4159.1999.0721179.x; Naldini A, 1998, J CELL PHYSIOL, V177, P76, DOI 10.1002/(SICI)1097-4652(199810)177:1<76::AID-JCP8>3.0.CO;2-B; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; Ofosu FA, 1998, BIOCHEM J, V336, P283, DOI 10.1042/bj3360283; OLIVIER D, 1998, AM J PHYSIOL, V274, pC1429; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Pyo H, 1998, NEUROREPORT, V9, P871, DOI 10.1097/00001756-199803300-00020; Pyo H, 1999, J BIOL CHEM, V274, P34584, DOI 10.1074/jbc.274.49.34584; Roebuck KA, 1999, INT J MOL MED, V4, P223; Rupalla K, 1998, ACTA NEUROPATHOL, V96, P172, DOI 10.1007/s004010050878; Sower LE, 1999, EXP CELL RES, V247, P422, DOI 10.1006/excr.1998.4372; Suidan HS, 1997, GLIA, V21, P244, DOI 10.1002/(SICI)1098-1136(199710)21:2<244::AID-GLIA7>3.0.CO;2-6; Turgeon VL, 1998, J NEUROSCI, V18, P6882; Ubl JJ, 1997, PFLUG ARCH EUR J PHY, V433, P312; Ubl JJ, 1998, NEUROSCIENCE, V86, P597, DOI 10.1016/S0306-4522(97)00686-6; Vlahopoulos S, 1999, BLOOD, V94, P1878, DOI 10.1182/blood.V94.6.1878; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhang ZG, 1997, BRAIN RES, V744, P189, DOI 10.1016/S0006-8993(96)01085-2; ZIELASEK J, 1992, CELL IMMUNOL, V141, P111, DOI 10.1016/0008-8749(92)90131-8	46	139	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29955	29959		10.1074/jbc.M001220200	http://dx.doi.org/10.1074/jbc.M001220200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893407	hybrid			2022-12-27	WOS:000089577900007
J	Arfin, SM; Long, AD; Ito, ET; Tolleri, L; Riehle, MM; Paegle, ES; Hatfield, GW				Arfin, SM; Long, AD; Ito, ET; Tolleri, L; Riehle, MM; Paegle, ES; Hatfield, GW			Global gene expression profiling in Escherichia coli K12 - The effects of integration host factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; ILVGMEDA OPERON; TRANSCRIPTIONAL ACTIVATION; HIMD SUBUNITS; GROWTH-PHASE; FACTOR IHF; IN-VITRO; PROMOTER; FNR; SITES	We have used nylon membranes spotted in duplicate with full-length polymerase chain reaction-generated products of each of the 4,290 predicted Escherichia coli K12 open reading frames (ORFs) to measure the gene expression profiles in otherwise isogenic integration host factor IHF+ and IHF- strains. Our results demonstrate that random hexamer rather than 3' ORF-specific priming of cDNA probe synthesis is required for accurate measurement of gene expression levels in bacteria. This is explained by the fact that the currently available set of 4,290 unique 3' ORF-specific primers do not hybridize to each ORF with equal efficiency and by the fact that widely differing degradation rates (steady-state levels) are observed for the 25-base pair region of each message complementary to each ORF-specific primer. To evaluate the DNA microarray data reported here, we used a linear analysis of variance (ANOVA) model appropriate for our experimental design. These statistical methods allowed us to identify and appropriately correct for experimental variables that affect the reproducibility and accuracy of DNA microarray measurements and allowed us to determine the statistical significance of gene expression differences between our IRF+ and IHF- strains. Our results demonstrate that small differences in gene expression levels can be accurately measured and that the significance of differential gene expression measurements cannot be assessed simply by the magnitude of the fold difference. Our statistical criteria, supported by excellent agreement between previously determined effects of IHF on gene expression and the results reported here, have allowed us to identify new genes regulated by IHF with a high degree of confidence.	Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Biol Sci, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Engn, Dept Chem Engn & Mat Sci, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Arfin, SM (corresponding author), Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92697 USA.			Long, Tony/0000-0002-5007-8514	NIGMS NIH HHS [GM55073] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; ARFIN SM, 1969, J BIOL CHEM, V244, P2250; AVIV M, 1994, MOL MICROBIOL, V14, P1021, DOI 10.1111/j.1365-2958.1994.tb01336.x; BENDER RA, 1977, J BACTERIOL, V129, P1001, DOI 10.1128/JB.129.2.1001-1009.1977; Benham CJ, 1996, COMPUT APPL BIOSCI, V12, P375; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; Chao GL, 1997, J BACTERIOL, V179, P4299, DOI 10.1128/jb.179.13.4299-4304.1997; CLAVERIEMARTIN F, 1992, J MOL BIOL, V227, P996, DOI 10.1016/0022-2836(92)90516-M; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DITTO MD, 1994, J BACTERIOL, V176, P3738, DOI 10.1128/JB.176.12.3738-3748.1994; Dubrac S, 2000, J BACTERIOL, V182, P3802, DOI 10.1128/JB.182.13.3802-3808.2000; DWIVEDI CM, 1982, BIOCHEMISTRY-US, V21, P3064, DOI 10.1021/bi00256a005; Ellenberger T, 1997, STRUCTURE, V5, P153, DOI 10.1016/S0969-2126(97)00174-3; FREUNDLICH M, 1992, MOL MICROBIOL, V6, P2557, DOI 10.1111/j.1365-2958.1992.tb01432.x; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; Futcher B, 1999, MOL CELL BIOL, V19, P7357; GAMAS P, 1987, MOL GEN GENET, V207, P302, DOI 10.1007/BF00331593; GILADI H, 1992, J MOL BIOL, V224, P937, DOI 10.1016/0022-2836(92)90461-R; Goodman SD, 1999, J BACTERIOL, V181, P3246, DOI 10.1128/JB.181.10.3246-3255.1999; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; Green J, 1997, MICROBIOL-SGM, V143, P2865, DOI 10.1099/00221287-143-9-2865; GUNSALUS RP, 1994, RES MICROBIOL, V145, P437, DOI 10.1016/0923-2508(94)90092-2; HASSAN HM, 1992, P NATL ACAD SCI USA, V89, P3217, DOI 10.1073/pnas.89.8.3217; HAUSER CA, 1984, P NATL ACAD SCI-BIOL, V81, P76, DOI 10.1073/pnas.81.1.76; Hengge-Aronis R., 1996, ESCHERICHIA COLI SAL, V5, P1497; Higgins CF, 1992, CURR OPIN GENET DEV, V2, P739, DOI 10.1016/S0959-437X(05)80134-0; Hiszczynska-Sawicka E, 1997, PLASMID, V38, P174, DOI 10.1006/plas.1997.1307; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; JACOB F, 1961, COLD SPRING HARB SYM, V26, P193, DOI 10.1101/SQB.1961.026.01.024; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; LAWRENCE JG, 1995, J BACTERIOL, V177, P6371, DOI 10.1128/jb.177.22.6371-6380.1995; MARTIN RG, 1967, J BIOL CHEM, V242, P1168; MILLER HI, 1980, CELL, V20, P711, DOI 10.1016/0092-8674(80)90317-7; MOITOSO DV, 1989, SCIENCE, V244, P1457; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NEIDHARDT FC, 1996, ESCHERICHIA COLI SAL, P1310; OBERTO J, 1994, BIOCHIMIE, V76, P901, DOI 10.1016/0300-9084(94)90014-0; PAGEL JM, 1991, J BIOL CHEM, V266, P1985; PAGEL JM, 1992, J MOL BIOL, V224, P919, DOI 10.1016/0022-2836(92)90460-2; Parekh BS, 1996, J BIOL CHEM, V271, P20258, DOI 10.1074/jbc.271.34.20258; Parekh BS, 1996, P NATL ACAD SCI USA, V93, P1173, DOI 10.1073/pnas.93.3.1173; PARK SJ, 1995, J BACTERIOL, V177, P6255, DOI 10.1128/jb.177.21.6255-6262.1995; PARK SJ, 1995, J BACTERIOL, V177, P6652, DOI 10.1128/jb.177.22.6652-6656.1995; Park SJ, 1997, J BACTERIOL, V179, P4138, DOI 10.1128/jb.179.13.4138-4142.1997; PRESUTTI DG, 1995, MOL GEN GENET, V246, P228, DOI 10.1007/BF00294686; Sheridan SD, 1998, J BIOL CHEM, V273, P21298, DOI 10.1074/jbc.273.33.21298; Sheridan SD, 1999, J BIOL CHEM, V274, P8169, DOI 10.1074/jbc.274.12.8169; VANBOGELEN RA, 1996, ESCHERICHIA COLI SAL, P2067; WEK RC, 1986, NUCLEIC ACIDS RES, V14, P2763, DOI 10.1093/nar/14.6.2763; WERNER MH, 1994, CURR BIOL, V4, P477, DOI 10.1016/S0960-9822(00)00108-1; Yang SW, 1995, EMBO J, V14, P6292, DOI 10.1002/j.1460-2075.1995.tb00319.x; ZABLEWSKA B, 1995, GENE, V160, P131, DOI 10.1016/0378-1119(95)00252-2; ZULIANELLO L, 1994, EMBO J, V13, P1534, DOI 10.1002/j.1460-2075.1994.tb06415.x	54	206	212	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29672	29684		10.1074/jbc.M002247200	http://dx.doi.org/10.1074/jbc.M002247200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10871608	hybrid			2022-12-27	WOS:000089439800067
J	Santos, MA; Jimenez, A; Revuelta, JL				Santos, MA; Jimenez, A; Revuelta, JL			Molecular characterization of FMN1, the structural gene for the monofunctional flavokinase of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE SYNTHETASE; RAT-LIVER; RIBOFLAVIN BIOSYNTHESIS; ESCHERICHIA-COLI; FAD SYNTHETASE; PROTEIN; YEAST; MITOCHONDRIA; PURIFICATION; EXPRESSION	Flavokinase catalyzes the transfer of the gamma-phosphoryl group of ATP to riboflavin to form the flavocoenzyme FMN. Consistent patterns of sequence similarities have identified the open reading frame of unknown function YDR236c as a candidate to encode flavokinase in Saccharomyces cerevisiae, In order to determine whether the product of this gene corresponds to yeast flavokinase, its coding region was amplified from S, cerevisiae genomic DNA by polymerase chain reaction and expressed in Escherichia coli, The purified form of the expressed recombinant protein efficiently catalyzed the formation of FMN from riboflavin and ATP, In contrast to bifunctional prokaryotic flavokinase/FAD synthetase enzymes, the yeast enzyme did not show accompanying FAD synthetase activity. Deletion of YDR236c produced yeast mutants unable to grow on rich medium; however, the growth of the ydr236c Delta mutants could be rescued by the addition of FMN to the medium. Overexpression of YDR236e caused a 50-fold increase in flavokinase specific activity in yeast cells. These findings demonstrate that YDR236e corresponds to the gene encoding a monofunctional flavokinase in yeast, which we propose to be designated as FMN1. The FMN1 gene codes for a 25-kDa protein with characteristics of signals for import into mitochondria. By immunoblotting analysis of Saccharomyces subcellular fractions, we provide evidence that the Fmn1 protein is localized in microsomes and in mitochondria, Analysis of submitochondrial fractions revealed that the mitochondrial form of Fmn1p is an integral protein of the inner membrane exposing its COOH-terminal domain to the matrix space. A similarity search in the data base banks revealed the presence of sequences homologous to yeast flavokinase in the genome of several eukaryotic organisms such as Schizosaccharomyces pombe, Arabidopsis thaliana, Drosophila melanogaster, Caenorhabditis elegans, and humans.	Univ Salamanca, CSIC, Dept Genet & Microbiol, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca	Revuelta, JL (corresponding author), Univ Salamanca, CSIC, Dept Genet & Microbiol, Campus Miguel de Unamuno, Salamanca 37007, Spain.		Santos, Maria Angeles/H-2239-2015; Jiménez, Alberto/A-6234-2009; Revuelta, Jose Luis/ABG-1502-2020; Revuelta, Jose L/C-2324-2012	Santos, Maria Angeles/0000-0002-1257-7611; Jiménez, Alberto/0000-0003-3685-6479; Revuelta, Jose Luis/0000-0001-7838-5308; Revuelta, Jose L/0000-0001-7838-5308				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BARILE M, 1993, ARCH BIOCHEM BIOPHYS, V305, P442, DOI 10.1006/abbi.1993.1444; Brachmann CB, 1998, YEAST, V14, P115; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cooperman J.M., 1984, HDB VITAMINS NUTR BI, P299; Dawson R. M. C., 1991, DATA BIOCH RES, V3rd, P363; Forster C, 1999, J BIOL CHEM, V274, P9442, DOI 10.1074/jbc.274.14.9442; GARCIARAMIREZ JJ, 1995, J BIOL CHEM, V270, P23801, DOI 10.1074/jbc.270.40.23801; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOMES B, 1983, P SOC EXP BIOL MED, V172, P250; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Jacq C, 1997, NATURE, V387, P75, DOI 10.1038/387s075; KEARNEY EB, 1979, J BIOL CHEM, V254, P9551; Koonin EV, 1998, CURR OPIN STRUC BIOL, V8, P355, DOI 10.1016/S0959-440X(98)80070-5; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mack M, 1998, J BACTERIOL, V180, P950, DOI 10.1128/JB.180.4.950-955.1998; MANSTEIN DJ, 1986, J BIOL CHEM, V261, P6169; MCCORMICK DB, 1989, PHYSIOL REV, V69, P1170, DOI 10.1152/physrev.1989.69.4.1170; MCCORMICK DB, 1987, FLAVINS FLAVOPROTEIN, P459; MERRILL AH, 1980, J BIOL CHEM, V255, P1335; MITSUDA H, 1966, P JPN ACAD, V42, P940, DOI 10.2183/pjab1945.42.940; NAKANO H, 1991, FLAVINS AND FLAVOPROTEINS 1990, P89; NAKANO H, 1991, J BIOL CHEM, V266, P22125; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OKA M, 1987, J BIOL CHEM, V262, P7418; Pallotta ML, 1998, FEBS LETT, V428, P245, DOI 10.1016/S0014-5793(98)00544-4; REDDY ARV, 1980, J BIOSCIENCE, V2, P211; REID GA, 1982, J BIOL CHEM, V257, P3068; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; SANTOS MA, 1995, J BIOL CHEM, V270, P437, DOI 10.1074/jbc.270.1.437; SCHRECKER AW, 1950, J BIOL CHEM, V182, P795; Sherman F., 1986, METHODS YEAST GENETI, P163; SOBHANADITYA J, 1981, BIOCHEM J, V197, P227, DOI 10.1042/bj1970227; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Tzagoloff A, 1996, J BIOL CHEM, V271, P7392, DOI 10.1074/jbc.271.13.7392; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WU M, 1995, MOL CELL BIOL, V15, P264, DOI 10.1128/MCB.15.1.264; YAMADA Y, 1990, ARCH BIOCHEM BIOPHYS, V278, P125, DOI 10.1016/0003-9861(90)90240-Y; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	45	59	63	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28618	28624		10.1074/jbc.M004621200	http://dx.doi.org/10.1074/jbc.M004621200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10887197	hybrid			2022-12-27	WOS:000089330700039
J	Du, J; Mitch, WE; Wang, XN; Price, SR				Du, J; Mitch, WE; Wang, XN; Price, SR			Glucocorticoids induce proteasome C3 subunit expression in L6 muscle cells by opposing the suppression of its transcription by NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN; PROTEOLYSIS; DEGRADATION; PROTEINS; PATHWAY; ACTIVATION; RATS; TRANSACTIVATION; REPRESSION; INHIBITORS	Muscle wasting in catabolic conditions results from activation of the ubiquitin-proteasome proteolytic pathway by a process that requires glucocorticoids and is generally associated with increased levels of mRNAs encoding components of this proteolytic system. In L6 muscle cells, dexamethasone stimulates proteolysis and increases the amount of the proteasome C3 subunit protein by augmenting its transcription. Transfection studies with human C3 promoter-luciferase reporter genes and electrophoretic mobility shift assays revealed that a NF-kappa B-protein complex containing Rel A is abundant in L6 muscle cell nuclei, Glucocorticoids stimulate C3 subunit expression by antagonizing the interaction of this NF-kappa B protein with an NF-kappa B response element in the C3 subunit promoter region. Dexamethasone also increased the cytosolic amounts of the NF-kappa B p65 subunit and the I kappa B alpha inhibitor proteins in L6 cells. Incubation of L6 cells with a cytokine mixture not only increased the amount of activated NF-kappa B but also decreased C3 promoter activity and lowered endogenous C3 subunit mRNA. Thus, NP-kappa B is a repressor of C3 proteasome subunit transcription in muscle cells, and glucocorticoids stimulate C3 subunit expression by opposing this suppressor action.	Emory Univ, Div Renal, Atlanta, GA 30322 USA	Emory University	Price, SR (corresponding author), Emory Univ, Div Renal, Rm 388 WMB,1639 Pierce Dr, Atlanta, GA 30322 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045317, R01HL045317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037175, R01DK050740, R37DK037175] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45317] Funding Source: Medline; NIDDK NIH HHS [DK37175, R37 DK037175, DK50740] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY JL, 1995, AM J PHYSIOL-CELL PH, V269, pC706, DOI 10.1152/ajpcell.1995.269.3.C706; Bailey JL, 1996, J CLIN INVEST, V97, P1447, DOI 10.1172/JCI118566; BEDARD S, 1997, BIOCHEM J, V325, P467; Bellocq A, 1998, J BIOL CHEM, V273, P5086, DOI 10.1074/jbc.273.9.5086; Chang HR, 1998, JPEN-PARENTER ENTER, V22, P156, DOI 10.1177/0148607198022003156; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGLAND BK, 1995, AM J PHYSIOL-CELL PH, V268, pC1395, DOI 10.1152/ajpcell.1995.268.6.C1395; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; GULVE EA, 1989, BIOCHEM J, V260, P377, DOI 10.1042/bj2600377; HAIRE MF, 1995, ARCH BIOCHEM BIOPHYS, V318, P15, DOI 10.1006/abbi.1995.1198; Isozaki Y, 1996, P NATL ACAD SCI USA, V93, P1967, DOI 10.1073/pnas.93.5.1967; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; MITCH WE, 1994, J CLIN INVEST, V93, P2127, DOI 10.1172/JCI117208; Mitch WE, 1999, AM J PHYSIOL-CELL PH, V276, pC1132, DOI 10.1152/ajpcell.1999.276.5.C1132; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; PRICE SR, 1994, AM J PHYSIOL-CELL PH, V267, pC955, DOI 10.1152/ajpcell.1994.267.4.C955; Price SR, 1996, J CLIN INVEST, V98, P1703, DOI 10.1172/JCI118968; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Sen CK, 1997, BIOCHEM BIOPH RES CO, V237, P645, DOI 10.1006/bbrc.1997.7206; Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690; TAMURA T, 1994, J MOL BIOL, V244, P117, DOI 10.1006/jmbi.1994.1710; Tawa NE, 1997, J CLIN INVEST, V100, P197, DOI 10.1172/JCI119513; TIAO G, 1994, J CLIN INVEST, V94, P2255, DOI 10.1172/JCI117588; Tiao G, 1996, J CLIN INVEST, V97, P339, DOI 10.1172/JCI118421; Tiao Gregory M., 1995, Surgical Forum, V46, P10; WING SS, 1993, AM J PHYSIOL, V264, P668	33	114	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19661	19666		10.1074/jbc.M907258199	http://dx.doi.org/10.1074/jbc.M907258199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867022	hybrid			2022-12-27	WOS:000087941300031
J	Norlin, M; Andersson, U; Bjorkhem, I; Wikvall, K				Norlin, M; Andersson, U; Bjorkhem, I; Wikvall, K			Oxysterol 7 alpha-hydroxylase activity by cholesterol 7 alpha-hydroxylase (CYP7A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; BILE-ACID BIOSYNTHESIS; NUCLEAR RECEPTOR LXR; STEROL 27-HYDROXYLASE; MOLECULAR-CLONING; SIDE-CHAIN; 27-HYDROXYCHOLESTEROL; IDENTIFICATION; PATHWAY; BRAIN	A 7 alpha -hydroxylation is necessary for conversion of both cholesterol and 27-hydroxycholesterol into bile acids. According to current, theories, cholesterol 7 alpha -hydroxylase (CYP7A) is responsible for the former and oxysterol 7 alpha -hydroxylase (CYP7B) for the latter reaction. CYP7A is believed to have a very high substrate specificity whereas CYP7B is active toward oxysterols, dehydroepiandrosterone, and pregnenolone, In the present study, 7 alpha -hydroxylation of various oxysterols in liver and kidney was investigated. Surprisingly, human cholesterol 7 alpha -hydroxylase, CYP7A, expressed as a recombinant in Escherichia coli and COS cells, was active toward 20(S)-hydroxycholesterol, 25-hydroxycholesterol, and 27-hydroxycholesterol, This enzyme has previously been thought to be specific for cholesterol and cholestanol, A partially purified and reconstituted cholesterol 7 alpha -hydroxylase enzyme fraction from pig liver showed 7 alpha -hydroxylase activity toward the same oxysterols as metabolized by expressed recombinant human and rat CYP7A. The 7 alpha -hydroxylase activity toward 20(S)-hydroxycholesterol, 25-hydroxycholesterol, and 27-hydroxycholesterol in rat Liver was significantly increased by treatment with cholestyramine, an inducer of CYP7A From the present results it may be concluded that CYP7A is able to function as an oxysterol 7 alpha -hydroxylase, in addition to the previously known human oxysterol 7 alpha -hydroxylase, CYP7B. These findings may have implications for oxysterol-mediated regulation of gene expression and for pathways of bile acid biosynthesis, A possible use of 20(S)-hydroxycholesterol as a marker substrate for CYP7A is proposed.	Univ Uppsala, Dept Pharmaceut Biosci, Div Biochem, S-75123 Uppsala, Sweden; Huddinge Univ Hosp, Karolinska Inst, Div Clin Chem, S-14186 Huddinge, Sweden	Uppsala University; Karolinska Institutet	Norlin, M (corresponding author), Univ Uppsala, Dept Pharmaceut Biosci, Div Biochem, Box 578, S-75123 Uppsala, Sweden.			Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190; Norlin, Maria/0000-0003-4348-6269				ANDERSON CD, 1985, PHOTODERMATOLOGY, V2, P111; AXELSON M, 1990, J STEROID BIOCHEM, V36, P631, DOI 10.1016/0022-4731(90)90182-R; Babiker A, 1999, J LIPID RES, V40, P1417; BJORKHEM I, 1992, J LIPID RES, V33, P455; BJORKHEM I, 1992, BIOCHIM BIOPHYS ACTA, V1128, P73, DOI 10.1016/0005-2760(92)90259-X; BROWN MJG, 1974, EUR J BIOCHEM, V44, P37, DOI 10.1111/j.1432-1033.1974.tb03455.x; Coon M J, 1978, Methods Enzymol, V52, P109; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JAVITT NB, 1981, J BIOL CHEM, V256, P2644; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; JOHANSSO.G, 1970, EUR J BIOCHEM, V17, P292, DOI 10.1111/j.1432-1033.1970.tb01167.x; KARAM WG, 1994, J LIPID RES, V35, P1222; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND E, 1992, J BIOL CHEM, V267, P12462; MARTIN KO, 1993, J LIPID RES, V34, P581; Martin KO, 1997, J LIPID RES, V38, P1053; Norlin M, 1998, BBA-LIPID LIPID MET, V1390, P269, DOI 10.1016/S0005-2760(97)00193-8; NOSHIRO M, 1989, FEBS LETT, V257, P97, DOI 10.1016/0014-5793(89)81795-8; NOSHIRO M, 1990, FEBS LETT, V268, P137, DOI 10.1016/0014-5793(90)80992-R; OGISHIMA T, 1987, J BIOL CHEM, V262, P7646; Parish EJ, 1999, CRIT REV BIOCHEM MOL, V34, P265, DOI 10.1080/10409239991209291; PAYNE DW, 1995, J BIOL CHEM, V270, P18888, DOI 10.1074/jbc.270.32.18888; Rose KA, 1997, P NATL ACAD SCI USA, V94, P4925, DOI 10.1073/pnas.94.10.4925; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; SCHEER I, 1956, J AM CHEM SOC, V78, P4733, DOI 10.1021/ja01599a054; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; SCHWARTZ MA, 1983, J LIPID RES, V24, P28; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; Setchell KDR, 1998, J CLIN INVEST, V102, P1690, DOI 10.1172/JCI2962; STAPLETON G, 1995, J BIOL CHEM, V270, P29739, DOI 10.1074/jbc.270.50.29739; Stravitz RT, 1996, J STEROID BIOCHEM, V57, P337, DOI 10.1016/0960-0760(95)00282-0; TOLL A, 1994, EUR J BIOCHEM, V224, P309, DOI 10.1111/j.1432-1033.1994.00309.x; TOLL A, 1992, FEBS LETT, V296, P73, DOI 10.1016/0014-5793(92)80406-7; Waterman MR, 1986, CYTOCHROME P450 STRU, P345; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Wu ZL, 1999, J LIPID RES, V40, P2195; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; ZHANG J, 1995, CR ACAD SCI III-VIE, V318, P345	42	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34046	34053		10.1074/jbc.M002663200	http://dx.doi.org/10.1074/jbc.M002663200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10882719	hybrid			2022-12-27	WOS:000165095300009
J	Kopf, E; Plassat, JL; Vivat, V; de The, H; Chambon, P; Rochette-Egly, C				Kopf, E; Plassat, JL; Vivat, V; de The, H; Chambon, P; Rochette-Egly, C			Dimerization with retinoid x receptors and phosphorylation modulate the retinoic acid-induced degradation of retinoic acid receptors alpha and gamma through the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; LIGAND-BINDING DOMAIN; TERATOCARCINOMA STEM-CELLS; ACTIVATION FUNCTION AF-1; RAR-ALPHA; NUCLEAR RECEPTORS; F9 CELLS; DEPENDENT DEGRADATION; MEDIATED DEGRADATION; TRANSCRIPTION FACTOR	In eukaryotic cells, the ubiquitin-proteasome pathway is the major mechanism for targeted degradation of proteins. We show that, in F9 cells and in transfected COS-I cells, the nuclear retinoid receptors, retinoic acid receptor gamma2 (RAR gamma2), RAR alpha1, and retinoid X receptor alpha1 (RXR alpha1) are degraded in a retinoic acid-dependent manner through the ubiquitin-proteasome pathway. The degradation of RAR gamma2 is entirely dependent on its phosphorylation and an its heterodimerization with liganded RXR alpha1. In contrast. RAR alpha1 degradation can occur in the absence of heterodimerization, whereas it is inhibited by phosphorylation, and heterodimerization reverses that inhibition. RXR alpha1 degradation is also modulated by heterodimerization. Thus, each partner of RAR gamma /RXR alpha and RAR alpha /RXR alpha heterodimers modulates the degradation of the other. We conclude that the ligand-dependent degradation of RARs and RXRs by the ubiquitin-proteasome pathway, which is regulated by heterodimerization and by phosphorylation, could be important for the regulation of the magnitude and duration of the effects of retinoid signals.	Coll France, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM,ULP, F-67404 Illkirch Graffenstaden, France; Hop St Louis, CNRS, UPR 9051, F-75475 Paris 10, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Rochette-Egly, C (corresponding author), Coll France, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM,ULP, BP 163,CU Strasbourg, F-67404 Illkirch Graffenstaden, France.	cegly@igbmc.u-strasbg.fr						Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; BOUILLET P, 1995, DEV BIOL, V170, P420, DOI 10.1006/dbio.1995.1226; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Chiba H, 1997, J CELL BIOL, V139, P735, DOI 10.1083/jcb.139.3.735; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Fuchs SY, 1999, MOL CELL BIOL, V19, P3289; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; Ghyselinck NB, 1997, INT J DEV BIOL, V41, P425; Haas AL, 1997, FASEB J, V11, P1257; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Imhof MO, 1996, MOL CELL BIOL, V16, P2594; Kastner P, 1997, DEVELOPMENT, V124, P313; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marchal C, 1998, MOL CELL BIOL, V18, P314, DOI 10.1128/MCB.18.1.314; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Masuyama H, 1998, J CELL BIOCHEM, V71, P429, DOI 10.1002/(SICI)1097-4644(19981201)71:3<429::AID-JCB11>3.0.CO;2-P; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Rubin DM, 1997, MOL BIOL REP, V24, P17; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Schulman IG, 1997, GENE DEV, V11, P299, DOI 10.1101/gad.11.3.299; Scita G, 1996, J BIOL CHEM, V271, P6502, DOI 10.1074/jbc.271.11.6502; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Vivat V, 1997, EMBO J, V16, P5697, DOI 10.1093/emboj/16.18.5697; WAN YJY, 1994, EXP CELL RES, V210, P56, DOI 10.1006/excr.1994.1009; Weeda G, 1997, NUCLEIC ACIDS RES, V25, P2274, DOI 10.1093/nar/25.12.2274; WEILERGUETTLER H, 1992, P NATL ACAD SCI USA, V89, P2155, DOI 10.1073/pnas.89.6.2155; WILLY PJ, 1999, HORMONE SIGNALING, P307; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	69	123	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33280	33288		10.1074/jbc.M002840200	http://dx.doi.org/10.1074/jbc.M002840200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10869350	hybrid			2022-12-27	WOS:000090104600017
J	Moltedo, O; Verde, C; Capasso, A; Parisi, E; Remondelli, P; Bonatti, S; Alvarez-Hernandez, X; Glass, J; Alvino, CG; Leone, A				Moltedo, O; Verde, C; Capasso, A; Parisi, E; Remondelli, P; Bonatti, S; Alvarez-Hernandez, X; Glass, J; Alvino, CG; Leone, A			Zinc transport and metallothionein secretion in the intestinal human cell line Caco-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFERS RESISTANCE; GENE-EXPRESSION; PLASMA-MEMBRANE; SINDBIS VIRUS; PROTEIN; ABSORPTION; COPPER; MOUSE; DIFFERENTIATION; BIOSYNTHESIS	Caco-2, a human cell line, displays several biochemical and morphological characteristics of differentiated enterocytes. Among these is the ability to transport zinc from the apical to the basal compartment. This process was enhanced following exposure by the apical compartment to increasing concentrations of the metal. High pressure liquid chromatography fractionation of the media obtained from cells labeled with radioactive zinc showed that metallothioneins (MTs), small metal-binding, cysteine-rich proteins), were present in the apical and basal media of controls as well as in cells grown in the presence of high concentrations of zinc. Following exposure to the metal, the levels of Zn-MTs in the apical medium increased, while in the basal compartment the greatest part of zinc appeared in a free form with minor changes in the levels of basal MTs. Metabolic labeling experiments with radioactive cysteine confirmed the apical secretion of MTs. A stable transfectant clone of Caco-8 cells (CL11) was selected for its ability to express constitutively high levels of the mouse metallothionein I protein. This cell line showed an enhanced transport of the metal following exposure to high concentrations of zinc and a constitutive secretion of the mouse metallothionein I protein in the apical compartment. Together, these findings strongly support the hypothesis of a functional role between the biosynthesis and secretion of MTs and the transport of zinc in intestinal cells.	Univ Salerno, Dipartimento Sci Farmaceut, I-84084 Salerno, Italy; Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; CNR, Ist Biochim Prot & Enzimol, I-80125 Naples, Italy; Louisiana State Univ, Hlth Sci Ctr, Dept Med, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA; CNR, Ctr Endocrinol & Oncol Sperimentale G Salvatore, I-80131 Naples, Italy	University of Salerno; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Consiglio Nazionale delle Ricerche (CNR)	Leone, A (corresponding author), Univ Salerno, Dipartimento Sci Farmaceut, Via Ponte Don Melillo, I-84084 Salerno, Italy.		Remondelli, Paolo/X-7805-2019	REMONDELLI, Paolo/0000-0002-3698-3497; VERDE, Cinzia/0000-0001-6185-282X	Telethon [E.0373] Funding Source: Medline	Telethon(Fondazione Telethon)		Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; BONATTI S, 1983, METHOD ENZYMOL, V96, P512; BREMNER I, 1990, ANNU REV NUTR, V10, P63, DOI 10.1146/annurev.nu.10.070190.000431; BREMNER I, 1987, METALLOTHIONEIN, V2, P52; Chesters J. K., 1997, Handbook of nutritionally essential mineral elements., P185; Cigliano S, 1996, EXP CELL RES, V228, P173, DOI 10.1006/excr.1996.0314; COUSINS RJ, 1985, PHYSIOL REV, V65, P238, DOI 10.1152/physrev.1985.65.2.238; Davis SR, 1998, J NUTR, V128, P825, DOI 10.1093/jn/128.5.825; DURNAM DM, 1980, P NATL ACAD SCI-BIOL, V77, P6511, DOI 10.1073/pnas.77.11.6511; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; FALCK FY, 1983, BRIT J IND MED, V40, P305; FLANAGAN PR, 1983, J NUTR, V113, P962, DOI 10.1093/jn/113.5.962; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HEMPE JM, 1991, P NATL ACAD SCI USA, V88, P9671, DOI 10.1073/pnas.88.21.9671; HEMPE JM, 1992, J NUTR, V122, P89, DOI 10.1093/jn/122.1.89; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; JACKSON MJ, 1981, BRIT J NUTR, V46, P15, DOI 10.1079/BJN19810005; JACKSON MJ, 1984, BRIT J NUTR, V51, P199, DOI 10.1079/BJN19840024; LONNERDAL B, 1988, ZINC HUMAN BIOL, P33; MENARD MP, 1981, J NUTR, V111, P1353, DOI 10.1093/jn/111.8.1353; MIGLIACCIO G, 1990, EUR J CELL BIOL, V52, P291; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; NETTESHEIM DG, 1985, BIOCHEMISTRY-US, V24, P6744, DOI 10.1021/bi00345a003; Otvos J D, 1987, Experientia Suppl, V52, P171; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; PINTO M, 1983, BIOL CELL, V47, P323; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; RICHARDS MP, 1975, BIOCHEM BIOPH RES CO, V64, P1215, DOI 10.1016/0006-291X(75)90822-0; Rubartelli A., 1997, UNUSUAL SECRETORY PA, P87, DOI [10.1007/978-3-662-22581-3_3, DOI 10.1007/978-3-662-22581-3_3]; SANTERRE RF, 1984, GENE, V30, P147, DOI 10.1016/0378-1119(84)90115-X; SATO M, 1984, J NUTR, V114, P1683, DOI 10.1093/jn/114.9.1683; SCHMIDT CJ, 1986, P NATL ACAD SCI USA, V83, P3346, DOI 10.1073/pnas.83.10.3346; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WELCH WJ, 1979, J VIROL, V29, P1186, DOI 10.1128/JVI.29.3.1186-1195.1979	41	48	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31819	31825		10.1074/jbc.M002907200	http://dx.doi.org/10.1074/jbc.M002907200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10896936	hybrid			2022-12-27	WOS:000089858900040
J	Pluskota, E; Chen, YM; D'Souza, SE				Pluskota, E; Chen, YM; D'Souza, SE			Src homology domain 2-containing tyrosine phosphatase 2 associates with intercellular adhesion molecule 1 to regulate cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; LEUKOCYTE ADHESION; FIBRINOGEN BINDING; PROTEIN; RECEPTOR; ICAM-1; ACTIVATION; SHP-2; INTEGRIN	Intercellular adhesion molecule-1 (ICAM-1) binds to the plasma protein fibrinogen (Fg) to mediate leukocyte/ endothelial cell interactions. In our studies, the ligation of Fg to ICAM-1 on tumor necrosis factor-alpha-stimulated endothelial cells resulted in the tyrosine phosphorylation of Src homology domain 2 (SH2)-containing phosphatase-2 (SHP-2). The ICAM-1 cytoplasmic sequence IKKYRLQ conforms poorly to the concensus immunoreceptor tyrosine based inhibition motifs found in receptors that bind SHP-2. Nevertheless, the tyrosine phosphorylated sequence (IKKpYRLQ) bound specifically to the SH2 domain proximal to the NH2-terminal of SHP-2 (SHP-2-N) but not to the SH2 domain proximal on the COOH-terminal side (SHP-2-C). Phosphorylated ICAM-1 bound SHP-2-N. In immunoprecipitation experiments, SHP-2 associated with phosphorylated ICAM-1. Cells expressing truncated ICAM-1 that lacked the cytoplasmic sequence (ICAM-1(TR)) failed to associate with SHP-2. ICAM-1 containing the tyrosine to alanine substitution at position 485 (ICAM-1(Y485A)) associated weakly with SHP-2. Cells expressing ICAM-1(TR) and ICAM-1(Y485A) underwent apoptosis upon adhesion to Fg, whereas the wild type ICAM-1 maintained cell survival. These results indicate that ICAM-1 interactions with SHP-2 allow better cellular survival mediated through Fg-ICAM-1 ligation.	Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	D'Souza, SE (corresponding author), Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Lerner Res Inst, 9500 Euclid Ave,NB-50, Cleveland, OH 44195 USA.				NCRR NIH HHS [RR-00080] Funding Source: Medline; NHLBI NIH HHS [HL 43721] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043721, R29HL043721] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adamson P, 1999, J IMMUNOL, V162, P2964; ALTIERI DC, 1995, J BIOL CHEM, V270, P696, DOI 10.1074/jbc.270.2.696; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; Aplin AE, 1998, PHARMACOL REV, V50, P197; Bombeli T, 1998, J EXP MED, V187, P329, DOI 10.1084/jem.187.3.329; BUDZYNSK.AZ, 1974, J BIOL CHEM, V249, P2294; Byzova TV, 1998, THROMB HAEMOSTASIS, V80, P726; Campbell KS, 1996, J EXP MED, V184, P93, DOI 10.1084/jem.184.1.93; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHIRATHAWORN C, 1995, J IMMUNOL, V155, P5479; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; DSouza SE, 1996, J BIOL CHEM, V271, P24270, DOI 10.1074/jbc.271.39.24270; Duperray A, 1997, J BIOL CHEM, V272, P435; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; Etienne S, 1998, J IMMUNOL, V161, P5755; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; Gardiner EE, 1997, J BIOL CHEM, V272, P15474, DOI 10.1074/jbc.272.24.15474; Gardiner EE, 1999, J BIOL CHEM, V274, P11930, DOI 10.1074/jbc.274.17.11930; Hayflick JS, 1998, IMMUNOL RES, V17, P313, DOI 10.1007/BF02786454; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Holland J, 1997, J BIOL CHEM, V272, P9108; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Huyer G, 1999, CURR BIOL, V9, pR129, DOI 10.1016/S0960-9822(99)80080-3; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; Lienard H, 1999, J BIOL CHEM, V274, P32493, DOI 10.1074/jbc.274.45.32493; Manes S, 1999, MOL CELL BIOL, V19, P3125; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Massberg S, 1999, BLOOD, V94, P3829, DOI 10.1182/blood.V94.11.3829.423k35_3829_3838; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; Nakamura MC, 1997, J EXP MED, V185, P673, DOI 10.1084/jem.185.4.673; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Olcese L, 1996, J IMMUNOL, V156, P4531; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Philosof-Oppenheimer R, 2000, EUR J BIOCHEM, V267, P703, DOI 10.1046/j.1432-1327.2000.01044.x; Pluskota E, 1999, BLOOD, V94, p226A; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHANKAR R, 1994, J BIOL CHEM, V269, P13936; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; vandeStolpe A, 1996, THROMB HAEMOSTASIS, V75, P182; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649; Zhao RX, 1999, BIOCHEM J, V338, P35, DOI 10.1042/0264-6021:3380035	54	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30029	30036		10.1074/jbc.M000240200	http://dx.doi.org/10.1074/jbc.M000240200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10864922	hybrid			2022-12-27	WOS:000089577900016
J	Furukawa, T; Tanese, N				Furukawa, T; Tanese, N			Assembly of partial TFIID complexes in mammalian cells reveals distinct activities associated with individual TATA box-binding protein-associated factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CORE PROMOTER SELECTIVITY; HISTONE-LIKE TAFS; LARGE T-ANTIGEN; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; CYCLE PROGRESSION; MOLECULAR-CLONING; TERMINAL DOMAIN; 230-KDA SUBUNIT	The TATA box-binding protein (TBP) and TBP-associated factors (TAF(II)s) compose the general transcription factor TFIID. The TAF(II) subunits mediate activated transcription by RNA polymerase II by interacting directly with site-specific transcriptional regulators. TAF(II)s also participate in promoter recognition by contacting core promoter elements in the context of TFIID. To further dissect the contribution of individual TAF(II) subunits to mammalian TFIID function, we employed a vaccinia virus-based protein expression system to study protein-protein interactions and complex assembly. We identified the domains of human (h) TAF(II)130 required for TAF(II)-TAF(II) interactions and formation of a complex with hTBP, hTAF(II)100, and hTAF(II)250. Functional analysis of partial TFIID complexes formed in vivo indicated that hTAF(II)130 was required for transcriptional activation by Sp1 in vitro. DNase I footprinting experiments demonstrated that purified hTBP/hTAF(II)250 complex reconstituted with or without additional TAF(II)s was significantly reduced for TATA box binding las much as 9-fold) compared with free hTBP. By contrast, hTAF(II)130 stabilized binding of hTBP to the TATA box, whereas hTAF(II)100 had little effect. Thus, our biochemical analysis supports the notion that TAF(II)s possess distinct functions to regulate the activity of TFIID.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Tanese, N (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.			Tanese, Naoko/0000-0002-1946-3211	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051314] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51314] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; AUSUBEL FM, 1988, CURRENT PROTOCOLS MO, V2; Bjorklund S, 1999, CELL, V96, P759, DOI 10.1016/S0092-8674(00)80586-3; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Burley SK, 1998, CELL, V94, P551, DOI 10.1016/S0092-8674(00)81596-2; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CLEARY MA, 1995, MOL CELL BIOL, V15, P2090; Coleman RA, 1999, MOL CELL, V4, P451, DOI 10.1016/S1097-2765(00)80453-0; Damania B, 1998, MOL CELL BIOL, V18, P3926, DOI 10.1128/MCB.18.7.3926; Damania B, 1996, GENE DEV, V10, P1369, DOI 10.1101/gad.10.11.1369; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; Gangloff YG, 2000, MOL CELL BIOL, V20, P340, DOI 10.1128/MCB.20.1.340-351.2000; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; Kaufmann J, 1996, GENE DEV, V10, P873, DOI 10.1101/gad.10.7.873; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; KOKUBO T, 1993, P NATL ACAD SCI USA, V90, P5896, DOI 10.1073/pnas.90.13.5896; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Marshak DR, 1996, STRATEGIES PROTEIN P; Martin J, 1999, MOL CELL BIOL, V19, P5548; Martinez E, 1998, MOL CELL BIOL, V18, P6571, DOI 10.1128/MCB.18.11.6571; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; MOSS B, 1990, NATURE, V348, P919; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ozer J, 1998, J BIOL CHEM, V273, P14293, DOI 10.1074/jbc.273.23.14293; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; Ruppert SML, 1996, HYBRIDOMA, V15, P55, DOI 10.1089/hyb.1996.15.55; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Sauer F, 1997, CURR OPIN GENET DEV, V7, P176, DOI 10.1016/S0959-437X(97)80126-8; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; Tao Y, 1997, J BIOL CHEM, V272, P6714, DOI 10.1074/jbc.272.10.6714; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; Zhou JM, 1998, P NATL ACAD SCI USA, V95, P13483, DOI 10.1073/pnas.95.23.13483	72	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29847	29856		10.1074/jbc.M002989200	http://dx.doi.org/10.1074/jbc.M002989200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896937	hybrid			2022-12-27	WOS:000089439800091
J	Hosoya, M; Moriya, T; Kawamata, Y; Ohkubo, S; Fujii, R; Matsui, H; Shintani, Y; Fukusumi, S; Habata, Y; Hinuma, S; Onda, H; Nishimura, O; Fujino, M				Hosoya, M; Moriya, T; Kawamata, Y; Ohkubo, S; Fujii, R; Matsui, H; Shintani, Y; Fukusumi, S; Habata, Y; Hinuma, S; Onda, H; Nishimura, O; Fujino, M			Identification and functional characterization of a novel subtype of neuromedin U receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SPINAL-CORD; PROLACTIN-RELEASING PEPTIDE; SMALL-INTESTINE; GUINEA-PIG; GASTROINTESTINAL-TRACT; SUBSTANCE-P; RAT; IMMUNOREACTIVITY; EXPRESSION; CLONING	Neuromedin U is a bioactive peptide isolated originally from the porcine spinal cord. We recently identified neuromedin U as the cognate ligand for the orphan Gr protein-coupled receptor FM-3. In this study, we isolated cDNA coding for a novel G protein-coupled receptor, TGR-1, which was highly homologous with FM-3, We found that neuromedin U specifically and clearly elevated the extracellular acidification rates, arachidonic acid metabolite release, and intracellular Ca2+ mobilization in Chinese hamster ovary cells expressing TGR-1. Radiolabeled neuromedin U specifically bound with high affinity to membrane fractions prepared from these cells. These results show that TGR-1, like FM-3, is a specific and functional receptor for neuromedin U, We analyzed TGR-1 mRNA tissue distribution in rats using quantitative reverse transcription-polymerase chain reaction and found it to considerably differ from that of FM-3 mRNA. TGR-1 mRNA was primarily expressed in the uterus, suggesting that TGR-1 mediates the contractile activity of neuromedin U in this tissue. The identification of specific and functional receptor subtypes for neuromedin U will facilitate the study of their physiological roles and the search for their specific agonists and antagonists.	Takeda Chem Ind Ltd, Pharmaceut Discovery Res Div, Tsukuba, Ibaraki 3004293, Japan	Takeda Chemical Industries	Hinuma, S (corresponding author), Takeda Chem Ind Ltd, Pharmaceut Discovery Res Div, Wadai 10, Tsukuba, Ibaraki 3004293, Japan.			Kawamata, Yuji/0000-0001-5652-4899				AUGOOD SJ, 1988, REGUL PEPTIDES, V20, P281, DOI 10.1016/0167-0115(88)90063-8; AUSTIN C, 1995, J MOL ENDOCRINOL, V14, P157, DOI 10.1677/jme.0.0140157; BALLESTA J, 1988, NEUROSCIENCE, V25, P797, DOI 10.1016/0306-4522(88)90037-1; BENITOORFILA MA, 1991, EUR J PHARMACOL, V193, P329, DOI 10.1016/0014-2999(91)90147-I; BROWN DR, 1988, EUR J PHARMACOL, V155, P159, DOI 10.1016/0014-2999(88)90415-3; DOMIN J, 1986, BIOCHEM BIOPH RES CO, V140, P1127, DOI 10.1016/0006-291X(86)90752-7; DOMIN J, 1987, PEPTIDES, V8, P779, DOI 10.1016/0196-9781(87)90058-1; Fujii R, 2000, J BIOL CHEM, V275, P21068, DOI 10.1074/jbc.M001546200; Fujii R, 1999, REGUL PEPTIDES, V83, P1, DOI 10.1016/S0167-0115(99)00028-2; FURNESS JB, 1989, CELL TISSUE RES, V257, P415, DOI 10.1007/BF00261844; Hinuma S, 1999, J MOL MED, V77, P495, DOI 10.1007/s001090050403; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; HINUMA S, 1994, BBA-GENE STRUCT EXPR, V1219, P251, DOI 10.1016/0167-4781(94)90046-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MAGGI CA, 1990, BRIT J PHARMACOL, V99, P186, DOI 10.1111/j.1476-5381.1990.tb14675.x; MALENDOWICZ LK, 1994, NEUROPEPTIDES, V26, P47, DOI 10.1016/0143-4179(94)90092-2; MINAMINO N, 1985, PEPTIDES, V6, P245, DOI 10.1016/0196-9781(85)90381-X; MINAMINO N, 1985, BIOCHEM BIOPH RES CO, V130, P1078, DOI 10.1016/0006-291X(85)91726-7; Nandha KA, 1999, PEPTIDES, V20, P1203, DOI 10.1016/S0196-9781(99)00124-2; NANDHA KA, 1993, ENDOCRINOLOGY, V133, P482, DOI 10.1210/en.133.2.482; STEEL JH, 1988, ENDOCRINOLOGY, V122, P270, DOI 10.1210/endo-122-1-270; SUMI S, 1987, LIFE SCI, V41, P1585, DOI 10.1016/0024-3205(87)90725-9; Tan CP, 1998, GENOMICS, V52, P223, DOI 10.1006/geno.1998.5441; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; TIMMERMANS JP, 1990, CELL TISSUE RES, V260, P367, DOI 10.1007/BF00318639; TIMMERMANS JP, 1989, CELL TISSUE RES, V258, P331, DOI 10.1007/BF00239453	26	102	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29528	29532		10.1074/jbc.M004261200	http://dx.doi.org/10.1074/jbc.M004261200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887190	hybrid			2022-12-27	WOS:000089439800047
J	Kronman, C; Chitlaru, T; Elhanany, E; Velan, B; Shafferman, A				Kronman, C; Chitlaru, T; Elhanany, E; Velan, B; Shafferman, A			Hierarchy of post-translational modifications involved in the circulatory longevity of glycoproteins - Demonstration of concerted contributions of glycan sialylation and subunit assembly to the pharmacokinetic behavior of bovine acetylcholinesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; RECOMBINANT HUMAN ACETYLCHOLINESTERASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; HAMSTER OVARY CELLS; MOLECULAR-FORMS; MASS-SPECTROMETRY; ACTIVE-CENTER; HUMAN BUTYRYLCHOLINESTERASE; QUATERNARY ASSOCIATIONS; MONOCLONAL-ANTIBODIES	The tetrameric form of native serum-derived bovine acetylcholinesterase is retained in the circulation for much longer periods (mean residence time, MRT = 1390 min) than recombinant bovine acetylcholinesterase (rBoAChE) produced in the HEK-293 cell system (MRT = 57 min). Extensive matrix-assisted laser desorption ionization-time of flight analyses established that the basic structures of the N-glycans associated with the native and recombinant enzymes are similar (the major species (50-60%) are of the biantennary fucosylated type and 20-30% are of the triantennary type), yet the glycan termini of the native enzyme are mostly capped with sialic acid (82%) and alpha-galactose (12%), whereas glycans of the recombinant enzyme exhibit a high level of exposed beta-galactose residues (50%) and a lack of alpha-galactose, Glycan termini of both fetal bovine serum and rBoAChE were altered in vitro using exoglycosidases and sialyltransferase or in vivo by a HEK-293 cell line developed specifically to allow efficient sialic acid capping of beta-galactose-exposed termini, In addition, the dimeric and monomeric forms of rBoAChE were quantitatively converted to tetramers by complexation with a synthetic peptide representing the human ColQ-derived proline-rich attachment domain. Thus by controlling both the level and nature of N-glycan capping and subunit assembly, we generated and characterized 9 distinct bovine AChE glycoforms displaying a 400-fold difference in their circulatory lifetimes (MRT = 3.5-1390 min). This revealed some general rules and a hierarchy of post-translation factors determining the circulatory profile of glycoproteins, Accordingly, an rBoAChE was generated that displayed a circulatory profile indistinguishable from the native form.	Israel Inst Biol Res, Dept Biochem & Mol Genet, IL-74100 Ness Ziona, Israel		Shafferman, A (corresponding author), Israel Inst Biol Res, Dept Biochem & Mol Genet, IL-74100 Ness Ziona, Israel.	avigdor@iibr.gov.il						ALLEMAND P, 1981, J NEUROCHEM, V36, P860, DOI 10.1111/j.1471-4159.1981.tb01673.x; Anumula KR, 1998, GLYCOBIOLOGY, V8, P685, DOI 10.1093/glycob/8.7.685; ASHANI Y, 1991, BIOCHEM PHARMACOL, V41, P37, DOI 10.1016/0006-2952(91)90008-S; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; ATACK JR, 1987, J NEUROCHEM, V48, P1845, DOI 10.1111/j.1471-4159.1987.tb05746.x; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; Bon S, 1997, J BIOL CHEM, V272, P3007, DOI 10.1074/jbc.272.5.3007; Bon S, 1997, J BIOL CHEM, V272, P3016, DOI 10.1074/jbc.272.5.3016; BORREBAECK CAK, 1993, IMMUNOL TODAY, V14, P477, DOI 10.1016/0167-5699(93)90259-N; Borrebaeck CAK, 1999, NAT BIOTECHNOL, V17, P621, DOI 10.1038/10798; Bourne Y, 1999, J BIOL CHEM, V274, P30370, DOI 10.1074/jbc.274.43.30370; Chitlaru T, 1998, BIOCHEM J, V336, P647, DOI 10.1042/bj3360647; Douchet J.-C., 1982, TRAV SCI, V3, P342; DRICKAMER K, 1991, CELL, V67, P1029, DOI 10.1016/0092-8674(91)90278-7; DUVAL N, 1992, EMBO J, V11, P3255, DOI 10.1002/j.1460-2075.1992.tb05403.x; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; Fiete DJ, 1998, P NATL ACAD SCI USA, V95, P2089, DOI 10.1073/pnas.95.5.2089; FISCHER M, 1993, CELL MOL NEUROBIOL, V13, P25, DOI 10.1007/BF00712987; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; Giles K, 1998, STRUCTURE AND FUNCTION OF CHOLINESTERASES AND RELATED PROTEINS, P442; HOSSNER KL, 1981, ENDOCRINOLOGY, V108, P1780, DOI 10.1210/endo-108-5-1780; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; Junghans RP, 1999, NAT BIOTECHNOL, V17, P938, DOI 10.1038/13593; KRONMAN C, 1992, GENE, V121, P295, DOI 10.1016/0378-1119(92)90134-B; KRONMAN C, 1995, BIOCHEM J, V311, P959, DOI 10.1042/bj3110959; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; Laub PB, 1996, J PHARM SCI, V85, P393, DOI 10.1021/js9503744; LAZAR M, 1980, J NEUROCHEM, V35, P1067, DOI 10.1111/j.1471-4159.1980.tb07860.x; LEFORT GP, 1984, ENDOCRINOLOGY, V115, P1551, DOI 10.1210/endo-115-4-1551; LEGAY C, 1993, FEBS LETT, V315, P163, DOI 10.1016/0014-5793(93)81155-S; LOCKRIDGE O, 1982, J BIOL CHEM, V257, P2012; Massoulie J, 1999, CHEM-BIOL INTERACT, V119, P29, DOI 10.1016/S0009-2797(99)00011-3; MAXWELL DM, 1992, TOXICOL APPL PHARM, V115, P44, DOI 10.1016/0041-008X(92)90365-Y; Mendelson I, 1998, BIOCHEM J, V334, P251, DOI 10.1042/bj3340251; Millard CB, 1998, BIOCHEMISTRY-US, V37, P237, DOI 10.1021/bi972057c; Monica TJ, 1997, GLYCOBIOLOGY, V7, P515, DOI 10.1093/glycob/7.4.515; NIMTZ M, 1993, EUR J BIOCHEM, V213, P39, DOI 10.1111/j.1432-1033.1993.tb17732.x; Ohno K, 1998, P NATL ACAD SCI USA, V95, P9654, DOI 10.1073/pnas.95.16.9654; Okafo G, 1996, ANAL CHEM, V68, P4424, DOI 10.1021/ac960721+; Okafo G, 1997, ANAL CHEM, V69, P4985, DOI 10.1021/ac9707139; Ordentlich A, 1999, BIOCHEMISTRY-US, V38, P3055, DOI 10.1021/bi982261f; Ordentlich A, 1996, J BIOL CHEM, V271, P11953, DOI 10.1074/jbc.271.20.11953; Papac DI, 1996, ANAL CHEM, V68, P3215, DOI 10.1021/ac960324z; Powell AK, 1996, RAPID COMMUN MASS SP, V10, P1027; RALSTON JS, 1985, J BIOL CHEM, V260, P4312; RAVEH L, 1993, BIOCHEM PHARMACOL, V45, P2465, DOI 10.1016/0006-2952(93)90228-O; ROTUNDO RL, 1979, J BIOL CHEM, V254, P4790; Rowland M, 2011, CLIN PHARMACOKINET, V4, P201; Saxena A, 1998, MOL PHARMACOL, V53, P112, DOI 10.1124/mol.53.1.112; Saxena A, 1997, BIOCHEMISTRY-US, V36, P7481, DOI 10.1021/bi963156d; Shafferman A, 1996, BIOCHEM J, V318, P833, DOI 10.1042/bj3180833; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; Simon S, 1998, EMBO J, V17, P6178, DOI 10.1093/emboj/17.21.6178; STIEGER S, 1989, J NEUROCHEM, V52, P1188, DOI 10.1111/j.1471-4159.1989.tb01865.x; TANIGAWARA Y, 1990, CHEM PHARM BULL, V38, P517, DOI 10.1248/cpb.38.517; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TAYLOR PB, 1981, J BIOL CHEM, V256, P3827; THOMAS P, 1983, DIGEST DIS SCI, V28, P216, DOI 10.1007/BF01295116; VELAN B, 1991, J BIOL CHEM, V266, P23977; VIGNY M, 1979, J NEUROCHEM, V33, P559, DOI 10.1111/j.1471-4159.1979.tb05188.x; VOSTAL JG, 1991, THROMB RES, V63, P299, DOI 10.1016/0049-3848(91)90133-H; Weikert S, 1999, NAT BIOTECHNOL, V17, P1116, DOI 10.1038/15104; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; Weiss P, 1989, Prog Clin Biol Res, V300, P169; WOLFE AD, 1987, FUND APPL TOXICOL, V9, P266, DOI 10.1016/0272-0590(87)90048-0; YAN SB, 1993, GLYCOBIOLOGY, V3, P597, DOI 10.1093/glycob/3.6.597; YOUNKIN SG, 1982, J BIOL CHEM, V257, P13630	70	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29488	29502		10.1074/jbc.M004298200	http://dx.doi.org/10.1074/jbc.M004298200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10867010	hybrid			2022-12-27	WOS:000089439800043
J	Webster, CRL; Blanch, CJ; Phillips, J; Anwer, MS				Webster, CRL; Blanch, CJ; Phillips, J; Anwer, MS			Cell swelling-induced translocation of rat liver Na+/taurocholate cotransport polypeptide is mediated via the phosphoinositide 3-kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADENOSINE-MONOPHOSPHATE; PROTEIN-KINASE-B; BILE-ACID UPTAKE; PHOSPHATIDYLINOSITOL 3-KINASE; TAUROCHOLATE EXCRETION; GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; LIPID PRODUCTS; HEPATOCYTES; EXPRESSION	Cell swelling stimulates phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) in hepatocytes, and the PI3K signaling pathway is involved in cAMP-mediated translocation of sinusoidal Na+/taurocholate (TC) cotransporter (Ntcp) to the plasma membrane. We determined whether cell swelling also stimulates TC uptake and Ntcp translocation via the PI3K and/or MAPK signaling pathway. All studies were conducted in isolated rat hepatocytes, Hepatocyte swelling induced by hypotonic media resulted in: 1) time- and medium osmolarity-dependent increases in TC uptake, 2) an increase in the V-max of Na+/TC cotransport, and 3) wortmannin-sensitive increases in TC uptake and plasma membrane Ntcp mass. Hepatocyte swelling also induced wortmannin-sensitive activation of PI3K, protein kinase B, and p70(S6K). Rapamycin, an inhibitor of p70(S6K), inhibited cell swelling-induced activation of p70(S6K) but failed to inhibit cell swelling-induced stimulation of TC uptake. Because PD98095, an inhibitor of MAPK, did not inhibit cell swelling-induced increases in TC uptake, it is unlikely that the effect of cell swelling on TC uptake is mediated via the MAPK signaling pathway. Taken together, these results indicate that 1) cell swelling stimulates TC uptake by translocating Ntcp to the plasma membrane, 2) this effect is mediated via the PI3K, but not MAPK, signaling pathway, and 3) protein kinase B, but not p70(S6K), is a likely downstream effector of PI3K.	Tufts Univ, Sch Vet Med, Dept Biomed Sci, North Grafton, MA 01536 USA	Tufts University	Anwer, MS (corresponding author), Tufts Univ, Sch Vet Med, Dept Biomed Sci, 200 Westboro Rd, North Grafton, MA 01536 USA.	SANWER@INFONET.TUFTS.EDU			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033436] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33436] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANTHANARAYANAN M, 1994, AM J PHYSIOL-GASTR L, V267, pG637, DOI 10.1152/ajpgi.1994.267.4.G637; ANWER MS, 1978, H-S Z PHYSIOL CHEM, V359, P181; ANWER MS, 1976, H-S Z PHYSIOL CHEM, V357, P1477, DOI 10.1515/bchm2.1976.357.2.1477; ANWER MS, 1993, ADV VET SCI COMP MED, V37, P1; BRUCK R, 1992, AM J PHYSIOL, V262, pG806, DOI 10.1152/ajpgi.1992.262.5.G806; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CORASANTI JG, 1990, AM J PHYSIOL, V258, pG290, DOI 10.1152/ajpgi.1990.258.2.G290; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dranoff JA, 1999, HEPATOLOGY, V30, P223, DOI 10.1002/hep.510300136; Feranchak AP, 1999, J BIOL CHEM, V274, P30979, DOI 10.1074/jbc.274.43.30979; Feranchak AP, 1998, J BIOL CHEM, V273, P14906, DOI 10.1074/jbc.273.24.14906; Folli F, 1997, GASTROENTEROLOGY, V113, P954, DOI 10.1016/S0016-5085(97)70192-6; Gartung C, 1996, GASTROENTEROLOGY, V110, P199, DOI 10.1053/gast.1996.v110.pm8536857; Gatmaitan ZC, 1997, AM J PHYSIOL-GASTR L, V272, pG1041, DOI 10.1152/ajpgi.1997.272.5.G1041; Glavy JS, 2000, J BIOL CHEM, V275, P1479, DOI 10.1074/jbc.275.2.1479; GRUNE S, 1993, J BIOL CHEM, V268, P17734; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HALLBRUCKER C, 1992, BIOCHEM J, V281, P593, DOI 10.1042/bj2810593; Haussinger D, 1996, BIOCHEM J, V313, P697; HAUSSINGER D, 1993, BIOCHEM J, V291, P355; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Koopen NR, 1999, J HEPATOL, V30, P14, DOI 10.1016/S0168-8278(99)80003-8; Krause U, 1996, J BIOL CHEM, V271, P16668, DOI 10.1074/jbc.271.28.16668; KUTIZ R, 1991, GASTROENTEROLOGY, V113, P1438; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG D, 1993, HEPATOLOGY, V18, P1162; Liu Y, 1997, AM J PHYSIOL-GASTR L, V272, pG46, DOI 10.1152/ajpgi.1997.272.1.G46; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Misra S, 1999, HEPATOLOGY, V30, p306A; Moseley RH, 1996, AM J PHYSIOL-GASTR L, V271, pG137, DOI 10.1152/ajpgi.1996.271.1.G137; Mukhopadhayay S, 1997, AM J PHYSIOL-GASTR L, V273, pG842, DOI 10.1152/ajpgi.1997.273.4.G842; Mukhopadhyay S, 1998, J BIOL CHEM, V273, P30039, DOI 10.1074/jbc.273.45.30039; Mukhopadhyay S, 1998, HEPATOLOGY, V28, P1629, DOI 10.1002/hep.510280624; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; Noe B, 1996, GASTROENTEROLOGY, V110, P858, DOI 10.1053/gast.1996.v110.pm8608896; PFALLER W, 1993, J CELL PHYSIOL, V154, P248, DOI 10.1002/jcp.1041540206; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Reichel C, 1999, GASTROENTEROLOGY, V117, P688, DOI 10.1016/S0016-5085(99)70463-4; Simon FR, 1996, AM J PHYSIOL-GASTR L, V271, pG1043, DOI 10.1152/ajpgi.1996.271.6.G1043; STIEGER B, 1994, GASTROENTEROLOGY, V107, P1781, DOI 10.1016/0016-5085(94)90821-4; Su TZ, 1998, J BIOL CHEM, V273, P3173, DOI 10.1074/jbc.273.6.3173; SUSA M, 1992, J BIOL CHEM, V267, P22951; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Webster CRL, 1999, AM J PHYSIOL-GASTR L, V277, pG1165, DOI 10.1152/ajpgi.1999.277.6.G1165; Webster CRL, 1998, HEPATOLOGY, V27, P1324, DOI 10.1002/hep.510270519; WETTSTEIN M, 1995, HEPATOLOGY, V22, P235, DOI 10.1002/hep.1840220134; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520; YANO H, 1993, J BIOL CHEM, V268, P25846	50	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29754	29760		10.1074/jbc.M002831200	http://dx.doi.org/10.1074/jbc.M002831200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10889198	hybrid			2022-12-27	WOS:000089439800078
J	Harris, VK; Coticchia, CM; List, HJ; Wellstein, A; Riegel, AT				Harris, VK; Coticchia, CM; List, HJ; Wellstein, A; Riegel, AT			Mitogen-induced expression of the fibroblast growth factor-binding protein is transcriptionally repressed through a non-canonical E-box element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; HUMAN CANCERS; PROMOTER ELEMENTS; IN-VIVO; MYC; GENE; METHYLATION; USF; FAMILY; HYPOMETHYLATION	The fibroblast growth factor-binding protein (FGF-BP) stimulates FGP-2-mediated angiogenesis and is thought to play an important role in the progression of squamous cell, colon, and breast carcinomas, 12-O-Tetradecanoylphorbol-13-acetate (TPA) induction of the FGF-BP gene occurs through transcriptional mechanisms involving Sp1, AP-1, and CCAATT/enhancer-binding protein sites in the proximal FGF-BP gene promoter. The level of TPA induction, however, is limited due to the presence of a repressor element that shows similarity to a non-canonical E-box (AACGTG), Mutation or deletion of the repressor element led to enhanced induction by TPA or epidermal growth factor in cervical squamous cell and breast carcinoma cell lines. Repression was dependent on the adjacent AP-1 site, without discernible alteration in the binding affinity or composition of AP-1, We investigated the following two possible mechanisms for E-box-mediated repression: 1) CpG methylation of the core of the E-box element, and 2) binding of a distinct protein complex to this site. Point mutation of the CpG methylation site in the E-box showed loss of repressor activity. Conversely, in vitro methylation of this site significantly reduced TPA induction. In vitro gel shift analysis revealed distinct and TPA-dependent binding of USF1 and USF2 to the repressor element that required nucleotides within the E-box. Furthermore, chromatin immunoprecipitation assay showed that USF, c-Myc, and Max proteins were associated with the FGF-BP promoter in vivo, Overall, these findings suggested that the balance between trans-activation by AP-1 and repression through the E-box is an important control mechanism for fine-tuning the angiogenic response to growth factor-activated pathways.	Georgetown Univ, Dept Oncol, Vincent T Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University	Riegel, AT (corresponding author), Georgetown Univ, Dept Oncol, Vincent T Lombardi Canc Ctr, REs Bldg,Rm E307,3970 Reservoir Rd NW, Washington, DC 20007 USA.			Wellstein, Anton/0000-0002-0570-4950	NCI NIH HHS [CA71508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; VLODAVSKY I, 1991, ANN NY ACAD SCI, V638, P207; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WU DQ, 1991, J BIOL CHEM, V266, P16778	28	23	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28539	28548		10.1074/jbc.M001677200	http://dx.doi.org/10.1074/jbc.M001677200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10871606	hybrid			2022-12-27	WOS:000089330700029
J	Hazebrouck, S; Camoin, L; Faltin, Z; Strosberg, AD; Eshdat, Y				Hazebrouck, S; Camoin, L; Faltin, Z; Strosberg, AD; Eshdat, Y			Substituting selenocysteine for catalytic cysteine 41 enhances enzymatic activity of plant phospholipid hydroperoxide glutathione peroxidase expressed in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; UGA CODON; THIOREDOXIN REDUCTASE; FORMATE DEHYDROGENASE; SECIS ELEMENTS; GENE; PROTEIN; INSERTION; CITRUS; STRESS	The citrus phospholipid hydroperoxide glutathione peroxidase (cit-PHGPx) was the first plant peroxidase demonstrated to exhibit PHGPx-specific enzymatic activity, although it was 500-fold weaker than that of the pig heart analog. This relatively low activity is accounted for the catalytic residue of cit-PHGPx, which was found to be cysteine and not the rare selenocysteine (Sec) present in animal enzymes. Sec incorporation into proteins is encoded by a UGA codon, usually a STOP codon, which, in prokaryotes, is suppressed by an adjacent downstream mRNA stem-loop structure, the Sec insertion sequence (SECIS). By performing appropriate nucleotide substitutions into the gene encoding cit-PHGPx, we introduced bacterial-type SECIS elements that afforded the substitution of the catalytic Cys(41) by Sec, as established by mass spectrometry, while preserving the functional integrity of the peroxidase. The recombinant enzyme, whose synthesis is selenium-dependent, displayed a 4-fold enhanced peroxidase activity as compared with the Cys-containing analog, thus confirming the higher catalytic power of Sec compared with Cys in cit-PHGPx active site. The study led also to refinement of the minimal sequence requirements of the bacterial-type SECIS, and, for the first time, to the heterologous expression in Escherichia coli of a eukaryotic selenoprotein containing a SECIS in its open reading frame.	Agr Res Org, Volcani Ctr, Dept Fruit Tree Breeding & Mol Genet, IL-50250 Bet Dagan, Israel; Inst Cochin Genet Mol, CNRS UPR 415, F-75014 Paris, France	VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Eshdat, Y (corresponding author), Agr Res Org, Volcani Ctr, Dept Fruit Tree Breeding & Mol Genet, POB 6, IL-50250 Bet Dagan, Israel.		Camoin, Luc/AAB-3856-2019	Camoin, Luc/0000-0002-1230-4787				Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; Baron Christian, 1995, P529; BEEORTZAHAR T, 1995, FEBS LETT, V366, P151, DOI 10.1016/0014-5793(95)00521-A; BENHAYYIM G, 1993, PLANT SCI, V88, P129, DOI 10.1016/0168-9452(93)90084-D; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; Boschi-Muller S, 1998, FEBS LETT, V439, P241, DOI 10.1016/S0014-5793(98)01377-5; CHEN GT, 1992, MOL MICROBIOL, V6, P781, DOI 10.1111/j.1365-2958.1992.tb01528.x; CHU FF, 1992, BLOOD, V79, P3233; Ding L, 1998, BIOCHEM J, V332, P251, DOI 10.1042/bj3320251; Eshdat Y, 1997, PHYSIOL PLANTARUM, V100, P234, DOI 10.1034/j.1399-3054.1997.1000204.x; Faltin Z, 1998, PHYSIOL PLANTARUM, V104, P741, DOI 10.1034/j.1399-3054.1998.1040432.x; Flohe L., 1982, LIPID PEROXIDES BIOL, P149; Gladyshev VN, 1999, BIOCHEM BIOPH RES CO, V259, P244, DOI 10.1006/bbrc.1999.0765; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; HOLLAND D, 1994, FEBS LETT, V337, P52, DOI 10.1016/0014-5793(94)80628-4; Kromayer M, 1996, J MOL BIOL, V262, P413, DOI 10.1006/jmbi.1996.0525; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; Liu JQ, 1998, BIOTECHNOL LETT, V20, P693, DOI 10.1023/A:1005378709179; Liu ZS, 1998, NUCLEIC ACIDS RES, V26, P896, DOI 10.1093/nar/26.4.896; Liu ZS, 1999, J MOL BIOL, V294, P1073, DOI 10.1006/jmbi.1999.3307; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MAIORINO M, 1995, BIOL CHEM H-S, V376, P651, DOI 10.1515/bchm3.1995.376.11.651; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; MULLER S, 1994, BIOCHEMISTRY-US, V33, P3404, DOI 10.1021/bi00177a034; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; ROCHER C, 1992, EUR J BIOCHEM, V205, P955, DOI 10.1111/j.1432-1033.1992.tb16862.x; Sandman KE, 2000, NUCLEIC ACIDS RES, V28, P755, DOI 10.1093/nar/28.3.755; SHEN QC, 1993, J BIOL CHEM, V268, P11463; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Tate WP, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1342; Tormay P, 1997, J BACTERIOL, V179, P576, DOI 10.1128/jb.179.3.576-582.1997; Tormay P, 1996, MOL MICROBIOL, V21, P1253, DOI 10.1046/j.1365-2958.1996.881450.x; URSINI F, 1995, METHOD ENZYMOL, V252, P38; Wilting R, 1998, ARCH MICROBIOL, V169, P71; ZINONI F, 1987, P NATL ACAD SCI USA, V84, P3156, DOI 10.1073/pnas.84.10.3156; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660	38	60	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28715	28721		10.1074/jbc.M004985200	http://dx.doi.org/10.1074/jbc.M004985200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10874045	hybrid			2022-12-27	WOS:000089330700052
J	Chauhan, D; Pandey, P; Hideshima, T; Treon, S; Raje, N; Davies, FE; Shima, Y; Tai, YT; Rosen, S; Avraham, S; Kharbanda, S; Andersons, KC				Chauhan, D; Pandey, P; Hideshima, T; Treon, S; Raje, N; Davies, FE; Shima, Y; Tai, YT; Rosen, S; Avraham, S; Kharbanda, S; Andersons, KC			SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; PHOSPHOTYROSINE PHOSPHATASE; SIGNAL-TRANSDUCTION; KINASE ACTIVATION; ADHESION KINASE; PYK2; PATHWAY; IDENTIFICATION; EXPRESSION; MECHANISM	Our previous studies have shown that activation of a related adhesion focal tyrosine kinase (RAFTK) (also known as Pyk2) is required for dexamethasone (Dex)-induced apoptosis in multiple myeloma (MM) cells and that human interleukin-6 (IL-6), a known growth and survival factor for MM cells, blocks both RAFTK activation and apoptosis induced by Dex. However, the mechanism whereby IL-6 inhibits Dex-induced apoptosis is undefined. In this study, we demonstrate that protein-tyrosine phosphatase SHP2 mediates this protective effect. me show that IL-6 triggers selective activation of SHP2 and its association with RAFTK in Dex-treated MM cells. SHP2 interacts with RAFTK through a region other than its Src homology 2 domains. We demonstrate that RAFTK is a direct substrate of SHP2 both in vitro and in vivo, and that Tyr(906) in the C-terminal domain of RAFTK mediates its interaction with SHP2. Moreover, overexpression of dominant negative SHP2 blocked the protective effect of IL-6 against Dex-induced apoptosis. These findings demonstrate that SHP2 mediates the anti-apoptotic effect of IL-6 and suggest SHP2 as a novel therapeutic target in MM.	Dana Farber Canc Inst, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Harvard Inst Med, Div Expt Med & Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Andersons, KC (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu		Davies, Faith/0000-0002-3971-2393	NCI NIH HHS [CA 50947, CA 75216] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050947, R01CA075216] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson K, 1999, SEMIN ONCOL, V26, P10; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; Hamel W, 1996, CYTOMETRY, V25, P173, DOI 10.1002/(SICI)1097-0320(19961001)25:2<173::AID-CYTO6>3.0.CO;2-I; HARDIN J, 1994, BLOOD, V84, P3063; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Kim H, 1999, MOL CELL BIOL, V19, P5326; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kumar S, 1999, J BIOL CHEM, V274, P30657, DOI 10.1074/jbc.274.43.30657; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MOALLI PA, 1992, BLOOD, V79, P213; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Ogata A, 1997, J IMMUNOL, V159, P2212; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Tang H, 2000, J BIOL CHEM, V275, P8389, DOI 10.1074/jbc.275.12.8389; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Van Vactor D, 1998, CURR OPIN GENET DEV, V8, P112, DOI 10.1016/S0959-437X(98)80070-1; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Xu FH, 1998, BLOOD, V92, P241, DOI 10.1182/blood.V92.1.241.413k28_241_251; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	36	154	162	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27845	27850						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10880513				2022-12-27	WOS:000089197100045
J	Thomas, MG; Thompson, TB; Rayment, I; Escalante-Semerena, JC				Thomas, MG; Thompson, TB; Rayment, I; Escalante-Semerena, JC			Analysis of the adenosylcobinamide kinase/adenosylcobinamidephosphate guanylyltransferase (CobU) enzyme of Salmonella typhimurium LT2 - Identification of residue his-46 as the site of guanylylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACCINIA VIRUS GUANYLYLTRANSFERASE; MESSENGER-RNA GUANYLYLTRANSFERASE; GTP-GTP GUANYLYLTRANSFERASE; BRINE SHRIMP ARTEMIA; RECA PROTEIN; PHOSPHATE GUANYLYLTRANSFERASE; ESCHERICHIA-COLI; ACTIVE-SITE; 3-DIMENSIONAL STRUCTURE; GUANYLATE INTERMEDIATE	CobU is a bifunctional enzyme involved in adenosylcobalamin (coenzyme B-12) biosynthesis in Salmonella typhimurium LT2, In this bacterium, CobU is the adenosylcobinamide kinase/adenosyleobinamide-phosphate guanylyltransferase needed to convert cobinamide to adenosylcobinamide-GDP during the late steps of adenosylcobalamin biosynthesis, The guanylyltransferase reaction has been proposed to proceed via a covalently modified CobU-GMP intermediate. Here we show that CobU requires a nucleoside upper ligand on cobinamide for substrate recognition, with the nucleoside base, but not the 2'-OH group of the ribose, being important for this recognition. During the kinase reaction, both the nucleotide base and the 2'-OH group of the ribose are important for gamma-phosphate donor recognition, and GTP is the only nucleotide competent for the complete nucleotidyltransferase reaction, Analysis of the ATP:adenosylcobinamide kinase reaction shows CobU becomes less active during this reaction due to the formation of a covalent CobU-AMP complex that holds CobU in an altered conformation, Characterization of the GTP:adenosylcobinamide-phosphate guanylyltransferase reaction shows the covalent CobU-GMP intermediate is on the reaction pathway for the generation of adenosylcobinamide-GDP. Identification of a modified histidine and analysis of cobU mutants indicate that histidine 46 is the site of guanylylation.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Inst Enzyme Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Escalante-Semerena, JC (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.	jcescala@facstaff.wisc.edu	rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835; Thompson, Thomas/0000-0002-7041-5047	NIGMS NIH HHS [GM58218, GM40413, GM08293, R01 GM040313] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008293] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANCHE F, 1991, J BACTERIOL, V173, P6052, DOI 10.1128/jb.173.19.6052-6057.1991; Brushaber KR, 1998, J BIOL CHEM, V273, P2684, DOI 10.1074/jbc.273.5.2684; CAMERON B, 1991, J BACTERIOL, V173, P6066, DOI 10.1128/jb.173.19.6066-6073.1991; Cartwright JL, 1999, ARCH BIOCHEM BIOPHYS, V361, P101, DOI 10.1006/abbi.1998.0970; Ellouze C, 1999, EUR J BIOCHEM, V262, P88, DOI 10.1046/j.1432-1327.1999.00357.x; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; GALLAGHER SR, 1996, CURRENT PROTOCOLS MO, V2; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; KAHN R, 1984, J BIOL CHEM, V259, P7495; KUNITZ M, 1952, J GEN PHYSIOL, V35, P423, DOI 10.1085/jgp.35.3.423; LIU JJ, 1994, J BIOL CHEM, V269, P11787; Maggio-Hall LA, 1999, P NATL ACAD SCI USA, V96, P11798, DOI 10.1073/pnas.96.21.11798; MARTIN SA, 1975, J BIOL CHEM, V250, P9330; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MICHAEL SF, 1994, BIOTECHNIQUES, V16, P410; OTOOLE GA, 1994, J BIOL CHEM, V269, P26503; OTOOLE GA, 1995, J BIOL CHEM, V270, P23560, DOI 10.1074/jbc.270.40.23560; OTOOLE GA, 1996, ESCHERICHIA COLI SAL, V1, P710; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Rondon MR, 1997, PROG NUCLEIC ACID RE, V56, P347, DOI 10.1016/S0079-6603(08)61010-7; RONZIO RA, 1967, BIOCHEMISTRY-US, V6, P2344, DOI 10.1021/bi00860a009; ROTH MJ, 1984, J BIOL CHEM, V259, P3488; Schafer DA, 1998, CELL MOTIL CYTOSKEL, V39, P166, DOI 10.1002/(SICI)1097-0169(1998)39:2<166::AID-CM7>3.0.CO;2-4; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; SZUMILO T, 1993, J BIOL CHEM, V268, P17943; Thompson TB, 1999, BIOCHEMISTRY-US, V38, P12995, DOI 10.1021/bi990910x; Thompson TB, 1998, BIOCHEMISTRY-US, V37, P7686, DOI 10.1021/bi973178f; TOYAMA R, 1983, EMBO J, V2, P2195, DOI 10.1002/j.1460-2075.1983.tb01723.x; Trzebiatowski JR, 1997, J BIOL CHEM, V272, P17662, DOI 10.1074/jbc.272.28.17662; Tuhackova Z, 1996, BIOCHEM BIOPH RES CO, V218, P61, DOI 10.1006/bbrc.1996.0012; WEI YF, 1991, METHOD ENZYMOL, V200, P388; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P883; YANG SLL, 1979, BIOCHEMISTRY-US, V18, P2980, DOI 10.1021/bi00581a011; [No title captured]	38	23	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27576	27586						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869342				2022-12-27	WOS:000089197100010
J	Gijon, MA; Spencer, DM; Siddiqi, AR; Bonventre, JV; Leslie, CC				Gijon, MA; Spencer, DM; Siddiqi, AR; Bonventre, JV; Leslie, CC			Cytosolic phospholipase a, is required for macrophage arachidonic acid release by agonists that do and do not mobilize calcium - Novel role of mitogen-activated protein kinase pathways in cytosolic phospholipase A(2) regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED HUMAN PLATELETS; C2 DOMAIN; PHOSPHORYLATION SITES; NUCLEAR-ENVELOPE; MAP KINASE; CELLS; IDENTIFICATION; TRANSLOCATION; INDUCTION; MEMBRANE	The 85-kDa cytosolic phospholipase A(2) (cPLA(2)) mediates agonist-induced arachidonic acid release and eicosanoid production. Calcium and phosphorylation on Ser-505 by mitogen-activated protein kinases (MAPKs) regulate cPLA(2). Arachidonic acid release and eicosanoid production induced by stimuli that do (A23187, zymosan) or do not (phorbol myristate acetate (PMA), okadaic acid) mobilize calcium were quantitatively suppressed in cPLA(2)-deficient mouse peritoneal macrophages. The contribution of MAPKs to cPLA(2)-mediated arachidonic acid release was investigated. Both extracellular signal-regulated kinases (ERKs) and p38 contributed to cPLA(2) phosphorylation on Ser-505. However, although ERK inhibition did not affect A23187-induced arachidonic acid release, it suppressed zymosan-, PMA-, and okadaic acid-induced arachidonic acid release under conditions where phosphorylation of cPLA(2) on Ser-505 was unaffected. This indicates an additional regulatory mechanism for the ERK pathway. A role for transcriptional regulation is suggested by data showing that cycloheximide and actinomycin D inhibited arachidonic acid release induced by zymosan, PMA and, okadaic acid but not by A23181, Our results show that MAPK pathways contribute to arachidonic acid release in macrophages through alternative mechanisms in addition to their ability to phosphorylate cPLA(2) on Ser-505 and suggest a role for new protein synthesis.	Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80262 USA; Harvard Univ, Massachusetts Gen Hosp E, Sch Med, Dept Med, Charlestown, MA 02129 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University	Leslie, CC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.	lesliec@njc.org			NHLBI NIH HHS [HL34308, HL61378, P01 HL034303] Funding Source: Medline; NIDDK NIH HHS [DK38452] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038452] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADEREM AA, 1986, J EXP MED, V163, P139, DOI 10.1084/jem.163.1.139; Akiba S, 1999, J BIOL CHEM, V274, P19906, DOI 10.1074/jbc.274.28.19906; AMBS P, 1995, BIOCHEM J, V311, P189, DOI 10.1042/bj3110189; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1996, EUR J BIOCHEM, V235, P480, DOI 10.1111/j.1432-1033.1996.00480.x; Bayon Y, 1997, BIOCHEM J, V323, P281, DOI 10.1042/bj3230281; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONNEY RJ, 1980, BIOCHIM BIOPHYS ACTA, V633, P410, DOI 10.1016/0304-4165(80)90199-3; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432-1033.1997.t01-1-00751.x; Branch AD, 1998, TRENDS BIOCHEM SCI, V23, P45, DOI 10.1016/S0968-0004(97)01155-9; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; Hirabayashi T, 1999, J BIOL CHEM, V274, P5163, DOI 10.1074/jbc.274.8.5163; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kim JH, 1999, J IMMUNOL, V163, P5462; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lin WW, 1999, BRIT J PHARMACOL, V126, P1419, DOI 10.1038/sj.bjp.0702436; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; PetersGolden M, 1996, BIOCHEM J, V318, P797, DOI 10.1042/bj3180797; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schalkwijk CG, 1996, BIOCHEM J, V313, P91, DOI 10.1042/bj3130091; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SierraHonigmann R, 1996, LAB INVEST, V74, P684; Song CZ, 1999, J BIOL CHEM, V274, P17063, DOI 10.1074/jbc.274.24.17063; Syrbu SI, 1999, J IMMUNOL, V162, P2334; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Wang AJ, 1999, BBA-MOL CELL BIOL L, V1437, P157, DOI 10.1016/S1388-1981(99)00012-8; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; XU XX, 1994, J BIOL CHEM, V269, P31693	64	193	208	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20146	20156		10.1074/jbc.M908941199	http://dx.doi.org/10.1074/jbc.M908941199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867029	hybrid			2022-12-27	WOS:000087941300096
J	Kotamraju, S; Konorev, EA; Joseph, J; Kalyanaraman, B				Kotamraju, S; Konorev, EA; Joseph, J; Kalyanaraman, B			Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen - Role of reactive oxygen and nitrogen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL FORMATION; DAUNORUBICIN-INDUCED APOPTOSIS; OXIDATIVE STRESS MEASUREMENTS; INDUCED CARDIOTOXICITY; SUPEROXIDE-DISMUTASE; HORSERADISH-PEROXIDASE; INDUCED CARDIOMYOPATHY; GLUTATHIONE SYNTHESIS; REDUCED GLUTATHIONE; ELECTRON-TRANSPORT	Doxorubicin (DOX) is a broad spectrum anthracycline antibiotic used to treat a variety of cancers. Redox activation of DOX to form reactive oxygen species has been implicated in DOX-induced cardiotoxicity, In this work we investigated DOX-induced apoptosis in cultured bovine aortic endothelial cells and cardiomyocytes isolated from adult rat heart. Exposure of bovine aortic endothelial cells or myocytes to submicromolar levels of DOX induced significant apoptosis as measured by DNA fragmentation and terminal deoxynucleotidyltransferase-mediated nick-end labeling assays, Pretreatment of cells with 100 muM nitrone spin traps, N-tert-butyl-alpha -phenylnitrone (PBN) or alpha-(4-pyridyl-1-oxide)-N-tert-butylnitrone (POBN) dramatically inhibited DOX-induced apoptosis, Ebselen (20-50 muM), a glutathione peroxidase mimetic, also significantly inhibited apoptosis, DOX (0.5-1 muM) inactivated mitochondrial complex I by a superoxide-dependent mechanism. PEN (100 muM), POBN (100 muM), and ebselen (50 muM) restored complex I activity. These compounds also inhibited DOX-induced caspase-3 activation and cytochrome c release. PEN and ebselen also restored glutathione levels in DOX-treated cells. We conclude that nitrone spin traps and ebselen inhibit the DOX-induced apoptotic signaling mechanism and that this antiapoptotic mechanism may be linked in part to the inhibition in formation or scavenging of hydrogen peroxide. Therapeutic strategies to mitigate DOX cardiotoxicity should be reexamined in light of these emerging antiapoptotic mechanisms of antioxidants.	Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Biophys Res Inst, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	balarama@mcw.edu			NATIONAL CANCER INSTITUTE [R01CA077822] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; Asakura T, 1999, BRIT J CANCER, V80, P711, DOI 10.1038/sj.bjc.6690414; Atamna H, 2000, J BIOL CHEM, V275, P6741, DOI 10.1074/jbc.275.10.6741; BACHUR NR, 1977, MOL PHARMACOL, V13, P901; BALLA G, 1991, ARTERIOSCLER THROMB, V11, P1700, DOI 10.1161/01.ATV.11.6.1700; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUZDAR AU, 1985, CANCER, V55, P2761, DOI 10.1002/1097-0142(19850615)55:12<2761::AID-CNCR2820551206>3.0.CO;2-P; Chen QM, 2000, ARCH BIOCHEM BIOPHYS, V373, P242, DOI 10.1006/abbi.1999.1558; COVA D, 1992, FREE RADICAL RES COM, V15, P353, DOI 10.3109/10715769209049151; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; Day BJ, 1995, J PHARMACOL EXP THER, V275, P1227; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; GOODMAN J, 1977, BIOCHEM BIOPH RES CO, V77, P797, DOI 10.1016/S0006-291X(77)80048-X; GOTOH N, 1993, BIOCHEM J, V296, P151, DOI 10.1042/bj2960151; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; HANDA K, 1976, GANN, V67, P523; Hensley K, 1998, J NEUROCHEM, V71, P2549; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Ito A, 1999, BBA-MOL CELL RES, V1452, P263, DOI 10.1016/S0167-4889(99)00131-7; JANZEN EG, 1979, TETRAHEDRON LETT, P3229; KALYANARAMAN B, 1980, BIOCHIM BIOPHYS ACTA, V630, P119, DOI 10.1016/0304-4165(80)90142-7; Karoui H, 1996, J BIOL CHEM, V271, P6000, DOI 10.1074/jbc.271.11.6000; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KONOPA J, 1988, BIOCHEM PHARMACOL, V37, P2303, DOI 10.1016/0006-2952(88)90355-3; Konorev EA, 1999, ARCH BIOCHEM BIOPHYS, V368, P421, DOI 10.1006/abbi.1999.1337; Konorev EA, 1996, BRIT J PHARMACOL, V119, P511, DOI 10.1111/j.1476-5381.1996.tb15701.x; Kotake Y, 1999, ANTIOXID REDOX SIGN, V1, P481, DOI 10.1089/ars.1999.1.4-481; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Messner UK, 1999, KIDNEY INT, V55, P2322, DOI 10.1046/j.1523-1755.1999.00473.x; Minotti G, 1999, FASEB J, V13, P199, DOI 10.1096/fasebj.13.2.199; MONTI E, 1991, FREE RADICAL RES COM, V14, P41, DOI 10.3109/10715769109088940; MYERS C, 1986, FASEB J, V45, P2792; Myers C, 1998, SEMIN ONCOL, V25, P10; MYERS CE, 1977, SCIENCE, V197, P165, DOI 10.1126/science.877547; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Piper H, 1990, CELL CULTURE TECHNIQ, P36; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; Robinson KA, 1999, J NEUROSCI RES, V55, P724, DOI 10.1002/(SICI)1097-4547(19990315)55:6<724::AID-JNR7>3.3.CO;2-0; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; Rota C, 1999, FREE RADICAL BIO MED, V27, P873, DOI 10.1016/S0891-5849(99)00137-9; Sarvazyan N, 1996, AM J PHYSIOL-HEART C, V271, pH2079, DOI 10.1152/ajpheart.1996.271.5.H2079; Sawyer DB, 1999, CIRC RES, V84, P257, DOI 10.1161/01.RES.84.3.257; Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; Sussman MA, 1997, CIRC RES, V80, P52, DOI 10.1161/01.RES.80.1.52; SVINGEN BA, 1981, ARCH BIOCHEM BIOPHYS, V209, P119, DOI 10.1016/0003-9861(81)90263-0; SWIFT ML, 2000, AM J PHYSIOL, V278, pH982; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Vasquez-Vivar J, 2000, J BIOL CHEM, V275, P14064, DOI 10.1074/jbc.275.19.14064; VasquezVivar J, 1997, BIOCHEMISTRY-US, V36, P11293, DOI 10.1021/bi971475e; Yang CF, 2000, ARCH BIOCHEM BIOPHYS, V374, P142, DOI 10.1006/abbi.1999.1574; Yen HC, 1999, ARCH BIOCHEM BIOPHYS, V362, P59, DOI 10.1006/abbi.1998.1011; Zhu WD, 1999, CIRCULATION, V100, P2100, DOI 10.1161/01.CIR.100.20.2100	65	317	328	2	28	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33585	33592		10.1074/jbc.M003890200	http://dx.doi.org/10.1074/jbc.M003890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10899161	hybrid			2022-12-27	WOS:000090104600058
J	Ko, YH; Hullihen, J; Hong, S; Pedersen, PL				Ko, YH; Hullihen, J; Hong, S; Pedersen, PL			Mitochondrial F(0)F1 ATP synthase - Subunit regions on the F-1 motor shielded by F-0, functional significance, and evidence for an involvement of the unique F-0 subunit F-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; ESCHERICHIA-COLI F1-ATPASE; RAT-LIVER MITOCHONDRIA; GAMMA-SUBUNIT; SUBMITOCHONDRIAL PARTICLES; OXIDATIVE-PHOSPHORYLATION; MEMBRANE TOPOGRAPHY; EPSILON-SUBUNIT; CROSS-LINKING; DELTA-SUBUNIT	Studies reported here were undertaken to gain greater molecular insight into the complex structure of mitochondrial ATP synthase (F0F1) and its relationship to the enzyme's function and motor-related properties. Significantly, these studies, which employed N-terminal sequence, mass spectral, proteolytic, immunological, and functional analyses, led to the following novel findings. First, at the top of F-1 within F0F1, all six N-terminal regions derived from alpha + beta subunits are shielded, indicating that one or more F-0 subunits forms a "cap." Second, at the bottom of F-1 within F0F1, the N-terminal region of the single delta subunit and the C-terminal regions of all three alpha subunits are shielded also by F-0. Third, and in contrast, part of the gamma subunit located at the bottom of F-1 is already shielded in F-1, indicating that there is a preferential propensity for interaction with other F-1 subunits, most likely delta and epsilon. Fourth, and consistent with the first two conclusions above that specific regions at the top and bottom of F-1 are shielded by F-0, further proteolytic shaving of alpha and beta subunits at these locations eliminates the capacity of F-1 to couple a proton gradient to ATP synthesis. Finally, evidence was obtained that the F-0 subunit called "F-6," unique to animal ATP syntheses, is involved in shielding F-1. The significance of the studies reported here, in relation to current views about ATP synthase structure and function in animal mitochondria, is discussed.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Pedersen, PL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL CANCER INSTITUTE [R01CA010951, R37CA010951] Funding Source: NIH RePORTER; NCI NIH HHS [CA 10951] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Altendorf K, 2000, J EXP BIOL, V203, P19; Bakhtiari N, 1999, J BIOL CHEM, V274, P16363, DOI 10.1074/jbc.274.23.16363; Belogrudov GI, 1996, J BIOL CHEM, V271, P20340, DOI 10.1074/jbc.271.34.20340; BELOGRUDOV GI, 1995, J BIOL CHEM, V270, P2053, DOI 10.1074/jbc.270.5.2053; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; BOYER PD, 1997, ANNU REV BIOCHEM, V66, P714; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; Collinson IR, 1996, BIOCHEMISTRY-US, V35, P12640, DOI 10.1021/bi960969t; COLLINSON IR, 1994, J MOL BIOL, V242, P408; COLLINSON IR, 1994, BIOCHEM J, V303, P639, DOI 10.1042/bj3030639; CROSS RL, 1981, ANNU REV BIOCHEM, V50, P681, DOI 10.1146/annurev.bi.50.070181.003341; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; DOOLITTLE RF, 1968, BIOCHEMISTRY-US, V7, P516, DOI 10.1021/bi00842a005; EDMAN P, 1950, ACTA CHEM SCAND, V4, P283, DOI 10.3891/acta.chem.scand.04-0283; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; FESSENDENRADEN JM, 1972, J BIOL CHEM, V247, P2351; GOGEL EP, 1987, FEBS LETT, V219, P274; Hausrath AC, 1999, P NATL ACAD SCI USA, V96, P13697, DOI 10.1073/pnas.96.24.13697; HEKMAN C, 1991, J BIOL CHEM, V266, P13564; HUNKAPILLER MW, 1983, SCIENCE, V219, P650, DOI 10.1126/science.6687410; JACOBS EE, 1956, J BIOL CHEM, V223, P147; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P376, DOI 10.1016/0003-9861(92)90005-H; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; KAGAWA Y, 1972, BIOCHIM BIOPHYS ACTA, V265, P297, DOI 10.1016/0304-4157(72)90012-3; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Kinosita K, 1998, CELL, V93, P21, DOI 10.1016/S0092-8674(00)81142-3; Ko YH, 1997, J BIOL CHEM, V272, P18875, DOI 10.1074/jbc.272.30.18875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCENERY MW, 1984, J BIOL CHEM, V259, P4642; NAGLEY P, 1988, TRENDS GENET, V4, P46, DOI 10.1016/0168-9525(88)90066-2; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Oster G, 1999, STRUCTURE, V7, pR67, DOI 10.1016/S0969-2126(99)80046-X; Pan WY, 1998, BIOCHEMISTRY-US, V37, P6911, DOI 10.1021/bi9800698; PEDERSEN PL, 1978, J BIOL CHEM, V253, P2176; PEDERSEN PL, 1995, J BIOL CHEM, V270, P1775, DOI 10.1074/jbc.270.4.1775; PENIN F, 1990, BIOCHEMISTRY-US, V29, P9358, DOI 10.1021/bi00492a008; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SCHIGGER H, 1987, ANAL BIOCHEM, V166, P368; SEBALD W, 1981, CURR TOP BIOENERG, V12, P1; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; SOPER JW, 1979, J BIOL CHEM, V254, P1170; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; WALKER JE, 1994, FEBS LETT, V346, P39, DOI 10.1016/0014-5793(94)00368-8; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381; WILKENS S, 1994, FEBS LETT, V354, P37, DOI 10.1016/0014-5793(94)01059-5; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	56	23	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32931	32939		10.1074/jbc.M004453200	http://dx.doi.org/10.1074/jbc.M004453200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10887193	hybrid			2022-12-27	WOS:000090003800077
J	Reichard, P; Eliasson, R; Ingemarson, R; Thelander, L				Reichard, P; Eliasson, R; Ingemarson, R; Thelander, L			Cross-talk between the allosteric effector-binding sites in mouse ribonucleotide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CALF THYMUS; PROTEIN R1; DIPHOSPHATE REDUCTASE; SUBUNIT INTERACTION; RECOMBINANT MOUSE; PURIFICATION; MUTANT; ENZYMES; CELLS	We compared the allosteric regulation and effector binding properties of wild type R1 protein and R1 protein with a mutation in the "activity site" (D57N) of mouse ribonucleotide reductase, Wild type R1 had two effector-binding sites per polypeptide chain: one site (activity site) for dATP and ATP, with dATP-inhibiting and ATP-stimulating catalytic activity; and a second site (specificity site) for dATP, ATP, dTTP, and dGTP, directing substrate specificity. Binding of dATP to the specificity site had a 20-fold higher affinity than to the activity site. In all these respects, mouse R1 resembles Escherichia cold R1, Results with D57N were complicated by the instability of the protein, but two major changes were apparent. First, enzyme activity was stimulated by both dATP and ATP, suggesting that D57N no longer distinguished between the two nucleotides. Second, the two binding sites for dATP both had the same low affinity for the nucleotide, similar to that of the activity site of wild type R1, Thus the mutation in the activity site had decreased the affinity for dATP at the specificity site, demonstrating the interaction between the two sites.	Umea Univ, Dept Med Biosci, SE-90187 Umea, Sweden; Karolinska Inst, Med Nobel Inst, Dept Biochem 1, MBB, SE-17177 Stockholm, Sweden	Umea University; Karolinska Institutet	Thelander, L (corresponding author), Umea Univ, Dept Med Biosci, SE-90187 Umea, Sweden.	lars.thelander@medchem.umu.se						BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; CARAS IW, 1988, MOL CELL BIOL, V8, P2698, DOI 10.1128/MCB.8.7.2698; DAVIS R, 1994, J BIOL CHEM, V269, P23171; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; Eliasson R, 1999, J BIOL CHEM, V274, P7182, DOI 10.1074/jbc.274.11.7182; ELIASSON R, 1994, J BIOL CHEM, V269, P26052; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; ERIKSSON S, 1979, BIOCHEMISTRY-US, V18, P2948, DOI 10.1021/bi00581a005; ERIKSSON S, 1981, J BIOL CHEM, V256, P193; Fontecave M., 1992, ADV ENZYMOL RELAT AR, V65, P147; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofer A, 1998, J BIOL CHEM, V273, P34098, DOI 10.1074/jbc.273.51.34098; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; Jordan A, 1997, P NATL ACAD SCI USA, V94, P13487, DOI 10.1073/pnas.94.25.13487; Jordan A, 1999, J BACTERIOL, V181, P3974, DOI 10.1128/JB.181.13.3974-3980.1999; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; ORMO M, 1990, ANAL BIOCHEM, V182, P674; Rova U, 1999, J BIOL CHEM, V274, P23746, DOI 10.1074/jbc.274.34.23746; Stubbe JA, 1995, CHEM BIOL, V2, P793, DOI 10.1016/1074-5521(95)90084-5; THELANDER L, 1980, J BIOL CHEM, V255, P7426; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; ULLMAN B, 1981, J BIOL CHEM, V256, P189	27	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33021	33026		10.1074/jbc.M005337200	http://dx.doi.org/10.1074/jbc.M005337200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10884394	hybrid			2022-12-27	WOS:000090003800088
J	Qu, ZQ; Yang, ZJ; Cui, NR; Zhu, GY; Liu, CX; Xu, HX; Chanchevalap, S; Shen, WZ; Wu, JP; Li, YJ; Jiang, C				Qu, ZQ; Yang, ZJ; Cui, NR; Zhu, GY; Liu, CX; Xu, HX; Chanchevalap, S; Shen, WZ; Wu, JP; Li, YJ; Jiang, C			Gating of inward rectifier K+ channels by proton-mediated interactions of N- and C-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-GATED CHANNELS; POTASSIUM CHANNEL; MOLECULAR-BASIS; OPEN-STATE; PH; ACTIVATION; IDENTIFICATION; INACTIVATION; RESIDUE; INHIBITION	Ion channels play an important role in cellular functions, and specific cellular activity can be produced by gating them. One important gating mechanism is produced by intra- or extracellular ligands, Although the ligand-mediated channel gating is an important cellular process, the relationship between ligand binding and channel gating is not well understood, It is possible that ligands are involved in the interactions of different protein domains of the channel leading to opening or closing. To test this hypothesis, we studied the gating of Kir2.3 (HIR) by intracellular protons. Our results showed that hypercapnia or intracellular acidification strongly inhibited these channels. This effect relied on both the N and C termini, The CO2/pH sensitivities were abolished or compromised when one of the intracellular termini was replaced. Using purified N- and C-terminal peptides, we found that the N and C termini bound to each other in vitro. Although their binding was weak at pH 7.4, stronger binding was seen at pH 6.6, Two short sequences in the N and C termini were found to be critical for the N/C-terminal interaction. Interestingly, there was no titratable residue in these motifs, To identify the potential protonation sites, we systematically mutated most histidine residues in the intracellular N and C termini, We found that mutations of several histidine residues in the C but not the N terminus had a major effect on channel sensitivities to CO2 and pH(i). These results suggest that at acidic pH, protons appear to interact with the C-terminal histidine residues and present the C terminus to the N terminus. Consequentially, these two intracellular termini bound to each other through two short motifs and closed the channel. Thus, a novel mechanism for K+ channel gating is demonstrated, which involves the N- and C-terminal interaction with protons as the mediator.	Georgia State Univ, Dept Biol, Atlanta, GA 30302 USA	University System of Georgia; Georgia State University	Jiang, C (corresponding author), Georgia State Univ, Dept Biol, 24 Peachtree Cent Ave, Atlanta, GA 30303 USA.			Wu, Jianping/0000-0002-2684-6122; Yang, Zhenjiang/0000-0002-9315-154X	NHLBI NIH HHS [R01 HL058410, R01 HL58410] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058410] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams CM, 1998, J BIOL CHEM, V273, P30204, DOI 10.1074/jbc.273.46.30204; Buckley JT, 1995, BIOCHEMISTRY-US, V34, P16450, DOI 10.1021/bi00050a028; Cao YW, 1998, J NEUROSCI, V18, P7739; Chanchevalap S, 2000, J BIOL CHEM, V275, P7811, DOI 10.1074/jbc.275.11.7811; Choe H, 1997, AM J PHYSIOL-RENAL, V273, pF516, DOI 10.1152/ajprenal.1997.273.4.F516; COULTER KL, 1995, NEURON, V15, P1157, DOI 10.1016/0896-6273(95)90103-5; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; EK JF, 1994, CIRC RES, V74, P1058, DOI 10.1161/01.RES.74.6.1058; EkVitorin JF, 1996, BIOPHYS J, V71, P1273, DOI 10.1016/S0006-3495(96)79328-1; England PM, 1999, CELL, V96, P89, DOI 10.1016/S0092-8674(00)80962-9; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; HILLE B, 1992, IONIC CHANNELS EXCIT, P472; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Hoth S, 1997, P NATL ACAD SCI USA, V94, P4806, DOI 10.1073/pnas.94.9.4806; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; Klockner U, 1996, J BIOL CHEM, V271, P22293; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; Meera P, 1997, P NATL ACAD SCI USA, V94, P14066, DOI 10.1073/pnas.94.25.14066; Morrill JA, 1999, J GEN PHYSIOL, V114, P71, DOI 10.1085/jgp.114.1.71; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Paoletti P, 1999, J GEN PHYSIOL, V113, P17, DOI 10.1085/jgp.113.1.17; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Qu Z., 1999, Society for Neuroscience Abstracts, V25, P935; Qu ZQ, 1999, J BIOL CHEM, V274, P13783, DOI 10.1074/jbc.274.20.13783; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Schreiber M, 1999, NAT NEUROSCI, V2, P416, DOI 10.1038/8077; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; Schulte U, 1998, J BIOL CHEM, V273, P34575, DOI 10.1074/jbc.273.51.34575; Shuck ME, 1997, J BIOL CHEM, V272, P586; Steidl JV, 1999, MOL PHARMACOL, V55, P812; Stergiopoulos K, 1999, CIRC RES, V84, P1144, DOI 10.1161/01.RES.84.10.1144; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1999, J BIOL CHEM, V274, P33393, DOI 10.1074/jbc.274.47.33393; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Varnum MD, 1997, SCIENCE, V278, P110, DOI 10.1126/science.278.5335.110; WANG TL, 1995, J NEUROSCI, V15, P7684; XU H, 2000, IN PRESS AM J PHYSL; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; Yang ZJ, 1999, J PHYSIOL-LONDON, V520, P921, DOI 10.1111/j.1469-7793.1999.00921.x; Zhu GY, 1999, J PHYSIOL-LONDON, V516, P699, DOI 10.1111/j.1469-7793.1999.0699u.x; Zhu GY, 2000, J CELL PHYSIOL, V183, P53, DOI 10.1002/(SICI)1097-4652(200004)183:1<53::AID-JCP7>3.3.CO;2-I	44	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31573	31580		10.1074/jbc.M003473200	http://dx.doi.org/10.1074/jbc.M003473200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10896660	hybrid			2022-12-27	WOS:000089858900005
J	Stachelek, SJ; Kowalik, TF; Farwell, AP; Leonard, JL				Stachelek, SJ; Kowalik, TF; Farwell, AP; Leonard, JL			Myosin V plays an essential role in the thyroid hormone-dependent endocytosis of type II iodothyronine 5 '-deiodinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-GENETIC DISSECTION; SUBSTRATE-BINDING SUBUNIT; STIMULATED GLIAL-CELLS; ACTIN-BASED TRANSPORT; RAT CEREBRAL-CORTEX; UNCONVENTIONAL MYOSINS; ENZYME INACTIVATION; DILUTE MELANOCYTES; REGION MUTATIONS; TAIL REGION	In astrocytes, thyroxine modulates type II iodothyronine 5'-deiodinase levels by initiating the binding of the endosomes containing the enzyme to microfilaments, followed by actin-based endocytosis. Myosin V is a molecular motor thought to participate in vesicle trafficking in the brain. In this report, we developed an in vitro actin-binding assay to characterize the thyroid hormone-dependent binding of endocytotic vesicles to microfilaments. Thyroxine and reverse triiodothyronine (EC,, levels similar to 1 nM) were >100-fold more potent than 3,5,3'-triiodothyronine in initiating vesicle binding to actin fibers in vitro, Thyroxine-dependent vesicle binding was calcium-, magnesium-, and ATP-dependent, suggesting the participation of one or more myosin motors, presumably myosin V. Addition of the myosin V globular tail, lacking the actin-binding head, specifically blocked thyroid hormone-dependent vesicle binding, and direct binding of the myosin V tail to enzyme-containing endosomes was thyroxine-dependent, Progressive NH2-terminal deletion of the myosin V tail and domain-specific antibody inhibition studies revealed that the thyroxine-dependent vesicle-tethering domain was localized to the last 21 amino acids of the COOP terminus. These data show that myosin V is responsible for thyroid hormone-dependent binding of primary endosomes to the microfilaments and suggest that this motor mediates the actin-based endocytosis of the type II iodothyronine deiodinase.	Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Leonard, JL (corresponding author), Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.			Farwell, Alan/0000-0001-7716-2719				Bridgman PC, 1999, J CELL BIOL, V146, P1045, DOI 10.1083/jcb.146.5.1045; Catlett NL, 1998, P NATL ACAD SCI USA, V95, P14799, DOI 10.1073/pnas.95.25.14799; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Evans LL, 1997, J CELL SCI, V110, P439; Evans LL, 1998, J CELL SCI, V111, P2055; FARWELL AP, 1989, J BIOL CHEM, V264, P20561; FARWELL AP, 1992, ENDOCRINOLOGY, V131, P721, DOI 10.1210/en.131.2.721; Farwell AP, 1996, J BIOL CHEM, V271, P16369, DOI 10.1074/jbc.271.27.16369; FARWELL AP, 1993, J BIOL CHEM, V268, P5055; FARWELL AP, 1990, J BIOL CHEM, V265, P18546; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Huang JD, 1998, GENETICS, V148, P1951; Huang JD, 1998, GENETICS, V148, P1963; KOHRLE J, 1990, J BIOL CHEM, V265, P6155; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langford GM, 1998, BRAIN RES REV, V28, P1, DOI 10.1016/S0165-0173(98)00020-4; Leonard DM, 2000, J BIOL CHEM, V275, P25194, DOI 10.1074/jbc.M002036200; LEONARD JL, 1984, ENDOCRINOLOGY, V114, P998, DOI 10.1210/endo-114-3-998; LEONARD JL, 1990, J BIOL CHEM, V265, P940; LEONARD JL, 1988, BIOCHEM BIOPH RES CO, V151, P1164, DOI 10.1016/S0006-291X(88)80488-1; LEONARD JL, 1983, ENDOCRINOLOGY, V112, P1153, DOI 10.1210/endo-112-3-1153; MANI F, 1994, BRAZ J MED BIOL RES, V27, P2639; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Miller KE, 2000, J BIOL CHEM, V275, P2598, DOI 10.1074/jbc.275.4.2598; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; Oppenheimer JH, 1997, ENDOCR REV, V18, P462, DOI 10.1210/er.18.4.462; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P265, DOI 10.1016/S0968-0004(00)89040-4; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; SIEGRISTKAISER CA, 1990, J BIOL CHEM, V265, P5296; SILVA JE, 1985, ENDOCRINOLOGY, V116, P1627, DOI 10.1210/endo-116-4-1627; Tabb JS, 1998, J CELL SCI, V111, P3221; VISSER TJ, 1982, P NATL ACAD SCI-BIOL, V79, P5080, DOI 10.1073/pnas.79.16.5080; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; Wei Q, 1997, J MUSCLE RES CELL M, V18, P517, DOI 10.1023/A:1018659117569; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899	39	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31701	31707		10.1074/jbc.M004221200	http://dx.doi.org/10.1074/jbc.M004221200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10882730	hybrid			2022-12-27	WOS:000089858900024
J	Thomson, AM; Rogers, JT; Leedman, PJ				Thomson, AM; Rogers, JT; Leedman, PJ			Thyrotropin-releasing hormone and epidermal growth factor regulate iron-regulatory protein binding in pituitary cells via protein kinase C-dependent and -independent signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; TRANSFERRIN RECEPTOR EXPRESSION; TUMOR-NECROSIS-FACTOR; RESPONSIVE ELEMENT; OXIDATIVE STRESS; GH3 CELLS; DIFFERENTIAL REGULATION; THYROID-HORMONE; NITRIC-OXIDE; HEAVY-CHAIN	Intracellular iron homeostasis is regulated, in part, by interactions between iron-regulatory proteins (IRP1 and IRP2) and iron-responsive elements (IREs) in ferritin and transferrin receptor mRNAs. In addition to iron, cellular oxidative stress induced by H2O2, nitric oxide, and hypoxia, and hormonal activation by thyroid hormone and erythropoeitin have each been shown to regulate IRP binding to IREs. Hormonal signals, in particular mediated through protein kinase C (PKC), play a central role in the modulation of IRP/IRE interactions since phorbol esters were shown to activate IRP binding (Eisenstein, R. S., Tuazon, P. T., Schalinske, K. L., Anderson, S. A., and Traugh, J. A. (1993) J. Biol. Chem. 268, 27363-27370). In pituitary thyrotrophs (TtT97), we found that thyrotropin releasing hormone (TRH) and epidermal growth factor (EGF) increased IRP binding to a ferritin IRE, dependent on PKC and mitogen-activated protein kinase (MAPK) activity. In contrast, TRH and EGF decreased IRP binding in pituitary lactotrophs (GH3), despite activation of PKC and MAPK. IRP1 and IRP2 levels remained constant and IRP2 binding was predominant throughout. TRH and EGF markedly decreased IRP binding in MAPK kinase inhibitor-treated GH3 cells, whereas, they increased IRP binding in phosphatase inhibitor-treated GH3 cells. IRE-dependent CAT reporter translational expression closely reflected IRP binding to the ferritin IRE in both GH3 and TtT97 cells. Interestingly, ferritin protein levels were regulated similarly by TRH in both cell lines. These data link two different cell receptor systems to common signaling pathways that regulate IRP binding and ferritin expression. Remarkably, for TRH and EGF, these effects may be PKC-dependent or -independent determined by the cell type.	Univ Western Australia, Royal Perth Hosp, Western Australian Inst Med Res, Dept Med, Perth, WA 6000, Australia; Univ Western Australia, Royal Perth Hosp, Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6000, Australia; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Genet & Aging Unit, Charlestown, MA 02129 USA	Royal Perth Hospital; University of Western Australia; Royal Perth Hospital; University of Western Australia; Harvard University	Leedman, PJ (corresponding author), Univ Perth, Royal Perth Hosp, Dept Med, Box X2213 GPO, Perth, WA 6001, Australia.	peterl@cyllene.uwa.edu.au	Leedman, Peter J/O-4044-2014	Rogers, Jack/0000-0003-1262-8578				BRUNET N, 1981, J CELL PHYSIOL, V109, P363, DOI 10.1002/jcp.1041090220; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHAIDARUN SS, 1994, ENDOCRINOLOGY, V135, P2012, DOI 10.1210/en.135.5.2012; CHAZENBALK GD, 1990, MOL ENDOCRINOL, V4, P1117, DOI 10.1210/mend-4-8-1117; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P666; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; COLUCCIDAMATO LG, 1989, BIOCHEM BIOPH RES CO, V165, P506, DOI 10.1016/0006-291X(89)91098-X; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DAVIS RC, 1987, DEV BIOL, V119, P164, DOI 10.1016/0012-1606(87)90218-1; Dawson John F., 1999, Frontiers in Bioscience, V4, pd646, DOI 10.2741/Dawson; DESILVA DM, 1993, CAN J PHYSIOL PHARM, V71, P715, DOI 10.1139/y93-107; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; EISENSTEIN RS, 1993, J BIOL CHEM, V268, P27363; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; Faccenda E, 1996, CLIN ENDOCRINOL, V44, P341, DOI 10.1046/j.1365-2265.1996.684506.x; Fleming RE, 2000, P NATL ACAD SCI USA, V97, P2214, DOI 10.1073/pnas.040548097; GAMA R, 1995, POSTGRAD MED J, V71, P297, DOI 10.1136/pgmj.71.835.297; GATTI RA, 1987, AM J HUM GENET, V41, P654; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; Gray NK, 1996, P NATL ACAD SCI USA, V93, P4925, DOI 10.1073/pnas.93.10.4925; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; GUO B, 1994, J BIOL CHEM, V269, P24252; Hanson ES, 1998, J BIOL CHEM, V273, P7588, DOI 10.1074/jbc.273.13.7588; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HINKLE PM, 1991, ENDOCRINOLOGY, V129, P1283, DOI 10.1210/endo-129-3-1283; Iwasaki H, 1999, ENDOCRINOLOGY, V140, P4659, DOI 10.1210/en.140.10.4659; JinsiParimoo A, 1997, ENDOCRINOLOGY, V138, P1471, DOI 10.1210/en.138.4.1471; Kanasaki H, 1999, BIOL REPROD, V61, P319, DOI 10.1095/biolreprod61.1.319; Ke YH, 1998, J BIOL CHEM, V273, P23637, DOI 10.1074/jbc.273.37.23637; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KIM HY, 1995, J BIOL CHEM, V270, P4983, DOI 10.1074/jbc.270.10.4983; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KLAUSNER RD, 1996, P NATL ACAD SCI USA, V93, P8175; Konijn AM, 1999, BLOOD, V94, P2128, DOI 10.1182/blood.V94.6.2128.418k20_2128_2134; Leedman PJ, 1996, J BIOL CHEM, V271, P12017, DOI 10.1074/jbc.271.20.12017; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; MONDEN T, 1995, J MOL ENDOCRINOL, V15, P73, DOI 10.1677/jme.0.0150073; NARAYANAN CS, 1992, J BIOL CHEM, V267, P17296; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; Palomero T, 1998, MOL PHARMACOL, V53, P613, DOI 10.1124/mol.53.4.613; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; Phillips JD, 1996, BLOOD, V87, P2983, DOI 10.1182/blood.V87.7.2983.bloodjournal8772983; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; ROGERS JT, 1994, NUCLEIC ACIDS RES, V22, P2678, DOI 10.1093/nar/22.13.2678; Rogers JT, 1996, BLOOD, V87, P2525, DOI 10.1182/blood.V87.6.2525.bloodjournal8762525; ROGERS JT, 1992, IRON HUMAN DIS, P78; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Schalinske KL, 1997, P NATL ACAD SCI USA, V94, P10681, DOI 10.1073/pnas.94.20.10681; Schalinske KL, 1997, BIOCHEMISTRY-US, V36, P3950, DOI 10.1021/bi9624447; Schalinske KL, 1996, J BIOL CHEM, V271, P7168, DOI 10.1074/jbc.271.12.7168; SCHONBRUNN A, 1980, J CELL BIOL, V85, P786, DOI 10.1083/jcb.85.3.786; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; Staton JM, 1998, ENDOCRINOLOGY, V139, P1093, DOI 10.1210/en.139.3.1093; Thomson AM, 1999, INT J BIOCHEM CELL B, V31, P1139, DOI 10.1016/S1357-2725(99)00080-1; Thomson AM, 1999, BIOTECHNIQUES, V27, P1032, DOI 10.2144/99275rr03; Thorner MO, 1998, WILLIAMS TXB ENDOCRI, P249; Toth I, 1999, J BIOL CHEM, V274, P4467, DOI 10.1074/jbc.274.7.4467; TSUJI Y, 1991, J BIOL CHEM, V266, P7257; URSINI MV, 1988, BIOCHEM BIOPH RES CO, V150, P287, DOI 10.1016/0006-291X(88)90518-9; Wang W, 1999, ENDOCRINOLOGY, V140, P4916, DOI 10.1210/en.140.10.4916; Weiss G, 1997, BLOOD, V89, P680, DOI 10.1182/blood.V89.2.680; YAJIMA Y, 1982, IN VITRO CELL DEV B, V18, P1009, DOI 10.1007/BF02796376; YAJIMA Y, 1984, J CELL PHYSIOL, V120, P249, DOI 10.1002/jcp.1041200220	70	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31609	31615		10.1074/jbc.M002354200	http://dx.doi.org/10.1074/jbc.M002354200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10889193	hybrid			2022-12-27	WOS:000089858900010
J	Boulanger, A; Liu, SY; Henningsgaard, AA; Yu, S; Redmond, TM				Boulanger, A; Liu, SY; Henningsgaard, AA; Yu, S; Redmond, TM			The upstream region of the Rpe65 gene confers retinal pigment epithelium-specific expression in vivo and in vitro and contains critical octamer and E-box binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR OTF-1; HELIX-LOOP-HELIX; MESSENGER-RNA; VISUAL CYCLE; CONGENITAL AMAUROSIS; MICROSOMAL PROTEIN; SEQUENCE ELEMENTS; TRANSGENIC MICE; FACTOR OCT-1; CELL LINE	RPE65 is essential for all-trans- to Il-cis-retinoid isomerization, the hallmark reaction of the retinal pigment epithelium (RPE). Here, we identify regulatory elements in the Rpe65 gene and demonstrate their functional relevance to Rpe65 gene expression. We show that the 5' flanking region of the mouse Rpe65 gene, like the human gene, lacks a canonical TATA box and consensus GC and CAAT boxes. The mouse and human genes do share several cis acting elements, including an octamer, a nuclear factor one (NFI) site, and two E-box sites, suggesting a conserved mode of regulation. A mouse Rpe65 promoter/beta-galactosidase transgene containing bases -655 to +52 (TR4) of the mouse 5' flanking region was sufficient to direct high RPE-specific expression in transgenic mice, whereas shorter fragments (-297 to +52 or -188 to +52) generated only background activity. Furthermore, transient transfection of analogous TR4/luciferase constructs also directed high reporter activity in the human RPE cell line D407 but weak activity in the non-RPE cell Lines HeLa, HepG2, and HS27. Functional binding of potential transcription factors to the octamer sequence, AP-4, and NFI sites was demonstrated by directed mutagenesis, electrophoretic mobility shift assay, and cross linking. Mutations of these sites abolished binding and corresponding transcriptional activity and indicated that octamer and E-box transcription factors synergistically regulate the RPE65 promoter function. Thus, we have identified the regulatory region in the Rpe65 gene that accounts for tissue-specific expression in the RPE and found that octamer and E-box transcription factors play a critical role in the transcriptional regulation of the Rpe65 gene.	NEI, LRCMB, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Boulanger, A (corresponding author), NEI, LRCMB, Bldg 6,Rm 339,6 Ctr Dr,MSC 2740, Bethesda, MD 20892 USA.			Redmond, T. Michael/0000-0002-1813-5291	NATIONAL EYE INSTITUTE [Z01EY000260, ZIAEY000260] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aguirre G D, 1998, Mol Vis, V4, P23; BERNSTEIN PS, 1986, BIOCHEMISTRY-US, V25, P6473, DOI 10.1021/bi00369a020; BOBOLA N, 1995, J BIOL CHEM, V270, P1289, DOI 10.1074/jbc.270.3.1289; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DENT CL, 1991, NUCLEIC ACIDS RES, V19, P4531, DOI 10.1093/nar/19.16.4531; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020; Fadel BM, 1999, J BIOL CHEM, V274, P20376, DOI 10.1074/jbc.274.29.20376; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GORING DR, 1987, SCIENCE, V235, P456, DOI 10.1126/science.3099390; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; HAMEL CP, 1993, J BIOL CHEM, V268, P15751; HAMEL CP, 1994, GENOMICS, V20, P509, DOI 10.1006/geno.1994.1212; HAMEL CP, 1993, J NEUROSCI RES, V34, P414, DOI 10.1002/jnr.490340406; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KEMLER I, 1990, FASEB J, V4, P1444, DOI 10.1096/fasebj.4.5.2407588; Kennedy BN, 1998, J BIOL CHEM, V273, P5591, DOI 10.1074/jbc.273.10.5591; Lakich MM, 1998, J BIOL CHEM, V273, P15217, DOI 10.1074/jbc.273.24.15217; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Li SM, 1998, J BIOL CHEM, V273, P31191, DOI 10.1074/jbc.273.47.31191; Liu SY, 1998, ARCH BIOCHEM BIOPHYS, V357, P37, DOI 10.1006/abbi.1998.0817; Ma JX, 1998, BBA-GENE STRUCT EXPR, V1443, P255, DOI 10.1016/S0167-4781(98)00221-8; Manes G, 1998, FEBS LETT, V423, P133, DOI 10.1016/S0014-5793(98)00081-7; Marlhens F, 1998, EUR J HUM GENET, V6, P527, DOI 10.1038/sj.ejhg.5200205; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; NICOLETTI A, 1995, HUM MOL GENET, V4, P641, DOI 10.1093/hmg/4.4.641; Nicoletti A, 1998, INVEST OPHTH VIS SCI, V39, P637; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337; SAARI JC, 1988, J BIOL CHEM, V263, P8084; SAARI JC, 1994, BIOCHEMISTRY-US, V33, P3106, DOI 10.1021/bi00176a045; SAARI JC, 1988, EXP EYE RES, V46, P569, DOI 10.1016/S0014-4835(88)80013-7; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; TVERBERG LA, 1993, J BIOL CHEM, V268, P15965; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; Winston A, 1998, BIOCHEMISTRY-US, V37, P2044, DOI 10.1021/bi971908d; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8; ZHOU DX, 1991, MOL CELL BIOL, V11, P1353, DOI 10.1128/MCB.11.3.1353	51	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31274	31282		10.1074/jbc.M003441200	http://dx.doi.org/10.1074/jbc.M003441200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896939	hybrid			2022-12-27	WOS:000089762700075
J	Nowotny, M; Bhattacharya, S; Filipek, A; Krezel, AM; Chazin, W; Kuznicki, J				Nowotny, M; Bhattacharya, S; Filipek, A; Krezel, AM; Chazin, W; Kuznicki, J			Characterization of the interaction of calcyclin (S100A6) and calcyclin-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCITES-TUMOR-CELLS; ANNEXIN-II; MOLECULAR-CLONING; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; STRONG HOMOLOGY; GROWTH-FACTOR; IDENTIFICATION; EXPRESSION; TARGET; COMPLEX	Calcyclin (S100A6) is an S100 calcium-binding protein whose expression is up-regulated in proliferating and differentiating cells. A novel 30-kDa protein exhibiting calcium dependent calcyclin-binding (calcyclin-binding protein, CacyBP) had been identified, purified, and cloned previously (Filipek, A, and Kuznicki, J, (1998) J. Neurochem. 70, 1793-1798). Here, we have defined the calcyclin binding region using limited proteolysis and a set of deletion mutants of CacyBP. A fragment encompassing residues 178-229 (CacyBP-(178-229)) was capable of full binding to calcyclin, CacyBP-(178-229) was expressed in Escherichia coli as a glutathione S-transferase fusion protein and purified. The protein fragment cleaved from the glutathione S-transferase fusion protein was shown by CD to contain 5% alpha-helix, 15% beta-sheet, and 81% random coil. Fluorescence spectroscopy was used to determine calcyclin dissociation constants of 0.96 and 1.2 mu M for intact CacyBP and CacyBP-(178-229), respectively, indicating that the fragment can be used for characterization of calcyclin-CacyBP interactions. NMR analysis of CacyBP-(178-229) binding-induced changes in the chemical shifts of N-15-enriched calcyclin revealed that CacyBP binding occurs at a discrete site on calcyclin with micromolar affinity.	M Nencki Inst Expt Biol, Dept Mol & Cellular Neurobiol, PL-02093 Warsaw, Poland; Vanderbilt Univ, Dept Biol Mol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Vanderbilt University; Vanderbilt University	Kuznicki, J (corresponding author), M Nencki Inst Expt Biol, Dept Mol & Cellular Neurobiol, 3 Pasteur St, PL-02093 Warsaw, Poland.	jacek@nencki.gov.pl	Kuznicki, Jacek/AAW-9239-2020	Kuznicki, Jacek/0000-0001-6486-0657; Filipek, Anna/0000-0001-9484-9555	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062112] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM-62112] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; CALABRETTA B, 1986, P NATL ACAD SCI USA, V83, P1495, DOI 10.1073/pnas.83.5.1495; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; FILIPEK A, 1995, INT J BIOCHEM CELL B, V27, P1123, DOI 10.1016/1357-2725(95)00096-8; Filipek A, 1998, J NEUROCHEM, V70, P1793, DOI 10.1046/j.1471-4159.1998.70051793.x; FILIPEK A, 1991, EUR J BIOCHEM, V195, P795, DOI 10.1111/j.1432-1033.1991.tb15768.x; Filipek A, 1996, BIOCHEM J, V320, P585, DOI 10.1042/bj3200585; FINDLAY WA, 1995, BIOCHEMISTRY-US, V34, P2087, DOI 10.1021/bi00007a001; GUO XJ, 1990, CELL GROWTH DIFFER, V1, P333; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Jastrzebska B, 2000, J HISTOCHEM CYTOCHEM, V48, P1195, DOI 10.1177/002215540004800903; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; KUZNICKI J, 1989, BIOCHEM J, V263, P951; KUZNICKI J, 1987, BIOCHEM J, V247, P663, DOI 10.1042/bj2470663; KUZNICKI J, 1992, EXP CELL RES, V200, P425, DOI 10.1016/0014-4827(92)90191-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; MANI RS, 1993, BIOCHEMISTRY-US, V32, P11217, DOI 10.1021/bi00092a035; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Sastry M, 1998, STRUCTURE, V6, P223, DOI 10.1016/S0969-2126(98)00023-9; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seemann J, 1996, BIOCHEM J, V319, P123, DOI 10.1042/bj3190123; Sudo T, 1999, FEBS LETT, V444, P11, DOI 10.1016/S0014-5793(99)00014-9; Sudo T, 1998, J BIOL CHEM, V273, P6351, DOI 10.1074/jbc.273.11.6351; TOKUMITSU H, 1992, BIOCHEM BIOPH RES CO, V186, P1227, DOI 10.1016/S0006-291X(05)81537-2; TOKUMITSU H, 1992, J BIOL CHEM, V267, P8919; TONINI GP, 1991, CANCER RES, V51, P1733; ZENG FY, 1993, INT J BIOCHEM, V25, P1019, DOI 10.1016/0020-711X(93)90116-V; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	34	39	41	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31178	31182		10.1074/jbc.M001622200	http://dx.doi.org/10.1074/jbc.M001622200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10884380	hybrid			2022-12-27	WOS:000089762700061
J	Camoretti-Mercado, B; Liu, HW; Halayko, AJ; Forsythe, SM; Kyle, JW; Li, B; Fu, YP; McConville, J; Kogut, P; Vieira, JE; Patel, NM; Hershenson, MB; Fuchs, E; Sinha, S; Miano, JM; Parmacek, MS; Burkhardt, JK; Solway, J				Camoretti-Mercado, B; Liu, HW; Halayko, AJ; Forsythe, SM; Kyle, JW; Li, B; Fu, YP; McConville, J; Kogut, P; Vieira, JE; Patel, NM; Hershenson, MB; Fuchs, E; Sinha, S; Miano, JM; Parmacek, MS; Burkhardt, JK; Solway, J			Physiological control of smooth muscle-specific gene expression through regulated nuclear translocation of serum response factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; DNA-BINDING ACTIVITY; ALPHA-ACTIN EXPRESSION; FACTOR-KAPPA-B; TRANSCRIPTION FACTOR; MYOGENIC DIFFERENTIATION; TRANSGENIC MICE; CASEIN KINASE; GLUCOCORTICOID RECEPTOR; FOS-EXPRESSION	Prolonged serum deprivation induces a structurally and functionally contractile phenotype in about 1/6 of cultured airway myocytes, which exhibit morphological elongation and accumulate abundant contractile apparatus-associated proteins. We tested the hypothesis that transcriptional activation of genes encoding these proteins accounts for their accumulation during this phenotypic transition by measuring the transcriptional activities of the murine SM22 and human smooth muscle myosin heavy chain promoters during transient transfection in subconfluent, serum fed or 7 day serum-deprived cultured canine tracheal smooth muscle cells. Contrary to our expectation, SM22 and smooth muscle myosin heavy chain promoter activities (but not viral murine sarcoma virus-long terminal repeat promoter activity) were decreased in long term serum-deprived myocytes by at least 8-fold. Because serum response factor (SRF) is a required transcriptional activator of these and other smooth muscle-specific promoters, we evaluated the expression and function of SRF in subconfluent and long term serum-deprived cells. Whole cell SRP mRNA and protein were maintained at high levels in serum-deprived myocytes, but SRF transcription-promoting activity, nuclear SRF binding to consensus CArG sequences, and nuclear SRF protein were reduced. Furthermore, immunocytochemistry revealed extranuclear redistribution of SRF in serum-deprived myocytes; nuclear localization of SRF was restored after serum refeeding. These results uncover a novel mechanism for physiological control of smooth muscle-specific gene expression through extranuclear redistribution of SRF and consequent down-regulation of its transcription-promoting activity.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Rochester, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago; University of Rochester; University of Pennsylvania	Solway, J (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC 6026, Chicago, IL 60637 USA.		vieira, joaquim e/D-3147-2013; Solway, Julian/B-1116-2008; Miano, Joseph/L-5634-2018	vieira, joaquim e/0000-0002-6225-8985; Solway, Julian/0000-0002-0898-8530; Halayko, Andrew/0000-0002-7865-4552; Miano, Joseph/0000-0001-7522-3207	NHLBI NIH HHS [HL56399, HL63314, HL64095] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063314, R01HL064095, P50HL056399] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; Browning CL, 1998, DEV BIOL, V194, P18, DOI 10.1006/dbio.1997.8808; Camoretti-Mercado B, 1998, GENOMICS, V49, P452, DOI 10.1006/geno.1998.5267; CHAUHAN D, 1995, LEUKEMIA RES, V19, P337, DOI 10.1016/0145-2126(94)00132-T; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Firulli AB, 1997, TRENDS GENET, V13, P364, DOI 10.1016/S0168-9525(97)01171-2; Galigniana MD, 1999, J BIOL CHEM, V274, P16222, DOI 10.1074/jbc.274.23.16222; GAUTHIERROUVIERE C, 1995, MOL CELL BIOL, V15, P433, DOI 10.1128/MCB.15.1.433; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Halayko AJ, 1999, AM J PHYSIOL-LUNG C, V276, pL197, DOI 10.1152/ajplung.1999.276.1.L197; Hautmann MB, 1997, CIRC RES, V81, P600, DOI 10.1161/01.RES.81.4.600; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; JANKNECHT R, 1993, EUR J BIOCHEM, V216, P469, DOI 10.1111/j.1432-1033.1993.tb18165.x; KATOH Y, 1994, J BIOL CHEM, V269, P30538; Kim S, 1997, J CLIN INVEST, V100, P1006, DOI 10.1172/JCI119611; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; LIU SH, 1993, J BIOL CHEM, V268, P21147; Ma XF, 1998, AM J PHYSIOL-CELL PH, V274, pC1206, DOI 10.1152/ajpcell.1998.274.5.C1206; Mack CP, 1999, CIRC RES, V84, P852; Madsen CS, 1997, J BIOL CHEM, V272, P29842, DOI 10.1074/jbc.272.47.29842; Madsen CS, 1998, CIRC RES, V82, P908; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; MANAK JR, 1993, ONCOGENE, V8, P703; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; Meyyappan M, 1996, BIOL SIGNAL, V5, P130; Miano JM, 2000, J BIOL CHEM, V275, P9814, DOI 10.1074/jbc.275.13.9814; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; Moessler H, 1996, DEVELOPMENT, V122, P2415; MOKENTIN JD, 1996, CURR OPIN GENE DEV, V6, P445; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; Okamoto K, 1999, J BIOL CHEM, V274, P10363, DOI 10.1074/jbc.274.15.10363; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; PAPAVASSILIOU AG, 1994, ANTICANCER RES, V14, P1923; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; SCHNEIDER MD, 1988, MOL NEUROBIOL, V2, P1, DOI 10.1007/BF02935631; SHARROCKS AD, 1995, FEBS LETT, V368, P77, DOI 10.1016/0014-5793(95)00604-8; Sinha S, 2000, MOL CELL BIOL, V20, P2543, DOI 10.1128/MCB.20.7.2543-2555.2000; Solway J, 1998, AM J RESP CRIT CARE, V158, pS100, DOI 10.1164/ajrccm.158.supplement_2.13tac500; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; Strubing C, 1999, J GEN PHYSIOL, V113, P239, DOI 10.1085/jgp.113.2.239; THWEATT R, 1992, BIOCHEM BIOPH RES CO, V187, P1, DOI 10.1016/S0006-291X(05)81449-4; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; VAN AL, 1997, GENE DEV, V11, P2295; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zilberman A, 1998, CIRC RES, V82, P566, DOI 10.1161/01.RES.82.5.566; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225	59	100	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30387	30393		10.1074/jbc.M000840200	http://dx.doi.org/10.1074/jbc.M000840200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10866994	hybrid			2022-12-27	WOS:000089577900064
J	Nakajima, A; Sugimoto, Y; Yoneyama, H; Nakae, T				Nakajima, A; Sugimoto, Y; Yoneyama, H; Nakae, T			Localization of the outer membrane subunit OprM of resistance-nodulation-cell division family multicomponent efflux pump in Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; MULTIDRUG EFFLUX; EXTRUSION; OVEREXPRESSION; RESOLUTION; PROTEINS; CHANNELS; SYSTEMS; OPERON	The outer membrane subunit OprM of the multicomponent efflux pump of Pseudomonas aeruginosa has been assumed to form a transmembrane xenobiotic exit channel across the outer membrane. We challenged this hypothesis to clarify the underlying ambiguity by manipulating the amino-terminal signal sequence of the OprM protein of the MexAB-OprM efflux pump in P. aeruginosa, [H-3]Palmitate uptake experiments revealed that OprM is a lipoprotein. The following lines of evidence unequivocally established that the OprM protein functioned at the periplasmic space. (i) The OprM protein, in which a signal sequence including Cys-18 was replaced with that of periplasmic azurin, appeared in the periplasmic space but not in the outer membrane fraction, and the protein fully functioned as the pump subunit. (ii) The hybrid OprM containing the N-terminal transmembrane segment of the inner membrane protein, MexF, appeared exclusively in the inner membrane fraction. The hybrid protein containing 186 or 331 amino acid residues of MexF was fully active for the antibiotic extrusion, but a 42-residue protein was totally inactive. (iii) The mutant OprM, in which the N-terminal cysteine residue was replaced with another amino acid, appeared unmodified with fatty acid and was fractionated in both the periplasmic space and the inner membrane fraction but not in the outer membrane fraction. The Cys-18-modified OprM functioned for the antibiotic extrusion indistinguishably from that in the wild-type strain. We concluded, based on these results, that the OprM protein was anchored in the outer membrane via fatty acid(s) attached to the N-terminal cysteine residue and that the entire polypeptide moiety was exposed to the periplasmic space.	Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 2591193, Japan	Tokai University	Nakae, T (corresponding author), Tokai Univ, Sch Med, Dept Mol Life Sci, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	nakae@is.icc.u-tokai.ac.jp						COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Forst D, 1998, NAT STRUCT BIOL, V5, P37, DOI 10.1038/nsb0198-37; Guan L, 1999, J BIOL CHEM, V274, P10517, DOI 10.1074/jbc.274.15.10517; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; Kohler T, 1996, ANTIMICROB AGENTS CH, V40, P2288, DOI 10.1128/AAC.40.10.2288; Kohler T, 1997, ANTIMICROB AGENTS CH, V41, P2540, DOI 10.1128/AAC.41.11.2540; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEI Y, 1991, FEMS MICROBIOL LETT, V80, P337; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma Dzwokai, 1994, Trends in Microbiology, V2, P489, DOI 10.1016/0966-842X(94)90654-8; Mine T, 1999, ANTIMICROB AGENTS CH, V43, P415, DOI 10.1128/AAC.43.2.415; MIZUNO T, 1978, J BIOCHEM, V84, P179, DOI 10.1093/oxfordjournals.jbchem.a132106; MORSHED SRM, 1995, BIOCHEM BIOPH RES CO, V210, P356, DOI 10.1006/bbrc.1995.1669; NAKAE T, 1979, J BIOL CHEM, V254, P1457; Nakae Taiji, 1997, J Infect Chemother, V3, P173, DOI 10.1007/BF02490031; NAKAMURA K, 1976, J BIOCHEM, V80, P1411, DOI 10.1093/oxfordjournals.jbchem.a131414; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; POOLE K, 1993, J BACTERIOL, V175, P7363, DOI 10.1128/JB.175.22.7363-7372.1993; Poole K, 1996, MOL MICROBIOL, V21, P713, DOI 10.1046/j.1365-2958.1996.281397.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RELLA M, 1982, ANTIMICROB AGENTS CH, V22, P242, DOI 10.1128/AAC.22.2.242; ROSENBUSCH JP, 1974, J BIOL CHEM, V249, P8019; Saito K, 1999, FEMS MICROBIOL LETT, V179, P67, DOI 10.1016/S0378-1097(99)00394-8; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Srikumar R, 2000, J BACTERIOL, V182, P1410, DOI 10.1128/JB.182.5.1410-1414.2000; Tseng Tsai-Tien, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P107; WEISS MS, 1992, J MOL BIOL, V227, P493, DOI 10.1016/0022-2836(92)90903-W; Wong KKY, 2000, J BACTERIOL, V182, P2402, DOI 10.1128/JB.182.9.2402-2410.2000; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; Yoneyama H, 1997, BIOCHEM BIOPH RES CO, V233, P611, DOI 10.1006/bbrc.1997.6506; Yoneyama H, 2000, J BIOL CHEM, V275, P4628, DOI 10.1074/jbc.275.7.4628; Yoneyama H, 1998, BIOCHEM BIOPH RES CO, V244, P898, DOI 10.1006/bbrc.1998.8351; Zgurskaya HI, 1999, P NATL ACAD SCI USA, V96, P7190, DOI 10.1073/pnas.96.13.7190	40	37	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30064	30068		10.1074/jbc.M005742200	http://dx.doi.org/10.1074/jbc.M005742200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10889211	hybrid			2022-12-27	WOS:000089577900021
J	Ruiz-Gomez, A; Humrich, J; Murga, C; Quitterer, U; Lohse, MJ; Mayor, F				Ruiz-Gomez, A; Humrich, J; Murga, C; Quitterer, U; Lohse, MJ; Mayor, F			Phosphorylation of phosducin and phosducin-like protein by G protein-coupled receptor kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; MICROSOMAL-MEMBRANES; HIGH-AFFINITY; ACTIVATION; BINDING; INHIBITION; TRANSDUCIN; REGULATOR; GRK2; DESENSITIZATION	G protein-coupled receptor kinase 2 (GRK2) is able to phosphorylate a variety of agonist-occupied G protein-coupled receptors (GPCR) and plays an important role in GPCR modulation, However, recent studies suggest additional cellular functions for GRK2. Phosducin and phosducin-like protein (PhLP) are cytosolic proteins that bind G beta gamma subunits and act as regulators of G-protein signaling. In this report, we identify phosducin and PhLP as novel GRK2 substrates, The phosphorylation of purified phosducin and PhLP by recombinant GRK2 proceeds rapidly and stoichiometrically (0.82 +/- 0.1 and 0.83 +/- 0.09 mol of P-i/mol of protein, respectively). The phosphorylation reactions exhibit apparent K-m values in the range of 40-100 nM, strongly suggesting that both proteins could be endogenous targets for GRK2 activity. Our data show that the site of phosducin phosphorylation by GRK2 is different and independent from that previously reported for the cAMP-dependent protein kinase. Analysis of GRK2 phosphorylation of a variety of deletion mutants of phosducin and PhLP indicates that the critical region for GRK2 phosphorylation is localized in the C-terminal domain of both phosducin and PhLP (between residues 204 and 245 and 195 and 218, respectively). This region is important for the interaction of these proteins with G beta gamma subunits, Phosphorylation of phosducin by GRK2 markedly reduces its G beta gamma binding ability, suggesting that GRK2 may modulate the activity of the phosducin protein family by disrupting this interaction. The identification of phosducin and PhLP as new substrates for GRK2 further expands the cellular roles of this kinase and suggests new mechanisms for modulating GPCR signal transduction.	Univ Autonoma Madrid, Dept Biol Mol, E-28049 Madrid, Spain; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain; Univ Wurzburg, Inst Pharmakol & Toxikol, D-97078 Wurzburg, Germany	Autonomous University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); University of Wurzburg	Mayor, F (corresponding author), Univ Autonoma Madrid, Dept Biol Mol, E-28049 Madrid, Spain.	fmayor@cbm.uam.es	Mayor, Federico/N-7644-2016; Ruiz-Gomez, Ana/ABF-3079-2021; Ruiz-Gómez, Ana/H-2092-2015; Lohse, Martin J/A-7160-2012; Murga, Cristina/E-1965-2014	Ruiz-Gómez, Ana/0000-0002-1646-3072; Lohse, Martin J/0000-0002-0599-3510; Murga, Cristina/0000-0002-8964-4077; Mayor Menendez, Federico/0000-0003-1434-8449				Aragay AM, 1998, FEBS LETT, V430, P37, DOI 10.1016/S0014-5793(98)00495-5; Bauer PH, 1998, J BIOL CHEM, V273, P9465, DOI 10.1074/jbc.273.16.9465; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Bluml K, 1997, EMBO J, V16, P4908, DOI 10.1093/emboj/16.16.4908; Boekhoff I, 1997, J BIOL CHEM, V272, P4606, DOI 10.1074/jbc.272.7.4606; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Danner S, 1996, P NATL ACAD SCI USA, V93, P10145, DOI 10.1073/pnas.93.19.10145; DebBurman SK, 1996, J BIOL CHEM, V271, P22552, DOI 10.1074/jbc.271.37.22552; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; GARCIAHIGUERA I, 1994, J BIOL CHEM, V269, P1348; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; HAGA K, 1994, J BIOL CHEM, V269, P12594; HEKMAN M, 1994, FEBS LETT, V343, P120, DOI 10.1016/0014-5793(94)80302-1; Iacovelli L, 1999, FASEB J, V13, P1; KIM CM, 1993, J BIOL CHEM, V268, P15412; KRUPNICK JG, 1998, ANN REV PHARM TOXICO, V38, P238; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lohse MJ, 1996, KIDNEY INT, V49, P1047, DOI 10.1038/ki.1996.153; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Mayor F, 1998, TRENDS CARDIOVAS MED, V8, P234, DOI 10.1016/S1050-1738(98)00008-5; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; Murga C, 1996, J BIOL CHEM, V271, P985, DOI 10.1074/jbc.271.2.985; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Sarnago S, 1999, J BIOL CHEM, V274, P34411, DOI 10.1074/jbc.274.48.34411; Schroder S, 1997, FEBS LETT, V401, P243, DOI 10.1016/S0014-5793(96)01483-4; Schroder S, 1996, P NATL ACAD SCI USA, V93, P2100, DOI 10.1073/pnas.93.5.2100; Schulz K, 1996, J BIOL CHEM, V271, P22546, DOI 10.1074/jbc.271.37.22546; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Thibault C, 1997, J BIOL CHEM, V272, P12253, DOI 10.1074/jbc.272.19.12253; Thulin CD, 1999, MOL VIS, V5, pU13; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	48	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29724	29730		10.1074/jbc.M001864200	http://dx.doi.org/10.1074/jbc.M001864200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10884381	hybrid			2022-12-27	WOS:000089439800073
J	Pluciennik, A; Iyer, RR; Parniewski, P; Wells, RD				Pluciennik, A; Iyer, RR; Parniewski, P; Wells, RD			Tandem duplication - A novel type of triplet repeat instability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTER-DOT-CAG; HEREDITARY-DISEASE GENES; GRAM-NEGATIVE BACTERIA; REPLICATION IN-VIVO; RNA-DNA HYBRID; ESCHERICHIA-COLI; TRINUCLEOTIDE REPEATS; CTG REPEATS; SUPERCOILED DNA; MISMATCH REPAIR	Triplet repeat sequence (TRS) inserts containing (CTG.CAG)(n) (17-175 units in length) were tandemly duplicated when propagated in plasmids in Escherichia coli, The products of this novel type of TRS genetic instability are tracts of as many as 34 multiple units, which contain the entire TRS as well as 129 base pairs of nonrepetitive flanking sequence. The duplication process required the presence of two or more TRS-containing units. Close proximity (170 base pairs) of the TRS to the R6K gamma origin of replication of the pUTminiTn5Cm-derived constructs stimulated the tandem duplication process. These events are proposed to occur due to secondary structure formation, stalling of DNA synthesis, and slippage-mediated misalignment of the complementary strands relative to each other during DNA replication. This mechanism may account for the TRS-associated duplications in protein kinase and metalloprotease genes in neuroblastomas and melanomas, as well as the massive repeat expansions in type II triplet repeat neurological diseases.	Texas A&M Univ, Texas Med Ctr, Inst Biosci & Technol, Ctr Genome Res, Houston, TX 77030 USA	Baylor College of Medicine; Texas A&M University System	Wells, RD (corresponding author), Texas A&M Univ, Texas Med Ctr, Inst Biosci & Technol, Ctr Genome Res, 2121 Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamu.edu			NIGMS NIH HHS [GM52982] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERTINI AM, 1982, CELL, V29, P319, DOI 10.1016/0092-8674(82)90148-9; ARMOUR JAL, 1994, HUM MOL GENET, V3, P599, DOI 10.1093/hmg/3.4.599; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; Bacolla A, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P467; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; Bichara M, 2000, GENETICS, V154, P533; BOWATER R, 1991, BIOCHEMISTRY-US, V30, P11495, DOI 10.1021/bi00113a003; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Bowater RP, 1997, NUCLEIC ACIDS RES, V25, P2861, DOI 10.1093/nar/25.14.2861; BURD JF, 1975, J BIOL CHEM, V250, P6002; BURD JF, 1975, J BIOL CHEM, V250, P5109; Canceill D, 1999, J BIOL CHEM, V274, P27481, DOI 10.1074/jbc.274.39.27481; Canceill D, 1996, P NATL ACAD SCI USA, V93, P6647, DOI 10.1073/pnas.93.13.6647; Chastain PD, 1995, BIOCHEMISTRY-US, V34, P16125, DOI 10.1021/bi00049a027; Chen DZ, 1998, J MOL BIOL, V282, P775, DOI 10.1006/jmbi.1998.2055; DALENCON E, 1994, EMBO J, V13, P2725, DOI 10.1002/j.1460-2075.1994.tb06563.x; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; Feschenko VV, 1998, J MOL BIOL, V276, P559, DOI 10.1006/jmbi.1997.1566; FILUTOWICZ M, 1986, P NATL ACAD SCI USA, V83, P9645, DOI 10.1073/pnas.83.24.9645; Filutowicz M, 1998, GENE, V223, P195, DOI 10.1016/S0378-1119(98)00367-9; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; Gao XL, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P623; Gellibolian R, 1997, J BIOL CHEM, V272, P16793, DOI 10.1074/jbc.272.27.16793; Gururajan R, 1998, GENOME RES, V8, P929, DOI 10.1101/gr.8.9.929; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; HIASA H, 1994, J BIOL CHEM, V269, P6058; Hirst MC, 1998, NUCLEIC ACIDS RES, V26, P2353, DOI 10.1093/nar/26.10.2353; Iyer RR, 2000, J BIOL CHEM, V275, P2174, DOI 10.1074/jbc.275.3.2174; Iyer RR, 1999, J BIOL CHEM, V274, P3865, DOI 10.1074/jbc.274.6.3865; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Lovett ST, 1996, P NATL ACAD SCI USA, V93, P7120, DOI 10.1073/pnas.93.14.7120; LOVETT ST, 1993, GENETICS, V135, P631; Lupski JR, 1998, TRENDS GENET, V14, P417, DOI 10.1016/S0168-9525(98)01555-8; Mariappan SVS, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P647; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; Mazzarella R, 1998, GENOME RES, V8, P1007, DOI 10.1101/gr.8.10.1007; Miret JJ, 1997, MOL CELL BIOL, V17, P3382, DOI 10.1128/MCB.17.6.3382; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; MURCHIE AIH, 1992, BIOCHIM BIOPHYS ACTA, V1131, P1, DOI 10.1016/0167-4781(92)90091-D; NADEL Y, 1995, J BIOL CHEM, V270, P28970, DOI 10.1074/jbc.270.48.28970; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Parniewski P, 2000, J MOL BIOL, V299, P865, DOI 10.1006/jmbi.2000.3796; Parniewski P, 1999, NUCLEIC ACIDS RES, V27, P616, DOI 10.1093/nar/27.2.616; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Pearson CE, 1998, BIOCHEMISTRY-US, V37, P2701, DOI 10.1021/bi972546c; PEARSON CE, 1996, AM J HUM GENET, V59, P244; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; Rosche WA, 1996, J BACTERIOL, V178, P5042, DOI 10.1128/jb.178.16.5042-5044.1996; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sarkar PS, 1998, CELL, V95, P531, DOI 10.1016/S0092-8674(00)81620-7; Schumacher S, 1998, J MOL BIOL, V279, P1101, DOI 10.1006/jmbi.1998.1827; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; STANTON DJ, 1994, GENETICS, V137, P233; Stoike LL, 1998, GENETICS, V149, P347; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; SULLIVAN KM, 1988, NUCLEIC ACIDS RES, V16, P1079, DOI 10.1093/nar/16.3.1079; SULLIVAN KM, 1986, CELL, V47, P817, DOI 10.1016/0092-8674(86)90524-6; SULLIVAN KM, 1988, J BIOL CHEM, V263, P13074; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; Wells R.D., 1998, GENETIC INSTABILITIE; Wells RD, 1998, J BIOL CHEM, V273, P19532, DOI 10.1074/jbc.273.31.19532	76	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28386	28397		10.1074/jbc.M000154200	http://dx.doi.org/10.1074/jbc.M000154200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10877999	hybrid			2022-12-27	WOS:000089330700009
J	Benkusky, NA; Fergus, DJ; Zucchero, TM; England, SK				Benkusky, NA; Fergus, DJ; Zucchero, TM; England, SK			Regulation of the Ca2+-sensitive domains of the maxi-K channel in the mouse myometrium during gestation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; SMOOTH-MUSCLE; BETA-SUBUNIT; CA CHANNELS; CELLS; SENSITIVITY; MODULATION; EXPRESSION; PREGNANCY; ISOFORMS	Large conductance Ca2+-activated K+ channels (maxi-K channels) are known to modulate uterine activity during gestation. Electrophysiological recordings demonstrate that myometrial maxi-K current is suppressed in term-pregnant compared to non-pregnant mice. We sought to determine whether maxi-K current suppression is due to reduction of maxi-K channel protein or differential expression of maxi-K channel isoforms that vary in their Ca2+ and voltage sensitivities. Immunoblot analyses show an increase of maxi-K channel protein throughout gestation. Polymerase chain reaction of mouse myometrial cDNA identified four alternatively spliced sites within the maxi-K transcript and three within the Ca2+-sensitive "tail" domain. Ribonuclease protection analyses demonstrate that total channel transcript levels mimic protein expression; however transcript levels of alternatively spliced regions of regulatory domains that alter sensitivity to voltage and Ca2+ differ in their gestational expression. An insert that increases the maxi-K channel sensitivity to voltage and Ca2+ is present at steady levels throughout gestation, differing from total channel transcript regulation. The insert-less form of this transcript, which reduces the channel voltage and Ca2+ sensitivity, is not detected until midterm pregnancy. These findings verify that multiple isoforms of the maxi-K channel are present in the mouse myometrium and are regulated differentially during gestation, which is a likely mechanism for modulation of myometrial excitability during pregnancy.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	England, SK (corresponding author), Univ Iowa, Dept Physiol & Biophys, 5-660 Bowen Sci Bldg, Iowa City, IA 52242 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD037831] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-37831] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ANWER K, 1993, AM J PHYSIOL, V265, pC976, DOI 10.1152/ajpcell.1993.265.4.C976; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Hanaoka K, 1999, J MEMBRANE BIOL, V172, P193, DOI 10.1007/s002329900596; Jackson WF, 1997, MICROCIRCULATION-LON, V4, P35, DOI 10.3109/10739689709148316; Khan RN, 1998, HUM REPROD, V13, P208, DOI 10.1093/humrep/13.1.208; KHAN RN, 1993, P ROY SOC B-BIOL SCI, V251, P9, DOI 10.1098/rspb.1993.0002; KNAUS HG, 1995, J BIOL CHEM, V270, P22434, DOI 10.1074/jbc.270.38.22434; Knittle TJ, 1996, AM J PHYSIOL-CELL PH, V270, pC688, DOI 10.1152/ajpcell.1996.270.2.C688; LUDMIR J, 1993, MICROSC RES TECHNIQ, V25, P134, DOI 10.1002/jemt.1070250206; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; MEERA P, 1995, AM J PHYSIOL-CELL PH, V269, pC312, DOI 10.1152/ajpcell.1995.269.2.C312; Navaratnam DS, 1997, NEURON, V19, P1077, DOI 10.1016/S0896-6273(00)80398-0; Okawa T, 1999, AM J OBSTET GYNECOL, V181, P649, DOI 10.1016/S0002-9378(99)70508-9; PALLANCK L, 1994, HUM MOL GENET, V3, P1239, DOI 10.1093/hmg/3.8.1239; PEREZ G, 1994, AM J PHYSIOL, V266, pC1459, DOI 10.1152/ajpcell.1994.266.5.C1459; Rosenblatt KP, 1997, NEURON, V19, P1061, DOI 10.1016/S0896-6273(00)80397-9; Saito M, 1997, J BIOL CHEM, V272, P11710, DOI 10.1074/jbc.272.18.11710; SANBORN BM, 1995, SEMIN PERINATOL, V19, P31, DOI 10.1016/S0146-0005(95)80045-X; Song M, 1999, FEBS LETT, V460, P427, DOI 10.1016/S0014-5793(99)01394-0; SPERELAKIS N, 1992, CAN J PHYSIOL PHARM, V70, P491, DOI 10.1139/y92-064; Toro L, 1998, NEWS PHYSIOL SCI, V13, P112; TORO L, 1990, P NATL ACAD SCI USA, V87, P2892, DOI 10.1073/pnas.87.8.2892; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Wallner M, 1996, P NATL ACAD SCI USA, V93, P14922, DOI 10.1073/pnas.93.25.14922; Wang SY, 1998, J GEN PHYSIOL, V112, P737, DOI 10.1085/jgp.112.6.737; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; Xie JY, 1998, SCIENCE, V280, P443, DOI 10.1126/science.280.5362.443	29	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27712	27719						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871603				2022-12-27	WOS:000089197100027
J	Jezewska, MJ; Rajendran, S; Bujalowski, W				Jezewska, MJ; Rajendran, S; Bujalowski, W			Escherichia coli replicative helicase PriA protein-single-stranded DNA complex - Stoichiometries, free energy of binding, and cooperativities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMENSIONAL HOMOGENEOUS LATTICE; FLUORESCENT NUCLEOTIDE ANALOGS; FACTOR-Y; DEPENDENT ATPASE; LARGE LIGANDS; NUCLEIC-ACID; SITE; ENZYME; MACROMOLECULE; HEXAMER	Analyses of interactions of the Escherichia coli replicative helicase, PriA protein, with a single-stranded (ss) DNA have been performed, using the quantitative fluorescence titration technique. The stoichiometry of the PriA helicase.ssDNA complex has been examined in binding experiments with a series of ssDNA oligomers. The total site-size of the PriA.ssDNA complex, i.e. the maximum number of nucleotide residues occluded by the PriA helicase in the complex, is 20 +/- 3 residues per protein monomer, However, the protein can efficiently form a complex with a minimum of 8 nucleotides, Thus, the enzyme has a strong ssDNA-binding site that engages in direct interactions with a significantly smaller number of nucleotides than the total site-size, The ssDNA-binding site is located in the center of the enzyme molecule, with the protein matrix protruding over a distance of similar to 6 nucleotides on both sides of the binding site. The analysis of the binding of two PriA molecules to long oligomers was performed using statistical thermodynamic models that take into account the overlap of potential binding sites, cooperative interactions, and the protein.ssDNA complexes with different stoichiometries. The intrinsic affinity depends little upon the length of the ssDNA. Moreover, the binding is accompanied by weak cooperative interactions.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Bujalowski, W (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 301 Univ Blvd, Galveston, TX 77555 USA.				NIGMS NIH HHS [GM-46679, GM-58675] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER BM, 1978, BIOPOLYMERS, V17, P1361, DOI 10.1002/bip.1978.360170519; Bujalowski W, 2000, BIOCHEMISTRY-US, V39, P2106, DOI 10.1021/bi992413m; BUJALOWSKI W, 1994, BIOCHEMISTRY-US, V33, P4682, DOI 10.1021/bi00181a028; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31359; Bujalowski W, 2000, J MOL BIOL, V295, P831, DOI 10.1006/jmbi.1999.3378; BUJALOWSKI W, 1993, BIOCHEMISTRY-US, V32, P5888, DOI 10.1021/bi00073a023; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; BUJALOWSKI W, 1989, BIOPOLYMERS, V28, P1637, DOI 10.1002/bip.360280912; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EPSTEIN IR, 1978, BIOPHYS CHEM, V8, P327, DOI 10.1016/0301-4622(78)80015-5; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HILL TL, 1985, COOPERATIVITY THEORY, P34; Jezewska MJ, 1997, BIOPHYS CHEM, V64, P253, DOI 10.1016/S0301-4622(96)02221-1; Jezewska MJ, 1996, BIOCHEMISTRY-US, V35, P2117, DOI 10.1021/bi952344l; Jezewska MJ, 1998, J BIOL CHEM, V273, P9058, DOI 10.1074/jbc.273.15.9058; Jezewska MJ, 1997, BIOCHEMISTRY-US, V36, P10320, DOI 10.1021/bi970712a; Jezewska MJ, 1998, BIOCHEMISTRY-US, V37, P3116, DOI 10.1021/bi972564u; Jezewska MJ, 1996, BIOCHEMISTRY-US, V35, P2129, DOI 10.1021/bi952345d; Jezewska MJ, 1998, J BIOL CHEM, V273, P10515, DOI 10.1074/jbc.273.17.10515; KORNBERG A, 1992, DNA REPLICATION, P275; KUBOTA Y, 1983, BIOPHYS CHEM, V18, P233, DOI 10.1016/0301-4622(83)80036-2; Lakowicz JR., 1999, PRINCIPLES FLUORESCE, P25; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEDNEVA RK, 1978, NUCLEIC ACIDS RES, V5, P4225, DOI 10.1093/nar/5.11.4225; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; Marians KJ, 2000, PROG NUCLEIC ACID RE, V63, P39; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; MCMACKEN R, 1977, P NATL ACAD SCI USA, V74, P4190, DOI 10.1073/pnas.74.10.4190; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; SECRIST JA, 1972, BIOCHEMISTRY-US, V11, P3499, DOI 10.1021/bi00769a001; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SHLOMAI J, 1980, J BIOL CHEM, V255, P6794; TOLMAN GL, 1974, BIOCHEMISTRY-US, V13, P4869, DOI 10.1021/bi00721a001; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P3342, DOI 10.1073/pnas.72.9.3342; ZIPURSKY SL, 1980, P NATL ACAD SCI-BIOL, V77, P6521, DOI 10.1073/pnas.77.11.6521	44	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27865	27873						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10875934				2022-12-27	WOS:000089197100048
J	Raman, V; Tamori, A; Vali, M; Zeller, K; Korz, D; Sukumar, S				Raman, V; Tamori, A; Vali, M; Zeller, K; Korz, D; Sukumar, S			HOXA5 regulates expression of the progesterone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX GENES; MAMMARY-GLAND	The majority of breast carcinomas show reduced or no expression of the transcription factor, HOXA5. Recently, we have shown that HOXA5 is a potent transactivator of p53 in breast cells and thus may affect the response of breast cancer cells to DNA damage. To determine whether HOXA5 played a role in growth and homeostasis in breast cells, we studied its interaction with the progesterone receptor. The progesterone receptor (PR) belongs to the superfamily of nuclear receptors whose members co-ordinate morphogenesis of the mammary gland in response to binding to their cognate ligands. An increased expression of the endogenous PR gene was seen in MCF-7 cells following induced expression of an exogenously transfected HOXA5 gene. HOXA5, but not HOXB4, -B5, or -B7 activated the PR promoter in two breast cancer cell lines, MCF-7 and Hs578T. Deletion and mutation analysis of the promoter identified a single HOXA5-binding site required for transactivation of the PR gene by HOXA5. HOXA5 binds directly to this site in the PR promoter. Thus, HOXA5 may behave as a transcriptional regulator of multiple target genes, two among which are p53 and the progesterone receptor.	Johns Hopkins Oncol Ctr, Breast Canc Program, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Sukumar, S (corresponding author), Johns Hopkins Oncol Ctr, Breast Canc Program, 1650 Orleans St, Baltimore, MD 21231 USA.				NATIONAL CANCER INSTITUTE [T32CA009630] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA8943, T32 CA09630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATTERSBY S, 1992, BRIT J CANCER, V65, P601, DOI 10.1038/bjc.1992.122; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Chen F, 1999, P NATL ACAD SCI USA, V96, P541, DOI 10.1073/pnas.96.2.541; Cillo C, 1999, EXP CELL RES, V248, P1, DOI 10.1006/excr.1999.4451; Conneely OM, 2000, J SOC GYNECOL INVEST, V7, pS25, DOI 10.1016/S1071-5576(99)00062-3; Greer JM, 2000, NATURE, V403, P661, DOI 10.1038/35001077; Katzenellenbogen BS, 2000, J SOC GYNECOL INVEST, V7, pS33, DOI 10.1177/1071557600007001S10; Korach KS, 2000, J SOC GYNECOL INVEST, V7, pS16, DOI 10.1177/1071557600007001S06; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Moutsatsou P, 1997, ANN NY ACAD SCI, V816, P99, DOI 10.1111/j.1749-6632.1997.tb52134.x; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; RAMAN V, 1993, INT J DEV BIOL, V37, P499; Shyamala G, 2000, P NATL ACAD SCI USA, V97, P3044, DOI 10.1073/pnas.97.7.3044; van Oostveen JW, 1999, LEUKEMIA, V13, P1675, DOI 10.1038/sj.leu.2401562; Veraksa A, 2000, MOL GENET METAB, V69, P85, DOI 10.1006/mgme.2000.2963	15	67	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26551	26555		10.1074/jbc.C000324200	http://dx.doi.org/10.1074/jbc.C000324200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10875927	hybrid			2022-12-27	WOS:000088999700092
J	Schleef, RR; Chuang, TL				Schleef, RR; Chuang, TL			Protease inhibitor 10 inhibits tumor necrosis factor alpha-induced cell death - Evidence for the formation of intracellular high M-r protease inhibitor 10-containing complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR-INHIBITOR; HUMAN SERPIN; TYPE-2; IDENTIFICATION; INSERTION; MECHANISM; APOPTOSIS; TRYPSIN; BOMAPIN	Protease inhibitor 10 (PI10) is a member of the ovalbumin family of serine protease inhibitors (ov-serpin) that is expressed at elevated levels in patients with acute myeloid leukemia and chronic myelomonocytic leukemia. Based upon the ability of the related serpin plasminogen activator inhibitor 2 (PAI-8) to protect cells against tumor necrosis factor alpha (TNF alpha)-induced cell death, this study was initiated to investigate the potential cytoprotective activity of PI10, Two different expression systems (i.e. plasmids encoding either PI10 alone or PI10 fused to the tag: enhanced green fluorescent protein, EG;FP) were utilized to stably transfect an eukaryotic model cell system (i.e. HeLa cells) that neither expresses PAI-2 nor PI10. The level of PI10 expression in the stable transfectants was found to correlate with their resistance to TNF alpha-induced cell death. Immunoprecipitation/immunoblotting experiments demonstrated that PI10 is able to form SDS-stable complexes (i.e, M-r >100,000) with a cytosolic protein(s). Increased levels of the PI10-containing complexes can be detected by TNF alpha treatment by preventing intracellular degradative activities with the proteasome inhibitor N-carbobenzyloxy-leucine-leucine-norvalinal. PI10-containing complexes are dissociated with conditions known to separate classical protease-serpin complexes (i.e., 1.5 hz ammonium hydroxide in the presence of SDS). These data support a role for the regulation of intracellular protease activities by ov-serpins.	Scripps Res Inst, Dept Vasc Biol VB1, La Jolla, CA 92037 USA	Scripps Research Institute	Schleef, RR (corresponding author), Scripps Res Inst, Dept Vasc Biol VB1, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045954] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45954] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACHMANN F, 1995, THROMB HAEMOSTASIS, V74, P175; Chuang TL, 1999, J BIOL CHEM, V274, P11194, DOI 10.1074/jbc.274.16.11194; DANIELSSON A, 1982, BIOCHEM J, V207, P21, DOI 10.1042/bj2070021; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; Haas M, 1998, J LEUKOCYTE BIOL, V63, P395, DOI 10.1002/jlb.63.3.395; JENSEN PH, 1994, J BIOL CHEM, V269, P15394; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; KRUITHOF EKO, 1995, BLOOD, V86, P4007, DOI 10.1182/blood.V86.11.4007.bloodjournal86114007; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; KUMAR S, 1991, J BIOL CHEM, V266, P20960; MANCHANDA N, 1995, J BIOL CHEM, V270, P20032, DOI 10.1074/jbc.270.34.20032; Ny T, 1997, ADV EXP MED BIOL, V425, P123; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; PHILIPS M, 1984, BIOCHIM BIOPHYS ACTA, V802, P99, DOI 10.1016/0304-4165(84)90039-4; Riewald M, 1996, J BIOL CHEM, V271, P14526, DOI 10.1074/jbc.271.24.14526; Riewald M, 1996, J BIOL CHEM, V271, P7160, DOI 10.1074/jbc.271.12.7160; Riewald M, 1998, BLOOD, V91, P1256, DOI 10.1182/blood.V91.4.1256; RIEWALD M, 1995, J BIOL CHEM, V270, P26754, DOI 10.1074/jbc.270.45.26754; SCHLEEF RR, 1989, J CLIN INVEST, V83, P1747, DOI 10.1172/JCI114076; WIMAN B, 1979, J BIOL CHEM, V254, P9291	20	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26385	26389		10.1074/jbc.C000389200	http://dx.doi.org/10.1074/jbc.C000389200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10871600	hybrid			2022-12-27	WOS:000088999700069
J	Tibbetts, AS; Appling, DR				Tibbetts, AS; Appling, DR			Characterization of two 5-aminoimidazole-4-carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase isozymes from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; SUBUNIT STRUCTURE; ESCHERICHIA-COLI; PROTEIN BAS1P; GENE-PRODUCT; YEAST-CELLS; IN-VIVO; EXPRESSION; DNA; TRANSFORMATION	The Saccharomyces cerevisiae ADE16 and ADE17 genes encode 5-aminoimidazole-4-carboxamide ribonucleotide transformylase isozymes that catalyze the penultimate step of the de novo purine biosynthesis pathway. Disruption of these two chromosomal genes results in adenine auxotrophy, whereas expression of either gene alone is sufficient to support growth without adenine. In this work, me show that an ade16 ade17 double disruption also leads to histidine auxotrophy, similar to the adenine/histidine auxotrophy of ade3 mutant yeast strains. We also report the purification and characterization of the ADE16 and ADE17 gene products (Ad16p and Ade17p). Like their counterparts in other organisms, the yeast isozymes are bifunctional, containing both 5-aminoimidazole-4-carboxamide ribonucleotide transformylase and inosine monophosphate cyclohydrolase activities, and exist as homodimers based on cross-linking studies. Both isozymes are localized to the cytosol, as shown by subcellular fractionation experiments and immunofluorescent staining. Epitope-tagged constructs were used to study expression of the two isozymes, The expression of Ade17p is repressed by the addition of adenine to the media, whereas Ade16p expression is not affected by adenine. Ade16p was observed to be more abundant in cells grown on nonfermentable carbon sources than in glucose-grown cells, suggesting a role for this isozyme in respiration or sporulation.	Univ Texas, Dept Chem & Biochem, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Texas, Inst Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Appling, DR (corresponding author), Univ Texas, Dept Chem & Biochem, Inst Mol & Cellular Biol, Austin, TX 78712 USA.	dappling@mail.utexas.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009276] Funding Source: NIH RePORTER; NCRR NIH HHS [RR09276] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARLOWE CK, 1990, MOL CELL BIOL, V10, P5679, DOI 10.1128/MCB.10.11.5679; Beardsley GP, 1998, ADV EXP MED BIOL, V431, P221; BLACK SL, 1978, ANAL BIOCHEM, V90, P397, DOI 10.1016/0003-2697(78)90042-8; Cleland W W, 1979, Methods Enzymol, V63, P103; DALE GE, 1994, PROTEIN ENG, V7, P925, DOI 10.1093/protein/7.7.925; DAUM G, 1982, J BIOL CHEM, V257, P3028; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; Denis V, 1998, MOL MICROBIOL, V30, P557, DOI 10.1046/j.1365-2958.1998.01087.x; Eisinger DP, 1997, BIOTECHNIQUES, V22, P250, DOI 10.2144/97222bm11; Esposito R. E., 1981, MOL BIOL YEAST SACCH, V11, P211; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FELICIELLO I, 1993, ANAL BIOCHEM, V212, P394, DOI 10.1006/abio.1993.1346; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; Kastanos EK, 1997, BIOCHEMISTRY-US, V36, P14956, DOI 10.1021/bi971610n; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KOEPP DM, 1998, CELLS LAB MANUAL; MUELLER WT, 1981, BIOCHEMISTRY-US, V20, P337, DOI 10.1021/bi00505a017; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; PASTERNACK LB, 1994, BIOCHEMISTRY-US, V33, P74, DOI 10.1021/bi00167a010; Pinson B, 1998, NUCLEIC ACIDS RES, V26, P3977, DOI 10.1093/nar/26.17.3977; RABINOWITZ JC, 1963, METHOD ENZYMOL, V6, P814, DOI 10.1016/0076-6879(63)06256-X; Rayl EA, 1996, J BIOL CHEM, V271, P2225, DOI 10.1074/jbc.271.4.2225; ROMAN H, 1956, CR TRAV LAB CARLS P, V26, P299; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Rowe P.B, 1971, METHODS ENZYMOL B, V18, P733; SATHE GM, 1991, NUCLEIC ACIDS RES, V19, P4775, DOI 10.1093/nar/19.17.4775; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Springer C, 1996, J BIOL CHEM, V271, P29637, DOI 10.1074/jbc.271.47.29637; Tibbetts AS, 1997, ARCH BIOCHEM BIOPHYS, V340, P195, DOI 10.1006/abbi.1997.9919; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7	34	29	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20920	20927		10.1074/jbc.M909851199	http://dx.doi.org/10.1074/jbc.M909851199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10877846	hybrid			2022-12-27	WOS:000088084500098
J	Harendza, S; Lovett, DH; Stahl, RAK				Harendza, S; Lovett, DH; Stahl, RAK			The hematopoietic transcription factor PU.1 represses gelatinase A transcription in glomerular mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; MURINE TISSUE MACROPHAGES; BETA-C GENE; MATRIX METALLOPROTEINASE-2; IV COLLAGENASE; DNA-BINDING; EXPRESSION; PROMOTER; RAT; ACTIVATION	The matrix metalloproteinase gelatinase A plays a key role in the evolution of glomerular injury and is a major contributing factor to the development of glomerulosclerosis, Prior studies have focused on a potent cis-acting enhancer element located in the near 5'-flanking region of the rat and human gelatinase A genes (Harendza, S., Pollock, A. S., Mertens, P. R., and Lovett, D. H. (1995) J. Biol. Chem. 270, 18286-18796; Mertens, P. R., Alfonso-Jaume, M. A., Steinmann, K., and Lovett, D. H. (1999) J. Am. Soc. Nephrol. 10, 2480-2487). Given the combinatorial nature of transcriptional regulation, we examined additional regions of the 5'-flanking region of the rat gelatinase A gene to identify further regulatory elements. In this study the identification of a silencing element located between -1903 and -1847 base pairs of the 5'-flanking region of the rat gelatinase A gene is reported. Sequence analysis, electrophoretic mobility studies, and transfection experiments demonstrate that a specific binding sequence for the hematopoietic transcription factor PU.1 is present within the silencing sequence. PU.1 activity is absolutely required for the expression of silencing activity within the context of transfected glomerular mesangial cells. Western blots identify the PU.1 protein within nuclear extracts of mesangial cells, and cotransfection with a PU.1 expression vector directly augments silencing activity. These studies underscore the complex patterns of gelatinase A transcriptional regulation and also strongly suggest that glomerular mesangial cells are ultimately derived from bone marrow cells.	Univ Hamburg, Dept Med, Div Nephrol, D-20246 Hamburg, Germany; Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94121 USA	University of Hamburg; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Harendza, S (corresponding author), Univ Hamburg, Krankenhaus Eppendorf, Med Klin, Abt Nephrol & Osteol, Pavillon 61,Martinistr 52, D-20246 Hamburg, Germany.	harendza@uke.uni-hamburg.de			NIDDK NIH HHS [DK 39776] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK039776, R01DK039776] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson KL, 1999, BLOOD, V94, P2310, DOI 10.1182/blood.V94.7.2310.419k34_2310_2318; Antalis TM, 1996, BLOOD, V88, P3686, DOI 10.1182/blood.V88.10.3686.bloodjournal88103686; Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; Benyon RC, 1999, HEPATOLOGY, V30, P977, DOI 10.1002/hep.510300431; BORRAS FE, 1995, J BIOL CHEM, V270, P24385, DOI 10.1074/jbc.270.41.24385; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Carey JO, 1996, BLOOD, V87, P4316, DOI 10.1182/blood.V87.10.4316.bloodjournal87104316; CAROME MA, 1994, J AM SOC NEPHROL, V5, P1391; FARRELL FX, 1990, MOL CELL BIOL, V10, P2349, DOI 10.1128/MCB.10.5.2349; Harendza S, 1997, NEPHROL DIAL TRANSPL, V12, P2537, DOI 10.1093/ndt/12.12.2537; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; Harendza S, 1999, NEPHROL DIAL TRANSPL, V14, P2873, DOI 10.1093/ndt/14.12.2873; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Kim MK, 1996, MOL CELL BIOL, V16, P4366; Li SL, 1999, J BIOL CHEM, V274, P32453, DOI 10.1074/jbc.274.45.32453; Liu B, 1996, J BIOL CHEM, V271, P26281, DOI 10.1074/jbc.271.42.26281; Lodie TA, 1997, J IMMUNOL, V158, P1848; LopezRodriguez C, 1997, EUR J IMMUNOL, V27, P1843, DOI 10.1002/eji.1830270804; LOVETT DH, 1992, AM J PATHOL, V141, P85; Marecki S, 1999, J IMMUNOL, V163, P2713; MARTI HP, 1993, BIOCHEM J, V291, P441, DOI 10.1042/bj2910441; McKercher SR, 1999, J LEUKOCYTE BIOL, V66, P727, DOI 10.1002/jlb.66.5.727; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1999, J AM SOC NEPHROL, V10, P2480; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; Ogbourne S, 1998, BIOCHEM J, V331, P1; Preaux AM, 1999, HEPATOLOGY, V30, P944, DOI 10.1002/hep.510300432; RADEKE HH, 1994, KIDNEY INT, V45, P763, DOI 10.1038/ki.1994.101; REPONEN P, 1992, J BIOL CHEM, V267, P7856; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; SHACKELFORD R, 1995, J IMMUNOL, V154, P1374; TUREK J, 1996, J BIOL CHEM, V25, P15074; UTSUNOMIYA Y, 1999, J AM SOC NEPHROL, V10, P406; van Dijk TB, 1999, J IMMUNOL, V163, P2674; van Dijk TB, 1998, BLOOD, V92, P3636, DOI 10.1182/blood.V92.10.3636.422k45_3636_3646; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Xue Y, 1999, BIOCHEM BIOPH RES CO, V254, P211, DOI 10.1006/bbrc.1998.9905; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	43	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19552	19559		10.1074/jbc.M001322200	http://dx.doi.org/10.1074/jbc.M001322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867017	hybrid			2022-12-27	WOS:000087941300018
J	Fontoura, BMA; Blobel, G; Yaseen, NR				Fontoura, BMA; Blobel, G; Yaseen, NR			The nucleoporin Nup98 is a site for GDP/GTP exchange on Ran and termination of karyopherin beta 2-mediated nuclear import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOGENOUS LEUKEMIA; GTPASE-ACTIVATING PROTEIN; ACUTE MYELOID-LEUKEMIA; PORE COMPLEX PROTEIN; MESSENGER-RNA; CHROMOSOME-TRANSLOCATION; BIOGENESIS PATHWAY; BINDING-PROTEIN; HOMEOBOX GENE; P62 COMPLEX	Karyopherin beta 2 (Kap beta 2, transportin) binds the MS sequence of human ribonucleoprotein Al and mediates its nuclear import. Here we show a role for the nucleoporin Nup98 in the disassembly of Kap beta 2 import complexes at the nuclear side of the nuclear pore complex (NPC). Kap beta 2 bound to a region at the N terminus of Nup98 that contains an MS-like sequence. The human ribonucleoprotein Al MS sequence competed with Nup98 for binding to Kap beta 2, indicating that Nup98 can dissociate Kappa from its substrate. Binding of Kap beta 2 to Nup98 was inhibited by Ran loaded with guanylyl imidophosphate, suggesting that RanGTP dissociates Kappa from Nup98, RanGTP is produced from RanGDP through nucleotide exchange mediated by RanGEF (RCC1). Immunoelectron microscopy and nucleotide exchange assays revealed functional RanGEF on both sides of the NPC. On the nuclear side, the localization of RanGEF coincided with that of Nup98. RanGEF bound to Nup98 at a region adjacent to the Kappa-binding site. These findings suggest a model where 1) import substrate is released from Kap beta 2 at the nucleoplasmic side of the NPC by competition with the Nup98 MS-like site, 2) Nup98-bound RanGEF catalyzes the formation of RanGTP, and 3) RanGTP dissociates Kappa from Nup98 allowing repeated cycles of import.	Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University; Cornell University	Blobel, G (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, 1230 York Ave, New York, NY 10021 USA.	blobel@rockvax.rockefeller.edu		Yaseen, Nabeel/0000-0001-6902-5116	NCI NIH HHS [K08 CA72959] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA072959] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahuja HG, 1999, BLOOD, V94, P3258, DOI 10.1182/blood.V94.9.3258.421a40_3258_3261; AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; Arai Y, 1997, BLOOD, V89, P3936, DOI 10.1182/blood.V89.11.3936; Avis JM, 1996, J CELL SCI, V109, P2423; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; Bonifaci N, 1997, P NATL ACAD SCI USA, V94, P5055, DOI 10.1073/pnas.94.10.5055; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BUSS F, 1994, J CELL SCI, V107, P631; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cole CN, 1998, CURR BIOL, V8, pR368, DOI 10.1016/S0960-9822(98)70239-8; Cordes VC, 1997, J CELL BIOL, V136, P515, DOI 10.1083/jcb.136.3.515; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; Delphin C, 1997, MOL BIOL CELL, V8, P2379, DOI 10.1091/mbc.8.12.2379; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; Emtage JLT, 1997, J CELL SCI, V110, P911; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; Floer M, 1999, J BIOL CHEM, V274, P16279, DOI 10.1074/jbc.274.23.16279; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Fontoura BMA, 1999, J CELL BIOL, V144, P1097, DOI 10.1083/jcb.144.6.1097; Goldberg MW, 1996, J MOL BIOL, V257, P848, DOI 10.1006/jmbi.1996.0206; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; GUAN TL, 1995, MOL BIOL CELL, V6, P1591, DOI 10.1091/mbc.6.11.1591; Hatano Y, 1999, BRIT J HAEMATOL, V107, P600, DOI 10.1046/j.1365-2141.1999.01754.x; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; Hussey DJ, 1999, BLOOD, V94, P2072; Ikeda T, 1999, INT J HEMATOL, V69, P160; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; Kwong YL, 1999, GENE CHROMOSOME CANC, V25, P70, DOI 10.1002/(SICI)1098-2264(199905)25:1<70::AID-GCC11>3.0.CO;2-E; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; Nakamura T, 1999, BLOOD, V94, P741, DOI 10.1182/blood.V94.2.741.414k04_741_747; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nakielny S, 1998, CURR BIOL, V8, P89, DOI 10.1016/S0960-9822(98)70039-9; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Nemergut ME, 2000, J CELL BIOL, V149, P835, DOI 10.1083/jcb.149.4.835; Nishiyama M, 1999, GENE CHROMOSOME CANC, V26, P215, DOI 10.1002/(SICI)1098-2264(199911)26:3<215::AID-GCC5>3.3.CO;2-T; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; Pritchard CEJ, 1999, J CELL BIOL, V145, P237, DOI 10.1083/jcb.145.2.237; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Raza-Egilmez SZ, 1998, CANCER RES, V58, P4269; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 1999, CURR BIOL, V9, P47, DOI 10.1016/S0960-9822(99)80046-3; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; RIS H, 1991, EMSA B, V21, P54; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; Schwoebel ED, 1998, J BIOL CHEM, V273, P35170, DOI 10.1074/jbc.273.52.35170; Seki T, 1996, J BIOCHEM, V120, P207; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; Teixeira MT, 1997, EMBO J, V16, P5086, DOI 10.1093/emboj/16.16.5086; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; Wong KF, 1999, CANCER GENET CYTOGEN, V115, P70, DOI 10.1016/S0165-4608(99)00085-0; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Yaseen NR, 1999, J BIOL CHEM, V274, P26493, DOI 10.1074/jbc.274.37.26493; Yaseen NR, 1999, P NATL ACAD SCI USA, V96, P5516, DOI 10.1073/pnas.96.10.5516; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	72	70	71	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31289	31296		10.1074/jbc.M004651200	http://dx.doi.org/10.1074/jbc.M004651200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10875935	hybrid			2022-12-27	WOS:000089762700077
J	Benning, MM; Hong, SB; Raushel, FM; Holden, HM				Benning, MM; Hong, SB; Raushel, FM; Holden, HM			The binding of substrate analogs to phosphotriesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; BACTERIAL PHOSPHOTRIESTERASE	Phosphotriesterase (PTE) from Pseudomonas diminuta catalyzes the detoxification of organophosphates such as the widely utilized insecticide paraoxon and the chemical warfare agent sarin. The three-dimensional structure of the enzyme is known from high resolution x-ray crystallographic analyses. Each subunit of the homodimer folds into a so-called TIM barrel, with eight strands of parallel beta-sheet. The two zinc ions required for activity are positioned at the C-terminal portion of the beta P-barrel. Here, we describe the three dimensional structure of PTE complexed with the inhibitor diisopropyl methyl phosphonate, which serves as a mimic for sarin. Additionally, the structure of the enzyme complexed with triethyl phosphate is also presented. In the case of the PTE-diisopropyl methyl phosphonate complex, the phosphoryl oxygen of the inhibitor coordinates to the more solvent-exposed zinc ion (2.5 Angstrom), thereby lending support to the presumed catalytic mechanism involving metal coordination of the substrate. In the PTE-triethyl phosphate complex, the phosphoryl oxygen of the inhibitor is positioned at 3.4 Angstrom from the more solvent-exposed zinc ion. The two structures described in this report provide additional molecular understanding for the ability of this remarkable enzyme to hydrolyze such a wide range of organophosphorus substrates.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Triad Therapeut, San Diego, CA 92121 USA	University of Wisconsin System; University of Wisconsin Madison; Texas A&M University System; Texas A&M University College Station	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.		Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033894] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33894, GM55513] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNING MM, 1995, BIOCHEMISTRY-US, V34, P7973, DOI 10.1021/bi00025a002; BENNING MM, 1994, BIOCHEMISTRY-US, V33, P15001, DOI 10.1021/bi00254a008; CALDWELL SR, 1991, APPL BIOCHEM BIOTECH, V31, P59, DOI 10.1007/BF02922126; Hong SB, 1996, BIOCHEMISTRY-US, V35, P10904, DOI 10.1021/bi960663m; Hong SB, 1999, BIOCHEMISTRY-US, V38, P1159, DOI 10.1021/bi982204m; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OMBURO GA, 1992, J BIOL CHEM, V267, P13278; Raushel FM, 2000, ADV ENZYMOL RAMB, V74, P51; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Vanhooke JL, 1996, BIOCHEMISTRY-US, V35, P6020, DOI 10.1021/bi960325l; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539	16	79	109	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30556	30560		10.1074/jbc.M003852200	http://dx.doi.org/10.1074/jbc.M003852200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10871616	hybrid			2022-12-27	WOS:000089577900088
J	Pabon, A; Chan, KW; Sui, JL; Wu, XY; Logothetis, DE; Thornhill, WB				Pabon, A; Chan, KW; Sui, JL; Wu, XY; Logothetis, DE; Thornhill, WB			Glycosylation of GIRK1 at Asn(119) and ROMK1 at Asn(117) has different consequences in potassium channel function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; MUSCARINIC K+ CHANNEL; BETA-GAMMA-SUBUNITS; INWARD RECTIFIER; ACETYLCHOLINE-RECEPTOR; SODIUM-CHANNELS; XENOPUS-OOCYTES; I-KACH; EXPRESSION; CLONING	GIRK (G protein-gated inward rectifier K+ channel) proteins play critical functional roles in heart and brain physiology, Using antibodies directed to either GIRK1 or GIRK4, site-directed mutagenesis, and specific glycosidases, we have investigated the effects of glycosylation in the biosynthesis and heteromerization of these proteins expressed in oocytes, Both GIRK1 and GIRK4 have one extracellular consensus N-glycosylation site. Using chimeras between GIRK1 and GIRK4 as well as a GIRK1 N-glycosylation mutant, we report that GIRK1 was glycosylated at Asn(119), whereas GIRK4 was not glycosylated at Asn(132). GIRK1 membrane-spanning domain 1 was required for optimal glycosylation at Asn(119) because a chimera that contained GIRK4 membrane-spanning domain I significantly reduced the addition of a carbohydrate structure at this site. This finding may partly account for the reason that GIRK4 is not glycosylated at Asn(132), either as a homomer or when coexpressed with GIRK1, When the GIRK1(N119Q) mutant was coexpressed with GIRK4, the biophysical properties of the heteromeric channel and the magnitude of the agonist-induced currents were similar to those of controls, Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A. Wang, Z., Wible, B. A. and Brown, A. M. (1995) J. Biol. Chem. 270, 15336-15340).	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Thornhill, WB (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, 1 Gustave Levy Pl, New York, NY 10029 USA.				NHLBI NIH HHS [HL54185] Funding Source: Medline; NINDS NIH HHS [NS29633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, V2; Bennett E, 1997, J GEN PHYSIOL, V109, P327, DOI 10.1085/jgp.109.3.327; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; Castillo C, 1997, DEV BRAIN RES, V104, P119, DOI 10.1016/S0165-3806(97)00159-4; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; COLEMAN A, 1984, TRANSCRIPTION TRANSL, P271; COVARRUBIAS M, 1989, J GEN PHYSIOL, V93, P765, DOI 10.1085/jgp.93.5.765; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FERRER J, 1995, J BIOL CHEM, V270, P26086, DOI 10.1074/jbc.270.44.26086; Gurnett CA, 1996, NEURON, V16, P431, DOI 10.1016/S0896-6273(00)80061-6; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harlow E., 1988, ANTIBODIES LAB MANUA, P449; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LENNARZ W, 1983, METHOD ENZYMOL, V98, P91; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; NEHRKE K, 1996, J BIOL CHEM, V271, P8061; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; Ponce A, 1996, J NEUROSCI, V16, P1990; RECIOPINTO E, 1990, NEURON, V5, P675, DOI 10.1016/0896-6273(90)90221-Z; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; SCHWALBE RA, 1995, J BIOL CHEM, V270, P15336, DOI 10.1074/jbc.270.25.15336; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; Spauschus A, 1996, J NEUROSCI, V16, P930; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; TAKAHASHI N, 1984, P NATL ACAD SCI-BIOL, V81, P2021, DOI 10.1073/pnas.81.7.2021; Thornhill WB, 1996, J BIOL CHEM, V271, P19093, DOI 10.1074/jbc.271.32.19093; THOTAKURA NR, 1987, METHOD ENZYMOL, V138, P350; VIVAUDOU MB, 1991, J MEMBRANE BIOL, V122, P165, DOI 10.1007/BF01872639; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	46	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30677	30682		10.1074/jbc.M005338200	http://dx.doi.org/10.1074/jbc.M005338200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10889209	hybrid			2022-12-27	WOS:000089577900104
J	Read, J; Anderson, TA; Ritchie, PJ; Vanloo, B; Amey, J; Levitt, D; Rosseneu, M; Scott, J; Shoulders, CC				Read, J; Anderson, TA; Ritchie, PJ; Vanloo, B; Amey, J; Levitt, D; Rosseneu, M; Scott, J; Shoulders, CC			A mechanism of membrane neutral lipid acquisition by the microsomal triglyceride transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDES; BINDING; ABETALIPOPROTEINEMIA; LIPOVITELLIN; LIPOPROTEINS; TRANSPORT; LOCATION; VARIANT; FUSION; MODELS	The microsomal triglyceride transfer protein (MTP) and apolipoprotein B (apoB) belong to the vitellogenin (VTG) family of lipid transfer proteins. MTP is essential for the intracellular assembly and secretion of apoB-containing lipoproteins, the key intravascular lipid transport proteins in vertebrates. We report the predicted three-dimensional structure of the C-terminal lipid binding cavity of MTP, modeled on the crystal structure of the lamprey VTG gene product, lipovitellin. The cavity in MTP resembles those found in the intracellular lipid-binding proteins and bactericidal/permeability-increasing protein. Two conserved helices, designated A and B, at the entrance to the MTP cavity mediate lipid acquisition and binding. Helix A (amino acids 725-736) interacts with membranes in a manner similar to viral fusion peptides. Mutation of helix A blocks the interaction of MTP with phospholipid vesicles containing triglyceride and impairs triglyceride binding. Mutations of helix B (amino acids 781-786) and of N780Y, which causes abetalipoproteinemia, have no impact on the interaction of MTP with phospholipid vesicles but impair triglyceride binding. We propose that insertion of helix A into lipid membranes is necessary for the acquisition of neutral lipids and that helix B is required for their transfer to the lipid binding cavity of MTP.	Hammersmith Hosp, Imperial Coll, Sch Med, Mol Med Grp,MRC,Clin Sci Ctr, London W12 0NN, England; Hammersmith Hosp, Imperial Coll, Sch Med, Natl Heart & Lung Inst, London W12 0NN, England; Univ Minnesota, Sch Med, Dept Biochem, Minneapolis, MN 55455 USA; Univ Ghent, Dept Biochem, Lab Lipoprot Chem, B-9000 Ghent, Belgium	Imperial College London; Imperial College London; University of Minnesota System; University of Minnesota Twin Cities; Ghent University	Shoulders, CC (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, Mol Med Grp,MRC,Clin Sci Ctr, Du Cane Rd, London W12 0NN, England.	carol.shoulders@csc.mrc.ac.uk						Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; Beamer LJ, 1997, SCIENCE, V276, P1861, DOI 10.1126/science.276.5320.1861; Bernlohr DA, 1997, ANNU REV NUTR, V17, P277, DOI 10.1146/annurev.nutr.17.1.277; Bradbury P, 1999, J BIOL CHEM, V274, P3159, DOI 10.1074/jbc.274.5.3159; Brasseur R, 1997, TRENDS BIOCHEM SCI, V22, P167, DOI 10.1016/S0968-0004(97)01047-5; Bruce C, 1998, CURR OPIN STRUC BIOL, V8, P426, DOI 10.1016/S0959-440X(98)80118-8; Cajal Y, 2000, BIOCHEMISTRY-US, V39, P413, DOI 10.1021/bi991927i; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Cistola DP, 1996, BIOCHEMISTRY-US, V35, P7559, DOI 10.1021/bi952912x; Decout A, 1998, BBA-BIOMEMBRANES, V1372, P102, DOI 10.1016/S0005-2736(98)00050-9; EPAND RM, 1998, BIOCHIM BIOPHYS ACTA, V3, P353; Han X, 1999, BIOCHEMISTRY-US, V38, P15052, DOI 10.1021/bi991232h; Hebbachi AM, 1999, BBA-MOL CELL BIOL L, V1441, P36, DOI 10.1016/S1388-1981(99)00138-9; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LESK AM, 1986, PROTEIN ENG, V1, P77, DOI 10.1093/protein/1.1.77; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; MILLER KW, 1983, BIOCHEMISTRY-US, V22, P443, DOI 10.1021/bi00271a030; NARCISI TME, 1995, AM J HUM GENET, V57, P1298; OHASHI K, 1996, CIRCULATION, V94, P346; Peelman F, 1998, PROTEIN SCI, V7, P587, DOI 10.1002/pro.5560070307; Peelman F, 1997, EUR J BIOCHEM, V249, P708, DOI 10.1111/j.1432-1033.1997.t01-2-00708.x; Penel S, 1999, J MOL BIOL, V287, P127, DOI 10.1006/jmbi.1998.2549; Ritchie PJ, 1999, BIOCHEM J, V338, P305, DOI 10.1042/0264-6021:3380305; Schwarz R, 1979, ATLAS PROTEIN SEQUEN, P353, DOI DOI 10.2307/2408678; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; TIMMINS PA, 1992, SCIENCE, V257, P652, DOI 10.1126/science.1496377; Viguera AR, 1999, PROTEIN SCI, V8, P1733, DOI 10.1110/ps.8.9.1733; VONECHE V, 1992, P NATL ACAD SCI USA, V89, P3810, DOI 10.1073/pnas.89.9.3810	31	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30372	30377		10.1074/jbc.C000364200	http://dx.doi.org/10.1074/jbc.C000364200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893406	hybrid			2022-12-27	WOS:000089577900062
J	Cao, J; Hymowitz, M; Conner, C; Bahou, WF; Zucker, S				Cao, J; Hymowitz, M; Conner, C; Bahou, WF; Zucker, S			The propeptide domain of membrane type 1-matrix metalloproteinase acts as an intramolecular chaperone when expressed in trans with the mature sequence in COS-l cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTASE-PHLORHIZIN HYDROLASE; PRO-GELATINASE-A; MATRIX-METALLOPROTEINASE; PROGELATINASE-A; TISSUE INHIBITOR; TRANSMEMBRANE DOMAIN; CATALYTIC DOMAIN; ACTIVATION; SURFACE; ENZYME	It has been assumed that cleavage of the N-terminal propeptide domain of membrane type-1 matrix metalloproteinase (MT1-MMP) is required for enzyme function, We recently demonstrated that the propeptide domain of MT1-MMP is not cleaved and actually is required for function of the membrane-bound enzyme in transfected COS-1 cells (Cao, J., Drews, M., Lee, H. M., Conner, C., Bahou, W. F., and Zucker, S. (1998) J. Biol. Chem. 273, 34745-34752). In this report, we have inserted the cDNA encoding the signal and propeptide sequences of MT1-MMP (MT(1-109)) and the cDNA encoding propeptide-deleted mature MT1-MMP (MT Delta pro) in expression vectors that were then transfected into matrix metalloproteinase-deficient COS-1 cells. Co-expression of both the mature sequence and the prosequence of MT1-MMP as independent polypeptides (in trans) in COS-1 cells resulted in reconstitution of MT1-MMP function in terms of facilitating (125)I-labeled tissue inhibitor of metalloproteinase 2 binding to transfected cells and subsequent activation of progelatinase A. Transfection of cells with either cDNA alone resulted in non-functional cells, These results are consistent with the propeptide sequence of MT1-MMP functioning as an intramolecular chaperone involved in protein folding and trafficking to the cell surface.	SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; Dept Vet Affairs Med Ctr, Northport, NY 11768 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Zucker, S (corresponding author), Vet Adm Med Ctr, Mail Code 151, Northport, NY 11768 USA.	s_zucker@yahoo.com			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002431] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-49149, HL-02431] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BISWAS C, 1995, CANCER RES, V55, P434; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Cao J, 1998, J BIOL CHEM, V273, P34745, DOI 10.1074/jbc.273.52.34745; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; Imai K, 1996, CANCER RES, V56, P2707; Kinoshita T, 1996, CANCER RES, V56, P2535; Kolkenbrock H, 1997, BIOL CHEM, V378, P71, DOI 10.1515/bchm.1997.378.2.71; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; MACH L, 1994, J BIOL CHEM, V269, P13036; Marie-Claire C, 1999, J MOL BIOL, V285, P1911, DOI 10.1006/jmbi.1998.2449; Nagamune K, 1997, J BIOL CHEM, V272, P1338, DOI 10.1074/jbc.272.2.1338; OBERHOLZER T, 1993, FEBS LETT, V333, P127, DOI 10.1016/0014-5793(93)80389-C; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shinde U, 1996, ADV EXP MED BIOL, V379, P147; Sohl JL, 1998, NATURE, V395, P817, DOI 10.1038/27470; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, GENE, V155, P293, DOI 10.1016/0378-1119(94)00637-8; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wuthrich M, 1997, FEBS LETT, V405, P321, DOI 10.1016/S0014-5793(97)00206-8; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	30	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29648	29653		10.1074/jbc.M001920200	http://dx.doi.org/10.1074/jbc.M001920200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10889191	hybrid			2022-12-27	WOS:000089439800064
J	Hussain, MM; Obunike, JC; Shaheen, A; Hussain, MJ; Shelness, GS; Goldberg, IJ				Hussain, MM; Obunike, JC; Shaheen, A; Hussain, MJ; Shelness, GS; Goldberg, IJ			High affinity binding between lipoprotein lipase and lipoproteins involves multiple ionic and hydrophobic interactions, does not require enzyme activity, and is modulated by glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY-LIPOPROTEIN; TERMINALLY TRUNCATED FORMS; APOLIPOPROTEIN-B; MONOCLONAL-ANTIBODY; CELLS; SECRETION; SITE; EXPRESSION; ASSOCIATION	Lipoprotein lipase (LPL) physically associates with lipoproteins and hydrolyzes triglycerides. To characterize the binding of LPL to lipoproteins, we studied the binding of low density lipoproteins (LDL), apolipoprotein (apo) B17, and various apoB-FLAG (DYKDDDDK octapeptide) chimeras to purified LPL. LDL bound to LPL with high affinity (K-d values of 10(-12) M) similar to that observed for the binding of LDL to its receptors and 1D1, a monoclonal antibody to LDL, and was greater than its affinity for microsomal triglyceride transfer protein. LDL-LPL binding was sensitive to both salt and detergents, indicating the involvement of both hydrophobic and hydrophilic interactions. In contrast, the N-terminal 17% of apoB interacted with LPL mainly via ionic interactions. Binding of various apoB fusion peptides suggested that LPL bound to apoB at multiple sites within apoB17, Tetrahydrolipstatin, a potent enzyme activity inhibitor, had no effect on apoB-LPL binding, indicating that the enzyme activity was not required for apoB binding. LDL-LPL binding was inhibited by monoclonal antibodies that recognize amino acids 380-410 in the C-terminal region of LPL, a region also shown to interact with heparin and LDL receptor-related protein. The LDL-LPL binding was also inhibited by glycosaminoglycans (GAGs); heparin inhibited the interactions by similar to 50% and removal of trace amounts of heparin from LPL preparations increased LDL binding. Thus, we conclude that the high affinity binding between LPL and lipoproteins involves multiple ionic and hydrophobic interactions, does not require enzyme activity and is modulated by GAGs. It is proposed that LPL contains a surface exposed positively charged amino acid cluster that may be important for various physiological interactions of LPL with different biologically important molecules. Moreover, we postulate that by binding to this cluster, GAGs modulate the association between LDL and LPL and the in vivo metabolism of LPL.	SUNY Hlth Sci Ctr, Dept Anat & Cell Biol & Pediat, Brooklyn, NY 11203 USA; Med Coll Penn & Hahnemann Univ, Sch Med, Dept Biochem, Philadelphia, PA 19129 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Drexel University; Wake Forest University; Wake Forest Baptist Medical Center; Columbia University	Hussain, MM (corresponding author), SUNY Hlth Sci Ctr, Dept Anat & Cell Biol & Pediat, 450 Clarkson Ave,Box 5, Brooklyn, NY 11203 USA.	mahmoodhussain@netmail.hscbklyn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062301, R01HL064272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046900, R29DK046900] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62301, HL-64272] Funding Source: Medline; NIDDK NIH HHS [DK-46900] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bakillah A, 1997, LIPIDS, V32, P1113, DOI 10.1007/s11745-997-0143-8; BENGTSSON G, 1983, BIOCHIM BIOPHYS ACTA, V751, P254, DOI 10.1016/0005-2760(83)90180-7; Bhatnagar D, 1999, LIPOPROTEINS IN HEALTH AND DISEASE, P737; Bradbury P, 1999, J BIOL CHEM, V274, P3159, DOI 10.1074/jbc.274.5.3159; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunzell J.D., 1995, METABOLIC MOL BASES, P1913; Chang SF, 1998, J LIPID RES, V39, P2350; Choi SY, 1997, J LIPID RES, V38, P77; CHOI SY, 1995, J BIOL CHEM, V270, P8081, DOI 10.1074/jbc.270.14.8081; DU EZ, 1994, J BIOL CHEM, V269, P24169; Goldberg IJ, 1998, J BIOL CHEM, V273, P35355, DOI 10.1074/jbc.273.52.35355; GOLDBERG IJ, 1986, BIOCHIM BIOPHYS ACTA, V878, P168, DOI 10.1016/0005-2760(86)90143-8; Goldberg IJ, 1996, J LIPID RES, V37, P693; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HADVARY P, 1991, J BIOL CHEM, V266, P2021; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; Hussain MM, 1997, BIOCHEMISTRY-US, V36, P13060, DOI 10.1021/bi971395a; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; LOOKENE A, 1994, EUR J BIOCHEM, V222, P395, DOI 10.1111/j.1432-1033.1994.tb18878.x; Nielsen MS, 1997, J BIOL CHEM, V272, P5821, DOI 10.1074/jbc.272.9.5821; Nielsen MS, 1999, J BIOL CHEM, V274, P8832, DOI 10.1074/jbc.274.13.8832; OBUNIKE JC, 1994, J BIOL CHEM, V269, P13129; Pang L, 1996, J BIOL CHEM, V271, P19518, DOI 10.1074/jbc.271.32.19518; PEASE RJ, 1990, J BIOL CHEM, V265, P553; Segrest JP, 1998, J LIPID RES, V39, P85; Segrest JP, 1999, J LIPID RES, V40, P1401; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; Tietge UJF, 1999, J LIPID RES, V40, P2134; WANG HX, 1994, J BIOL CHEM, V269, P18514; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; YAO ZM, 1991, J BIOL CHEM, V266, P3300; Yin BY, 1997, J CLIN INVEST, V100, P649, DOI 10.1172/JCI119576	38	12	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29324	29330		10.1074/jbc.M005317200	http://dx.doi.org/10.1074/jbc.M005317200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882743	hybrid			2022-12-27	WOS:000089439800021
J	Kawano, K; Qin, SC; Lin, M; Tall, AR; Jiang, XC				Kawano, K; Qin, SC; Lin, M; Tall, AR; Jiang, XC			Cholesteryl ester transfer protein and phospholipid transfer protein have nonoverlapping functions in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; BINDING CASSETTE TRANSPORTER-1; TRANSGENIC MICE; TANGIER-DISEASE; PLASMA-LIPOPROTEINS; EXCHANGE PROTEIN; APOLIPOPROTEIN-E; KNOCKOUT MICE; GENE; MUTATIONS	Plasma phospholipid transfer protein (PLTP) and cholesteryl ester transfer protein (CETP) are homologous molecules that mediate neutral lipid and phospholipid exchange between plasma lipoproteins, Biochemical experiments suggest that only CETP can transfer neutral lipids but that there could be overlap in the ability of PLTP and CETP to transfer or exchange phospholipids. Recently developed PLTP gene knock-out (PLTP0) mice have complete deficiency of plasma phospholipid transfer activity and markedly reduced high density lipoprotein (HDL) levels. To see whether CETP can compensate for PLTP deficiency in vivo, we bred the CETP transgene (CETPTg) into the PLTP0 background. Using an in vivo assay to measure the transfer of [H-3]PC from VLDL into HDL or an in vitro assay that determined [H-3]PC transfer from vesicles into HDL, we could detect no phospholipid transfer activity in either PLTP0 or CETPTg/PLTP0 mice. On a chow diet, HDL-PL, HDL-CE, and HDL-apolipoprotein Al in CETPTg/PLTP0 mice were significantly lower than in PLTP0 mice (45 +/- 7 versus 79 +/- 9 mg/dl; 9 +/- 2 versus 16 +/- 5 mg/dl; and 51 +/- 6 versus 100 +/- 9, arbitrary units, respectively). Similar results were obtained on a high fat, high cholesterol diet. These results indicate 1) that there is no redundancy in function of PLTP and CETP in vivo and 2) that the combination of the CETP transgene with PLTP deficiency results in an additive lowering of HDL levels, suggesting that the phenotype of a human PLTP deficiency state would include reduced HDL levels.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Columbia University	Jiang, XC (corresponding author), Columbia Univ, Dept Med, Div Mol Med, 630 W 168th St, New York, NY 10032 USA.		Tall, Alan/AAT-8528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1991, J BIOL CHEM, V266, P10796; Beamer LJ, 1997, SCIENCE, V276, P1861, DOI 10.1126/science.276.5320.1861; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BRESLOW JL, 1989, METABOLIC BASIS INHE, P1251; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; Brown ML, 1990, CURR OPIN LIPIDOL, V1, P122; Bruce C, 1998, CURR OPIN STRUC BIOL, V8, P426, DOI 10.1016/S0959-440X(98)80118-8; DAY JR, 1994, J BIOL CHEM, V269, P9388; FRANCONE OL, 1995, J CLIN INVEST, V96, P1440, DOI 10.1172/JCI118180; HAYEK T, 1993, J CLIN INVEST, V92, P1143, DOI 10.1172/JCI116683; HAYEK T, 1992, J CLIN INVEST, V90, P505, DOI 10.1172/JCI115887; HESLER CB, 1987, J BIOL CHEM, V262, P2275; Huuskonen J, 1999, J LIPID RES, V40, P1123; INAZU A, 1994, J CLIN INVEST, V94, P1872, DOI 10.1172/JCI117537; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; Jeong TS, 1998, J CLIN INVEST, V101, P905, DOI 10.1172/JCI870; JIANG XC, 1993, J BIOL CHEM, V268, P27406; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; LAGROST L, 1994, J LIPID RES, V35, P825; Lusa S, 1996, BIOCHEM J, V313, P275, DOI 10.1042/bj3130275; MasucciMagoulas L, 1996, J CLIN INVEST, V97, P154, DOI 10.1172/JCI118384; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; MORTON RE, 1983, J BIOL CHEM, V258, P1751; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; Qin SC, 2000, J LIPID RES, V41, P269; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SWENSON TL, 1987, J BIOL CHEM, V262, P16271; TALL AR, 1983, J BIOL CHEM, V258, P2174; TALL AR, 1985, J LIPID RES, V26, P842; WANG S, 1992, J BIOL CHEM, V267, P17487; Wittrup HH, 1999, CIRCULATION, V99, P2901, DOI 10.1161/01.CIR.99.22.2901; Yu B, 1997, J CLIN INVEST, V99, P315, DOI 10.1172/JCI119160	35	49	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29477	29481		10.1074/jbc.M003523200	http://dx.doi.org/10.1074/jbc.M003523200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893412	hybrid			2022-12-27	WOS:000089439800041
J	Mouledous, L; Topham, CM; Mazarguil, H; Meunier, JC				Mouledous, L; Topham, CM; Mazarguil, H; Meunier, JC			Direct identification of a peptide binding region in the opioid receptor-like 1 receptor by photoaffinity labeling with [Bpa(10),Tyr(14)]nociceptin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; AMINO-TERMINAL TAIL; P NK-1 RECEPTOR; DYNORPHIN-A; NOCICEPTIN/ORPHANIN FQ; ORL1 RECEPTOR; ORPHANIN-FQ; SECRETIN RECEPTOR; SUBSTANCE-P; DOMAINS	The heptadecapeptide nociceptin, also known as orphanin FQ, is the endogenous agonist of the opioid receptor-like 1 (ORL1) G protein-coupled receptor, An affinity labeling approach has been implemented to probe the interactions of the neuropeptide with the receptor using the photolabile nociceptin derivative, [p-benzoyl-L-Phe(10),Tyr(14)]nociceptin ([Bpa(10),Tyr(14)]noc). In recombinant Chinese hamster ovary cells expressing the human ORL1 receptor, [Bpa(10),Tyr(14)]noc binds the receptor with high affinity (K-i similar to 0.7 nM) and is as potent as nociceptin in the inhibition of forskolin-induced cAMP synthesis (EC50 similar to 0.5 nM). UV irradiation at 365 nm of the complex formed by the ORL1 receptor and radioiodinated [Bpa(10),Tyr(14)]noc results in the irreversible labeling of a glycoprotein of similar to 65 kDa, determined by SDS-polyacrylamide gel electrophoresis. Complete digestion of the partially purified 65-kDa complex with kallikrein generates a single labeled fragment (similar to 6.5 kDa) that is readily cleaved by endoproteinase Glu-C to yield a labeled fragment of similar to 3.2 kDa, Kallikrein treatment of the photoaffinity cross-linked Glu(295) --> Asp mutant receptor also yields a single labeled fragment of similar to 6.5 kDa but is resistant to further cleavage by endoproteinase Glu-C. Based upon the expected proteolytic fingerprint of the labeled receptor, the photoreactive region can be identified as ORL1-(296-302; residues Thr-Ala-Val-Ala-Ile-Leu-Arg) spanning the C terminus of extracellular loop 3 and the N terminus of transmembrane helix VII. Molecular modeling of the ORL1 receptor complex with [Bpa(10)]noc suggests that reaction of the Bpa carbonyl group may occur with the side chain of Ile(300) within the experimentally identified photoreactive region.	Inst Pharmacol & Biol Struct, CNRS, UMR 5089, F-31077 Toulouse 4, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Meunier, JC (corresponding author), Inst Pharmacol & Biol Struct, CNRS, UMR 5089, 205 Route Narbonne, F-31077 Toulouse 4, France.	jcm@ipbs.fr		Mouledous, Lionel/0000-0002-7675-3493				ALVAREZ R, 1992, ANAL BIOCHEM, V203, P76, DOI 10.1016/0003-2697(92)90045-9; Anders J, 1999, BIOCHEMISTRY-US, V38, P6043, DOI 10.1021/bi990269z; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; Becker JAJ, 1999, J BIOL CHEM, V274, P27513, DOI 10.1074/jbc.274.39.27513; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; Butour JL, 1997, EUR J PHARMACOL, V321, P97, DOI 10.1016/S0014-2999(96)00919-3; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Darland T, 1998, TRENDS NEUROSCI, V21, P215, DOI 10.1016/S0166-2236(97)01204-6; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dong MQ, 1999, J BIOL CHEM, V274, P4778, DOI 10.1074/jbc.274.8.4778; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Dooley CT, 1996, LIFE SCI, V59, pPL23, DOI 10.1016/0024-3205(96)00261-5; Dooley CT, 1997, J PHARMACOL EXP THER, V283, P735; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FRISCH MJ, 1995, GAUSSIAN 94; Guerrini R, 1997, J MED CHEM, V40, P1789, DOI 10.1021/jm970011b; Hadac EM, 1999, J MED CHEM, V42, P2105, DOI 10.1021/jm980732q; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Henderson G, 1997, TRENDS PHARMACOL SCI, V18, P293, DOI 10.1016/S0165-6147(97)90645-3; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lapalu S, 1997, FEBS LETT, V417, P333, DOI 10.1016/S0014-5793(97)01318-5; Lapalu S, 1998, FEBS LETT, V427, P296, DOI 10.1016/S0014-5793(98)00452-9; LAPALU S, 1999, THESIS U P SABATIER; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; Meunier JC, 2000, EXPERT OPIN THER PAT, V10, P371, DOI 10.1517/13543776.10.4.371; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Meunier JC, 1997, EUR J PHARMACOL, V340, P1, DOI 10.1016/S0014-2999(97)01411-8; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; Mollereau C, 1999, MOL PHARMACOL, V55, P324, DOI 10.1124/mol.55.2.324; Mouledous L, 2000, MOL PHARMACOL, V57, P495, DOI 10.1124/mol.57.3.495; Phalipou S, 1997, J BIOL CHEM, V272, P26536, DOI 10.1074/jbc.272.42.26536; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Reinscheid RK, 1996, J BIOL CHEM, V271, P14163, DOI 10.1074/jbc.271.24.14163; Reinscheid RK, 1998, J BIOL CHEM, V273, P1490, DOI 10.1074/jbc.273.3.1490; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Servant G, 1997, J BIOL CHEM, V272, P8653, DOI 10.1074/jbc.272.13.8653; Topham CM, 1998, PROTEIN ENG, V11, P1163, DOI 10.1093/protein/11.12.1163; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216	44	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29268	29274		10.1074/jbc.M004971200	http://dx.doi.org/10.1074/jbc.M004971200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10880520	hybrid			2022-12-27	WOS:000089439800014
J	Yang, YZ; Xia, ZP; Liu, YH				Yang, YZ; Xia, ZP; Liu, YH			SNAP-25 functional domains in SNARE core complex assembly and glutamate release of cerebellar granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; MEMBRANE-FUSION COMPLEX; T-SNARE; SYNTAXIN; EXOCYTOSIS; PALMITOYLATION; SYNAPTOBREVIN; SYNAPTOTAGMIN; MACHINERY; NEURONS	Synaptosomal associated protein of 25 kDa (SNAP-25) is a member of the SNARE protein complex that has been implicated in synaptic vesicle docking and fusion, In this report, we have generated SNAP-25 mutants and assayed their functions in SNARE complex formation and glutamate release from cultured rat cerebellar granule cells. In vitro binding studies show that a deletion mutant lacking the C-terminal 181-206 amino acid sequence inhibits the formation of the SNARE core complex. Additional deletion of an N-terminal 1-31 amino acid sequence abolished this inhibitory activity. Adenovirus-mediated gene transfer is used to overexpress wild-type and mutant SNAP-25 in cerebellar granule cells. Neurons overexpressing the wild-type protein show slight reductions in glutamate release, ranging from 10 to 15% in both the developing and mature granule cells. A 30-35% inhibition is obtained with the C-terminal deletion mutant, and the inhibitory effect is abolished in the N- and C-terminal double deletion mutant. These results demonstrate that the SNARE core complex exists in a dynamic and reversible state, and the formation of the core complex is necessary for neurotransmitter release in neurons.	Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Liu, YH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, POB 26901, Oklahoma City, OK 73190 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035167] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35167] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Coorssen JR, 1998, J CELL BIOL, V143, P1845, DOI 10.1083/jcb.143.7.1845; Criado M, 1999, P NATL ACAD SCI USA, V96, P7256, DOI 10.1073/pnas.96.13.7256; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; GALLO V, 1982, P NATL ACAD SCI-BIOL, V79, P7919, DOI 10.1073/pnas.79.24.7919; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HESS DT, 1992, J NEUROSCI, V12, P4634; Jahn R, 1998, NATURE, V393, P14, DOI 10.1038/29871; Lane SR, 1997, J NEUROCHEM, V69, P1864; MARINI AM, 1992, P NATL ACAD SCI USA, V89, P6555, DOI 10.1073/pnas.89.14.6555; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; Mehta PP, 1996, P NATL ACAD SCI USA, V93, P10471, DOI 10.1073/pnas.93.19.10471; OConnor V, 1997, P NATL ACAD SCI USA, V94, P12186, DOI 10.1073/pnas.94.22.12186; Owe-Larsson B, 1999, EUR J NEUROSCI, V11, P1981, DOI 10.1046/j.1460-9568.1999.00614.x; OYLER GA, 1991, P NATL ACAD SCI USA, V88, P5247, DOI 10.1073/pnas.88.12.5247; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PEVSNER J, 1994, NEURON, V13, P355; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Sanders JD, 1998, J NEUROSCI RES, V53, P670, DOI 10.1002/(SICI)1097-4547(19980915)53:6<670::AID-JNR5>3.3.CO;2-H; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Venkatakrishnan A, 1996, J CHROMATOGR B, V676, P1, DOI 10.1016/0378-4347(95)00403-3; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X	34	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29482	29487		10.1074/jbc.M003237200	http://dx.doi.org/10.1074/jbc.M003237200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882724	hybrid			2022-12-27	WOS:000089439800042
J	Hahn, H; Wojnowski, L; Specht, K; Kappler, R; Calzada-Wack, J; Potter, D; Zimmer, A; Muller, U; Samson, E; Quintanilla-Martinez, L; Zimmer, A				Hahn, H; Wojnowski, L; Specht, K; Kappler, R; Calzada-Wack, J; Potter, D; Zimmer, A; Muller, U; Samson, E; Quintanilla-Martinez, L; Zimmer, A			Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-II; BECKWITH-WIEDEMANN-SYNDROME; SIGNALING PATHWAY; SONIC HEDGEHOG; GENE; EXPRESSION; CANCER; TUMORIGENESIS; RECEPTOR; DISEASE	Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children (Dagher, R., and Helman, L, (1999) Oncologist 4, 34-44), whereas medulloblastoma, a highly malignant tumor of the cerebellum, accounts for 20% of childhood brain tumors (Goodrich, L, V,, and Scott, M. P. (1998) Neuron 21, 1243-1257), Both tumors are associated with a deficiency in the tumor suppressor Patched (PTCH) in Gorlin syndrome (Gorlin, R, J, (1987) Medicine (Baltimore) 66, 98-113), and they are present in the corresponding murine models. RMS in Ptch mutant mice consistently contain elevated levels of the tumor growth-promoting insulin-like growth factor 2 (Igf2), We have investigated the mechanism of Igf2 overexpression and its significance in medulloblastoma and RMS tumorigenesis, Here we report that Igf2 is indispensable for the formation of medulloblastoma and RMS in Ptch mutants. Overexpression of Igf2 in RMS in these mice does not involve loss of imprinting, uniparental disomy, amplification of the Igf2 locus, or polyploidy, Since Igf2 is also overexpressed in non-tumor tissue deficient in Ptch, these observations suggest that Ptch regulates Igf2 levels through a transcriptional mechanism. They also identify Igf2 as a potential target for medulloblastoma and RMS.	Tech Univ Munich, Inst Pathol, GSF, Res Ctr Environm & Hlth, D-85758 Neuherberg, Germany; NIMH, Genet Lab, NIH, Bethesda, MD 20892 USA; NIMH, Vet Med & Resources Branch, NIH, Bethesda, MD 20892 USA; Univ Bonn, Psychiat Clin, D-53105 Bonn, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Bonn	Hahn, H (corresponding author), Tech Univ Munich, Inst Pathol, GSF, Res Ctr Environm & Hlth, D-85758 Neuherberg, Germany.	heidi.hakn@gsf.de	Zimmer, Andreas/B-8357-2009	Calzada, Julia/0000-0003-0816-9305; Kappler, Roland/0000-0002-8581-2803				Bleyer WA, 1997, EUR J CANCER, V33, P1439, DOI 10.1016/S0959-8049(97)00249-9; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; Dagher R, 1999, Oncologist, V4, P34; Davis TL, 1998, DEV GENET, V23, P111, DOI 10.1002/(SICI)1520-6408(1998)23:2&lt;111::AID-DVG3&gt;3.0.CO;2-9; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; Falls JG, 1999, AM J PATHOL, V154, P635, DOI 10.1016/S0002-9440(10)65309-6; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Hahn H, 1999, J MOL MED-JMM, V77, P459, DOI 10.1007/s001099900018; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hassan AB, 2000, CANCER RES, V60, P1070; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Ingham PW, 1998, CURR OPIN GENET DEV, V8, P88, DOI 10.1016/S0959-437X(98)80067-1; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Joyce JA, 1997, HUM MOL GENET, V6, P1543, DOI 10.1093/hmg/6.9.1543; LEE JE, 1990, DEVELOPMENT, V110, P151; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Miyaki M, 1998, NAT MED, V4, P1236, DOI 10.1038/3214; O'Dell SD, 1998, INT J BIOCHEM CELL B, V30, P767, DOI 10.1016/S1357-2725(98)00048-X; PEDONE PV, 1994, HUM MOL GENET, V3, P1117, DOI 10.1093/hmg/3.7.1117; Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; Zhan S, 1998, NAT MED, V4, P559, DOI 10.1038/nm0598-559	29	172	174	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28341	28344		10.1074/jbc.C000352200	http://dx.doi.org/10.1074/jbc.C000352200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10884376	hybrid			2022-12-27	WOS:000089330700001
J	Jewell-Motz, EA; Small, KM; Theiss, CT; Liggett, SB				Jewell-Motz, EA; Small, KM; Theiss, CT; Liggett, SB			alpha(2A)/alpha(2C)-adrenergic receptor third loop chimera show that agonist interaction with receptor subtype backbone establishes G protein-coupled receptor kinase phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD INTRACELLULAR LOOP; PROMOTED DESENSITIZATION; ALPHA-2-ADRENERGIC RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; SITES; ALPHA-2C10; MECHANISMS; CELLS; G(S)	alpha(2A)-adrenergic receptor (AR) undergoes rapid agonist-promoted desensitization due to phosphorylation by G protein-coupled receptor kinases (GRKs) 2 and 3 at serines in the third intracellular loop of the receptor. In contrast, the alpha(2C)AR fails to display such desensitization or phosphorylation, which has been. presumed to be due to this receptor lacking GRK phosphorylation sites. However, the alpha(2C)AR has multiple serines and threonines in putative favorable motifs within its third intracellular loop. We considered that the conformation of the third intracellular loop imposed by agonists binding to the transmembrane-spanning domains could be the basis of this subtype-specific property, rather than the presence or absence of phosphoacceptors per se. To address this, alpha(2A)/alpha(2C) third loop chimeric receptors were constructed. In whole cell phosphorylation studies, the alpha(2A) with the alpha(2C) third loop receptor underwent agonist-promoted phosphorylation while the alpha(2C) with the alpha(2A) third loop receptor did not, indicating that the agonist interaction with the parent receptor backbone establishes the phosphorylation phenotype. We postulated then that agonists with diverse structures that distinctly interact with alpha(2)AR should display different degrees of phosphorylation independent of receptor activation. Indeed, several full and partial agonists were identified, which evoked phosphorylation that was not related to intrinsic activity as established by [S-35]guanosine 5'-3-O-(thio)triphosphate binding. Taken together, it appears that phosphorylation of the alpha(2)AR evoked by agonist is highly sensitive to the conformation of the third intracellular loop induced/stabilized by agonist to such an extent that these properties dictate the extent of phosphorylation of the loop when phosphoacceptors are present, and are the basis for subtype-specific phosphorylation.	Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Liggett, SB (corresponding author), Univ Cincinnati, Coll Med, Dept Med, 231 Bethesda Ave,Rm 7507, Cincinnati, OH 45267 USA.	stephen.liggett@uc.edu	liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [HL41496] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BENOVIC JL, 1988, J BIOL CHEM, V263, P3893; Bristow MR, 1998, LANCET, V352, P8; EASON MG, 1992, J BIOL CHEM, V267, P15795; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; EASON MG, 1994, MOL PHARMACOL, V45, P696; EASON MG, 1992, J BIOL CHEM, V267, P25473; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; Kukkonen JP, 1998, J PHARMACOL EXP THER, V287, P667; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROSE H, 1994, J BIOL CHEM, V269, P10093; Liggett S B, 1998, Adv Pharmacol, V42, P438; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; Liggett SB, 1993, REGULATION CELLULAR, P71; Lohse MJ, 1996, BASIC RES CARDIOL, V91, P29, DOI 10.1007/BF00795359; McGraw DW, 1998, CELL SIGNAL, V10, P197, DOI 10.1016/S0898-6568(97)00112-5; METZGER H, 1991, CLIN EXP ALLERGY, V21, P269, DOI 10.1111/j.1365-2222.1991.tb01658.x; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Small KM, 2000, J BIOL CHEM, V275, P23059, DOI 10.1074/jbc.M000796200; VON ZM, 1993, J BIOL CHEM, V268, P763	23	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28989	28993		10.1074/jbc.M005381200	http://dx.doi.org/10.1074/jbc.M005381200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893245	hybrid			2022-12-27	WOS:000089330700085
J	Mimuro, H; Suzuki, T; Suetsugu, S; Miki, H; Takenawa, T; Sasakawa, C				Mimuro, H; Suzuki, T; Suetsugu, S; Miki, H; Takenawa, T; Sasakawa, C			Profilin is required for sustaining efficient intra- and intercellular spreading of Shigella flexneri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BASED MOTILITY; N-WASP; LISTERIA-MONOCYTOGENES; ARP2/3 COMPLEX; F-ACTIN; DEPOLYMERIZING PROTEIN; FOCAL ADHESION; CELLS; PLASMID; BINDING	The ability of Shigella to mediate actin-based motility within the host cell is a prominent pathogenic feature of bacillary dysentery. The ability is dependent on the interaction of VirG with neural Wiskott-Aldrich syndrome protein (N-WASP), which in turn mediates recruitment of Arp2/3 complex and several actin-related proteins. In the present study, we show that profilin I is essential to the rapid movement of Shigella in epithelial cells, for which the capacity of profilin to interact with G-actin and N-WASP is critical. In COS-7 cells overexpressing either mutated profilin H119E, which failed to bind G-actin, or H133S, which is unable to interact with poly-L-proline, Shigella motility was significantly inhibited. Similarly, depletion of profilin from Xenopus egg extracts resulted in a decrease in bacterial motility that was completely rescued by adding back profilin I but not R119E or H133S. In COS-7 cells overexpressing a N-WASP mutant lacking the proline-rich domain (Delta p) unable to interact with profilin, the actin tail formation of intracellular Shigella was inhibited. In N-WASP-depleted extracts, addition of hp but not full-length N-WASP was unable to restore the bacterial motility, Furthermore, in a plaque formation assay with Madin-Darby canine kidney cell monolayers infected by Shigella, Madin-Darby canine kidney cells stably expressing H119E, H133S, or Delta p reduced the bacterial cell-to-cell spreading. These results indicate that profilin I associated with N-WASP is an essential host factor for sustaining efficient intra- and intercellular spreading of Shigella.	Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Bacterial Infect,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Bacterial Toxicol, Suita, Osaka 5650871, Japan	University of Tokyo; University of Tokyo; Osaka University	Sasakawa, C (corresponding author), Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Bacterial Infect,Minato Ku, Tokyo 1088639, Japan.	sasakawa@ims.u-tokyo.ac.jp	Suetsugu, Shiro/B-3300-2010; Suetsugu, Shiro/AAF-4427-2019; Suetsugu, Shiro/ABB-6033-2020	Suetsugu, Shiro/0000-0002-4612-0628; Suetsugu, Shiro/0000-0002-4612-0628; 				BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; BjorkegrenSjogren C, 1997, FEBS LETT, V418, P258, DOI 10.1016/S0014-5793(97)01376-8; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Frischknecht F, 1999, CURR BIOL, V9, P89, DOI 10.1016/S0960-9822(99)80020-7; Fukuoka M, 1997, GENE, V196, P43, DOI 10.1016/S0378-1119(97)00184-4; Geese M, 2000, J CELL SCI, V113, P1415; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GOLDBERG MB, 1993, J BACTERIOL, V175, P2189, DOI 10.1128/JB.175.8.2189-2196.1993; GOLDBERG MB, 1993, INFECT IMMUN, V61, P4941, DOI 10.1128/IAI.61.12.4941-4946.1993; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; HONORE B, 1993, FEBS LETT, V330, P151, DOI 10.1016/0014-5793(93)80262-S; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; KADURUGAMUWA JL, 1991, INFECT IMMUN, V59, P3463, DOI 10.1128/IAI.59.10.3463-3471.1991; Kaiser DA, 1999, J CELL SCI, V112, P3779; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; LAMBRECHTS A, 1995, EUR J BIOCHEM, V230, P281, DOI 10.1111/j.1432-1033.1995.0281i.x; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LETT MC, 1989, J BACTERIOL, V171, P353, DOI 10.1128/jb.171.1.353-359.1989; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; MAKINO S, 1986, CELL, V46, P551, DOI 10.1016/0092-8674(86)90880-9; Miki H, 1998, BIOCHEM BIOPH RES CO, V243, P73, DOI 10.1006/bbrc.1997.8064; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mullins RD, 1998, MOL BIOL CELL, V9, P841, DOI 10.1091/mbc.9.4.841; NAKATA N, 1993, MOL MICROBIOL, V9, P459, DOI 10.1111/j.1365-2958.1993.tb01707.x; PREVOST MC, 1992, INFECT IMMUN, V60, P4088; Purich DL, 1999, METHOD ENZYMOL, V308, P93; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SASAKAWA C, 1986, INFECT IMMUN, V51, P470, DOI 10.1128/IAI.51.2.470-475.1986; Schluter K, 1997, BBA-MOL CELL RES, V1359, P97, DOI 10.1016/S0167-4889(97)00100-6; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; Southwick FS, 2000, CELL MOTIL CYTOSKEL, V45, P272, DOI 10.1002/(SICI)1097-0169(200004)45:4<272::AID-CM3>3.0.CO;2-E; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; Suzuki T, 2000, J EXP MED, V191, P1905, DOI 10.1084/jem.191.11.1905; Suzuki T, 1996, J BIOL CHEM, V271, P21878, DOI 10.1074/jbc.271.36.21878; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; TANAKA M, 1985, EUR J BIOCHEM, V151, P291, DOI 10.1111/j.1432-1033.1985.tb09099.x; Theriot JA, 1998, METHOD ENZYMOL, V298, P114, DOI 10.1016/S0076-6879(98)98013-2; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Zeile WL, 1996, J CELL BIOL, V133, P49, DOI 10.1083/jcb.133.1.49; Zigmond SH, 1998, CURR BIOL, V8, pR654, DOI 10.1016/S0960-9822(07)00415-0	52	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28893	28901		10.1074/jbc.M003882200	http://dx.doi.org/10.1074/jbc.M003882200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10867004	hybrid			2022-12-27	WOS:000089330700074
J	Sorensen, TLM; Andersen, JP				Sorensen, TLM; Andersen, JP			Importance of stalk segment S5 for intramolecular communication in the sarcoplasmic reticulum Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; FUNCTIONAL CONSEQUENCES; CALCIUM-PUMP; AMINO-ACIDS; DIVALENT-CATION; SKELETAL-MUSCLE; ATP HYDROLYSIS; CA2+ TRANSPORT; BINDING; CA-2+-ATPASE	Sixteen residues in stalk segment S5 of the Ca2+- ATPase of sarcoplasmic reticulum were studied by site-directed mutagenesis, The rate of the Ca2+ binding transition, determined at 0 degrees C, was enhanced relative to wild type in mutants Ile(743) --> Ala, Val(747) --> Ala, Glu(748) --> Ala, Glu(749) --> Ala, Met(757) --> Gly, and Gln(759) --> Ala and reduced in mutants Asp(737) --> Ala, Asp(738) --> Ala, Ala(752) --> Leu, and Tyr(754) --> Ala, In mutant Arg(762) --> Ile, the rate of the Ca2+ binding transition was wild type like at 0 degrees C, whereas it was 3.5-fold reduced relative to wild type at 25 degrees C. The rate of dephosphorylation of the ADP-insensitive phosphoenzyme was increased conspicuously in mutants Ile(743) --> Ala and Tyr(754) --> Ala (close to 10-fold in the absence of K+) and increased to a lesser extent in Asn(739) --> Ala, Glu(749) --> Ala, Gly(760) --> Ala, Ala(752) --> Gly, Met(757) --> Gly, and Arg(762) --> Ile, whereas it was reduced in mutants Asp(737) --> Ala, Val(744) --> Gly, Val(744) --> Ala, Val(747) --> Ala, and Ala(752) --> Leu. In mutants Ile(743) --> Ale, Tyr754, Ala, and Arg(762) --> Ile, the apparent affinities for vanadate were enhanced 23-, 30-, and le-fold, respectively, relative to wild type, The rate of Ca2+ dissociation was Ii-fold increased in Gly(750) --> Ala and 2-fold reduced in Val(747) --> Ala. Mutants with alterations to Arg(751) either were not expressed at a significant level or were completely nonfunctional. The findings show that S5 plays a crucial role in mediating communication between the Ca2+ binding pocket and the catalytic domain and that Arg(751) is important for both structural and functional integrity of the enzyme.	Aarhus Univ, Dept Physiol, DK-8000 Aarhus C, Denmark	Aarhus University	Andersen, JP (corresponding author), Aarhus Univ, Dept Physiol, Ole Worms Alle 160, DK-8000 Aarhus C, Denmark.	jpa@fi.au.dk	Sørensen, Thomas Lykke-Møller/AAA-7052-2020	Andersen, Jens Peter/0000-0003-0654-4300; Sorensen, Thomas Lykke-Moller/0000-0003-3873-3499				ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; ANDERSEN JP, 1985, BIOCHIM BIOPHYS ACTA, V815, P9, DOI 10.1016/0005-2736(85)90467-5; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BAGINSKI ES, 1967, CLIN CHEM, V13, P326; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1986, J BIOL CHEM, V261, P6372; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; FERSHT AR, 1974, PROC R SOC SER B-BIO, V187, P397, DOI 10.1098/rspb.1974.0084; FORGE V, 1993, J BIOL CHEM, V268, P10961; HARA H, 1986, J BIOL CHEM, V261, P6584; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; LEATHERBARROW RJ, 1985, P NATL ACAD SCI USA, V82, P7840, DOI 10.1073/pnas.82.23.7840; LUND S, 1988, J BIOL CHEM, V263, P1654; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; Mintz E, 1995, BIOSCIENCE REP, V15, P377, DOI 10.1007/BF01788369; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; REED PW, 1972, J BIOL CHEM, V247, P6970; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; SHIGEKAWA M, 1976, J BIOL CHEM, V251, P6947; SHIGEKAWA M, 1985, J BIOL CHEM, V260, P1679; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; SUMIDA M, 1978, J BIOL CHEM, V253, P8772; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VILSEN B, 1991, J BIOL CHEM, V266, P16157; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WEBER K, 1969, J BIOL CHEM, V244, P4406; YU X, 1993, BIOPHYS J, V64, P1232, DOI 10.1016/S0006-3495(93)81489-9; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; ZHANG Z, 1995, J BIOL CHEM, V270, P16283	41	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28954	28961		10.1074/jbc.M004072200	http://dx.doi.org/10.1074/jbc.M004072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10871620	hybrid			2022-12-27	WOS:000089330700081
J	Babu, PS; Krishnamurthy, H; Chedrese, PJ; Sairam, MR				Babu, PS; Krishnamurthy, H; Chedrese, PJ; Sairam, MR			Activation of extracellular-regulated kinase pathways in ovarian granulosa cells by the novel growth factor type 1 follicle-stimulating hormone receptor - Role in hormone signaling and cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTICULAR FOLLITROPIN RECEPTOR; DEOXYRIBONUCLEIC-ACID SYNTHESIS; HUMAN CHORIONIC-GONADOTROPIN; SPLICED MESSENGER-RNA; FSH RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT ACTIVATION; TRANSMEMBRANE DOMAIN; MOLECULAR-CLONING; PROTEIN-KINASES	Follicle-stimulating hormone (FSH) regulated growth and function of the ovarian follicle was previously thought to be mediated solely through activation of G(s)-coupled receptors, In this study, we show for the first time that this function is predominantly mediated through the alternatively spliced and novel growth factor type 1 receptor (oFSH-R3) that is also present in the ovary. Immortalized granulosa cells lacking endogenous FSH receptors, when transfected with either oFSH-R3 cDNA (JC-RS) or the G(s)-coupled oFSH-R1 (JC-R1), expressed the corresponding glycosylated receptor. In JC-R3 or JC-R1 cells labeled with bromodeoxyuridine or [H-3]thymidine, FSH: stimulated the cells to progress through S-phase and divide. The growth promoting effect of recombinant FSH in JC-R3 cells was preceded by the rapid activation of ERK1 and ERK2. This effect was hormone-specific and transient. In JC-R3 cells inhibitors like calphostin C, PD98059, Ag 18, or calcium chelators EGTA or 1,2-bis(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid/AM inhibited both mitogen-activated protein kinase activation and bromodeoxyuridine incorporation, FSH induced phosphorylation of the FSH-R3 receptor was blocked by pretreating cells with calphostin C, There was no cAMP induction by FSH in JC-R3 cells. The cAMP independent growth promoting effect of FSH is mediated by activation of Ca2+ and mitogen-activated protein kinase-dependent pathways. Thus, alternative splicing of a G-protein coupled receptor creates the expression of a novel receptor motif that can mediate a widely recognized function of the glycoprotein hormone.	Clin Res Inst Montreal, Mol Reprod Res Lab, Montreal, PQ H2W 1R7, Canada; Univ Saskatchewan, Dept Obstet Gynecol & Reprod Sci, Saskatoon, SK S7N 0W8, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Saskatchewan	Sairam, MR (corresponding author), Clin Res Inst Montreal, Mol Reprod Res Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ascoli M, 1996, BIOCHEM PHARMACOL, V52, P1647, DOI 10.1016/S0006-2952(96)00553-9; Babu P S, 1999, Mol Cell Biol Res Commun, V2, P21, DOI 10.1006/mcbr.1999.0139; Bley MA, 1997, J STEROID BIOCHEM, V62, P11, DOI 10.1016/S0960-0760(97)00021-6; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Cameron MR, 1996, BIOL REPROD, V55, P111, DOI 10.1095/biolreprod55.1.111; CAMP TA, 1991, MOL ENDOCRINOL, V5, P1405, DOI 10.1210/mend-5-10-1405; CAMPBELL JS, 1995, RECENT PROG HORM RES, V50, P131; Chedrese PJ, 1998, J MOL ENDOCRINOL, V20, P287, DOI 10.1677/jme.0.0200287; Chew SL, 1997, TRENDS ENDOCRIN MET, V8, P405, DOI 10.1016/S1043-2760(97)00167-7; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Das S, 1996, ENDOCRINOLOGY, V137, P967, DOI 10.1210/en.137.3.967; DATTATREYAMURTY B, 1992, ENDOCRINOLOGY, V131, P2437, DOI 10.1210/en.131.5.2437; DAVIS D, 1995, MOL ENDOCRINOL, V9, P159, DOI 10.1210/me.9.2.159; DELIDOW BC, 1990, ENDOCRINOLOGY, V126, P2302, DOI 10.1210/endo-126-5-2302; Dierich A, 1998, P NATL ACAD SCI USA, V95, P13612, DOI 10.1073/pnas.95.23.13612; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; FRISWOLD MD, 1993, SORTOLI CELL, P493; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GASINSKA A, 1988, BRIT J RADIOL, V61, P133, DOI 10.1259/0007-1285-61-722-133; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; GRAVES PN, 1992, BIOCHEM BIOPH RES CO, V187, P1135, DOI 10.1016/0006-291X(92)91315-H; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; KELTON CA, 1992, MOL CELL ENDOCRINOL, V89, P141, DOI 10.1016/0303-7207(92)90220-Z; Khan H, 1997, J MOL ENDOCRINOL, V19, P183, DOI 10.1677/jme.0.0190183; KHAN H, 1993, BIOCHEM BIOPH RES CO, V190, P888, DOI 10.1006/bbrc.1993.1132; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297-201; LAPOLT PS, 1992, ENDOCRINOLOGY, V130, P1289, DOI 10.1210/en.130.3.1289; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LIU XX, 1994, ENDOCRINOLOGY, V135, P682, DOI 10.1210/en.135.2.682; LOGANZO F, 1992, MOL ENDOCRINOL, V6, P1259, DOI 10.1210/me.6.8.1259; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; Miller TM, 1997, J BIOL CHEM, V272, P9847; MINEGISHI T, 1989, P NATL ACAD SCI USA, V86, P1470, DOI 10.1073/pnas.86.5.1470; Moudgal NR, 1997, ENDOCRINOLOGY, V138, P3065, DOI 10.1210/en.138.7.3065; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; PENNYBACKER M, 1991, MOL CELL ENDOCRINOL, V80, P11, DOI 10.1016/0303-7207(91)90138-I; QUINTANA J, 1994, J BIOL CHEM, V269, P8772; Robker RL, 1998, BIOL REPROD, V59, P476, DOI 10.1095/biolreprod59.3.476; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P508; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rodway MR, 1999, MOL CELL ENDOCRINOL, V148, P87, DOI 10.1016/S0303-7207(98)00233-0; ROY SK, 1993, FERTIL STERIL, V59, P783; Sairam MR, 1996, BIOCHEM BIOPH RES CO, V226, P717, DOI 10.1006/bbrc.1996.1419; Sairam MR, 1997, MOL REPROD DEV, V48, P480, DOI 10.1002/(SICI)1098-2795(199712)48:4&lt;480::AID-MRD8&gt;3.0.CO;2-M; Sairam MR, 1997, MOL REPROD DEV, V48, P471, DOI 10.1002/(SICI)1098-2795(199712)48:4&lt;471::AID-MRD7&gt;3.0.CO;2-N; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SHIBATA EF, 1992, ENDOCRINOLOGY, V131, P979, DOI 10.1210/en.131.2.979; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TERRY NHA, 1991, CYTOMETRY, V12, P234, DOI 10.1002/cyto.990120305; THEMMEN APN, 1994, MOL CELL ENDOCRINOL, V100, P15, DOI 10.1016/0303-7207(94)90272-0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Touraine P, 1999, MOL ENDOCRINOL, V13, P1844, DOI 10.1210/me.13.11.1844; Touyz RM, 2000, BIOL REPROD, V62, P1067, DOI 10.1095/biolreprod62.4.1067; Yarney TA, 1997, MOL REPROD DEV, V48, P458, DOI 10.1002/(SICI)1098-2795(199712)48:4&lt;458::AID-MRD6&gt;3.0.CO;2-P; YARNEY TA, 1993, MOL CELL ENDOCRINOL, V93, P219, DOI 10.1016/0303-7207(93)90127-6; Yarney TA, 1997, J MOL ENDOCRINOL, V18, P113, DOI 10.1677/jme.0.0180113	64	93	95	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27615	27626						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869352				2022-12-27	WOS:000089197100014
J	Rodrigues-Lima, F; Fensomes, AC; Josephs, M; Evans, J; Veldman, RJ; Katan, M				Rodrigues-Lima, F; Fensomes, AC; Josephs, M; Evans, J; Veldman, RJ; Katan, M			Structural requirements for catalysis and membrane targeting of mammalian enzymes with neutral sphingomyelinase and lysophospholipid phospholipase C activities - Analysis by chemical modification and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CEREUS SPHINGOMYELINASE; MULTIPLE SEQUENCE ALIGNMENT; PROTEIN SECONDARY STRUCTURE; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; DISULFIDE BRIDGE; ACID-RESIDUES; IDENTIFICATION; DEHYDROGENASE; REDUCTION	The sequence similarity with bacterial neutral sphingomyelinase resulted in the isolation of putative mammalian counterparts and, subsequently, identification of similar molecules in a number of other eukaryotic organisms. Based on sequence similarities and previous characterization of the mammalian enzymes, we have chemically modified specific residues and pet-formed site-directed mutagenesis in order to identify critical catalytic residues and determinants for membrane localization, Modification of histidine residues and the substrate protection experiments demonstrated the presence of reactive histidine residues within the active site. Site directed mutagenesis suggested an essential role in catalysis for two histidine residues (His-136 and His-272), which are conserved in all sequences. Mutations of two additional histidines (His-138 and His-151), consented only in eukaryotes, resulted in reduced neutral sphingomyelinase activity. In addition to sphingomyelin, the enzyme also hydrolyzed lysophosphatidylcholine, Exposure to an oxidizing environment or modification of cysteine residues using several specific compounds also inactivated the enzyme. Site-directed mutagenesis of eight cysteine residues and gel-shift analysis demonstrated that these residues did not participate in the catalytic reaction and suggested the involvement of cysteines in the formation/breakage of disulfide bonds, which could underlie the reversible inactivation by the oxidizing compounds. Cellular localization studies of a series of deletion mutants, expressed as green fluorescent protein fusion proteins, demonstrated that the transmembrane region contains determinants for the endoplasmic reticulum localization.	Inst Canc Res, Chester Beatty Labs, Canc Res Campaign, Ctr Cell & Mol Biol, London SW3 6JB, England; CHU Rangueil, INSERM, U466, Biochim Lab, F-31403 Toulouse 4, France	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Katan, M (corresponding author), Inst Canc Res, Chester Beatty Labs, Canc Res Campaign, Ctr Cell & Mol Biol, Fulham Rd, London SW3 6JB, England.	matilda@icr.ac.uk						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Carr PD, 1999, STRUCTURE, V7, P461, DOI 10.1016/S0969-2126(99)80058-6; Chatterjee S, 1999, J BIOL CHEM, V274, P37407, DOI 10.1074/jbc.274.52.37407; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Debarbieux L, 1999, CELL, V99, P117, DOI 10.1016/S0092-8674(00)81642-6; Dziewanowska K, 1996, ARCH BIOCHEM BIOPHYS, V335, P102, DOI 10.1006/abbi.1996.0486; Fensome AC, 2000, J BIOL CHEM, V275, P1128, DOI 10.1074/jbc.275.2.1128; Fischer D, 1996, PROTEIN SCI, V5, P947; Fischer D, 1999, PROTEINS, P209; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Heinz DW, 1998, J MOL BIOL, V275, P635, DOI 10.1006/jmbi.1997.1490; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; HUTERER S, 1984, BIOCHIM BIOPHYS ACTA, V794, P1, DOI 10.1016/0005-2760(84)90290-X; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Kang JG, 1999, EMBO J, V18, P4292, DOI 10.1093/emboj/18.15.4292; Kronke M, 1999, CHEM PHYS LIPIDS, V102, P157, DOI 10.1016/S0009-3084(99)00084-5; Letourneur F, 1998, J BIOL CHEM, V273, P33273, DOI 10.1074/jbc.273.50.33273; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Mahoney CW, 1996, J BIOL CHEM, V271, P28798, DOI 10.1074/jbc.271.46.28798; Majoul I, 1997, FEBS LETT, V401, P104, DOI 10.1016/S0014-5793(96)01447-0; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; Matsuo Y, 1996, PROTEIN SCI, V5, P2459, DOI 10.1002/pro.5560051208; Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sawai H, 1999, J BIOL CHEM, V274, P38131, DOI 10.1074/jbc.274.53.38131; Shriver Z, 1998, J BIOL CHEM, V273, P10160, DOI 10.1074/jbc.273.17.10160; TAMURA H, 1995, BIOCHEM J, V309, P757, DOI 10.1042/bj3090757; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; TOMITA M, 1993, BIOCHIM BIOPHYS ACTA, V1203, P85, DOI 10.1016/0167-4838(93)90039-T; Tomiuk S, 2000, J BIOL CHEM, V275, P5710, DOI 10.1074/jbc.275.8.5710; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Tonnetti L, 1999, J EXP MED, V189, P1581, DOI 10.1084/jem.189.10.1581; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664	40	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28316	+						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871611				2022-12-27	WOS:000089197100104
J	Turner, RJ; Lovato, M; Schimmel, P				Turner, RJ; Lovato, M; Schimmel, P			One of two genes encoding glycyl-tRNA synthetase in Saccharomyces cerevisiae provides mitochondrial and cytoplasmic functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; SPECIES-SPECIFIC AMINOACYLATION; ASPARTYL-TRANSFER RNA; THERMUS-THERMOPHILUS; BINDING DOMAINS; LYSYL-TRANSFER; MESSENGER-RNA; BOMBYX-MORI; YEAST; SEQUENCE	In the yeast Saccharomyces cerevisiae, two genes (GRS1 and GRS2) encode glycyl-tRNA synthetase (GlyRS1 and GlyRS2, respectively). 59% of the sequence of GlyRS2 is identical to that of GlyRS1. Others have proposed that GRS1 and GRS2 encode the cytoplasmic and mitochondrial enzymes, respectively. In this work, we show that GRS1 encodes both functions, whereas GRS2 is dispensable. In addition, both cytoplasmic and mitochondrial phenotypes of the knockout allele of GRS1 in S. cerevisiae are complemented by the expression of the only known gene for glycyl-tRNA synthetase in Schizosaccharomyces pombe, Thus, a single gene for glycyl-tRNA synthetase likely encodes both cytoplasmic and mitochondrial activities in most or all yeast. Phylogenetic analysis shows that GlyRS2 is a predecessor of all yeast GlyRS homologues, Thus, GRS1 appears to be the result of a duplication of GRS2, which itself is pseudogene-like.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd,Mail Code BCC 379, La Jolla, CA 92037 USA.	schimmel@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23562] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1998, CURRENT PROTOCOLS MO; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Benson DA, 1999, NUCLEIC ACIDS RES, V27, P12, DOI 10.1093/nar/27.1.12; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHATTON B, 1988, J BIOL CHEM, V263, P52; Chihade JW, 1999, P NATL ACAD SCI USA, V96, P12316, DOI 10.1073/pnas.96.22.12316; CHIU MI, 1992, GENETICS, V132, P987; Clayton RA, 1997, NATURE, V387, P459, DOI 10.1038/387459a0; COHEN SS, 1958, P NATL ACAD SCI USA, V44, P1004, DOI 10.1073/pnas.44.10.1004; Coligan JE., 1998, CURRENT PROTOCOLS PR; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DANNEBERG PB, 1958, CANCER RES, V18, P329; DIGNAM SS, 1984, J BIOL CHEM, V259, P4043; DUCHENE AM, 1997, PLANT PHYSIOL, V115, P1730; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FELSENSTEIN J, 1993, PHYLIP VERSION 3 573; GAMPEL A, 1989, P NATL ACAD SCI USA, V86, P6023, DOI 10.1073/pnas.86.16.6023; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Glasfeld E, 1997, BIOCHEMISTRY-US, V36, P6739, DOI 10.1021/bi970151n; Glasfeld E, 1996, BIOCHEMISTRY-US, V35, P4139, DOI 10.1021/bi9527810; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; HIPPS D, 1995, P NATL ACAD SCI USA, V92, P5550, DOI 10.1073/pnas.92.12.5550; HOHMANN S, 1992, GENE, V120, P43, DOI 10.1016/0378-1119(92)90007-C; Hopper AK, 1998, SCIENCE, V282, P2003, DOI 10.1126/science.282.5396.2003; HOUNTONDJI C, 1986, BIOCHIMIE, V68, P1071, DOI 10.1016/S0300-9084(86)80181-X; John TR, 1997, YEAST, V13, P37, DOI 10.1002/(SICI)1097-0061(199701)13:1<37::AID-YEA55>3.0.CO;2-L; KERN D, 1981, BIOCHEMISTRY-US, V20, P122, DOI 10.1021/bi00504a021; LOGAN DT, 1995, EMBO J, V14, P4156, DOI 10.1002/j.1460-2075.1995.tb00089.x; LUDMERER SW, 1987, J BIOL CHEM, V262, P10801; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; Magrath C, 1999, GENETICS, V152, P129; MANNHAUPT G, 1994, YEAST, V10, P1363, DOI 10.1002/yea.320101014; MARTINDALE DW, 1989, CURR GENET, V15, P99, DOI 10.1007/BF00435455; Mazauric MH, 1999, BIOCHEMISTRY-US, V38, P13094, DOI 10.1021/bi991392t; Mazauric MH, 1998, EUR J BIOCHEM, V251, P744, DOI 10.1046/j.1432-1327.1998.2510744.x; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; MIRANDE M, 1986, BIOCHIMIE, V68, P1001, DOI 10.1016/S0300-9084(86)80043-8; MYERS AM, 1985, J BIOL CHEM, V260, P5371; NADA S, 1993, J BIOL CHEM, V268, P7660; Nameki N, 1997, J MOL BIOL, V268, P640, DOI 10.1006/jmbi.1997.0993; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; OSTREM DL, 1970, P NATL ACAD SCI USA, V67, P1967, DOI 10.1073/pnas.67.4.1967; PAPE LK, 1985, J BIOL CHEM, V260, P5362; PAPE LK, 1985, NUCLEIC ACIDS RES, V13, P6171, DOI 10.1093/nar/13.17.6171; RIPMASTER TL, 1995, P NATL ACAD SCI USA, V92, P4932, DOI 10.1073/pnas.92.11.4932; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANNI A, 1991, P NATL ACAD SCI USA, V88, P8387, DOI 10.1073/pnas.88.19.8387; Sarkar S, 1999, P NATL ACAD SCI USA, V96, P14366, DOI 10.1073/pnas.96.25.14366; SCHIMMEL P, 1991, TRENDS BIOCHEM SCI, V16, P1, DOI 10.1016/0968-0004(91)90002-D; SELLAMI M, 1986, NUCLEIC ACIDS RES, V14, P1657, DOI 10.1093/nar/14.4.1657; SHIBA K, 1994, J BIOL CHEM, V269, P30049; Shiba K, 1997, TRENDS BIOCHEM SCI, V22, P453, DOI 10.1016/S0968-0004(97)01135-3; Souciet G, 1999, EUR J BIOCHEM, V266, P848, DOI 10.1046/j.1432-1327.1999.00922.x; SURGUCHOV AP, 1975, EUR J BIOCHEM, V54, P175, DOI 10.1111/j.1432-1033.1975.tb04127.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TZAGOLOFF A, 1989, EUR J BIOCHEM, V179, P365, DOI 10.1111/j.1432-1033.1989.tb14562.x; TZAGOLOFF A, 1995, EUR J BIOCHEM, V230, P582; Uwer U, 1998, PLANT CELL, V10, P1277, DOI 10.1105/tpc.10.8.1277; WALTER P, 1983, P NATL ACAD SCI-BIOL, V80, P2437, DOI 10.1073/pnas.80.9.2437; Wang CC, 1999, J BIOL CHEM, V274, P16508, DOI 10.1074/jbc.274.23.16508; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; Whelihan EF, 1997, EMBO J, V16, P2968, DOI 10.1093/emboj/16.10.2968; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000	66	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27681	27688						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10874035				2022-12-27	WOS:000089197100022
J	Song, YS; Ji, I; Beauchamp, J; Isaacs, NW; Ji, TH				Song, YS; Ji, I; Beauchamp, J; Isaacs, NW; Ji, TH			Hormone interactions to Leu-rich repeats in the gonadotropin receptors - I. Analysis of Leu-rich repeats of human luteinizing hormone/chorionic gonadotropin receptor and follicle-stimulating hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; HUMAN CHORIONIC-GONADOTROPIN; AMINO-TERMINAL REGION; EXTRACELLULAR DOMAIN; HIGH-AFFINITY; FUNCTIONAL EXPRESSION; SIGNAL-TRANSDUCTION; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; LIGAND-BINDING	The luteinizing hormone receptor (LHR) and follicle-stimulating hormone receptor (FSHR) have an similar to 350-amino acid-long, N-terminal extracellular exodomain, This exodomain binds hormone with high affinity and specificity and contains eight to nine putative Leu-rich repeat (LRR) sequences. LRRs are known to assume the horseshoe structure in ribonuclease inhibitors, and the inner lining of the horseshoe consists of the P-stranded Leu/Ile-X-Leu/Ile motif. In the case of ribonuclease inhibitors, these beta strands interact with ribonuclease, However, it is unclear whether the putative LRRs of LHR and FSHR play any role in the structure and function. In this work, the P-stranded Leu/Ile residues in all LRRs of the human LHR and FSHR were Ale-scanned and characterized. In addition, the 23 residues around LRR2 of LHR were Ala-scanned, The results show that beta -stranded Leu and Ile residues in all LRRs are important but not equally. These Leu/Ile-X-Leu/Ile motifs appear to form the hydrophobic core of the LRR loop, crucial for the LRR structure. Interestingly, the hot spots are primarily in the upstream and downstream LRRs of the LHR exodomain, whereas important LRRs spread throughout the FSHR exodomain. This may explain the distinct hormone specificity despite the structural similarity of the two receptors.	Univ Kentucky, Dept Chem, Lexington, KY 40506 USA; Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul 110744, South Korea; Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland	University of Kentucky; Seoul National University (SNU); University of Glasgow	Ji, TH (corresponding author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.		Song, Yong Sang/E-7824-2012	SONG, YONGSANG/0000-0001-7115-4021	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051469] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-18702] Funding Source: Medline; NIDDK NIH HHS [DK-51469] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abell A, 1996, J BIOL CHEM, V271, P4518; ADASHI EY, 1996, REPROD ENDOCRINOLOGY, V1, P17; Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; Bhowmick N, 1999, ENDOCRINOLOGY, V140, P4558, DOI 10.1210/en.140.10.4558; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHIANG CM, 1993, PEPTIDE RES, V6, P62; Couture L, 1996, J MOL ENDOCRINOL, V16, P15, DOI 10.1677/jme.0.0160015; DAVIS D, 1995, MOL ENDOCRINOL, V9, P159, DOI 10.1210/me.9.2.159; Dias JA, 1998, BIOL REPROD, V58, P1331, DOI 10.1095/biolreprod58.6.1331; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; GRISWOLD MD, 1993, SERTOLI CELLS, P496; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hong SH, 1998, J BIOL CHEM, V273, P13835, DOI 10.1074/jbc.273.22.13835; Hong SH, 1997, J BIOL CHEM, V272, P4166, DOI 10.1074/jbc.272.7.4166; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; HSUEH AJW, 1983, J REPROD FERTIL, V69, P325, DOI 10.1530/jrf.0.0690325; HUANG JN, 1995, J BIOL CHEM, V270, P30023; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; Ji IH, 1995, ENDOCRINE, V3, P907, DOI 10.1007/BF02738896; JI IH, 1995, J BIOL CHEM, V270, P15970, DOI 10.1074/jbc.270.27.15970; JI T, 1996, GONADOTROPIN RECEPTO, P21; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LIU XX, 1994, ENDOCRINOLOGY, V135, P682, DOI 10.1210/en.135.2.682; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; Osuga Y, 1997, J BIOL CHEM, V272, P25006, DOI 10.1074/jbc.272.40.25006; Papageorgiou AC, 1997, EMBO J, V16, P5162, DOI 10.1093/emboj/16.17.5162; Phang T, 1998, J BIOL CHEM, V273, P13841, DOI 10.1074/jbc.273.22.13841; PRIKETT K, 1989, BIOTECHNIQUES, V7, P580; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; Ryu K, 1998, J BIOL CHEM, V273, P28953, DOI 10.1074/jbc.273.44.28953; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; Sundstrom M, 1996, J BIOL CHEM, V271, P32197, DOI 10.1074/jbc.271.50.32197; Thomas D, 1996, MOL ENDOCRINOL, V10, P760, DOI 10.1210/me.10.6.760; TILLY JL, 1992, ENDOCRINOLOGY, V131, P799, DOI 10.1210/en.131.2.799; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; XIE YB, 1990, J BIOL CHEM, V265, P21411; Zhang R, 1996, J BIOL CHEM, V271, P5755, DOI 10.1074/jbc.271.10.5755	51	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3426	3435		10.1074/jbc.M003772200	http://dx.doi.org/10.1074/jbc.M003772200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	10880516	hybrid			2022-12-27	WOS:000166784900058
J	Komori, K; Miyata, T; Daiyasu, H; Toh, H; Shinagawa, H; Ishino, Y				Komori, K; Miyata, T; Daiyasu, H; Toh, H; Shinagawa, H; Ishino, Y			Domain analysis of an archaeal RadA protein for the strand exchange activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECA PROTEIN; HOMOLOGOUS RECOMBINATION; HYPERTHERMOPHILIC ARCHAEON; SYNAPTONEMAL COMPLEXES; PYROCOCCUS-FURIOSUS; ESCHERICHIA-COLI; TERMINAL DOMAIN; DNA-BINDING; REPAIR; BRCA2	Archaeal RadA, like eukaryotic Rad51 and bacterial Reck promotes strand exchange between DNA strands with homologous sequences in vitro and is believed to participate in the homologous recombination in cells. The amino acid sequences of the archaeal RadA proteins are more similar to the eukaryotic Rad51s rather than the bacterial Reck, and the N-terminal region containing domain I is conserved among the RadA and Rad51 proteins but is absent from Reck To understand the structure-function relationship of RadA, we divided the RadA protein from Pyrococcus furiosus into two parts, the N-terminal one-third (RadA-n) and the residual C-terminal two-thirds (RadA-c), the latter of which contains the central core domain (domain II) of the RecA/Rad51 family proteins, RadA-c had the DNA-dependent ATPase activity and the strand exchange activity by itself, although much weaker (10%) than that of the intact RadA. These activities of RadA-c were restored to 60% of those of RadA by addition of RadA-n, indicating that the proper active structure of RadA was reconstituted in vitro. These results suggest that the basic activities of the RecA/Rad51 family proteins for homologous recombination are derived from domain II, and the N-terminal region may help to enhance the catalytic efficiencies.	Biomol Engn Res Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan; Biomol Engn Res Inst, Dept Biol Struct, Suita, Osaka 5650874, Japan; Biomol Engn Res Inst, Dept Bioinformat, Suita, Osaka 5650874, Japan; Osaka Univ, Res Inst Microbial Dis, Dept Mol Microbiol, Suita, Osaka 5650871, Japan	Osaka University	Ishino, Y (corresponding author), Biomol Engn Res Inst, Dept Mol Biol, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.	ishino@beri.co.jp		Ishino, Yoshizumi/0000-0001-9419-0826				ADACHI J, 1996, MOLPHY VERSION 2 3B3; Aihara H, 1999, J MOL BIOL, V290, P495, DOI 10.1006/jmbi.1999.2904; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; DiRuggiero J, 1999, J MOL EVOL, V49, P474, DOI 10.1007/PL00006570; DiRuggiero J, 1997, J BACTERIOL, V179, P4643, DOI 10.1128/jb.179.14.4643-4645.1997; DONOVAN JW, 1994, GENE DEV, V8, P2552, DOI 10.1101/gad.8.21.2552; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FELSENSTEIN J, 1993, PHYLIP VERSION 3 5C; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; Kil YV, 2000, J BACTERIOL, V182, P130, DOI 10.1128/JB.182.1.130-134.2000; Komori K, 2000, J BIOL CHEM, V275, P33791, DOI 10.1074/jbc.M004556200; Kovalenko OV, 1997, NUCLEIC ACIDS RES, V25, P4946, DOI 10.1093/nar/25.24.4946; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kurumizaka H, 1996, J BIOL CHEM, V271, P33515, DOI 10.1074/jbc.271.52.33515; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; MORIMATSU K, 1995, EUR J BIOCHEM, V228, P779, DOI 10.1111/j.1432-1033.1995.0779m.x; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sandler SJ, 1999, J BACTERIOL, V181, P907, DOI 10.1128/JB.181.3.907-915.1999; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Seitz EM, 1998, GENE DEV, V12, P1248, DOI 10.1101/gad.12.9.1248; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SPIES M, EUR J BIOCH, V267, P1125; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Tarsounas M, 1999, J CELL BIOL, V147, P207, DOI 10.1083/jcb.147.2.207; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uemori T, 1997, GENES CELLS, V2, P499, DOI 10.1046/j.1365-2443.1997.1380336.x; Voloshin ON, 1996, SCIENCE, V272, P868, DOI 10.1126/science.272.5263.868; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Woods WG, 1997, MOL MICROBIOL, V23, P791, DOI 10.1046/j.1365-2958.1997.2651626.x	45	85	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33791	33797		10.1074/jbc.M004556200	http://dx.doi.org/10.1074/jbc.M004556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10887195	hybrid			2022-12-27	WOS:000090104600085
J	Ostergaard, H; Rasmussen, SK; Roberts, TH; Hejgaard, J				Ostergaard, H; Rasmussen, SK; Roberts, TH; Hejgaard, J			Inhibitory serpins from wheat grain with reactive centers resembling glutamine-rich repeats of prolamin storage proteins - Cloning and characterization of five major molecular forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE INHIBITORS; PLANT SERPIN; BARLEY ENDOSPERM; MANDUCA-SEXTA; CENTER LOOP; INSECTS; CHYMOTRYPSIN; SUPERFAMILY; EXPRESSION; HOMOLOGY	Genes encoding proteins of the serpin superfamily are widespread in the plant kingdom, but the properties of very few plant serpins have been studied, and physiological functions have not been elucidated. Six distinct set-pins have been identified in grains of hexaploid bread wheat (Triticum aestivum L.) by partial purification and amino acid sequencing. The reactive centers of all but one of the serpins resemble the glutamine-rich repetitive sequences in prolamin storage proteins of wheat grain. Five of the serpins, classified into two protein Z subfamilies, WSZ1 and WSZ2, have been cloned, expressed in Escherichia coli, and purified. Inhibitory specificity toward 17 proteinases of mammalian, plant, and microbial origin was studied. All five serpins were suicide substrate inhibitors of chymotrypsin and cathepsin G. WSZ1a and WSZ1b inhibited at the unusual reactive center P-1-P-1' Gln-Gln, and WSZ2b at P-2-P-1 Leu-Arg-one of two overlapping reactive centers. WSZ1c with P-1-P-1' Leu-Gln was the fastest inhibitor of chymotrypsin (k(a) = 1.3 x 10(6) M-1 s(-1)). WSZ1a was as efficient an inhibitor of chymotrypsin as WSZ2a (k(a) similar to 10(5) M-1 s(-1)), which has P-1-P-1' Leu-Ser-a reactive center common in animal serpins. WSZ2b inhibited plasmin at P-1-P-1' Arg-Gln (k(a) similar to 10(3) M-1 s(-1)). None of the five serpins inhibited Bacillus subtilisin A, Fusarium trypsin, or two subtilisin-like plant serine proteinases, hordolisin from barley green malt and cucumisin D from honeydew melon. Possible functions involving interactions with endogenous or exogenous proteinases adapted to prolamin degradation are discussed.	Tech Univ Denmark, Dept Biochem & Nutr, DK-2800 Lyngby, Denmark; Riso Natl Lab, Plant Biol & Biogeochem Dept, DK-4000 Roskilde, Denmark	Technical University of Denmark; Technical University of Denmark	Hejgaard, J (corresponding author), Tech Univ Denmark, Dept Biochem & Nutr, Bldg 224, DK-2800 Lyngby, Denmark.		Rasmussen, Soren K./F-6728-2014; Roberts, Thomas H/H-2071-2012	Rasmussen, Soren K./0000-0001-6169-2504; Roberts, Thomas H/0000-0003-3831-3240				BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; Bottomley SP, 1998, PROTEIN ENG, V11, P1243, DOI 10.1093/protein/11.12.1243; BRANDT A, 1990, EUR J BIOCHEM, V194, P499, DOI 10.1111/j.1432-1033.1990.tb15644.x; Dahl SW, 1996, FEBS LETT, V394, P165, DOI 10.1016/0014-5793(96)00940-4; Dahl SW, 1996, J BIOL CHEM, V271, P25083, DOI 10.1074/jbc.271.41.25083; Davy A, 1998, PLANT PHYSIOL, V117, P255, DOI 10.1104/pp.117.1.255; Egelund R, 1998, BIOCHEMISTRY-US, V37, P6375, DOI 10.1021/bi973043+; Gauthier M, 1997, ANAL BIOCHEM, V248, P228, DOI 10.1006/abio.1997.2133; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; Goodwin RL, 1996, MOL BIOL EVOL, V13, P346, DOI 10.1093/oxfordjournals.molbev.a025594; GUTIERREZ C, 1990, PLANT SCI, V72, P37, DOI 10.1016/0168-9452(90)90184-P; HEJGAARD J, 1985, FEBS LETT, V180, P89, DOI 10.1016/0014-5793(85)80238-6; HEJGAARD J, 1982, PHYSIOL PLANTARUM, V54, P174, DOI 10.1111/j.1399-3054.1982.tb06322.x; Jiang HB, 1997, J BIOL CHEM, V272, P1082, DOI 10.1074/jbc.272.2.1082; Jongsma MA, 1997, J INSECT PHYSIOL, V43, P885, DOI 10.1016/S0022-1910(97)00040-1; LONGSTAFF C, 1992, BLOOD COAGUL FIBRIN, V3, P89, DOI 10.1097/00001721-199202000-00013; LUNDGARD R, 1989, CARLSBERG RES COMMUN, V54, P173, DOI 10.1007/BF02904471; MARSHALL CJ, 1993, PHILOS T ROY SOC B, V342, P101, DOI 10.1098/rstb.1993.0141; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Rasmussen SK, 1996, BBA-PROTEIN STRUCT M, V1297, P127, DOI 10.1016/S0167-4838(96)00115-X; RASMUSSEN SK, 1993, BIOCHIM BIOPHYS ACTA, V1172, P151, DOI 10.1016/0167-4781(93)90282-I; Rasmussen SK, 1996, PLANT MOL BIOL, V30, P673, DOI 10.1007/BF00049343; ROSENKRANDS I, 1994, FEBS LETT, V343, P75, DOI 10.1016/0014-5793(94)80610-1; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; Sambrook J., 2002, MOL CLONING LAB MANU; Schick C, 1998, BIOCHEMISTRY-US, V37, P5258, DOI 10.1021/bi972521d; SHEWRY PR, 1995, PLANT CELL, V7, P945, DOI 10.1105/tpc.7.7.945; SHEWRY PR, 2000, SEED PROTEINS; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Terp N, 2000, J PLANT PHYSIOL, V156, P468, DOI 10.1016/S0176-1617(00)80161-3; THOMAS JC, 1995, PLANT PHYSIOL BIOCH, V33, P611; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; UCHIKOBA T, 1993, PHYTOCHEMISTRY, V33, P1005, DOI 10.1016/0031-9422(93)85012-G; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; Whisstock JC, 2000, J MOL BIOL, V295, P651, DOI 10.1006/jmbi.1999.3375; YAMAGATA H, 1994, J BIOL CHEM, V269, P32725	38	102	105	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33272	33279		10.1074/jbc.M004633200	http://dx.doi.org/10.1074/jbc.M004633200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10874043	hybrid			2022-12-27	WOS:000090104600016
J	Garon, L; Rousseau, F; Gagnon, E; Isenring, P				Garon, L; Rousseau, F; Gagnon, E; Isenring, P			Cloning and functional characterization of a cation-Cl(-)cotransporter-interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; CHLORIDE COTRANSPORTER; BUMETANIDE BINDING; MOLECULAR-CLONING; EXPRESSION; CELLS; LOCALIZATION; RAT; GLYCOSYLATION; TRANSPORT	To date, the cation-Cl- cotransporter (CCC) family comprises two branches of homologous membrane proteins. One branch includes the Na+-K+-Cl- cotransporters (NKCCs) and the Na+-Cl- cotransporter, and the other branch includes the K+-Cl- cotransporters. Here, we have isolated the first member of a third CCC family branch. This member shares similar to 25% identity in amino acid sequence with each of the other known mammalian CCCs. The corresponding cDNA, obtained from a human heart library and initially termed WO3.3 encodes a 914-residue polypeptide of 96.2 kDa (calculated mass). Sequence analyses predict a 12-transmembrane domain (tm) region, two N-linked glycosylation sites between tm, and tm,, and a large intracellular carboxyl terminus containing protein kinase C phosphorylation sites. Northern blot analysis uncovers an similar to 3.7-kilobase pair transcript present in muscle, placenta, brain, and kidney. With regard to function, WO3.3 expressed either in HEK-293 cells or Xenopus laevis oocytes does not increase Rb+-, Na+-, and Cl--coupled transport during 5-or 6-h fluxes, respectively. In the oocyte, however, WO3.3 specifically inhibits human NKCC1-mediated Rb-86(+) flux In addition, coimmunoprecipitation studies using lysates from WO3.3-transfected HEK-293 cells suggest a direct interaction of WO3.3 with endogenous NKCC. Thus, we have cloned and characterized the first putative heterologous CCC-interacting protein (CIP) known at present. CIP1 may be part of a novel family of proteins that modifies the activity or kinetics of CCCs through heterodimer formation.	Univ Laval, Fac Med, Grp Rech Nephrol, Quebec City, PQ G1R 2J6, Canada; Univ Laval, Fac Med, Dept Med, Quebec City, PQ G1R 2J6, Canada; Univ Laval, Fac Med, Unite Rech Genet Humaine & Mol, Quebec City, PQ G1R 2J6, Canada; Univ Laval, Fac Med, Dept Med Biol, Quebec City, PQ G1R 2J6, Canada	Laval University; Laval University; Laval University; Laval University	Garon, L (corresponding author), CHUQ, Hotel Dieu, Res Ctr, 10 Rue McMahon,Rm 3852, Quebec City, PQ G1R 2J6, Canada.							Bartter FC, 1998, J AM SOC NEPHROL, V9, P516; BECK PJ, 1990, MOL CELL BIOL, V10, P4612, DOI 10.1128/MCB.10.9.4612; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; Ecelbarger CA, 1996, AM J PHYSIOL-RENAL, V271, pF619, DOI 10.1152/ajprenal.1996.271.3.F619; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Gillen CM, 1999, AM J PHYSIOL-CELL PH, V276, pC328, DOI 10.1152/ajpcell.1999.276.2.C328; Haas M, 1998, J BIOENERG BIOMEMBR, V30, P161, DOI 10.1023/A:1020521308985; Hiki K, 1999, J BIOL CHEM, V274, P10661, DOI 10.1074/jbc.274.15.10661; ICHINOSE M, 1999, J AM SOC NEPHROL, V10, P34; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; ISENRING P, 1992, HYPERTENSION, V19, P371, DOI 10.1161/01.HYP.19.4.371; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; JACOBY SC, 1999, AM J PHYSIOL, V277, pC6845; Karet FE, 1997, RECENT PROG HORM RES, V52, P263; Karpa KD, 1999, MOL PHARMACOL, V56, P1071, DOI 10.1124/mol.56.5.1071; Kelley SJ, 1996, AM J PHYSIOL-CELL PH, V270, pC1122; KRACKE GR, 1990, P NATL ACAD SCI USA, V87, P8575, DOI 10.1073/pnas.87.21.8575; LAUF PK, 1992, AM J PHYSIOL, V263, pC917, DOI 10.1152/ajpcell.1992.263.5.C917; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LYTLE C, 1992, J BIOL CHEM, V267, P25428; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; Lytle C, 1995, AM J PHYSIOL-CELL PH, V269, pC1496, DOI 10.1152/ajpcell.1995.269.6.C1496; Lytle C, 1997, J BIOL CHEM, V272, P15069, DOI 10.1074/jbc.272.24.15069; MATTHEWS JB, 1994, J BIOL CHEM, V269, P15703; MITANI A, 1992, AM J PHYSIOL, V263, pH333, DOI 10.1152/ajpheart.1992.263.2.H333; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; PAYNE JA, 1995, CURR OPIN CELL BIOL, V7, P493, DOI 10.1016/0955-0674(95)80005-0; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Plata C, 1999, AM J PHYSIOL-RENAL, V276, pF359, DOI 10.1152/ajprenal.1999.276.3.F359; SUN A, 1991, J MEMBRANE BIOL, V120, P83, DOI 10.1007/BF01868594; Tanphaichitr VS, 1998, J CLIN INVEST, V102, P2173, DOI 10.1172/JCI4836; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	37	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32027	32036		10.1074/jbc.M000108200	http://dx.doi.org/10.1074/jbc.M000108200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10871601	hybrid			2022-12-27	WOS:000089858900066
J	Richardson, RT; Batova, IN; Widgren, EE; Zheng, LX; Whitfield, M; Marzluff, WF; O'Rand, MG				Richardson, RT; Batova, IN; Widgren, EE; Zheng, LX; Whitfield, M; Marzluff, WF; O'Rand, MG			Characterization of the histone H1-binding protein, NASP, as a cell cycle-regulated somatic protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR AUTOANTIGENIC PROTEIN; NUCLEOSOME ASSEMBLY INVITRO; DNA-REPLICATION INVITRO; XENOPUS-LAEVIS OOCYTES; BINDING-PROTEIN; ACROSOME REACTION; MESSENGER-RNA; EXPRESSION; LOCALIZATION; CHROMATIN	Nuclear autoantigenic sperm protein (NASP), initially described as a highly autoimmunogenic testis and sperm-specific protein, is a histone-binding protein that is a homologue of the N1/N2 gene expressed in oocytes of Xenopus laevis. Here, we report a somatic form of NASP (sNASP) present in all mitotic cells examined, including mouse embryonic cells and several mouse and human tissue culture cell lines. Affinity chromatography and histone isolation demonstrate that NASP from myeloma cells is complexed only with H1, linker histones. Somatic NASP is a shorter version of testicular NASP (tNASP) with two deletions in the coding region arising from alternative splicing and differs from tNASP in its 5' untranslated regions. We examined the relationship between NASP mRNA expression and the cell cycle and report that in cultures of synchronized mouse 3T3 cells and HeLa cells sNASP mRNA levels increase during S-phase and decline in G(2), concomitant with histone mRNA levels. NASP protein levels remain stable in these cells but become undetectable in confluent cultures of nondividing CV-1 cells and in nonmitotic cells in various body tissues. Expression of sNASP mRNA is regulated during the cell cycle and, consistent with a role as a histone transport protein, NASP mRNA expression parallels histone mRNA expression.	Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	O'Rand, MG (corresponding author), Univ N Carolina, Dept Cell Biol & Anat, CB 7090, Chapel Hill, NC 27599 USA.	morand@unc.edu	Whitfield, Michael/AAC-5010-2020; , UNC Flow Cytometry Core/AGU-9839-2022					ALMOUZNI G, 1990, NUCLEIC ACIDS RES, V18, P5767, DOI 10.1093/nar/18.19.5767; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Batova I, 1996, BIOL REPROD, V54, P1238, DOI 10.1095/biolreprod54.6.1238; BORUN TW, 1975, CELL, V4, P59, DOI 10.1016/0092-8674(75)90134-8; BROWN DT, 1993, J BIOL CHEM, V268, P713; CHIU IM, 1982, BIOCHIM BIOPHYS ACTA, V699, P173, DOI 10.1016/0167-4781(82)90105-1; DABAUVALLE MC, 1982, P NATL ACAD SCI-BIOL, V79, P5302, DOI 10.1073/pnas.79.17.5302; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; Ito T, 1996, MOL CELL BIOL, V16, P3112; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KIM YJ, 1987, DEV BIOL, V124, P23, DOI 10.1016/0012-1606(87)90455-6; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; KLEINSCHMIDT JA, 1988, EMBO J, V7, P1605, DOI 10.1002/j.1460-2075.1988.tb02986.x; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KROHNE G, 1985, EXP CELL RES, V158, P205, DOI 10.1016/0014-4827(85)90444-6; LASKOV R, 1970, Journal of Experimental Medicine, V131, P515, DOI 10.1084/jem.131.3.515; Lorain S, 1998, MOL CELL BIOL, V18, P5546, DOI 10.1128/MCB.18.9.5546; MEISTRICH ML, 1985, DEV BIOL, V112, P230, DOI 10.1016/0012-1606(85)90137-X; O'Rand MG, 2000, SERONO SYMP, P143; ORAND MG, 1992, DEV BIOL, V154, P37, DOI 10.1016/0012-1606(92)90045-I; RICHARDSON RT, 1991, BIOL REPROD, V45, P20, DOI 10.1095/biolreprod45.1.20; RICHARDSON RT, 1994, DEV BIOL, V165, P688, DOI 10.1006/dbio.1994.1285; RICHARDSON RT, 1993, SERONO SYM, V97, P41; Rodriguez P, 1997, GENOMICS, V44, P253, DOI 10.1006/geno.1997.4868; SALIK J, 1981, J CELL BIOL, V90, P385, DOI 10.1083/jcb.90.2.385; SAPP M, 1990, J BIOL CHEM, V265, P9357; SITTMAN DB, 1983, P NATL ACAD SCI-BIOL, V80, P1849, DOI 10.1073/pnas.80.7.1849; Sivashanmugam P, 1999, J ANDROL, V20, P384; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; WAITHE WI, 1983, BIOCHEMISTRY-US, V22, P1778, DOI 10.1021/bi00277a006; Wang ZF, 1997, J MOL BIOL, V271, P124, DOI 10.1006/jmbi.1997.1166; WASSARMAN PM, 1981, DEV BIOL, V84, P364, DOI 10.1016/0012-1606(81)90405-X; Watanabe TK, 1996, CYTOGENET CELL GENET, V74, P281, DOI 10.1159/000134435; WELCH JE, 1990, BIOL REPROD, V43, P559, DOI 10.1095/biolreprod43.4.559; WELCH JE, 1990, BIOL REPROD, V43, P569, DOI 10.1095/biolreprod43.4.569; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	42	111	113	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30378	30386		10.1074/jbc.M003781200	http://dx.doi.org/10.1074/jbc.M003781200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893414	hybrid, Green Published			2022-12-27	WOS:000089577900063
J	Stimmel, JB; Merrill, BM; Kuyper, LF; Moxham, CP; Hutchins, JT; Fling, ME; Kull, FC				Stimmel, JB; Merrill, BM; Kuyper, LF; Moxham, CP; Hutchins, JT; Fling, ME; Kull, FC			Site-specific conjugation on serine -> cysteine variant monoclonal antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENGINEERED HUMAN-IGG; ANTIGEN; PROTEIN; TUMOR; CARBOHYDRATE; CAMPATH-1H; THERAPY; CANCER; ACID	We have engineered a cysteine residue at position 442 (EU/OU numbering) in the third constant domain (C(H)3) of the heavy chain of several IgGs with different specificities, isoforms, and variants with the intent to introduce a site for chemical conjugation. The variants were expressed in NS0 mouse myeloma cells, where monomeric IgG is the major form and formation of aggregate was minimal. Monomeric IgG contained no free thiol; however, it was discovered that the engineered thiols were reversibly blocked and could be reduced under controlled conditions. Following reduction, reactive thiol was conjugated with a cysteine-specific bifunctional chelator, bromoacetyl-TMT to a humanized 323/A3 IgG4 variant. Conjugation had no significant effect on antibody affinity. To prove that the conjugation was site-specific, an antibody-TMT conjugate was labeled with lutetium-177 and subjected to peptide mapping followed by sequence analysis. Glu-C digestion demonstrated that 91% of the label was recovered in the COOH-terminal peptide fragment containing the engineered cysteine.	Glaxo Wellcome Inc, Dept Mol Sci, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Struct Chem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Discovery Genet, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Stimmel, JB (corresponding author), Glaxo Wellcome Inc, Dept Mol Sci, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.							ACKERMAN E, 1979, MED PROG TECHNOL, V6, P81; BODMER M, 1993, Patent No. 5219996; Boyd PN, 1995, MOL IMMUNOL, V32, P1311, DOI 10.1016/0161-5890(95)00118-2; CARON PC, 1992, J EXP MED, V176, P1191, DOI 10.1084/jem.176.4.1191; Corper AL, 1997, NAT STRUCT BIOL, V4, P374, DOI 10.1038/nsb0597-374; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DESHPANDE SV, 1990, J NUCL MED, V31, P473; EDWARDS DP, 1986, CANCER RES, V46, P1306; GOLDENBERG DM, 1978, NEW ENGL J MED, V298, P1384, DOI 10.1056/NEJM197806222982503; GOLDMAN A, 1984, J PEDIATR-US, V105, P252, DOI 10.1016/S0022-3476(84)80122-5; HOARE DG, 1966, J AM CHEM SOC, V88, P2057, DOI 10.1021/ja00961a045; Hutchins JT, 1995, P NATL ACAD SCI USA, V92, P11980, DOI 10.1073/pnas.92.26.11980; ISAACS JD, 1992, J IMMUNOL, V148, P3062; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KHAW BA, 1980, SCIENCE, V209, P295, DOI 10.1126/science.7384803; LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437; LUND J, 1990, MOL IMMUNOL, V27, P1145, DOI 10.1016/0161-5890(90)90103-7; LYONS A, 1990, PROTEIN ENG, V3, P703, DOI 10.1093/protein/3.8.703; MEARES CF, 1984, ANAL BIOCHEM, V142, P68, DOI 10.1016/0003-2697(84)90517-7; MEARES CF, 1990, BR J CANC S, P21; MOLDOFSKY PJ, 1984, NEW ENGL J MED, V311, P106, DOI 10.1056/NEJM198407123110207; MORRISON RT, 1984, INT J NUCL MED BIOL, V11, P184, DOI 10.1016/0047-0740(84)90059-7; OSHANNESSY DJ, 1987, J IMMUNOL METHODS, V99, P153, DOI 10.1016/0022-1759(87)90120-7; PARTIS MD, 1983, J PROTEIN CHEM, V2, P263, DOI 10.1007/BF01025358; RAINSBURY RM, 1983, LANCET, V2, P934; RODWELL JD, 1986, P NATL ACAD SCI USA, V83, P2632, DOI 10.1073/pnas.83.8.2632; SCHEINBERG DA, 1982, SCIENCE, V215, P1511, DOI 10.1126/science.7199757; SHOPES B, 1992, J IMMUNOL, V148, P2918; SHOPES B, 1993, MOL IMMUNOL, V30, P603, DOI 10.1016/0161-5890(93)90035-A; Stimmel JB, 1998, NUCL MED BIOL, V25, P117, DOI 10.1016/S0969-8051(97)00151-0; TAO MH, 1989, J IMMUNOL, V143, P2595; THIERS R E, 1957, Methods Biochem Anal, V5, P273; TONER JL, 1989, Patent No. 4859777; TRAIL PA, 1995, DRUG DEVELOP RES, V34, P196, DOI 10.1002/ddr.430340209; Weber RW, 1990, BIOCONJUGATE CHEM, V1, P431, DOI 10.1021/bc00006a010; Wilder RB, 1996, J CLIN ONCOL, V14, P1383, DOI 10.1200/JCO.1996.14.4.1383; YAMADA H, 1981, BIOCHEMISTRY-US, V20, P4836, DOI 10.1021/bi00520a005	37	56	96	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30445	30450		10.1074/jbc.M001672200	http://dx.doi.org/10.1074/jbc.M001672200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10880507	hybrid			2022-12-27	WOS:000089577900072
J	Huang, L; Grammatikakis, N; Yoneda, M; Banerjee, SD; Toole, BP				Huang, L; Grammatikakis, N; Yoneda, M; Banerjee, SD; Toole, BP			Molecular characterization of a novel intracellular hyaluronan-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-CARCINOMA CELLS; SMOOTH-MUSCLE CELLS; MONOCLONAL-ANTIBODY; HEPARAN-SULFATE; IN-VIVO; CD44; LOCALIZATION; GLYCOSAMINOGLYCANS; IDENTIFICATION; EXPRESSION	Hyaluronan has well defined functions in extracellular matrices and at the surface of cells. However, several studies have now shown that significant pools of hyaluronan are also present intracellularly, but its function therein is unknown. One avenue of investigation that may assist in defining the function of intracellular hyaluronan is to identify intracellular hyaluronan-binding proteins. In previous studies we identified CDC37, a cell cycle regulatory protein, using a monoclonal antibody that recognizes a novel group of hyaluronan-binding proteins. In this study, we have identified a second hyaluronan-binding protein with this antibody and characterized its properties. This protein, which we have termed IHABP4, was also found to be an intracellular and a specific hyaluronan-binding protein, containing several hyaluronan-binding motifs: (R/K)X-7(R/K) (where R/K denotes arginine or lysine and X denotes non-acidic amino acids). Furthermore, we have determined the gene organization of IHABP4 and cloned cDNAs for the chick, mouse, and human homologs. Comparison of the deduced chick, mouse, and human protein sequences showed that the hyaluronan-binding motifs, (R/K)X-7(R/ K), in these sequences are conserved; both chick and mouse IHABP4 were shown directly to bind hyaluronan. Biochemical fractionation and immunofluorescent localization of epitope-tagged IHABP4 indicated that it is mainly present in the cytoplasm. These data support the possibility that intracellular hyaluronan and its binding proteins may play important roles in cell behavior.	Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA	Tufts University	Toole, BP (corresponding author), Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA.				NCI NIH HHS [CA82867, CA73839] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073839, R01CA082867] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assmann V, 1998, J CELL SCI, V111, P1685; BANERJEE SD, 1991, DEV BIOL, V146, P186, DOI 10.1016/0012-1606(91)90459-G; BRECHT M, 1986, BIOCHEM J, V239, P445, DOI 10.1042/bj2390445; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; Cleves AE, 1997, CURR BIOL, V7, pR318, DOI 10.1016/S0960-9822(06)00148-5; Collis L, 1998, FEBS LETT, V440, P444, DOI 10.1016/S0014-5793(98)01505-1; CULTY M, 1994, J CELL PHYSIOL, V160, P275, DOI 10.1002/jcp.1041600209; Deb TB, 1996, J BIOL CHEM, V271, P2206, DOI 10.1074/jbc.271.4.2206; EGGLI PS, 1995, J HISTOCHEM CYTOCHEM, V43, P689, DOI 10.1177/43.7.7608523; Entwistle J, 1996, J CELL BIOCHEM, V61, P569, DOI 10.1002/(SICI)1097-4644(19960616)61:4<569::AID-JCB10>3.0.CO;2-B; Evanko SP, 1999, J HISTOCHEM CYTOCHEM, V47, P1331, DOI 10.1177/002215549904701013; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; FEDARKO NS, 1989, J CELL PHYSIOL, V139, P287, DOI 10.1002/jcp.1041390210; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FURUKAWA K, 1979, BIOCHIM BIOPHYS ACTA, V585, P575, DOI 10.1016/0304-4165(79)90190-9; GERBER LD, 1992, J BIOL CHEM, V267, P12168; GRAMMATIKAKIS N, 1995, J BIOL CHEM, V270, P16198, DOI 10.1074/jbc.270.27.16198; Huang L, 1998, J BIOL CHEM, V273, P3598, DOI 10.1074/jbc.273.6.3598; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Itano N, 1999, CANCER RES, V59, P2499; Kincade PW, 1997, CURR OPIN CELL BIOL, V9, P635, DOI 10.1016/S0955-0674(97)80116-0; Kobarg J, 1997, EXP CLIN IMMUNOGENET, V14, P273; Kosaki R, 1999, CANCER RES, V59, P1141; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; Liu DC, 1996, P NATL ACAD SCI USA, V93, P7832, DOI 10.1073/pnas.93.15.7832; Lord JM, 1998, J CELL BIOL, V140, P733; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Olofsson AM, 1999, J CLIN INVEST, V104, P885, DOI 10.1172/JCI6671; Pavasant P, 1996, J CELL SCI, V109, P327; Peterson RM, 2000, AM J PATHOL, V156, P2159, DOI 10.1016/S0002-9440(10)65086-9; RIPELLINO JA, 1988, J CELL BIOL, V106, P845, DOI 10.1083/jcb.106.3.845; ROHDE D, 1992, AM J PATHOL, V140, P473; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; Sleeman JP, 1997, J BIOL CHEM, V272, P31837, DOI 10.1074/jbc.272.50.31837; Takada Y, 1999, CELL TISSUE RES, V298, P317, DOI 10.1007/s004419900082; TOOLE BP, 1999, GUIDEBOOK EXTRACELLU, P430; TOOLE BP, 2000, PROTEOGLYCANS STRUCT, P61; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35	44	63	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29829	29839		10.1074/jbc.M002737200	http://dx.doi.org/10.1074/jbc.M002737200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887182	hybrid			2022-12-27	WOS:000089439800089
J	Krappmann, D; Hatada, EN; Tegethoff, S; Li, J; Klippel, A; Giese, K; Baeuerle, PA; Scheidereit, C				Krappmann, D; Hatada, EN; Tegethoff, S; Li, J; Klippel, A; Giese, K; Baeuerle, PA; Scheidereit, C			The I kappa B kinase (IKK) complex is tripartite and contains IKK gamma but not IKAP as a regular component	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; BETA SUBUNIT; ACTIVATION; ALPHA; PHOSPHORYLATION; PROTEIN; MICE; IDENTIFICATION; MECHANISMS; HOLOENZYME	A critical step in the activation of NF-kappa B is the phosphorylation of I kappa Bs by the I kappa B kinase (IKK) complex. IKK alpha and IKK beta are the two catalytic subunits of the IRK complex and two additional molecules, IKK gamma/NEMO and IKAP, have been described as further integral members. We have analyzed the function of both proteins for IKK complex composition and NF-kappa B signaling. IKAP and IKK gamma belong to distinct cellular complexes. Quantitative association of IKK gamma was observed with IKK alpha and IKK beta. In contrast IKAP was complexed with several distinct polypeptides. Overexpression of either IKK gamma or IKAP blocked tumor necrosis factor alpha induction of an NF-kappa B-dependent reporter construct, but IKAP in addition affected several NF-kappa B-independent promoters. Whereas specific down-regulation of IKK gamma protein levels by antisense oligonucleotides significantly reduced cytokine-mediated activation of the IKK complex and subsequent NF-kappa B activation, a similar reduction of IKAP protein levels had no effect on NF-kappa B signaling. Using solely IKK alpha, IKK beta, and IKK gamma, we could reconstitute a complex whose apparent molecular weight is comparable to that of the endogenous IKK complex. We conclude that while IKK gamma is a stoichiometric component of the IKK complex, obligatory for NF-kappa B signaling, IKAP is not associated with IKKs and plays no specific role in cytokine-induced NF-kappa B activation.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Boehringer Ingelheim Pharmaceut Inc, Dept Biol, Ridgefield, CT 06877 USA; Atugen AG, D-13125 Berlin, Germany; Micromet GmbH, D-82152 Martinsried, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Boehringer Ingelheim; Amgen; Amgen Research Munich GmbH	Scheidereit, C (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.		Krappmann, Daniel/AAT-4354-2021; Krappmann, Daniel/ABF-4038-2021	Krappmann, Daniel/0000-0001-7640-3234; Krappmann, Daniel/0000-0001-7640-3234				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li YG, 1998, MOL CELL BIOL, V18, P1601, DOI 10.1128/MCB.18.3.1601; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; May MJ, 1999, SCIENCE, V284, P271, DOI 10.1126/science.284.5412.271; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROONEY JW, 1990, IMMUNOGENETICS, V31, P73, DOI 10.1007/BF00661216; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Scheidereit C, 1998, NATURE, V395, P225, DOI 10.1038/26121; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zandi E, 1999, MOL CELL BIOL, V19, P4547	41	102	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29779	29787		10.1074/jbc.M003902200	http://dx.doi.org/10.1074/jbc.M003902200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893415	hybrid			2022-12-27	WOS:000089439800082
J	Szymczyna, BR; Arrowsmith, CH				Szymczyna, BR; Arrowsmith, CH			DNA binding specificity studies of four ETS proteins support an indirect read-out mechanism of protein-DNA recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; MURINE ETS-1; PU.1; EXPRESSION; MOTIF; SITES; GENE; IDENTIFICATION; SEQUENCES	Members of the ETS family of transcription factors are involved in several developmental and physiological processes, and, when overexpressed or misexpressed, can contribute to a variety of cancers. Each family member has a conserved DNA-binding domain that recognizes DNA sequences containing a G-G-A trinucleotide, Discrimination between potential ETS-binding sites appears to be governed by both the nucleotides flanking the G-G-A sequence and protein-protein interactions. We have used an adaptation of the "length-encoded multiplex" approach (Desjarlais, J. R., and Berg, J. M. (1994) Proc. Natl, Acad Sci. U.S. A. 91, 11099-11103) to define DNA binding specificities for four ETS proteins: Fli-1, SAP-1, PU.1, and TEL. Our results support a model in which cooperative effects among neighboring bases flanking the central G-G-A site contribute to the formation of stable ETS/DNA complexes. These results are consistent with a mechanism for specific DNA binding that is partially governed by an indirect read-out of the DNA sequence, in which a sequence-specific DNA conformation is sensed or induced.	Univ Toronto, Ontario Canc Inst, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Arrowsmith, CH (corresponding author), Univ Toronto, Ontario Canc Inst, 610 Univ Ave, Toronto, ON, Canada.			Arrowsmith, Cheryl/0000-0002-4971-3250				Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Bemark M, 1999, J BIOL CHEM, V274, P10259, DOI 10.1074/jbc.274.15.10259; Brown LA, 1998, ONCOGENE, V17, P93, DOI 10.1038/sj.onc.1201911; Brown LA, 1999, ONCOGENE, V18, P7985, DOI 10.1038/sj.onc.1203197; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; DESJARLAIS JR, 1994, P NATL ACAD SCI USA, V91, P11099, DOI 10.1073/pnas.91.23.11099; DICKERSON RE, 1992, METHOD ENZYMOL, V211, P67; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; FISHER RJ, 1991, ONCOGENE, V6, P2249; Gross P, 1998, BIOCHEMISTRY-US, V37, P5129, DOI 10.1021/bi972591k; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; John S, 1996, J EXP MED, V183, P743, DOI 10.1084/jem.183.3.743; KLUG SJ, 1994, MOL BIOL REP, V20, P97, DOI 10.1007/BF00996358; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Li SL, 1999, J BIOL CHEM, V274, P32453, DOI 10.1074/jbc.274.45.32453; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAROULAKOU IG, 1994, ONCOGENE, V9, P151; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; Mo Y, 2000, NAT STRUCT BIOL, V7, P292; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Pio F, 1999, PROTEIN SCI, V8, P2098, DOI 10.1110/ps.8.10.2098; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; RAYGALLET D, 1995, ONCOGENE, V11, P303; SAMBROOK J, 1989, MOL CLONING LAB APPR; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; StraussSoukup JK, 1997, J BIOL CHEM, V272, P31570, DOI 10.1074/jbc.272.50.31570; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; Taylor JM, 1997, MOL CELL BIOL, V17, P5550, DOI 10.1128/MCB.17.9.5550; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Werner MH, 1997, J BIOMOL NMR, V10, P317, DOI 10.1023/A:1018399711996; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699	42	83	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28363	28370		10.1074/jbc.M004294200	http://dx.doi.org/10.1074/jbc.M004294200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10867009	hybrid			2022-12-27	WOS:000089330700006
J	Lin, KM; Mejillano, M; Yin, HL				Lin, KM; Mejillano, M; Yin, HL			Ca2+ regulation of gelsolin by its C-terminal tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING DOMAIN; PLASMA GELSOLIN; F-ACTIN; CALCIUM; IDENTIFICATION; PROTEIN; SITES; FILAMENTS; COMPLEX; GCAP39	Gelsolin is activated by Ca2+ to sever actin filaments. Ca2+ regulation is conferred on the N-terminal half by the C-terminal half. This paper seeks to understand how Ca2+ regulates gelsolin by testing the "tail helix latch hypothesis," which is based on the structural data showing that gelsolin has a C-terminal tail helix that contacts the N-terminal half in the absence of Ca2+. Ca2+ activation of gelsolin at 37 degrees C occurs in three steps, with apparent K-d for Ca2+ of 0.1, 0.3, and 6.4 x 10(-6) M. Tail helix truncation decreases the apparent Ca2+ requirement for severing to 10(-7) M and eliminates the conformational change observed at 10(-6) M Ca2+. The large decrease in Ca2+ requirement for severing is not due to a change in Ca2+ binding nor to Ca2+-independent activation of the C-terminal half per se. Thus, the tail helix latch is primarily responsible for transmitting micromolar Ca2+ information from the gelsolin C-terminal half to the N-terminal half. Occupation of submicromolar Ca2+-binding sites primes gelsolin for severing, but gelsolin cannot sever because the fail latch is still engaged. Unlatching the tail helix by 10(-6) M Ca2+ releases the final constraint to initiate the severing cascade.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yin, HL (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	hyin@mednet.swmed.edu			NIGMS NIH HHS [R01-GM5112] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN PG, 1994, J BIOL CHEM, V269, P32916; Allen PG, 1997, FEBS LETT, V401, P89, DOI 10.1016/S0014-5793(96)01439-1; Arcaro A, 1998, J BIOL CHEM, V273, P805, DOI 10.1074/jbc.273.2.805; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYAN J, 1984, J BIOL CHEM, V259, P7480; BRYAN J, 1986, J CELL BIOL, V102, P1439, DOI 10.1083/jcb.102.4.1439; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; CHAPONNIER C, 1987, J EXP MED, V165, P97, DOI 10.1084/jem.165.1.97; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1985, J BIOL CHEM, V260, P5232; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAMB JA, 1993, J BIOL CHEM, V268, P8999; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; LIU YT, 1998, G PROTEINS CYTOSKELE; Lueck A, 2000, BIOCHEMISTRY-US, V39, P5274, DOI 10.1021/bi992871v; MATSUDAIRA P, 1985, NATURE, V315, P248, DOI 10.1038/315248a0; McGough A, 1998, BIOPHYS J, V74, P764, DOI 10.1016/S0006-3495(98)74001-9; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; PATKOWSKI A, 1990, BIOPOLYMERS, V30, P427, DOI 10.1002/bip.360300320; POPE B, 1991, FEBS LETT, V280, P70, DOI 10.1016/0014-5793(91)80206-I; POPE B, 1995, BIOCHEMISTRY-US, V34, P1583, DOI 10.1021/bi00005a014; Pope BJ, 1997, BIOCHEMISTRY-US, V36, P15848, DOI 10.1021/bi972192p; Robinson RC, 1999, SCIENCE, V286, P1939, DOI 10.1126/science.286.5446.1939; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Selden LA, 1998, BIOPHYS J, V75, P3092, DOI 10.1016/S0006-3495(98)77750-1; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; SUN HQ, 1998, PHAGOCYTOSIS PATHOGE, V5, P319; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WEEDS AG, 1995, FEBS LETT, V360, P227, DOI 10.1016/0014-5793(95)00109-M; WEEDS AG, 1986, EUR J BIOCHEM, V161, P69, DOI 10.1111/j.1432-1033.1986.tb10125.x; Wen DY, 1996, BIOCHEMISTRY-US, V35, P9700, DOI 10.1021/bi960920n; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; YIN HL, 1981, J BIOL CHEM, V256, P9693; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1991, J BIOL CHEM, V266, P19269	40	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27746	27752						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862770				2022-12-27	WOS:000089197100032
J	Vial, D; Okazaki, H; Siraganian, RP				Vial, D; Okazaki, H; Siraganian, RP			The NH2-terminal region of focal adhesion kinase reconstitutes high affinity IgE receptor-induced secretion in mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; DROSOPHILA-MELANOGASTER; PROTEIN; MIGRATION; DOMAIN; FAK; PP125(FAK); SRC; ASSOCIATION	Focal adhesion kinase (FAK) is tyrosine-phosphorylated by adherence of cells and also by Fc epsilon RI aggregation in RBL-2H3 mast cells. Using phosphorylation site-specific antibodies, we observed that Fc epsilon RI activation in these cells led to an increase in FAK phosphorylation at the same tyrosine residues that are phosphorylated by integrin-induced activation. Previous studies in the 3B6 line, a FAK-deficient variant of the RBL-2H3 cells, suggest that FAK plays a role in Fc epsilon RI-induced secretion. Stable cell lines expressing either full-length or truncated forms of FAK were isolated after transfection of the FAK-deficient 3B6 variant cells. The NH2 domain of FAK, which lacks the enzymatic and the COOH-terminal regions, was sufficient to reconstitute secretion. The different truncated forms of FAK were still tyrosine-phosphorylated after Fc epsilon RI aggregation. Therefore, the kinase domain and the COOH-terminal region are not essential for Fc epsilon RI-induced tyrosine phosphorylation of FAK or for secretion. Taken together, our data demonstrate that the reconstitution of secretion is dissociated from FAK activation and that the NH2-terminal region of FAK is the only critical element that may play a role in Fc epsilon RI-induced secretion by acting as an adaptor or linker molecule.	NIDCR, OIIB, Receptors & Signal Transduct Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Vial, D (corresponding author), NIDCR, OIIB, Receptors & Signal Transduct Sect, NIH, Bldg 10,Rm 1N106, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000696, ZIADE000696] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Fox GL, 1999, P NATL ACAD SCI USA, V96, P14978, DOI 10.1073/pnas.96.26.14978; Fujimoto J, 1999, J BIOL CHEM, V274, P29196, DOI 10.1074/jbc.274.41.29196; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; HAMAWY MM, 1992, J IMMUNOL, V149, P615; HAMAWY MM, 1994, J IMMUNOL, V153, P4655; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; Hamawy MM, 1997, J BIOL CHEM, V272, P30498, DOI 10.1074/jbc.272.48.30498; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; ILLC D, 1995, NATURE, V377, P539; Maung K, 1999, ONCOGENE, V18, P6824, DOI 10.1038/sj.onc.1203094; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Palmer RH, 1999, J BIOL CHEM, V274, P35621, DOI 10.1074/jbc.274.50.35621; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Richardson A, 1997, BIOCHEM J, V324, P141, DOI 10.1042/bj3240141; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Sieg DJ, 1999, J CELL SCI, V112, P2677; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Zhang J, 1998, J IMMUNOL, V161, P4366; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	35	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28269	28275						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862765				2022-12-27	WOS:000089197100098
J	Wan, YJY; Cai, Y; Lungo, W; Fu, P; Locker, J; French, S; Sucov, HM				Wan, YJY; Cai, Y; Lungo, W; Fu, P; Locker, J; French, S; Sucov, HM			Peroxisome proliferator-activated receptor alpha-mediated pathways are altered in hepatocyte-specific retinoid X receptor alpha-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; PPAR-ALPHA; RXR-ALPHA; SIGNALING PATHWAYS; ADAPTIVE RESPONSE; FATTY-ACIDS; MUTANT MICE; RAT-LIVER; GENE; EXPRESSION	Retinoid x receptor alpha (RXR alpha) serves as an active partner of peroxisome proliferator-activated receptor (PPAR alpha). In order to dissect the functional role of RXR alpha and PPAR alpha in PPAR alpha-mediated pathways, the hepatocyte PPAR alpha deficient mice have been challenged with physiological and pharmacological stresses, fasting and Wy14,643, respectively. The data demonstrate that RXR alpha and PPAR alpha deficiency are different in several aspects. At the basal untreated level, RXR alpha deficiency resulted in marked induction of apolipoprotein A-I and C-III (apoA-I and apoC-III) mRNA levels and serum cholesterol and triglyceride levels, which was not found in PPAR alpha-null mice. Fasting-induced PPAR alpha activation was drastically prevented in the absence of hepatocyte RXR alpha. Wy14,643-mediated pleiotropic effects were also altered due to the absence of hepatocyte RXR alpha. Hepatocyte RXR alpha deficiency did not change the basal acyl-CoA oxidase, medium chain acyl-CoA dehydrogenase, and malic enzyme mRNA levels, However, the inducibility of those genes by Wy14,643 was markedly reduced in the mutant mouse livers. In contrast, the basal cytochrome P450 4A1, liver fatty acid-binding protein, and apoA-I and apoC-III mRNA levels were significantly altered in the mutant mouse livers, but the regulatory effect of Wy14,643 on expression of those genes remained the same, Wy14,643-induced hepatomegaly was partially inhibited in hepatocyte RXR alpha-deficient mice. Wy14,643-induced hepatocyte peroxisome proliferation was preserved in the absence of hepatocyte RXRa. These data suggested that in comparison to PPAR alpha, hepatocyte RXR alpha has its unique role in lipid homeostasis and that the effect of RXR alpha, -beta, and -gamma is redundant in certain aspects.	Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Pathol, Torrance, CA 90509 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Biochem & Mol Biol & Cell & Neurobiol, Los Angeles, CA 90033 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of Southern California	Wan, YJY (corresponding author), Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Pathol, 1000 W Carson St, Torrance, CA 90509 USA.			Sucov, Henry/0000-0002-3792-3795	NCI NIH HHS [CA53596, R01 CA053596] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053596, R29CA053596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; Chen J, 1998, DEVELOPMENT, V125, P1943; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; DESVERGNE B, 1995, INDUCIBLE GENE EXPRE, V1, P142; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FAN CY, 1999, HEPATOLOGY ELSEWHERE, V29, P606; GE RW, 1994, J BIOL CHEM, V269, P13185; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HARDWICK JP, 1987, J BIOL CHEM, V262, P801; HERTZ R, 1996, BIOCHEM J, V319, P341; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Kastner P, 1996, GENE DEV, V10, P80, DOI 10.1101/gad.10.1.80; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7356; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; Ohata M, 2000, EXP MOL PATHOL, V68, P13, DOI 10.1006/exmp.1999.2284; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Poirier H, 1997, FEBS LETT, V412, P480, DOI 10.1016/S0014-5793(97)00830-2; QUAN F, 1986, NUCLEIC ACIDS RES, V14, P5321, DOI 10.1093/nar/14.13.5321; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SOHLENIUS AK, 1995, BBA-LIPID LIPID MET, V1258, P257, DOI 10.1016/0005-2760(95)00123-T; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; Ulven SM, 1998, EUR J CELL BIOL, V77, P111, DOI 10.1016/S0171-9335(98)80078-2; VU DN, 1996, MOL CELL BIOL, V16, P3350; Wan YJY, 2000, MOL CELL BIOL, V20, P4436, DOI 10.1128/MCB.20.12.4436-4444.2000; Westin S, 1997, MOL CELL ENDOCRINOL, V129, P169, DOI 10.1016/S0303-7207(97)04055-0	38	64	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28285	28290						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10866995				2022-12-27	WOS:000089197100100
J	Gasa, R; Jensen, PB; Berman, HK; Brady, MJ; DePaoli-Roach, AA; Newgard, CB				Gasa, R; Jensen, PB; Berman, HK; Brady, MJ; DePaoli-Roach, AA; Newgard, CB			Distinctive regulatory and metabolic properties of glycogen-targeting subunits of protein phosphatase-1 (PTG, G(L), G(M)/R-G1) expressed in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MAGNETIC-RESONANCE; DIABETES-MELLITUS; LIVER-GLYCOGEN; GLUCOKINASE; GLUCOSE; ACTIVATION; MECHANISM; BINDING; RAT	Glycogen-targeting subunits of protein phosphatase-1 facilitate interaction of the phosphatase with enzymes of glycogen metabolism. We have shown that overexpression of one member of the family, protein targeting to glycogen (PTG), causes large increases in glycogen storage in isolated hepatocytes or intact rat liver. In the current study, we have compared the metabolic and regulatory properties of PTG (expressed in many tissues), with two other members of the gene family, G(L) (expressed primarily in liver) and G(M)/R-G1 (expressed primarily in striated muscle). Adenovirus-mediated expression of these proteins in hepatocytes led to the following hey observations. 1) G(L) has the highest glycogenic potency among the three forms studied. 2) Glycogen synthase activity ratio is much higher in G(L)- overexpressing cells than in PTG or G(M)/R-G1-overexpressing cells. Thus, at moderate levels of Cf, overexpression, glycogen synthase activity is increased by insulin treatment, but at higher levels of G(L) expression, insulin is no longer required to achieve maximal synthase activity. In contrast, cells with high levels of PTG overexpression retain dose-dependent regulation of glycogen synthesis and glycogen synthase enzyme activity by insulin. 3) G(L)- and G(M)/R-G1-overexpressing cells exhibit a strong glycogenolytic response to forskolin, whereas PTG-overexpressing cells are less responsive. This difference may be explained in part by a lesser forskolin-induced increase in glycogen phosphorylase activity in PTG-overexpressing cells. Based on these re suits, we suggest that expression of either G(L) or G(M)/R-G1 in liver of diabetic animals may represent a strategy for lowering of blood glucose levels in diabetes.	Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Cell Biol, Ann Arbor, MI 48105 USA; Indiana Univ, Sch Med, Dept Biochem, Indianapolis, IN 46202 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pfizer; Indiana University System; Indiana University-Purdue University Indianapolis	Newgard, CB (corresponding author), Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Rm Y8-212,5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Jensen, Per Bo/0000-0002-2277-1135	NIDDK NIH HHS [P01 DK58398, DK 36569] Funding Source: Medline; PHS HHS [P50 H2598801] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058398, R01DK036569] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antinozzi PA, 1999, ANNU REV NUTR, V19, P511, DOI 10.1146/annurev.nutr.19.1.511; Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; Armstrong CG, 1998, BIOCHEM J, V336, P699, DOI 10.1042/bj3360699; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Berman HK, 1998, J BIOL CHEM, V273, P26421, DOI 10.1074/jbc.273.41.26421; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLINE GW, 1994, J CLIN INVEST, V94, P2369, DOI 10.1172/JCI117602; COATS WS, 1991, J BIOL CHEM, V266, P16113; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Ferre T, 1996, P NATL ACAD SCI USA, V93, P7225, DOI 10.1073/pnas.93.14.7225; Hariharan N, 1997, DIABETES, V46, P11, DOI 10.2337/diabetes.46.1.11; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; MASSAGUE J, 1978, BIOCHIM BIOPHYS ACTA, V543, P269, DOI 10.1016/0304-4165(78)90073-9; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; NEWGARD CB, 1983, J BIOL CHEM, V258, P8046; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; O'Doherty RM, 2000, J CLIN INVEST, V105, P479, DOI 10.1172/JCI8673; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; TANG PM, 1991, J BIOL CHEM, V266, P15782; Velho G, 1996, J CLIN INVEST, V98, P1755, DOI 10.1172/JCI118974	26	68	73	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26396	26403		10.1074/jbc.M002427200	http://dx.doi.org/10.1074/jbc.M002427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10862764	hybrid			2022-12-27	WOS:000088999700071
J	Seipelt, J; Liebig, HD; Sommergruber, W; Gerner, C; Kuechler, E				Seipelt, J; Liebig, HD; Sommergruber, W; Gerner, C; Kuechler, E			2A proteinase of human rhinovirus cleaves cytokeratin 8 in infected HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUTH-DISEASE VIRUS; SYNTHESIS INITIATION FACTOR-EIF-4-GAMMA; ENCODED PROTEASE 3C(PRO); POLIOVIRUS INFECTION; RNA TRANSLATION; IN-VITRO; POLY(A)-BINDING PROTEIN; INTERMEDIATE FILAMENTS; MEDIATED STIMULATION; CELLULAR PROTEINS	Rhino- and enteroviruses encode two proteinases, 2A and 3C, which are responsible for the processing of the viral polyprotein and for cleavage of several cellular proteins. To identify further targets of the 2A proteinase of human rhinovirus serotype 2 (HRV2), an in vitro cleavage assay followed by two-dimensional electrophoresis was employed. Cytokeratin 8, a member of the intermediate filament group of proteins, was found to be proteolytically cleaved in vitro by the 2A proteinase of HRV2 and of coxsackievirus B4 and in vivo during HRV2 infection of HeLa cells. The cleavage results in removal of 14 amino acids from the N-terminal head domain of cytokeratin 8. However, other intermediate filament proteins (cytokeratins 7 and 18 and vimentin) were not cleaved in the course of the HRV2 infection. Compared with the processing of the eucaryotic translation initiation factors 4GI and 4GII, cleavage of cytokeratin 8 occurs late in the infection cycle at the time of the onset of the cytopathic effect.	Univ Vienna, Inst Med Biochem, Div Biochem, A-1030 Vienna, Austria; Boehringer Ingelheim Austria, A-1123 Vienna, Austria; Univ Vienna, Inst Canc Res, A-1090 Vienna, Austria	University of Vienna; Boehringer Ingelheim; University of Vienna	Kuechler, E (corresponding author), Univ Vienna, Inst Med Biochem, Div Biochem, Dr Bohrgasse 9-3, A-1030 Vienna, Austria.	kuechler@bch.univie.ac.at		Gerner, Christopher/0000-0003-4964-0642; Seipelt, Joachim/0000-0001-9865-814X				APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BADER BL, 1991, J CELL BIOL, V115, P1293, DOI 10.1083/jcb.115.5.1293; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; CHEN PH, 1993, J VIROL, V67, P3507, DOI 10.1128/JVI.67.6.3507-3514.1993; CLARK ME, 1993, MOL CELL BIOL, V13, P1232, DOI 10.1128/MCB.13.2.1232; CLARK ME, 1991, EMBO J, V10, P2941, DOI 10.1002/j.1460-2075.1991.tb07844.x; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; DEVANEY MA, 1988, J VIROL, V62, P4407, DOI 10.1128/JVI.62.11.4407-4409.1988; DOEDENS J, 1994, ARCH VIROL, P159; ETCHISON D, 1985, J VIROL, V54, P634, DOI 10.1128/JVI.54.2.634-638.1985; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Gerner C, 1999, J CELL BIOCHEM, V74, P145, DOI 10.1002/(SICI)1097-4644(19990801)74:2<145::AID-JCB1>3.0.CO;2-#; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; Hunt SL, 1999, VIRUS RES, V62, P119, DOI 10.1016/S0168-1702(99)00039-8; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1990, ENZYME, V44, P292, DOI 10.1159/000468766; JOACHIMS M, 1995, VIROLOGY, V211, P451, DOI 10.1006/viro.1995.1427; JOACHIMS M, 1992, J VIROL, V66, P5797, DOI 10.1128/JVI.66.10.5797-5804.1992; Joachims M, 1999, J VIROL, V73, P718, DOI 10.1128/JVI.73.1.718-727.1999; Kerekatte V, 1999, J VIROL, V73, P709, DOI 10.1128/JVI.73.1.709-717.1999; KIRCHWEGER R, 1994, J VIROL, V68, P5677, DOI 10.1128/JVI.68.9.5677-5684.1994; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LENK R, 1979, CELL, V16, P289, DOI 10.1016/0092-8674(79)90006-0; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; MOLLA A, 1993, VIROLOGY, V196, P739, DOI 10.1006/viro.1993.1531; Morley SJ, 1997, RNA, V3, P1085; PALLAI PV, 1989, J BIOL CHEM, V264, P9738; SCHECHTER I, 1966, BIOCHEMISTRY-US, V5, P3371, DOI 10.1021/bi00874a041; SHOEMAN RL, 1991, ADV EXP MED BIOL, V306, P533; SHOEMAN RL, 1990, P NATL ACAD SCI USA, V87, P6336, DOI 10.1073/pnas.87.16.6336; SKERN T, 1991, VIROLOGY, V181, P46, DOI 10.1016/0042-6822(91)90468-Q; SKERN T, 1984, VIROLOGY, V136, P125, DOI 10.1016/0042-6822(84)90253-8; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOMMERGRUBER W, 1994, VIROLOGY, V198, P741, DOI 10.1006/viro.1994.1089; SOMMERGRUBER W, 1992, J BIOL CHEM, V267, P22639; SONENBERG N, 1990, ENZYME, V44, P278, DOI 10.1159/000468765; Svitkin YV, 1999, J VIROL, V73, P3467, DOI 10.1128/JVI.73.4.3467-3472.1999; TESAR M, 1990, VIROLOGY, V174, P364, DOI 10.1016/0042-6822(90)90090-E; URZAINQUI A, 1989, J VIROL, V63, P4729, DOI 10.1128/JVI.63.11.4729-4735.1989; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Yalamanchili P, 1997, VIROLOGY, V239, P176, DOI 10.1006/viro.1997.8862; Yalamanchili P, 1997, J VIROL, V71, P1220, DOI 10.1128/JVI.71.2.1220-1226.1997; YAN RQ, 1992, J BIOL CHEM, V267, P23226; ZHANG Y, 1994, J VIROL, V68, P2544, DOI 10.1128/JVI.68.4.2544-2555.1994; ZIEGLER E, 1995, VIROLOGY, V213, P549	49	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20084	20089		10.1074/jbc.275.26.20084	http://dx.doi.org/10.1074/jbc.275.26.20084			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867028	hybrid			2022-12-27	WOS:000087941300088
J	Baudoux, L; Defechereux, P; Rentier, B; Piette, J				Baudoux, L; Defechereux, P; Rentier, B; Piette, J			Gene activation by varicella-zoster virus IE4 protein requires its dimerization and involves both the arginine-rich sequence, the central part, and the carboxyl-terminal cysteine-rich region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; IMMEDIATE-EARLY PROTEIN; READING FRAME-4 ENCODES; ALPHA PROTEIN-ICP27; FUNCTIONALLY DISTINCT; TRANS-REPRESSOR; NUCLEAR IMPORT; LEUCINE-ZIPPER; ICP27 MAP; K-PROTEIN	Varicella-zoster virus (VZV) open reading frame 4-encoded protein (IE4) possesses transactivating properties for VZV genes as well as for those of heterologous viruses. Since most transcription factors act as dimers, IE4 dimerization was studied using the mammalian two-hybrid system. Introduction of mutations in the IE4 open reading frame demonstrated that both the central region and the carboxyl-terminal cysteine-rich domain were important for efficient dimerization. Within the carboxyl-terminal domain, substitution of amino acids encompassing residues 443-447 totally abolished dimerization. Gene activation by IE4 was studied by transient transfection with an IE4 expression plasmid and a reporter gene under the control of either the human immunodeficiency virus, type 1, long terminal repeat or the VZV thymidine kinase promoter. Regions of IE4 important for dimerization were also shown to be crucial for transactivation. In addition, the arginine-rich domains Rb and Re of the amino-terminal region were also demonstrated to be important for transactivation, whereas the Ra domain as well as an acidic and bZIP-containing regions were shown to be dispensable for gene transactivation. A nucleocytoplasmic shuttling of IE4 has also been characterized, involving a nuclear localization signal identified within the Rb domain and a nuclear export mechanism partially depending on Crm-1.	Univ Liege, Inst Pathol, Lab Fundamental Virol & Immunol B23, B-4000 Liege, Belgium	University of Liege	Piette, J (corresponding author), Univ Liege, Inst Pathol, Lab Fundamental Virol & Immunol B23, B-4000 Liege, Belgium.	jpiette@ulg.ac.be						Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; BAUDOUX L, 1995, NUCLEIC ACIDS RES, V23, P1341, DOI 10.1093/nar/23.8.1341; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DEBRUS S, 1995, J VIROL, V69, P3240, DOI 10.1128/JVI.69.5.3240-3245.1995; Defechereux P, 1996, J GEN VIROL, V77, P1505, DOI 10.1099/0022-1317-77-7-1505; Defechereux P, 1997, J VIROL, V71, P7073, DOI 10.1128/JVI.71.9.7073-7079.1997; DEFECHEREUX P, 1993, J VIROL, V67, P4379, DOI 10.1128/JVI.67.7.4379-4385.1993; Defechereux P, 1998, J BIOL CHEM, V273, P13636, DOI 10.1074/jbc.273.22.13636; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ELLENBERGER T, 1994, CURR OPIN STRUC BIOL, V4, P12, DOI 10.1016/S0959-440X(94)90054-X; EVERETT RD, 1986, J GEN VIROL, V67, P2507, DOI 10.1099/0022-1317-67-11-2507; FORGHANI B, 1990, VIRUS RES, V16, P195, DOI 10.1016/0168-1702(90)90023-5; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; HARDWICKE MA, 1989, J VIROL, V63, P4590, DOI 10.1128/JVI.63.11.4590-4602.1989; HAY J, 1994, SEMIN VIROL, V5, P241, DOI 10.1006/smvy.1994.1026; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; HIBBARD MK, 1995, J VIROL, V69, P4656, DOI 10.1128/JVI.69.8.4656-4667.1995; HONESS RW, 1974, J VIROL, V14, P8, DOI 10.1128/JVI.14.1.8-19.1974; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; INCHAUSPE G, 1989, VIROLOGY, V173, P700, DOI 10.1016/0042-6822(89)90583-7; Kruyt FAE, 1999, J BIOL CHEM, V274, P34212, DOI 10.1074/jbc.274.48.34212; MCMAHAN L, 1990, J VIROL, V64, P3471, DOI 10.1128/JVI.64.7.3471-3485.1990; Mears WE, 1996, J VIROL, V70, P7445, DOI 10.1128/JVI.70.11.7445-7453.1996; MEARS WE, 1995, J VIROL, V69, P935, DOI 10.1128/JVI.69.2.935-947.1995; Michael WM, 2000, TRENDS CELL BIOL, V10, P46, DOI 10.1016/S0962-8924(99)01695-5; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MORIUCHI H, 1994, J VIROL, V68, P1987, DOI 10.1128/JVI.68.3.1987-1992.1994; MORIUCHI H, 1993, J VIROL, V67, P4290, DOI 10.1128/JVI.67.7.4290-4295.1993; MORIUCHI H, 1993, J VIROL, V67, P2739, DOI 10.1128/JVI.67.5.2739-2746.1993; MORIUCHI M, 1995, VIROLOGY, V208, P376, DOI 10.1006/viro.1995.1164; NAGPAL S, 1991, J VIROL, V65, P5289, DOI 10.1128/JVI.65.10.5289-5296.1991; NICHOLAS J, 1988, J VIROL, V62, P3250, DOI 10.1128/JVI.62.9.3250-3257.1988; Panagiotidis CA, 1997, J VIROL, V71, P1547, DOI 10.1128/JVI.71.2.1547-1557.1997; PERERA LP, 1994, J VIROL, V68, P2468, DOI 10.1128/JVI.68.4.2468-2477.1994; PERERA LP, 1992, J VIROL, V66, P5298, DOI 10.1128/JVI.66.9.5298-5304.1992; Phelan A, 1998, SEMIN VIROL, V8, P309, DOI 10.1006/smvy.1997.0133; RICE SA, 1988, J VIROL, V62, P3814, DOI 10.1128/JVI.62.10.3814-3823.1988; RICE SA, 1990, J VIROL, V64, P1704, DOI 10.1128/JVI.64.4.1704-1715.1990; RICE SA, 1993, J VIROL, V67, P1778, DOI 10.1128/JVI.67.4.1778-1787.1993; Sandri-Goldin RM, 1998, GENE DEV, V12, P868, DOI 10.1101/gad.12.6.868; SandriGoldin RM, 1996, J VIROL, V70, P108, DOI 10.1128/JVI.70.1.108-118.1996; SEKULOVICH RE, 1988, J VIROL, V62, P4510, DOI 10.1128/JVI.62.12.4510-4522.1988; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SMITH IL, 1991, J VIROL, V65, P3656, DOI 10.1128/JVI.65.7.3656-3666.1991; SMITH RH, 1993, J VIROL, V67, P1105, DOI 10.1128/JVI.67.2.1105-1109.1993; Soliman TM, 2000, J VIROL, V74, P2814, DOI 10.1128/JVI.74.6.2814-2825.2000; Soliman TM, 1997, J VIROL, V71, P9188, DOI 10.1128/JVI.71.12.9188-9197.1997; SU LS, 1989, VIROLOGY, V170, P496, DOI 10.1016/0042-6822(89)90441-8; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Wadd S, 1999, J BIOL CHEM, V274, P28991, DOI 10.1074/jbc.274.41.28991; Zhi Y, 1999, VIROLOGY, V257, P341, DOI 10.1006/viro.1999.9698	55	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32822	32831		10.1074/jbc.M001444200	http://dx.doi.org/10.1074/jbc.M001444200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10889190	Green Submitted, hybrid			2022-12-27	WOS:000090003800062
J	Murakami, M; Naraba, H; Tanioka, T; Semmyo, N; Nakatani, Y; Kojima, F; Ikeda, T; Fueki, M; Ueno, A; Oh-ishi, S; Kudo, I				Murakami, M; Naraba, H; Tanioka, T; Semmyo, N; Nakatani, Y; Kojima, F; Ikeda, T; Fueki, M; Ueno, A; Oh-ishi, S; Kudo, I			Regulation of prostaglandin E-2 biosynthesis by inducible membrane-associated prostaglandin E-2 synthase that acts in concert with cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RAT PERITONEAL-MACROPHAGES; ARACHIDONIC-ACID RELEASE; H SYNTHASE-1; FUNCTIONAL-ASPECTS; MESSENGER-RNA; COLON-CANCER; MAST-CELLS; EXPRESSION	Here we report the molecular identification of membrane-bound glutathione (GSH)-dependent prostaglandin (PG) E-2 synthase (mPGES), a terminal enzyme of the cyclooxygenase (COX)-2-mediated PGE(2) biosynthetic pathway. The activity of mPGES was increased markedly in macrophages and osteoblasts following proinflammatory stimuli. cDNA for mouse and rat mPGESs encoded functional proteins that showed high homology with the human ortholog (microsomal glutathione S-transferase-like 1). mPGES expression was markedly induced by proinflammatory stimuli in various tissues and cells and was down-regulated by dexamethasone, accompanied by changes in COX-2 expression and delayed PGE(2) generation. Arg(110), a residue well conserved in the microsomal GSH S-transferase family, was essential for catalytic function, mPGES was functionally coupled with COX-2 in marked preference to COX-1, particularly when the supply of arachidonic acid was limited. Increased supply of arachidonic acid by explosive activation of cytosolic phospholipase A(2) allowed mPGES to be coupled with COX-1. mPGES colocalized with both COX isozymes in the perinuclear envelope. Moreover, cells stably cotransfected with COX-2 and mPGES grew faster, were highly aggregated, and exhibited aberrant morphology. Thus, COX-2 and mPGES are essential components for delayed PGE(2) biosynthesis, which may be linked to inflammation, fever, osteogenesis, and even cancer.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan; Kitasato Univ, Sch Pharmaceut Sci, Dept Pharmacol, Minato Ku, Tokyo 1080072, Japan	Showa University; Kitasato University	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.							Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Fournier T, 1997, J BIOL CHEM, V272, P31065, DOI 10.1074/jbc.272.49.31065; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Harada Y, 1996, PROSTAG OTH LIPID M, V51, P19, DOI 10.1016/0090-6980(95)00168-9; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Higashi S, 2000, INFLAMM RES, V49, P102, DOI 10.1007/s000110050566; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Lam BK, 1997, J BIOL CHEM, V272, P13923, DOI 10.1074/jbc.272.21.13923; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; LIN LL, 1992, J BIOL CHEM, V267, P23451; MARNETT LJ, 1992, CANCER RES, V52, P5575; Matsumoto H, 1997, BIOCHEM BIOPH RES CO, V230, P110, DOI 10.1006/bbrc.1996.5894; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 1997, J BIOL CHEM, V272, P19891, DOI 10.1074/jbc.272.32.19891; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NAKANO T, 1990, J BIOL CHEM, V265, P12745; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Naraba H, 1998, J IMMUNOL, V160, P2974; Newton R, 1998, J BIOL CHEM, V273, P32312, DOI 10.1074/jbc.273.48.32312; OGOROCHI T, 1987, J NEUROCHEM, V48, P900, DOI 10.1111/j.1471-4159.1987.tb05602.x; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; Raisz L G, 1993, Osteoporos Int, V3 Suppl 1, P136, DOI 10.1007/BF01621888; RAO CV, 1995, CANCER RES, V55, P1464; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; Salinas AE, 1999, CURR MED CHEM, V6, P279; SANO H, 1995, CANCER RES, V55, P3785; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Shitashige M, 1998, BBA-LIPID LIPID MET, V1389, P57, DOI 10.1016/S0005-2760(97)00129-X; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Watanabe K, 1999, BBA-MOL CELL BIOL L, V1439, P406, DOI 10.1016/S1388-1981(99)00084-0; Watanabe K, 1997, BIOCHEM BIOPH RES CO, V235, P148, DOI 10.1006/bbrc.1997.6708; Weinander R, 1997, J BIOL CHEM, V272, P8871; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	55	794	837	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32783	32792		10.1074/jbc.M003505200	http://dx.doi.org/10.1074/jbc.M003505200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10869354	hybrid			2022-12-27	WOS:000090003800057
J	Collazo, R; Fan, LZ; Hu, MC; Zhao, H; Wiederkehr, MR; Moe, OW				Collazo, R; Fan, LZ; Hu, MC; Zhao, H; Wiederkehr, MR; Moe, OW			Acute regulation of Na+/H+ exchanger NHE3 by parathyroid hormone via NHE3 phosphorylation and dynamin-dependent endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL BRUSH-BORDER; PROTEIN-KINASE-A; CAMP-MEDIATED INHIBITION; OPOSSUM KIDNEY-CELLS; PROXIMAL TUBULE CELLS; H+ EXCHANGER; CALCIUM-TRANSPORT; APICAL MEMBRANE; ISOFORM NHE3; BICARBONATE ABSORPTION	Parathyroid hormone (PTH) is a potent inhibitor of mammalian renal proximal tubule Na+ transport via its action on the apical membrane Na+/H+ exchanger NHE3. In the opossum kidney cell line, inhibition of NHE3 activity was detected from 5 to 45 min after PTH addition. Increase in NHE3 phosphorylation on multiple serines was evident after 5 min of PTH, but decrease in surface NHE3 antigen was not detectable until after 30 min of PTH. The decrease in surface NHE3 antigen was due to increased NHE3 endocytosis. When endocytic trafficking was arrested with a dominant negative dynamin mutant (K44A), the early inhibition (5 min) of NHE3 activity by PTH was not affected, whereas the late inhibition (30 min) and decreased surface NHE3 antigen induced by PTH were abrogated. We conclude that PTH acutely inhibits NHE3 activity in a biphasic fashion by NHE3 phosphorylation followed by dynamin-dependent endocytosis.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Vet Affairs Med Ctr, Med Serv, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Moe, OW (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048482, R01DK054396, R29DK048482, T32DK007257] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-48482, DK-54396, T32 DK07257-17] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUS ZS, 1973, AM J PHYSIOL, V224, P1143, DOI 10.1152/ajplegacy.1973.224.5.1143; Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; Azarani A, 1996, J BIOL CHEM, V271, P14931, DOI 10.1074/jbc.271.25.14931; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; BANK N, 1976, J CLIN INVEST, V58, P336, DOI 10.1172/JCI108477; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; Biemesderfer D, 1999, J BIOL CHEM, V274, P17518, DOI 10.1074/jbc.274.25.17518; BIEMESDERFER D, 1997, J AM SOC NEPHROL, V8, P3; BINDELS RJM, 1993, J EXP BIOL, V184, P89; BOURDEAU JE, 1993, SEMIN NEPHROL, V13, P191; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; Cavet ME, 1999, AM J PHYSIOL-CELL PH, V277, pC1111, DOI 10.1152/ajpcell.1999.277.6.C1111; Chow CW, 1999, J BIOL CHEM, V274, P37551, DOI 10.1074/jbc.274.53.37551; Chow CW, 1999, J BIOL CHEM, V274, P10481, DOI 10.1074/jbc.274.15.10481; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; Fan LZ, 1999, J BIOL CHEM, V274, P11289, DOI 10.1074/jbc.274.16.11289; GESEK FA, 1990, AM J PHYSIOL, V258, pF514, DOI 10.1152/ajprenal.1990.258.3.F514; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V416, P615, DOI 10.1007/BF00370605; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V415, P461, DOI 10.1007/BF00373624; HORIE S, 1990, P NATL ACAD SCI USA, V87, P4742, DOI 10.1073/pnas.87.12.4742; IINO Y, 1979, AM J PHYSIOL, V236, pF387, DOI 10.1152/ajprenal.1979.236.4.F387; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; KAHN AM, 1985, AM J PHYSIOL, V248, pF212, DOI 10.1152/ajprenal.1985.248.2.F212; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; LIU FY, 1989, J CLIN INVEST, V84, P83, DOI 10.1172/JCI114174; MARONE CC, 1983, J LAB CLIN MED, V101, P264; MCKINNEY TD, 1980, AM J PHYSIOL, V239, pF127, DOI 10.1152/ajprenal.1980.239.2.F127; MCKINNEY TD, 1980, AM J PHYSIOL, V238, pF166, DOI 10.1152/ajprenal.1980.238.3.F166; MILLER RT, 1987, J BIOL CHEM, V262, P9115; Minkoff C, 1999, CURR OPIN NEPHROL HY, V8, P603, DOI 10.1097/00041552-199909000-00012; Moe OW, 1997, CURR OPIN NEPHROL HY, V6, P440, DOI 10.1097/00041552-199709000-00006; Moe OW, 1999, J AM SOC NEPHROL, V10, P2412; MOE OW, 1991, J CLIN INVEST, V88, P1703, DOI 10.1172/JCI115487; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; MORAN A, 1988, BIOCHIM BIOPHYS ACTA, V969, P48, DOI 10.1016/0167-4889(88)90087-0; MORI Y, 1992, PHARMACOL TOXICOL, V70, P201, DOI 10.1111/j.1600-0773.1992.tb00457.x; MRKIC B, 1992, J MEMBRANE BIOL, V130, P205; MRKIC B, 1993, PFLUG ARCH EUR J PHY, V424, P377, DOI 10.1007/BF00374897; Nath SK, 1999, AM J PHYSIOL-CELL PH, V276, pC873, DOI 10.1152/ajpcell.1999.276.4.C873; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; PASTORIZAMUNOZ E, 1992, J CLIN INVEST, V89, P1485, DOI 10.1172/JCI115739; Peng Y, 1999, AM J PHYSIOL-CELL PH, V276, pC938, DOI 10.1152/ajpcell.1999.276.4.C938; PENG Y, 1999, J AM SOC NEPHROL, V10, P459; POLLOCK AS, 1986, AM J PHYSIOL, V250, pF217, DOI 10.1152/ajprenal.1986.250.2.F217; PRIESIG PA, 1987, J CLIN INVEST, V80, P970; PUSCHETT JB, 1976, KIDNEY INT, V9, P501, DOI 10.1038/ki.1976.64; RESHKIN SJ, 1991, J MEMBRANE BIOL, V124, P227, DOI 10.1007/BF01994356; SASAKI S, 1991, AM J PHYSIOL, V260, pF883; SCHMID SL, 1995, FASEB J, V9, P1445, DOI 10.1096/fasebj.9.14.7589986; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Seldin DW, 1999, NEPHRON, V81, P2, DOI 10.1159/000046292; SUKI WN, 1979, AM J PHYSIOL, V237, pF1, DOI 10.1152/ajprenal.1979.237.1.F1; SUTTON RAL, 1979, KIDNEY INT, V15, P520, DOI 10.1038/ki.1979.67; TALOR Z, 1988, RES COMMUN CHEM PATH, V61, P335; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1995, J BIOL CHEM, V270, P26460, DOI 10.1074/jbc.270.44.26460; WEINMAN EJ, 1987, AM J PHYSIOL, V252, pF19, DOI 10.1152/ajprenal.1987.252.1.F19; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; WEINMAN EJ, 1990, AM J PHYSIOL, V258, pF1254; WEINMAN EJ, 1989, J MEMBRANE BIOL, V109, P233, DOI 10.1007/BF01870280; WEINMAN EJ, 1988, J MEMBRANE BIOL, V101, P11, DOI 10.1007/BF01872815; WEINMAN EJ, 1986, J MEMBRANE BIOL, V93, P133, DOI 10.1007/BF01870805; Wiederkehr MR, 1999, AM J PHYSIOL-CELL PH, V276, pC1205, DOI 10.1152/ajpcell.1999.276.5.C1205; Yip JW, 1997, J BIOL CHEM, V272, P18473, DOI 10.1074/jbc.272.29.18473; Yip KP, 1998, AM J PHYSIOL-RENAL, V275, pF565, DOI 10.1152/ajprenal.1998.275.4.F565; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1; Zhang YB, 1996, AM J PHYSIOL-RENAL, V270, pF1004, DOI 10.1152/ajprenal.1996.270.6.F1004; Zhang YB, 1999, AM J PHYSIOL-RENAL, V276, pF711, DOI 10.1152/ajprenal.1999.276.5.F711; Zhang YB, 1998, AM J PHYSIOL-CELL PH, V274, pC1090, DOI 10.1152/ajpcell.1998.274.4.C1090; Zhang YBB, 1998, J AM SOC NEPHROL, V9, P531; Zhao H, 1999, J BIOL CHEM, V274, P3978, DOI 10.1074/jbc.274.7.3978; Zizak M, 1999, J BIOL CHEM, V274, P24753, DOI 10.1074/jbc.274.35.24753; [No title captured]	86	97	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31601	31608		10.1074/jbc.M000600200	http://dx.doi.org/10.1074/jbc.M000600200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10866993	hybrid			2022-12-27	WOS:000089858900009
J	Machide, M; Kamitori, K; Kohsaka, S				Machide, M; Kamitori, K; Kohsaka, S			Hepatocyte growth factor-induced differential activation of phospholipase C gamma 1 and phosphatidylinositol 3-kinase is regulated by tyrosine phosphatase SHP-1 in astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; C-MET/HGF RECEPTOR; NEUROTROPHIC FACTOR; EPITHELIAL-CELLS; KINASE RECEPTOR; PROTEIN; MET; PHOSPHORYLATION; IDENTIFICATION; SITE	Hepatocyte growth factor (HGF) elicits pleiotropic effects on various types of cells through the c-Met receptor tyrosine kinase. However, the mechanisms underlying the diverse responses of cells remain unknown. We show here that HGF promoted chemokinesis of rat primary astrocytes through the activation of phosphatidylinositol 3 (PI3)-kinase without any influence on mitogenesis of the cells. Under the same condition, phospholipase C gamma 1 (PLC gamma 1), which is another signal mediator of c-Met, was not tyrosine-phosphorylated during HGF stimulation. However, treatment of the cells with orthovanadate, a tyrosine phosphatase inhibitor, restored the HGF-induced tyrosine phosphorylation of PLC gamma 1. A tyrosine phosphatase, SHP-1, was associated with both PIS-kinase and PLC gamma 1 before HGF stimulation, but it was dissociated only from PB-kinase after the stimulation. Furthermore, transfectants of catalytically inactive mutant of SHP-1 showed tyrosine phosphorylation of PLC gamma 1 and mitogenic responses to HGF, and the mitogenic response was blocked with U73122, an inhibitor of phosphatidylinositol-specific PLC, and calphostin C, an inhibitor of protein kinase C downstream of the PLC gamma 1. These results indicate that PLC gamma 1 is selectively prevented from being a signal mediator by constitutive association of SHP-1, and that this selective inhibition of PLC gamma 1 may determine the cellular response of astrocytes to HGF.	Natl Inst Neurosci, Dept Neurochem, Kodaira, Tokyo 1878502, Japan	National Center for Neurology & Psychiatry - Japan	Kohsaka, S (corresponding author), Natl Inst Neurosci, Dept Neurochem, 4-1-1 Ogawa Higashi, Kodaira, Tokyo 1878502, Japan.							BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; BURRIDGE K, 1995, ANAL BIOCHEM, V232, P56, DOI 10.1006/abio.1995.9961; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; Derman MP, 1996, J BIOL CHEM, V271, P4251; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; FIXMAN ED, 1995, ONCOGENE, V10, P237; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; GUAN KL, 1991, J BIOL CHEM, V266, P17026; Hamanoue M, 1996, J NEUROSCI RES, V43, P554, DOI 10.1002/(SICI)1097-4547(19960301)43:5<554::AID-JNR5>3.0.CO;2-H; HONDA S, 1995, MOL BRAIN RES, V32, P197, DOI 10.1016/0169-328X(95)00075-4; Imani F, 1997, J BIOL CHEM, V272, P7927, DOI 10.1074/jbc.272.12.7927; LEE CC, 1995, J BIOL CHEM, V270, P507, DOI 10.1074/jbc.270.2.507; LEE CC, 1994, J BIOL CHEM, V269, P19457; Machide M, 1998, J NEUROCHEM, V71, P592; Maina F, 1999, NAT NEUROSCI, V2, P213, DOI 10.1038/6310; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NALDINI L, 1991, ONCOGENE, V6, P501; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; OKANO Y, 1993, BIOCHEM BIOPH RES CO, V190, P842, DOI 10.1006/bbrc.1993.1125; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; TAKAISHI K, 1994, ONCOGENE, V9, P273; Wang ZX, 1998, MOL CELL BIOL, V18, P590, DOI 10.1128/MCB.18.1.590; Yamada M, 1999, J NEUROCHEM, V73, P41, DOI 10.1046/j.1471-4159.1999.0730041.x; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; YOSHIDA K, 1986, NEUROSCI LETT, V70, P34, DOI 10.1016/0304-3940(86)90433-7; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	36	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31392	31398		10.1074/jbc.M002817200	http://dx.doi.org/10.1074/jbc.M002817200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896658	hybrid			2022-12-27	WOS:000089762700091
J	Born, TL; Smith, DE; Garka, KE; Renshaw, BR; Bertles, JS; Sims, JE				Born, TL; Smith, DE; Garka, KE; Renshaw, BR; Bertles, JS; Sims, JE			Identification and characterization of two members of a novel class of the interleukin-1 receptor (IL-1R) family - Delineation of a new class of IL-1R-related proteins based on signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA TOLL PROTEIN; MAP KINASE KINASE; NF-KAPPA-B; ACCESSORY PROTEIN; MOLECULAR-CLONING; CULTURED-CELLS; HUMAN MYD88; ACTIVATION; GENE; IRAK	Two novel members of the interleukin-1 receptor (IL-1R) family, identified by homology searches of human genomic sequence data bases, are described. The genes have been named according to their structural features: TIGIRR-1 (three immunoglobulin domain-containing IL-1 receptor-related) and TIGIRR-2. TIGIRR-2 has recently been identified as causing mental retardation when mutated (Carrie, A., Jun, L., Bienvenu, T., Vinet, M. C., McDonell, N., Couvert, P., Zemni, R., Cardona, A., Van Buggenhout, G., Frints, S., Hamel, B., Moraine, C., Ropers, H. H., Strom, T., Howell, G. R., Whittaker, A., Boss, M. T., Kahn, A., Fryns, J. P., Beldjord, C., Marynen, P., and Chelly, J. (1999) Nat. Genet. 23, 25-31) and called IL1RAPL, a name we will also use henceforth. Neither receptor alone was able to mediate transcriptional activation of NF-kappa B in response to IL-1 alpha, IL-1 beta, or IL-18. In order to begin to elucidate the function of these and other orphan IL-1R family members, we have developed a functional assay utilizing a panel of chimeric receptors containing the extracellular and transmembrane domains of either type I IL-1R or IL-1R accessory protein (AcP) coupled to the cytoplasmic domains of all family members. Coexpression of each IL-1R chimera with each AcP chimera and an NF-kappa B-responsive reporter demonstrated that the cytoplasmic domains could be classified as IL-1R-like, AcP-like, or neither. Any IL-1R-like cytoplasmic domain could cooperate with any AcP-like cytoplasmic domain. The TIGIRR-1 and IL1RAPL cytoplasmic domains, however, were unable to signal as either IL-1R-like or AcP-like components, suggesting that they function as a new class of receptors within this family.	Immunex Corp, Seattle, WA 98101 USA	Immunex Corporation	Sims, JE (corresponding author), Immunex Corp, 51 Univ St, Seattle, WA 98101 USA.	simsj@immunex.com		Sims, John/0000-0002-5667-9185				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; BIRD TA, 1994, J BIOL CHEM, V269, P31836; BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; Bonnert TP, 1997, FEBS LETT, V402, P81, DOI 10.1016/S0014-5793(96)01506-2; Born TL, 2000, J IMMUNOL, V164, P3246, DOI 10.4049/jimmunol.164.6.3246; Born TL, 1998, J BIOL CHEM, V273, P29445, DOI 10.1074/jbc.273.45.29445; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Carrie A, 1999, NAT GENET, V23, P25, DOI 10.1038/12623; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; Cullinan EB, 1998, J IMMUNOL, V161, P5614; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Hardiman G, 1996, ONCOGENE, V13, P2467; HEGUY A, 1992, J BIOL CHEM, V267, P2605; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Janeway CA, 1999, CURR BIOL, V9, pR879, DOI 10.1016/S0960-9822(00)80073-1; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; LORD KA, 1990, ONCOGENE, V5, P1095; Lovenberg TW, 1996, J NEUROIMMUNOL, V70, P113, DOI 10.1016/S0165-5728(96)00047-1; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; NORRIS JL, 1995, GENE DEV, V9, P358, DOI 10.1101/gad.9.3.358; Orencole S F, 1989, Cytokine, V1, P14, DOI 10.1016/1043-4666(89)91044-2; Parnet P, 1996, J BIOL CHEM, V271, P3967; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Ridley SH, 1997, J IMMUNOL, V158, P3165; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; SIMS JE, 1995, CYTOKINE, V7, P483, DOI 10.1006/cyto.1995.0066; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; Smith DE, 2000, J BIOL CHEM, V275, P1169, DOI 10.1074/jbc.275.2.1169; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Thomas JA, 1999, J IMMUNOL, V163, P978; Thomassen E, 1998, J INTERF CYTOK RES, V18, P1077, DOI 10.1089/jir.1998.18.1077; Thomassen E, 1999, CYTOKINE, V11, P389, DOI 10.1006/cyto.1998.0452; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; Volpe F, 1997, FEBS LETT, V419, P41, DOI 10.1016/S0014-5793(97)01426-9; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Wesche H, 1998, FEBS LETT, V429, P303, DOI 10.1016/S0014-5793(98)00468-2; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U	59	77	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					29946	29954		10.1074/jbc.M004077200	http://dx.doi.org/10.1074/jbc.M004077200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10882729	hybrid			2022-12-27	WOS:000089577900006
J	Olosz, F; Malek, TR				Olosz, F; Malek, TR			Three loops of the common gamma chain ectodomain required for the binding of interleukin-2 and interleukin-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; IL-2 RECEPTOR; ERYTHROPOIETIN RECEPTOR; EPO RECEPTOR; COMPLEX; IDENTIFICATION; AFFINITY; EXPRESSION; GROWTH; MUTAGENESIS	The common gamma chain (gamma c), a subunit of the interleukin (IL)-2, IL-4, IL-7, IL-9, and IL-15 receptors, contributes to both cytokine binding and subsequent signal transduction. Using a model-based site-directed mutagenesis strategy, we have identified residues of the mouse gamma c extracellular domain that are required for normal gamma c-dependent enhancement of IL-2 and IL-7 binding. One of these sites, Tyr-103, is homologous to key ligand-interacting residues in the growth hormone and erythropoietin receptors, whereas Cys-161, Cys-210, and Gly-211 may function indirectly by maintaining the functional conformation of gamma c via formation of an intramolecular disulfide bond. These two cysteines are also required for the integrity of a putative epitope recognized by TUGm2, an antagonistic monoclonal antibody that blocks gamma c-dependent cytokine binding and bioactivity. These results are consistent with the involvement of three predicted loops in gamma c that contribute to the binding of both IL-2 and IL-7. Mutations in these loops have also been noted in the gamma c gene of patients with X-linked severe combined immunodeficiency.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33101 USA	University of Miami	Malek, TR (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, POB 016960 R-138, Miami, FL 33101 USA.				NIAID NIH HHS [AI40114] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI040114, R01AI040114] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALASUBRAMANIAN S, 1995, INT IMMUNOL, V7, P1839, DOI 10.1093/intimm/7.11.1839; BAMBOROUGH P, 1994, STRUCTURE, V2, P839, DOI 10.1016/S0969-2126(94)00085-9; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Chastagner P, 1996, EUR J IMMUNOL, V26, P201, DOI 10.1002/eji.1830260131; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GUSTCHINA A, 1995, PROTEINS, V21, P140, DOI 10.1002/prot.340210208; He YW, 1998, CRIT REV IMMUNOL, V18, P503, DOI 10.1615/CritRevImmunol.v18.i6.20; HE YW, 1995, J IMMUNOL, V154, P1596; Horsten U, 1997, J BIOL CHEM, V272, P23748, DOI 10.1074/jbc.272.38.23748; IMLER JL, 1992, EMBO J, V11, P2047, DOI 10.1002/j.1460-2075.1992.tb05262.x; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; Kroemer RT, 1996, PROTEIN ENG, V9, P1135, DOI 10.1093/protein/9.12.1135; Layton JE, 1997, J BIOL CHEM, V272, P29735, DOI 10.1074/jbc.272.47.29735; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; MALEK TR, 1995, J INTERF CYTOK RES, V15, P447, DOI 10.1089/jir.1995.15.447; MALEK TR, 1983, P NATL ACAD SCI-BIOL, V80, P5694, DOI 10.1073/pnas.80.18.5694; Middleton SA, 1999, J BIOL CHEM, V274, P14163, DOI 10.1074/jbc.274.20.14163; Middleton SA, 1996, J BIOL CHEM, V271, P14045, DOI 10.1074/jbc.271.24.14045; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Puck JM, 1996, IMMUNOL TODAY, V17, P507, DOI 10.1016/0167-5699(96)30062-5; Rajotte D, 1997, J EXP MED, V185, P1939, DOI 10.1084/jem.185.11.1939; Raskin N, 1998, J IMMUNOL, V161, P3474; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SARAGOVI H, 1987, J IMMUNOL, V139, P1918; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; Sugamura K, 1996, ANNU REV IMMUNOL, V14, P179, DOI 10.1146/annurev.immunol.14.1.179; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559	32	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30100	30105		10.1074/jbc.M004976200	http://dx.doi.org/10.1074/jbc.M004976200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10887198	hybrid			2022-12-27	WOS:000089577900027
J	Provost, PR; Tremblay, Y				Provost, PR; Tremblay, Y			Length increase of the human alpha-globin 3 '-untranslated region disrupts stability of the pre-mRNA but not that of the mature mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEIC-ACID LEVELS; RNA 3'-END FORMATION; MESSENGER-RNA; 3-BETA-HYDROXYSTEROID DEHYDROGENASE; GENE-EXPRESSION; TRANSGENIC MICE; SIMIAN VIRUS-40; SITE SELECTION; LAST INTRON; IN-VIVO	Polyadenylation increases the stability of mRNA molecules. By studying the effect of the length of 3'-untranslated region (UTR) on mRNA levels, we have found that alpha-globin pre-mRNA is stabilized by a mechanism that does not modulate the half-life of mature mRNA. The insertion of DNA fragments of various unrelated sequences into the 3'-UTR of the human alpha-globin gene strongly reduces mRNA abundance upon transfection into choriocarcinoma JEG-3 cells. We found an inverse relationship between mRNA levels and the length of the introduced fragments. In fact, mRNA levels as low as 1% were observed after inserting a 477-nucleotide (nt) fragment, whereas inserting a fragment of 86 nt at the same position had no effect on mRNA accumulation. DNA insertion induced no change in transcription rate or in half-life of mature mRNA. Semi-quantitative reverse transcription-polymerase chain reaction revealed that inserting a 477-nt fragment in the 3'-UTR resulted in decreased levels of nuclear pre-mRNA in proportion to that observed for mature mRNA. In contrast, the insertion of the 477-nt exogenous DNA in the last intron had no effect on mRNA levels despite the presence of intronic sequences in the pre-mRNA. This shows that the reduction of pre-mRNA level was not due to the insertion of putative ribonuclease cleavage sites or the insertion of a segment DNA that reduces the elongation efficiency. Taken together, our results strongly support the existence of a pre-mRNA stabilizing mechanism that can be disrupted by increasing the length of the 3'-UTR. The fact that the half-life of mature mRNA is not affected by DNA insertion is compatible with a pre-mRNA-specific stabilizing mechanism that acts specifically before polyadenylation.	CHU Quebec, Lab Ontogeny & Reprod, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Dept Obstet & Gynecol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Tremblay, Y (corresponding author), CHU Laval, Res Ctr, Lab Otogeny & Reprod CRBR, Room T-1-58,2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.	yves.tremblay@crchul.ulaval.ca						AKAHANE K, 1992, BLOOD, V79, P3188; Antoniou M, 1998, NUCLEIC ACIDS RES, V26, P721, DOI 10.1093/nar/26.3.721; ASH J, 1993, MOL CELL BIOL, V13, P1565, DOI 10.1128/MCB.13.3.1565; Beaudoin C, 1997, J ENDOCRINOL, V154, P379, DOI 10.1677/joe.0.1540379; BEAUDOIN C, 1995, ENDOCRINOLOGY, V136, P3807, DOI 10.1210/en.136.9.3807; Beaudoin C, 1997, MOL CELL ENDOCRINOL, V133, P63, DOI 10.1016/S0303-7207(97)00143-3; BIRD AP, 1987, EMBO J, V6, P999, DOI 10.1002/j.1460-2075.1987.tb04851.x; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; CHIOU HC, 1991, J VIROL, V65, P6677, DOI 10.1128/JVI.65.12.6677-6685.1991; ElMeskini R, 1997, ENDOCRINOLOGY, V138, P5256, DOI 10.1210/en.138.12.5256; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GASSER CS, 1982, P NATL ACAD SCI-BIOL, V79, P6522, DOI 10.1073/pnas.79.21.6522; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GRUSS P, 1979, P NATL ACAD SCI USA, V76, P4317, DOI 10.1073/pnas.76.9.4317; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAMER DH, 1979, CELL, V18, P1299, DOI 10.1016/0092-8674(79)90240-X; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LIU XD, 1993, NUCLEIC ACIDS RES, V21, P5256, DOI 10.1093/nar/21.22.5256; Luu The V, 1989, Mol Endocrinol, V3, P1301; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; MILLER JT, 1992, J VIROL, V66, P4242, DOI 10.1128/JVI.66.7.4242-4251.1992; MOORE CL, 1984, CELL, V36, P581, DOI 10.1016/0092-8674(84)90337-4; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; Moore M., 1993, RNA WORLD, P303; NESIC D, 1994, GENE DEV, V8, P363, DOI 10.1101/gad.8.3.363; NESIC D, 1993, MOL CELL BIOL, V13, P3359, DOI 10.1128/MCB.13.6.3359; NEUBERGER MS, 1988, NUCLEIC ACIDS RES, V16, P6713, DOI 10.1093/nar/16.14.6713; NIWA M, 1992, NATURE, V360, P277, DOI 10.1038/360277a0; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PANDEY NB, 1990, NUCLEIC ACIDS RES, V18, P3161, DOI 10.1093/nar/18.11.3161; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RAYMOND V, 1989, ONCOGENE RES, V5, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHATKIN AJ, 1987, BIOESSAYS, V7, P275, DOI 10.1002/bies.950070611; THE VL, 1989, MOL ENDOCRINOL, V3, P1310, DOI 10.1210/mend-3-8-1310; TREMBLAY Y, 1988, P NATL ACAD SCI USA, V85, P8890, DOI 10.1073/pnas.85.23.8890; TREMBLAY Y, 1993, MOL ENDOCRINOL, V7, P355, DOI 10.1210/me.7.3.355; TREMBLAY Y, 1989, J BIOL CHEM, V264, P20458; TREMBLAY Y, 1994, DNA CELL BIOL, V13, P1199, DOI 10.1089/dna.1994.13.1199; VILLARREAL LP, 1983, MOL CELL BIOL, V3, P1381, DOI 10.1128/MCB.3.8.1381; Wahle E, 1997, PROG NUCLEIC ACID RE, V57, P41, DOI 10.1016/S0079-6603(08)60277-9; WASSARMAN KM, 1993, GENE DEV, V7, P647, DOI 10.1101/gad.7.4.647	46	5	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30248	30255		10.1074/jbc.M002969200	http://dx.doi.org/10.1074/jbc.M002969200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10867002	hybrid			2022-12-27	WOS:000089577900047
J	Savage, JR; McLaughlin, JN; Skiba, NP; Hamm, HE; Willardson, BM				Savage, JR; McLaughlin, JN; Skiba, NP; Hamm, HE; Willardson, BM			Functional roles of the two domains of phosducin and phosducin-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCIN BETA-GAMMA; ROD OUTER SEGMENTS; GTPASE-ACTIVATING PROTEINS; SURFACE-PLASMON RESONANCE; HETEROTRIMERIC G-PROTEINS; CRYSTAL-STRUCTURE; RETINAL RODS; BINDING PROTEIN; ALPHA-SUBUNITS; RGS PROTEIN	Phosducin and phosducin-like protein regulate G protein signaling pathways by binding the beta gamma subunit complex (G beta gamma) and blocking G beta gamma association with G alpha subunits, effector enzymes, or membranes. Both proteins are composed of two structurally independent domains, each constituting approximately half of the molecule. We investigated the functional roles of the two domains of phosducin and phosducin-like protein in binding retinal G(t)beta gamma. Kinetic measurements using surface plasmon resonance showed that: 1) phosducin bound G(t)beta gamma with a 2.5-fold greater affinity than phosducin-like protein; 2) phosphorylation of phosducin decreased its affinity by 3-fold, principally as a result of a decrease in k(1); and 3) most of the free energy of binding comes from the N-terminal domain with a lesser contribution from the C-terminal domain. In assays measuring the association of G(t)beta gamma with G(t)alpha and light-activated rhodopsin, both N-terminal domains inhibited binding while neither of the C-terminal domains had any effect. In assays measuring membrane binding of G(t)beta gamma, both the N- and C-terminal domains inhibited membrane association, but much less effectively than the fall-length proteins. This inhibition could only be described by models that included a change in G(t)beta gamma to a conformation that did not bind the membrane. These models yielded a free energy change of +1.5 +/- 0.25 kcal/moI for the transition from the G(t)alpha-binding to the Pd-binding conformation of G(t)beta gamma.	Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA; Northwestern Univ, Sch Med, Inst Neurosci, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA	Brigham Young University; Northwestern University	Willardson, BM (corresponding author), Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA.			Willardson, Barry/0000-0002-8503-2268	NEI NIH HHS [EY06062, EY12287] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012287, R01EY006062] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Bluml K, 1997, EMBO J, V16, P4908, DOI 10.1093/emboj/16.16.4908; BORNANCIN F, 1989, EUR J BIOCHEM, V184, P687, DOI 10.1111/j.1432-1033.1989.tb15068.x; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Chen FY, 1997, BIOCHEM BIOPH RES CO, V233, P370, DOI 10.1006/bbrc.1997.6460; CRAFT CM, 1991, GENOMICS, V10, P400, DOI 10.1016/0888-7543(91)90325-9; Craft CM, 1998, BIOCHEMISTRY-US, V37, P15758, DOI 10.1021/bi980921a; Danner S, 1996, P NATL ACAD SCI USA, V93, P10145, DOI 10.1073/pnas.93.19.10145; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; FUNG BKK, 1983, J BIOL CHEM, V258, P495; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gaudet R, 1999, MOL CELL, V3, P649, DOI 10.1016/S1097-2765(00)80358-5; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HAWES BE, 1994, J BIOL CHEM, V269, P29825; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LIEBMAN PA, 1984, ADV CYCLIC NUCL PROT, V17, P215; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; Morton TA, 1998, METHOD ENZYMOL, V295, P268; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; REIG JA, 1990, J BIOL CHEM, V265, P5816; Schroder S, 1996, P NATL ACAD SCI USA, V93, P2100, DOI 10.1073/pnas.93.5.2100; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Tanaka H, 1997, NEUROCHEM INT, V31, P625, DOI 10.1016/S0197-0186(96)00053-8; Tanaka H, 1996, BIOCHEM BIOPH RES CO, V223, P587, DOI 10.1006/bbrc.1996.0939; Thibault C, 1997, J BIOL CHEM, V272, P12253, DOI 10.1074/jbc.272.19.12253; THULIN CD, 1999, MOL VIS, V5, P40; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wilkins JF, 1996, J BIOL CHEM, V271, P19232, DOI 10.1074/jbc.271.32.19232; Willardson BM, 1996, P NATL ACAD SCI USA, V93, P1475, DOI 10.1073/pnas.93.4.1475; WILLARDSON BM, 1993, J BIOL CHEM, V268, P6371; XU J, 1995, P NATL ACAD SCI USA, V92, P2986; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	43	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30399	30407		10.1074/jbc.M005120200	http://dx.doi.org/10.1074/jbc.M005120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896945	hybrid			2022-12-27	WOS:000089577900066
J	Schafer, BW; Fritschy, JM; Murmann, P; Troxler, H; Durussel, I; Heizmann, CW; Cox, JA				Schafer, BW; Fritschy, JM; Murmann, P; Troxler, H; Durussel, I; Heizmann, CW; Cox, JA			Brain S100A5 is a novel calcium-, zinc-, and copper ion-binding protein of the EF-hand superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-BINDING PROTEINS; SIGNAL-TRANSDUCTION; BOVINE BRAIN; METAL-IONS; FAMILY; CA2+; CALCYCLIN; IDENTIFICATION; LOCALIZATION; PURIFICATION	S100A5 is a novel member of the EF-hand superfamily of calcium-binding proteins that is poorly characterized at the protein level. Immunohistochemical analysis demonstrates that it is expressed in very restricted regions of the adult brain. Here we characterized the human recombinant S100A5, especially its interaction with Ca2+, Zn2+, and Cu2+. Flow dialysis revealed that the homodimeric S100A5 binds four Ca2+ ions with strong positive cooperativity and an affinity 20-100-fold higher than the other S100 proteins studied under identical conditions. S100A5 also binds two Zn2+ ions and four Cu2+ ions per dimer, Cu2+ binding strongly impairs the binding of Ca2+; however, none of these ions change the alpha-helical-rich secondary structure. After covalent labeling of an exposed thiol with 2-(4'-(iodoacetamide) anilino)-naphthalene-6-sulfonic acid, binding of Cu2+, but not of Ca2+ or Zn2+, strongly decreased its fluorescence. In light of the three-dimensional structure of S100 proteins, our data suggest that in each subunit the single Zn2+ site is located at the opposite side of the EF-hands, The two Cu2+-binding sites likely share ligands of the EF-hands. The potential role of S100A5 in copper homeostasis is discussed.	Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland; Univ Zurich, Inst Pharmacol, CH-8057 Zurich, Switzerland; Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland	University of Zurich; University of Zurich; University of Geneva	Heizmann, CW (corresponding author), Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, Steinweisstr 75, CH-8032 Zurich, Switzerland.	heizmann@kispi.unizh.ch		Fritschy, Jean-Marc/0000-0002-8552-3702; Schafer, Beat/0000-0001-5988-2915				Barber KR, 1999, J BIOL CHEM, V274, P1502, DOI 10.1074/jbc.274.3.1502; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; Boni R, 1997, BRIT J DERMATOL, V137, P39, DOI 10.1046/j.1365-2133.1997.17651853.x; Brodersen DE, 1999, BIOCHEMISTRY-US, V38, P1695, DOI 10.1021/bi982483d; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Camby I, 2000, NEUROPATH APPL NEURO, V26, P76, DOI 10.1046/j.1365-2990.2000.00223.x; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; Cox J.A., 1996, GUIDEBOOK CALCIUM BI, P1; Csernoch L, 1998, BIOPHYS J, V75, P957, DOI 10.1016/S0006-3495(98)77584-8; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Drohat AC, 1998, BIOCHEMISTRY-US, V37, P2729, DOI 10.1021/bi972635p; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ENGELKAMP D, 1993, P NATL ACAD SCI USA, V90, P6547, DOI 10.1073/pnas.90.14.6547; FOHR UG, 1995, J BIOL CHEM, V270, P21056, DOI 10.1074/jbc.270.36.21056; Franz C, 1998, J BIOL CHEM, V273, P18826, DOI 10.1074/jbc.273.30.18826; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; Fritz G, 1998, BBA-MOL CELL RES, V1448, P264, DOI 10.1016/S0167-4889(98)00138-4; Gasmi G, 1997, J PEPT RES, V49, P500; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Gribenko AV, 1998, J MOL BIOL, V283, P679, DOI 10.1006/jmbi.1998.2116; Harrison MD, 1999, J BIOL INORG CHEM, V4, P145, DOI 10.1007/s007750050297; Hasler DW, 1998, BIOCHEMISTRY-US, V37, P14966, DOI 10.1021/bi9813734; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; Heizmann CW, 1999, NEUROCHEM RES, V24, P1097, DOI 10.1023/A:1020700117665; Heizmann CW, 1996, MOL CELLS, V6, P629; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Kilby PM, 1996, STRUCTURE, V4, P1041, DOI 10.1016/S0969-2126(96)00111-6; MARTELL AE, 1974, CRITICAL STABILITY C, V1, P3; Matsumura H, 1998, STRUCTURE, V6, P233, DOI 10.1016/S0969-2126(98)00024-0; McRee DE, 1998, NAT STRUCT BIOL, V5, P8, DOI 10.1038/nsb0198-8; Nishikawa T, 1997, J BIOL CHEM, V272, P23037, DOI 10.1074/jbc.272.37.23037; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PEDROCCHI M, 1994, BIOCHEMISTRY-US, V33, P6732, DOI 10.1021/bi00187a045; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; Precheur B, 1996, FEBS LETT, V395, P89, DOI 10.1016/0014-5793(96)01007-1; Prince RC, 1998, TRENDS BIOCHEM SCI, V23, P197, DOI 10.1016/S0968-0004(98)01209-2; Putkey JA, 1997, BIOCHEMISTRY-US, V36, P970, DOI 10.1021/bi9617466; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Sastry M, 1998, STRUCTURE, V6, P223, DOI 10.1016/S0969-2126(98)00023-9; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; SKELTON NJ, 1994, NAT STRUCT BIOL, V1, P239, DOI 10.1038/nsb0494-239; Smith SP, 1998, STRUCTURE, V6, P211, DOI 10.1016/S0969-2126(98)00022-7; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Takizawa T, 1999, J HISTOCHEM CYTOCHEM, V47, P525, DOI 10.1177/002215549904700411; Troxler H, 1999, REV SCI INSTRUM, V70, P2257, DOI 10.1063/1.1149749; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Wicki R, 1996, BIOCHEM BIOPH RES CO, V227, P594, DOI 10.1006/bbrc.1996.1551; Yamashita N, 1999, J COMP NEUROL, V404, P235	53	72	76	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30623	30630		10.1074/jbc.M002260200	http://dx.doi.org/10.1074/jbc.M002260200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10882717	hybrid			2022-12-27	WOS:000089577900097
J	Seo, T; Al-Haideri, M; Treskova, E; Worgall, TS; Kako, Y; Goldberg, IJ; Deckelbaum, RJ				Seo, T; Al-Haideri, M; Treskova, E; Worgall, TS; Kako, Y; Goldberg, IJ; Deckelbaum, RJ			Lipoprotein lipase-mediated selective uptake from low density lipoprotein requires cell surface proteoglycans and is independent of scavenger receptor class B type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; MOUSE ADRENOCORTICAL-CELLS; CHOLESTERYL ESTERS; PLASMA-LIPOPROTEINS; HEPATIC LIPASE; SR-BI; ATHEROSCLEROTIC LESIONS; HUMAN FIBROBLASTS; TRANSGENIC MICE; CULTURED-CELLS	Lipoprotein lipase (LpL) hydrolyzes chylomicron and very low density lipoprotein triglycerides to provide fatty acids to tissues. Aside from its lipolytic activity, LpL promotes lipoprotein uptake by increasing the association of these particles with cell surfaces allowing for the internalization by receptors and proteoglycans. Recent studies also indicate that LpL stimulates selective uptake of lipids from high density lipoprotein (HDL) and very low density Lipoprotein. To study whether LpL can mediate selective uptake of lipids from low density lipoprotein (LDL), LpL was incubated with LDL receptor negative fibroblasts, and the uptake of LDL protein, labeled with I-125 and cholesteryl esters traced with [H-3]cholesteryl oleoyl ether, was compared. LpL mediated greater uptake of [H-3]cholesteryl oleoyl ether than I-125-LDL protein, a result that indicated selective lipid uptake. Lipid enrichment of cells was confirmed by measuring cellular cholesterol mass, LpL-mediated LDL selective uptake was not affected by the LpL inhibitor tetrahydrolipstatin but was nearly abolished by heparin, monoclonal anti-LpL antibodies, or chlorate treatment of cells and was not found using proteoglycan-deficient Chinese hamster ovary cells. Selective uptake from HDL, but not LDL, was 2-3-fold greater in scavenger receptor class B type I overexpressing cells (SR-BI cells) than compared control cells. LpL, however, induced similar increases in selective uptake from LDL and HDL in either control or SR-BI cells, indicative of the SR-BI-independent pathway. This was further supported by ability of LpL to promote selective uptake from LDL in human embryonal kidney 293 cells, cells that do not express SR-BI. In Chinese hamster ovary cell lines that overexpress LpL, we also found that selective uptake from LDL was induced by both endogenous and exogenous LpL. Transgenic mice that overexpress hu man LpL via a muscle creatine kinase promoter had more LDL selective uptake in muscle than did wild type mice. In summary LpL stimulates selective uptake of cholesteryl esters from LDL via pathways that are distinct from SR-BI, Moreover this process also occurs in vivo in tissues where abundant LpL is present.	Columbia Univ, Inst Human Nutr, Dept Pediat, New York, NY 10032 USA; Columbia Univ, Inst Human Nutr, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University	Deckelbaum, RJ (corresponding author), Columbia Univ, Inst Human Nutr, Dept Pediat, 630W 168th St,PH 1512, New York, NY 10032 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040404, R01HL045095, R37HL045095, P50HL056984] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56984, HL40404, HL45095] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Auerbach BJ, 1996, J BIOL CHEM, V271, P1329, DOI 10.1074/jbc.271.3.1329; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; BERRYMAN DE, 1995, J BIOL CHEM, V270, P24525, DOI 10.1074/jbc.270.41.24525; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1976, CELL, V9, P663, DOI 10.1016/0092-8674(76)90130-6; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; Charest MC, 1999, EUR J BIOCHEM, V263, P402, DOI 10.1046/j.1432-1327.1999.00527.x; CORESH J, 1993, J LIPID RES, V34, P1687; DECKELBAUM RJ, 1992, BIOCHEMISTRY-US, V31, P8544, DOI 10.1021/bi00151a023; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; ESKO JD, 1987, J BIOL CHEM, V262, P12189; FernandezBorja M, 1996, J LIPID RES, V37, P464; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Galeano NF, 1998, J LIPID RES, V39, P1263; GLASS C, 1985, J BIOL CHEM, V260, P744; GOLDBERG IJ, 1986, BIOCHIM BIOPHYS ACTA, V878, P168, DOI 10.1016/0005-2760(86)90143-8; Goldberg IJ, 1996, J LIPID RES, V37, P693; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GREEN SR, 1991, J LIPID RES, V32, P667; ISHIKAWA TT, 1974, J LIPID RES, V15, P286; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; Lambert G, 1999, J LIPID RES, V40, P1294; LevakFrank S, 1997, J BIOL CHEM, V272, P17182, DOI 10.1074/jbc.272.27.17182; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; LOOKENE A, 1994, EUR J BIOCHEM, V222, P395, DOI 10.1111/j.1432-1033.1994.tb18878.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUOMA J, 1994, J CLIN INVEST, V93, P2014, DOI 10.1172/JCI117195; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; MISRA KB, 1994, J BIOL CHEM, V269, P23838; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; MULDER M, 1993, J BIOL CHEM, V268, P9369; Obunike JC, 1996, J LIPID RES, V37, P2439; Panzenboeck U, 1997, J LIPID RES, V38, P239; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rinninger F, 1998, J LIPID RES, V39, P1335; RUMSEY SC, 1992, J LIPID RES, V33, P1551; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; RUMSEY SC, 1995, J BIOL CHEM, V270, P10008, DOI 10.1074/jbc.270.17.10008; Santamarina-Fojo Silvia, 1994, Current Opinion in Lipidology, V5, P117; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P895, DOI 10.1161/01.ATV.9.6.895; Sendak RA, 1998, J LIPID RES, V39, P1310; Seo T, 1997, J LIPID RES, V38, P765; SOCORRO L, 1985, J BIOL CHEM, V260, P6324; Swarnakar S, 1998, J BIOL CHEM, V273, P12140, DOI 10.1074/jbc.273.20.12140; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; THOMAS MS, 1983, ANAL BIOCHEM, V130, P215, DOI 10.1016/0003-2697(83)90672-3; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; Zechner R, 1997, CURR OPIN LIPIDOL, V8, P77, DOI 10.1097/00041433-199704000-00005	53	72	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30355	30362		10.1074/jbc.M910327199	http://dx.doi.org/10.1074/jbc.M910327199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896681	hybrid			2022-12-27	WOS:000089577900060
J	de Bruyn, KMT; de Rooij, J; Wolthuis, RMF; Rehmann, H; Wesenbeek, J; Cool, RH; Wittinghofer, AH; Bos, JL				de Bruyn, KMT; de Rooij, J; Wolthuis, RMF; Rehmann, H; Wesenbeek, J; Cool, RH; Wittinghofer, AH; Bos, JL			RalGEF2, a pleckstrin homology domain containing guanine nucleotide exchange factor for Ral	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GDP DISSOCIATION STIMULATOR; C-FOS PROMOTER; PHOSPHOLIPASE-D; PUTATIVE EFFECTOR; SIGNAL-TRANSDUCTION; BINDING PROTEIN-1; GENE-EXPRESSION; IDENTIFICATION; FAMILY	Ral is a ubiquitously expressed Ras-like small GTPase. Several guanine nucleotide exchange factors for Ral have been identified, including members of the RalGDS family, which exhibit a Pas binding domain and are regulated by binding to RasGTP. Here we describe a novel type of RalGEF, RalGEF2. This guanine nucleotide exchange factor has a characteristic Cdc25-like catalytic domain at the N terminus and a pleckstrin homology (PH) domain at the C terminus. RalGEF2 is able to activate Ral both in vivo and in vitro. Deletion of the PH domain results in an increased cytoplasmic localization of the protein and a corresponding reduction in activity in vivo, suggesting that the PH domain functions as a membrane anchor necessary for optimal activity in vivo.	Univ Med Ctr Utrecht, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Med Ctr Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44227 Dortmund, Germany	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Max Planck Society	Bos, JL (corresponding author), Univ Med Ctr Utrecht, Dept Physiol Chem, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.		de rooij, johan/C-1325-2019	Cool, Robbert/0000-0002-9845-2202; Wolthuis, Rob/0000-0002-3109-1588				Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Bauer B, 1999, J BIOL CHEM, V274, P17763, DOI 10.1074/jbc.274.25.17763; Bhullar RP, 1996, BBA-MOL CELL RES, V1311, P181, DOI 10.1016/0167-4889(96)00002-X; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; EMKEY R, 1991, J BIOL CHEM, V266, P9703; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Fruman DA, 1999, CELL, V97, P817, DOI 10.1016/S0092-8674(00)80792-8; Fuller SJ, 1998, BIOCHEM J, V335, P241, DOI 10.1042/bj3350241; Goi T, 1999, MOL CELL BIOL, V19, P1731; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; Hoshinoso M, 1999, J BIOL CHEM, V274, P17837, DOI 10.1074/jbc.274.25.17837; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Liscovitch M, 1999, BBA-MOL CELL BIOL L, V1439, P245, DOI 10.1016/S1388-1981(99)00098-0; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; M'Rabet L, 1999, J BIOL CHEM, V274, P21847, DOI 10.1074/jbc.274.31.21847; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Murai H, 1997, J BIOL CHEM, V272, P10483; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Park SH, 1995, ONCOGENE, V11, P2349; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Verheijen MHG, 1999, ONCOGENE, V18, P4435, DOI 10.1038/sj.onc.1202834; VOB M, 1999, J BIOL CHEM, V274, P34691; Wang KL, 1999, J BIOL CHEM, V274, P14525, DOI 10.1074/jbc.274.21.14525; Wang KL, 1997, J BIOL CHEM, V272, P16002, DOI 10.1074/jbc.272.25.16002; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	56	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29761	29766		10.1074/jbc.M001160200	http://dx.doi.org/10.1074/jbc.M001160200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10889189	hybrid			2022-12-27	WOS:000089439800079
J	Kussel-Andermann, P; El-Amraoui, A; Safieddine, S; Hardelin, JP; Nouaille, S; Camonis, J; Petit, C				Kussel-Andermann, P; El-Amraoui, A; Safieddine, S; Hardelin, JP; Nouaille, S; Camonis, J; Petit, C			Unconventional myosin VIIA is a novel A-kinase-anchoring protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG COCHLEA; OUTER HAIR-CELLS; USHER 1B SYNDROME; RI-ALPHA; PHOTORECEPTOR CELLS; REGULATORY SUBUNITS; SHAKER-1 MUTATIONS; SENSORY EPITHELIA; GENE; DOMAIN	To gain an insight into the cellular function of the unconventional myosin VIIA, we sought proteins interacting with its tail region, using the yeast two-hybrid system. Here we report on one of the five candidate interactors we identified, namely the type I alpha regulatory subunit (RI alpha) of protein kinase A. The interaction of RI alpha with myosin VIIA tail was demonstrated by coimmunoprecipitation from transfected HEK293 cells. Analysis of deleted constructs in the yeast two-hybrid system showed that the interaction of myosin VIIA with RI alpha involves the dimerization domain of RI alpha. In vitro binding assays identified the C-terminal "4.1, ezrin, radixin, moesin" (FERM)-like domain of myosin VIIA as the interacting domain. In humans and mice, mutations in the myosin VIIA gene underlie hereditary hearing loss, which may or may not be associated with visual deficiency, Immunohistofluorescence revealed that myosin VILA and RI alpha are coexpressed in the outer hair cells of the cochlea and rod photoreceptor cells of the retina. Our results strongly suggest that myosin VILA is a novel protein kinase A-anchoring protein that targets protein kinase A to definite subcellular sites of these sensory cells.	CNRS, URA 1968, Unite Genet Deficits Sensoriels, F-75724 Paris 15, France; Inst Curie, INSERM, U248, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Petit, C (corresponding author), CNRS, URA 1968, Unite Genet Deficits Sensoriels, 25 Rue Dr Roux, F-75724 Paris 15, France.	cpetit@pasteur.fr		Safieddine, Saaid/0000-0002-6159-0572; Petit, Christine/0000-0002-9069-002X; EL-AMRAOUI, Aziz/0000-0003-2692-4984				ALGRAIN M, 1993, CURR BIOL, V3, P451, DOI 10.1016/0960-9822(93)90354-Q; Angelo R, 1998, J BIOL CHEM, V273, P14633, DOI 10.1074/jbc.273.23.14633; CARR DW, 1991, J BIOL CHEM, V266, P14188; Chen ZY, 1996, GENOMICS, V36, P440, DOI 10.1006/geno.1996.0489; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; COGHLAN VM, 1993, MOL CELL BIOCHEM, V128, P309, DOI 10.1007/BF01076780; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Dunah AW, 1998, MOL PHARMACOL, V53, P429, DOI 10.1124/mol.53.3.429; ElAmraoui A, 1996, HUM MOL GENET, V5, P1171, DOI 10.1093/hmg/5.8.1171; ELAMRAOUI A, 1997, J AUDIOL MED, V6, P170; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Hasson T, 1997, CELL MOTIL CYTOSKEL, V37, P127, DOI 10.1002/(SICI)1097-0169(1997)37:2<127::AID-CM5>3.0.CO;2-5; HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; Jagger DJ, 1999, PFLUG ARCH EUR J PHY, V437, P409, DOI 10.1007/s004240050795; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; Leon DA, 1997, J BIOL CHEM, V272, P28431, DOI 10.1074/jbc.272.45.28431; Levy G, 1997, HUM MOL GENET, V6, P111, DOI 10.1093/hmg/6.1.111; Liu XR, 1999, J NEUROSCI, V19, P6267; Liu XR, 1997, CELL MOTIL CYTOSKEL, V37, P240, DOI 10.1002/(SICI)1097-0169(1997)37:3<240::AID-CM6>3.3.CO;2-2; Liu XR, 1998, NAT GENET, V19, P117, DOI 10.1038/470; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Mburu Philomena, 1997, Genes and Function, V1, P191; Miki K, 1999, J BIOL CHEM, V274, P29057, DOI 10.1074/jbc.274.41.29057; Oliver TN, 1999, CELL MOL LIFE SCI, V56, P243, DOI 10.1007/s000180050426; Reddy ASN, 1996, J BIOL CHEM, V271, P7052, DOI 10.1074/jbc.271.12.7052; Ricci AJ, 1997, J PHYSIOL-LONDON, V501, P111, DOI 10.1111/j.1469-7793.1997.111bo.x; Richardson GP, 1997, J NEUROSCI, V17, P9506; Sahly I, 1997, ANAT EMBRYOL, V196, P159, DOI 10.1007/s004290050088; Self T, 1998, DEVELOPMENT, V125, P557; Solberg R, 1997, ENDOCRINOLOGY, V138, P169, DOI 10.1210/en.138.1.169; TASKEN K, 1993, J BIOL CHEM, V268, P21276; Titus MA, 1999, CURR BIOL, V9, P1297, DOI 10.1016/S0960-9822(00)80051-2; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Van den Abbeele T, 1999, AM J PHYSIOL-CELL PH, V277, pC913, DOI 10.1152/ajpcell.1999.277.5.C913; VanDenAbbeele T, 1996, J PHYSIOL-LONDON, V494, P77, DOI 10.1113/jphysiol.1996.sp021477; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALTER U, 1984, ADV CYCLIC NUCL PROT, V17, P249; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; Weil D, 1996, P NATL ACAD SCI USA, V93, P3232, DOI 10.1073/pnas.93.8.3232; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Wolbring G, 1996, BIOCHEMISTRY-US, V35, P11013, DOI 10.1021/bi960699e; Wolfrum U, 1998, CELL MOTIL CYTOSKEL, V40, P261, DOI 10.1002/(SICI)1097-0169(1998)40:3<261::AID-CM5>3.3.CO;2-#	53	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29654	29659		10.1074/jbc.M004393200	http://dx.doi.org/10.1074/jbc.M004393200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10889203	hybrid			2022-12-27	WOS:000089439800065
J	Manganas, LN; Trimmer, JS				Manganas, LN; Trimmer, JS			Subunit composition determines Kv1 potassium channel surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNELS; RAT HIPPOCAMPAL-NEURONS; BETA-SUBUNITS; ENDOPLASMIC-RETICULUM; MAMMALIAN BRAIN; ALPHA-SUBUNIT; XENOPUS-OOCYTES; PROTEIN; CELLS; ASSOCIATION	Shaker-related or Kv1 voltage-gated K+ channels play critical roles in regulating the excitability of mammalian neurons. Native Kv1 channel complexes are octamers of four integral membrane alpha subunits and four cytoplasmic beta subunits, such that a tremendous diversity of channel complexes can be assembled from the array of alpha and beta subunits expressed in the brain. However, biochemical and immunohistochemical studies have demonstrated that only certain complexes predominate in the mammalian brain, suggesting that regulatory mechanisms exist that ensure plasma membrane targeting of only physiologically appropriate channel complexes. Here we show that Kv1 channels assembled as homo- or heterotetrameric complexes had distinct surface expression characteristics in both transfected mammalian cells and hippocampal neurons. Homotetrameric Kv1.1 channels were localized to endoplasmic reticulum, Kv1.4 channels to the cell surface, and Kv1.2 channels to both endoplasmic reticulum and the cell surface. Heteromeric assembly with Kv1.4 resulted in dose-dependent increases in cell surface expression of coassembled Kv1.1 and Kv1.2, while coassembly with Kv1.1 had a dominant-negative effect on Kv1.2 and Kv1.4 surface expression. Coassembly with Kv beta subunits promoted cell surface expression of each Kv1 heteromeric complex. These data suggest that subunit composition and stoichiometry determine surface expression characteristics of Kv1 channels in excitable cells.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Trimmer, JS (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS034383, R01NS034383] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM008444] Funding Source: Medline; NINDS NIH HHS [NS34383] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BekeleArcuri Z, 1996, NEUROPHARMACOLOGY, V35, P851, DOI 10.1016/0028-3908(96)00128-1; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; CHANDY KG, 1995, LIGAND VOLTAGE GATED, P1; Coleman SK, 1999, J NEUROCHEM, V73, P849, DOI 10.1046/j.1471-4159.1999.0730849.x; Felix JP, 1999, BIOCHEMISTRY-US, V38, P4922, DOI 10.1021/bi982954w; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; Green WN, 1999, J GEN PHYSIOL, V113, P163, DOI 10.1085/jgp.113.2.163; Hille B., 1992, IONIC CHANNELS EXCIT; HOPKINS WF, 1994, PFLUG ARCH EUR J PHY, V428, P382, DOI 10.1007/BF00724522; HSU VW, 1992, CELL, V69, P625, DOI 10.1016/0092-8674(92)90226-3; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P625; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Koch RO, 1997, J BIOL CHEM, V272, P27577, DOI 10.1074/jbc.272.44.27577; Li DQ, 2000, J BIOL CHEM, V275, P11597, DOI 10.1074/jbc.275.16.11597; Lim ST, 2000, NEURON, V25, P385, DOI 10.1016/S0896-6273(00)80902-2; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Murakoshi H, 1999, J NEUROSCI, V19, P1728; Nagaya N, 1999, RECEPTOR CHANNEL, V6, P229; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PONGS O, 1995, SEMIN NEUROSCI, V7, P137, DOI 10.1006/smns.1995.0015; Pongs O, 1999, FEBS LETT, V452, P31, DOI 10.1016/S0014-5793(99)00535-9; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; Rhodes KJ, 1996, J NEUROSCI, V16, P4846; RHODES KJ, 1995, J NEUROSCI, V15, P5360; Ribera AB, 1996, NEUROPHARMACOLOGY, V35, P1007, DOI 10.1016/0028-3908(96)00098-6; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Schulteis CT, 1998, J BIOL CHEM, V273, P26210, DOI 10.1074/jbc.273.40.26210; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Shi G, 1999, J MEMBRANE BIOL, V168, P265, DOI 10.1007/s002329900515; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; SHI GY, 1994, J BIOL CHEM, V269, P23204; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; Trimmer JS, 1998, CURR OPIN NEUROBIOL, V8, P370, DOI 10.1016/S0959-4388(98)80063-9; Trouet D, 1997, PFLUG ARCH EUR J PHY, V434, P632, DOI 10.1007/s004240050445; Wang FC, 1999, EUR J BIOCHEM, V263, P230, DOI 10.1046/j.1432-1327.1999.00493.x; Warren G, 1999, CELL, V98, P125, DOI 10.1016/S0092-8674(00)81006-5; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	51	144	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29685	29693		10.1074/jbc.M005010200	http://dx.doi.org/10.1074/jbc.M005010200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896669	hybrid			2022-12-27	WOS:000089439800068
J	Paul, MF; Barrientos, A; Tzagoloff, A				Paul, MF; Barrientos, A; Tzagoloff, A			A single amino acid change in subunit 6 of the yeast mitochondrial ATPase suppresses a null mutation in ATP10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE F-0 SECTOR; ESCHERICHIA-COLI; MEMBRANE SYSTEM; SACCHAROMYCES-CEREVISIAE; SEQUENCE-ANALYSIS; GENE; TOPOGRAPHY; IDENTIFICATION; CLEAVAGE; PROTEINS	In an earlier study, the ATP10 gene of Saccharomyces cerevisiae was shown to code for an inner membrane protein required for assembly of the F-0 sector of the mitochondrial ATPase complex (Ackerman, S., and Tzagoloff, A. (1990) J. Biol. Chem. 265, 9952-9959). To gain additional insights into the function of Atp10p, we have analyzed a revertant of an atp10 null mutant that displays partial recovery of oligomycin-sensitive ATPase and of respiratory competence. The suppressor mutation in the revertant has been mapped to the OLI2 locus in mitochondrial DNA and shown to be a single base change in the C-terminal coding region of the gene. The mutation results in the substitution of a valine for an alanine at residue 249 of subunit 6 of the ATPase. The ability of the subunit 6 mutation to compensate for the absence of Atp10p implies a functional interaction between the two proteins. Such an interaction is consistent with evidence indicating that the C-terminal region with the site of the mutation and the extramembrane domain of Atp10p are both on the matrix side of the inner membrane. Subunit 6 has been purified from the parental wild type strain, from the atp10 null mutant, and from the revertant. The N-terminal sequences of the three proteins indicated that they all start at Ser(11), the normal processing site of the subunit 6 precursor. Mass spectral analysis of the wild type and mutants subunit 6 failed to reveal any substantive difference of the wild type and mutant proteins when the mass of the latter was corrected for Ala --> Val mutation. These data argue against a role of Atp10p in post-translational modification of subunit 6. Although post-translational modification of another ATPase subunit interacting with subunit 6 cannot be excluded, a more likely function for Atp10p is that it acts as a subunit 6 chaperone during F-0 assembly.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Tzagoloff, A (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	spud@cubpet.bio.columbia.edu			NHLBI NIH HHS [R01 HL022174, HL 22174] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL022174, R37HL022174, R01HL022174] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; BIZZOZERO O, 1982, J CHROMATOGR, V227, P33, DOI 10.1016/S0378-4347(00)80353-9; DIECKMANN CL, 1984, J BIOL CHEM, V259, P4722; DIECKMANN CL, 1983, METHOD ENZYMOL, V97, P361; Douglas M, 1979, Methods Enzymol, V56, P58; DUJON B, 1980, MOL BIOL YEAST SACCH, P505; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FOURY F, 1976, EUR J BIOCHEM, V68, P113, DOI 10.1111/j.1432-1033.1976.tb10769.x; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACINO G, 1980, CELL, V20, P507, DOI 10.1016/0092-8674(80)90637-6; MAXAM AM, 1980, METHOD ENZYMOL, V65, P49; MICHON T, 1988, EUR J BIOCHEM, V172, P621, DOI 10.1111/j.1432-1033.1988.tb13934.x; MULLER PP, 1984, J MOL BIOL, V175, P431, DOI 10.1016/0022-2836(84)90178-5; NORAIS N, 1991, J BIOL CHEM, V266, P16541; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; Paumard P, 2000, BIOCHEMISTRY-US, V39, P4199, DOI 10.1021/bi992438l; PAYNE MJ, 1991, CURR GENET, V19, P343, DOI 10.1007/BF00309594; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SLONIMSKI PP, 1976, EUR J BIOCHEM, V61, P27, DOI 10.1111/j.1432-1033.1976.tb09994.x; Spannagel C, 1998, BIOCHEMISTRY-US, V37, P615, DOI 10.1021/bi9714971; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1970, J BIOL CHEM, V245, P1545; Tzagoloff A, 1979, Methods Enzymol, V55, P351; TZAGOLOFF A, 1971, J BIOL CHEM, V246, P7328; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; Velours J, 1998, BIOCHIMIE, V80, P793, DOI 10.1016/S0300-9084(00)88873-2; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; Wang ZG, 2000, EMBO J, V19, P1486, DOI 10.1093/emboj/19.7.1486; Wang ZG, 2000, J BIOL CHEM, V275, P5767, DOI 10.1074/jbc.275.8.5767; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1	37	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29238	29243		10.1074/jbc.M004546200	http://dx.doi.org/10.1074/jbc.M004546200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10867012	hybrid			2022-12-27	WOS:000089439800010
J	Sasaki, A; Yasukawa, H; Shouda, T; Kitamura, T; Dikic, I; Yoshimura, A				Sasaki, A; Yasukawa, H; Shouda, T; Kitamura, T; Dikic, I; Yoshimura, A			CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED STAT INHIBITOR; INDUCIBLE SH2 PROTEIN; JANUS TYROSINE KINASE; NEGATIVE REGULATORS; HEMATOPOIETIC-CELLS; TRANSGENIC MICE; CYTOKINE; GENE; ACTIVATION; FAMILY	The cytokine-inducible SH2 protein-3 (CIS3/SOCS-3/SSI-3) has been shown to inhibit the JAK/STAT pathway and act as a negative regulator of fetal liver erythropoiesis. Here, we studied the molecular mechanisms by which CIS3 regulates the erythropoietin (EPO) receptor (EPOR) signaling in erythroid progenitors and Ba/F3 cells expressing the EPOR (BF-ER). CIS3 binds directly to the EPOR as well as JAK2 and inhibits EPO-dependent proliferation and STAT5 activation. We have identified the region containing Tyr(401) in the cytoplasmic domain of the EPOR as a direct binding site for CIS3. Deletion of the Tyr401 legion of the EPOR reduced the inhibitory effect of CIS3, suggesting that binding of CIS3 to the EPOR augmented the negative effect of CIS3. Both N- and C-terminal regions adjacent to the SH2 domain of CIS3 were necessary for binding to EPOR and JAK2. In the N-terminal region of CIS3, the amino acid Gly(45) was critical for binding to the EPOR but not to JAK2, while Leu(22) was critical for binding to JAK2. The mutation of G45A partially reduced ability of CIS3 to inhibit EPO-dependent proliferation and STATE activation, while L22D mutant CIS3 was completely unable to suppress EPOR signaling. Moreover, overexpression of STAT5, which also binds to Tyr401, reduced the binding of CIS3 to the EPOR, and the inhibitory effect of CISB against EPO signaling, while it did not affect JAB/SOCS-1/SSI-1. These data demonstrate that binding of CIS3 to the EPOR augments the inhibitory effect of CIS3. CIS3 binding to both EPOR and JAK2 may explain a specific regulatory role of CIS3 in erythropoiesis.	Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Kurume Univ, Fac Med, Dept Internal Med 3, Kurume, Fukuoka 8300011, Japan; Kurume Univ, Fac Med, Dept Orthoped Surg, Kurume, Fukuoka 8300011, Japan; Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Tokyo 1088639, Japan; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Kurume University; Kurume University; Kurume University; University of Tokyo; Ludwig Institute for Cancer Research	Yoshimura, A (corresponding author), Kurume Univ, Inst Life Sci, Aikawa Machi 2432-3, Kurume, Fukuoka 8390861, Japan.		Yoshimura, Akihiko/K-5515-2013; Dikic, Ivan/O-4650-2015; Kitamura, Toshio/AAA-2071-2021	Dikic, Ivan/0000-0001-8156-9511; Sasaki, Atsuo/0000-0003-2963-4501				Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Alexander WS, 1999, J LEUKOCYTE BIOL, V66, P588, DOI 10.1002/jlb.66.4.588; Aman MJ, 1999, J BIOL CHEM, V274, P30266, DOI 10.1074/jbc.274.42.30266; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; Gisselbrecht S, 1999, EUR CYTOKINE NETW, V10, P463; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Helman D, 1998, FEBS LETT, V441, P287, DOI 10.1016/S0014-5793(98)01555-5; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kovanen PE, 1999, CURR BIOL, V9, pR899, DOI 10.1016/S0960-9822(00)80079-2; Li SC, 1999, CURR BIOL, V9, P1355, DOI 10.1016/S0960-9822(00)80080-9; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Minamoto S, 1997, BIOCHEM BIOPH RES CO, V237, P79, DOI 10.1006/bbrc.1997.7080; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Orkin SH, 1997, ANNU REV GENET, V31, P33, DOI 10.1146/annurev.genet.31.1.33; Orkin SH, 1998, INT J DEV BIOL, V42, P927; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; SPANGLER R, 1992, BLOOD, V79, P52; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Wakioka T, 1999, LEUKEMIA, V13, P760, DOI 10.1038/sj.leu.2401397; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	54	248	265	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29338	29347		10.1074/jbc.M003456200	http://dx.doi.org/10.1074/jbc.M003456200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882725	hybrid			2022-12-27	WOS:000089439800023
J	Jovanovic, T; Ascenso, C; Hazlett, KRO; Sikkink, R; Krebs, C; Litwiller, R; Benson, LM; Moura, I; Moura, JJG; Radolf, JD; Huynh, BH; Naylor, S; Rusnak, F				Jovanovic, T; Ascenso, C; Hazlett, KRO; Sikkink, R; Krebs, C; Litwiller, R; Benson, LM; Moura, I; Moura, JJG; Radolf, JD; Huynh, BH; Naylor, S; Rusnak, F			Neelaredoxin, an iron-binding protein from the syphilis spirochete, Treponema pallidum, is a superoxide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-DESULFURICANS ATCC-27774; COMPLETE GENOME SEQUENCE; CLOSTRIDIUM-PASTEURIANUM RUBREDOXIN; ALKYL-HYDROPEROXIDE REDUCTASE; SEXUALLY-TRANSMITTED DISEASES; PLASMA EMISSION-SPECTROSCOPY; IONIZATION MASS-SPECTROMETRY; AMINO-ACID-SEQUENCE; RBO GENE-PRODUCT; ESCHERICHIA-COLI	Treponema pallidum, the causative agent of venereal syphilis, is a microaerophilic obligate pathogen of humans. As it disseminates hematogenously and invades a wide range of tissues, T. pallidum presumably must tolerate substantial oxidative stress. Analysis of the T. pallidum genome indicates that the syphilis spirochete lacks most of the iron-binding proteins present in many other bacterial pathogens, including the oxidative defense enzymes superoxide dismutase, catalase, and peroxidase, but does possess an orthologue (TP0823) for neelaredoxin, an enzyme of hyperthermophilic and sulfate-reducing anaerobes shown to possess superoxide reductase activity. To analyze the potential role of neelaredoxin in treponemal oxidative defense, we examined the biochemical, spectroscopic, and antioxidant properties of recombinant T, pallidum neelaredoxin. Neelaredoxin was shown to be expressed in T. pallidum by reverse transcriptase-polymerase chain reaction and Western blot analysis. Recombinant neelaredoxin is a 26-kDa alpha(2) homodimer containing, on average, 0.7 iron atoms/subunit. Mossbauer and EPR analysis of the purified protein indicates that the iron atom exists as a mononuclear center in a mixture of high spin ferrous and ferric oxidation states. The fully oxidized form, obtained by the addition of K-3(Fe(CN)(6)), exhibits an optical spectrum with absorbances at 280, 320, and 656 nm; the last feature is responsible for the protein's blue color, which disappears upon ascorbate reduction. The fully oxidized protein has a A(280)/A(656) ratio of 10.3. Enzymatic studies revealed that T. pallidum neelaredoxin is able to catalyze a redox equilibrium between superoxide and hydrogen peroxide, a result consistent with it being a superoxide reductase. This finding, the first description of a T. pallidum iron-binding protein, indicates that the syphilis spirochete copes with oxidative stress via a primitive mechanism, which, thus far, has not been described in pathogenic bacteria.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Hematol Res Sect, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Biomed Mass Spectrometry & Funct Proteom Facil, Rochester, MN 55905 USA; Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, P-2825 Monte De Caparica, Portugal; Univ Nova Lisboa, Fac Ciencias & Tecnol, Ctr Quim Fina & Biotecnol, P-2825 Monte De Caparica, Portugal; Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, Farmington, CT 06030 USA; Emory Univ, Dept Phys, Atlanta, GA 30322 USA	Mayo Clinic; Mayo Clinic; Universidade Nova de Lisboa; Universidade Nova de Lisboa; University of Connecticut; University of Connecticut; Emory University	Rusnak, F (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Hematol Res Sect, 200 1st St SW, Rochester, MN 55905 USA.		Krebs, Carsten/D-4773-2009; Moura, Isabel/D-6339-2013; Moura, José J G/D-6426-2013	Krebs, Carsten/0000-0002-3302-7053; Moura, Isabel/0000-0003-0971-4977; Moura, José J G/0000-0002-4726-2388; Jovanovic-Talisman, Tijana/0000-0003-1928-4763; Ascenso, Carla/0000-0001-5134-7387	NIAID NIH HHS [AI 26756] Funding Source: Medline; NIGMS NIH HHS [GM58778] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI026756, R37AI026756, R01AI026756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058778] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonomi F, 1998, J BIOL INORG CHEM, V3, P595, DOI 10.1007/s007750050272; BRUMLIK MJ, 1990, J BACTERIOL, V172, P7289, DOI 10.1128/jb.172.12.7289-7292.1990; BRUMLIK MJ, 1989, J BACTERIOL, V171, P4996, DOI 10.1128/jb.171.9.4996-5004.1989; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHEN LA, 1994, EUR J BIOCHEM, V226, P613, DOI 10.1111/j.1432-1033.1994.tb20087.x; Coelho AV, 1997, J BIOL INORG CHEM, V2, P680, DOI 10.1007/s007750050184; COVER WH, 1982, SEX TRANSM DIS, V9, P1, DOI 10.1097/00007435-198201000-00001; COX CD, 1983, PATHOGENESIS IMMUNOL, P57; COX DL, 1990, APPL ENVIRON MICROB, V56, P3063, DOI 10.1128/AEM.56.10.3063-3072.1990; Crapo J D, 1978, Methods Enzymol, V53, P382; CZAJA C, 1995, J BIOL CHEM, V270, P20273, DOI 10.1074/jbc.270.35.20273; D'souza VM, 1999, BIOCHEMISTRY-US, V38, P11079, DOI 10.1021/bi990872h; Devreese B, 1996, FEBS LETT, V385, P138, DOI 10.1016/0014-5793(96)00364-X; EIDSNESS MK, 1992, PROTEIN ENG, V5, P367, DOI 10.1093/protein/5.4.367; FASSEL VA, 1978, SCIENCE, V202, P183, DOI 10.1126/science.202.4364.183; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Higuchi M, 1999, J BACTERIOL, V181, P5940, DOI 10.1128/JB.181.19.5940-5947.1999; Jenney FE, 1999, SCIENCE, V286, P306, DOI 10.1126/science.286.5438.306; Johnson KL, 1997, RAPID COMMUN MASS SP, V11, P939, DOI 10.1002/(SICI)1097-0231(199705)11:8<939::AID-RCM936>3.0.CO;2-3; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Liochev SI, 1997, J BIOL CHEM, V272, P25573, DOI 10.1074/jbc.272.41.25573; Lombard M, 2000, J BIOL CHEM, V275, P115, DOI 10.1074/jbc.275.1.115; MOURA I, 1990, J BIOL CHEM, V265, P21596; Nakashima AK, 1996, SEX TRANSM DIS, V23, P16, DOI 10.1097/00007435-199601000-00006; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; NIIMURA Y, 1995, J BIOL CHEM, V270, P25645, DOI 10.1074/jbc.270.43.25645; NIXON DE, 1986, CLIN CHEM, V32, P1660; NORRIS SJ, 1978, INFECT IMMUN, V22, P689, DOI 10.1128/IAI.22.3.689-697.1978; ORVILLE AM, 1992, BIOCHEMISTRY-US, V31, P4602, DOI 10.1021/bi00134a010; PERINE PL, 1994, MED J AUSTRALIA, V160, P358, DOI 10.5694/j.1326-5377.1994.tb138239.x; PETILLOT Y, 1993, BIOCHEM J, V296, P657, DOI 10.1042/bj2960657; Pianzzola MJ, 1996, J BACTERIOL, V178, P6736, DOI 10.1128/jb.178.23.6736-6742.1996; Poole LB, 1996, BIOCHEMISTRY-US, V35, P56, DOI 10.1021/bi951887s; Posey JE, 1999, P NATL ACAD SCI USA, V96, P10887, DOI 10.1073/pnas.96.19.10887; Posey JE, 2000, SCIENCE, V288, P1651, DOI 10.1126/science.288.5471.1651; Radolf JD, 1999, TRENDS MICROBIOL, V7, P7, DOI 10.1016/S0966-842X(98)01422-X; RADOLF JD, 1988, INFECT IMMUN, V56, P490, DOI 10.1128/IAI.56.2.490-498.1988; Romao CV, 1999, EUR J BIOCHEM, V261, P438, DOI 10.1046/j.1432-1327.1999.00278.x; SAWYER DT, 1974, EXPT ELECTROCHEMISTR, P41; SIEKER LC, 1994, METHOD ENZYMOL, V243, P203; Silva G, 1999, EUR J BIOCHEM, V259, P235, DOI 10.1046/j.1432-1327.1999.00025.x; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; STEINER B, 1984, BRIT J VENER DIS, V60, P14; STEINER BM, 1984, CAN J MICROBIOL, V30, P1467, DOI 10.1139/m84-234; TABOR S, 1990, CURRENT PROTOCOLS MO; TAVARES P, 1994, J BIOL CHEM, V269, P10504; TRAMONT EC, 1994, PRINCIPLES PRACTICE, P2117; VALENTINE JS, 1994, BIOINORG CHEM, P253; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; Yeh AP, 2000, BIOCHEMISTRY-US, V39, P2499, DOI 10.1021/bi992428k	51	91	93	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28439	28448		10.1074/jbc.M003314200	http://dx.doi.org/10.1074/jbc.M003314200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10874033	hybrid			2022-12-27	WOS:000089330700016
J	Wang, D; Chiara, DC; Xie, Y; Cohen, JB				Wang, D; Chiara, DC; Xie, Y; Cohen, JB			Probing the structure of the nicotinic acetylcholine receptor with 4-benzoylbenzoylcholine, a novel photoaffinity competitive antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SITES; NONCOMPETITIVE ANTAGONIST; ALPHA-SUBUNIT; AMINO-ACIDS; GAMMA-SUBUNIT; DELTA-SUBUNIT; IDENTIFICATION; RESIDUES; SELECTIVITY; CHANNEL	[H-3]4-Benzoylbenzoylcholine (Bz(2)choline) was synthesized as a photoaffinity probe for the Torpedo nicotinic acetylcholine receptor (nAChR). [H-3]Bz(2)choline acts as an nAChR competitive antagonist and binds at equilibrium with the same affinity (K-D = 1.4 mu M) to both agonist sites. Irradiation at 320 nm of nAChR-rich membranes equilibrated with [H-3]Bz(2)choline results in the covalent incorporation of [H-3]Bz(2)choline into the nAChR gamma- and delta-subunits that is inhibitable by agonist, with little specific incorporation in the alpha-subunits. To identify the sites of photoincorporation, gamma- and delta-subunits, isolated from nAChR-rich membranes photolabeled with [H-3]Bz(2)choline, were digested enzymatically, and the labeled fragments were isolated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and/or reversed-phase high performance liquid chromatography, For the gamma-subunit, Staphylococcus aureus V8 protease produced a specifically labeled peptide beginning at gamma VaI-102, whereas for the delta-subunit, endoproteinase Asp-N produced a labeled peptide beginning at delta Asp-99. Amino-terminal sequence analysis identified the homologous residues gamma Leu-109 and delta Leu-111 as the primary sites of [H-3]Bz(2)choline photoincorporation. This is the first identification by affinity labeling of non-reactive amino acids within the acetylcholine-binding sites, and these results establish that when choline esters of benzoic acid are bound to the nAChR agonist sites, the para substituent is selectively oriented toward and in proximity to amino acids gamma Leu-109/delta Leu-111.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Cohen, JB (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.	jonathan_cohen@hms.harvard.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019522] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 19522] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Arias HR, 2000, NEUROCHEM INT, V36, P595, DOI 10.1016/S0197-0186(99)00154-0; Blanton MP, 1998, J BIOL CHEM, V273, P8659, DOI 10.1074/jbc.273.15.8659; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BOYD ND, 1984, BIOCHEMISTRY-US, V23, P4023, DOI 10.1021/bi00313a003; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; Bren N, 1997, J BIOL CHEM, V272, P30793, DOI 10.1074/jbc.272.49.30793; BROWNING ET, 1972, ANAL BIOCHEM, V46, P624, DOI 10.1016/0003-2697(72)90334-X; Chiara DC, 1999, BIOCHEMISTRY-US, V38, P6689, DOI 10.1021/bi9901735; Chiara DC, 1998, FEBS LETT, V423, P223, DOI 10.1016/S0014-5793(98)00093-3; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; COHEN JB, 1991, J BIOL CHEM, V266, P23354; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; CZAJKOWSKI C, 1995, J BIOL CHEM, V270, P3160, DOI 10.1074/jbc.270.7.3160; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; FU DX, 1994, J BIOL CHEM, V269, P26152; Gallagher MJ, 1999, MOL PHARMACOL, V56, P300, DOI 10.1124/mol.56.2.300; GALZI JL, 1991, P NATL ACAD SCI USA, V88, P5051, DOI 10.1073/pnas.88.11.5051; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GAO ZH, 1995, J BIOL CHEM, V270, P10125, DOI 10.1074/jbc.270.17.10125; KAO PN, 1984, J BIOL CHEM, V259, P1662; KOTZYBAHIBERT F, 1995, ANGEW CHEM INT EDIT, V34, P1296, DOI 10.1002/anie.199512961; LORING RH, 1993, METHODS NEUROSCI, V12, P324; MAHMOOD R, 1987, J BIOL CHEM, V262, P14479; Middleton RE, 1999, MOL PHARMACOL, V56, P290, DOI 10.1124/mol.56.2.290; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; Osaka H, 1999, J BIOL CHEM, V274, P9581, DOI 10.1074/jbc.274.14.9581; PEDERSEN SE, 1992, J BIOL CHEM, V267, P10489; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; Prestwich GD, 1997, PHOTOCHEM PHOTOBIOL, V65, P222, DOI 10.1111/j.1751-1097.1997.tb08548.x; PRINCE RJ, 1998, NICOTINIC ACETYLCHOL, P31; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; TETAZ T, 1990, BIOCHEM INT, V22, P561; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; WEILAND G, 1979, MOL PHARMACOL, V15, P197; WHITE BH, 1988, BIOCHEMISTRY-US, V27, P8741, DOI 10.1021/bi00424a009; WHITE BH, 1991, J BIOL CHEM, V266, P21595; WHITE BH, 1992, J BIOL CHEM, V267, P15770	46	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28666	28674		10.1074/jbc.M005441200	http://dx.doi.org/10.1074/jbc.M005441200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893246	hybrid			2022-12-27	WOS:000089330700045
J	Woo, PL; Cercek, A; Desprez, PY; Firestone, GL				Woo, PL; Cercek, A; Desprez, PY; Firestone, GL			Involvement of the helix-loop-helix protein Id-1 in the glucocorticoid regulation of tight junctions in mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-ALPHA; DOMINANT-NEGATIVE REGULATOR; TUMOR-CELLS; ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3-KINASE; ADIPOCYTE DIFFERENTIATION; DNA-BINDING; EXPRESSION; SUPPRESSION; CADHERIN	Mammary epithelial cell-cell junctions undergo morphological and structural differentiation during pregnancy and lactation, but little is known about the transcriptional regulators that are involved in this process. In Con8 mammary epithelial tumor cells, we have previously documented that the synthetic glucocorticoid, dexamethasone, induces the reorganization of the tight junction and adherens junction and stimulates the monolayer transepithelial electrical resistance (TER), a reliable in vitro measurement of tight junction sealing. Western blots demonstrated that dexamethasone treatment rapidly and strongly stimulated the level of the Id-1 protein, which is a serum-inducible helix-loop-helix transcriptional repressor. The steroid induction of Id-1 was robust by 4 h of treatment and maintained over a 24-h period. Isopropyl-1-thio-beta-D-galactopyranoside-inducible expression of exogenous Id-1 in Con8 cells was shown to strongly facilitate the dexamethasone induction of TER in the absence of serum without altering the dexamethasone-dependent reorganization of ZO-1, beta-catenin, or F-actin. Ectopic overexpression of Id-1 in the SCp2 nontumorigenic mammary epithelial cells, which does not undergo complete dexamethasone-dependent tight junction reorganization, enhanced the dexamethasone-induced ZO-1 tight junction localization and stimulated the monolayer TER. Moreover, antisense reduction of Id-1 protein in SCp2 cells prevented the apical junction reorganization and dexamethasone-stimulated TER. Our results implicate Id-1 as acting as a critical regulator of mammary epithelial cell-cell interactions at an early step in the glucocorticoid-dependent signaling pathway that controls tight junction integrity.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA; Calif Pacific Med Ctr, Geraldine Brush Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; California Pacific Medical Center	Firestone, GL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 591 LSA, Berkeley, CA 94720 USA.	glfire@uclink4.berkeley.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042799, R56DK042799] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09041] Funding Source: Medline; NIDDK NIH HHS [DK-42799] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER DB, 1993, CANCER RES, V53, P1808; Baonza A, 1999, MECH DEVELOP, V80, P133, DOI 10.1016/S0925-4773(98)00198-1; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; BUSE P, 1995, J BIOL CHEM, V270, P6505, DOI 10.1074/jbc.270.12.6505; BUSE P, 1995, J BIOL CHEM, V270, P28223; Chen HP, 1999, BIOCHEM BIOPH RES CO, V256, P614, DOI 10.1006/bbrc.1999.0386; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Cooper CL, 1997, BLOOD, V89, P3155, DOI 10.1182/blood.V89.9.3155; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; DEED RW, 1993, ONCOGENE, V8, P599; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; EINARSON MB, 1995, MOL CELL BIOL, V15, P4175; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GOYA L, 1993, CANCER RES, V53, P1816; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HARA E, 1994, J BIOL CHEM, V269, P2139; Ishiguro A, 1995, LEUKEMIA RES, V19, P989, DOI 10.1016/0145-2126(95)00084-4; Ishiguro A, 1996, BLOOD, V87, P5225, DOI 10.1182/blood.V87.12.5225.bloodjournal87125225; Israel MA, 1999, CANCER RES, V59, p1726S; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Matter K, 1999, INT REV CYTOL, V186, P117; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Moldes M, 1997, MOL CELL BIOL, V17, P1796, DOI 10.1128/MCB.17.4.1796; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Morita K, 1999, J CELL BIOL, V145, P579, DOI 10.1083/jcb.145.3.579; Nguyen DAD, 1998, J MAMMARY GLAND BIOL, V3, P233, DOI 10.1023/A:1018707309361; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Rescan PY, 1997, EUR J BIOCHEM, V247, P870, DOI 10.1111/j.1432-1033.1997.00870.x; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Sablitzky F, 1998, CELL GROWTH DIFFER, V9, P1015; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sawai S, 1997, MECH DEVELOP, V65, P175, DOI 10.1016/S0925-4773(97)00071-3; SINGER KL, 1994, J BIOL CHEM, V269, P16108; Spath GF, 1998, J CELL BIOL, V140, P935, DOI 10.1083/jcb.140.4.935; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Swisshelm K, 1999, GENE, V226, P285, DOI 10.1016/S0378-1119(98)00553-8; Takahisa M, 1996, GENE DEV, V10, P1783, DOI 10.1101/gad.10.14.1783; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; WEBSTER MK, 1990, J BIOL CHEM, V265, P4831; Wice BM, 1998, J BIOL CHEM, V273, P25310, DOI 10.1074/jbc.273.39.25310; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; WILSON R, 1995, MECH DEVELOP, V49, P211, DOI 10.1016/0925-4773(94)00319-I; Wong V, 1999, J BIOL CHEM, V274, P5443, DOI 10.1074/jbc.274.9.5443; Woo PL, 1999, J BIOL CHEM, V274, P32818, DOI 10.1074/jbc.274.46.32818; Woo PL, 1996, J BIOL CHEM, V271, P404, DOI 10.1074/jbc.271.1.404; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; Xu YR, 1997, J BIOL CHEM, V272, P13463, DOI 10.1074/jbc.272.21.13463; ZETTL KS, 1992, P NATL ACAD SCI USA, V89, P9069, DOI 10.1073/pnas.89.19.9069; ZHU WJ, 1995, MOL BRAIN RES, V30, P312, DOI 10.1016/0169-328X(95)00017-M	73	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28649	28658		10.1074/jbc.M910373199	http://dx.doi.org/10.1074/jbc.M910373199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878025	hybrid			2022-12-27	WOS:000089330700043
J	Kunz, WS; Kudin, A; Vielhaber, S; Elger, CE; Attardi, G; Villani, G				Kunz, WS; Kudin, A; Vielhaber, S; Elger, CE; Attardi, G; Villani, G			Flux control of cytochrome c oxidase in human skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL DISEASES; IN-VIVO; ENCEPHALOMYOPATHIES; RESPIRATION; INHIBITOR; PHENOTYPE; MUTATION; GENOTYPE; FIBERS; CELL	In the present work, by titrating cytochrome c oxidase (COX) with the specific inhibitor KCN, the flux control coefficient and the metabolic reserve capacity of COX have been determined in human saponin-permeabilized muscle fibers. In the presence of the substrates glutamate and malate, a 2.3 +/- 0.2-fold excess capacity of COX was observed in ADP-stimulated human skeletal muscle fibers. This value was found to be dependent on the mitochondrial substrate supply. In the combined presence of glutamate, malate, and succinate, which supported an approximately 1.4-fold higher rate of respiration, only a 1.4 +/- 0.2-fold excess capacity of COX was determined, In agreement with these findings, the flux control of COX increased, in the presence of the three substrates, from 0.27 +/- 0.03 to 0.36 +/- 0.08. These results indicate a tight in vivo control of respiration by COX in human skeletal muscle. This tight control may have significant implications for mitochondrial myopathies, In support of this conclusion, the analysis of skeletal muscle fibers from two patients with chronic progressive external ophthalmoplegia, which carried deletions in 11 and 49% of their mitochondrial DNA, revealed a substantially lowered reserve capacity and increased flux control coefficient of COX, indicating severe rate limitations of oxidative phosphorylation by this enzyme.	Univ Bonn, Med Ctr, Dept Epileptol, D-53105 Bonn, Germany; Univ Magdeburg, Med Ctr, Dept Neurol 2, D-39120 Magdeburg, Germany; CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Bari, Dept Med Biochem & Biol, I-70124 Bari, Italy	University of Bonn; Otto von Guericke University; California Institute of Technology; Universita degli Studi di Bari Aldo Moro	Kunz, WS (corresponding author), Univ Bonn, Med Ctr, Dept Epileptol, Sigmund Freud Str 25, D-53105 Bonn, Germany.		Kunz, Wolfram/K-1232-2019	Kunz, Wolfram/0000-0003-1113-3493				Arnold S, 1997, EUR J BIOCHEM, V249, P350, DOI 10.1111/j.1432-1033.1997.t01-1-00350.x; Balaban RS, 1996, ANAL BIOCHEM, V237, P274, DOI 10.1006/abio.1996.0239; Bruno C, 1999, AM J HUM GENET, V65, P611, DOI 10.1086/302546; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; GELLERICH FN, 1990, FEBS LETT, V274, P167, DOI 10.1016/0014-5793(90)81355-R; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HEINRICH R, 1974, EUR J BIOCHEM, V42, P97, DOI 10.1111/j.1432-1033.1974.tb03319.x; KACSER H, 1973, RATE CONTROL BIOL PR, P65; Kadenbach B, 1999, FEBS LETT, V447, P131, DOI 10.1016/S0014-5793(99)00229-X; Kuznetsov AV, 1996, J BIOL CHEM, V271, P283, DOI 10.1074/jbc.271.1.283; Kuznetsov AV, 1997, BBA-MOL BASIS DIS, V1360, P142, DOI 10.1016/S0925-4439(96)00072-5; Kuznetsov AV, 1998, J CELL BIOL, V140, P1091, DOI 10.1083/jcb.140.5.1091; LETELLIER T, 1994, BIOCHEM J, V302, P171, DOI 10.1042/bj3020171; Mootha VK, 1997, AM J PHYSIOL-HEART C, V272, pH769, DOI 10.1152/ajpheart.1997.272.2.H769; Morgan-Hughes JA, 1999, BBA-BIOENERGETICS, V1410, P125, DOI 10.1016/S0005-2728(98)00162-5; Reipert S, 1999, EXP CELL RES, V252, P479, DOI 10.1006/excr.1999.4626; Rossignol R, 1999, J BIOL CHEM, V274, P33426, DOI 10.1074/jbc.274.47.33426; Rossignol R, 2000, BIOCHEM J, V347, P45, DOI 10.1042/0264-6021:3470045; Saks VA, 1998, MOL CELL BIOCHEM, V184, P81, DOI 10.1023/A:1006834912257; Schroder R, 2000, J NEUROPATH EXP NEUR, V59, P353, DOI 10.1093/jnen/59.5.353; SCHWERZMANN K, 1989, P NATL ACAD SCI USA, V86, P1583, DOI 10.1073/pnas.86.5.1583; TAYLOR RW, 1994, J BIOL CHEM, V269, P3523; Tracey I, 1997, MUSCLE NERVE, V20, P1352; Vielhaber S, 2000, BRAIN, V123, P1339, DOI 10.1093/brain/123.7.1339; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; VILLANI G, 2000, IN PRESS FREE RADIC; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1993, TRENDS GENET, V9, P128, DOI 10.1016/0168-9525(93)90207-X; Wiedemann FR, 1998, FEBS LETT, V422, P33, DOI 10.1016/S0014-5793(97)01586-X; Wiedemann FR, 2000, ANAL BIOCHEM, V279, P55, DOI 10.1006/abio.1999.4434	30	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27741	27745						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869362				2022-12-27	WOS:000089197100031
J	VanDuijn, MM; Tijssen, K; VanSteveninck, J; Van den Broek, PJA; Van der Zee, J				VanDuijn, MM; Tijssen, K; VanSteveninck, J; Van den Broek, PJA; Van der Zee, J			Erythrocytes reduce extracellular ascorbate free radicals using intracellular ascorbate as an electron donor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMAFFIN GRANULE MEMBRANE; DEHYDROASCORBIC ACID; VITAMIN-C; THIOREDOXIN REDUCTASE; PLASMA-MEMBRANE; HUMAN NEUTROPHILS; ALPHA-TOCOPHEROL; TRANSPORT; NADH; FERRICYANIDE	Ascorbate is readily oxidized in aqueous solution by ascorbate oxidase. Ascorbate radicals are formed, which disproportionate to ascorbate and dehydroascorbic acid. Addition of erythrocytes with increasing intracellular ascorbate concentrations decreased the oxidation of ascorbate in a concentration-dependent manner. Concurrently, it was found, utilizing electron spin resonance spectroscopy, that extracellular ascorbate radical levels were decreased. Control experiments showed that these results could not be explained by leakage of ascorbate from the cells, inactivation of ascorbate oxidase, or oxygen depletion. Thus, this means that intracellular ascorbate is directly responsible for the decreased oxidation of extracellular ascorbate. Exposure of ascorbate-loaded erythrocytes to higher levels of extracellular ascorbate radicals resulted in the detection of intracellular ascorbate radicals. Moreover, efflux of dehydroascorbic acid was observed under these conditions. These data confirm the view that intracellular ascorbate donates electrons to extracellular ascorbate free radical via a plasma membrane redox system. Such a redox system enables the cells to effectively counteract oxidative processes and thereby prevent depletion of extracellular ascorbate.	Leiden Univ, Med Ctr, Sylvius Lab, Dept Mol Cell Biol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Van den Broek, PJA (corresponding author), Leiden Univ, Med Ctr, Sylvius Lab, Dept Mol Cell Biol, POB 9503, NL-2300 RA Leiden, Netherlands.			van Duijn, Martijn/0000-0002-6654-994X				ALVAREZ J, 1986, BIOCHIM BIOPHYS ACTA, V856, P408, DOI 10.1016/0005-2736(86)90055-6; BIANCHI J, 1986, TOXICOLOGY, V40, P75, DOI 10.1016/0300-483X(86)90047-8; BLOCK G, 1991, AM J CLIN NUTR, V54, pS1310, DOI 10.1093/ajcn/54.6.1310s; BODE AM, 1990, CLIN CHEM, V36, P1807; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; DILIBERTO EJ, 1982, J NEUROCHEM, V39, P563, DOI 10.1111/j.1471-4159.1982.tb03982.x; EVANS RM, 1982, BRIT J NUTR, V47, P473, DOI 10.1079/BJN19820059; GERSHOFF SN, 1993, NUTR REV, V51, P313, DOI 10.1111/j.1753-4887.1993.tb03757.x; GOLDENBERG H, 1994, J BIOENERG BIOMEMBR, V26, P359, DOI 10.1007/BF00762776; GOLDENBERG H, 1983, BIOCHEM INT, V6, P1; Himmelreich U, 1998, BIOCHEMISTRY-US, V37, P7578, DOI 10.1021/bi970765s; Jung CH, 1998, ARCH BIOCHEM BIOPHYS, V355, P9, DOI 10.1006/abbi.1998.0713; May JM, 1999, BBA-BIOMEMBRANES, V1421, P19, DOI 10.1016/S0005-2736(99)00107-8; May JM, 1998, J BIOL CHEM, V273, P23039, DOI 10.1074/jbc.273.36.23039; May JM, 1999, FASEB J, V13, P995, DOI 10.1096/fasebj.13.9.995; May JM, 1997, J BIOL CHEM, V272, P22607, DOI 10.1074/jbc.272.36.22607; May JM, 2000, BIOCHEM BIOPH RES CO, V267, P118, DOI 10.1006/bbrc.1999.1906; May JM, 1996, FREE RADICAL BIO MED, V20, P543, DOI 10.1016/0891-5849(95)02130-2; MAY JM, 1995, BBA-BIOMEMBRANES, V1238, P127, DOI 10.1016/0005-2736(95)00120-R; May JM, 1998, ARCH BIOCHEM BIOPHYS, V349, P281, DOI 10.1006/abbi.1997.0473; MAY JM, 1995, BIOCHEMISTRY-US, V34, P12721, DOI 10.1021/bi00039a031; MEHLHORN RJ, 1991, J BIOL CHEM, V266, P2724; Mendiratta S, 1998, FREE RADICAL BIO MED, V25, P221, DOI 10.1016/S0891-5849(98)00060-4; MOMSEN G, 1981, ARCH BIOCHEM BIOPHYS, V210, P160, DOI 10.1016/0003-9861(81)90176-4; ORRINGER EP, 1979, J CLIN INVEST, V63, P53, DOI 10.1172/JCI109277; PADH H, 1990, BIOCHEM CELL BIOL, V68, P1166, DOI 10.1139/o90-173; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; PENCE LA, 1979, TOXICOL APPL PHARM, V50, P57, DOI 10.1016/0041-008X(79)90492-7; PRUSS RM, 1987, NEUROSCIENCE, V22, P149, DOI 10.1016/0306-4522(87)90205-3; ROSE RC, 1993, FASEB J, V7, P1135, DOI 10.1096/fasebj.7.12.8375611; ROSE RC, 1992, LIFE SCI, V50, P1543, DOI 10.1016/0024-3205(92)90145-F; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Schweinzer E, 1996, CELL BIOCHEM FUNCT, V14, P27, DOI 10.1002/(SICI)1099-0844(199603)14:1<27::AID-CBF635>3.3.CO;2-P; SRIVASTAVA M, 1984, J BIOL CHEM, V259, P8072; ULRICH EL, 1985, BIOCHEMISTRY-US, V24, P2501, DOI 10.1021/bi00331a016; Van Duijn MM, 1998, J BIOL CHEM, V273, P13415, DOI 10.1074/jbc.273.22.13415; Van Duijn MM, 1998, PROTOPLASMA, V205, P122, DOI 10.1007/BF01279302; VERA JC, 1995, J BIOL CHEM, V270, P23706, DOI 10.1074/jbc.270.40.23706; VILLALBA JM, 1993, J BIOENERG BIOMEMBR, V25, P411, DOI 10.1007/BF00762467; WAGNER TC, 1994, ANAL BIOCHEM, V222, P417, DOI 10.1006/abio.1994.1511; WAKEFIELD LM, 1986, J BIOL CHEM, V261, P9746; WAKEFIELD LM, 1986, J BIOL CHEM, V261, P9739; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; YAMAZAKI I, 1961, BIOCHIM BIOPHYS ACTA, V50, P62, DOI 10.1016/0006-3002(61)91060-5	44	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27720	27725						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10871632				2022-12-27	WOS:000089197100028
J	Chiravuri, M; Lee, H; Mathieu, SL; Huber, BT				Chiravuri, M; Lee, H; Mathieu, SL; Huber, BT			Homodimerization via a leucine zipper motif is required for enzymatic activity of quiescent cell proline dipeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSINASE-C; COILED-COIL; ACTIVATION; CLEAVAGE; DOMAIN; DIMERIZATION; HYDROXYLASE; CHEMOKINE; PROTEASE; PATHWAY	Quiescent cell proline dipeptidase (QPP) is an intracellular serine protease that is also secreted upon cellular activation. This enzyme cleaves N-terminal Xaa-Pro dipeptides from proteins, an unusual substrate specificity shared with dipeptidyl peptidase IV (CD26/DPPIV), QPP is a 58-kDa protein that elutes as a 120-130-kDa species from gel filtration, indicating that it forms a homodimer, We analyzed this dimerization with in vivo co-immunoprecipitation assays. The amino acid sequence of QPP revealed a putative leucine zipper motif, and mutational analyses indicated that this leucine zipper is required for homodimerization. The leucine zipper mutants showed a complete lack of enzymatic activity, suggesting that homodimerization is important for QPP function. On the other hand, an enzyme active site mutant retained its ability to homodimerize. These data are the first to demonstrate a role for a leucine zipper motif in a proteolytic enzyme and suggest that leucine zipper motifs play a role in mediating dimerization of a diverse array of proteins.	Tufts Univ, Sch Med, Dept Pathol, Program Immunol, Boston, MA 02111 USA	Tufts University	Huber, BT (corresponding author), Tufts Univ, Sch Med, Dept Pathol, Program Immunol, 136 Harrison Ave, Boston, MA 02111 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043469, R01AI036696] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43469, AI36696] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chiravuri M, 1999, J IMMUNOL, V163, P3092; Fan H, 1997, EUR J BIOCHEM, V246, P243, DOI 10.1111/j.1432-1033.1997.00243.x; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; Hufton SE, 1998, BBA-PROTEIN STRUCT M, V1382, P295, DOI 10.1016/S0167-4838(97)00171-4; INOUE H, 1991, J BIOL CHEM, V266, P11896; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Morimoto C, 1998, IMMUNOL REV, V161, P55, DOI 10.1111/j.1600-065X.1998.tb01571.x; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; Proost P, 1999, J BIOL CHEM, V274, P3988, DOI 10.1074/jbc.274.7.3988; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Skidgel RA, 1998, IMMUNOL REV, V161, P129, DOI 10.1111/j.1600-065X.1998.tb01577.x; TAN FL, 1993, J BIOL CHEM, V268, P16631; Underwood R, 1999, J BIOL CHEM, V274, P34053, DOI 10.1074/jbc.274.48.34053; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; von Bonin A, 1998, IMMUNOL REV, V161, P43; VRANA KE, 1994, J NEUROCHEM, V63, P2014; Watson B, 1997, GENOMICS, V44, P365, DOI 10.1006/geno.1997.4883	23	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26994	26999						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10867015				2022-12-27	WOS:000089144800044
J	Garcia-Gras, EA; Chi, P; Thompson, EA				Garcia-Gras, EA; Chi, P; Thompson, EA			Glucocorticoid-mediated destabilization of cyclin D3 mRNA involves RNA-protein interactions in the 3 '-untranslated region of the mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; GAP-43 MESSENGER-RNA; C-PROTEINS; POLYPYRIMIDINE TRACT; GENE-EXPRESSION; BINDING-PROTEIN; RICH SEQUENCES; LYMPHOID-CELLS; ELEMENT; PURIFICATION	Glucocorticoids regulate the expression of the G(1) progression factor, cyclin D3, Cyclin D3 messenger RNA (CcnDS mRNA) stability decreases rapidly when murine T lymphoma cells are treated with the synthetic glucocorticoid dexamethasone. Basal stability of CcnDS mRNA is regulated by sequences within the 3'-untranslated region (3'-UTR), RNA-protein interactions occurring within the CcnD3 3'-UTR have been analyzed by RNA electrophoretic mobility shift assay, Three sites of RNA-protein interaction have been mapped using this approach, These elements include three pyrimidine-rich domains of 25, 26, and 37 nucleotides. When the cyclin D3 3'-UTR was stably overexpressed, the endogenous CcnD3 mRNA was no longer regulated by dexamethasone, Likewise, overexpression of a 215-nucleotide transgene that contains the 26- and 37-nucleotide elements blocks glucocorticoid inhibition of CcnD3 mRNA expression. These observations suggest that the 215-nucleotide 3'-UTR element may act as a molecular decoy, competing for proteins that bind to the endogenous transcript and thereby attenuating glucocorticoid responsiveness. W-cross-linking experiments showed that two proteins of approximate molecular weight 37,000 and 52,000 bind to this 3'-UTR element.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Thompson, EA (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.							AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BOTHWELL ALM, 1991, J BIOL CHEM, V266, P24657; CHANG KH, 1993, J VIROL, V67, P6716, DOI 10.1128/JVI.67.11.6716-6725.1993; CHANGNOVICH D, 1996, J BIOL CHEM, V271, P33580; CHANGNOVICH D, 1996, J BIOL CELL, V271, P33587; Cohen J J, 1992, Semin Immunol, V4, P363; CzyzykKrzeska MF, 1996, J BIOL CHEM, V271, P3293, DOI 10.1074/jbc.271.6.3293; DOMPENCIEL RE, 1995, J BIOL CHEM, V270, P6108, DOI 10.1074/jbc.270.11.6108; FORSTHOEFEL AM, 1987, MOL ENDOCRINOL, V1, P899, DOI 10.1210/mend-1-12-899; GADSON P, 1993, BIOCHIM BIOPHYS ACTA, V1173, P22, DOI 10.1016/0167-4781(93)90238-9; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HOLCOMB ER, 1984, J BIOL CHEM, V259, P31; HONORE B, 1995, J BIOL CHEM, V270, P28780; Irwin N, 1997, NUCLEIC ACIDS RES, V25, P1281, DOI 10.1093/nar/25.6.1281; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; Kohn DT, 1996, MOL BRAIN RES, V36, P240, DOI 10.1016/0169-328X(95)00239-O; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PETERSEN DD, 1989, P NATL ACAD SCI USA, V86, P7800, DOI 10.1073/pnas.86.20.7800; REISMAN D, 1995, MOL ENDOCRINOL, V9, P1500, DOI 10.1210/me.9.11.1500; RHEE K, 1995, CANCER RES, V55, P4188; Sakai K, 1999, FEBS LETT, V446, P157, DOI 10.1016/S0014-5793(99)00206-9; SCHWARTZMAN RA, 1994, INT ARCH ALLERGY IMM, V105, P347, DOI 10.1159/000236781; Sun XL, 1996, J BIOL CHEM, V271, P25539; Wang XM, 1996, EMBO J, V15, P5040, DOI 10.1002/j.1460-2075.1996.tb00884.x; Wang ZF, 1996, GENE DEV, V10, P3028, DOI 10.1101/gad.10.23.3028; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796; ZAIDI SHE, 1995, J BIOL CHEM, V270, P17292, DOI 10.1074/jbc.270.29.17292	35	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22001	22008		10.1074/jbc.M001048200	http://dx.doi.org/10.1074/jbc.M001048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10896950	hybrid			2022-12-27	WOS:000088363800036
J	Smith, E; Redman, RA; Logg, CR; Coetzee, GA; Kasahara, N; Frenkel, B				Smith, E; Redman, RA; Logg, CR; Coetzee, GA; Kasahara, N; Frenkel, B			Glucocorticoids inhibit developmental stage-specific osteoblast cell cycle - Dissociation of cyclin A-cyclin-dependent kinase 2 from E2F4-p130 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOMA-CELLS; GROWTH-FACTOR-I; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; GENE-EXPRESSION; MESSENGER-RNA; BONE-CELLS; C-MYC; SUBCELLULAR-LOCALIZATION; INDUCED OSTEOPOROSIS	Unique cell cycle control is instituted in confluent osteoblast cultures, driving growth to high density. The postconfluent dividing cells share features with cells that normally exit the cell cycle; p27(kip1) is increased, p21(waf1/cip1) is decreased, free E2F DNA binding activity is reduced, and E2F4 is primarily nuclear. E2F4-p130 becomes the predominant E2F-pocket complex formed on E2F sites, but, unlike the complex that typifies resting cells, cyclin A and CDK2 are also present. Administration of dexamethasone at this, but not earlier stages, results in reduction of cyclin A and CDK2 levels with a parallel decrease in the associated kinase activity, dissociation of cyclin A-CDK2 from the E2F4-p130 complexes, and inhibition of G(1)/S transition. The glucocorticoid-mediated cell cycle attenuation is also accompanied by, but not attributable to, increased p27(kip1) and decreased p21(waf1/cip1) levels. The attenuation of osteoblast growth to high density by dexamethasone is associated with severe impairment of mineralized extracellular matrix formation, unless treatment commences in cultures that have already grown to high density. Both the antimitotic and the antiphenotypic effects are reversible, and both are antagonized by RU486. Thus, glucocorticoids induce premature attenuation of the osteoblast cell cycle, possibly contributing to the osteoporosis induced by these drugs in vivo.	Univ So Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Norris Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Orthopaed Surg, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Urol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Frenkel, B (corresponding author), Univ So Calif, Keck Sch Med, Inst Med Genet, 2250 Alcazar St,CSC-IGM240, Los Angeles, CA 90033 USA.		Coetzee, Gerhard/AAG-8439-2019; coetzee, Gerhard/AAT-6203-2020	Coetzee, Gerhard/0000-0001-8820-8364; Kasahara, Noriyuki/0000-0002-6069-9082	NATIONAL CANCER INSTITUTE [T32CA009659] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 09659] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; CANALIS E, 1983, ENDOCRINOLOGY, V112, P931, DOI 10.1210/endo-112-3-931; Cha HH, 1998, J BIOL CHEM, V273, P1998, DOI 10.1074/jbc.273.4.1998; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Chen TL, 1999, CALCIFIED TISSUE INT, V64, P304, DOI 10.1007/s002239900624; CHEN TL, 1983, ENDOCRINOLOGY, V112, P1739, DOI 10.1210/endo-112-5-1739; CHEN TL, 1977, ENDOCRINOLOGY, V100, P619, DOI 10.1210/endo-100-3-619; Cheng SL, 1996, J CELL BIOCHEM, V61, P182, DOI 10.1002/(SICI)1097-4644(19960501)61:2<182::AID-JCB3>3.0.CO;2-Q; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHOE J, 1978, J STEROID BIOCHEM, V9, P265, DOI 10.1016/0022-4731(78)90160-7; Choi JY, 1996, J CELL BIOCHEM, V61, P609, DOI 10.1002/(SICI)1097-4644(19960616)61:4<609::AID-JCB15>3.3.CO;2-Q; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Corroyer S, 1997, ENDOCRINOLOGY, V138, P3677, DOI 10.1210/en.138.9.3677; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DELANY AM, 1995, J CELL BIOCHEM, V57, P488, DOI 10.1002/jcb.240570314; DELANY AM, 1995, ENDOCRINOLOGY, V136, P4776, DOI 10.1210/en.136.11.4776; Dempster DW, 1997, J ENDOCRINOL, V154, P397, DOI 10.1677/joe.0.1540397; EASTMANREKS SB, 1986, CANCER RES, V46, P2457; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORSTHOEFEL AM, 1987, MOL ENDOCRINOL, V1, P899, DOI 10.1210/mend-1-12-899; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Ishida Y, 1998, J BONE MINER RES, V13, P1822, DOI 10.1359/jbmr.1998.13.12.1822; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lian JB, 1997, ENDOCRINOLOGY, V138, P2117, DOI 10.1210/en.138.5.2117; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; LUKERT B, 1997, OSTEOPOROSIS, P801; Lukert Barbara P., 1996, P533; Maiyar AC, 1997, MOL ENDOCRINOL, V11, P312, DOI 10.1210/me.11.3.312; Manolagas SC, 1999, J BONE MINER RES, V14, P1061, DOI 10.1359/jbmr.1999.14.7.1061; MCCARTHY TL, 1990, ENDOCRINOLOGY, V126, P1569, DOI 10.1210/endo-126-3-1569; Meagher LC, 1996, J IMMUNOL, V156, P4422; MIESFELD RL, 1997, INHALED GLUCOCORTICO, P3; Miyoshi H, 1997, LEUKEMIA RES, V21, P45, DOI 10.1016/S0145-2126(96)00089-6; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1992, ONCOGENE, V7, P1681; POCKWINSE SM, 1995, EXP CELL RES, V216, P244, DOI 10.1006/excr.1995.1031; REISMAN D, 1995, MOL ENDOCRINOL, V9, P1500, DOI 10.1210/me.9.11.1500; RHEE K, 1995, CANCER RES, V55, P4188; RHEE K, 1995, CELL GROWTH DIFFER, V6, P691; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; Rogatsky I, 1999, MOL CELL BIOL, V19, P5036; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411; Sharrock WJ, 1998, J BONE MINER RES, V13, P537, DOI 10.1359/jbmr.1998.13.4.537; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; Smith E, 1997, J CELL BIOCHEM, V66, P141, DOI 10.1002/(SICI)1097-4644(19970801)66:2<141::AID-JCB2>3.0.CO;2-Q; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; STEFFEN M, 1988, CANCER RES, V48, P7212; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Swolin D, 1996, J ENDOCRINOL, V149, P397, DOI 10.1677/joe.0.1490397; TCHEKNEVA E, 1994, J IMMUNOL, V152, P5912; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; WONG GL, 1979, J BIOL CHEM, V254, P6337; Yamasaki L, 1998, Results Probl Cell Differ, V22, P199; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11086, DOI 10.1073/pnas.92.24.11086; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	67	89	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19992	20001		10.1074/jbc.M001758200	http://dx.doi.org/10.1074/jbc.M001758200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867026	hybrid			2022-12-27	WOS:000087941300077
J	Kumar, S; Kalsi, J; Ravirajan, CT; Rahman, A; Athwal, D; Latchman, DS; Isenberg, DA; Pearl, LH				Kumar, S; Kalsi, J; Ravirajan, CT; Rahman, A; Athwal, D; Latchman, DS; Isenberg, DA; Pearl, LH			Molecular cloning and expression of the fabs of human autoantibodies in Escherichia coli - Determination of the heavy or light chain contribution to the anti-DNA/-cardiolipin activity of the Fab	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; V-LAMBDA REPERTOIRE; MONOCLONAL-ANTIBODY; BINDING; SPECIFICITY; NEPHRITIS; CDR3; REACTIVITY; DIVERSITY; PROFILES	The Fabs of three human autoantibodies (B3/33H11, anti-DNA; UK4, anti-phospholipid) and six related hybrids have been cloned, expressed in Escherichia coli, and purified to homogeneity, SDS-polyacrylamide gel electrophoresis and Western blot analysis of the recombinant Feb demonstrated the purified Fab to be of correct size and in assembled form. Protein expression levels of up to 5-9 mg per liter of culture were achievable. A sensitive and reliable comparative anti-DNA enzyme-linked immunosorbent assay, involving a defined biotinylated 35-mer oligonucleotide in its single- or double-stranded form, is also described. Crithidia assay and anti-DNA or anti-cardiolipin antibody enzyme-linked immunosorbent assay analyses demonstrated convincing binding of the recombinant Fab proteins to DNA/cardiolipin, confirming the expression of functional molecule. The comparative DNA/cardiolipin binding analyses of the nine Fabs revealed that the anti-DNA (light, B3/33H11) or anti-cardiolipin (heavy, UK4) activity lies predominantly on one of the two chains. However, a compatible partner chain is necessary for optimum antigen binding activity of the antibody.	UCL, Ctr Rheumatol, Bloomsbury Rheumatol Unit, London W1P 9PG, England; UCL, Dept Med, London W1P 9PG, England; UCL, Dept Biochem & Mol Biol, London W1P 9PG, England; Celltech Ltd, Therapeut, Slough SL1 4EN, Berks, England; Inst Child Hlth, London WC1N 1EH, England	University of London; University College London; University of London; University College London; University of London; University College London; Celltech Group Ltd; University of London; University College London	Kumar, S (corresponding author), Inst Canc Res, Chester Beatty Labs, 237 Fulham Rd, London SW3 6JB, England.	sanjeev@icr.ac.uk		Isenberg, David/0000-0001-9514-2455; Pearl, Laurence/0000-0002-6910-1809				BENCHETRIT E, 1988, IMMUNOLOGY, V65, P479; BOLLAG DM, 1991, PROTEIN METHODS, P46; BRINKMAN K, 1990, IMMUNOL TODAY, V11, P232, DOI 10.1016/0167-5699(90)90095-Q; de Wildt RMT, 1999, J MOL BIOL, V285, P895, DOI 10.1006/jmbi.1998.2396; EHRENSTEIN M, 1993, CLIN EXP IMMUNOL, V92, P39; EHRENSTEIN MR, 1995, KIDNEY INT, V48, P705, DOI 10.1038/ki.1995.341; EHRENSTEIN MR, 1994, J CLIN INVEST, V93, P1787, DOI 10.1172/JCI117164; Greagg MA, 1999, P NATL ACAD SCI USA, V96, P9045, DOI 10.1073/pnas.96.16.9045; HIETER PA, 1981, NATURE, V294, P536, DOI 10.1038/294536a0; IBRAHIM SM, 1995, J IMMUNOL, V155, P3223; Ignatovich O, 1997, J MOL BIOL, V268, P69, DOI 10.1006/jmbi.1997.0956; Isenberg D. A., 1998, OXFORD TXB RHEUMATOL, P1145; ISENBERG DA, 1987, ANN RHEUM DIS, V46, P448, DOI 10.1136/ard.46.6.448; Isenberg DA, 1997, BRIT J RHEUMATOL, V36, P229; Kalsi JK, 1996, MOL IMMUNOL, V33, P471, DOI 10.1016/0161-5890(95)00138-7; Kalsi JK, 1997, LUPUS, V6, P317, DOI 10.1177/096120339700600321; Katsube Y, 1998, INT J MOL MED, V1, P863; KIEBEREMMONS T, 1994, IMMUNOL RES, V13, P172, DOI 10.1007/BF02918278; KUMAR S, 1992, INT J PARASITOL, V22, P563, DOI 10.1016/0020-7519(92)90003-4; LACOUR M, 1991, EUR J IMMUNOL, V21, P839, DOI 10.1002/eji.1830210347; LEPAGE SH, 1989, CLIN EXP IMMUNOL, V77, P314; Marion TN, 1997, METHODS, V11, P3, DOI 10.1006/meth.1996.0381; Menon S, 1997, J AUTOIMMUN, V10, P43, DOI 10.1006/jaut.1996.0106; Mockridge CI, 1996, J IMMUNOL, V157, P2449; MORROW J, 1999, AUTOIMMUNE RHEUMATIC, P216; NISSONOFF A, 1975, ANTIBODY MOL, P299; OKAMURA M, 1993, ANN RHEUM DIS, V52, P14, DOI 10.1136/ard.52.1.14; Panayotou G, 1998, J BIOL CHEM, V273, P45, DOI 10.1074/jbc.273.1.45; PewznerJung Y, 1996, J IMMUNOL, V156, P3065; POLYMENIS M, 1994, J IMMUNOL, V152, P5318; PRODROMOU C, 1992, PROTEIN ENG, V5, P827, DOI 10.1093/protein/5.8.827; RADIC MZ, 1991, J IMMUNOL, V146, P176; RADIC MZ, 1993, J IMMUNOL, V150, P4966; Ravirajan CT, 1998, EUR J IMMUNOL, V28, P339, DOI 10.1002/(SICI)1521-4141(199801)28:01<339::AID-IMMU339>3.0.CO;2-C; RAVIRAJAN CT, 1992, LUPUS, V1, P157, DOI 10.1177/096120339200100307; RETTER MW, 1995, J IMMUNOL, V155, P2248; Roben P, 1996, J CLIN INVEST, V98, P2827, DOI 10.1172/JCI119111; SCHONER BE, 1984, P NATL ACAD SCI-BIOL, V81, P5403, DOI 10.1073/pnas.81.17.5403; SINGH AK, 1994, AUTOIMMUNITY, V18, P65, DOI 10.3109/08916939409014681; Stellar BD, 1997, METHODS, V11, P12, DOI 10.1006/meth.1996.0382; SWAAK AJG, 1979, ARTHRITIS RHEUM, V22, P226, DOI 10.1002/art.1780220304; Tomlinson IM, 1996, V BASE SEQUENCE DIRE; Williams SC, 1996, J MOL BIOL, V264, P220, DOI 10.1006/jmbi.1996.0636; WINKLER TH, 1991, CLIN EXP IMMUNOL, V85, P379; Wloch MK, 1997, J IMMUNOL, V159, P6083; YARRANTON GT, 1992, PROTEIN ENG PRACTICA, P302; ZOUALI M, 1986, J IMMUNOL METHODS, V90, P105, DOI 10.1016/0022-1759(86)90390-X	47	18	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35129	35136		10.1074/jbc.M001976200	http://dx.doi.org/10.1074/jbc.M001976200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10893224	hybrid			2022-12-27	WOS:000165422800042
J	Komine, M; Rao, LMS; Kaneko, T; Tomic-Canic, M; Tamaki, K; Freedberg, IM; Blumenberg, M				Komine, M; Rao, LMS; Kaneko, T; Tomic-Canic, M; Tamaki, K; Freedberg, IM; Blumenberg, M			Inflammatory versus proliferative processes in epidermis - Tumor necrosis factor alpha induces K6b keratin synthesis through a transcriptional complex containing NF kappa B and C/EBP ss	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNERGISTICALLY ACTIVATE TRANSCRIPTION; GROWTH-FACTOR-ALPHA; NUCLEAR-FACTOR; TNF RECEPTOR; HUMAN SKIN; NUDE-MICE; PACHYONYCHIA-CONGENITA; ICAM-1 EXPRESSION; PSORIATIC SKIN; FAMILY MEMBERS	Epidermal keratinocytes respond to injury by becoming activated, i.e. hyperproliferative, migratory, and proinflammatory. These processes are regulated by growth factors and cytokines. One of the markers of activated keratinocytes is keratin K6. We used a novel organ culture system to show that tumor necrosis factor alpha (TNF alpha) induces the expression of K6 protein and mRNA in human skin. Multiple isoforms of K6 are encoded by distinct genes and have distinct patterns of expression. By having shown previously that proliferative signals, such as epidermal growth factor (EGF), induce expression of the cytoskeletal protein keratin K6b, we here demonstrate that the same isoform, K6b, is also induced by TNF alpha, a proinflammatory cytokine. Specifically, TNF alpha induces the transcription of the K6b gene promoter. By using co-transfection, specific inhibitors, and antisense oligonucleotides, we have identified NF kappa B and C/EBP beta as the transcription factors that convey the TNFa! signal. Both transcription factors are necessary for the induction of K6b by TNFa and act as a complex, although only C/EBP beta binds the K6b promoter DNA. By using transfection, site-directed mutagenesis, and footprinting, we have mapped the site that responds to TNF alpha, NF kappa B, and C/EBP beta. This site is separate from the one responsive to EGF and AP1. Our results show that the proinflammatory (TNF alpha) and the proliferative (EGF) signals in epidermis separately and independently regulate the expression of the same K6b keratin isoform. Thus, the cytoskeletal responses in epidermal cells can be precisely tuned by separate proliferative and inflammatory signals to fit the nature of the injuries that caused them.	NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA; NYU, Med Ctr, Ronald O Perelman Dept Dermatol, New York, NY 10016 USA; NYU, Med Ctr, Dept Cell Biol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Comprehens Canc, New York, NY 10016 USA; Univ Tokyo, Fac Med, Dept Dermatol, Bunkyo Ku, Tokyo 113, Japan	New York University; New York University; New York University; New York University; University of Tokyo	Blumenberg, M (corresponding author), NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA.			Komine, Mayumi/0000-0002-1086-1803; Blumenberg, Miroslav/0000-0002-8672-7774	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041850, R01AR040522, R01AR030682] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR30682, AR41850, AR40522] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BARKER JNWN, 1991, LANCET, V337, P211, DOI 10.1016/0140-6736(91)92168-2; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bernerd Francoise, 1993, Gene Expression, V3, P187; BHORA FY, 1995, J SURG RES, V59, P236, DOI 10.1006/jsre.1995.1160; BOWDEN PE, 1995, NAT GENET, V10, P363, DOI 10.1038/ng0795-363; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; DICKINSON AM, 1994, BONE MARROW TRANSPL, V13, P65; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Gilhar A, 1996, CLIN EXP IMMUNOL, V106, P134, DOI 10.1046/j.1365-2249.1996.d01-802.x; GRIFFITHS CEM, 1989, J AM ACAD DERMATOL, V20, P617, DOI 10.1016/S0190-9622(89)70073-6; HSU W, 1993, MOL CELL BIOL, V13, P2515, DOI 10.1128/MCB.13.4.2515; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; JIANG CK, 1994, MOL CELL BIOL, V14, P4759, DOI 10.1128/MCB.14.7.4759; JIANG CK, 1991, J INVEST DERMATOL, V97, P969, DOI 10.1111/1523-1747.ep12491889; JIANG CK, 1993, P NATL ACAD SCI USA, V90, P6786, DOI 10.1073/pnas.90.14.6786; KATARANOVSKI M, 1999, ACTA DERM-VENEREOL, V8, P131; KLAMPFER L, 1994, MOL CELL BIOL, V14, P6561, DOI 10.1128/MCB.14.10.6561; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Komine M, 1996, J INVEST DERMATOL, V107, P569, DOI 10.1111/1523-1747.ep12582820; Kondo S, 1997, EUR J IMMUNOL, V27, P1713, DOI 10.1002/eji.1830270718; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KRISTENSEN M, 1993, CLIN EXP IMMUNOL, V94, P354; KUNSCH C, 1994, J IMMUNOL, V153, P153; KUPPER TS, 1995, J INVEST DERMATOL, V105, P62; KUTSCH CL, 1993, J INVEST DERMATOL, V101, P79, DOI 10.1111/1523-1747.ep12360119; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Ma SH, 1997, GENE EXPRESSION, V6, P361; Magae J, 1997, ONCOGENE, V15, P759, DOI 10.1038/sj.onc.1201251; Maniatis T., 1989, MOL CLONING LAB MANU; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; Matsumoto K, 1997, EXP DERMATOL, V6, P13, DOI 10.1111/j.1600-0625.1997.tb00140.x; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; MIDDLETON MH, 1995, J INVEST DERMATOL, V104, P489, DOI 10.1111/1523-1747.ep12605923; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MUTASIM DF, 1993, J INVEST DERMATOL, V101, P624, DOI 10.1111/1523-1747.ep12366084; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Natesan S, 1997, NATURE, V390, P349, DOI 10.1038/37019; NAVARRO JM, 1995, J BIOL CHEM, V270, P21362, DOI 10.1074/jbc.270.36.21362; NESTLE FO, 1994, J INVEST DERMATOL, V103, P569, DOI 10.1111/1523-1747.ep12396876; NICKOLOFF BJ, 1993, AM J PATHOL, V143, P325; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; NOVAK TJ, 1990, MOL CELL BIOL, V10, P6325, DOI 10.1128/MCB.10.12.6325; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; OXHOLM A, 1988, BRIT J DERMATOL, V118, P369, DOI 10.1111/j.1365-2133.1988.tb02430.x; PILLAI S, 1989, J CLIN INVEST, V83, P816, DOI 10.1172/JCI113963; Qin JZ, 1999, J BIOL CHEM, V274, P37957, DOI 10.1074/jbc.274.53.37957; RANDOLPH RK, 1993, J BIOL CHEM, V268, P9198; RAY A, 1995, DNA CELL BIOL, V14, P795, DOI 10.1089/dna.1995.14.795; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; REUNING U, 1995, NUCLEIC ACIDS RES, V23, P3887, DOI 10.1093/nar/23.19.3887; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Rothnagel JA, 1999, DIFFERENTIATION, V65, P119, DOI 10.1046/j.1432-0436.1999.6520119.x; SCHERMER A, 1989, DIFFERENTIATION, V42, P103, DOI 10.1111/j.1432-0436.1989.tb00611.x; Schweizer Juergen, 1993, P33; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; SELLS SF, 1995, MOL CELL BIOL, V15, P682; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; Smith FJD, 1998, HUM MOL GENET, V7, P1143, DOI 10.1093/hmg/7.7.1143; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Takahashi K, 1998, GENOMICS, V53, P170, DOI 10.1006/geno.1998.5476; Takahashi K, 1997, J BIOL CHEM, V272, P11979, DOI 10.1074/jbc.272.18.11979; TAKAHASHI K, 1995, J BIOL CHEM, V270, P18581, DOI 10.1074/jbc.270.31.18581; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TOMIC M, 1990, NUCLEIC ACIDS RES, V18, P1656, DOI 10.1093/nar/18.6.1656; Tomic-Canic M, 1998, J DERMATOL SCI, V17, P167, DOI 10.1016/S0923-1811(98)00016-4; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TREFZER U, 1991, J INVEST DERMATOL, V97, P911, DOI 10.1111/1523-1747.ep12491668; VALYINAGY I, 1992, J INVEST DERMATOL, V99, P350, DOI 10.1111/1523-1747.ep12616672; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; WETZELS RHW, 1991, AM J PATHOL, V138, P751; White PJ, 1999, J INVEST DERMATOL, V112, P887, DOI 10.1046/j.1523-1747.1999.00593.x; Wojcik SM, 1999, DIFFERENTIATION, V65, P97, DOI 10.1046/j.1432-0436.1999.6520097.x; WOODWORTH CD, 1995, P NATL ACAD SCI USA, V92, P2840, DOI 10.1073/pnas.92.7.2840; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	89	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32077	32088		10.1074/jbc.M001253200	http://dx.doi.org/10.1074/jbc.M001253200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10887174	hybrid			2022-12-27	WOS:000089858900073
J	Kirk, RI; Sanderson, MR; Lerea, KM				Kirk, RI; Sanderson, MR; Lerea, KM			Threonine phosphorylation of the beta(3) integrin cytoplasmic tail, at a site recognized by PDK1 and Akt/PKB in vitro, regulates Shc binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; HUMAN PLATELETS; PHOSPHATIDYLINOSITOL 3,4-BISPHOSPHATE; PROTEIN-KINASE; OKADAIC ACID; RAS PATHWAY; DOMAIN; ACTIVATION	The mechanism of outside-in signaling by integrins parallels that for growth factor receptors, In both pathways, phosphorylation of a cytoplasmic segment on tyrosine generates a docking site for proteins containing Src homology 2 (SH2) and phosphotyrosine binding domains. We recently observed that phosphorylation of a threonine (Thr-753), six amino acids proximal to tyrosine 759 in beta(3) of the platelet specific integrin alpha(IIb)beta(3) inhibits outside-in signaling through this receptor. We hypothesized that the presence of phosphothreonine 753 either renders beta(3) a poor substrate for tyrosine kinases or inhibits the docking capabilities of the tyrosylphosphorylated form of beta(3). The first alternative was tested by comparing the phosphorylation of beta(3) model peptides by the tyrosine kinase pp60(c-src) and we found that the presence of a phosphate group on a residue corresponding to Thr-753 did not detectably alter the kinetics of tyrosine phosphorylation. However, the presence of phosphate on this threonine inhibited the binding of Shc to tyrosyl-phosphorylated beta(3) peptide. The inhibitory effect of the phosphate group could be mimicked by substituting an aspartic acid for Thr-753, suggesting that a negative charge at this position modulates the binding of Shc and possibly other phosphotyrosine binding domain- and SH2-containing proteins. A survey of several protein kinases revealed that Thr-753 was avidly phosphorylated by PDK1 and Akt/PKB in vitro. These observations suggest that activation of PDK1 and/or Akt/PHB in platelets may modulate the binding activity and/or specificity of beta(3) for signaling molecules.	New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA	New York Medical College	Lerea, KM (corresponding author), New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA.	ken_lerea@nymc.edu	Lerea, Ken/GWU-8597-2022					Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Banfic H, 1998, J BIOL CHEM, V273, P13, DOI 10.1074/jbc.273.1.13; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Blystone SD, 1996, J BIOL CHEM, V271, P31458, DOI 10.1074/jbc.271.49.31458; Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HILLERY CA, 1991, J BIOL CHEM, V266, P14663; HOYT CH, 1994, BLOOD, V83, P3517; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; KARAKI H, 1989, BRIT J PHARMACOL, V98, P590, DOI 10.1111/j.1476-5381.1989.tb12633.x; Kroll MH, 1996, BLOOD, V88, P1525; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LEREA KM, 1992, BIOCHEMISTRY-US, V31, P6553, DOI 10.1021/bi00143a027; LEREA KM, 1991, BIOCHEMISTRY-US, V30, P6819, DOI 10.1021/bi00242a003; Lerea KM, 1999, J BIOL CHEM, V274, P1914, DOI 10.1074/jbc.274.4.1914; Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Schaffner-Reckinger E, 1998, J BIOL CHEM, V273, P12623, DOI 10.1074/jbc.273.20.12623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; vanWilligen G, 1996, BIOCHEM J, V314, P769, DOI 10.1042/bj3140769; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128	38	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30901	30906		10.1074/jbc.M001908200	http://dx.doi.org/10.1074/jbc.M001908200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896934	hybrid			2022-12-27	WOS:000089762700026
J	Sanchez-Gongora, E; Lisbona, C; de Gregorio, R; Ballester, A; Calvo, V; Perez-Jurado, L; Alemany, S				Sanchez-Gongora, E; Lisbona, C; de Gregorio, R; Ballester, A; Calvo, V; Perez-Jurado, L; Alemany, S			COT kinase proto-oncogene expression in T cells - Implication of the JNK/SAPK signal transduction pathway in COT promoter activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TPL-2; PROTOONCOGENE; GENE; INTERLEUKIN-2; TRANSLATION; ONCOPROTEIN; INITIATION; EUKARYOTES; LYMPHOMAS; ELEMENTS	COT/Tpl-2 proto oncogene encodes a serine/threonine kinase implicated in cellular activation. In this study we have identified the human COT gene promoter region and three different human COT transcripts. These transcripts, with the same initiation site, display heterogeneity in their 5' untranslated regions and in their subcellular localization. Activation of Jurkat T cells with either calcium ionophore A23187 or alpha CD3 and a phorbol ester increases the levels of the different COT transcripts. Analysis of the 5' flanking region of the human COT gene reveals a unique transcription initiation site and a TATA element 20 nucleotides upstream. Transient expression of COT promoter constructs containing a reporter gene indicates that the transcriptional activity of the 5' flanking region of the COT gene is regulated by T cell-activating signals. Cotransfection of a dominant negative version of SEK-2 abolishes the inducible transcriptional activity of COT promoter, indicating that the inducible expression of the COT gene by T cell activating signals is mediated by the JNK/SAPK signal transduction pathway. All these data indicate stringent regulation of COT kinase proto-oncogene expression.	Univ Autonoma Madrid, Inst Invest Biomed, Consejo Super Invest Cient, Fac Med, E-28029 Madrid, Spain; Univ Madrid, Hosp La Paz, Serv Genet, Madrid 28046, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Hospital Universitario La Paz	Alemany, S (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed, Consejo Super Invest Cient, Fac Med, Arturo Duperier 4, E-28029 Madrid, Spain.	salemany@biomed.iib.uam.es	Pérez Jurado, Luis Alberto/M-7706-2015; Alemany, Susana/J-6307-2014; Calvo, Victor/L-5024-2014	Alemany, Susana/0000-0002-4089-7620; Calvo, Victor/0000-0002-5913-7058; Ballester Jareno, Alicia/0000-0002-6474-7248				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AOKI M, 1991, ONCOGENE, V6, P1515; AOKI M, 1993, J BIOL CHEM, V268, P22723; Ballester A, 1998, J BIOL CHEM, V273, P14099, DOI 10.1074/jbc.273.23.14099; Ballester A, 1997, J IMMUNOL, V159, P1613; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; CHAN AML, 1993, ONCOGENE, V8, P1329; Erny KM, 1996, ONCOGENE, V13, P2015; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Jackson RJ, 1997, CURR OPIN GENET DEV, V7, P233, DOI 10.1016/S0959-437X(97)80133-5; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; OHARA R, 1993, JPN J CANCER RES, V84, P518, DOI 10.1111/j.1349-7006.1993.tb00170.x; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sourvinos G, 1999, ONCOGENE, V18, P4968, DOI 10.1038/sj.onc.1202891; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827; WEIL D, 1990, MOL CELL BIOL, V10, P5865, DOI 10.1128/MCB.10.11.5865	37	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31379	31386		10.1074/jbc.M000382200	http://dx.doi.org/10.1074/jbc.M000382200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896655	hybrid			2022-12-27	WOS:000089762700089
J	Eckenhoff, RG; Petersen, CE; Ha, CE; Bhagavan, NV				Eckenhoff, RG; Petersen, CE; Ha, CE; Bhagavan, NV			Inhaled anesthetic binding sites in human serum albumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOTHANE BINDING; HYDROGEN-EXCHANGE; THYROXINE-BINDING; CRYSTAL-STRUCTURE; SOLUBLE-PROTEINS; RESOLUTION; STABILITY; RECEPTORS; INCREASES; AFFINITY	Previous evidence suggests multiple anesthetic binding sites on human serum albumin, but to date, we have only identified Trp-214 in an interdomain cleft as contributing to a binding site. We used a combination of site-directed mutagenesis, photoaffinity labeling, amide hydrogen exchange, and tryptophan fluorescence spectroscopy to evaluate the importance to binding of a large domain III cavity and compare it to binding character of the 214 interdomain cleft. The data show anesthetic binding in this domain III cavity of similar character to the interdomain cleft, but selectivity for different classes of anesthetics exists. Occupancy of these sites stabilizes the native conformation of human serum albumin. The features necessary for binding in the cleft appear to be fairly degenerate, but in addition to hydrophobicity, there is evidence for the importance of polarity. Finally, myristate isosterically competes with anesthetic binding in the domain III cavity and allosterically enhances anesthetic binding in the interdomain cleft.	Univ Penn, Med Ctr, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Hawaii, John A Burns Sch Med, Dept Biochem & Biophys, Honolulu, HI 96822 USA	University of Pennsylvania; University of Hawaii System	Eckenhoff, RG (corresponding author), Univ Penn, Med Ctr, Dept Anesthesia, Philadelphia, PA 19104 USA.			Eckenhoff, Roderic/0000-0002-5581-746X	NIGMS NIH HHS [GM 55876, GM 51595] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAI YW, 1994, PROTEINS, V20, P4, DOI 10.1002/prot.340200103; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; DUBOIS BW, 1992, BIOCHEMISTRY-US, V31, P7069, DOI 10.1021/bi00146a007; Eckenhoff MF, 1998, J PHARMACOL EXP THER, V285, P371; ECKENHOFF RG, 1993, ANESTHESIOLOGY, V79, P96, DOI 10.1097/00000542-199307000-00015; Eckenhoff RG, 1998, MOL PHARMACOL, V54, P610; Eckenhoff RG, 1996, J BIOL CHEM, V271, P15521, DOI 10.1074/jbc.271.26.15521; Eckenhoff RG, 1997, PHARMACOL REV, V49, P343; Eckenhoff RG, 1999, MOL PHARMACOL, V56, P414, DOI 10.1124/mol.56.2.414; ENGLANDER SW, 1994, METHOD ENZYMOL, V232, P26; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; GLATZ JFC, 1983, J BIOCHEM BIOPH METH, V8, P57, DOI 10.1016/0165-022X(83)90021-0; HARRIS BD, 1994, EUR J PHARM-MOLEC PH, V267, P269, DOI 10.1016/0922-4106(94)90150-3; JOHANSSON JS, 1995, ANESTHESIOLOGY, V83, P316, DOI 10.1097/00000542-199508000-00012; KOBLIN DD, 1994, ANESTH ANALG, V79, P1043; MOSS GWJ, 1991, P NATL ACAD SCI USA, V88, P134, DOI 10.1073/pnas.88.1.134; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; PETERSEN CE, 1995, BIOCHEM BIOPH RES CO, V214, P1121, DOI 10.1006/bbrc.1995.2402; Petersen CE, 1996, J BIOL CHEM, V271, P19110, DOI 10.1074/jbc.271.32.19110; Petersen CE, 1997, BIOCHEMISTRY-US, V36, P7012, DOI 10.1021/bi970225v; Raines DE, 1999, ANESTHESIOLOGY, V90, P135, DOI 10.1097/00000542-199901000-00019; Scharf D, 1996, CHEM PHYS LETT, V258, P276, DOI 10.1016/0009-2614(96)00652-5; Sugio S, 1999, PROTEIN ENG, V12, P439, DOI 10.1093/protein/12.6.439; Tanner JW, 1999, BBA-PROTEIN STRUCT M, V1430, P46, DOI 10.1016/S0167-4838(98)00258-1; Ueda I, 1997, BIOPHYS J, V72, P1812, DOI 10.1016/S0006-3495(97)78827-1	26	47	50	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30439	30444		10.1074/jbc.M005052200	http://dx.doi.org/10.1074/jbc.M005052200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896670	hybrid			2022-12-27	WOS:000089577900071
J	Gamez, A; Perez, B; Ugarte, M; Desviat, LR				Gamez, A; Perez, B; Ugarte, M; Desviat, LR			Expression analysis of phenylketonuria mutations - effect on folding and stability of the phenylalanie hydroxylase protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; DEHYDROGENASE; ENZYME; DEGRADATION; DISEASE; BACTERIAL; PHENOTYPE; MECHANISM; GENOTYPE; DOMAIN	Phenylketonuria is an autosomal recessive human genetic disease caused by mutations in the phenylalanine hydroxylase (PAH) gene. In the present work we have used different expression systems to reveal folding defects of the PAH protein caused by phenylketonuria mutations L348V, S349L, and V388M. The amount of mutant proteins and/or the residual activity can be rescued by chaperonin co-overexpression in Escherichia coli or growth at low temperature in COS cells. Thermal stability profiles and degradation time courses of PAH expressed in E. coli show that the mutant proteins are less stable than the wild-type enzyme, also confirmed by pulse-chase experiments using a coupled in vitro transcription-translation system. Size exclusion chromatography shows altered oligomerization, partially corrected with chaperonins coexpression, except for the S349L mutant protein, which is recovered as inactive aggregates. PAH subunit interaction is affected in the S349L protein, as demonstrated in a mammalian two-hybrid assay. In conclusion, serine 349, located in the three-dimensional structure lining the active site and involved in the structural maintenance of the iron binding site, is essential for the structural stability and assembly and also for the catalytic properties of the PAH enzyme, whereas the L348V and V388M mutations affect the folding properties and stability of the protein. The experimental modulation of mutant residual activity provides a potential explanation for the existing inconsistencies in the genotype-phenotype correlations.	Univ Autonoma Madrid, Ctr Biol Mol, CSIC, Dept Biol Mol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Ugarte, M (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol, CSIC, Dept Biol Mol, Campus Cantoblanco, E-28049 Madrid, Spain.	mugarte@cbm.uam.es	Gamez, Alejandra/T-6898-2017; DESVIAT, LOURDES R/L-3055-2013	Gamez, Alejandra/0000-0002-2414-2586; DESVIAT, LOURDES R/0000-0003-0492-3323				Bjorgo E, 1998, EUR J BIOCHEM, V257, P1, DOI 10.1046/j.1432-1327.1998.2570001.x; BROSS P, 1993, BIOCHIM BIOPHYS ACTA, V1182, P264, DOI 10.1016/0925-4439(93)90068-C; Bross P, 1999, HUM MUTAT, V14, P186, DOI 10.1002/(SICI)1098-1004(1999)14:3<186::AID-HUMU2>3.0.CO;2-J; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Chehin R, 1998, FEBS LETT, V422, P225, DOI 10.1016/S0014-5793(97)01596-2; Corydon MJ, 1996, PEDIATR RES, V39, P1059, DOI 10.1203/00006450-199606000-00021; De Lucca M, 1998, HUM MUTAT, V11, P354; Desviat LR, 1999, EUR J HUM GENET, V7, P386, DOI 10.1038/sj.ejhg.5200312; DESVIAT LR, 1995, AM J HUM GENET, V57, P337; Eiken HG, 1996, HUM MUTAT, V7, P228, DOI 10.1002/(SICI)1098-1004(1996)7:3<228::AID-HUMU7>3.0.CO;2-6; Erlandsen H, 1997, NAT STRUCT BIOL, V4, P995, DOI 10.1038/nsb1297-995; Feldman DE, 2000, CURR OPIN STRUC BIOL, V10, P26, DOI 10.1016/S0959-440X(99)00044-5; Fusetti F, 1998, J BIOL CHEM, V273, P16962, DOI 10.1074/jbc.273.27.16962; GULBERG P, 1998, AM J HUM GENET, V63, P71; Hufton SE, 1998, BBA-PROTEIN STRUCT M, V1382, P295, DOI 10.1016/S0167-4838(97)00171-4; HUFTON SE, 1995, BIOCHEM J, V311, P353, DOI 10.1042/bj3110353; JENSEN TG, 1995, HUM MUTAT, V6, P226, DOI 10.1002/humu.1380060305; Kayaalp E, 1997, AM J HUM GENET, V61, P1309, DOI 10.1086/301638; Kleppe R, 1999, J BIOL CHEM, V274, P33251, DOI 10.1074/jbc.274.47.33251; Knappskog PM, 1996, EUR J BIOCHEM, V242, P813, DOI 10.1111/j.1432-1033.1996.0813r.x; Kobe B, 1999, NAT STRUCT BIOL, V6, P442, DOI 10.1038/8247; KWOK SCM, 1985, BIOCHEMISTRY-US, V24, P556, DOI 10.1021/bi00324a002; Levy HL, 1999, P NATL ACAD SCI USA, V96, P1811, DOI 10.1073/pnas.96.5.1811; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; Nowacki PM, 1998, NUCLEIC ACIDS RES, V26, P220, DOI 10.1093/nar/26.1.220; Scriver CR, 1999, TRENDS GENET, V15, P267, DOI 10.1016/S0168-9525(99)01761-8; Teigen K, 1999, J MOL BIOL, V294, P807, DOI 10.1006/jmbi.1999.3288; Waters PJ, 1999, J INHERIT METAB DIS, V22, P208, DOI 10.1023/A:1005533825980; Waters PJ, 1998, HUM MUTAT, V11, P4; Waters PJ, 2000, MOL GENET METAB, V69, P101, DOI 10.1006/mgme.2000.2965; Wynn RM, 1998, J BIOL CHEM, V273, P13110, DOI 10.1074/jbc.273.21.13110	31	72	73	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29737	29742		10.1074/jbc.M003231200	http://dx.doi.org/10.1074/jbc.M003231200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10875932	hybrid			2022-12-27	WOS:000089439800075
J	Nadimpalli, R; Yalpani, N; Johal, GS; Simmons, CR				Nadimpalli, R; Yalpani, N; Johal, GS; Simmons, CR			Prohibitins, stomatins, and plant disease response genes compose a protein superfamily that controls cell proliferation, ion channel regulation, and death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS; EXPRESSION; CHROMOSOME-17; LYMPHOCYTES; ACTIVATION; ALIGNMENT; PROGRAMS; MEMBRANE; TOBACCO; CLUSTAL	Prohibitins, stomatins, and a group of plant defense response genes are demonstrated to belong to a novel protein superfamily, This superfamily is bound by similar primary and secondary predicted protein structures and hydropathy profiles. A PROSITE-formatted regular expression was generated that is highly predictive for identifying members of this superfamily using PHI-BLAST. The superfamily is named PID (proliferation, ion, and death) because prohibitins are involved in proliferation and cell cycle control, stomatins are involved in ion channel regulation, and the plant defense-related genes are involved in cell death. The plant defense gene family is named HIR (hypersensitive induced reaction) because its members are associated with hypersensitive reactions involving cell death and pathogen resistance. For this study, eight novel maize genes were introduced: four closely related to prohibitins (Zm-phb1, Zm-phb2, Zm-phb3, and Zm-phb4), one to stomatins (Zm-stm1), and three to a gene implicated in plant disease responses (Zm-hir1, Zm-hir2, and Zm-hir3). The maize Zm-hir3 gene transcript is up-regulated in a disease lesion mimic mutation (Les9), supporting a role in maize defense responses. Members of this gene superfamily are involved in diverse functions, but their structural similarity suggests a conserved molecular mechanism, which we postulate to be ion channel regulation.	Pioneer HiBred Int Inc, Bioinformat Dept, Johnston, IA 50131 USA; Pioneer HiBred Int Inc, Dis Resistance Dept, Johnston, IA 50131 USA; Hoffmann La Roche Inc, Vitamins Div, Nutley, NJ 07110 USA	DuPont; DuPont; Roche Holding	Simmons, CR (corresponding author), Pioneer HiBred Int Inc, Bioinformat Dept, 7250 NW 62nd Ave,OB 552, Johnston, IA 50131 USA.	simmonscr@phibred.com	Johal, Guri/F-5056-2017	Johal, Guri/0000-0001-8101-8410				Agrios G.N., 2005, PLANT PATHOL, V5th; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ATKINSON MM, 1985, PLANT PHYSIOL, V79, P843, DOI 10.1104/pp.79.3.843; Atlante A, 1998, NEUROSCI LETT, V245, P127, DOI 10.1016/S0304-3940(98)00195-5; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Avdonin V, 1998, P NATL ACAD SCI USA, V95, P11703, DOI 10.1073/pnas.95.20.11703; CHOONGKITTAWORN NM, 1993, BIOL REPROD, V49, P300, DOI 10.1095/biolreprod49.2.300; Coates PJ, 1997, CURR BIOL, V7, P607, DOI 10.1016/S0960-9822(06)00261-2; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; del Pozo O, 1998, CURR BIOL, V8, P1129, DOI 10.1016/S0960-9822(98)70469-5; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; Furlong IJ, 1998, CELL DEATH DIFFER, V5, P214, DOI 10.1038/sj.cdd.4400335; Greenberg JT, 1996, P NATL ACAD SCI USA, V93, P12094, DOI 10.1073/pnas.93.22.12094; Grundy WN, 1997, BIOCHEM BIOPH RES CO, V231, P760, DOI 10.1006/bbrc.1997.6193; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOISINGTON DA, 1986, MAIZE GENET COOP NEW, V60, P51; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; JOHAL GS, 1995, BIOESSAYS, V17, P685, DOI 10.1002/bies.950170805; Karrer EE, 1998, PLANT MOL BIOL, V36, P681, DOI 10.1023/A:1005949304445; King RD, 1997, COMPUT APPL BIOSCI, V13, P473; Kosuge T., 1983, GENETIC ENG PLANTS A, P431, DOI [10.1007/978-1-4684-4544-2_29, DOI 10.1007/978-1-4684-4544-2_29, DOI 10.1007/978-1-4684-4544-2_]; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; LEGGETT B, 1995, BRIT J CANCER, V71, P1070, DOI 10.1038/bjc.1995.206; MCCLUNG JK, 1995, EXP GERONTOL, V30, P99, DOI 10.1016/0531-5565(94)00069-7; Neuenschwander U, 1996, PLANT MICROBE INTERA, V1, P81; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; ROSKAMS AJI, 1993, J CELL PHYSIOL, V157, P289, DOI 10.1002/jcp.1041570211; ROSS KD, 1996, PROTEIN SCI, V5, P2298; RYALS JA, 1997, Patent No. 5614395; SATO T, 1992, CANCER RES, V52, P1643; Schulz JB, 1998, NEUROSCI LETT, V245, P9, DOI 10.1016/S0304-3940(98)00166-9; STEWART GW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P15, DOI 10.1016/0925-4439(93)90116-I; Stewart GW, 1997, INT J BIOCHEM CELL B, V29, P271, DOI 10.1016/S1357-2725(96)00072-6; STEWART GW, 1992, BLOOD, V79, P1593, DOI 10.1182/blood.V79.6.1593.bloodjournal7961593; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Xu B, 1996, AM J PHYSIOL-CELL PH, V271, pC2037, DOI 10.1152/ajpcell.1996.271.6.C2037; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; Zhang Z, 1998, NUCLEIC ACIDS RES, V26, P3986, DOI 10.1093/nar/26.17.3986; Zong ZP, 1998, CELL STRUCT FUNCT, V23, P231, DOI 10.1247/csf.23.231	44	135	151	6	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29579	29586		10.1074/jbc.M002339200	http://dx.doi.org/10.1074/jbc.M002339200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10862763	hybrid			2022-12-27	WOS:000089439800054
J	Rivard, A; Berthou-Soulie, L; Principe, N; Kearney, M; Curry, C; Branellec, D; Semenza, GL; Isner, JM				Rivard, A; Berthou-Soulie, L; Principe, N; Kearney, M; Curry, C; Branellec, D; Semenza, GL; Isner, JM			Age-dependent defect in vascular endothelial growth factor expression is associated with reduced hypoxia-inducible factor 1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; UBIQUITIN-PROTEASOME PATHWAY; SMOOTH-MUSCLE CELLS; FACTOR 1-ALPHA; GENE-EXPRESSION; ERYTHROPOIETIN; TRANSCRIPTION; VEGF; STABILIZATION; ANGIOGENESIS	Previous studies have indicated that advanced age is associated with impaired angiogenesis in part because of reduced levels of vascular endothelial growth factor (VEGF) expression. To investigate potential mechanisms responsible for this age-dependent defect in VEGF expression, aortic smooth muscle cells isolated from young rabbits (ages 6-8 months) or old rabbits (ages 4-5 years) were exposed to normoxic (21% oxygen) or hypoxic (0.1% oxygen) conditions, Hypoxia-induced VEGF expression was significantly lower in old versus young cells. VEGF mRNA stability in hypoxic conditions was similar in both young and old cells. However, transient transfection with a luciferase reporter gene that was transcriptionally regulated by the VEGF promoter revealed a significant defect in VEGF up-regulation following hypoxia in old versus young cells (a 43 versus 117% increase in luciferase activity, p < 0.05); this difference was not seen when a deletion construct lacking the hypoxia-inducible 1 (HIF-1) binding site was used. Moreover, although HIF-1 alpha-mRNA expression was shown to be similar in young and old smooth muscle cells, HIF-1 alpha protein and DNA binding activity were significantly reduced in old versus young smooth muscle cells that were exposed to hypoxia. We propose that age-dependent reduction in hypoxia-induced VEGF expression results from reduced HIF-1 activity and may explain the previously described age-dependent impairment of angiogenesis in response to ischemia.	Tufts Univ, Sch Med, St Elizabeth Med Ctr, Dept Med Cardiol, Boston, MA 02136 USA; Rhone Poulenc Rorer Gencell, Dept Rech Cardiovasc, F-94403 Vitry Sur Seine, France; Johns Hopkins Univ, Sch Med, Inst Med Genet, Dept Pediat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA	St. Elizabeth's Medical Center; Tufts University; Sanofi-Aventis; Johns Hopkins University; Johns Hopkins University	Isner, JM (corresponding author), St Elizabeth Med Ctr, Dept Med Cardiol, 736 Cambridge St, Brighton, MA 02135 USA.							BANAI S, 1994, CARDIOVASC RES, V28, P1176, DOI 10.1093/cvr/28.8.1176; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; Bunn HF, 1998, J EXP BIOL, V201, P1197; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Frenkel-Denkberg G, 1999, FEBS LETT, V462, P341, DOI 10.1016/S0014-5793(99)01552-5; GERSHON H, 1973, P NATL ACAD SCI USA, V70, P909, DOI 10.1073/pnas.70.3.909; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; MADER SL, 1992, J GERONTOL, V47, pB32, DOI 10.1093/geronj/47.2.B32; NAFZIGER J, 1993, AM J HEMATOL, V43, P172, DOI 10.1002/ajh.2830430303; REISS U, 1976, EUR J BIOCHEM, V63, P617, DOI 10.1111/j.1432-1033.1976.tb10266.x; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; Ribatti D, 1999, BLOOD, V93, P2627, DOI 10.1182/blood.V93.8.2627.408k21_2627_2636; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; Roy AK, 1997, MOL MED, V3, P496, DOI 10.1007/BF03401696; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEIN I, 1995, MOL CELL BIOL, V15, P5363; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang RY, 1996, J GERONTOL A-BIOL, V51, pB434, DOI 10.1093/gerona/51A.6.B434; WEISBROTH SH, 1974, NEOPLASTIC DIS BIOL, P331; Zhong H, 1999, CANCER RES, V59, P5830	38	226	228	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29643	29647		10.1074/jbc.M001029200	http://dx.doi.org/10.1074/jbc.M001029200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882714	hybrid			2022-12-27	WOS:000089439800063
J	Pasquet, JM; Quek, L; Pasquet, S; Poole, A; Matthews, JR; Lowell, C; Watson, SP				Pasquet, JM; Quek, L; Pasquet, S; Poole, A; Matthews, JR; Lowell, C; Watson, SP			Evidence of a role for SHP-1 in platelet activation by the collagen receptor glycoprotein VI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; ADHESION MOLECULE-1 PECAM-1; GAMMA-CHAIN; PHOSPHOLIPASE C-GAMMA-2; INHIBITORY RECEPTORS; INOSITOL PHOSPHATES; BINDING MOTIFS; B-LYMPHOCYTES; ASSOCIATION; PHOSPHORYLATION	The Src homology (SH)2 domain-containing protein-tyrosine phosphatase SHP-1 is tyrosine phosphorylated in platelets in response to the glycoprotein VI (GPVI)-selective agonist collagen-related peptide (CRP), collagen, and thrombin. Two major unidentified tyrosine-phosphorylated bands of 28 and 32 kDa and a minor band of 130 kDa coprecipitate with SHP-1 in response to all three agonists. Additionally, tyrosine-phosphorylated proteins of 50-55 and 70 kDa specifically associate with SHP-1 following stimulation by CRP and collagen. The tyrosine kinases Lyn, which exists as a 53 and 56-kDa doublet, and Syk were identified as major components of these bands, respectively. Kinase assays on SHP-1 immunoprecipitates performed in the presence of the Src family kinase inhibitor PP1 confirmed the presence of a Src kinase in CRP- but not thrombin-stimulated cells. Lyn, Syk, and SLP-76, along with tyrosine-phosphorylated 28-, 32-, and 130-kDa proteins, bound selectively to a glutathione S-transferase protein encoding the SH2 domains of SHP-1, suggesting that this is the major site of interaction. Platelets isolated from motheaten viable mice (mev/mev) revealed the presence of a heavily tyrosine-phosphorylated 26-kDa protein that was not found in wild-type platelets. CRP-stimulated mev/mev platelets manifested hypophosphorylation of Syk and Lyn and reduced P-selectin expression relative to controls. These observations provide evidence of a functional role for SHP-1 in platelet activation by GPVI.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England; Univ Coll N Wales, Dept Med, Cardiff CF4 4XX, S Glam, Wales; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 91443 USA	University of Oxford; University of Bristol; Bangor University; University of California System; University of California San Francisco	Watson, SP (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.		PASQUET, JEAN-MAX/T-4906-2019; PASQUET, JEAN-MAX/I-9702-2014; Watson, Stephen P/Q-6292-2016	PASQUET, JEAN-MAX/0000-0002-1345-3776; Watson, Stephen P/0000-0002-7846-7423; Poole, Alastair/0000-0002-0868-297X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050267] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54467] Funding Source: Medline; NIDDK NIH HHS [DK50267] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Binstadt BA, 1998, J BIOL CHEM, V273, P27518, DOI 10.1074/jbc.273.42.27518; BLAKE RA, 1993, BIOCHEM J, V290, P471, DOI 10.1042/bj2900471; BLAKE RA, 1994, FEBS LETT, V342, P15, DOI 10.1016/0014-5793(94)80575-X; Briddon SJ, 1999, BLOOD, V93, P3847, DOI 10.1182/blood.V93.11.3847.411k17_3847_3855; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DEFRANCO AL, 1995, SCIENCE, V268, P263, DOI 10.1126/science.7716518; Edmead CE, 1999, FEBS LETT, V459, P27, DOI 10.1016/S0014-5793(99)01209-0; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Falet H, 1998, BIOCHEM BIOPH RES CO, V252, P51, DOI 10.1006/bbrc.1998.9593; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; Farndale RW, 1995, EQUINE VET J, V27, P407, DOI 10.1111/j.2042-3306.1995.tb04419.x; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Jackson DE, 1997, J BIOL CHEM, V272, P24868, DOI 10.1074/jbc.272.40.24868; Jackson SP, 1996, THROMB HAEMOSTASIS, V76, P640; MIZUNO K, 1996, J EXP MED, V184; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; ORourke L, 1997, CURR OPIN IMMUNOL, V9, P324, DOI 10.1016/S0952-7915(97)80077-5; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Pasquet JM, 1999, BIOCHEM J, V342, P171, DOI 10.1042/0264-6021:3420171; Pasquet JM, 1998, BIOCHEM J, V333, P591, DOI 10.1042/bj3330591; Presek P, 1997, HANDB EXP PHARM, V126, P263; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; Shultz LD, 1997, TRENDS BIOTECHNOL, V15, P302, DOI 10.1016/S0167-7799(97)01060-3; Thomas M L, 1995, Semin Immunol, V7, P279, DOI 10.1006/smim.1995.0032; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; Yang WT, 1998, BLOOD, V91, P3746	32	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28526	28531		10.1074/jbc.M001531200	http://dx.doi.org/10.1074/jbc.M001531200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10871605	hybrid			2022-12-27	WOS:000089330700027
J	Yamaguchi, K; Subramanian, AR				Yamaguchi, K; Subramanian, AR			The plastid ribosomal proteins - Identification of all the proteins in the 50 S subunit of an organelle ribosome (chloroplast)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; RNA-BINDING-PROPERTIES; SPINACH-CHLOROPLASTS; CYTOPLASMIC PRECURSOR; NUCLEOTIDE-SEQUENCE; RECYCLING FACTOR; GENE-EXPRESSION; PURIFICATION; TRANSLATION; EVOLUTION	We have completed identification of all the ribosomal proteins (RPs) in spinach plastid (chloroplast) ribosomal 50 S subunit via a proteomic approach using two-dimensional electrophoresis, electroblotting/protein sequencing, high performance liquid chromatography purification, polymerase chain reaction-based screening of cDNA library/nucleotide sequencing, and mass spectrometry (reversed-phase HPLC coupled to electrospray ionization mass spectrometry and electrospray ionization mass spectrometry), Spinach plastid 50 S subunit comprises 33 proteins, of which 31 are orthologues of Escherichia coli RPs and two are plastid-specific RPs (PSRP-5 and PSRP-6) having no homologues in other types of ribosomes, Orthologues of E. coli L25 and L30 are absent in spinach plastid ribosome. 25 of the plastid 50 S RPs are encoded in the nuclear genome and synthesized on cytosolic ribosomes, whereas eight of the plastid RPs are encoded in the plastid organelle genome and synthesized on plastid ribosomes, Sites for transit peptide cleavages in the cytosolic RP precursors and formyl Met processing in the plastid-synthesized RPs were established. Post-translational modifications were observed in several mature plastid RPs, including multiple forms of L10, L18, L31, and PSRP-5 and N-terminal/internal modifications in L2, L11 and L16. Comparison of the RPs in gradient-purified 70 S ribosome with those in the 30 and 50 S subunits revealed an additional protein, in approximately stoichiometric amount, specific to the 70 S ribosome, It was identified to be plastid ribosome recycling factor. Combining with our recent study of the proteins in plastid 30 S subunit (Yamaguchi, K,, von Knoblauch, K,, and Subramanian, A R. (2000) J, Biol, Chem, 275, 28455-28465), we show that spinach plastid ribosome comprises 59 proteins (33 in 50 S subunit and 25 in 30 S subunit and ribosome recycling factor in 70 S), of which 53 are E. coli orthologues and 6 are plastid-specific proteins (PSRP-1 to PSRP-6), We propose the hypothesis that PSRPs were evolved to perform functions unique to plastid translation and its regulation, including protein targeting/translocation to thylalroid membrane via plastid 50 S subunit.	Univ Arizona, Dept Biochem, Tucson, AZ 85712 USA; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	University of Arizona; Max Planck Society	Subramanian, AR (corresponding author), 5110 E Woodgate Ln, Tucson, AZ 85712 USA.							Agafonov DE, 1999, P NATL ACAD SCI USA, V96, P12345, DOI 10.1073/pnas.96.22.12345; Arnold RJ, 1999, ANAL BIOCHEM, V269, P105, DOI 10.1006/abio.1998.3077; BARKAN A, 1993, PLANT CELL, V5, P389, DOI 10.1105/tpc.5.4.389; BARTSCH M, 1982, P NATL ACAD SCI-BIOL, V79, P6871, DOI 10.1073/pnas.79.22.6871; BOGORAD L, 1975, SCIENCE, V188, P891, DOI 10.1126/science.1138359; BROSIUS J, 1976, FEBS LETT, V68, P105, DOI 10.1016/0014-5793(76)80415-2; BROSIUS J, 1978, BIOCHEMISTRY-US, V17, P501, DOI 10.1021/bi00596a020; BRUNE DC, 1992, ANAL BIOCHEM, V207, P285, DOI 10.1016/0003-2697(92)90013-W; BUBUNENKO MG, 1994, J MOL BIOL, V240, P28, DOI 10.1006/jmbi.1994.1415; CAROL P, 1993, NUCLEIC ACIDS RES, V21, P635, DOI 10.1093/nar/21.3.635; CAROL P, 1991, GENE, V103, P139, DOI 10.1016/0378-1119(91)90266-E; DABBS ER, 1985, STRUCTURE FUNCTION G, P733; DOGNIN MJ, 1980, EUR J BIOCHEM, V112, P131, DOI 10.1111/j.1432-1033.1980.tb04995.x; Eistetter AJ, 1999, FEMS MICROBIOL LETT, V180, P345, DOI 10.1111/j.1574-6968.1999.tb08816.x; ERIKSON E, 1988, 2ND MESSENGERS PHOSP, V12, P135; FRANZETTI B, 1992, J BIOL CHEM, V267, P19075; Freyer R, 1997, P NATL ACAD SCI USA, V94, P6285, DOI 10.1073/pnas.94.12.6285; FROMM H, 1985, EMBO J, V4, P291, DOI 10.1002/j.1460-2075.1985.tb03628.x; GANTT JS, 1988, CURR GENET, V14, P519, DOI 10.1007/BF00521278; *GEN COMP GROUP, 1998, WISC PACK VERS 10 0; GIESE K, 1989, BIOCHEMISTRY-US, V28, P3525, DOI 10.1021/bi00434a056; Goldschmidt-Reisin S, 1998, J BIOL CHEM, V273, P34828, DOI 10.1074/jbc.273.52.34828; Graack HR, 1998, BIOCHEM J, V329, P433, DOI 10.1042/bj3290433; GRAY PN, 1972, EUR J BIOCHEM, V28, P412, DOI 10.1111/j.1432-1033.1972.tb01927.x; Grimm R, 1997, FEBS LETT, V408, P350, DOI 10.1016/S0014-5793(97)00462-6; GUITTON C, 1984, BIOCHEM BIOPH RES CO, V121, P297, DOI 10.1016/0006-291X(84)90722-8; HARDY SJS, 1969, BIOCHEMISTRY-US, V8, P2897, DOI 10.1021/bi00835a031; HARRIS EH, 1994, MICROBIOL REV, V58, P700, DOI 10.1128/MMBR.58.4.700-754.1994; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Janosi L, 1996, ADV BIOPHYS, V32, P121, DOI 10.1016/0065-227X(96)84743-5; JOHNSON CH, 1990, J BIOL CHEM, V265, P12790; KAMP RM, 1984, FEBS LETT, V167, P59, DOI 10.1016/0014-5793(84)80832-7; KAMP RM, 1987, BIOCHEMISTRY-US, V26, P5866, DOI 10.1021/bi00392a043; Karimi R, 1999, MOL CELL, V3, P601, DOI 10.1016/S1097-2765(00)80353-6; KAVOUSI M, 1995, THESIS FREE U BERLIN; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI K, 1975, ANAL BIOCHEM, V64, P121, DOI 10.1016/0003-2697(75)90413-3; Maki Y, 2000, PLANT CELL PHYSIOL, V41, P289, DOI 10.1093/pcp/41.3.289; MALONE P, 1988, J CELL BIOL, V106, P609; Mueller F, 2000, J MOL BIOL, V298, P35, DOI 10.1006/jmbi.2000.3635; O'Brien TW, 1999, J BIOL CHEM, V274, P36043, DOI 10.1074/jbc.274.51.36043; OSSWALD M, 1990, NUCLEIC ACIDS RES, V18, P6755; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Planta RJ, 1998, YEAST, V14, P471, DOI 10.1002/(SICI)1097-0061(19980330)14:5<471::AID-YEA241>3.0.CO;2-U; POSNO M, 1984, CURR GENET, V8, P147, DOI 10.1007/BF00420227; RAMAGOPA.S, 1974, P NATL ACAD SCI USA, V71, P2136, DOI 10.1073/pnas.71.5.2136; RAUE HA, 1988, PROG BIOPHYS MOL BIO, V51, P77, DOI 10.1016/0079-6107(88)90011-9; Rochaix JD, 1996, PLANT MOL BIOL, V32, P327, DOI 10.1007/BF00039389; Rolland N, 1999, P NATL ACAD SCI USA, V96, P5464, DOI 10.1073/pnas.96.10.5464; Sambrook J., 2002, MOL CLONING LAB MANU; Sato N, 1998, PLANT CELL PHYSIOL, V39, P1367, DOI 10.1093/oxfordjournals.pcp.a029343; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT J, 1992, PLANT MOL BIOL, V20, P459, DOI 10.1007/BF00040605; SCHMIDT J, 1996, THESIS FREE U BERLIN; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; SMOOKER PM, 1990, BIOCHEMISTRY-US, V29, P9733, DOI 10.1021/bi00493a032; SPIERER P, 1978, BIOCHEMISTRY-US, V17, P5394, DOI 10.1021/bi00618a012; Stern DB, 1997, TRENDS PLANT SCI, V2, P308, DOI 10.1016/S1360-1385(97)89953-0; SUBRAMAN.AR, 1968, P NATL ACAD SCI USA, V61, P761, DOI 10.1073/pnas.61.2.761; SUBRAMANIAN AR, 1974, EUR J BIOCHEM, V45, P541, DOI 10.1111/j.1432-1033.1974.tb03579.x; SUBRAMANIAN AR, 1985, ESSAYS BIOCHEM, V21, P45; SUBRAMANIAN AR, 1975, J MOL BIOL, V95, P1, DOI 10.1016/0022-2836(75)90330-7; SUBRAMANIAN AR, 1993, TRENDS BIOCHEM SCI, V18, P177, DOI 10.1016/0968-0004(93)90110-9; SUBRAMANIAN AR, 1970, NATURE, V228, P1273, DOI 10.1038/2281273a0; SUBRAMANIAN AR, 1997, PLANT MOL BIOL BIOTE, P86; SUBRAMANIAN AR, 1990, MOL BIOL PLASTIDS, P191; Sugiura M, 1998, ANNU REV GENET, V32, P437, DOI 10.1146/annurev.genet.32.1.437; TAKAIWA F, 1982, EUR J BIOCHEM, V124, P13, DOI 10.1111/j.1432-1033.1982.tb05901.x; TOUKIFIMPA R, 1989, BIOCHEMISTRY-US, V28, P5840, DOI 10.1021/bi00440a021; Trifa Y, 1998, J BIOL CHEM, V273, P3980, DOI 10.1074/jbc.273.7.3980; VOGEL DW, 1984, FEBS LETT, V169, P67, DOI 10.1016/0014-5793(84)80291-4; Wada A, 1998, GENES CELLS, V3, P203, DOI 10.1046/j.1365-2443.1998.00187.x; WALSH MJ, 1988, BIOCHEMISTRY-US, V27, P6867, DOI 10.1021/bi00418a032; WEGLOHNER W, 1994, J BIOL CHEM, V269, P7330; WETTENHALL REH, 1992, J BIOL CHEM, V267, P9021; WITTMANN HG, 1982, ANNU REV BIOCHEM, V51, P155, DOI 10.1146/annurev.bi.51.070182.001103; WITTMANN HG, 1980, RIBOSOMES STRUCTURE, P51; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101; Yamaguchi K, 2000, J BIOL CHEM, V275, P28455, DOI 10.1074/jbc.M004350200; Yohn CB, 1998, P NATL ACAD SCI USA, V95, P2238, DOI 10.1073/pnas.95.5.2238; Yu NJ, 1998, J BIOL CHEM, V273, P3871, DOI 10.1074/jbc.273.7.3871; ZHOU DX, 1989, MOL GEN GENET, V216, P439, DOI 10.1007/BF00334388; ZURAWSKI G, 1984, NUCLEIC ACIDS RES, V12, P6547, DOI 10.1093/nar/12.16.6547	83	185	229	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28466	28482		10.1074/jbc.M005012200	http://dx.doi.org/10.1074/jbc.M005012200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10874046	hybrid			2022-12-27	WOS:000089330700019
J	Carter, KB; Hunninghake, GW				Carter, KB; Hunninghake, GW			A constitutive active MEK -> ERK pathway negatively regulates NF-kappa B-dependent gene expression by modulating TATA-binding protein phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALVEOLAR MACROPHAGES; TRANSCRIPTION FACTOR-IIB; NECROSIS-FACTOR-ALPHA; IMMEDIATE-EARLY GENE; PRO-INFLAMMATORY CYTOKINES; MAP KINASES; IN-VIVO; TYROSINE-PHOSPHATASE; FAMILY MEMBERS; T-CELLS	Endotoxin-induced cytokine gene expression is regulated, in part, by NF-kappa B. We have shown that both the ERK and p38 mitogen-activated protein (MAP) kinases are necessary for cytokine gene transcription and that the p38 MAP kinase is required for NF-kappa B-driven transcription, so we hypothesized that the MEK --> ERK pathway regulated NF-kappa B-driven transcription as well. We found that a constitutive active MEK --> ERK pathway inhibited NF-kappa B-driven transcription. In addition, both PD 98059 and a dominant negative ERK2 augmented NF-kappa B-driven transcription; however, neither PD 98059 nor MEK1 altered NF-kappa B activation at any level. The constitutive active MEK --> ERK pathway inhibited the phosphorylation of TBP, which is necessary for both interaction with RelA and binding to the TATA box. Due to the fact that we have shown that the p38 MAP kinase modulates TBP activation, we evaluated the effect of the constitutive active MEK --> ERK pathway on p38 MAP kinase activity. We found that the MEK --> ERK pathway negatively regulates NF-kappa B-driven transcription, in part, by inhibiting p38 MAP kinase activity. Thus, the ERK and p38 MAP kinases have differential effects on NF-kappa B-driven transcription.	Univ Iowa Hosp & Clin, Div Pulm & Crit Care Med, Iowa City, IA 52242 USA; Vet Adm Med Ctr, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Carter, KB (corresponding author), Univ Iowa Hosp & Clin, Div Pulm & Crit Care Med, C33 GH,200 Hawkins Dr, Iowa City, IA 52242 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060316] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035018] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03860, HL60316] Funding Source: Medline; NIAID NIH HHS [AI35018] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Carter AB, 1998, AM J RESP CELL MOL, V18, P384, DOI 10.1165/ajrcmb.18.3.2972; Carter AB, 1999, AM J RESP CELL MOL, V20, P751, DOI 10.1165/ajrcmb.20.4.3420; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chen D, 1999, J IMMUNOL, V163, P5796; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chibazakura T, 1997, EUR J BIOCHEM, V247, P1166, DOI 10.1111/j.1432-1033.1997.01166.x; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; DeSilva DR, 1996, J EXP MED, V183, P2017, DOI 10.1084/jem.183.5.2017; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Feng GJ, 1999, J IMMUNOL, V163, P6403; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; HUNNINGHAKE GW, 1989, J VIROL, V63, P3026, DOI 10.1128/JVI.63.7.3026-3033.1989; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Monick MM, 1999, J BIOL CHEM, V274, P18075, DOI 10.1074/jbc.274.25.18075; Monick MM, 1999, J IMMUNOL, V162, P3005; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; REIMANN T, 1994, J IMMUNOL, V153, P5740; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	61	110	111	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27858	27864						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10878013				2022-12-27	WOS:000089197100047
J	Komeima, K; Hayashi, Y; Naito, Y; Watanabe, Y				Komeima, K; Hayashi, Y; Naito, Y; Watanabe, Y			Inhibition of neuronal nitric-oxide synthase by calcium/calmodulin-dependent protein kinase II alpha through Ser(847) phosphorylation in NG108-15 neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; ENDOTHELIAL NO SYNTHASE; BINDING DOMAIN; CDNA CLONING; IDENTIFICATION; LOCALIZATION; EXPRESSION; PURIFICATION; ACTIVATION; SYSTEM	We have previously demonstrated that phosphorylation of neuronal nitric-oxide synthase (nNOS) at Ser(847) by Ca2+/calmodulin-dependent protein kinases (CaM kinases) attenuates the catalytic activity of the enzyme in vitro (Hayashi Y,, Nishio M., Naito Y., Yokokura H., Nimura Y,, Hidaka H,, and Watanabe Y, (1999) J, Biol, Chem. 274, 20597-20602), In the present study we determined that CaM kinase II alpha (CaM-K II alpha) can directly phosphorylate nNOS on Sers(847), leading to a reduction of nNOS activity in cells, The phosphorylation abilities of purified CaM kinase I alpha (CaM-K I alpha), CaM-K II alpha, and CaM-kinase IV (CaM-K TV) on Ser(847) mere analyzed using the synthetic peptide nNOS-(836-859) (Glu-Glu-Arg-Lys-Ser-Tyr-Lys-Val-Arg-Phe-Asn-Ser-Val- Ser-Asp-Ser-Arg-Lys-Ser-Ser-Gly) from nNOS as substrate. The relative V-max/K-m ratios of CaM kinases for nNOS-(836-859) were found to be as follows: CaM-K II alpha, 100; CaM-K I alpha 54.5; CaM-K IV, 9.1, Co-transfection of constitutively active CaM-K II alpha 1-274 but not inactive CaM-K II alpha 1-274, generated by mutation of Lys(42) to Ala, with nNOS into NG108-15 cells, resulted in increased Ser(847) phosphorylation in the presence of okadaic acid, an inhibitor of protein phosphatase (PP)1 and PP2A, with a concomitant inhibition of NOS enzyme activity. In addition, this latter decrease could be reversed by treatment with exogenous PP2A. Cells expressing mutant nNOS (S847A) proved resistant to phosphorylation and a decrease of NOS activity. Thus, our results indicate that Ca2+ triggers cross-talk signal transduction between CaM kinase and NO and CaM-K II alpha phosphorylating nNOS on Ser(847), which in turn decreases the gaseous second messenger NO in neuronal cells.	Nagoya Univ, Sch Med, Dept Pharmacol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Ophthalmol, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University	Watanabe, Y (corresponding author), Nagoya Univ, Sch Med, Dept Pharmacol, Showa Ku, Nagoya, Aichi 4668550, Japan.			Watanabe, Yasuo/0000-0003-2232-0091				ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; BRUNE B, 1991, BIOCHEM BIOPH RES CO, V181, P921, DOI 10.1016/0006-291X(91)91279-L; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; CARLIN RK, 1981, J CELL BIOL, V89, P449, DOI 10.1083/jcb.89.3.449; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DINERMAN JL, 1994, NEUROPHARMACOLOGY, V33, P1245, DOI 10.1016/0028-3908(94)90023-X; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; Hayashi N, 1998, PROTEIN EXPRES PURIF, V12, P25, DOI 10.1006/prep.1997.0807; Hayashi Y, 1999, J BIOL CHEM, V274, P20597, DOI 10.1074/jbc.274.29.20597; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; Kantor DB, 1996, SCIENCE, V274, P1744, DOI 10.1126/science.274.5293.1744; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; Matsubara M, 1996, BIOCHEMISTRY-US, V35, P14651, DOI 10.1021/bi9613988; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Watanabe Y, 1997, FEBS LETT, V403, P75, DOI 10.1016/S0014-5793(97)00012-4; YAMAGATA Y, 1991, J BIOL CHEM, V266, P15391; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851	47	147	155	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28139	28143						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10874031				2022-12-27	WOS:000089197100080
J	Kroner, C; Eybrechts, K; Akkerman, JWN				Kroner, C; Eybrechts, K; Akkerman, JWN			Dual regulation of platelet protein kinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; GLYCOGEN-SYNTHASE KINASE-3; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; MOLECULAR-CLONING; THROMBIN RECEPTOR; ACTIVATION; AKT; BINDING; PHOSPHORYLATION; IDENTIFICATION	Protein kinase B (PKB) is a serine/threonine kinase that is activated by growth hormones and implicated in prevention of apoptosis, glycogen metabolism, and glucose uptake. A key enzyme in PKB activation is phosphatidylinositide 3-kinase (PI-3K), which triggers the dual phosphorylation of PKB by phosphatidylinositol-dependent kinases (PDKs). Here we report that the major PKB subtype in platelets is PKB alpha, which is activated by phosphorylation of Thr(308) and Ser(473) and has a constitutively phosphorylated Thr(450) that does not contribute to PKB activation. alpha-Thrombin and thrombopoietin activate PKB alpha via PI-3K and trigger the concurrent phosphorylation of Thr(308) (via PDK1) and Ser473 (via a not vet identified PDK2). In addition, alpha-thrombin activates a PI-3K-independent pathway involving phospholipase C beta and calcium-dependent protein kinase C subtypes (PKC alpha/beta). This route is specific for phosphorylation of Ser(473) and can be initiated by direct PRC activation with phorbol ester or purified active PKC catalytic fragment in platelet lysate. Different degrees of Ser(473) and Thr(308) phosphorylation correlate with different degrees of enzyme activity. These data reveal a PI-3K-independent PKB activation in which PKC alpha/beta regulates the phosphorylation of Ser(473) in PKB alpha. The independent control of the two phosphorylation sites may contribute to fine regulation of PKB alpha activity.	Univ Utrecht, Med Ctr, Lab Thrombosis & Haemostasis, Dept Haematol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University	Kroner, C (corresponding author), Univ Utrecht, Med Ctr, Lab Thrombosis & Haemostasis, Dept Haematol, POB 85500,3508 GA Utrecht, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.							Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; COCKCROFT S, 1992, BIOCHEM J, V288, P1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; Ezumi Y, 1998, EUR J BIOCHEM, V258, P976, DOI 10.1046/j.1432-1327.1998.2580976.x; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Hers I, 1998, ARTERIOSCL THROM VAS, V18, P404, DOI 10.1161/01.ATV.18.3.404; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; KOHN AD, 1995, EMBO J, V14, P4286; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Miyakawa Y, 1996, BLOOD, V87, P439, DOI 10.1182/blood.V87.2.439.bloodjournal872439; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Ogura T, 1997, J NEUROSCI, V17, P3580; Parker PJ, 1999, PHARMACOL THERAPEUT, V82, P263, DOI 10.1016/S0163-7258(98)00047-3; RodriguezLinares B, 1996, BIOCHEM J, V316, P93, DOI 10.1042/bj3160093; Rossler P, 1998, EUR J CELL BIOL, V77, P253; SABLE CL, 1997, FEBS LETT, V409, P252; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; VANWILLIGEN G, 1995, BIOCHEM BIOPH RES CO, V214, P254, DOI 10.1006/bbrc.1995.2282; VIGNON I, 1993, BLOOD, V82, P877; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265	42	113	120	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27790	27798		10.1074/jbc.M000540200	http://dx.doi.org/10.1074/jbc.M000540200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10874027	hybrid			2022-12-27	WOS:000089197100038
J	Dorman, CM; Johnson, SE				Dorman, CM; Johnson, SE			Activated Raf inhibits myogenesis through a mechanism independent of activator protein 1-mediated myoblast transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DIFFERENTIATION; SIGNALING PATHWAYS; MULTIPLE MECHANISMS; DNA-BINDING; AP-1; PROMOTER; EXPRESSION; GROWTH; GENE; JUN	Skeletal myogenesis is acutely affected by growth factors and subsequent activation of their respective intracellular signaling cascades. Components of the mitogenic Ras/Raf/mitogen-activated protein kinase (MAPK) signaling module are potent inhibitors of myoblast differentiation. However, the means by which these kinases prevent myocyte formation and activation of the muscle gene program is unknown. Activator protein 1 (AP-1) is a transcriptional regulator the actions of which are up-regulated by signaling events, including elevated MAPK, Because activated Raf inhibits avian myogenesis in a MAPK-dependent fashion, we investigated the role of AP-1 as a mediator of the Raf-imposed block to myogenesis. Avian myoblasts overexpressing activated Raf contain elevated levels of AP 1 DNA binding and transcriptional activity, Introduction of an AP-1 dominant inhibitory protein (AFOS) into Raf-expressing myoblasts prevented Requisition of a transformed morphology. Interestingly, these cells remained differentiation-defective. Myogenic cells cotransduced with RCAS(A)-Raf BXB and RCAS(B)-AFOS remained mononuclear and myosin-negative and did not activate significantly muscle-specific reporter genes. These results argue that Raf inhibits muscle differentiation independent of AP-1-mediated cell transformation. Our results provide evidence for AP-1 as a critical component of the transforming capacity of activated Raf and evidence that AP-1 is not involved in the myogenic inhibitory effects of the kinase.	Penn State Univ, Dept Poultry Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Johnson, SE (corresponding author), Penn State Univ, Dept Poultry Sci, University Pk, PA 16802 USA.	sej4@psu.edu						ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Blagden CS, 1999, CELL TISSUE RES, V296, P141, DOI 10.1007/s004410051275; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1998, ONCOGENE, V17, P213, DOI 10.1038/sj.onc.1201917; Husmann Irene, 1996, Cytokine and Growth Factor Reviews, V7, P249, DOI 10.1016/S1359-6101(96)00029-9; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR A, 1996, CURR OPIN NEUROBIOL, V6, P445; Lehtinen SK, 1996, BIOCHEM BIOPH RES CO, V229, P36, DOI 10.1006/bbrc.1996.1754; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PEDRAZAALVA G, 1994, J BIOL CHEM, V269, P6978; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Ried S, 1999, J BIOL CHEM, V274, P16377, DOI 10.1074/jbc.274.23.16377; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Silberman S, 1997, J BIOL CHEM, V272, P5927, DOI 10.1074/jbc.272.9.5927; SU HY, 1991, ONCOGENE, V6, P1759; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; Zhang YJ, 1999, NUCLEIC ACIDS RES, V27, P4090, DOI 10.1093/nar/27.20.4090	35	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27481	27487						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10867013				2022-12-27	WOS:000089144800107
J	Lametsch, R; Rasmussen, JT; Johnsen, LB; Purup, S; Sejrsen, K; Petersen, TE; Heegaard, CW				Lametsch, R; Rasmussen, JT; Johnsen, LB; Purup, S; Sejrsen, K; Petersen, TE; Heegaard, CW			Structural characterization of the fibroblast growth factor-binding protein purified from bovine prepartum mammary gland secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; RETINOIC ACID; IN-VIVO; ANGIOGENESIS; EXPRESSION; RELEASE; FGF; COMPLEX; IDENTIFICATION; PURIFICATION	A novel heparin-binding protein was purified to homogeneity from bovine prepartum mammary gland secretion using heparin-Sepharose chromatography and reverse-phase high performance liquid chromatography successively. Structural information obtained by N-terminal amino acid sequencing of a series of proteolytically generated peptides permitted the cloning of the corresponding cDNA. The isolated cDNA was 1170 base pairs long and consisted of an 83-base pair 5'-untranslated region followed by a 702-base pair coding region and a 385-base pair 3'-untranslated region. The open reading frame resulted in a protein comprising 234-amino acid residues, including a signal sequence. Instead of Lys(24) as the predicted N terminus, Edman degradation of the native protein revealed N-terminal processing at two sites as follows: a primary site between Arg(31)-Gly(32) and a secondary site between Arg(51)-Ser(52). The amino acid sequence showed a significant similarity with that of human (60%) and mouse (53%) fibroblast growth factor-binding protein (FGF-BP). Accordingly, ligand blotting experiments revealed that bovine FGF-BP bound FGF-2. The theoretical mass of the protein predicted from the cDNA sequence is 22.5 kDa. However, the molecular mass of the purified protein was estimated to 28.6 kDa by mass spectrometry and 36 kDa by electrophoresis, The apparent molecular weight differences are most likely due to post-transcriptional modifications, shown to involve N- and O-glycosylation of Asn(155) and Ser(172), respectively. All 10 cysteine residues in the protein participated in disulfide bonds, and the pattern was identified as Cys(71)-Cys(88), Cys(97)-Cys(130), Cys(106)-Cys(142), Cys(198)-Cys(234), and Cys(214)-Cys(222). As the 10 cysteines of the three known FGF-BPs are positionally conserved, the disulfide bond pattern of bovine FGF-BP may be regarded as representative for the FGF-BP family.	Aarhus Univ, Dept Biol Mol & Struct, Prot Chem Lab, DK-8000 Aarhus C, Denmark; Danish Inst Anim Sci, Res Ctr Foulum, DK-8830 Tjele, Denmark	Aarhus University; Aarhus University	Heegaard, CW (corresponding author), Aarhus Univ, Dept Biol Mol & Struct, Prot Chem Lab, Sci Pk,Gustav Wieds Vej 10, DK-8000 Aarhus C, Denmark.	cwh@imsb.au.dk	Heegaard, Christian W/A-4814-2019; Lametsch, René/E-6174-2015; Lametsch, René/AAQ-4582-2021	Lametsch, René/0000-0002-4189-806X; Lametsch, René/0000-0002-4189-806X; Wurtz Heegaard, Christian/0000-0002-7989-2624; Purup, Stig/0000-0003-0653-4751; Rasmussen, Jan Trige/0000-0002-2809-7225				BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BRUNNER G, 1991, J CELL BIOL, V114, P1275, DOI 10.1083/jcb.114.6.1275; Buczek-Thomas JA, 1999, J BIOL CHEM, V274, P25167, DOI 10.1074/jbc.274.35.25167; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; Dinbergs ID, 1996, J BIOL CHEM, V271, P29822, DOI 10.1074/jbc.271.47.29822; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Hvarregaard J, 1996, EUR J BIOCHEM, V240, P628, DOI 10.1111/j.1432-1033.1996.0628h.x; Jackson D, 1997, J CELL SCI, V110, P1261; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klein S, 1997, EXS, V79, P159; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Lavandero S, 1998, FEBS LETT, V439, P351, DOI 10.1016/S0014-5793(98)01370-2; LiaudetCoopman EDE, 1997, CLIN CANCER RES, V3, P179; LiaudetCoopman EDE, 1996, J BIOL CHEM, V271, P21303, DOI 10.1074/jbc.271.35.21303; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Metzger RJ, 1999, SCIENCE, V284, P1635, DOI 10.1126/science.284.5420.1635; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Okamoto T, 1996, IN VITRO CELL DEV-AN, V32, P69; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; Plath A, 1998, J DAIRY SCI, V81, P2604, DOI 10.3168/jds.S0022-0302(98)75818-7; Rak J, 1997, NAT MED, V3, P1083, DOI 10.1038/nm1097-1083; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SANDOWSKI Y, 1993, LIVEST PROD SCI, V35, P35, DOI 10.1016/0301-6226(93)90180-P; Talhouk RS, 1996, J REPROD FERTIL, V106, P221, DOI 10.1530/jrf.0.1060221; Wang XC, 1998, BIOCHEM MOL BIOL INT, V46, P81; WU DQ, 1991, J BIOL CHEM, V266, P16778	34	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19469	19474		10.1074/jbc.M002550200	http://dx.doi.org/10.1074/jbc.M002550200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867016	hybrid			2022-12-27	WOS:000087941300007
J	Song, YS; Ji, I; Beauchamp, J; Isaacs, NW; Ji, TH				Song, YS; Ji, I; Beauchamp, J; Isaacs, NW; Ji, TH			Hormone interactions to Leu-rich repeats in the gonadotropin receptors - II. Analysis of Leu-rich repeat 4 of human luteinizing hormone/chorionic gonadotropin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; CHORIONIC-GONADOTROPIN; EXTRACELLULAR DOMAIN; BINDING; ACTIVATION; AFFINITY; SEQUENCE; GENE; RAT	The luteinizing hormone receptor (LHR) consists of an similar to 350-amino acid-long N-terminal extracellular exodomain and a membrane-associated endodomain of similar size. Human chorionic gonadotropin (hCG) binds to the exodomain, and then hCG/exodomain complex is thought to make a secondary contact with the endodomain and generate hormone signals. The sequence alignment of the exodomain shows imperfectly matching eight to nine Leu-rich repeats (LRRs), In the preceding article (Song, Y., Ji, I., Beauchamp, J., Isaacs, N., and Ji, T, (2001) J. Biol. Chem. 276, 3426-3435), we have shown that LRR2 and LRR4 are crucial for hormone binding. In this work, we have examined the residues of LRR4, in particular Leu(103) and Ile(105) in the putative beta strand. Our data show that Leu(103) and Ile(105) are involved in the specific, hydrophobic interaction of the LRR4 loop, likely to form the hydrophobic core. This loop is crucial for the structural integrity of all of the LRRs. In contrast, the downstream sequence consisting of Asn(107), Thr(108), Gly(109), and Ile(110) of LRR4 is crucial for cAMP induction but not for hormone binding, folding, and surface expression. This implicates, for the first time, its involvement in the interaction with the endodomain and signal generation. The evidence for the interaction is presented in the following article.	Univ Kentucky, Dept Chem, Lexington, KY 40506 USA; Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul 110744, South Korea; Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland	University of Kentucky; Seoul National University (SNU); University of Glasgow	Ji, TH (corresponding author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.		Song, Yong Sang/E-7824-2012	SONG, YONGSANG/0000-0001-7115-4021	NICHD NIH HHS [HD-18702] Funding Source: Medline; NIDDK NIH HHS [DK-51469] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051469] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abell A, 1996, J BIOL CHEM, V271, P4518; Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Couture L, 1996, J MOL ENDOCRINOL, V16, P15, DOI 10.1677/jme.0.0160015; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; GRISWOLD MD, 1993, SERTOLI CELLS, P496; Hong SH, 1998, J BIOL CHEM, V273, P13835, DOI 10.1074/jbc.273.22.13835; HSUEH AJW, 1983, J REPROD FERTIL, V69, P325, DOI 10.1530/jrf.0.0690325; Jeoung MK, 2001, J BIOL CHEM, V276, P3443, DOI 10.1074/jbc.M003774200; JI IH, 1995, J BIOL CHEM, V270, P15970, DOI 10.1074/jbc.270.27.15970; JI L, 1991, ENDOCRINOLOGY, V128, P2648; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; LIU XX, 1994, ENDOCRINOLOGY, V135, P682, DOI 10.1210/en.135.2.682; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; PRIKETT K, 1989, BIOTECHNIQUES, V7, P580; Song YS, 2001, J BIOL CHEM, V276, P3426, DOI 10.1074/jbc.M003772200; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; XIE YB, 1990, J BIOL CHEM, V265, P21411	25	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3436	3442		10.1074/jbc.M003773200	http://dx.doi.org/10.1074/jbc.M003773200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	10884391	hybrid			2022-12-27	WOS:000166784900059
J	Chen, ZJ; Fitzgerald, RL; Averna, MR; Schonfeld, G				Chen, ZJ; Fitzgerald, RL; Averna, MR; Schonfeld, G			A targeted apolipoprotein B-38.9-producing mutation causes fatty livers in mice due to the reduced ability of apolipoprotein B-38.9 to transport triglycerides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B MESSENGER-RNA; FAMILIAL HYPOBETALIPOPROTEINEMIA; NONSENSE MUTATION; APO-B; TRUNCATED APOLIPOPROTEIN; HETEROZYGOUS HYPOBETALIPOPROTEINEMIA; EMBRYONIC LETHALITY; PLASMA-LIPOPROTEINS; MOUSE MODEL; GENE	Nonphysiological truncations of apolipoprotein (apo) B-100 cause familial hypobetalipoproteinemia (FHBL) in humans and mice. An elucidation of the mechanisms underlying the FHBL phenotypes may provide valuable information on the metabolism of apo B-containing lipoproteins and the structure-function relationship of apo B. To generate a faithful mouse model of human FHBL, a subtle mutation was introduced into the mouse apo B gene by targeting embryonic stem cells using homologous recombination followed by removal of the selection marker gene by Cre-loxP-mediated site-specific recombination. The engineered mice bear a premature stop codon at residue 1767 and a 42-base pair loxP inserted into intron 24 of the apo B gene, thus closely resembling the apo B-38.9-producing mutation in humans. Apo B-38.9 was the sole apo B protein in homozygote (apob(38.9/38.9)) plasma. In heterozygotes (apob(+/38.9)), apo B-100 and apo B-48 were reduced by 75 and 40%, respectively, and apo B-38.9 represented 20% of total circulating apo B. Hepatic apo B-38.9 mRNA levels were reduced by 40%. In cultured apob(+/38.9) hepatocytes, apo B-100 was produced in trace quantities, and the synthesis rate of apo B-38.9 relative to apo B-48 was reduced by 40%. However, almost equimolar amounts of apo B-38.9 and apo B-48 were secreted into the media, Pulse-chase studies revealed that apo B-38.9 was secreted at a faster rate and more efficiently than apoB-48. Nevertheless, both apob(+/38.9) and apob(38.9/38.9) mice had reduced hepatic triglyceride secretion rates and fatty livers. Thus, low mRNA levels or defective secretion of apo B-38.9 may not be responsible for the FHBL phenotypes caused by the apo B-38.9 mutation. Rather, a reduced capacity of apo B-38.9 for triglyceride transport may account for the fatty livers in these mice.	Washington Univ, Sch Med, Dept Med, Div Atherosclerosis Nutr & Lipid Res, St Louis, MO 63110 USA	Washington University (WUSTL)	Chen, ZJ (corresponding author), Washington Univ, Sch Med, Dept Med, Div Atherosclerosis Nutr & Lipid Res, Box 8046,660 S Euclid Ave, St Louis, MO 63110 USA.	zchen@im.wustl.edu	Averna, Maurizio/U-9527-2017	Averna, Maurizio/0000-0003-3558-9209	NHLBI NIH HHS [R37 HL-424460, R01 HL-59515] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059515] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmed A, 1998, AM J GASTROENTEROL, V93, P2598, DOI 10.1016/S0002-9270(98)00613-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; Castellano G, 1997, J CLIN GASTROENTEROL, V25, P379, DOI 10.1097/00004836-199707000-00021; Cavallo D, 1998, J BIOL CHEM, V273, P33397, DOI 10.1074/jbc.273.50.33397; CHAN L, 1992, J BIOL CHEM, V267, P25621; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Chen ZJ, 1999, J CLIN INVEST, V103, P1419, DOI 10.1172/JCI4921; Chen ZJ, 1999, CIRCULATION, V100, P329; Elias N, 1999, ARTERIOSCL THROM VAS, V19, P2714, DOI 10.1161/01.ATV.19.11.2714; Farese RV, 1996, P NATL ACAD SCI USA, V93, P6393, DOI 10.1073/pnas.93.13.6393; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; FRANGI D, 1991, J CLIN INVEST, V88, P755, DOI 10.1172/JCI115373; GREEVE J, 1993, J LIPID RES, V34, P1367; GROENEWEGEN WA, 1994, J LIPID RES, V35, P1012; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HIGUCHI K, 1992, J LIPID RES, V33, P1753; HOMANICS GE, 1993, P NATL ACAD SCI USA, V90, P2389, DOI 10.1073/pnas.90.6.2389; HUANG LS, 1995, J CLIN INVEST, V96, P2152, DOI 10.1172/JCI118269; Hug BA, 1996, MOL CELL BIOL, V16, P2906; JIAO S, 1990, J LIPID RES, V31, P467; Kim E, 1998, J BIOL CHEM, V273, P33977, DOI 10.1074/jbc.273.51.33977; Kim E, 1998, J CLIN INVEST, V101, P1468; KRUL ES, 1992, J LIPID RES, V33, P1037; LEHRMAN MA, 1987, J BIOL CHEM, V262, P401; Li XH, 1996, J LIPID RES, V37, P210; LIEBHABER SA, 1987, J CLIN INVEST, V80, P154, DOI 10.1172/JCI113041; LINTON MF, 1993, J LIPID RES, V34, P521; LONGO N, 1992, AM J HUM GENET, V50, P998; MARWELL MAK, 1978, ANAL BIOCHEM, V87, P206; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; Ogata H, 1997, AM J GASTROENTEROL, V92, P339; PARHOFER KG, 1992, J CLIN INVEST, V89, P1931, DOI 10.1172/JCI115799; Parhofer KG, 1996, J LIPID RES, V37, P844; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; SCHONFELD G, 1995, ANNU REV NUTR, V15, P23, DOI 10.1146/annurev.nu.15.070195.000323; Srivastava N, 1996, METABOLISM, V45, P1296, DOI 10.1016/S0026-0495(96)90251-6; Tarugi P, 1996, GASTROENTEROLOGY, V111, P1125, DOI 10.1016/S0016-5085(96)70082-3; Toth LR, 1996, GENE, V178, P161, DOI 10.1016/0378-1119(96)00360-5; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; WINSLOW RM, 1976, J CLIN INVEST, V57, P772, DOI 10.1172/JCI108336; Wu JS, 1999, J LIPID RES, V40, P955; YAO ZM, 1991, J BIOL CHEM, V266, P3300; Zhu XF, 1997, ARTERIOSCL THROM VAS, V17, P1032, DOI 10.1161/01.ATV.17.6.1032	47	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32807	32815		10.1074/jbc.M004913200	http://dx.doi.org/10.1074/jbc.M004913200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10893242	hybrid			2022-12-27	WOS:000090003800060
J	Gunnarsson, A; Hellmark, T; Wieslander, J				Gunnarsson, A; Hellmark, T; Wieslander, J			Molecular properties of the Goodpasture epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR BASEMENT-MEMBRANE; IV COLLAGEN; ALPHA-3(IV) CHAIN; GBM ANTIBODIES; AUTOANTIGEN; ANTIGEN; DOMAIN; AUTOANTIBODIES; DISEASE; REGION	Goodpasture disease fulfils all criteria for a classical autoimmune disease, where autoantibodies targeted against the non-collagenous domain of the alpha 3-chain of collagen TV initiates an inflammatory destruction of the basement membrane in kidney glomeruli and lung alveoli. This leads to a rapidly progressive glomerulonephritis and severe pulmonary hemorrhage. Previous studies have indicated a limited epitope for the toxic antibodies in the N-terminal part of the non-collagenous domain. The epitope has been partially characterized by recreating the epitope in the non-reactive alpha 1-chain by exchanging nine residues to the corresponding ones of alpha 3. In this study we have investigated to what extent each of these amino acids contribute to the antibody binding in different patient sera. The results show that seven of the nine substitutions are enough to get an epitope that is recognized equally well as the native alpha 3-chain by all sera from 20 clinically verified Goodpasture patients. Furthermore, the patient sera reactivity against the different recombinant chains used in the study are very similar, with some minor exceptions, strongly supporting a highly defined and restricted epitope. We are convinced that the restriction of the epitope is of significant importance for the understanding of the etiology of the disease. Thereby also making every step on the way to characterization of the epitope a crucial step on the way to specific therapy for the disease.	Wieslab AB, S-22370 Lund, Sweden; Univ Lund Hosp, Dept Nephrol, S-22185 Lund, Sweden	Lund University; Skane University Hospital	Wieslander, J (corresponding author), Wieslab AB, S-22370 Lund, Sweden.		Hellmark, Thomas/U-6289-2017	Hellmark, Thomas/0000-0002-2952-1155				Borza DB, 2000, J BIOL CHEM, V275, P6030, DOI 10.1074/jbc.275.8.6030; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; HELLMARK T, 1994, KIDNEY INT, V46, P823, DOI 10.1038/ki.1994.338; Hellmark T, 1996, CLIN EXP IMMUNOL, V105, P504, DOI 10.1046/j.1365-2249.1996.119808.x; Hellmark T, 1999, J BIOL CHEM, V274, P25862, DOI 10.1074/jbc.274.36.25862; Hellmark T, 1999, KIDNEY INT, V55, P936, DOI 10.1046/j.1523-1755.1999.055003936.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KALLURI R, 1991, J BIOL CHEM, V266, P24018; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; LERNER RA, 1967, J EXP MED, V126, P989, DOI 10.1084/jem.126.6.989; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; Phelps RG, 1999, KIDNEY INT, V56, P1638, DOI 10.1046/j.1523-1755.1999.00720.x; Phelps RG, 1998, J BIOL CHEM, V273, P11440, DOI 10.1074/jbc.273.19.11440; PUSEY CD, 1987, LAB INVEST, V56, P23; QUINONES S, 1992, J BIOL CHEM, V267, P19780; Ryan JJ, 1998, CLIN EXP IMMUNOL, V113, P17, DOI 10.1046/j.1365-2249.1998.00623.x; Schulte S, 1998, J BIOL CHEM, V273, P1551, DOI 10.1074/jbc.273.3.1551; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; TURNER N, 1993, DISEASES KIDNEY, P1865; WIESLANDER J, 1984, P NATL ACAD SCI-BIOL, V81, P1544, DOI 10.1073/pnas.81.5.1544; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564	22	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30844	30848		10.1074/jbc.M004717200	http://dx.doi.org/10.1074/jbc.M004717200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896942	hybrid			2022-12-27	WOS:000089762700018
J	Kuwasako, K; Shimekake, Y; Masuda, M; Nakahara, K; Yoshida, T; Kitaura, M; Kitamura, K; Eto, T; Sakata, T				Kuwasako, K; Shimekake, Y; Masuda, M; Nakahara, K; Yoshida, T; Kitaura, M; Kitamura, K; Eto, T; Sakata, T			Visualization of the calcitonin receptor-like receptor and its receptor activity-modifying proteins during internalization and recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; GREEN FLUORESCENT PROTEIN; GASTRIN-RELEASING PEPTIDE; AORTIC ENDOTHELIAL-CELLS; BETA(2)-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; ENDOCYTIC PATHWAY; LIGAND; ADRENOMEDULLIN	Expression of the calcitonin receptor-like receptor (CRLR) and its receptor activity modifying proteins (RAMPs) can produce calcitonin gene-related peptide (CGRP) receptors (CRLR/RAMP1) and adrenomedullin (AM) receptors (CRLR/RAMP2 or -3), A chimera of the CRLR and green fluorescent protein (CRLR-GFP) was used to study receptor localization and trafficking in stably transduced HEK 293 cells, with or without cotransfection of RAMPs, CRLR-GFP failed to generate responses to CGRP or AM without RAMPs, Furthermore, CRLR-GFP was not found in the plasma membrane and its localization was unchanged after agonist exposure. When stably coexpressed with RAMPs, CRLR-GFP appeared on the cell surface and was fully active in intracellular cAMP production and calcium mobilization, Agonist-mediated internalization of CRLR-GFP was observed in RAMP1/CGRP or AM, RAMP2/AM, and RAMP3/AM, which occurred with similar kinetics, indicating the existence of ligand-specific regulation of CRLR internalization by RAMPs. This internalization was strongly inhibited by hypertonic medium (0.45 M sucrose) and paralleled localization of rhodamine-labeled transferrin, suggesting that CRLR endocytosis occurred predominantly through a clathrin-dependent pathway. A significant proportion of CRLR was targeted to lysosomes upon binding of the ligands, and recycling of the internalized CRLR was not efficient. In HER 293 cells stably expressing CRLR-GFP and Myc-RAMPs, these rhodamine-labeled RAMPs were co-localized with CRLR-GFP in the presence and absence of the ligands, Thus, the CRLR is endocytosed together with RAMPs via clathrin-coated vesicles, and both the internalized molecules are targeted to the degradative pathway.	Shionogi & Co Ltd, Shionogi Inst Med Sci, Settsu, Osaka 5660022, Japan; Miyazaki Med Coll, Dept Internal Med 1, Miyazaki 8891692, Japan; Natl Cardiovasc Res Inst, Dept Struct Anal, Osaka 5658565, Japan	Shionogi & Company Limited; University of Miyazaki; National Cerebral & Cardiovascular Center - Japan	Sakata, T (corresponding author), Shionogi & Co Ltd, Shionogi Inst Med Sci, 2-5-1 Mishima, Settsu, Osaka 5660022, Japan.		Kuwasako, Kenji/H-8065-2016					Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; Drissi H, 1998, J BIOL CHEM, V273, P20168, DOI 10.1074/jbc.273.32.20168; FLUHMANN B, 1995, BIOCHEM BIOPH RES CO, V206, P341, DOI 10.1006/bbrc.1995.1047; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; GOODMAN EC, 1986, LIFE SCI, V38, P2169, DOI 10.1016/0024-3205(86)90568-0; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; GUON XM, 1992, J BIOL CHEM, V267, P21995; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Kitamura K, 1997, CURR OPIN NEPHROL HY, V6, P80, DOI 10.1097/00041552-199701000-00015; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; KRUGER L, 1988, BRAIN RES, V463, P223, DOI 10.1016/0006-8993(88)90395-2; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Muff R, 1998, FEBS LETT, V441, P366, DOI 10.1016/S0014-5793(98)01587-7; Mundell SJ, 1998, BRIT J PHARMACOL, V125, P1594, DOI 10.1038/sj.bjp.0702234; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; PERKINS JP, 1991, BETA ADRENERGIC RECE, P125; POYNER DR, 1992, PHARMACOL THERAPEUT, V56, P23, DOI 10.1016/0163-7258(92)90036-Y; Samson WK, 1998, FRONT NEUROENDOCRIN, V19, P100, DOI 10.1006/frne.1998.0164; SHIMEKAKE Y, 1995, J BIOL CHEM, V270, P4412, DOI 10.1074/jbc.270.9.4412; SLICE LW, 1994, J BIOL CHEM, V269, P21755; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; Tarasova NI, 1998, J BIOL CHEM, V273, P15883, DOI 10.1074/jbc.273.26.15883; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; ZIMMERMANN U, 1995, PEPTIDES, V16, P421, DOI 10.1016/0196-9781(94)00195-C	41	138	145	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29602	29609		10.1074/jbc.M004534200	http://dx.doi.org/10.1074/jbc.M004534200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10882736	hybrid			2022-12-27	WOS:000089439800057
J	Mayer, M; Kies, U; Kammermeier, R; Buchner, J				Mayer, M; Kies, U; Kammermeier, R; Buchner, J			BiP and PDI cooperate in the oxidative folding of antibodies in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; IMMUNOGLOBULIN HEAVY-CHAIN; CHAPERONE-LIKE ACTIVITY; ENDOPLASMIC-RETICULUM; BINDING-PROTEIN; LIGHT-CHAIN; RESIDENT PROTEIN; ATPASE ACTIVITY; SEQUENCES; HOMOLOG	Immunoglobulin heavy chain binding protein (BiP), a member of the Hsp70 chaperone family, and the oxidoreductase protein-disulfide isomerase (PDI) play an important role in the folding and oxidation of proteins in the endoplasmic reticulum. However, it was not clear whether both cooperate in this process. We show here that BiP and PDI act synergistically in the in vitro folding of the denatured and reduced Fab fragment. Several ATP-dependent cycles of binding, release, and rebinding of the unfolded antibody chains by Rip are required for efficient reactivation. Our data suggest that in the absence of BiP unfolded antibody chains collapse rapidly upon refolding, rendering cysteine side chains inaccessible for PDI. BiP binds the unfolded polypeptide chains and keeps them in a conformation in which the cysteine residues are accessible for PDI. These findings support the idea of a network of folding helper proteins in the endoplasmic reticulum, which makes this organelle a dedicated protein-processing compartment.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				BERGERON JJ, 1997, TRENDS BIOCHEM SCI, V19, P124; BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; Bies C, 1999, BIOL CHEM, V380, P1175, DOI 10.1515/BC.1999.149; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGHTMAN SE, 1995, GENE, V153, P249, DOI 10.1016/0378-1119(94)00741-A; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; BUCKEL P, 1987, GENE, V51, P13, DOI 10.1016/0378-1119(87)90469-0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CAI H, 1994, J BIOL CHEM, V269, P24550; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FREEDMAN RB, 1991, CONFORMATIONS FORCES, P204; GAUT JR, 1993, J BIOL CHEM, V268, P7248; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; GETHING MJ, 1997, MOL CHAPERONES PROTE, P59; GOTO Y, 1981, J MOL BIOL, V146, P321, DOI 10.1016/0022-2836(81)90391-0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; Knarr G, 1999, J BIOL CHEM, V274, P29850, DOI 10.1074/jbc.274.42.29850; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; LILIE H, 1994, J BIOL CHEM, V269, P14290; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Nishikawa S, 1997, J BIOL CHEM, V272, P12889, DOI 10.1074/jbc.272.20.12889; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; RUDOLPH R, 1990, MODERN METHOD IN PROTEIN- AND NUCLEIC ACID RESEARCH, P149; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SEGAL MS, 1992, J CELL BIOL, V118, P227, DOI 10.1083/jcb.118.2.227; Skowronek MH, 1999, BIOL CHEM, V380, P1133, DOI 10.1515/BC.1999.142; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; Stevens FJ, 1999, SEMIN CELL DEV BIOL, V10, P443, DOI 10.1006/scdb.1999.0315; Wang CC, 1998, ANN NY ACAD SCI, V864, P9, DOI 10.1111/j.1749-6632.1998.tb10283.x; WANG CC, 1993, FASEB J, V7, P1515, DOI 10.1096/fasebj.7.15.7903263; WEI JY, 1995, J BIOL CHEM, V270, P26670, DOI 10.1074/jbc.270.44.26670; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651	43	88	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29421	29425		10.1074/jbc.M002655200	http://dx.doi.org/10.1074/jbc.M002655200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10893409	hybrid			2022-12-27	WOS:000089439800034
J	Davis, MS; Solbiati, J; Cronan, JE				Davis, MS; Solbiati, J; Cronan, JE			Overproduction of acetyl-CoA carboxylase activity increases the rate of fatty acid biosynthesis in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; ACYL CARRIER PROTEIN; BACTERIOPHAGE-T7 RNA-POLYMERASE; PHOSPHOLIPID-SYNTHESIS; BIOTIN CARBOXYLASE; EXPRESSION; CARBOXYLTRANSFERASE; OVEREXPRESSION; PURIFICATION; INHIBITION	Acetyl-CoA carboxylase (ACC) catalyzes the first committed step of the fatty acid synthetic pathway. Although ACC has often been proposed to be a major rate-controlling enzyme of this pathway, no direct tests of this proposal in vivo have been reported. We have tested this proposal in Escherichia coli. The genes encoding the four subunits off. coli ACC were cloned in a single plasmid under the control of a bacteriophage T7 promoter. Upon induction of gene expression, the four ACC subunits were overproduced in equimolar amounts. Overproduction of the proteins resulted in greatly increased ACC activity with a concomitant increase in the intracellular level of malonyl-CoA The effects of ACC overexpression on the rate of fatty acid synthesis were examined in the presence of a thioesterase, which provided a metabolic sink for fatty acid overproduction. Under these conditions ACC overproduction resulted in a 6-fold increase in the rate of fatty acid synthesis.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.	j-cronan@life.uiuc.edu	Cronan, John/V-6626-2019					Abu-Elheiga L, 2000, P NATL ACAD SCI USA, V97, P1444, DOI 10.1073/pnas.97.4.1444; ALBERTS AW, 1972, ENZYMES, V6, P37; Blanchard CZ, 1998, J BIOL CHEM, V273, P19140, DOI 10.1074/jbc.273.30.19140; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; CHO HS, 1995, J BIOL CHEM, V270, P4216, DOI 10.1074/jbc.270.9.4216; Emmerling M, 2000, BIOTECHNOL BIOENG, V67, P623, DOI [10.1002/(SICI)1097-0290(20000305)67:5<623::AID-BIT13>3.0.CO;2-W, 10.1002/(SICI)1097-0290(20000305)67:5&lt;623::AID-BIT13&gt;3.0.CO;2-W]; FALL RR, 1976, BIOCHIM BIOPHYS ACTA, V450, P475, DOI 10.1016/0005-2760(76)90022-9; FELL D, 1996, UNDERSTANDING CONTRO; GELMANN EP, 1972, J BACTERIOL, V112, P381, DOI 10.1128/JB.112.1.381-387.1972; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; HARDER ME, 1972, P NATL ACAD SCI USA, V69, P3105, DOI 10.1073/pnas.69.11.3105; HARWOOD JL, 1990, METHODS PLANT BIOCH, P96; HEATH RJ, 1994, J BIOL CHEM, V269, P26584; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; HEATH RJ, 1995, J BIOL CHEM, V270, P15531, DOI 10.1074/jbc.270.26.15531; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; Heinrich R., 1996, REGULATION CELLULAR; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JENG ST, 1992, J BIOL CHEM, V267, P19306; JIANG P, 1994, J BACTERIOL, V176, P2814, DOI 10.1128/JB.176.10.2814-2821.1994; JOSHI VC, 1971, ARCH BIOCHEM BIOPHYS, V143, P493, DOI 10.1016/0003-9861(71)90234-7; Kim KH, 1997, ANNU REV NUTR, V17, P77, DOI 10.1146/annurev.nutr.17.1.77; LI SJ, 1992, J BACTERIOL, V174, P5755, DOI 10.1128/JB.174.17.5755-5757.1992; LI SJ, 1992, J BIOL CHEM, V267, P855; LI SJ, 1992, J BIOL CHEM, V267, P16841; LI SJ, 1993, J BACTERIOL, V175, P332, DOI 10.1128/JB.175.2.332-340.1993; Liao JC, 1996, BIOTECHNOL BIOENG, V52, P129, DOI 10.1002/(SICI)1097-0290(19961005)52:1<129::AID-BIT13>3.0.CO;2-J; Lyakhov DL, 1998, J MOL BIOL, V280, P201, DOI 10.1006/jmbi.1998.1854; METZGER S, 1988, J BIOL CHEM, V263, P15699; Millard CS, 1996, APPL ENVIRON MICROB, V62, P1808, DOI 10.1128/AEM.62.5.1808-1810.1996; Munday MR, 1999, ADV ENZYME REGUL, V39, P205, DOI 10.1016/S0065-2571(98)00016-8; PAGE RA, 1994, BBA-LIPID LIPID MET, V1210, P369, DOI 10.1016/0005-2760(94)90242-9; POLAKIS SE, 1973, J BIOL CHEM, V248, P7957; POLAKIS SE, 1974, J BIOL CHEM, V249, P6657; SANKAR P, 1993, J BACTERIOL, V175, P5145, DOI 10.1128/JB.175.16.5145-5152.1993; SILBERT DF, 1974, FED PROC, V33, P1725; SILBERT DF, 1976, J BACTERIOL, V126, P1351, DOI 10.1128/JB.126.3.1351-1354.1976; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WALSH K, 1985, P NATL ACAD SCI USA, V82, P3577, DOI 10.1073/pnas.82.11.3577	40	335	415	1	80	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28593	28598		10.1074/jbc.M004756200	http://dx.doi.org/10.1074/jbc.M004756200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893421	hybrid			2022-12-27	WOS:000089330700036
J	Morris, MC; Heitz, A; Mery, J; Heitz, F; Divita, G				Morris, MC; Heitz, A; Mery, J; Heitz, F; Divita, G			An essential phosphorylation-site domain of human cdc25C interacts with both 14-3-3 and cyclins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MITOTIC INDUCER; PROTEIN-KINASE; CELL-CYCLE; DNA-DAMAGE; CHECKPOINT CONTROL; DEPENDENT KINASES; CHEMICAL-SHIFTS; HUMAN HOMOLOG; PHOSPHATASE	Human cdc25C is a dual-specificity phosphatase involved in the regulation of cell cycle progression in both unperturbed cells and in cells subject to DNA damage or replication checkpoints. In this study, we describe the structure-function relationship of an essential domain of human cdc25C that interacts with 14-3-3 proteins. We show that this domain is a hi-functional interactive motif that interacts with cyclins primarily through their P-box motif in addition to 14-3-3 proteins. Characterization of the structural features of this domain by NMR and circular dichroism reveals two distinct cu helical moieties interconnected by a loop carrying the 14-3-3 binding site. Moreover, the helical folding is induced upon binding to 14-3-3, suggestive of a conformational regulation of this domain of cdc25C through interactions with partner proteins in vivo. Combining our structural and biochemical data, we propose a detailed model of the molecular mechanism of cdc25C regulation by differential association with 14-3-3 and cdc2-cyclin B.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Fac Pharm Montpellier, INSERM U414, F-34060 Montpellier, France; CNRS, UMR 9955, Ctr Biochim Struct, F-34060 Montpellier, France; CNRS UPR 1086, Ctr Rech Biochim Macromol, Biophys Unit, F-34293 Montpellier 5, France	Scripps Research Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Divita, G (corresponding author), Scripps Res Inst, Dept Mol Biol, MB4,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gilles@scripps.edu	MORRIS, May C/J-5940-2016; MORRIS, May/ABB-2629-2021	MORRIS, May C/0000-0001-8106-9728; MORRIS, May/0000-0001-8106-9728				Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown NR, 1999, J BIOL CHEM, V274, P8746, DOI 10.1074/jbc.274.13.8746; Chaloin L, 1997, BIOCHEMISTRY-US, V36, P11179, DOI 10.1021/bi9708491; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Guermeur Y, 1999, BIOINFORMATICS, V15, P413, DOI 10.1093/bioinformatics/15.5.413; Heitz F, 1997, BIOCHEMISTRY-US, V36, P4995, DOI 10.1021/bi962349y; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; KONTAXIS G, 1994, J MAGN RESON SER A, V111, P70, DOI 10.1006/jmra.1994.1227; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LAMB NJC, 1994, ADV PROTEIN PHOSPHAT, V8, P133; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Morris MC, 1999, J MOL BIOL, V286, P475, DOI 10.1006/jmbi.1998.2475; Morris MC, 1999, J PEPT SCI, V5, P263, DOI 10.1002/(SICI)1099-1387(199906)5:6<263::AID-PSC191>3.3.CO;2-1; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NAGATA A, 1991, NEW BIOL, V3, P959; OGG S, 1994, J BIOL CHEM, V269, P30461; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Reynolds RA, 1999, J MOL BIOL, V293, P559, DOI 10.1006/jmbi.1999.3168; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; THANABAL V, 1994, J BIOMOL NMR, V4, P47; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Wuthrich K., 1996, NMR PROTEINS NUCL AC; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; ZHENG XF, 1993, CELL, V75, P155, DOI 10.1016/S0092-8674(05)80092-3	51	38	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28849	28857		10.1074/jbc.M002942200	http://dx.doi.org/10.1074/jbc.M002942200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10864927	Green Published, hybrid			2022-12-27	WOS:000089330700068
J	Tsuji, Y; Shimada, Y; Takeshita, T; Kajimura, N; Nomura, S; Sekiyama, N; Otomo, J; Usukura, J; Nakanishi, S; Jingami, H				Tsuji, Y; Shimada, Y; Takeshita, T; Kajimura, N; Nomura, S; Sekiyama, N; Otomo, J; Usukura, J; Nakanishi, S; Jingami, H			Cryptic dimer interface and domain organization of the extracellular region of metabotropic glutamate receptor subtype 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE PHEROMONE RECEPTORS; PERIPLASMIC BINDING-PROTEINS; LIGAND-BINDING; DIMERIZATION; EXPRESSION; COMPLEX; HETERODIMERIZATION; IDENTIFICATION; PURIFICATION; LOCALIZATION	Previously, we produced the whole extracellular region of metabotropic glutamate receptor subtype 1 (mGluR1) in a soluble form. The soluble receptor retained a ligand affinity comparable with that of the full-length membrane-bound receptor and formed a disulfide-linked dimer, Here, we have identified a cysteine residue responsible for the intermolecular disulfide bond and determined domain organization of the extracellular region of mGluR1, A mutant, C140A, was a monomer under nonreduced conditions by SDS-polyacrylamide gel electrophoresis; however, C140A was eluted at the position similar to that of mGluR113, the wild type soluble receptor, by size exclusion column chromatography, Furthermore, C140A bound a Ligand, [H-3]quisqualate, with an affinity similar to that obtained by mGluR113, Oocytes injected with RNA for full-length mGluR1 containing C140A mutation showed responses to ligands at magnitudes similar to those with wild type full-length RNA. Thus, elimination of the disulfide linkage did not perturb the dimer formation and ligand signaling, suggesting that cryptic dimer interface(s) possibly exist in mGluR1, Limited proteolysis of the whole extracellular fragment (residue 33-592) revealed two trypsin-sensitive sites, after the residues Arg(139) and Arg(521). A 15-kDa NH2-terminal proteolytic fragment (residue 33-139) was associated with the downstream part after the digestion. Arg(521) was located before a cysteine-rich stretch preceding the transmembrane region. A new shorter soluble receptor (residue 33-522) lacking the cysteine-rich region was designed based on the protease-sensitive boundary. The purified receptor protein gave a K-d value of 58.1 +/- 0.84 nM, which is compatible to a reported value of the full-length receptor. The B-max value was 7.06 +/- 0.82 nmol/mg of protein. These results indicated that the ligand-binding specificity of mGluR1 is confined to the NH2-terminal 490-amino acid region of the mature protein.	Biomol Engn Res Inst, Dept Mol Biol, Osaka 5650874, Japan; Biomol Engn Res Inst, Dept Biol Struct, Osaka 5650874, Japan; Hitachi Ltd, Adv Res Lab, Hatoyama, Saitama 3500395, Japan; Nagoya Univ, Sch Med, Dept Anat, Showa Ku, Nagoya, Aichi 4668550, Japan; Kyoto Univ, Fac Med, Dept Biol Sci, Sakyo Ku, Kyoto 6068501, Japan	Hitachi Limited; Nagoya University; Kyoto University	Jingami, H (corresponding author), Biomol Engn Res Inst, Dept Mol Biol, 6-2-3 Furuedai, Osaka 5650874, Japan.		Kajimura, Naoko/R-9267-2019	Usukura, Jiro/0000-0003-2286-5403				Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Costantino G, 1999, J MED CHEM, V42, P5390, DOI 10.1021/jm990353c; Goldsmith PK, 1999, J BIOL CHEM, V274, P11303, DOI 10.1074/jbc.274.16.11303; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Miyazaki J, 1999, BIOCHEM J, V340, P687, DOI 10.1042/0264-6021:3400687; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; Neki A, 1996, NEUROSCI LETT, V202, P197, DOI 10.1016/0304-3940(95)12248-6; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Ohashi H., 1997, Society for Neuroscience Abstracts, V23, P2023; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487	35	115	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28144	28151						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10874032				2022-12-27	WOS:000089197100081
J	Kirschnek, S; Paris, F; Weller, M; Grassme, H; Ferlinz, K; Riehle, A; Fuks, Z; Kolesnick, R; Gulbins, E				Kirschnek, S; Paris, F; Weller, M; Grassme, H; Ferlinz, K; Riehle, A; Fuks, Z; Kolesnick, R; Gulbins, E			CD95-mediated apoptosis in vivo involves acid sphingomyelinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIEMANN-PICK DISEASE; SECRETORY SPHINGOMYELINASE; SIGNALING PATHWAY; CELL-DEATH; CERAMIDE; MICE; LYMPHOBLASTS; TRAFFICKING; GENE	Acid sphingomyelinase (ASM) is reported to have an essential function in stress-induced apoptosis although the physiological function of ASM in receptor-triggered apoptosis is unknown. Here, we delineate a pivotal role for ASM in CD95-triggered apoptosis of peripheral lymphocytes or hepatocytes in vivo. We employed intravenous injection of anti-CD4 antibodies or phytohemagglutinin that was previously shown to result in apoptosis of peripheral blood lymphocytes or hepatocytes via the endogenous CD95/CD95 ligand system. Our results demonstrate a high susceptibility in normal mice whereas ASM knock-out mice fail to immunodeplete T cells or develop autoimmune-like hepatitis. Likewise, ASM-deficient mice or hepatocytes and splenocytes ex vivo manifest resistance to anti-CD95 treatment. These results provide in vivo evidence for an important physiological function of ASM in CD95-induced apoptosis.	Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Neurol, D-72076 Tubingen, Germany; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Gulbins, E (corresponding author), Univ Tubingen, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.		Gulbins, Erich/L-6989-2014; Paris, francois E/L-4915-2015	Gulbins, Erich/0000-0002-3117-1342; Paris, francois E/0000-0002-0176-7348; Weller, Michael/0000-0002-1748-174X	NATIONAL CANCER INSTITUTE [R01CA052462] Funding Source: NIH RePORTER; NCI NIH HHS [CA52462, CA42385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Brenner B, 1998, CELL DEATH DIFFER, V5, P29, DOI 10.1038/sj.cdd.4400307; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grullich C, 2000, J BIOL CHEM, V275, P8650, DOI 10.1074/jbc.275.12.8650; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; LEVADE T, 1986, J CLIN CHEM CLIN BIO, V24, P205; Lin T, 2000, J BIOL CHEM, V275, P8657, DOI 10.1074/jbc.275.12.8657; Lin XH, 1998, J BIOL CHEM, V273, P14374, DOI 10.1074/jbc.273.23.14374; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; Ni HT, 1999, J IMMUNOL, V162, P5183; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; SANDHOFF K, 1994, FEBS LETT, V346, P103, DOI 10.1016/0014-5793(94)00282-7; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schissel SL, 1998, J BIOL CHEM, V273, P18250, DOI 10.1074/jbc.273.29.18250; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; Seino KI, 1997, GASTROENTEROLOGY, V113, P1315, DOI 10.1053/gast.1997.v113.pm9322527; Simarro M, 1999, J IMMUNOL, V162, P5149; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; WANG ZQ, 1994, EUR J IMMUNOL, V24, P1549, DOI 10.1002/eji.1830240714; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5	30	117	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27316	27323						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10867001				2022-12-27	WOS:000089144800087
J	Barbagallo, RP; Breyton, C; Finazzi, G				Barbagallo, RP; Breyton, C; Finazzi, G			Kinetic effects of the electrochemical proton gradient on plastoquinone reduction at the Qi site of the cytochrome b(6)f complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER CHAIN; IRON-SULFUR PROTEIN; OPEN READING FRAME; CHLAMYDOMONAS-REINHARDTII; B/F COMPLEX; BC(1) COMPLEX; BF COMPLEX; OXYGENIC PHOTOSYNTHESIS; REDOX REACTIONS; PHOTOSYSTEM-I	We have investigated the effects of the light-induced thylakoid transmembrane potential on the turnover of the b(6)f complex in cells of the unicellular green alga Chlamydomonas reinhardtii. The reduction of the potential by either decreasing the light intensity or by adding increasing concentrations of the ionophore carbonylcyanide p-(trifluoromethoxy)phenylhydrazone (FCCP) revealed a marked inhibition of the cytochrome b(6) oxidation rate (10-fold) without substantial modifications of cytochrome f oxidation kinetics. Partial recovery of this inhibition could be obtained in the presence of ionophores provided that the membrane potential was re-established by illumination with a train of actinic flashes fired at a frequency higher than its decay. Measurements of isotopic effects on the kinetics of cytochrome b(6), oxidation revealed a synergy between the effects of ionophores and the H2O-D2O exchange. We propose therefore, that protonation events influence the kinetics of cytochrome b(6) oxidation at the Qi site and that these reactions are strongly influenced by the light-dependent generation of a transmembrane potential.	CNR, Ctr Studio Biol Cellulare & Mol Piante, I-20133 Milan, Italy; Max Planck Inst Biophys, Dept Biol Struct, D-60528 Frankfurt, Germany	Consiglio Nazionale delle Ricerche (CNR); Max Planck Society	Finazzi, G (corresponding author), CNR, Ctr Studio Biol Cellulare & Mol Piante, Via Celoria 26, I-20133 Milan, Italy.	giovanni.finazzi@unimi.it						Barbagallo RP, 1999, BIOCHEMISTRY-US, V38, P12814, DOI 10.1021/bi990424+; Barzda V, 1996, BIOCHEMISTRY-US, V35, P8981, DOI 10.1021/bi960114g; BENDALL DS, 1982, BIOCHIM BIOPHYS ACTA, V683, P119, DOI 10.1016/0304-4173(82)90008-8; BENNOUN P, 1970, BIOCHIM BIOPHYS ACTA, V216, P357, DOI 10.1016/0005-2728(70)90227-6; Breyton C, 1997, J BIOL CHEM, V272, P21892, DOI 10.1074/jbc.272.35.21892; Brugna M, 1998, J BACTERIOL, V180, P3719, DOI 10.1128/JB.180.14.3719-3723.1998; Comolli LR, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1589; Connors K. A, 1990, CHEM KINETICS STUDY; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; CRAMER WA, 1989, ENERGY TRANSDUCTION, P79; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; Crofts AR, 1998, CURR OPIN STRUC BIOL, V8, P501, DOI 10.1016/S0959-440X(98)80129-2; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; Crofts AR, 1999, P NATL ACAD SCI USA, V96, P10021, DOI 10.1073/pnas.96.18.10021; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; Deniau C, 2000, BIOCHEMISTRY-US, V39, P3304, DOI 10.1021/bi992445+; DINER B, 1973, BIOCHIM BIOPHYS ACTA, V305, P329, DOI 10.1016/0005-2728(73)90180-1; DUTTON PL, 1972, EUR J BIOCHEM, V30, P495, DOI 10.1111/j.1432-1033.1972.tb02121.x; Finazzi G, 1998, BIOCHEMISTRY-US, V37, P9999, DOI 10.1021/bi980320j; Finazzi G, 1997, BIOCHEMISTRY-US, V36, P2867, DOI 10.1021/bi962717y; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; Hager M, 1999, EMBO J, V18, P5834, DOI 10.1093/emboj/18.21.5834; Hauska G., 1996, OXYGENIC PHOTOSYNTHE, P377; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JOLIOT P, 1986, BIOCHIM BIOPHYS ACTA, V849, P211, DOI 10.1016/0005-2728(86)90027-7; JOLIOT P, 1994, P NATL ACAD SCI USA, V91, P1034, DOI 10.1073/pnas.91.3.1034; JOLIOT P, 1974, BIOCHIM BIOPHYS ACTA, V357, P267, DOI 10.1016/0005-2728(74)90066-8; JOLIOT P, 1989, BIOCHIM BIOPHYS ACTA, V975, P355, DOI 10.1016/S0005-2728(89)80343-3; JOLIOT P, 1988, BIOCHIM BIOPHYS ACTA, V933, P319, DOI 10.1016/0005-2728(88)90039-4; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; JONES RW, 1988, BIOCHIM BIOPHYS ACTA, V933, P258, DOI 10.1016/0005-2728(88)90033-3; JUNGE W, 1968, Z NATURFORSCH B, V24, P1038; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; KLUGHAMMER C, 1993, FEBS LETT, V336, P491, DOI 10.1016/0014-5793(93)80862-O; Klughammer C, 1998, PHOTOSYNTH RES, V56, P117, DOI 10.1023/A:1005998729041; KRAMER DM, 1994, BBA-BIOENERGETICS, V1184, P193, DOI 10.1016/0005-2728(94)90223-2; LANCASTER CR, 1995, REACTION CTR PHOTOSY; LAVERGNE J, 1991, TRENDS BIOCHEM SCI, V16, P129, DOI 10.1016/0968-0004(91)90054-Y; LAVERGNE J, 1983, BIOCHIM BIOPHYS ACTA, V725, P25, DOI 10.1016/0005-2728(83)90220-7; LEMAIRE C, 1986, BIOCHIM BIOPHYS ACTA, V851, P229, DOI 10.1016/0005-2728(86)90130-1; Matsuno-Yagi A, 1999, J BIOL CHEM, V274, P9283, DOI 10.1074/jbc.274.14.9283; MIKI T, 1994, J BIOL CHEM, V269, P1827; MITCHELL P, 1975, FEBS LETT, V56, P1, DOI 10.1016/0014-5793(75)80098-6; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NITSCHKE W, 1992, BIOCHIM BIOPHYS ACTA, V1102, P266, DOI 10.1016/0167-4838(92)90519-J; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; Ponamarev MV, 1998, BIOCHEMISTRY-US, V37, P17199, DOI 10.1021/bi981814j; ROBERTSON DE, 1984, FEBS LETT, V178, P343, DOI 10.1016/0014-5793(84)80630-4; RUMBERG B, 1968, Z NATURFORSCH PT B, VB 23, P239; SELAK MA, 1984, PHOTOCHEM PHOTOBIOL, V39, P485; Soriano GM, 1996, BIOCHEMISTRY-US, V35, P14590, DOI 10.1021/bi9616211; SvenssonEk M, 1996, BIOCHEMISTRY-US, V35, P13673, DOI 10.1021/bi961466q; Takahashi Y, 1996, EMBO J, V15, P3498, DOI 10.1002/j.1460-2075.1996.tb00718.x; Tolkatchev D, 1996, J BIOL CHEM, V271, P12356, DOI 10.1074/jbc.271.21.12356; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; WITT HT, 1979, BIOCHIM BIOPHYS ACTA, V505, P355, DOI 10.1016/0304-4173(79)90008-9; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YAM R, 1991, BIOPHYS J, V59, P4, DOI 10.1016/S0006-3495(91)82192-0; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zito F, 1998, BIOCHEMISTRY-US, V37, P10395, DOI 10.1021/bi980238o	61	9	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26121	26127		10.1074/jbc.M002299200	http://dx.doi.org/10.1074/jbc.M002299200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10866998	hybrid			2022-12-27	WOS:000088999700034
J	Vertommen, D; Rider, M; Ni, YP; Waelkens, E; Merlevede, W; Vandenheede, JR; Van Lint, J				Vertommen, D; Rider, M; Ni, YP; Waelkens, E; Merlevede, W; Vandenheede, JR; Van Lint, J			Regulation of protein kinase D by multisite phosphorylation - Identification of phosphorylation sites by mass spectrometry and characterization by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; PLECKSTRIN HOMOLOGY DOMAIN; C-MU; PHORBOL ESTERS; D ACTIVATION; PROTEOLYTIC ACTIVATION; CATALYTIC DOMAIN; STRUCTURAL BASIS; PKD ACTIVATION; INTACT-CELLS	Activation of the serine/threonine kinase, protein kinase D (PKD/PKC mu) via a phorbol ester/PKC-dependent pathway involves phosphorylation events. The present study identifies five in vivo phosphorylation sites by mass spectrometry, and the role of four of them was investigated by site-directed mutagenesis. Four sites are autophosphorylation sites, the first of which (Ser(916)) is located in the C terminus; its phosphorylation modifies the conformation of the kinase and influences duration of kinase activation but is not required for phorbol ester-mediated activation of PKD. The second autophosphorylation site (Ser(203)) lies in that region of the regulatory domain, which in PKC mu interacts with 14-3-3 tau. The last two autophosphorylation sites (Ser(744) and Ser(748)) are located in the activation loop but are only phosphorylated in the isolated PKD-catalytic domain and not in the full-length PKD; they may affect enzyme catalysis but are not involved in the activation of wildtype PKD by phorbol ester. We also present evidence for proteolytic activation of PKD. The fifth site (Ser(255)) is transphosphorylated downstream of a PKC-dependent pathway after in vivo stimulation with phorbol ester, In vivo phorbol ester stimulation of an S255E mutant no longer requires PKC-mediated events. In conclusion, our results show that PKD is a multisite phosphorylated enzyme and suggest that its phosphorylation may be an intricate process that regulates its biological functions in very distinct ways.	Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochem, B-3000 Louvain, Belgium; Catholic Univ Louvain, Inst Cellular Pathol, Hormone & Metab Res Unit, B-1200 Brussels, Belgium	KU Leuven; Universite Catholique Louvain	Van Lint, J (corresponding author), Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochem, Herestr 49, B-3000 Louvain, Belgium.	johan.vanlint@med.kuleuven.ac.be	Van Lint, Johan/P-9073-2019	Van Lint, Johan/0000-0002-0275-571X				Abedi H, 1998, FEBS LETT, V427, P209, DOI 10.1016/S0014-5793(98)00427-X; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ALLEN G, 1989, SEQUENCING PROTEINS, P140; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; DeGnore JP, 1998, J AM SOC MASS SPECTR, V9, P1175, DOI 10.1016/S1044-0305(98)00088-9; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Haussermann S, 1999, FEBS LETT, V462, P442, DOI 10.1016/S0014-5793(99)01577-X; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; Iglesias T, 1999, FEBS LETT, V454, P53, DOI 10.1016/S0014-5793(99)00772-3; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; INOUE M, 1977, J BIOL CHEM, V252, P7610; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; Johannes FJ, 1999, FEBS LETT, V461, P68, DOI 10.1016/S0014-5793(99)01424-6; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; PARKER PJ, 1997, PROTEIN KINASE C; PEERSON RT, 1999, CURR BIOL, V9, pR521; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rennecke J, 1999, INT J CANCER, V80, P98, DOI 10.1002/(SICI)1097-0215(19990105)80:1<98::AID-IJC19>3.3.CO;2-4; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; TAN JL, 1990, J BIOL CHEM, V265, P13818; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Yonemoto W, 1997, PROTEIN ENG, V10, P915, DOI 10.1093/protein/10.8.915; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	55	78	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19567	19576		10.1074/jbc.M001357200	http://dx.doi.org/10.1074/jbc.M001357200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867018	hybrid			2022-12-27	WOS:000087941300020
J	Lim, J; Wong, ESM; Ong, SH; Yusoff, P; Low, BC; Guy, GR				Lim, J; Wong, ESM; Ong, SH; Yusoff, P; Low, BC; Guy, GR			Sprouty proteins are targeted to membrane ruffles upon growth factor receptor tyrosine kinase activation - Identification of a novel translocation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASES; FUNCTIONS DOWNSTREAM; CELL-MIGRATION; PC12 CELLS; DROSOPHILA; FGF; SEVENLESS; HOMOLOG; PATHWAYS	Sprouty (Spry) was first identified in a genetic screen in Drosophila to be an antagonist of fibroblast growth factor and epidermal growth factor (EGF) signaling, seemingly by inhibiting the Ras/MAP kinase pathway. Data base searches lead to the identification and cloning of, to date, four mammalian sprouty genes. The primary sequences of the mammalian sprouty gene products share a well conserved cysteine-rich C-terminal domain with the Drosophila protein, The N-terminal regions, however, do not exhibit significant homology, This study aimed at determining the disposition of Spry proteins in intact cells before and after stimulation of the EGF receptor tyrosine kinase, Full-length or deletion mutants of Spry, tagged at the N termini with the FLAG-epitope, were expressed in COS-1 cells by transient transfection and analyzed by immunofluorescence microscopy before and after EGF stimulation of the cells. In unstimulated cells, the Spry proteins were distributed throughout the cytosol except for human Sprouty2 (hSpry2), which, although generally located in the cytosol, co-localized with microtubules. In all cases, the Spry proteins underwent rapid translocation to membrane ruffles following EGF stimulation. The optimal translocation domain was identified by deletion and immunofluorescence analysis to be a highly conserved 105-amino acid domain in the C-terminal half of the hSpry2 protein. The translocation of this conserved domain, based on hSpry2 data, was independent of the activation of phosphatidylinositol-3 kinase.	Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Guy, GR (corresponding author), Inst Mol & Cell Biol, Signal Transduct Lab, 30 Med Dr, Singapore 117609, Singapore.	mcbgg@imcb.nus.edu.sg	Low, Boon Chuan/H-8049-2012; Lim, Jormay/A-7257-2011; Low, Boon Chuan/AAU-7685-2021	Low, Boon Chuan/0000-0003-0756-096X; Lim, Jormay/0000-0001-7191-545X; Low, Boon Chuan/0000-0003-0756-096X				AltunGultekin ZF, 1996, J NEUROSCI RES, V44, P308, DOI 10.1002/(SICI)1097-4547(19960515)44:4<308::AID-JNR2>3.0.CO;2-G; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Beiman M, 1996, GENE DEV, V10, P2993, DOI 10.1101/gad.10.23.2993; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; DELAAT SW, 1985, BIOCHEM SOC SYMP, P205; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GLAZER L, 1991, GENE DEV, V5, P697, DOI 10.1101/gad.5.4.697; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; JIANG WG, 1995, EXP CELL RES, V220, P424, DOI 10.1006/excr.1995.1334; Kramer S, 1999, DEVELOPMENT, V126, P2515; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Minowada G, 1999, DEVELOPMENT, V126, P4465; MIYATA Y, 1989, EXP CELL RES, V181, P454, DOI 10.1016/0014-4827(89)90102-X; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Provenzano C, 1998, EXP CELL RES, V242, P186, DOI 10.1006/excr.1998.4095; Reich A, 1999, DEVELOPMENT, V126, P4139; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; Stenmark H, 1999, J CELL SCI, V112, P4175; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; Venkateswarlu K, 1999, J CELL SCI, V112, P1957; Vincent S, 1998, MOL CELL, V2, P515, DOI 10.1016/S1097-2765(00)80151-3; Weed SA, 1998, J CELL SCI, V111, P2433; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129	38	87	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32837	32845		10.1074/jbc.M002156200	http://dx.doi.org/10.1074/jbc.M002156200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10887178	hybrid			2022-12-27	WOS:000090003800064
J	Tynan, SH; Gee, MA; Vallee, RB				Tynan, SH; Gee, MA; Vallee, RB			Distinct but overlapping sites within the cytoplasmic dynein heavy chain for dimerization and for intermediate chain and light intermediate chain binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR DOMAIN; LOCALIZATION; TRANSPORT	Cytoplasmic dynein is a molecular motor complex consisting of four major classes of polypeptide: the catalytic heavy chains (HC), intermediate chains (IC), light intermediate chains (LIC), and light chains (LC). Previous studies have reported that the ICs bind near the N terminus of the HCs, which is thought to correspond to the base of the dynein complex. In this study, we co-overexpressed cytoplasmic dynein subunits in COS-7 cells to map HC binding sites for the ICs and LICs, as well as HC dimerization. We have found that the LICs bind directly to the N terminus of the HC, adjacent to and overlapping with the IC binding site, consistent with a role for the LICs in cargo binding. Mutation of the LIC P-loop had no detectable effect on RC binding, We detected no direct interaction between the ICs and LICs. Using triple overexpression of HC, IC and LIC, we found that both IC and LIC are present in the same complexes, a result verified by anti-IC immunoprecipitation of endogenous complexes and immunoblotting, Our results indicate that the LICs and ICs must be located on independent surfaces of cytoplasmic dynein to allow each to interact with other proteins without steric interference.	Univ Massachusetts, Med Ctr, Dept Cell Biol, Worcester, MA 01605 USA; Tropix PE Biosyst, Bedford, MA 01730 USA	University of Massachusetts System; University of Massachusetts Worcester	Vallee, RB (corresponding author), Univ Massachusetts, Med Ctr, Dept Cell Biol, 377 Plantat St, Worcester, MA 01605 USA.							DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; Dillman JF, 1996, J NEUROSCI, V16, P6742; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; Habura A, 1999, J BIOL CHEM, V274, P15447, DOI 10.1074/jbc.274.22.15447; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; KING SM, 1990, J BIOL CHEM, V265, P19807; Mazumdar M, 1996, P NATL ACAD SCI USA, V93, P6552, DOI 10.1073/pnas.93.13.6552; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; Purohit A, 1999, J CELL BIOL, V147, P481, DOI 10.1083/jcb.147.3.481; Samso M, 1998, J MOL BIOL, V276, P927, DOI 10.1006/jmbi.1997.1584; Steffen W, 1996, J STRUCT BIOL, V117, P227, DOI 10.1006/jsbi.1996.0087; Tynan SH, 2000, J BIOL CHEM, V275, P32763, DOI 10.1074/jbc.M001536200; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; VAUGHAN KT, 1995, BIOCHEM SOC T, V23, P50, DOI 10.1042/bst0230050; Young A, 2000, MOL BIOL CELL, V11, P2047, DOI 10.1091/mbc.11.6.2047	16	93	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32769	32774		10.1074/jbc.M001537200	http://dx.doi.org/10.1074/jbc.M001537200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10893223	hybrid			2022-12-27	WOS:000090003800055
J	Shih, SJ; Allan, C; Grehan, S; Tse, E; Moran, C; Taylor, JM				Shih, SJ; Allan, C; Grehan, S; Tse, E; Moran, C; Taylor, JM			Duplicated downstream enhancers control expression of the human apolipoprotein E gene in macrophages and adipose tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC CONTROL REGION; BONE-MARROW TRANSPLANTATION; E-DEFICIENT MICE; E MESSENGER-RNA; TRANSGENIC MICE; APOPROTEIN-E; C/EBP-ALPHA; IN-VIVO; C-I; ALZHEIMERS-DISEASE	Two distal enhancers that specify apolipoprotein (apo) E gene expression in isolated macrophages and adipose tissue were identified in transgenic mice that were generated with constructs of the human apoE/C-I/C-I'/C-IV/C-II gene cluster. One of these enhancers, multienhancer 1, consists of a 620-nucleotide sequence located 3.3 kilobases (kb) downstream of the apoE gene. The second enhancer, multienhancer 2, is a 619-nucleotide sequence located 15.9 kb downstream of the apoE gene and 5.9 kb downstream of the apoC-I gene. The two enhancers are 95% identical in sequence, and they are likely to have arisen as a consequence of the gene duplication event that yielded the apoC-I gene and the apoC-I' pseudogene. Both enhancer sequences appear to have equivalent activity in directing apoE gene expression in peritoneal macrophages and in adipocytes, suggesting that their activity in specific cell types may be determined by common regulatory elements.	J David Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Taylor, JM (corresponding author), J David Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037063] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37063] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN CM, 1995, J BIOL CHEM, V270, P26278, DOI 10.1074/jbc.270.44.26278; ALLAN CM, 1995, GENOMICS, V28, P291, DOI 10.1006/geno.1995.1144; Allan CM, 1997, J BIOL CHEM, V272, P29113, DOI 10.1074/jbc.272.46.29113; BASHEERUDDIN K, 1994, BBA-GENE STRUCT EXPR, V1218, P235, DOI 10.1016/0167-4781(94)90021-3; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BOISVERT WA, 1995, J CLIN INVEST, V96, P1118, DOI 10.1172/JCI118098; DANG Q, 1995, J BIOL CHEM, V270, P22577, DOI 10.1074/jbc.270.38.22577; Dang Q, 1996, J BIOL CHEM, V271, P28667, DOI 10.1074/jbc.271.45.28667; DAWSON PA, 1989, J LIPID RES, V30, P403; DESCAMPS O, 1993, J BIOL CHEM, V268, P974; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; GILMAN M, 1993, CURRENT PROTOCOLS MO, V1; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Iwama A, 1998, NUCLEIC ACIDS RES, V26, P3034, DOI 10.1093/nar/26.12.3034; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kapitonov V, 1996, J MOL EVOL, V42, P59, DOI 10.1007/BF00163212; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1995, METABOLIC MOL BASES, P1953; Masliah E, 1996, PROG NEUROBIOL, V50, P493, DOI 10.1016/S0301-0082(96)00038-X; MAZZONE T, 1989, J LIPID RES, V30, P1055; Nakai M, 1996, NEUROSCI LETT, V211, P41, DOI 10.1016/0304-3940(96)12716-6; Okada N, 1991, CURR OPIN GENET DEV, V1, P498, DOI 10.1016/S0959-437X(05)80198-4; PAIK YK, 1985, P NATL ACAD SCI USA, V82, P3445, DOI 10.1073/pnas.82.10.3445; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; RAISONNIER A, 1991, J MOL EVOL, V32, P211; RALL SC, 1982, J BIOL CHEM, V257, P4171; REARDON CA, 1986, J BIOL CHEM, V261, P9858; ROSENFELD ME, 1993, ARTERIOSCLER THROMB, V13, P1382, DOI 10.1161/01.ATV.13.9.1382; ROSES AD, 1994, CURR NEUROL, V14, P111; SALOMON RN, 1992, P NATL ACAD SCI USA, V89, P2814, DOI 10.1073/pnas.89.7.2814; SHACHTER NS, 1993, J LIPID RES, V34, P1699; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SIMONET WS, 1991, J BIOL CHEM, V266, P8651; SING CF, 1985, AM J HUM GENET, V37, P268; Stone DJ, 1997, EXP NEUROL, V143, P313, DOI 10.1006/exnr.1996.6360; TAYLOR JM, 1993, CURR OPIN LIPIDOL, V4, P84, DOI 10.1097/00041433-199304000-00002; TAYLOR JM, 1991, CURR OPIN LIPIDOL, V2, P73; Valledor AF, 1998, J LEUKOCYTE BIOL, V63, P405, DOI 10.1002/jlb.63.4.405; van Dijk TB, 1999, J IMMUNOL, V163, P2674; WEISGRABER KH, 1985, ANAL BIOCHEM, V151, P455, DOI 10.1016/0003-2697(85)90204-0; WEISGRABER KH, 1994, CURR OPIN STRUC BIOL, V4, P507, DOI 10.1016/S0959-440X(94)90212-7; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WERB Z, 1983, J EXP MED, V158, P1272, DOI 10.1084/jem.158.4.1272; WERB Z, 1983, J CELL BIOL, V97, P1113, DOI 10.1083/jcb.97.4.1113; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P1033, DOI 10.1021/bi00507a059; ZECHNER R, 1991, J BIOL CHEM, V266, P10583; ZUCKERMAN SH, 1993, ATHEROSCLEROSIS, V103, P43, DOI 10.1016/0021-9150(93)90038-V	54	85	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31567	31572		10.1074/jbc.M005468200	http://dx.doi.org/10.1074/jbc.M005468200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10893248	hybrid			2022-12-27	WOS:000089858900004
J	Li, GH; Lee, EM; Blair, D; Holding, C; Poronnik, P; Cook, DI; Barden, JA; Bennett, MR				Li, GH; Lee, EM; Blair, D; Holding, C; Poronnik, P; Cook, DI; Barden, JA; Bennett, MR			The distribution of P2X receptor clusters on individual neurons in sympathetic ganglia and their redistribution on agonist activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; SMOOTH-MUSCLE CELLS; RAT URINARY-BLADDER; GATED ION CHANNELS; NERVE VARICOSITIES; ATP; PURINOCEPTORS; ADENOVIRUSES; EXPRESSION; RELEASE	The distribution of P2X receptors on neurons in rat superior cervical ganglia and lability of P2X receptors on exposure to agonists were determined, Antibody labeling of each P2X subtype P2X(1)-P2X(7) showed neurons isolated into culture possessed primarily P2X, subunits with others occurring in order P2X(7) > P2X(6) > P2X(3) > P2X(1) > P2X(5) > P2X(4). Application of ATP and alpha,beta-meATP to neurons showed they possessed a predominantly nondesensitizing P2X receptor type insensitive to alpha,beta-meATP, consistent with immunohistochemical observations. P2X(1)-green fluorescent protein (GFP) was used to study the time course of P2X, receptor clustering in plasma membranes of neurons and internalization of receptors following prolonged exposure to ATP, At 12-24 h after adenoviral infection, P2X(1)-GFP formed clusters about 1 mu m diameter in the neuron membrane, Application of ATP and alpha,beta-meATP showed these neurons possessed a predominantly desensitizing P2X receptor type sensitive to alpha,beta-meATP. Infection converted the major functional P2X receptor type in the membrane to P2X,, Exposure of infected neurons to alpha,beta-meATP for less than 60 s led to the disappearance of P2X(1)-GFP fluorescence from the cell surface that was blocked by monensin, indicating the chimera is normally endocytosed into these organelles on exposure to agonist.	Univ Sydney, Biomed Res Inst, Dept Physiol, Neurobiol Lab, Sydney, NSW 2006, Australia; Univ Sydney, Biomed Res Inst, Dept Physiol, Exocrine Physiol & Biophys Labs, Sydney, NSW 2006, Australia; Univ Sydney, Biomed Res Inst, Dept Anat & Histol, Prot Struct Lab, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney; University of Sydney	Bennett, MR (corresponding author), Univ Sydney, Biomed Res Inst, Dept Physiol, Neurobiol Lab, Sydney, NSW 2006, Australia.	maxb@physiol.usyd.edu.au		Poronnik, Philip/0000-0002-6246-528X				Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Barden JA, 1999, J NEUROCYTOL, V28, P469, DOI 10.1023/A:1007053004771; Boehm S, 1999, J NEUROSCI, V19, P737; BOEHM S, 1994, N-S ARCH PHARMACOL, V350, P454; Bueno OF, 1998, MOL BRAIN RES, V59, P165, DOI 10.1016/S0169-328X(98)00129-6; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; CHEMASCHI D, 1996, BIOCHIM BIOPHYS ACTA, V1280, P27; Collo G, 1996, J NEUROSCI, V16, P2495; Connor JX, 1998, J BIOL CHEM, V273, P28906, DOI 10.1074/jbc.273.44.28906; Dutton JL, 1999, J NEUROCYTOL, V28, P3, DOI 10.1023/A:1007043132537; DUTTON JL, 2000, IN PRESS NEUROPHARMA, V39; Evans RJ, 1996, NEUROSCI LETT, V212, P212, DOI 10.1016/0304-3940(96)12804-4; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; Hansen MA, 1998, J NEUROCYTOL, V27, P529, DOI 10.1023/A:1006908010642; Hansen MA, 1999, J AUTONOM NERV SYST, V75, P147, DOI 10.1016/S0165-1838(98)00189-1; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; Poronnik P, 1998, CELL CALCIUM, V24, P97, DOI 10.1016/S0143-4160(98)90077-X; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Vulchanova L, 1996, P NATL ACAD SCI USA, V93, P8063, DOI 10.1073/pnas.93.15.8063; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; Worthington RA, 1999, ELECTROPHORESIS, V20, P2065; Xiang ZH, 1998, NEUROSCI LETT, V256, P105, DOI 10.1016/S0304-3940(98)00774-5	26	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29107	29112		10.1074/jbc.M910277199	http://dx.doi.org/10.1074/jbc.M910277199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10869366	hybrid			2022-12-27	WOS:000089330700099
J	Sidovar, MF; Kozlowski, P; Lee, JW; Collins, MA; He, YQ; Graves, LM				Sidovar, MF; Kozlowski, P; Lee, JW; Collins, MA; He, YQ; Graves, LM			Phosphorylation of serine 43 is not required for inhibition of c-Raf kinase by the cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATES MAP KINASE; NIH 3T3 CELLS; B-RAF; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; THREONINE KINASE; CYCLIC-AMP; PC12 CELLS; PATHWAY; CASCADE	The activity of the serine/threonine kinase c-Raf (Raf) is inhibited by increased intracellular cAMP. This is believed to require phosphorylation with the cAMP-dependent protein kinase (PKA), although the mechanism by which PRA inhibits Raf is controversial. We investigated the requirement for PKA phosphorylation using Raf mutants expressed in HEK293 or NIH 3T3 cells. Phosphopeptide mapping of P-32-labeled Raf (WT) or a mutant lacking a putative PKA phosphorylation site (serine to alanine, S43A) confirmed that serine 43 (Ser(43)) was the major cAMP (forskolin)-stimulated phosphorylation site in vivo. Interestingly, the EGF-stimulated Raf kinase activity of the S43A mutant was inhibited by forskolin equivalently to that of the WT Raf. Forskolin also inhibited the activation of an N-terminal deletion mutant Delta 5-50 Raf completely lacking this phosphorylation site. Although WT Raf was phosphorylated by PKA, phosphorylation did not inhibit Raf catalytic activity in vitro, nor did forskolin treatment inhibit the activity of an N-terminally truncated Raf protein (Raf 22W) or a full-length Raf protein (Raf-CAAX) expressed in NIH 3T3 cells. In contrast, forskolin inhibited the EGF-dependent activation of a Raf isoform (B-Raf), lacking an analogous phosphorylation site to Ser43. Thus, these results demonstrate that PKA exerts its inhibitory effects independently of direct Raf phosphorylation and suggests instead that PKA prevents an event required for the EGF-dependent activation of Raf.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Graves, LM (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.		Lee, Jung Weon/AAC-1146-2020; Lee, Jung Weon/F-9149-2012; Graves, Lee/AAG-5470-2021	Lee, Jung Weon/0000-0003-2722-8200; 	NIGMS NIH HHS [GM54010] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054010] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; BURGERING BMT, 1993, BIOCHEM SOC T, V21, P888, DOI 10.1042/bst0210888; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Graves LM, 1996, TRENDS ENDOCRIN MET, V7, P43, DOI 10.1016/1043-2760(95)00204-9; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hu CD, 1999, J BIOL CHEM, V274, P48, DOI 10.1074/jbc.274.1.48; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li XO, 1997, J BIOL CHEM, V272, P14996, DOI 10.1074/jbc.272.23.14996; MacNicol MC, 1999, J BIOL CHEM, V274, P13193, DOI 10.1074/jbc.274.19.13193; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; RAY LB, 1988, J BIOL CHEM, V263, P12721; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SIESS W, 1990, BIOCHEM BIOPH RES CO, V170, P944, DOI 10.1016/0006-291X(90)92182-Y; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Sprenkle AB, 1997, FEBS LETT, V403, P254, DOI 10.1016/S0014-5793(97)00062-8; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	52	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28688	28694		10.1074/jbc.M909351199	http://dx.doi.org/10.1074/jbc.M909351199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10862777	Green Published, hybrid			2022-12-27	WOS:000089330700048
J	Haas, M; Askari, A; Xie, ZJ				Haas, M; Askari, A; Xie, ZJ			Involvement of Src and epidermal growth factor receptor in the signal-transducing function of Na+/K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAT CARDIAC MYOCYTES; SMOOTH-MUSCLE CELLS; C-SRC; TYROSINE KINASES; RESPONSE GENES; HYPERTROPHY; PATHWAYS; EXPRESSION; OUABAIN	Nontoxic concentrations of ouabain, causing partial inhibition of the cardiac myocyte Na+/K+-ATPase, induce hypertrophy and several growth-related genes through signal pathways that include the activation of Ras and p42/44 mitogen-activated protein kinase (MAPK). The aim of this work was to examine the ouabain-induced events upstream of the Ras/MAPK cascade. Treatment of myocytes with genistein antagonized ouabain-induced activation of the MAPK, suggesting that protein tyrosine phosphorylation has a role. Tyrosine phosphorylation of several myocyte proteins was increased rapidly upon cell exposure to ouabain, Lowering of extracellular K+ had a similar ouabain-like effect. Ouabain also increased protein tyrosine phosphorylation in A7r5, HeLa, and L929 cells. In cardiac myocytes and A7r5 cells, herbimycin A antagonized the ouabain-induced increase in protein tyrosine phosphorylation and MAPK activation. In both cell types, ouabain stimulated Src kinase activity, Src translocation to the Triton-insoluble fraction, Src association with the epidermal growth factor receptor, and the tyrosine phosphorylation of this receptor on site(s) other than its major autophosphorylation site, Tyr(1173). The findings suggest that (a) the ouabain-induced activation of Src and the Src-induced phosphorylation of the growth factor receptor provide the scaffolding for the recruitment of adaptor proteins and Ras and the activation of Ras/MAPK cascade; and (b) the activation of such pathways may be a common feature of the signal-transducing function of Na+/K+-ATPase in most cells.	Med Coll Ohio, Dept Pharmacol, Toledo, OH 43614 USA		Xie, ZJ (corresponding author), Med Coll Ohio, Dept Pharmacol, 3035 Arlington Ave, Toledo, OH 43614 USA.	mheck@mco.edu			NHLBI NIH HHS [HL-63238, HL-36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573, R01HL063238] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARYSTARKHOVA E, 1994, SODIUM PUMP, P230; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CHENG HC, 1992, J BIOL CHEM, V267, P9248; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; EISNER DA, 1992, HEART CARDIOVASCULAR, V1, P863; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Haas MS, 2000, BIOPHYS J, V78, p78A; Hefti MA, 1997, J MOL CELL CARDIOL, V29, P2873, DOI 10.1006/jmcc.1997.0523; Huang LY, 1997, J MOL CELL CARDIOL, V29, P429, DOI 10.1006/jmcc.1996.0320; Huang LY, 1997, J MOL CELL CARDIOL, V29, P3157, DOI 10.1006/jmcc.1997.0546; KELLY RA, 1993, J AM COLL CARDIOL, V22, pA107, DOI 10.1016/0735-1097(93)90472-D; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; Kovacic B, 1998, J BIOL CHEM, V273, P35185; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu J, 2000, J BIOL CHEM, V275, P27838; MCCALL D, 1985, CIRC RES, V56, P370, DOI 10.1161/01.RES.56.3.370; ORLOWSKI J, 1990, J BIOL CHEM, V265, P3462; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; Perry G, 1997, NEW ENGL J MED, V336, P525; RUSANESCU G, 1995, BIOPHYS J, V78, pA79; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; TIRUPATTUR PR, 1993, AM J HYPERTENS, V6, P626, DOI 10.1093/ajh/6.7.626; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323	34	287	301	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27832	27837						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10874030				2022-12-27	WOS:000089197100043
J	Hossain, MA; Bouton, CML; Pevsner, J; Laterra, J				Hossain, MA; Bouton, CML; Pevsner, J; Laterra, J			Induction of vascular endothelial growth factor in human astrocytes by lead - Involvement of a protein kinase c/activator protein-1 complex-dependent and hypoxia-inducible factor 1-independent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-BRAIN-BARRIER; DNA-BINDING ACTIVITY; C-FOS; NERVOUS-SYSTEM; PC12 CELLS; INORGANIC LEAD; MESSENGER-RNA; RAT; GENE; JUN	The mechanism(s) underlying lead neurotoxicity are not fully elucidated. cDNA expression microarray analysis identified lead-sensitive genes in immortalized human fetal astrocytes (SV-FHA), Of the represented genes expressed, vascular endothelial growth factor (VEGF) was one of the most sensitive, Lead induced VEGF mRNA 3-fold and VEGF protein similar to 2-fold with maximum mRNA induction following incubation with 10 mu M lead acetate for 24 h. Phorbol 12-myristate 13-acetate (PMA), a potent protein kinase C (PKC) activator, increased VEGF mRNA 2-fold and PKC inhibition by GF-109203 completely blocked VEGF induction by lead. Expression of dominant-negative PKC-epsilon, but not PKC-alpha, completely inhibited VEGF mRNA induction by lead. Lead activated the transcription factor AP-1 and increased AP-1-dependent luciferase expression >2-fold. Transfection of cells with a c-jun dominant-negative effectively inhibited both AP-1 activation and VEGF mRNA induction by lead. Hypoxia-inducible factor 1 (HIF-1) activity in SV-FHAs was moderately increased by lead (86%) and PMA (96%). Pretreatment with GF-109203 completely inhibited these effects of lead and PMA. However, lead did not alter HIF-1-dependent luciferase expression and a HIF-1 alpha dominant-negative had no effects on the induction of VEGF mRNA by lead. These findings indicate that lead induces VEGF expression in SV-FHAs via a PKC/AP-1-dependent and HIF-1-independent signaling pathway.	Kennedy Krieger Res Inst, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Hossain, MA (corresponding author), Kennedy Krieger Res Inst, Dept Neurol, 707 N Broadway, Baltimore, MD 21205 USA.	hossain@kennedykrieger.org			NIEHS NIH HHS [P01 ES08131-02] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES008131] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		*AG TOX SUBST DIS, 1992, TOX PROF LEAD, P105; AUDESIRK G, 1989, IN VITRO CELL DEV B, V25, P1121; Bartholdi D, 1997, EUR J NEUROSCI, V9, P2549, DOI 10.1111/j.1460-9568.1997.tb01684.x; Bates DO, 1996, AM J PHYSIOL-HEART C, V271, pH2520, DOI 10.1152/ajpheart.1996.271.6.H2520; BelloniOlivi L, 1996, BIOCHEM J, V315, P401, DOI 10.1042/bj3150401; BRADBURY MWB, 1984, FED PROC, V43, P186; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bressler J, 1999, NEUROCHEM RES, V24, P595, DOI 10.1023/A:1022596115897; BRESSLER JP, 1991, BIOCHEM PHARMACOL, V41, P479, DOI 10.1016/0006-2952(91)90617-E; Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; BROWN PH, 1994, ONCOGENE, V9, P791; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; Centers for Disease Control, 1991, PREV LEAD POIS YOUNG; Chakraborti T, 1999, J NEUROCHEM, V73, P187, DOI 10.1046/j.1471-4159.1999.0730187.x; Cheng SY, 1997, P NATL ACAD SCI USA, V94, P12081, DOI 10.1073/pnas.94.22.12081; CLASEN RA, 1974, AM J PATHOL, V74, P215; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GEBHART AM, 1988, TOXICOL APPL PHARM, V94, P191, DOI 10.1016/0041-008X(88)90261-X; GOLDSTEIN GW, 1983, LIFE SCI, V33, P1001, DOI 10.1016/0024-3205(83)90757-9; GOLDSTEIN GW, 1974, ARCH NEUROL-CHICAGO, V31, P382, DOI 10.1001/archneur.1974.00490420048005; GOLDSTEIN GW, 1991, HUMAN LEAD EXPOSURE, P125; GOLDSTEIN GW, 1988, ANN NY ACAD SCI, V25, P31; HABERMANN E, 1983, ARCH TOXICOL, V54, P61, DOI 10.1007/BF00277816; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; HOLTZMAN D, 1987, TOXICOL APPL PHARM, V89, P211, DOI 10.1016/0041-008X(87)90042-1; Hossain MA, 1998, EUR J NEUROSCI, V10, P2490, DOI 10.1046/j.1460-9568.1998.00259.x; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KAZANIETZ MG, 1996, CELLULAR MOL PATHOGE, P389; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; Kim FA, 2000, J NEUROCHEM, V74, P1140; Kim K, 1997, INT J DEV NEUROSCI, V15, P175, DOI 10.1016/S0736-5748(96)00085-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATERRA J, 1992, P NATL ACAD SCI USA, V89, P10748, DOI 10.1073/pnas.89.22.10748; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LING TL, 1989, J COMP NEUROL, V286, P345, DOI 10.1002/cne.902860305; LONG GJ, 1994, J BIOL CHEM, V269, P834; LUBRAN MM, 1980, ANN CLIN LAB SCI, V10, P402; MARKOVAC J, 1988, NATURE, V334, P71, DOI 10.1038/334071a0; Muruganandam A, 1997, FASEB J, V11, P1187, DOI 10.1096/fasebj.11.13.9367354; Nriagu JO, 1996, SCIENCE, V272, P223, DOI 10.1126/science.272.5259.223; PRESS MF, 1977, J NEUROPATH EXP NEUR, V36, P169, DOI 10.1097/00005072-197701000-00014; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Ramesh GT, 1999, TOXICOL APPL PHARM, V155, P280, DOI 10.1006/taap.1999.8624; SAMBROOK J, 1996, MOL CLONING; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SINGH AK, 1993, NEUROTOXICOLOGY, V14, P417; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; St-Denis A, 1998, J BIOL CHEM, V273, P32787, DOI 10.1074/jbc.273.49.32787; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TOMSIG JL, 1995, J NEUROCHEM, V64, P2667; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WHO, 1995, ENV HLTH CRIT, P165; Winneke G, 1996, ARCH TOX S, V18, P57; Ying Z, 1996, MOL BRAIN RES, V39, P109, DOI 10.1016/0169-328X(96)00015-0; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713	60	64	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27874	27882						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10882716				2022-12-27	WOS:000089197100049
J	Peng, JB; Chen, XZ; Berger, UV; Vassilev, PM; Brown, EM; Hediger, MA				Peng, JB; Chen, XZ; Berger, UV; Vassilev, PM; Brown, EM; Hediger, MA			A rat kidney-specific calcium transporter in the distal nephron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; CATION CHANNEL; CA2+ CHANNELS; FACILITATED DIFFUSION; PARATHYROID-HORMONE; FEEDBACK INHIBITION; CAPSAICIN-RECEPTOR; CONVOLUTED TUBULE; ENTRY CHANNEL; ION-CHANNEL	Active absorption of calcium from the intestine and reabsorption of calcium from the kidney are major determinants of whole body calcium homeostasis. Two recently cloned proteins, CaT1 and ECaC, have been postulated to mediate apical calcium uptake by rat intestine and rabbit kidney, respectively. By screening a rat kidney cortex library with a CaT1 probe, we isolated a cDNA encoding a protein (CaT2) with 84.2 and 73.4% amino acid identities to ECaC and CaT1, respectively. Unlike ECaC, CaT2 is kidney-specific in the rat and was not detected in intestine, brain, adrenal gland, heart, skeletal muscle, liver, lung, spleen, thymus, and testis by Northern analysis or reverse transcription polymerase chain reaction. The expression pattern of CaT2 in kidney was similar to that of calbindin D-28K and the sodium calcium exchanger 1, NCX1, by in situ hybridization of adjacent sections. Furthermore, the mRNAs for CaT2 and calbindin D-28K were colocalized in the same cells. CaT2 mediated saturable calcium uptake with a Michaelis constant (K-m) of 0.66 mM when expressed in Xenopus laevis oocytes, Under voltage clamp condition, CaT2 promoted inward currents in X. laevis oocytes upon external application of Ca2+. Sr2+ and Ba2+ but not Mg2+ also evoked inward currents in CaT2-expressing oocytes. Similar to the alkaline earth metal ions, application of Cd2+ elicited inward current in CaT2-expressing oocytes with a K-m of 1.3 mM. Cd2+, however, also potently inhibited CaT2-mediated Ca2+ uptake with an IC50 of 5.4 mu M. Ca2+ evoked currents were reduced at low pH and increased at high pH and were only slightly affected by the L-type voltage-dependent calcium channel antagonists, nifedipine, verapamil, diltiazem, and the agonist, Bay a 8644, even at relatively high concentrations, In conclusion, CaT2 may participate in calcium entry into the cells of the distal convoluted tubule and connecting segment of the nephron, where active reabsorption of calcium takes place via the transcellular route. The high sensitivity of CaT2 to Cd2+ also provides a potential explanation for Cd2+-induced hypercalciuria and resultant renal stone formation.	Brigham & Womens Hosp, Membrane Biol Program, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Endocrine Hypertens, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Hediger, MA (corresponding author), Harvard Inst Med, Room 570,77 Ave Louis Pasteur, Boston, MA 02115 USA.	mhediger@rics.bwh.harvard.edu		Hediger, Matthias/0000-0003-1946-027X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052005, R01DK041415, R01DK048330] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48330, DK52005, DK41415] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; BACSKAI BJ, 1990, NATURE, V347, P388, DOI 10.1038/347388a0; Barry ELR, 1998, J MEMBRANE BIOL, V161, P55, DOI 10.1007/s002329900314; Berger UV, 1998, ANAT EMBRYOL, V198, P13, DOI 10.1007/s004290050161; BINDELS RJM, 1993, J EXP BIOL, V184, P89; BINDELS RJM, 1991, J AM SOC NEPHROL, V2, P1122; BIRGE SJ, 1987, CLIN DISORDERS MEMBR, P121; BORKE JL, 1989, AM J PHYSIOL, V257, pF842, DOI 10.1152/ajprenal.1989.257.5.F842; BORKE JL, 1990, PFLUG ARCH EUR J PHY, V417, P120, DOI 10.1007/BF00370781; Bronner F., 1997, Handbook of nutritionally essential mineral elements., P13; BRONNER F, 1992, J NUTR, V122, P641, DOI 10.1093/jn/122.suppl_3.641; Bronner F, 1998, J NUTR, V128, P917, DOI 10.1093/jn/128.5.917; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; CHRISTAKOS S, 1992, J NUTR, V122, P678, DOI 10.1093/jn/122.suppl_3.678; Colbert HA, 1997, J NEUROSCI, V17, P8259; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; EDWARDS NA, 1965, CLIN SCI, V29, P143; FEHER JJ, 1992, AM J PHYSIOL, V262, pC517, DOI 10.1152/ajpcell.1992.262.2.C517; Fierro L, 1999, J MEMBRANE BIOL, V168, P9, DOI 10.1007/s002329900493; FRIEDMAN PA, 1994, TOXICOL APPL PHARM, V128, P257, DOI 10.1006/taap.1994.1205; Friedman PA, 1998, ANNU REV PHYSIOL, V60, P179, DOI 10.1146/annurev.physiol.60.1.179; FULLMER CS, 1992, J NUTR, V122, P644, DOI 10.1093/jn/122.suppl_3.644; Funayama M, 1996, MOL BRAIN RES, V43, P259, DOI 10.1016/S0169-328X(96)00208-2; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; Hoenderop JGJ, 1999, BIOCHEM BIOPH RES CO, V261, P488, DOI 10.1006/bbrc.1999.1059; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HUNZIKER W, 1988, MOL ENDOCRINOL, V2, P465, DOI 10.1210/mend-2-5-465; Jaquemar D, 1999, J BIOL CHEM, V274, P7325, DOI 10.1074/jbc.274.11.7325; JARUP L, 1993, BRIT J IND MED, V50, P598; Johnson J A, 1994, Curr Opin Nephrol Hypertens, V3, P424, DOI 10.1097/00041552-199407000-00008; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; KARBACH U, 1992, J NUTR, V122, P672, DOI 10.1093/jn/122.suppl_3.672; Kazantzis G, 1979, Contrib Nephrol, V16, P161; KUMAR R, 1995, J CELL BIOCHEM, V57, P392, DOI 10.1002/jcb.240570304; KUROKAWA K, 1994, KIDNEY INT, V45, pS97; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; LITZOW JR, 1967, J CLIN INVEST, V46, P280, DOI 10.1172/JCI105530; MATSUNAGA H, 1994, AM J PHYSIOL, V267, pC157, DOI 10.1152/ajpcell.1994.267.1.C157; Nomura H, 1998, J BIOL CHEM, V273, P25967, DOI 10.1074/jbc.273.40.25967; Parekh AB, 1998, J BIOL CHEM, V273, P14925, DOI 10.1074/jbc.273.24.14925; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; PONCET V, 1992, PFLUG ARCH EUR J PHY, V422, P112, DOI 10.1007/BF00370410; SCOTT R, 1978, Urology, V11, P462, DOI 10.1016/0090-4295(78)90157-7; SCOTT R, 1980, UROLOGY, V15, P356, DOI 10.1016/0090-4295(80)90469-0; STACY BD, 1970, J PHYSIOL-LONDON, V210, P549, DOI 10.1113/jphysiol.1970.sp009226; STEIN WD, 1992, J NUTR, V122, P651, DOI 10.1093/jn/122.suppl_3.651; SUKI WN, 1996, KIDNEY, P472; SUTTON RAL, 1979, KIDNEY INT, V15, P520, DOI 10.1038/ki.1979.67; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; TAN S, 1993, J CLIN INVEST, V92, P2731, DOI 10.1172/JCI116890; Trimmer JS, 1998, CURR OPIN NEUROBIOL, V8, P370, DOI 10.1016/S0959-4388(98)80063-9; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; VanBaal J, 1996, AM J PHYSIOL-RENAL, V271, pF985, DOI 10.1152/ajprenal.1996.271.5.F985; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; WASSERMAN RH, 1995, J NUTR, V125, pS1971, DOI 10.1093/jn/125.suppl_7.1971S; WASSERMAN RH, 1992, J NUTR, V122, P662, DOI 10.1093/jn/122.suppl_3.662; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wissenbach U, 1998, FEBS LETT, V429, P61, DOI 10.1016/S0014-5793(98)00561-4; Wu GQ, 1998, GENOMICS, V54, P564, DOI 10.1006/geno.1998.5618; YU ASL, 1992, AM J PHYSIOL, V263, pF680, DOI 10.1152/ajprenal.1992.263.4.F680; YU ASL, 1992, P NATL ACAD SCI USA, V89, P10494, DOI 10.1073/pnas.89.21.10494; YU ASL, 1995, AM J PHYSIOL-RENAL, V268, pF525, DOI 10.1152/ajprenal.1995.268.3.F525; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301	71	118	119	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28186	28194						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10875938				2022-12-27	WOS:000089197100087
J	Price, B; Dennison, C; Tschesche, H; Elliott, E				Price, B; Dennison, C; Tschesche, H; Elliott, E			Neutrophil tissue inhibitor of matrix metalloproteinases-1 occurs in novel vesicles that do not fuse with the phagosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; HUMAN-BONE-MARROW; RHEUMATOID SYNOVIAL-FLUID; GRANULE CONSTITUENTS; CYTOPLASMIC GRANULES; BIOLOGICAL FUNCTIONS; POLYACRYLAMIDE GELS; ELECTRON-MICROSCOPY; SECRETORY VESICLES; AZUROPHIL GRANULES	The human neutrophil granule location of precursors of matrix metalloproteinases (MMPs), MMP-8 and -9, has been established, but that of the tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) has not. In this study, labeling for TIMP-1, pro-MMP-8, pro-MMP-9, and established granule marker proteins reveals that TIMP-1 is mainly located in distinct oval, electron translucent organelles, a little larger than azurophil granules. A lack of labeling for the fluid phase endocytic marker, bovine serum albumin-gold, the lysosome-associated membrane protein markers, and for glycosylphosphatidylinositol-linked proteins, which are enriched in secretory vesicles, indicates the nonendosomal, non-lysosomal, and non-secretory nature of this organelle. Density gradient cofractionation with the least dense, secretory population and some pleomorphism of the organelle suggest it is a "vesicle" rather than a "granule" population. Colocalization with pro-MMP-9 or pro-MMP-8, in minor subpopulations, suggests that TIMP-1 vesicle biogenesis occurs between metamyelocytic and terminal differentiation and before secretory vesicle synthesis. Pulse-chased IgG-coated latex beads and immunolabeling show that specific and azurophil granules fuse with the phagosome whereas TIMP-1 and pro-MMP-9-containing organelles do not. This suggests that these play no role in phagosomal destruction of IgG-opsonized bacteria. Separate localization and colocalization of these proteins may, however, facilitate fine regulation of extracellular proteolysis.	Univ KwaZulu Natal, Dept Biochem, Sch Mol & Cellular Biosci, ZA-3209 Pietermaritzburg, South Africa; Univ Bielefeld, Fac Chem, Dept Biochem, D-33615 Bielefeld, Germany	University of Kwazulu Natal; University of Bielefeld	Elliott, E (corresponding author), Univ KwaZulu Natal, Dept Biochem, Sch Mol & Cellular Biosci, Private Bag X01, ZA-3209 Pietermaritzburg, South Africa.	elliott@unpsunl.cc.unp.ac.za		Price, Brendon/0000-0001-8894-6666				Absolom D R, 1986, Methods Enzymol, V132, P95; Andrews P C, 1986, Methods Enzymol, V132, P369; BABBS CF, 1990, METHOD ENZYMOL, V186, P137; BAINTON DF, 1973, J CELL BIOL, V58, P249, DOI 10.1083/jcb.58.2.249; BAINTON DF, 1971, J EXP MED, V134, P907, DOI 10.1084/jem.134.4.907; BAKOWSKI B, 1992, BIOL CHEM H-S, V373, P529; BENTWOOD BJ, 1980, J IMMUNOL, V124, P855; BERGER M, 1994, J CLIN INVEST, V94, P1113, DOI 10.1172/JCI117426; BERGMANN U, 1989, J CLIN CHEM CLIN BIO, V27, P351; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOLLAG DM, 1991, PROTEIN METHODS, P173; BORREGAARD N, 1992, J CLIN INVEST, V90, P86, DOI 10.1172/JCI115860; BORREGAARD N, 1995, BLOOD, V85, P812, DOI 10.1182/blood.V85.3.812.bloodjournal853812; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; BOYUM A, 1976, SCAND J IMMUNOL, P9, DOI 10.1111/j.1365-3083.1976.tb03851.x; BRETONGORIUS J, 1980, AM J PATHOL, V99, P413; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; CAWSTON TE, 1986, BIOCHEM J, V238, P677, DOI 10.1042/bj2380677; CAWSTON TE, 1986, PROTEINASES INFLAMMA, P189; CHESLER L, 1995, BLOOD, V86, P4506, DOI 10.1182/blood.V86.12.4506.bloodjournal86124506; Cieutat AM, 1998, BLOOD, V91, P1044, DOI 10.1182/blood.V91.3.1044.1044_1044_1058; CRAMER E, 1985, BLOOD, V65, P423; DAVIS GE, 1991, ARCH BIOCHEM BIOPHYS, V286, P551, DOI 10.1016/0003-9861(91)90078-W; DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N; Dennison C, 1997, PROTEIN EXPRES PURIF, V11, P149, DOI 10.1006/prep.1997.0779; DEWALD B, 1982, J CLIN INVEST, V70, P518, DOI 10.1172/JCI110643; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DROUIN L, 1988, J PERIODONTAL RES, V23, P370, DOI 10.1111/j.1600-0765.1988.tb01615.x; Edwards S.L., 1994, BIOCH PHYSL NEUTROPH; EGESTEN A, 1994, BLOOD, V83, P2985, DOI 10.1182/blood.V83.10.2985.2985; FOURET P, 1989, J EXP MED, V169, P833, DOI 10.1084/jem.169.3.833; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 1998, BLOOD, V92, P1342, DOI 10.1182/blood.V92.4.1342.416k22_1342_1349; Gullberg U, 1997, EUR J HAEMATOL, V58, P137; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; ISHIBASHI H, 1988, METHOD ENZYMOL, V163, P485; ITOH Y, 1995, J BIOL CHEM, V270, P16518, DOI 10.1074/jbc.270.28.16518; JOINER KA, 1989, J CELL BIOL, V109, P2771, DOI 10.1083/jcb.109.6.2771; JOST CR, 1990, BLOOD, V75, P144; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; KJELDSEN L, 1993, BLOOD, V82, P3183; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; KO YG, 1995, ANAL BIOCHEM, V224, P166, DOI 10.1006/abio.1995.1024; KOBAYASHI T, 1991, J CELL BIOL, V113, P743, DOI 10.1083/jcb.113.4.743; LeCabec V, 1996, P NATL ACAD SCI USA, V93, P6454, DOI 10.1073/pnas.93.13.6454; LEW PD, 1984, J CELL BIOL, V99, P1212, DOI 10.1083/jcb.99.4.1212; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; LOW MG, 1987, BIOCHEM J, V241, P615, DOI 10.1042/bj2410615; Mackarel AJ, 1999, AM J RESP CELL MOL, V20, P1209; Mandeville JTH, 1997, J LEUKOCYTE BIOL, V61, P188, DOI 10.1002/jlb.61.2.188; MATSUDAIRA P, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P1; MERCER E, 1985, BIOCHEM J, V231, P505, DOI 10.1042/bj2310505; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; MURPHY G, 1980, BIOCHEM J, V192, P517, DOI 10.1042/bj1920517; NITSCH M, 1990, BIOL CHEM H-S, V371, P611, DOI 10.1515/bchm3.1990.371.2.611; ODA T, 1995, MEDIAT INFLAMM, V4, P133, DOI 10.1155/S0962935195000238; Oda T, 1992, Mediators Inflamm, V1, P403, DOI 10.1155/S0962935192000619; OREN A, 1995, J LAB CLIN MED, V125, P340; OSTHUES A, 1992, FEBS LETT, V296, P16, DOI 10.1016/0014-5793(92)80393-U; PATARCA R, 1985, NATURE, V318, P390, DOI 10.1038/318390a0; POLSON A, 1964, BIOCHIM BIOPHYS ACTA, V82, P463, DOI 10.1016/0304-4165(64)90438-6; POLSON A, 1985, IMMUNOL INVEST, V14, P323, DOI 10.3109/08820138509022667; PRYZWANSKY KB, 1985, LAB INVEST, V53, P664; RICE WG, 1987, BLOOD, V70, P757; ROBERTS IM, 1975, J MICROSC-OXFORD, V103, P113, DOI 10.1111/j.1365-2818.1975.tb04542.x; Roos D, 1986, Methods Enzymol, V132, P225; ROTHWELL SW, 1989, J CELL BIOL, V108, P2313, DOI 10.1083/jcb.108.6.2313; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHETTLER A, 1991, EUR J BIOCHEM, V197, P197, DOI 10.1111/j.1432-1033.1991.tb15899.x; SEGAL AW, 1980, J CELL BIOL, V85, P42, DOI 10.1083/jcb.85.1.42; SENGELOV H, 1995, J IMMUNOL, V154, P4157; Sengelov H, 1996, EUR J HAEMATOL, V57, P6; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; Steadman R, 1997, INT J BIOCHEM CELL B, V29, P993, DOI 10.1016/S1357-2725(97)00038-1; Stricklin G P, 1992, Matrix Suppl, V1, P325; TAKIGAWA M, 1990, BIOCHEM BIOPH RES CO, V171, P1264, DOI 10.1016/0006-291X(90)90822-5; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIEBEL S, 1995, EUR J BIOCHEM, V231, P714, DOI 10.1111/j.1432-1033.1995.tb20752.x; Uesugi M, 1998, J IMMUNOL, V161, P1422; Weibel E.R., 1979, STEREOLOGICAL METHOD, VI, P1; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Yu AE, 1996, BIOCHEM CELL BIOL, V74, P823, DOI 10.1139/o96-088; Zhao WQ, 1998, J CELL SCI, V111, P1147; Zor T, 1996, ANAL BIOCHEM, V236, P302, DOI 10.1006/abio.1996.0171	89	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28308	28315						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869345				2022-12-27	WOS:000089197100103
J	Gomez-Angelats, M; Bortner, CD; Cidlowski, JA				Gomez-Angelats, M; Bortner, CD; Cidlowski, JA			Protein kinase C (PKC) inhibits Fas receptor-induced apoptosis through modulation of the loss of K+ and cell shrinkage - A role for PKC upstream of caspases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; CEREBELLAR GRANULE CELLS; JURKAT T-CELLS; MEDIATED APOPTOSIS; DNA FRAGMENTATION; PROTEOLYTIC ACTIVATION; INTRACELLULAR SIGNALS; SELECTIVE-INHIBITION; IMMUNE-SYSTEM; ICE-LIKE	Cell shrinkage and loss of intracellular K+ are early requisite features for the activation of effector caspases and apoptotic nucleases in Fas receptor-mediated apoptosis of Jurkat cells, although the mechanisms responsible for both process remain unclear (Bortner, C. D., Hughes, F. M., Jr., and Cidlowski, J. A. (1997) J. Biol Chem, 272, 32436-32442), We have now investigated the role of protein kinase C (PKC)-dependent signaling in the regulation of Fas-induced cell shrinkage and loss of KC during apoptosis, Anti-Fas induced cell shrinkage was blocked during PKC stimulation by the phorbol ester 12-O-tetradecanoylphorbol-3-acetate (PMA) and by bryostatin-1. Conversely, inhibition of PKC with Go6976, enhanced the anti-Fas-mediated loss of cell volume. Analyses of mitochondrial membrane potential and DNA fragmentation revealed that the PKC-mediated effect observed in cell volume is propagated to these late features of apoptosis, Flow cytometric analyses and Rb-86 efflux experiments revealed that a primary effect of PKC appears to be on the modulation of Fas-induced K+ efflux, since both PMA and bryostatin-1 inhibited extrusion of K+ that occurs during Fas-mediated cell death, and Go6976 exacerbated the effect of anti-Fas. Interestingly, high extracellular K+ significantly blocked the effect of anti-Fas alone or anti-Fas combined with Go6976, suggesting an underlying effect of PKC on K+ loss. Western blot analyses showed the caspase-dependent proteolysis of PKC isotypes delta, epsilon, and theta in whole cell extracts from anti-Fas treated Jurkat T cells. However, stimulation of PKC by PMA or bryostatin-1 prevented this isotypic-specific PKC cleavage during apoptosis, providing further evidence that PKC itself exerts an upstream signal in apoptosis and controls the caspase-dependent proteolytic degradation of PKC isotypes, Finally, we show that PMA or bryostatin-1 prevents the activation of caspase-3 and caspase-8, Thus, this study shows that the protective effect that PRC stimulation exerts in the Fas-mediated apoptotic pathway occurs at a site upstream of caspases-3 and -8.	NIEHS, Mol Endocrinol Grp, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Mol Endocrinol Grp, Lab Signal Transduct, NIH, 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.		Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BAIER G, 1993, J BIOL CHEM, V268, P4997; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; Basu A, 1999, BIOCHEMISTRY-US, V38, P4245, DOI 10.1021/bi982854q; Benson RSP, 1996, AM J PHYSIOL-CELL PH, V270, pC1190, DOI 10.1152/ajpcell.1996.270.4.C1190; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bortner CD, 1998, BIOCHEM PHARMACOL, V56, P1549, DOI 10.1016/S0006-2952(98)00225-1; Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; Cahalan MD, 1997, CURR OPIN BIOTECH, V8, P749, DOI 10.1016/S0958-1669(97)80130-9; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chang JY, 1997, NEUROCHEM RES, V22, P43, DOI 10.1023/A:1027373220133; Chen CY, 1999, J BIOL CHEM, V274, P15320, DOI 10.1074/jbc.274.22.15320; Chevaile A, 1998, CONTRIB NEPHROL, V123, P110, DOI 10.1159/000059924; Chung I, 1997, J MEMBRANE BIOL, V156, P73, DOI 10.1007/s002329900189; Cidlowski JA, 1996, RECENT PROG HORM RES, V51, P457; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Drew L, 1998, INT IMMUNOL, V10, P877, DOI 10.1093/intimm/10.7.877; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRINSTEIN S, 1984, AM J PHYSIOL, V246, pC204, DOI 10.1152/ajpcell.1984.246.3.C204; Haussermann S, 1999, FEBS LETT, V462, P442, DOI 10.1016/S0014-5793(99)01577-X; HENNINGS H, 1987, CARCINOGENESIS, V8, P1343, DOI 10.1093/carcin/8.9.1343; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; IMBODEN JB, 1988, IMMUNOL TODAY, V9, P17, DOI 10.1016/0167-5699(88)91350-3; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kawiak J, 1989, Postepy Biochem, V35, P265; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; Kennedy NJ, 1998, J IMMUNOL, V160, P4881; KILEY SC, 1995, BIOCHEM SOC T, V23, P601, DOI 10.1042/bst0230601; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KVANTA A, 1991, FEBS LETT, V283, P321, DOI 10.1016/0014-5793(91)80618-D; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LW, 1999, MOL CELL BIOL, V19, P8547; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Mochly-Rosen D, 1998, FASEB J, V12, P35; Moustakas A, 1998, CONTRIB NEPHROL, V123, P121, DOI 10.1159/000059925; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; O'Neill WC, 1999, AM J PHYSIOL-CELL PH, V276, pC995, DOI 10.1152/ajpcell.1999.276.5.C995; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; PAYET MD, 1992, J BIOL CHEM, V267, P18270; Pedemonte CH, 1997, J MEMBRANE BIOL, V155, P219, DOI 10.1007/s002329900174; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; RuizRuiz MD, 1997, EUR J IMMUNOL, V27, P1442, DOI 10.1002/eji.1830270622; Sawai H, 1997, J BIOL CHEM, V272, P2452; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Suda T, 1997, J ALLERGY CLIN IMMUN, V100, pS97, DOI 10.1016/S0091-6749(97)70013-7; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TSUTSUMI A, 1993, J IMMUNOL, V150, P1746; Varadhachary AS, 1999, J IMMUNOL, V163, P4772; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Villalba M, 1998, NEUROREPORT, V9, P2381, DOI 10.1097/00001756-199807130-00042; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WILLMAN CL, 1989, SEMIN DIAGN PATHOL, V6, P3; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	91	108	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19609	19619		10.1074/jbc.M909563199	http://dx.doi.org/10.1074/jbc.M909563199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10867019	hybrid			2022-12-27	WOS:000087941300025
J	Law, PY; Kouhen, OME; Solberg, J; Wang, W; Erickson, LJ; Loh, HH				Law, PY; Kouhen, OME; Solberg, J; Wang, W; Erickson, LJ; Loh, HH			Deltorphin II-induced rapid desensitization of delta-opioid receptor requires both phosphorylation and internalization of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-MEDIATED INTERNALIZATION; SIGNAL-REGULATED KINASES; G-PROTEIN; SOMATOSTATIN RECEPTOR; BETA-ARRESTIN; ADENOSINE RECEPTOR; MAMMALIAN-CELLS; TRAFFICKING; RESENSITIZATION; INVOLVEMENT	Similar to other G protein-coupled receptors, rapid phosphorylation of the delta-opioid receptor in the presence of agonist has been reported. Hence, agonist-induced desensitization of the delta-opioid receptor has been suggested to be via the receptor phosphorylation, arrestin-mediated pathway. However, due to the highly efficient coupling between the delta-opioid receptor and the adenylyl cyclase, the direct correlation between the rates of receptor phosphorylation and receptor desensitization as measured by the adenylyl cyclase activity could not be established. In the current studies, using an ecdysone-inducible expression system to control the 6-opioid receptor levels in HEK293 cells, we could demonstrate that the rate of deltorphin II-induced receptor desensitization is dependent oil the receptor level. Only at receptor concentrations less than or equal to 90 fmol/mg of protein were rapid desensitizations (t(1/2) <10 min) observed. Apparently, deltorphin II-induced receptor desensitization involves cellular events in addition to receptor phosphorylation. Mutation of Ser(363) in the carboxyl tail of the 6-opioid receptor to Ala completely abolished the deltorphin II-induced receptor phosphorylation but not the desensitization response. Although the magnitude of desensitization was attenuated, the rate of deltorphin II-induced receptor desensitization remained the same in the S363A mutant as compared with wild type. Also, the S363A mutant could internalize in the presence of deltorphin II. Only when the agonist-induced clathrin-coated pit-mediated receptor internalization was blocked by 0.4 M sucrose that the deltorphin II-induced receptor desensitization was abolished in the S363A mutant. Similarly, 0.4 M sucrose could partially block the agonist-induced rapid desensitization in HEK293 cells expressing the wild type delta-opioid receptor. Taken together, these data supported the hypothesis that rapid desensitization of the delta-opioid receptor involves both the phosphorylation and the internalization of the receptor.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Law, PY (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA.			Law, Ping-Yee/0000-0002-5364-1093	NIDA NIH HHS [DA00564, DA07339, DA11806] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA000564, R01DA007339, P50DA011806] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; Appleyard SM, 1997, J NEUROCHEM, V69, P2405; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Bastepe M, 1997, MOL PHARMACOL, V51, P343, DOI 10.1124/mol.51.2.343; Beaumont V, 1998, J BIOL CHEM, V273, P33174, DOI 10.1074/jbc.273.50.33174; Capeyrou R, 1997, FEBS LETT, V415, P200, DOI 10.1016/S0014-5793(97)01124-1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng ZJ, 1998, J BIOL CHEM, V273, P24328, DOI 10.1074/jbc.273.38.24328; El Kouhen R, 1999, J BIOL CHEM, V274, P9207, DOI 10.1074/jbc.274.14.9207; FANTOZZI R, 1981, MOL PHARMACOL, V20, P8; Hasbi A, 1998, J NEUROCHEM, V70, P2129; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; Holtmann MH, 1996, J BIOL CHEM, V271, P23566, DOI 10.1074/jbc.271.38.23566; Ko JL, 1999, MOL BRAIN RES, V69, P171, DOI 10.1016/S0169-328X(99)00094-7; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; KOOVER A, 1997, J BIOL CHEM, V272, P27605; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; LAW PY, 1994, J PHARMACOL EXP THER, V271, P1689; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Pak Y, 1996, MOL PHARMACOL, V50, P1214; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; Palmer TM, 1996, J BIOL CHEM, V271, P15272, DOI 10.1074/jbc.271.25.15272; Palmer TM, 1997, BIOCHEMISTRY-US, V36, P832, DOI 10.1021/bi962290v; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PEI G, 1995, MOL PHARMACOL, V48, P173; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Wang CH, 1998, BIOCHEM BIOPH RES CO, V249, P321, DOI 10.1006/bbrc.1998.9080; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1999, J RECEPT SIGNAL TR R, V19, P301, DOI 10.3109/10799899909036653; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	38	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32057	32065		10.1074/jbc.M002395200	http://dx.doi.org/10.1074/jbc.M002395200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10893226	hybrid			2022-12-27	WOS:000089858900070
J	Liu, C; Yang, ZY; Yang, J; Xia, ZX; Ao, SH				Liu, C; Yang, ZY; Yang, J; Xia, ZX; Ao, SH			Regulation of the yeast transcriptional factor PHO2 activity by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSIBLE ACID-PHOSPHATASE; CYCLIN-CDK COMPLEX; SACCHAROMYCES-CEREVISIAE; PROTEIN; GENE; PHO80-PHO85; EXPRESSION; ACTIVATION; SYSTEM; INTERACT	The induction of yeast Saccharomyces cerevisiae gene PHO5 expression is mediated by transcriptional factors PHO2 and PHO4. PHO4 protein has been reported to be phosphorylated and inactivated by a cyclin-CDK (cyclin-dependent kinase) complex, PH080-PH085. We report here that PHO2 can also be phosphorylated. A Ser-230 to Ala mutation in the consensus sequence (SPIK) recognized by cdc2/CDC28-related kinase in PHO2 protein led to complete loss of its ability to activate the transcription of PHO5 gene. Further investigation showed that the Pro-231 to Ser mutation inactivated PHO2 protein as well, whereas the Ser-230 to Asp mutation did not affect PHO2 activity. Since the PHO2 Asp-230 mutant mimics Ser-230-phosphorylated PHO2, we postulate that only phosphorylated PHO2 protein could activate the transcription of PHO5 gene. Two hybrid assays showed that yeast CDC28 could interact with PHO2. CDC28 immunoprecipitate derived from the YPH499 strain grown under low phosphate conditions phosphorylated GST-PHO2 in vitro. A phosphate switch regulates the transcriptional activation activity of PHO2, and mutations of the (SPIK) site affect the transcriptional activation activity of PHO2 and the interaction between PHO2 and PHO4. BIAcore(R) analysis indicated that the negative charge in residue 230 of PHO2 was sufficient to help PHO2 interact with PHO4 in vitro.	Chinese Acad Sci, Shanghai Inst Biochem, State Key Lab Mol Biol, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Ao, SH (corresponding author), Chinese Acad Sci, Shanghai Inst Biochem, State Key Lab Mol Biol, Shanghai 200031, Peoples R China.	aosz@sunm.shcnc.ac.cn						ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BERBEN G, 1988, GENE, V66, P307, DOI 10.1016/0378-1119(88)90367-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUS G, 1989, EMBO J, V8, P939, DOI 10.1002/j.1460-2075.1989.tb03455.x; BRAZAS RM, 1993, P NATL ACAD SCI USA, V90, P11237, DOI 10.1073/pnas.90.23.11237; BURGLIN TR, 1988, CELL, V53, P339, DOI 10.1016/0092-8674(88)90153-5; BURKHOLDER PR, 1943, AM J BOT, V29, P459; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; GILLIQUET V, 1993, FEMS MICROBIOL LETT, V108, P333, DOI 10.1016/0378-1097(93)90564-I; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HILL CS, 1990, EMBO J, V9, P805, DOI 10.1002/j.1460-2075.1990.tb08177.x; HIRST K, 1994, EMBO J, V13, P5410, DOI 10.1002/j.1460-2075.1994.tb06876.x; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; Jeoung DI, 1998, MOL CELL BIOL, V18, P433, DOI 10.1128/MCB.18.1.433; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Magbanua JPV, 1997, J BIOCHEM, V121, P1182; MATSUMOTO K, 1984, GENETICS, V108, P53; MEASDAY V, 1994, SCIENCE, V266, P1392; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; OSHIMA Y, 1981, MOL BIOL YEAST SACCH, P159; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SENGSTAG C, 1988, GENE, V67, P223, DOI 10.1016/0378-1119(88)90399-X; SENGSTAG C, 1987, NUCLEIC ACIDS RES, V15, P233, DOI 10.1093/nar/15.1.233; Shao DL, 1996, MOL GEN GENET, V251, P358, DOI 10.1007/BF02172527; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; Wu JS, 1996, ACTA BIOCH BIOPH SIN, V28, P507; YANG J, 1995, ACTA BIOCH BIOPH SIN, V27, P165; YOSHIDA K, 1989, MOL GEN GENET, V217, P40, DOI 10.1007/BF00330940; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171	42	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31972	31978		10.1074/jbc.M003055200	http://dx.doi.org/10.1074/jbc.M003055200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10884387	hybrid			2022-12-27	WOS:000089858900059
J	de Kreij, A; Venema, G; van den Burg, B				de Kreij, A; Venema, G; van den Burg, B			Substrate specificity in the highly heterogeneous M4 peptidase family is determined by a small subset of amino acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOLYSIN-LIKE PROTEASES; BACILLUS NEUTRAL PROTEASES; 3-DIMENSIONAL STRUCTURE; MOLECULAR-CLONING; THERMAL-STABILITY; ACTIVE-SITE; SEQUENCE; GENE; SUBTILIS; CEREUS	The members of the M4 peptidase family are involved in processes as diverse as pathogenicity and industrial applications. For the first time a number of M4 family members, also known as thermolysin-like proteases, has been characterized with an identical substrate set and a uniform set of assay conditions. Characterization with peptide substrates as well as high performance liquid chromatography analysis of p-casein digests shows that the M4 family is a homogeneous family in terms of catalysis, even though there is a significant degree of amino acid sequence variation. The results of this study show that differences in substrate specificity within the M4 family do not correlate with overall sequence differences but depend on a small number of identifiable amino acids. Indeed, molecular modeling followed by site-directed mutagenesis of one of the substrate binding pocket residues of the thermolysin-like proteases of Bacillus stearothermophilus converted the catalytic characteristics of this variant into that of thermolysin.	Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotecchnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Venema, G (corresponding author), Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotecchnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.							Banbula A, 1998, STRUCTURE, V6, P1185, DOI 10.1016/S0969-2126(98)00118-X; Barrett A.J., 1998, HDB PROTEOLYTIC ENZY; Dhanaraj V, 1996, Drug Des Discov, V13, P3; DOMANN E, 1991, INFECT IMMUN, V59, P65, DOI 10.1128/IAI.59.1.65-72.1991; EIJSINK VGH, 1995, NAT STRUCT BIOL, V2, P374, DOI 10.1038/nsb0595-374; EIJSINK VGH, 1992, PROTEINS, V14, P224, DOI 10.1002/prot.340140209; FEDER J, 1971, BIOCHIM BIOPHYS ACTA, V251, P74, DOI 10.1016/0005-2795(71)90061-4; FEDER J, 1970, BIOCHEMISTRY-US, V9, P2784, DOI 10.1021/bi00816a005; FEDER J, 1968, BIOCHEMISTRY-US, V6, P2088; FUJII M, 1983, J BACTERIOL, V154, P831, DOI 10.1128/JB.154.2.831-837.1983; Gaucher JF, 1999, BIOCHEMISTRY-US, V38, P12569, DOI 10.1021/bi991043z; HARDY F, 1994, PROTEIN ENG, V7, P425, DOI 10.1093/protein/7.3.425; HAUSRATH AC, 1994, J BIOL CHEM, V269, P18839; HOLMES MA, 1983, BIOCHEMISTRY-US, V22, P236, DOI 10.1021/bi00270a034; HOLT C, 1988, PROTEIN ENG, V2, P251, DOI 10.1093/protein/2.4.251; HUNTER A, 1945, J BIOL CHEM, V157, P427; Jin YH, 1998, BIOORG MED CHEM LETT, V8, P3515, DOI 10.1016/S0960-894X(98)00643-X; KESTER WR, 1977, BIOCHEMISTRY-US, V16, P2506, DOI 10.1021/bi00630a030; KUBO M, 1988, J GEN MICROBIOL, V134, P1883; Kunugi S, 1996, EUR J BIOCHEM, V241, P368, DOI 10.1111/j.1432-1033.1996.00368.x; LENNARZ WJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P149, DOI 10.1016/0304-4157(91)90022-O; Mansfeld J, 1997, J BIOL CHEM, V272, P11152, DOI 10.1074/jbc.272.17.11152; MARIECLAIRE C, 1997, BIOCHEMISTRY-US, V36, P13984; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; MORIHARA K, 1995, METHOD ENZYMOL, V248, P242; MORIHARA K, 1970, EUR J BIOCHEM, V15, P374, DOI 10.1111/j.1432-1033.1970.tb01018.x; MOSIMANN S, 1995, PROTEINS, V23, P301, DOI 10.1002/prot.340230305; ODonohue MJ, 1996, J BIOL CHEM, V271, P26477, DOI 10.1074/jbc.271.43.26477; Rao MB, 1998, MICROBIOL MOL BIOL R, V62, P597, DOI 10.1128/MMBR.62.3.597-635.1998; Sabat A, 2000, INFECT IMMUN, V68, P973, DOI 10.1128/IAI.68.2.973-976.2000; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; STARK W, 1902, EUR J BIOCHEM, V984, P1; THAYER MM, 1991, J BIOL CHEM, V266, P2864; TRAN L, 1991, J BACTERIOL, V173, P6364, DOI 10.1128/jb.173.20.6364-6372.1991; Van den Burg B, 1999, BIOTECHNOL APPL BIOC, V30, P35; Van den Burg B, 1998, P NATL ACAD SCI USA, V95, P2056, DOI 10.1073/pnas.95.5.2056; VANAALTEN DMF, 1995, PROTEINS, V22, P45, DOI 10.1002/prot.340220107; VANDENBURG B, 1989, J BIOCHEM BIOPH METH, V18, P209, DOI 10.1016/0165-022X(89)90005-5; Veltman OR, 1998, BIOCHEMISTRY-US, V37, P5305, DOI 10.1021/bi972374j; Veltman OR, 1997, EUR J BIOCHEM, V248, P433, DOI 10.1111/j.1432-1033.1997.00433.x; Veltman OR, 1997, FEBS LETT, V405, P241, DOI 10.1016/S0014-5793(97)00193-2; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; VRIEND G, 1993, J COMPUT AID MOL DES, V7, P367, DOI 10.1007/BF02337558; Vriend G, 1998, J BIOL CHEM, V273, P35074, DOI 10.1074/jbc.273.52.35074; WEAVER LH, 1977, J MOL BIOL, V114, P119, DOI 10.1016/0022-2836(77)90286-8; WETMORE DR, 1992, MOL MICROBIOL, V6, P1593, DOI 10.1111/j.1365-2958.1992.tb00884.x; WETMORE DR, 1994, MOL MICROBIOL, V12, P747, DOI 10.1111/j.1365-2958.1994.tb01062.x	47	38	40	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31115	31120		10.1074/jbc.M003889200	http://dx.doi.org/10.1074/jbc.M003889200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10869357	hybrid			2022-12-27	WOS:000089762700053
J	Liu, Y; Hong, YH; Androphy, EJ; Chen, JJ				Liu, Y; Hong, YH; Androphy, EJ; Chen, JJ			Rb-independent induction of apoptosis by bovine papillomavirus type 1 E7 in response to tumor necrosis factor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; OPEN READING FRAME; CYTOSOLIC PHOSPHOLIPASE A(2); EARLY REGION TRANSFORMATION; CELL-CYCLE; ADENOVIRUS E1A; HPV-16 E7; HUMAN KERATINOCYTES; ARACHIDONIC-ACID; GROWTH ARREST	Bovine papillomavirus type 1 (BPV-1) is a small DNA virus that causes fibropapillomas of the host. BPV-1 has served as the prototype for studies of the molecular biology of the papillomaviruses. BPV-1 efficiently induces anchorage-independent growth and focus formation in murine C127 cells, The transforming properties of BPV-1 primarily reside in two genes, E5 and E6. Each of these genes is sufficient to transform cells. Although no independent transformation activity has been detected for E7, it was shown to be required for full transformation of C127 by BPV-1. We investigated the biological activities of BPV-1 E7 in several assays. Our results indicate that expression of BPV-1 E7 sensitizes cells to tumor necrosis factor alpha (TNF)-induced apoptosis. The TNF-induced apoptosis in E7-expressing cells was accompanied by increased release of arachidonic acid, indicating that phospholipase A(2) was activated. Unlike the E7 proteins from the cancer-related human papillomaviruses, the BPV-1 E7 protein does not associate efficiently with the retinoblastoma protein (pRB) in vitro, nor does it significantly affect the pRB levels in cultured cells. Furthermore, BPV-1 E7 sensitizes Rb-null cells to TNF-induced apoptosis. These studies indicate that BPV-1 E7 can sensitize cells to apoptosis through mechanisms that are independent of pRB.	New England Med Ctr, Dept Dermatol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Chen, JJ (corresponding author), New England Med Ctr, Dept Dermatol, 750 Washington St,Box 166, Boston, MA 02111 USA.			Androphy, Elliot/0000-0002-8104-0703	NCI NIH HHS [R01 CA73558] Funding Source: Medline; PHS HHS [F32] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073558] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BANKS L, 1990, ONCOGENE, V5, P833; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; BERG L, 1986, CELL, V46, P753, DOI 10.1016/0092-8674(86)90351-X; BERG LJ, 1986, MOL CELL BIOL, V6, P859, DOI 10.1128/MCB.6.3.859; Bergqvist A, 1997, J VIROL, V71, P276, DOI 10.1128/JVI.71.1.276-283.1997; Boyer SN, 1996, CANCER RES, V56, P4620; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Ferlini C, 1996, CELL PROLIFERAT, V29, P427, DOI 10.1111/j.1365-2184.1996.tb00985.x; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GAGE JR, 1990, J VIROL, V64, P723, DOI 10.1128/JVI.64.2.723-730.1990; Green DR, 1997, SCIENCE, V278, P1246, DOI 10.1126/science.278.5341.1246; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; HICKMAN ES, 1994, ONCOGENE, V9, P2177; Hickman ES, 1997, J VIROL, V71, P3710, DOI 10.1128/JVI.71.5.3710-3718.1997; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Howley M. P., 1996, FIELDS VIROLOGY, P2045; Iglesias M, 1998, ONCOGENE, V17, P1195, DOI 10.1038/sj.onc.1202054; JAREBORG N, 1992, J VIROL, V66, P4957, DOI 10.1128/JVI.66.8.4957-4965.1992; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KANDA T, 1988, J VIROL, V62, P610, DOI 10.1128/JVI.62.2.610-613.1988; Krajcsi P, 1996, J VIROL, V70, P4904, DOI 10.1128/JVI.70.8.4904-4913.1996; LASTER SM, 1988, J IMMUNOL, V141, P2629; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; LUSKY M, 1985, J VIROL, V53, P955, DOI 10.1128/JVI.53.3.955-965.1985; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morozov A, 1997, J VIROL, V71, P3451, DOI 10.1128/JVI.71.5.3451-3457.1997; MUNGER K, 1991, J VIROL, V65, P3943; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Munger K, 1997, HUMAN PAPILLOMAVIRUS, P17; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; NEARY K, 1989, J VIROL, V63, P259, DOI 10.1128/JVI.63.1.259-266.1989; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PATRICK DR, 1994, J BIOL CHEM, V269, P6842; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Puthenveettil JA, 1996, ONCOGENE, V13, P1123; RABSON MS, 1986, J VIROL, V60, P626, DOI 10.1128/JVI.60.2.626-634.1986; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Rapp L, 1999, ONCOGENE, V18, P607, DOI 10.1038/sj.onc.1202373; Ruesch MN, 1997, J VIROL, V71, P5570, DOI 10.1128/JVI.71.7.5570-5578.1997; SATO H, 1989, VIROLOGY, V168, P196; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, J VIROL, V57, P1; SCHILLER JT, 1986, CANC CELLS DNA TUMOR, V4, P571; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; STOREY A, 1990, J GEN VIROL, V71, P165, DOI 10.1099/0022-1317-71-1-165; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TANAKA A, 1989, J VIROL, V63, P1465, DOI 10.1128/JVI.63.3.1465-1469.1989; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Thomas JT, 1998, J VIROL, V72, P1131, DOI 10.1128/JVI.72.2.1131-1137.1998; Thomas JT, 1999, P NATL ACAD SCI USA, V96, P8449, DOI 10.1073/pnas.96.15.8449; Thorne TE, 1996, J VIROL, V70, P8502, DOI 10.1128/JVI.70.12.8502-8507.1996; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VANDEPOL SB, 1995, J VIROL, V69, P395, DOI 10.1128/JVI.69.1.395-402.1995; VoelkelJohnson C, 1996, J IMMUNOL, V156, P201; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	90	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30894	30900		10.1074/jbc.M000640200	http://dx.doi.org/10.1074/jbc.M000640200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10887172	hybrid			2022-12-27	WOS:000089762700025
J	Jeon, H; Shipley, GG				Jeon, H; Shipley, GG			Vesicle-reconstituted low density lipoprotein receptor - Visualization by cryoelectron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT COMPONENT C9; GROWTH-FACTOR PRECURSOR; CYSTEINE-RICH REPEAT; LDL RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA; ELECTRON-MICROSCOPY; 3-DIMENSIONAL STRUCTURE; MEDIATED ENDOCYTOSIS; CYTOPLASMIC DOMAIN; INSULIN-RECEPTOR	The low density lipoprotein (LDL) receptor is a key protein for maintaining cellular cholesterol homeostasis by binding cholesterol-rich lipoproteins through their apoB and apoE apoproteins. The LDL receptor is a transmembrane glycoprotein of M-r similar to 115 kDa; based on its primary sequence, five distinct structural domains have been identified (Yamamoto, T., Davis, C. G., Brown, M. S., Schneider, W. J., Casey, M. L., Goldstein, J. L., and Russell, D. W. (1984) Cell 39, 27-38). As a first step toward providing a structural description of the intact LDL receptor, the receptor has been purified from bovine adrenal cortices, reconstituted into unilamellar egg yolk phosphatidylcholine vesicles, and imaged using cryoelectron microscopy (cryoEM). CryoEM has the advantage of providing images of the reconstituted LDL receptor in its frozen, fully hydrated state. LDL receptor molecules were visualized as elongated, stick-like projections from the vesicle surface with maximum dimensions similar to 120-Angstrom length by similar to 45-Angstrom width. In some of the images, a short arm (or arms) was visible at the distal end of the stick-like projections. The LDL receptor was labeled via accessible free cysteine residues, probably including that corresponding to Cys-431 of the known full-length sequence of the human LDL receptor. The accessible cysteine was demonstrated using a maleimide-biotin streptavidin conjugate and confirmed by labeling with monomaleimido-Nanogold. Images obtained by cryoEM showed that the extracellular stick-like domain of the reconstituted LDL receptor was labeled by Nanogold. This combined cryoEM-Nanogold labeling study has provided the first low resolution structural images of the reconstituted, full-length bovine LDL receptor.	Boston Univ, Sch Med, Ctr Adv Biomed Res, Dept Biophys, Boston, MA 02118 USA; Boston Univ, Sch Med, Ctr Adv Biomed Res, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Shipley, GG (corresponding author), Boston Univ, Sch Med, Ctr Adv Biomed Res, Dept Biophys, 715 Albany St, Boston, MA 02118 USA.			Shipley, G./0000-0001-9603-5555	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL026335, R01HL057405] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 26335, HL 57405] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; Bieri S, 1998, BIOCHEMISTRY-US, V37, P10994, DOI 10.1021/bi980452c; BISHOP RW, 1992, J LIPID RES, V33, P549; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597; CHRISTIANSEN K, 1991, P NATL ACAD SCI USA, V88, P249, DOI 10.1073/pnas.88.1.249; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DELOOF H, 1986, P NATL ACAD SCI USA, V83, P2295; Dirlam KA, 1996, PROTEIN EXPRES PURIF, V8, P489, DOI 10.1016/S1046-5928(96)90129-1; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EYTAN GD, 1982, BIOCHIM BIOPHYS ACTA, V694, P185, DOI 10.1016/0304-4157(82)90024-7; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; HOFFER MJV, 1993, BIOCHEM BIOPH RES CO, V191, P880, DOI 10.1006/bbrc.1993.1299; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Jeon H, 2000, J BIOL CHEM, V275, P30465, DOI 10.1074/jbc.M002582200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE LY, 1989, NUCLEIC ACIDS RES, V17, P1259, DOI 10.1093/nar/17.3.1259; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARAZZITI D, 1988, BIOCHEMISTRY-US, V27, P6529, DOI 10.1021/bi00417a050; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; North CL, 1999, BIOCHEMISTRY-US, V38, P3926, DOI 10.1021/bi9821622; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; Saxena K, 1997, BIOCHEMISTRY-US, V36, P15940, DOI 10.1021/bi971579p; SCHNEIDER WJ, 1985, METHOD ENZYMOL, V109, P405; Simmons T, 1997, J BIOL CHEM, V272, P25531, DOI 10.1074/jbc.272.41.25531; Springer TA, 1998, J MOL BIOL, V283, P837, DOI 10.1006/jmbi.1998.2115; STANLEY KK, 1985, EMBO J, V4, P375, DOI 10.1002/j.1460-2075.1985.tb03639.x; TOLLESHAUG H, 1982, CELL, V30, P715, DOI 10.1016/0092-8674(82)90276-8; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; Woldin CN, 1999, J BIOL CHEM, V274, P34981, DOI 10.1074/jbc.274.49.34981; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	44	23	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30458	30464		10.1074/jbc.M002583200	http://dx.doi.org/10.1074/jbc.M002583200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10889196	hybrid			2022-12-27	WOS:000089577900074
J	Ling, SZ; Woronuk, G; Sy, L; Lev, S; Braun, AP				Ling, SZ; Woronuk, G; Sy, L; Lev, S; Braun, AP			Enhanced activity of a large conductance, calcium-sensitive K+ channel in the presence of Src tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; SPONTANEOUSLY HYPERTENSIVE RATS; PROTEIN-COUPLED RECEPTORS; FOCAL ADHESION KINASE; SMOOTH-MUSCLE CELLS; ION CHANNELS; ACETYLCHOLINE-RECEPTOR; TRANSMITTER RELEASE; GABA(A) RECEPTORS; CYSTIC-FIBROSIS	Large conductance, calcium-sensitive K+ channels (BKCa channels) contribute to the control of membrane potential in a variety of tissues, including smooth muscle, where they act as the target effector for intracellular "calcium sparks" and the endothelium-derived vasodilator nitric oxide. Various signal transduction pathways, including protein phosphorylation can regulate the activity of BKCa channels, along with many other membrane ion channels. In our study, we have examined the regulation of BKCa channels by the cellular Src gene product (cSrc), a soluble tyrosine kinase that has been implicated in the regulation of both voltage and ligand-gated ion channels. Using a heterologous expression system, we observed that co-expression of murine BKCa channel and the human cSrc tyrosine kinase in HEK 293 cells led to a calcium-sensitive enhancement of BKCa, channel activity in excised membrane patches. In contrast, co-expression with a catalytically inactive cSrc mutant produced no change in BKCa, channel activity, demonstrating the requirement for a functional cSrc molecule. Furthermore, we observed that BKCa channels underwent direct tyrosine phosphorylation in cells co-transfected with BKCa, channels and active cSre but not in cells co-transfected with the kinase inactive form of the enzyme. A single Tyr to Phe substitution in the C-terminal half of the channel largely prevented this observed phosphorylation, Given that cSre may become activated by receptor tyrosine kinases or G-protein-coupled receptors, these findings suggest that cSrc-dependent tyrosine phosphorylation of BKCa, channels in situ may represent a novel regulatory mechanism for altering membrane potential and calcium entry.	Univ Calgary, Fac Med, Dept Pharmacol & Therapeut, Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	University of Calgary; Weizmann Institute of Science	Braun, AP (corresponding author), Univ Calgary, Fac Med, Dept Pharmacol & Therapeut, Smooth Muscle Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	abraun@ucalgary.ca	Ling, Shizhang/J-6114-2014; Lev, Sima/AAP-7880-2020	Ling, Shizhang/0000-0002-6856-3577; Lev, Sima/0000-0002-2108-3330				Akhand AK, 1999, J BIOL CHEM, V274, P25821, DOI 10.1074/jbc.274.36.25821; ASANO M, 1995, J PHARMACOL EXP THER, V275, P775; ASANO M, 1993, BRIT J PHARMACOL, V108, P214, DOI 10.1111/j.1476-5381.1993.tb13465.x; BIELEFELDT K, 1994, J PHYSIOL-LONDON, V475, P241, DOI 10.1113/jphysiol.1994.sp020065; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BULTER A, 1993, SCIENCE, V261, P221; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHENG HC, 1992, J BIOL CHEM, V267, P9248; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; Cui J, 1997, J GEN PHYSIOL, V109, P647, DOI 10.1085/jgp.109.5.647; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Hall SK, 2000, J BIOL CHEM, V275, P3749, DOI 10.1074/jbc.275.6.3749; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HARTZELL HC, 1988, PROG BIOPHYS MOL BIO, V52, P165, DOI 10.1016/0079-6107(88)90014-4; Holmes TC, 1996, J NEUROSCI, V16, P1581; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; Hu XQ, 1998, J BIOL CHEM, V273, P5337, DOI 10.1074/jbc.273.9.5337; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; KUME H, 1992, P NATL ACAD SCI USA, V89, P11051, DOI 10.1073/pnas.89.22.11051; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; KUME H, 1991, AM J PHYSIOL, V261, pC1204, DOI 10.1152/ajpcell.1991.261.6.C1204; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; MCCOBB DP, 1995, AM J PHYSIOL-HEART C, V269, pH767, DOI 10.1152/ajpheart.1995.269.3.H767; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; PALLANCK L, 1994, HUM MOL GENET, V3, P1239, DOI 10.1093/hmg/3.8.1239; PELZER D, 1990, REV PHYSIOL BIOCH P, V114, P107; REINHART PH, 1991, J NEUROSCI, V11, P1627; ROBITAILLE R, 1993, NEURON, V11, P645, DOI 10.1016/0896-6273(93)90076-4; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; VALENZUELA CF, 1995, MOL BRAIN RES, V31, P165, DOI 10.1016/0169-328X(95)00048-W; Vogalis F, 1996, AM J PHYSIOL-GASTR L, V271, pG629, DOI 10.1152/ajpgi.1996.271.4.G629; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zamponi GW, 1998, CURR OPIN NEUROBIOL, V8, P351, DOI 10.1016/S0959-4388(98)80060-3	53	76	80	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30683	30689		10.1074/jbc.M004292200	http://dx.doi.org/10.1074/jbc.M004292200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10893418	hybrid			2022-12-27	WOS:000089577900105
J	Li, B; Fuh, G; Meng, G; Xin, XH; Gerritsen, ME; Cunningham, B; de Vos, AM				Li, B; Fuh, G; Meng, G; Xin, XH; Gerritsen, ME; Cunningham, B; de Vos, AM			Receptor-selective variants of human vascular endothelial growth factor - Generation and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; KINASE DOMAIN RECEPTOR; HIGH-AFFINITY BINDING; CRYSTAL-STRUCTURE; FLT-1 RECEPTOR; ANGSTROM RESOLUTION; KDR/FLK-1 RECEPTOR; TYROSINE KINASE; FACTOR VEGF; ORF VIRUS	Vascular endothelial growth factor (VEGF) is a pleiotropic factor that exerts a multitude of biological effects through its interaction with two receptor tyrosine kinases, fms-like tyrosine kinase (Flt-1) or VEGF receptor 1 and kinase insert domain-containing receptor (KDR) or VEGF receptor 2. Whereas it is commonly accepted that KDR is responsible for the proliferative activities of VEGF, considerable controversy and uncertainty exist about the role of the individual receptors in eliciting many of the other effects. Based on a comprehensive mutational analysis of the receptor-binding site of VEGF, an Flt-1-selective variant was created containing four substitutions from the wild-type protein. This variant bound with wild-type affinity to Flt-1, was at least 470-fold reduced in binding to KDR, and had no activity in cell-based assays measuring autophosphorylation of KDR or proliferation of primary human vascular endothelial cells. Using a competitive phage display strategy, two KDR-selective variants were discovered with three and four changes from wild-type, respectively. Both variants had approximately wild-type affinity for KDR, were about 2000-fold reduced in binding to Flt-1, and showed activity comparable with the wild-type protein in KDR autophosphorylation and endothelial cell proliferation assays. These variants will serve as useful reagents in elucidating the roles of Flt-1 and KDR.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioanalyt Technol, San Francisco, CA 94080 USA; Genentech Inc, Dept Cardiovasc Res, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	de Vos, AM (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, San Francisco, CA 94080 USA.	devos@gene.com						Bauters C, 1997, CLIN CARDIOL, V20, P52; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; PARK JE, 1994, J BIOL CHEM, V269, P25646; Parry TJ, 1999, NUCLEIC ACIDS RES, V27, P2569, DOI 10.1093/nar/27.13.2569; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884; Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071	37	80	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29823	29828		10.1074/jbc.M002015200	http://dx.doi.org/10.1074/jbc.M002015200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10878003	hybrid			2022-12-27	WOS:000089439800088
J	Porat, A; Elazar, Z				Porat, A; Elazar, Z			Regulation of intra-Golgi membrane transport by calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PROTEIN; FUSION; RELEASE; BUFFERS; COMPARTMENTS; CHANNEL; CALNUC; STEP	Calcium cations play a critical role in regulating vesicular transport between different intracellular membrane-bound compartments. The role of calcium in transport between the Golgi cisternae, however, remains unclear. Using a well characterized cell-free intra-Golgi transport assay, we now show that changes in free Ca2+ concentration in the physiological range regulate this transport process. The calcium-chelating agent 1,2-bis(2-aminophenoxy)ethane-N,N,N,N'-tetraacetic acid blocked transport with an IC50 of approximately 0.8 mM. The effect of 1,2-bis(2- aminophenoxy)ethane-N,N,N',N'-tetraacetic acid was reversible by addition of fresh cytosol and was irreversible when performed in the presence of a Ca2+ ionophore that depletes calcium from lumenal stores, We demonstrate here that intra-Golgi transport is stimulated by low Ca2+ concentrations (20-100 nM) but is inhibited by higher concentrations (above 100 nM). Further, we show that calmodulin antagonists specifically block intra-Golgi transport, implying a role for calmodulin in mediating the effect of calcium. Our results suggest that Ca2+ efflux from intracellular pools may play an essential role in regulating intra-Golgi transport.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elazar, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.							AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Barroso MR, 1996, J BIOL CHEM, V271, P10183, DOI 10.1074/jbc.271.17.10183; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Colombo MI, 1997, J BIOL CHEM, V272, P7707, DOI 10.1074/jbc.272.12.7707; FERRIS CD, 1992, J NEUROSCI, V12, P1567; FILL M, 1988, TRENDS NEUROSCI, V11, P453, DOI 10.1016/0166-2236(88)90198-1; FRIES E, 1980, P NATL ACAD SCI-BIOL, V77, P3870, DOI 10.1073/pnas.77.7.3870; HOCHNER B, 1991, NEUROSCI LETT, V125, P215, DOI 10.1016/0304-3940(91)90032-O; Holroyd C, 1999, MOL BIOL CELL, V10, P3035, DOI 10.1091/mbc.10.9.3035; Legesse-Miller A, 1998, J BIOL CHEM, V273, P3105, DOI 10.1074/jbc.273.5.3105; Lin P, 1999, J CELL BIOL, V145, P279, DOI 10.1083/jcb.145.2.279; Lin P, 1998, J CELL BIOL, V141, P1515, DOI 10.1083/jcb.141.7.1515; Lin P, 2000, P NATL ACAD SCI USA, V97, P674, DOI 10.1073/pnas.97.2.674; LLINAS R, 1995, NEUROPHARMACOLOGY, V34, P1443, DOI 10.1016/0028-3908(95)00150-5; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Porat A, 2000, J BIOL CHEM, V275, P14457, DOI 10.1074/jbc.275.19.14457; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; SCHELLER RH, 1995, NEURON, V14, P893; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; TAYLOR TC, 1994, MOL BIOL CELL, V5, P237, DOI 10.1091/mbc.5.2.237; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Wang SSH, 1995, BIOPHYS J, V69, P1683, DOI 10.1016/S0006-3495(95)80086-X	33	73	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29233	29237		10.1074/jbc.M005316200	http://dx.doi.org/10.1074/jbc.M005316200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10871627	hybrid			2022-12-27	WOS:000089439800009
J	Tong, XK; Hussain, NK; Adams, AG; O'Bryan, JP; McPherson, PS				Tong, XK; Hussain, NK; Adams, AG; O'Bryan, JP; McPherson, PS			Intersectin can regulate the Ras/MAP kinase pathway independent of its role in endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; NUCLEOTIDE EXCHANGE FACTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; RECEPTOR INTERNALIZATION; SIGNAL-TRANSDUCTION; PHENYLARSINE OXIDE; ADAPTER PROTEIN; EPS15 HOMOLOGY; BETA-ARRESTIN	We previously identified intersectin, a multiple EH and SH3 domain-containing protein, as a component of the endocytic machinery. Overexpression of the SH3 domains of intersectin blocks transferrin receptor endocytosis, possibly by disrupting targeting of accessory proteins of clathrin-coated pit formation. More recently, we identified mammalian Sos, a guanine-nucleotide exchange factor for Pas, as an intersectin SH3 domain-binding partner. We now demonstrate that overexpression of intersectin's SH3 domains blocks activation of Ras and MAP kinase in various cell lines. Several studies suggest that activation of MAP kinase downstream of multiple receptor types is dependent on endocytosis. Thus, the dominant-negative effect of the SH3 domains on Ras/MAP kinase activation may be indirectly mediated through a block in endocytosis. Consistent with this idea, incubating cells at 4 degrees C or with phenylarsine oxide, treatments previously established to inhibit EGF receptor endocytosis, blocks EGF-dependent activation of MAP kinase. However, under these conditions, Pas activity is unaffected and overexpression of the SH3 domains of intersectin is still able to block Pas activation. Thus, intersectin SH3 domain overexpression can effect EGF-mediated MAP kinase activation directly through a block in Pas, consistent with a functional role for intersectin in Ras activation.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; NIEHS, Lab Signal Transduct, Res Triangle Pk, NC 27709 USA	McGill University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	McPherson, PS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	mcpm@musica.mcgill.ca		O'Bryan, John/0000-0001-5386-1080	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090091] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams A, 2000, J BIOL CHEM, V275, P27414; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Guipponi M, 1998, GENOMICS, V53, P369, DOI 10.1006/geno.1998.5521; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HERTEL C, 1985, J BIOL CHEM, V260, P2547; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; KATO Y, 1992, P NATL ACAD SCI USA, V89, P8507, DOI 10.1073/pnas.89.18.8507; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; Okamoto M, 1999, J BIOL CHEM, V274, P18446, DOI 10.1074/jbc.274.26.18446; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Roos J, 1999, CURR BIOL, V9, P1411, DOI 10.1016/S0960-9822(00)80087-1; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Sorkina T, 1999, J CELL SCI, V112, P317; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Zhang JS, 1999, CURR BIOL, V9, P1458, DOI 10.1016/S0960-9822(00)80115-3; Zhao H, 1998, J BIOL CHEM, V273, P12061, DOI 10.1074/jbc.273.20.12061	54	68	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29894	29899		10.1074/jbc.M004096200	http://dx.doi.org/10.1074/jbc.M004096200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896662	hybrid			2022-12-27	WOS:000089439800097
J	Walter, L; Nogueira, V; Leverve, X; Heitz, MP; Bernardi, P; Fontaine, E				Walter, L; Nogueira, V; Leverve, X; Heitz, MP; Bernardi, P; Fontaine, E			Three classes of ubiquinone analogs regulate the mitochondrial permeability transition pore through a common site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; COENZYME Q(10); INDUCED DEGENERATION; LIPID COMPOSITIONS; CELL-DEATH; APOPTOSIS; ISCHEMIA; NEURONS; BRAIN; DYSFUNCTION	To identify the structural features required for regulation of the mitochondrial permeability transition pore (PTP) by ubiquinone analogs (Fontaine, E., Ichas, F., and Bernardi, P. (1998) J. Biol. Chem. 40, 25734-25740), we have carried out an analysis with quinone structural variants. We show that three functional classes can be defined: (i) PTP inhibitors (ubiquinone 0, decylubiquinone, ubiquinone 10, 2,3-dimethyl-6-decyl-1,4-benzoquinone, and 2,3,5-trimethyl-6-geranyl-1,4-benzoquinone); (ii) PTP inducers (2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone and 2,5-dihydroxy-6-undecyl-1,4-benzoquinone); and (iii) PTP-inactive quinones that counteract the effects of both inhibitors and inducers (ubiquinone 5 and 2,3,5-trimethyl-6-(3-hydroxyisoamyl)-1,4-benzoquinone). The structure-function correlation indicates that minor modifications in the isoprenoid side chain can turn an inhibitor into an activator, and that the methoxy groups are not essential for the effects of quinones on the PTP. Since the ubiquinone analogs used in this study have a similar midpoint potential and decrease mitochondrial production of reactive oxygen species to the same extent, these results support the hypothesis that quinones modulate the PTP through a common binding site rather than through oxidation-reduction reactions. Occupancy of this site can modulate the PTP open-closed transitions, possibly through secondary changes of the PTP Ca2+ binding affinity.	Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, F-38041 Grenoble 09, France; F Hoffmann La Roche & Co Ltd, Discovery Chem, Div Pharma, CH-4070 Basel, Switzerland; Univ Padua, Sch Med, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Sch Med, CNR, Unit Study Biomembranes, I-35121 Padua, Italy	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Roche Holding; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Fontaine, E (corresponding author), Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, F-38041 Grenoble 09, France.		Fontaine, Eric/ABA-8853-2020; Walter, Ludivine/S-4456-2017; Bernardi, Paolo/C-3656-2008	Fontaine, Eric/0000-0002-5204-9477; Walter, Ludivine/0000-0001-7214-0676; Bernardi, Paolo/0000-0001-9187-3736				BEAL MF, 1994, ANN NEUROL, V36, P882, DOI 10.1002/ana.410360613; Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; BROUILLET E, 1994, NEUROSCI LETT, V177, P58, DOI 10.1016/0304-3940(94)90044-2; Crestanello JA, 1996, J THORAC CARDIOV SUR, V111, P443, DOI 10.1016/S0022-5223(96)70455-5; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; EDLUND C, 1994, J NEUROCHEM, V63, P634; EDLUND C, 1992, BIOCHEM CELL BIOL, V70, P422, DOI 10.1139/o92-065; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; FAVIT A, 1992, J CEREBR BLOOD F MET, V12, P638, DOI 10.1038/jcbfm.1992.88; Ferrand-Drake M, 1999, NEUROSCIENCE, V90, P1325, DOI 10.1016/S0306-4522(98)00559-4; Fontaine E, 1999, J BIOENERG BIOMEMBR, V31, P335, DOI 10.1023/A:1005475802350; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; GENOVA ML, 1995, BIOCHEM J, V311, P105, DOI 10.1042/bj3110105; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; KALEN A, 1989, LIPIDS, V24, P579, DOI 10.1007/BF02535072; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Leist M, 1997, BIOCHEM BIOPH RES CO, V236, P1, DOI 10.1006/bbrc.1997.6890; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Matthews RT, 1998, P NATL ACAD SCI USA, V95, P8892, DOI 10.1073/pnas.95.15.8892; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; SODERBERG M, 1990, J NEUROCHEM, V54, P415, DOI 10.1111/j.1471-4159.1990.tb01889.x; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TAKEO S, 1987, J PHARMACOL EXP THER, V243, P1131; VINOGRADOV A, 1972, ARCH BIOCHEM BIOPHYS, V152, P646, DOI 10.1016/0003-9861(72)90261-5; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339	35	127	140	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29521	29527		10.1074/jbc.M004128200	http://dx.doi.org/10.1074/jbc.M004128200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10889201	hybrid			2022-12-27	WOS:000089439800046
J	Lopez-Rovira, T; Chalaux, E; Rosa, JL; Bartrons, R; Ventura, F				Lopez-Rovira, T; Chalaux, E; Rosa, JL; Bartrons, R; Ventura, F			Interaction and functional cooperation of NF-kappa B with Smads - Transcriptional regulation of the junB promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CREB-BINDING-PROTEIN; TGF-BETA; SIGNAL-TRANSDUCTION; DNA-BINDING; TUMOR-SUPPRESSOR; GENE; ACTIVATION; IDENTIFICATION; ELEMENTS	The transforming growth factor-beta (TGF-beta) family of cytokines regulates diverse cellular processes through control of the expression of target genes. Smad proteins are a recently identified family of signal transducers for members of the TGF-beta family. Smads act as transcriptional regulators through binding to DNA and interacting with a variety of transcription factors. Here, we identified a ICE Site as a TGF-beta-responsive region in the 3'-downstream junB promoter region. We also demonstrate that kappa B sites alone are sufficient to mediate immediate transcriptional activation by TGF-beta. Transactivation of kappa B Sites by TGF-beta requires an intact NF-kappa B pathway, cooperates with known activators of this pathway, and is mediated by Smad family members. Furthermore, we show that Smads interacts with p52 in vivo. These data expand the model in which Smad proteins undergo multiple interactions with several transcription factors that could induce either activation or repression of gene expression.	Univ Barcelona, Dept Ciencies Fisiol 2, E-08907 Lhospitalet De Llobregat, Spain	University of Barcelona	Ventura, F (corresponding author), Univ Barcelona, Unitat Bioquim, Campus Bellvitge,Feixa Llarga S-N, E-08907 Lhospitalet De Llobregat, Spain.	fventura@bellvitge.bvg.ub.es	Rosa, Jose Luis/K-6685-2014; Ventura, Francesc/ABG-2285-2020; Ventura, Francesc/K-9700-2014	Rosa, Jose Luis/0000-0002-6161-5688; Ventura, Francesc/0000-0001-9673-9405; Ventura, Francesc/0000-0001-9673-9405; Bartrons, Ramon/0000-0001-9349-5847				ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Brown RT, 1995, J BIOL CHEM, V270, P31129, DOI 10.1074/jbc.270.52.31129; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; COUSSENS LM, 1994, J CELL PHYSIOL, V160, P435, DOI 10.1002/jcp.1041600306; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawabata M, 1999, J BIOCHEM, V125, P9, DOI 10.1093/oxfordjournals.jbchem.a022273; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kon A, 1999, ONCOGENE, V18, P1837, DOI 10.1038/sj.onc.1202495; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Li JM, 1998, MOL CELL BIOL, V18, P110, DOI 10.1128/MCB.18.1.110; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; MUCHARDT C, 1992, J VIROL, V66, P244, DOI 10.1128/JVI.66.1.244-250.1992; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	55	91	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28937	28946		10.1074/jbc.M909923199	http://dx.doi.org/10.1074/jbc.M909923199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10874048	Green Published, hybrid			2022-12-27	WOS:000089330700079
J	McCloskey, DE; Pegg, AE				McCloskey, DE; Pegg, AE			Altered spermidine/spermine N-1-acetyltransferase activity as a mechanism of cellular resistance to bis(ethyl)polyamine analogues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; SUBSTITUTED POLYAMINE ANALOGS; L1210 LEUKEMIA-CELLS; BREAST-CANCER CELLS; SPERMINE N1-ACETYLTRANSFERASE; TUMOR-CELLS; ANTITUMOR-ACTIVITY; GROWTH-INHIBITION; LUNG-CARCINOMA; IN-VITRO	To develop a model system to investigate mechanisms of antiproliferative action of bis(ethyl)polyamine analogues, intermittent analogue treatments followed by recovery periods in drug-free medium were used to select an N-1,N-12-bis(ethyl)spermine-resistant derivative of the Chinese hamster ovary cell line C55.7. The resulting C55,7Res line was at least 10-fold resistant to N-1,N-11-bis(ethyl)spermine and N-1,N-11-bis(ethyl)norspermine. The stability of the resistance in the absence of selection pressure was greater than or equal to 9 months, indicating that a heritable genotypic change was responsible for the resistance phenotype. Polyamine transport alterations and multi-drug resistance were eliminated as causes of the resistance. Spermidine/spermine N-1-acetyltransferase (SSAT) activity and regulation were altered in C55,7Res cells as basal activity was decreased, and no activity induction resulted from exposure to analogue concentrations, which caused 300-fold enzyme induction in parental cells. SSAT mRNA levels in the absence and presence of analogue were unchanged, but no SSAT protein was detected in C55,7Res cells. A point mutation, which results in the change leucine156 (a fully conserved residue) to phenylalanine, was identified in the C55,7Res SSAT cDNA. Expression of wtSSAT activity in C55.7Res cells restored sensitivity to bis(ethyl)polyamines. These results provided definitive evidence that SSAT activity is a critical target of the cytotoxic action of these analogues.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	McCloskey, DE (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA.	dem15@psu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026290] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-26290] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU HS, 1994, CANCER RES, V54, P6210; BASU HS, 1993, CANCER RES, V53, P3948; BASU HS, 1993, ANTICANCER RES, V13, P1525; BASU HS, 1990, CANCER RES, V50, P3137; BERGERON RJ, 1988, J MED CHEM, V31, P1183, DOI 10.1021/jm00401a019; BYERS TL, 1989, AM J PHYSIOL, V257, pC545, DOI 10.1152/ajpcell.1989.257.3.C545; BYERS TL, 1990, J CELL PHYSIOL, V143, P460, DOI 10.1002/jcp.1041430309; CASERO RA, 1989, CANCER RES, V49, P639; CASERO RA, 1990, BIOCHEM J, V270, P615, DOI 10.1042/bj2700615; CASERO RA, 1995, CANCER CHEMOTH PHARM, V36, P69; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1991, J BIOL CHEM, V266, P810; CASERO RA, 1994, CANCER RES, V54, P3955; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; COLEMAN CS, 1995, BIOCHEMISTRY-US, V34, P13423, DOI 10.1021/bi00041a020; Coleman CS, 1996, BIOCHEM J, V316, P697, DOI 10.1042/bj3160697; DAVIDSON NE, 1993, CANCER RES, V53, P2071; EDWARDS ML, 1990, J MED CHEM, V33, P1369, DOI 10.1021/jm00167a014; Gabrielson EW, 1999, CLIN CANCER RES, V5, P1638; Germann U A, 1993, Semin Cell Biol, V4, P63; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Ha HC, 1998, CANCER RES, V58, P2711; Hazlehurst LA, 1999, CANCER RES, V59, P1021; HYVONEN T, 1994, BBA-MOL CELL RES, V1221, P279, DOI 10.1016/0167-4889(94)90251-8; KRAMER D, 1995, J BIOL CHEM, V270, P2124, DOI 10.1074/jbc.270.5.2124; KRAMER DL, 1993, J CELL PHYSIOL, V155, P399, DOI 10.1002/jcp.1041550222; Marverti G, 1998, INT J CANCER, V78, P33, DOI 10.1002/(SICI)1097-0215(19980925)78:1<33::AID-IJC7>3.0.CO;2-Y; MATSUI I, 1981, J BIOL CHEM, V256, P2454; McCloskey DE, 1999, J BIOL CHEM, V274, P6175, DOI 10.1074/jbc.274.10.6175; McCloskey DE, 1996, CLIN CANCER RES, V2, P441; McCloskey DE, 2000, CLIN CANCER RES, V6, P17; MCCLOSKEY DE, 1995, CANCER RES, V55, P3233; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1989, BIOCHEMISTRY-US, V28, P8446, DOI 10.1021/bi00447a026; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1989, J BIOL CHEM, V264, P11744; PEGG AE, 1992, BIOCHIM BIOPHYS ACTA, V1171, P106, DOI 10.1016/0167-4781(92)90148-S; PERSSON L, 1988, CANCER RES, V48, P4807; PILZ RB, 1990, J BIOL CHEM, V265, P8880; PIZZORNO G, 1988, CANCER RES, V48, P2149; PORTER CW, 1985, CANCER RES, V45, P2050; PORTER CW, 1991, CANCER RES, V51, P3715; PORTER CW, 1988, ADV ENZYME REGUL, V27, P57; PORTER CW, 1993, CANCER RES, V53, P581; SAAB NH, 1993, J MED CHEM, V36, P2998, DOI 10.1021/jm00072a020; Salvatore C, 1999, ANTI-CANCER DRUG, V10, P663, DOI 10.1097/00001813-199908000-00006; SEPPANEN P, 1981, EUR J BIOCHEM, V118, P571, DOI 10.1111/j.1432-1033.1981.tb05557.x; SEPPANEN P, 1981, BIOCHIM BIOPHYS ACTA, V674, P169, DOI 10.1016/0304-4165(81)90375-5; Webb HK, 1999, J MED CHEM, V42, P1415, DOI 10.1021/jm980603+; Wyler B, 1997, BRIT J HAEMATOL, V97, P65, DOI 10.1046/j.1365-2141.1997.52649.x; Zagaja GP, 1998, CANCER CHEMOTH PHARM, V41, P505, DOI 10.1007/s002800050774	52	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28708	28714		10.1074/jbc.M004120200	http://dx.doi.org/10.1074/jbc.M004120200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10887189	hybrid			2022-12-27	WOS:000089330700051
J	Ramakers, GMJ; Heinen, K; Gispen, WH; de Graan, PNE				Ramakers, GMJ; Heinen, K; Gispen, WH; de Graan, PNE			Long term depression in the CA1 field is associated with a transient decrease in pre- and postsynaptic PKC substrate phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CALMODULIN-BINDING DOMAIN; ADULT-RAT BRAIN; B-50 GAP-43; AREA CA1; SYNAPTIC TRANSMISSION; NERVOUS-SYSTEM; MULTIPLE FORMS; VISUAL-CORTEX; POTENTIATION	Induction of homosynaptic long term depression (LTD) in the CA1 field of the hippocampus is thought to require activation of N-methyl-D-aspartate receptors, an elevation of postsynaptic Ca2+ levels, and a subsequent increase in phosphatase activity. To investigate the spatial and temporal changes in protein phosphatase activity following LTD induction, we determined the in situ phosphorylation state of a pre- (GAP-43/B-50) and postsynaptic (RC3) protein kinase C substrate during N-methyl-D-aspartate receptor-dependent LTD in the CA1 field of rat hippocampal slices. We show that LTD is associated with a transient (<30 min) and D-APS-sensitive reduction in GAP-43/B-50 and RC3 phosphorylation and that LTD is prevented by the phosphatase inhibitors okadaic acid and cyclosporin A. Our data provide strong evidence for a transient increase in pre- and postsynaptic phosphatase activity during LTD. Since the in situ phosphorylation of the calmodulin-binding proteins GAP-43/B-50 and RC3 changes during both LTD and long term potentiation, these proteins may form part of the link between the Ca2+ signal and Ca2+/calmodulin-dependent processes implicated in long term potentiation and LTD.	Rudolf Magnus Inst Neurosci, Dept Med Pharmacol, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Ramakers, GMJ (corresponding author), Rudolf Magnus Inst Neurosci, Dept Med Pharmacol, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	g.m.j.ramakers@med.uu.nl		Ramakers, Geert/0000-0001-7499-6996				Arancio O, 1996, J PHYSIOLOGY-PARIS, V90, P321, DOI 10.1016/S0928-4257(97)87907-7; ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BAUDIER J, 1991, J BIOL CHEM, V266, P229; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPAGNE MV, 1990, J NEUROCYTOL, V19, P948, DOI 10.1007/BF01186822; Chakravarthy B, 1999, TRENDS NEUROSCI, V22, P12, DOI 10.1016/S0166-2236(98)01288-0; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; COHEN RW, 1993, BRAIN RES, V627, P147, DOI 10.1016/0006-8993(93)90758-F; COLLEY PA, 1993, BRAIN RES REV, V18, P115, DOI 10.1016/0165-0173(93)90009-O; Cummings JA, 1996, NEURON, V16, P825, DOI 10.1016/S0896-6273(00)80102-6; DANIELSON PE, 1994, GENOMICS, V19, P454, DOI 10.1006/geno.1994.1094; DEGRAAN PNE, 1990, J NEUROCHEM, V55, P2139; DEKKER LV, 1990, J NEUROCHEM, V54, P1645, DOI 10.1111/j.1471-4159.1990.tb01217.x; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; DUDEK SM, 1993, J NEUROSCI, V13, P2910; FIGUROV A, 1993, EUR J NEUROSCI, V5, P1035, DOI 10.1111/j.1460-9568.1993.tb00956.x; Gage AT, 1997, HIPPOCAMPUS, V7, P286; GERENDASY DD, 1995, J BIOL CHEM, V270, P6741, DOI 10.1074/jbc.270.12.6741; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; Hansel C, 1997, EUR J NEUROSCI, V9, P2309, DOI 10.1111/j.1460-9568.1997.tb01648.x; Hens JJH, 1996, J NEUROCHEM, V66, P1933; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; Hjelmstad GO, 1997, NEURON, V19, P1309, DOI 10.1016/S0896-6273(00)80421-3; Hrabetova S, 1996, J NEUROSCI, V16, P5324; HUANG KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P570, DOI 10.1006/abbi.1993.1463; INIGUEZ MA, 1992, J CLIN INVEST, V90, P554, DOI 10.1172/JCI115894; Kamal A, 1999, EUR J NEUROSCI, V11, P3512, DOI 10.1046/j.1460-9568.1999.00769.x; Kameyama K, 1998, NEURON, V21, P1163, DOI 10.1016/S0896-6273(00)80633-9; KIRKWOOD A, 1994, J NEUROSCI, V14, P3404; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; LISMAN JE, 1985, P NATL ACAD SCI USA, V82, P3055, DOI 10.1073/pnas.82.9.3055; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; McNamara RK, 1997, J COMP NEUROL, V379, P48; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NICHOLS RA, 1994, J BIOL CHEM, V269, P23817; Oestreicher AB, 1997, PROG NEUROBIOL, V53, P627, DOI 10.1016/S0301-0082(97)00043-9; Oliet SHR, 1996, SCIENCE, V271, P1294, DOI 10.1126/science.271.5253.1294; Prichard L, 1999, J BIOL CHEM, V274, P7689, DOI 10.1074/jbc.274.12.7689; Ramakers GMJ, 1999, J NEUROCHEM, V73, P2175; RAMAKERS GMJ, 1995, J BIOL CHEM, V270, P13892, DOI 10.1074/jbc.270.23.13892; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; Reyes M, 1996, J NEUROSCI, V16, P5951; Roberson ED, 1996, LEARN MEMORY, V3, P1, DOI 10.1101/lm.3.1.1; SEKI K, 1995, ARCH BIOCHEM BIOPHYS, V316, P673, DOI 10.1006/abbi.1995.1090; Stanton PK, 1996, HIPPOCAMPUS, V6, P35, DOI 10.1002/(SICI)1098-1063(1996)6:1<35::AID-HIPO7>3.0.CO;2-6; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; Wu J, 1997, NEUROSCIENCE, V78, P393, DOI 10.1016/S0306-4522(97)84911-1; Yang SN, 1999, J NEUROPHYSIOL, V81, P781, DOI 10.1152/jn.1999.81.2.781; Zhuo M, 1999, P NATL ACAD SCI USA, V96, P4650, DOI 10.1073/pnas.96.8.4650	58	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28682	28687		10.1074/jbc.M003068200	http://dx.doi.org/10.1074/jbc.M003068200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10867003	hybrid			2022-12-27	WOS:000089330700047
J	Elberg, G; Gimble, JM; Tsai, SY				Elberg, G; Gimble, JM; Tsai, SY			Modulation of the murine peroxisome proliferator-activated receptor gamma 2 promoter activity by CCAAT/enhancer-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; NF-KAPPA-B; C/EBP-BETA; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; MESSENGER-RNA; ADIPOCYTE DIFFERENTIATION; P21(WAF1/CIP1) GENE; ECTOPIC EXPRESSION; DNA-BINDING	Peroxisome proliferator-activated receptor gamma (PPAR gamma) and CCAAT/enhancer-binding proteins (C/EBPs) are transcriptional regulators essential for adipocyte differentiation and function. Previous findings indicate that PPAR gamma 2 transcription is regulated by members of the C/EBP family. We demonstrate here that C/EBP alpha and C/EBP delta, but not C/EBP beta, induce the activity of the PPAR gamma 2 promoter in transiently transfected 3T3-L1 preadipocytes and bind to two juxtaposed low affinity C/EBP binding sites. Results obtained with chimeras containing interchanged C/EBP alpha-C/EBP beta N-terminal transactivation domain and C-terminal DNA binding dimerization domain indicate that the N-terminal part of C/EBP beta prevents it from binding to the PPAR gamma 2 promoter. Indeed, deletion mutants of C/EBP beta lacking the N-terminal part of the molecule are able to bind to the PPAR gamma 2 promoter. We further demonstrate that deletion of a region located between amino acids 184-212, upstream of the DNA binding domain, permits C/EBP beta binding to the PPAR gamma 2 promoter, implicating an inhibitory region in C/EBP beta for modulating DNA binding specificity to the PPAR gamma 2 promoter. In summary, this study indicates that C/EBP beta but not C/EBP alpha or C/EBP delta is unable to bind to C/EBP binding sites in the mouse PPAR gamma 2 promoter. The lack of binding is due to a region N-terminal of the C/EBP beta DNA binding domain. Our findings illustrate a mechanism by which C/EBP isoforms differentially modulate the transactivation of the PPAR gamma 2 promoter.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Surg, Oklahoma City, OK 73190 USA	Baylor College of Medicine; University of Oklahoma System; University of Oklahoma Health Sciences Center	Tsai, SY (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R29CA050898, R01CA050898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055636, R01DK044988] Funding Source: NIH RePORTER; NCI NIH HHS [CA50898] Funding Source: Medline; NIDDK NIH HHS [DK44988, DK55636] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Busch K, 1997, MOL ENDOCRINOL, V11, P379, DOI 10.1210/me.11.3.379; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Catron KM, 1998, CELL GROWTH DIFFER, V9, P949; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; Crosson SM, 2000, J BIOL CHEM, V275, P5804, DOI 10.1074/jbc.275.8.5804; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Gimble JM, 1998, BIOCHEM BIOPH RES CO, V253, P813, DOI 10.1006/bbrc.1998.9858; GRUNDY SM, 1990, DM-DIS MON, V36, P641; Hansen AJ, 1998, MOL PHARMACOL, V53, P1027; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Krishnan V, 1997, MOL ENDOCRINOL, V11, P1458, DOI 10.1210/me.11.10.1458; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lee SJ, 1998, J NEUROIMMUNOL, V92, P196, DOI 10.1016/S0165-5728(98)00209-4; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Lu M, 1997, J BIOL CHEM, V272, P28349, DOI 10.1074/jbc.272.45.28349; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; POLL V, 1990, CELL, V63, P643; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Saladin R, 1999, CELL GROWTH DIFFER, V10, P43; Shi XM, 2000, J CELL BIOCHEM, V76, P518, DOI 10.1002/(SICI)1097-4644(20000301)76:3<518::AID-JCB18>3.0.CO;2-M; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Trautwein C, 1996, J BIOL CHEM, V271, P22262, DOI 10.1074/jbc.271.36.22262; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128	43	91	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27815	27822						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862621				2022-12-27	WOS:000089197100041
J	Ghirlando, R; Trainor, CD				Ghirlando, R; Trainor, CD			GATA-1 bends DNA in a site-independent fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID TRANSCRIPTION FACTOR; BINDING DOMAIN; FINGER; PROMOTER; COMPLEX; ZINC; EXPRESSION; PROTEINS; CGATA-1; FAMILY	The DNA binding domain of GATA-1 consists of two adjacent homologous zinc fingers, of which only the C-terminal finger binds DNA independently. Solution structure studies have shown that the DNA is bent by about 15 degrees in the complex formed with the single C-terminal finger of GATA-1, The N-terminal finger stabilizes DNA binding at some sites. To determine whether it contributes to DNA bending, we have performed circular permutation DNA bending experiments with a variety of DNA-binding sites recognized by GATA-1, By using a series of full-length GATA-1, double zinc finger, and single C-terminal finger constructs, we show that GATA-1 bends DNA by about 24 degrees, irrespective of the DNA-binding site. We propose that the N- and C-terminal fingers of GATA-1 adopt different orientations when bound to different cognate DNA sites. Furthermore, we characterize circular permutation bending artifacts arising from the reduced gel mobility of the protein-DNA complexes.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Ghirlando, R (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.		Ghirlando, Rodolfo/A-8880-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036121] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; Hagerman PJ, 1996, P NATL ACAD SCI USA, V93, P9993, DOI 10.1073/pnas.93.19.9993; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Kowalski K, 1999, J BIOMOL NMR, V13, P249, DOI 10.1023/A:1008309602929; LEVENE SD, 1989, SCIENCE, V245, P396, DOI 10.1126/science.2756426; Mackay JP, 1998, J BIOL CHEM, V273, P30560, DOI 10.1074/jbc.273.46.30560; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; SCHWARTZBAUER G, 1992, NUCLEIC ACIDS RES, V20, P4429, DOI 10.1093/nar/20.17.4429; SHARROCKS AD, 1995, NUCLEIC ACIDS RES, V23, P2442, DOI 10.1093/nar/23.13.2442; SHULEMOVICH K, 1995, NUCLEIC ACIDS RES, V23, P811, DOI 10.1093/nar/23.5.811; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; Trainor CD, 2000, J BIOL CHEM, V275, P28157; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; ZWEIB C, 1994, METHOD MOL BIOL, V30, P281	26	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28152	28156						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862761				2022-12-27	WOS:000089197100082
J	Vacratsis, PO; Gallo, KA				Vacratsis, PO; Gallo, KA			Zipper-mediated oligomerization of the mixed lineage kinase SPRK/MLK-3 is not required for its activation by the GTPase cdc 42 but is necessary for its activation of the JNK Pathway - Monomeric SPRK L410P does not catalyze the activating phosphorylation of Thr(258) of murine mitogen-activated protein kinase kinase 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN4 LEUCINE-ZIPPER; COILED-COIL; MOLECULAR-CLONING; HUMAN BRAIN; MAP KINASE; C-JUN; DOMAIN; RESIDUES; BINDING; PROLINE	Src homology 3 domain-containing proline-rich kinase (SPRK)/mixed lineage kinase-3 is a serine/threonine kinase that has been identified as an upstream activator of the c-Jun NH2-terminal kinase (JNK) pathway. SPRK is capable of activating MKK4 by phosphorylation of serine and threonine residues, and mutant forms of MKK4 that lack the phosphorylation sites Ser(254) and Thr(258) block SPRK-induced JNK activation. A region of 63 amino acids following the kinase domain of SPRK is predicted to form a leucine zipper. The leucine zipper domain of SPRK has been shown to be necessary and sufficient for SPRK oligomerization, but its role in regulating activation of SPRK and downstream signaling remains unclear. In this study, we substituted a proposed stabilizing leucine residue in the zipper domain with a helix-disrupting proline to abrogate zipper-mediated SPRK oligomerization. We demonstrate that constitutively activated Cdc42 fully activates this monomeric SPRK mutant in terms of both autophosphorylation and histone phosphorylation activity and induces the same in vivo phosphorylation pattern as wild type SPRK. However, this catalytically active SPRK zipper mutant is unable to activate JNK. Our data show that the monomeric SPRK mutant fails to phosphorylate one of the two activating phosphorylation sites, Thr(258), of MKK4. These studies suggest that zipper-mediated SPRK oligomerization is not required for SPRK activation by Cdc42 but instead is critical for proper interaction and phosphorylation of a downstream target, MKK4.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Gallo, KA (corresponding author), Michigan State Univ, Dept Physiol, 108 Giltner Hall, E Lansing, MI 48824 USA.				NATIONAL CANCER INSTITUTE [R29CA076306] Funding Source: NIH RePORTER; NCI NIH HHS [CA76306] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLONDEL A, 1991, PROTEIN ENG, V4, P457, DOI 10.1093/protein/4.4.457; Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Butch ER, 1996, J BIOL CHEM, V271, P4230; Chakrabarti P, 1998, J MOL BIOL, V284, P867, DOI 10.1006/jmbi.1998.2199; Chang DK, 1999, J STRUCT BIOL, V128, P270, DOI 10.1006/jsbi.1999.4182; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; Hirai S, 1996, ONCOGENE, V12, P641; HODGES R S, 1990, Peptide Research, V3, P123; HODGES R S, 1988, Peptide Research, V1, P19; HODGES RS, 1981, J BIOL CHEM, V256, P1214; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; HU JC, 1993, PROTEIN SCI, V2, P1072, DOI 10.1002/pro.5560020701; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; KATOH M, 1995, ONCOGENE, V10, P1447; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; Nihalani D, 2000, J BIOL CHEM, V275, P7273, DOI 10.1074/jbc.275.10.7273; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; Roe JL, 1997, J BIOL CHEM, V272, P5838, DOI 10.1074/jbc.272.9.5838; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANKARARAMAKRISHNAN R, 1990, BIOPOLYMERS, V30, P287, DOI 10.1002/bip.360300307; SCOTT A, 1995, J BIOL CHEM, V270, P24540, DOI 10.1074/jbc.270.41.24540; Shugars DC, 1996, J VIROL, V70, P2982, DOI 10.1128/JVI.70.5.2982-2991.1996; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; YAN MH, 1994, NATURE, V372, P798; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	46	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27893	27900						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10862766				2022-12-27	WOS:000089197100051
J	Abu-Amer, Y; Erdmann, J; Alexopoulou, L; Kollias, G; Ross, FP; Teitelbaum, SL				Abu-Amer, Y; Erdmann, J; Alexopoulou, L; Kollias, G; Ross, FP; Teitelbaum, SL			Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; ESTROGEN DEFICIENCY; STROMAL CELLS; TNF RECEPTOR; MICE LACKING; BONE LOSS; ALPHA; MACROPHAGES; APOPTOSIS; PROTEIN	The potent osteoclastogenic agent, tumor necrosis factor-alpha (TNF), exerts its biological effects via two receptors, namely TNF receptors 1 (p55r) and 2 (p75r), each present on osteoclast precursors. Thus, we asked if p55r and p75r differentially impact the osteoclastogenic process. Marrow derived from mice expressing only p55r generates substantially more osteoclasts, in the basal state, than does wild type, while marrow expressing only p75r, produces substantially fewer. Reflecting its preferential activation of pb5r, exogenous TNF stimulates osteoclast formation by p55r(+/+)p75r(-/-), but not p65r(-/-)p76r(+/+), marrow. Consistent with the fact that NF-kappa B is essential for osteoclastogenesis, this transcription complex is activated, relative to wild type, in p55r(+/+)p75r(-/-) osteoclast precursors and suppressed in those expressing only p75r. Because p55r enhances, and p75r suppresses, osteoclastogenesis, we asked if their principal ligands, namely soluble and membrane-residing TNF, respectively, differrentially impact basal osteoclast recruitment. We find, in contrast to the significant level of osteoclast formation in wild type marrow, osteoclastogenesis by that derived from mice expressing membrane, but not soluble, TNF, is negligible. Thus, optimal therapeutic inhibition of bone resorption may entail selective TNF receptor modulation and/or arrested cleavage of membrane TNF to its soluble form.	Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Hellenic Pasteur Inst, Dept Mol Genet, Athens 11521, Greece	Washington University (WUSTL); Washington University (WUSTL)	Abu-Amer, Y (corresponding author), Washington Univ, Sch Med, Dept Orthoped Surg, 1 Barnes Jewish Hosp Plaza,11300 W Pavil,Campus B, St Louis, MO 63110 USA.	abuamery@msnotes.wustl.edu	Kollias, George/A-7079-2012; Alexopoulou, Lena/A-5041-2017	Kollias, George/0000-0003-1867-3150; Alexopoulou, Lena/0000-0003-4619-697X; Teitelbaum, Steven/0000-0002-4054-6679	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013754] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42404] Funding Source: Medline; NIDCR NIH HHS [DE05413, DE13754] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; ABUAMER Y, 1998, BONE, V23, pS190; Alexopoulou L, 1997, EUR J IMMUNOL, V27, P2588, DOI 10.1002/eji.1830271018; Ammann P, 1997, J CLIN INVEST, V99, P1699, DOI 10.1172/JCI119333; BJORNBERG F, 1994, LYMPHOKINE CYTOK RES, V13, P203; Deswal A, 1999, CIRCULATION, V99, P3224, DOI 10.1161/01.CIR.99.25.3224; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Douni E, 1996, J INFLAMM, V47, P27; DROUET C, 1991, J IMMUNOL, V147, P1694; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; Goeddel DV, 1999, CHEST, V116, p69S, DOI 10.1378/chest.116.suppl_1.69S; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Grell M, 1998, EUR J IMMUNOL, V28, P257, DOI 10.1002/(SICI)1521-4141(199801)28:01<257::AID-IMMU257>3.0.CO;2-G; Horie T, 1999, EXP HEMATOL, V27, P512, DOI 10.1016/S0301-472X(98)00058-7; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; Kassem Moustapha, 1996, P691; Kimble RB, 1996, J BIOL CHEM, V271, P28890, DOI 10.1074/jbc.271.46.28890; Kimble RB, 1997, J BONE MINER RES, V12, P935, DOI 10.1359/jbmr.1997.12.6.935; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002-9440(10)65266-2; Pacifici R, 1996, J BONE MINER RES, V11, P1043; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260	32	161	169	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27307	27310						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10874036				2022-12-27	WOS:000089144800085
J	Yan, SD; Zhu, YC; Stern, ED; Hwang, YYC; Hori, O; Ogawa, S; Frosch, MP; Connolly, ES; McTaggert, R; Pinsky, DJ; Clarke, S; Stern, DM; Ramasamy, R				Yan, SD; Zhu, YC; Stern, ED; Hwang, YYC; Hori, O; Ogawa, S; Frosch, MP; Connolly, ES; McTaggert, R; Pinsky, DJ; Clarke, S; Stern, DM; Ramasamy, R			Amyloid beta-peptide-binding alcohol dehydrogenase is a component of the cellular response to nutritional stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBRAL-ARTERY OCCLUSION; COENZYME-A DEHYDROGENASE; CULTURED RAT ASTROCYTES; C-13 NMR-SPECTROSCOPY; ALZHEIMERS-DISEASE; BOVINE LIVER; END-PRODUCTS; PROTEIN; HEART; BRAIN	Amyloid beta-peptide-binding alcohol dehydrogenase (ABAD) is a member of the family of short chain dehydrogenase/reductases whose distinctive properties include the capacity to bind amyloid beta-peptide and enzymatic activity toward a broad array of substrates including n-isopropanol and beta-estradiol, In view of the wide substrate specificity of ABAD and its high activity on L-beta-hydroxyacyl-CoA derivatives, we asked whether it might also catalyze the oxidation of the ketone body D-3-hydroxybutyrate. This was indeed the case, and oxidation proceeded with K-m of similar to 4.5 mM and V-max of similar to 4 nmol/min/mg protein. When placed in medium with D-beta-hydroxybutyrate as the principal energy substrate, COS cells stably transfected to overexpress wild-type ABAD (COS/wtABAD) better maintained 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide reduction, cellular energy charge, and morphologic phenotype compared with COS/vector cells. Using a severe model of metabolic perturbation, transgenic mice with targeted neuronal expression of ABAD subjected to transient middle cerebral artery occlusion showed strokes of smaller volume and lower neurologic deficit scores in parallel with increased brain ATP and decreased lactate, compared with nontransgenic controls. These data suggest that ABAD contributes to the protective response to metabolic stress, especially in the setting of ischemia.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg & Med, New York, NY 10032 USA; Kanazawa Med Univ, Dept Neuroanat, Kanazawa, Ishikawa, Japan; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	Columbia University; Columbia University; Columbia University; Columbia University; Kanazawa Medical University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; University of California System; University of California Los Angeles	Yan, SD (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, 630 W 168th St,P&S 17-401, New York, NY 10032 USA.	sdy1@columbia.edu	Frosch, Matthew P/ABD-7456-2021	Frosch, Matthew P/0000-0002-3940-9861; Ramasamy, Ravichandran/0000-0002-3666-3346	NATIONAL INSTITUTE ON AGING [R01AG016736, R01AG014103] Funding Source: NIH RePORTER; NIA NIH HHS [AG16736, AG14103, AG00690] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BADARGOFFER RS, 1990, BIOCHEM J, V266, P133, DOI 10.1042/bj2660133; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Berezovska O, 1999, MOL BRAIN RES, V69, P273, DOI 10.1016/S0169-328X(99)00119-9; BOCK HG, 1975, J BIOL CHEM, V250, P5774; CHATHAM JC, 1995, J BIOL CHEM, V270, P7999, DOI 10.1074/jbc.270.14.7999; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Connolly ES, 1996, NEUROSURGERY, V38, P523, DOI 10.1097/00006123-199603000-00021; Connolly ES, 1997, CIRC RES, V81, P304, DOI 10.1161/01.RES.81.3.304; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; Du YS, 1997, J NEUROCHEM, V69, P1382; Evertsen F, 1999, ACTA PHYSIOL SCAND, V167, P247; FITZPATRICK SM, 1990, J CEREBR BLOOD F MET, V10, P170, DOI 10.1038/jcbfm.1990.32; FREDERIKS WM, 1995, J PATHOL, V175, P339, DOI 10.1002/path.1711750312; Furuta S, 1997, BBA-GENE STRUCT EXPR, V1350, P317, DOI 10.1016/S0167-4781(96)00171-6; GOLDGABER D, 1993, ANN NY ACAD SCI, V695, P139, DOI 10.1111/j.1749-6632.1993.tb23042.x; HARDY J, 1997, TRENDS NEUROSCI, V296, P28570; He XY, 1999, J BIOL CHEM, V274, P15014, DOI 10.1074/jbc.274.21.15014; He XY, 1998, J BIOL CHEM, V273, P10741, DOI 10.1074/jbc.273.17.10741; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; Huang J, 1999, SCIENCE, V285, P595, DOI 10.1126/science.285.5427.595; Imuta N, 1998, J NEUROCHEM, V70, P550; JEFFREY FMH, 1995, BASIC RES CARDIOL, V90, P388, DOI 10.1007/BF00788500; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; Jones JG, 1997, ANAL BIOCHEM, V249, P201, DOI 10.1006/abio.1997.2172; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kang DE, 1999, J NEUROSCI, V19, P4229; King LM, 1998, MOL CELL BIOCHEM, V180, P3, DOI 10.1023/A:1006870419309; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; Kobayashi A, 1996, J BIOCHEM-TOKYO, V119, P775, DOI 10.1093/oxfordjournals.jbchem.a021307; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; LAMPRECHT W, 1995, METHOD ENZYMATIC ANA; LEHNINGER AL, 1960, J BIOL CHEM, V235, P2450; LEVITSKY LL, 1977, PEDIATR RES, V11, P298, DOI 10.1203/00006450-197704000-00008; Liao A, 1998, HUM MOL GENET, V7, P1953, DOI 10.1093/hmg/7.12.1953; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; LONDON RE, 1988, PROG NUCL MAG RES SP, V20, P337, DOI 10.1016/0079-6565(88)80010-4; MALLOY CR, 1987, FEBS LETT, V212, P58, DOI 10.1016/0014-5793(87)81556-9; MARK R, 1996, MOL NEUROBIOL, V12, P915; MATTSON MP, 1995, BRAIN RES, V676, P219, DOI 10.1016/0006-8993(95)00148-J; MATTSON MP, 1995, NEUROBIOL AGING, V16, P679, DOI 10.1016/0197-4580(95)00063-K; MCCANN WP, 1957, J BIOL CHEM, V226, P15; MCINTYRE JO, 1988, ARCH BIOCHEM BIOPHYS, V262, P85, DOI 10.1016/0003-9861(88)90171-3; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; OWEN OE, 1967, J CLIN INVEST, V46, P1589, DOI 10.1172/JCI105650; PETERSSON B, 1972, ACTA PAEDIATR SCAND, V61, P273; Roses AD, 1998, ANN NY ACAD SCI, V855, P738, DOI 10.1111/j.1749-6632.1998.tb10653.x; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Segel IH, 1975, ENZYME KINETICS BEHA; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SELLEVOLD OFM, 1986, J MOL CELL CARDIOL, V18, P517, DOI 10.1016/S0022-2828(86)80917-8; SONNEWALD U, 1993, DEV NEUROSCI-BASEL, V15, P351, DOI 10.1159/000111355; St George-Hyslop PH, 1998, NEUROBIOL AGING, V19, P133, DOI 10.1016/S0197-4580(98)00020-7; Torroja L, 1998, J CELL BIOL, V141, P1009, DOI 10.1083/jcb.141.4.1009; Trueblood N, 1998, AM J PHYSIOL-HEART C, V275, pH75, DOI 10.1152/ajpheart.1998.275.1.H75; UEDA H, 1988, J BIOCHEM, V104, P81, DOI 10.1093/oxfordjournals.jbchem.a122427; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; Yan SD, 1997, NATURE, V389, P689; YAN SD, 1998, J BIOL CHEM, V274, P2145	61	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27100	27109						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10869339				2022-12-27	WOS:000089144800059
J	Adamkewicz, JI; Mueller, CGF; Hansen, KE; Prud'homme, WA; Thorner, J				Adamkewicz, JI; Mueller, CGF; Hansen, KE; Prud'homme, WA; Thorner, J			Purification and enzymic properties of Mot1 ATPase, a regulator of basal transcription in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; RNA-POLYMERASE-II; CROSS-LINKED DNA; GENE-TRANSCRIPTION; CRYSTAL-STRUCTURE; TBP-BINDING; GLOBAL REPRESSOR; FAMILY MEMBER; IN-VIVO; HELICASE	The 1867-residue Mot1 protein is a member of a superfamily of ATPases, some of which are helicases, that interact with protein-nucleic acid assemblies. Mot1 is an essential regulator of RNA polymerase II-dependent transcription in vivo and dissociates TATA box-binding protein (TBP)-DNA complexes in vitro. Mot1-(His)(6) was purified to apparent homogeneity from yeast extracts. The preparation efficiently dissociated TBP TATA complexes, suggesting that no other protein or cofactor is required. Mot1 behaved as a non-globular monomer in hydrodynamic studies, and no association was detected between differentially tagged co-expressed Mot1 constructs. ATPase activity was stimulated about 10-fold by high ionic strength or alkaline pH, or by deletion of the N-terminal TBP-binding segment, suggesting that the N-terminal domain negatively regulates the C-terminal ATPase domain (Mot1C). Correspondingly, at moderate salt concentration, Mot1 ATPase (but not Mot1C) was stimulated greater than or equal to 10-fold by yeast TBP, suggesting that interaction with TBP relieves a conformational constraint in Mot1. Double- or single-stranded TATA-containing DNA did not affect ATPase activity of Mot1 or Mot1C, with or without TBP. Mot1 did not exhibit detectable helicase activity in strand displacement assays using substrates with flush ends or 5'- or 3'-overhangs. Mot1-catalyzed dissociation of TBP from DNA was not prevented by a psoralen cross-link positioned immediately preceding the TATA sequence. Thus, Mot1 most likely promotes release of TBP from TATA-containing DNA by causing a structural change in TBP itself, rather than by strand unwinding.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Thorner, J (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Rm 401,Barker Hall, Berkeley, CA 94720 USA.	jeremy@socrates.berkeley.edu	THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X; Mueller, Christopher/0000-0002-4119-2729	NIGMS NIH HHS [GM21841] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021841, R37GM021841] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMKEWICZ JI, 1999, THESIS U CALIFORNIA; Ashraf SI, 1998, CURR BIOL, V8, pR683, DOI 10.1016/S0960-9822(98)70435-X; Auble DT, 1999, MOL CELL BIOL, V19, P412; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Auble DT, 1997, MOL CELL BIOL, V17, P4842, DOI 10.1128/MCB.17.8.4842; BENTON BM, 1994, J CELL BIOL, V127, P623, DOI 10.1083/jcb.127.3.623; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Chang MP, 1997, NUCLEIC ACIDS RES, V25, P4861, DOI 10.1093/nar/25.24.4861; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHENG S, 1988, J BIOL CHEM, V263, P15110; CHENG S, 1990, THESIS U CALIFORNIA; Chicca JJ, 1998, MOL CELL BIOL, V18, P1701, DOI 10.1128/MCB.18.3.1701; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; Citterio E, 1998, J BIOL CHEM, V273, P11844, DOI 10.1074/jbc.273.19.11844; CLELAND WW, 1967, ANNU REV BIOCHEM, V36, P77, DOI 10.1146/annurev.bi.36.070167.000453; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cross RA, 2000, CURR BIOL, V10, pR124, DOI 10.1016/S0960-9822(00)00309-2; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; Goppelt A, 1996, NUCLEIC ACIDS RES, V24, P4450, DOI 10.1093/nar/24.22.4450; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Guzder SN, 1996, J BIOL CHEM, V271, P18314, DOI 10.1074/jbc.271.31.18314; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; HANSEN K, 1996, THESIS U CALIFORNIA; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; INOSTROZA JA, 1992, CELL, V70, P477; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JONES EW, 1991, METHOD ENZYMOL, V194, P428; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; Kim J, 1996, J BIOL CHEM, V271, P18405, DOI 10.1074/jbc.271.31.18405; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Kim S, 1997, P NATL ACAD SCI USA, V94, P820, DOI 10.1073/pnas.94.3.820; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; Li C, 1998, MOL CELL BIOL, V18, P3771, DOI 10.1128/MCB.18.7.3771; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Marians KJ, 1997, STRUCTURE, V5, P1129, DOI 10.1016/S0969-2126(97)00263-3; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; McKay LM, 1999, NUCLEIC ACIDS RES, V27, P3064, DOI 10.1093/nar/27.15.3064; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; MOORE D, 1999, CURRENT PROTOCOLS MO, V1; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; NAEGELI H, 1992, J BIOL CHEM, V267, P7839; PARVIN JD, 1995, NATURE, V373, P724, DOI 10.1038/373724a0; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Peterson CL, 1998, COLD SPRING HARB SYM, V63, P545, DOI 10.1101/sqb.1998.63.545; PIATTI S, 1992, CHROMOSOMA, V102, pS107, DOI 10.1007/BF02451793; POON D, 1993, J BIOL CHEM, V268, P15325; POON D, 1994, J BIOL CHEM, V269, P23135; Reece RJ, 1997, BIOESSAYS, V19, P1001, DOI 10.1002/bies.950191110; Reinberg D, 1998, COLD SPRING HARB SYM, V63, P83, DOI 10.1101/sqb.1998.63.83; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sauer F, 1997, CURR OPIN GENET DEV, V7, P176, DOI 10.1016/S0959-437X(97)80126-8; Sherman F., 1986, METHODS YEAST GENETI; SPIELMANN HP, 1995, BIOCHEMISTRY-US, V34, P12937, DOI 10.1021/bi00040a004; STARR DB, 1995, J MOL BIOL, V250, P434; TOMIC MT, 1987, SCIENCE, V238, P1722, DOI 10.1126/science.3686011; Travers A, 1996, CURR BIOL, V6, P401, DOI 10.1016/S0960-9822(02)00507-9; Wade PA, 1996, MOL CELL BIOL, V16, P1641; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; YANCEYWRONA JE, 1992, NUCLEIC ACIDS RES, V20, P6713, DOI 10.1093/nar/20.24.6713; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	81	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21158	21168		10.1074/jbc.M002639200	http://dx.doi.org/10.1074/jbc.M002639200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10887203	hybrid			2022-12-27	WOS:000088230600028
J	Tamir, Y; Bengal, E				Tamir, Y; Bengal, E			Phosphoinositide 3-kinase induces the transcriptional activity of MEF2 proteins during muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; CELL-CYCLE WITHDRAWAL; SKELETAL-MUSCLE; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; MYOGENIC DIFFERENTIATION; IGF-I; RETINOBLASTOMA PROTEIN; KINASE PATHWAY; ENHANCER	The activity of phosphoinositide 3-kinase (PI3-K) is essential for the differentiation of skeletal muscle cells by largely unknown mechanisms. Here we show that inhibition of PIS-K activity by the pharmacological agent LY294002 affects early processes of myoblast differentiation including the transcriptional activation of myogenin, Previous studies indicated that transcription of myogenin was dependent on MyoD and MEF2 proteins. We find that expression of a dominant negative form of PI3-K or growth in the presence of LY294002 inhibits cellular activity of MEF2 but not of MyoD. Evidence reveals that whereas MEF2 transcriptional activity is inhibited, its DNA binding activity remains unaffected. Recent studies demonstrated that phosphorylation by p38 mitogen-activated protein kinase (MAPK) induced transcriptional activity of MEFS proteins. We show that the phosphorylation of MEF2 occurring during muscle differentiation is prevented if the activity of PI3-K is inhibited. However, our results also indicate that p38 MAPK is not affected by PIS-K in muscle cells. Nevertheless, p38 MAPK. can substitute for PIS-K in the induction of MEF2 and muscle transcription. Together, these findings indicate that PI3-K affects skeletal muscle differentiation by inducing phosphorylation and transcriptional activity of MEF2 proteins in a parallel but distinct route from p38 MAPK.	Technion Israel Inst Technol, Fac Med, Rappaport Inst Res Med Sci, Dept Biochem, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Bengal, E (corresponding author), Technion Israel Inst Technol, Fac Med, Rappaport Inst Res Med Sci, Dept Biochem, POB 9649, IL-31096 Haifa, Israel.							Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Blaeser F, 2000, J BIOL CHEM, V275, P197, DOI 10.1074/jbc.275.1.197; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Engert JC, 1996, J CELL BIOL, V135, P431, DOI 10.1083/jcb.135.2.431; FLORINI JR, 1990, J BIOL CHEM, V265, P13435; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1987, MUSCLE NERVE, V10, P577, DOI 10.1002/mus.880100702; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; FLORINI JR, 1989, AM J PHYSIOL, V256, P701; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Musaro A, 1999, MOL CELL BIOL, V19, P3115; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Ornatsky OI, 1999, NUCLEIC ACIDS RES, V27, P2646, DOI 10.1093/nar/27.13.2646; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; QUINN LS, 1994, J CELL PHYSIOL, V159, P387, DOI 10.1002/jcp.1041590302; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; ROSENTHAL SM, 1995, P NATL ACAD SCI USA, V92, P10307, DOI 10.1073/pnas.92.22.10307; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; Yang CC, 1998, NUCLEIC ACIDS RES, V26, P4771, DOI 10.1093/nar/26.20.4771; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhao M, 1999, MOL CELL BIOL, V19, P21	56	84	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34424	34432		10.1074/jbc.M005815200	http://dx.doi.org/10.1074/jbc.M005815200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10896679	hybrid			2022-12-27	WOS:000165095300058
J	Hayne, C; Tzivion, G; Luo, ZJ				Hayne, C; Tzivion, G; Luo, ZJ			Raf-1/MEK/MAPK pathway is necessary for the G(2)/M transition induced by nocodazole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SPINDLE ASSEMBLY CHECKPOINT; XENOPUS EGG EXTRACTS; CELL-CYCLE; MAP KINASE; M-PHASE; RAF-1 ACTIVATION; 3T3 CELLS; RAS; PHOSPHORYLATION	The dynamic balance between polymerization and depolymerization of microtubules is critical for cells to enter and exit mitosis, and drugs that disrupt this balance, such as taxol, colchicine, and nocodazole, arrest the cell cycle in mitosis. Although the Raf/MEK/MAPK pathway can be activated by these drugs, its role in mitosis has not been addressed. Here, we characterize activation of Raf/MEK/MAPK by nocodazole when mitosis is induced. We find that at early time points (up to 3 h) in nocodazole induction, Raf/MEK/MAPK is activated, and inhibition of MAPK activation by a MEK inhibitor, PD98059 or U0126, reduces the number of cells entering mitosis by creating a block at G(2). At later time points and in mitosis, activation of MEK/MAPK is severely inhibited, even though Raf-l activity remains high and can be further increased by growth factor. This inhibition is reversed when cells are released from metaphase and enter G(0)/G(1) phase. In addition, we find that binding of Raf-1 to 14-3-3 is progressively induced by nocodazole, reaching a maximum in mitosis, and that this binding is necessary to maintain mitotic Raf-l activity. Our present study indicates that activation of the Raf/MEK/MAPK pathway is necessary for the G(2)/M progression.	Boston Univ, Sch Med, Evans Dept Med, Endocrinol Sect,Diabet & Metab Res Unit, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Med Serv, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol, Boston, MA 02114 USA	Boston University; Boston University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Luo, ZJ (corresponding author), Boston Univ, Sch Med, Evans Dept Med, Endocrinol Sect,Diabet & Metab Res Unit, 650 Albany St,Rm 820, Boston, MA 02118 USA.		Luo, Zhijun/AAE-9302-2019; Tzivion, Guri/D-8954-2011	Luo, Zhijun/0000-0001-8105-5289; 	NIGMS NIH HHS [GM 57959] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057959] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; Andersen SSL, 1999, BIOESSAYS, V21, P53, DOI 10.1002/(SICI)1521-1878(199901)21:1<53::AID-BIES7>3.0.CO;2-L; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bhatt RR, 1999, SCIENCE, V286, P1362, DOI 10.1126/science.286.5443.1362; Bitangcol JC, 1998, MOL BIOL CELL, V9, P451, DOI 10.1091/mbc.9.2.451; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Chau ASS, 1999, J BIOL CHEM, V274, P32085, DOI 10.1074/jbc.274.45.32085; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; Gross SD, 1999, SCIENCE, V286, P1365, DOI 10.1126/science.286.5443.1365; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; Laird AD, 1999, J BIOL CHEM, V274, P4430, DOI 10.1074/jbc.274.7.4430; Laird AD, 1997, CELL SIGNAL, V9, P249, DOI 10.1016/S0898-6568(96)00176-3; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lovric J, 1996, ONCOGENE, V12, P1109; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; MACNICOL AM, 1995, MOL CELL BIOL, V15, P6686; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MORISHITA T, 1995, SCIENCE, V270, P1213, DOI 10.1126/science.270.5239.1213; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Murakami MS, 1998, DEVELOPMENT, V125, P237; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Rommel C, 1996, ONCOGENE, V12, P609; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Schmid-Alliana A, 1998, J BIOL CHEM, V273, P3394, DOI 10.1074/jbc.273.6.3394; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; Torres K, 1998, CANCER RES, V58, P3620; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Van der Hoeven PCJ, 2000, BIOCHEM J, V345, P297, DOI 10.1042/0264-6021:3450297; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; Winston JT, 1996, ONCOGENE, V12, P127; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Ziogas A, 1998, J BIOL CHEM, V273, P24108, DOI 10.1074/jbc.273.37.24108	50	93	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31876	31882		10.1074/jbc.M002766200	http://dx.doi.org/10.1074/jbc.M002766200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10884385	hybrid			2022-12-27	WOS:000089858900047
J	Coulson, EJ; Reid, K; Baca, M; Shipham, KA; Hulett, SM; Kilpatrick, TJ; Bartlett, PF				Coulson, EJ; Reid, K; Baca, M; Shipham, KA; Hulett, SM; Kilpatrick, TJ; Bartlett, PF			Chopper, a new death domain of the p75 neurotrophin receptor that mediates rapid neuronal cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NF-KAPPA-B; AMYLOID PRECURSOR PROTEIN; ZINC-FINGER PROTEIN; FACTOR-ALPHA; CASPASE ACTIVATION; SENSORY NEURONS; TRUNCATED FORM; SCHWANN-CELLS; NGF RECEPTOR	The cytoplasmic juxtamembrane region of the p75 neurotrophin receptor (p75(NTR)) has been found to be necessary and sufficient to initiate neural cell death. The region was named "Chopper" to distinguish it from CD95-like death domains. A 29-amino acid peptide corresponding to the Chopper region induced caspase- and calpain-mediated death in a variety of neural and nonneural cell types and was not inhibited by signaling through Trk (unlike killing by full-length p75(NTR)). Chopper triggered cell death only when bound to the plasma membrane by a lipid anchor, whereas non-anchored Chopper acted in a dominant-negative manner, blocking p75(NTR)-mediated death both in vitro and in vivo. Removal of the ectodomain of p75(NTR) increased the potency of Chopper activity, suggesting that it regulates the association of Chopper with downstream signaling proteins.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute	Coulson, EJ (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.		Coulson, Elizabeth J./C-8766-2009; Bartlett, Perry/F-3813-2012	Coulson, Elizabeth J./0000-0003-3783-6197; Kilpatrick, Trevor/0000-0003-3999-085X				Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; BARKER PA, 1991, J BIOL CHEM, V266, P19113; BARKER PA, 1994, J BIOL CHEM, V269, P30645; Barrett GL, 1996, J NEUROSCI RES, V45, P117, DOI 10.1002/(SICI)1097-4547(19960715)45:2<117::AID-JNR4>3.0.CO;2-D; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; Brann AB, 1999, J NEUROSCI, V19, P8199; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.0.CO;2-K; Cheema SS, 1996, J NEUROSCI RES, V46, P239, DOI 10.1002/(SICI)1097-4547(19961015)46:2<239::AID-JNR12>3.0.CO;2-Y; CHEVAILLIER P, 1993, INT J BIOCHEM, V25, P479, DOI 10.1016/0020-711X(93)90653-V; Chittka A, 1999, P NATL ACAD SCI USA, V96, P10705, DOI 10.1073/pnas.96.19.10705; Coulson EJ, 1999, MOL NEUROBIOL, V20, P29, DOI 10.1007/BF02741363; Coulson EJ, 1999, J BIOL CHEM, V274, P16387, DOI 10.1074/jbc.274.23.16387; Davey F, 1998, CURR BIOL, V8, P915, DOI 10.1016/S0960-9822(07)00371-5; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DISTEFANO PS, 1991, ANN NEUROL, V29, P13, DOI 10.1002/ana.410290105; DISTEFANO PS, 1993, J NEUROSCI, V13, P2405, DOI 10.1523/JNEUROSCI.13-06-02405.1993; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Ferri CC, 1998, J NEUROBIOL, V34, P1; Frade JM, 1998, NEURON, V20, P35, DOI 10.1016/S0896-6273(00)80432-8; Frade JM, 1997, DEVELOPMENT, V124, P3313; Frade JM, 1996, NATURE, V383, P166; Gu CH, 1999, J NEUROSCI, V19, P3043; Hamanoue M, 1999, MOL CELL NEUROSCI, V14, P28, DOI 10.1006/mcne.1999.0770; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; Hileman MR, 1997, FEBS LETT, V415, P145, DOI 10.1016/S0014-5793(97)01113-7; Hooper NM, 1998, CURR BIOL, V8, pR114, DOI 10.1016/S0960-9822(98)70984-4; Huang C, 1999, J BIOL CHEM, V274, P36707, DOI 10.1074/jbc.274.51.36707; Jiang H, 1999, J BIOL CHEM, V274, P26209, DOI 10.1074/jbc.274.37.26209; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Kong H, 1999, CELL DEATH DIFFER, V6, P1133, DOI 10.1038/sj.cdd.4400587; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; Ladiwala U, 1998, J NEUROSCI, V18, P1297; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; LINDNER MD, 1993, ARCH NEUROL-CHICAGO, V50, P1054, DOI 10.1001/archneur.1993.00540100049013; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Majdan M, 1997, J NEUROSCI, V17, P6988; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; MONUKI ES, 1993, P NATL ACAD SCI USA, V90, P9978, DOI 10.1073/pnas.90.21.9978; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Niv H, 1999, J BIOL CHEM, V274, P1606, DOI 10.1074/jbc.274.3.1606; PAPINI E, 1993, J BIOL CHEM, V268, P1567; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Ramarao MK, 1998, P NATL ACAD SCI USA, V95, P4007, DOI 10.1073/pnas.95.7.4007; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Soilu-Hanninen M, 1999, J NEUROSCI, V19, P4828; Spencer DM, 1996, CURR BIOL, V6, P839, DOI 10.1016/S0960-9822(02)00607-3; Syroid DE, 2000, J NEUROSCI, V20, P5741, DOI 10.1523/JNEUROSCI.20-15-05741.2000; Tang P, 1996, BIOCHEMISTRY-US, V35, P8226, DOI 10.1021/bi952183l; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VONBARTHELD CS, 1994, NEURON, V12, P639, DOI 10.1016/0896-6273(94)90219-4; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Yoon SO, 1998, J NEUROSCI, V18, P3273; Zaheer A, 1995, NEUROCHEM RES, V20, P1457, DOI 10.1007/BF00970594; ZUPAN AA, 1989, J BIOL CHEM, V264, P11714	80	92	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30537	30545		10.1074/jbc.M005214200	http://dx.doi.org/10.1074/jbc.M005214200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10882742	hybrid			2022-12-27	WOS:000089577900085
J	Hayakawa, A; Kitamura, N				Hayakawa, A; Kitamura, N			Early endosomal localization of hrs requires a sequence within the proline- and glutamine-rich region but not the FYVE finger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN; BINDING; GROWTH; DOMAIN; MOTIF; EEA1; ACTIVATION; VACUOLAR; HOMOLOG	Hrs is an early endosomal protein that is tyrosine-phosphorylated in cells stimulated with growth factors. Hrs is thought to play a regulatory role in endocytosis of growth factor-receptor complexes through early endosomes. Early endosomal localization of Hrs seems to be essential for Hrs to exert its function in the endocytosis. Hrs has a FYVE finger domain that binds specifically to phosphatidylinositol 3-phosphate in vitro, The FYVE finger is a likely domain that mediates membrane association of endosomal proteins. In this study, we examined whether the FYVE finger participates in early endosomal targeting of Hrs. Hrs with a zinc binding-defective FYVE finger was still localized to early endosomes. In addition, the N-terminal FYVE finger-containing fragment of Hrs showed a cytosolic distribution in mammalian cells. These results indicate that the FYVE finger is not required for the localization of Hrs to early endosomes, Furthermore, by analyzing a series of deletion mutants of Hrs, we identified a sequence of about 100 amino acids within the C-terminal proline- and glutamine-rich region as a domain essential for the targeting of Hrs to early endosomes.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Kitamura, N (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Dept Life Sci, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.							Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; Lohi O, 1998, FEBS LETT, V440, P255, DOI 10.1016/S0014-5793(98)01401-X; Lohi O, 1998, J BIOL CHEM, V273, P21408, DOI 10.1074/jbc.273.33.21408; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Peterson MR, 1999, CURR BIOL, V9, P159, DOI 10.1016/S0960-9822(99)80071-2; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; Takata H, 2000, GENES CELLS, V5, P57, DOI 10.1046/j.1365-2443.2000.00303.x; Tall GG, 1999, MOL BIOL CELL, V10, P1873, DOI 10.1091/mbc.10.6.1873; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Webb GC, 1997, MOL BIOL CELL, V8, P871, DOI 10.1091/mbc.8.5.871; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525	27	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29636	29642		10.1074/jbc.M002696200	http://dx.doi.org/10.1074/jbc.M002696200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10889197	hybrid			2022-12-27	WOS:000089439800062
J	Keller, G; Gross, C; Kelleher, M; Winge, DR				Keller, G; Gross, C; Kelleher, M; Winge, DR			Functional independence of the two cysteine-rich activation domains in the yeast Mac1 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER TRANSPORT PROTEIN; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; GENE; EXPRESSION; IDENTIFICATION; REPRESSION; OXIDASE; CTR1P	Mac1 is a transcriptional activator whose activity is inhibited by copper ions. Mutagenesis studies were carried out to map residues important in the copper inhibition of Mac1 activity. Seven new missense mutations were identified that resulted in copper-independent Mac1 transcriptional activation. All seven mutations were clustered in one of two C-terminal cysteine-rich motifs, designated the C1 motif. All but one of the constitutive Mac1 mutations occurred in one of the conserved six residues in the (CXC)-C-264(X)(4)CXC(X)(2)C(X)(2)H-279 C1 motif. The lone exception was a L260S substitution. Two additional MAC1 mutations exhibiting constitutive activity were in-frame deletions encompassing portions C1, Engineered mutations in the second cysteine-rich motif did not yield a constitutively active Mac1. These results are consistent with the C1 motif being the copper-regulatory switch. Both cysteine-rich motifs exhibited transactivation activity, although the C1 activator was weak relative to the C2 activator. Limited copper metalloregulation of Mac1 was observed with only the C1 activator fused to the N-terminal DNA binding domain. Thus, the two Cys-rich motifs appear to function independently. The C1 motif appears to be a functional copper-regulatory domain.	Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Winge, Dennis/G-3611-2010		NATIONAL CANCER INSTITUTE [P30CA042014, R01CA061286] Funding Source: NIH RePORTER; NCI NIH HHS [5P30-CA 42014, CA 61286] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai C, 1997, METHOD ENZYMOL, V283, P141; BAKERBRACHMANN C, 1998, YEAST, V14, P115; Borghouts C, 1998, MOL GEN GENET, V260, P492, DOI 10.1007/s004380050922; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1998, J PEDIAT, V12, P24; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Jensen LT, 1998, J BIOL CHEM, V273, P23805, DOI 10.1074/jbc.273.37.23805; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; MARTINS L, 1997, J BIOL CHEM, V273, P23716; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Serpe M, 1999, J BIOL CHEM, V274, P29211, DOI 10.1074/jbc.274.41.29211; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Wang D, 1997, J BIOL CHEM, V272, P19383, DOI 10.1074/jbc.272.31.19383; Winge DR, 1998, CURR OPIN CHEM BIOL, V2, P216, DOI 10.1016/S1367-5931(98)80063-X; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; Zhu ZW, 1998, J BIOL CHEM, V273, P1277, DOI 10.1074/jbc.273.3.1277	29	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29193	29199		10.1074/jbc.M001552200	http://dx.doi.org/10.1074/jbc.M001552200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10887177	hybrid			2022-12-27	WOS:000089439800004
J	Nagai, T; Kawabata, S				Nagai, T; Kawabata, S			A link between blood coagulation and prophenol oxidase activation in arthropod host defense	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE ZYMOGEN; HORSESHOE-CRAB; CDNA CLONING; PROCLOTTING ENZYME; GROWTH-FACTOR; INSECT; HEMOCYANIN; PROTEINS; TYROSINASE; HEMOLYMPH	Phenol oxidase, a copper-containing enzyme, is widely distributed not only in animals but also in plants and fungi, which is responsible for initiating the biosynthesis of melanin. Activation of prophenol oxidase in arthropods is important in host defense. However, the prophenol oxidase-activating system remains poorly understood at the molecular level. Here we show that the coagulation cascade of the horseshoe crab Tachypleus tridentatus is linked to prophenol oxidase activation, with the oxygen carrier hemocyanin functioning as a substitute for prophenol oxidase. Tachypleus clotting enzyme functionally transforms hemocyanin to phenol oxidase, and the conversion reaches a plateau at 1:1 stoichiometry without proteolytic cleavage. The active site-masked clotting enzyme also has the same effect, suggesting that complex formation of the clotting enzyme with hemocyanin is critical for the conversion. The two systems of blood coagulation and prophenol oxidase activation may have evolved from a common ancestral protease cascade.	Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Kawabata, S (corresponding author), Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan.	skawascb@mbox.nc.kyushu-u.ac.jp						Ashida M., 1990, P239; ASPAN A, 1995, P NATL ACAD SCI USA, V92, P939, DOI 10.1073/pnas.92.4.939; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bergner A, 1996, EMBO J, V15, P6789, DOI 10.1002/j.1460-2075.1996.tb01070.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burmester T, 1996, J MOL EVOL, V42, P713, DOI 10.1007/BF02338804; Decker H, 1998, J BIOL CHEM, V273, P25889, DOI 10.1074/jbc.273.40.25889; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hyuk T, 1997, MOL CELLS, V7, P90; Iwanaga S, 1998, J BIOCHEM, V123, P1; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; LINZEN B, 1985, SCIENCE, V229, P519, DOI 10.1126/science.4023698; MUTA T, 1991, J BIOL CHEM, V266, P6554; MUTA T, 1993, J BIOL CHEM, V268, P21384; MUTA T, 1990, J BIOL CHEM, V265, P22426; Nellaiappan K, 1996, COMP BIOCHEM PHYS B, V113, P163, DOI 10.1016/0305-0491(95)02047-0; PYE AE, 1974, NATURE, V251, P610, DOI 10.1038/251610a0; RZEPECKI LM, 1989, ANAL BIOCHEM, V179, P375, DOI 10.1016/0003-2697(89)90148-6; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; SEKI N, 1994, J BIOL CHEM, V269, P1370; SMITH CL, 1994, NATURE, V368, P548, DOI 10.1038/368548a0; SMITH CL, 1992, PROTEIN SCI, V1, P1225, DOI 10.1002/pro.5560010915; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; TAKAGI T, 1980, J BIOCHEM, V87, P1785, DOI 10.1093/oxfordjournals.jbchem.a132923; Terwilliger NB, 1999, AM ZOOL, V39, P589; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; WINDER AJ, 1991, EUR J BIOCHEM, V198, P317, DOI 10.1111/j.1432-1033.1991.tb16018.x; Zlateva T, 1996, FEBS LETT, V384, P251, DOI 10.1016/0014-5793(96)00326-2	31	134	151	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29264	29267		10.1074/jbc.M002556200	http://dx.doi.org/10.1074/jbc.M002556200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10880508	hybrid			2022-12-27	WOS:000089439800013
J	Furdui, C; Ragsdale, SW				Furdui, C; Ragsdale, SW			The role of pyruvate ferredoxin oxidoreductase in pyruvate synthesis during autotrophic growth by the Wood-Ljungdahl pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHANOSARCINA-BARKERI FUSARO; CATALYTIC ELECTRON-TRANSPORT; IRON-SULFUR PROTEIN; CLOSTRIDIUM-THERMOACETICUM; PYROCOCCUS-FURIOSUS; SUCCINATE-DEHYDROGENASE; CARBON-MONOXIDE; PURIFICATION; ENZYME; VOLTAMMETRY	Pyruvate:ferredoxin oxidoreductase (PFOR) catalyzes the oxidative decarboxylation of pyruvate to acetyl-CoA and CO2. The catalytic proficiency of this enzyme for the reverse reaction, pyruvate synthase, is poorly understood. Conversion of acetyl-CoA to pyruvate links the Wood-Ljungdahl pathway of autotrophic CO2 fixation to the reductive tricarboxylic acid cycle, which in these autotrophic anaerobes is the stage for biosynthesis of all cellular macromolecules. The results described here demonstrate that the Clostridium thermoaceticum PFOR is a highly efficient pyruvate synthase. The Michaelis-Menten parameters for pyruvate synthesis by PFOR are: V-max = 1.6 unit/mg (k(cat) = 3.2 s(-1)), K-m(Acetyl-CoA) = 9 mu M, and K-m(CO2) = 2 mM. The intracellular concentrations of acetyl-CoA, CoASH, and pyruvate have been measured. The predicted rate of pyruvate synthesis at physiological concentrations of substrates clearly is sufficient to support the role of PFOR as a pyruvate synthase in vivo. Measurements of its k(cat)/K-m values demonstrate that ferredoxin is a highly efficient electron carrier in both the oxidative and reductive reactions. On the other hand, rubredoxin is a poor substitute in the oxidative direction and is inept in donating electrons for pyruvate synthesis.	Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Ragsdale, SW (corresponding author), Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA.			Furdui, Cristina M./0000-0003-3771-7999	NIGMS NIH HHS [GM-39451] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039451, R01GM039451] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MWW, 1996, ADV PROTEIN CHEM, V48, P101; BAHL H, 1983, THESIS U GOETTINGEN; BLAMEY JM, 1993, BIOCHIM BIOPHYS ACTA, V1161, P19, DOI 10.1016/0167-4838(93)90190-3; Bock AK, 1996, EUR J BIOCHEM, V237, P35, DOI 10.1111/j.1432-1033.1996.0035n.x; BOCK AK, 1995, J BACTERIOL, V177, P2002, DOI 10.1128/jb.177.8.2002-2007.1995; Bock AK, 1997, FEBS LETT, V414, P209, DOI 10.1016/S0014-5793(97)00998-8; Butt JN, 1997, EUR J BIOCHEM, V245, P116, DOI 10.1111/j.1432-1033.1997.00116.x; CHEN JS, 1979, ANAL BIOCHEM, V93, P216, DOI 10.1016/S0003-2697(79)80140-2; DANIEL SL, 1990, J BACTERIOL, V172, P4464, DOI 10.1128/jb.172.8.4464-4471.1990; ELLIOTT JI, 1982, J BACTERIOL, V151, P328, DOI 10.1128/JB.151.1.328-333.1982; ELLIOTT JI, 1978, ARCH BIOCHEM BIOPHYS, V190, P351, DOI 10.1016/0003-9861(78)90285-0; FUCHS G, 1986, FEMS MICROBIOL LETT, V39, P181, DOI 10.1111/j.1574-6968.1986.tb01859.x; Gomes CM, 1997, J BIOL CHEM, V272, P22502, DOI 10.1074/jbc.272.36.22502; GRUPE H, 1991, THESIS U GOETTINGEN; HIRSCH CA, 1963, J BIOL CHEM, V238, P3770; Hirst J, 1996, J AM CHEM SOC, V118, P5031, DOI 10.1021/ja9534361; Hirst J, 1997, J AM CHEM SOC, V119, P7434, DOI 10.1021/ja9631413; HRDY I, 1995, J MOL EVOL, V41, P388, DOI 10.1007/BF01215186; Jenney FE, 1999, SCIENCE, V286, P306, DOI 10.1126/science.286.5438.306; Kletzin A, 1996, J BACTERIOL, V178, P248, DOI 10.1128/jb.178.1.248-257.1996; LAPADO J, 1990, P NATL ACAD SCI USA, V87, P5598; LeJohn H B, 1975, Methods Enzymol, V41, P293; LINDAHL PA, 1990, J BIOL CHEM, V265, P3873; Maklashina E, 1998, J BACTERIOL, V180, P5989, DOI 10.1128/JB.180.22.5989-5996.1998; Menon AL, 1998, BIOCHEMISTRY-US, V37, P12838, DOI 10.1021/bi980979p; Menon S, 1997, BIOCHEMISTRY-US, V36, P8484, DOI 10.1021/bi970403k; Menon S, 1996, BIOCHEMISTRY-US, V35, P12119, DOI 10.1021/bi961014d; NEUER G, 1982, BIOCHIM BIOPHYS ACTA, V716, P358, DOI 10.1016/0304-4165(82)90028-9; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; Pershad HR, 1999, BIOCHEMISTRY-US, V38, P8992, DOI 10.1021/bi990108v; RAEBURN S, 1971, ARCH BIOCHEM BIOPHYS, V146, P21, DOI 10.1016/S0003-9861(71)80037-1; RAEBURN S, 1971, ARCH BIOCHEM BIOPHYS, V146, P9, DOI 10.1016/S0003-9861(71)80036-X; RAGSDALE SW, 1984, J BACTERIOL, V157, P1; RAGSDALE SW, 1983, J BIOL CHEM, V258, P2364; RAGSDALE SW, 2000, BIOL INORGANIC CHEM; RAGSDALE SW, 1998, VITAMIN B12 B12 PROT, P167; RAGSDALE SW, 1997, BIOFACTORS, V9, P1; RAJAGOPAL BS, 1994, CURR MICROBIOL, V28, P307, DOI 10.1007/BF01573211; SHIEH JS, 1987, J BACTERIOL, V169, P5327, DOI 10.1128/jb.169.11.5327-5329.1987; Simpson Peter G., 1993, P445; Stephens PJ, 1996, CHEM REV, V96, P2491, DOI 10.1021/cr950045w; TERLESKY KC, 1988, J BIOL CHEM, V263, P4080; Tersteegen A, 1997, EUR J BIOCHEM, V244, P862, DOI 10.1111/j.1432-1033.1997.00862.x; UYEDA K, 1971, J BIOL CHEM, V246, P3120; UYEDA K, 1971, J BIOL CHEM, V246, P3111; WAHL RC, 1987, J BIOL CHEM, V262, P10489; Yakunin AF, 1998, BBA-BIOENERGETICS, V1409, P39, DOI 10.1016/S0005-2728(98)00145-5; Yoon KS, 1999, J BIOL CHEM, V274, P29772, DOI 10.1074/jbc.274.42.29772; Zhang Q, 1996, J BIOCHEM-TOKYO, V120, P587	49	120	163	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28494	28499		10.1074/jbc.M003291200	http://dx.doi.org/10.1074/jbc.M003291200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10878009	hybrid			2022-12-27	WOS:000089330700022
J	Sorgine, MHF; Logullo, C; Zingali, RB; Paiva-Silva, GO; Juliano, L; Oliveira, PL				Sorgine, MHF; Logullo, C; Zingali, RB; Paiva-Silva, GO; Juliano, L; Oliveira, PL			A heme-binding aspartic proteinase from the eggs of the hard tick Boophilus microplus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YOLK DEGRADATION; POLYACRYLAMIDE GELS; RHODNIUS-PROLIXUS; BOMBYX-MORI; IRON; IDENTIFICATION; SENSITIVITY; HEMOGLOBIN; ALIGNMENT; PROTEASES	An aspartic proteinase that binds heme with a 1:1 stoichiometry was isolated and cloned from the eggs of the cattle tick Boophilus microplus. This proteinase, herein named THAP (tick heme-binding aspartic proteinase) showed pepstatin-sensitive hydrolytic activity against several peptide and protein substrates, Although hemoglobin was a good substrate for THAP, low proteolytic activity was observed against globin devoid of the heme prosthetic group. Hydrolysis of globin by THAP increased as increasing amounts of heme were added to globin, with maximum activation at a heme-to-globin 1:1 ratio. Further additions of heme to the reaction medium inhibited proteolysis, back to a level similar to that observed against globin alone. The addition of heme did not change THAP activity toward a synthetic peptide or against ribonuclease, a non-hemeprotein substrate. The major storage protein of tick eggs, vitellin (VT), the probable physiological substrate of THAP, is a hemeprotein. Hydrolysis of VT by THAP was also inhibited by the addition of heme to the incubation media. Taken together, our results suggest that THAP uses heme bound to VT as a docking site to increase specificity and regulate VT degradation according to heme availability.	Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Ciencias Biomed, Dept Bioquim Med, BR-21910590 Rio De Janeiro, Brazil; UNIFESP, Escola Paulista Med, Dept Biofis, BR-04044020 Sao Paulo, Brazil; Univ Fed Fluminense, Inst Biol, Dept Biol Celular & Mol, BR-24001970 Niteroi, RJ, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal Fluminense	Sorgine, MHF (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Ciencias Biomed, Dept Bioquim Med, BR-21910590 Rio De Janeiro, Brazil.		Logullo de Oliveira, Carlos Jorge/G-3436-2013; Juliano, Luiz/D-7204-2012; Zingali, Russolina/G-4862-2012; L. Oliveira, Pedro/A-9438-2010	Juliano, Luiz/0000-0002-5589-2822; Zingali, Russolina/0000-0003-3156-6923; L. Oliveira, Pedro/0000-0003-0307-354X				AFT RL, 1984, J BIOL CHEM, V259, P301; Ascoli F, 1981, Methods Enzymol, V76, P72; Braz GRC, 1999, CURR BIOL, V9, P703, DOI 10.1016/S0960-9822(99)80312-1; DeCarlo AA, 1999, J BACTERIOL, V181, P3784, DOI 10.1128/JB.181.12.3784-3791.1999; FAGOTTO F, 1995, J CELL SCI, V108, P3645; FAGOTTO F, 1990, ARCH INSECT BIOCHEM, V14, P217, DOI 10.1002/arch.940140403; FAGOTTO F, 1991, DEV GROWTH DIFFER, V33, P57; Filippova IY, 1996, ANAL BIOCHEM, V234, P113, DOI 10.1006/abio.1996.0062; GARESSE R, 1979, EUR J BIOCHEM, V99, P253, DOI 10.1111/j.1432-1033.1979.tb13252.x; GUTTERIDGE JMC, 1988, BIOCHEM J, V256, P861, DOI 10.1042/bj2560861; HAGEDORN HH, 1979, ANNU REV ENTOMOL, V24, P475, DOI 10.1146/annurev.en.24.010179.002355; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Henikoff S, 1999, BIOINFORMATICS, V15, P471, DOI 10.1093/bioinformatics/15.6.471; Hirata IY, 1995, LETT PEPT SCI, V1, P299, DOI DOI 10.1007/BF00119771; IKEDA M, 1990, INSECT BIOCHEM, V20, P725, DOI 10.1016/0020-1790(90)90087-B; KACZMAREK E, 1987, BIOCHIM BIOPHYS ACTA, V914, P275, DOI 10.1016/0167-4838(87)90286-X; KUBINOWA M, 1998, BIOCHEM BIOPH RES CO, V249, P38; KUNKEL JG, 1985, COMPREHENSIVE INSECT, V1, P83; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Logullo C, 1998, PARASITOLOGY, V116, P525, DOI 10.1017/S0031182098002698; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCINISZYN J, 1976, J BIOL CHEM, V251, P7088; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Mendiola J, 1996, EXP PARASITOL, V82, P27, DOI 10.1006/expr.1996.0004; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; NUSSENZVEIG RH, 1992, ARCH INSECT BIOCHEM, V21, P253, DOI 10.1002/arch.940210402; Oliveira MF, 1999, NATURE, V400, P517, DOI 10.1038/22910; OLIVEIRA PL, 1995, J BIOL CHEM, V270, P10897, DOI 10.1074/jbc.270.18.10897; Otto BR, 1998, J EXP MED, V188, P1091, DOI 10.1084/jem.188.6.1091; Ponka P, 1997, BLOOD, V89, P1; Raikhel A.S., 1990, P147; ROOSELL R, 1991, INSECT BIOCHEM MOLEC, V21, P871; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHACTER BA, 1988, SEMIN HEMATOL, V25, P349; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; TAKAHASHI SY, 1993, J BIOCHEM, V114, P267, DOI 10.1093/oxfordjournals.jbchem.a124165; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUITSUI K, 1982, ANAL BIOCHEM, V121, P244; Uzel C, 1998, SEMIN HEMATOL, V35, P27; VINCENT SH, 1989, SEMIN HEMATOL, V26, P105; VINCENT SH, 1985, J BIOL CHEM, V260, P4521	43	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28659	28665		10.1074/jbc.M005675200	http://dx.doi.org/10.1074/jbc.M005675200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10896678	hybrid			2022-12-27	WOS:000089330700044
J	Zhao, T; Heyduk, T; Allis, CD; Eissenberg, JC				Zhao, T; Heyduk, T; Allis, CD; Eissenberg, JC			Heterochromatin protein 1 binds to nucleosomes and DNA in Vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITION-EFFECT VARIEGATION; NONHISTONE CHROMOSOMAL PROTEIN; RESONANCE ENERGY-TRANSFER; DROSOPHILA HETEROCHROMATIN; HISTONE ACETYLATION; SACCHAROMYCES-CEREVISIAE; CHROMODOMAIN PROTEINS; CHROMATIN STRUCTURE; SELF-ASSOCIATION; RNA-POLYMERASE	Heterochromatin protein 1 (HP1) is a nonhistone chromosomal protein primarily associated with the pericentric heterochromatin and telomeres in Drosophila, The molecular mechanism by which HP1 specifically recognizes and binds to chromatin is unknown. The purpose of this study was to test whether HP1 can bind directly to nucleosomes. HP1 binds nucleosome core particles and naked DNA. HP1-DNA complex formation is length-dependent and cooperative but relatively sequence-independent. We show that histone H4 aminoterminal peptides bind to monomeric and dimeric HP1 in vitro. Acetylation of lysine residues had no significant effect on in vitro binding. The C-terminal chrome shadow domain of HPI specifically binds H4 N-terminal peptide. Neither the chrome domain nor chrome shadow domain alone binds DNA; intact native HP1 is required for such interactions. Together, these observations suggest that HP1 may serve as a cross-linker in chromatin, linking nucleosomal DNA and nonhistone protein complexes to form higher order chromatin structures.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Biol, Charlottesville, VA 22908 USA	Saint Louis University; University of Virginia	Eissenberg, JC (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.				NIGMS NIH HHS [GM50514, GM53512, GM57005] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050514, R01GM053512, R55GM057005, R37GM053512, R21GM050514] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; AASLAND R, 1995, NUCLEIC ACIDS RES, V23, P3168; Ball LJ, 1997, EMBO J, V16, P2473, DOI 10.1093/emboj/16.9.2473; BAUMANN H, 1995, J MOL BIOL, V247, P840, DOI 10.1006/jmbi.1995.0184; BELYAEVA ES, 1993, CHROMOSOMA, V102, P583, DOI 10.1007/BF00368351; Brasher SV, 2000, EMBO J, V19, P1587, DOI 10.1093/emboj/19.7.1587; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; CLARKE DJ, 1993, BIOCHEM J, V294, P557, DOI 10.1042/bj2940557; Cleard F, 1997, EMBO J, V16, P5280, DOI 10.1093/emboj/16.17.5280; Cowell IG, 1997, BBA-PROTEIN STRUCT M, V1337, P198, DOI 10.1016/S0167-4838(96)00165-3; Cryderman DE, 1998, CHROMOSOMA, V107, P277, DOI 10.1007/s004120050309; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Dorsett D, 1999, CURR OPIN GENET DEV, V9, P505, DOI 10.1016/S0959-437X(99)00002-7; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; EDMONDSON SP, 1995, BIOCHEMISTRY-US, V34, P13289, DOI 10.1021/bi00041a004; EISSENBERG JC, 1992, GENETICS, V131, P345; EISSENBERG JC, 1994, J BIOL CHEM, V269, P21315; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; Festenstein R, 1999, NAT GENET, V23, P457, DOI 10.1038/70579; Frankel S, 1997, J CELL SCI, V110, P1999; GRIGLIATTI T, 1991, METHOD CELL BIOL, V35, P587; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Heyduk E, 1997, ANAL BIOCHEM, V248, P216, DOI 10.1006/abio.1997.2148; Heyduk E, 1999, J BIOL CHEM, V274, P3315, DOI 10.1074/jbc.274.6.3315; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; KELLUM R, 1995, J CELL SCI, V108, P1407; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LORENTZ A, 1992, MOL GEN GENET, V233, P436, DOI 10.1007/BF00265441; Lu BY, 2000, GENETICS, V155, P699; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Matlock DL, 1999, ANAL BIOCHEM, V270, P140, DOI 10.1006/abio.1999.4078; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; POWERS JA, 1993, J CELL BIOL, V120, P291, DOI 10.1083/jcb.120.2.291; Robinson H, 1998, NATURE, V392, P202, DOI 10.1038/32455; SAUNDERS WS, 1993, J CELL SCI, V104, P573; Smothers JF, 2000, CURR BIOL, V10, P27, DOI 10.1016/S0960-9822(99)00260-2; Spofford J., 1976, GENET BIOL DROSOPHIL, VVolume 1, P955; Sugimoto K, 1996, J BIOCHEM, V120, P153; TARTOF KD, 1984, CELL, V37, P869, DOI 10.1016/0092-8674(84)90422-7; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640; Yamada T, 1999, J BIOCHEM, V125, P832, DOI 10.1093/oxfordjournals.jbchem.a022356; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653; Ye QA, 1997, J BIOL CHEM, V272, P14983, DOI 10.1074/jbc.272.23.14983; Zhao T, 1999, J BIOL CHEM, V274, P15095, DOI 10.1074/jbc.274.21.15095	56	98	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28332	28338						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10882726				2022-12-27	WOS:000089197100106
J	Iwamoto, S; Suganuma, H; Kamesaki, T; Omi, T; Okuda, H; Kajii, E				Iwamoto, S; Suganuma, H; Kamesaki, T; Omi, T; Okuda, H; Kajii, E			Cloning and characterization of erythroid-specific DNase I-hypersensitive site in human rhesus-associated glycoprotein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN LOCUS; TRANSCRIPTION FACTOR GATA-1; BLOOD-GROUP ANTIGENS; RED-CELL MEMBRANE; CONTROL REGION; MOLECULAR-CLONING; CHROMATIN STRUCTURE; PROMOTER REGION; RH POLYPEPTIDE; EXPRESSION	fRhesus-associated glycoprotein is a critical co-factor in the expression of rhesus blood group antigens. We identified and cloned an erythroid-specific major DNase I-hypersensitive site located about 10 kilobases upstream from the translation start site of the RHAG gene. A short core enhancer sequence of 195 base pairs that corresponded with the major hypersensitive site and possessed position- and orientation-independent enhancer activity in K562 cells. In vitro DNase I footprint analysis revealed four protected regions in the core enhancer; two GATA motifs, an Ets-like motif and an unknown motif. The GATA motifs bound GATA-1 and mutagenesis analysis revealed that the proximal one is critical for the enhancing activity. Homology plot analysis using the 5' sequence of the mouse RHAG gene revealed four homologous stretches and multiple insertions of repetitive sequences among them; four LINE/L1 and four Alu in the human and as well as one LINE/L1 and one LTR/MaLR in the mouse gene. The highly conservative enhancer region was flanked by SINE and LINE/L1 in both species. These results suggest that the 5'-flanking sequence of RHAG gene is a preferable target sequence for retroviral transposition and that the enhancer was inserted in the same manner, resulting in the acquisition of erythroid dominant expression.	Jichi Med Sch, Dept Legal Med & Human Genet, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Med Ctr, Dept Surg, Omiya, Saitama 3308503, Japan	Jichi Medical University; Jichi Medical University	Iwamoto, S (corresponding author), Jichi Med Sch, Dept Legal Med & Human Genet, 3311-1 Minamikawachi Machi, Minami Kawachi, Tochigi 32904, Japan.			Omi, Toshinori/0000-0001-9303-2746				AGRE P, 1991, BLOOD, V78, P551, DOI 10.1182/blood.V78.3.551.bloodjournal783551; ARCE MA, 1993, BLOOD, V82, P651; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; AVENT N, 1988, BIOCHEM J, V251, P499, DOI 10.1042/bj2510499; AVENT ND, 1990, BIOCHEM J, V271, P821, DOI 10.1042/bj2710821; BECKER P, 1984, EMBO J, V3, P2015, DOI 10.1002/j.1460-2075.1984.tb02084.x; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Bony V, 1999, BRIT J HAEMATOL, V107, P263, DOI 10.1046/j.1365-2141.1999.01721.x; Boyes J, 1998, J MOL BIOL, V279, P529, DOI 10.1006/jmbi.1998.1783; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Bulger M, 1999, P NATL ACAD SCI USA, V96, P5129, DOI 10.1073/pnas.96.9.5129; CHERIFZAHAR B, 1994, GENOMICS, V19, P68, DOI 10.1006/geno.1994.1014; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; CherifZahar B, 1996, NAT GENET, V12, P168, DOI 10.1038/ng0296-168; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; Hardison R, 1997, GENE, V205, P73, DOI 10.1016/S0378-1119(97)00474-5; HARTELSCHENK S, 1992, J BIOL CHEM, V267, P5569; Huang CH, 1998, J BIOL CHEM, V273, P2207, DOI 10.1074/jbc.273.4.2207; Ikuta T, 1996, J BIOL CHEM, V271, P14082, DOI 10.1074/jbc.271.24.14082; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; Iwamoto S, 1998, BIOCHEM BIOPH RES CO, V243, P233, DOI 10.1006/bbrc.1997.8023; KAJII E, 1993, HUM GENET, V91, P157; Kawano M, 1998, ANN HUM GENET, V62, P107, DOI 10.1046/j.1469-1809.1998.6220107.x; KUHNERT P, 1992, NUCLEIC ACIDS RES, V20, P1943, DOI 10.1093/nar/20.8.1943; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; LEONARD M, 1993, BLOOD, V82, P1071; LEVANKIM C, 1992, P NATL ACAD SCI USA, V89, P10925, DOI 10.1073/pnas.89.22.10925; Li QL, 1999, GENOMICS, V61, P183, DOI 10.1006/geno.1999.5954; Liu Z, 1999, BIOCHEM GENET, V37, P119, DOI 10.1023/A:1018726303397; Marini AM, 1997, TRENDS BIOCHEM SCI, V22, P460, DOI 10.1016/S0968-0004(97)01132-8; MOLLISON PL, 1993, BLOOD TRANSFUSION CL; MOORE S, 1982, NATURE, V295, P529, DOI 10.1038/295529a0; MOORE S, 1987, BIOCHEM J, V244, P735, DOI 10.1042/bj2440735; Pomerantz O, 1998, NUCLEIC ACIDS RES, V26, P5684, DOI 10.1093/nar/26.24.5684; Radomska HS, 1998, GENE, V222, P305, DOI 10.1016/S0378-1119(98)00491-0; RIDGWELL K, 1992, BIOCHEM J, V287, P223, DOI 10.1042/bj2870223; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seack J, 1997, IMMUNOGENETICS, V46, P493, DOI 10.1007/s002510050310; Southcott MJG, 1999, BLOOD, V93, P4425, DOI 10.1182/blood.V93.12.4425.412k22_4425_4435; STAMATOYANNOPOULOS JA, 1995, EMBO J, V14, P106, DOI 10.1002/j.1460-2075.1995.tb06980.x; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; Tippett P, 1990, Transfus Med Rev, V4, P56, DOI 10.1016/S0887-7963(90)70248-9; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; TUAN D, 1984, P NATL ACAD SCI-BIOL, V81, P2718, DOI 10.1073/pnas.81.9.2718; Vyas P, 1999, DEVELOPMENT, V126, P2799; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YANG TP, 1987, MOL CELL BIOL, V7, P2994, DOI 10.1128/MCB.7.8.2994; YOUSSOUFIAN H, 1994, BLOOD, V83, P1428	50	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27324	27331						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10862620				2022-12-27	WOS:000089144800088
J	Jones, CE; Mueser, TC; Nossal, NG				Jones, CE; Mueser, TC; Nossal, NG			Interaction of the bacteriophage T4 gene 59 helicase loading protein and gene 41 helicase with each other and with fork, flap, and cruciform DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLAR BRANCH MIGRATION; DOUBLE-STRAND BREAKS; 4-WAY JUNCTION DNA; REPLICATION COMPLEX; ASSEMBLY PROTEIN; PRIMASE-HELICASE; BINDING; RECOMBINATION; POLYMERASE; PURIFICATION	Bacteriophage T4 gene 59 helicase loading protein accelerates the loading of T4 gene 41 DNA helicase and is required for recombination-dependent DNA replication late in T4 phage infection. The crystal structure of 59 protein revealed a two-domain alpha-helical protein, whose N-terminal domain has strong structural similarity to the DNA binding domain of high mobility group family proteins (Mueser, T. C., Jones, C. E., Nossal, N. G., and Hyde, C, C, (2000) J. Mel. Biol, 296, 597-612), We have previously shown that 59 protein binds preferentially to fork DNA, Here we show that 59 protein binds to completely duplex forks but cannot load the helicase unless there is a single-stranded gap of more than 5 nucleotides on the fork arm corresponding to the lagging strand template. Consistent with the roles of these proteins in recombination, we find that 59 protein binds to and stimulates 41 helicase activity on Holliday junction DNA, and on a substrate that resembles a strand invasion structure. 59 protein forms a stable complex with wild type 41 helicase and fork DNA in the presence of adenosine 5'-O-(thiotriphosphate). The unwinding activity of 41 helicase missing 20 C-terminal amino acids is not stimulated by 59 protein, and it does not form a complex with 59 protein on fork DNA.	NIDDKD, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA; NIAMS, Struct Biol Res Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Nossal, NG (corresponding author), NIDDKD, Mol & Cellular Biol Lab, NIH, Bldg 8,Rm 2A19, Bethesda, MD 20892 USA.		Jones, Charles/GVS-9497-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057801] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allain FHT, 1999, EMBO J, V18, P2563, DOI 10.1093/emboj/18.9.2563; BARRY J, 1994, J BIOL CHEM, V269, P33049; CarlesKinch K, 1997, EMBO J, V16, P4142, DOI 10.1093/emboj/16.13.4142; CHA TA, 1989, J BIOL CHEM, V264, P12220; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; CUNNINGHAM RP, 1978, VIROLOGY, V88, P62, DOI 10.1016/0042-6822(78)90110-1; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Dong F, 1996, P NATL ACAD SCI USA, V93, P14456, DOI 10.1073/pnas.93.25.14456; Fenley MO, 1998, BIOPHYS CHEM, V74, P135, DOI 10.1016/S0301-4622(98)00171-9; Gariglio M, 1997, EXP CELL RES, V236, P472, DOI 10.1006/excr.1997.3742; GAUSS P, 1994, J BACTERIOL, V176, P1667, DOI 10.1128/jb.176.6.1667-1672.1994; George JW, 1996, GENETICS, V143, P1507; Hill DA, 1999, NUCLEIC ACIDS RES, V27, P2135, DOI 10.1093/nar/27.10.2135; HINTON DM, 1985, J BIOL CHEM, V260, P2851; HINTON DM, 1987, J BIOL CHEM, V262, P10873; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Jones JM, 1999, J MOL BIOL, V289, P503, DOI 10.1006/jmbi.1999.2783; Jones JM, 2000, MOL MICROBIOL, V36, P519, DOI 10.1046/j.1365-2958.2000.01888.x; Kong DC, 1997, J BIOL CHEM, V272, P8380; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; KREUZER KN, 1988, J BIOL CHEM, V263, P11348; KREUZER KN, 1994, MOL BIOL BACTERIOP T, V4, P89; Kuroki E, 1999, MOL GEN GENET, V262, P525, DOI 10.1007/s004380051114; Lefebvre SD, 1997, J MOL BIOL, V272, P312, DOI 10.1006/jmbi.1997.1264; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; Liu J, 1999, J BIOL CHEM, V274, P25033, DOI 10.1074/jbc.274.35.25033; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; Mosig G, 1998, ANNU REV GENET, V32, P379, DOI 10.1146/annurev.genet.32.1.379; Mueser TC, 2000, J MOL BIOL, V296, P597, DOI 10.1006/jmbi.1999.3438; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; Pohler JRG, 1998, EMBO J, V17, P817, DOI 10.1093/emboj/17.3.817; Raney KD, 1996, J BIOL CHEM, V271, P14074, DOI 10.1074/jbc.271.24.14074; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; SALINAS F, 1995, CELL, V82, P111, DOI 10.1016/0092-8674(95)90057-8; Sandler SJ, 2000, J BACTERIOL, V182, P9, DOI 10.1128/JB.182.1.9-13.2000; SHAH DB, 1976, J VIROL, V17, P175, DOI 10.1128/JVI.17.1.175-182.1976; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1990, CURRENT PROTOCOLS MO, V3; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; WU R, 1975, J VIROL, V16, P5, DOI 10.1128/JVI.16.1.5-16.1975; YONESAKI T, 1994, GENETICS, V138, P247; YONESAKI T, 1994, J BIOL CHEM, V269, P1284; Yu X, 1997, J MOL BIOL, V266, P217, DOI 10.1006/jmbi.1996.0799; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421	51	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27145	27154						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10871615				2022-12-27	WOS:000089144800065
J	Taheri, M; Saragovi, U; Fuks, A; Makkerh, J; Mort, J; Stanners, CP				Taheri, M; Saragovi, U; Fuks, A; Makkerh, J; Mort, J; Stanners, CP			Self recognition in the Ig superfamily - Identification of precise subdomains in carcinoembryonic antigen required for intercellular adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN SUPERGENE FAMILY; HUMAN-TUMOR-MARKER; CELL-ADHESION; 3-DIMENSIONAL STRUCTURE; HOMOPHILIC BINDING; MOLECULAR-BIOLOGY; CRYSTAL-STRUCTURE; HUMAN CD4; DOMAINS; CEA	The homophilic binding of extracellular domains of membrane-bound immunoglobulin superfamily (IgSF) molecules is often required for intercellular adhesion and signaling. Carcinoembryonic antigen (CEA), a member of the IgSF, is a widely used tumor marker that functions in vitro as a homotypic intercellular adhesion molecule, CEA has also been shown to contribute to tumorigenicity by inhibiting cellular differentiation, an effect that requires the hemophilic binding of its extracellular domains, It was of interest, therefore, to identify small subdomain sequences In CEA that could serve as a focus in the design of peptides that disrupt CEA-mediated intercellular adhesion. Three subdomains in the N-terminal domain of CEA, identified by site-directed deletions and point mutations, were shown to be required for intercellular adhesion. Cyclized peptides representing two of these subdomains, (42)NRQII and (80)QNDTG, were found to be effective in blocking CEA-mediated cellular aggregation when added to CEA-expressing transfectants in suspension. Intermolecular binding involving each of these subdomains is therefore essential for intercellular adhesion and cannot be compensated for by known binding contributions of other regions in the CEA molecule. In further support of this assumption, the binding epitope of an anti-CEA monoclonal antibody (monoclonal antibody A20) known to block CEA-mediated adhesion, was shown to bridge two of the three required subdomains: (42)NRQII and (30)GYSWYK.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Shriners Hosp Children, Montreal, PQ H3G 1A6, Canada	McGill University; McGill University; McGill University; McGill University	Stanners, CP (corresponding author), McGill Univ, McGill Canc Ctr, 3655 Promenade Sir Williams Osler, Montreal, PQ H3G 1Y6, Canada.	stanners@med.mcgill.ca						AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BATES PA, 1992, FEBS LETT, V301, P207, DOI 10.1016/0014-5793(92)81249-L; BEAUCHEMIN N, 1987, MOL CELL BIOL, V7, P3221, DOI 10.1128/MCB.7.9.3221; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; Boehm MK, 1996, J MOL BIOL, V259, P718, DOI 10.1006/jmbi.1996.0353; CHEVINSKY AH, 1991, SEMIN SURG ONCOL, V7, P162, DOI 10.1002/ssu.2980070309; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; Doherty P, 1992, Curr Opin Neurobiol, V2, P595, DOI 10.1016/0959-4388(92)90024-F; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EIDELMAN FJ, 1993, J CELL BIOL, V123, P467, DOI 10.1083/jcb.123.2.467; GOLD P, 1965, J EXP MED, V122, P467, DOI 10.1084/jem.122.3.467; HEFTA SA, 1988, P NATL ACAD SCI USA, V85, P4648, DOI 10.1073/pnas.85.13.4648; HIGUCHI R, 1989, USING PCR ENG DNA PC, P177; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; Huang ZW, 1997, BIOPOLYMERS, V43, P367, DOI 10.1002/(SICI)1097-0282(1997)43:5<367::AID-BIP3>3.0.CO;2-T; JESSUP JM, 1993, INT J CANCER, V55, P262, DOI 10.1002/ijc.2910550216; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KOIVUNEN E, 1994, METHOD ENZYMOL, V245, P346; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leahy DJ, 1997, ANNU REV CELL DEV BI, V13, P363, DOI 10.1146/annurev.cellbio.13.1.363; LESK AM, 1982, J MOL BIOL, V160, P325, DOI 10.1016/0022-2836(82)90179-6; LEVIN LV, 1991, CANCER LETT, V60, P143, DOI 10.1016/0304-3835(91)90221-3; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OIKAWA S, 1987, BIOCHEM BIOPH RES CO, V144, P634, DOI 10.1016/S0006-291X(87)80013-X; OIKAWA S, 1992, BIOCHEM BIOPH RES CO, V186, P881, DOI 10.1016/0006-291X(92)90828-9; OIKAWA S, 1987, BIOCHEM BIOPH RES CO, V142, P511, DOI 10.1016/0006-291X(87)90304-4; OIKAWA S, 1991, J BIOL CHEM, V266, P7995; PAXTON RJ, 1987, P NATL ACAD SCI USA, V84, P920, DOI 10.1073/pnas.84.4.920; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; Ranheim TS, 1996, P NATL ACAD SCI USA, V93, P4071, DOI 10.1073/pnas.93.9.4071; RAO Y, 1993, J BIOL CHEM, V268, P20630; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SARAGOVI HU, 1992, BIO-TECHNOL, V10, P773, DOI 10.1038/nbt0792-773; Screaton RA, 1997, J CELL BIOL, V137, P939, DOI 10.1083/jcb.137.4.939; SHIVELY JE, 1985, CRC CR REV ONCOL-HEM, V2, P355, DOI 10.1016/S1040-8428(85)80008-1; Sippel CJ, 1996, J BIOL CHEM, V271, P33095, DOI 10.1074/jbc.271.51.33095; Stanners CP, 1998, CELL ADHES COMMUN S, V5, P57; STANNERS CP, 1971, NATURE-NEW BIOL, V230, P52, DOI 10.1038/newbio230052a0; TAKAMI N, 1988, J BIOL CHEM, V263, P12716; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZHOU H, 1993, CANCER RES, V53, P3817; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951; ZHOU H, 1990, CELL GROWTH DIFFER, V1, P209	49	42	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26935	26943						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10864933				2022-12-27	WOS:000089144800037
J	Allal, C; Favre, G; Couderc, B; Salicio, S; Sixou, S; Hamilton, AD; Sebti, SM; Lajoie-Mazenc, I; Pradines, A				Allal, C; Favre, G; Couderc, B; Salicio, S; Sixou, S; Hamilton, AD; Sebti, SM; Lajoie-Mazenc, I; Pradines, A			RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYLTRANSFERASE-I INHIBITOR; GTP-BINDING PROTEIN; SWISS 3T3 CELLS; BOTULINUM C3 EXOENZYME; ADP-RIBOSYLATION; EXCHANGE PROTEIN; GAMMA-SUBUNIT; MEMBRANE ASSOCIATION; RAS TRANSFORMATION; PHOSPHOLIPASE-D	The importance of post-translational geranylgeranylation of the GTPase RhoA for its ability to induce cellular proliferation and malignant transformation is not well understood. In this manuscript we demonstrate that geranylgeranylation is required for the proper cellular localization of V14RhoA and for its ability to induce actin stress fiber and focal adhesion formation. Furthermore, V14RhoA geranylgeranylation was also required for suppressing p21(WAF) transcription, promoting cell cycle progression and cellular proliferation. The ability of V14RhoA to induce focus formation and enhance plating efficiency and oncogenic Ras anchorage-dependent growth was also dependent on its geranylgeranylation. The only biological activity of V14RhoA that was not dependent on its prenylation was its ability to induce serum response element transcriptional activity. Furthermore, we demonstrate that a farnesylated form of V14RhoA was also able to bind RhoGDI-1, was able to induce cytoskeleton organization, proliferation, and transformation, and was just as potent as geranylgeranylated V14RhoA at suppressing p21(WAF) transcriptional activity. These results demonstrate that RhoA geranylgeranylation is required for its biological activity and that the nature of the lipid modification is not critical.	Univ Toulouse 3, Ctr Lutte Contre Canc Claudius Regaud, F-31052 Toulouse, France; Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06511 USA	UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Yale University	Pradines, A (corresponding author), Univ Toulouse 3, Ctr Lutte Contre Canc Claudius Regaud, EA 2048,20-24 Rue Pont St Pierre, F-31052 Toulouse, France.		Lajoie-Mazenc, Isabelle/M-4636-2014; Pradines, Anne/M-3935-2014; FAVRE, Gilles/K-9189-2014; ALLAL, Ben C/I-8146-2014; Sixou, Sophie/O-1322-2018; Couderc, Bettina/P-1576-2014	Pradines, Anne/0000-0002-2449-678X; FAVRE, Gilles/0000-0002-2344-1883; ALLAL, Ben C/0000-0002-4207-2219; Sixou, Sophie/0000-0001-7525-7538; Couderc, Bettina/0000-0002-4530-5508	NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [CA67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; AEPFELBACHER M, 1995, BIOCHEM J, V308, P853, DOI 10.1042/bj3080853; BARON R, 2000, IN PRESS P NATL ACAD; Berton M, 1997, BBA-MOL CELL RES, V1355, P7, DOI 10.1016/S0167-4889(96)00111-5; BIFULCO M, 1993, J CELL PHYSIOL, V155, P340, DOI 10.1002/jcp.1041550215; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COX AD, 1993, J BIOL CHEM, V268, P11548; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX AD, 1994, J BIOL CHEM, V269, P19203; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; Ghosh PM, 1999, ONCOGENE, V18, P4120, DOI 10.1038/sj.onc.1202792; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORI Y, 1991, ONCOGENE, V6, P515; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kanaho Y, 1996, J LIPID MEDIAT CELL, V14, P223, DOI 10.1016/0929-7855(96)00529-9; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; Kranenburg O, 1997, J CELL SCI, V110, P2417; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; Matsuda T, 1998, BIOCHEMISTRY-US, V37, P9843, DOI 10.1021/bi973194c; Menager C, 1999, EXP CELL RES, V249, P221, DOI 10.1006/excr.1999.4481; Miquel K, 1997, CANCER RES, V57, P1846; MIURA Y, 1993, J BIOL CHEM, V268, P510; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; Mondal MS, 2000, BIOCHEMISTRY-US, V39, P406, DOI 10.1021/bi991856n; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SASAKI T, 1993, J BIOL CHEM, V268, P23959; SCHMIDT RA, 1982, J CELL BIOL, V95, P144, DOI 10.1083/jcb.95.1.144; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Strassheim D, 2000, J BIOL CHEM, V275, P6699, DOI 10.1074/jbc.275.10.6699; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1995, ONCOGENE, V11, P39; UEDA T, 1990, J BIOL CHEM, V265, P9373; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	67	86	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31001	31008		10.1074/jbc.M005264200	http://dx.doi.org/10.1074/jbc.M005264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10896672	hybrid			2022-12-27	WOS:000089762700039
J	Moon, NS; Berube, G; Nepveu, A				Moon, NS; Berube, G; Nepveu, A			CCAAT displacement activity involves CUT repeats 1 and 2, not the CUT homeodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX ATTACHMENT REGION; CELL TYPE SPECIFICATION; NEGATIVE REGULATORY ELEMENT; DNA-BINDING SPECIFICITY; SENSORY ORGAN IDENTITY; DROSOPHILA WING MARGIN; HISTONE H4 GENE; GLUTATHIONE TRANSFERASE; PROGESTERONE-RECEPTOR; TRANSCRIPTION FACTORS	The CCAAT displacement protein, the homolog of the Drosophila melanogaster CUT protein, contains four DNA-binding domains: three CUT repeats (CR1, CR2, and CR3) and the CUT homeodomain (HD). Using a panel of fusion proteins, we found that a CUT repeat cannot bind to DNA as a monomer, but that certain combinations of domains exhibit high DNA-binding affinity: CR1+2, CR3HD, CR1HD, and CR2HD. One combination (CR1+2) exhibited strikingly different DNA-binding kinetics and specificities. CR1+2 displayed rapid on and off rates and bound preferably to two C(A/G)AT sites, organized as direct or inverted repeats. Accordingly, only CR1+2 was able to bind to the CCAAT sequence, and its affinity was increased by the presence of a C(A/G)AT site at close proximity. A purified CCAAT displacement protein/CUT protein exhibited DNA-binding properties similar to those of CR1+2; and in nuclear extracts, the CCAAT displacement activity also required the simultaneous presence of a C(A/G)AT site. Moreover, CR1+2, but not CR3HD, was able to displace nuclear factor Y, Thus, the CCAAT displacement activity requires the presence of an additional sequence (CAAT or CGAT) and involves CR1 and CR2, but not the CUT homeodomain.	McGill Univ, Mol Oncol Grp, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University; McGill University	Nepveu, A (corresponding author), McGill Univ, Mol Oncol Grp, Ctr Hlth, Rm H5-21,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	alain@lan1.molonc.mcgill.ca	/AAB-8315-2020	Moon, Nam-Sung/0000-0002-0455-927X				ACETO A, 1992, BIOCHEM J, V285, P241, DOI 10.1042/bj2850241; Ai WD, 1999, J VIROL, V73, P4220, DOI 10.1128/JVI.73.5.4220-4229.1999; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; Aziz F, 1998, MOL BIOL REP, V25, P1, DOI 10.1023/A:1006888731301; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Blanc Richard, 1942, UNIV CALIFORNIA PUBL ZOOL, V49, P1; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Braun W, 1940, J EXP ZOOL, V84, P325, DOI 10.1002/jez.1400840302; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; Catt D, 1999, CELL MOL BIOL, V45, P1149; Chattopadhyay S, 1998, J BIOL CHEM, V273, P29838, DOI 10.1074/jbc.273.45.29838; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; Dickinson LA, 1997, J BIOL CHEM, V272, P11463; ELHODIRI HM, 1995, MOL CELL BIOL, V15, P3587; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; HARADA R, 1994, J BIOL CHEM, V269, P2062; Hertweck H, 1931, Z WISS ZOOL ABT A, V139, P559; Heuvel GBV, 1996, KIDNEY INT, V50, P453, DOI 10.1038/ki.1996.336; Higgy NA, 1997, BBA-GENE STRUCT EXPR, V1351, P313, DOI 10.1016/S0167-4781(96)00221-7; JACK J, 1992, GENETICS, V131, P353; JACK J, 1991, DEVELOPMENT, V113, P735; JACK JW, 1985, CELL, V42, P869, DOI 10.1016/0092-8674(85)90283-1; KhannaGupta A, 1997, BLOOD, V90, P2784, DOI 10.1182/blood.V90.7.2784.2784_2784_2795; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Last TJ, 1998, GENE, V221, P267, DOI 10.1016/S0378-1119(98)00415-6; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; Liu JQ, 1997, MOL CELL BIOL, V17, P5275, DOI 10.1128/MCB.17.9.5275; LIU S, 1992, DEV BIOL, V150, P133, DOI 10.1016/0012-1606(92)90013-7; LIU S, 1991, GENETICS, V127, P151; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Mailly F, 1996, MOL CELL BIOL, V16, P5346; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; Pattison S, 1997, J VIROL, V71, P2013, DOI 10.1128/JVI.71.3.2013-2022.1997; PRENDERGAST P, 1994, J STEROID BIOCHEM, V48, P1, DOI 10.1016/0960-0760(94)90245-3; SACCHETTA P, 1993, EUR J BIOCHEM, V215, P741, DOI 10.1111/j.1432-1033.1993.tb18087.x; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; Teerawatanasuk N, 1999, J NEUROCHEM, V72, P29, DOI 10.1046/j.1471-4159.1999.0720029.x; VALARCHE I, 1993, DEVELOPMENT, V119, P881; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; vanWijnen AJ, 1997, J CELL BIOCHEM, V66, P512, DOI 10.1002/(SICI)1097-4644(19970915)66:4<512::AID-JCB10>3.0.CO;2-D; Wang ZY, 1999, MOL CELL BIOL, V19, P284; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365	57	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31325	31334		10.1074/jbc.M002912200	http://dx.doi.org/10.1074/jbc.M002912200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10864926	hybrid			2022-12-27	WOS:000089762700082
J	Sapranauskas, R; Sasnauskas, G; Lagunavicius, A; Vilkaitis, G; Lubys, A; Siksnys, V				Sapranauskas, R; Sasnauskas, G; Lagunavicius, A; Vilkaitis, G; Lubys, A; Siksnys, V			Novel subtype of type IIs restriction enzymes - BfiI endonuclease exhibits similarities to the EDTA-resistant nuclease Nuc of Salmonella typhimurium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE KINETIC-ANALYSIS; PHOSPHOLIPASE-D FAMILY; PLASMID DNA; HAEMOPHILUS-PARAHAEMOLYTICUS; ALKALINE EXTRACTION; SINGLE-TURNOVER; FOKI; SUPERFAMILY; MECHANISM; SYNTHASES	The type IIs restriction enzyme BfiI recognizes the non-palindromic nucleotide sequence 5'-ACTGGG-3' and cleaves complementary DNA strands 5/4 nucleotides downstream of the recognition sequence. The genes coding for the BfiI restriction-modification (R-M) system were cloned/sequenced and biochemical characterization of BfiI restriction enzyme was performed. The BfiI R-M system contained three proteins: two N4-methylcytosine methyltransferases and a restriction enzyme, Sequencing of bisulfite-treated methylated DNA indicated that each methyltransferase modifies cytosines on opposite strands of the recognition sequence. The N-terminal part of the BfiI restriction enzyme amino acid sequence revealed intriguing similarities to an EDTA-resistant nuclease of Salmonella typhimurium. Biochemical analyses demonstrated that BfiI, like the nuclease of S. typhimurium, cleaves DNA in the absence of Mg2+ ions and hydrolyzes an artificial substrate bis(p-nitrophenyl) phosphate. However, unlike the nonspecific S. typhimurium nuclease, BfiI restriction enzyme cleaves DNA specifically. We propose that the DNA-binding specificity of BfiI stems from the C-terminal part of the protein. The catalytic N-terminal subdomain of BfiI radically differs from that of type II restriction enzymes and is presumably similar to the EDTA-resistant nonspecific nuclease of S. typhimurium; therefore, BfiI did not require metal ions for catalysis. We suggest that BfiI represents a novel subclass of type IIs restriction enzymes that differs from the archetypal KokI endonuclease by the fold of its cleavage domain, the domain location, and reaction mechanism.	Inst Biotechnol, LT-2028 Vilnius, Lithuania	Vilnius University	Siksnys, V (corresponding author), Inst Biotechnol, Graiciuno 8, LT-2028 Vilnius, Lithuania.		Vilkaitis, Giedrius/AAI-9157-2021; Sasnauskas, Giedrius/AAE-8191-2019	Vilkaitis, Giedrius/0000-0003-2427-3997				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; GordonBeresford RMH, 1996, PROTEINS, V25, P180, DOI 10.1002/(SICI)1097-0134(199606)25:2<180::AID-PROT4>3.0.CO;2-M; Gottlin EB, 1998, P NATL ACAD SCI USA, V95, P9202, DOI 10.1073/pnas.95.16.9202; Gunn JS, 1997, NUCLEIC ACIDS RES, V25, P4147, DOI 10.1093/nar/25.20.4147; KITA K, 1992, NUCLEIC ACIDS RES, V20, P618, DOI 10.1093/nar/20.3.618; KITA K, 1992, NUCLEIC ACIDS RES, V20, P4167, DOI 10.1093/nar/20.16.4167; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P242, DOI 10.1016/0968-0004(96)30024-8; LI L, 1993, GENE, V133, P79, DOI 10.1016/0378-1119(93)90227-T; LI L, 1992, P NATL ACAD SCI USA, V89, P4275, DOI 10.1073/pnas.89.10.4275; Lubys A, 1996, NUCLEIC ACIDS RES, V24, P2760, DOI 10.1093/nar/24.14.2760; MARKO MA, 1982, ANAL BIOCHEM, V121, P382, DOI 10.1016/0003-2697(82)90497-3; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POHLMAN RF, 1993, NUCLEIC ACIDS RES, V21, P4867, DOI 10.1093/nar/21.21.4867; Ponting CP, 1996, PROTEIN SCI, V5, P914; Roberts R, 1993, NUCLEASES, P35; Sambrook J., 2002, MOL CLONING LAB MANU; Sasnauskas G, 1999, BIOCHEMISTRY-US, V38, P4028, DOI 10.1021/bi982456n; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Stuckey JA, 1999, NAT STRUCT BIOL, V6, P278; SUGISAKI H, 1981, GENE, V16, P73; SZYBALSKI W, 1991, GENE, V100, P13, DOI 10.1016/0378-1119(91)90345-C; TIMINSKAS A, 1995, GENE, V157, P3, DOI 10.1016/0378-1119(94)00783-O; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6082, DOI 10.1021/bi00141a018; Vilkaitis G, 1999, ANAL BIOCHEM, V271, P116, DOI 10.1006/abio.1999.4116; Vitkute J, 1998, NUCLEIC ACIDS RES, V26, P3348, DOI 10.1093/nar/26.14.3348; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; WHITEHEAD PR, 1985, ARCH MICROBIOL, V141, P70, DOI 10.1007/BF00446742; WINANS SC, 1983, J BACTERIOL, V154, P1117, DOI 10.1128/JB.154.3.1117-1125.1983; Wright DJ, 1999, J BIOL CHEM, V274, P31896, DOI 10.1074/jbc.274.45.31896; Zhao Y, 1997, PROTEIN SCI, V6, P2655	35	81	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30878	30885		10.1074/jbc.M003350200	http://dx.doi.org/10.1074/jbc.M003350200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10880511	hybrid			2022-12-27	WOS:000089762700023
J	Grzeskowiak, R; Amin, J; Oetjen, E; Knepel, W				Grzeskowiak, R; Amin, J; Oetjen, E; Knepel, W			Insulin responsiveness of the glucagon gene conferred by interactions between proximal promoter and more distal enhancer-like elements involving the paired-domain transcription factor Pax6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; CELL-SPECIFIC EXPRESSION; PANCREATIC-ISLET CELLS; RESPONSE ELEMENT; PHOSPHOENOLPYRUVATE CARBOXYKINASE; NUCLEAR-PROTEIN; MEMBRANE DEPOLARIZATION; PROGLUCAGON GENE; PATHO-PHYSIOLOGY; CYCLOSPORINE-A	Regulation of gene transcription is an important aspect of insulin's action. However, the mechanisms involved are poorly understood. Insulin inhibits glucagon gene transcription, and insulin deficiency is associated with hyperglucagonemia that contributes to hyperglycemia in diabetes mellitus. Transfecting glucagon-reporter fusion genes into a glucagon-producing pancreatic islet cell line, a 5'-, 3'-, and internal deletion analysis, and oligonucleotide cassette insertions failed in the present study to identify a single insulin-responsive element in the glucagon gene. They rather indicate that insulin responsiveness depends on the presence of both proximal promoter elements and more distal enhancer-like elements. When the paired domain transcription factor Pax6 binding sites within the proximal promoter element G1 and the enhancer-like element G3 were mutated into GAL4 binding sites, the expression of GAL4-Pax6 and GAL4-VP16 restored basal activity, whereas only GAL4-Pax6 restored also insulin responsiveness. Likewise, GAL4-CBP activity was inhibited by insulin within the glucagon promoter context. The results suggest that insulin responsiveness is conferred to the glucagon gene by the synergistic interaction of proximal promoter and more distal enhancer-like elements, with Pax6 and its potential coactivator the CREB-binding protein being critical components. These data thereby support concepts of insulin-responsive element-independent mechanisms of insulin action to inhibit gene transcription.	Univ Gottingen, Dept Mol Pharmacol, D-37070 Gottingen, Germany	University of Gottingen	Knepel, W (corresponding author), Univ Gottingen, Dept Mol Pharmacol, Robert-Koch-Str 40,Postfach 3742, D-37070 Gottingen, Germany.							ALEXANDERBRIDGES M, 1992, BIOCHEM SOC T, V20, P691, DOI 10.1042/bst0200691; Andersen FG, 1999, FEBS LETT, V445, P306, DOI 10.1016/S0014-5793(99)00145-3; Barroso I, 1999, J BIOL CHEM, V274, P17997, DOI 10.1074/jbc.274.25.17997; Beimesche S, 1999, MOL ENDOCRINOL, V13, P718, DOI 10.1210/me.13.5.718; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chapman SC, 1999, J BIOL CHEM, V274, P18625, DOI 10.1074/jbc.274.26.18625; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CORDIERBUSSAT M, 1995, MOL CELL BIOL, V15, P3904; Creutzfeldt WOC, 1996, DIABETES CARE, V19, P580, DOI 10.2337/diacare.19.6.580; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Dumonteil E, 1998, J BIOL CHEM, V273, P19945, DOI 10.1074/jbc.273.32.19945; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Eckner R, 1996, BIOL CHEM, V377, P685; Freyse EJ, 1997, DIABETES, V46, P824, DOI 10.2337/diabetes.46.5.824; Furstenau U, 1999, J BIOL CHEM, V274, P5851, DOI 10.1074/jbc.274.9.5851; Furstenau U, 1997, MOL CELL BIOL, V17, P1805; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; Hussain MA, 1997, MOL CELL BIOL, V17, P7186, DOI 10.1128/MCB.17.12.7186; Hussain MA, 1999, J BIOL CHEM, V274, P28950, DOI 10.1074/jbc.274.41.28950; Jin TR, 1996, MOL CELL BIOL, V16, P19; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; KNEPEL W, 2000, IN PRESS MOL BASIS E; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kruger M, 1997, N-S ARCH PHARMACOL, V356, P433, DOI 10.1007/PL00005073; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Leahy P, 1999, J BIOL CHEM, V274, P8813, DOI 10.1074/jbc.274.13.8813; LEFEBVRE PJ, 1995, DIABETES CARE, V18, P715, DOI 10.2337/diacare.18.5.715; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; Mikkola I, 1999, J BIOL CHEM, V274, P15115, DOI 10.1074/jbc.274.21.15115; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OETJEN E, 1994, J BIOL CHEM, V269, P27036; Ortiz L, 1999, J BIOL CHEM, V274, P15213, DOI 10.1074/jbc.274.21.15213; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1989, J CLIN INVEST, V84, P672, DOI 10.1172/JCI114214; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; Pierreux CE, 1999, MOL CELL ENDOCRINOL, V147, P1, DOI 10.1016/S0303-7207(98)00238-X; Pierreux CE, 1998, MOL ENDOCRINOL, V12, P1343, DOI 10.1210/me.12.9.1343; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SCHWANINGER M, 1993, J BIOL CHEM, V268, P23111; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; Streeper RS, 1998, MOL ENDOCRINOL, V12, P1778, DOI 10.1210/me.12.11.1778; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; THOMPSON MJ, 1994, J BIOL CHEM, V269, P21127; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; UNGER RH, 1981, NEW ENGL J MED, V304, P1575, DOI 10.1056/NEJM198106253042604; UNGER RH, 1981, NEW ENGL J MED, V304, P1518, DOI 10.1056/NEJM198106183042504; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367; Wrege Antje, 1995, Gene Expression, V4, P205; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743	70	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30037	30045		10.1074/jbc.M000984200	http://dx.doi.org/10.1074/jbc.M000984200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10862760	hybrid			2022-12-27	WOS:000089577900017
J	Henderson, JM; Wells, L; Fridovich-Keil, JL				Henderson, JM; Wells, L; Fridovich-Keil, JL			Covalent heterogeneity of the human enzyme galactose-1-phosphate uridylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST EXPRESSION SYSTEM; URIDYLYL TRANSFERASE; ESCHERICHIA-COLI; MOLECULAR-BASIS; UDP-GALACTOSE; URIDYLTRANSFERASE; SITE; PURIFICATION; MUTATIONS; IDENTIFICATION	Galactose-1-phosphate uridylyltransferase (GALT) acts by a double displacement mechanism, catalyzing the second step in the Leloir pathway of galactose metabolism. Impairment of this enzyme results in the potentially lethal disorder, galactosemia. Although the microheterogeneity of native human GALT has long been recognized, the biochemical basis for this heterogeneity has remained obscure. We have explored the possibility of covalent GALT heterogeneity using denaturing two dimensional gel electrophoresis and Western blot analysis to fractionate and visualize hemolysate hGALT, as well as the human enzyme expressed in yeast. In both contexts, two predominant GALT species were observed. To define the contribution of uridylylated enzyme intermediate to the two-spot pattern, we exploited the null allele, H186G-hGALT. The Escherichia coli counterpart of this mutant protein (H166G-eGALT) has previously been demonstrated to fold properly, although it cannot form covalent intermediate. Analysis of the H186G-hGALT protein demonstrated a single predominant species, implicating covalent intermediate as the basis for the second spot in the wild-type pattern. In contrast, three naturally occurring mutations, N314D, Q188R, and S135L-hGALT, all demonstrated the two-spot pattern. Together, these data suggest that uridylylated hGALT comprises a significant fraction of the total GALT enzyme pool in normal human cells and that three of the most common patient mutations do not disrupt this distribution.	Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Nutr & Hlth Sci, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Biochem & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Fridovich-Keil, JL (corresponding author), Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA.		Wells, Lance/H-3118-2013	Wells, Lance/0000-0003-4956-5363	NIDDK NIH HHS [DK46403] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046403, R01DK046403] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARABSHAHI A, 1986, BIOCHEMISTRY-US, V25, P5583, DOI 10.1021/bi00367a036; BANROQUES J, 1981, BIOCHIM BIOPHYS ACTA, V657, P374, DOI 10.1016/0005-2744(81)90323-5; BANROQUES J, 1983, BIOCHIMIE, V65, P7, DOI 10.1016/S0300-9084(83)80023-6; Crews C, 2000, J BIOL CHEM, V275, P22847, DOI 10.1074/jbc.M001053200; DALE GL, 1976, J BIOL CHEM, V251, P1057; Elsevier JP, 1996, P NATL ACAD SCI USA, V93, P7166, DOI 10.1073/pnas.93.14.7166; FIELD TL, 1989, BIOCHEMISTRY-US, V28, P2094, DOI 10.1021/bi00431a019; FREY PA, 1982, METHOD ENZYMOL, V87, P20; FRIDOVICHKEIL JL, 1995, AM J HUM GENET, V56, P640; FRIDOVICHKEIL JL, 1993, P NATL ACAD SCI USA, V90, P398, DOI 10.1073/pnas.90.2.398; FridovichKeil JL, 1995, BIOCHEM MOL MED, V56, P121, DOI 10.1006/bmme.1995.1067; Geeganage S, 1998, BIOCHEMISTRY-US, V37, P14500, DOI 10.1021/bi9815546; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guthrie C, 1991, METHODS ENZYMOLOGY; HOLTON JB, 2000, IN PRESS METABOLIC M; KELLEY RI, 1983, HUM GENET, V63, P274; KIM JM, 1990, BIOCHEMISTRY-US, V29, P10590, DOI 10.1021/bi00499a003; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lai K, 1999, J BIOL CHEM, V274, P6559, DOI 10.1074/jbc.274.10.6559; Lai K, 1996, J PEDIATR-US, V128, P89, DOI 10.1016/S0022-3476(96)70432-8; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Quimby BB, 1996, J BIOL CHEM, V271, P26835, DOI 10.1074/jbc.271.43.26835; REICHARDT JKV, 1992, BIOCHEMISTRY-US, V31, P5430, DOI 10.1021/bi00139a002; REICHARDT JKV, 1991, P NATL ACAD SCI USA, V88, P2633, DOI 10.1073/pnas.88.7.2633; SCHAPIRA F, 1978, BIOCHEM BIOPH RES CO, V80, P291, DOI 10.1016/0006-291X(78)90675-7; Segal S, 1995, METABOLIC MOL BASIS, P967; SHIN YS, 1995, EUR J PEDIATR, V154, pS75, DOI 10.1007/BF02143808; SHIN YS, 1987, CLIN CHIM ACTA, V166, P27, DOI 10.1016/0009-8981(87)90191-4; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P1212, DOI 10.1021/bi9626517; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; Wedekind JE, 1996, BIOCHEMISTRY-US, V35, P11560, DOI 10.1021/bi9612677; Wells L, 1997, J INHERIT METAB DIS, V20, P633, DOI 10.1023/A:1005314207513; WONG LJ, 1974, J BIOL CHEM, V249, P2322; WONG LJ, 1977, BIOCHEMISTRY-US, V16, P1010, DOI 10.1021/bi00624a032	34	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30088	30091		10.1074/jbc.M005259200	http://dx.doi.org/10.1074/jbc.M005259200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10884393	hybrid			2022-12-27	WOS:000089577900025
J	Scott, IC; Imamura, Y; Pappano, WN; Troedel, JM; Recklies, AD; Roughley, PJ; Greenspan, DS				Scott, IC; Imamura, Y; Pappano, WN; Troedel, JM; Recklies, AD; Roughley, PJ; Greenspan, DS			Bone morphogenetic protein-1 processes probiglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN C-PROTEINASE; PROTEOGLYCAN-II DECORIN; MAMMALIAN TOLLOID-LIKE; GROWTH-FACTOR-BETA; DERMATAN SULFATE PROTEOGLYCANS; HUMAN ARTICULAR-CARTILAGE; COMPLETE CDNA CLONING; GENOMIC ORGANIZATION; TARGETED DISRUPTION; FIBROGENIC CELLS	Bone morphogenetic protein-1 (BMP-1) is a metalloprotease that plays important roles in regulating the deposition of fibrous extracellular matrix in vertebrates, including provision of the procollagen C-proteinase activity that processes the major fibrillar collagens I-III. Biglycan, a small leucine-rich proteoglycan, is a nonfibrillar extracellular matrix component with functions that include the positive regulation of bone formation. Biglycan is synthesized as a precursor with an NH2-terminal propeptide that is cleaved to yield the mature form found in vertebrate tissues. Here, we show that BMP-1 cleaves probiglycan at a single site, removing the propeptide and producing a biglycan molecule with an NH2 terminus identical to that of the mature form found in tissues. BMP-1-related proteases mammalian Tolloid and mammalian Tolloid-like 1 (mTLL-1) are shown to have low but detectable levels of probiglycan-cleaving activity. Comparison shows that wild type mouse embryo fibroblasts (MEFs) produce only fully processed biglycan, whereas MEFs derived from embryos homozygous null for the Bmp1 gene, which encodes both BMP-1 and mammalian Tolloid, produce predominantly unprocessed probiglycan, and MEFs homozygous null for both the Bmp1 gene and the mTLL-1 gene Tll1 produce only unprocessed probiglycan. Thus, all detectable probiglycan-processing activity in MEFs is accounted for by the products of these two genes.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Shriners Hosp Children, Joint Dis Lab, Montreal, PQ H3G 1A6, Canada; Shriners Hosp Children, Genet Unit, Montreal, PQ H3G 1A6, Canada; McGill Univ, Dept Surg, Montreal, PQ H3G 1A6, Canada	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; McGill University; McGill University; McGill University	Greenspan, DS (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA.	dsgreens@facstaff.wisc.edu	Imamura, Yasutada/AAI-3078-2020	Greenspan, Daniel/0000-0001-8096-7446; Imamura, Yasutada/0000-0001-6264-1709; Pappano, William/0000-0003-2848-2219	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043621] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43621] Funding Source: Medline; NIGMS NIH HHS [GM46846] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON SR, 1992, BIOCHIM BIOPHYS ACTA, V1132, P225, DOI 10.1016/0167-4781(92)90019-V; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; CHOI HU, 1989, J BIOL CHEM, V264, P2876; Clark TG, 1999, DEVELOPMENT, V126, P2631; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DREHER KL, 1990, EUR J CELL BIOL, V53, P296; FISHER LW, 1987, J BIOL CHEM, V262, P9702; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; LI W, 1992, ARCH BIOCHEM BIOPHYS, V296, P190, DOI 10.1016/0003-9861(92)90562-B; MORRIS NP, 1975, J BIOL CHEM, V250, P5719; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; ROUGHLEY PJ, 1989, BIOCHEM J, V262, P823, DOI 10.1042/bj2620823; Roughley PJ, 1996, BIOCHEM J, V318, P779, DOI 10.1042/bj3180779; SAWHNEY RS, 1991, J BIOL CHEM, V266, P9231; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; SCOTT JE, 1981, BIOCHEM J, V197, P213, DOI 10.1042/bj1970213; Suzuki N, 1996, DEVELOPMENT, V122, P3587; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; TOROK MA, 1993, BIOCHIM BIOPHYS ACTA, V1173, P81, DOI 10.1016/0167-4781(93)90247-B; UITTO J, 1976, BIOCHEM BIOPH RES CO, V71, P60, DOI 10.1016/0006-291X(76)90249-7; WEGROWSKI Y, 1995, GENOMICS, V30, P8, DOI 10.1006/geno.1995.0002; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YEO TK, 1995, J VASC RES, V32, P175, DOI 10.1159/000159091; ZHAN Q, 1995, INVEST OPHTH VIS SCI, V36, P206	50	117	129	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30504	30511		10.1074/jbc.M004846200	http://dx.doi.org/10.1074/jbc.M004846200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10896944	hybrid			2022-12-27	WOS:000089577900080
J	Deguchi, M; Iizuka, T; Hata, Y; Nishimura, W; Hirao, K; Yao, I; Kawabe, H; Takai, Y				Deguchi, M; Iizuka, T; Hata, Y; Nishimura, W; Hirao, K; Yao, I; Kawabe, H; Takai, Y			Papin - A novel multiple PSD-95/Dlg-A/ZO-1 protein interacting with neural plakophilin-related armadillo repeat protein/delta-catenin and p0071	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; JUNCTION-ASSOCIATED PROTEIN; TYROSINE KINASE SUBSTRATE; DOMAIN-CONTAINING PROTEIN; BETA-CATENIN; POSTSYNAPTIC DENSITY; DESMOSOMAL PLAQUE; MULTIGENE FAMILY; BAND-6 PROTEIN; DELTA-CATENIN	A neural plakophilin-related armadillo repeat protein (NPRAP)/delta-catenin interacts with one of Alzheimer disease-related gene products, presenilin 1. We have previously reported the interaction of NPRAP/delta-catenin with synaptic scaffolding molecule, which is involved in the assembly of synaptic components. NPRAP/delta-catenin also interacts with E-cadherin and beta-catenin and is implicated in the organization of cell-cell junctions. p0071, a ubiquitous isoform of NPRAP/delta-catenin, is localized at desmosomes in HeLa and A431 cells and at adherens junctions in Madin-Darby bovine kidney cells. We have identified here a novel protein interacting with NPRAP/ delta-catenin and p0071 and named this protein plakophilin-related armadillo repeat protein-interacting PSD-95/ Dlg-A/ZO-1 (PDZ) protein (PAPIN). PAPIN has six PDZ domains and binds to NPRAP/delta-catenin and p0071 via the second PDZ domain. PAPIN and p0071 are ubiquitously expressed in various tissues and are localized at cell-cell junctions in normal rat kidney cells and bronchial epithelial cells. PAPIN may be a scaffolding protein connecting components of epithelial junctions with p0071.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, Exploratory Res Adv Technol, Takai Biotimer Project, Kobe, Hyogo 6512241, Japan; Tokyo Med & Dent Univ, Dept Med Biochem, Bunkyo Ku, Tokyo 1138519, Japan	Osaka University; Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU)	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Kawabe, Hiroshi/U-7325-2018; Nishimura, Wataru/R-9215-2019	Nishimura, Wataru/0000-0002-8068-1277; Kawabe, Hiroshi/0000-0001-5650-8696				Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hata Y, 1996, J NEUROSCI, V16, P2488; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; HATZFELD M, 1994, J CELL SCI, V107, P2259; Hatzfeld M, 1996, J CELL SCI, V109, P2767; HEID HW, 1994, DIFFERENTIATION, V58, P113; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Ide N, 1999, BIOCHEM BIOPH RES CO, V256, P456, DOI 10.1006/bbrc.1999.0364; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Kurschner C, 1998, MOL CELL NEUROSCI, V11, P161, DOI 10.1006/mcne.1998.0679; Levesque G, 1999, J NEUROCHEM, V72, P999, DOI 10.1046/j.1471-4159.1999.0720999.x; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Mertens C, 1996, J CELL BIOL, V135, P1009, DOI 10.1083/jcb.135.4.1009; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; Shimizu K, 1996, J BIOL CHEM, V271, P27013, DOI 10.1074/jbc.271.43.27013; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; Sirotkin H, 1997, GENOMICS, V41, P75, DOI 10.1006/geno.1997.4627; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SRIVASTAVA S, 1998, NEURON, V22, P179; STADDON JM, 1995, J CELL BIOL, V130, P369, DOI 10.1083/jcb.130.2.369; Stahl B, 1999, J BIOL CHEM, V274, P9141, DOI 10.1074/jbc.274.14.9141; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tanahashi H, 1999, NEUROREPORT, V10, P563, DOI 10.1097/00001756-199902250-00022; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	48	53	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29875	29880		10.1074/jbc.M005384200	http://dx.doi.org/10.1074/jbc.M005384200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896674	hybrid			2022-12-27	WOS:000089439800094
J	Ratti, S; Curnis, F; Longhi, R; Colombo, B; Gasparri, A; Magni, F; Manera, E; Metz-Boutigue, MH; Corti, A				Ratti, S; Curnis, F; Longhi, R; Colombo, B; Gasparri, A; Magni, F; Manera, E; Metz-Boutigue, MH; Corti, A			Structure-activity relationships of chromogranin A in cell adhesion - Identification of an adhesion site for fibroblasts and smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MONOCLONAL-ANTIBODIES; TERMINAL FRAGMENTS; ENDOCRINE-CELLS; PROTEIN FAMILY; A FRAGMENT; IN-VITRO; VASOSTATINS; SECRETION; PITUITARY	Previous studies showed that chromogranin A (CgA), a glycoprotein stored and co-released with various hormones by neuroendocrine cells and neurons, can modulate cell adhesion. We have investigated the structure-activity relationships of CgA using fibroblasts and coronary artery smooth muscle cells in adhesion assays. A recombinant CgA fragment 1-78 and a peptide 7-57 containing reduced and alkylated cysteines (Cys(17) and Cys(38)) induced cell adhesion after adsorption onto solid phases at 50-100 nM. Peptides lacking the disulfide loop region, including residues 47-68, 39-59, and 39-68, induced cell adhesion, either bound to solid phases at 200-400 nM or added to the liquid phase at 5-10 mu M, whereas peptide 60-68 was inactive, suggesting that residues 47-57 are important for activity. The effect of CgA-(1-78) was blocked by anti-CgA antibodies against epitopes including residues Arg(53), His(54), and Leu(57). Substitutions of residues His(54) Gln(55), and Asn(56) with alanine decreased the cell adhesion activity of peptide 47-68. These results suggest that the region 47-57 (RILSILRHQNL) contains a cell adhesion site and that the disulfide bridge is not necessary for the proadhesive activity. The ability of soluble peptides to elicit proadhesive effects suggests an indirect mechanism. The high sequence conservation and accessibility to antibodies suggest that this region is important for the physiological role of CgA.	San Raffaele Sci Inst, Dept Biol & Technol Res, I-20132 Milan, Italy; CNR, IRBM, I-20132 Milan, Italy; INSERM, Unite Biol Commun Cellulaire 338, F-67084 Strasbourg, France	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Corti, A (corresponding author), San Raffaele Sci Inst, Dept Biol & Technol Res, Via Olgettina 58, I-20132 Milan, Italy.		Corti, Angelo/F-7046-2012; Gasparri, Anna Maria/AAN-5071-2020; Curnis, Flavio/AAK-3542-2020; Colombo, Barbara/AAN-5045-2020; Magni, Fulvio/A-7340-2014	Corti, Angelo/0000-0002-0893-6191; Gasparri, Anna Maria/0000-0002-1757-8699; Curnis, Flavio/0000-0002-7231-9569; Colombo, Barbara/0000-0002-5887-5868; Subba, Rajkrishna/0000-0003-0051-0062; Magni, Fulvio/0000-0002-8663-0374				AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; BRANDT DW, 1994, P SOC EXP BIOL MED, V205, P316; Ciesielski-Treska J, 1998, J BIOL CHEM, V273, P14339, DOI 10.1074/jbc.273.23.14339; Corti A, 1998, CANCER RES, V58, P3866; Corti A, 1997, EUR J BIOCHEM, V248, P692, DOI 10.1111/j.1432-1033.1997.00692.x; Corti A, 1996, EUR J BIOCHEM, V235, P275, DOI 10.1111/j.1432-1033.1996.00275.x; Corti A, 1996, BRIT J CANCER, V73, P924, DOI 10.1038/bjc.1996.183; DEFTOS LJ, 1990, BONE MINER, V9, P169, DOI 10.1016/0169-6009(90)90035-E; DEFTOS LJ, 1991, ENDOCR REV, V12, P181, DOI 10.1210/edrv-12-2-181; FERRER M, 1992, INT J PEPT PROT RES, V40, P194; Gasparri A, 1997, J BIOL CHEM, V272, P20835, DOI 10.1074/jbc.272.33.20835; GORR SU, 1988, BONE MINER, V4, P17; HELLE KB, 1993, J NEUROENDOCRINOL, V5, P413, DOI 10.1111/j.1365-2826.1993.tb00502.x; IACANGELO A, 1988, FEBS LETT, V227, P115, DOI 10.1016/0014-5793(88)80880-9; IGUCHI H, 1992, EUR J CANCER, V28A, P1458, DOI 10.1016/0959-8049(92)90543-B; KONECKI DS, 1987, J BIOL CHEM, V262, P17026; LAZURE C, 1990, PEPTIDES, V11, P79, DOI 10.1016/0196-9781(90)90114-K; LIANG F, 1995, ACTA PHYSIOL SCAND, V155, P23, DOI 10.1111/j.1748-1716.1995.tb09944.x; Lugardon K, 2000, J BIOL CHEM, V275, P10745, DOI 10.1074/jbc.275.15.10745; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; PELAGI M, 1989, MOL CELL PROBE, V3, P87, DOI 10.1016/0890-8508(89)90039-X; QIAN J, 1988, J NEUROIMMUNOL, V17, P159, DOI 10.1016/0165-5728(88)90023-9; ROSA P, 1994, J ENDOCRINOL INVEST, V17, P207, DOI 10.1007/BF03347721; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUSSELL J, 1994, ENDOCRINOLOGY, V135, P337, DOI 10.1210/en.135.1.337; SERCKHANSSEN G, 1984, J BIOL CHEM, V259, P1597; SIMON JP, 1989, BIOCHEM J, V262, P1; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; Soriano JV, 1999, BIOCHEM BIOPH RES CO, V259, P563, DOI 10.1006/bbrc.1999.0826; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; Turquier V, 1999, ENDOCRINOLOGY, V140, P4104, DOI 10.1210/en.140.9.4104; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WU HJ, 1991, J BIOL CHEM, V266, P13130; YOO SH, 1990, J BIOL CHEM, V265, P14414; YOO SH, 1992, BIOCHEMISTRY-US, V31, P6134, DOI 10.1021/bi00141a025	40	72	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29257	29263		10.1074/jbc.M003796200	http://dx.doi.org/10.1074/jbc.M003796200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10875933	hybrid			2022-12-27	WOS:000089439800012
J	Bortnick, AE; Rothblat, GH; Stoudt, G; Hoppe, KL; Royer, LJ; McNeish, J; Francone, OL				Bortnick, AE; Rothblat, GH; Stoudt, G; Hoppe, KL; Royer, LJ; McNeish, J; Francone, OL			The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; TANGIER-DISEASE; SULFONYLUREA RECEPTOR; ABC TRANSPORTERS; MESSENGER-RNA; LIPID EFFLUX; MACROPHAGES; GENE; FIBROBLASTS	Studies show that lipid-free apoA-I stimulates release of cholesterol and phospholipid from fibroblasts and macrophages. ATP-binding cassette 1 (ABC1) is implicated in this release and has been identified as the genetic defect in Tangier disease, evidence that ABC1 is critical to the biogenesis of high density lipoprotein. We quantified levels of ABC1 mRNA protein, and cholesterol efflux from J774 mouse macrophages rt exposure to a cAMP analog. Up-regulating ABC1 mRNA correlated to increased cholesterol efflux in a dose- and time-dependent manner, mRNA levels rose after 15 min of exposure while protein levels rose after 1 h, with increased efflux 2-4 h post-treatment. In contrast to cells from wild-type mice, peritoneal macrophages from the Abc1 -/- mouse showed a lower level of basal efflux and no increase with cAMP treatment. The stimulation of efflux exhibits specificity for apoA-I, high density lipoprotein, and other apolipoproteins as cholesterol accepters, but not for small unilamellar vesicles, bile acid micelles, or cyclodextrin, We have studied a number of cell types and found that while other cell lines express ABC1 constitutively, only J774 and elicited mouse macrophages show a substantial increase of mRNA and efflux with cAMP treatment. ApoA-I-stimulated efflux was detected from the majority of cell lines examined, independent of treatment.	Pfizer Inc, Div Cent Res, Dept Cardiovasc & Metab Dis, Groton, CT 06340 USA; Med Coll Penn & Hahnemann Univ, Dept Biochem, Philadelphia, PA 19129 USA; Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA	Pfizer; Drexel University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Francone, OL (corresponding author), Pfizer Inc, Div Cent Res, Dept Cardiovasc & Metab Dis, 118B-206B,Eastern Point Rd, Groton, CT 06340 USA.	omar_l_francone@groton.pfizer.com	Eckhardt, Erik/G-1567-2010; Bortnick, Anna/V-5983-2019	Hoppe, Kenneth/0000-0001-5950-6813	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07443, HL22633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; BERNARD DW, 1991, J BIOL CHEM, V266, P710; Bielicki JK, 1999, J LIPID RES, V40, P85; BIELICKI JK, 1991, BIOCHIM BIOPHYS ACTA, V1085, P7, DOI 10.1016/0005-2760(91)90225-7; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Christian AE, 1997, J LIPID RES, V38, P2264; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; Demolombe S, 1996, TRENDS PHARMACOL SCI, V17, P273, DOI 10.1016/0165-6147(96)10037-7; Fournier N, 2000, ARTERIOSCL THROM VAS, V20, P1283, DOI 10.1161/01.ATV.20.5.1283; FRANCESCHINI G, 1991, ATHEROSCLEROSIS, V88, P99, DOI 10.1016/0021-9150(91)90073-C; Francis GA, 1999, BIOCHEMISTRY-US, V38, P16315, DOI 10.1021/bi991742b; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; GLOMSET JA, 1968, J LIPID RES, V9, P155; HARA H, 1991, J BIOL CHEM, V266, P3080; Hatch F T, 1968, Adv Lipid Res, V6, P1; HUANG YD, 1995, ARTERIOSCL THROM VAS, V15, P1746, DOI 10.1161/01.ATV.15.10.1746; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Jain MK, 1998, J BIOL CHEM, V273, P5993, DOI 10.1074/jbc.273.11.5993; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; Johnstone RW, 2000, TRENDS BIOCHEM SCI, V25, P1, DOI 10.1016/S0968-0004(99)01493-0; KLANSEK JJ, 1995, J LIPID RES, V36, P2261; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Kozyraki R, 1999, NAT MED, V5, P656, DOI 10.1038/9504; Kritharides L, 1998, ARTERIOSCL THROM VAS, V18, P1589, DOI 10.1161/01.ATV.18.10.1589; Lafleur RL, 1998, INFECT IMMUN, V66, P4087; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Li QQ, 1995, BBA-LIPID LIPID MET, V1259, P227, DOI 10.1016/0005-2760(95)00165-4; Li QQ, 1997, BIOCHEMISTRY-US, V36, P12045, DOI 10.1021/bi970079t; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCLOSKEY HM, 1987, BIOCHIM BIOPHYS ACTA, V921, P320, DOI 10.1016/0005-2760(87)90033-6; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; MENDEZ AJ, 1991, T ASSOC AM PHYSICIAN, V104, P48; Mendez AJ, 1997, BBA-LIPID LIPID MET, V1346, P285, DOI 10.1016/S0005-2760(97)00031-3; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; Mendez AJ, 1997, J LIPID RES, V38, P1807; Oram JF, 1999, J LIPID RES, V40, P1769; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; Rothblat GH, 1999, J LIPID RES, V40, P781; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sakr SW, 1999, BBA-MOL CELL BIOL L, V1438, P85, DOI 10.1016/S1388-1981(99)00041-4; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; Tsujita M, 1996, BIOCHEMISTRY-US, V35, P13011, DOI 10.1021/bi960734h; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; von Eckardstein A, 1998, J LIPID RES, V39, P987; WALTER M, 1994, BIOCHEM BIOPH RES CO, V205, P850, DOI 10.1006/bbrc.1994.2742; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021	58	260	267	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28634	28640		10.1074/jbc.M003407200	http://dx.doi.org/10.1074/jbc.M003407200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10893411	hybrid			2022-12-27	WOS:000089330700041
J	Dirksen, WP; Li, XL; Mayeda, A; Krainer, AR; Rottman, FM				Dirksen, WP; Li, XL; Mayeda, A; Krainer, AR; Rottman, FM			Mapping the SF2/ASF binding sites in the bovine growth hormone exonic splicing enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; PROTEIN-PROTEIN INTERACTIONS; T ALTERNATIVE EXON; SR-PROTEINS; PREMESSENGER RNA; RECOGNITION MOTIFS; 5'-SPLICE-SITE RECOGNITION; FACTORS ASF/SF2; FACTOR SF2	Splicing of the last intron (intron D) of the bovine growth hormone pre-mRNA requires the presence of a downstream exonic splicing enhancer (ESE). This enhancer is contained within a 115-nucleotide FspI-PvuII (FP) fragment located in the middle of the last exon (exon 5). Previous work showed that the splicing factor SF2/ASF binds to this FP region and stimulates splicing of intron D in vitro. However, the precise sequences recognized by SF2/ASF within the FP region had not been determined. Here we used multiple strategies to map the SF2/ASF binding sites and determine their importance for ESE function. Taking advantage of the fact that SF2/ASF ultraviolet (UV) cross-links specifically to RNA containing the FP sequence, we first mapped a major SF2/ASF binding site by UV cross-linking and reverse transcription. This strategy identified a 29-nucleotide SF2/ASF binding region in the middle of the FP sequence containing the 7-nucleotide purine-rich motif described previously. Interestingly, this binding region is neither sufficient, nor absolutely required for SF2/ASF-mediated splicing, suggesting that additional SF2/ASF binding sites are present. The location of these additional sites was determined by electrophoretic mobility shift analysis of various subfragments of the FP sequence, Antisense 2'-O-methyl oligoribonucleotides complementary to selected SF2/ASF binding sites block bovine growth hormone intron D splicing. Thus, multiple SF2/ASF binding sites within the exonic splicing enhancer contribute to maximal enhancer activity.	Case Western Reserve Univ, Dept Mol Biol & Microbiol, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Sch Med, Cleveland, OH 44106 USA; Novartis Agribusiness Biotechnol Res Inc, Res Triangle Pk, NC 27709 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Case Western Reserve University; Case Western Reserve University; Novartis; University of Miami; Cold Spring Harbor Laboratory	Rottman, FM (corresponding author), Case Western Reserve Univ, Dept Mol Biol & Microbiol, Sch Med, Wood Bldg W235,10900 Euclid Ave, Cleveland, OH 44106 USA.	fmr@po.cwru.edu	Mayeda, Akila/ABC-1134-2020	Mayeda, Akila/0000-0002-9562-550X; Krainer, Adrian/0000-0001-9024-9501	NIDDK NIH HHS [DK32770] Funding Source: Medline; NIGMS NIH HHS [GM42699] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042699] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; CACERES JF, 1997, EUKARYOTIC MRNA PROC, P174; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; Chandler SD, 1997, P NATL ACAD SCI USA, V94, P3596, DOI 10.1073/pnas.94.8.3596; Chiara MD, 1996, MOL CELL BIOL, V16, P3317; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; CRISPINO JD, 1994, SCIENCE, V265, P1866, DOI 10.1126/science.8091213; DIRKSEN WP, 1994, J BIOL CHEM, V269, P6431; DIRKSEN WP, 1995, J BIOL CHEM, V270, P5346, DOI 10.1074/jbc.270.10.5346; DOMINSKI Z, 1994, MOL CELL BIOL, V14, P7445, DOI 10.1128/MCB.14.11.7445; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; EPERON IC, 1993, EMBO J, V12, P3607, DOI 10.1002/j.1460-2075.1993.tb06034.x; FU XD, 1995, RNA, V1, P663; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Gontarek RR, 1996, MOL CELL BIOL, V16, P2325; GREENBERG JR, 1980, NUCLEIC ACIDS RES, V8, P5685, DOI 10.1093/nar/8.23.5685; HAMPSON RK, 1989, MOL CELL BIOL, V9, P1604, DOI 10.1128/MCB.9.4.1604; Hanamura A, 1998, RNA, V4, P430; HEINRICHS V, 1995, EMBO J, V14, P3987, DOI 10.1002/j.1460-2075.1995.tb00070.x; Hertel KJ, 1998, MOL CELL, V1, P449, DOI 10.1016/S1097-2765(00)80045-3; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LAMOND AI, 1990, MOL BIOL REP, V14, P201, DOI 10.1007/BF00360473; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MAYEDA A, 1990, J BIOCHEM-TOKYO, V108, P399, DOI 10.1093/oxfordjournals.jbchem.a123213; Nagel RJ, 1998, RNA, V4, P11; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Selvakumar M, 1999, RNA, V5, P378, DOI 10.1017/S1355838299981050; Shi H, 1997, MOL CELL BIOL, V17, P2649, DOI 10.1128/MCB.17.5.2649; SMITH KC, 1976, RAD INDUCED ADDITION; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; SUN Q, 1993, J BIOL CHEM, V268, P15659; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; TARN WY, 1994, GENE DEV, V8, P2704, DOI 10.1101/gad.8.22.2704; TIAN HC, 1995, MOL CELL BIOL, V15, P6291; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; Yeakley JM, 1996, P NATL ACAD SCI USA, V93, P7582, DOI 10.1073/pnas.93.15.7582; ZAHLER AM, 1995, P NATL ACAD SCI USA, V92, P2642, DOI 10.1073/pnas.92.7.2642; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; Zheng ZM, 1997, J VIROL, V71, P9096, DOI 10.1128/JVI.71.12.9096-9107.1997; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	63	22	33	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29170	29177		10.1074/jbc.M001126200	http://dx.doi.org/10.1074/jbc.M001126200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10880506	hybrid			2022-12-27	WOS:000089330700107
J	Mair, G; Ullu, E; Tschudi, C				Mair, G; Ullu, E; Tschudi, C			Cotranscriptional cap 4 formation on the Trypanosoma brucei spliced leader RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXY-TERMINAL DOMAIN; MESSENGER-RNA; POLYMERASE-II; CAPPING ENZYME; TRANSCRIPTION; INVITRO; BINDING; SYSTEM; GENE	mRNA cap formation in trypanosomatid protozoa is mediated through trans-splicing of the capped spliced leader (SL) sequence of the SL RNA onto the 5' end of all mRNAs. The SL RNA cap structure in Trypanosoma brucei is unique among eukaryotes and consists of 7-methylguanosine (m(7)G) followed by four methylated nucleotides (cap 4): m(7)Gpppm(2)(6)AmpAmpCmpm(3)Um. Using transcriptional arrest in permeable T. brucei cells, we have analyzed the temporal progression of cap 4 formation on the 140-nucleotide-long SL RNA. m7G capping of the SL RNA could be detected on prematurely terminated SL RNA transcripts of 56 nucleotides in length and longer. Subsequent modifications characteristic of the SL RNA cap 4 were added successively in a 5' to 3' direction and appeared to be independent of core ribonucleoprotein formation. Transcripts between 56 and 67 nucleotides in length were partially modified and carried methyl groups on the first two adenosine residues, whereas a fully modified cap 4 structure was present on transcripts arrested at position 117 and beyond, Taken together, our results are consistent with a cotranscriptional mechanism for generating the cap 4 structure on the SL RNA.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	Yale University; Yale University	Tschudi, C (corresponding author), Yale Univ, Sch Med, Dept Internal Med, POB 208022,333 Cedar St, New Haven, CT 06520 USA.			Mair, Gunnar/0000-0002-5187-3691	NIAID NIH HHS [AI43594] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043594] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANGS JD, 1992, J BIOL CHEM, V267, P9805; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; COPPOLA JA, 1983, P NATL ACAD SCI-BIOL, V80, P1251, DOI 10.1073/pnas.80.5.1251; Gunzl A, 1997, MOL BIOCHEM PARASIT, V85, P67, DOI 10.1016/S0166-6851(96)02816-2; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; JOVE R, 1984, J BIOL CHEM, V259, P8513; Lucke S, 1996, EMBO J, V15, P4380, DOI 10.1002/j.1460-2075.1996.tb00811.x; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; MIZUMOTO K, 1987, PROG NUCLEIC ACID RE, V34, P1, DOI 10.1016/S0079-6603(08)60491-2; PALFI Z, 1992, J BIOL CHEM, V267, P20159; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0; Silberklang M, 1979, Methods Enzymol, V59, P58; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; ULLU E, 1995, J BIOL CHEM, V270, P20365, DOI 10.1074/jbc.270.35.20365; ULLU E, 1990, NUCLEIC ACIDS RES, V18, P3319, DOI 10.1093/nar/18.11.3319; Varani G, 1997, STRUCTURE, V5, P855, DOI 10.1016/S0969-2126(97)00239-6; Yu MC, 1998, MOL BIOCHEM PARASIT, V94, P265, DOI 10.1016/S0166-6851(98)00083-8; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	21	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28994	28999		10.1074/jbc.M004193200	http://dx.doi.org/10.1074/jbc.M004193200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10880518	hybrid			2022-12-27	WOS:000089330700086
J	Duffieux, F; Van Roy, J; Michels, PKM; Opperdoes, FR				Duffieux, F; Van Roy, J; Michels, PKM; Opperdoes, FR			Molecular characterization of the first two enzymes of the pentose-phosphate pathway of Trypanosoma brucei - Glucose-6-phosphate dehydrogenase and 6-phosphogluconolactonase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEISHMANIA-MEXICANA MEXICANA; BLOOD-STREAM FORMS; GLYCOLYTIC-ENZYMES; ESCHERICHIA-COLI; SUBCELLULAR-DISTRIBUTION; PURIFICATION; GENE; LOCALIZATION; GLYCOSOMES; SEQUENCE	Trypanosomatids are parasitic protists that have part of their glycolytic pathway sequestered inside peroxisome-like organelles: the glycosomes. So far, at least one enzyme of the pentose-phosphate pathway has been found to be associated partially with glycosomes. Here, we describe how two genes from Trypanosoma brucei, coding for the first two enzymes of the pentose-phosphate pathway, i.e. glucose-8 phosphate dehydrogenase and 6-phosphogluconolactonase, were identified by in silico screening of trypanosome genome project data bases. These genes were cloned and sequenced. Analysis of the lactonase sequence revealed that it contained a C-terminal peroxisome targeting signal in agreement with its subcellular localization in the bloodstream form trypanosome (15% glycosomal and 85% cytosolic), However, the dehydrogenase sequence did not reveal any targeting signal, despite its localization inside glycosomes, The corresponding enzymes have been overexpressed in Escherichia coli and purified, and their biochemical characteristics have been determined.	Christian De Duve Inst Cellulat Pathol, Trop Dis Res Unit, Brussels, Belgium; Catholic Univ Louvain, Biochem Lab, B-1200 Brussels, Belgium	Universite Catholique Louvain	Opperdoes, FR (corresponding author), Christian De Duve Inst Cellulat Pathol, Trop Dis Res Unit, Brussels, Belgium.	opperdoes@trop.ucl.ac.be	Opperdoes, Fred/N-9922-2019; Michels, Paul A/A-5637-2009	Opperdoes, Fred/0000-0003-1984-3764; Michels, Paul A/0000-0003-3726-6104; Duffieux, Francis/0000-0003-4906-0314				Adje CA, 1997, MOL BIOCHEM PARASIT, V90, P155, DOI 10.1016/S0166-6851(97)00152-7; ALLERT S, 1991, EUR J BIOCHEM, V200, P19, DOI 10.1111/j.1432-1033.1991.tb21043.x; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANTONENKOV VD, 1989, EUR J BIOCHEM, V183, P75, DOI 10.1111/j.1432-1033.1989.tb14898.x; Au SWN, 2000, STRUCTURE, V8, P293, DOI 10.1016/S0969-2126(00)00104-0; Barrett MP, 1997, PARASITOL TODAY, V13, P11, DOI 10.1016/S0169-4758(96)10075-2; BARRETT MP, 1993, MOL BIOCHEM PARASIT, V57, P89, DOI 10.1016/0166-6851(93)90247-U; BARRETT MP, 1994, PROTEIN EXPRES PURIF, V5, P44, DOI 10.1006/prep.1994.1006; BAUER HP, 1983, EUR J BIOCHEM, V133, P163, DOI 10.1111/j.1432-1033.1983.tb07442.x; Beutler E, 1996, BLOOD REV, V10, P45, DOI 10.1016/S0268-960X(96)90019-3; Collard F, 1999, FEBS LETT, V459, P223, DOI 10.1016/S0014-5793(99)01247-8; Cosgrove MS, 1998, BIOCHEMISTRY-US, V37, P2759, DOI 10.1021/bi972069y; CRONIN CN, 1989, FEBS LETT, V244, P26, DOI 10.1016/0014-5793(89)81154-8; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DANPURE CJ, 1995, TRENDS CELL BIOL, V5, P230, DOI 10.1016/S0962-8924(00)89016-9; DEWALQUE S, 1996, ARCH PHYSIOL BIOCHEM, V104, pB49; Elgersma Y, 1996, BBA-REV BIOMEMBRANES, V1286, P269, DOI 10.1016/S0304-4157(96)00012-3; Hanau S, 1996, EUR J BIOCHEM, V240, P592, DOI 10.1111/j.1432-1033.1996.0592h.x; HANKOGLU I, 1989, EUR J BIOCHEM, V180, P479; HANNAERT V, 2000, IN PRESS RES REV PAR, V59; Hausler T, 1996, J CELL BIOL, V132, P311, DOI 10.1083/jcb.132.3.311; Heise N, 1999, MOL BIOCHEM PARASIT, V99, P21, DOI 10.1016/S0166-6851(98)00176-5; Heise N, 1997, MOL BIOCHEM PARASIT, V89, P61, DOI 10.1016/S0166-6851(97)00101-1; KAGAWA Y, 1964, J BIOCHEM-TOKYO, V56, P364, DOI 10.1093/oxfordjournals.jbchem.a128003; KOHL L, 1994, EUR J BIOCHEM, V220, P331, DOI 10.1111/j.1432-1033.1994.tb18629.x; KUPOR SR, 1972, J BIOL CHEM, V247, P1904; LAIRD PW, 1989, TRENDS GENET, V5, P204, DOI 10.1016/0168-9525(89)90082-6; LUPIANEZ JA, 1987, INT J BIOCHEM, V19, P1085, DOI 10.1016/0020-711X(87)90310-7; Mason PJ, 1999, BLOOD CELL MOL DIS, V25, P30, DOI 10.1006/bcmd.1999.0224; MICHELS PAM, 1991, EUR J BIOCHEM, V198, P421, DOI 10.1111/j.1432-1033.1991.tb16031.x; MISSET O, 1986, EUR J BIOCHEM, V157, P441, DOI 10.1111/j.1432-1033.1986.tb09687.x; NYAME K, 1994, MOL BIOCHEM PARASIT, V67, P269, DOI 10.1016/0166-6851(94)00139-1; OBRIEN E, 1994, MOL BIOCHEM PARASIT, V64, P313, DOI 10.1016/0166-6851(94)00028-X; Oliva G, 1995, STRUCTURE, V3, P1323, DOI 10.1016/S0969-2126(01)00270-2; OPPERDOES FR, 1984, FEBS LETT, V169, P35, DOI 10.1016/0014-5793(84)80284-7; OPPERDOES FR, 1977, FEBS LETT, V80, P360, DOI 10.1016/0014-5793(77)80476-6; Peterson GC, 1997, EXP PARASITOL, V85, P16, DOI 10.1006/expr.1996.4114; Phillips C, 1998, J MOL BIOL, V282, P667, DOI 10.1006/jmbi.1998.2059; Rakitzis ET, 1998, CHEM-BIOL INTERACT, V113, P205, DOI 10.1016/S0009-2797(98)00026-X; ROSEMEYER MA, 1987, CELL BIOCHEM FUNCT, V5, P79, DOI 10.1002/cbf.290050202; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOFIELD PJ, 1976, BIOCHEM BIOPH RES CO, V71, P1313, DOI 10.1016/0006-291X(76)90798-1; SMITH K, 1991, MOL BIOCHEM PARASIT, V48, P109, DOI 10.1016/0166-6851(91)90170-B; Staden R, 1996, MOL BIOTECHNOL, V5, P233, DOI 10.1007/BF02900361; STEIGER RF, 1980, EUR J BIOCHEM, V105, P163, DOI 10.1111/j.1432-1033.1980.tb04486.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VISSER N, 1981, EUR J BIOCHEM, V118, P521, DOI 10.1111/j.1432-1033.1981.tb05550.x; WIERENGA RK, 1987, EMBO J, V6, P215, DOI 10.1002/j.1460-2075.1987.tb04741.x; Zomer AWM, 1999, MOL BIOCHEM PARASIT, V104, P55, DOI 10.1016/S0166-6851(99)00141-3	49	64	65	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27559	27565						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10867008				2022-12-27	WOS:000089197100008
J	Xu, YX; Liu, L; Michaeli, S				Xu, YX; Liu, L; Michaeli, S			Functional analyses of positions across the 5 ' splice site of the trypanosomatid spliced leader RNA - Implications for base-pair Interaction with U5 and U6 snRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR-RNA; LEPTOMONAS-COLLOSOMA; U1 SNRNA; CRITHIDIA-FASCICULATA; MUTATIONAL ANALYSIS; PREMESSENGER RNA; GU DINUCLEOTIDE; CLEAVAGE SITE; ACTIVE-SITE	In this study, we have used a genetic compensatory approach to examine the functional significance of the previously proposed interaction of spliced leader (SL) RNA with U5 small nuclear RNA (snRNA) (Dungan, J. D., Watkins, K. P., and Agabian, N. (1996) EMBO J. 15, 4016-4029; Xu, Y.-X., Ben Shlomo, H., and Michaeli, S. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 8473-8478) and the interaction of the SL RNA intron with U6 snRNA analogous to cis-splicing. Mutations were introduced at positions -4, -1, +1, +4, +5, and +7/+8 relative to the SL RNA 5' splice site that were proposed to interact with U5 and U6 snRNAs, All mutants exhibited altered splicing phenotypes compared with the parental strain, showing the importance of these intron and exon positions for transsplicing. Surprisingly, mutation at invariant +1 position did not abolish splicing completely, unlike cia-splicing, but position +2 had the most severe effect on transsplicing. Compensatory mutations were introduced in U5 and U6 snRNAs to examine whether the defects resulted from failure to interact with these snRNAs by base pairing, Suppression was observed only for positions +5 and +7/+8 with U5 compensatory mutations and for position +5 with a U6 compensatory mutation, supporting the existence of a base pair interaction of U5 and U6 with the SL RNA intron region. The failure to suppress the other SL RNA mutants by the U5 compensatory mutations suggests that another factor(s) interacts with these key SL RNA positions.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Bar Ilan University; Weizmann Institute of Science	Michaeli, S (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.		Michaeli, Shulamit/AAC-8255-2022; Xu, Yu-Xin/G-4041-2010	Xu, Yu-Xin/0000-0002-0200-4633; Liu, Li/0000-0002-3733-6961				AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Bell M, 1999, NUCLEIC ACIDS RES, V27, P3986, DOI 10.1093/nar/27.20.3986; Ben-Shlomo H, 1997, NUCLEIC ACIDS RES, V25, P4977, DOI 10.1093/nar/25.24.4977; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; Collins CA, 1999, GENE DEV, V13, P1970, DOI 10.1101/gad.13.15.1970; Dungan JM, 1996, EMBO J, V15, P4016, DOI 10.1002/j.1460-2075.1996.tb00775.x; Goldring A, 1996, EXP PARASITOL, V84, P28, DOI 10.1006/expr.1996.0087; GOLDRING A, 1995, GENE, V156, P139, DOI 10.1016/0378-1119(95)00048-B; GOLDRING A, 1995, EXPT PARASITOLOGY, V80, P333; Goncharov I, 1999, J BIOL CHEM, V274, P12217, DOI 10.1074/jbc.274.18.12217; Goncharov I, 1998, NUCLEIC ACIDS RES, V26, P2200, DOI 10.1093/nar/26.9.2200; HANNON GJ, 1992, SCIENCE, V258, P1775, DOI 10.1126/science.1465612; HARTSHORNE T, 1990, GENE DEV, V4, P2121, DOI 10.1101/gad.4.12a.2121; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; Lucke S, 1996, EMBO J, V15, P4380, DOI 10.1002/j.1460-2075.1996.tb00811.x; Mair G, 2000, RNA, V6, P163, DOI 10.1017/S135583820099229X; MARONEY PA, 1991, EMBO J, V10, P3869, DOI 10.1002/j.1460-2075.1991.tb04956.x; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; OKeefe RT, 1996, CELL, V86, P679, DOI 10.1016/S0092-8674(00)80140-3; PALFI Z, 1994, J BIOL CHEM, V269, P30620; PARKER R, 1985, CELL, V41, P107, DOI 10.1016/0092-8674(85)90065-0; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; Reyes J, 1996, RNA, V2, P213; Reyes JL, 1999, RNA, V5, P167, DOI 10.1017/S1355838299981785; Roberts TG, 1996, MOL BIOCHEM PARASIT, V83, P163, DOI 10.1016/S0166-6851(96)02762-4; Sambrook J., 2002, MOL CLONING LAB MANU; Schnare MN, 1999, FEBS LETT, V459, P215, DOI 10.1016/S0014-5793(99)01235-1; Schnare MN, 1999, J BIOL CHEM, V274, P23691, DOI 10.1074/jbc.274.34.23691; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; Siatecka M, 1999, GENE DEV, V13, P1983, DOI 10.1101/gad.13.15.1983; SILICIANO PG, 1987, SCIENCE, V237, P1484, DOI 10.1126/science.3306922; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; Sturm NR, 1998, J BIOL CHEM, V273, P18689, DOI 10.1074/jbc.273.30.18689; Sturm NR, 1999, J BIOL CHEM, V274, P19361, DOI 10.1074/jbc.274.27.19361; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; ULLU E, 1997, MOL BIOL PARASITIC P, P115; WATKINS KP, 1994, CELL, V76, P171, DOI 10.1016/0092-8674(94)90181-3; XU GL, 1994, MOL CELL BIOL, V14, P4565, DOI 10.1128/MCB.14.7.4565; Xu YX, 1997, P NATL ACAD SCI USA, V94, P8473, DOI 10.1073/pnas.94.16.8473; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	49	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27883	27892						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10875928				2022-12-27	WOS:000089197100050
J	Zhao, J; Grafi, G				Zhao, J; Grafi, G			The high mobility group I/Y protein is hypophosphorylated in endoreduplicating maize endosperm cells and is involved in alleviating histone H1-mediated transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP CHROMOSOMAL-PROTEINS; CHROMATIN STRUCTURE; DNA INTERACTIONS; GENE-EXPRESSION; GAMMA-ZEIN; HMG-I/Y; BINDING; H1; PROMOTER; PHOSPHORYLATION	During maize endosperm development, cells shift from a mitotic cycle to endoreduplication, driving the massive synthesis of storage proteins (zeins) and starch. In this developmental context, we studied changes in expression levels of histone H1 and high mobility group I/Y (HMG-YY), two chromatin architectural proteins that are known to affect gene transcription. Almost no change was found in the level of histone H1 during endosperm development, despite a dramatic increase in DNA content (endoreduplication); hence, the histone H1/DNA ratio decreased substantially. Concurrently with a reduction in the Cdc2 kinase activity at the shift to endoreduplication, significant changes were found in the level and mobility of the HMG-I/Y protein; the faster migrating forms were, at least partly, hypophosphorylated. Purified maize HMG-I/Y protein was found to be phophorylated in vitro by the Cdc2 kinase and bound efficiently to the gamma-zein promoter AT-rich tract (gamma Z-AT). Using an in vitro transcription assay, we demonstrated the capability of the maize HMG-I/Y protein to relieve the inhibitory effect exerted by histone H1 on templates containing the gamma Z-AT sequence, These data suggest that during maize endosperm development transcription and perhaps replication are controlled, at least partly, by the activity of the Cdc2 kinase and the interplay between histone H1 and HMG-I/Y proteins.	Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Grafi, G (corresponding author), Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel.							Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CARTWRIGHT IL, 1988, ARCHITECTURE EUKARYO, P283; CLARK DJ, 1986, J MOL BIOL, V187, P569, DOI 10.1016/0022-2836(86)90335-9; COLASANTI J, 1991, P NATL ACAD SCI USA, V88, P3377, DOI 10.1073/pnas.88.8.3377; Ding HF, 1997, MOL CELL BIOL, V17, P5843, DOI 10.1128/MCB.17.10.5843; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; GARRARD WT, 1991, BIOESSAYS, V13, P87, DOI 10.1002/bies.950130208; GOODWIN G, 1988, ARCHITECTURE EUKARYO, P187; GRAFI G, 1995, SCIENCE, V269, P1262, DOI 10.1126/science.269.5228.1262; Grasser KD, 1996, J BIOL CHEM, V271, P32900, DOI 10.1074/jbc.271.51.32900; Gunjan A, 1999, J BIOL CHEM, V274, P37950, DOI 10.1074/jbc.274.53.37950; HILL CS, 1991, EMBO J, V10, P1939, DOI 10.1002/j.1460-2075.1991.tb07720.x; HUTH JR, 1997, NAT STRUCT BIOL, V4, P122; IVACHENKO MG, 1988, ELECTROPHORESIS, V9, P812; JACOBSEN K, 1990, PLANT CELL, V2, P85, DOI 10.1105/tpc.2.1.85; KAHL G, 1988, ARCHITECTURE EUKARYO, P301; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; Kowles R.V., 1988, INT REV CYTOL, P97, DOI [10.1016/s0074-7696(08)62007-0, DOI 10.1016/S0074-7696(08)62007-0]; Krech AB, 1999, GENE, V230, P1, DOI 10.1016/S0378-1119(99)00067-0; LAUX T, 1991, NUCLEIC ACIDS RES, V19, P4768, DOI 10.1093/nar/19.17.4768; Lu ZH, 1998, MOL BIOL CELL, V9, P1163, DOI 10.1091/mbc.9.5.1163; Martinez-Garcia JF, 1999, PLANT J, V18, P173, DOI 10.1046/j.1365-313X.1999.00440.x; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; NIETOSOTELO J, 1994, NUCLEIC ACIDS RES, V22, P1115, DOI 10.1093/nar/22.6.1115; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; OR E, 1993, PLANT CELL, V5, P1599, DOI 10.1105/tpc.5.11.1599; PEDERSEN TJ, 1991, PLANT MOL BIOL, V16, P95, DOI 10.1007/BF00017920; PrymakowskaBosak M, 1996, P NATL ACAD SCI USA, V93, P10250, DOI 10.1073/pnas.93.19.10250; PWEE KH, 1994, PLANT MOL BIOL, V26, P1907, DOI 10.1007/BF00019502; REEVES R, 1992, Current Opinion in Cell Biology, V4, P413, DOI 10.1016/0955-0674(92)90006-X; Schwanbeck R, 2000, J BIOL CHEM, V275, P1793, DOI 10.1074/jbc.275.3.1793; SINGER DS, 1978, BIOCHEMISTRY-US, V17, P2086, DOI 10.1021/bi00604a011; SO JS, 1991, MOL CELL, V1, P145; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; SPIKER S, 1988, ARCHITECTURE EUKARYO, P143; SUN JM, 1990, EMBO J, V9, P1651, DOI 10.1002/j.1460-2075.1990.tb08285.x; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; VicenteCarbajosa J, 1997, P NATL ACAD SCI USA, V94, P7685, DOI 10.1073/pnas.94.14.7685; WALLACE JC, 1990, PLANT PHYSIOL, V92, P191, DOI 10.1104/pp.92.1.191; Wang ZD, 1998, GENE, V223, P321, DOI 10.1016/S0378-1119(98)00244-3; Yamamoto S, 1997, PLANT MOL BIOL, V33, P537, DOI 10.1023/A:1005791728975; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; ZLATANOVA J, 1991, DNA CELL BIOL, V10, P239, DOI 10.1089/dna.1991.10.239	43	37	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27494	27499						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10864924				2022-12-27	WOS:000089144800109
J	Dienz, O; Hehner, SP; Droge, W; Schmitz, ML				Dienz, O; Hehner, SP; Droge, W; Schmitz, ML			Synergistic activation of NF-kappa B by functional cooperation between Vav and PKC theta in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE C-THETA; SIGNAL-TRANSDUCTION PATHWAYS; IL-2 PROMOTER; DEPENDENT ACTIVATION; CELL ACTIVATION; REL PROTEINS; JNK/SAPK; EXCHANGE; ISOFORMS; UV	Here we identified PKC theta as an activator of transcription factor NF-kappa B in T cells. PK theta-induced NF-kappa B activation was synergistically augmented by Vav, Several experimental approaches revealed that PKC theta is located downstream from Vav in the control of the pathway leading to synergistic NF-kappa B activation. In addition to the synergistic activation cascade, Vav also triggered NF-kappa B activity on a separate route. CD3/CD28-induced activation of NF-kappa B was inhibited by dominant negative forms of Vav or PKC theta, revealing their essential role in this activation pathway. The Vav/PKC theta-mediated signals preferentially activated I kappa B kinase P. Vav and PRC theta were found to be constitutively associated in unstimulated T cells. Only the ligation of the costimulatory CD28 receptor, but not of the T cell receptor, resulted in the transient dissociation of the Vav-PKC theta complex. In contrast, T cell receptor/CD28 costimulation resulted in faster dissociation and slower reassociation kinetics.	German Canc Res Ctr, Dept Immunochem G0200, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Schmitz, ML (corresponding author), German Canc Res Ctr, Dept Immunochem G0200, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				BAIER G, 1993, J BIOL CHEM, V268, P4997; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Ghaffari-Tabrizi N, 1999, EUR J IMMUNOL, V29, P132; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Hehner SP, 2000, J IMMUNOL, V164, P3829, DOI 10.4049/jimmunol.164.7.3829; Hofmann TG, 2000, ONCOGENE, V19, P1153, DOI 10.1038/sj.onc.1203406; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Khoshnan A, 1999, J IMMUNOL, V163, P5444; Kong YY, 1998, J EXP MED, V188, P2099, DOI 10.1084/jem.188.11.2099; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lanzavecchia A, 1999, CELL, V96, P1, DOI 10.1016/S0092-8674(00)80952-6; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li-Weber M, 1998, J BIOL CHEM, V273, P32460, DOI 10.1074/jbc.273.49.32460; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Meller N, 1996, MOL CELL BIOL, V16, P5782; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Portoles P, 1999, CELL IMMUNOL, V195, P96, DOI 10.1006/cimm.1999.1529; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; Vespa GNR, 1999, J IMMUNOL, V162, P799; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101	35	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24547	24551		10.1074/jbc.C000177200	http://dx.doi.org/10.1074/jbc.C000177200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10862755	hybrid			2022-12-27	WOS:000088683300043
J	Kumar, LVS; Rao, CM				Kumar, LVS; Rao, CM			Domain swapping in human alpha A and alpha B crystalline affects oligomerisation and enhances chaperone-like activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SITE-DIRECTED MUTATIONS; DESMIN-RELATED MYOPATHY; MOLECULAR CHAPERONE; MISSENSE MUTATION; EXPRESSION; GENE; DISEASE; LENS; FILAMENTS	alpha A and alpha B crystalline, members of the small heat shock protein family, prevent aggregation of proteins by their chaperone-like activity. These two proteins, although very homologous, particularly in the C-terminal region, which contains the highly conserved "alpha-crystallin domain," show differences in their protective ability toward aggregation-prone target proteins. In order to investigate the differences between alpha A and alpha B crystallins, we engineered two chimeric proteins, alpha ANBC and alpha BNAC, by swapping the N-terminal domains of alpha A and alpha B crystallins. The chimeras were cloned and expressed in Escherichia coli, The purified recombinant wild-type and chimeric proteins were characterized by fluorescence and circular dichroism spectroscopy and gel permeation chromatography to study the changes in secondary, tertiary, and quaternary structure. Circular dichroism studies show structural changes in the chimeric proteins, alpha BNAC binds more 8-anilinonaphthalene-1-sulfonic acid than the alpha ANBC and the wild-type proteins, indicating increased accessible hydrophobic regions. The oligomeric state of alpha ANBC is comparable to wild-type alpha B homoaggregate. However, there is a large increase in the oligomer size of the alpha BNAC chimera. Interestingly, swapping domains results in complete loss of chaperone-like activity of alpha ANBC, whereas alpha BNAC shows severalfold increase in its protective ability. Our findings show the importance of the N- and C-terminal domains of alpha A and alpha B crystallins in subunit oligomerization and chaperone-like activity. Domain swapping results in an engineered protein with significantly enhanced chaperone-like activity.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Rao, CM (corresponding author), Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.	mohan@ccmb.ap.nic.in						Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Datta SA, 1999, J BIOL CHEM, V274, P34773, DOI 10.1074/jbc.274.49.34773; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; Der Perng M, 1999, J BIOL CHEM, V274, P33235, DOI 10.1074/jbc.274.47.33235; Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5; Djabali K, 1997, J CELL SCI, V110, P2759; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; Kumar LVS, 1999, J BIOL CHEM, V274, P24137, DOI 10.1074/jbc.274.34.24137; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; Muchowski PJ, 1999, J MOL BIOL, V289, P397, DOI 10.1006/jmbi.1999.2759; NGO JT, 1989, GENOMICS, V5, P665, DOI 10.1016/0888-7543(89)90106-7; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; QUAXJEUKEN Y, 2000, P NATL ACAD SCI USA, V39, P1420; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RENKAWEK K, 1992, ACTA NEUROPATHOL, V83, P324, DOI 10.1007/BF00296796; Renkawek K, 1999, NEUROREPORT, V10, P2273, DOI 10.1097/00001756-199908020-00009; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; SCOTTING P, 1991, FEBS LETT, V285, P75, DOI 10.1016/0014-5793(91)80728-L; Shroff NP, 2000, BIOCHEMISTRY-US, V39, P1420, DOI 10.1021/bi991656b; Smulders RHPH, 1998, INT J BIOL MACROMOL, V22, P187, DOI 10.1016/S0141-8130(98)00016-6; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9	38	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22009	22013		10.1074/jbc.M003307200	http://dx.doi.org/10.1074/jbc.M003307200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10896951	hybrid			2022-12-27	WOS:000088363800037
